PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sugino, Y; Misawa, A; Inoue, J; Kitagawa, M; Hosoi, H; Sugimoto, T; Imoto, I; Inazawa, J				Sugino, Y.; Misawa, A.; Inoue, J.; Kitagawa, M.; Hosoi, H.; Sugimoto, T.; Imoto, I.; Inazawa, J.			Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas	ONCOGENE			English	Article						neuroblastoma; PTGER2; tumor suppressor; DNA methylation; histone modification; cAMP	CPG ISLAND AMPLIFICATION; COLORECTAL-CANCER; DNA METHYLATION; CHROMATIN-STRUCTURE; GENE-EXPRESSION; CELL-LINES; APOPTOSIS; GROWTH; ACTIVATION; EP2	We previously identified a cluster of prostanoid receptor genes, prostaglandin D2 receptor (PTGDR) and prostaglandin E receptor 2 (PTGER2), as possible targets for DNA methylation in advanced types of neuroblastoma ( NB) using bacterial artificial chromosome array-based methylated CpG island amplification method. Among them, in this study, we found that PTGER2 was frequently silenced in NB cell lines, especially in those with MYCN amplification, through epigenetic mechanisms. In NB cell lines, DNA methylation pattern within a part of CpG island was inversely correlated with PTGER2 expression, and histone H3 and H4 deacetylation and histone H3 lysine 9 methylation within the putative promoter region were more directly correlated with silencing of this gene. Methylation of PTGER2 was observed more frequently in advanced-type of primary NBs compared with early-stage tumors. Growth of NB cells lacking endogenous PTGER2 expression was inhibited by restoration of the gene product by transient and stable transfection. A PTGER2-selective agonist, butaprost, increased intracellular cyclic adenosine monophosphate ( cAMP) level, inhibited cell growth and induced apoptosis of NB cells stably expressing exogenous PTGER2. 8-Bromo-cAMP also inhibited growth of NB cells lacking PTGER2 expression, but not cells expressing this gene. Taken together, it is suggested that NB cells may lose responsiveness to PTGER2-mediated growth inhibition/apoptosis through epigenetic silencing of PTGER2 and/or disruption of downstream cAMP-dependent pathway during the neuroblastomagenesis.	Tokyo Med & Dent Univ, Sch Biomed Sci, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; Japan Sci & Technol Corp, Core Res Evolutionary Sci & Technol, Satiama, Japan; Kyoto Prefectural Univ Med, Dept Pediat, Kyoto, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Pathol & Immunol, Tokyo, Japan; Tokyo Med & Dent Univ, Grad Sch, Hard Tissue Genom Res Ctr, Dept Genom Med, Tokyo, Japan; Tokyo Med & Dent Univ, Cent Ctr Excellence Program Mol D & R T & B 21st, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Kyoto Prefectural University of Medicine; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Imoto, Issei/AAD-5799-2020; imoto, Issei/D-8065-2012					Abe M, 2005, CANCER RES, V65, P828; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen TC, 1998, LAB INVEST, V78, P165; Fedyk ER, 1996, MOL IMMUNOL, V33, P33, DOI 10.1016/0161-5890(95)00130-1; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; FULTON AM, 1989, J CELL PHYSIOL, V139, P93, DOI 10.1002/jcp.1041390114; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; Mejia MD, 2002, ARCH MED RES, V33, P466, DOI 10.1016/S0188-4409(02)00384-3; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Okuyama T, 2002, J LAB CLIN MED, V140, P92, DOI 10.1067/mlc.2002.125784; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Saito-Ohara F, 2003, CANCER RES, V63, P1876; SANTORO MG, 1977, CANCER RES, V37, P3774; Schubeler D, 2000, MOL CELL BIOL, V20, P9103, DOI 10.1128/MCB.20.24.9103-9112.2000; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698; Takadera T, 2004, NEUROCHEM INT, V45, P713, DOI 10.1016/j.neuint.2004.02.005; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thompson PM, 2001, MED PEDIATR ONCOL, V36, P28, DOI 10.1002/1096-911X(20010101)36:1<28::AID-MPO1008>3.0.CO;2-0; Toyota M, 1999, CANCER RES, V59, P2307; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wang WH, 2005, INORG CHEM COMMUN, V8, P109, DOI 10.1016/j.inoche.2004.11.025; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamada N, 2006, INT J CANCER, V119, P1850, DOI 10.1002/ijc.22047; Yan P, 2003, GENE CHROMOSOME CANC, V36, P129, DOI 10.1002/gcc.10150; Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331; Yang QW, 2003, CANCER RES, V63, P6299	44	39	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7401	7413		10.1038/sj.onc.1210550	http://dx.doi.org/10.1038/sj.onc.1210550			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17533365				2022-12-25	WOS:000251282000002
J	Lehen'kyi, V; Flourakis, M; Skryma, R; Prevarskaya, N				Lehen'kyi, V.; Flourakis, M.; Skryma, R.; Prevarskaya, N.			TRPV6 channel controls prostate cancer cell proliferation via Ca2+/NFAT-dependent pathways	ONCOGENE			English	Article						prostate cancer; TRPV6; Ca2+ uptake; NFAT; proliferation; LNCaP cells	OPERATED CA2+ CURRENT; EPITHELIAL-CELLS; ANDROGEN RECEPTOR; APOPTOTIC RESISTANCE; STORE DEPLETION; EXPRESSION; HOMEOSTASIS; GROWTH; INVOLVEMENT; PROGRESSION	The transient receptor potential channel, subfamily V, member 6 (TRPV6), is strongly expressed in advanced prostate cancer and significantly correlates with the Gleason > 7 grading, being undetectable in healthy and benign prostate tissues. However, the role of TRPV6 as a highly Ca2+-selective channel in prostate carcinogenesis remains poorly understood. Here, we report that TRPV6 is directly involved in the control of prostate cancer cell (LNCaP cell line) proliferation by decreasing: (i) proliferation rate; (ii) cell accumulation in the S-phase of cell cycle and (iii) proliferating cell nuclear antigen (PCNA) expression. We demonstrate that the Ca2+ uptake into LNCaP cells is mediated by TRPV6, with the subsequent downstream activation of the nuclear factor of activated T-cell transcription factor (NFAT). TRPV6-mediated Ca2+ entry is also involved in apoptosis resistance of LNCaP cells. Our results suggest that TRPV6 expression in LNCaP cells is regulated by androgen receptor, however, in a ligand-independent manner. We conclude that the upregulation of TRPV6 Ca2+ channel in prostate cancer cells may represent a mechanism for maintaining a higher proliferation rate, increasing cell survival and apoptosis resistance as well.	Univ Sci & Tech Lille, INSERM, Lab Cell Physiol, Villeneuve Dascq, France; INSERM, Equipe Ligue Natl Contre Canc, Villeneuve Dascq, France; Univ Sci & Tech Lille, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Prevarskaya, N (corresponding author), Univ Sci & Tech Lille, INSERM, Lab Cell Physiol, Bat SN3, Villeneuve Dascq, France.	natacha.prevarskaya@univ-lille1.fr		Flourakis, Matthieu/0000-0002-5366-9125; LEHEN'KYI, V'yacheslav/0000-0003-0806-8766; Prevarskaya, natacha/0000-0003-0316-197X				Bidaux G, 2005, ENDOCR-RELAT CANCER, V12, P367, DOI 10.1677/erc.1.00969; Bodding M, 2004, J BIOL CHEM, V279, P36546, DOI 10.1074/jbc.M404679200; Bodding M, 2003, J BIOL CHEM, V278, P50872, DOI 10.1074/jbc.M308800200; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Cooperberg MR, 2005, J CLIN ONCOL, V23, P8146, DOI 10.1200/JCO.2005.02.9751; Fixemer T, 2003, ONCOGENE, V22, P7858, DOI 10.1038/sj.onc.1206895; Korkmaz KS, 2002, J BIOL CHEM, V277, P36689, DOI 10.1074/jbc.M202414200; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Lipskaia L, 2004, BIOL CELL, V96, P55, DOI 10.1016/j.biolcel.2003.11.001; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Prevarskaya N, 2004, BIOCHEM BIOPH RES CO, V322, P1326, DOI 10.1016/j.bbrc.2004.08.037; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Schwarz EC, 2006, CELL CALCIUM, V39, P163, DOI 10.1016/j.ceca.2005.10.006; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376; Vanden Abeele F, 2004, J BIOL CHEM, V279, P30326, DOI 10.1074/jbc.M400106200; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Wang LG, 1999, BIOCHEM BIOPH RES CO, V259, P21, DOI 10.1006/bbrc.1999.0655; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wissenbach U, 2004, BIOCHEM BIOPH RES CO, V322, P1359, DOI 10.1016/j.bbrc.2004.08.042; Xiao F, 2005, MOL ENDOCRINOL, V19, P2964, DOI 10.1210/me.2004-0408	24	177	184	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7380	7385		10.1038/sj.onc.1210545	http://dx.doi.org/10.1038/sj.onc.1210545			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533368	Green Submitted			2022-12-25	WOS:000250955700010
J	Nicolas, O; Gavin, R; Braun, N; Urena, JM; Fontana, X; Soriano, E; Aguzzi, A; del Rio, JA				Nicolas, Oriol; Gavin, Rosalina; Braun, Nathalie; Urena, Jesus Mariano; Fontana, Xavier; Soriano, Eduardo; Aguzzi, Adriano; del Rio, Jose Antonio			Bcl-2 overexpression delays caspase-3 activation and rescues cerebellar degeneration in prion-deficient mice that overexpress amino-terminally truncated prion	FASEB JOURNAL			English	Article						cerebellar syndrome; granule cells; oxidative damage; prion protein	PURKINJE-CELL DEGENERATION; PRP KNOCKOUT MICE; PROTEIN PRPC; NEURITE OUTGROWTH; DOPPEL PROTEIN; NEURONS; EXPRESSION; STAUROSPORINE; APOPTOSIS; TOXICITY	Prnp knockout mice that overexpress an amino-truncated form of PrPc (Delta PrP) are ataxic and display cerebellar cell loss and premature death. Studies on the molecular and intracellular events that trigger cell death in these mutants may contribute to elucidate the functions of PrPc and to the design of treatments for prion disease. Here we examined the effects of Bcl-2 overexpression in neurons on the development of the neurological syndrome and cerebellar pathology of Delta PrP. We show that Delta PrP overexpression activates the stress-associated kinases ERK1 -2 in reactive astroglia, p38 and the phosphorylation of p53, which leads to the death of cerebellar neurons in mutant mice. We found that the expression of Delta PrP in cell lines expressing very low levels of PrPc strongly induces the activation of apoptotic pathways, thereby leading to caspase-3 activation and cell death, which can be prevented by coexpressing Bcl-2. Finally, we corroborate in vivo that neuronal-directed Bcl-2 overexpression in Delta PrP mice (Delta PrP Bcl-2) markedly reduces caspase-3 activation, glial activation, and neuronal cell death in cerebellum by improving locomotor deficits and life expectancy.	Univ Barcelona, Inst Res Biomed, Dept Cell Biol, Samitier 1-5, E-08028 Barcelona, Spain; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of Zurich; University Zurich Hospital	del Rio, JA (corresponding author), Univ Barcelona, Inst Res Biomed, Dept Cell Biol, Samitier 1-5, E-08028 Barcelona, Spain.	jadelrio@pcb.ub.es	Del Rio Fernandez, Jose A/AAD-1121-2020; del rio, jose antonio/L-9232-2014; Urena, Jesus/R-5385-2017; Gavín, Rosalina/D-4341-2014; Aguzzi, Adriano/A-3351-2008; Soriano, Eduardo/AAB-3216-2019	del rio, jose antonio/0000-0002-5214-4909; Urena, Jesus/0000-0003-1408-6039; Gavín, Rosalina/0000-0003-1982-2162; Soriano, Eduardo/0000-0002-3204-9285; Aguzzi, Adriano/0000-0002-0344-6708				Anderson L, 2004, P NATL ACAD SCI USA, V101, P3644, DOI 10.1073/pnas.0308681101; Baumann F, 2007, EMBO J, V26, P538, DOI 10.1038/sj.emboj.7601510; Behrens A, 2002, TRENDS NEUROSCI, V25, P150, DOI 10.1016/S0166-2236(00)02089-0; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Chattopadhyay M, 2005, J AM CHEM SOC, V127, P12647, DOI 10.1021/ja053254z; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Cregan SP, 1999, J NEUROSCI, V19, P7860; Cui T, 2003, MOL CELL NEUROSCI, V23, P144, DOI 10.1016/S1044-7431(03)00017-4; ER E, 2006, BIOCH BIOPHYS ACTA; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2003, EMBO J, V22, P3095, DOI 10.1093/emboj/cdg285; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Gavin R, 2005, FEBS LETT, V579, P4099, DOI 10.1016/j.febslet.2005.06.037; Lee DC, 2006, MICROBIOL IMMUNOL, V50, P203, DOI 10.1111/j.1348-0421.2006.tb03787.x; Li AM, 2007, EMBO J, V26, P548, DOI 10.1038/sj.emboj.7601507; Li AM, 2007, J NEUROSCI, V27, P852, DOI 10.1523/JNEUROSCI.4244-06.2007; Li AM, 2000, AM J PATHOL, V157, P1447, DOI 10.1016/S0002-9440(10)64782-7; Maglio LE, 2004, MOL BRAIN RES, V131, P58, DOI 10.1016/j.molbrainres.2004.08.004; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McLennan NF, 2004, AM J PATHOL, V165, P227, DOI 10.1016/S0002-9440(10)63291-9; Paitel E, 2004, J BIOL CHEM, V279, P612, DOI 10.1074/jbc.M310453200; Paitel E, 2003, J BIOL CHEM, V278, P10061, DOI 10.1074/jbc.M211580200; Paitel E, 2002, J NEUROCHEM, V83, P1208, DOI 10.1046/j.1471-4159.2002.01234.x; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Radovanovic I, 2005, J NEUROSCI, V25, P4879, DOI 10.1523/JNEUROSCI.0328-05.2005; Rambold AS, 2006, MOL BIOL CELL, V17, P3356, DOI 10.1091/mbc.E06-01-0083; Roucou X, 2004, J NEUROSCI RES, V75, P153, DOI 10.1002/jnr.10864; Sakudo A, 2006, MINI-REV MED CHEM, V6, P589, DOI 10.2174/138955706776876159; Sakudo A, 2005, BIOCHEM BIOPH RES CO, V328, P14, DOI 10.1016/j.bbrc.2004.12.132; Sakudo A, 2003, BIOCHEM BIOPH RES CO, V307, P678, DOI 10.1016/S0006-291X(03)01239-7; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Steele AD, 2006, P NATL ACAD SCI USA, V103, P3416, DOI 10.1073/pnas.0511290103; Sunyach C, 2007, J BIOL CHEM, V282, P1956, DOI 10.1074/jbc.M609663200; Taylor DR, 2005, J CELL SCI, V118, P5141, DOI 10.1242/jcs.02627; Vassallo N, 2003, J NEUROCHEM, V86, P538, DOI 10.1046/j.1471-4159.2003.01882.x; Watt NT, 2005, J BIOL CHEM, V280, P35914, DOI 10.1074/jbc.M507327200; Weise J, 2004, NEUROSCI LETT, V372, P146, DOI 10.1016/j.neulet.2004.09.030; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; Yin SM, 2006, J BIOL CHEM, V281, P10698, DOI 10.1074/jbc.M511819200; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	48	31	33	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3107	3117		10.1096/fj.06-7827com	http://dx.doi.org/10.1096/fj.06-7827com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17494993				2022-12-25	WOS:000249781600012
J	Zantl, N; Weirich, G; Zall, H; Seiffert, BM; Fischer, SF; Kirschnek, S; Hartmann, C; Fritsch, RM; Gillissen, B; Daniel, PT; Hacker, G				Zantl, N.; Weirich, G.; Zall, H.; Seiffert, B. M.; Fischer, S. F.; Kirschnek, S.; Hartmann, C.; Fritsch, R. M.; Gillissen, B.; Daniel, P. T.; Haecker, G.			Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance	ONCOGENE			English	Article						renal cell carcinoma; apoptosis; Bim; Bcl-2; expression	BCL-2 FAMILY-MEMBER; BH3-ONLY PROTEINS; MITOCHONDRIAL-MEMBRANE; MALIGNANT-DISEASE; BH3 DOMAINS; DEATH; BAX; PATHWAY; PUMA; GENE	Renal cell carcinoma (RCC) is resistant to chemotherapy, and this resistance is mirrored by a high apoptosis resistance of many RCC lines in vitro. Here, we report the loss of the pro-apoptotic BH3-only protein Bim in a large part of clinical RCC cases and provide evidence for a functional relevance of this loss. Immunohistochemistry of clear cell renal cell carcinoma cases and corresponding normal kidney showed strong Bim reactivity in renal tubules of all cases but loss of Bim in 35 of 45 RCC samples. Out of nine RCC cell lines investigated, six showed strongly diminished or undetectable levels of Bim protein by western blotting. Four RCC lines of varying apoptosis sensitivity were analysed further. Bcl-2, Bcl-x(L), Mcl-1, Bax and Bak expression did not correlate with apoptosis sensitivity. All cell lines underwent apoptosis upon forced expression of Bax and Bim, suggesting an upstream difference. In all four lines, adriamycin induced p53 but not its targets Puma or Noxa. However, apoptosis sensitivity correlated with levels of Bim protein. Bim siRNA reduced apoptosis sensitivity in a susceptible cell line. Furthermore, inhibition of histone deacetylation restored Bim expression in cell lines. These data suggest that Bim has a function as a tumor suppressor in RCC.	Tech Univ Munich, Inst Med Microbiol, D-81675 Munich, Germany; Tech Univ Munich, Dept Urol, D-81675 Munich, Germany; Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany; Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hacker, G (corresponding author), Tech Univ Munich, Inst Med Microbiol, Trogerstr 9, D-81675 Munich, Germany.	hacker@lrz.tum.de		Fritsch, Ralph/0000-0001-9639-3213; Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Coultas L, 2005, EMBO J, V24, P3963, DOI 10.1038/sj.emboj.7600857; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; Fischer SF, 2001, INFECT IMMUN, V69, P7121, DOI 10.1128/IAI.69.11.7121-7129.2001; Gerhard MC, 2003, BRIT J CANCER, V89, P2147, DOI 10.1038/sj.bjc.6601436; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gurova KV, 2004, CANCER RES, V64, P1951, DOI 10.1158/0008-5472.CAN-03-1541; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang A, 1999, J UROLOGY, V162, P610, DOI 10.1016/S0022-5347(05)68635-1; Janzen NK, 2003, UROL CLIN N AM, V30, P843, DOI 10.1016/S0094-0143(03)00056-9; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kallio JP, 2004, J UROLOGY, V172, P2158, DOI 10.1097/01.ju.0000144334.97639.bf; Kane RC, 2006, CLIN CANCER RES, V12, P7271, DOI 10.1158/1078-0432.CCR-06-1249; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kolenko V, 1999, CANCER RES, V59, P2838; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Mickisch GHJ, 2002, BJU INT, V89, P488, DOI 10.1046/j.1464-410X.2002.02654.x; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Phillips JL, 2001, GENE CHROMOSOME CANC, V31, P1, DOI 10.1002/gcc.1111; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	53	73	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					7038	7048		10.1038/sj.onc.1210510	http://dx.doi.org/10.1038/sj.onc.1210510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486061				2022-12-25	WOS:000250412200009
J	Bellamy-Mclntyre, AK; Lay, CS; Bar, S; Maerz, AL; Talbo, GH; Drummer, HE; Poumbourios, P				Bellamy-Mclntyre, Anna K.; Lay, Chan-Sien; Baer, Severine; Maerz, Anne L.; Talbo, Gert H.; Drummer, Heidi E.; Poumbourios, Pantelis			Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 ENVELOPE GLYCOPROTEIN; VIRION-ASSOCIATED CHOLESTEROL; HUMAN MONOCLONAL-ANTIBODIES; CELL-CELL FUSION; HIV-1 GP41; INFLUENZA HEMAGGLUTININ; RECEPTOR-BINDING; EXTERNAL REGION; NEUTRALIZING ANTIBODIES; CONFORMATIONAL-CHANGES	The binding of CD4 and chemokine receptors to the gp120 attachment glycoprotein of human immunodeficiency virus triggers refolding of the associated gp41 fusion glycoprotein into a trimer of hairpins with a 6-helix bundle (6HB) core. These events lead to membrane fusion and viral entry. Here, we examined the functions of the fusion peptide-proximal polar segment and membrane-proximal Trp-rich region (MPR), which are exterior to the 6HB. Alanine substitution of Trp(666), Trp(672), Phe(673), and Ile(675) in the MPR reduced entry by up to 120-fold without affecting gp120-gp41 association or cell-cell fusion. The L537A polar segment mutation led to the loss of gp120 from the gp120-gp41 complex, reduced entry by similar to 10-fold, but did not affect cell-cell fusion. Simultaneous Ala substitution of Leu(537) with Trp(666), Trp(672), Phe(673), or Ile(675) abolished entry with 50-80% reductions in cell-cell fusion. gp120-gp41 complexes of fusion-defective double mutants were resistant to soluble CD4-induced shedding of gp120, suggesting that their ability to undergo receptorinduced conformational changes was compromised. Consistent with this idea, a representative mutation, L537A/W666A, led to an similar to 80% reduction in lipophilic fluorescent dye transfer between gp120-gp41-expressing cells and receptor-expressing targets, indicating a block prior to the lipid-mixing phase. The L537A/W666A double mutation increased the chymotrypsin sensitivity of the polar segment in a trimer of hairpins model, comprising the 6HB core, the polar segment, and MPR linked N-terminally to maltose-binding protein. The data indicate that the polar segment and MPR of gp41 act synergistically in forming a fusion-competent gp120-gp41 complex and in stabilizing the membrane-interactive end of the trimer of hairpins.	Macfarlane Burnet Inst Med Res & Publ Hlth, Prahran, Vic 3004, Australia; Monash Univ, Dept Microbiol, Clayton, Vic 3070, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3058, Australia; Inst Cochin, Dept Cell Biol, F-75014 Paris, France; Baker Heart Res Inst, Proteom Ctr, Melbourne, Vic 3004, Australia	Burnet Institute; Monash University; University of Melbourne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Baker Heart and Diabetes Institute	Poumbourios, P (corresponding author), 85 Commercial Rd, Melbourne, Vic 3004, Australia.	apoumbourios@burnet.edu.au	Bar, Severine/D-4060-2017; Bär, Séverine/AAC-4889-2019	Drummer, Heidi/0000-0002-0042-6277; Bar, Severine/0000-0003-2009-6110				ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; Bar S, 2004, J VIROL, V78, P811, DOI 10.1128/JVI.78.2.811-820.2004; Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002; Bhattacharya J, 2006, J VIROL, V80, P5292, DOI 10.1128/JVI.01469-05; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Bjorndal A, 1997, J VIROL, V71, P7478; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; Borrego-Diaz E, 2003, VIROLOGY, V316, P234, DOI 10.1016/j.virol.2003.07.006; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Campbell SM, 2002, AIDS, V16, P2253, DOI 10.1097/00002030-200211220-00004; Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chang DK, 1999, J BIOL CHEM, V274, P5299, DOI 10.1074/jbc.274.9.5299; Chang DK, 1997, J VIROL, V71, P6593, DOI 10.1128/JVI.71.9.6593-6602.1997; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Chen J, 1999, P NATL ACAD SCI USA, V96, P8967, DOI 10.1073/pnas.96.16.8967; Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Davis MR, 2006, J VIROL, V80, P2405, DOI 10.1128/JVI.80.5.2405-2417.2006; de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dimitrov AS, 2007, BIOCHEMISTRY-US, V46, P1398, DOI 10.1021/bi062245f; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Egashira M, 2002, BIOCHEMISTRY-US, V41, P4165, DOI 10.1021/bi011885+; Finnegan CM, 2002, J VIROL, V76, P12123, DOI 10.1128/JVI.76.23.12123-12134.2002; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; Gordon LM, 2002, BBA-BIOMEMBRANES, V1559, P96, DOI 10.1016/S0005-2736(01)00443-6; Gorny MK, 2000, J VIROL, V74, P6186, DOI 10.1128/JVI.74.13.6186-6192.2000; Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002; HAIGWOOD NL, 1990, AIDS RES HUM RETROV, V6, P855, DOI 10.1089/aid.1990.6.855; He Y, 2003, J VIROL, V77, P1666, DOI 10.1128/JVI.77.3.1666-1671.2003; Hoffman NG, 2002, J VIROL, V76, P3852, DOI 10.1128/JVI.76.8.3852-3864.2002; Jaroniec CP, 2005, BIOCHEMISTRY-US, V44, P16167, DOI 10.1021/bi051672a; Kielian M, 2006, NAT REV MICROBIOL, V4, P67, DOI 10.1038/nrmicro1326; Kuhmann SE, 2000, J VIROL, V74, P7005, DOI 10.1128/JVI.74.15.7005-7015.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lamb RA, 2006, VIROLOGY, V344, P30, DOI 10.1016/j.virol.2005.09.007; Lay CS, 2004, FEBS LETT, V567, P183, DOI 10.1016/j.febslet.2004.04.054; Liao ZH, 2003, AIDS RES HUM RETROV, V19, P675, DOI 10.1089/088922203322280900; Lorizate M, 2006, BIOCHEMISTRY-US, V45, P14337, DOI 10.1021/bi0612521; Lorizate M, 2006, J MOL BIOL, V360, P45, DOI 10.1016/j.jmb.2006.04.056; Lorizate M, 2006, J BIOL CHEM, V281, P39598, DOI 10.1074/jbc.M605998200; Maerz AL, 2001, J VIROL, V75, P6635, DOI 10.1128/JVI.75.14.6635-6644.2001; Markosyan RM, 2005, MOL BIOL CELL, V16, P5502, DOI 10.1091/mbc.E05-06-0496; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Melikyan GB, 2005, P NATL ACAD SCI USA, V102, P8728, DOI 10.1073/pnas.0501864102; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Munoz-Barroso I, 1999, J VIROL, V73, P6089; Murakami T, 2000, J VIROL, V74, P3548, DOI 10.1128/JVI.74.8.3548-3554.2000; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; MYERS R, 1993, 93 GEN M AM SOC MICR; Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004; Park HE, 2003, NAT STRUCT BIOL, V10, P1048, DOI 10.1038/nsb1012; Pastore C, 2006, J VIROL, V80, P750, DOI 10.1128/JVI.80.2.750-758.2006; Pierson TC, 2003, CURR TOP MICROBIOL, V281, P1; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; Poumbourios P, 2003, J BIOL CHEM, V278, P42149, DOI 10.1074/jbc.M305223200; POUMBOURIOS P, 1995, J VIROL, V69, P1209, DOI 10.1128/JVI.69.2.1209-1218.1995; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Rosen O, 2006, P NATL ACAD SCI USA, V103, P13950, DOI 10.1073/pnas.0606312103; Sackett K, 2005, J MOL BIOL, V350, P790, DOI 10.1016/j.jmb.2005.05.030; Sackett K, 2006, J BIOL CHEM, V281, P21755, DOI 10.1074/jbc.M603135200; Saez-Cirion A, 2002, J BIOL CHEM, V277, P21776, DOI 10.1074/jbc.M202255200; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; SATTENTAU QJ, 1995, VIROLOGY, V206, P713, DOI 10.1016/S0042-6822(95)80094-8; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; Shnaper S, 2004, J BIOL CHEM, V279, P18526, DOI 10.1074/jbc.M304950200; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Suarez T, 2000, FEBS LETT, V477, P145, DOI 10.1016/S0014-5793(00)01785-3; Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILLEY RL, 1994, J VIROL, V68, P1029, DOI 10.1128/JVI.68.2.1029-1039.1994; Wyma DJ, 2000, J VIROL, V74, P9381, DOI 10.1128/JVI.74.20.9381-9387.2000; XU JY, 1991, J VIROL, V65, P4832, DOI 10.1128/JVI.65.9.4832-4838.1991; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200; Yang XZ, 2006, J VIROL, V80, P4388, DOI 10.1128/JVI.80.9.4388-4395.2006; Yang XZ, 2005, J VIROL, V79, P12132, DOI 10.1128/JVI.79.19.12132-12147.2005; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116; Zanetti G, 2006, PLOS PATHOG, V2, DOI 10.1371/journal.ppat.0020083; Zhu P, 2003, P NATL ACAD SCI USA, V100, P15812, DOI 10.1073/pnas.2634931100; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817; Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	96	65	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23104	23116		10.1074/jbc.M703485200	http://dx.doi.org/10.1074/jbc.M703485200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17526486	hybrid			2022-12-25	WOS:000248577500013
J	Tanneberger, K; Kirchberger, J; Bar, J; Schellenberger, W; Rothemund, S; Kamprad, M; Otto, H; Schoneberg, T; Edelmann, A				Tanneberger, Katrin; Kirchberger, Juergen; Bar, Joerg; Schellenberger, Wolfgang; Rothemund, Sven; Kamprad, Manja; Otto, Henning; Schoeneberg, Torsten; Edelmann, Anke			A novel form of 6-phosphofructokinase - Identification and functional relevance of a third type of subunit in pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST PHOSPHOFRUCTOKINASE; FRUCTOSE 2,6-BISPHOSPHATE; CARBOHYDRATE-METABOLISM; FLOCCULATION; EVOLUTION; GENE; PURIFICATION; GLYCOLYSIS; PROTEINS	Classically, 6-phosphofructokinases are homo-and heterooligomeric enzymes consisting of alpha subunits and alpha/beta subunits, respectively. Herein, we describe a new form of 6-phosphofructokinase (Pfk) present in several Pichia species, which is composed of three different types of subunit, alpha,beta, and gamma. The sequence of the gamma subunit shows no similarity to classic Pfk subunits or to other known protein sequences. In-depth structural and functional studies revealed that the gamma subunit is a constitutive component of Pfk from Pichia pastoris (PpPfk). Analyses of the purified PpPfk suggest a heterododecameric assembly from the three different subunits. Accordingly, it is the largest and most complex Pfk identified yet. Although, the gamma subunit is not required for enzymatic activity, the gamma subunit-deficient mutant displays a decreased growth on nutrient limitation and reduced cell flocculation when compared with the P. pastoris wild-type strain. Subsequent characterization of purified Pfks from wildtype and gamma subunit-deficient strains revealed that the allosteric regulation of the PpPfk by ATP, fructose 2,6-bisphosphate, and AMP is fine-tuned by the gamma subunit. Therefore, we suggest that the gamma subunit contributes to adaptation of P. pastoris to energy resources.	Univ Leipzig, Fac Med, Inst Biochem, D-04103 Leipzig, Germany; Univ Leipzig, Fac Med, IZKF Core Unit Peptide Technol, D-04103 Leipzig, Germany; Univ Leipzig, Fac Med, Inst Clin Immunol & Transfus Med, D-04103 Leipzig, Germany; Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany	Leipzig University; Leipzig University; Leipzig University; Free University of Berlin	Edelmann, A (corresponding author), Univ Leipzig, Fac Med, Inst Biochem, Johannisallee 30, D-04103 Leipzig, Germany.	schoberg@medizin.uni-leipzig.de	Kamprad, Manja/B-2222-2008					Alves AMCR, 2001, J BACTERIOL, V183, P7231, DOI 10.1128/JB.183.24.7231-7240.2001; ARVANITIDIS A, 1994, J BIOL CHEM, V269, P8911; Bapteste E, 2003, GENE, V318, P185, DOI 10.1016/S0378-1119(03)00797-2; Bar J, 1997, YEAST, V13, P1309, DOI 10.1002/(SICI)1097-0061(199711)13:14<1309::AID-YEA181>3.0.CO;2-#; Bar J, 2000, BIOCHEMISTRY-US, V39, P6960, DOI 10.1021/bi9928142; Barelle CJ, 2006, CELL MICROBIOL, V8, P961, DOI 10.1111/j.1462-5822.2005.00676.x; BARTRONS R, 1982, FEBS LETT, V143, P137, DOI 10.1016/0014-5793(82)80290-1; Bony M, 1998, YEAST, V14, P25, DOI 10.1002/(SICI)1097-0061(19980115)14:1<25::AID-YEA197>3.3.CO;2-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLIFTON D, 1978, GENETICS, V88, P1; Dlauchy D, 2003, ANTON LEEUW INT J G, V83, P327, DOI 10.1023/A:1023318829389; Edelmann A, 2005, J CLIN MICROBIOL, V43, P6164, DOI 10.1128/JCM.43.12.6164-6166.2005; Edelmann A, 2002, YEAST, V19, P949, DOI 10.1002/yea.889; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; FERNANDES PA, 1993, YEAST, V9, P859, DOI 10.1002/yea.320090806; Flores CL, 2005, MICROBIOL-SGM, V151, P1465, DOI 10.1099/mic.0.27856-0; Flores CL, 2000, FEMS MICROBIOL REV, V24, P507, DOI 10.1111/j.1574-6976.2000.tb00553.x; FOE LG, 1985, J BIOL CHEM, V260, P726; Fraenkel DG, 2003, CURR OPIN MICROBIOL, V6, P198, DOI 10.1016/S1369-5274(03)00023-7; GANCEDO JM, 1973, BIOCHIMIE, V55, P205, DOI 10.1016/S0300-9084(73)80393-1; HEINISCH J, 1989, GENE, V78, P309; HEINISCH J, 1986, CURR GENET, V11, P227, DOI 10.1007/BF00420611; HERS HG, 1982, BIOCHEM J, V206, P1; HOFMANN E, 1982, METHOD ENZYMOL, V90, P49; HOFMANN E, 1976, REV PHYSIOL BIOCH P, V75, P1, DOI 10.1007/BFb0030484; HOLLAND MJ, 1987, MOL CELL BIOL, V7, P813, DOI 10.1128/MCB.7.2.813; HUSE K, 1988, FEBS LETT, V234, P185, DOI 10.1016/0014-5793(88)81330-9; HUSE K, 1983, FEBS LETT, V155, P50, DOI 10.1016/0014-5793(83)80207-5; Kemp RG, 2002, BIOCHEMISTRY-US, V41, P9426, DOI 10.1021/bi020110d; Kirchberger J, 2002, YEAST, V19, P933, DOI 10.1002/yea.885; KIRSCHENBAUM DM, 1973, ANAL BIOCHEM, V56, P237, DOI 10.1016/0003-2697(73)90186-3; Klinder A, 1998, YEAST, V14, P323, DOI 10.1002/(SICI)1097-0061(19980315)14:4<323::AID-YEA223>3.0.CO;2-W; KOPPERSCHLAGER G, 1995, FEBS LETT, V363, P17, DOI 10.1016/0014-5793(95)00269-F; KOPPERSCHLAGER G, 1992, PROTEIN INTERACTIONS, P345; KOPPERSCHLAGER G, 1977, EUR J BIOCHEM, V81, P317, DOI 10.1111/j.1432-1033.1977.tb11954.x; Kricke J, 1999, INT J BIOL MACROMOL, V24, P27, DOI 10.1016/S0141-8130(98)00063-4; Larsson C, 2000, YEAST, V16, P797, DOI 10.1002/1097-0061(20000630)16:9<797::AID-YEA553>3.3.CO;2-X; MBAWALA A, 1990, J GEN MICROBIOL, V136, P1279, DOI 10.1099/00221287-136-7-1279; MOORE PA, 1991, MOL CELL BIOL, V11, P5330, DOI 10.1128/MCB.11.10.5330; Muller M, 2001, J BACTERIOL, V183, P6714, DOI 10.1128/JB.183.22.6714-6716.2001; Nakagawa T, 2000, APPL ENVIRON MICROB, V66, P4253, DOI 10.1128/AEM.66.10.4253-4257.2000; NISSLER K, 1983, BIOCHEM BIOPH RES CO, V111, P294, DOI 10.1016/S0006-291X(83)80150-8; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; Pearce AK, 2001, MICROBIOL-SGM, V147, P391, DOI 10.1099/00221287-147-2-391; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Rais B, 2000, BBA-PROTEIN STRUCT M, V1479, P303, DOI 10.1016/S0167-4838(00)00047-9; Rakus D, 2004, BIOCHEMISTRY-US, V43, P14948, DOI 10.1021/bi048886x; Reuter R, 2000, YEAST, V16, P1273, DOI 10.1002/1097-0061(200010)16:14<1273::AID-YEA621>3.3.CO;2-R; Ruiz T, 2003, J STRUCT BIOL, V143, P124, DOI 10.1016/S1047-8477(03)00140-0; Sakai Y, 1998, J CELL BIOL, V141, P625, DOI 10.1083/jcb.141.3.625; Sampermans S, 2005, J APPL MICROBIOL, V98, P525, DOI 10.1111/j.1365-2672.2004.02486.x; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; Schroter A, 1996, FEMS MICROBIOL LETT, V142, P247; Schwock J, 2004, YEAST, V21, P483, DOI 10.1002/yea.1114; SHEN LC, 1968, BIOCHEMISTRY-US, V7, P4041, DOI 10.1021/bi00851a035; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SIERKSTRA LN, 1992, J GEN MICROBIOL, V138, P2559, DOI 10.1099/00221287-138-12-2559; Slamovits CH, 2006, EUKARYOT CELL, V5, P148, DOI 10.1128/EC.5.1.148-154.2006; Spivey HO, 1999, METHODS, V19, P306, DOI 10.1006/meth.1999.0858; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; Verstrepen KJ, 2006, MOL MICROBIOL, V60, P5, DOI 10.1111/j.1365-2958.2006.05072.x; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Yuan WP, 1997, J CELL SCI, V110, P1935	66	11	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23687	23697		10.1074/jbc.M611547200	http://dx.doi.org/10.1074/jbc.M611547200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17522059	hybrid			2022-12-25	WOS:000248577500072
J	Wada, M; DeLong, CJ; Hong, YH; Rieke, CJ; Song, I; Sidhu, RS; Yuan, C; Warnock, M; Schmaier, AH; Yokoyama, C; Smyth, EM; Wilson, SJ; FitzGerald, GA; Garavito, M; Sui, DX; Regan, JW; Smith, WL				Wada, Masayuki; DeLong, Cynthia J.; Hong, Yu H.; Rieke, Caroline J.; Song, Inseok; Sidhu, Ranjinder S.; Yuan, Chong; Warnock, Mark; Schmaier, Alvin H.; Yokoyama, Chieko; Smyth, Emer M.; Wilson, Stephen J.; FitzGerald, Garret A.; Garavito, Michael; Sui, De Xin; Regan, John W.; Smith, William L.			Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CYTOSOLIC PHOSPHOLIPASE A(2); POLYUNSATURATED FATTY-ACIDS; ENDOPEROXIDE-H SYNTHASE-1; CORONARY-HEART-DISEASE; PROTEIN-KINASE-C; CYCLOOXYGENASE ACTIVITIES; DOCOSAHEXAENOIC ACID; FISH CONSUMPTION; MICE LACKING; VASCULAR-PERMEABILITY	Dietary fish oil containing omega 3 highly unsaturated fatty acids has cardioprotective and anti-inflammatory effects. Prostaglandins ( PGs) and thromboxanes are produced in vivo both from the omega 6 fatty acid arachidonic acid (AA) and the omega 3 fatty acid eicosapentaenoic acid (EPA). Certain beneficial effects of fish oil may result from altered PG metabolism resulting from increases in the EPA/AA ratios of precursor phospholipids. Here we report in vitro specificities of prostanoid enzymes and receptors toward EPA-derived, 3-series versus AA-derived, 2-series prostanoid substrates and products. The largest difference was seen with PG endoperoxide H synthase ( PGHS)-1. Under optimal conditions purified PGHS-1 oxygenates EPA with only 10% of the efficiency of AA, and EPA significantly inhibits AA oxygenation by PGHS-1. Two- to 3-fold higher activities or potencies with 2-series versus 3-series compounds were observed with PGHS-2, PGD synthases, microsomal PGE synthase-1 and EP1, EP2, EP3, and FP receptors. Our most surprising observation was that AA oxygenation by PGHS-2 is only modestly inhibited by EPA (i.e. PGHS-2 exhibits a marked preference for AA when EPA and AA are tested together). Also unexpectedly, TxA(3) is about equipotent to TxA(2) at the TP alpha receptor. Our biochemical data predict that increasing phospholipidEPA/AA ratios in cells would dampen prostanoid signaling with the largest effects being on PGHS-1 pathways involving PGD, PGE, and PGF. Production of 2-series prostanoids from AA by PGHS-2 would be expected to decrease in proportion to the compensatory decrease in the AA content of phospholipids that would result from increased incorporation of omega 3 fatty acids such as EPA.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, 21st Century Ctr Excellence Program, Tokyo 1138549, Japan; Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48109 USA; Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Case Western Reserve University; Tokyo Medical & Dental University (TMDU); University of Pennsylvania; Pennsylvania Medicine; Michigan State University; University of Arizona	Smith, WL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 5301 Med Sci Res Bldg III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	smithww@umich.edu	FitzGerald, Garret A/A-4222-2010; Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234; DeLong, Cynthia/0000-0002-6823-8619	NHLBI NIH HHS [HL075993, HL56773] Funding Source: Medline; NIGMS NIH HHS [GM68848] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL075993, R01HL056773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068848] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTI M, 1992, GASTROENTEROLOGY, V103, P883, DOI 10.1016/0016-5085(92)90021-P; Aronoff DM, 2006, CLIN PHARMACOL THER, V79, P9, DOI 10.1016/j.clpt.2005.09.009; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bortuzzo C, 1996, BBA-LIPID LIPID MET, V1300, P240, DOI 10.1016/0005-2760(96)00003-3; Boulet L, 2004, J BIOL CHEM, V279, P23229, DOI 10.1074/jbc.M400443200; BRADEN GA, 1990, CIRCULATION, V82, P178, DOI 10.1161/01.CIR.82.1.178; Burr G, 1932, J BIOL CHEM, V97, P1; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cowart LA, 2002, J BIOL CHEM, V277, P35105, DOI 10.1074/jbc.M201575200; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; De Caterina R, 2001, LIPIDS, V36, pS69, DOI 10.1007/s11745-001-0685-9; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOLECEK TA, 1991, WORLD REV NUTR DIET, V66, P205; Fan YY, 2004, J IMMUNOL, V173, P6151, DOI 10.4049/jimmunol.173.10.6151; FISHER SK, 1989, MOL PHARMACOL, V35, P195; Fujino H, 2000, J BIOL CHEM, V275, P29907, DOI 10.1074/jbc.M003467200; Fujino H, 2006, MOL PHARMACOL, V69, P13, DOI 10.1124/mol.105.017749; Fujino H, 2002, J BIOL CHEM, V277, P48786, DOI 10.1074/jbc.M209393200; FUNK CD, 1993, J BIOL CHEM, V268, P26767; Gao L, 2006, J BIOL CHEM, V281, P14092, DOI 10.1074/jbc.M601035200; Gawrisch K, 2003, LIPIDS, V38, P445, DOI 10.1007/s11745-003-1082-0; Ghosh M, 2007, J BIOL CHEM, V282, P11676, DOI 10.1074/jbc.M608458200; GLOMSET JA, 2006, SCI STKE, pE6; Goulet JL, 2004, J IMMUNOL, V173, P1321, DOI 10.4049/jimmunol.173.2.1321; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HANSEN HS, 1983, LIPIDS, V18, P682, DOI 10.1007/BF02534534; HECKER M, 1989, J BIOL CHEM, V264, P141; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hu FB, 2002, JAMA-J AM MED ASSOC, V287, P1815, DOI 10.1001/jama.287.14.1815; Huang YC, 1996, LIPIDS, V31, pS313, DOI 10.1007/BF02637099; Jho David H, 2004, Integr Cancer Ther, V3, P98, DOI 10.1177/1534735404264736; Jump DB, 2004, CRIT REV CL LAB SCI, V41, P41, DOI 10.1080/10408360490278341; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Kanaoka Y, 2003, PROSTAG LEUKOTR ESS, V69, P163, DOI 10.1016/S0952-3278(03)00077-2; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x; Kobzar G, 2001, CELL PHYSIOL BIOCHEM, V11, P279, DOI 10.1159/000047814; Kotani M, 1997, GENOMICS, V40, P425, DOI 10.1006/geno.1996.4585; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Kris-Etherton PM, 2003, ARTERIOSCL THROM VAS, V23, pE20, DOI 10.1161/01.ATV.0000038493.65177.94; KROMHOUT D, 1995, INT J EPIDEMIOL, V24, P340, DOI 10.1093/ije/24.2.340; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 2005, BIOCHEM BIOPH RES CO, V338, P25, DOI 10.1016/j.bbrc.2005.08.030; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; LANDS WEM, 1992, BIOCHIM BIOPHYS ACTA, V1180, P147, DOI 10.1016/0925-4439(92)90063-S; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Leaf A, 2003, CIRCULATION, V107, P2646, DOI 10.1161/01.CIR.0000069566.78305.33; Lee JY, 2003, J LIPID RES, V44, P479, DOI 10.1194/jlr.M200361-JLR200; Liu W, 2006, FASEB J, V20, P1097, DOI 10.1096/fj.05-5273com; MAHADEVAPPA VG, 1987, J LIPID RES, V28, P1275; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Malkowski MG, 2001, J BIOL CHEM, V276, P37547, DOI 10.1074/jbc.M105982200; Marszalek JR, 2005, ANNU REV CELL DEV BI, V21, P633, DOI 10.1146/annurev.cellbio.21.122303.120624; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Mbonye UR, 2006, J BIOL CHEM, V281, P35770, DOI 10.1074/jbc.M608281200; Mitchell DC, 2003, J PEDIATR-US, V143, pS80, DOI 10.1067/S0022-3476(03)00405-0; MOHRHAUER H, 1963, J LIPID RES, V4, P151; Monneret G, 2003, J PHARMACOL EXP THER, V304, P349, DOI 10.1124/jpet.102.042937; MORITA I, 1983, J BIOL CHEM, V258, P197; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Murakami M, 2002, PROSTAG OTH LIPID M, V68-9, P383, DOI 10.1016/S0090-6980(02)00043-6; Murakami M, 2006, CURR PHARM DESIGN, V12, P943, DOI 10.2174/138161206776055912; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; Ni Z, 2006, J BIOL CHEM, V281, P16245, DOI 10.1074/jbc.M513874200; Niu SL, 2004, J BIOL CHEM, V279, P31098, DOI 10.1074/jbc.M404376200; Ouellet M, 2002, PROTEIN EXPRES PURIF, V26, P489, DOI 10.1016/S1046-5928(02)00566-1; Pessach I, 2001, J BIOL CHEM, V276, P33495, DOI 10.1074/jbc.M011417200; Peters-Golden M, 2005, J IMMUNOL, V174, P589, DOI 10.4049/jimmunol.174.2.589; Petrik MBH, 2000, J NUTR, V130, P1153, DOI 10.1093/jn/130.5.1153; Pinzar E, 2000, J BIOL CHEM, V275, P31239, DOI 10.1074/jbc.M000750200; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Quackenbush FW, 1942, J NUTR, V24, P213, DOI 10.1093/jn/24.3.213; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Sano Y, 2003, J BIOL CHEM, V278, P27406, DOI 10.1074/jbc.M206810200; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Schachter JB, 1996, BBA-GEN SUBJECTS, V1291, P167, DOI 10.1016/0304-4165(96)00063-3; Schneider A, 2004, KIDNEY INT, V65, P1205, DOI 10.1111/j.1523-1755.2004.00493.x; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; SHIKANO M, 1994, BBA-LIPID LIPID MET, V1212, P211, DOI 10.1016/0005-2760(94)90255-0; Smith W.L., 2002, BIOCH LIPIDS LIPOPRO; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Song I, 2001, BIOCHEM BIOPH RES CO, V289, P869, DOI 10.1006/bbrc.2001.6071; Strokin M, 2003, BRIT J PHARMACOL, V139, P1014, DOI 10.1038/sj.bjp.0705326; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; TANAKA Y, 1987, J BIOL CHEM, V262, P1374; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Thoren S, 2003, J BIOL CHEM, V278, P22199, DOI 10.1074/jbc.M303227200; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; Ungrin MD, 2001, MOL PHARMACOL, V59, P1446, DOI 10.1124/mol.59.6.1446; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1985, J BIOL CHEM, V260, P2410; URADE Y, 1995, J BIOL CHEM, V270, P1422, DOI 10.1074/jbc.270.3.1422; Waclawik A, 2006, ENDOCRINOLOGY, V147, P210, DOI 10.1210/en.2005-0880; Wada M, 2004, J BIOCHEM, V135, P455, DOI 10.1093/jb/mvh059; Wang Y, 2002, J AM CHEM SOC, V124, P7690, DOI 10.1021/ja0200488; Watanabe K, 2002, PROSTAG OTH LIPID M, V68-9, P401, DOI 10.1016/S0090-6980(02)00044-8; WHITAKER MO, 1979, P NATL ACAD SCI USA, V76, P5919, DOI 10.1073/pnas.76.11.5919; Wilson SJ, 2006, J BIOL CHEM, V281, P11780, DOI 10.1074/jbc.M513110200; YOKOYAMA C, 1993, FEBS LETT, V318, P91, DOI 10.1016/0014-5793(93)81335-W; Yu Y, 2005, J CLIN INVEST, V115, P986, DOI 10.1172/JCI23683; Yu Y, 2007, J BIOL CHEM, V282, P1498, DOI 10.1074/jbc.M609930200; Yuan C, 2006, P NATL ACAD SCI USA, V103, P6142, DOI 10.1073/pnas.0601805103; Zeyda M, 2002, J BIOL CHEM, V277, P28418, DOI 10.1074/jbc.M203343200; Zhang JJ, 1999, PREV MED, V28, P520, DOI 10.1006/pmed.1998.0472; Zhang L, 2006, MOL PHARMACOL, V69, P1433, DOI 10.1124/mol.105.019703	120	308	368	3	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22254	22266		10.1074/jbc.M703169200	http://dx.doi.org/10.1074/jbc.M703169200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17519235	hybrid			2022-12-25	WOS:000248354200003
J	Kim, T; Buratowski, S				Kim, TaeSoo; Buratowski, Stephen			Two Saccharomyces cerevisiae JmjC domain proteins demethylate histone H3 Lys(36) in transcribed regions to promote elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DOMAIN; PHD FINGER; METHYLATION; SET2; METHYLTRANSFERASE; PHOSPHORYLATION; KINASE; YEAST; BUR1; TRIMETHYLATION	Histone methylation is a reversible modification regulated by the antagonistic functions of residue-specific histone methyl-transferases and demethylases. Although methylation of histone H3 at lysines 4 and 36 is linked to transcription, the roles of histone demethylases in transcription regulation are not understood. Here we show that overexpression of either Jhd1 or Rph1, two JmjC-domain proteins, bypasses the requirement for the positive elongation factor gene BUR1. Biochemical analysis and chromatin immunoprecipitation experiments indicate that Rph1 functions as a specific demethylase for H3 K36me3 and K36me2, directly regulating Lys(36) methylation in transcribed regions. Both Jhd1 and Rph1 are required for normal levels of RNA polymerase II cross-linking to genes. Taken together, these findings indicate that a general function of histone demethylases for H3 Lys(36) is to promote transcription elongation by antagonizing repressive Lys(36) methylation by Set2.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Buratowski, S (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	SteveB@hms.harvard.edu		Kim, TaeSoo/0000-0002-3902-1058	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046498, R29GM046498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024; Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003; Chu YY, 2006, MOL CELL BIOL, V26, P3029, DOI 10.1128/MCB.26.8.3029-3038.2006; Dyson MH, 2001, FRONT BIOSCI, V6, pD853, DOI 10.2741/Dyson; Eissenberg JC, 2007, NAT STRUCT MOL BIOL, V14, P344, DOI 10.1038/nsmb1217; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; Howe L, 2002, MOL CELL BIOL, V22, P5047, DOI 10.1128/MCB.22.14.5047-5053.2002; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; HUARTE M, 2007, J BIOL CHEM     0605, DOI DOI 10.1074/JBCM703897200; Jang YK, 1999, MOL CELL BIOL, V19, P7630; Joshi AA, 2005, MOL CELL, V20, P971, DOI 10.1016/j.molcel.2005.11.021; Keogh MC, 2005, CELL, V123, P593, DOI 10.1016/j.cell.2005.10.025; Keogh MC, 2003, MOL CELL BIOL, V23, P7005, DOI 10.1128/MCB.23.19.7005-7018.2003; Kim EM, 2002, NUCLEIC ACIDS RES, V30, P643, DOI 10.1093/nar/30.3.643; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Klose RJ, 2007, MOL CELL BIOL, V27, P3951, DOI 10.1128/MCB.02180-06; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lee N, 2007, NAT STRUCT MOL BIOL, V14, P341, DOI 10.1038/nsmb1216; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Liang G, 2007, NAT STRUCT MOL BIOL, V14, P243, DOI 10.1038/nsmb1204; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Nelson CJ, 2006, CELL, V126, P905, DOI 10.1016/j.cell.2006.07.026; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; PRELICH G, 1993, GENETICS, V135, P665; Schaft D, 2003, NUCLEIC ACIDS RES, V31, P2475, DOI 10.1093/nar/gkg372; Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007; Seward DJ, 2007, NAT STRUCT MOL BIOL, V14, P240, DOI 10.1038/nsmb1200; Shi XB, 2007, J BIOL CHEM, V282, P2450, DOI 10.1074/jbc.C600286200; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Tu SJ, 2007, J BIOL CHEM, V282, P14262, DOI 10.1074/jbc.M609900200; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wood A, 2005, MOL CELL, V20, P589, DOI 10.1016/j.molcel.2005.09.010; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Yao S, 2000, MOL CELL BIOL, V20, P7080, DOI 10.1128/MCB.20.19.7080-7087.2000; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zofall M, 2006, MOL CELL, V22, P681, DOI 10.1016/j.molcel.2006.05.010	56	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20827	20835		10.1074/jbc.M703034200	http://dx.doi.org/10.1074/jbc.M703034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17525156	hybrid			2022-12-25	WOS:000248047500008
J	Zhou, RF; Patel, SV; Snyder, PM				Zhou, Ruifeng; Patel, Saumil V.; Snyder, Peter M.			Nedd4-2 catalyzes ubiquitination and degradation of cell surface ENaC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; LIDDLES-SYNDROME; SODIUM-CHANNEL; PROTEIN LIGASE; EXPRESSION; PHOSPHORYLATION; INHIBITION; SERUM; ENDOCYTOSIS; MECHANISM	Epithelial Na+ absorption is regulated by Nedd4-2, an E3 ubiquitin-protein ligase that reduces expression of the epithelial Na+ channel ENaC at the cell surface. Defects in this regulation cause Liddle syndrome, an inherited form of hypertension. Previous work found that Nedd4-2 binds to ENaC via PY motifs located in the C termini of alpha-, beta-, and gamma ENaC. However, little is known about the mechanism by which Nedd4-2 regulates ENaC surface expression. Here we found that Nedd4-2 catalyzes ubiquitination of alpha-, beta-, and gamma ENaC; Nedd4-2 overexpression increased ubiquitination, whereas Nedd4-2 silencing decreased ubiquitination. Although Nedd4-2 increased both mono/oligoubiquitinated and multiubiquitinated forms of ENaC, monoubiquitination was sufficient for Nedd4-2 to reduce ENaC surface expression and reduce ENaC current. Ubiquitination was disrupted by Liddle syndrome-associated mutations in ENaC or mutation of the catalytic HECT domain in Nedd4-2. Several findings suggest that the interaction between Nedd4-2 and ENaC is localized to the cell surface. First, Nedd4-2 bound to a population of ENaC at the cell surface. Second, Nedd4-2 catalyzed ubiquitination of cell surface ENaC. Third, Nedd4-2 selectively reduced ENaC expression at the cell surface but did not alter the quantity of immature ENaC in the biosynthetic pathway. Finally, Nedd4-2 induced degradation of the cell surface pool of ENaC. Together, the data suggest a model in which Nedd4-2 binds to and ubiquitinates ENaC at the cell surface, which targets surface ENaC for degradation, and thus, reduces epithelial Na+ transport.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Snyder, PM (corresponding author), Univ Iowa, Coll Med, 371 EMRB, Iowa City, IA 52242 USA.	peter-snyder@uiowa.edu						BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Hampe C, 2006, HUM MOL GENET, V15, P2059, DOI 10.1093/hmg/ddl131; Itani OA, 2005, AM J PHYSIOL-RENAL, V289, pF334, DOI 10.1152/ajprenal.00394.2004; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Knight KK, 2006, P NATL ACAD SCI USA, V103, P2805, DOI 10.1073/pnas.0511184103; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Malik B, 2005, AM J PHYSIOL-RENAL, V289, pF107, DOI 10.1152/ajprenal.00179.2002; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Schild L, 2004, REV PHYSIOL BIOCH P, V151, P93, DOI 10.1007/s10254-004-0023-7; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Wang H, 2006, J BIOL CHEM, V281, P14129, DOI 10.1074/jbc.M512511200; Zhou RF, 2005, J BIOL CHEM, V280, P4518, DOI 10.1074/jbc.M411053200	27	158	161	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20207	20212		10.1074/jbc.M611329200	http://dx.doi.org/10.1074/jbc.M611329200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17502380	hybrid			2022-12-25	WOS:000247819300022
J	Ko, MH; Puglielli, L				Ko, Mi Hee; Puglielli, Luigi			The sterol carrier protein SCP-x/Pro-SCP-2 gene has transcriptional activity and regulates the Alzheimer disease gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PEPTIDE GENERATION; BINDING-SITE; MEMBRANE; DOMAIN; CELLS; IDENTIFICATION; LOCALIZATION; RESOLUTION; PROMOTER; RECEPTOR	The sterol carrier protein SCP-x/pro-SCP-2 gene is a fusion gene having two initiation sites that generate a long (SCP-x; 58.9-kDa) and a short (pro-SCP- 2; 15.4-kDa) product, both containing the common SCP-2 module at the C terminus. Here, we show that SCP-x is processed on the peroxisomal surface to liberate a short C-terminal product of 12.9 kDa. This fragment has DNA binding activity in vivo and in vitro, as assessed by chromatin immunoprecipitation analysis, DNA-protein pull-down, electrophoretic mobility shift assay, and luciferase reporter activity. In addition, it is preferentially found in the nucleus where it regulates the transcription of CD147, the regulatory subunit of the Alzheimer disease gamma-secretase. Overexpression of SCP-x increased, whereas antisense oligonucleotides against scp-x decreased, the generation of the above transcription factor. Both biochemical and genetic approaches indicate that pro-SCP-2 acts as a competitive inhibitor of SCP- x processing, thereby controlling the release of the 12.9-kDa transcriptionally active fragment. The transcription regulatory function of proSCP-2 requires a peroxisomal targeting sequence at the C terminus and a 20-amino acid leading sequence at the N terminus. Finally, pro-SCP- 2 has also cholesterol carrier activity, which is functionally separated from the transcription regulatory one. In conclusion, we have identified two novel functions (transcriptional and transcription regulatory) of the SCP-x/pro-SCP-2 gene that have impact on gamma-secretase activity.	Univ Wisconsin, Dept Med, Madison, WI 53705 USA; Vet Affairs Med Ctr, Geriatr Res Educ Clin Ctr, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Puglielli, L (corresponding author), Univ Wisconsin, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA.	lp1@medicine.wisc.edu						Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; Brissette L, 1996, BIOCHEM J, V318, P841, DOI 10.1042/bj3180841; Costantini C, 2005, BIOCHEM J, V391, P59, DOI 10.1042/BJ20050700; Costantini C, 2006, EMBO J, V25, P1997, DOI 10.1038/sj.emboj.7601062; Das S, 2006, J BIOL CHEM, V281, P3244, DOI 10.1074/jbc.M510612200; Della Ragione F, 2003, J BIOL CHEM, V278, P23360, DOI 10.1074/jbc.M300771200; Dyer DH, 2003, J BIOL CHEM, V278, P39085, DOI 10.1074/jbc.M306214200; Edqvist J, 2006, J MOL EVOL, V62, P292, DOI 10.1007/s00239-005-0086-3; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Guo HM, 1998, GENE, V220, P99, DOI 10.1016/S0378-1119(98)00400-4; Haapalainen AM, 2001, J MOL BIOL, V313, P1127, DOI 10.1006/jmbi.2001.5084; Huang H, 2002, BIOCHEMISTRY-US, V41, P12149, DOI 10.1021/bi0260536; Lan Q, 2004, J LIPID RES, V45, P1468, DOI 10.1194/jlr.M400003-JLR200; Lensink MF, 2002, J MOL BIOL, V323, P99, DOI 10.1016/S0022-2836(02)00939-7; Liang L, 2002, GENE, V282, P75, DOI 10.1016/S0378-1119(01)00847-2; OHBA T, 1995, BIOCHEMISTRY-US, V34, P10660, DOI 10.1021/bi00033a042; OHBA T, 1994, GENOMICS, V24, P370, DOI 10.1006/geno.1994.1630; Puglielli L, 1996, BIOCHEM J, V317, P681, DOI 10.1042/bj3170681; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Puglielli L, 2008, NEUROBIOL AGING, V29, P795, DOI 10.1016/j.neurobiolaging.2007.01.010; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Schroeder F, 2000, J BIOL CHEM, V275, P25547, DOI 10.1074/jbc.M000431200; Shetty S, 2000, J BIOL CHEM, V275, P13771, DOI 10.1074/jbc.275.18.13771; Vetrivel KS, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-4; Zanlungo S, 2000, GASTROENTEROLOGY, V119, P1708, DOI 10.1053/gast.2000.20198; Zhou SX, 2005, P NATL ACAD SCI USA, V102, P7499, DOI 10.1073/pnas.0502768102	31	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19742	19752		10.1074/jbc.M611426200	http://dx.doi.org/10.1074/jbc.M611426200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17485462	hybrid			2022-12-25	WOS:000247650600049
J	Wang, LF; Harris, TE; Roth, RA; Lawrence, JC				Wang, Lifu; Harris, Thurl E.; Roth, Richard A.; Lawrence, John C., Jr.			PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TARGET; RAPAMYCIN MTOR; CELL-GROWTH; PHAS-I; DISTINCT ROLES; PHOSPHORYLATION; RAPTOR; TOR; INSULIN; AKT	Mammalian target of rapamycin ( mTOR) functions in two distinct signaling complexes, mTORC1 and mTORC2. In response to insulin and nutrients, mTORC1, consisting of mTOR, raptor (regulatory-associated protein of mTOR), and mLST8, is activated and phosphorylates eukaryotic initiation factor 4E-binding protein (4EBP) and p70 S6 kinase to promote protein synthesis and cell size. Previously we found that activation of mTOR kinase in response to insulin was associated with increased 4EBP1 binding to raptor. Here we identify prolinerich Akt substrate 40 (PRAS40) as a binding partner for mTORC1. A putative TOR signaling motif, FVMDE, is identified in PRAS40 and shown to be required for interaction with raptor. Insulin stimulation markedly decreases the level of PRAS40 bound by mTORC1. Recombinant PRAS40 inhibits mTORC1 kinase activity in vivo and in vitro, and this inhibition depends on PRAS40 association with raptor. Furthermore, decreasing PRAS40 expression by short hairpin RNA enhances 4E-BP1 binding to raptor, and recombinant PRAS40 competes with 4E-BP1 binding to raptor. We, therefore, propose that PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.	Univ Virginia Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA; Stanford Univ, Sch Med, Dept Chem & Syst Biol, Stanford, CA 94305 USA	University of Virginia; Stanford University	Wang, LF (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, PO Box 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	lw6j@virginia.edu	wang, lifu/E-1436-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK052753] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52753, DK28312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; HARRIS TE, 2003, SCI STKE 2003; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang LF, 2006, J BIOL CHEM, V281, P24293, DOI 10.1074/jbc.M603566200; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979	36	349	362	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					20036	20044		10.1074/jbc.M702376200	http://dx.doi.org/10.1074/jbc.M702376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17510057	hybrid			2022-12-25	WOS:000247650600077
J	Shen, YQ; Khusial, PR; Li, X; Ichikawa, H; Moreno, AP; Goldberg, GS				Shen, Yongquan; Khusial, P. Raaj; Li, Xun; Ichikawa, Hitoshi; Moreno, Alonso P.; Goldberg, Gary S.			Src utilizes Cas to block gap junctional communication mediated by connexin43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRK-ASSOCIATED SUBSTRATE; TYROSINE PHOSPHORYLATION SITES; FOCAL ADHESION KINASE; C6 GLIOMA-CELLS; V-SRC; INTERCELLULAR COMMUNICATION; IN-VIVO; TRANSFORMED-CELLS; TUMOR-CELLS; GROWTH	The Src tyrosine kinase phosphorylates Cas (Crk-associated substrate) to confer anchorage independence and invasive growth potential to transformed cells. Gap junctional communication is often lower between aggressive tumor cells compared with normal or benign precursors. The gap junction protein connexin43 (Cx43) is a tumor suppressor that can inhibit tumor cell growth. Src can phosphorylate Cx43 to block gap junctional communication between transformed cells. However, mechanisms by which this event actually closes intercellular channels have not been clearly defined. Here, we report that Src and Cas associate with each other at intercellular junctions. In addition, Cas is required for Src to reduce dye transfer and electrical coupling between cells expressing Cx43. Thus, Src utilizes Cas to inhibit gap junctional communication mediated by Cx43. This finding introduces a novel role of the Cas focal adhesion linker protein in the gap junction complex. This observation may help explain how gap junctional communication can be suppressed between malignant and metastatic tumor cells.	Univ Med & Dent New Jersey, Ctr Sci, Dept Mol Biol, Stratford, NJ 08084 USA; Natl Canc Ctr, Res Inst, Canc Transcriptome Project, Chuo Ku, Tokyo 1040045, Japan; Univ Utah, Nora Eccles Harrison Cardiovasc Res&Training Inst, Salt Lake City, UT 84112 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; National Cancer Center - Japan; Utah System of Higher Education; University of Utah	Goldberg, GS (corresponding author), Univ Med & Dent New Jersey, Ctr Sci, Dept Mol Biol, 2 Med Ctr Dr, Stratford, NJ 08084 USA.	garygoldberg@comcast.net			NCI NIH HHS [CA88805] Funding Source: Medline; NEI NIH HHS [EY014479] Funding Source: Medline; NHLBI NIH HHS [HL63969] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088805] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R03EY014479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063969] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander DB, 2003, CURR MED CHEM, V10, P2045, DOI 10.2174/0929867033456927; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Burnham MR, 1996, ONCOGENE, V12, P2467; Duffy HS, 2004, CIRC RES, V94, P215, DOI 10.1161/01.RES.0000113924.06926.11; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goldberg GS, 2000, CANCER RES, V60, P6018; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; GOLDBERG GS, 1995, BIOTECHNIQUES, V18, P490; GOLDBERG GS, 1993, BIOCHEM J, V295, P735, DOI 10.1042/bj2950735; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Goldberg GS, 2001, METH MOL B, V154, P329; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Huang RP, 1998, CANCER RES, V58, P5089; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jansen LAM, 1996, CARCINOGENESIS, V17, P1527, DOI 10.1093/carcin/17.7.1527; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Laird DW, 1999, CANCER RES, V59, P4104; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; Lin R, 2006, CELL COMMUN ADHES, V13, P199, DOI 10.1080/15419060600848516; Loo LWM, 1999, MOL CARCINOGEN, V25, P187, DOI 10.1002/(SICI)1098-2744(199907)25:3<187::AID-MC5>3.3.CO;2-F; Naus CC, 2005, GAP JUNCTIONS IN DEVELOPMENT AND DISEASE, P253, DOI 10.1007/3-540-28621-7_12; Naus CCG, 2002, CAN J PHYSIOL PHARM, V80, P136, DOI 10.1139/Y02-009; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Patwardhan P, 2006, J BIOL CHEM, V281, P20689, DOI 10.1074/jbc.M602311200; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Roginskaya V, 1999, LEUKEMIA, V13, P855, DOI 10.1038/sj.leu.2401429; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Shen YQ, 2006, CANCER RES, V66, P1543, DOI 10.1158/0008-5472.CAN-05-3152; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Sieg DJ, 1999, J CELL SCI, V112, P2677; Singh D, 2005, J BIOL CHEM, V280, P30416, DOI 10.1074/jbc.M506799200; Sohl G, 2004, CARDIOVASC RES, V62, P228, DOI 10.1016/j.cardiores.2003.11.013; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	54	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18914	18921		10.1074/jbc.M608980200	http://dx.doi.org/10.1074/jbc.M608980200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17488714	Green Published, hybrid			2022-12-25	WOS:000247475300032
J	Qanungo, S; Starke, DW; Pai, HV; Mieyal, JJ; Nieminen, AL				Qanungo, Suparna; Starke, David W.; Pai, Harish V.; Mieyal, John J.; Nieminen, Anna-Liisa			Glutathione supplementation potentiates hypoxic apoptosis by S-glutathionylation of p65-NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACETYL-L-CYSTEINE; REDOX SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; PROTEIN-THIOLS; THIOLTRANSFERASE GLUTAREDOXIN; CRYSTAL-STRUCTURE; NITRIC-OXIDE; ACTIVATION; EXPRESSION	In murine embryonic fibroblasts, N-acetyl-L-cysteine (NAC), a GSH generating agent, enhances hypoxic apoptosis by blocking the NF kappa B survival pathway (Qanungo, S., Wang, M., and Nieminen, A. L. (2004) J. Biol. Chem. 279, 50455-50464). Here, we examined sulfhydryl modifications of the p65 subunit of NF kappa B that are responsible for NF kappa B inactivation. In MIA PaCa-2 pancreatic cancer cells, hypoxia increased p65-NF kappa B DNA binding and NF kappa B transactivation by 2.6- and 2.8-fold, respectively. NAC blocked these events without having an effect on p65-NF kappa B protein levels and p65-NF kappa B nuclear translocation during hypoxia. Pharmacological inhibition of the NF kappa B pathway also induced hypoxic apoptosis, indicating that the NF kappa B signaling pathway is a major protective mechanism against hypoxic apoptosis. In cell lysates after hypoxia and treatment with N-ethylmaleimide (thiol alkylating agent), dithiothreitol (disulfide reducing agent) was not able to increase binding of p65-NF kappa B to DNA, suggesting that most sulfhydryls in p65-NF kappa B protein were in reduced and activated forms after hypoxia, thereby being blocked by N-ethylmaleimide. In contrast, with hypoxic cells that were also treated with NAC, dithiothreitol increased p65-NF kappa B DNA binding. Glutaredoxin (GRx), which specifically catalyzes reduction of protein-SSG mixed disulfides, reversed inhibition of p65-NF kappa B DNA binding in extracts from cells treated with hypoxia plus NAC and restored NF kappa B activity. This finding indicated that p65-NF kappa B-SSG was formed in situ under hypoxia plus NAC conditions. In cells, knock-down of endogenous GRx1, which also promotes protein glutathionylation under hypoxic radical generating conditions, prevented NAC-induced NF kappa B inactivation and hypoxic apoptosis. The results indicate that GRx-dependent S-glutathionylation of p65-NF kappa B is most likely responsible for NAC-mediated NF kappa B inactivation and enhanced hypoxic apoptosis.	Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Dept Anat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Nieminen, AL (corresponding author), 3-134 Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.	axn25@case.edu			NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885, R01AG024413] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA43703] Funding Source: Medline; NIA NIH HHS [R01 AG024413, P01 AG15885] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berkowitz B, 2002, J BIOL CHEM, V277, P24694, DOI 10.1074/jbc.M200006200; Biaglow JE, 2006, RADIAT RES, V165, P307, DOI 10.1667/RR3505.1; Biswas S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI 10.1016/j.bcp.2005.10.044; Brar SS, 2004, MOL CANCER THER, V3, P1049; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Chiueh CC, 1999, ANN NY ACAD SCI, V890, P301, DOI 10.1111/j.1749-6632.1999.tb08007.x; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Cotgreave IA, 2002, METHOD ENZYMOL, V348, P175, DOI 10.1016/S0076-6879(02)48636-3; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; GALLOGLY MM, 2007, IN PRESS CURR OPIN P; Ghezzi P, 2005, BIOCHEM SOC T, V33, P1378, DOI 10.1042/BST0331378; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; Guo GW, 2006, ANTIOXID REDOX SIGN, V8, P911, DOI 10.1089/ars.2006.8.911; Huang DB, 2005, J MOL BIOL, V346, P147, DOI 10.1016/j.jmb.2004.11.042; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; Huxford T, 1999, COLD SPRING HARB SYM, V64, P533, DOI 10.1101/sqb.1999.64.533; Jiang BB, 2000, HYPERTENSION, V35, P914, DOI 10.1161/01.HYP.35.4.914; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; Kabe Y, 2005, ANTIOXID REDOX SIGN, V7, P395, DOI 10.1089/ars.2005.7.395; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Li YQ, 2006, ACTA PHARMACOL SIN, V27, P339, DOI 10.1111/j.1745-7254.2006.00264.x; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Moodie FM, 2004, FASEB J, V18, P1897, DOI 10.1096/fj.04-1506fje; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Qanungo S, 2004, J BIOL CHEM, V279, P50455, DOI 10.1074/jbc.M406749200; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Sarkar A, 2004, J BIOL CHEM, V279, P33768, DOI 10.1074/jbc.M403424200; Shackelford RE, 2005, ANTIOXID REDOX SIGN, V7, P940, DOI 10.1089/ars.2005.7.940; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Shin HM, 2004, FEBS LETT, V571, P50, DOI 10.1016/j.febslet.2004.06.056; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; Starke DW, 2003, J BIOL CHEM, V278, P14607, DOI 10.1074/jbc.M210434200; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Vaupel P, 2005, TRANSFUS CLIN BIOL, V12, P5, DOI 10.1016/j.tracli.2004.11.005; Wang CY, 1999, MOL CELL BIOL, V19, P5923; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; Zhu S, 1998, ENVIRON HEALTH PERSP, V106, P1157, DOI 10.2307/3433979	46	132	136	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18427	18436		10.1074/jbc.M610934200	http://dx.doi.org/10.1074/jbc.M610934200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17468103	hybrid			2022-12-25	WOS:000247302000049
J	Lee, HH; Behringer, RR				Lee, Hu-Hui; Behringer, Richard R.			Conditional Expression of Wnt4 during Chondrogenesis Leads to Dwarfism in Mice	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR-3; VEGF; PROLIFERATION; ANGIOGENESIS; CHONDROCYTES; PATHWAY; LACKING; KIDNEY; ROLES	Wnts are expressed in the forming long bones, suggesting roles in skeletogenesis. To examine the action of Wnts in skeleton formation, we developed a genetic system to conditionally express Wnt4 in chondrogenic tissues of the mouse. A mouse Wnt4 cDNA was introduced into the ubiquitously expressed Rosa26 (R26) locus by gene targeting in embryonic stem (ES) cells. The expression of Wnt4 from the R26 locus was blocked by a neomycin selection cassette flanked by loxP sites (floxneo) that was positioned between the Rosa26 promoter and the Wnt4 cDNA, creating the allele designated R26(floxneoWnt4). Wnt4 expression was activated during chondrogenesis using Col2a1-Cre transgenic mice that express Cre recombinase in differentiating chondrocytes. R26(floxneoWnt4); Col2a1-Cre double heterozygous mice exhibited a growth deficiency, beginning approximately 7 to 10 days after birth, that resulted in dwarfism. In addition, they also had craniofacial abnormalities, and delayed ossification of the lumbar vertebrae and pelvic bones. Histological analysis revealed a disruption in the organization of the growth plates and a delay in the onset of the primary and secondary ossification centers. Molecular studies showed that Wnt4 overexpression caused decreased proliferation and altered maturation of chondrocytes. In addition, R26(floxneoWnt4); Col2a1-Cre mice had decreased expression of vascular endothelial growth factor (VEGF). These studies demonstrate that Wnt4 overexpression leads to dwarfism in mice. The data indicate that Wnt4 levels must be regulated in chondrocytes for normal growth plate development and skeletogenesis. Decreased VEGF expression suggests that defects in vascularization may contribute to the dwarf phenotype.	[Lee, Hu-Hui; Behringer, Richard R.] Univ Texas MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Behringer, RR (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.	rrb@mdanderson.org			National Institutes of Health (NIH) [AR42919, CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health (NIH) grant AR42919 to R. R. B. Veterinary and DNA sequencing resources were supported by the NIH Cancer Center Support Grant CA16672.	ALBECHT U, 1997, MOL CELLULAR METHODS, P23; Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen L, 2001, HUM MOL GENET, V10, P457, DOI 10.1093/hmg/10.5.457; Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; Enomoto-Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704; Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Ivanova A, 2005, GENESIS, V43, P129, DOI 10.1002/gene.20162; Jager R, 2004, GENESIS, V38, P145, DOI 10.1002/gene.20014; Jeays-Ward K, 2003, DEVELOPMENT, V130, P3663, DOI 10.1242/dev.00591; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Kitagaki J, 2003, OSTEOARTHR CARTILAGE, V11, P36, DOI 10.1053/joca.2002.0863; Kwan KM, 2002, GENESIS, V32, P49, DOI 10.1002/gene.10068; Lako M, 1998, GENE, V219, P101, DOI 10.1016/S0378-1119(98)00393-X; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Lim J, 2005, GENESIS, V42, P150, DOI 10.1002/gene.20142; Lin CL, 2006, J AM SOC NEPHROL, V17, P2812, DOI 10.1681/ASN.2005121355; Lyons JP, 2004, EXP CELL RES, V298, P369, DOI 10.1016/j.yexcr.2004.04.036; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; Maurus D, 2005, EMBO J, V24, P1181, DOI 10.1038/sj.emboj.7600603; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Nagy A., 2003, MANIPULATING MOUSE E; Naski MC, 1998, DEVELOPMENT, V125, P4977; Osafune K, 2006, DEVELOPMENT, V133, P151, DOI 10.1242/dev.02174; Ovchinnikov DA, 2000, GENESIS, V26, P145, DOI 10.1002/(SICI)1526-968X(200002)26:2<145::AID-GENE14>3.0.CO;2-C; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Spater D, 2006, DEVELOPMENT, V133, P3039, DOI 10.1242/dev.02471; Spater D, 2006, EUR CELLS MATER, V12, P71; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; Yoon BS, 2005, P NATL ACAD SCI USA, V102, P5062, DOI 10.1073/pnas.0500031102; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; Zelzer E, 2002, DEVELOPMENT, V129, P1893; Zhang XB, 2001, CANCER RES, V61, P6050; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	55	30	32	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e450	10.1371/journal.pone.0000450	http://dx.doi.org/10.1371/journal.pone.0000450			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505543	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445900009
J	Marneros, AG; She, H; Zambarakji, H; Hashizume, H; Connolly, EJ; Kim, I; Gragoudas, ES; Miller, JW; Olsen, BR				Marneros, Alexander G.; She, Haicheng; Zambarakji, Hadi; Hashizume, Hiroya; Connolly, Edward J.; Kim, Ivana; Gragoudas, Evangelos S.; Miller, Joan W.; Olsen, Bjorn R.			Endogenous endostatin inhibits choroidal neovascularization	FASEB JOURNAL			English	Article						angiogenesis; collagen XVIII; Bruch's membrane; age-related macular degeneration	ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; COLLAGEN-XVIII; MACULAR DEGENERATION; TUMOR-GROWTH; FACTOR VEGF; BASEMENT-MEMBRANE; FACTOR EXPRESSION; KNOBLOCH-SYNDROME; AGE	Endostatin, a fragment of the basement membrane component collagen XVIII, exhibits antiangiogenic properties in vitro and in vivo when high doses are administered. It is not known whether endogenous endostatin at physiological levels has a protective role as an inhibitor of pathological angiogenesis, such as choroidal neovascularization ( CNV) in age- related macular degeneration. Using a laser injury model, we induced CNV in mice lacking collagen XVIII/ endostatin and in control mice. CNV lesions in mutant mice were similar to 3-fold larger than in control mice and showed increased vascular leakage. These differences were independent of age- related changes at the choroid-retina interface. Ultrastructural analysis of the choroidal vasculature in mutant mice excluded morphological vascular abnormalities as a cause for the larger CNV lesions. When recombinant endostatin was administered to collagen XVIII/ endostatin- deficient mice, CNV lesions were similar to those seen in control mice. In control mice treated with recombinant endostatin, CNV lesions were almost undetectable. These findings demonstrate that endogenous endostatin is an inhibitor of induced angiogenesis and that administration of endostatin potently inhibits CNV growth and vascular leakage. Endostatin may have a regulatory role in the pathogenesis of CNV and could be used therapeutically to inhibit growth and leakage of CNV lesions.	Harvard Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; Harvard Med Sch, Dept Cell Biol, Boston, MA USA; Harvard Med Sch, Massachusetts Eye & Ear Infirm, Angiogenesis Lab & Retina Serv, Boston, MA USA; Niigata Univ, Postgrad Sch Med & Dental Sci, Div Microscop Anatomy & Bioimaging, Niigata, Japan	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Niigata University	Marneros, AG (corresponding author), Harvard Sch Dent Med, Dept Dev Biol, 188 Longwood Ave, Boston, MA 02115 USA.	alexander_marneros@yahoo.com	Zambarakji, Hadi/AAM-6095-2020	Marneros, Alexander/0000-0003-3866-020X; Kim, Ivana/0000-0003-0310-6129; Miller, Joan/0000-0003-2046-3996	NEI NIH HHS [P30EY14104] Funding Source: Medline; NIAMS NIH HHS [AR36820] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036820, R01AR036820] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582; BERNFIELD M, 1984, CIBA F SYMP, V108, P179; Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007; Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862; Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3; Brankin B, 2005, EXP EYE RES, V81, P22, DOI 10.1016/j.exer.2005.01.005; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X; Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; HOOK M, 1984, CIBA F SYMP, V108, P44; Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7; Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723; Kisker O, 2001, CANCER RES, V61, P7669; Li Q, 2004, AM J PATHOL, V165, P415, DOI 10.1016/S0002-9440(10)63307-X; Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X; Marneros AG, 2005, FASEB J, V19, P716, DOI 10.1096/fj.04-2134rev; Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014; Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5; Nicolo M, 2003, AM J OPHTHALMOL, V135, P7, DOI 10.1016/S0002-9394(02)01839-1; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1; Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051; Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje; Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641; Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267	40	54	60	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2007	21	14					3809	3818		10.1096/fj.07-8422com	http://dx.doi.org/10.1096/fj.07-8422com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	236DP	17526870				2022-12-25	WOS:000251283500005
J	Giagkousiklidis, S; Vellanki, SH; Debatin, KM; Fulda, S				Giagkousiklidis, S.; Vellanki, S. H.; Debatin, K-M; Fulda, S.			Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition	ONCOGENE			English	Article						apoptosis; radiotherapy; IAPs; pancreatic cancer	RADIATION-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; X-LINKED INHIBITOR; PROTEIN XIAP; SURVIVIN; CANCER; MITOCHONDRIA; ACTIVATOR	Resistance of pancreatic cancer to current treatments including radiotherapy remains a major challenge in oncology and may be caused by defects in apoptosis programs. Since 'inhibitor of apoptosis proteins' (IAPs) block apoptosis at the core of the apoptotic machinery by inhibiting caspases, therapeutic modulation of IAPs could tackle a key resistance mechanism. Here, we report that targeting X-linked inhibitor of apoptosis (XIAP) by RNA-interference-mediated knockdown or overexpression of second mitochondria-derived activator of caspase significantly enhanced apoptosis and markedly reduced clonogenic growth of pancreatic carcinoma cells upon gamma-irradiation. Analysis of signaling pathways revealed that antagonizing XIAP increased activation of caspase-2, -3, -8 and -9 and loss of mitochondrial membrane potential upon gamma-irradiation. Interestingly, inhibition of caspases also reduced the cooperative effect of XIAP targeting and gamma-irradiation to trigger mitochondrial perturbations, suggesting that XIAP controls a feedback mitochondrial amplification loop by regulating caspase activity. Importantly, our data demonstrate for the first time that small molecule XIAP inhibitors sensitized pancreatic carcinoma cells for gamma-irradiation-induced apoptosis, whereas they had no effect on gamma-irradiation-mediated apoptosis of non-malignant fibroblasts indicating some tumor specification. In conclusion, targeting XIAP, for example by small molecules, is a promising novel approach to enhance radiosensitivity of pancreatic cancer that warrants further investigation.	Univ Childrens Hosp, D-89075 Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Cao C, 2004, ONCOGENE, V23, P7047, DOI 10.1038/sj.onc.1207929; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; FULDA S, 2006, APOPTOSIS CANC THERA, P849; Fulda S, 2006, RECENT PAT ANTI-CANC, V1, P81, DOI 10.2174/157489206775246539; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; JENDROSSEK V, 2006, APOPTOSIS CANC THERA, P1049; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vogler M, 2007, ONCOGENE, V26, P248, DOI 10.1038/sj.onc.1209776; Vogler M, 2005, ONCOGENE, V24, P7190, DOI 10.1038/sj.onc.1208876; Westphal Sabine, 2003, Mol Cancer, V2, P6, DOI 10.1186/1476-4598-2-6; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004	28	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					7006	7016		10.1038/sj.onc.1210502	http://dx.doi.org/10.1038/sj.onc.1210502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17471230				2022-12-25	WOS:000250412200006
J	Joshi, MB; Ivanov, D; Philippova, M; Erne, P; Resink, TJ				Joshi, Manjunath B.; Ivanov, Danila; Philippova, Maria; Erne, Paul; Resink, Therese J.			Integrin-linked kinase is an essential mediator for T-cadherin-dependent signaling via Akt and GSK3 beta in endothelial cells	FASEB JOURNAL			English	Article						GPI-anchored protein; signal transduction; active beta-catenin accumulation; proliferation; survival	GLYCOGEN-SYNTHASE KINASE-3-BETA; PROTEIN-KINASE; GROWTH-FACTOR; BETA-CATENIN; EXTRACELLULAR-MATRIX; TUMOR ANGIOGENESIS; PLASMA-MEMBRANE; VASCULAR CELLS; LIPID RAFTS; IN-VITRO	Glycosylphosphatidylinositol-anchored T-cadherin (T-cad) influences several parameters of angiogenesis including endothelial cell (EC) differentiation, migration, proliferation, and survival. This presupposes signal transduction networking via mediatory regulators and molecular adaptors since T-cad lacks transmembrane and cytosolic domains. Here, using pharmacological inhibition of PI3K, adenoviral-mediated T-cad-overexpression, siRNA-mediated T-cad-depletion, and agonistic antibody-mediated ligation, we demonstrate signaling by T-cad through PI3K-Akt-GSK3 beta pathways in EC. T-cad-overexpressing EC exhibited increased levels and nuclear accumulation of active beta-catenin, which was transcriptionally active as shown by increased Lef/ Tcf reporter activity and cyclin D1 levels. Cotransduction of EC with constitutively active GSK3 beta (S9A-GSK3 beta) abrogated the stimulatory effects of T-cad on active beta-catenin accumulation, proliferation, and survival. Integrin-linked kinase (ILK), a membrane proximal upstream regulator of Akt and GSK3 beta, was considered a candidate signaling mediator for T-cad. T-cad was present in anti-ILK immunoprecipitates, and confocal microscopy revealed colocalization of T-cad and ILK within lamellipodia of migrating cells. ILK-siRNA abolished T-cad-dependent effects on (Ser-473)Akt/ (Ser-9)GSK3 beta phosphorylation, active beta-catenin accumulation, and survival. We conclude ILK is an essential mediator for T-cad signaling via Akt and GSK3 beta in EC. This is the first demonstration that ILK can regulate inward signaling by GPI-anchored proteins. Furthermore, ILK-GSK3 beta-dependent modulation of active beta-catenin levels by GPI-anchored T-cad represents a novel mechanism for controlling cellular beta-catenin activity.	Univ Basel Hosp, Cardiovasc Labs, Res Dept, CH-4031 Basel, Switzerland; Luzern Kantonsspital, Div Cardiol, Luzern, Switzerland	University of Basel; Lucerne Cantonal Hospital	Resink, TJ (corresponding author), Univ Basel Hosp, Cardiovasc Labs, Res Dept, Hebelstr 20, CH-4031 Basel, Switzerland.	therese-j.resink@unibas.ch	Joshi, Manjunath B/G-2052-2012; Filippova, Maria/GXH-7313-2022	Joshi, Manjunath/0000-0002-1310-5480; Filippova, Maria/0000-0003-3124-3155				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cavallaro U, 2006, EXP CELL RES, V312, P659, DOI 10.1016/j.yexcr.2005.09.019; Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Cho HJ, 2005, ARTERIOSCL THROM VAS, V25, P1154, DOI 10.1161/01.ATV.0000164312.20008.93; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Friedrich EB, 2004, MOL CELL BIOL, V24, P8134, DOI 10.1128/MCB.24.18.8134-8144.2004; Gong R, 2006, KIDNEY INT, V69, P1166, DOI 10.1038/sj.ki.5000246; Gonzalez E, 2006, J BIOL CHEM, V281, P3210, DOI 10.1074/jbc.M510434200; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Huang JA, 2006, BIOCHEM J, V396, P193, DOI 10.1042/BJ20051772; Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Ivanov D, 2001, HISTOCHEM CELL BIOL, V115, P231; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Joshi MB, 2005, FASEB J, V19, P1737, DOI 10.1096/fj.05-3834fje; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kudrjashova E, 2002, HISTOCHEM CELL BIOL, V118, P281, DOI 10.1007/s00418-002-0463-6; Kuzmenko YS, 1998, FEBS LETT, V434, P183, DOI 10.1016/S0014-5793(98)00977-6; Lee SP, 2006, CIRCULATION, V114, P150, DOI 10.1161/CIRCULATIONAHA.105.595918; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Oloumi A, 2006, ONCOGENE, V25, P7747, DOI 10.1038/sj.onc.1209752; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Philippova M, 2005, FASEB J, V19, P588, DOI 10.1096/fj.04-2430fje; Philippova M, 2003, HISTOCHEM CELL BIOL, V120, P353, DOI 10.1007/s00418-003-0584-6; Philippova M, 2006, ARTERIOSCL THROM VAS, V26, P2222, DOI 10.1161/01.ATV.0000238356.20565.92; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; Riou P, 2006, FASEB J, V20, P2291, DOI 10.1096/fj.06-6085com; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; Vouret-Craviari V, 2004, J CELL SCI, V117, P4559, DOI 10.1242/jcs.01331; Watanabe M, 2005, BIOL PROCED ONLINE, V7, P41, DOI 10.1251/bpo104; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wyder L, 2000, CANCER RES, V60, P4682; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x; Zervas CG, 2002, CURR BIOL, V12, pR350, DOI 10.1016/S0960-9822(02)00856-4; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	62	49	53	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3083	3095		10.1096/fj.06-7723com	http://dx.doi.org/10.1096/fj.06-7723com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17485554				2022-12-25	WOS:000249781600010
J	Islinger, M; Luers, GH; Li, KW; Loos, M; Volkl, A				Islinger, Markus; Luers, Georg H.; Li, Ka Wan; Loos, Maarten; Volkl, Alfred			Rat liver peroxisomes after fibrate treatment - A survey using quantitative mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; ISOLATED SUBCELLULAR MEMBRANES; GLUTATHIONE-S-TRANSFERASE; BETA-OXIDATION; BINDING PROTEIN; GENE-EXPRESSION; MULTIFUNCTIONAL PROTEIN-2; SPECTROPHOTOMETRIC ASSAY; SELECTIVE INDUCTION; PROTEOMIC ANALYSIS	Fibrates are known to induce peroxisome proliferation and the expression of peroxisomal beta-oxidation enzymes. To analyze fibrate-induced changes of complex metabolic networks, we have compared the proteome of rat liver peroxisomes from control and bezafibrate-treated rats. Highly purified peroxisomes were subfractionated, and the proteins of the matrix, peripheral, and integral membrane subfractions thus obtained were analyzed by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass spectrometry after labeling of tryptic peptides with the iTRAQ reagent. By means of this quantitative technique, we were able to identify 134 individual proteins, covering most of the known peroxisomal proteome. Ten predicted new open reading frames were verified by cDNA cloning, and seven of them could be localized to peroxisomes by immunocytochemistry. Moreover, quantitative mass spectrometry substantiated the induction of most of the known peroxisome proliferator-activated receptor alpha-regulated peroxisomal proteins upon treatment with bezafibrate, documenting the suitability of the iTRAQ procedure in larger scale experiments. However, not all proteins reacted to a similar extent but exerted a fibrate-specific induction scheme showing the variability of peroxisome proliferator-activated receptor alpha-transmitted responses to specific ligands. In view of our data, rat hepatic peroxisomes are apparently not specialized to sequester very long chain fatty acids (C22-C26) but rather metabolize preferentially long chain fatty acids (C16-18).	Heidelberg Univ, Dept Anat & Cell Biol, D-69120 Heidelberg, Germany; Univ Marburg, Dept Anat & Cell Biol, D-35033 Marburg, Germany; Vrije Univ Amsterdam, Res Inst Neurosci, NL-1081 HV Amsterdam, Netherlands	Ruprecht Karls University Heidelberg; Philipps University Marburg; Vrije Universiteit Amsterdam	Islinger, M (corresponding author), Heidelberg Univ, Dept Anat & Cell Biol, Im Neuenheimer Feld 307, D-69120 Heidelberg, Germany.	Markus.Islinger@urz.uni-heidelberg.de	Loos, Maarten/A-2768-2012	Loos, Maarten/0000-0003-1629-2928; li, ka wan/0000-0001-6983-5055				ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; Anantharaman V, 2002, FEMS MICROBIOL LETT, V207, P55, DOI 10.1016/S0378-1097(01)00515-8; Andersen JS, 2006, EMBO REP, V7, P874, DOI 10.1038/sj.embor.7400780; ANGERMULLER S, 1987, EUR J CELL BIOL, V45, P137; Antonenkov VD, 2006, BIOCHEM J, V394, P475, DOI 10.1042/BJ20051058; Antonenkov VD, 2004, J CELL SCI, V117, P5633, DOI 10.1242/jcs.01485; AOYAMA T, 1994, BIOCHEM BIOPH RES CO, V201, P1541, DOI 10.1006/bbrc.1994.1879; Baes M, 2000, J BIOL CHEM, V275, P16329, DOI 10.1074/jbc.M001994200; Bagshaw RD, 2005, MOL CELL PROTEOMICS, V4, P133, DOI 10.1074/mcp.M400128-MCP200; Baker VA, 2004, ENVIRON HEALTH PERSP, V112, P428, DOI 10.1289/ehp.6677; BEIER K, 1988, EUR J CELL BIOL, V46, P383; BELL DR, 1992, EUR J BIOCHEM, V206, P979, DOI 10.1111/j.1432-1033.1992.tb17009.x; CHEN NH, 1992, BIOCHEM J, V283, P605, DOI 10.1042/bj2830605; Cornwell PD, 2004, MUTAT RES-FUND MOL M, V549, P131, DOI 10.1016/j.mrfmmm.2003.12.019; FAHIMI HD, 1982, ANN NY ACAD SCI, V386, P111, DOI 10.1111/j.1749-6632.1982.tb21410.x; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; FOWLER S, 1976, J CELL BIOL, V71, P535, DOI 10.1083/jcb.71.2.535; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Goshe MB, 2003, J PROTEOME RES, V2, P153, DOI 10.1021/pr0255607; Helledie T, 2002, J BIOL CHEM, V277, P26821, DOI 10.1074/jbc.M111295200; Hogenboom S, 2003, MOL GENET METAB, V80, P290, DOI 10.1016/S1096-7192(03)00143-4; Honsho M, 2002, J BIOL CHEM, V277, P44513, DOI 10.1074/jbc.M206139200; HORIE S, 1986, J BIOCHEM, V99, P1345, DOI 10.1093/oxfordjournals.jbchem.a135602; HOVIK R, 1989, BIOCHEM J, V263, P297, DOI 10.1042/bj2630297; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Huyghe S, 2006, BBA-MOL CELL BIOL L, V1761, P973, DOI 10.1016/j.bbalip.2006.04.006; Ichida K, 2001, BIOCHEM BIOPH RES CO, V282, P1194, DOI 10.1006/bbrc.2001.4719; INESTROSA NC, 1979, LIFE SCI, V25, P1127, DOI 10.1016/0024-3205(79)90134-6; Islinger M, 2006, PROTEOMICS, V6, P804, DOI 10.1002/pmic.200401347; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; Kovacs WJ, 2001, EUR J BIOCHEM, V268, P4850, DOI 10.1046/j.0014-2956.2001.02409.x; Kurochkin IV, 2007, EMBO J, V26, P835, DOI 10.1038/sj.emboj.7601525; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Latruffe N, 2000, BIOL CELL, V92, P389, DOI 10.1016/S0248-4900(00)01083-2; LAZAROW PB, 1982, FEBS LETT, V150, P307, DOI 10.1016/0014-5793(82)80757-6; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LAZAROW PB, 1977, SCIENCE, V197, P580, DOI 10.1126/science.195342; LEIGHTON F, 1975, J CELL BIOL, V67, P281, DOI 10.1083/jcb.67.2.281; Li HY, 2003, PLANT MOL BIOL, V51, P483, DOI 10.1023/A:1022330304402; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; MIYAUCHI K, 1993, CELL STRUCT FUNCT, V18, P427, DOI 10.1247/csf.18.427; MIYAZAWA S, 1981, J BIOCHEM, V90, P511, DOI 10.1093/oxfordjournals.jbchem.a133499; MOODY DE, 1976, J CELL BIOL, V71, P768, DOI 10.1083/jcb.71.3.768; Morel F, 2004, J BIOL CHEM, V279, P16246, DOI 10.1074/jbc.M313357200; Moser HW, 2000, FRONT BIOSCI, V5, pD298, DOI 10.2741/Moser; NEMALI MR, 1988, CANCER RES, V48, P5316; Ong SE, 2005, NAT CHEM BIOL, V1, P252, DOI 10.1038/nchembio736; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; PILL J, 1992, ARCH TOXICOL, V66, P327, DOI 10.1007/BF01973627; Raymond Gerald V., 1999, Current Opinion in Pediatrics, V11, P572, DOI 10.1097/00008480-199912000-00017; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reguenga C, 1999, BBA-GENE STRUCT EXPR, V1445, P337, DOI 10.1016/S0167-4781(99)00061-5; REMACLE J, 1976, J CELL BIOL, V71, P551, DOI 10.1083/jcb.71.2.551; Richert L, 2003, TOXICOL APPL PHARM, V191, P130, DOI 10.1016/S0041-008X(03)00231-X; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schirmer EC, 2005, TRENDS BIOCHEM SCI, V30, P551, DOI 10.1016/j.tibs.2005.08.003; Schluter A, 2007, NUCLEIC ACIDS RES, V35, pD815, DOI 10.1093/nar/gkl935; Schrader M, 1998, EUR J CELL BIOL, V75, P87, DOI 10.1016/S0171-9335(98)80051-4; SMALL GM, 1985, BIOCHEM J, V227, P205, DOI 10.1042/bj2270205; Thoms S, 2005, FEBS J, V272, P5169, DOI 10.1111/j.1742-4658.2005.04939.x; Van Ael E, 2006, BBA-MOL CELL RES, V1763, P1629, DOI 10.1016/j.bbamcr.2006.08.020; VANBROEKHOVEN A, 1981, BIOCHEM BIOPH RES CO, V100, P305, DOI 10.1016/S0006-291X(81)80097-6; Visser WF, 2007, BIOCHEM J, V401, P365, DOI 10.1042/BJ20061352; VOLKL A, 1985, EUR J BIOCHEM, V149, P257, DOI 10.1111/j.1432-1033.1985.tb08920.x; Wanders RJA, 2006, ANNU REV BIOCHEM, V75, P295, DOI 10.1146/annurev.biochem.74.082803.133329; Weber G, 2004, ELECTROPHORESIS, V25, P1735, DOI 10.1002/elps.200305834; Wu CC, 2003, NAT BIOTECHNOL, V21, P532, DOI 10.1038/nbt819; Yadetie F, 2003, PHYSIOL GENOMICS, V15, P9, DOI 10.1152/physiolgenomics.00064.2003; Zhang XG, 2006, BIOCHEM BIOPH RES CO, V346, P1307, DOI 10.1016/j.bbrc.2006.06.042	70	79	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23055	23069		10.1074/jbc.M610910200	http://dx.doi.org/10.1074/jbc.M610910200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17522052	Green Published, hybrid			2022-12-25	WOS:000248577500008
J	Richard, MN; Deniset, JF; Kneesh, AL; Blackwood, D; Pierce, GN				Richard, Melanie N.; Deniset, Justin F.; Kneesh, Annette L.; Blackwood, David; Pierce, Grant N.			Mechanical stretching stimulates smooth muscle cell growth, nuclear protein import, and nuclear pore expression through mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RATS; BLOOD-VESSELS; COMPLEX; NUCLEOPORINS; STRESS; CYCLE; ATHEROSCLEROSIS; CARDIOMYOCYTES; HYPERTROPHY; ANGIOTENSIN	Although it is known that mechanical stretching of cells can induce significant increases in cell growth and shape, the intracellular signaling pathways that induce this response at the level of the cell nucleus is unknown. The transport of molecules from the cell cytoplasm to the nucleoplasm through the nuclear pore is a key pathway through which gene expression can be controlled in some conditions. It is presently unknown if mechanical stimuli can induce changes in nuclear pore expression and/or function. The purpose of the present investigation was to determine if mechanical stretching of a cell will alter nuclear protein import and the mechanisms that may be responsible. Vascular smooth muscle cells that were mechanically stretched exhibited an increase in proliferating cell nuclear antigen expression, cell number, and cell size within 24-48 h. Cells were microinjected with marker proteins for nuclear import. Nuclear protein import was significantly stimulated in stretched cells when compared with control. This was associated with an increase in the expression of nuclear pore proteins as detected by Western blots. Inhibition of the MAPK pathway blocked the stretch-induced stimulation of both cell proliferation and nuclear protein import. We conclude that nuclear protein import and nuclear pore density can adapt to mechanical stimuli during the process of cell growth through a MAPK-mediated mechanism.	Univ Manitoba, St Boniface Gen Hosp, Fac Med & Pharm,Res Ctr, Dept Physiol,Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba	Pierce, GN (corresponding author), Univ Manitoba, St Boniface Gen Hosp, Fac Med & Pharm,Res Ctr, Dept Physiol,Inst Cardiovasc Sci, 351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	gpierce@sbrc.ca						ADAM SA, 1991, METHOD CELL BIOL, V35, P469; Allen TD, 2000, J CELL SCI, V113, P1651; Bagley S, 2000, J CELL SCI, V113, P3885; Batetta B, 2002, CELL PROLIFERAT, V35, P143; Boehmer T, 2003, P NATL ACAD SCI USA, V100, P981, DOI 10.1073/pnas.252749899; Cheng JJ, 1996, HYPERTENSION, V28, P386, DOI 10.1161/01.HYP.28.3.386; Cornelissen J, 2004, ARTERIOSCL THROM VAS, V24, P451, DOI 10.1161/01.ATV.0000116690.17017.8b; Csermely P, 1995, BBA-REV BIOMEMBRANES, V1241, P425, DOI 10.1016/0304-4157(95)00015-1; Czubryt MP, 2000, J CELL BIOL, V148, P7, DOI 10.1083/jcb.148.1.7; DEVLIN AM, 1995, J HYPERTENS, V13, P211; DEVLIN AM, 1995, J HUM HYPERTENS, V9, P497; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Dzau V J, 1993, Curr Opin Nephrol Hypertens, V2, P27, DOI 10.1097/00041552-199301000-00004; Faustino RS, 2007, MOL PHARMACOL, V71, P438, DOI 10.1124/mol.105.021667; Faustino RS, 2006, CAN J PHYSIOL PHARM, V84, P469, DOI 10.1139/Y05-131; Faustino RS, 2002, METHOD ENZYMOL, V352, P123; HOLLANDER W, 1976, AM J CARDIOL, V38, P786, DOI 10.1016/0002-9149(76)90357-X; Hosokawa H, 2002, BIOL PHARM BULL, V25, P1588, DOI 10.1248/bpb.25.1588; Irace C, 2004, STROKE, V35, P464, DOI 10.1161/01.STR.0000111597.34179.47; Iwasaki H, 2000, AM J PHYSIOL-HEART C, V278, pH521, DOI 10.1152/ajpheart.2000.278.2.H521; Jankowski R, 2000, J PHARMACOL TOXICOL, V44, P421, DOI 10.1016/S1056-8719(00)00119-2; Kleinstreuer C, 2001, CRIT REV BIOMED ENG, V29, P1, DOI 10.1615/CritRevBiomedEng.v29.i1.10; LEE RMKW, 1995, CAN J PHYSIOL PHARM, V73, P574, DOI 10.1139/y95-073; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; Lehoux S, 2003, J BIOMECH, V36, P631, DOI 10.1016/S0021-9290(02)00441-4; Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898-6568(00)00096-6; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; MARKOVICS J, 1974, EXP CELL RES, V85, P443, DOI 10.1016/0014-4827(74)90148-7; MAUL GG, 1977, J CELL BIOL, V74, P492, DOI 10.1083/jcb.74.2.492; MAUL GG, 1972, J CELL BIOL, V55, P433, DOI 10.1083/jcb.55.2.433; MAUL GG, 1980, CYTOGENET CELL GENET, V26, P175, DOI 10.1159/000131439; MAUL GG, 1971, J CELL BIOL, V51, P405, DOI 10.1083/jcb.51.2.405; MAUL HM, 1973, J CELL BIOL, V59, P669, DOI 10.1083/jcb.59.3.669; Oeckler RA, 2003, CIRC RES, V92, P23, DOI 10.1161/01.RES.0000051860.84509.CE; OWENS GK, 1985, CIRC RES, V57, P695, DOI 10.1161/01.RES.57.5.695; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; OWENS GK, 1988, HYPERTENSION, V11, P198, DOI 10.1161/01.HYP.11.2.198; PAULETTO P, 1994, AM J HYPERTENS, V7, P661, DOI 10.1093/ajh/7.7.661; Perez-Terzic C, 2003, CIRC RES, V92, P444, DOI 10.1161/01.RES.0000059415.25070.54; Perez-Terzic C, 1999, CIRC RES, V84, P1292, DOI 10.1161/01.RES.84.11.1292; Quinn TP, 2002, AM J PHYSIOL-LUNG C, V282, pL897, DOI 10.1152/ajplung.00044.2001; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Shaw Anthony, 2003, Current Vascular Pharmacology, V1, P41, DOI 10.2174/1570161033386745; Shyu KG, 2005, CARDIOVASC RES, V68, P405, DOI 10.1016/j.cardiores.2005.06.028; Spofford CM, 2001, AM J PHYSIOL-HEART C, V280, pH1354, DOI 10.1152/ajpheart.2001.280.3.H1354; Zeidan A, 2003, ARTERIOSCL THROM VAS, V23, P1528, DOI 10.1161/01.ATV.0000090129.75275.C2; Zettler ME, 2003, AM J PHYSIOL-HEART C, V284, pH644, DOI 10.1152/ajpheart.00494.2001	48	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23081	23088		10.1074/jbc.M703602200	http://dx.doi.org/10.1074/jbc.M703602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17525165	hybrid			2022-12-25	WOS:000248577500010
J	Cho, YW; Hong, T; Hong, S; Guo, H; Yu, H; Kim, D; Guszczynski, T; Dressler, GR; Copeland, TD; Kalkum, M; Ge, K				Cho, Young-Wook; Hong, Teresa; Hong, SunHwa; Guo, Hong; Yu, Hong; Kim, Doyeob; Guszczynski, Tad; Dressler, Gregory R.; Copeland, Terry D.; Kalkum, Markus; Ge, Kai			PTIP associates with MLL3-and MLL4-containing histone H3 lysine 4 methyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DROSOPHILA-TRITHORAX; ACTIVE CHROMATIN; SET1 COMPLEX; TARGET GENES; METHYLATION; PROTEIN; COACTIVATOR; GROWTH; MLL2	PTIP, a protein with tandem BRCT domains, has been implicated in DNA damage response. However, its normal cellular functions remain unclear. Here we show that while ectopically expressed PTIP is capable of interacting with DNA damage response proteins including 53BP1, endogenous PTIP, and a novel protein PA1 are both components of a Set1-like histone methyltransferase (HMT) complex that also contains ASH2L, RBBP5, WDR5, hDPY-30, NCOA6, SET domain-containing HMTsMLL3 and MLL4, and substoichiometric amount of JmjC domain-containing putative histone demethylase UTX. PTIP complex carries robust HMT activity and specifically methylates lysine 4 (K4) on histone H3. Furthermore, PA1 binds PTIP directly and requires PTIP for interaction with the rest of the complex. Moreover, we show that hDPY-30 binds ASH2L directly. The evolutionarily conserved hDPY-30, ASH2L, RBBP5, and WDR5 likely constitute a subcomplex that is shared by all human Set1-likeHMTcomplexes. In contrast, PTIP, PA1, and UTX specifically associate with the PTIP complex. Thus, in cells without DNA damage agent treatment, the endogenous PTIP associates with a Set1-like HMT complex of unique subunit composition. As histone H3 K4 methylation associates with active genes, our study suggests a potential role of PTIP in the regulation of gene expression.	NIDDK, NIH, Nucl Receptor Biol Sect, Bethesda, MD 20892 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; NCI, Natl Inst Hlth, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); City of Hope; Beckman Research Institute of City of Hope; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ge, K (corresponding author), NIDDK, NIH, Nucl Receptor Biol Sect, Bethesda, MD 20892 USA.	kaig@niddk.nih.gov	Cho, Young-Wook/F-8269-2011; Ge, Kai/H-2810-2019	Ge, Kai/0000-0002-7442-5138; Kalkum, Markus/0000-0002-9506-671X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075003, Z01DK075003, ZIADK047055, ZIADK075017, Z01DK047055] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 DK047055-01, Z01 DK075003-04, Z99 DK999999] Funding Source: Medline; NIDDK NIH HHS [ZIADK075003-06, ZIADK075017-01, ZIADK047055-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Cho EA, 2003, MOL CELL BIOL, V23, P1666, DOI 10.1128/MCB.23.5.1666-1673.2003; Dehe PM, 2006, J BIOL CHEM, V281, P35404, DOI 10.1074/jbc.M603099200; DOU Y, 2006, NAT STRUCT MOL BIOL, V20, P586; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Jowsey PA, 2004, J BIOL CHEM, V279, P55562, DOI 10.1074/jbc.M411021200; Kalkum M, 2003, P NATL ACAD SCI USA, V100, P2795, DOI 10.1073/pnas.0436605100; Kim D, 2007, J AM SOC NEPHROL, V18, P1458, DOI 10.1681/ASN.2006060625; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Lee JH, 2005, J BIOL CHEM, V280, P41725, DOI 10.1074/jbc.M508312200; Lee S, 2006, P NATL ACAD SCI USA, V103, P15392, DOI 10.1073/pnas.0607313103; Mahajan MA, 2005, ENDOCR REV, V26, P583, DOI 10.1210/er.2004-0012; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Milne TA, 2005, P NATL ACAD SCI USA, V102, P14765, DOI 10.1073/pnas.0503630102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Noma K, 2002, P NATL ACAD SCI USA, V99, P16438, DOI 10.1073/pnas.182436399; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schlichter A, 2005, EMBO J, V24, P1222, DOI 10.1038/sj.emboj.7600607; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Shimizu K, 2001, MOL CELL BIOL, V21, P3901, DOI 10.1128/MCB.21.12.3901-3912.2001; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zhang K, 2005, CELL, V122, P723, DOI 10.1016/j.cell.2005.06.021	40	404	425	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20395	20406		10.1074/jbc.M701574200	http://dx.doi.org/10.1074/jbc.M701574200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17500065	Green Accepted, hybrid			2022-12-25	WOS:000247819300042
J	Deikus, G; Bechhofer, DH				Deikus, Gintaras; Bechhofer, David H.			Initiation of decay of Bacillus subtilis trp leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING ATTENUATION PROTEIN; MESSENGER-RNA; ESCHERICHIA-COLI; POLYNUCLEOTIDE PHOSPHORYLASE; TRANSCRIPTION ATTENUATION; DEGRADATION; STRAIN	Transcription termination in the leader region of the Bacillus subtilis trp operon is regulated by binding of the 11-mer TRAP complex to nascent trp RNA, which results in formation of a terminator structure. Rapid decay of trp leader RNA, which is required to release the TRAP complex and maintain a sufficient supply of free TRAP, is mediated by polynucleotide phosphorylase (PNPase). Using purified B. subtilis PNPase, we showed that, when TRAP was present, PNPase binding to the 3' end of trp leader RNA and PNPase digestion of trp leader RNA from the 3' end were inefficient. These results suggested that initiation of trp leader RNA may begin with an endonuclease cleavage upstream of the transcription terminator structure. Such cleavage was observed in vivo. Mutagenesis of nucleotides at the cleavage site abolished processing and resulted in a 4-fold increase in trp leader RNA half-life. This is the first mapping of a decay-initiating endonuclease cleavage site on a native B. subtilis RNA.	NYU, Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University	Bechhofer, DH (corresponding author), NYU, Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, 550 1St Ave, New York, NY 10029 USA.	david.bechhofer@mssm.edu			NIGMS NIH HHS [GM 48804] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; BROSIUS J, 1992, METHOD ENZYMOL, V216, P469; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Coburn GA, 1998, J MOL BIOL, V279, P1061, DOI 10.1006/jmbi.1998.1842; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; Condon C, 2003, MICROBIOL MOL BIOL R, V67, P157, DOI 10.1128/MMBR.67.2.157-174.2003; Deikus G, 2004, P NATL ACAD SCI USA, V101, P2747, DOI 10.1073/pnas.0307343101; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Hambraeus G, 2003, MOL GENET GENOMICS, V269, P706, DOI 10.1007/s00438-003-0883-6; Henkin TM, 2002, BIOESSAYS, V24, P700, DOI 10.1002/bies.10125; Kagedal L., 1998, PROTEIN PURIFICATION, P311; Kossen K, 1999, NUCLEIC ACIDS RES, V27, P3811, DOI 10.1093/nar/27.19.3811; LEDEAUX JR, 1995, J BACTERIOL, V177, P166, DOI 10.1128/jb.177.1.166-175.1995; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LITTAUER UZ, 1980, ENZYMES, P517; Marujo PE, 2003, MOL MICROBIOL, V50, P1283, DOI 10.1046/j.1365-2958.2003.03753.x; Matsunaga J, 1996, MOL MICROBIOL, V22, P977, DOI 10.1046/j.1365-2958.1996.01529.x; Oussenko IA, 2005, J BACTERIOL, V187, P2758, DOI 10.1128/JB.187.8.2758-2767.2005; Sharp JS, 2003, J BACTERIOL, V185, P5372, DOI 10.1128/JB.185.18.5372-5379.2003; Stickney LM, 2005, J BACTERIOL, V187, P7214, DOI 10.1128/JB.187.21.7214-7221.2005; Wang W, 1996, J BACTERIOL, V178, P2375, DOI 10.1128/jb.178.8.2375-2382.1996; Yakhnin AV, 2000, J BIOL CHEM, V275, P4519, DOI 10.1074/jbc.275.6.4519	26	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20238	20244		10.1074/jbc.M702747200	http://dx.doi.org/10.1074/jbc.M702747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17507374	hybrid			2022-12-25	WOS:000247819300026
J	Figueiredo, RT; Fernandez, PL; Mourao-Sa, DS; Porto, BN; Dutra, FF; Alves, LS; Oliveira, MF; Oliveira, PL; Graca-Souza, AV; Bozza, MT				Figueiredo, Rodrigo T.; Fernandez, Patricia L.; Mourao-Sa, Diego S.; Porto, Barbara N.; Dutra, Fabianno F.; Alves, Leticia S.; Oliveira, Marcus F.; Oliveira, Pedro L.; Graca-Souza, Aurelio V.; Bozza, Marcelo T.			Characterization of heme as activator of toll-like receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; TUMOR-NECROSIS-FACTOR; MURINE MACROPHAGES; DENDRITIC CELLS; ENDOTOXIN CONTAMINATION; CUTTING EDGE; TLR4; MICE; LIPOPOLYSACCHARIDE; IDENTIFICATION	Heme is an ancient and ubiquitous molecule present in organisms of all kingdoms, composed of an atom of iron linked to four ligand groups of porphyrin. A high amount of free heme, a potential amplifier of the inflammatory response, is a characteristic feature of diseases with increased hemolysis or extensive cell damage. Here we demonstrate that heme, but not its analogs/ precursors, induced tumor necrosis factor-alpha (TNF-alpha) secretion by macrophages dependently on MyD88, TLR4, and CD14. The activation of TLR4 by heme is exquisitely strict, requiring its coordinated iron and the vinyl groups of the porphyrin ring. Signaling of heme through TLR4 depended on an interaction distinct from the one established between TLR4 and lipopolysaccharide (LPS) since anti-TLR4/MD2 antibody or a lipid A antagonist inhibited LPS-induced TNF-alpha secretion but not heme activity. Conversely, protoporphyrin IX antagonized heme without affecting LPS-induced activation. Moreover, heme induced TNF-alpha and keratinocyte chemokine but was ineffective to induce interleukin-6, interleukin-12, and interferon-inducible protein-10 secretion or co-stimulatory molecule expression. These findings support the concept that the broad ligand specificity of TLR4 and the different activation profiles might in part reside in its ability to recognize different ligands in different binding sites. Finally, heme induced oxidative burst, neutrophil recruitment, and heme oxygenase-1 expression independently of TLR4. Thus, our results presented here reveal a previous unrecognized role of heme as an extracellular signaling molecule that affects the innate immune response through a receptor-mediated mechanism.	Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, CCS Bloco I, BR-21941 Rio De Janeiro, RJ, Brazil; Inst Adv Sci Invest & High Technol Serv, Panama City 0816, Panama; Univ Fed Rio de Janeiro, Inst Med Biochem, Program Biotechnol & Biol Mol, BR-21941 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, CCS Bloco I, Avenida Carlos Chagas Filho,373 Cidade Univ, BR-21941 Rio De Janeiro, RJ, Brazil.	mbozza@micro.ufrj.br	Ferreira Dutra, Fabianno/AAE-2895-2022; Mourao-Sa, Diego/C-5977-2009; Oliveira, Marcus/G-3158-2011; Dutra, Fabianno F/C-1387-2015; L. Oliveira, Pedro/A-9438-2010; Figueiredo, Rodrigo/F-5176-2016	Ferreira Dutra, Fabianno/0000-0003-3106-7585; Oliveira, Marcus/0000-0002-9890-8425; Dutra, Fabianno F/0000-0003-3106-7585; Bozza, Marcelo/0000-0003-3683-7550; Llanes Fernandez, Patricia/0000-0002-0762-0566; L. Oliveira, Pedro/0000-0003-0307-354X; Mourao, Diego/0000-0001-6618-6969; Figueiredo, Rodrigo/0000-0002-7551-8782				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; ASEA A, 2001, J IMMUNOL, V167, P2887; Balla J, 2000, BLOOD, V95, P3442, DOI 10.1182/blood.V95.11.3442.011k51_3442_3450; Barsness KA, 2004, AM J PHYSIOL-REG I, V287, pR592, DOI 10.1152/ajpregu.00412.2003; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Bittencourt VCB, 2006, J BIOL CHEM, V281, P22614, DOI 10.1074/jbc.M511417200; CHOU AC, 1980, J CLIN INVEST, V66, P856, DOI 10.1172/JCI109925; Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; GALBRAITH RA, 1990, J HEPATOL, V10, P305, DOI 10.1016/0168-8278(90)90137-G; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160; Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Krishnamurthy PC, 2006, NATURE, V443, P586, DOI 10.1038/nature05125; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Mullarkey M, 2003, J PHARMACOL EXP THER, V304, P1093, DOI 10.1124/jpet.102.044487; MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Perera PY, 1997, J IMMUNOL, V158, P4422; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Quigley JG, 2004, CELL, V118, P757, DOI 10.1016/j.cell.2004.08.014; Reed RC, 2003, J BIOL CHEM, V278, P31853, DOI 10.1074/jbc.M305480200; Rossignol Daniel P, 2005, Curr Opin Investig Drugs, V6, P496; Saemann MD, 2005, J CLIN INVEST, V115, P468, DOI 10.1172/JCI200522720; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; SCHMITT TH, 1993, ARCH BIOCHEM BIOPHYS, V307, P96, DOI 10.1006/abbi.1993.1566; Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tang XD, 2003, NATURE, V425, P531, DOI 10.1038/nature02003; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Visintin A, 2005, J IMMUNOL, V175, P6465, DOI 10.4049/jimmunol.175.10.6465; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5	55	389	404	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20221	20229		10.1074/jbc.M610737200	http://dx.doi.org/10.1074/jbc.M610737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17502383	hybrid			2022-12-25	WOS:000247819300024
J	Tembe, V; Henderson, BR				Tembe, Varsha; Henderson, Beric R.			BARD1 translocation to mitochondria correlates with bax oligomerization, loss of mitochondrial membrane potential, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; RING DOMAIN; TUMOR-SUPPRESSOR; CELL-DEATH; P53-DEPENDENT APOPTOSIS; BRCA1/BARD1 HETERODIMER; NUCLEAR EXPORT; BREAST-CANCER; CYTOCHROME-C; DNA-DAMAGE	The breast cancer regulatory protein-1 (BRCA1)-associated RING domain 1 (BARD1) gene is mutated in a subset of breast/ovarian cancers. BARD1 functions as a heterodimer with BRCA1 in nuclear DNA repair. BARD1 also has a BRCA1-independent apoptotic activity. Here we investigated the link between cytoplasmic localization and apoptotic function of BARD1. We used immunofluorescence microscopy and deconvolution analysis to resolve BARD1 cytoplasmic staining patterns and detected endogenous BARD1 at mitochondria. BARD1 was also detected in mitochondrial cell fractions by immunoblotting. The targeting of BARD1 to mitochondria was modestly stimulated by DNA damage and did not require BRCA1 as indicated by RNA interference and peptide-competition experiments. Transiently expressed yellow fluorescence protein-BARD1 localized to mitochondria, and the targeting sequences were mapped to both the N and C terminus of BARD1. Ectopic yellow fluorescence protein-BARD1 induced apoptosis and loss of mitochondrial membrane potential in MCF-7 breast tumor cells. BARD1 apoptotic function was associated with stimulation of Bax oligomerization at mitochondria. This distinguishes it from BRCA1, which is pro-apoptotic but did not induce Bax oligomerization. The cancer-associated BARD1 splice-variant Delta RIN (lacks the BRCA1 binding domain and ankyrin repeats) was recruited to mitochondria but did not stimulate apoptosis or alter membrane permeability. We propose that BARD1 has two main sites of action in its cellular response to DNA damage, the nucleus, where it promotes cell survival through DNA repair, and the mitochondria, where BARD1 regulates apoptosis.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au						Arima Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200; Au WWY, 2005, J BIOL CHEM, V280, P6993, DOI 10.1074/jbc.M408879200; Ayi TC, 1998, ONCOGENE, V17, P2143, DOI 10.1038/sj.onc.1202123; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Breckenridge DG, 2004, CURR OPIN CELL BIOL, V16, P647, DOI 10.1016/j.ceb.2004.09.009; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Charlot JF, 2004, APOPTOSIS, V9, P333, DOI 10.1023/B:APPT.0000025810.58981.4c; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chen DX, 2006, CANCER RES, V66, P3485, DOI 10.1158/0008-5472.CAN-05-4103; Coene ED, 2005, MOL BIOL CELL, V16, P997, DOI 10.1091/mbc.E04-10-0895; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Fabbro M, 2004, EXP CELL RES, V298, P661, DOI 10.1016/j.yexcr.2004.05.004; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Gautier F, 2000, CANCER RES, V60, P6895; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Henderson BR, 2005, BIOESSAYS, V27, P884, DOI 10.1002/bies.20277; Irminger-Finger I, 2006, NAT REV CANCER, V6, P382, DOI 10.1038/nrc1878; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Jefford CE, 2004, ONCOGENE, V23, P3509, DOI 10.1038/sj.onc.1207427; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Karppinen SM, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.020669; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; Mishra S, 2005, TRENDS MOL MED, V11, P192, DOI 10.1016/j.molmed.2005.02.004; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Rodriguez JA, 2004, ONCOGENE, V23, P1809, DOI 10.1038/sj.onc.1207302; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Schuchner S, 2005, J BIOL CHEM, V280, P8855, DOI 10.1074/jbc.M413741200; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tsuzuki M, 2006, CANCER LETT, V233, P108, DOI 10.1016/j.canlet.2005.03.012; Westermark UK, 2003, MOL CELL BIOL, V23, P7926, DOI 10.1128/MCB.23.21.7926-7936.2003; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	47	35	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20513	20522		10.1074/jbc.M702627200	http://dx.doi.org/10.1074/jbc.M702627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17510055	hybrid			2022-12-25	WOS:000247819300054
J	De Nicola, F; Bruno, T; Iezzi, S; Di Padova, M; Floridi, A; Passananti, C; Del Sal, G; Fanciulli, M				De Nicola, Francesca; Bruno, Tiziana; Iezzi, Simona; Di Padova, Monica; Floridi, Aristide; Passananti, Claudio; Del Sal, Giannino; Fanciulli, Maurizio			The prolyl isomerase Pin1 affects Che-1 stability in response to apoptotic DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; P53 STABILITY; CELL-GROWTH; PHOSPHORYLATION; INTERACTS; RB; DOMAINS; MDM2; TAU; IDENTIFICATION	We have previously demonstrated that DNA damage leads to stabilization and accumulation of Che-1, an RNA polymerase II-binding protein that plays an important role in transcriptional activation of p53 and in maintenance of the G2/M checkpoint. Here we show that Che-1 is down-regulated during the apoptotic process. We found that the E3 ligase HMD2 physically and functionally interacts with Che-1 and promotes its degradation via the ubiquitin-dependent proteasomal system. Furthermore, we found that in response to apoptotic stimuli Che-1 interacts with the peptidyl-prolyl isomerase Pin1 and that conformational changes generated by Pin1 are required for Che-1/HDM2 interaction. Notably, a Che-1 mutant lacking the capacity to bind Pin1 exhibits an increased half-life and this correlates with a diminished apoptosis in response to genotoxic stress. Our results establish Che-1 as a new Pin1 and HDM2 target and confirm its important role in the cellular response to DNA damage.	Regina Elena Inst Canc Res, Lab B Expt Res Ctr, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Reome Oncogenom Ctr, I-00158 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; CNR, Ist Biol & Patol Mol, I-00137 Rome, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, Lab Nazl Consorzio Interuniv Biotechnol, I-34100 Trieste, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); University of Trieste	Fanciulli, M (corresponding author), Regina Elena Inst Canc Res, Lab B Expt Res Ctr, Via delle Messi Oro 156, I-00158 Rome, Italy.	fanciulli@.ifo.it	Passananti, Claudio/K-9593-2016; De Nicola, Francesca/AAC-6887-2022; Fanciulli, Marco/J-9940-2013; bruno, tiziana/AAC-4913-2022; fanciulli, maurizio/ABH-6745-2020; Iezzi, Simona/AAA-3275-2021	Fanciulli, Marco/0000-0003-2951-0859; bruno, tiziana/0000-0003-0352-4523; Iezzi, Simona/0000-0002-7484-5861; PASSANANTI, CLAUDIO/0000-0002-9288-5736; De Nicola, FRANCESCA/0000-0002-2187-7544; DEL SAL, GIANNINO/0000-0003-2185-6003; DI PADOVA, Monica/0000-0003-3808-7159				Barbato C, 2003, MOL CELL NEUROSCI, V24, P1038, DOI 10.1016/j.mcn.2003.08.002; Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Bruno T, 2006, CANCER CELL, V10, P473, DOI 10.1016/j.ccr.2006.10.012; Burgdorf S, 2004, J BIOL CHEM, V279, P17524, DOI 10.1074/jbc.M313703200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Di Padova M, 2003, J BIOL CHEM, V278, P36496, DOI 10.1074/jbc.M306694200; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leister P., 2003, SIGNAL TRANSDUCTION, V3, P17, DOI [10.1002/sita.200300020, DOI 10.1002/SITA.200300020]; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lindfors K, 2000, BIOCHEM BIOPH RES CO, V276, P660, DOI 10.1006/bbrc.2000.3480; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Monaco L, 2003, GENE, V321, P57, DOI 10.1016/S0378-1119(03)00834-5; Oh H, 2002, P NATL ACAD SCI USA, V99, P5430, DOI 10.1073/pnas.082123999; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Pathan N, 2001, NEOPLASIA, V3, P70, DOI 10.1038/sj.neo.7900131; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Thomas T, 2000, DEV BIOL, V227, P324, DOI 10.1006/dbio.2000.9915; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	38	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19685	19691		10.1074/jbc.M610282200	http://dx.doi.org/10.1074/jbc.M610282200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17468107	hybrid			2022-12-25	WOS:000247650600043
J	Grigorian, A; Lee, SU; Tian, WQ; Chen, IJ; Gao, GY; Mendelsohn, R; Dennis, JW; Demetriou, M				Grigorian, Ani; Lee, Sung-Uk; Tian, Wenqiang; Chen, I.-Ju; Gao, Guoyan; Mendelsohn, Richard; Dennis, James W.; Demetriou, Michael			Control of T cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; MULTIPLE-SCLEROSIS; CBL-B; ACETYLGLUCOSAMINYLTRANSFERASE-V; NEGATIVE REGULATION; MOLECULAR MIMICRY; VITAMIN-D; ENCEPHALOMYELITIS; GLYCOSYLATION; GLUCOSAMINE	Autoimmunity is a complex trait disease where the environment influences susceptibility to disease by unclear mechanisms. T cell receptor clustering and signaling at the immune synapse, T cell proliferation, CTLA-4 endocytosis, TH1 differentiation, and autoimmunity are negatively regulated by beta 1,6GlcNAc-branched N-glycans attached to cell surface glycoproteins. beta 1,6GlcNAc-branched N-glycan expression in T cells is dependent on metabolite supply to UDP-GlcNAc biosynthesis ( hexosamine pathway) and in turn to Golgi N-acetylglucosaminyltransferases Mgat1,-2, -4, and -5. In Jurkat T cells, beta 1,6GlcNAc- branching in N-glycans is stimulated by metabolites supplying the hexosamine pathway including glucose, GlcNAc, acetoacetate, glutamine, ammonia, or uridine but not by control metabolites mannosamine, galactose, mannose, succinate, or pyruvate. Hexosamine supplementation in vitro and in vivo also increases beta 1,6GlcNAc- branched N-glycans in naive mouse T cells and suppresses T cell receptor signaling, T cell proliferation, CTLA-4 endocytosis, TH1 differentiation, experimental autoimmune encephalomyelitis, and autoimmune diabetes in non-obese diabetic mice. Our results indicate that metabolite flux through the hexosamine and N-glycan pathways conditionally regulates autoimmunity by modulating multiple T cell functionalities downstream of beta 1,6GlcNAc- branched N-glycans. This suggests metabolic therapy as a potential treatment for autoimmune disease.	Univ Calif Irvine, Dept Neurol & Microbiol & Mol Genet, Irvine, CA 92697 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L5, Canada	University of California System; University of California Irvine; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Demetriou, M (corresponding author), Univ Calif Irvine, Dept Neurol & Microbiol & Mol Genet, 250 Sprague Hall, Irvine, CA 92697 USA.	mdemetri@uci.edu	Dennis, James/E-7268-2013	Demetriou, Michael/0000-0002-2224-7798				Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146/annurev.immunol.23.021704.115643; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bettelli E, 2004, J EXP MED, V200, P79, DOI 10.1084/jem.20031819; Brewer CF, 2002, CURR OPIN STRUC BIOL, V12, P616, DOI 10.1016/S0959-440X(02)00364-0; Broschat KO, 2002, J BIOL CHEM, V277, P14764, DOI 10.1074/jbc.M201056200; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; Frauwirth KA, 2004, J IMMUNOL, V172, P4661, DOI 10.4049/jimmunol.172.8.4661; Granovsky M, 2000, NAT MED, V6, P306; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Lau KS, 2007, CELL, V129, P123, DOI 10.1016/j.cell.2007.01.049; LEMIRE JM, 1991, J CLIN INVEST, V87, P1103, DOI 10.1172/JCI115072; Ma LL, 2002, J BIOL CHEM, V277, P39343, DOI 10.1074/jbc.M204924200; Morgan R, 2004, J IMMUNOL, V173, P7200, DOI 10.4049/jimmunol.173.12.7200; Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38; Nakagawa H, 1996, EUR J BIOCHEM, V237, P76, DOI 10.1111/j.1432-1033.1996.0076n.x; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Nieminen J, 2007, J BIOL CHEM, V282, P1374, DOI 10.1074/jbc.M604506200; Ohtsubo K, 2005, CELL, V123, P1307, DOI 10.1016/j.cell.2005.09.041; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Redondo MJ, 2001, DIABETOLOGIA, V44, P354, DOI 10.1007/s001250051626; Salvatore S, 2000, ALIMENT PHARM THER, V14, P1567, DOI 10.1046/j.1365-2036.2000.00883.x; Sasai K, 2002, GLYCOBIOLOGY, V12, P119, DOI 10.1093/glycob/12.2.119; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SCHAEFER HF, 1989, CHIMIA, V43, P1; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Tao X, 1997, J IMMUNOL, V159, P5956; Tomiya N, 2001, ANAL BIOCHEM, V293, P129, DOI 10.1006/abio.2001.5091; TSOUKAS CD, 1984, SCIENCE, V224, P1438, DOI 10.1126/science.6427926; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; WALL KA, 1988, P NATL ACAD SCI USA, V85, P5644, DOI 10.1073/pnas.85.15.5644; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Zella JB, 2003, ARCH BIOCHEM BIOPHYS, V417, P77, DOI 10.1016/S0003-9861(03)00338-2; Zhang GX, 2005, J IMMUNOL, V175, P7202, DOI 10.4049/jimmunol.175.11.7202	47	97	107	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					20027	20035		10.1074/jbc.M701890200	http://dx.doi.org/10.1074/jbc.M701890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17488719	Green Published, hybrid			2022-12-25	WOS:000247650600076
J	Ito, K; Ikebe, M; Kashiyama, T; Mogami, T; Kon, T; Yamamoto, K				Ito, Kohji; Ikebe, Mitsuo; Kashiyama, Taku; Mogami, Toshifumi; Kon, Takahide; Yamamoto, Keiichi			Kinetic mechanism of the fastest motor protein, Chara myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOTOR; DUTY RATIO MOTOR; DICTYOSTELIUM-DISCOIDEUM MYOSIN; LARGE STEP-SIZE; ATPASE ACTIVITY; SMOOTH-MUSCLE; ACTOMYOSIN SUBFRAGMENT-1; NUCLEOTIDE-BINDING; CONFORMATIONAL-CHANGE; MOTILE PROPERTIES	Chara corallina class XI myosin is by far the fastest molecular motor. To investigate the molecular mechanism of this fast movement, we performed a kinetic analysis of a recombinant motor domain of Chara myosin. We estimated the time spent in the strongly bound state with actin by measuring rate constants of ADP dissociation from actin(.)motor domain complex and ATP-induced dissociation of the motor domain from actin. The rate constant of ADP dissociation from acto-motor domain was > 2800 s(-1), and the rate constant of ATP-induced dissociation of the motor domain from actin at physiological ATP concentration was 2200 s(-1). From these data, the time spent in the strongly bound state with actin was estimated to be < 0.82 ms. This value is the shortest among known values for various myosins and yields the duty ratio of < 0.3 with a V-max value of the actin-activated ATPase activity of 390 s(-1). The addition of the long neck domain of myosin Va to the Chara motor domain largely increased the velocity of the motility without increasing the ATP hydrolysis cycle rate, consistent with the swinging lever model. In addition, this study reveals some striking kinetic features of Chara myosin that are suited for the fast movement: a dramatic acceleration of ADP release by actin (1000-fold) and extremely fast ATP binding rate.	Chiba Univ, Dept Biol, Inage Ku, Chiba 263, Japan; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 153, Japan	Chiba University; University of Massachusetts System; University of Massachusetts Worcester; University of Tokyo	Ito, K (corresponding author), Chiba Univ, Dept Biol, Inage Ku, Chiba 263, Japan.	k-ito@faculty.chiba-u.jp	Ito, Kohji/K-8441-2017; Kon, Takahide/AAG-6975-2021	Ito, Kohji/0000-0001-9573-432X; Kon, Takahide/0000-0002-1231-7609	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048526, R01AR048898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006103] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR048526, AR048898] Funding Source: Medline; NIDCD NIH HHS [DC006103] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Awata J, 2003, J MOL BIOL, V326, P659, DOI 10.1016/S0022-2836(02)01469-9; Awata J, 2001, PLANT CELL PHYSIOL, V42, P828, DOI 10.1093/pcp/pce107; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; Batra R, 1999, BIOCHEMISTRY-US, V38, P6126, DOI 10.1021/bi982251e; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Dose AC, 2007, J BIOL CHEM, V282, P216, DOI 10.1074/jbc.M605964200; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Foth BJ, 2006, P NATL ACAD SCI USA, V103, P3681, DOI 10.1073/pnas.0506307103; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; GEEVES MA, 1988, BIOCHEM J, V256, P41, DOI 10.1042/bj2560041; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; Henn A, 2005, J BIOL CHEM, V280, P39665, DOI 10.1074/jbc.M507667200; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; HIGASHIFUJIME S, 1995, FEBS LETT, V375, P151, DOI 10.1016/0014-5793(95)01208-V; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Homma K, 2005, J BIOL CHEM, V280, P29381, DOI 10.1074/jbc.M504779200; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Ito K, 2003, BIOCHEM BIOPH RES CO, V312, P958, DOI 10.1016/j.bbrc.2003.10.202; Ito K, 2003, J BIOL CHEM, V278, P31049, DOI 10.1074/jbc.M304138200; Iwane AH, 2005, J MOL BIOL, V353, P213, DOI 10.1016/j.jmb.2005.08.013; Joel PB, 2003, BIOCHEMISTRY-US, V42, P9160, DOI 10.1021/bi034415j; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; Kad NM, 2003, J CELL BIOL, V162, P481, DOI 10.1083/jcb.200304023; Kambara T, 2006, J BIOL CHEM, V281, P37291, DOI 10.1074/jbc.M603823200; Kashiyama T, 2000, J BIOCHEM-TOKYO, V127, P1065, DOI 10.1093/oxfordjournals.jbchem.a022699; Kimura Y, 2003, J MOL BIOL, V328, P939, DOI 10.1016/S0022-2836(03)00341-3; Kitamura K, 1999, NATURE, V397, P129, DOI 10.1038/16403; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; Li XD, 2005, J BIOL CHEM, V280, P17815, DOI 10.1074/jbc.M413295200; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; Miller BM, 2003, J BIOL CHEM, V278, P50293, DOI 10.1074/jbc.M308318200; Morimatsu M, 2000, BIOCHEM BIOPH RES CO, V270, P147, DOI 10.1006/bbrc.2000.2391; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Rock RS, 2005, MOL CELL, V17, P603, DOI 10.1016/j.molcel.2005.01.015; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Seki M, 2004, J MOL BIOL, V344, P311, DOI 10.1016/j.jmb.2004.09.039; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; Silva R, 2003, J MUSCLE RES CELL M, V24, P489, DOI 10.1023/B:JURE.0000009809.69829.74; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; Uyeda TQP, 2002, BIOCHEMISTRY-US, V41, P9525, DOI 10.1021/bi026177i; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Warshaw DM, 2000, J BIOL CHEM, V275, P37167, DOI 10.1074/jbc.M006438200; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; WILLIAMS R, 1994, CELL MOTIL CYTOSKEL, V27, P41, DOI 10.1002/cm.970270105; Woodward SKA, 1995, BIOCHEMISTRY-US, V34, P16056, DOI 10.1021/bi00049a020; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; YAMAMOTO K, 1994, P JPN ACAD B-PHYS, V70, P175, DOI 10.2183/pjab.70.175; Yang Y, 2005, J BIOL CHEM, V280, P32061, DOI 10.1074/jbc.M506765200; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200	77	52	52	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19534	19545		10.1074/jbc.M611802200	http://dx.doi.org/10.1074/jbc.M611802200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17488711	hybrid			2022-12-25	WOS:000247650600028
J	Papa, S; Monti, SM; Vitale, RM; Bubici, C; Jayawardena, S; Alvarez, K; De Smaele, E; Dathan, N; Pedone, C; Ruvo, M; Franzoso, G				Papa, Salvatore; Monti, Simona M.; Vitale, Rosa Maria; Bubici, Concetta; Jayawardena, Shanthi; Alvarez, Kellean; De Smaele, Enrico; Dathan, Nina; Pedone, Carlo; Ruvo, Menotti; Franzoso, Guido			Insights into the structural basis of the GADD45 beta-mediated inactivation of the JNK kinase, MKK7/JNKK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CRYSTAL-STRUCTURE; CELL-DEATH; ACTIVATION; PROTEIN; GADD45; DIFFERENTIATION; TRANSDUCTION; INHIBITION; HOMOLOGY	NF-kappa B/Rel factors control programmed cell death (PCD), and this control is crucial to oncogenesis, cancer chemoresistance, and antagonism of tumor necrosis factor (TNF) alpha-induced killing. With TNF alpha, NF-kappa B-mediated protection involves suppression of the c-Jun-N-terminal kinase (JNK) cascade, and we have identified Gadd45 beta, a member of the Gadd45 family, as a pivotal effector of this activity of NF-kappa B. Inhibition of TNF alpha-induced JNK signaling by Gadd45 beta depends on direct targeting of the JNK kinase, MKK7/JNKK2. The mechanism by which Gadd45 beta blunts MKK7, however, is unknown. Here we show that Gadd45 beta is a structured protein with a predicted four-stranded beta-sheet core, five alpha-helices, and two acidic loops. Association of Gadd45 beta with MKK7 involves a network of interactions mediated by its putative helices alpha 3 and alpha 4 and loops 1 and 2. Whereas alpha 3 appears to primarily mediate docking to MKK7, loop 1 and alpha 4-loop 2 seemingly afford kinase inactivation by engaging the ATP-binding site and causing conformational changes that impede catalytic function. These data provide a basis for Gadd45 beta-mediated blockade of MKK7, and ultimately, TNF alpha-induced PCD. They also have important implications for treatment of widespread diseases.	Ist Biostrutture & Bioemmagini, Consiglio Nazl Rich, I-80134 Naples, Italy		Ruvo, M (corresponding author), Univ Chicago, Ben May Inst, Ben May Inst Canc Res, Chicago, IL 60637 USA.	menotti.ruvo@unina.it; gfranzos@midway.uchicago.edu	Papa, Salvatore/J-9413-2012; Vitale, Rosa Maria/AAY-1522-2020; Franzoso, Guido/GRR-8628-2022; De Smaele, Enrico/C-1124-2013; Monti, Simona M/J-5214-2012; MONTI, SIMONA MARIA/GQQ-0129-2022	Papa, Salvatore/0000-0002-8369-6538; Vitale, Rosa Maria/0000-0001-9243-1307; De Smaele, Enrico/0000-0003-4524-4423; MONTI, SIMONA MARIA/0000-0001-9647-7089; Franzoso, Guido/0000-0002-0778-988X; Bubici, Concetta/0000-0002-8074-4661	NATIONAL CANCER INSTITUTE [R01CA084040, R01CA098583] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA84040, R01 CA098583] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Claudio E, 2006, CELL DEATH DIFFER, V13, P697, DOI 10.1038/sj.cdd.4401894; D'Ambrosio C, 2003, BIOCHEMISTRY-US, V42, P4430, DOI 10.1021/bi0206715; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Gupta M, 2005, ONCOGENE, V24, P7170, DOI 10.1038/sj.onc.1208847; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Ijiri K, 2005, J BIOL CHEM, V280, P38544, DOI 10.1074/jbc.M504202200; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Koonin EV, 1997, J MOL MED-JMM, V75, P236; Kovalsky O, 2001, J BIOL CHEM, V276, P39330, DOI 10.1074/jbc.M105115200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Liebermann DA, 2002, ONCOGENE, V21, P3391, DOI 10.1038/sj.onc.1205312; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Salvador JM, 2005, NAT IMMUNOL, V6, P396, DOI 10.1038/ni1176; Schultz A, 2006, MOL CELL BIOL, V26, P5146, DOI 10.1128/MCB.02374-05; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Snyder EL, 2001, CURR OPIN MOL THER, V3, P147; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Vidovic I, 2000, MOL CELL, V6, P1331, DOI 10.1016/S1097-2765(00)00131-3; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhou TJ, 2004, STRUCTURE, V12, P1891, DOI 10.1016/j.str.2004.07.021	35	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19029	19041		10.1074/jbc.M703112200	http://dx.doi.org/10.1074/jbc.M703112200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17485467	hybrid			2022-12-25	WOS:000247475300045
J	Moreno, CS; Matyunina, L; Dickerson, EB; Schubert, N; Bowen, NJ; Logani, S; Benigno, BB; McDonald, JF				Moreno, Carlos S.; Matyunina, Lilya; Dickerson, Erin B.; Schubert, Nina; Bowen, Nathan J.; Logani, Sanjay; Benigno, Benedict B.; McDonald, John F.			Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas	PLOS ONE			English	Article							WILD-TYPE P53; PATHOLOGICAL RESPONSE; TUMOR-CELLS; GENE; EXPRESSION; MUTATIONS; RESISTANCE; CANCER; IDENTIFICATION; SURVIVAL	Gene expression profiles of malignant tumors surgically removed from ovarian cancer patients pre-treated with chemotherapy (neo-adjuvant) prior to surgery group into two distinct clusters. One group clusters with carcinomas from patients not pre-treated with chemotherapy prior to surgery (C-L), while the other clusters with non-malignant adenomas (A-L). We show here that although the C-L cluster is preferentially associated with p53 loss-of-function (LOF) mutations, the C-L cluster cancer patients display a more favorable clinical response to chemotherapy as evidenced by enhanced long-term survivorships. Our results support a model whereby p53 mediated cell-cycle-arrest/DNA repair serves as a barrier to optimal chemotherapeutic treatment of ovarian and perhaps other carcinomas and suggest that inhibition of p53 during chemotherapy may enhance clinical outcome.	[Matyunina, Lilya; Dickerson, Erin B.; Schubert, Nina; Bowen, Nathan J.; McDonald, John F.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; [Moreno, Carlos S.; Logani, Sanjay] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Moreno, Carlos S.] Winship Canc Inst, Atlanta, GA USA; [Matyunina, Lilya; Dickerson, Erin B.; Schubert, Nina; Bowen, Nathan J.; Benigno, Benedict B.; McDonald, John F.] Ovarian Canc Inst, Atlanta, GA USA	University System of Georgia; Georgia Institute of Technology; Emory University	McDonald, JF (corresponding author), Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA.	john.mcdonald@biology.gatech.edu	Bowen, Nathan J./M-3202-2019; Bowen, Nathan/F-3132-2010; Benigno, Benedict/GPW-8134-2022; Moreno, Carlos S/B-3863-2009	Bowen, Nathan J./0000-0002-1609-6698; Bowen, Nathan/0000-0002-1609-6698; Moreno, Carlos S/0000-0002-5582-0028; McDonald, John F/0000-0002-4263-8155	Georgia Cancer Coalition; Georgia Tech Research Foundation; Robinson Family Foundation; Larry and Beth Lawrence Foundation; Department of Pathology and Laboratory Medicine, Emory University;  [R01 CA106826]; NATIONAL CANCER INSTITUTE [R01CA106826] Funding Source: NIH RePORTER	Georgia Cancer Coalition; Georgia Tech Research Foundation; Robinson Family Foundation; Larry and Beth Lawrence Foundation; Department of Pathology and Laboratory Medicine, Emory University; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by grants to JM from the Georgia Cancer Coalition, the Georgia Tech Research Foundation, the Robinson Family Foundation and the Larry and Beth Lawrence Foundation. CSM received support from R01 CA106826 and the Department of Pathology and Laboratory Medicine, Emory University.	Ameyar M, 1999, ONCOGENE, V18, P5464, DOI 10.1038/sj.onc.1202919; Andrews GA, 2004, HEAD NECK-J SCI SPEC, V26, P870, DOI 10.1002/hed.20029; Banks E, 2000, METH MOLEC MED, V39, P3; Beissbarth T, 2004, BIOINFORMATICS, V20, P1464, DOI 10.1093/bioinformatics/bth088; BERCHUCK A, 1994, AM J OBSTET GYNECOL, V170, P246; Berns A, 2006, NATURE, V443, P153, DOI 10.1038/443153a; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Coukos G, 1998, OBSTET GYNECOL, V91, P783, DOI 10.1016/S0029-7844(98)00054-4; Daoud SS, 2003, CANCER RES, V63, P2782; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Erenpreisa J, 2005, CELL BIOL INT, V29, P1012, DOI 10.1016/j.cellbi.2005.10.005; Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Katabuchi H, 1998, INT J GYNECOL PATHOL, V17, P54, DOI 10.1097/00004347-199801000-00010; Keshelava N, 2000, MED PEDIATR ONCOL, V35, P563, DOI 10.1002/1096-911X(20001201)35:6<563::AID-MPO15>3.0.CO;2-J; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Lambert HE, 2004, INT J GYNECOL CANCER, V14, P772, DOI 10.1111/j.1048-891X.2004.014507.x; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma YX, 2006, ANTI-CANCER DRUG, V17, P733, DOI 10.1097/01.cad.0000217429.67455.18; MALOAS JS, 1979, J ROY SOC MED, V72, P357; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; Meyer E, 2005, CANCER RES, V65, P4261, DOI 10.1158/0008-5472.CAN-04-2908; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; NIMEUSMALMSTROM E, 2006, EUR J CANC IN PRESS; Osugi H, 2002, INT J ONCOL, V21, P637; PESTELL KE, 2004, MOL PHARM, V57, P503; Razani B, 2000, BIOCHEMISTRY-US, V39, P13916, DOI 10.1021/bi001489b; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Reles A, 2001, CLIN CANCER RES, V7, P2984; Ribeiro U, 1998, CANCER, V83, P7, DOI 10.1002/(SICI)1097-0142(19980701)83:1<7::AID-CNCR2>3.0.CO;2-R; Sakamoto M, 2001, Hum Cell, V14, P305; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070; Spentzos D, 2005, J CLIN ONCOL, V23, P7911, DOI 10.1200/JCO.2005.02.9363; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Warrenfeltz S, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-27; Yamaguchi A, 2002, J BIOL CHEM, V277, P623, DOI 10.1074/jbc.M107435200	45	47	51	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e441	10.1371/journal.pone.0000441	http://dx.doi.org/10.1371/journal.pone.0000441			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505532	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445900001
J	Boer, U; Alejel, T; Beimesche, S; Cierny, I; Krause, D; Knepel, W; Flugge, G				Boeer, Ulrike; Alejel, Tahseen; Beimesche, Stephan; Cierny, Irmgard; Krause, Doris; Knepel, Willhart; Fluegge, Gabriele			CRE/CREB-Driven Up-Regulation of Gene Expression by Chronic Social Stress in CRE-Luciferase Transgenic Mice: Reversal by Antidepressant Treatment	PLOS ONE			English	Article								Background. It has been suggested that stress provokes neuropathological changes and may thus contribute to the precipitation of affective disorders such as depression. Likewise, the pharmacological therapy of depression requires chronic treatment and is thought to induce a positive neuronal adaptation, presumably based on changes in gene transcription. The transcription factor cAMP-responsive element binding protein (CREB) and its binding site (CRE) have been suggested to play a major role in both the development of depression and antidepressive therapy. Methodology/Principle Findings. To investigate the impact of stress and antidepressant treatment on CRE/CREB transcriptional activity, we generated a transgenic mouse line in which expression of the luciferase reporter gene is controlled by four copies of CRE. In this transgene, luciferase enzyme activity and protein were detected throughout the brain, e. g., in the hippocampal formation. Chronic social stress significantly increased (by 45 to 120%) CRE/CREB-driven gene expression measured as luciferase activity in several brain regions. This was also reflected by increased CREB-phosphorylation determined by immunoblotting. Treatment of the stressed mice with the antidepressant imipramine normalized luciferase expression to control levels in all brain regions and likewise reduced CREB-phosphorylation. In non-stressed animals, chronic (21 d) but not acute (24 h) treatment with imipramine (2 x 10 mg/kg/d) reduced luciferase expression in the hippocampus by 40-50%. Conclusions/Significance. Our results emphasize a role of CREB in stress-regulated gene expression and support the view that the therapeutic actions of antidepressants are mediated via CRE/CREB-directed transcription.	[Boeer, Ulrike; Alejel, Tahseen; Beimesche, Stephan; Cierny, Irmgard; Krause, Doris; Knepel, Willhart] Univ Gottingen, Dept Mol Pharmacol, Gottingen, Germany; [Fluegge, Gabriele] DFG Res Ctr Mol Physiol Brain CMPB, Gottingen, Germany; [Fluegge, Gabriele] German Primate Ctr, Lab Clin Neurobiol, Gottingen, Germany	University of Gottingen; German Research Foundation (DFG); Deutsches Primatenzentrum (DPZ)	Boer, U (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Gottingen, Germany.	uboeer1@gwdg.de			Deutsche Forschungsgemeinschaft [SFB 402 (A3)]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The work was supported by a grant from the Deutsche Forschungsgemeinschaft SFB 402 (A3).	Abumaria N, 2006, CELL MOL NEUROBIOL, V26, P145, DOI 10.1007/s10571-006-9024-1; Aktories K, 2004, INT J MED MICROBIOL, V293, P557, DOI 10.1078/1438-4221-00305; Alfonso J, 2005, REV NEUROSCIENCE, V16, P43; BANERJEE SP, 1977, NATURE, V268, P455, DOI 10.1038/268455a0; Bartolomucci A, 2004, PSYCHONEUROENDOCRINO, V29, P899, DOI 10.1016/j.psyneuen.2003.08.003; Beimesche S, 1999, MOL ENDOCRINOL, V13, P718, DOI 10.1210/me.13.5.718; Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972; Blendy JA, 1998, J MOL MED-JMM, V76, P104, DOI 10.1007/s001090050197; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandao ML, 2003, EUR J PHARMACOL, V463, P225, DOI 10.1016/S0014-2999(03)01284-6; Butterweck V, 2001, MOL PSYCHIATR, V6, P547, DOI 10.1038/sj.mp.4000937; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; DEKLOET ER, 1990, J STEROID BIOCHEM, V37, P387, DOI 10.1016/0960-0760(90)90489-8; Fuchs E, 2002, PHARMACOL BIOCHEM BE, V73, P247, DOI 10.1016/S0091-3057(02)00795-5; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HENINGER GR, 1988, ACTA PSYCHIAT SCAND, V77, P138, DOI 10.1111/j.1600-0447.1988.tb08559.x; Holoubek G, 2004, PHARMACOPSYCHIATRY, V37, pS113, DOI 10.1055/s-2004-832664; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104; KUDRYAVTSEVA NN, 1991, PHARMACOL BIOCHEM BE, V38, P315, DOI 10.1016/0091-3057(91)90284-9; Kuipers SD, 2003, J NEUROCHEM, V85, P1312, DOI 10.1046/j.1471-4159.2003.01770.x; Laifenfeld D, 2005, NEUROBIOL DIS, V20, P432, DOI 10.1016/j.nbd.2005.03.023; Lesch KP, 2004, J PSYCHIATR NEUROSCI, V29, P174; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Manier DH, 2002, J NEURAL TRANSM, V109, P91, DOI 10.1007/s702-002-8239-6; Matsuda S, 1996, NEUROSCI RES, V26, P157, DOI 10.1016/S0168-0102(96)01088-7; Meyer H, 2000, BRAIN RES, V880, P147, DOI 10.1016/S0006-8993(00)02787-6; MEYERSON LR, 1980, PHARMACOL BIOCHEM BE, V12, P943, DOI 10.1016/0091-3057(80)90457-8; Moore AN, 1996, J BIOL CHEM, V271, P14214, DOI 10.1074/jbc.271.24.14214; NAIR A, 2006, NEUROPSYCHOPHARMACOL; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; NESTLER EJ, 1990, P NATL ACAD SCI USA, V87, P7522, DOI 10.1073/pnas.87.19.7522; Nibuya M, 1996, J NEUROSCI, V16, P2365; NIBUYA M, 1995, J NEUROSCI, V15, P7539; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Pardon MC, 2005, NEUROSCIENCE, V132, P561, DOI 10.1016/j.neuroscience.2005.01.033; PAXINOS G, 1972, J COMP PHYSIOL PSYCH, V79, P219, DOI 10.1037/h0032530; POST RM, 1992, AM J PSYCHIAT, V149, P999; Rygula R, 2005, BEHAV BRAIN RES, V162, P127, DOI 10.1016/j.bbr.2005.03.009; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1995, MOL PHARMACOL, V47, P1112; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stanford SC, 1995, PHARMACOL THERAPEUT, V68, P297, DOI 10.1016/0163-7258(95)02010-1; STERNBERGER LA, 1979, J HISTOCHEM CYTOCHEM, V27, P1424, DOI 10.1177/27.11.92498; Suzuki S, 2004, J COMP NEUROL, V479, P70, DOI 10.1002/cne.20310; Swank MW, 2000, NEUROREPORT, V11, P1625, DOI 10.1097/00001756-200006050-00006; Tardito D, 2006, PHARMACOL REV, V58, P115, DOI 10.1124/pr.58.1.7; Thome J, 2000, J NEUROSCI, V20, P4030; VETULANI J, 1975, NATURE, V257, P495, DOI 10.1038/257495a0; Zhu MY, 2005, MOL BRAIN RES, V133, P167, DOI 10.1016/j.molbrainres.2004.10.009	52	35	40	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e431	10.1371/journal.pone.0000431	http://dx.doi.org/10.1371/journal.pone.0000431			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487276	gold, Green Published			2022-12-25	WOS:000207445800013
J	Dahlberg, J; Nilsson, LO; von Wowern, F; Melander, O				Dahlberg, Jonas; Nilsson, Lars-Olof; von Wowern, Fredrik; Melander, Olle			Polymorphism in NEDD4L Is Associated with Increased Salt Sensitivity, Reduced Levels of P-renin and Increased Levels of Nt-proANP	PLOS ONE			English	Article								Objective. Neuronal precursor cell expressed developmentally down-regulated 4-like (NEDD4L) is a regulator of the amiloride-sensitive epithelial sodium channel (ENaC), thus a candidate gene for salt sensitivity. Carriers of an intact NEDD4L C2-domain, encoded by the NEDD4L rs4149601 (G/A) GG genotype, together with the C-allele of the NEDD4L rs2288774 (C/T) polymorphism have previously been shown to have increased blood pressure. Our aim was to test if genetic variation in NEDD4L is associated with increased salt sensitivity. Methods. 39 normotensive subjects were studied. The difference in 24-hour systolic blood pressure after four weeks on 150 mmol/day NaCl intake and four weeks on 50 mmol/day NaCl was defined as salt sensitivity. The rs4149601 and rs2288774 polymorphisms were genotyped using PCR-based techniques. Results. Carriers of the rs4149601 GG-genotype together with the rs2288774 CC-genotype had significantly higher salt sensitivity (median, IQR) (18.0, 7.5-20.0 mmHg vs 6.0, 0.0-10.0 mmHg, P = 0.007) and lower plasma renin concentration (P-renin) (6.0, 2.0-9.5 mU/L vs 15.0, 9.0-24.0 mU/L, P = 0.005) as compared to non-carriers of these genotypes. In carriers of the rs4149601 GG-genotype together with the rs2288774 CC-or CT-genotype, as compared to non-carriers, salt sensitivity was (8.0, 6.0-18.0 mmHg vs 5.0, 0.0-10.0 mmHg, P = 0.07) and P-renin (9.0, 6.0-16.0 mU/L vs 15.0, 9.0-28.0 mU/L, P = 0.03). Conclusion. Genetic NEDD4L variation seems to affect salt sensitivity and P-renin in normotensive subjects, suggesting that genotyping of NEDD4L may be clinically useful in order to identify subjects who benefit from dietary salt restriction in the prevention of hypertension.	[Dahlberg, Jonas] Malmo Univ Hosp, Dept Clin Sci, Malmo, Sweden; Lund Univ, Malmo, Sweden	Lund University; Skane University Hospital; Lund University	Dahlberg, J (corresponding author), Malmo Univ Hosp, Dept Clin Sci, Malmo, Sweden.	jonas.dahlberg@med.lu.se		Melander, Olle/0000-0002-2581-484X	Swedish Medical Research Council; Swedish Heart and Lung Foundation; Medical Faculty of Lund University, Malmo University Hospital; Albert Pahlsson Research Foundation; Crafoord Foundation; Ernhold Lundstroms Research Foundation; Region Skane, Hulda; Conrad Mossfelt Foundation; King Gustaf V and Queen Victoria Foundation	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Medical Faculty of Lund University, Malmo University Hospital; Albert Pahlsson Research Foundation; Crafoord Foundation; Ernhold Lundstroms Research Foundation; Region Skane, Hulda; Conrad Mossfelt Foundation; King Gustaf V and Queen Victoria Foundation	This study supported by grants from the Swedish Medical Research Council, the Swedish Heart and Lung Foundation, the Medical Faculty of Lund University, Malmo University Hospital, the Albert Pahlsson Research Foundation, the Crafoord Foundation, the Ernhold Lundstroms Research Foundation, the Region Skane, Hulda and Conrad Mossfelt Foundation and King Gustaf V and Queen Victoria Foundation The sponsors had no role in the study design, collection, analysis, interpretation of data or the writing and submission of the manuscript.	Dunn DM, 2002, J HUM GENET, V47, P665, DOI 10.1007/s100380200102; Fava C, 2006, KIDNEY INT, V70, P562, DOI 10.1038/sj.ki.5001590; Fava C, 2004, J HYPERTENS, V22, P1717, DOI 10.1097/00004872-200409000-00015; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; GUYTON AC, 1987, HYPERTENSION, V10, P1, DOI 10.1161/01.HYP.10.1.1; GUYTON AC, 1989, AM J HYPERTENS, V2, P575, DOI 10.1093/ajh/2.7.575; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; He F, 2002, J HUM HYPERTENS, V16, P761, DOI 10.1038/sj.jhh.1001459; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Melander O, 2003, AM J HYPERTENS, V16, P729, DOI 10.1016/S0895-7061(03)00981-6; Melander O, 2002, HYPERTENSION, V39, P996, DOI 10.1161/01.HYP.0000017552.91014.2A; Melander O, 2001, BLOOD PRESSURE, V10, P254, DOI 10.1080/080370501753400575; Melander O, 2007, J HYPERTENS, V25, P619, DOI 10.1097/HJH.0b013e328013cd50; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; SBU, 2004, MOD EL BLOOD PRESS; Sharma A M, 1996, Blood Press Suppl, V1, P59; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Svetkey LP, 1996, HYPERTENSION, V28, P854, DOI 10.1161/01.HYP.28.5.854; VANDENPLAS S, 1984, J MED GENET, V21, P164, DOI 10.1136/jmg.21.3.164; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; Zeggini E, 2007, DIABETOLOGIA, V50, P1, DOI 10.1007/s00125-006-0507-x	25	57	57	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e432	10.1371/journal.pone.0000432	http://dx.doi.org/10.1371/journal.pone.0000432			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487281	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445800014
J	Efroni, S; Schaefer, CF; Buetow, KH				Efroni, Sol; Schaefer, Carl F.; Buetow, Kenneth H.			Identification of Key Processes Underlying Cancer Phenotypes Using Biologic Pathway Analysis	PLOS ONE			English	Article								Cancer is recognized to be a family of gene-based diseases whose causes are to be found in disruptions of basic biologic processes. An increasingly deep catalogue of canonical networks details the specific molecular interaction of genes and their products. However, mapping of disease phenotypes to alterations of these networks of interactions is accomplished indirectly and non-systematically. Here we objectively identify pathways associated with malignancy, staging, and outcome in cancer through application of an analytic approach that systematically evaluates differences in the activity and consistency of interactions within canonical biologic processes. Using large collections of publicly accessible genome-wide gene expression, we identify small, common sets of pathways - Trka Receptor, Apoptosis response to DNA Damage, Ceramide, Telomerase, CD40L and Calcineurin - whose differences robustly distinguish diverse tumor types from corresponding normal samples, predict tumor grade, and distinguish phenotypes such as estrogen receptor status and p53 mutation state. Pathways identified through this analysis perform as well or better than phenotypes used in the original studies in predicting cancer outcome. This approach provides a means to use genome-wide characterizations to map key biological processes to important clinical features in disease.	[Efroni, Sol; Schaefer, Carl F.; Buetow, Kenneth H.] NCI, Ctr Bioinformat, Rockville, MD USA; [Buetow, Kenneth H.] NCI, Lab Populat Genet, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Buetow, KH (corresponding author), NCI, Ctr Bioinformat, Rockville, MD USA.	buetowk@mail.nih.gov	Efroni, Sol/I-6752-2012	Efroni, Sol/0000-0001-7927-6349	NIH, National Cancer Institute	NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the intramural research program of the NIH, National Cancer Institute.	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bianco RB, 2006, EUR J CANCER, V42, P290, DOI 10.1016/j.ejca.2005.07.034; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; BITTNER M, 2006, INT GENOMICS CONSORT; Bonnaud S, 2007, CANCER RES, V67, P1803, DOI 10.1158/0008-5472.CAN-06-2802; Buchholz M, 2007, CELL CYCLE, V6, P16, DOI 10.4161/cc.6.1.3650; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Buetow KH, 2002, CANCER CELL, V1, P315, DOI 10.1016/S1535-6108(02)00065-X; Claus R., 2000, Current Drug Targets, V1, P185, DOI 10.2174/1389450003349272; Dolle L, 2004, CURR CANCER DRUG TAR, V4, P463, DOI 10.2174/1568009043332853; DUDA RO, 2001, PATTERN CLASSIFICATI, pR20; Gielen SCJP, 2005, ENDOCR-RELAT CANCER, V12, P1037, DOI 10.1677/erc.1.01046; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HASTIE T, 2001, ELEMENTS STAT LEARNI, pR16; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Lin CF, 2006, CURR MED CHEM, V13, P1609, DOI 10.2174/092986706777441986; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; *NAT CANC I CTR BI, NAT CANC I CTR BIOIN; Padron JM, 2006, CURR MED CHEM, V13, P755, DOI 10.2174/092986706776055553; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Regev A, 2002, NATURE, V419, P343, DOI 10.1038/419343a; Rhodes DR, 2005, NAT BIOTECHNOL, V23, P951, DOI 10.1038/nbt1103; Rhodes DR, 2005, NAT GENET, V37, pS31, DOI 10.1038/ng1570; ROTH RB, 2006, NEUROGENETICS; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schaefer CF, 2004, ANN NY ACAD SCI, V1020, P77, DOI 10.1196/annals.1310.009; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Sharma S, 2003, HUM GENE THER, V14, P1511, DOI 10.1089/104303403322495025; Stepulak A, 2005, P NATL ACAD SCI USA, V102, P15605, DOI 10.1073/pnas.0507679102; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; THEODORIDIS S, 2003, PATTERN RECOGN, pR14; Thevissen K, 2006, MINI-REV MED CHEM, V6, P699, DOI 10.2174/138955706777435643; Tomfohr J, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-225; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Watters JW, 2006, MOL CANCER THER, V5, P2444, DOI 10.1158/1535-7163.MCT-06-0340; WEBB AR, 2002, STAT PATTERN RECOGNI, pR18; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	47	91	92	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e425	10.1371/journal.pone.0000425	http://dx.doi.org/10.1371/journal.pone.0000425			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487280	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445800007
J	Maxwell, PJ; Gallagher, R; Seaton, A; Wilson, C; Scullin, P; Pettigrew, J; Stratford, IJ; Williams, KJ; Johnston, PG; Waugh, DJJ				Maxwell, P. J.; Gallagher, R.; Seaton, A.; Wilson, C.; Scullin, P.; Pettigrew, J.; Stratford, I. J.; Williams, K. J.; Johnston, P. G.; Waugh, D. J. J.			HIF-1 and NF-kappa B-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells	ONCOGENE			English	Article						IL-8; hypoxia; CXCR1; CXCR2; HIF-1; NF-kappa B	ENDOTHELIAL GROWTH-FACTOR; CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN-8 EXPRESSION; INDUCIBLE FACTOR; GENE-EXPRESSION; ACTIVATION; ANGIOGENESIS; TUMORIGENICITY; TRANSCRIPTION; METASTASIS	Hypoxic cancer cells are resistant to treatment, leading to the selection of cells with a more malignant phenotype. The expression of interleukin-8 (IL-8) plays an important role in the tumorigenesis and metastasis of solid tumors including prostate cancer. Recently, we detected elevated expression of IL-8 and IL-8 receptors in human prostate cancer tissue. The objective of the current study was to determine whether hypoxia increases IL-8 and IL-8 receptor expression in prostate cancer cells and whether this contributes to a survival advantage in hypoxic cells. IL-8, CXCR1 and CXCR2 messenger RNA (mRNA) expression in PC3 cells was upregulated in response to hypoxia in a time-dependent manner. Elevated IL-8 secretion following hypoxia was detected by enzyme-linked immunosorbent assay, while immunoblotting confirmed elevated receptor expression. Attenuation of hypoxia-inducible factor (HIF-1) and nuclear factor-kappa B (NF-kappa B) transcriptional activity using small interfering RNA (siRNA), a HIF-1 dominant-negative and pharmacological inhibitors, abrogated hypoxia-induced transcription of CXCR1 and CXCR2 in PC3 cells. Furthermore, chromatin-IP analysis demonstrated binding of HIF-1 and NF-kappa B to CXCR1. Finally, inhibition of IL-8 signaling potentiated etoposide-induced cell death in hypoxic PC3 cells. These results suggest that IL-8 signaling confers a survival advantage to hypoxic prostate cancer cells, and therefore, strategies to inhibit IL-8 signaling may sensitize hypoxic tumor cells to conventional treatments.	Queens Univ Belfast, Ctr Canc Res &Cell Biol, Belfast BT9 7AB, Antrim, North Ireland; Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England	Queens University Belfast; University of Manchester	Waugh, DJJ (corresponding author), Queens Univ Belfast, Ctr Canc Res &Cell Biol, Univ Flr, Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.waugh@qub.ac.uk		WAUGH, DAVID/0000-0002-4022-3765; stratford, ian/0000-0002-5222-4765	Medical Research Council [G0500366] Funding Source: Medline; Wellcome Trust [067104/Z/02/Z] Funding Source: Medline; MRC [G0500366] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Brown LM, 2006, MOL PHARMACOL, V69, P411, DOI 10.1124/mol.105.015743; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Cairns RA, 2004, CANCER RES, V64, P2054, DOI 10.1158/0008-5472.CAN-03-3196; Carnell DM, 2006, INT J RADIAT ONCOL, V65, P91, DOI 10.1016/j.ijrobp.2005.11.044; Coffey RNT, 2005, CANCER-AM CANCER SOC, V103, P1363, DOI 10.1002/cncr.20918; Cvetkovic D, 2001, UROLOGY, V57, P821, DOI 10.1016/S0090-4295(00)01044-X; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Ghafar MA, 2003, PROSTATE, V54, P58, DOI 10.1002/pros.10162; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Grutkoski PS, 1999, J LEUKOCYTE BIOL, V65, P171, DOI 10.1002/jlb.65.2.171; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Inoue K, 2000, CANCER RES, V60, P2290; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kim KS, 2006, J IMMUNOL, V177, P7211, DOI 10.4049/jimmunol.177.10.7211; KOONG AC, 1994, CANCER RES, V54, P1425; Kunz M, 1999, AM J PATHOL, V155, P753, DOI 10.1016/S0002-9440(10)65174-7; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Li Aihua, 2005, Angiogenesis, V8, P63, DOI 10.1007/s10456-005-5208-4; MACMANUS CF, 2007, IN PRESS MOL CANC RE; Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294; Moldobaeva A, 2005, AM J PHYSIOL-LUNG C, V288, pL1117, DOI 10.1152/ajplung.00370.2004; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Movsas B, 1999, UROLOGY, V53, P11, DOI 10.1016/S0090-4295(98)00500-7; MURPHY C, 2005, CLIN CANCER RES, V11, P4702; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Shi Q, 2001, J INTERF CYTOK RES, V21, P553, DOI 10.1089/10799900152547812; Shi QA, 1999, J INTERF CYTOK RES, V19, P1363, DOI 10.1089/107999099312821; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Sowter HM, 2003, CANCER RES, V63, P6130; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takami M, 2002, J IMMUNOL, V168, P4559, DOI 10.4049/jimmunol.168.9.4559; Trisciuoglio D, 2005, MOL BIOL CELL, V16, P4153, DOI 10.1091/mbc.E04-12-1087; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xu L, 1999, CANCER RES, V59, P5822; Xu L, 2004, CLIN CANCER RES, V10, P701, DOI 10.1158/1078-0432.CCR-0953-03; Yan SF, 1997, J BIOL CHEM, V272, P4287, DOI 10.1074/jbc.272.7.4287; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447	49	173	184	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7333	7345		10.1038/sj.onc.1210536	http://dx.doi.org/10.1038/sj.onc.1210536			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533374				2022-12-25	WOS:000250955700005
J	Depaux, A; Regnier-Ricard, F; Germani, A; Varin-Blank, N				Depaux, A.; Regnier-Ricard, F.; Germani, A.; Varin-Blank, N.			A crosstalk between hSiah2 and Pias E3-ligases modulates Pias-dependent activation	ONCOGENE			English	Article						Siah; Pias; ubiquitination; proteasome	C-JUN; PROTEIN INHIBITOR; SIAH-1 INTERACTS; GENE-ACTIVATION; P53 ACTIVITY; RECEPTOR; SUMO; DEGRADATION; HOMOLOGS; DEGRADES	Protein inhibitor of activated STAT ( Pias) and human homologues of seven in absentia ( hSiah) proteins both exhibit properties of ubiquitin- family peptides conjugating enzymes. Pias present E3- ligase activity for small ubiquitin-related modifiers ( Sumo) covalent attachment to their targets. This post- translational modi. cation is responsible for the activation of different transcription factors such as AP1. HSiah proteins possess ubiquitin- E3-ligase activity that triggers their partners to proteasomal-dependent degradation. The present study identifies Pias as a new hSiah2- interacting protein. We demonstrate that hSiah2 regulates specifically the proteasome-dependent degradation of Pias proteins. On reverse, Pias does not prevent hSiah2 degradation. We provide evidences for hSiah2- dependent degradation of Pias as being a mechanism in the regulation of c- jun N- terminal kinase- activating pathways. This report describes a new interconnection between sumoylation and ubiquitination pathways by regulating the levels of the E3-ligases available for these processes.	Univ Paris 05, Inst Cochin, Dept Hematol, CNRS, F-75014 Paris, France; Inserm, U567, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Varin-Blank, N (corresponding author), Univ Paris 05, Inst Cochin, Dept Hematol, CNRS, Bat G Roussy ,7eme etage,27 Rue Fg St Jacques, F-75014 Paris, France.	varin@cochin.inserm.fr		VARIN-BLANK, Nadine/0000-0003-2769-018X				Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Depaux A, 2006, BIOCHEM BIOPH RES CO, V348, P857, DOI 10.1016/j.bbrc.2006.07.092; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Liu ZH, 1998, ACTA POLYM SIN, P1; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Millot GA, 2002, EXP HEMATOL, V30, P166, DOI 10.1016/S0301-472X(01)00776-7; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nakayama K, 2004, CELL CYCLE, V3, P1345, DOI 10.4161/cc.3.11.1207; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Reed JC, 2002, NAT STRUCT BIOL, V9, P8, DOI 10.1038/nsb0102-8; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Simon MC, 2004, CELL, V117, P851, DOI 10.1016/j.cell.2004.06.010; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	50	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6665	6676		10.1038/sj.onc.1210486	http://dx.doi.org/10.1038/sj.onc.1210486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17533377				2022-12-25	WOS:000250081500008
J	Johnson, C; Marriott, SJ; Levy, LS				Johnson, C.; Marriott, S. J.; Levy, L. S.			Overexpression of p101 activates PI3K gamma signaling in T cells and contributes to cell survival	ONCOGENE			English	Article						phosphatidylinositol-3-kinase-gamma; retrovirus integration site; lymphoma; apoptosis	G-BETA-GAMMA; PHOSPHOINOSITIDE 3-KINASE; REGULATORY SUBUNIT; FREQUENT INACTIVATION; CANCER; PIK3CA; P110-GAMMA; P110-DELTA; EXPRESSION; MUTATIONS	p101, the regulatory subunit of phosphatidylinositol--3-kinase- gamma (PI3KC gamma), was recently reported as a common site of retroviral insertion in T-cell lymphomas induced in mice by MoFe2-MuLV, a unique recombinant gammaretrovirus. The common interruption of p101 by retroviral integration suggests that the locus encodes an oncogene whose altered expression is related to the induction of T-cell malignancy. To examine a possible role in the malignant process, p101 was overexpressed in human T-cell lines Molt-4 and Jurkat. Transient overexpression of p101 induced apoptosis in recipient cells; however, stable expression could be established in cells that expressed moderate levels of p101. Constitutive p101 overexpression in those cells conferred significant protection against ultraviolet-induced apoptosis. Protection against apoptotic induction was attributed to p101-mediated activation of the Akt pathway. Constitutive overexpression of p101 enhanced the activity of p110 gamma and further sensitized it to activation upon stimulation of G protein-coupled receptor. These findings are the first to implicate altered expression of p101 in malignancy, specifically in T-cell lymphoma. The findings further provide insight into the regulation of p110 gamma, indicating that the stoichiometry of p110 gamma and p101 are important in regulating PI3K gamma signaling.	Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Tualne Canc Ctr, New Orleans, LA 70112 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA	Tulane University; Tulane University; Baylor College of Medicine; Baylor College of Medicine	Levy, LS (corresponding author), Tulane Univ, Sch Med, Dept Microbiol & Immunol, 1430 Tulane Ave SL-38, New Orleans, LA 70112 USA.	llevy@tulane.edu			NATIONAL CANCER INSTITUTE [R01CA083823] Funding Source: NIH RePORTER; NCI NIH HHS [CA83823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbdelMageed AB, 1997, CANCER GENE THER, V4, P199; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cairns P, 1997, CANCER RES, V57, P4997; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Curnock AP, 2002, IMMUNOLOGY, V105, P125, DOI 10.1046/j.1365-2567.2002.01345.x; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hickey FB, 2006, J BIOL CHEM, V281, P2441, DOI 10.1074/jbc.M511173200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Johnson C, 2005, J VIROL, V79, P57, DOI 10.1128/JVI.79.1.57-66.2005; Jucker M, 2002, LEUKEMIA, V16, P894, DOI 10.1038/sj.leu.2402484; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Voigt P, 2006, J BIOL CHEM, V281, P9977, DOI 10.1074/jbc.M512502200; Voigt P, 2005, J BIOL CHEM, V280, P5121, DOI 10.1074/jbc.M413104200; Woenckhaus J, 2002, J PATHOL, V198, P335, DOI 10.1002/path.1207	31	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					7049	7057		10.1038/sj.onc.1210504	http://dx.doi.org/10.1038/sj.onc.1210504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486067	Bronze			2022-12-25	WOS:000250412200010
J	Lukasiewicz, R; Velazquez-Dones, A; Huynh, N; Hagopian, J; Fu, XD; Adams, J; Ghosh, G				Lukasiewicz, Randall; Velazquez-Dones, Adolfo; Huynh, Nhat; Hagopian, Jonathan; Fu, Xiang-Dong; Adams, Joseph; Ghosh, Gourisankar			Structurally unique yeast and mammalian serine-arginine protein kinases catalyze evolutionarily conserved phosphorylation reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH SPLICING FACTORS; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; NUCLEAR IMPORT; SRPK1; CLK/STY; SKY1P; MOTIF; INACTIVATION; METHYLATION	The mammalian serine-arginine (SR) protein, ASF/SF2, contains multiple contiguous RS dipeptides at the C terminus, and similar to 12 of these serines are processively phosphorylated by the SR protein kinase 1 (SRPK1). We have recently shown that a docking motif in ASF/SF2 specifically interacts with a groove in SRPK1, and this interaction is necessary for processive phosphorylation. We previously showed that SRPK1 and its yeast ortholog Sky1p maintain their active conformations using diverse structural strategies. Here we tested if the mechanism of ASF/SF2 phosphorylation by SRPK is evolutionarily conserved. We show that Sky1p forms a stable complex with its heterologous mammalian substrate ASF/SF2 and processively phosphorylates the same sites as SRPK1. We further show that Sky1p utilizes the same docking groove to bind yeast SR-like protein Gbp2p and phosphorylates all three serines present in a contiguous RS dipeptide stretch. However, the mechanism of Gbp2p phosphorylation appears to be non-processive. Thus, there are physical attributes of SR and SR-like substrates that dictate the mechanism of phosphorylation, whereas the ability to processively phosphorylate substrates is inherent to SR protein kinases.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr,3103 Nat Sci Bldg, La Jolla, CA 92093 USA.	gghosh@ucsd.edu			NCI NIH HHS [T32 CA009523] Funding Source: Medline; NIGMS NIH HHS [GM08326, GM67969] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067969] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aubol BE, 2003, P NATL ACAD SCI USA, V100, P12601, DOI 10.1073/pnas.1635129100; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; Ding JH, 2006, MOL BIOL CELL, V17, P876, DOI 10.1091/mbc.E05-10-0963; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1995, RNA, V1, P663; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Izaurralde E, 2004, NAT STRUCT MOL BIOL, V11, P210, DOI 10.1038/nsmb0304-210; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Lukasiewicz R, 2007, J MOL BIOL, V367, P249, DOI 10.1016/j.jmb.2006.12.031; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; Ngo JCK, 2007, STRUCTURE, V15, P123, DOI 10.1016/j.str.2006.11.011; Ngo JCK, 2005, MOL CELL, V20, P77, DOI 10.1016/j.molcel.2005.08.025; Nolen B, 2001, NAT STRUCT BIOL, V8, P176, DOI 10.1038/84178; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; Sanford J R, 2003, Prog Mol Subcell Biol, V31, P33; Schenk PW, 2001, CANCER RES, V61, P6982; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Siebel CW, 1999, P NATL ACAD SCI USA, V96, P5440, DOI 10.1073/pnas.96.10.5440; Stojdl DF, 1999, BIOCHEM CELL BIOL, V77, P293, DOI 10.1139/bcb-77-4-293; Velazquez-Dones A, 2005, J BIOL CHEM, V280, P41761, DOI 10.1074/jbc.M504156200; Windgassen M, 2003, EMBO REP, V4, P278, DOI 10.1038/sj.embor.embor763; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707	28	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23036	23043		10.1074/jbc.M611305200	http://dx.doi.org/10.1074/jbc.M611305200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17517895	hybrid			2022-12-25	WOS:000248577500006
J	Braun, GS; Kretzler, M; Heider, T; Floege, J; Holzman, LB; Kriz, W; Moeller, MJ				Braun, Gerald S.; Kretzler, Matthias; Heider, Torsten; Floege, Juergen; Holzman, Lawrence B.; Kriz, Wilhelm; Moeller, Marcus J.			Differentially spliced isoforms of FAT1 are asymmetrically distributed within migrating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAFFOLDING PROTEINS; MAMMALIAN-CELLS; ACTIN DYNAMICS; EXPRESSION; GENE; ASSOCIATION; POLARIZATION; STABILITY; MOLECULES; CADHERINS	Cadherin FAT1 is localized along the leading edge of mammalian cells and is necessary for polarization and directed migration. It is essential for maintenance of the complex cytoarchitecture of the glomerular filtration barrier within the kidney. In this study, three novel splice isoforms of FAT1 with important functional differences in comparison with wild-type FAT1, FAT1(WT), were identified. The novel variants contained additional short peptide sequences at a specific site of the cytoplasmic domain (+ 12 or + 32 or + 8 amino acids, the latter resulting in a premature stop codon). FAT1(+ 12) was expressed in all peripheral tissues together with FAT1(WT), whereas FAT1(+ 32) and -( + 8TR) were brain-specific. At the subcellular level, exclusively FAT1(WT) was localized along the cellular leading edge, whereas spliced FAT1 isoforms were confined to intercellular junctions. A shift of FAT1(WT) expression toward a predominance of FAT1(+ 12) was observed in migratory versus quiescent cells. A similar shift was observed in vivo when glomeruli from healthy individuals were compared with those from patients affected by glomerulonephritis. At the molecular level, the differential subcellular localization of FAT1 isoforms was mediated by a novel region harboring a phosphotyrosine-binding-like motif( DN_XYH), which was disrupted by the peptide inserts in the alternative splice variants. Overexpression of FAT1(WT) or specific knockdown of spliced FAT1 isoforms resulted in formation of cellular protrusions or increased wound healing, respectively. In summary, FAT1(WT) is the only FAT1 isoform located along the cellular leading edge. Only FAT1(WT) is up-regulated in migration, induces cellular process formation when overexpressed, and is necessary for efficient wound healing.	Rhein Westfal TH Aachen, Div Nephrol & Immunol, D-52074 Aachen, Germany; Univ Heidelberg, Inst Anat & Cell Biol 1, D-69120 Heidelberg, Germany; Univ Michigan, Div Nephrol, Ann Arbor, MI 48109 USA	RWTH Aachen University; Ruprecht Karls University Heidelberg; University of Michigan System; University of Michigan	Moeller, MJ (corresponding author), Rhein Westfal TH Aachen, Div Nephrol & Immunol, Pauwelsstr 30, D-52074 Aachen, Germany.	mmoeller@ukaachen.de	Moeller, Marcus J/L-1836-2015	Braun, Gerald/0000-0002-4783-9669; Holzman, Lawrence/0000-0002-8961-234X				Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Blair IP, 2006, MOL PSYCHIATR, V11, P372, DOI 10.1038/sj.mp.4001784; Braun GS, 2002, PFLUG ARCH EUR J PHY, V445, P321, DOI 10.1007/s00424-002-0906-x; Capon F, 2004, HUM MOL GENET, V13, P2361, DOI 10.1093/hmg/ddh273; Castillejo-Lopez C, 2004, J BIOL CHEM, V279, P24034, DOI 10.1074/jbc.M313878200; Ciani L, 2003, MOL CELL BIOL, V23, P3575, DOI 10.1128/MCB.23.10.3575-3582.2003; Gundersen GG, 2004, CURR OPIN CELL BIOL, V16, P106, DOI 10.1016/j.ceb.2003.11.010; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hou R, 2006, J CELL BIOL, V173, P417, DOI 10.1083/jcb.200508121; Huber TB, 2005, CURR OPIN NEPHROL HY, V14, P211, DOI 10.1097/01.mnh.0000165885.85803.a8; Ichimura K, 2003, J HISTOCHEM CYTOCHEM, V51, P1589, DOI 10.1177/002215540305101203; Inoue T, 2001, KIDNEY INT, V59, P1003, DOI 10.1046/j.1523-1755.2001.00583.x; Kodama A, 2004, J CELL BIOL, V167, P203, DOI 10.1083/jcb.200408047; Kodama A, 2003, CELL, V115, P343, DOI 10.1016/S0092-8674(03)00813-4; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Ma D, 2003, NATURE, V421, P543, DOI 10.1038/nature01366; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; Moeller MJ, 2006, NEPHRON EXP NEPHROL, V103, pE69, DOI 10.1159/000090619; Moeller MJ, 2004, EMBO J, V23, P3769, DOI 10.1038/sj.emboj.7600380; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Schiwek D, 2004, KIDNEY INT, V66, P91, DOI 10.1111/j.1523-1755.2004.00711.x; Schmid H, 2003, J AM SOC NEPHROL, V14, P2958, DOI 10.1097/01.ASN.0000090745.85482.06; Schreiner D, 2006, FEBS LETT, V580, P5295, DOI 10.1016/j.febslet.2006.08.079; Tanoue T, 2005, J CELL SCI, V118, P2347, DOI 10.1242/jcs.02398; Tanoue T, 2004, J CELL BIOL, V165, P517, DOI 10.1083/jcb.200403006; Uhlik MT, 2005, J MOL BIOL, V345, P1, DOI 10.1016/j.jmb.2004.10.038; Vaughan KT, 2005, J CELL BIOL, V171, P197, DOI 10.1083/jcb.200509150; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wu Q, 2005, GENETICS, V169, P2179, DOI 10.1534/genetics.104.037606; Zhang LH, 2001, J BIOL CHEM, V276, P10476, DOI 10.1074/jbc.M008991200	33	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22823	22833		10.1074/jbc.M701758200	http://dx.doi.org/10.1074/jbc.M701758200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17500054	hybrid			2022-12-25	WOS:000248354200060
J	Panne, D; McWhirter, SM; Maniatis, T; Harrison, SC				Panne, Daniel; McWhirter, Sarah M.; Maniatis, Tom; Harrison, Stephen C.			Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; IRF-3 TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; VIRUS-INFECTION; GENE-EXPRESSION; VIRAL-INFECTION; BETA ENHANCER; IKK-EPSILON; IN-VIVO; KAPPA-B	The transcription factor interferon regulatory factor 3 (IRF-3) regulates genes in the innate immune response. IRF-3 is activated through phosphorylation by the kinases IKK is an element of and/or TBK1. Phosphorylation results in IRF-3 dimerization and removal of an autoinhibitory structure to allow interaction with the coactivators CBP/p300. The precise role of the different phosphorylation sites has remained controversial. Using purified proteins we show that TBK1 can directly phosphorylate full-length IRF-3 in vitro. Phosphorylation at residues in site 2 (Ser(396) - Ser(405)) alleviates autoinhibition to allow interaction with CBP ((C) under bar CREB-(b) under bar binding (p) under bar protein) and facilitates phosphorylation at site 1 (Ser(385) or Ser(386)). Phosphorylation at site 1 is, in turn, required for IRF-3 dimerization. The data support a two-step phosphorylation model for IRF-3 activation mediated by TBK1.	Harvard Univ, Sch Med, Howard Huges Med Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Mol & Cell Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University	Harrison, SC (corresponding author), Harvard Univ, Sch Med, Howard Huges Med Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	harrison@crystal.harvard.edu	Panne, Daniel/I-8368-2017	Panne, Daniel/0000-0001-9158-5507				Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; JOHNSON J, 2007, J BIOL CHEM; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Panne D, 2004, EMBO J, V23, P4384, DOI 10.1038/sj.emboj.7600453; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Qin BY, 2005, STRUCTURE, V13, P1269, DOI 10.1016/j.str.2005.06.011; Qin BY, 2003, NAT STRUCT BIOL, V10, P913, DOI 10.1038/nsb1002; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Suhara W, 2000, J BIOCHEM-TOKYO, V128, P301, DOI 10.1093/oxfordjournals.jbchem.a022753; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	23	118	121	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22816	22822		10.1074/jbc.M703019200	http://dx.doi.org/10.1074/jbc.M703019200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17526488	Green Published, hybrid			2022-12-25	WOS:000248354200059
J	Narayanan, S; Sato, T; Wolfe, MS				Narayanan, Saravanakumar; Sato, Toru; Wolfe, Michael S.			A C-terminal region of signal peptide peptidase defines a functional domain for intramembrane aspartic protease catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE REVEALS; ACTIVE-SITE; TRANSMEMBRANE DOMAIN; PRESENILIN; PROTEOLYSIS; FAMILY; IDENTIFICATION; RECONSTITUTION; ORGANIZATION; NICASTRIN	Intramembrane proteolysis is now firmly established as a prominent biological process, and structure elucidation is emerging as the new frontier in the understanding of these novel membrane-embedded enzymes. Reproducing this unusual hydrolysis within otherwise water-excluding transmembrane regions with purified proteins is a challenging prerequisite for such structural studies. Here we show the bacterial expression, purification, and reconstitution of proteolytically active signal peptide peptidase (SPP), a membrane-embedded enzyme in the presenilin family of aspartyl proteases. This finding formally proves that, unlike presenilin, SPP does not require any additional proteins for proteolysis. Surprisingly, the conserved C-terminal half of SPP is sufficient for proteolytic activity; purification and reconstitution of this engineered fragment of several SPP orthologues revealed that this region defines a functional domain for an intramembrane aspartyl protease. The discovery of minimal requirements for intramembrane proteolysis should facilitate mechanistic and structural analysis and help define general biochemical principles of hydrolysis in a hydrophobic environment.	Brigham & Womens Hosp, Harvard Med Sch, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Wolfe, MS (corresponding author), Brigham & Womens Hosp, Harvard Med Sch, Ctr Neurol Dis, 77 Ave Louis Pasteur,HIM 754, Boston, MA 02115 USA.	mwolfe@rics.bwh.harvard.edu			NATIONAL INSTITUTE ON AGING [P01AG015379, R01AG017574] Funding Source: NIH RePORTER; NIA NIH HHS [AG 17574, AG 15379] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama Y, 2004, EMBO J, V23, P4434, DOI 10.1038/sj.emboj.7600449; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Ben-Shem A, 2007, P NATL ACAD SCI USA, V104, P462, DOI 10.1073/pnas.0609773104; Brunkan AL, 2005, J NEUROCHEM, V94, P1315, DOI 10.1111/j.1471-4159.2005.03278.x; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2004, BIOORG MED CHEM LETT, V14, P1935, DOI 10.1016/j.bmcl.2004.01.077; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Friedmann E, 2004, J BIOL CHEM, V279, P50790, DOI 10.1074/jbc.M407898200; Huppert SS, 2005, DEV CELL, V8, P677, DOI 10.1016/j.devcel.2005.02.019; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kornilova AY, 2006, BIOCHEMISTRY-US, V45, P7598, DOI 10.1021/bi060107k; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Lazarov VK, 2006, P NATL ACAD SCI USA, V103, P6889, DOI 10.1073/pnas.0602321103; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; Loureiro J, 2006, NATURE, V441, P894, DOI 10.1038/nature04830; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; Nyborg AC, 2004, J BIOL CHEM, V279, P43148, DOI 10.1074/jbc.M405879200; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Ogura T, 2006, BIOCHEM BIOPH RES CO, V343, P525, DOI 10.1016/j.bbrc.2006.02.158; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Sato T, 2006, BIOCHEMISTRY-US, V45, P8649, DOI 10.1021/bi060597g; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tu HP, 2006, CELL, V126, P981, DOI 10.1016/j.cell.2006.06.059; Urban S, 2005, P NATL ACAD SCI USA, V102, P1883, DOI 10.1073/pnas.0408306102; Wang J, 2006, J NEUROCHEM, V96, P218, DOI 10.1111/j.1471-4159.2005.03548.x; Wang YC, 2006, NATURE, V444, P179, DOI 10.1038/nature05255; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wu ZR, 2006, NAT STRUCT MOL BIOL, V13, P1084, DOI 10.1038/nsmb1179	34	56	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20172	20179		10.1074/jbc.M701536200	http://dx.doi.org/10.1074/jbc.M701536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17517891	hybrid			2022-12-25	WOS:000247819300018
J	Ji, JY; Lee, RT; Vergnes, L; Fong, LG; Stewart, CL; Reue, K; Young, SG; Zhang, QP; Shanahan, CM; Lammerding, J				Ji, Julie Y.; Lee, Richard T.; Vergnes, Laurent; Fong, Loren G.; Stewart, Colin L.; Reue, Karen; Young, Stephen G.; Zhang, Qiuping; Shanahan, Catherine M.; Lammerding, Jan			Cell nuclei spin in the absence of lamin B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; MEMBRANE-PROTEIN; MAMMALIAN-CELLS; GENE-EXPRESSION; INTERPHASE NUCLEI; ENVELOPE PROTEINS; CHROMATIN MOTION; BUILDING-BLOCKS; PORE COMPLEXES; LIVING CELLS	Mutations of the nuclear lamins cause a wide range of human diseases, including Emery-Dreifuss muscular dystrophy and Hutchinson-Gilford progeria syndrome. Defects in A-type lamins reduce nuclear structural integrity and affect transcriptional regulation, but few data exist on the biological role of B-type lamins. To assess the functional importance of lamin B1, we examined nuclear dynamics in fibroblasts from Lmnb1(Delta/Delta) and wild-type littermate embryos by time-lapse videomicroscopy. Here, we report that Lmnb1(Delta/Delta) cells displayed striking nuclear rotation, with similar to 90% of Lmnb1(Delta/Delta) nuclei rotating at least 90 during an 8-h period. The rotation involved the nuclear interior as well as the nuclear envelope. The rotation of nuclei required an intact cytoskeletal network and was eliminated by expressing lamin B1 in cells. Nuclear rotation could also be abolished by expressing larger nesprin isoforms with long spectrin repeats. These findings demonstrate that lamin B1 serves a fundamental role within the nuclear envelope: anchoring the nucleus to the cytoskeleton.	Partners Res Facil, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Div Cardiovasc, Cambridge, MA 02139 USA; NCI, NIH, Frederick, MD 21702 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90073 USA; Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Cardiovasc Med, Cambridge CB2 2QQ, England	Harvard University; Brigham & Women's Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Lammerding, J (corresponding author), Partners Res Facil, 65 Landsdowne St, Cambridge, MA 02139 USA.	jlammerding@rics.bwh.harvard.edu	Lammerding, Jan/A-9498-2016; Zhang, Qiuping/L-3522-2019	Lammerding, Jan/0000-0003-4335-8611; Zhang, Qiuping/0000-0002-4000-3957; Shanahan, Catherine/0000-0002-8352-8171; Lee, Richard/0000-0003-4687-1381; vergnes, laurent/0000-0002-8804-589X; Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL073809, HL64858, HL079862, R01 HL082792, HL082792] Funding Source: Medline; NIAMS NIH HHS [AR050200] Funding Source: Medline; NINDS NIH HHS [R01 NS059348] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010377] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073809, R01HL082792, F32HL079862, P01HL064858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059348] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BARD F, 1985, BIOL CELL, V54, P135, DOI 10.1111/j.1768-322X.1985.tb00388.x; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Cao H, 2000, HUM MOL GENET, V9, P109, DOI 10.1093/hmg/9.1.109; Crisp M, 2006, J CELL BIOL, V172, P41, DOI 10.1083/jcb.200509124; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274; DEBONI U, 1988, ANTICANCER RES, V8, P885; ENGLANDER LL, 1987, J CELL BIOL, V104, P87, DOI 10.1083/jcb.104.1.87; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fan J, 2004, J CELL SCI, V117, P619, DOI 10.1242/jcs.00892; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Georgatos SD, 2001, EMBO J, V20, P2989, DOI 10.1093/emboj/20.12.2989; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Grady RM, 2005, P NATL ACAD SCI USA, V102, P4359, DOI 10.1073/pnas.0500711102; Haque F, 2006, MOL CELL BIOL, V26, P3738, DOI 10.1128/MCB.26.10.3738-3751.2006; Harborth J, 2001, J CELL SCI, V114, P4557; Hasan S, 2006, FEBS LETT, V580, P1263, DOI 10.1016/j.febslet.2006.01.039; HAY M, 1991, CELL MOTIL CYTOSKEL, V18, P63, DOI 10.1002/cm.970180107; Herbomel P, 1999, CURR BIOL, V9, pR627, DOI 10.1016/S0960-9822(99)80407-2; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; Hutchison CJ, 2001, J CELL SCI, V114, P9; King MC, 2006, NATURE, V442, P1003, DOI 10.1038/nature05075; Lammerding J, 2005, J CELL BIOL, V170, P781, DOI 10.1083/jcb.200502148; Lammerding J, 2006, J BIOL CHEM, V281, P25768, DOI 10.1074/jbc.M513511200; Lee JSH, 2005, MOL BIOL CELL, V16, P871, DOI 10.1091/mbc.e03-12-0910; Libotte T, 2005, MOL BIOL CELL, V16, P3411, DOI 10.1091/mbc.E04-11-1009; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; MAISON C, 1995, EMBO J, V14, P3311, DOI 10.1002/j.1460-2075.1995.tb07338.x; Malhas A, 2007, J CELL BIOL, V176, P593, DOI 10.1083/jcb.200607054; Malone CJ, 2003, CELL, V115, P825, DOI 10.1016/S0092-8674(03)00985-1; McGee MD, 2006, MOL BIOL CELL, V17, P1790, DOI 10.1091/mbc.E05-09-0894; Mislow JMK, 2002, FEBS LETT, V525, P135, DOI 10.1016/S0014-5793(02)03105-8; Muchir A, 2000, HUM MOL GENET, V9, P1453, DOI 10.1093/hmg/9.9.1453; Munter S, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-23; Padiath QS, 2006, NAT GENET, V38, P1114, DOI 10.1038/ng1872; Padmakumar VC, 2005, J CELL SCI, V118, P3419, DOI 10.1242/jcs.02471; Padmakumar VC, 2004, EXP CELL RES, V295, P330, DOI 10.1016/j.yexcr.2004.01.014; Pare GC, 2005, EXP CELL RES, V303, P388, DOI 10.1016/j.yexcr.2004.10.009; POMERAT CM, 1953, EXP CELL RES, V5, P191, DOI 10.1016/0014-4827(53)90104-9; Rabut G, 2004, NAT CELL BIOL, V6, P1114, DOI 10.1038/ncb1184; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Smythe C, 2000, EMBO J, V19, P3918, DOI 10.1093/emboj/19.15.3918; Soderqvist H, 1997, EUR J BIOCHEM, V250, P808, DOI 10.1111/j.1432-1033.1997.00808.x; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Szabo B, 2004, CELL MOTIL CYTOSKEL, V59, P38, DOI 10.1002/cm.20022; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; Vergnes L, 2004, P NATL ACAD SCI USA, V101, P10428, DOI 10.1073/pnas.0401424101; Wilhelmsen K, 2005, J CELL BIOL, V171, P799, DOI 10.1083/jcb.200506083; Worman HJ, 2006, TRENDS CELL BIOL, V16, P67, DOI 10.1016/j.tcb.2005.12.006; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; Zhang QP, 2005, J CELL SCI, V118, P673, DOI 10.1242/jcs.01642; Zhang QP, 2001, J CELL SCI, V114, P4485	57	73	74	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					20015	20026		10.1074/jbc.M611094200	http://dx.doi.org/10.1074/jbc.M611094200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17488709	hybrid			2022-12-25	WOS:000247650600075
J	Khoo, SK; Loll, B; Chan, WT; Shoeman, RL; Ngoo, L; Yeo, CC; Meinhart, A				Khoo, Seok Kooi; Loll, Bernhard; Chan, Wai Ting; Shoeman, Robert L.; Ngoo, Lena; Yeo, Chew Chieng; Meinhart, Anton			Molecular and structural characterization of the PezAT chromosomal toxin-antitoxin system of the human pathogen Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; PLASMID MAINTENANCE; CRYSTAL-STRUCTURE; MESSENGER-RNAS; CELL-DEATH; PSM19035; LOCI; INACTIVATION; MECHANISM	The chromosomal pezT gene of the Gram-positive pathogen Streptococcus pneumoniae encodes a protein that is homologous to the zeta toxin of the Streptococcus pyogenes plasmid pSM19035-encoded epsilon-zeta toxin-antitoxin system. Overexpression of pezT in Escherichia coli led to severe growth inhibition from which the bacteria recovered similar to 3 h after induction of expression. The toxicity of PezT was counteracted by PezA, which is encoded immediately upstream of pezT and shares weak sequence similarities in the C-terminal region with the epsilon antitoxin. The pezAT genes form a bicistronic operon that is co-transcribed from a sigma(70)-like promoter upstream of pezA and is negatively autoregulated with PezA functioning as a transcriptional repressor and PezT as a co-repressor. Both PezA and the non-toxic PezA(2)PezT(2) protein complex bind to a palindrome sequence that overlaps the promoter. This differs from the epsilon-zeta system in which epsilon functions solely as the antitoxin and transcriptional regulation is carried out by another protein designated omega. Results from site-directed mutagenesis experiments demonstrated that the toxicity of PezT is dependent on a highly conserved phosphoryltransferase active site and an ATP/GTP nucleotide binding site. In the PezA(2)PezT(2) complex, PezA neutralizes the toxicity of PezT by blocking the nucleotide binding site through steric hindrance.	Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany; Malaysia Univ Sci & Technol, Dept Biotechnol, Petaling Jaya, Malaysia	Max Planck Society	Yeo, CC (corresponding author), Max Planck Inst Med Res, Dept Biomol Mech, Jahnstr 29, D-69120 Heidelberg, Germany.	ccyeo@must.edu.my	Yeo, Chew Chieng/I-7082-2019; Loll, Bernhard/J-4815-2019; Meinhart, Anton/M-9647-2014	Yeo, Chew Chieng/0000-0002-9644-6925; Loll, Bernhard/0000-0001-7928-4488; 				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Brown JS, 2004, INFECT IMMUN, V72, P1587, DOI 10.1128/IAI.72.3.1587-1593.2004; Brown JS, 2001, MOL MICROBIOL, V40, P572, DOI 10.1046/j.1365-2958.2001.02414.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camacho AG, 2002, BIOL CHEM, V383, P1701, DOI 10.1515/BC.2002.191; CEGLOWSKI P, 1993, GENE, V136, P1, DOI 10.1016/0378-1119(93)90441-5; CEGLOWSKI P, 1993, MOL GEN GENET, V241, P579, DOI 10.1007/BF00279900; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Christensen-Dalsgaard M, 2006, MOL MICROBIOL, V62, P397, DOI 10.1111/j.1365-2958.2006.05385.x; Correia FF, 2006, J BACTERIOL, V188, P8360, DOI 10.1128/JB.01237-06; de la Hoz AB, 2000, P NATL ACAD SCI USA, V97, P728, DOI 10.1073/pnas.97.2.728; Gerdes K, 2005, NAT REV MICROBIOL, V3, P371, DOI 10.1038/nrmicro1147; Hayes F, 2003, SCIENCE, V301, P1496, DOI 10.1126/science.1088157; Izard T, 2000, EMBO J, V19, P2690, DOI 10.1093/emboj/19.11.2690; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kamada K, 2005, MOL CELL, V19, P497, DOI 10.1016/j.molcel.2005.07.004; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lioy VS, 2006, MICROBIOL-SGM, V152, P2365, DOI 10.1099/mic.0.28950-0; Mattison K, 2006, J BIOL CHEM, V281, P37942, DOI 10.1074/jbc.M605198200; McLean BW, 1997, CAN J MICROBIOL, V43, P981, DOI 10.1139/m97-141; Meinhart A, 2003, P NATL ACAD SCI USA, V100, P1661, DOI 10.1073/pnas.0434325100; Meinhart A, 2003, J BIOL CHEM, V278, P15917, DOI 10.1074/jbc.M301643200; Murayama K, 2001, J MOL BIOL, V314, P789, DOI 10.1006/jmbi.2001.5157; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nieto C, 2006, MOL MICROBIOL, V59, P1280, DOI 10.1111/j.1365-2958.2006.05027.x; Nieto C, 2007, J BACTERIOL, V189, P1266, DOI 10.1128/JB.01130-06; Pandey DP, 2005, NUCLEIC ACIDS RES, V33, P966, DOI 10.1093/nar/gki201; Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x; Pellegrini O, 2005, MOL MICROBIOL, V56, P1139, DOI 10.1111/j.1365-2958.2005.04606.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Weihofen WA, 2006, NUCLEIC ACIDS RES, V34, P1450, DOI 10.1093/nar/gkl015; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7; Zhu L, 2006, J BIOL CHEM, V281, P18638, DOI 10.1074/jbc.M512693200; Zielenkiewicz U, 2005, J BACTERIOL, V187, P6094, DOI 10.1128/JB.187.17.6094-6105.2005	39	84	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19606	19618		10.1074/jbc.M701703200	http://dx.doi.org/10.1074/jbc.M701703200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17488720	Green Published, hybrid			2022-12-25	WOS:000247650600035
J	Cheng, M; Foo, SY; Shi, ML; Tang, RH; Kong, LS; Law, SKA; Tan, SM				Cheng, Ming; Foo, Shen-Yun; Shi, Min-Long; Tang, Ren-Hong; Kong, Le-Sheng; Law, S. K. Alex; Tan, Suet-Mien			Mutation of a conserved asparagine in the I-like domain promotes constitutively active integrins alpha(L)ss(2) and alpha(IIb)ss(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION DEFICIENCY; ALPHA(L)BETA(2) HYBRID DOMAIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; EXTRACELLULAR SEGMENT; MONOCLONAL-ANTIBODY; SURFACE EXPRESSION; BETA-2 INTEGRINS; DISULFIDE BONDS; A-DOMAIN	The leukocyte beta(2) integrins are heterodimeric adhesion receptors required for a functional immune system. Many leukocyte adhesion deficiency-1 (LAD-1) mutations disrupt the expression and function of beta(2) integrins. Herein, we further characterized the LAD-1 mutation N329S in the beta(2) inserted (I)-like domain. This mutation converted alpha(L)beta(2) from a resting into a high affinity conformer because alpha(L)beta(2)N329S transfectants adhered avidly to ligand intercellular adhesion molecule (ICAM)-3 in the absence of additional activating agent. An extended open conformation is adopted by alpha(L)beta(2)N329S because of its reactivity with the beta(2) activation reporter monoclonal antibodies MEM148 and KIM127. A corresponding mutation in beta(3) generated constitutively active alpha(IIb)beta(3) that adhered to fibrinogen. This Asn is conserved in all human beta sub-units, and it resides before the last helix of the I-like domain, which is known to be important in activation signal propagation. By mutagenesis studies and review of existing integrin structures, we conjectured that this conserved Asn may have a primary role in shaping the I- like domain by stabilizing the conformation of the alpha 7 helix and the beta 6-alpha 7 loop in the I-like domain.	Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore; Natl Univ Singapore, Computat Res Grp, Res Link 1, Temasek Life Sci Lab, Singapore 117604, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore	Law, SKA (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	alaw@ntu.edu.sg; smtan@ntu.edu.sg	Tan, Suet/A-2224-2011; Kong, Lesheng/O-8933-2015; Law, Alex/A-2212-2011; shi, minlong/G-8734-2013	Kong, Lesheng/0000-0002-9225-3421; Tan, Suet-Mien/0000-0003-2371-8739				ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Artoni A, 2004, P NATL ACAD SCI USA, V101, P13114, DOI 10.1073/pnas.0404201101; Barclay A. N., 1997, LEUCOCYTE ANTIGEN FA, V2nd; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Brower DL, 1997, P NATL ACAD SCI USA, V94, P9182, DOI 10.1073/pnas.94.17.9182; Chen JF, 2004, J BIOL CHEM, V279, P55556, DOI 10.1074/jbc.M407773200; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; Hogg N, 2000, MATRIX BIOL, V19, P211, DOI 10.1016/S0945-053X(00)00066-4; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Lu CF, 2001, J IMMUNOL, V166, P5629, DOI 10.4049/jimmunol.166.9.5629; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Luo BH, 2006, CURR OPIN CELL BIOL, V18, P579, DOI 10.1016/j.ceb.2006.08.005; Mathew EC, 2000, CLIN EXP IMMUNOL, V121, P133, DOI 10.1046/j.1365-2249.2000.01277.x; Mould AP, 2003, J BIOL CHEM, V278, P51622, DOI 10.1074/jbc.M306655200; NELSON C, 1992, J BIOL CHEM, V267, P3351; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; Shaw JM, 2001, CLIN EXP IMMUNOL, V126, P311, DOI 10.1046/j.1365-2249.2001.01661.x; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2002, P NATL ACAD SCI USA, V99, P16737, DOI 10.1073/pnas.252633099; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, BIOCHEMISTRY-US, V41, P4339, DOI 10.1021/bi016047u; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tang RH, 2005, J BIOL CHEM, V280, P29208, DOI 10.1074/jbc.M503239200; Tng E, 2004, J BIOL CHEM, V279, P54334, DOI 10.1074/jbc.M407818200; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2004, J BIOL CHEM, V279, P40252, DOI 10.1074/jbc.C400362200; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101; Yang W, 2004, P NATL ACAD SCI USA, V101, P2333, DOI 10.1073/pnas.0307291101	48	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18225	18232		10.1074/jbc.M701386200	http://dx.doi.org/10.1074/jbc.M701386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17468108	hybrid			2022-12-25	WOS:000247302000029
J	Ali, GS; Palusa, SG; Golovkin, M; Prasad, J; Manley, JL; Reddy, ASN				Ali, Gul Shad; Palusa, Saiprasad G.; Golovkin, Maxim; Prasad, Jayendra; Manley, James L.; Reddy, Anireddy S. N.			Regulation of Plant Developmental Processes by a Novel Splicing Factor	PLOS ONE			English	Article							SERINE/ARGININE-RICH PROTEINS; MADS DOMAIN PROTEIN; PRE-MESSENGER-RNAS; FLOWERING-TIME; ARABIDOPSIS-THALIANA; BINDING-PROTEIN; GENE CONTROLS; SR PROTEINS; MERISTEM; ENCODES	Serine/arginine-rich (SR) proteins play important roles in constitutive and alternative splicing and other aspects of mRNA metabolism. We have previously isolated a unique plant SR protein (SR45) with atypical domain organization. However, the biological and molecular functions of this novel SR protein are not known. Here, we report biological and molecular functions of this protein. Using an in vitro splicing complementation assay, we showed that SR45 functions as an essential splicing factor. Furthermore, the alternative splicing pattern of transcripts of several other SR genes was altered in a mutant, sr45-1, suggesting that the observed phenotypic abnormalities in sr45-1 are likely due to altered levels of SR protein isoforms, which in turn modulate splicing of other pre-mRNAs. sr45-1 exhibited developmental abnormalities, including delayed flowering, narrow leaves and altered number of petals and stamens. The late flowering phenotype was observed under both long days and short days and was rescued by vernalization. FLC, a key flowering repressor, is up-regulated in sr45-1 demonstrating that SR45 influences the autonomous flowering pathway. Changes in the alternative splicing of SR genes and the phenotypic defects in the mutant were rescued by SR45 cDNA, further confirming that the observed defects in the mutant are due to the lack of SR45. These results indicate that SR45 is a novel plant-specific splicing factor that plays a crucial role in regulating developmental processes.	[Ali, Gul Shad; Palusa, Saiprasad G.; Golovkin, Maxim; Reddy, Anireddy S. N.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; [Ali, Gul Shad; Palusa, Saiprasad G.; Golovkin, Maxim; Reddy, Anireddy S. N.] Colorado State Univ, Program Mol Plant Biol, Ft Collins, CO 80523 USA; [Prasad, Jayendra; Manley, James L.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Colorado State University; Colorado State University; Columbia University	Reddy, ASN (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.	reddy@colostate.edu		Manley, James/0000-0002-8341-1459; Reddy, Anireddy/0000-0002-4038-4091	Department of Energy [FG02-04ER15556]; NIH [GM048259]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048259, R37GM048259] Funding Source: NIH RePORTER	Department of Energy(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a grant from the Department of Energy (DE-FG02-04ER15556) to ASNR and NIH grant GM048259 to JLM.	Ali GS, 2003, PLANT J, V36, P883, DOI 10.1046/j.1365-313X.2003.01932.x; Ali GS, 2006, J CELL SCI, V119, P3527, DOI 10.1242/jcs.03144; Ausin I, 2004, NAT GENET, V36, P162, DOI 10.1038/ng1295; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger D, 2000, GENE DEV, V14, P1119; Bergmann DC, 2004, SCIENCE, V304, P1494, DOI 10.1126/science.1096014; BOSS PK, 2004, ENABLING PROMOTING R, V16, pS18; Byrne ME, 2005, CURR OPIN PLANT BIOL, V8, P59, DOI 10.1016/j.pbi.2004.11.009; Chalfun A, 2005, PLANT MOL BIOL, V57, P559, DOI 10.1007/s11103-005-0698-4; CLARK SE, 1993, DEVELOPMENT, V119, P397; CLARK SE, 1995, DEVELOPMENT, V121, P2057; Fletcher JC, 2001, DEVELOPMENT, V128, P1323; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; Golovkin M, 1996, PLANT CELL, V8, P1421, DOI 10.1105/tpc.8.8.1421; Golovkin M, 1998, PLANT CELL, V10, P1637, DOI 10.1105/tpc.10.10.1637; Golovkin M, 1999, J BIOL CHEM, V274, P36428, DOI 10.1074/jbc.274.51.36428; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hanson J, 2001, PLANT MOL BIOL, V45, P247, DOI 10.1023/A:1006464907710; He YH, 2005, TRENDS PLANT SCI, V10, P30, DOI 10.1016/j.tplants.2004.11.003; He YH, 2003, SCIENCE, V302, P1751, DOI 10.1126/science.1091109; Horiguchi G, 2005, PLANT J, V43, P68, DOI 10.1111/j.1365-313X.2005.02429.x; Huang YQ, 2005, MOL CELL, V17, P613, DOI 10.1016/j.molcel.2005.02.020; Iida K, 2006, MOL BIOL EVOL, V23, P1085, DOI 10.1093/molbev/msj118; Isshiki M, 2006, PLANT CELL, V18, P146, DOI 10.1105/tpc.105.037069; Jack T, 2004, PLANT CELL, V16, pS1, DOI 10.1105/tpc.017038; Kalyna M, 2004, BIOCHEM SOC T, V32, P561, DOI 10.1042/BST0320561; Kalyna M, 2003, MOL BIOL CELL, V14, P3565, DOI 10.1091/mbc.E03-02-0109; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kayes JM, 1998, DEVELOPMENT, V125, P3843; Kim GT, 1998, PLANTA, V206, P175, DOI 10.1007/s004250050389; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Lazar G, 2000, PLANT MOL BIOL, V42, P571, DOI 10.1023/A:1006394207479; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lim MH, 2004, PLANT CELL, V16, P731, DOI 10.1105/tpc.019331; Lopato S, 2002, J BIOL CHEM, V277, P39989, DOI 10.1074/jbc.M206455200; Lopato S, 1999, GENE DEV, V13, P987, DOI 10.1101/gad.13.8.987; Macknight R, 2002, PLANT CELL, V14, P877, DOI 10.1105/tpc.010456; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Mockler TC, 2004, P NATL ACAD SCI USA, V101, P12759, DOI 10.1073/pnas.0404552101; Nelissen H, 2003, PLANT CELL, V15, P639, DOI 10.1105/tpc.007062; Noh YS, 2003, PLANT CELL, V15, P1671, DOI 10.1105/tpc.012161; Palusa SG, 2007, PLANT J, V49, P1091, DOI 10.1111/j.1365-313X.2006.03020.x; Prasad J, 1999, MOL CELL BIOL, V19, P6991; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Reddy ASN, 2007, ANNU REV PLANT BIOL, V58, P267, DOI 10.1146/annurev.arplant.58.032806.103754; Reddy ASN, 2004, TRENDS PLANT SCI, V9, P541, DOI 10.1016/j.tplants.2004.09.007; Reddy ASN, 2001, CRIT REV PLANT SCI, V20, P523, DOI 10.1016/S0735-2689(01)80004-6; Reddy VS, 2004, PLANT CELL, V16, P185, DOI 10.1105/tpc.016600; ROMAC JMJ, 1995, GENE DEV, V9, P1400, DOI 10.1101/gad.9.11.1400; Running MP, 2004, P NATL ACAD SCI USA, V101, P7815, DOI 10.1073/pnas.0402385101; Sanford J R, 2003, Prog Mol Subcell Biol, V31, P33; Schomburg FM, 2001, PLANT CELL, V13, P1427, DOI 10.1105/tpc.13.6.1427; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Shen HH, 2004, MOL CELL, V13, P367, DOI 10.1016/S1097-2765(04)00025-5; Shpak ED, 2005, SCIENCE, V309, P290, DOI 10.1126/science.1109710; Simpson GG, 2003, CELL, V113, P777, DOI 10.1016/S0092-8674(03)00425-2; Sung S, 2005, ANNU REV PLANT BIOL, V56, P491, DOI 10.1146/annurev.arplant.56.032604.144307; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Theodoris G, 2003, P NATL ACAD SCI USA, V100, P6837, DOI 10.1073/pnas.1132113100; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsukaya H, 2006, ANNU REV PLANT BIOL, V57, P477, DOI 10.1146/annurev.arplant.57.032905.105320; Wagner TA, 2001, PLANT CELL, V13, P303, DOI 10.1105/tpc.13.2.303; Wang BB, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-r102; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Yang M, 1995, PLANT CELL, V7, P2227, DOI 10.1105/tpc.7.12.2227; Ziegelhoffer EC, 2000, P NATL ACAD SCI USA, V97, P7633, DOI 10.1073/pnas.130189397	70	98	104	3	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e471	10.1371/journal.pone.0000471	http://dx.doi.org/10.1371/journal.pone.0000471			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534421	Green Published, Green Submitted, gold			2022-12-25	WOS:000207448800001
J	Absalon, S; Kohl, L; Branche, C; Blisnick, T; Toutirais, G; Rusconi, F; Cosson, J; Bonhivers, M; Robinson, D; Bastin, P				Absalon, Sabrina; Kohl, Linda; Branche, Carole; Blisnick, Thierry; Toutirais, Geraldine; Rusconi, Filippo; Cosson, Jacky; Bonhivers, Melanie; Robinson, Derrick; Bastin, Philippe			Basal Body Positioning Is Controlled by Flagellum Formation in Trypanosoma brucei	PLOS ONE			English	Article								To perform their multiple functions, cilia and flagella are precisely positioned at the cell surface by mechanisms that remain poorly understood. The protist Trypanosoma brucei possesses a single flagellum that adheres to the cell body where a specific cytoskeletal structure is localised, the flagellum attachment zone (FAZ). Trypanosomes build a new flagellum whose distal tip is connected to the side of the old flagellum by a discrete structure, the flagella connector. During this process, the basal body of the new flagellum migrates towards the posterior end of the cell. We show that separate inhibition of flagellum assembly, base-to-tip motility or flagella connection leads to reduced basal body migration, demonstrating that the flagellum contributes to its own positioning. We propose a model where pressure applied by movements of the growing new flagellum on the flagella connector leads to a reacting force that in turn contributes to migration of the basal body at the proximal end of the flagellum.	[Absalon, Sabrina; Kohl, Linda; Branche, Carole; Toutirais, Geraldine; Rusconi, Filippo; Bastin, Philippe] Museum Natl Hist Nat, INSERM, F-75231 Paris, France; [Absalon, Sabrina; Kohl, Linda; Branche, Carole; Blisnick, Thierry; Toutirais, Geraldine; Rusconi, Filippo; Bastin, Philippe] CNRS, Paris, France; [Absalon, Sabrina; Branche, Carole; Blisnick, Thierry; Bastin, Philippe] Inst Pasteur, Trypanosome Cell Biol Unit, Paris, France; [Bonhivers, Melanie; Robinson, Derrick] CNRS, Bordeaux, France; [Bonhivers, Melanie; Robinson, Derrick] Univ Bordeaux 2, F-33076 Bordeaux, France; [Cosson, Jacky] CNRS, Stn Zool, Villefranche Sur Mer, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Bastin, P (corresponding author), Museum Natl Hist Nat, INSERM, F-75231 Paris, France.	pbastin@pasteur.fr	Bastin, Philippe/E-6688-2017; Bastin, Philippe/B-1402-2014; Bonhivers, Melanie/Z-5889-2019; Bastin, Philippe/O-4230-2019	Bonhivers, Melanie/0000-0001-9179-8473; Bastin, Philippe/0000-0002-3042-8679; Absalon, Sabrina/0000-0003-2468-8156; Rusconi, Filippo Matteo/0000-0003-1822-0397; Absalon, Sabrina/0000-0002-4167-3071	CNRS; ACI; Programme Proteomique et Genie des Proteines; GIS; MRT; FRM; European Science Foundation	CNRS(Centre National de la Recherche Scientifique (CNRS)); ACI; Programme Proteomique et Genie des Proteines; GIS; MRT; FRM(Fondation pour la Recherche Medicale); European Science Foundation(European Science Foundation (ESF)European Commission)	This work was funded by the CNRS, an ACI grant "Dynamique et Reactivite des Assemblages Biologiques'' (PB & DR), by a Programme Proteomique et Genie des Proteines (DR & PB), an ACI grant in Development Biology and by a GIS grant on rare genetic diseases (PB). S. A. was funded by a MRT fellowship and by a FRM doctoral fellowship; C. B. was funded by a European Science Foundation fellowship.	Adhiambo C, 2005, MOL BIOCHEM PARASIT, V143, P216, DOI 10.1016/j.molbiopara.2005.04.017; Bastin P, 1999, MOL CELL BIOL, V19, P8191; Bastin P, 1996, PARASITOL TODAY, V12, P302, DOI 10.1016/0169-4758(96)10031-4; Bastin P, 1998, NATURE, V391, P548, DOI 10.1038/35300; Bastin P, 2000, J CELL SCI, V113, P3321; Beisson J, 2003, CURR OPIN CELL BIOL, V15, P96, DOI 10.1016/S0955-0674(02)00017-0; BIRKETT CR, 1985, FEBS LETT, V187, P211, DOI 10.1016/0014-5793(85)81244-8; BOISVIEUXULRICH E, 1990, CELL TISSUE RES, V259, P443, DOI 10.1007/BF01740770; Branche C, 2006, J CELL SCI, V119, P3443, DOI 10.1242/jcs.03078; Briggs LJ, 2004, J CELL SCI, V117, P1641, DOI 10.1242/jcs.00995; BRUGEROLLE G, 1992, BIOSYSTEMS, V28, P203, DOI 10.1016/0303-2647(92)90021-P; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Davidge JA, 2006, J CELL SCI, V119, P3935, DOI 10.1242/jcs.03203; Dawe HR, 2005, J CELL SCI, V118, P5421, DOI 10.1242/jcs.02659; Deane JA, 2001, CURR BIOL, V11, P1586, DOI 10.1016/S0960-9822(01)00484-5; Dilbeck V, 1999, J CELL SCI, V112, P4687; Durand-Dubief M, 2003, MOL BIOCHEM PARASIT, V129, P11, DOI 10.1016/S0166-6851(03)00071-9; El-Amraoui A, 2005, J CELL SCI, V118, P4593, DOI 10.1242/jcs.02636; Follit JA, 2006, MOL BIOL CELL, V17, P3781, DOI 10.1091/mbc.E06-02-0133; Hagiwara H, 2004, INT REV CYTOL, V234, P101, DOI 10.1016/S0074-7696(04)34003-9; Hutchings NR, 2002, J CELL BIOL, V156, P867, DOI 10.1083/jcb.200201036; Kohl L, 2003, EMBO J, V22, P5336, DOI 10.1093/emboj/cdg518; Kohl L, 1999, J EUKARYOT MICROBIOL, V46, P105, DOI 10.1111/j.1550-7408.1999.tb04592.x; Kohl L, 2005, INT REV CYTOL, V244, P227, DOI 10.1016/S0074-7696(05)44006-1; Kohl L, 1998, MOL BIOCHEM PARASIT, V93, P1, DOI 10.1016/S0166-6851(98)00014-0; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; Matthews KR, 2005, J CELL SCI, V118, P283, DOI 10.1242/jcs.01649; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Noel C, 2003, PARASITOL RES, V89, P487, DOI 10.1007/s00436-002-0811-4; Nohynkova E, 2006, EUKARYOT CELL, V5, P753, DOI 10.1128/EC.5.4.753-761.2006; Pradel LC, 2006, J CELL SCI, V119, P1852, DOI 10.1242/jcs.02900; Quarmby LM, 2005, J CELL BIOL, V169, P707, DOI 10.1083/jcb.200503053; Ralston KS, 2006, EUKARYOT CELL, V5, P696, DOI 10.1128/EC.5.4.696-711.2006; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; Simons M, 2006, KIDNEY INT, V70, P854, DOI 10.1038/sj.ki.5001534; Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534; Wang Q, 2006, CELL, V125, P549, DOI 10.1016/j.cell.2006.02.044; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODS A, 1989, J CELL SCI, V93, P491	44	66	66	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e437	10.1371/journal.pone.0000437	http://dx.doi.org/10.1371/journal.pone.0000437			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487282	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445800019
J	Rock, F; Hadeler, KP; Rammensee, HG; Overath, P				Roeck, Frank; Hadeler, Karl-Peter; Rammensee, Hans-Georg; Overath, Peter			Quantitative Analysis of Mouse Urine Volatiles: In Search of MHC-ependent Differences	PLOS ONE			English	Article								Genes of the major histocompatibility complex (MHC), which play a critical role in immune recognition, influence mating preference and other social behaviors in mice. Training experiments using urine scent from mice differing only in the MHC complex, from MHC class I mutants or from knock-out mice lacking functional MHC class I molecules (beta 2m-deficient), suggest that these behavioral effects are mediated by differences in MHC-dependent volatile components. In search for the physical basis of these behavioral studies, we have conducted a comparison of urinary volatiles in three sub-strains of C57BL/6 mice, a beta 2m-deficient mutant lacking functional MHC class I expression and two unrelated inbred strains, using the technique of sorptive extraction with polydimethylsiloxan and subsequent analysis by gas chromatography/mass spectrometry. We show (i) that qualitative differences occur between different inbred strains but not in mice with the C57BL/6 background, (ii) that the individual variability in abundance in the same mouse strain is strongly component-dependent, (iii) that C57BL/6 sub-strains obtained from different provenance show a higher fraction of quantitative differences than a sub-strain and its beta 2m-mutant obtained from the same source and (iv) that comparison of the spectra of beta 2m mice and the corresponding wild type reveals no qualitative differences in close to 200 major and minor components and only minimal differences in a few substances from an ensemble of 69 selected for quantitative analysis. Our data suggest that odor is shaped by ontogenetic, environmental and genetic factors, and the gestalt of this scent may identify a mouse on the individual and population level; but, within the limits of the ensemble of components analysed, the results do not support the notion that functional MHC class I molecules influence the urinary volatile composition.	[Roeck, Frank] Univ Tubingen, Inst Phys Chem, Interfak Inst Zellbiol, Tubingen, Germany; [Rammensee, Hans-Georg; Overath, Peter] Univ Tubingen, Interfak Inst Zellbiol, Immunol Abt, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Overath, P (corresponding author), Univ Tubingen, Interfak Inst Zellbiol, Immunol Abt, Tubingen, Germany.	peter.overath@tuebingen.mpg.de			Max-Planck-Gesellschaft; Fonds der Chemischen Industrie	Max-Planck-Gesellschaft(Max Planck Society); Fonds der Chemischen Industrie(Fonds der Chemischen IndustrieEuropean Commission)	This work was funded in part by the Max-Planck-Gesellschaft and the Fonds der Chemischen Industrie.	Baltussen E, 2002, ANAL BIOANAL CHEM, V373, P3, DOI 10.1007/s00216-002-1266-2; Bard J, 2000, IMMUNOGENETICS, V51, P514, DOI 10.1007/s002510000165; Beauchamp GK, 2003, BIOCHEM SOC T, V31, P147; Boehm T, 2006, TRENDS NEUROSCI, V29, P100, DOI 10.1016/j.tins.2005.11.006; BROWN RE, 1989, BEHAV GENET, V19, P658, DOI 10.1007/BF01066029; Carroll LS, 2002, P NATL ACAD SCI USA, V99, P2187, DOI 10.1073/pnas.042244899; Curran AM, 2005, J CHEM ECOL, V31, P1607, DOI 10.1007/s10886-005-5801-4; Eggert Frank, 1996, Physiology and Behavior, V59, P57, DOI 10.1016/0031-9384(95)02029-2; Harvey LM, 2006, J FORENSIC SCI, V51, P1109, DOI 10.1111/j.1556-4029.2006.00231.x; Jacob S, 2002, NAT GENET, V30, P175, DOI 10.1038/ng830; Kelliher KR, 2003, P NATL ACAD SCI USA, V100, P4299, DOI 10.1073/pnas.0736071100; KLEIN J, 1982, IMMUNOLOGY SCI SELF, P47; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Leinders-Zufall T, 2004, SCIENCE, V306, P1033, DOI 10.1126/science.1102818; Montag S, 2001, P NATL ACAD SCI USA, V98, P9249, DOI 10.1073/pnas.161266398; Novotny MV, 2007, J CHEM ECOL, V33, P417, DOI 10.1007/s10886-006-9230-9; Novotny MV, 2003, BIOCHEM SOC T, V31, P117, DOI 10.1042/BST0310117; Penn D, 1998, ADV IMMUNOL, V69, P411, DOI 10.1016/S0065-2776(08)60612-4; Penn D, 1998, PHYSIOL BEHAV, V64, P235, DOI 10.1016/S0031-9384(98)00052-3; Penn DJ, 2007, J R SOC INTERFACE, V4, P331, DOI 10.1098/rsif.2006.0182; Rock F, 2006, J CHEM ECOL, V32, P1333, DOI 10.1007/s10886-006-9091-2; Santos PSC, 2005, HORM BEHAV, V47, P384, DOI 10.1016/j.yhbeh.2004.11.005; Schaefer ML, 2002, J NEUROSCI, V22, P9513; SCHWENDE FJ, 1984, J CHEM ECOL, V10, P1603, DOI 10.1007/BF00988428; Singer AG, 1997, P NATL ACAD SCI USA, V94, P2210, DOI 10.1073/pnas.94.6.2210; Soini HA, 2005, J CHEM ECOL, V31, P377, DOI 10.1007/s10886-005-1347-8; Spehr M, 2006, J NEUROSCI, V26, P1961, DOI 10.1523/JNEUROSCI.4939-05.2006; THOMAS L, 1975, IMMUNE SYSTEM INFECT, P2; Wedekind C, 2000, NEPHROL DIAL TRANSPL, V15, P1269, DOI 10.1093/ndt/15.9.1269; Willse A, 2005, ANAL CHEM, V77, P2348, DOI 10.1021/ac048711t; Willse A, 2006, IMMUNOGENETICS, V58, P967, DOI 10.1007/s00251-006-0162-x; Wysocki CJ, 2004, HORM BEHAV, V46, P241, DOI 10.1016/j.yhbeh.2004.02.010; Xu FQ, 2005, J COMP NEUROL, V489, P491, DOI 10.1002/cne.20652; YAMAGUCHI M, 1981, P NATL ACAD SCI-BIOL, V78, P5817, DOI 10.1073/pnas.78.9.5817; YAMAZAKI K, 1983, P NATL ACAD SCI-BIOL, V80, P5685, DOI 10.1073/pnas.80.18.5685; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; YAMAZAKI K, 1979, J EXP MED, V150, P755, DOI 10.1084/jem.150.4.755; Yamazaki K, 2005, CHEM SENSES, V30, pI142, DOI 10.1093/chemse/bjh154; YAMAZAKI K, 1982, P NATL ACAD SCI-BIOL, V79, P7828, DOI 10.1073/pnas.79.24.7828	39	16	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e429	10.1371/journal.pone.0000429	http://dx.doi.org/10.1371/journal.pone.0000429			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487279	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445800011
J	Zhang, YL; Wada, J; Yasuhara, A; Iseda, I; Eguchi, J; Fukui, K; Yang, Q; Yamagata, K; Hiesberger, T; Igarashi, P; Zhang, H; Wang, HY; Akagi, S; Kanwar, YS; Makino, H				Zhang, Yanling; Wada, Jun; Yasuhara, Akihiro; Iseda, Izumi; Eguchi, Jun; Fukui, Kenji; Yang, Qin; Yamagata, Kazuya; Hiesberger, Thomas; Igarashi, Peter; Zhang, Hong; Wang, Haiyan; Akagi, Shigeru; Kanwar, Yashpal S.; Makino, Hirofumi			The Role for HNF-1 beta-Targeted Collectrin in Maintenance of Primary Cilia and Cell Polarity in Collecting Duct Cells	PLOS ONE			English	Article								Collectrin, a homologue of angiotensin converting enzyme 2 (ACE2), is a type I transmembrane protein, and we originally reported its localization to the cytoplasm and apical membrane of collecting duct cells. Recently, two independent studies of targeted disruption of collectrin in mice resulted in severe and general defects in renal amino acid uptake. Collectrin has been reported to be under the transcriptional regulation by HNF-1 alpha, which is exclusively expressed in proximal tubules and localized at the luminal side of brush border membranes. The deficiency of collectrin was associated with reduction of multiple amino acid transporters on luminal membranes. In the current study, we describe that collectrin is a target of HNF-1 beta and heavily expressed in the primary cilium of renal collecting duct cells. Collectrin is also localized in the vesicles near the peri-basal body region and binds to gamma-actin-myosin II-A, SNARE, and polycystin-2-polaris complexes, and all of these are involved in intracellular and ciliary movement of vesicles and membrane proteins. Treatment of mIMCD3 cells with collectrin siRNA resulted in defective cilium formation, increased cell proliferation and apoptosis, and disappearance of polycystin-2 in the primary cilium. Suppression of collectrin mRNA in metanephric culture resulted in the formation of multiple longitudinal cysts in ureteric bud branches. Taken together, the cystic change and formation of defective cilium with the interference in the collectrin functions would suggest that it is necessary for recycling of the primary cilia-specific membrane proteins, the maintenance of the primary cilia and cell polarity of collecting duct cells. The transcriptional hierarchy between HNF-1 beta and PKD (polycystic kidney disease) genes expressed in the primary cilia of collecting duct cells has been suggested, and collectrin is one of such HNF-1 beta regulated genes.	[Zhang, Yanling; Wada, Jun; Yasuhara, Akihiro; Iseda, Izumi; Eguchi, Jun; Makino, Hirofumi] Okayama Univ, Grad Sch Med, Dept Med & Clin Sci, Okayama, Japan; [Zhang, Yanling] Hebei Med Univ, Hosp 3, Dept Nephrol, Shijiazhuang, Peoples R China; [Fukui, Kenji; Yang, Qin; Yamagata, Kazuya] Osaka Univ, Grad Sch Med, Dept Metab Med, Osaka, Japan; [Yang, Qin] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; [Hiesberger, Thomas; Igarashi, Peter] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Hiesberger, Thomas; Igarashi, Peter] Univ Texas SW Med Ctr Dallas, Div Basic Sci, Dallas, TX 75390 USA; [Zhang, Hong; Wang, Haiyan] Peking Univ, Hosp 1, Inst Nephrol, Div Renal, Beijing 100871, Peoples R China; [Akagi, Shigeru; Kanwar, Yashpal S.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA	Okayama University; Hebei Medical University; Osaka University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Peking University; Northwestern University; Feinberg School of Medicine	Wada, J (corresponding author), Okayama Univ, Grad Sch Med, Dept Med & Clin Sci, Okayama, Japan.	junwada@md.okayama-u.ac.jp	WADA, Jun/B-2023-2011	WADA, Jun/0000-0003-1468-5170; Igarashi, Peter/0000-0001-8698-1185	JSPS (Japan Society for the Promotion of Science); Ministry of Education, Science and Culture, Japan [17590829]; Uehara Memorial Foundation; Scientific Research, Ministry of Education, Science and Culture, Japan [18390249]; NIH [R01DK42921, R01DK67565, DK28492, DK60635];  [1604241]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060635, R37DK028492, R01DK067565, R01DK042921, R01DK028492] Funding Source: NIH RePORTER	JSPS (Japan Society for the Promotion of Science)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Science and Culture, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Uehara Memorial Foundation(Uehara Memorial Foundation); Scientific Research, Ministry of Education, Science and Culture, Japan; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by Grant-in-Aid for Scientific Research (1604241) to Y. Z and Y. Z. is a recipient of JSPS (Japan Society for the Promotion of Science) fellow. Grant-in-Aid for Scientific Research, Ministry of Education, Science and Culture, Japan (17590829) to J. W. and Uehara Memorial Foundation, Grant-in-Aid for Scientific Research, Ministry of Education, Science and Culture, Japan (18390249) to H. M., NIH grants (R01DK42921 and R01DK67565) to P. I. and NIH grants (DK28492 and DK60635) to Y. S. K. We thank Dr. Bradley K. Yoder in University of Alabama at Birmingham for the Polaris antibody.	Akpinar P, 2005, CELL METAB, V2, P385, DOI 10.1016/j.cmet.2005.11.001; Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Buxton P, 2003, BIOCHEM J, V375, P433, DOI 10.1042/BJ20030427; Danilczyk U, 2006, NATURE, V444, P1088, DOI 10.1038/nature05475; Eguchi J, 2005, BIOCHEM J, V387, P343, DOI 10.1042/BJ20041709; Fukui K, 2005, CELL METAB, V2, P373, DOI 10.1016/j.cmet.2005.11.003; FUKUI K, CELL METAB IN PRESS; Gouraud S, 2002, J CELL SCI, V115, P3667, DOI 10.1242/jcs.00053; Gresh L, 2004, EMBO J, V23, P1657, DOI 10.1038/sj.emboj.7600160; Hidaka S, 2004, J BIOL CHEM, V279, P35009, DOI 10.1074/jbc.M314206200; Hiesberger T, 2004, J CLIN INVEST, V113, P814, DOI 10.1172/JCI200420083; Hiesberger T, 2005, J BIOL CHEM, V280, P10578, DOI 10.1074/jbc.M414121200; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Jerdeva GV, 2005, J CELL SCI, V118, P4797, DOI 10.1242/jcs.02573; JOHNSON KA, 1992, J CELL BIOL, V119, P1605, DOI 10.1083/jcb.119.6.1605; Kottgen M, 2005, EMBO J, V24, P705, DOI 10.1038/sj.emboj.7600566; KOTTGEN M, 2005, PFLUGERS ARCH; Linz-McGillem LA, 2003, EXP EYE RES, V76, P543, DOI 10.1016/S0014-4835(03)00031-9; MALAKAUSKAS SM, 2006, AM J PHYSL RENAL PHY; Mandon B, 1996, J CLIN INVEST, V98, P906, DOI 10.1172/JCI118873; MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N; Mochizuki T, 1998, NATURE, V395, P177, DOI 10.1038/26006; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Mykytyn K, 2004, P NATL ACAD SCI USA, V101, P8664, DOI 10.1073/pnas.0402354101; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Neco P, 2004, J BIOL CHEM, V279, P27450, DOI 10.1074/jbc.M311462200; Neco P, 2002, BIOCHEM J, V368, P405, DOI 10.1042/BJ20021090; Ong ACM, 2003, LANCET, V361, P774, DOI 10.1016/S0140-6736(03)12662-1; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Quarmby LM, 2005, J CELL BIOL, V169, P707, DOI 10.1083/jcb.200503053; Rogers KK, 2004, BIOCHEM BIOPH RES CO, V319, P138, DOI 10.1016/j.bbrc.2004.04.165; ROSENBAUM JL, 1967, J CELL BIOL, V34, P345, DOI 10.1083/jcb.34.1.345; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; Togo T, 2004, MOL BIOL CELL, V15, P688, DOI 10.1091/mbc.E03-06-0430; Veizis IE, 2005, AM J PHYSIOL-RENAL, V288, pF474, DOI 10.1152/ajprenal.00227.2004; Wada J, 1996, J CELL BIOL, V132, P1161, DOI 10.1083/jcb.132.6.1161; Wada J, 1998, P NATL ACAD SCI USA, V95, P144, DOI 10.1073/pnas.95.1.144; Wheatley DN, 1995, PATHOBIOLOGY, V63, P222, DOI 10.1159/000163955; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; Witzgall R, 2005, N-S ARCH PHARMACOL, V371, P342, DOI 10.1007/s00210-005-1027-9; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Zhang H, 1999, KIDNEY INT, V56, P549, DOI 10.1046/j.1523-1755.1999.00561.x; Zhang H, 2001, J BIOL CHEM, V276, P17132, DOI 10.1074/jbc.M006723200; [张志强 Zhang Zhiqiang], 2004, [自然资源学报, Journal of Natural Resources], V19, P230	51	44	45	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e414	10.1371/journal.pone.0000414	http://dx.doi.org/10.1371/journal.pone.0000414			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476336	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445700016
J	Pecha, J; Ankrapp, D; Jiang, C; Tang, W; Hoshino, I; Bruck, K; Wagner, KU; Xiao, H				Pecha, J.; Ankrapp, D.; Jiang, C.; Tang, W.; Hoshino, I.; Bruck, K.; Wagner, K-U; Xiao, H.			Deletion of Tip30 leads to rapid immortalization of murine mammary epithelial cells and ductal hyperplasia in the mammary gland	ONCOGENE			English	Article						tip30; mammary epithelial cell; hyperplasia; proliferation	HUMAN BREAST-CANCER; EXPRESSION; ESTROGEN; MICE; SUSCEPTIBILITY; PROGRESSION; ALPHA; GENE	Transformation of mammary epithelial cells (MECs) from the normal to the neoplastic stage requires the dysregulation of tumor suppressor genes and proto-oncogenes. Tip30 is a tumor suppressor that can inhibit estrogen receptor-mediated transcription in MECs, but its role in MEC proliferation remains unknown. Here, we show that deleting the Tip30 gene leads to ductal hyperplasia in mouse mammary glands early in life and extensive mammary hyperplasia with age. Tip30 (-/-) mammary glands transplanted into wild-type mammary fat pads also display mammary trees with extensive ductal hyperplasia. Strikingly, Tip30 deletion promotes proliferation of primary MECs and results in rapid immortalization of MECs in vitro relative to wild-type cells. Gene array analysis identified significant increases in the expression of mammary epithelial growth factors Wisp2 and Igf-1 in Tip30(-/-) cells. Knockdown of either Wisp2 or Igf-1 using short interfering RNA dramatically inhibited proliferation of Tip30(-/-) cells. Together, these results suggest that Tip30 is an intrinsic and negative regulator of MEC proliferation partly through the inhibition of Wisp2 and Igf-1 expression, and its absence in the mammary gland may predispose MECs to neoplastic transformation.	Michigan State Univ, Dept Pathol Physiol, E Lansing, MI 48824 USA; Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA	Michigan State University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Xiao, H (corresponding author), Michigan State Univ, Dept Pathol Physiol, 3193 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	xiaoh@msu.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NIDDK NIH HHS [DK066110-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066110] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Dimri GP, 2002, CANCER RES, V62, P4736; Hewitt RE, 2000, J PATHOL, V192, P455; Ito M, 2003, CANCER RES, V63, P8763; Jiang C, 2004, J BIOL CHEM, V279, P27781, DOI 10.1074/jbc.M401809200; King FW, 2004, MOL CELL BIOL, V24, P7091, DOI 10.1128/MCB.24.16.7091-7101.2004; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee L W, 2004, Ann Acad Med Singap, V33, pS30; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; Medina D, 2002, BBA-REV CANCER, V1603, P1, DOI 10.1016/S0304-419X(02)00053-7; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Nonet GH, 2001, CANCER RES, V61, P1250; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; Radice GL, 1997, J CELL BIOL, V139, P1025, DOI 10.1083/jcb.139.4.1025; Saxena N, 2001, MOL CELL BIOCHEM, V228, P99, DOI 10.1023/A:1013338912642; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P1309, DOI 10.1210/me.16.6.1309; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang S, 2005, J MOL ENDOCRINOL, V35, P433, DOI 10.1677/jme.1.01858; Zhang Y, 2004, J BIOL CHEM, V279, P34353, DOI 10.1074/jbc.M401300200; Zhao J, 2007, HUM PATHOL, V38, P293, DOI 10.1016/j.humpath.2006.08.005	27	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7423	7431		10.1038/sj.onc.1210548	http://dx.doi.org/10.1038/sj.onc.1210548			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17533366				2022-12-25	WOS:000251282000004
J	Sauve, V; Bruno, S; Berks, BC; Hemmings, AM				Sauve, Veronique; Bruno, Stefano; Berks, Ben C.; Hemmings, Andrew M.			The SoxYZ complex carries sulfur cycle intermediates on a peptide swinging arm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM ALLOCHROMATIUM-VINOSUM; PARACOCCUS-PANTOTROPHUS; ESCHERICHIA-COLI; GENE-CLUSTER; OXIDATION; PROTEIN; BIOSYNTHESIS; THIOSULFATE; MECHANISM; ENZYME	The bacterial Sox (sulfur oxidizing) system allows the utilization of inorganic sulfur compounds in energy metabolism. Central to this process is the SoxYZ complex that carries the pathway intermediates on a cysteine residue near the C terminus of SoxY. Crystal structures have been determined for Paracoccus pantotrophus SoxYZ with the carrier cysteine in the underivatized state, conjugated to the polysulfide mimic beta-mercaptoethanol, and as the sulfonate adduct pathway intermediate. The carrier cysteine is located on a peptide swinging arm and is bracketed on either side by diglycine dipeptides acting as molecular universal joints. This structure provides a novel solution to the requirement that the cysteine-bound intermediates be able to access and orient themselves within the active sites of multiple partner enzymes. Adjacent to the swinging arm there is a conserved, deep, apolar pocket into which the beta-mercaptoethanol adduct extends. This pocket would be well suited to a role in protecting labile pathway intermediates from adventitious reactions.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England	University of Oxford; University of East Anglia; University of East Anglia	Berks, BC (corresponding author), Univ Oxford, Dept Biochem, Oxford OX1 3QU, England.	ben.berks@bioch.ox.ac.uk; a.hemmings@uea.ac.uk	Bruno, Stefano/A-4582-2011; HEMMINGS, ANDREW MICHAEL/E-5517-2011	Bruno, Stefano/0000-0002-7890-2472; HEMMINGS, ANDREW MICHAEL/0000-0003-3053-3134; Berks, Ben/0000-0001-9685-4067				Appia-Ayme C, 2001, J BACTERIOL, V183, P6107, DOI 10.1128/JB.183.20.6107-6118.2001; BAK F, 1987, ARCH MICROBIOL, V147, P184, DOI 10.1007/BF00415282; Bamford VA, 2002, EMBO J, V21, P5599, DOI 10.1093/emboj/cdf566; Beinert H, 2000, EUR J BIOCHEM, V267, P5657, DOI 10.1046/j.1432-1327.2000.01637.x; Beller HR, 2006, J BACTERIOL, V188, P1473, DOI 10.1128/JB.188.4.1473-1488.2006; Binkowski TA, 2003, J MOL BIOL, V332, P505, DOI 10.1016/S0022-2836(03)00882-9; Bordo D, 2000, J MOL BIOL, V298, P691, DOI 10.1006/jmbi.2000.3651; Cort JR, 2001, EUR J BIOCHEM, V268, P5842, DOI 10.1046/j.0014-2956.2001.02529.x; Dahl C, 2005, J BACTERIOL, V187, P1392, DOI 10.1128/JB.187.4.1392-1404.2005; Dahl C., 2002, BIOPOLYMERS, P35; Dambe T, 2005, J STRUCT BIOL, V152, P229, DOI 10.1016/j.jsb.2005.09.002; Friedrich CG, 2005, CURR OPIN MICROBIOL, V8, P253, DOI 10.1016/j.mib.2005.04.005; Friedrich CG, 2001, APPL ENVIRON MICROB, V67, P2873, DOI 10.1128/AEM.67.7.2873-2882.2001; Hensen D, 2006, MOL MICROBIOL, V62, P794, DOI 10.1111/j.1365-2958.2006.05408.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Iciek M, 2001, POL J PHARMACOL, V53, P215; Ikeuchi Y, 2006, MOL CELL, V21, P97, DOI 10.1016/j.molcel.2005.11.001; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; LANDAU M, 2003, BIOINFORMATICS, V19, P163; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lehmann C, 2006, BIOCHEMISTRY-US, V45, P11, DOI 10.1021/bi051502y; Lengeler J. W., 1999, BIOL PROKARYOTES; Lin YJ, 2004, BIOCHEMISTRY-US, V43, P1418, DOI 10.1021/bi0356597; Mukhopadhyaya PN, 2000, J BACTERIOL, V182, P4278, DOI 10.1128/JB.182.15.4278-4287.2000; Nagano N, 1999, FEBS LETT, V458, P69, DOI 10.1016/S0014-5793(99)01122-9; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PIERIK AJ, 1992, EUR J BIOCHEM, V205, P111, DOI 10.1111/j.1432-1033.1992.tb16757.x; Quentmeier A, 2003, BIOCHEM BIOPH RES CO, V312, P1011, DOI 10.1016/j.bbrc.2003.11.021; Quentmeier A, 2001, FEBS LETT, V503, P168, DOI 10.1016/S0014-5793(01)02727-2; Rawlings DE, 2002, ANNU REV MICROBIOL, V56, P65, DOI 10.1146/annurev.micro.56.012302.161052; Rother D, 2001, J BACTERIOL, V183, P4499, DOI 10.1128/JB.183.15.4499-4508.2001; Rudolph MJ, 2003, J BIOL CHEM, V278, P14514, DOI 10.1074/jbc.M300449200; SMITH AJ, 1966, J GEN MICROBIOL, V42, P357, DOI 10.1099/00221287-42-3-357; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Urich T, 2006, SCIENCE, V311, P996, DOI 10.1126/science.1120306; Wodara C, 1997, J BACTERIOL, V179, P5014, DOI 10.1128/jb.179.16.5014-5023.1997; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; Yeh AP, 2000, BIOCHEMISTRY-US, V39, P2499, DOI 10.1021/bi992428k	41	67	68	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23194	23204		10.1074/jbc.M701602200	http://dx.doi.org/10.1074/jbc.M701602200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17522046	hybrid			2022-12-25	WOS:000248577500021
J	Kao, GD; Jiang, Z; Fernandes, AM; Gupta, AK; Maity, A				Kao, Gary D.; Jiang, Zibin; Fernandes, Anne Marie; Gupta, Anjali K.; Maity, Amit			Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DEPENDENT PROTEIN-KINASE; HUMAN TUMOR-CELLS; HISTONE H2AX; 3-KINASE INHIBITORS; GENOMIC INSTABILITY; IN-VITRO; LY294002; PATHWAY; RAS	Radiation therapy is a mainstay in the treatment of glioblastomas, but these tumors are often associated with radioresistance. Activation of the phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway, which occurs frequently in glioblastomas due to inactivation of the tumor suppressor phosphatase and tensin homologue (PTEN), correlates with radioresistance. To directly test the link between Akt activation and radioresistance, we utilized PTEN-deficient U251 glioblastoma cells engineered to inducibly restore PTEN upon exposure to doxycycline. These cells showed high basal levels of Akt activation (i.e. high levels of phospho-Akt), but induction of PTEN led to substantially decreased phospho-Akt and was associated with radiosensitization. To investigate whether the PTEN-induced radiosensitization was attributable to impaired sensing versus repair of DNA damage, we assessed levels of gamma-H2AX after ionizing radiation in U251 cells induced for PTEN. Initial post-radiation levels of alpha-H2AX foci were not decreased in PTEN-induced cells; however, the resolution of these foci was significantly delayed. In contrast to these results, induction of phosphatase-dead PTEN showed no appreciable effect. Finally, exposure of cells to the PI3K inhibitor LY294002 did not decrease the occurrence of alpha-H2AX foci after irradiation but did markedly delay their resolution. These results together support a direct link between Akt activation, repair of DNA damage, and radioresistance in glioblastoma. Targeting the PI3K/Akt pathway may modulate DNA repair to improve the efficacy of radiation therapy.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania	Maity, A (corresponding author), Univ Penn, Sch Med, Dept Radiat Oncol, 195 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	maity@xrt.upenn.edu	Gupta, Anjali/HCH-5986-2022	Maity, Amit/0000-0001-7151-2845	NCI NIH HHS [P01CA075138, P01 CA075138, R01 CA107956, R01 CA093638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107956, P01CA075138, R01CA093638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; BENNER SE, 1993, J CELL BIOCHEM, P250; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chakravarti A, 2004, J CLIN ONCOL, V22, P1926, DOI 10.1200/JCO.2004.07.193; Choe G, 2003, CANCER RES, V63, P2742; Edwards E, 2002, CANCER RES, V62, P4671; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Forrester HB, 2000, RADIAT RES, V154, P625, DOI 10.1667/0033-7587(2000)154[0625:CVTLAO]2.0.CO;2; Goodarzi AA, 2004, DNA REPAIR, V3, P753, DOI 10.1016/j.dnarep.2004.03.041; Gottschalk AR, 2005, INT J RADIAT ONCOL, V63, P1221, DOI 10.1016/j.ijrobp.2005.08.014; Grana TM, 2002, CANCER RES, V62, P4142; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2003, INT J RADIAT ONCOL, V56, P846, DOI 10.1016/S0360-3016(03)00214-1; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Izzard RA, 1999, CANCER RES, V59, P2581; Kim IA, 2005, CANCER RES, V65, P7902, DOI 10.1158/0008-5472.CAN-05-0513; Lee CM, 2006, CLIN CANCER RES, V12, P250, DOI 10.1158/1078-0432.CCR-05-1084; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; Nakamura JL, 2005, J NEURO-ONCOL, V71, P215, DOI 10.1007/s11060-004-1718-y; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; POWIS G, 1994, CANCER RES, V54, P2419; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Stopper H, 1997, MUTAT RES-DNA REPAIR, V383, P107, DOI 10.1016/S0921-8777(96)00049-3; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Toulany M, 2006, CLIN CANCER RES, V12, P4119, DOI 10.1158/1078-0432.CCR-05-2454; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Willers H, 2004, BRIT J CANCER, V90, P1297, DOI 10.1038/sj.bjc.6601729	38	182	193	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21206	21212		10.1074/jbc.M703042200	http://dx.doi.org/10.1074/jbc.M703042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17513297	hybrid, Green Accepted			2022-12-25	WOS:000248047500047
J	Al-Ayyoubi, M; Schwartz, BS; Gettins, PGW				Al-Ayyoubi, Maher; Schwartz, Bradford S.; Gettins, Peter G. W.			Maspin binds to urokinase-type and tissue-type plasminogen activator through exosite-exosite interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; SERPIN-PROTEINASE COMPLEX; ALPHA(1)-PROTEINASE INHIBITOR; TRYPSIN-INHIBITOR; SERINE PROTEASES; CELL-MIGRATION; SITE; MAMMARY; SYSTEM; CANCER	Maspin is a member of the serpin family with a reactive center loop that is incompatible with proteinase inhibition by the serpin conformational change mechanism. Despite this there are reports that maspin might regulate uPA-dependent processes in vivo. Using exogenous and endogenous fluorescence, we demonstrate here that maspin can bind uPA and tPA in both singlechain and double-chain forms, with K-d values between 300 and 600 nM. Binding is at an exosite on maspin close to, but outside of, the reactive center loop and is therefore insensitive to mutation of Arg(340) within the reactive center loop. The binding site on tPA does not involve the proteinase active site, with the result that maspin can bind to S195A tPA that is already complexed to plasminogen activator inhibitor-1. The ability of maspin to bind these proteinases without involvement of the reactive center loop leaves the latter free to engage in additional, as yet unidentified, maspin- protein interactions that may serve to regulate the properties of the exosite- bound proteinase. This may help to reconcile apparently conflicting studies that demonstrate the importance of the reactive center loop in certain maspin functions, despite the inability of maspin to directly inhibit tPA or uPA catalytic activity in in vitro assays through engagement between its reactive center loop and the active site of the proteinase.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign	Gettins, PGW (corresponding author), 900 S Ashland,M-C 669, Chicago, IL 60607 USA.	pgettins@uic.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015958] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049234] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR15958] Funding Source: Medline; NHLBI NIH HHS [R37 HL49234] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Ayyoubi M, 2004, J BIOL CHEM, V279, P55540, DOI 10.1074/jbc.M409957200; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Biliran H, 2001, CANCER RES, V61, P8676; Chen ZX, 2003, J UROLOGY, V169, P1316, DOI 10.1097/01.ju.0000050648.40164.0d; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; Filfil R, 2004, BIOCHEMISTRY-US, V43, P1315, DOI 10.1021/bi030188+; Gao F, 2004, DEVELOPMENT, V131, P1479, DOI 10.1242/dev.01048; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Ibarra CA, 2004, J BIOL CHEM, V279, P3643, DOI 10.1074/jbc.M310601200; Ke SH, 1997, J BIOL CHEM, V272, P20456, DOI 10.1074/jbc.272.33.20456; Khalkhali-Ellis Z, 2006, CLIN CANCER RES, V12, P7279, DOI 10.1158/1078-0432.CCR-06-1589; Krueger SR, 1997, J NEUROSCI, V17, P8984; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; McGowen R, 2000, CANCER RES, V60, P4771; NASKI MC, 1993, J BIOL CHEM, V268, P12367; Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135; Ngamkitidechakul C, 2003, J BIOL CHEM, V278, P31796, DOI 10.1074/jbc.M302408200; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; Pasternak A, 2001, PROTEIN SCI, V10, P1331, DOI 10.1110/ps.44101; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6275, DOI 10.1021/bi0100992; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schwartz BS, 1999, J BIOL CHEM, V274, P15278, DOI 10.1074/jbc.274.21.15278; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Shi HY, 2007, CELL MOTIL CYTOSKEL, V64, P338, DOI 10.1002/cm.20187; Smith SL, 2003, ONCOGENE, V22, P8677, DOI 10.1038/sj.onc.1207127; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Tesch LD, 2005, PROTEIN SCI, V14, P533, DOI 10.1110/ps.041104905; Yin SP, 2006, CANCER RES, V66, P4173, DOI 10.1158/0008-5472.CAN-05-3514; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	42	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19502	19509		10.1074/jbc.M702445200	http://dx.doi.org/10.1074/jbc.M702445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17510061	hybrid			2022-12-25	WOS:000247650600024
J	Swartz, JE; Bor, YC; Misawa, Y; Rekosh, D; Hammarskjold, ML				Swartz, Jennifer E.; Bor, Yeou-Cherng; Misawa, Yukiko; Rekosh, David; Hammarskjold, Marie-Louise			The shuttling SR protein 9G8 plays a role in translation of unspliced mRNA containing a constitutive transport element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRON-CONTAINING RNA; VIRUS ENV EXPRESSION; NUCLEAR-PORE COMPLEX; SPLICING FACTORS; MAMMALIAN-CELLS; NUCLEOCYTOPLASMIC EXPORT; TAP; REV; PHOSPHORYLATION; RECOGNITION	The splicing regulatory SR protein, 9G8, has recently been proposed to function in mRNA export in conjunction with the export protein, Tap/NXF1. Tap interacts directly with the Mason-Pfizer monkey virus constitutive transport element (CTE), an element that enables export of unspliced, intron-containing mRNA. Based on our previous finding that Tap can promote polysome association and translation of CTE-RNA, we investigated the effect of 9G8 on cytoplasmic RNA fate. 9G8 was shown to enhance expression of unspliced RNA containing either the Mason-Pfizer monkey virus-CTE or the recently discovered Tap-CTE. 9G8 also enhanced polyribosome association of unspliced RNA containing a CTE. Hyperphosphorylated 9G8 was present in monosomes and small polyribosomes, whereas soluble fractions contained only hypophosphorylated protein. Our results are consistent with a model in which hypophosphorylated SR proteins remain stably associated with messenger ribonucleoprotein ( mRNP) complexes during export and are released during translation initiation concomitant with increased phosphorylation. These results provide further evidence for crucial links between RNA splicing, export and translation.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr AIDS & Human Retrovirus Res, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Hammarskjold, ML (corresponding author), Univ Virginia, Dept Microbiol, PO Box 800734, Jordan Hall 7-85, Charlottesville, VA 22908 USA.	mh7g@virginia.edu			NIAID NIH HHS [AI054335, AI34721, AI47008] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034721, R01AI054335, R01AI047008] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bedard KM, 2007, EMBO J, V26, P459, DOI 10.1038/sj.emboj.7601494; Black BE, 1999, MOL CELL BIOL, V19, P8616; Blaustein M, 2005, NAT STRUCT MOL BIOL, V12, P1037, DOI 10.1038/nsmb1020; Blencowe BJ, 2003, CURR BIOL, V13, pR149, DOI 10.1016/S0960-9822(03)00079-4; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; CALZONE FJ, 1982, NUCLEIC ACIDS RES, V10, P2145, DOI 10.1093/nar/10.6.2145; Cao WH, 1997, RNA, V3, P1456; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; CULLEN BR, 1992, METHOD ENZYMOL, V216, P362; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Ernst RK, 1997, MOL CELL BIOL, V17, P135, DOI 10.1128/MCB.17.1.135; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fribourg S, 2001, MOL CELL, V8, P645, DOI 10.1016/S1097-2765(01)00348-3; FU XD, 1995, RNA, V1, P663; Gilbert W, 2004, MOL CELL, V13, P201, DOI 10.1016/S1097-2765(04)00030-9; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; Hammarskjold ML, 1997, SEMIN CELL DEV BIOL, V8, P83, DOI 10.1006/scdb.1996.0127; HAMMARSKJOLD ML, 1994, J VIROL, V68, P951; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; Hammarskjold ML, 2001, CURR TOP MICROBIOL, V259, P77; Hargous Y, 2006, EMBO J, V25, P5126, DOI 10.1038/sj.emboj.7601385; Huang YQ, 2005, MOL CELL, V17, P613, DOI 10.1016/j.molcel.2005.02.020; Huang YQ, 2004, P NATL ACAD SCI USA, V101, P9666, DOI 10.1073/pnas.0403533101; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Jin L, 2003, GENE DEV, V17, P3075, DOI 10.1101/gad.1155703; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Khandjian EW, 2004, P NATL ACAD SCI USA, V101, P13357, DOI 10.1073/pnas.0405398101; Lai MC, 2004, J BIOL CHEM, V279, P31745, DOI 10.1074/jbc.C400173200; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; Levesque L, 2001, J BIOL CHEM, V276, P44953, DOI 10.1074/jbc.M106558200; Li Y, 2006, NATURE, V443, P234, DOI 10.1038/nature05107; Lu SH, 2003, RNA, V9, P618, DOI 10.1261/rna.5260303; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Nott A, 2003, RNA, V9, P607, DOI 10.1261/rna.5250403; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Sanford J R, 2003, Prog Mol Subcell Biol, V31, P33; Sanford JR, 2005, P NATL ACAD SCI USA, V102, P15042, DOI 10.1073/pnas.0507827102; Sanford JR, 2004, J CELL SCI, V117, P6261, DOI 10.1242/jcs.01513; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; Shin C, 2004, NATURE, V427, P553, DOI 10.1038/nature02288; Shin CS, 2002, CELL, V111, P407, DOI 10.1016/S0092-8674(02)01038-3; Srinivasakumar N, 1997, J VIROL, V71, P5841, DOI 10.1128/JVI.71.8.5841-5848.1997; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Wehrly K, 1997, METHODS, V12, P288, DOI 10.1006/meth.1997.0481; Wiegand HL, 2003, P NATL ACAD SCI USA, V100, P11327, DOI 10.1073/pnas.1934877100; Wiegand HL, 2002, MOL CELL BIOL, V22, P245, DOI 10.1128/MCB.22.1.245-256.2002; Windgassen M, 2004, MOL CELL BIOL, V24, P10479, DOI 10.1128/MCB.24.23.10479-10491.2004; Yun CY, 2003, J BIOL CHEM, V278, P18050, DOI 10.1074/jbc.M211714200	75	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19844	19853		10.1074/jbc.M701660200	http://dx.doi.org/10.1074/jbc.M701660200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17513303	hybrid			2022-12-25	WOS:000247650600059
J	Yano, N; Suzuki, D; Endoh, M; Zhao, TC; Padbury, JF; Tseng, YT				Yano, Naohiro; Suzuki, Daisuke; Endoh, Masayuki; Zhao, Ting C.; Padbury, James F.; Tseng, Yi-Tang			A novel phosphoinositide 3-kinase-dependent pathway for angiotensin II/AT-1 receptor-mediated induction of collagen synthesis in MES-13 mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; REQUIRES METALLOPROTEINASE CLEAVAGE; EGF RECEPTOR TRANSACTIVATION; PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; INHIBITS APOPTOSIS; REGULATED KINASE; TYROSINE KINASE; PROHB-EGF	Chronic activation of the angiotensin II (ANG II) type 1 receptor (AT-1R) is critical in the development of chronic kidney disease. ANG II activates mesangial cells (MCs) and stimulates the synthesis of extracellular matrix components. To determine the molecular mechanisms underlying the induction of MC collagen, a mouse mesangial cell line MES-13 was employed. ANG II treatment induced an increase in collagen synthesis, which was abrogated by co-treatment with losartan (an AT-1R antagonist), wortmannin (a phosphoinositide 3-kinase (PI3K) inhibitor), an Akt inhibitor, and stable transfection of dominant negative-Akt1. ANG II induced a significant increase in PI3K activity, which was abolished by co-treatment with losartan or 2', 5'-dideoxyade-nosine (2', 5'-DOA, an adenylyl cyclase inhibitor) but not by PD123319 (an AT-2R antagonist) or H89 (a protein kinase A (PKA) inhibitor). The Epac (exchange protein directly activated by cAMP)-specific cAMP analog, 8-pHPT-2'-O-MecAMP, significantly increased PI3K activity, whereas a PKA-specific analog, 6-benzoyladenosine-cAMP, showed no effect. The ANG II-induced increase in PI3K activity was also blocked by co-treatment with PP2, an Src inhibitor, or AG1478, an epidermal growth factor receptor (EGFR) antagonist. ANG II induced phosphorylation of Akt and p70S6K and EGFR, which was abrogated by knockdown of c-Src by small interference RNA. Knockdown of Src also effectively abolished ANG II-induced collagen synthesis. Conversely, stable transfection of a constitutively active Src mutant enhanced basal PI3K activity and collagen production, which was abrogated by AG1478 but not by 2', 5'-DOA. Moreover, acute treatment with ANG II significantly increased Src activity, which was abrogated with co-treatment of 2', 5'-DOA. Taken together, these results suggest that ANG II induces collagen synthesis in MCs by activating the ANG II/AT-1R-EGFR-PI3K pathway. This transactivation is dependent on cAMP/Epac but not on PKA. Src kinase plays a pivotal role in this signaling pathway between cAMP and EGFR. This is the first demonstration that an AT1R-PI3K/Akt crosstalk, along with transactivation of EGFR, mediates ANG II-induced collagen synthesis in MCs.	Brown Univ, Women & Infants Hosp, Warren Alpert Med Sch, Dept Pediat, Providence, RI 02905 USA; Tokai Univ, Sch Med, Dept Internal Med, Div Nephrol & Metab, Isehara, Kanagawa 25911, Japan	Brown University; Women & Infants Hospital Rhode Island; Tokai University	Tseng, YT (corresponding author), Women & Infants Hosp Rhode Isl, Dept Pediat, 101 Dudley St,Kilguss 122, Providence, RI 02905 USA.	YTseng@wihri.org			NCRR NIH HHS [P20 RR018728] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018728] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Andresen BT, 2003, HYPERTENSION, V41, P781, DOI 10.1161/01.HYP.0000049426.61176.DF; Barnett AH, 2004, NEW ENGL J MED, V351, P1952, DOI 10.1056/NEJMoa042274; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; Bolick DT, 2003, ENDOCRINOLOGY, V144, P5227, DOI 10.1210/en.2003-0739; Brewster UC, 2004, AM J MED, V116, P263, DOI 10.1016/j.amjmed.2003.09.034; Butani L, 2005, PEDIATR NEPHROL, V20, P1651, DOI 10.1007/s00467-005-2031-5; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; Che Q, 2002, HYPERTENSION, V40, P700, DOI 10.1161/01.HYP.0000035524.10948.93; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; Cullen KA, 2004, AM J PHYSIOL-GASTR L, V287, pG334, DOI 10.1152/ajpgi.00517.2003; Deambrosis I, 2005, INT J IMMUNOPATH PH, V18, P327, DOI 10.1177/039463200501800215; Del Prete D, 2003, KIDNEY INT, V64, P149, DOI 10.1046/j.1523-1755.2003.00065.x; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; ERNSBERGE RP, 1992, AM J PHYSIOL, V263, pF411; Everett AD, 2001, AM J PHYSIOL-HEART C, V281, pH161, DOI 10.1152/ajpheart.2001.281.1.H161; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Gambaryan S, 2006, AM J PHYSIOL-ENDOC M, V290, pE423, DOI 10.1152/ajpendo.00128.2005; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghosh PM, 2001, AM J PHYSIOL-RENAL, V280, pF972, DOI 10.1152/ajprenal.2001.280.6.F972; GomezGarre D, 1996, HYPERTENSION, V27, P885, DOI 10.1161/01.HYP.27.4.885; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Haider UGB, 2005, MOL PHARMACOL, V68, P41, DOI 10.1124/mol.104.005421; Hamelink C, 2002, J NEUROSCI, V22, P5310; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hirshman CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1468, DOI 10.1152/ajpcell.2001.281.5.C1468; Hur EM, 2004, J BIOL CHEM, V279, P5852, DOI 10.1074/jbc.M311687200; Iodice C, 2003, KIDNEY INT, V63, P2214, DOI 10.1046/j.1523-1755.2003.00015.x; Ishimatsu S, 2006, PLACENTA, V27, P587, DOI 10.1016/j.placenta.2005.07.001; Iwamoto R, 2006, CELL STRUCT FUNCT, V31, P1, DOI 10.1247/csf.31.1; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Krepinsky JC, 2005, J AM SOC NEPHROL, V16, P1661, DOI 10.1681/ASN.2004100897; Krieg T, 2004, J MOL CELL CARDIOL, V36, P435, DOI 10.1016/j.yjmcc.2003.12.013; Lai KN, 2004, KIDNEY INT, V66, P1403, DOI 10.1111/j.1523-1755.2004.00874.x; Lautrette A, 2005, NAT MED, V11, P867, DOI 10.1038/nm1275; LEE LK, 1995, J CLIN INVEST, V96, P953, DOI 10.1172/JCI118143; Li XF, 2001, P NATL ACAD SCI USA, V98, P14416, DOI 10.1073/pnas.251547198; Nakamura T, 1999, KIDNEY INT, V55, P877, DOI 10.1046/j.1523-1755.1999.055003877.x; Ohashi H, 2004, CIRC RES, V94, P785, DOI 10.1161/01.RES.0000121103.03275.EC; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; Shimamura H, 2003, J AM SOC NEPHROL, V14, P1427, DOI 10.1097/01.ASN.0000066140.99610.32; Staples KJ, 2001, J IMMUNOL, V167, P2074, DOI 10.4049/jimmunol.167.4.2074; Stratta P, 2004, NEPHROL DIAL TRANSPL, V19, P587, DOI 10.1093/ndt/gfg604; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Tseng YT, 2005, AM J PHYSIOL-HEART C, V289, pH1834, DOI 10.1152/ajpheart.00435.2005; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WOLF G, 1992, AM J PATHOL, V140, P95; Yang H, 2001, ENDOCRINOLOGY, V142, P3502, DOI 10.1210/en.142.8.3502; YANO N, 2007, IN PRESS AM J PHYSL	59	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18819	18830		10.1074/jbc.M610537200	http://dx.doi.org/10.1074/jbc.M610537200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17493931	hybrid			2022-12-25	WOS:000247475300021
J	Wahlbom, M; Wang, X; Lindstrom, V; Carlemalm, E; Jaskolski, M; Grubb, A				Wahlbom, Maria; Wang, Xin; Lindstrom, Veronica; Carlemalm, Eric; Jaskolski, Mariusz; Grubb, Anders			Fibrillogenic oligomers of human cystatin C are formed by propagated domain swapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-LIKE FIBRILS; PRION PROTEIN; CRYSTAL-STRUCTURE; COMMON MECHANISM; AGGREGATION; DISEASE; DIMERIZATION; CONVERSION; IMPLIES; VARIANT	Cystatin C and the prion protein have been shown to form dimers via three-dimensional domain swapping, and this process has also been hypothesized to be involved in amyloidogenesis. Production of oligomers of other amyloidogenic proteins has been reported to precede fibril formation, suggesting oligomers as intermediates in fibrillogenesis. A variant of cystatin C, with a Leu(68)-> Gln substitution, is highly amyloidogenic, and carriers of this mutation suffer from massive cerebral amyloidosis leading to brain hemorrhage and death in early adulthood. This work describes doughnut-shaped oligomers formed by wild type and L68Q cystatin C upon incubation of the monomeric proteins. Purified oligomers of cystatin C are shown to fibrillize faster and at a lower concentration than the monomeric protein, indicating a role of the oligomers as fibril-assembly intermediates. Moreover, the present work demonstrates that three-dimensional domain swapping is involved in the formation of the oligomers, because variants of monomeric cystatin C, stabilized against three-dimensional domain swapping by engineered disulfide bonds, do not produce oligomers upon incubation under non-reducing conditions. Redox experiments using wild type and stabilized cystatin C strongly suggest that the oligomers, and thus probably the fibrils as well, are formed by propagated domain swapping rather than by assembly of domain-swapped cystatin C dimers.	Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden; Lund Univ, Dept Clin Sci, S-22362 Lund, Sweden; Adam Mickiewicz Univ, Ctr Biocrystallog Res, Inst Bioorgan Chem, Fac Chem, PL-60780 Poznan, Poland; Adam Mickiewicz Univ, Ctr Biocrystallog Res, Polish Acad Sci, Dept Crystallog, PL-60780 Poznan, Poland	Lund University; Skane University Hospital; Lund University; Adam Mickiewicz University; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Adam Mickiewicz University; Polish Academy of Sciences	Grubb, A (corresponding author), Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden.	anders.grubb@med.lu.se		Grubb, Anders/0000-0002-0125-3662; Jaskolski, Mariusz/0000-0003-1587-6489				ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Bennett MJ, 2006, STRUCTURE, V14, P811, DOI 10.1016/j.str.2006.03.011; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bjarnadottir M, 2001, AMYLOID, V8, P1, DOI 10.3109/13506120108993809; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Buxbaum JN, 2003, TRENDS BIOCHEM SCI, V28, P585, DOI 10.1016/j.tibs.2003.09.009; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Eakin CM, 2004, BIOCHEMISTRY-US, V43, P7808, DOI 10.1021/bi049792q; Ekiel I, 1996, J BIOL CHEM, V271, P1314, DOI 10.1074/jbc.271.3.1314; Gerhartz B, 1998, BIOCHEMISTRY-US, V37, P17309, DOI 10.1021/bi980873u; Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017; Grubb AO, 2001, ADV CLIN CHEM, V35, P63, DOI 10.1016/S0065-2423(01)35015-1; Guo ZF, 2006, P NATL ACAD SCI USA, V103, P8042, DOI 10.1073/pnas.0602607103; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Janowski R, 2005, PROTEINS, V61, P570, DOI 10.1002/prot.20633; Janowski R, 2004, J MOL BIOL, V341, P151, DOI 10.1016/j.jmb.2004.06.013; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; Jaskolski M, 2001, ACTA BIOCHIM POL, V48, P807; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LeVine H, 1999, METHOD ENZYMOL, V309, P467; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Nelson R., 2006, CURR OPIN STRUC BIOL, V16, P1; Newcomer ME, 2001, NAT STRUCT BIOL, V8, P282, DOI 10.1038/86134; Nilsson M, 2004, J BIOL CHEM, V279, P24236, DOI 10.1074/jbc.M402621200; Ohnishi S, 2004, CELL MOL LIFE SCI, V61, P511, DOI 10.1007/s00018-003-3264-8; Olafsson I, 2000, AMYLOID, V7, P70, DOI 10.3109/13506120009146827; Sabella S, 2004, ELECTROPHORESIS, V25, P3186, DOI 10.1002/elps.200406062; Sambashivan S, 2005, NATURE, V437, P266, DOI 10.1038/nature03916; SERPELL LC, 1995, J MOL BIOL, V254, P113, DOI 10.1006/jmbi.1995.0604; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x	46	101	103	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18318	18326		10.1074/jbc.M611368200	http://dx.doi.org/10.1074/jbc.M611368200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17470433	hybrid, Green Submitted			2022-12-25	WOS:000247302000038
J	Denoeud, L; Turbelin, C; Ansart, S; Valleron, AJ; Flahault, A; Carrat, F				Denoeud, Lise; Turbelin, Clement; Ansart, Severine; Valleron, Alain-Jacques; Flahault, Antoine; Carrat, Fabrice			Predicting Pneumonia and Influenza Mortality from Morbidity Data	PLOS ONE			English	Article								Background. Few European countries conduct reactive surveillance of influenza mortality, whereas most monitor morbidity. Methodology/Principal Findings. We developed a simple model based on Poisson seasonal regression to predict excess cases of pneumonia and influenza mortality during influenza epidemics, based on influenza morbidity data and the dominant types/subtypes of circulating viruses. Epidemics were classified in three levels of mortality burden ("high", "moderate" and "low"). The model was fitted on 14 influenza seasons and was validated on six subsequent influenza seasons. Five out of the six seasons in the validation set were correctly classified. The average absolute difference between observed and predicted mortality was 2.8 per 100,000 (18% of the average excess mortality) and Spearman's rank correlation coefficient was 0.89 (P=0.05). Conclusions/Significance. The method described here can be used to estimate the influenza mortality burden in countries where specific pneumonia and influenza mortality surveillance data are not available.	[Denoeud, Lise; Turbelin, Clement; Ansart, Severine; Valleron, Alain-Jacques; Flahault, Antoine; Carrat, Fabrice] Univ Paris 06, UMR S 707, Paris, France; [Denoeud, Lise; Turbelin, Clement; Ansart, Severine; Valleron, Alain-Jacques; Flahault, Antoine; Carrat, Fabrice] INSERM, U707, Paris, France; [Valleron, Alain-Jacques; Flahault, Antoine; Carrat, Fabrice] Hop St Antoine, AP HP, F-75571 Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Carrat, F (corresponding author), Univ Paris 06, UMR S 707, Paris, France.	carrat@u707.jussieu.fr	Carrat, Fabrice/AAU-8480-2020; Ansart, Severine/AAQ-1210-2021	Carrat, Fabrice/0000-0002-8672-7918; DENOEUD-NDAM, Lise/0000-0002-9482-1461	Universite Pierre et Marie Curie, Paris 6; INSERM	Universite Pierre et Marie Curie, Paris 6; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	This study received financial support from 'Universite Pierre et Marie Curie, Paris 6' and 'INSERM'.	CARRAT F, 1995, J EPIDEMIOL COMMUN H, V49, P419, DOI 10.1136/jech.49.4.419; Carrat F, 1998, J EPIDEMIOL COMMUN H, V52, p32S; COSTAGLIOLA D, 1991, AM J PUBLIC HEALTH, V81, P97, DOI 10.2105/AJPH.81.1.97; Cox NJ, 2000, ANNU REV MED, V51, P407, DOI 10.1146/annurev.med.51.1.407; Dushoff J, 2006, AM J EPIDEMIOL, V163, P181, DOI 10.1093/aje/kwj024; Fleming DM, 2003, VACCINE, V21, P1749, DOI 10.1016/S0264-410X(03)00066-5; FLEMING DM, 1993, LANCET, V342, P1507, DOI 10.1016/S0140-6736(05)80082-0; LEFEVRE H, 2005, SURVEILLANCE NATL MA; SERFLING RE, 1963, PUBLIC HEALTH REP, V78, P494, DOI 10.2307/4591848; Simonsen L, 1998, J INFECT DIS, V178, P53, DOI 10.1086/515616; Simonsen L, 1997, AM J PUBLIC HEALTH, V87, P1944, DOI 10.2105/AJPH.87.12.1944; Simonsen L, 2005, ARCH INTERN MED, V165, P265, DOI 10.1001/archinte.165.3.265; SPRENGER MJW, 1993, INT J EPIDEMIOL, V22, P334, DOI 10.1093/ije/22.2.334; SPRENGER MJW, 1991, INT J EPIDEMIOL, V20, P1118, DOI 10.1093/ije/20.4.1118; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Xia YC, 2005, J R STAT SOC C-APPL, V54, P659, DOI 10.1111/j.1467-9876.2005.05383.x	16	21	21	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e464	10.1371/journal.pone.0000464	http://dx.doi.org/10.1371/journal.pone.0000464			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520023	Green Published, Green Submitted, gold			2022-12-25	WOS:000207446000012
J	Sirvent, A; Boureux, A; Simon, V; Leroy, C; Roche, S				Sirvent, A.; Boureux, A.; Simon, V.; Leroy, C.; Roche, S.			The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells	ONCOGENE			English	Article						Src; Abl; ERK5; Rac; cell transformation; breast cancer	VASCULAR SMOOTH-MUSCLE; MIDDLE-T-ANTIGEN; C-ABL; FAMILY KINASES; GROWTH-FACTORS; DNA-SYNTHESIS; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; MYC EXPRESSION; RAC ACTIVATION	The cytoplasmic tyrosine kinase Src has been implicated in signal transduction induced by growth factors and integrins. Src also shows oncogenic activity when deregulated. Accumulating evidence indicates that the tyrosine kinase Abl is an important substrate for Src signalling in normal cells. Here we show that Abl is also required for Src-induced transformation of mouse fibroblasts. Abl does not mediate tyrosine phosphorylation of Stat3 and Shc, two important regulators of Src oncogenic activity. In contrast, Abl controls the activation of the small GTPase Rac for oncogenic signalling and active Rac partly rescued Src transformation in cells with inactive Abl. Moreover, Abl mediates Src-induced extracellular regulated kinase 5 (ERK5) activation to drive cell transformation. Finally, we find that Abl/Rac and Abl/ERK5 pathways also operate in human MCF7 and BT549 breast cancer cells, where neoplastic transformation depends on Src-like activities. Therefore, Abl is an important regulator of Src oncogenic activity both in mouse fibroblasts and in human cancer cells. Targeting these Abl-dependent signalling cascades may be of therapeutic value in breast cancers where Src-like function is important.	CNRS, CRBM, UMR 5237, F-34033 Montpellier, France; IGH, UPR1142 UMII, F-34095 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Roche, S (corresponding author), CNRS, CRBM, UMR 5237, BP 5051, F-34033 Montpellier, France.	serge.roche@crbm.cnrs.fr		roche, serge/0000-0003-3413-3859				Barros JC, 2005, J CELL SCI, V118, P1663, DOI 10.1242/jcs.02308; Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buschbeck M, 2005, EMBO REP, V6, P63, DOI 10.1038/sj.embor.7400316; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chen T, 2006, ANTI-CANCER DRUG, V17, P123, DOI 10.1097/00001813-200602000-00002; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; FINN RS, 2007, IN PRESS BREAST CANC; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Franco M, 2006, MOL CELL BIOL, V26, P1932, DOI 10.1128/MCB.26.5.1932-1947.2006; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Garaude J, 2006, J IMMUNOL, V177, P7607, DOI 10.4049/jimmunol.177.11.7607; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kayahara M, 2005, MOL CELL BIOL, V25, P3784, DOI 10.1128/MCB.25.9.3784-3792.2005; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Nicholson PR, 2001, EMBO J, V20, P6337, DOI 10.1093/emboj/20.22.6337; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Roussidis AE, 2004, ANTICANCER RES, V24, P1445; SEGINA NV, 2007, NATURE, V445, P437; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; Ushio-Fukai M, 2005, CIRC RES, V97, P829, DOI 10.1161/01.RES.0000185322.46009.F5; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zipfel PA, 2004, CURR BIOL, V14, P1222, DOI 10.1016/j.cub.2004.07.021; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	44	49	52	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7313	7323		10.1038/sj.onc.1210543	http://dx.doi.org/10.1038/sj.onc.1210543			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533370	Green Submitted			2022-12-25	WOS:000250955700003
J	Broude, EV; Swift, ME; Vivo, C; Chang, BD; Davis, BM; Kalurupalle, S; Blagosklonny, MV; Roninson, IB				Broude, E. V.; Swift, M. E.; Vivo, C.; Chang, B-D; Davis, B. M.; Kalurupalle, S.; Blagosklonny, M. V.; Roninson, I. B.			p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation	ONCOGENE			English	Article						p21; Rb; p27; damage response	RETROVIRAL VECTORS; TUMOR-CELLS; DNA-DAMAGE; SENESCENCE; ARREST; P21; P53; FIBROBLASTS; REQUIREMENT; SUPPRESSION	Damage-induced G1 checkpoint in mammalian cells involves upregulation of p53, which activates transcription of p21(Waf1) (CDKN1A). Inhibition of cyclin-dependent kinase (CDK)2 and CDK4/6 by p21 leads to dephosphorylation and activation of Rb. We now show that ectopic p21. expression in human HT1080 fibrosarcoma cells causes not only dephosphorylation but also depletion of Rb; this effect was p53-independent and susceptible to a proteasome inhibitor. CDK inhibitor p27 (CDKN1B) also caused Rb dephosphorylation and depletion, but another CDK inhibitor p16 (CDKN2A) induced only dephosphorylation but not depletion of Rb. Rb depletion was observed in both HT1080 and HCT116 colon carcinoma cells, where p21. was induced by DNA-damaging agents. Rb depletion after DNA damage did not occur in the absence of p21, and it was reduced when p21 induction was inhibited by p21-targeting short hairpin RNA or by a transdominant inhibitor of p53. These results indicate that p2l both activates Rb through dephosphorylation and inactivates it through degradation, suggesting negative feedback regulation of damage-induced cell-cycle checkpoint arrest.	Ordway Res Inst, Ctr Canc, Albany, NY 12208 USA; Univ Illinois, Dept Mol Genet, Chicago, IL USA	Ordway Research Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roninson, IB (corresponding author), Ordway Res Inst, Ctr Canc, 150 New Scotland Ave, Albany, NY 12208 USA.	roninson@ordwayresearch.org	Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NCI NIH HHS [R01 CA95727, R01 CA62099] Funding Source: Medline; NIA NIH HHS [R01 AG17921] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062099, R01CA095727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017921] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boyer SN, 1996, CANCER RES, V56, P4620; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kandel ES, 1997, SOMAT CELL MOLEC GEN, V23, P325, DOI 10.1007/BF02674280; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Maliyekkel A, 2006, CELL CYCLE, V5, P2390, DOI 10.4161/cc.5.20.3363; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515	21	64	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6954	6958		10.1038/sj.onc.1210516	http://dx.doi.org/10.1038/sj.onc.1210516			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486059				2022-12-25	WOS:000250188400011
J	Shtiegman, K; Kochupurakkal, BS; Zwang, Y; Pines, G; Starr, A; Vexler, A; Citri, A; Katz, M; Lavi, S; Ben-Basat, Y; Benjamin, S; Corso, S; Gan, J; Yosef, RB; Giordano, S; Yarden, Y				Shtiegman, K.; Kochupurakkal, B. S.; Zwang, Y.; Pines, G.; Starr, A.; Vexler, A.; Citri, A.; Katz, M.; Lavi, S.; Ben-Basat, Y.; Benjamin, S.; Corso, S.; Gan, J.; Yosef, R. B.; Giordano, S.; Yarden, Y.			Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling	ONCOGENE			English	Article						endocytosis; Gefitinib; growth factor; NSCLC; tyrosine kinase	GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; TYROSINE KINASES; ERBB RECEPTORS; BREAST-CANCER; GEFITINIB; ENDOCYTOSIS; MUTATIONS; PROTEINS; PHOSPHORYLATION	Several distinct mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are associated with non-small cell lung cancer, but mechanisms underlying their oncogenic potential are incompletely understood. Although normally ligand-induced kinase activation targets EGFR to Cbl-mediated receptor ubiquitinylation and subsequent degradation in lysosomes, we report that certain EGFR mutants escape this regulation. Defective endocytosis characterizes a deletion mutant of EGFR, as well as a point mutant (L858R-EGFR), whose association with c-Cbl and ubiquitinylation are impaired. Our data raise the possibility that refractoriness of L858R-EGFR to downregulation is due to enhanced heterodimerization with the oncogene product HER2, which leads to persistent stimulation.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Tel Aviv Sourasky Med Ctr, Div Oncol, Ramat Aviv, Israel; Tel Aviv Univ, Sch Med, Ramat Aviv, Israel; Tel Aviv Univ, Dept Cell Res & Immunol, Ramat Aviv, Israel; Univ Turin, Sch Med, Inst Cancer Res & Treatment, Dept Oncol Sci,Div Mol Oncol, Turin, Italy	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Tel Aviv University; University of Turin	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Room 32 Candiotty Bldg,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Pines, Gur/X-7501-2019; YARDEN, YOSEF/K-1467-2012; Giordano, Silvia/J-9858-2018; Citri, Ami/R-8973-2019	Pines, Gur/0000-0002-1757-6722; Giordano, Silvia/0000-0003-1854-1086; Citri, Ami/0000-0002-9914-0278; Starr, Alexander/0000-0002-9329-3740; CORSO, Simona/0000-0002-5069-1503	NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann J, 2005, CANCER RES, V65, P226; Baulida J, 1996, J BIOL CHEM, V271, P5251; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Ouyang XM, 2001, MOL CELL BIOCHEM, V218, P47, DOI 10.1023/A:1007249004222; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; PORTA DG, 1997, EMBO J, V16, P1647; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yang SC, 2006, CANCER RES, V66, P6990, DOI 10.1158/0008-5472.CAN-06-1042; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	31	103	106	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					6968	6978		10.1038/sj.onc.1210503	http://dx.doi.org/10.1038/sj.onc.1210503			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486068				2022-12-25	WOS:000250412200002
J	Yuen, JSP; Cockman, ME; Sullivan, M; Protheroe, A; Turner, GDH; Roberts, IS; Pugh, CW; Werner, H; Macaulay, VM				Yuen, J. S. P.; Cockman, M. E.; Sullivan, M.; Protheroe, A.; Turner, G. D. H.; Roberts, I. S.; Pugh, C. W.; Werner, H.; Macaulay, V. M.			The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma	ONCOGENE			English	Article						type IIGF receptor; renal cancer; VHL; Sp1; HuR	GROWTH-FACTOR-I; MESSENGER-RNA TURNOVER; LINDAU GENE-PRODUCT; FACTOR RECEPTOR; COLORECTAL-CANCER; PROSTATE-CANCER; HIF-ALPHA; HYPOXIA; BINDING; PROTEIN	Clear cell renal cell cancer (CC-RCC) is a highly chemoresistant tumor characterized by frequent inactivation of the von Hippel-Lindau (VHL) gene. The prognosis is reportedly worse in patients whose tumors express immunoreactive type I insulin-like growth factor receptor (IGF1R), a key mediator of tumor cell survival. We aimed to investigate how IGF1R expression is regulated, and found that IGF1R protein levels were unaffected by hypoxia, but were higher in CC-RCC cells harboring mutant inactive VHL than in isogenic cells expressing wild-type (WT) VHL. IGF1R mRNA and promoter activities were significantly lower in CC-RCC cells expressing WT VHL, consistent with a transcriptional effect. In Sp1-null Drosophila Schneider cells, IGF1R promoter activity was dependent on exogenous Sp1, and was suppressed by full-length VHL protein (pVHL) but only partially by truncated VHL lacking the Sp1-binding motif. pVHL also reduced the stability of IGF1R mRNA via sequestration of HuR protein. Finally, IGF1R mRNA levels were significantly higher in CC-RCC biopsies than benign kidney, confirming the clinical relevance of these findings. Thus, we have identified a new hypoxia-independent role for VHL in suppressing IGF1R transcription and mRNA stability. VHL inactivation leads to IGF1R upregulation, contributing to renal tumorigenesis and potentially also to chemoresistance.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Lab, Oxford OX3 9DS, England; Henry Wellcome Bldg Mol Pathol, Oxford, England; Churchill Hosp, Dept Urol, Oxford OX3 7LJ, England; Churchill Hosp, Dept Med Oncol, Oxford OX3 7LJ, England; John Radcliffe Hosp, Dept Cell Pathol, Oxford OX3 9DU, England; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Cancer Research UK; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Tel Aviv University; Sackler Faculty of Medicine	Macaulay, VM (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Lab, Headley Way, Oxford OX3 9DS, England.	macaulay@cancer.org.uk	Cockman, Matthew/V-9619-2019	Cockman, Matthew/0000-0002-3310-4821; Pugh, Chris/0000-0002-5170-1662	MRC [G0601061] Funding Source: UKRI; Medical Research Council [G0601061] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abramovitch S, 2003, FEBS LETT, V541, P149, DOI 10.1016/S0014-5793(03)00315-6; Ahmad N, 2004, HUM PATHOL, V35, P1132, DOI 10.1016/j.humpath.2004.05.012; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cohen HT, 1999, BIOCHEM BIOPH RES CO, V266, P43, DOI 10.1006/bbrc.1999.1767; Conaway RC, 2002, ADV CANCER RES, V85, P1, DOI 10.1016/S0065-230X(02)85001-1; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; Datta K, 2005, ONCOGENE, V24, P7850, DOI 10.1038/sj.onc.1208912; Dunn SE, 1997, CANCER RES, V57, P2687; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hakam A, 1999, HUM PATHOL, V30, P1128, DOI 10.1016/S0046-8177(99)90027-8; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hellawell GO, 2002, CANCER RES, V62, P2942; Iliopoulos O, 1997, MOL MED, V3, P289, DOI 10.1007/BF03401807; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kim KW, 1998, CANCER RES, V58, P348; Kruhoffer M, 2005, BRIT J CANCER, V92, P2240, DOI 10.1038/sj.bjc.6602621; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; MAMULA PW, 1992, DNA CELL BIOL, V11, P43, DOI 10.1089/dna.1992.11.43; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meng Z, 2005, NUCLEIC ACIDS RES, V33, P2962, DOI 10.1093/nar/gki603; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Ord JJ, 2005, BRIT J CANCER, V93, P346, DOI 10.1038/sj.bjc.6602666; Parker AS, 2004, CANCER-AM CANCER SOC, V100, P2577, DOI 10.1002/cncr.20322; Parker AS, 2003, J UROLOGY, V170, P420, DOI 10.1097/01.ju.0000071474.70103.92; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rafty LA, 2002, J CELL BIOCHEM, V85, P490, DOI 10.1002/jcb.10152; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Riedemann J, 2007, BIOCHEM BIOPH RES CO, V355, P707, DOI 10.1016/j.bbrc.2007.02.012; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; SELL C, 1995, CANCER RES, V55, P303; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Steinbrech DS, 2000, ANN PLAS SURG, V44, P529, DOI 10.1097/00000637-200044050-00012; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	55	70	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6499	6508		10.1038/sj.onc.1210474	http://dx.doi.org/10.1038/sj.onc.1210474			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17486080				2022-12-25	WOS:000249919800003
J	Zhang, ZH; Liao, B; Xu, M; Jin, Y				Zhang, Zhihong; Liao, Bing; Xu, Ming; Jin, Ying			Post-translational modification of POU domain transcription factor Oct-4 by SUMO-1	FASEB JOURNAL			English	Article						embryonic stem cells; sumoylation; protein stability; cYes	EMBRYONIC STEM-CELLS; KAPPA-B ACTIVATION; SELF-RENEWAL; GENE-EXPRESSION; UBIQUITIN; DIFFERENTIATION; PLURIPOTENCY; CONJUGATION; STABILITY; INTEGRITY	POU domain transcription factor Oct-4 plays a crucial role in maintaining self-renewal and pluripotency of embryonic stem (ES) cells in a concentration-dependent manner. However, the molecular mechanism controlling Oct-4 levels in ES cells remains largely unknown. To explore the molecular mechanism regulating Oct-4 function, we constructed a mouse ES cell cDNA library and performed yeast two-hybrid screening using the POU domain of Oct-4 as bait. Here, we present novel evidence for Oct-4 interaction with Ubc9, an E2 conjugation enzyme for SUMO modification, and its modification by SUMO-1. The SUMO acceptor site was identified at lysine residue 118. Importantly, disruption of Oct-4 sumoylation reduced Oct-4 protein stability and self-renewal capacity in ES cells. Interestingly, expression of cYes was found to reduce when Oct-4 sumoylation was disrupted or Oct-4 expression downregulated in ES cells. We further demonstrate that Oct-4 was recruited to the cYes promoter region, suggesting that cYes might be a novel downstream gene of Oct-4. Taken together, we first demonstrate the post-translational modification of endogenous Oct-4 by SUMO and the role of sumoylation in regulating Oct-4 protein stability and function. Our findings provide new evidence for the important role of post-translational modification in controlling Oct-4 function in ES cells.	Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Inst Stem Cell Res, Shanghai 200025, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Zhang, ZH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, 225 S Chongqing Rd, Shanghai 200025, Peoples R China.	yjin@sibs.ac.cn	zhang, zh/GWV-4677-2022; Xu, Ming/AAR-1681-2021; Xu, Ming/L-4044-2019	Xu, Ming/0000-0002-4477-939X; Liao, Bing/0000-0003-1279-1682; , jin ying/0000-0003-0070-2048				Anneren C, 2004, J BIOL CHEM, V279, P31590, DOI 10.1074/jbc.M403547200; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gresko E, 2005, BIOCHEM BIOPH RES CO, V329, P1293, DOI 10.1016/j.bbrc.2005.02.113; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Ramos-Mejia V, 2005, DEV DYNAM, V232, P180, DOI 10.1002/dvdy.20211; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; SMITH AG, 1992, DEV BIOL, V151, P339, DOI 10.1016/0012-1606(92)90174-F; Taylor KM, 2005, DEV CELL, V9, P593, DOI 10.1016/j.devcel.2005.09.016; Tsuruzoe S, 2006, BIOCHEM BIOPH RES CO, V351, P920, DOI 10.1016/j.bbrc.2006.10.130; Ulrich HD, 2005, TRENDS CELL BIOL, V15, P525, DOI 10.1016/j.tcb.2005.08.002; Wang J, 2004, J BIOL CHEM, V279, P49091, DOI 10.1074/jbc.M407494200; Xu HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	33	52	58	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3042	3051		10.1096/fj.06-6914com	http://dx.doi.org/10.1096/fj.06-6914com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17496161				2022-12-25	WOS:000249781600006
J	Zhen, Y; Sorensen, VS; Jin, Y; Suo, Z; Wiedlocha, A				Zhen, Y.; Sorensen, V. S.; Jin, Y.; Suo, Z.; Wiedlocha, A.			Indirubin-3 '-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK	ONCOGENE			English	Article						indirubin-3 '-monoxime; FGFR1; p38 MAPK; ERK1/2; CDK2; cell proliferation	ACTIVATED PROTEIN-KINASE; CELL MYELOPROLIFERATIVE DISORDER; CHINESE ANTILEUKEMIA MEDICINE; THR-160 PHOSPHORYLATION; INDIRUBIN DERIVATIVES; HEPARAN-SULFATE; TRANSLOCATION; APOPTOSIS; RECEPTOR; MECHANISMS	Indirubin-3'-monoxime is a derivative of the bis-indole alkaloid indirubin, an active ingredient of a traditional Chinese medical preparation that exhibits anti-inflammatory and anti-leukemic activities. Indirubin-3'-monoxime is mainly recognized as an inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3. It inhibits proliferation of cultured cells, mainly through arresting the cells in the G1/S or G2/M phase of the cell cycle. Here, we report that indirubin-3'-monoxime is able to inhibit proliferation of NIH/3T3 cells by specifically inhibiting autophosphorylation of fibroblast growth factor receptor 1(FGFR1), blocking in this way the receptor-mediated cell signaling. Indirubin-3'-monoxime inhibits the activity of FGFR1 at a concentration lower than that required for inhibition of phosphorylation of CDK2 and retinoblastoma protein and cell proliferation stimulated by fetal calf serum. The ability of indirubin-3'-monoxime to inhibit FGFR1 signa ling was similar to that of the FGFR1 inhibitor SU5402. In addition, we found that indirubin-3'-monoxime activates long-term p38 mitogen-activated protein kinase activity, which stimulates extracellular signal-regulated kinase 1/2 in a way unrelated to the activity of FGFR1. Furthermore, we show that indirubin-3'- monoxime can inhibit proliferation of the myeloid leukemia cell line KG-1a through inhibition of the activity of the FGFR1 tyrosine kinase. The data presented here demonstrate previously unknown activities of indirubin-3'-monoxime that may have clinical implications.	Univ Oslo, Norwegian Radium Hosp, Natl Hosp, Inst Canc Res,Dept Biochem, N-0310 Oslo, Norway; Univ Oslo, Norwegian Radium Hosp, Natl Hosp, Inst Canc Res,Dept Pathol, N-0310 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Wiedlocha, A (corresponding author), Univ Oslo, Norwegian Radium Hosp, Natl Hosp, Inst Canc Res,Dept Biochem, N-0310 Oslo, Norway.	antoni.wiedlocha@rr-research.no						Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chaffanet M, 1998, ONCOGENE, V16, P945, DOI 10.1038/sj.onc.1201601; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Furdui CM, 2006, MOL CELL, V21, P711, DOI 10.1016/j.molcel.2006.01.022; Gu TL, 2006, BLOOD, V108, P4202, DOI 10.1182/blood-2006-06-026666; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; Heredia A, 2005, AIDS, V19, P2087, DOI 10.1097/01.aids.0000194805.74293.11; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Jautelat R, 2005, CHEMBIOCHEM, V6, P531, DOI 10.1002/cbic.200400108; Kang YJ, 2006, J BIOL CHEM, V281, P26225, DOI 10.1074/jbc.M606800200; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Kosmopoulou MN, 2004, EUR J BIOCHEM, V271, P2280, DOI 10.1111/j.1432-1033.2004.04173.x; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Lin XH, 1999, DEVELOPMENT, V126, P3715; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MACDONALD D, 1995, LEUKEMIA, V9, P1628; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Nguyen DT, 2006, FREE RADICAL BIO MED, V41, P1225, DOI 10.1016/j.freeradbiomed.2006.06.026; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ribas J, 2006, ONCOGENE, V25, P6304, DOI 10.1038/sj.onc.1209648; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; Sethi G, 2006, J BIOL CHEM, V281, P23425, DOI 10.1074/jbc.M602627200; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Xie YB, 2004, NEUROSCI LETT, V367, P355, DOI 10.1016/j.neulet.2004.06.044; Yu ZP, 2000, TOXICOL APPL PHARM, V168, P200, DOI 10.1006/taap.2000.9033; ZHAN X, 1993, J BIOL CHEM, V268, P9611	46	48	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6372	6385		10.1038/sj.onc.1210473	http://dx.doi.org/10.1038/sj.onc.1210473			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17533378				2022-12-25	WOS:000249737600002
J	Liu, CH; Huang, SN; Cui, JK; Kim, YR; Farrar, CT; Moskowitz, MA; Rosen, BR; Liu, PK				Liu, Christina H.; Huang, Shuning; Cui, Jiankun; Kim, Young R.; Farrar, Christian T.; Moskowitz, Michael A.; Rosen, Bruce R.; Liu, Philip K.			MR contrast probes that trace gene transcripts for cerebral ischemia in live animals	FASEB JOURNAL			English	Article						cardiac arrest; immediate early genes; oxidative stress; nanotechnology; signal transduction	FOS MESSENGER-RNA; BLOOD-BRAIN-BARRIER; C-FOS; ANTISENSE OLIGONUCLEOTIDE; IN-VIVO; MOUSE-BRAIN; FOREBRAIN ISCHEMIA; CARDIAC-ARREST; EXPRESSION; PROTEIN	The aim of this research was to validate transcription magnetic resonance (MR) imaging (MRI) for gene transcript targeting in acute neurological disorders in live subjects. We delivered three MR probe variants with superparamagnetic iron oxide nanoparticles (SPION, a T-2 susceptibility agent) linked to a phosphorothioate-modified oligodeoxynucleotide (sODN) complementary to c-fos mRNA (SPION-cfos) or beta-actin mRNA (SPION-beta-actin) and to sODN with random sequence (SPION-Ran). Each probe (1 mu g Fe in 2 mu l) was delivered via intracerebroventricular infusion to the left cerebral ventricle of male C57Black6 mice. We demonstrated SPION retention, measured as decreased T-2* signal or increased R-2* value (R-2* = 1/T-2*). Animals that received the SPION-beta-actin probe exhibited the highest R-2* values, followed ( in descending order) by SPION- cfos and SPION- Ran. SPION- cfos retention was localized in brain regions where SPION-cfos was present and where hybrids of SPION- cfos and its target c-fos mRNA were detected by in situ reverse transcription PCR. In animals that experienced cerebral ischemia, SPION- cfos retention was significantly increased in locations where c-fos mRNA increased in response to the ischemic insult; these elevations were not observed for SPION-beta-actin and SPION-Ran. This study should enable MR detection of mRNA alteration in disease models of the central nervous system.-Liu, C. H., Huang, S., Cui, J., Kim, Y. R., Farrar, C. T., Moskowitz, M. A., Rosen. B. R., Liu, P. K. MR contrast probes that trace gene transcripts for cerebral ischemia in live animals.	Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT)	Liu, PK (corresponding author), Massachusetts Gen Hosp, Dept Radiol, 149 13th St,Rm 2410, Charlestown, MA 02129 USA.	philipl@nmr.mgh.harvard.edu		Liu, Christina/0000-0002-5723-177X; Farrar, Christian/0000-0001-6623-8220	NATIONAL CANCER INSTITUTE [T32CA009502] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P01AT002048] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR014075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [T32EB001680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS057556, R01NS045845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K25AG029415] Funding Source: NIH RePORTER; NCCIH NIH HHS [P01AT002048, P01 AT002048] Funding Source: Medline; NCI NIH HHS [5T32CA009502, T32 CA009502] Funding Source: Medline; NCRR NIH HHS [P41 RR014075, 5P41RR14075] Funding Source: Medline; NIA NIH HHS [K25 AG029415-04, K25 AG029415, K25 AG029415-01A1, K25 AG029415-05, K25 AG029415-03, K25 AG029415-02] Funding Source: Medline; NIBIB NIH HHS [T32 EB001680] Funding Source: Medline; NINDS NIH HHS [R01 NS045845-04, R21 NS057556-01A1S1, R01 NS045845, R01NS45845, R21 NS057556, R21 NS057556-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P1172, DOI 10.1097/01.WCB.0000137057.92786.F3; Back T, 2004, J NEUROL, V251, P388, DOI 10.1007/s00415-004-0399-y; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Chauhan NB, 2002, ANTISENSE NUCLEIC A, V12, P353, DOI 10.1089/108729002761381320; CHIASSON BJ, 1992, EUR J PHARM-MOLEC PH, V227, P451, DOI 10.1016/0922-4106(92)90167-T; Cho S, 2005, J CEREBR BLOOD F MET, V25, P493, DOI 10.1038/sj.jcbfm.9600058; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; Cui JK, 1999, J NEUROCHEM, V73, P1164, DOI 10.1046/j.1471-4159.1999.0731164.x; Cui JK, 2001, J BIOMED SCI, V8, P336, DOI 10.1007/BF02258375; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fujii M, 1997, STROKE, V28, P1805, DOI 10.1161/01.STR.28.9.1805; Gu ZZ, 1997, NEUROCHEM INT, V30, P417, DOI 10.1016/S0197-0186(96)00077-0; Huang CY, 2001, STROKE, V32, P741, DOI 10.1161/01.STR.32.3.741; Huang DY, 2000, FASEB J, V14, P407, DOI 10.1096/fasebj.14.2.407; Liu CH, 2004, MAGN RESON MED, V51, P978, DOI 10.1002/mrm.20047; LIU CH, IN PRESS MOL IMAGING; Liu CH, 2007, J NEUROSCI, V27, P713, DOI 10.1523/JNEUROSCI.4660-06.2007; LIU PK, 1993, MUTAT RES, V288, P229, DOI 10.1016/0027-5107(93)90089-X; LIU PK, 1994, ANN NEUROL, V36, P566, DOI 10.1002/ana.410360405; Liu PK, 2001, TRENDS NEUROSCI, V24, P581, DOI 10.1016/S0166-2236(00)01918-4; Liu PK, 1996, J NEUROSCI, V16, P6795; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; Lynch JR, 2004, STROKE, V35, P57, DOI 10.1161/01.STR.0000105927.62344.4C; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; McGirt MJ, 2002, NEUROSURGERY, V51, P1128, DOI 10.1097/00006123-200211000-00005; Morrow BA, 1999, J NEUROSCI, V19, P5666; MOSELEY ME, 1993, STROKE, V24, pI60; MOSSAKOWSKI MJ, 1994, ACTA NEUROCHIR, P274; Muldoon LL, 2004, NEUROPATH APPL NEURO, V30, P70, DOI 10.1046/j.0305-1846.2003.00512.x; Natt O, 2002, J NEUROSCI METH, V120, P203, DOI 10.1016/S0165-0270(02)00211-X; Neigh GN, 2004, EUR J NEUROSCI, V20, P1865, DOI 10.1111/j.1460-9568.2004.03649.x; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; Noguchi A, 1998, FEBS LETT, V433, P169, DOI 10.1016/S0014-5793(98)00837-0; Overhoff M, 2005, J MOL BIOL, V348, P871, DOI 10.1016/j.jmb.2005.03.012; PARDRIDGE WM, 1991, FEBS LETT, V288, P30, DOI 10.1016/0014-5793(91)80996-G; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; Saini S, 2000, CLIN RADIOL, V55, P690, DOI 10.1053/crad.2000.0504; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Shi NY, 2000, P NATL ACAD SCI USA, V97, P14709, DOI 10.1073/pnas.250332397; Tolliver BK, 2000, EUR J NEUROSCI, V12, P3399, DOI 10.1046/j.1460-9568.2000.00214.x; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; Weisbrot-Lefkowitz M, 1998, MOL BRAIN RES, V53, P333, DOI 10.1016/S0169-328X(97)00313-6; Wu CR, 2001, J NEUROSCI METH, V107, P101, DOI 10.1016/S0165-0270(01)00356-9; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Zhang MK, 2000, J CELL BIOCHEM, V76, P290, DOI 10.1002/(SICI)1097-4644(20000201)76:2<290::AID-JCB12>3.0.CO;2-V; Zhang Y, 1999, BRAIN RES, V832, P112, DOI 10.1016/S0006-8993(99)01459-6	50	22	23	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					3004	3015		10.1096/fj.07-8203com	http://dx.doi.org/10.1096/fj.07-8203com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17478745	Green Accepted			2022-12-25	WOS:000249237500040
J	Roujeinikova, A; Hothi, P; Masgrau, L; Sutcliffe, MJ; Scrutton, NS; Leys, D				Roujeinikova, Anna; Hothi, Parvinder; Masgrau, Laura; Sutcliffe, Michael J.; Scrutton, Nigel S.; Leys, David			New insights into the reductive half-reaction mechanism of aromatic amine dehydrogenase revealed by reaction with carbinolamine substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN TRYPTOPHYLQUINONE ENZYME; ALCALIGENES-FAECALIS; MOLECULAR-DYNAMICS	Aromatic amine dehydrogenase uses a tryptophan tryptophylquinone( TTQ) cofactor to oxidatively deaminate primary aromatic amines. In the reductive half-reaction, a proton is transferred from the substrate C1 to beta Asp-128 O-2, in a reaction that proceeds by H-tunneling. Using solution studies, kinetic crystallography, and computational simulation we show that the mechanism of oxidation of aromatic carbinolamines is similar to amine oxidation, but that carbinolamine oxidation occurs at a substantially reduced rate. This has enabled us to determine for the first time the structure of the intermediate prior to the H-transfer/reduction step. The proton-beta Asp-128 O-2 distance is similar to 3.7 angstrom, in contrast to the distance of similar to 2.7 angstrom predicted for the intermediate formed with the corresponding primary amine substrate. This difference of similar to 1.0 angstrom is due to an unexpected conformation of the substrate moiety, which is supported by molecular dynamic simulations and reflected in the similar to 10(7)-fold slower TTQ reduction rate with phenylaminoethanol compared with that with primary amines. A water molecule is observed near TTQ C-6 and is likely derived from the collapse of the preceding carbinolamine TTQ-adduct. We suggest this water molecule is involved in consecutive proton transfers following TTQ reduction, and is ultimately repositioned near the TTQ O-7 concomitant with protein rearrangement. For all carbinolamines tested, highly stable amide-TTQ adducts are formed following proton abstraction and TTQ reduction. Slow hydrolysis of the amide occurs after, rather than prior to, TTQ oxidation and leads ultimately to a carboxylic acid product.	Univ Manchester, Manchester Interdiscilinary Bioctr, Manchester M1 7DN, Lancs, England; Univ Manchester, Fac Life Sci, Manchester M1 7DN, Lancs, England; Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester M1 7DN, Lancs, England; Inst Pasteur, Unite Bioinformat Struct, F-75724 Paris, France	University of Manchester; University of Manchester; University of Manchester; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Leys, D (corresponding author), 131 Princess St, Manchester M1 7DN, Lancs, England.	david.leys@manchester.ac.uk	Masgrau, Laura/ABA-9339-2020; Masgrau, Laura/O-1214-2015	Masgrau, Laura/0000-0003-4495-508X; Masgrau, Laura/0000-0003-4495-508X; Roujeinikova, Anna/0000-0001-8478-4751; Sutcliffe, Mike/0000-0003-0414-1700	BBSRC [BB/D01963X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D01963X/1, B19724/2] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ARMSTRONG JM, 1964, BIOCHIM BIOPHYS ACTA, V86, P194; Basran J, 2001, J BIOL CHEM, V276, P6234, DOI 10.1074/jbc.M008141200; Bishop GR, 1998, BIOCHEM J, V330, P1159, DOI 10.1042/bj3301159; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1983, J CHEM PHYS, V79, P6312, DOI 10.1063/1.445724; Chistoserdov AY, 2001, MICROBIOL-SGM, V147, P2195, DOI 10.1099/00221287-147-8-2195; DAVIDSON VL, 1990, METHOD ENZYMOL, V188, P241; DAVIS CD, 1993, CANCER LETT, V73, P95, DOI 10.1016/0304-3835(93)90250-D; FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605; Gao JL, 1998, J PHYS CHEM A, V102, P4714, DOI 10.1021/jp9809890; GOVINDARAJ S, 1994, J BACTERIOL, V176, P2922, DOI 10.1128/JB.176.10.2922-2929.1994; Hothi P, 2005, FEBS J, V272, P5894, DOI 10.1111/j.1742-4658.2005.04990.x; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HYUN YL, 1995, BIOCHEMISTRY-US, V34, P816, DOI 10.1021/bi00003a015; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Masgrau L, 2006, SCIENCE, V312, P237, DOI 10.1126/science.1126002; Masgrau L, 2007, J PHYS CHEM B, V111, P3032, DOI 10.1021/jp067898k; MCLEOD RK, 1961, J ORG CHEM, V26, P1094, DOI 10.1021/jo01063a028; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NOZAKI M, 1987, METHOD ENZYMOL, V142, P650; Roujeinikova A, 2006, J BIOL CHEM, V281, P40264, DOI 10.1074/jbc.M605559200; Roussel A., 1991, SILICON GRAPHICS GEO, V86; Sukumar N, 2006, BIOCHEMISTRY-US, V45, P13500, DOI 10.1021/bi0612972	24	13	14	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23766	23777		10.1074/jbc.M700677200	http://dx.doi.org/10.1074/jbc.M700677200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17475620	hybrid			2022-12-25	WOS:000248686600005
J	Kusner, DJ; Thompson, CR; Melrose, NA; Pitson, SM; Obeid, LM; Iyer, SS				Kusner, David J.; Thompson, Christopher R.; Melrose, Natalie A.; Pitson, Stuart M.; Obeid, Lina M.; Iyer, Shankar S.			The localization and activity of sphingosine kinase 1 are coordinately regulated with actin cytoskeletal dynamics in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DEPENDENT SIGNAL-TRANSDUCTION; MEDIATED CA2+ MOBILIZATION; PHAGOSOME-LYSOSOME FUSION; PHOSPHOLIPASE-D ACTIVITY; MYCOBACTERIUM-TUBERCULOSIS; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; G-PROTEIN; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM	The physiologic and pathologic functions of sphingosine kinase (SK) require translocation to specific membrane compartments. Wetested the hypothesis that interactions with actin filaments regulate the localization of SK1 to membrane surfaces, including the plasma membrane and phagosome. Macrophage activation is accompanied by a marked increase in association of SK1 with actin filaments. Catalytically-inactive (CI)- and phosphorylation-defective (PD)-SK1 mutants exhibited reductions in plasma membrane translocation, colocalization with cortical actin filaments, membrane ruffling, and lamellipodia formation, compared with wild-type (WT)-SK1. However, translocation of CI- and PD-SK1 to phagosomes were equivalent to WT-SK1. SK1 exhibited constitutive- and stimulus-enhanced association with actin filaments and F-actin-enriched membrane fractions in both intact macrophages and a novel in vitro assay. In contrast, SK1 bound G-actin only under stimulated conditions. Actin inhibitors disrupted SK1 localization and modulated its activity. Conversely, reduction of SK1 levels or activity via RNA interference or specific chemical inhibition resulted in dysregulation of actin filaments. Thus, the localization and activity of SK1 are coordinately regulated with actin dynamics during macrophage activation.	Univ Iowa, Carver Coll Med, Inflammat Program, Div Infect Dis, Iowa City, IA 52245 USA; Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52245 USA; Univ Iowa, Carver Coll Med, Dept Physiol & Biophys, Iowa City, IA 52245 USA; Univ Iowa, Carver Coll Med, Grad Program Immunol, Iowa City, IA 52245 USA; Univ Iowa, Carver Coll Med, Grad Mol Biol, Iowa City, IA 52245 USA; Vet Affairs Med Ctr, Iowa City, IA 52245 USA; Univ Adelaide, Sch Mol & Biomed Sci, Inst Med & Vet Sci, Div Human Immunol,Hanson Inst, Adelaide, SA 5005, Australia; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kusner, DJ (corresponding author), 200 Hawkins Dr,SW54-8GH, Iowa City, IA 52245 USA.	david-kusner@uiowa.edu	Pitson, Stuart/B-9342-2009; Thompson, Christopher/AAB-1361-2021	Pitson, Stuart/0000-0002-9527-2740; obeid, lina/0000-0002-0734-0847	NIAID NIH HHS [R01 AI055916, P01 AI44642-08] Funding Source: Medline; NIGMS NIH HHS [R01 GM062887, R01 GM62302] Funding Source: Medline; PHS HHS [T32] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044642, R01AI055916] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887, R01GM062302] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aas V, 2001, CELL COMMUN ADHES, V8, P125, DOI 10.3109/15419060109080712; ALBERTS B, 2004, MOL BIOL CELL, P632; Alemany R, 2000, MOL PHARMACOL, V58, P491, DOI 10.1124/mol.58.3.491; Alemany R, 2001, FEBS LETT, V509, P239, DOI 10.1016/S0014-5793(01)03168-4; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Anes E, 2003, NAT CELL BIOL, V5, P793, DOI 10.1038/ncb1036; Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; Bader MF, 2004, BBA-MOL CELL RES, V1742, P37, DOI 10.1016/j.bbamcr.2004.09.028; Beaven MA, 1996, CURR BIOL, V6, P798, DOI 10.1016/S0960-9822(02)00598-5; Booth JW, 2001, SEMIN IMMUNOL, V13, P357, DOI 10.1006/smim.2001.0332; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; CHAO CP, 1994, J BIOL CHEM, V269, P5849; Choi OH, 1996, NATURE, V380, P634; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; Colton T, 1974, STAT MED; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; de Melker AA, 2004, J CELL SCI, V117, P5001, DOI 10.1242/jcs.01354; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Deretic V, 1999, MOL MICROBIOL, V31, P1603, DOI 10.1046/j.1365-2958.1999.01279.x; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; Eitzen G, 2003, BBA-MOL CELL RES, V1641, P175, DOI 10.1016/S0167-4889(03)00087-9; Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002; Funatsu N, 2000, NEUROSCI RES, V36, P311, DOI 10.1016/S0168-0102(99)00125-X; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gaus K, 2006, J CELL BIOL, V174, P725, DOI 10.1083/jcb.200603034; Greaves DR, 2005, J LIPID RES, V46, P11, DOI 10.1194/jlr.R400011-JLR200; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Hanna AN, 2001, MOL BIOL CELL, V12, P3618, DOI 10.1091/mbc.12.11.3618; Henry RM, 2004, J CELL BIOL, V164, P185, DOI 10.1083/jcb.200307080; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Hla T, 2000, ANN NY ACAD SCI, V905, P16; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Holzinger A, 2001, METH MOL B, V161, P109; Ignatov A, 2003, BIOCHEM BIOPH RES CO, V311, P329, DOI 10.1016/j.bbrc.2003.10.006; Itagaki K, 2005, J LEUKOCYTE BIOL, V77, P181, DOI 10.1189/jlb.0704390; Iyer SS, 2006, J IMMUNOL, V176, P3686, DOI 10.4049/jimmunol.176.6.3686; Iyer SS, 2004, J IMMUNOL, V173, P2615, DOI 10.4049/jimmunol.173.4.2615; Iyer SS, 1999, J BIOL CHEM, V274, P2350, DOI 10.1074/jbc.274.4.2350; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kaneider NC, 2003, J VIROL, V77, P5535, DOI 10.1128/JVI.77.9.5535-5539.2003; Kaneider NC, 2002, BIOCHEM BIOPH RES CO, V297, P806, DOI 10.1016/S0006-291X(02)02304-5; Katsuma S, 2002, GENES CELLS, V7, P1217, DOI 10.1046/j.1365-2443.2002.00594.x; Kee TH, 2005, CLIN EXP PHARMACOL P, V32, P153, DOI 10.1111/j.1440-1681.2005.04166.x; Kenworthy A, 2002, TRENDS BIOCHEM SCI, V27, P435, DOI 10.1016/S0968-0004(02)02178-3; Kihara A, 2006, J BIOL CHEM, V281, P4532, DOI 10.1074/jbc.M510308200; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kodama A, 2004, J CELL BIOL, V167, P203, DOI 10.1083/jcb.200408047; Kodama A, 2003, CELL, V115, P343, DOI 10.1016/S0092-8674(03)00813-4; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kusner DJ, 2003, ARCH BIOCHEM BIOPHYS, V412, P231, DOI 10.1016/S0003-9861(03)00052-3; Kusner DJ, 2002, J BIOL CHEM, V277, P50683, DOI 10.1074/jbc.M209221200; Kusner DJ, 2001, J IMMUNOL, V167, P3308, DOI 10.4049/jimmunol.167.6.3308; Lee S, 2001, J BIOL CHEM, V276, P28252, DOI 10.1074/jbc.M008521200; Li N, 2003, PROTEOMICS, V3, P536, DOI 10.1002/pmic.200390067; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Lorenzi R, 2000, BLOOD, V95, P2943, DOI 10.1182/blood.V95.9.2943.009k17_2943_2946; Luna EJ, 1998, METHOD ENZYMOL, V298, P32, DOI 10.1016/S0076-6879(98)98006-5; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Maceyka M, 2005, PROSTAG OTH LIPID M, V77, P15, DOI 10.1016/j.prostaglandins.2004.09.010; Maekawa S, 1997, BBA-BIOMEMBRANES, V1323, P1, DOI 10.1016/S0005-2736(96)00222-2; Malik ZA, 2000, J EXP MED, V191, P287, DOI 10.1084/jem.191.2.287; Malik ZA, 2003, J IMMUNOL, V170, P2811, DOI 10.4049/jimmunol.170.6.2811; Malik ZA, 2001, J IMMUNOL, V166, P3392, DOI 10.4049/jimmunol.166.5.3392; MAYERZU HD, 1999, FEBS LETT, V461, P217; Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Ohta Y, 2006, NAT CELL BIOL, V8, P803, DOI 10.1038/ncb1437; Olivera A, 2005, J IMMUNOL, V174, P1153, DOI 10.4049/jimmunol.174.3.1153; Panebra A, 2001, AM J PHYSIOL-CELL PH, V281, pC1046, DOI 10.1152/ajpcell.2001.281.3.C1046; Papakonstanti EA, 2000, MOL MED, V6, P303, DOI 10.1007/BF03401939; Pei ZD, 1996, BIOCHEM BIOPH RES CO, V228, P802, DOI 10.1006/bbrc.1996.1735; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pieters J, 2001, MICROBES INFECT, V3, P249, DOI 10.1016/S1286-4579(01)01376-4; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Pyne S, 2005, BIOCHEM SOC T, V33, P1370, DOI 10.1042/BST0331370; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; RENCH KJ, 2003, CANCER RES, V63, P5962; Reynolds HY, 2005, AM J RESP CRIT CARE, V171, P98, DOI 10.1164/rccm.200406-788PP; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Roy CR, 2002, J CELL BIOL, V158, P415, DOI 10.1083/jcb.200205011; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Scott CC, 2003, J MEMBRANE BIOL, V193, P137, DOI 10.1007/s00232-002-2008-2; Scott CC, 2005, J CELL BIOL, V169, P139, DOI 10.1083/jcb.200412162; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Stossel TP, 2006, J CELL SCI, V119, P3261, DOI 10.1242/jcs.02994; Sutherland CM, 2006, J BIOL CHEM, V281, P11693, DOI 10.1074/jbc.M601042200; Swanson JA, 2002, NATURE, V418, P286, DOI 10.1038/418286a; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Tejle K, 2002, BIOSCIENCE REP, V22, P529, DOI 10.1023/A:1022025903688; Thompson CR, 2005, J IMMUNOL, V174, P3551, DOI 10.4049/jimmunol.174.6.3551; Touret N, 2005, J LEUKOCYTE BIOL, V77, P878, DOI 10.1189/jlb.1104630; Touret N, 2005, CELL, V123, P157, DOI 10.1016/j.cell.2005.08.018; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; van Koppen CJ, 2001, LIFE SCI, V68, P2535, DOI 10.1016/S0024-3205(01)01049-9; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691; Wakatsuki T, 2001, J CELL SCI, V114, P1025; Wang F, 1999, CANCER RES, V59, P6185; Wattenberg BW, 2006, J LIPID RES, V47, P1128, DOI 10.1194/jlr.R600003-JLR200; Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359-7369.2004; Xu CB, 2002, ATHEROSCLEROSIS, V164, P237, DOI 10.1016/S0021-9150(02)00100-4; Yadav M, 2006, J IMMUNOL, V176, P5494, DOI 10.4049/jimmunol.176.9.5494; Yang LB, 1999, J BIOCHEM, V126, P84, DOI 10.1093/oxfordjournals.jbchem.a022440; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Young KW, 1999, BIOCHEM J, V343, P45, DOI 10.1042/0264-6021:3430045; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	125	22	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23147	23162		10.1074/jbc.M700193200	http://dx.doi.org/10.1074/jbc.M700193200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17519232				2022-12-25	WOS:000248577500017
J	Bergfeld, AK; Claus, H; Vogel, U; Muhlenhoff, M				Bergfeld, Anne K.; Claus, Heike; Vogel, Ulrich; Muehlenhoff, Martina			Biochemical characterization of thepolysialic acid-specific O-acetyltransferase NeuO of Escherichia coli K1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE ACYLTRANSFERASE; ACETYL-COENZYME-A; SIALIC-ACID; SERINE ACETYLTRANSFERASE; CAPSULAR POLYSACCHARIDE; CRYSTAL-STRUCTURE; POLYSIALIC ACID; BACTERIAL-MENINGITIS; NEONATAL MENINGITIS; FORM VARIATION	Escherichia coli K1 is a leading pathogen in neonatal sepsis and meningitis. The K1 capsule, composed of alpha 2,8-linked polysialic acid, represents the major virulence factor. In some K1 strains, phase-variable O-acetylation of the capsular polysaccharide is observed, a modification that is catalyzed by the prophage-encoded O-acetyltransferase NeuO. Phase variation is mediated by changes in the number of heptanucleotide repeats within the 5'-coding region of neuO, and full-length translation is restricted to repeat numbers that are a multiple of three. To understand the biochemical basis of K1 capsule O-acetylation, NeuO encoded by alleles containing 0, 12, 24, and 36 repeats was expressed and purified to homogeneity via a C-terminal hexahistidine tag. All NeuO variants assembled into hexamers and were enzymatically active with a high substrate specificity toward polysialic acid with > 14 residues. Remarkably, the catalytic efficiency (k(cat)/K-m(donor)) increased linearly with increasing numbers of repeats, revealing a new mechanism for modulating NeuO activity. Using homology modeling, we predicted a three-dimensional structure primarily composed of a left-handed parallel beta-helix with one protruding loop. Two amino acids critical for catalytic activity were identified and corresponding alanine substitutions, H119A and W143A, resulted in a complete loss of activity without affecting the oligomerization state. Our results indicate that in NeuO typical features of an acetyltransferase of the left- handed beta-helix family are combined with a unique regulatory mechanism based on variable N-terminal protein extensions formed by tandem copies of an RLKTQDS heptad.	Hannover Med Sch, Dept Cellular Chem, D-30625 Hannover, Germany; Univ Wurzburg, Inst Hyg & Microbiol, D-97080 Wurzburg, Germany	Hannover Medical School; University of Wurzburg	Muhlenhoff, M (corresponding author), Hannover Med Sch, Dept Cellular Chem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	muehlenhoff.martina@mh-hannover.de						ALPERS DH, 1965, J BIOL CHEM, V240, P10; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P6689, DOI 10.1021/bi980106v; Beaman TW, 1997, BIOCHEMISTRY-US, V36, P489, DOI 10.1021/bi962522q; BHATTACHARJEE AK, 1976, CAN J BIOCHEM CELL B, V54, P1, DOI 10.1139/o76-001; Bonacorsi S, 2005, INT J MED MICROBIOL, V295, P373, DOI 10.1016/j.ijmm.2005.07.011; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; Claus H, 2004, MOL MICROBIOL, V51, P227, DOI 10.1046/j.1365-2958.2003.03819.x; Deszo EL, 2005, P NATL ACAD SCI USA, V102, P5564, DOI 10.1073/pnas.0407428102; Dunn SM, 1996, PROTEIN SCI, V5, P538; Feng L, 2005, J BACTERIOL, V187, P758, DOI 10.1128/JB.187.2.758-764.2005; Fowler MI, 2004, CELL MICROBIOL, V6, P555, DOI 10.1111/j.1462-5822.2004.00382.x; FRASA H, 1993, J CLIN MICROBIOL, V31, P3174, DOI 10.1128/JCM.31.12.3174-3178.1993; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GAMIAN A, 1992, CARBOHYD RES, V236, P195, DOI 10.1016/0008-6215(92)85016-S; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; Harvey D, 1999, SEMIN PERINATOL, V23, P218, DOI 10.1016/S0146-0005(99)80066-4; HIGA HH, 1988, J BIOL CHEM, V263, P8872; Hindson VJ, 2000, J BIOL CHEM, V275, P461, DOI 10.1074/jbc.275.1.461; Houliston RS, 2006, J BIOL CHEM, V281, P11480, DOI 10.1074/jbc.M512183200; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; Johnson CM, 2005, ARCH BIOCHEM BIOPHYS, V433, P85, DOI 10.1016/j.abb.2004.08.014; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim KS, 2003, NAT REV NEUROSCI, V4, P376, DOI 10.1038/nrn1103; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; Lemercinier X, 1996, CARBOHYD RES, V296, P83, DOI 10.1016/S0008-6215(96)00253-4; LEWENDON A, 1995, J BIOL CHEM, V270, P26326, DOI 10.1074/jbc.270.44.26326; Lewis AL, 2006, J BIOL CHEM, V281, P11186, DOI 10.1074/jbc.M513772200; Lewis AL, 2004, P NATL ACAD SCI USA, V101, P11123, DOI 10.1073/pnas.0403010101; LEYING H, 1990, INFECT IMMUN, V58, P222, DOI 10.1128/IAI.58.1.222-227.1990; Lo Leggio L, 2003, BIOCHEMISTRY-US, V42, P5225, DOI 10.1021/bi0271446; MCCRACKEN GH, 1974, LANCET, V2, P246; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Olsen LR, 2004, BIOCHEMISTRY-US, V43, P6013, DOI 10.1021/bi0358521; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; ORSKOV F, 1979, J EXP MED, V149, P669, DOI 10.1084/jem.149.3.669; PELKONEN S, 1988, J BACTERIOL, V170, P2646, DOI 10.1128/jb.170.6.2646-2653.1988; PLUSCHKE G, 1983, INFECT IMMUN, V42, P907, DOI 10.1128/IAI.42.3.907-913.1983; Pye VE, 2004, J BIOL CHEM, V279, P40729, DOI 10.1074/jbc.M403751200; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROHR TE, 1980, J BIOL CHEM, V255, P2332; Saez-Llorens X, 2003, LANCET, V361, P2139, DOI 10.1016/S0140-6736(03)13693-8; SARFF LD, 1975, LANCET, V1, P1099; SKOZA L, 1976, BIOCHEM J, V159, P457, DOI 10.1042/bj1590457; Stummeyer K, 2006, MOL MICROBIOL, V60, P1123, DOI 10.1111/j.1365-2958.2006.05173.x; Sugantino M, 2002, BIOCHEMISTRY-US, V41, P2209, DOI 10.1021/bi011991b; Sulzenbacher G, 2001, J BIOL CHEM, V276, P11844, DOI 10.1074/jbc.M011225200; VAARA M, 1992, FEMS MICROBIOL LETT, V97, P249, DOI 10.1016/0378-1097(92)90344-N; van Belkum A, 1998, MICROBIOL MOL BIOL R, V62, P275, DOI 10.1128/MMBR.62.2.275-293.1998; Viguera E, 2001, EMBO J, V20, P2587, DOI 10.1093/emboj/20.10.2587; Vimr E, 2002, TRENDS MICROBIOL, V10, P254, DOI 10.1016/S0966-842X(02)02361-2; Vogel U, 1998, J CLIN MICROBIOL, V36, P2465, DOI 10.1128/JCM.36.9.2465-2470.1998; Wang XG, 2002, STRUCTURE, V10, P581, DOI 10.1016/S0969-2126(02)00741-4; Wyckoff TJO, 1999, J BIOL CHEM, V274, P27047, DOI 10.1074/jbc.274.38.27047; Xie Y, 2004, FEMS IMMUNOL MED MIC, V42, P271, DOI 10.1016/j.femsim.2004.09.001	56	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22217	22227		10.1074/jbc.M703044200	http://dx.doi.org/10.1074/jbc.M703044200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17519228	hybrid			2022-12-25	WOS:000248196800067
J	Sun, Q; Weber, CR; Sohail, A; Bernardo, MM; Toth, M; Zhao, H; Turner, JR; Fridman, R				Sun, Qing; Weber, Christopher R.; Sohail, Anjum; Bernardo, M. Margarida; Toth, Marta; Zhao, Huiren; Turner, Jerrold R.; Fridman, Rafael			MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; PRO-MMP-2 ACTIVATION; IV COLLAGENASE; CELL-SURFACE; LIPID RAFTS; MT1-MMP; BINDING; IDENTIFICATION; LOCALIZATION	MMP25 (MT6-MMP) is one of the two glycosylphosphatidylinositol-anchored matrix metalloproteinases (MMPs) that have been suggested to play a role in pericellular proteolysis. However, its role in cancer is unknown, and its biochemical properties are not well established. Here we found a marked increase in MT6-MMP expression within in situ dysplasia and invasive cancer in 61 samples of human colon cancer. Expression of MT6-MMP in HCT-116 human colon cancer cells promoted tumorigenesis in nude mice. Histologically, the MT6-MMP-expressing tumors demonstrated an infiltrative leading edge in contrast to a rounded leading edge in vector control tumors. Biochemical and biosynthesis analyses revealed that MT6-MMP displayed on the cell surface exists as a major form of 120 kDa that likely represents enzyme homodimers linked by disulfide bonds. Upon reduction, a single 57-kDa active MT6-MMP was detected. Interestingly, neither membrane-anchored nor phosphatidylinositol-specific phospholipase C-released MT6-MMPs were found to be associated with tissue inhibitor of metalloproteinases (TIMPs) and did not activate pro-gelatinases (pro-MMP-2 and pro-MMP-9) even in the presence of exogenous TIMP-2 or TIMP-1. A catalytic domain of MT6-MMP was inhibited preferentially by TIMP-1 (K-i = 0.2 nM) over TIMP-2 (K-i = 2.0 nM), because of a slower association rate. These results show that MT6-MMP may play a role in colon cancer and exhibit unique biochemical and structural properties that may regulate proteolytic function at the cell surface.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Chicago; University of Notre Dame	Fridman, R (corresponding author), Wayne State Univ, Dept Pathol, 580 E Canfield Ave, Detroit, MI 48201 USA.	rfridman@med.wayne.edu	Turner, Jerrold R/A-6895-2009; Turner, Jerrold/H-1502-2019	Turner, Jerrold R/0000-0003-0627-9455; Weber, Christopher/0000-0002-2117-3184; Sohail, Anjum/0000-0001-5567-9645	NATIONAL CANCER INSTITUTE [P30CA014599, R01CA100475, R01CA061986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK094954, P01DK067887, R01DK068271, R01DK061931] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA061986-12, R01 CA100475-04, R01 CA100475, R01 CA61986-11, CA100475, P30 CA014599, P30 CA14599, R01 CA061986] Funding Source: Medline; NIDDK NIH HHS [R01 DK68271, R01 DK061931-06, P01 DK067887, R56 DK094954, R01 DK068271-02, R01 DK61931, R01 DK061931, R01 DK068271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Or A, 2003, BRAIN, V126, P2738, DOI 10.1093/brain/awg285; Bernardo MM, 2002, J BIOL CHEM, V277, P11201, DOI 10.1074/jbc.M111021200; Chabottaux V, 2006, CANCER RES, V66, P5165, DOI 10.1158/0008-5472.CAN-05-3012; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; English JL, 2006, J BIOL CHEM, V281, P10337, DOI 10.1074/jbc.M512009200; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Kang TB, 2001, J BIOL CHEM, V276, P21960, DOI 10.1074/jbc.M007997200; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Maskos K, 2003, MOL BIOTECHNOL, V25, P241, DOI 10.1385/MB:25:3:241; Matsuda A, 2003, J BIOL CHEM, V278, P36350, DOI 10.1074/jbc.M301509200; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Nie J, 2004, EXP CELL RES, V296, P145, DOI 10.1016/j.yexcr.2004.02.008; Nie J, 2003, CANCER RES, V63, P6758; Nuttall RK, 2003, MOL CANCER RES, V1, P333; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Riddick ACP, 2005, BRIT J CANCER, V92, P2171, DOI 10.1038/sj.bjc.6602630; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; Sosne G, 2005, INVEST OPHTH VIS SCI, V46, P2388, DOI 10.1167/iovs.04-1368; STRONGIN AY, 1993, KIDNEY INT, V43, P158, DOI 10.1038/ki.1993.26; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Toth M, 2006, BIOCHEM BIOPH RES CO, V350, P377, DOI 10.1016/j.bbrc.2006.09.052; Velasco G, 2000, CANCER RES, V60, P877; Wallard MJ, 2006, BRIT J CANCER, V94, P569, DOI 10.1038/sj.bjc.6602931; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200; Zhuang LY, 2002, CANCER RES, V62, P2227; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	39	50	51	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21998	22010		10.1074/jbc.M701737200	http://dx.doi.org/10.1074/jbc.M701737200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17513868	Green Accepted, hybrid			2022-12-25	WOS:000248196800047
J	Degrace, P; Demizieux, L; Du, ZY; Gresti, J; Caverot, L; Djaouti, L; Jourdan, T; Moindrot, B; Guilland, JC; Hocquette, JF; Clouet, P				Degrace, Pascal; Demizieux, Laurent; Du, Zhen-yu; Gresti, Joseph; Caverot, Laurent; Djaouti, Louiza; Jourdan, Tony; Moindrot, Bastien; Guilland, Jean-Claude; Hocquette, Jean-Francois; Clouet, Pierre			Regulation of lipid flux between liver and adipose tissue during transient hepatic steatosis in carnitine-depleted rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; BUTYROBETAINE HYDROXYLASE INHIBITOR; PROLIFERATOR-ACTIVATED RECEPTORS; LIPOPROTEIN-LIPASE ACTIVITY; GAMMA-BUTYROBETAINE; LINOLEIC-ACID; PALMITOYLTRANSFERASE-I; INSULIN REGULATION; APOLIPOPROTEIN-B; GENE-EXPRESSION	Rats with carnitine deficiency due to trimethylhydrazinium propionate (mildronate) administered at 80 mg/100g body weight per day for 10 days developed liver steatosis only upon fasting. This study aimed to determine whether the transient steatosis resulted from triglyceride accumulation due to the amount of fatty acids preserved through impaired fatty acid oxidation and/or from up-regulation of lipid exchange between liver and adipose tissue. In liver, mildronate decreased the carnitine content by similar to 13-fold and, in fasted rats, lowered the palmitate oxidation rate by 50% in the perfused organ, increased 9-fold the triglyceride content, and doubled the hepatic very low density lipoprotein secretion rate. Concomitantly, triglyceridemia was 13-fold greater than in controls. Hepatic carnitine palmitoyltransferase I activity and palmitate oxidation capacities measured in vitro were increased after treatment. Gene expression of hepatic proteins involved in fatty acid oxidation, triglyceride formation, and lipid uptake were all increased and were associated with increased hepatic free fatty acid content in treated rats. In periepididymal adipose tissue, mildronate markedly increased lipoprotein lipase and hormone-sensitive lipase activities in fed and fasted rats, respectively. On refeeding, carnitine-depleted rats exhibited a rapid decrease in blood triglycerides and free fatty acids, then after similar to 2h, a marked drop of liver triglycerides and a progressive decrease in liver free fatty acids. Data show that up-regulation of liver activities, peripheral lipolysis, and lipoprotein lipase activity were likely essential factors for excess fat deposit and release alternately occurring in liver and adipose tissue of carnitine-depleted rats during the fed/fasted transition.	Univ Bourgogne, Fac Sci, INSERM, UMR 866,Equipe Physiopathol Dyslipidemies, F-21000 Dijon, France; Univ Bourgogne, Fac Med, LPPCE, F-21000 Dijon, France; INRA, Unite Rech Herbivores, F-63122 St Genes Champanelle, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; INRAE	Clouet, P (corresponding author), Univ Bourgogne, Fac Sci, INSERM, UMR 866,Equipe Physiopathol Dyslipidemies, 6 Blvd Gabriel, F-21000 Dijon, France.	pclouet@u-bourgogne.fr	Hocquette, Jean-Francois/I-1034-2019; Degrace, Pascal/AAF-5531-2021	Hocquette, Jean-Francois/0000-0003-2409-3881; Jourdan, Tony/0000-0001-7955-8127; Du, Zhen-Yu/0000-0001-6581-5313				AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Baillet L, 2000, J BIOL CHEM, V275, P36766, DOI 10.1074/jbc.M008265200; BATES EJ, 1977, FEBS LETT, V84, P229, DOI 10.1016/0014-5793(77)80694-7; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BELFRAGE P, 1969, J LIPID RES, V10, P341; BERGMEYER H, 1974, METHOD ENZYMAT AN, V3, P1128; BORENSZTAJN J, 1975, AM J PHYSIOL, V229, P394, DOI 10.1152/ajplegacy.1975.229.2.394; BRAY GA, 1984, INT J OBESITY, V8, P119; BRONFMAN M, 1979, BIOCHEM BIOPH RES CO, V88, P1030, DOI 10.1016/0006-291X(79)91512-2; Cao JS, 2006, P NATL ACAD SCI USA, V103, P19695, DOI 10.1073/pnas.0609140103; Chen ZJ, 2004, J LIPID RES, V45, P155, DOI 10.1194/jlr.M300275-JLR200; CHIODI P, 1992, BIOCHIM BIOPHYS ACTA, V1127, P81, DOI 10.1016/0005-2760(92)90204-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200; CLOUET P, 1995, J NUTR BIOCHEM, V6, P626, DOI 10.1016/0955-2863(95)00123-H; Degrace P, 2004, J NUTR, V134, P861, DOI 10.1093/jn/134.4.861; Degrace P, 2004, MOL CELL BIOCHEM, V258, P171, DOI 10.1023/B:MCBI.0000012853.20116.06; Degrace P, 2003, FEBS LETT, V546, P335, DOI 10.1016/S0014-5793(03)00610-0; Degrace P, 2006, ATHEROSCLEROSIS, V189, P328, DOI 10.1016/j.atherosclerosis.2006.01.012; Demizieux L, 2002, J LIPID RES, V43, P2112, DOI 10.1194/jlr.M200170-JLR200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garg A, 2002, J CLIN ENDOCR METAB, V87, P3019, DOI 10.1210/jc.87.7.3019; GEELEN MJH, 1980, DIABETES, V29, P1006, DOI 10.2337/diab.29.12.1006; Georges B, 2000, BIOCHEM PHARMACOL, V59, P1357, DOI 10.1016/S0006-2952(00)00265-3; GODBOLE V, 1978, DIABETOLOGIA, V14, P191, DOI 10.1007/BF00429780; Gondret F, 2004, REPROD NUTR DEV, V44, P1, DOI 10.1051/rnd:2004011; GUILLAND JC, 1986, ANN BIOL CLIN-PARIS, V44, P587; HALL M, 1985, BIOCHEM J, V226, P275, DOI 10.1042/bj2260275; HERDT TH, 1983, AM J VET RES, V44, P293; Iverius P H, 1986, Methods Enzymol, V129, P691; KAPLAN ML, 1981, AM J PHYSIOL, V240, pE101, DOI 10.1152/ajpendo.1981.240.2.E101; Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932; LEWIS JH, 1989, HEPATOLOGY, V9, P679, DOI 10.1002/hep.1840090504; LINDSTED.G, 1967, BIOCHEMISTRY-US, V6, P1271, DOI 10.1021/bi00857a007; LOPES-CARDOZO M, 1972, Biochimica et Biophysica Acta, V283, P1, DOI 10.1016/0005-2728(72)90092-8; Louet JF, 2001, BIOCHEM J, V354, P189, DOI 10.1042/0264-6021:3540189; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; Mantha L, 1999, AM J PHYSIOL-REG I, V277, pR455, DOI 10.1152/ajpregu.1999.277.2.R455; MCGARRY JD, 1973, J BIOL CHEM, V248, P270; McGarry JD, 1998, AM J CLIN NUTR, V67, p500S, DOI 10.1093/ajcn/67.3.500S; MCGARRY JD, 1976, J LIPID RES, V17, P277; Mensenkamp AR, 2004, J HEPATOL, V40, P599, DOI 10.1016/j.jhep.2003.12.011; Millar JS, 2006, J LIPID RES, V47, P2297, DOI 10.1194/jlr.M600213-JLR200; NIOT I, 1994, LIPIDS, V29, P481, DOI 10.1007/BF02578245; Oh WK, 2005, P NATL ACAD SCI USA, V102, P1384, DOI 10.1073/pnas.0409451102; PAUL HS, 1992, EUR J BIOCHEM, V203, P599, DOI 10.1111/j.1432-1033.1992.tb16589.x; Peschechera A, 2005, LIFE SCI, V77, P3078, DOI 10.1016/j.lfs.2005.03.029; Powell EE, 2005, HEPATOLOGY, V42, P5, DOI 10.1002/hep.20750; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RAYNOLDS MV, 1990, MOL ENDOCRINOL, V4, P1416, DOI 10.1210/mend-4-9-1416; Reid AE, 2001, GASTROENTEROLOGY, V121, P710, DOI 10.1053/gast.2001.27126; ROBINSON IN, 1982, BIOCHEM J, V206, P177, DOI 10.1042/bj2060177; RODBELL M, 1965, ANN NY ACAD SCI, V131, P302, DOI 10.1111/j.1749-6632.1965.tb34798.x; SAGGERSON ED, 1986, BIOCHEM J, V236, P137, DOI 10.1042/bj2360137; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SIMKHOVICH BZ, 1988, BIOCHEM PHARMACOL, V37, P195, DOI 10.1016/0006-2952(88)90717-4; Spaniol M, 2003, J LIPID RES, V44, P144, DOI 10.1194/jlr.M200200-JLR200; Spaniol M, 2001, EUR J BIOCHEM, V268, P1876, DOI 10.1046/j.1432-1327.2001.02065.x; Spurway TD, 1997, BIOCHEM J, V323, P119, DOI 10.1042/bj3230119; TOPPING DL, 1972, BIOCHEM J, V126, P295, DOI 10.1042/bj1260295; TSOKO M, 1995, BIOCHEM PHARMACOL, V49, P1403, DOI 10.1016/0006-2952(95)00019-V; Tsoko M, 1998, BIOCHIMIE, V80, P943, DOI 10.1016/S0300-9084(00)88891-4; VEERKAMP JH, 1983, BIOCHIM BIOPHYS ACTA, V753, P399, DOI 10.1016/0005-2760(83)90064-4; VYDELINGUM N, 1983, AM J PHYSIOL, V245, pE121, DOI 10.1152/ajpendo.1983.245.2.E121; WEISSBACH H, 1960, J BIOL CHEM, V235, P1160; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	67	30	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20816	20826		10.1074/jbc.M611391200	http://dx.doi.org/10.1074/jbc.M611391200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17496329	Green Published, hybrid			2022-12-25	WOS:000248047500007
J	Reigstad, CS; Hultgren, SJ; Gordon, JI				Reigstad, Christopher S.; Hultgren, Scott J.; Gordon, Jeffrey I.			Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY-TRACT-INFECTIONS; EPITHELIAL-CELLS; IRON-METABOLISM; EXPRESSION ANALYSIS; MOUSE INTESTINE; MESSENGER-RNA; HEME; K-12; DIFFERENTIATION; GENES	Uropathogenic Escherichia coli (UPEC), the principal cause of urinary tract infection in women, colonizes the gut as well as the genitourinary tract. Studies of mice inoculated with UTI89, a sequenced isolate, have revealed a complex life cycle that includes formation of intracellular bacterial communities (IBCs) in bladder urothelial cells. To understand how UPEC adapts to life in IBCs, we have used GeneChips and/or quantitative reverse transcriptase PCR to study UTI89 recovered from the distal gut of gnotobiotic mice and from IBCs harvested by laser capture microdissection from the bladder urothelium of infected C3H/HeJ female mice. Host responses were characterized in laser capture microdissected urothelial cells that do or do not contain IBCs. The results reveal components of ferric iron acquisition systems in UTI89 that are expressed at significantly higher levels in IBCs compared with the intestine, including the hemin receptor chuA (1,390 +/- 188-fold). Localized urothelial responses to IBCs help oppose bacterial salvage of host cell iron (e.g. up-regulation of Tfrc (transferrin receptor) and Lcn2 (lipocalin 2)), facilitate glucose import (e.g. Hk2 (hexokinase 2)), and maintain epithelial structural integrity (e.g. Ivl (involucrin) and Sbsn (suprabasin)). Delta chuA mutants produce significantly smaller IBCs compared with wild type UTI89. This difference was not observed in strains lacking sitA (ABC-type iron/manganese transporter subunit), iroN (salmochelin receptor), hlyA (alpha-hemolysin), or entF (enterobactin synthetase subunit). Together, these studies indicate that heme- and siderophore-associated iron play key roles in IBC development and provide a series of microbial and host biomarkers for comparing UPEC strains isolated from humans.	Washington Univ, Sch Med, Ctr Genome Sci, St Louis, MO 63108 USA; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Genome Sci, Campus Box 8510,4444 Forest Pk Blvd, St Louis, MO 63108 USA.	jgordon@wustl.edu			NIAMS NIH HHS [AR049475] Funding Source: Medline; PHS HHS [T32H000045] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson GG, 2003, SCIENCE, V301, P105, DOI 10.1126/science.1084550; Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BROCK JH, 1991, INFECT IMMUN, V59, P3185, DOI 10.1128/IAI.59.9.3185-3190.1991; Chang DE, 2004, P NATL ACAD SCI USA, V101, P7427, DOI 10.1073/pnas.0307888101; Chen SL, 2006, P NATL ACAD SCI USA, V103, P5977, DOI 10.1073/pnas.0600938103; Constantinidou C, 2006, J BIOL CHEM, V281, P4802, DOI 10.1074/jbc.M512312200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Foxman B, 2003, DM-DIS MON, V49, P53, DOI 10.1067/mda.2003.7; Garofalo CK, 2007, INFECT IMMUN, V75, P52, DOI 10.1128/IAI.01123-06; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; Glass JI, 2000, NATURE, V407, P757, DOI 10.1038/35037619; Hickey EK, 1997, INFECT IMMUN, V65, P133, DOI 10.1128/IAI.65.1.133-143.1997; Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Hooton TM, 2001, INT J ANTIMICROB AG, V17, P259, DOI 10.1016/S0924-8579(00)00350-2; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Janke B, 2001, FEMS MICROBIOL LETT, V199, P61, DOI 10.1111/j.1574-6968.2001.tb10651.x; Justice SS, 2004, P NATL ACAD SCI USA, V101, P1333, DOI 10.1073/pnas.0308125100; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; Kang YS, 2005, J BACTERIOL, V187, P1135, DOI 10.1128/JB.187.3.1135-1160.2005; KASTURI L, 1993, EXP CELL RES, V205, P84, DOI 10.1006/excr.1993.1061; Keseler IM, 2005, NUCLEIC ACIDS RES, V33, pD334, DOI 10.1093/nar/gki108; LEBEK G, 1985, INFECT IMMUN, V50, P682, DOI 10.1128/IAI.50.3.682-686.1985; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Murphy KC, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-11; Mysorekar IU, 2006, P NATL ACAD SCI USA, V103, P14170, DOI 10.1073/pnas.0602136103; Nagpal S, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh048; Nagy G, 2001, INFECT IMMUN, V69, P1924, DOI 10.1128/IAI.69.3.1924-1928.2001; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; Park GT, 2002, J BIOL CHEM, V277, P45195, DOI 10.1074/jbc.M205380200; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Runyen-Janecky LJ, 2003, INFECT IMMUN, V71, P1919, DOI 10.1128/IAI.71.4.1919-1928.2003; Sannes MR, 2004, J INFECT DIS, V190, P2121, DOI 10.1086/425984; Schilling JD, 2003, P NATL ACAD SCI USA, V100, P4203, DOI 10.1073/pnas.0736473100; Snyder JA, 2004, INFECT IMMUN, V72, P6373, DOI 10.1128/IAI.72.11.6373-6381.2004; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Straub KL, 2001, FEMS MICROBIOL ECOL, V34, P181, DOI 10.1016/S0168-6496(00)00088-X; Thomson AM, 1999, INT J BIOCHEM CELL B, V31, P1139, DOI 10.1016/S1357-2725(99)00080-1; Torres AG, 1997, MOL MICROBIOL, V23, P825, DOI 10.1046/j.1365-2958.1997.2641628.x; Turner PC, 1998, INFECT IMMUN, V66, P5215, DOI 10.1128/IAI.66.11.5215-5223.1998; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978	56	108	111	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21259	21267		10.1074/jbc.M611502200	http://dx.doi.org/10.1074/jbc.M611502200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17504765	hybrid			2022-12-25	WOS:000248047500054
J	Shumay, E; Tao, JC; Wang, HY; Malbon, CC				Shumay, Elena; Tao, Jiangchuan; Wang, Hsien-Yu; Malbon, Craig C.			Lysophosphatidic acid regulates trafficking of beta(2)-adrenergic receptors - The G alpha(13)/p115RhoGEF/JNK pathway stimulates receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-MEDIATED PATHWAYS; EMBRYONAL CARCINOMA-CELLS; BETA-ADRENERGIC-RECEPTORS; SIGNAL-TRANSDUCTION; CROSS-REGULATION; P115 RHOGEF; KINASE; ACTIVATION; EXPRESSION; MECHANISMS	Lysophosphatidic acid is an important lipid ligand regulating many aspects of cell function, including proliferation and migration. Operating via heterotrimeric G proteins to downstream effectors, lysophosphatidic acid was shown to regulate the function and trafficking of the G protein-coupled beta(2)-adrenergic receptor. C3 exotoxin, expression of dominant negative RhoA, and inhibition of c-Jun N-terminal kinase blocked the ability of lysophosphatidic acid to sequester the beta(2)-adrenergic receptor, whereas expression of constitutively active G alpha(13), p115RhoGEF, or RhoA mimicked lysophosphatidic acid (LPA) action, stimulating the internalization of the G alpha(s)-coupled beta(2)-adrenergic receptor. This study revealed a novel cross-talk exerted from the LPA/G alpha(13)/p115RhoGEF/RhoA pathway to the beta(2)-adrenergic receptor/G alpha(s)/adenylyl cyclase pathway, attenuating the ability of beta-adrenergic agonists to act following stimulation of cells by LPA as may occur during beta-adrenergic therapy of an inflammatory response.	SUNY Stony Brook, Sch Med, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Diabet & Metab Dis Res Prog, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Sch Med, Dept Pharmacol, Stony Brook, NY 11794 USA.	craig@pharm.sunysb.edu	malbon, craig/ABF-3604-2020		NIDDK NIH HHS [DK42510] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; Bhattacharya M, 2004, BIOCHEM SOC T, V32, P1040, DOI 10.1042/BST0321040; Bogoyevitch MA, 2004, BBA-PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Doronin S, 2002, J BIOL CHEM, V277, P15124, DOI 10.1074/jbc.M108771200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fan GF, 2001, J BIOL CHEM, V276, P24005, DOI 10.1074/jbc.M011199200; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gavi S, 2006, TRENDS ENDOCRIN MET, V17, P46, DOI 10.1016/j.tem.2006.01.006; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; Hains MD, 2006, MOL PHARMACOL, V69, P2068, DOI 10.1124/mol.105.017921; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Johnson GL, 2005, CURR OPIN CHEM BIOL, V9, P325, DOI 10.1016/j.cbpa.2005.04.004; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karoor V, 1996, PROG NEUROBIOL, V48, P555, DOI 10.1016/0301-0082(96)00004-4; Kay LJ, 2005, CHEM IMMUNOL ALLERGY, V87, P145, DOI 10.1159/000087641; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Lee YN, 2004, J BIOL CHEM, V279, P54896, DOI 10.1074/jbc.M407581200; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; ROS M, 1988, J BIOL CHEM, V263, P4362; Roumestan C, 2002, J ALLERGY CLIN IMMUN, V109, pS240, DOI 10.1016/S0091-6749(02)81866-8; Shumay E, 2004, J CELL SCI, V117, P593, DOI 10.1242/jcs.00890; Tao JC, 2003, EMBO J, V22, P6419, DOI 10.1093/emboj/cdg628; Ueda H, 2001, J BIOL CHEM, V276, P42527, DOI 10.1074/jbc.M102529200; Verhoeckx KCM, 2004, INT IMMUNOPHARMACOL, V4, P1499, DOI 10.1016/j.intimp.2004.07.008; WANG HY, 1991, INT J BIOCHEM, V23, P7; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Witkamp R, 2000, VET QUART, V22, P11, DOI 10.1080/01652176.2000.9695016; Yonemura S, 2002, J CELL SCI, V115, P2569	45	10	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21529	21541		10.1074/jbc.M701998200	http://dx.doi.org/10.1074/jbc.M701998200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17493936	hybrid			2022-12-25	WOS:000248047500080
J	Guerin, ME; Kordulakova, J; Schaeffer, F; Svetlikova, Z; Buschiazzo, A; Giganti, D; Gicquel, B; Mikusova, K; Jackson, M; Alzari, PM				Guerin, Marcelo E.; Kordulakova, Jana; Schaeffer, Francis; Svetlikova, Zuzana; Buschiazzo, Alejandro; Giganti, David; Gicquel, Brigitte; Mikusova, Katarina; Jackson, Mary; Alzari, Pedro M.			Molecular recognition and interfacial catalysis by the essential phosphatidylinositol mannosyltransferase PimA from mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER PROTEIN; ACHOLEPLASMA-LAIDLAWII; GLYCOGEN-PHOSPHORYLASE; GENETIC-REGULATION; CRYSTAL-STRUCTURE; BIOSYNTHESIS; COMPLEX; TUBERCULOSIS; STEP; GLYCOSYLTRANSFERASES	Mycobacterial phosphatidylinositol mannosides (PIMs) and metabolically derived cell wall lipoglycans play important roles in host-pathogen interactions, but their biosynthetic pathways are poorly understood. Here we focus on Mycobacterium smegmatis PimA, an essential enzyme responsible for the initial mannosylation of phosphatidylinositol. The structure of PimA in complex with GDP-mannose shows the two-domain organization and the catalytic machinery typical of GT-B glycosyltransferases. PimA is an amphitrophic enzyme that binds mono-disperse phosphatidylinositol, but its transferase activity is stimulated by high concentrations of non-substrate anionic surfactants, indicating that the early stages of PIM biosynthesis involve lipid-water interfacial catalysis. Based on structural, calorimetric, and mutagenesis studies, we propose a model wherein PimA attaches to the membrane through its N- terminal domain, and this association leads to enzyme activation. Our results reveal a novel mode of phosphatidylinositol recognition and provide a template for the development of potential anti-mycobacterial compounds.	Inst Pasteur, Ubite Biochim Struct, CNRS, URA 2185, F-75724 Paris, France; Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris, France; Inst Pasteur, Unite Bioinformat Struct, F-75724 Paris, France; Comenius Univ, Fac Nat Sci, Dept Biochem, Bratislava 84215, Slovakia	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Comenius University Bratislava	Alzari, PM (corresponding author), Inst Pasteur, Ubite Biochim Struct, CNRS, URA 2185, 25 Rue Dr Roux, F-75724 Paris, France.	alzari@pasteur.fr	Buschiazzo, Alejandro/W-1095-2018; Jackson, Mary/D-5345-2017; Kordulakova, Jana/I-3887-2014; Guerin, Marcelo M/N-7245-2016; Mikusova, Katarina/I-3622-2014	Buschiazzo, Alejandro/0000-0002-2509-6526; Jackson, Mary/0000-0002-9212-0258; Kordulakova, Jana/0000-0003-2834-0165; Guerin, Marcelo M/0000-0001-9524-3184; Giganti, David/0000-0001-5735-5679; Mikusova, Katarina/0000-0002-0100-4877; Alzari, Pedro/0000-0002-4233-1903	NIAID NIH HHS [R01 AI064798, AI 64798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Chatterjee D, 1997, CURR OPIN CHEM BIOL, V1, P579, DOI 10.1016/S1367-5931(97)80055-5; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Edman M, 2003, J BIOL CHEM, V278, P8420, DOI 10.1074/jbc.M211492200; Fernandez-Recio J, 2005, PROTEINS, V58, P134, DOI 10.1002/prot.20285; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Guerin ME, 2005, ACTA CRYSTALLOGR F, V61, P518, DOI 10.1107/S1744309105012364; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HILL DL, 1966, J BIOL CHEM, V241, P895; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Kordulakova J, 2003, J BIOL CHEM, V278, P36285, DOI 10.1074/jbc.M303639200; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; Li L, 2003, BIOCHEMISTRY-US, V42, P9677, DOI 10.1021/bi034360l; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Martinez-Fleites C, 2006, CHEM BIOL, V13, P1143, DOI 10.1016/j.chembiol.2006.09.005; Mildvan AS, 2005, ARCH BIOCHEM BIOPHYS, V433, P129, DOI 10.1016/j.abb.2004.08.017; Mitchell EP, 1996, BIOCHEMISTRY-US, V35, P7341, DOI 10.1021/bi960072w; Morita YS, 2006, J BIOL CHEM, V281, P25143, DOI 10.1074/jbc.M604214200; Morita YS, 2005, J BIOL CHEM, V280, P21645, DOI 10.1074/jbc.m414181200; Murray D, 2002, CURR TOP MEMBR, V52, P277; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; Schouten A, 2002, EMBO J, V21, P2117, DOI 10.1093/emboj/21.9.2117; Shields D, 1999, CURR OPIN CELL BIOL, V11, P489, DOI 10.1016/S0955-0674(99)80070-2; TAKAYAMA K, 1969, BIOCHIM BIOPHYS ACTA, V176, P196, DOI 10.1016/0005-2760(69)90089-7; Tilley SJ, 2004, STRUCTURE, V12, P317, DOI 10.1016/j.str.2004.01.013; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877; Wrabl JO, 2001, J MOL BIOL, V314, P365, DOI 10.1006/jmbi.2001.5151; Yoder MD, 2001, J BIOL CHEM, V276, P9246, DOI 10.1074/jbc.M010131200	51	106	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20705	20714		10.1074/jbc.M702087200	http://dx.doi.org/10.1074/jbc.M702087200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17510062	hybrid, Green Published			2022-12-25	WOS:000247819300073
J	Nakano, Y; Kohno, T; Hibi, T; Kohno, S; Baba, A; Mikoshiba, K; Nakajima, K; Hattori, M				Nakano, Yoshimi; Kohno, Takao; Hibi, Terumasa; Kohno, Shiori; Baba, Atsushi; Mikoshiba, Katsuhiko; Nakajima, Kazunori; Hattori, Mitsuharu			The extremely conserved C-terminal region of reelin is not necessary for secretion but is required for efficient activation of downstream signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAJAL-RETZIUS CELLS; BRAIN-DEVELOPMENT; LIPOPROTEIN RECEPTORS; SULFATE PROTEOGLYCANS; LAMINAR ORGANIZATION; HEPARAN-SULFATE; TYROSINE KINASE; MAMMALIAN BRAIN; IN-VIVO; EXPRESSION	Reelin is a very large secreted glycoprotein essential for correct development of the mammalian brain. It is also implicated in higher functions and diseases of human brain. However, whether or not secretion of Reelin is regulated and how Reelin transmits signals remain largely unknown. Reelin protein is composed of an N-terminal F-spondin-like domain, Reelin repeats, and a short and highly basic C-terminal region (CTR). The primary sequence of CTR is almost completely conserved among vertebrates except fishes, indicating its importance. A prevailing idea regarding the function of CTR is that it is required for the secretion of Reelin, although this remains unproven. Here we aimed to clarify the function of Reelin CTR. Neither deleting most of CTR nor replacing CTR with unrelated amino acids affected secretion efficiency, indicating that CTR is not absolutely required for the secretion of Reelin. We also found that Reelin mutants without CTR were less potent in activating the downstream signaling in cortical neurons. Although these mutants were able to bind to the Reelin receptor ectodomain as efficiently as wild-type Reelin, quite interestingly, their ability to bind to the isolated cell membrane bearing Reelin receptors or receptor-expressing cells (including cortical neurons) was much weaker than that of wild-type Reelin. Therefore, it is concluded that the CTR of Reelin is not essential for its secretion but is required for efficient activation of downstream signaling events, presumably via binding to an unidentified "coreceptor" molecule(s) on the cell membrane.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Biomed Sci, Nagoya, Aichi 4678603, Japan; Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Tokyo 1088639, Japan; RIKEN, Brain Sci Inst, Lab Dev Neurosci, Wako, Saitama 3510198, Japan; Keio Univ, Sch Med, Dept Anat, Tokyo 1608582, Japan; Jikei Univ, Sch Med, Inst DNA Med, Dept Mol Neurobiol, Tokyo 1058641, Japan	Nagoya City University; University of Tokyo; RIKEN; Keio University; Jikei University	Hattori, M (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe-dori, Nagoya, Aichi 4678603, Japan.	mhattori@phar.nagoya-cu.ac.jp	Mikoshiba, Katsuhiko/N-7943-2015; Hattori, Mitsuharu/F-3859-2010; Nakajima, Kazunori/L-3396-2013; Hibi, Terumasa/I-3407-2013	Hattori, Mitsuharu/0000-0002-0503-4969; Nakajima, Kazunori/0000-0003-1864-9425; Kohno, Takao/0000-0003-2557-4281; Hibi, Terumasa/0000-0001-9373-9602; Baba, Atsushi/0000-0002-6871-7249				Alcantara S, 1998, J NEUROSCI, V18, P7779; Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Arnaud L, 2003, MOL CELL BIOL, V23, P9293, DOI 10.1128/MCB.23.24.9293-9302.2003; Bannai H, 2004, J CELL SCI, V117, P163, DOI 10.1242/jcs.00854; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Botella-Lopez A, 2006, P NATL ACAD SCI USA, V103, P5573, DOI 10.1073/pnas.0601279103; Cariboni A, 2005, DEVELOPMENT, V132, P4709, DOI 10.1242/dev.02033; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; de Rouvroit CL, 1999, EXP NEUROL, V156, P229, DOI 10.1006/exnr.1999.7019; deBergeyck V, 1997, MOL BRAIN RES, V50, P85, DOI 10.1016/S0169-328X(97)00166-6; Derer P, 2001, J COMP NEUROL, V440, P136, DOI 10.1002/cne.1375; Eastwood SL, 2006, AM J PSYCHIAT, V163, P540, DOI 10.1176/appi.ajp.163.3.540; Fatemi SH, 2005, BIOL PSYCHIAT, V57, P777, DOI 10.1016/j.biopsych.2004.12.018; Fatemi SH, 2005, MOL PSYCHIATR, V10, P251, DOI 10.1038/sj.mp.4001613; Grayson DR, 2005, P NATL ACAD SCI USA, V102, P9341, DOI 10.1073/pnas.0503736102; Herz J, 2006, NAT REV NEUROSCI, V7, P850, DOI 10.1038/nrn2009; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Ichihara H, 2001, MOL BRAIN RES, V97, P190, DOI 10.1016/S0169-328X(01)00307-2; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; Jossin Y, 2004, J NEUROSCI, V24, P514, DOI 10.1523/JNEUROSCI.3408-03.2004; Kantor DB, 2004, NEURON, V44, P961, DOI 10.1016/j.neuron.2004.12.002; Kubo K, 2002, NEUROSCI RES, V43, P381, DOI 10.1016/S0168-0102(02)00068-8; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Luque JM, 2004, DEV BRAIN RES, V152, P269, DOI 10.1016/j.devbrainres.2004.06.005; Luque JM, 2007, BRAIN RES, V1140, P41, DOI 10.1016/j.brainres.2006.02.056; Magdaleno S, 2002, NEURON, V33, P573, DOI 10.1016/S0896-6273(02)00582-2; Meyer G, 2004, J NEUROSCI, V24, P9878, DOI 10.1523/JNEUROSCI.3060-04.2004; Morimura T, 2005, J BIOL CHEM, V280, P16901, DOI 10.1074/jbc.M409048200; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nakajima K, 1997, P NATL ACAD SCI USA, V94, P8196, DOI 10.1073/pnas.94.15.8196; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 1998, DEVELOPMENT, V125, P3719; SELLECK SB, 2005, SCI STKE, pPE17; Soriano E, 2005, NEURON, V46, P389, DOI 10.1016/j.neuron.2005.04.019; Strasser V, 2004, MOL CELL BIOL, V24, P1378, DOI 10.1128/MCB.24.3.1378-1386.2004; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Utsunomiya-Tate N, 2000, P NATL ACAD SCI USA, V97, P9729, DOI 10.1073/pnas.160272497; Yoshida M, 2006, DEVELOPMENT, V133, P537, DOI 10.1242/dev.02209	41	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20544	20552		10.1074/jbc.M702300200	http://dx.doi.org/10.1074/jbc.M702300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17504759	hybrid			2022-12-25	WOS:000247819300057
J	Pearce, MMP; Wang, Y; Kelley, GG; Wojcikiewicz, RJH				Pearce, Margaret M. P.; Wang, Yuan; Kelley, Grant G.; Wojcikiewicz, Richard J. H.			SPFH2 mediates the endoplasmic reticulum-associated degradation of inositol 1,4,5-trisphosphate receptors and other substrates in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; PROTEIN-DEGRADATION; UBIQUITIN-LIGASE; DOWN-REGULATION; QUALITY-CONTROL; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; REGULATED UBIQUITINATION; P97-UFD1-NPL4 COMPLEX; RAFT ASSOCIATION; DOMAIN PROTEIN	Inositol 1,4,5-trisphosphate (IP3) receptors are endoplasmic reticulum ( ER) membrane calcium channels that, upon activation, become substrates for the ER-associated degradation (ERAD) pathway. Although it is clear that IP3 receptors are polyubiquitinated upon activation and are transferred to the proteasome by a p97-based complex, currently nothing is known about the proteins that initially select activated IP3 receptors for ERAD. Here, we sought to identify novel proteins that associate with and mediate the ERAD of endogenous activated IP3 receptors. SPFH2, an uncharacterized SPFH domain-containing protein, rapidly associated with IP3 receptors in a manner that preceded significant polyubiquitination and the association of p97 and related proteins. SPFH2 was found to be an ER membrane protein largely residing within the ER lumen and in resting and stimulated cells was linked to ERAD pathway components, apparently via endogenous substrates undergoing degradation. Suppression of SPFH2 expression by RNA interference markedly inhibited IP3 receptor polyubiquitination and degradation and the processing of other ERAD substrates. Overall, these studies identify SPFH2 as a key ERAD pathway component and suggest that it may act as a substrate recognition factor.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Wojcikiewicz, RJH (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	wojcikir@upstate.edu		Panning Pearce, Margaret/0000-0002-5846-9632	NIDDK NIH HHS [DK 49194, DK 56294] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049194, R29DK049194, R01DK056294] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; Alzayady KJ, 2005, J BIOL CHEM, V280, P34530, DOI 10.1074/jbc.M508890200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bezprozvanny I, 2005, CELL CALCIUM, V38, P261, DOI 10.1016/j.ceca.2005.06.030; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Bosanac I, 2004, BBA-MOL CELL RES, V1742, P89, DOI 10.1016/j.bbamcr.2004.09.016; Browman DT, 2006, J CELL SCI, V119, P3149, DOI 10.1242/jcs.03060; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Chen B, 2006, P NATL ACAD SCI USA, V103, P341, DOI 10.1073/pnas.0506618103; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; Doolman R, 2004, J BIOL CHEM, V279, P38184, DOI 10.1074/jbc.M405935200; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gauss R, 2006, EMBO J, V25, P1827, DOI 10.1038/sj.emboj.7601088; Gauss R, 2006, NAT CELL BIOL, V8, P849, DOI 10.1038/ncb1445; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Higo T, 2005, CELL, V120, P85, DOI 10.1016/j.cell.2004.11.048; Huber TB, 2003, HUM MOL GENET, V12, P3397, DOI 10.1093/hmg/ddg360; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kihara A, 1997, P NATL ACAD SCI USA, V94, P5544, DOI 10.1073/pnas.94.11.5544; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Liang J, 2006, J CELL SCI, V119, P4011, DOI 10.1242/jcs.03163; Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Morrow IC, 2005, TRAFFIC, V6, P725, DOI 10.1111/j.1600-0854.2005.00318.x; Mueller B, 2006, J CELL BIOL, V175, P261, DOI 10.1083/jcb.200605196; Neuber O, 2005, NAT CELL BIOL, V7, P993, DOI 10.1038/ncb1298; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; Oda Y, 2006, J CELL BIOL, V172, P383, DOI 10.1083/jcb.200507057; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rivera-Milla E, 2006, CELL MOL LIFE SCI, V63, P343, DOI 10.1007/s00018-005-5434-3; Ruddock LW, 2006, J CELL SCI, V119, P4373, DOI 10.1242/jcs.03225; Schuberth C, 2005, NAT CELL BIOL, V7, P999, DOI 10.1038/ncb1299; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Shamu CE, 2001, MOL BIOL CELL, V12, P2546, DOI 10.1091/mbc.12.8.2546; Shearer AG, 2004, J BIOL CHEM, V279, P188, DOI 10.1074/jbc.M307734200; Shearer AG, 2005, EMBO J, V24, P149, DOI 10.1038/sj.emboj.7600498; Solis GP, 2007, BIOCHEM J, V403, P313, DOI 10.1042/BJ20061686; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; Sprenger RR, 2006, BIOCHEM J, V400, P401, DOI 10.1042/BJ20060355; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.e04-09-0807; Tavernarakis N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X; Taylor CW, 2004, TRENDS BIOCHEM SCI, V29, P210, DOI 10.1016/j.tibs.2004.02.010; Thrower EC, 2003, J BIOL CHEM, V278, P49699, DOI 10.1074/jbc.M309307200; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Umlauf E, 2006, J BIOL CHEM, V281, P23349, DOI 10.1074/jbc.M513720200; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Webster JM, 2003, J BIOL CHEM, V278, P38238, DOI 10.1074/jbc.M305600200; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102	64	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20104	20115		10.1074/jbc.M701862200	http://dx.doi.org/10.1074/jbc.M701862200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17502376	hybrid			2022-12-25	WOS:000247819300011
J	Weerachayaphorn, J; Pajor, AM				Weerachayaphorn, Jittima; Pajor, Ana M.			Sodium-dependent extracellular accessibility of Lys-84 in the sodium/dicarboxylate cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY SENSITIVE RESIDUES; NA+/DICARBOXYLATE COTRANSPORTER; GLUTAMATE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; DICARBOXYLATE COTRANSPORTER; SUBSTRATE RECOGNITION; NADC-1; PROTEIN; CATION; HOMOLOG	The N+/dicarboxylate cotransporter transports Na+ with citric acid cycle intermediates such as succinate and citrate. The present study focuses on transmembrane helix 3, which is highly conserved among the members of the SLC13 family. Fifteen amino acids in the extracellular half of transmembrane helix (amino acids 98-112) as well as Lys-84, previously shown to affect substrate affinity, were mutated individually to cysteine and expressed in the human retinal pigment epithelial cell line. Transport specificity ratio analysis shows that determinants for distinguishing succinate and citrate are found at amino acids Lys-84, Glu-101, Trp-103, His-106, and Leu-111. All of the mutants were tested for sensitivity to the membraneimpermeant cysteine-specific reagent (2-sulfonatoethyl) methanethiosulfonate ( MTSES), but only K84C was sensitive to MTSES inhibition. The sensitivity of K84C to MTSES was greatest in the presence of sodium, and the inhibition could be prevented by addition of substrate or replacement of sodium, indicating that the accessibility of Lys-84 changes with conformational state. The substrate protection of MTSES inhibition of K84C appears to occur early in the transport cycle, before the large-scale conformational change associated with translocation of substrate. The results point to a new location for Lys-84 within the substrate access pore of the Na+/dicarboxylate cotransporter, either in a transmembrane helix or a reentrant loop facing a water-filled pore.	Univ Texas, Dept Biochem & Mol Biol, Med Branch, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Pajor, AM (corresponding author), Univ Texas, Dept Biochem & Mol Biol, Med Branch, Galveston, TX 77555 USA.	ampajor@utmb.edu			NIDDK NIH HHS [R01 DK046269, R01 DK046269-17, DK 46269] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046269] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Fei YJ, 2003, J BIOL CHEM, V278, P6136, DOI 10.1074/jbc.M208763200; Griffith DA, 1999, BIOCHEMISTRY-US, V38, P7524, DOI 10.1021/bi990076b; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Javitch JA, 1998, METHOD ENZYMOL, V296, P331; Joshi AD, 2006, BIOCHEMISTRY-US, V45, P4231, DOI 10.1021/bi052064y; Kaback HR, 2007, P NATL ACAD SCI USA, V104, P491, DOI 10.1073/pnas.0609968104; Kahn ES, 1999, BIOCHEMISTRY-US, V38, P6151, DOI 10.1021/bi9827722; Karlin A, 1998, METHOD ENZYMOL, V293, P123; King Steven C., 2004, BMC Biochemistry, V5, P16, DOI 10.1186/1471-2091-5-16; Leighton BH, 2006, J BIOL CHEM, V281, P29788, DOI 10.1074/jbc.M604991200; Markovich D, 2004, PFLUG ARCH EUR J PHY, V447, P594, DOI 10.1007/s00424-003-1128-6; Oshiro N, 2006, BIOCHEMISTRY-US, V45, P2302, DOI 10.1021/bi052328g; Pajor AM, 2000, BIOCHEM J, V350, P677, DOI 10.1042/0264-6021:3500677; Pajor AM, 2006, PFLUG ARCH EUR J PHY, V451, P597, DOI 10.1007/s00424-005-1487-2; Pajor AM, 2005, J BIOL CHEM, V280, P18728, DOI 10.1074/jbc.M501265200; Pajor AM, 1998, J BIOL CHEM, V273, P18923, DOI 10.1074/jbc.273.30.18923; Pajor AM, 1999, BIOCHEM J, V344, P205, DOI 10.1042/0264-6021:3440205; Pajor AM, 1998, BBA-BIOMEMBRANES, V1370, P98, DOI 10.1016/S0005-2736(97)00249-6; Pajor AM, 1998, BIOCHEM J, V331, P257, DOI 10.1042/bj3310257; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; Pajor AM, 2001, J BIOL CHEM, V276, P29961, DOI 10.1074/jbc.M011387200; PAK CYC, 1991, AM J KIDNEY DIS, V18, P624, DOI 10.1016/S0272-6386(12)80602-0; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Rudnick G, 2006, J MEMBRANE BIOL, V213, P101, DOI 10.1007/s00232-006-0878-4; Shlaifer I, 2007, MOL PHARMACOL, V71, P1341, DOI 10.1124/mol.106.032607; Wadiche JI, 1998, J NEUROSCI, V18, P7650; Wong KF, 2005, P NATL ACAD SCI USA, V102, P6807, DOI 10.1073/pnas.0408343102; WRIGHT SH, 1983, J BIOL CHEM, V258, P5456; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yao XZ, 2000, AM J PHYSIOL-RENAL, V279, pF54, DOI 10.1152/ajprenal.2000.279.1.F54; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zhang FF, 2001, BBA-BIOMEMBRANES, V1511, P80, DOI 10.1016/S0005-2736(00)00385-0; Zhang YW, 2006, J BIOL CHEM, V281, P36213, DOI 10.1074/jbc.M605468200	36	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20213	20220		10.1074/jbc.M701113200	http://dx.doi.org/10.1074/jbc.M701113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17504760	Green Accepted, hybrid			2022-12-25	WOS:000247819300023
J	Choi, MM; Kim, EA; Yang, SJ; Choi, SY; Cho, SW; Huh, JW				Choi, Myung-Min; Kim, Eun-A; Yang, Seung-Ju; Choi, Soo Young; Cho, Sung-Woo; Huh, Jae-Wan			Amino acid changes within antenna helix are responsible for different regulatory preferences of human glutamate dehydrogenase isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERINSULINISM/HYPERAMMONEMIA SYNDROME; OLIVOPONTOCEREBELLAR ATROPHY; SPINOCEREBELLAR DEGENERATION; CASSETTE MUTAGENESIS; ESCHERICHIA-COLI; MOLECULAR-BASIS; BINDING DOMAIN; GENE; TISSUE; IDENTIFICATION	Human glutamate dehydrogenase (hGDH) exists in hGDH1 (housekeeping isozyme) and in hGDH2 (nerve-specific isozyme), which differ markedly in their allosteric regulation. Because they differ in only 16 of their 505 amino acids, the regulatory preferences must arise from amino acid residues that are not common between hGDH1 and hGDH2. To our knowledge none of the mutagenesis studies on the hGDH isozymes to date have identified the amino acid residues fully responsible for the different regulatory preferences between hGDH1 and hGDH2. In this study we constructed hGDH1(hGDH2390-448) hGDH1 (amino acid segment 390 448 of hGDH1 replaced by the corresponding hGDH2 segment) and hGDH2(hGDH1390-448) hGDH2 (amino acid segment 390-448 of hGDH2 replaced by the corresponding hGDH1 segment) by swapping the corresponding amino acid segments in hGDH1 and hGDH2. The chimeric enzymes by reciprocal swapping resulted in double mutations in amino acid sequences at 415 and 443 residues that are not common between hGDH1 and hGDH2 and are located in the C-terminal 48-residue "antenna" helix, which is thought to be part of the regulatory domain of mammalian GDHs. Functional analyses revealed that the doubly mutated chimeric enzymes almost completely acquired most of the different regulatory preferences between hGDH1 and hGDH2 for electrophoretic mobility, heat-stability, ADP activation, palmitoyl-CoA inhibition, and L-leucine activation, except for GTP inhibition. Our results indicate that substitutions of the residues in the antenna region may be important evolutionary changes that led to the adaptation of hGDH2 to the unique metabolic needs of the nerve tissue.	Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea; Kanyang Univ, Dept Biomed Lab Sci, Taejon 302718, South Korea; Hallym Univ, Dept Biomed Sci, Chunchon 200702, South Korea	University of Ulsan; Hallym University	Cho, SW (corresponding author), 388-1 Poongnap-2dong, Seoul 138736, South Korea.	swcho@amc.seoul.kr; jwhuh72@amc.seoul.kr						ABE T, 1992, INVEST OPHTH VIS SCI, V33, P447; Allen A, 2004, BIOCHEMISTRY-US, V43, P14431, DOI 10.1021/bi048817i; Banerjee S, 2003, BIOCHEMISTRY-US, V42, P3446, DOI 10.1021/bi0206917; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burki F, 2004, NAT GENET, V36, P1061, DOI 10.1038/ng1431; Cho SW, 1996, BIOCHEMISTRY-US, V35, P13907, DOI 10.1021/bi9618575; CHO SW, 1995, EUR J BIOCHEM, V233, P340, DOI 10.1111/j.1432-1033.1995.340_1.x; Cho SW, 2001, EUR J BIOCHEM, V268, P3205, DOI 10.1046/j.1432-1327.2001.02209.x; DUVOISIN RC, 1983, NEUROLOGY, V33, P1322; Fang J, 2002, BIOCHEM J, V363, P81, DOI 10.1042/0264-6021:3630081; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; Fiermonte G, 2002, J BIOL CHEM, V277, P19289, DOI 10.1074/jbc.M201572200; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HUSSAIN MM, 1989, J BIOL CHEM, V264, P20730; IWATSUJI K, 1989, GERONTOLOGY, V35, P218, DOI 10.1159/000213026; Jang SH, 2003, EXP MOL MED, V35, P249, DOI 10.1038/emm.2003.33; JULLIARD JH, 1979, J BIOL CHEM, V254, P3427; KAJIYAMA K, 1988, J NEUROL NEUROSUR PS, V51, P1078, DOI 10.1136/jnnp.51.8.1078; Kanavouras K, 2007, J NEUROSCI RES, V85, P1101, DOI 10.1002/jnr.21197; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; KONAGAYA Y, 1986, J NEUROL SCI, V74, P231, DOI 10.1016/0022-510X(86)90108-5; Lee EY, 2001, J BIOL CHEM, V276, P47930, DOI 10.1074/jbc.M108918200; MacMullen C, 2001, J CLIN ENDOCR METAB, V86, P1782, DOI 10.1210/jc.86.4.1782; Mastorodemos V, 2005, J NEUROSCI RES, V79, P65, DOI 10.1002/jnr.20353; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Plaitakis A, 2003, NEUROCHEM INT, V43, P401, DOI 10.1016/S0197-0186(03)00028-7; Plaitakis A, 2001, J NEUROSCI RES, V66, P899, DOI 10.1002/jnr.10054; PLAITAKIS A, 1982, SCIENCE, V216, P193, DOI 10.1126/science.6121377; Plaitakis A, 2000, J NEUROL, V247, P25, DOI 10.1007/PL00007757; Shashidharan P, 1997, J NEUROCHEM, V68, P1804; SHASHIDHARAN P, 1994, J BIOL CHEM, V269, P16971; Smith TJ, 2002, J MOL BIOL, V318, P765, DOI 10.1016/S0022-2836(02)00161-4; Smith TJ, 2001, J MOL BIOL, V307, P707, DOI 10.1006/jmbi.2001.4499; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tanizawa Y, 2002, DIABETES, V51, P712, DOI 10.2337/diabetes.51.3.712; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; Yang SJ, 2004, FEBS LETT, V562, P59, DOI 10.1016/S0014-5793(04)00183-8; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; Zaganas I, 2002, J BIOL CHEM, V277, P46552, DOI 10.1074/jbc.M208596200; Zaganas I, 2002, J BIOL CHEM, V277, P26422, DOI 10.1074/jbc.M200022200	43	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19510	19517		10.1074/jbc.M703018200	http://dx.doi.org/10.1074/jbc.M703018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17507377	hybrid			2022-12-25	WOS:000247650600025
J	Manavathi, B; Rayala, SK; Kumar, R				Manavathi, Bramanandam; Rayala, Suresh K.; Kumar, Rakesh			Phosphorylation-dependent regulation of stability and transforming potential of ETS transcriptional factor ESE-1 by p21-activated kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; PAK1 PHOSPHORYLATION; EXPRESSION; CANCER; FAMILY; GROWTH; GENE; DIFFERENTIATION; TRANSITION; EPITHELIUM	Differential phosphorylation of transcription factors by signal transduction pathways play an important role in regulation of gene expression and functions. ESE-1 is an epithelium-specific ETS transcription factor that transforms human breast epithelial cells through a serine- and aspartic acid-rich domain (SAR) by an unknown cytoplasmic mechanism. Here we found that a signaling kinase, p21-activated kinase-1 (Pak1), interacts with and phosphorylates ESE-1. Interestingly, Pak1 selectively phosphorylates ESE-1 at Ser207, which is located within the SAR domain. A S207A substitution in ESE-1 reduced its ability to transform breast cancer cells. We also found that ESE-1 is a labile protein and by interacting with F-box-binding protein beta-TrCP, undergoes ubiquitin-dependent proteolysis. Intriguingly, Pak1 phosphorylation inactive mutant ESE1-S207A is more unstable than either wild-type ESE-1 or its Pak1 phosphorylation mimetic mutant, i.e. ESE1-S207E. These findings provide novel insights into the mechanism of transformation potential of ESE-1 and discovered that ESE-1 functions are coordinately regulated by Pak1 phosphorylation and beta-TrCP-dependent ubiquitin-proteasome pathways.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803; Manavathi, Bramanandam/0000-0002-1797-398X; Rayala, Suresh/0000-0003-4394-4450	NCI NIH HHS [CA65746, CA90970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA065746, R01CA090970, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Brown C, 2004, J BIOL CHEM, V279, P12794, DOI 10.1074/jbc.M308593200; Cabral A, 2003, J BIOL CHEM, V278, P17792, DOI 10.1074/jbc.M300508200; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Feldman RJ, 2003, ANTICANCER RES, V23, P2125; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Grall FT, 2005, FEBS J, V272, P1676, DOI 10.1111/j.1742-4658.2005.04592.x; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Jobling AI, 2002, INVEST OPHTH VIS SCI, V43, P3530; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Kurpios NA, 2003, J MAMMARY GLAND BIOL, V8, P177, DOI 10.1023/A:1025948823955; Kwon JH, 2003, J BIOL CHEM, V278, P875, DOI 10.1074/jbc.M208241200; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Manavathi B, 2005, CANCER RES, V65, P5571, DOI 10.1158/0008-5472.CAN-04-4664; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Neve RM, 2002, ONCOGENE, V21, P3934, DOI 10.1038/sj.onc.1205503; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Prescott JD, 2004, MOL CELL BIOL, V24, P5548, DOI 10.1128/MCB.24.12.5548-5564.2004; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reddy SPM, 2003, J BIOL CHEM, V278, P21378, DOI 10.1074/jbc.M212258200; Schedin PJ, 2004, ONCOGENE, V23, P1766, DOI 10.1038/sj.onc.1207391; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Vadlamudi RK, 2005, ONCOGENE, V24, P4591, DOI 10.1038/sj.onc.1208672; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 2006, ONCOGENE, V25, P2931, DOI 10.1038/sj.onc.1209309; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wiese C, 2001, BIOTECHNIQUES, V30, P960, DOI 10.2144/01305bm07; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	43	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19820	19830		10.1074/jbc.M702309200	http://dx.doi.org/10.1074/jbc.M702309200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17491012	hybrid			2022-12-25	WOS:000247650600057
J	Park, KH; Sesti, F				Park, Ki Ho; Sesti, Federico			An arrhythmia susceptibility gene in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; CARDIAC POTASSIUM CURRENT; MINK-RELATED PEPTIDES; K+ CHANNEL; INWARD RECTIFICATION; LANGE-NIELSEN; I-KR; MUTATIONS; SUBUNITS; HERG	kcne are evolutionarily conserved genes that encode accessory subunits of voltage-gated K+ (Kv) channels. Missense mutations in kcne1, kcne2, and kcne3 are linked to congenital and acquired channelopathies in Homo sapiens. Here we show an unique example of conservation of kcne activities at genetic, physiological, functional, and pathophysiological level in Caenorhabditis elegans. Thus, mps-4 is the homologue of kcne1 that operates in human heart and inner ear. Like its KCNE relatives, MPS-4 assembles with a Kv channel, EXP-2, to form a complex that controls pharyngeal muscle contractility. MPS-4 modulates EXP-2 function in a similar fashion as KCNE proteins endow human channels. When defective, MPS-4, can induce abnormal repolarization by mechanisms that resemble the way KCNE proteins are thought to provoke arrhythmia in human heart. Mutation of a conserved aspartate residue associated with human disease (MPS-4-D74N) alters the functional attributes of the C. elegans current. Taken together these data underscore a significant conservation of KCNE activities in different pumps. This implies that C. elegans can develop into a system to study the molecular and genetic basis of KCNE-mediated muscle contractility and disease states.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Sesti, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.	sestife@UMDNJ.EDU	Park, Ki Ho/N-8153-2017; Park, Ki Ho/E-8921-2011	Park, Ki Ho/0000-0002-6193-9826; 	NIGMS NIH HHS [R01GM68581] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068581] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott GW, 2002, FASEB J, V16, DOI 10.1096/fj.01-0520hyp; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Anantharam A, 2003, J BIOL CHEM, V278, P11739, DOI 10.1074/jbc.M212751200; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Cai SQ, 2006, CELL BIOCHEM BIOPHYS, V46, P91, DOI 10.1385/CBB:46:1:91; Chandrasekhar KD, 2006, J BIOL CHEM, V281, P40015, DOI 10.1074/jbc.M604398200; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Davis MW, 1999, SCIENCE, V286, P2501, DOI 10.1126/science.286.5449.2501; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; Fleischhauer R, 2000, J NEUROSCI, V20, P511, DOI 10.1523/JNEUROSCI.20-02-00511.2000; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; McCrossan ZA, 2003, J NEUROSCI, V23, P8077; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Nicolas MT, 2001, HEARING RES, V153, P132, DOI 10.1016/S0378-5955(00)00268-9; Park KH, 2005, J BIOL CHEM, V280, P21893, DOI 10.1074/jbc.M502732200; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; Roepke TK, 2006, J BIOL CHEM, V281, P23740, DOI 10.1074/jbc.M604155200; SAKMANN B, 1995, SINGLE CHANNEL RECOR, V1; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Shtonda B, 2005, J EXP BIOL, V208, P2177, DOI 10.1242/jeb.01615; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Viskin S, 1999, LANCET, V354, P1625, DOI 10.1016/S0140-6736(99)02107-8; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yang YS, 1998, J GEN PHYSIOL, V112, P665, DOI 10.1085/jgp.112.6.665; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511	32	6	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19799	19807		10.1074/jbc.M701625200	http://dx.doi.org/10.1074/jbc.M701625200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17491013	hybrid			2022-12-25	WOS:000247650600055
J	Sullivan, M; Morgan, DO				Sullivan, Matt; Morgan, David O.			A novel destruction sequence targets the meiotic regulator Spo13 for anaphase-promoting complex-dependent degradation in anaphase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTROMERIC COHESION; KINASE CDC5; KEN-BOX; SACCHAROMYCES-CEREVISIAE; A-BOX; RECOGNITION; SUBUNIT; SEGREGATION; COMPLEX/CYCLOSOME; RECRUITMENT	The anaphase-promoting complex (APC) or cyclosome is a multisubunit ubiquitin-protein ligase that ubiquitinates and thereby promotes the destruction of the mitotic cyclins and the separase inhibitor, securin. The contributions of the APC to progression through the meiotic program are not clear. To clarify the function of the APC in meiosis, we screened several yeast meiotic proteins as APC substrates in vitro. We found that the meiotic regulator Spo13 is an APC substrate that is degraded during anaphase I. Spo13 is expressed only in meiotic cells, where it has multiple functions, including the promotion of monopolar chromosome attachment in the first division. Spo13 ubiquitination by the APC depends on an LxExxxN sequence (residues 26-32) that is distinct from previously described destruction sequences of APC substrates. Mutation of one residue, leucine 26, prevented Spo13 ubiquitination by the APC in vitro and stabilized the protein through the meiotic divisions. Analysis of meiotic progression and spore viability of yeast containing the stabilized Spo13 mutant revealed no significant defects, indicating that Spo13 destruction in anaphase I is not essential for meiosis. We propose that Spo13 destruction is one of multiple mechanisms underlying the switch from monopolar to bipolar chromosome attachment between the meiotic divisions.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Biophys, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Morgan, DO (corresponding author), Univ Calif San Francisco, Genentech Hall,Rm N312B,600 16th St, San Francisco, CA 94158 USA.	David.Morgan@ucsf.edu		Morgan, David/0000-0001-8753-4416	NIGMS NIH HHS [GM53270, R01 GM053270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053270, R37GM053270] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araki M, 2003, EMBO J, V22, P6115, DOI 10.1093/emboj/cdg573; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Carroll CW, 2005, CURR BIOL, V15, P11, DOI 10.1016/j.cub.2004.12.066; Carroll CW, 2002, NAT CELL BIOL, V4, P880, DOI 10.1038/ncb871; Castro A, 2003, MOL CELL BIOL, V23, P4126, DOI 10.1128/MCB.23.12.4126-4138.2003; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; Ferreira MG, 2000, MOL CELL BIOL, V20, P242; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hildebrandt ER, 2001, MOL BIOL CELL, V12, P3402, DOI 10.1091/mbc.12.11.3402; Katis VL, 2004, CURR BIOL, V14, P2183, DOI 10.1016/j.cub.2004.12.020; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; Lee BH, 2004, CURR BIOL, V14, P2168, DOI 10.1016/j.cub.2004.12.033; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee BH, 2002, GENE DEV, V16, P1672, DOI 10.1101/gad.989302; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Oelschlaegel T, 2005, CELL, V120, P773, DOI 10.1016/j.cell.2005.01.032; Penkner AM, 2005, CELL, V120, P789, DOI 10.1016/j.cell.2005.01.017; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Pfleger CM, 2000, GENE DEV, V14, P655; Rabitsch KP, 2003, DEV CELL, V4, P535, DOI 10.1016/S1534-5807(03)00086-8; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Schwickart M, 2004, MOL CELL BIOL, V24, P3562, DOI 10.1128/MCB.24.8.3562-3576.2004; Shonn MA, 2002, GENE DEV, V16, P1659, DOI 10.1101/gad.975802; Thornton BR, 2003, NAT CELL BIOL, V5, P1090, DOI 10.1038/ncb1066; Thornton BR, 2006, GENE DEV, V20, P3069, DOI 10.1101/gad.1478306; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Valentin G, 2006, J BIOL CHEM, V281, P2828, DOI 10.1074/jbc.M510626200; Zachariae W, 2004, MOL CELL, V13, P2, DOI 10.1016/S1097-2765(03)00530-6	36	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19710	19715		10.1074/jbc.M701507200	http://dx.doi.org/10.1074/jbc.M701507200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17493939	hybrid			2022-12-25	WOS:000247650600046
J	Gipson, CL; Xin, ZT; Danzy, SC; Parslow, TG; Ly, H				Gipson, Clay L.; Xin, Zhong-Tao; Danzy, Shamika C.; Parslow, Tristram G.; Ly, Hinh			Functional characterization of yeast telomerase RNA dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERASE; IMMUNODEFICIENCY-VIRUS RNA; BICOID MESSENGER-RNA; KISSING-LOOP HAIRPIN; REVERSE-TRANSCRIPTASE; IN-VIVO; CATALYTIC SUBUNIT; GENOMIC RNA; TETRAHYMENA-TELOMERASE; SECONDARY STRUCTURE	Telomerase is the cellular RNA-dependent DNA polymerase (i.e. reverse transcriptase) that uses an integral RNA template to synthesize telomeric DNA repeats at the ends of linear chromosomes. Human telomerase RNA (hTERC) is thought to function as a dimeric complex consisting of two RNAs that interact with each other physically as well as genetically. We show here for the first time that the yeast Saccharomyces cerevisiae telomerase RNA TLC1 likewise forms dimers in vitro. TLC1 dimerization depends on a unique 6-base self-complementary sequence, which closely mimics palindromic sequences that mediate functional dimerization of HIV-1 and other retroviral genomes. We found that dissimilar but comparably located TLC1 palindromes from other sensu stricto yeasts can functionally substitute for that of S. cerevisiae. Yeast cells expressing dimerization-defective TLC1 alleles have shorter telomeres than those with wild-type TLC1. This study, therefore, highlights dimerization as a functionally conserved feature of the RNA templates utilized by reverse transcriptases of both viral and cellular origins.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Div Expt Pathol, Atlanta, GA 30322 USA	Emory University; Emory University	Ly, H (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 615 Michael St,Whitehead Bldg,Rm105L, Atlanta, GA 30322 USA.	hly@emory.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040317] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-40317] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Bachand F, 2001, NUCLEIC ACIDS RES, V29, P3385, DOI 10.1093/nar/29.16.3385; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bosoy D, 2003, J BIOL CHEM, V278, P3882, DOI 10.1074/jbc.M210645200; Bryan TM, 2003, MOL BIOL CELL, V14, P4794, DOI 10.1091/mbc.E03-07-0474; Chapon C, 1997, RNA, V3, P1337; Chappell AS, 2004, MOL CELL BIOL, V24, P7720, DOI 10.1128/MCB.24.17.7720-7736.2004; Chen JL, 2004, P NATL ACAD SCI USA, V101, P14683, DOI 10.1073/pnas.0406204101; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chin MPS, 2005, P NATL ACAD SCI USA, V102, P9002, DOI 10.1073/pnas.0502522102; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; Comolli LR, 2002, P NATL ACAD SCI USA, V99, P16998, DOI 10.1073/pnas.262663599; Dandjinou AT, 2004, CURR BIOL, V14, P1148, DOI 10.1016/j.cub.2004.05.054; Doria-Rose NA, 1998, J VIROL, V72, P8073, DOI 10.1128/JVI.72.10.8073-8082.1998; Feng YX, 2000, J VIROL, V74, P10819, DOI 10.1128/JVI.74.22.10819-10821.2000; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; Keppler BR, 2004, BIOCHEMISTRY-US, V43, P334, DOI 10.1021/bi035583e; Laughrea M, 1997, BIOCHEMISTRY-US, V36, P9501, DOI 10.1021/bi970862l; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Laughrea M, 1997, J VIROL, V71, P3397, DOI 10.1128/JVI.71.5.3397-3406.1997; Lin J, 2004, P NATL ACAD SCI USA, V101, P14713, DOI 10.1073/pnas.0405879101; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Ly H, 2003, GENE DEV, V17, P1078, DOI 10.1101/gad.1060803; Marie-Egyptienne DT, 2005, NUCLEIC ACIDS RES, V33, P5446, DOI 10.1093/nar/gki848; MARQUET R, 1994, NUCLEIC ACIDS RES, V22, P145, DOI 10.1093/nar/22.2.145; Moriarty TJ, 2004, MOL CELL BIOL, V24, P3720, DOI 10.1128/MCB.24.9.3720-3733.2004; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Paillart JC, 2004, NAT REV MICROBIOL, V2, P461, DOI 10.1038/nrmicro903; Paillart JC, 1996, BIOCHIMIE, V78, P639, DOI 10.1016/S0300-9084(96)80010-1; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Ren XJ, 2003, NUCLEIC ACIDS RES, V31, P6509, DOI 10.1093/nar/gkg871; Rivera MA, 2004, J BIOL CHEM, V279, P53770, DOI 10.1074/jbc.M407768200; Sambrook J., 2001, MOL CLONING LAB MANU; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Theimer CA, 2005, MOL CELL, V17, P671, DOI 10.1016/j.molcel.2005.01.017; Wagner C, 2004, J BIOL CHEM, V279, P4560, DOI 10.1074/jbc.M306511200; Wang LB, 2002, NUCLEIC ACIDS RES, V30, P4032, DOI 10.1093/nar/gkf513; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zappulla DC, 2005, NAT STRUCT MOL BIOL, V12, P1072, DOI 10.1038/nsmb1019	48	7	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18857	18863		10.1074/jbc.M700057200	http://dx.doi.org/10.1074/jbc.M700057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17491007	hybrid			2022-12-25	WOS:000247475300025
J	Li, ZY; Yang, J; Gao, X; Lu, JY; Zhang, Y; Wang, KP; Cheng, MB; Wu, NH; Zhang, Y; Wu, ZG; Shen, YF				Li, Zhao-yong; Yang, Jun; Gao, Xin; Lu, Jian-yi; Zhang, Yi; Wang, Kepeng; Cheng, Mo-bin; Wu, Ning-hua; Zhang, Ye; Wu, Zhenguo; Shen, Yu-fei			Sequential recruitment of PCAF and BRG1 contributes to myogenin activation in 12-O-tetradecanoylphorbol-13-acetate-induced early differentiation of rhabdomyosarcoma-derived cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION; MYOD; CHROMATIN; P38; ACETYLATION; PROGRAM; P300; EXPRESSION; COMPLEXES; PATHWAY	Myogenin and its upstream regulator MyoD are known to be required for myogenic cell differentiation. Although both of them can be expressed in rhabdomyosarcoma-derived RD cells, the cells are unable to undergo full-scale terminal myogenic differentiation. 12-O-Tetradecanoylphorbol-13-acetate (TPA) has been found to be functional in the induction of RD cell differentiation, whereas its mechanism is not fully understood. By using quantitative real-time-based chromatin immunoprecipitation and real-time reverse transcription-PCR-based promoter activity assays, we examined the activation mechanism of the myogenin gene during TPA-induced differentiation of the RD cells. We have shown that a histone acetyltransferase PCAF and ATPase subunit BRG1 of the SWI/SNF chromatin remodeling complex are sequentially recruited to the promoter of the myogenin gene. Both PCAF and BRG1 are also involved in the activation of the myogenin gene. In addition, we have found that the p38 mitogen-activated protein kinase is required for BRG1 recruitment in TPA-mediated myogenin induction. We propose that there are two distinct activation steps for the induction of myogenin in TPA-induced early differentiation of RD cells: 1) an early step that requires PCAF activity to acetylate core histones and MyoD to initiate myogenin gene expression, and 2) a later step that requires p38-dependent activity of the SWI/SNF remodeling complex to provide an open conformation for the induction of myogenin. Our studies reveal an essential role for epigenetic regulation in TPA-induced differentiation of RD cells and provide potential drug targets for future treatment of the rhabdomyosarcoma.	Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, Natl Lab Med Mol Biol,Dept Biochem & Mol Biol, Beijing 100005, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Hong Kong University of Science & Technology	Wu, ZG (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, Natl Lab Med Mol Biol,Dept Biochem & Mol Biol, Beijing 100005, Peoples R China.	bczgwu@ust.hk; yfshen@ms.imicams.ac.cn	Li, zhao-yong/N-4288-2013; Zhang, Ye/D-5015-2011; Wang, Kepeng/F-8363-2014	Zhang, Ye/0000-0002-3494-7206; Wang, Kepeng/0000-0001-6428-4709; Wu, Zhenguo/0000-0003-3049-8324				AGUANNO S, 1990, CANCER RES, V50, P3377; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Mauro A, 2002, J CELL SCI, V115, P3587, DOI 10.1242/jcs.00037; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Puri PL, 2000, GENE DEV, V14, P574; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Roth JF, 2003, EMBO J, V22, P5186, DOI 10.1093/emboj/cdg473; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xiao L, 2000, CANCER RES, V60, P400; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JZ, 2006, STEM CELLS, V24, P2661, DOI 10.1634/stemcells.2006-0017; Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200	24	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18872	18878		10.1074/jbc.M609448200	http://dx.doi.org/10.1074/jbc.M609448200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17468105	hybrid			2022-12-25	WOS:000247475300027
J	Liu, J; Xia, JS; Cho, KH; Clapham, DE; Ren, DJ				Liu, Jin; Xia, Jingsheng; Cho, Kwang-Hyun; Clapham, David E.; Ren, Dejian			CatSper beta, a novel transmembrane protein in the CatSper channel complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM MOTILITY; MAMMALIAN SPERM; GENE-EXPRESSION; SODIUM-CHANNELS; MALE-FERTILITY; CA2+ ENTRY; TESTIS; FERTILIZATION; MECHANISMS; EVOLUTION	Four CatSper ion channel subunit genes (CatSpers 1-4) are required for sperm cell hyperactivation and male fertility. The four proteins assemble (presumably as a tetramer) to form a sperm-specific, alkalinization-activated Ca2+-selective channel. We set out to identify proteins associating with CatSper that might help explain its unique role in spermatozoa. Using a transgenic approach, a CatSper1 complex was purified from mouse testis that contained heat shock protein 70-2, a testis-specific chaperone, and CatSper beta, a novel protein with two putative transmembrane-spanning domains. Like the CatSper ion channel subunits, CatSper beta was restricted to testis and localized to the principal piece of the sperm tail. CatSper beta protein is absent in CatSper1(-/-) sperm, suggesting that it is required for trafficking or formation of a stable channel complex. CatSper beta is the first identified auxiliary protein to the CatSper channel.	Childrens Hosp, Howard Hughes Med Inst, Enders 1309, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Ren, DJ (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	dren@sas.upenn.edu	Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428; Cho, Kwang-Hyun/0000-0002-3972-4394				Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Avidan N, 2003, EUR J HUM GENET, V11, P497, DOI 10.1038/sj.ejhg.5200991; BABCOCK DF, 1987, J BIOL CHEM, V262, P15041; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; Carlson AE, 2003, P NATL ACAD SCI USA, V100, P14864, DOI 10.1073/pnas.2536658100; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Clapham DE, 2005, PHARMACOL REV, V57, P451, DOI 10.1124/pr.57.4.7; Darszon A, 2006, REPRODUCTION, V131, P977, DOI 10.1530/rep.1.00612; Eddy EM, 1998, J EXP ZOOL, V282, P261, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2&lt;261::AID-JEZ28&gt;3.0.CO;2-V; Evans JP, 2002, NAT CELL BIOL, V4, pS57, DOI 10.1038/ncb-nm-fertilityS57; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; FLORMAN HM, 1992, DEV BIOL, V152, P304, DOI 10.1016/0012-1606(92)90137-6; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hinzpeter A, 2006, AM J PHYSIOL-CELL PH, V290, pC45, DOI 10.1152/ajpcell.00209.2005; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Inaba K, 2002, MOL REPROD DEV, V62, P431, DOI 10.1002/mrd.10131; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Jimenez-Gonzalez C, 2006, HUM REPROD UPDATE, V12, P253, DOI 10.1093/humupd/dmi050; Jin JL, 2005, BIOL REPROD, V73, P1235, DOI 10.1095/biolreprod.105.045468; Kierszenbaum AL, 2002, MOL REPROD DEV, V63, P1, DOI 10.1002/mrd.10179; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; Lobley Anna, 2003, Reprod Biol Endocrinol, V1, P53, DOI 10.1186/1477-7827-1-53; Marquez B, 2007, DEV BIOL, V303, P214, DOI 10.1016/j.ydbio.2006.11.007; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Nikpoor P, 2004, HUM REPROD, V19, P124, DOI 10.1093/humrep/deh043; Okamura Y, 2005, PHYSIOL GENOMICS, V22, P269, DOI 10.1152/physiolgenomics.00229.2004; Qi HY, 2007, P NATL ACAD SCI USA, V104, P1219, DOI 10.1073/pnas.0610286104; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Reed RR, 2004, CELL, V116, P329, DOI 10.1016/S0092-8674(04)00047-9; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; Vial C, 2004, TRENDS PHARMACOL SCI, V25, P487, DOI 10.1016/j.tips.2004.07.008; Wennemuth G, 2000, J BIOL CHEM, V275, P21210, DOI 10.1074/jbc.M002068200; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; WOLF DE, 1990, P NATL ACAD SCI USA, V87, P6893, DOI 10.1073/pnas.87.17.6893; Yanagimachi R., 1994, P189; YU FH, 2004, SCI STKE	38	121	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18945	18952		10.1074/jbc.M701083200	http://dx.doi.org/10.1074/jbc.M701083200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17478420	hybrid			2022-12-25	WOS:000247475300036
J	Maas, E; Geissen, M; Groschup, MH; Rost, R; Onodera, T; Schatzl, H; Vorberg, IM				Maas, Elke; Geissen, Markus; Groschup, Martin H.; Rost, Romina; Onodera, Takashi; Schaetzl, Hermann; Vorberg, Ina M.			Scrapie infection of prion protein-deficient cell line upon ectopic expression of mutant prion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE NEUROBLASTOMA-CELLS; PRP KNOCKOUT MICE; TRANSGENIC MICE; NMR STRUCTURE; AMINO-ACID; SPECIES BARRIER; CULTURED-CELLS; RESISTANT PRP; PROPAGATION; CONVERSION	Expression of the cellular prion protein (PrPC) is crucial for susceptibility to prions. In vivo, ectopic expression of PrPC restores susceptibility to prions and transgenic mice that express heterologous PrP on a PrP knock-out background have been used extensively to study the role of PrP alterations for prion transmission and species barriers. Here we report that prion protein knock-out cells can be rendered permissive to scrapie infection by the ectopic expression of PrP. The system was used to study the influence of sheep PrP-specific residues in mouse PrP on the infection process with mouse adapted scrapie. These studies reveal several critical residues previously not associated with species barriers and demonstrate that amino acid residue alterations at positions known to have an impact on the susceptibility of sheep to sheep scrapie also drastically influence PrPSc formation by mouse-adapted scrapie strain 22L. Furthermore, our data suggest that amino acid polymorphisms located on the outer surfaces of helix 2 and 3 drastically impact conversion efficiency. In conclusion, this system allows for the fast generation of mutant PrPSc that is entirely composed of transgenic PrP and is, thus, ideally suited for testing if artificial PrP molecules can affect prion replication. Transmission of infectivity generated in HpL3-4 cells expressing altered PrP molecules to mice could also help to unravel the potential influence of mutant PrPSc on host cell tropism and strain characteristics in vivo.	Tech Univ Munich, Inst Virol, D-81675 Munich, Germany; Friedrich Loeffler Inst, Inst Novel & Emerging Infect Dis, D-17493 Greifswald, Germany; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Mol Immunol, Tokyo 113, Japan	Technical University of Munich; Friedrich Loeffler Institute; University of Tokyo	Vorberg, IM (corresponding author), Univ Hamburg, Inst Neuropathol, Martinistr 52, D-20246 Hamburg, Germany.	vorberg@lrz.tum.de	Schatzl, Hermann/G-4958-2011	Schatzl, Hermann/0000-0003-4972-8740				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Atarashi R, 2006, J VIROL, V80, P7854, DOI 10.1128/JVI.00424-06; Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CAUGHEY B, 1993, BRIT MED BULL, V49, P860, DOI 10.1093/oxfordjournals.bmb.a072651; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Glockshuber R, 1997, TRENDS BIOCHEM SCI, V22, P241, DOI 10.1016/S0968-0004(97)01070-0; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Harris B, 2003, CLIO MED, V71, P85; Holscher C, 1998, J VIROL, V72, P1153; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kanu N, 2002, CURR BIOL, V12, P523, DOI 10.1016/S0960-9822(02)00722-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Langedijk JPM, 2006, J MOL BIOL, V360, P907, DOI 10.1016/j.jmb.2006.05.042; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Lu XJ, 2007, P NATL ACAD SCI USA, V104, P1510, DOI 10.1073/pnas.0608447104; Lysek DA, 2005, P NATL ACAD SCI USA, V102, P640, DOI 10.1073/pnas.0408937102; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Norstrom EM, 2006, J VIROL, V80, P8521, DOI 10.1128/JVI.00366-06; Nunziante M, 2005, J CELL SCI, V118, P4959, DOI 10.1242/jcs.02609; Paquet S, 2007, J GEN VIROL, V88, P706, DOI 10.1099/vir.0.82336-0; Parizek P, 2001, J BIOL CHEM, V276, P44627, DOI 10.1074/jbc.M107458200; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Perrier V, 2002, P NATL ACAD SCI USA, V99, P13079, DOI 10.1073/pnas.182425299; PRIOLA SA, 1995, J VIROL, V69, P7754, DOI 10.1128/JVI.69.12.7754-7758.1995; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; RACE RE, 1988, J VIROL, V62, P2845, DOI 10.1128/JVI.62.8.2845-2849.1988; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Sabuncu E, 2003, J VIROL, V77, P2696, DOI 10.1128/JVI.77.4.2696-2700.2003; Schatzl HM, 1997, J VIROL, V71, P8821; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Solassol J, 2003, BRIT MED BULL, V66, P87, DOI 10.1093/bmb/66.1.87; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Vilette D, 2001, P NATL ACAD SCI USA, V98, P4055, DOI 10.1073/pnas.061337998; Vorberg I, 2004, J BIOL CHEM, V279, P29218, DOI 10.1074/jbc.M402576200; Vorberg I, 2004, J INFECT DIS, V189, P431, DOI 10.1086/381166; Vorberg I, 2003, J VIROL, V77, P2003, DOI 10.1128/JVI.77.3.2003-2009.2003; Vorberg I, 2001, J VIROL, V75, P10024, DOI 10.1128/JVI.75.21.10024-10032.2001; Weissmann C, 2003, BRIT MED BULL, V66, P43, DOI 10.1093/bmb/66.1.43; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; WOLFOROSI L, 2007, J BIOL CHEM, V282, P7465	60	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18702	18710		10.1074/jbc.M701309200	http://dx.doi.org/10.1074/jbc.M701309200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17468101	hybrid			2022-12-25	WOS:000247475300008
J	Shereda, RD; Bernstein, DA; Keck, JL				Shereda, Robert D.; Bernstein, Douglas A.; Keck, James L.			A central role for SSB in Escherichia coli RecQ DNA helicase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; ACID UNWINDING PROTEIN; BINDING-PROTEIN; REPLICATION FORKS; EXONUCLEASE-I; CRYSTAL-STRUCTURE; POSTREPLICATION REPAIR; GENETIC-RECOMBINATION; TOPOISOMERASE-III; TERMINAL DOMAIN	RecQ DNA helicases are critical components of DNA replication, recombination, and repair machinery in all eukaryotes and bacteria. Eukaryotic RecQ helicases are known to associate with numerous genome maintenance proteins that modulate their cellular functions, but there is little information regarding protein complexes involving the prototypical bacterial RecQ proteins. Here we use an affinity purification scheme to identify three heterologous proteins that associate with Escherichia coli RecQ: SSB (single-stranded DNA-binding protein), exonuclease I, and RecJ exonuclease. The RecQ-SSB interaction is direct and is mediated by the RecQ winged helix subdomain and the C terminus of SSB. Interaction with SSB has important functional consequences for RecQ. SSB stimulates RecQ-mediated DNA unwinding, whereas deletion of the C-terminal RecQ-binding site from SSB produces a variant that blocks RecQ DNA binding and unwinding activities, suggesting that RecQ recognizes both the SSB C terminus and DNA in SSB (.) DNA nucleoprotein complexes. These findings, together with the noted interactions between human RecQ proteins and Replication Protein A, identify SSB as a broadly conserved RecQ-binding protein. These results also provide a simple model that explains RecQ integration into genome maintenance processes in E. coli through its association with SSB.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Keck, JL (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Med Sci Ctr 550, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	jlkeck@wisc.edu		Keck, James/0000-0002-5961-0220	NIGMS NIH HHS [GM068061] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068061] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arifuzzaman M, 2006, GENOME RES, V16, P686, DOI 10.1101/gr.4527806; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bennett RJ, 2004, CRIT REV BIOCHEM MOL, V39, P79, DOI 10.1080/10409230490460756; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bernstein DA, 2005, STRUCTURE, V13, P1173, DOI 10.1016/j.str.2005.04.018; Bernstein DA, 2003, NUCLEIC ACIDS RES, V31, P2778, DOI 10.1093/nar/gkg376; Breyer WA, 2000, NAT STRUCT BIOL, V7, P1125; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Cadman CJ, 2004, NUCLEIC ACIDS RES, V32, P6378, DOI 10.1093/nar/gkh980; CHASE JW, 1984, J BIOL CHEM, V259, P805; Courcelle CT, 2006, P NATL ACAD SCI USA, V103, P9154, DOI 10.1073/pnas.0600785103; Courcelle J, 2003, SCIENCE, V299, P1064, DOI 10.1126/science.1081328; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; Courcelle J, 1999, J BACTERIOL, V181, P916, DOI 10.1128/JB.181.3.916-922.1999; Cui S, 2004, NUCLEIC ACIDS RES, V32, P2158, DOI 10.1093/nar/gkh540; Doherty KM, 2005, J BIOL CHEM, V280, P29494, DOI 10.1074/jbc.M500653200; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Garcia PL, 2004, EMBO J, V23, P2882, DOI 10.1038/sj.emboj.7600301; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; Han ES, 2006, NUCLEIC ACIDS RES, V34, P1084, DOI 10.1093/nar/gkj503; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Handa P, 2001, J BIOL CHEM, V276, P16992, DOI 10.1074/jbc.M100393200; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2003, J BIOL CHEM, V278, P42668, DOI 10.1074/jbc.M302994200; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Hegde SP, 1996, P NATL ACAD SCI USA, V93, P14468, DOI 10.1073/pnas.93.25.14468; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; Hu JS, 2005, P NATL ACAD SCI USA, V102, P18379, DOI 10.1073/pnas.0509380102; Huber MD, 2006, J MOL BIOL, V358, P1071, DOI 10.1016/j.jmb.2006.01.077; IRINO N, 1986, MOL GEN GENET, V205, P298, DOI 10.1007/BF00430442; Ivancic-Bace I, 2005, J BACTERIOL, V187, P1350, DOI 10.1128/JB.187.4.1350-1356.2005; Kitano K, 2007, J BIOL CHEM, V282, P2717, DOI 10.1074/jbc.M610142200; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KUSHNER SR, 1972, P NATL ACAD SCI USA, V69, P1366, DOI 10.1073/pnas.69.6.1366; Lee JW, 2005, MECH AGEING DEV, V126, P79, DOI 10.1016/j.mad.2004.09.011; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Matsumoto T, 2000, J BIOCHEM, V127, P329, DOI 10.1093/oxfordjournals.jbchem.a022611; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MOLINEUX IJ, 1974, J BIOL CHEM, V249, P6090; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Ozgenc A, 2005, MUTAT RES-FUND MOL M, V577, P237, DOI 10.1016/j.mrfmmm.2005.03.020; Possoz C, 2006, EMBO J, V25, P2596, DOI 10.1038/sj.emboj.7601155; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; SAMBROOK J, 2001, MOL CLONING LAB MANU, V3, pA1; Sandigursky M, 1996, RADIAT RES, V145, P619, DOI 10.2307/3579281; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; Shen JC, 2003, MECH AGEING DEV, V124, P921, DOI 10.1016/S0047-6374(03)00164-7; Stauffer ME, 2004, J BIOL CHEM, V279, P30915, DOI 10.1074/jbc.R400015200; TSENG YC, 1994, MUTAT RES, V315, P1; UMEZU K, 1994, J BIOL CHEM, V269, P30005; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; VALES LD, 1980, J BACTERIOL, V143, P887, DOI 10.1128/JB.143.2.887-896.1980; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; WANG TV, 1985, MOL GEN GENET, V201, P186, DOI 10.1007/BF00425658; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; Witte G, 2003, NUCLEIC ACIDS RES, V31, P4434, DOI 10.1093/nar/gkg498; Yamagata A, 2002, P NATL ACAD SCI USA, V99, P5908, DOI 10.1073/pnas.092547099; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	72	108	110	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19247	19258		10.1074/jbc.M608011200	http://dx.doi.org/10.1074/jbc.M608011200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17483090	hybrid			2022-12-25	WOS:000247475300065
J	Sloop, KW; Showalter, AD; Cox, AL; Cao, JXC; Siesky, AM; Zhang, HY; Irizarry, AR; Murray, SF; Booten, SL; Finger, EA; Mckay, RA; Monia, BP; Bhanot, S; Michael, MD				Sloop, Kyle W.; Showalter, Aaron D.; Cox, Amy L.; Cao, Julia X. C.; Siesky, Angela M.; Zhang, Hong Yan; Irizarry, Armando R.; Murray, Susan F.; Booten, Sheri L.; Finger, Eleftheria A.; Mckay, Robert A.; Monia, Brett P.; Bhanot, Sanjay; Michael, M. Dodson			Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGONUCLEOTIDE INHIBITOR; CHLOROGENIC ACID; MICROSOMAL GLUCOSE-6-PHOSPHATASE; GLUCOSE-PRODUCTION; GENE-THERAPY; MICE LACKING; MOUSE MODEL; METABOLISM; GLUCONEOGENESIS; EXPRESSION	D-Glucose-6-phosphatase is a key regulator of endogenous glucose production, and its inhibition may improve glucose control in type 2 diabetes. Herein, 2'-O-(2-methoxy) ethyl-modified phosphorothioate antisense oligonucleotides (ASOs) specific to the glucose 6-phosphate transporter-1 (G6PT1) enabled reduction of hepatic D-Glu-6-phosphatase activity in diabetic ob/ob mice. Treatment with G6PT1 ASOs decreased G6PT1 expression, reduced G6PT1 activity, blunted glucagon-stimulated glucose production, and lowered plasma glucose concentration in a dose-dependent manner. In contrast to G6PT1 knock-out mice and patients with glycogen storage disease, excess hepatic and renal glycogen accumulation, hyperlipidemia, neutropenia, and elevations in plasma lactate and uric acid did not occur. In addition, hypoglycemia was not observed in animals during extended periods of fasting, and the ability of G6PT1 ASO-treated mice to recover from an exogenous insulin challenge was not impaired. Together, these results demonstrate that effective glucose lowering by G6PT1 inhibitors can be achieved without adversely affecting carbohydrate and lipid metabolism.	Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Greenfield, IN 46140 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	Eli Lilly; Eli Lilly; Isis Pharmaceuticals Inc	Sloop, KW (corresponding author), Lilly Res Labs, Indianapolis, IN 46285 USA.	sloop_kyle_w@lilly.com		Michael, Mervyn/0000-0002-0224-1065				ARION WJ, 1989, METHOD ENZYMOL, V174, P58; ARION WJ, 1980, J BIOL CHEM, V255, P396; ARION WJ, 1975, MOL CELL BIOCHEM, V6, P75, DOI 10.1007/BF01732001; Arion WJ, 1998, ARCH BIOCHEM BIOPHYS, V351, P279, DOI 10.1006/abbi.1997.0563; Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874; Bandsma RHJ, 2001, DIABETES, V50, P2591, DOI 10.2337/diabetes.50.11.2591; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Butler M, 1997, LAB INVEST, V77, P379; Chen LY, 2003, HUM MOL GENET, V12, P2547, DOI 10.1093/hmg/ddg263; Cheung YY, 2007, J CLIN INVEST, V117, P784, DOI 10.1172/JCI30443; Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104; Chou JY, 2002, EUR J PEDIATR, V161, pS56, DOI 10.1007/s00431-002-1005-x; CORI GT, 1952, J BIOL CHEM, V199, P661; Crooke RM, 2005, J LIPID RES, V46, P872, DOI 10.1194/jlr.M400492-JLR200; DEFRONZO RA, 1989, METABOLISM, V38, P387, DOI 10.1016/0026-0495(89)90129-7; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; Graham MJ, 2001, BIOCHEM PHARMACOL, V62, P297, DOI 10.1016/S0006-2952(01)00669-4; Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360; Herling AW, 1998, AM J PHYSIOL-GASTR L, V274, pG1087, DOI 10.1152/ajpgi.1998.274.6.G1087; Herling AW, 1999, EUR J PHARMACOL, V386, P75, DOI 10.1016/S0014-2999(99)00748-7; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; Igarashi Y, 1980, J Inherit Metab Dis, V2, P45; IGARASHI Y, 1984, BIOCHEM BIOPH RES CO, V119, P593, DOI 10.1016/S0006-291X(84)80290-9; Krssak M, 2004, DIABETES, V53, P3048, DOI 10.2337/diabetes.53.12.3048; Kurukulasuriya R, 2003, CURR MED CHEM, V10, P99, DOI 10.2174/0929867033368547; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Link James T, 2003, Curr Opin Investig Drugs, V4, P421; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Meyer C, 2004, AM J PHYSIOL-ENDOC M, V287, pE1049, DOI 10.1152/ajpendo.00041.2004; Nordlie RC, 1999, ANNU REV NUTR, V19, P379, DOI 10.1146/annurev.nutr.19.1.379; NORDLIE RC, 1993, P SOC EXP BIOL MED, V203, P274; Pan CJ, 1999, J BIOL CHEM, V274, P13865, DOI 10.1074/jbc.274.20.13865; Parker JC, 1998, DIABETES, V47, P1630, DOI 10.2337/diabetes.47.10.1630; Radziuk J, 2001, DIABETES-METAB RES, V17, P250, DOI 10.1002/dmrr.217; Roden M, 2001, RECENT PROG HORM RES, V56, P219, DOI 10.1210/rp.56.1.219; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200; Simon C, 2000, ARCH BIOCHEM BIOPHYS, V373, P418, DOI 10.1006/abbi.1999.1560; Sloop KW, 2004, J CLIN INVEST, V113, P1571, DOI 10.1172/JCI200420911; Soler M, 2004, ANTIVIR THER, V9, P953; Staehr P, 2002, DIABETES OBES METAB, V4, P215, DOI 10.1046/j.1463-1326.2002.00177.x; van Dijk TH, 2001, J BIOL CHEM, V276, P25727, DOI 10.1074/jbc.M101223200; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; WADDELL ID, 1990, BIOCHEM J, V267, P549, DOI 10.1042/bj2670549; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; Yiu WH, 2007, GENE THER, V14, P219, DOI 10.1038/sj.gt.3302869; Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475; Zingone A, 2000, J BIOL CHEM, V275, P828, DOI 10.1074/jbc.275.2.828; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	57	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19113	19121		10.1074/jbc.M610759200	http://dx.doi.org/10.1074/jbc.M610759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17478431	hybrid			2022-12-25	WOS:000247475300053
J	Xia, Y; Yu, PB; Sidis, Y; Beppu, H; Bloch, KD; Schneyer, AL; Lin, HY				Xia, Yin; Yu, Paul B.; Sidis, Yisrael; Beppu, Hideyuki; Bloch, Kenneth D.; Schneyer, Alan L.; Lin, Herbert Y.			Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA; IDENTIFICATION; MEMBRANE; INHIBIN; DRAGON; ANTAGONIST; EXPRESSION; PATHWAYS; ELEMENTS; ACTIVIN	Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta superfamily of multifunctional ligands that transduce their signals through type I and II serine/ threonine kinase receptors and intracellular Smad proteins. Recently, we identified the glycosylphosphatidylinositol-anchored repulsive guidance molecules RGMa, DRAGON (RGMb), and hemojuvelin (RGMc) as coreceptors for BMP signaling (Babbit, J. L., Huang, F. W., Wrighting, D. W., Xia, Y., Sidis, Y., Samad, T. A., Campagna, J. A., Chung, R., Schneyer, A., Woolf, C. J., Andrews, N. C., and Lin, H. Y. (2006) Nat. Genet. 38, 531-539; Babbit, J. L., Zhang, Y., Samad, T. A., Xia, Y., Tang, J., Schneyer, A., Woolf, C. J., and Lin, H. Y. (2005) J. Biol. Chem. 280, 29820-29827; Samad, T. A., Rebbapragada, A., Bell, E., Zhang, Y., Sidis, Y., Jeong, S. J., Campagna, J. A., Perusini, S., Fabrizio, D. A., Schneyer, A. L., Lin, H. Y., Brivanlou, A. H., Attisano, L., and Woolf, C. J. (2005) J. Biol. Chem. 280, 14122-14129). However, the mechanism by which RGM family members enhance BMP signaling remains unknown. Here, we report that RGMa bound to radiolabeled BMP2 and BMP4 with K-d values of 2.4 +/- 0.2 and 1.4 +/- 0.1 nM, respectively. In KGN human ovarian granulosa cells and mouse pulmonary artery smooth muscle cells, BMP2 and BMP4 signaling required BMP receptor type II (BMPRII), but not activin receptor type IIA (ActRIIA) or ActRIIB, based on changes in BMP signaling by small interfering RNA inhibition of receptor expression. In contrast, cells transfected with RGMa utilized both BMPRII and ActRIIA for BMP2 or BMP4 signaling. Furthermore, in BmpRII-null pulmonary artery smooth muscle cells, BMP2 and BMP4 signaling was reduced by inhibition of endogenous RGMa expression, and RGMa-mediated BMP signaling required ActRIIA expression. These findings suggest that RGMa facilitates the use of ActRIIA by endogenous BMP2 and BMP4 ligands that otherwise prefer signaling via BMPRII and that increased utilization of ActRIIA leads to generation of an enhanced BMP signal.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Div Nephrol,Program Membrane Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Reprod Endocrine Unit,Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Lin, HY (corresponding author), Richard B Simches Res Ctr, Program Membrane Biol, 185 Cambridge St,CPZN 8216, Boston, MA 02114 USA.	hlin@partners.org	Yu, Paul B./J-7540-2019; Xia, Yin/M-5440-2018	Yu, Paul B./0000-0003-2145-4944; Xia, Yin/0000-0003-0315-7532	NHLBI NIH HHS [K08 HL079943-01A1, K08 HL079943, HL74352] Funding Source: Medline; NIDDK NIH HHS [DK069533, DK076143, DK076158, DK071837] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074352, K08HL079943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069533, R01DK071837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aspenberg P, 2001, J BONE MINER RES, V16, P497, DOI 10.1359/jbmr.2001.16.3.497; Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Babitt JL, 2005, J BIOL CHEM, V280, P29820, DOI 10.1074/jbc.M503511200; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Lin JM, 2005, NAT MED, V11, P387, DOI 10.1038/nm1217; LIU F, 1995, MOL CELL BIOL, V15, P3479; Martinez AR, 2004, HAEMATOLOGICA, V89, P1441; Massague J, 2000, GENE DEV, V14, P627; Mazerbourg S, 2005, J BIOL CHEM, V280, P32122, DOI 10.1074/jbc.M504629200; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Samad TA, 2005, J BIOL CHEM, V280, P14122, DOI 10.1074/jbc.M410034200; Samad TA, 2004, J NEUROSCI, V24, P2027, DOI 10.1523/JNEUROSCI.4115-03.2004; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Szabo A, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r59; Welt CK, 1997, J CLIN ENDOCR METAB, V82, P3720, DOI 10.1210/jc.82.11.3720; Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200; Xia Y, 2005, ENDOCRINOLOGY, V146, P3614, DOI 10.1210/en.2004-1676; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Yu PB, 2005, J BIOL CHEM, V280, P24443, DOI 10.1074/jbc.M502825200	33	88	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18129	18140		10.1074/jbc.M701679200	http://dx.doi.org/10.1074/jbc.M701679200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17472960	hybrid			2022-12-25	WOS:000247302000019
J	del Rio, G; Kane, DJ; Ball, KD; Bredesen, DE				del Rio, Gabriel; Kane, Darci J.; Ball, Keith D.; Bredesen, Dale E.			A Novel Motif Identified in Dependence Receptors	PLOS ONE			English	Article								Programmed cell death signaling is a critical feature of development, cellular turnover, oncogenesis, and neurodegeneration, among other processes. Such signaling may be transduced via specific receptors, either following ligand binding-to death receptors-or following the withdrawal of trophic ligands-from dependence receptors. Although dependence receptors display functional similarities, no common structural domains have been identified. Therefore, we employed the Multiple Expectation Maximization for Motif Elicitation and the Motif Alignment and Search Tool software programs to identify a novel transmembrane motif, dubbed dependence-associated receptor transmembrane (DART) motif, that is common to all described dependence receptors. Of 3,465 human transmembrane proteins, 25 (0.7%) display the DART motif. The predicted secondary structure features an alpha helical structure, with an unusually high percentage of valine residues. At least four of the proteins undergo regulated intramembrane proteolysis. To date, we have not identified a function for this putative domain. We speculate that the DART motif may be involved in protein processing, interaction with other proteins or lipids, or homomultimerization.	[del Rio, Gabriel; Kane, Darci J.; Ball, Keith D.; Bredesen, Dale E.] Buck Inst Age Res, Novato, CA USA; [Bredesen, Dale E.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	Buck Institute for Research on Aging; University of California System; University of California San Francisco	Bredesen, DE (corresponding author), Buck Inst Age Res, Novato, CA USA.	dbredesen@buckinstitute.org			American Bioscience, Inc.; NIH [NS45093, AG12282, NS33376]; CoNaCyT [SEP-2004-C01-47399/A-1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033376, R01NS045093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	American Bioscience, Inc.; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CoNaCyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by a grant to the Buck Institute from American Bioscience, Inc., by NIH grants NS45093, AG12282 and NS33376 to DEB and by CoNaCyT grant SEP-2004-C01-47399/A-1 to GDR.	Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; Bredesen DE, 2004, PHYSIOL REV, V84, P411, DOI 10.1152/physrev.00027.2003; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Caceres J, 1997, J CELL BIOCHEM, V65, P145, DOI 10.1002/(SICI)1097-4644(199705)65:2<145::AID-JCB2>3.0.CO;2-U; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Mehlen P, 2004, APOPTOSIS, V9, P37, DOI 10.1023/B:APPT.0000012120.66221.b2; MEHLEN P, 2003, SCI STKE, pPE55; Williamson TG, 1996, J BIOL CHEM, V271, P31215, DOI 10.1074/jbc.271.49.31215	16	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e463	10.1371/journal.pone.0000463	http://dx.doi.org/10.1371/journal.pone.0000463			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520022	Green Published, gold, Green Submitted			2022-12-25	WOS:000207446000011
J	Hurowitz, EH; Drori, I; Stodden, VC; Donoho, DL; Brown, PO				Hurowitz, Evan H.; Drori, Iddo; Stodden, Victoria C.; Donoho, David L.; Brown, Patrick O.			Virtual Northern Analysis of the Human Genome	PLOS ONE			English	Article							RNA; DATABASE	Background. We applied the Virtual Northern technique to human brain mRNA to systematically measure human mRNA transcript lengths on a genome-wide scale. Methodology/Principal Findings. We used separation by gel electrophoresis followed by hybridization to cDNA microarrays to measure 8,774 mRNA transcript lengths representing at least 6,238 genes at high (>90%) confidence. By comparing these transcript lengths to the Refseq and H-Invitational full-length cDNA databases, we found that nearly half of our measurements appeared to represent novel transcript variants. Comparison of length measurements determined by hybridization to different cDNAs derived from the same gene identified clones that potentially correspond to alternative transcript variants. We observed a close linear relationship between ORF and mRNA lengths in human mRNAs, identical in form to the relationship we had previously identified in yeast. Some functional classes of protein are encoded by mRNAs whose untranslated regions (UTRs) tend to be longer or shorter than average; these functional classes were similar in both human and yeast. Conclusions/Significance. Human transcript diversity is extensive and largely unannotated. Our length dataset can be used as a new criterion for judging the completeness of cDNAs and annotating mRNA sequences. Similar relationships between the lengths of the UTRs in human and yeast mRNAs and the functions of the proteins they encode suggest that UTR sequences serve an important regulatory role among eukaryotes.	[Hurowitz, Evan H.; Brown, Patrick O.] Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; [Drori, Iddo; Stodden, Victoria C.; Donoho, David L.] Stanford Univ, Dept Stat, Stanford, CA 94305 USA; [Brown, Patrick O.] Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Brown, PO (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.	pbrown@cmgm.stanford.edu			NIH [CA77097]; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant CA77097 and by the Howard Hughes Medical Institute. P.O.B. is an investigator of the Howard Hughes Medical Institute. Neither the NIH nor HHMI participated in the design and conduct of the study or the manuscript.	Chen SSB, 1998, SIAM J SCI COMPUT, V20, P33, DOI 10.1137/S1064827596304010; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Donoho D.L, 2004, COMM PURE APPL MATH; Donoho DL, 2005, P NATL ACAD SCI USA, V102, P9446, DOI 10.1073/pnas.0502269102; Hurowitz EH, 2004, GENOME BIOL, V5; Imanishi T, 2004, PLOS BIOL, V2, P856, DOI 10.1371/journal.pbio.0020162; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; SAUNDERS MA, 2005, PDCO PRIMAL DUAL INT; Stamm S, 2000, DNA CELL BIOL, V19, P739, DOI 10.1089/104454900750058107; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Wheeler DL, 2004, NUCLEIC ACIDS RES, V32, pD35, DOI 10.1093/nar/gkh073; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492	23	9	9	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e460	10.1371/journal.pone.0000460	http://dx.doi.org/10.1371/journal.pone.0000460			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520019	gold, Green Published			2022-12-25	WOS:000207446000008
J	Van Ert, MN; Easterday, WR; Huynh, LY; Okinaka, RT; Hugh-Jones, ME; Ravel, J; Zanecki, SR; Pearson, T; Simonson, TS; U'Ren, JM; Kachur, SM; Leadem-Dougherty, RR; Rhoton, SD; Zinser, G; Farlow, J; Coker, PR; Smith, KL; Wang, BX; Kenefic, LJ; Fraser-Liggett, CM; Wagner, DM; Keim, P				Van Ert, Matthew N.; Easterday, W. Ryan; Huynh, Lynn Y.; Okinaka, Richard T.; Hugh-Jones, Martin E.; Ravel, Jacques; Zanecki, Shaylan R.; Pearson, Talima; Simonson, Tatum S.; U'Ren, Jana M.; Kachur, Sergey M.; Leadem-Dougherty, Rebecca R.; Rhoton, Shane D.; Zinser, Guenevier; Farlow, Jason; Coker, Pamala R.; Smith, Kimothy L.; Wang, Bingxiang; Kenefic, Leo J.; Fraser-Liggett, Claire M.; Wagner, David M.; Keim, Paul			Global Genetic Population Structure of Bacillus anthracis	PLOS ONE			English	Article								Anthrax, caused by the bacterium Bacillus anthracis, is a disease of historical and current importance that is found throughout the world. The basis of its historical transmission is anecdotal and its true global population structure has remained largely cryptic. Seven diverse B. anthracis strains were whole-genome sequenced to identify rare single nucleotide polymorphisms (SNPs), followed by phylogenetic reconstruction of these characters onto an evolutionary model. This analysis identified SNPs that define the major clonal lineages within the species. These SNPs, in concert with 15 variable number tandem repeat (VNTR) markers, were used to subtype a collection of 1,033 B. anthracis isolates from 42 countries to create an extensive genotype data set. These analyses subdivided the isolates into three previously recognized major lineages (A, B, and C), with further subdivision into 12 clonal sub-lineages or sub-groups and, finally, 221 unique MLVA15 genotypes. This rare genomic variation was used to document the evolutionary progression of B. anthracis and to establish global patterns of diversity. Isolates in the A lineage are widely dispersed globally, whereas the B and C lineages occur on more restricted spatial scales. Molecular clock models based upon genome-wide synonymous substitutions indicate there was a massive radiation of the A lineage that occurred in the mid-Holocene (3,064-6,127 ybp). On more recent temporal scales, the global population structure of B. anthracis reflects colonial-era importation of specific genotypes from the Old World into the New World, as well as the repeated industrial importation of diverse genotypes into developed countries via spore-contaminated animal products. These findings indicate humans have played an important role in the evolution of anthrax by increasing the proliferation and dispersal of this now global disease. Finally, the value of global genotypic analysis for investigating bioterrorist-mediated outbreaks of anthrax is demonstrated.	[Van Ert, Matthew N.; Easterday, W. Ryan; Huynh, Lynn Y.; Okinaka, Richard T.; Zanecki, Shaylan R.; Pearson, Talima; Simonson, Tatum S.; U'Ren, Jana M.; Kachur, Sergey M.; Leadem-Dougherty, Rebecca R.; Rhoton, Shane D.; Zinser, Guenevier; Farlow, Jason; Smith, Kimothy L.; Kenefic, Leo J.; Wagner, David M.; Keim, Paul] No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA; [Okinaka, Richard T.; Keim, Paul] Los Alamos Natl Lab, Los Alamos, NM USA; [Hugh-Jones, Martin E.; Coker, Pamala R.] Louisiana State Univ, Dept Environm Studies, Baton Rouge, LA 70803 USA; [Ravel, Jacques; Fraser-Liggett, Claire M.] Inst Genom Res, Rockville, MD USA; [Wang, Bingxiang] Lanzhou Inst Biol Prod, Lanzhou, Peoples R China; [Keim, Paul] Translat Genom Res Inst, Pathogen Genom Div, Phoenix, AZ USA	Northern Arizona University; United States Department of Energy (DOE); Los Alamos National Laboratory; Louisiana State University System; Louisiana State University; J. Craig Venter Institute; Translational Genomics Research Institute	Keim, P (corresponding author), No Arizona Univ, Dept Biol Sci, Box 5640, Flagstaff, AZ 86011 USA.	Paul.Keim@nau.edu	Pearson, Talima/O-7840-2019; Smith, Kimothy/AAI-9775-2020; U'Ren, Jana M/Y-2113-2019; Ravel, Jacques/D-2530-2009; Keim, Paul S/A-2269-2010; Wagner, David M/A-5125-2010; Easterday, W. Ryan/M-6732-2015	Pearson, Talima/0000-0003-3696-041X; U'Ren, Jana M/0000-0001-7608-5029; Easterday, W. Ryan/0000-0001-5865-7062; Ravel, Jacques/0000-0002-0851-2233; Wagner, David/0000-0003-2684-6007; Fraser, Claire/0000-0003-1462-2428	National Institutes of Health, General Medical Sciences; U.S. Departments of Energy and Homeland Security	National Institutes of Health, General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); U.S. Departments of Energy and Homeland Security	Funding for this work was provided by the National Institutes of Health, General Medical Sciences and the U.S. Departments of Energy and Homeland Security.	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; [Anonymous], 1997, GUNS GERMS STEEL; Bradley DG, 1996, P NATL ACAD SCI USA, V93, P5131, DOI 10.1073/pnas.93.10.5131; Cheung DTL, 2005, J CLIN MICROBIOL, V43, P1992, DOI 10.1128/JCM.43.4.1992-1994.2005; Diamond J, 2002, NATURE, V418, P700, DOI 10.1038/nature01019; DOIG AT, 1951, LANCET, V260, P1011; Dragon DC, 1999, J APPL MICROBIOL, V87, P208, DOI 10.1046/j.1365-2672.1999.00872.x; Drake JW, 1999, ANN NY ACAD SCI, V870, P100, DOI 10.1111/j.1749-6632.1999.tb08870.x; Drake JW, 1998, GENETICS, V148, P1667; Easterday WR, 2005, J CLIN MICROBIOL, V43, P1995, DOI 10.1128/JCM.43.4.1995-1997.2005; Fasanella A, 2005, J CLIN MICROBIOL, V43, P3398, DOI 10.1128/JCM.43.7.3398-3401.2005; Fouet AS, 2002, J CLIN MICROBIOL, V40, P4732, DOI 10.1128/JCM.40.12.4732-4734.2002; GEERING W, 1997, ANTHRAX AUSTR; Gierczynski R, 2004, FEMS MICROBIOL LETT, V239, P235, DOI 10.1016/j.femsle.2004.08.038; GREEN DM, 1958, LANCET, V2, P153; HANSON RP, 1959, J AM VET MDE ASS, V135; Hoffmaster AR, 2002, EMERG INFECT DIS, V8, P1111, DOI 10.3201/eid0810.020394; JAMIESON WM, 1955, LANCET, V1, P560; JONES WI, 1967, J BACTERIOL, V94, P600, DOI 10.1128/JB.94.3.600-608.1967; Kassen R, 2004, NATURE, V431, P984, DOI 10.1038/nature02923; Keim P, 2000, J BACTERIOL, V182, P2928, DOI 10.1128/JB.182.10.2928-2936.2000; Keim P, 2001, J CLIN MICROBIOL, V39, P4566, DOI 10.1128/JCM.39.12.4566-4567.2001; Keim P, 2004, INFECT GENET EVOL, V4, P205, DOI 10.1016/j.meegid.2004.02.005; KEIM PS, 2007, INTRO EVOLU IN PRESS; KLEMM DORIS M., 1959, JOUR AMER VET MED ASSOC, V135, P458; KOLONIN G V, 1971, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, V48, P118; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Legge TM, 1905, LANCET, V1, P841; Lowell JL, 2005, J CLIN MICROBIOL, V43, P650, DOI 10.1128/JCM.43.2.650-656.2005; Maho A, 2006, J CLIN MICROBIOL, V44, P3422, DOI 10.1128/JCM.01269-06; Mignot T, 2001, MOL MICROBIOL, V42, P1189, DOI 10.1046/j.1365-2958.2001.02692.x; Morin PA, 1999, BIOTECHNIQUES, V27, P538, DOI 10.2144/99273rr02; Okinaka R, 2006, PLOS PATHOG, V2, P1025, DOI 10.1371/journal.ppat.0020122; Pearson T, 2004, P NATL ACAD SCI USA, V101, P13536, DOI 10.1073/pnas.0403844101; Read TD, 2002, SCIENCE, V296, P2028, DOI 10.1126/science.1071837; Slamti L, 2004, J BACTERIOL, V186, P3531, DOI 10.1128/JB.186.11.3531-3538.2004; Smith KL, 2000, J CLIN MICROBIOL, V38, P3780, DOI 10.1128/JCM.38.10.3780-3784.2000; Stephens AJ, 2006, J MED MICROBIOL, V55, P43, DOI 10.1099/jmm.0.46157-0; Van Ert MN, 2007, J CLIN MICROBIOL, V45, P47, DOI 10.1128/JCM.01233-06; VANNESS GB, 1971, SCIENCE, V172, P1303, DOI 10.1126/science.172.3990.1303; Vogler AJ, 2002, ANTIMICROB AGENTS CH, V46, P511, DOI 10.1128/AAC.46.2.511-513.2002; Worobey M, 2005, HEREDITY, V94, P459, DOI 10.1038/sj.hdy.6800636; ZINSER G, 2002, EVOLUTIONARY RELATIO	43	271	283	2	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e461	10.1371/journal.pone.0000461	http://dx.doi.org/10.1371/journal.pone.0000461			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520020	Green Published, gold, Green Submitted			2022-12-25	WOS:000207446000009
J	Kim, TW; Christy, JH; Choe, JC				Kim, Tae Won; Christy, John H.; Choe, Jae C.			A Preference for a Sexual Signal Keeps Females Safe	PLOS ONE			English	Article							MALE FIDDLER-CRABS; SENSORY TRAP HYPOTHESIS; PREDATION RISK; MATE CHOICE; MATING-BEHAVIOR; SELECTION; BENEFITS; ATTRACTIVENESS; COURTSHIP; COSTS	Predation is generally thought to constrain sexual selection by female choice and limit the evolution of conspicuous sexual signals. Under high predation risk, females usually become less choosy, because they reduce their exposure to their predators by reducing the extent of their mate searching. However, predation need not weaken sexual selection if, under high predation risk, females exhibit stronger preferences for males that use conspicuous signals that help females avoid their predators. We tested this prediction in the fiddler crab Uca terpsichores by increasing females' perceived predation risk from crab-eating birds and measuring the attractiveness of a courtship signal that females use to find mates. The sexual signal is an arching mound of sand that males build at the openings of their burrows to which they attract females for mating. We found that the greater the risk, the more attractive were males with those structures. The benefits of mate preferences for sexual signals are usually thought to be linked to males' reproductive contributions to females or their young. Our study provides the first evidence that a female preference for a sexual signal can yield direct survival benefits by keeping females safe as they search for mates.	[Choe, Jae C.] Ewha Womans Univ, Grad Program EcoSci, Seoul, South Korea; [Kim, Tae Won] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea; [Christy, John H.] Smithsonian Trop Res Inst, Naos Lab, Balboa, Ancon, Panama	Ewha Womans University; Seoul National University (SNU); Smithsonian Institution; Smithsonian Tropical Research Institute	Choe, JC (corresponding author), Ewha Womans Univ, Grad Program EcoSci, Seoul, South Korea.	jaechoe@ewha.ac.kr			Korean Government (MOEHRD) [KRF-2005-213-D00043]; Ewha Womans University	Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government); Ewha Womans University	This research was supported by a Korean Research Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2005-213-D00043). Jae C. Choe was funded by the Ewha Womans University Research Grant of 2006. The Smithsonian Tropical Research Institute provided space and logistical support.	ALATALO RV, 1990, ANIM BEHAV, V39, P601, DOI 10.1016/S0003-3472(05)80430-0; BREDEN F, 1987, NATURE, V329, P831, DOI 10.1038/329831a0; Choe J.C., 1997, EVOLUTION MATING SYS; Christy JH, 2003, ANIM BEHAV, V66, P89, DOI 10.1006/anbe.2003.2196; CHRISTY JH, 1995, AM NAT, V146, P171, DOI 10.1086/285793; Christy JH, 2003, BEHAV ECOL SOCIOBIOL, V53, P84, DOI 10.1007/s00265-002-0553-4; Christy JH, 2002, BEHAV ECOL, V13, P366, DOI 10.1093/beheco/13.3.366; Cotton S, 2006, CURR BIOL, V16, pR755, DOI 10.1016/j.cub.2006.08.022; Crane J., 1975, FIDDLER CRABS WORLD, V1st, DOI [10.1515/9781400867936, DOI 10.1515/9781400867936]; CROWLEY PH, 1991, AM NAT, V137, P567, DOI 10.1086/285184; Derivera CE, 2005, ANIM BEHAV, V70, P289, DOI 10.1016/j.anbehav.2004.10.027; FORSGREN E, 1992, AM NAT, V140, P1041, DOI 10.1086/285455; Godin JGJ, 1996, ANIM BEHAV, V51, P117, DOI 10.1006/anbe.1996.0010; Head ML, 2005, PLOS BIOL, V3, P289, DOI 10.1371/journal.pbio.0030033; HUBBELL SP, 1987, AM NAT, V130, P91, DOI 10.1086/284700; Jennions MD, 2000, BIOL REV, V75, P21, DOI 10.1017/S0006323199005423; Johnson JB, 2003, BEHAV ECOL, V14, P619, DOI 10.1093/beheco/arg046; Koga T, 1998, P ROY SOC B-BIOL SCI, V265, P1385, DOI 10.1098/rspb.1998.0446; Moller AP, 2001, NATURWISSENSCHAFTEN, V88, P401, DOI 10.1007/s001140100255; POMIANKOWSKI A, 1987, J THEOR BIOL, V128, P195, DOI 10.1016/S0022-5193(87)80169-8; SIH A, 1990, AM NAT, V135, P284, DOI 10.1086/285044; Warner RR, 2000, BEHAV ECOL, V11, P444, DOI 10.1093/beheco/11.4.444; Zeil J, 2002, CRUSTACEAN EXPERIMENTAL SYSTEMS IN NEUROBIOLOGY, P227; Zeil J, 1998, J COMP PHYSIOL A, V183, P367, DOI 10.1007/s003590050263	24	37	37	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e422	10.1371/journal.pone.0000422	http://dx.doi.org/10.1371/journal.pone.0000422			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487270	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445800004
J	Calhim, S; Immler, S; Birkhead, TR				Calhim, Sara; Immler, Simone; Birkhead, Tim R.			Postcopulatory Sexual Selection Is Associated with Reduced Variation in Sperm Morphology	PLOS ONE			English	Article							EXTRA-PAIR PATERNITY; RELATIVE TESTIS SIZE; COMPETITION GAMES; MAMMALIAN SPERM; MATING SYSTEMS; NO EVIDENCE; EVOLUTION; COEVOLUTION; MIDPIECE; LENGTH	Background. The evolutionary role of postcopulatory sexual selection in shaping male reproductive traits, including sperm morphology, is well documented in several taxa. However, previous studies have focused almost exclusively on the influence of sperm competition on variation among species. In this study we tested the hypothesis that intraspecific variation in sperm morphology is driven by the level of postcopulatory sexual selection in passerine birds. Methodology/Findings. Using two proxy measures of sperm competition level, (i) relative testes size and (ii) extrapair paternity level, we found strong evidence that intermale variation in sperm morphology is negatively associated with the degree of postcopulatory sexual selection, independently of phylogeny. Conclusions/Significance. Our results show that the role of postcopulatory sexual selection in the evolution of sperm morphology extends to an intraspecific level, reducing the variation towards what might be a species-specific 'optimum' sperm phenotype. This finding suggests that while postcopulatory selection is generally directional (e.g., favouring longer sperm) across avian species, it also acts as a stabilising evolutionary force within species under intense selection, resulting in reduced variation in sperm morphology traits. We discuss some potential evolutionary mechanisms for this pattern.	[Calhim, Sara; Immler, Simone; Birkhead, Tim R.] Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Calhim, S (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.	s.calhim@sheffield.ac.uk	Calhim, Sara/D-5335-2009; Immler, Simone/A-1707-2014; Immler, Simone/F-8708-2014		FCT Portugal; Roche Research Foundation; Leverhulme Trust	FCT Portugal(Portuguese Foundation for Science and TechnologyEuropean Commission); Roche Research Foundation; Leverhulme Trust(Leverhulme Trust)	This study was funded by FCT Portugal (SC), Roche Research Foundation (SI), and the Leverhulme Trust (TRB).	ALATALO RV, 1988, BIOL J LINN SOC, V34, P363, DOI 10.1111/j.1095-8312.1988.tb01969.x; Anderson MJ, 2006, J ZOOL, V270, P682, DOI 10.1111/j.1469-7998.2006.00173.x; Anderson MJ, 2005, J ZOOL, V267, P135, DOI 10.1017/S0952836905007284; Anderson MJ, 2002, NATURE, V416, P496, DOI 10.1038/416496a; Andersson Malte, 1994; [Anonymous], [No title captured]; Bakst M. R., 1994, Poultry Science Reviews, V5, P117; Balshine S, 2001, BEHAV ECOL, V12, P726, DOI 10.1093/beheco/12.6.726; Beatty R. A., 1972, The genetics of the spermatozoon. Proceedings, International Symposium, Edinburgh, 16-20 August, 1971., P97; BEATTY RA, 1970, BIOL REV, V45, P73, DOI 10.1111/j.1469-185X.1970.tb01076.x; Birkhead TR, 2006, AUK, V123, P383, DOI 10.1642/0004-8038(2006)123[383:USMITE]2.0.CO;2; BIRKHEAD TR, 1990, BEHAV ECOL SOCIOBIOL, V27, P315, DOI 10.1007/BF00164002; Birkhead TR, 2005, NATURE, V434, P383, DOI 10.1038/nature03374; Birkhead TR, 2002, NAT REV GENET, V3, P262, DOI 10.1038/nrg774; Birkhead TR, 1992, SPERM COMPETITION BI; BIRKHEAD TR, 2006, SPERMATOLOGY S, V65; Birkhead TR, 1998, SPERM COMPETITION SE; BIRKHEAD TR, 2007, TRENDS ECOL IN PRESS; Breed WG, 2000, J MAMMAL, V81, P758, DOI 10.1644/1545-1542(2000)081&lt;0758:BMTMAS&gt;2.3.CO;2; Briskie JV, 1997, EVOLUTION, V51, P937, DOI 10.1111/j.1558-5646.1997.tb03674.x; BRISKIE JV, 1992, P ROY SOC B-BIOL SCI, V247, P89, DOI 10.1098/rspb.1992.0013; BRISKIE JV, 1993, CONDOR, V95, P442, DOI 10.2307/1369366; Byrne PG, 2003, P ROY SOC B-BIOL SCI, V270, P2079, DOI 10.1098/rspb.2003.2433; Calhim S, 2007, BEHAV ECOL, V18, P271, DOI 10.1093/beheco/arl076; CARDULLO RA, 1991, CELL MOTIL CYTOSKEL, V19, P180, DOI 10.1002/cm.970190306; CARTAR RV, 1985, NATURWISSENSCHAFTEN, V72, P157, DOI 10.1007/BF00490407; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; COHEN J, 1977, REPRODUCTION; Double M, 2000, P ROY SOC B-BIOL SCI, V267, P465, DOI 10.1098/rspb.2000.1023; Dunn PO, 2001, EVOLUTION, V55, P161; DYBAS LK, 1981, EVOLUTION, V35, P168, DOI 10.1111/j.1558-5646.1981.tb04869.x; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Freckleton RP, 2002, AM NAT, V160, P712, DOI 10.1086/343873; Froman DP, 2005, BIOL REPROD, V72, P562, DOI 10.1095/biolreprod.104.035113; GAGE MJG, 1994, P ROY SOC B-BIOL SCI, V258, P247, DOI 10.1098/rspb.1994.0169; Gage MJG, 2003, P ROY SOC B-BIOL SCI, V270, P625, DOI 10.1098/rspb.2002.2258; Garamszegi LZ, 2005, HORM BEHAV, V47, P389, DOI 10.1016/j.yhbeh.2004.11.008; GOMENDIO M, 1993, P ROY SOC B-BIOL SCI, V252, P7, DOI 10.1098/rspb.1993.0039; Griffith SC, 2002, MOL ECOL, V11, P2195, DOI 10.1046/j.1365-294X.2002.01613.x; HARCOURT AH, 1991, EVOLUTION, V45, P314, DOI [10.2307/2409666, 10.1111/j.1558-5646.1991.tb04406.x]; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hosken DJ, 2001, ECOL LETT, V4, P10, DOI 10.1046/j.1461-0248.2001.00198.x; HUNTER FM, 1992, ANIM BEHAV, V44, P149, DOI 10.1016/S0003-3472(05)80764-X; Immler S, 2005, IBIS, V147, P827, DOI 10.1111/j.1474-919x.2005.00456.x; Immler S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000170; Immler S, 2007, P ROY SOC B-BIOL SCI, V274, P561, DOI 10.1098/rspb.2006.3752; Katz D.F., 1990, P125; LaMunyon CW, 1999, P ROY SOC B-BIOL SCI, V266, P263, DOI 10.1098/rspb.1999.0631; LESSELLS CM, 1987, AUK, V104, P116, DOI 10.2307/4087240; Malo AF, 2006, BIOL LETTERS, V2, P246, DOI 10.1098/rsbl.2006.0449; Miller GT, 2002, SCIENCE, V298, P1230, DOI 10.1126/science.1076968; Minder AM, 2005, J EVOLUTION BIOL, V18, P60, DOI 10.1111/j.1420-9101.2004.00799.x; MOLLER AP, 1991, AM NAT, V137, P882, DOI 10.1086/285199; MOLLER AP, 1995, BEHAV ECOL SOCIOBIOL, V36, P357, DOI 10.1007/BF00167797; Morrow EH, 2001, HEREDITY, V87, P356, DOI 10.1046/j.1365-2540.2001.00921.x; Morrow EH, 2000, P ROY SOC B-BIOL SCI, V267, P307, DOI 10.1098/rspb.2000.1001; Morrow EH, 2003, ECOL LETT, V6, P228, DOI 10.1046/j.1461-0248.2003.00418.x; Morrow EH, 2001, J ZOOL, V254, P147, DOI 10.1017/S0952836901000656; PARKER GA, 1982, J THEOR BIOL, V96, P281, DOI 10.1016/0022-5193(82)90225-9; PARKER GA, 1993, P ROY SOC B-BIOL SCI, V253, P245, DOI 10.1098/rspb.1993.0110; PARKER GA, 1993, P ROY SOC B-BIOL SCI, V253, P255, DOI 10.1098/rspb.1993.0111; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; PESGRAVES DC, 1999, P ROY SOC LOND B BIO, V266, P1041; Pitcher TE, 2005, J EVOLUTION BIOL, V18, P557, DOI 10.1111/j.1420-9101.2004.00874.x; Pitnick S, 2001, P ROY SOC B-BIOL SCI, V268, P1071, DOI 10.1098/rspb.2001.1621; R Development Core Team, 2006, R LANG ENV STAT COMP; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Rowe L, 1996, P ROY SOC B-BIOL SCI, V263, P1415, DOI 10.1098/rspb.1996.0207; Simmons L. W., 2001, MG BEH ECOL; Snook RR, 2005, TRENDS ECOL EVOL, V20, P46, DOI 10.1016/j.tree.2004.10.011; Stockley P, 1997, AM NAT, V149, P933, DOI 10.1086/286031; STUTCHBURY BJ, 1995, BEHAVIOUR, V132, P675, DOI 10.1163/156853995X00081; SUTTLE JM, 1988, J EXP ZOOL, V247, P166, DOI 10.1002/jez.1402470208; VANVALEN L, 2005, VARIATION; Ward PI, 1998, HEREDITY, V80, P655, DOI 10.1046/j.1365-2540.1998.00401.x	76	130	131	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e413	10.1371/journal.pone.0000413	http://dx.doi.org/10.1371/journal.pone.0000413			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476335	Green Accepted, Green Published, Green Submitted, gold			2022-12-25	WOS:000207445700015
J	Yoda, M; Eguchi, K; Terada, TP; Sasai, M				Yoda, Mitsumasa; Eguchi, Kohei; Terada, Tomoki P.; Sasai, Masaki			Monomer-Shuffling and Allosteric Transition in KaiC Circadian Oscillation	PLOS ONE			English	Article							CLOCK PROTEIN KAIB; PHOSPHORYLATION CYCLE; CRYSTAL-STRUCTURE; RHYTHMS; EXPRESSION; BINDING; SYSTEM; MODEL; SASA	Circadian rhythms in living organisms have long been attributed solely to a transcription-translation loop comprising a negative or positive feedback. The rhythms in cyanobacteria are known to be modulated by kaiC, kaiA and kaiB genes. It was recently shown, however, that their product proteins KaiC, KaiA and KaiB are sufficient to reconstitute the circadian rhythm in the phosphorylation level of KaiC in vitro. It has since been unclear why such an oscillatory behavior can occur in the absence of the apparent transcription-translation feedback. In the meantime, it has been reported that the monomer exchange between KaiC hexamers occurs in a phosphorylation-dependent manner, which suggests that the monomer shuffling is also involved in the circadian rhythm (H. Kageyama et al., Mol. Cell, 23, 161 (2006)). To further clarify the role of the monomer shuffling, we have performed a computational modeling of interactions among Kai proteins assuming the allosteric transition of KaiC hexamer as well as the monomer shuffling. The results show that the existence of both monomer shuffling and allosteric transition can synchronize the phosphorylation level of the KaiC hexamers, and stabilizes its oscillation.	[Yoda, Mitsumasa; Eguchi, Kohei; Terada, Tomoki P.; Sasai, Masaki] Nagoya Univ, Dept Computat Sci & Engn, Nagoya, Aichi 4648601, Japan; [Sasai, Masaki] CREST Japan Sci & Technol Agcy, Nagoya, Aichi, Japan	Nagoya University; Japan Science & Technology Agency (JST)	Sasai, M (corresponding author), Nagoya Univ, Dept Computat Sci & Engn, Nagoya, Aichi 4648601, Japan.	sasai@cse.nagoya-u.ac.jp	Terada, Tomoki P./I-6671-2014	Terada, Tomoki P./0000-0001-8231-9274	Ministry of Education, Culture, Sports, Science, and Technology, Japan; Japan Society for Promotion of Science	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, and from Japan Society for Promotion of Science and by grants for the 21st century COE program for Frontiers of Computational Science.	Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633; Emberly E, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.038303; Garces RG, 2004, EMBO J, V23, P1688, DOI 10.1038/sj.emboj.7600190; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Hitomi K, 2005, J BIOL CHEM, V280, P19127, DOI 10.1074/jbc.M411284200; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; Iwase R, 2005, J BIOL CHEM, V280, P43141, DOI 10.1074/jbc.M503360200; Kageyama H, 2003, J BIOL CHEM, V278, P2388, DOI 10.1074/jbc.M208899200; Kageyama H, 2006, MOL CELL, V23, P161, DOI 10.1016/j.molcel.2006.05.039; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Kurosawa G, 2006, BIOPHYS J, V91, P2015, DOI 10.1529/biophysj.105.076554; Mehra A, 2006, PLOS COMPUT BIOL, V2, P816, DOI 10.1371/journal.pcbi.0020096; Miyoshi F, 2007, J BIOL RHYTHM, V22, P69, DOI 10.1177/0748730406295749; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mori T, 2002, P NATL ACAD SCI USA, V99, P17203, DOI 10.1073/pnas.262578499; Naef F, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100002; Nakahira Y, 2004, P NATL ACAD SCI USA, V101, P881, DOI 10.1073/pnas.0307411100; Nakajima M, 2005, SCIENCE, V308, P414, DOI 10.1126/science.1108451; Nishiwaki T, 2004, P NATL ACAD SCI USA, V101, P13927, DOI 10.1073/pnas.0403906101; Nishiwaki T, 2000, P NATL ACAD SCI USA, V97, P495, DOI 10.1073/pnas.97.1.495; Pattanayek R, 2006, EMBO J, V25, P2017, DOI 10.1038/sj.emboj.7601086; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; Takai N, 2006, P NATL ACAD SCI USA, V103, P12109, DOI 10.1073/pnas.0602955103; Takigawa-Imamura H, 2006, J BIOL RHYTHM, V21, P405, DOI 10.1177/0748730406291329; Uzumaki T, 2004, NAT STRUCT MOL BIOL, V11, P623, DOI 10.1038/nsmb781; Xu Y, 2004, P NATL ACAD SCI USA, V101, P13933, DOI 10.1073/pnas.0404768101; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168; Ye S, 2004, J BIOL CHEM, V279, P20511, DOI 10.1074/jbc.M400077200; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	34	39	42	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e408	10.1371/journal.pone.0000408	http://dx.doi.org/10.1371/journal.pone.0000408			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476330	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445700010
J	Pollock, PM; Gartside, MG; Dejeza, LC; Powell, MA; Mallon, MA; Davies, H; Mohammadi, M; Futreal, PA; Stratton, MR; Trent, JM; Goodfellow, PJ				Pollock, P. M.; Gartside, M. G.; Dejeza, L. C.; Powell, M. A.; Mallon, M. A.; Davies, H.; Mohammadi, M.; Futreal, P. A.; Stratton, M. R.; Trent, J. M.; Goodfellow, P. J.			Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes	ONCOGENE			English	Article						endometrial cancer; mutation; FGFR2; apert; syndrome	FIBROBLAST-GROWTH-FACTOR; FACTOR RECEPTOR-3; STRUCTURAL BASIS; SPLICE SITES; EXPRESSION; CANCER; SPECIFICITY	Endometrial carcinoma is the most common gynecological malignancy in the United States. Although most women present with early disease confined to the uterus, the majority of persistent or recurrent tumors are refractory to current chemotherapies. We have identified a total of 11 different FGFR2 mutations in 3/10 ( 30%) of endometrial cell lines and 19/187 ( 10%) of primary uterine tumors. Mutations were seen primarily in tumors of the endometrioid histologic subtype ( 18/115 cases investigated, 16%). The majority of the somatic mutations identified were identical to germline activating mutations in FGFR2 and FGFR3 that cause Apert Syndrome, Beare-Stevenson Syndrome, hypochondroplasia, achondroplasia and SADDAN syndrome. The two most common somatic mutations identified were S252W ( in eight tumors) and N550K ( in five samples). Four novel mutations were identified, three of which are also likely to result in receptor gain-of-function. Extensive functional analyses have already been performed on many of these mutations, demonstrating they result in receptor activation through a variety of mechanisms. The discovery of activating FGFR2 mutations in endometrial carcinoma raises the possibility of employing anti-FGFR molecularly targeted therapies in patients with advanced or recurrent endometrial carcinoma.	Translat Genom Res Inst, Canc & Cell Biol Div, Phoenix, AZ 85004 USA; Translat Genom Res Inst, DNA Sequencing Ctr, Pharmaceut Genom Div, Phoenix, AZ 85004 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; NYU, Sch Med, Dept Pharmacol, New York, NY USA; Translat Genom Res Inst, Genet Basis Human Dis Div, Phoenix, AZ 85004 USA	Translational Genomics Research Institute; Translational Genomics Research Institute; Washington University (WUSTL); Washington University (WUSTL); New York University; Translational Genomics Research Institute	Pollock, PM (corresponding author), Translat Genom Res Inst, Canc & Cell Biol Div, 445 N 5th St, Phoenix, AZ 85004 USA.	ppollock@tgen.org	kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Pollock, Pamela/0000-0001-8420-1026	NATIONAL CANCER INSTITUTE [R01CA071754, P30CA091842, R01CA109544] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA109544, P30 CA091842, CA091842, R01 CA071754, R01 CA71754] Funding Source: Medline; Wellcome Trust [077012] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Burgar HR, 2002, J BIOL CHEM, V277, P4018, DOI 10.1074/jbc.M107785200; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; Cho JY, 2004, P NATL ACAD SCI USA, V101, P609, DOI 10.1073/pnas.2237184100; Chong A, 2004, GENOMICS, V84, P762, DOI 10.1016/j.ygeno.2004.05.007; GOLD LI, 1994, CANCER RES, V54, P2347; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Ibrahimi OA, 2004, HUM MOL GENET, V13, P2313, DOI 10.1093/hmg/ddh235; Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Moller B, 2001, MOL HUM REPROD, V7, P65, DOI 10.1093/molehr/7.1.65; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; Obel Jennifer C, 2006, Clin Adv Hematol Oncol, V4, P459; Ornitz DM, 2001, GENOME BIOL, V2; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; Sangha RK, 1997, LAB INVEST, V77, P389; Tsai SJ, 2002, ENDOCRINOLOGY, V143, P2715, DOI 10.1210/en.143.7.2715; van Rhijn BWG, 2001, CANCER RES, V61, P1265; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	22	229	279	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7158	7162		10.1038/sj.onc.1210529	http://dx.doi.org/10.1038/sj.onc.1210529			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17525745	Green Accepted			2022-12-25	WOS:000250715000010
J	Ticchioni, M; Essafi, M; Jeandel, PY; Davi, F; Cassuto, JP; Deckert, M; Bernard, A				Ticchioni, M.; Essafi, M.; Jeandel, P. Y.; Davi, F.; Cassuto, J. P.; Deckert, M.; Bernard, A.			Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a	ONCOGENE			English	Article						B-CLL; chemokines; survival; akt; FOXO3a	FACTOR-I; UP-REGULATION; APOPTOSIS; ACTIVATION; KINASE; INHIBITION; EXPRESSION; MIGRATION; PATHWAY; DIFFERENTIATION	B-chronic lymphocytic leukemia (B-CLL) cell is characterized by the accumulation of long-lived CD5+ B lymphocytes, whose survival in vivo is in part dependent on exogenous factors such as cytokines and/or extracellular matrix proteins. Homeostatic chemokines are critical mediators of lymphoid cell trafficking. However, how they function in cell signaling and survival remains ill-defined. In this study, we have investigated the role of the homeostatic chemokines, CXCL12, CCL21, CCL19 and CXCL13, in B-CLL cell survival. Using primary leukemic cells isolated from 26 patients, we observed that each chemokine enhances cell survival. Chemokines induced the phosphorylation of ERK1/2 and p90RSK, and of Akt and its effectors GSK3 and FOXO3a. Consistently, inhibitors against mitogen-activated protein kinase/extracellular signal-regulated kinase and phosphatidylinositol 3-kinase inhibited chemokine-induced survival. Moreover, using a constitutively active mutated form of FOXO3a or siRNAs against FOXO3a in transfection experiments performed in primary B-CLL cells, we directly demonstrated the critical role of FOXO3a in both spontaneous and chemokine-induced B-CLL cell survival. Overall, our data support the notion that homeostatic chemokines contribute to B-CLL resistance to cell death through inactivation of the transcription factor FOXO3a, which may represent a novel therapeutic target in this hematopoietic malignancy.	Univ Nice, Hop Archet, Dept Immunol, Immunol Lab, F-06202 Nice 3, France; Hop Archet, INSERM, UMR576, F-06202 Nice, France; Univ Nice, Hop Archet, Dept Med Interne, F-06202 Nice 3, France; Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Hematol, Paris, France; Univ Nice, Hop Archet, Dept Hematol, F-06202 Nice 3, France	CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur	Ticchioni, M (corresponding author), Univ Nice, Hop Archet, Dept Immunol, Immunol Lab, Route St Antoine Ginestiere, F-06202 Nice 3, France.	michel.ticchioni@unice.fr; deckert@unice.fr	Deckert, Marcel/M-4998-2016; Ticchioni, Michel/P-8095-2016; Essafi, Makram/V-8411-2019; Jeandel, Pierre-Yves/ABD-6658-2020; Deckert, Marcel/T-3566-2019	Deckert, Marcel/0000-0003-2094-559X				AUBIN J, 1995, LEUKEMIA, V9, P471; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burger JA, 2000, BLOOD, V96, P2655; Burger M, 2005, BLOOD, V106, P1824, DOI 10.1182/blood-2004-12-4918; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Charvet C, 2003, ONCOGENE, V22, P4557, DOI 10.1038/sj.onc.1206778; Colamussi ML, 2001, J LEUKOCYTE BIOL, V69, P263; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Durig J, 2002, LEUKEMIA, V16, P30, DOI 10.1038/sj.leu.2402339; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Glimm H, 2002, BLOOD, V99, P3454, DOI 10.1182/blood.V99.9.3454; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Kamiguti AS, 2003, ONCOGENE, V22, P2272, DOI 10.1038/sj.onc.1206398; Kipps TJ, 2003, CURR OPIN HEMATOL, V10, P312, DOI 10.1097/00062752-200307000-00010; Lataillade JJ, 2002, BLOOD, V99, P1117, DOI 10.1182/blood.V99.4.1117; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Leupin N, 2003, BRIT J HAEMATOL, V121, P97, DOI 10.1046/j.1365-2141.2003.04227.x; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Majka M, 2000, BLOOD, V96, P4142, DOI 10.1182/blood.V96.13.4142.h8004142_4142_4151; Mori M, 2003, J CELL PHYSIOL, V195, P290, DOI 10.1002/jcp.10245; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nishio M, 2005, BLOOD, V106, P1012, DOI 10.1182/blood-2004-03-0889; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Pepper C, 2003, BLOOD, V101, P2454, DOI 10.1182/blood-2002-07-1984; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Suzuki Y, 2001, J IMMUNOL, V167, P3064, DOI 10.4049/jimmunol.167.6.3064; Ticchioni M, 2002, BLOOD, V99, P3111, DOI 10.1182/blood.V99.9.3111; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407	35	76	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7081	7091		10.1038/sj.onc.1210519	http://dx.doi.org/10.1038/sj.onc.1210519			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496928				2022-12-25	WOS:000250715000002
J	Glauser, DA; Schlegel, W				Glauser, Dominique A.; Schlegel, Werner			Sequential actions of ERK1/2 on the AP-1 transcription factor allow temporal integration of metabolic signals in pancreatic beta cells	FASEB JOURNAL			English	Article						Langerhans islets; c-fos; protein stability; proteolysis	ACTIVATED PROTEIN-KINASE; GLUCAGON-LIKE PEPTIDE-1; C-FOS; REGULATED KINASE; GENE-EXPRESSION; GLUCOINCRETIN PEPTIDES; INSULIN-SECRETION; BINDING-PROTEIN; GLUCOSE; PHOSPHORYLATION	The AP-1 transcription factor composed of fos and jun gene products mediates transcriptional responses to hormonal and metabolic stimulations of pancreatic beta cells. Here, we investigated the mechanisms that dynamically control expression of AP-1 subunit proteins. In MIN6 cells, glucose and GLP-1 raised c-FOS protein with biphasic kinetics, an initial peak being followed by a plateau that persisted as long as stimuli were maintained. ERK1/2 activation paralleled c-FOS expression. Whereas initial induction of c-FOS protein required ERK1/2-dependent activation of c-fos transcription and de novo protein synthesis, persistent accumulation of c-FOS under sustained stimulation did not. Indeed, dependent on ERK1/2 activation, c-FOS accumulated in its hyperphosphorylated form protected from degradation through the proteasome pathway. The implication of ERK1/2 in the accumulation of c-FOS protein was confirmed in rat primary beta cells, and the functional consequences of this mechanism were demonstrated with DNA-binding and reporter assays. Altogether these findings reveal a sequential regulation of AP-1 by ERK1/2, which initially increases transcription of c-fos and, if stimulation persists, stabilizes freshly synthesized c-FOS protein to efficiently activate the transcription of AP-1-regulated genes. This ERK1/2-AP-1 module can function as a temporal integrator converting metabolic stimuli of different durations into differential transcriptional outputs.	Univ Geneva, Fdn Rech Med, CH-1211 Geneva, Switzerland	University of Geneva	Schlegel, W (corresponding author), Univ Geneva, Fdn Rech Med, Av Roseraie 64, CH-1211 Geneva, Switzerland.	werner.schlegel@medecine.unige.ch	Glauser, Dominique/B-3918-2012	Glauser, Dominique/0000-0002-3228-7304				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Acquaviva C, 2002, ANN NY ACAD SCI, V973, P426, DOI 10.1111/j.1749-6632.2002.tb04677.x; Arnette D, 2003, J BIOL CHEM, V278, P32517, DOI 10.1074/jbc.M301174200; Benes C, 1999, BIOCHEM J, V340, P219, DOI 10.1042/0264-6021:3400219; Bernal-Mizrachi E, 2001, AM J PHYSIOL-ENDOC M, V281, pE1286, DOI 10.1152/ajpendo.2001.281.6.E1286; Borge PD, 2002, DIABETES, V51, pS427, DOI 10.2337/diabetes.51.2007.S427; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; Burch PM, 2004, MOL CELL BIOL, V24, P4696, DOI 10.1128/MCB.24.11.4696-4709.2004; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Coronella-Wood J, 2004, J BIOL CHEM, V279, P33567, DOI 10.1074/jbc.M404013200; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; Fujita T, 2007, NUCLEIC ACIDS RES, V35, P1007, DOI 10.1093/nar/gkl1138; Glauser DA, 2006, NUCLEIC ACIDS RES, V34, P5175, DOI 10.1093/nar/gkl654; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hinke SA, 2004, J PHYSIOL-LONDON, V558, P369, DOI 10.1113/jphysiol.2004.064881; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Jonas JC, 2001, J BIOL CHEM, V276, P35375, DOI 10.1074/jbc.M105020200; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Lawrence MC, 2005, J BIOL CHEM, V280, P26751, DOI 10.1074/jbc.M503158200; Lilla V, 2003, ENDOCRINOLOGY, V144, P1368, DOI 10.1210/en.2002-220916; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Reffas S, 2000, BIOCHEM J, V352, P701, DOI 10.1042/0264-6021:3520701; Ryser S, 2007, J BIOL CHEM, V282, P5075, DOI 10.1074/jbc.M607847200; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Schuit F, 2002, DIABETES, V51, pS326, DOI 10.2337/diabetes.51.2007.S326; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Susini S, 2000, FASEB J, V14, P128, DOI 10.1096/fasebj.14.1.128; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; Thorens B, 1995, DIABETES METAB, V21, P311; Torres C, 2000, J CELL BIOCHEM, V80, P11; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044	44	28	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3240	3249		10.1096/fj.06-7798com	http://dx.doi.org/10.1096/fj.06-7798com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17504975				2022-12-25	WOS:000249781600024
J	Saeki, N; Kim, DH; Usui, T; Aoyagi, K; Tatsuta, T; Aoki, K; Yanagihara, K; Tamura, M; Mizushima, H; Sakamoto, H; Ogawa, K; Ohki, M; Shiroishi, T; Yoshida, T; Sasaki, H				Saeki, N.; Kim, D. H.; Usui, T.; Aoyagi, K.; Tatsuta, T.; Aoki, K.; Yanagihara, K.; Tamura, M.; Mizushima, H.; Sakamoto, H.; Ogawa, K.; Ohki, M.; Shiroishi, T.; Yoshida, T.; Sasaki, H.			GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-beta-dependent apoptotic signalling	ONCOGENE			English	Article						gastric pit cells; apoptosis; LMO1; TGF-beta; GASDERMIN	MOUSE-CHROMOSOME 11; RUNX3 KNOCKOUTS; STOMACH-CANCER; CELL-LINES; NUDE-MICE; EXPRESSION; GENE; ESTABLISHMENT; CARCINOMA; EMBRYOGENESIS	Defining apoptosis-regulatory cascades of the epithelium is important for understanding carcinogenesis, since cancer cells are considered to arise as a result of the collapse of the cascades. We previously reported that a novel gene GASDERMIN (GSDM) is expressed in the stomach but suppressed in gastric cancer cell lines. Furthermore, in this study, we demonstrated that GSDM is expressed in the mucus-secreting pit cells of the gastric epithelium and frequently silenced in primary gastric cancers. We found that GSDM has a highly apoptotic activity and its expression is regulated by a transcription factor LIM domain only 1 (LMO1) through a sequence to which Runt-related transcription factor 3 (RUNX3) binds, in a GSDM promoter region. We observed coexpression of GSDM with LMO1, RUNX3 and type II transforming growth factor-beta receptor (TGF-beta RII) in the pit cells, and found that TGF-beta upregulates the LMO1- and GSDM-expression in the gastric epithelial cell line and induces apoptosis, which was confirmed by the finding that the apoptosis induction is inhibited by suppression of each LMO1-, RUNX3- and GSDM expression, respectively. The present data suggest that TGF-beta, LMO1, possibly RUNX3, and GSDM form a regulatory pathway for directing the pit cells to apoptosis.	Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 104, Japan; Natl Inst Canc Res, Ctr Med Genom, Chuo Ku, Tokyo, Japan; Tokyo Womens Med Univ, Sch Med, Med Ctr E, Tokyo, Japan; Natl Inst Canc Res, Sect Studies Host Immune Response, Chuo Ku, Tokyo, Japan; Natl Inst Canc Res, Cent Anim Lab, Chuo Ku, Tokyo, Japan; Natl Inst Genet, Genet Strains Res Ctr, Mammalian Genet Lab, Shizuoka, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Tokyo Women's Medical University; National Cancer Center - Japan; National Cancer Center - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Sasaki, H (corresponding author), Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tukiji 5-Chome, Tokyo 104, Japan.	hksasaki@gan2.res.ncc.go.jp	Tamura, Masaru/D-1416-2017	Tamura, Masaru/0000-0002-0311-8827				Aoyagi K, 2003, BIOCHEM BIOPH RES CO, V300, P915, DOI 10.1016/S0006-291X(02)02967-4; Bae SC, 2003, EMBO REP, V4, P538, DOI 10.1038/sj.embor.embor875; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DEBOLOS C, 1995, GASTROENTEROLOGY, V109, P723, DOI 10.1016/0016-5085(95)90379-8; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; Fujihara T, 1998, CLIN EXP METASTAS, V16, P389; Fukaya M, 2006, GASTROENTEROLOGY, V131, P14, DOI 10.1053/j.gastro.2006.05.008; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; KARAM S, 1995, MICROSC RES TECHNIQ, V31, P93; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lunny DP, 2005, J INVEST DERMATOL, V124, P615, DOI 10.1111/j.0022-202X.2005.23623.x; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; Meyers S, 1996, ONCOGENE, V13, P303; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Runkel F, 2004, GENOMICS, V84, P824, DOI 10.1016/j.ygeno.2004.07.003; Saeki N, 2000, MAMM GENOME, V11, P718, DOI 10.1007/s003350010138; Sato H, 1998, MAMM GENOME, V9, P20, DOI 10.1007/s003359900673; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; Sekiguchi M., 1994, ATLAS HUMAN TUMOR CE, P287; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; YANAGIHARA K, 1992, CANCER RES, V52, P4042	26	97	105	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	45					6488	6498		10.1038/sj.onc.1210475	http://dx.doi.org/10.1038/sj.onc.1210475			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471240				2022-12-25	WOS:000249919800002
J	Wu, J; Jin, YJ; Calaf, GM; Huang, WL; Yin, Y				Wu, J.; Jin, Y. J.; Calaf, G. M.; Huang, W-L; Yin, Y.			PAC1 is a direct transcription target of E2F-1 in apoptotic signaling	ONCOGENE			English	Article						E2F-1; PAC1; MAP kinases; 4-HPR; apoptosis; chemotherapeutics	STRESS-INDUCED APOPTOSIS; MAP KINASE; OXIDATIVE STRESS; E2F-1-INDUCED APOPTOSIS; CELL-PROLIFERATION; GROWTH SUPPRESSION; NITRIC-OXIDE; IN-VIVO; PHOSPHATASE; ACTIVATION	E2F-1 controls multiple cellular activities through transcriptional regulation of its target genes. As a mediator of cell death, E2F-1 can eliminate latent neoplastic cells through apoptosis. However, the mechanism by which E2F-1 mediates cancer cell killing is largely unknown. In this paper, we report that phosphatase of activated cells 1 (PAC1) phosphatase is a direct transcription target of E2F-1 in signaling apoptosis. We show that ectopic E2F-1 increases expression of PAC1 at both transcriptional and translational levels in breast cancer cells. E2F-1 physically interacts with the promoter of PAC1, binds to its consensus sequence in the promoter and transactivates the PAC1 promoter. E2F-1 suppresses extracellular signal-regulated kinase (ERK) phosphorylation through PAC1 and causes cancer cell death by apoptosis following treatment with a chemotherapeutic agent N-4-hydroxy-phenylretinamide (4-HPR). Furthermore, ectopic PAC1 inhibits ERK phosphorylation and mediates cell killing. Moreover, endogenous E2F-1 upregulates PAC1 and suppresses ERK activity, leading to cell death in response to 4-HPR. These results reveal a crucial role of PAC1 in E2F-1-directed apoptosis. Our study demonstrates that E2F-1 mediates apoptosis through transcriptional regulation of PAC1 and subsequent suppression of the ERK signaling. Our findings establish a functional link between E2F-1 and mitogen-activated protein kinases. The E2F-1 PAC1 cascade in cancer cell killing may provide a molecular basis for cancer therapeutic intervention.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, Dept Radiat Oncol, New York, NY 10032 USA; Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou, Peoples R China	Columbia University; Sun Yat Sen University	Yin, Y (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, Dept Radiat Oncol, VC11-213,630 W 168th St, New York, NY 10032 USA.	yy151@columbia.edu	huang, wen/GXW-0661-2022		NCI NIH HHS [CA102447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bednarek A, 1999, CARCINOGENESIS, V20, P879, DOI 10.1093/carcin/20.5.879; Bell R, 2004, EJC SUPPL, V2, P1, DOI 10.1016/J.EJCSUP.2004.01.001; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Husain SS, 2001, LIFE SCI, V69, P3045, DOI 10.1016/S0024-3205(01)01411-4; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kim HJ, 2006, ONCOGENE, V25, P2785, DOI 10.1038/sj.onc.1209303; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Malone W, 2003, EXPERT OPIN INV DRUG, V12, P1829, DOI 10.1517/eoid.12.11.1829.21882; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; MOON RC, 1989, PREV MED, V18, P576, DOI 10.1016/0091-7435(89)90031-5; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; Simeone AM, 2003, ONCOGENE, V22, P6739, DOI 10.1038/sj.onc.1206786; Simeone AM, 2002, MOL CANCER THER, V1, P1009; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITMARSH AJ, 1999, SCI STKE; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yan WS, 2006, J BIOL CHEM, V281, P7856, DOI 10.1074/jbc.M512655200; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Zhang Q, 2005, J MOL BIOL, V354, P777, DOI 10.1016/j.jmb.2005.10.006; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011	37	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6526	6535		10.1038/sj.onc.1210484	http://dx.doi.org/10.1038/sj.onc.1210484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471234				2022-12-25	WOS:000249919800006
J	Wei, W; Hackmann, K; Xu, HX; Germino, G; Qian, F				Wei, Wen; Hackmann, Karl; Xu, Hangxue; Germino, Gregory; Qian, Feng			Characterization of cis-autoproteolysis of polycystin-1, the product of human polycystic kidney disease 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URCHIN SPERM RECEPTOR; KIDNEY-DISEASE; PLASMA-MEMBRANE; PROTEIN; PKD1; CLEAVAGE; DOMAIN; IDENTIFICATION; ACTIVATION; MUTATIONS	Polycystin-1 (PC1), the PKD1 gene product, plays a critical role in renal tubule diameter control and disruption of its function causes cyst formation in human autosomal dominant polycystic kidney disease. Recent evidence shows that PC1 undergoes cleavage at the juxtamembrane G protein-coupled receptor proteolytic site (GPS), a process likely to be essential for its biological activity. Here we further characterized the proteolytic cleavage of PC1 at the GPS domain. We determined the actual cleavage site to be between leucine and threonine of the tripeptide HLT3049 of human PC1. Cleavage occurs in the early intracellular secretory pathway and requires initial N-glycan attachment but not its subsequent trimming. We provide evidence that the cleavage occurs via a cis-autoproteolytic mechanism involving an ester intermediate as shown for Ntn hydrolases and EMR2.	Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA	Johns Hopkins University	Qian, F (corresponding author), 720 Rutland Ave,Ross Bldg 954, Baltimore, MD 21205 USA.	fqjhupkd@jhmi.edu		Germino, Gregory/0000-0002-3609-5588	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062199] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK062199] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Appenzeller-Herzog C, 2006, J CELL SCI, V119, P2173, DOI 10.1242/jcs.03019; Boletta A, 2001, AM J KIDNEY DIS, V38, P1421, DOI 10.1053/ajkd.2001.29282; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; Bornstein P, 1977, Methods Enzymol, V47, P132; Butscheid Y, 2006, MOL REPROD DEV, V73, P350, DOI 10.1002/mrd.20410; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Drenth JPH, 2004, GASTROENTEROLOGY, V126, P1819, DOI 10.1053/j.gastro.2004.02.023; Drenth JPH, 2003, NAT GENET, V33, P345, DOI 10.1038/ng1104; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Galindo BE, 2004, DEV GROWTH DIFFER, V46, P53; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Harris PC, 2006, CURR OPIN NEPHROL HY, V15, P456, DOI 10.1097/01.mnh.0000232888.65895.e7; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Li AR, 2003, GENOMICS, V81, P596, DOI 10.1016/S0888-7543(03)00048-X; Li AR, 2003, AM J HUM GENET, V72, P691, DOI 10.1086/368295; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Malemud CJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1696, DOI 10.2741/1915; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Qian F, 2005, J BIOL CHEM, V280, P40723, DOI 10.1074/jbc.M509650200; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Trombetta ES, 2001, BIOCHEMISTRY-US, V40, P10717, DOI 10.1021/bi010629u; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5; YU SQ, 2006, J AM SOC NEPHROL, V17, pA89; Yuasa T, 2004, GENOMICS, V84, P126, DOI 10.1016/j.ygeno.2004.02.008	48	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21729	21737		10.1074/jbc.M703218200	http://dx.doi.org/10.1074/jbc.M703218200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17525154	hybrid			2022-12-25	WOS:000248196800020
J	Jeong, HW; Li, Z; Brown, MD; Sacks, DB				Jeong, Ha-Won; Li, Zhigang; Brown, Matthew D.; Sacks, David B.			IQGAP1 binds Rap1 and modulates its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; SMALL GTPASES; IQ MOTIFS; MYOSIN-V; CDC42; CALMODULIN; PROTEIN; IDENTIFICATION; RAC1; CYTOSKELETON	IQGAP1 is a scaffolding protein involved in multiple fundamental cellular activities, including transcription, cell-cell attachment, and regulation of the cytoskeleton. To function in these pathways, IQGAP1 associates with numerous proteins such as actin, calmodulin, E-cadherin, beta-catenin, CLIP-170, and components of the mitogen-activated protein kinase pathway. Moreover, IQGAP1 binds to active Cdc42 and Rac1 but not RhoA or Ras. Here we show that IQGAP1 also binds to the small GTPase Rap1. In vitro analysis demonstrates a direct interaction between Rap1 and IQGAP1, which is augmented by activation (GTP loading) of Rap1. Cdc42 does not modulate the interaction between Rap1 and IQGAP1. In contrast, the association is eliminated by calmodulin both in the absence and presence of Ca2+. The binding of Rap1 to a point mutant IQGAP1 construct that is unable to interact with calmodulin is 2.5-fold more than to wild type IQGAP1. Consistent with these findings, Rap1 binds to the IQ region of IQGAP1. Confocal microscopy demonstrates that Rap1 and IQGAP1 co-localize at the periphery of human epithelial cells but not in the cytoplasm. The interaction has functional sequelae. Overexpression of IQGAP1 substantially reduces adhesion-mediated activation of Rap1. In addition, Rap1 activation by cAMP is attenuated in cells that overexpress IQGAP1 and enhanced in cells lacking IQGAP1. These findings reveal that the interaction of IQGAP1 with Rap1 differs in several respects from its interaction with other small GTPases. Furthermore, our data suggest that IQGAP1 may link the calmodulin and Rap1 signaling pathways.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735				Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Baldassa S, 2003, MOL BRAIN RES, V119, P111, DOI 10.1016/j.molbrainres.2003.08.020; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Brown MD, 2006, TRENDS CELL BIOL, V16, P242, DOI 10.1016/j.tcb.2006.03.002; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Houdusse A, 2006, P NATL ACAD SCI USA, V103, P19326, DOI 10.1073/pnas.0609436103; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kholmanskikh SS, 2006, NAT NEUROSCI, V9, P50, DOI 10.1038/nn1619; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 2005, J BIOL CHEM, V280, P13871, DOI 10.1074/jbc.M413482200; Li ZG, 2003, J BIOL CHEM, V278, P4347, DOI 10.1074/jbc.M208579200; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mataraza JM, 2003, BIOCHEM BIOPH RES CO, V305, P315, DOI 10.1016/S0006-291X(03)00759-9; Mateer SC, 2003, CELL MOTIL CYTOSKEL, V55, P147, DOI 10.1002/cm.10118; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ren JG, 2005, J BIOL CHEM, V280, P34548, DOI 10.1074/jbc.M507321200; Roy M, 2005, MOL CELL BIOL, V25, P7940, DOI 10.1128/MCB.25.18.7940-7952.2005; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; Sokol SY, 2001, J BIOL CHEM, V276, P48425, DOI 10.1074/jbc.M107975200; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Terrak M, 2005, P NATL ACAD SCI USA, V102, P12718, DOI 10.1073/pnas.0503899102; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Vasilescu J, 2004, PROTEOMICS, V4, P3845, DOI 10.1002/pmic.200400856; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660	47	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20752	20762		10.1074/jbc.M700487200	http://dx.doi.org/10.1074/jbc.M700487200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17517894	hybrid			2022-12-25	WOS:000247819300077
J	Levine, YC; Li, GK; Michel, T				Levine, Yehoshua C.; Li, Gordon K.; Michel, Thomas			Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells - Evidence for an AMPK -> Rac1 -> Akt -> Endothelial nitric-oxide synthase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-TALK; DIFFERENTIAL REGULATION; SIGNALING PATHWAYS; RNA INTERFERENCE; FATTY-ACID; PHOSPHORYLATION; AKT; ANGIOGENESIS; RECEPTORS; BETA	The endothelial isoform of nitric-oxide synthase (eNOS), a key determinant of vascular homeostasis, is a calcium/calmodulin-dependent phosphoprotein regulated by diverse cell surface receptors. Vascular endothelial growth factor (VEGF) and sphingosine 1-phosphate (S1P) stimulate eNOS activity through Akt/phosphoinositide 3-kinase and calcium-dependent pathways. AMP-activated protein kinase (AMPK) also activates eNOS in endothelial cells; however, the molecular mechanisms linking agonist-mediated AMPK regulation with eNOS activation remain incompletely understood. We studied the role of AMPK in VEGF- and S1P-mediated eNOS activation and found that both agonists led to a striking increase in AMPK phosphorylation in pathways involving the calcium/calmodulin-dependent protein kinase kinase beta. Treatment with tyrosine kinase inhibitors or the phosphoinositide 3-kinase inhibitor wortmannin demonstrated differential effects of VEGF versus S1P. Small interfering RNA (siRNA)-mediated knockdown of AMPK alpha 1 or Akt1 impaired the stimulatory effects of both VEGF and S1P on eNOS activation. AMPK alpha 1 knockdown impaired agonist-mediated Akt phosphorylation, whereas Akt1 knockdown did not affect AMPK activation, thus suggesting that AMPK lies upstream of Akt in the pathway leading from receptor activation to eNOS stimulation. Importantly, we found that siRNA-mediated knockdown of AMPK alpha 1 abrogates agonist-mediated activation of the small GTPase Rac1. Conversely, siRNA-mediated knockdown of Rac1 decreased the agonist-mediated phosphorylation of AMPK substrates without affecting that of AMPK, implicating Rac1 as a molecular link between AMPK and Akt in agonist-mediated eNOS activation. Finally, siRNA-mediated knockdown of caveolin-1 significantly enhanced AMPK phosphorylation, suggesting that AMPK is negatively regulated by caveolin-1. Taken together, these results suggest that VEGF and S1P differentially regulate AMPK and establish a central role for an agonist-modulated AMPK -> Rac1 -> Akt axis in the control of eNOS in endothelial cells.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Michel, T (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	tmichel@research.bwh.harvard.edu			NHLBI NIH HHS [HL 48743, HL 46457] Funding Source: Medline; NIGMS NIH HHS [GM 36259] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, P01HL048743, R29HL046457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036259, R01GM036259] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Birnbaum MJ, 2005, MOL CELL, V19, P289, DOI 10.1016/j.molcel.2005.07.012; Brandes RP, 2003, ANTIOXID REDOX SIGN, V5, P803, DOI 10.1089/152308603770380115; Brownsey RW, 2006, BIOCHEM SOC T, V34, P223, DOI 10.1042/BST0340223; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Chen JH, 2005, NAT MED, V11, P1188, DOI 10.1038/nm1307; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Dudzinski DM, 2006, ANNU REV PHARMACOL, V46, P235, DOI 10.1146/annurev.pharmtox.44.101802.121844; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gonzalez E, 2006, J BIOL CHEM, V281, P3210, DOI 10.1074/jbc.M510434200; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; GRANT DS, 1994, PATHOL RES PRACT, V190, P854; Greif DM, 2002, BIOCHEMISTRY-US, V41, P15845, DOI 10.1021/bi026732g; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Horman S, 2006, J BIOL CHEM, V281, P5335, DOI 10.1074/jbc.M506850200; HORS B, 2004, FEBS LETT, V573, P175; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100; Jozkowicz A, 2004, GROWTH FACTORS, V22, P19, DOI 10.1080/0897719041682863; Kang YJ, 2006, J BIOL CHEM, V281, P26225, DOI 10.1074/jbc.M606800200; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Kou RQ, 2005, BIOCHEMISTRY-US, V44, P15064, DOI 10.1021/bi0509898; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; Mount PF, 2005, AM J PHYSIOL-RENAL, V289, pF1103, DOI 10.1152/ajprenal.00458.2004; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Palanivel R, 2005, ENDOCRINE, V26, P71, DOI 10.1385/ENDO:26:1:071; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200; Quintero M, 2006, P NATL ACAD SCI USA, V103, P5379, DOI 10.1073/pnas.0601026103; Reihill JA, 2007, BIOCHEM BIOPH RES CO, V354, P1084, DOI 10.1016/j.bbrc.2007.01.110; Reznick RM, 2006, J PHYSIOL-LONDON, V574, P33, DOI 10.1113/jphysiol.2006.109512; Rikitake Y, 2002, ARTERIOSCL THROM VAS, V22, P108, DOI 10.1161/hq0102.101843; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Sambandam N, 2003, PROG LIPID RES, V42, P238, DOI 10.1016/S0163-7827(02)00065-6; Schulz E, 2005, CIRCULATION, V111, P3473, DOI 10.1161/CIRCULATIONAHA.105.546812; Seebach J, 2005, THROMB HAEMOSTASIS, V94, P620, DOI 10.1160/TH05-01-0015; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Soltys CLM, 2006, AM J PHYSIOL-HEART C, V290, pH2472, DOI 10.1152/ajpheart.01206.2005; Somanath PR, 2006, CELL CYCLE, V5, P512, DOI 10.4161/cc.5.5.2538; Sun W, 2006, CIRCULATION, V114, P2655, DOI 10.1161/CIRCULATIONAHA.106.630194; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tokumitsu H, 2003, J BIOL CHEM, V278, P10908, DOI 10.1074/jbc.M213183200; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhang Q, 2006, J BIOL CHEM, V281, P10174, DOI 10.1074/jbc.M513008200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	64	174	182	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20351	20364		10.1074/jbc.M702182200	http://dx.doi.org/10.1074/jbc.M702182200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17519230	hybrid			2022-12-25	WOS:000247819300038
J	Bourguignon, LYW; Gilad, E; Peyrollier, K				Bourguignon, Lilly Y. W.; Gilad, Eli; Peyrollier, Karine			Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-BINDING DOMAIN; CD44 INTERACTION; NUCLEAR TRANSLOCATION; FACTOR RECEPTOR; PROTEIN-KINASE; CYTOSKELETON FUNCTION; CYCLE PROGRESSION; HUMAN-BREAST; RHO GTPASES; PROMOTES	Heregulin (HRG)-induced cell responses are mediated by the ErbB family of tyrosine kinase receptors. In this study we have investigated HRG activation of ErbB2, extracellular signal-regulated kinase (ERK) signaling, and their role in regulating hyaluronan synthase (HAS) activity in human ovarian tumor cells (SK-OV-3.ipl cells). Immunological and biochemical analyses indicate that ErbB2, ErbB3, and ErbB4 are all expressed in SK-OV-3.ipl cells and that ErbB4 (but not ErbB3) is physically linked to ErbB2 following HRG stimulation. Furthermore, our data indicate that the HRG-induced ErbB2(.)ErbB4 complexes stimulate ErbB2 tyrosine kinase, which induces both ERK phosphorylation and kinase activity. The activated ERK then increases the phosphorylation of HAS1, HAS2, and HAS3. Consequently, all three HAS isozymes are activated resulting in hyaluronan (HA) production. Because HRG-mediated HAS isozyme phosphorylation/activation can be effectively blocked by either AG825 (an ErbB2 inhibitor) or thiazolidinedione compound (an ERK blocker), we conclude that ErbB2-ERK signaling and HAS isozyme phosphorylation/HA production are functionally coupled in SK-OV-3.ipl cells. HRG also promotes HA- and CD44-dependent oncogenic events (e. g. CD44-Cdc42 association, p21-activated kinase 1 activation, and p21-activated kinase 1-filamin complex formation) and tumor cell-specific behaviors in an ErbB2-ERK signaling-dependent manner. Finally, we have found that the down-regulation of HAS isozyme expression (by transfecting cells with HAS1/HAS2/HAS3-specific small interfering RNAs) not only inhibits HRG-mediated HAS phosphorylation/ activation and HA production but also impairs CD44-specific Cdc42-PAK1/filamin signaling, cytoskeleton activation and tumor cell behaviors. Taken together, these findings clearly indicate that HRG activation of ErbB2-ERK signaling modulates HAS phosphorylation/activation and HA production leading to CD44-mediated oncogenic events and ovarian cancer progression.	Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, Endocrine Unit 111N, 4150 Clemen St, San Francisco, CA 94121 USA.	lilly.bourguignon@ucsf.edu			NCI NIH HHS [R01 CA78633, R01 CA66163] Funding Source: Medline; NIAMS NIH HHS [P01 AR39448] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078633, R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anttila MA, 2000, CANCER RES, V60, P150; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BAUKNECHT T, 1988, GYNECOL ONCOL, V29, P147, DOI 10.1016/0090-8258(88)90209-0; BERCHUCK A, 1990, CANCER RES, V50, P4087; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bourguignon LYW, 2007, J BIOL CHEM, V282, P1265, DOI 10.1074/jbc.M604672200; Bourguignon LYW, 2006, J BIOL CHEM, V281, P14026, DOI 10.1074/jbc.M507734200; Bourguignon LYW, 2005, J BIOL CHEM, V280, P11961, DOI 10.1074/jbc.M411985200; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Campiglio M, 1999, J CELL BIOCHEM, V73, P522, DOI 10.1002/(SICI)1097-4644(19990615)73:4<522::AID-JCB10>3.0.CO;2-4; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cook AC, 2006, J BIOL CHEM, V281, P24381, DOI 10.1074/jbc.M602694200; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; FOX H, 1990, CLIN GYNAECOLOGICAL, P188; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Gilmour LMR, 2002, CLIN CANCER RES, V8, P3933; Gilmour LMR, 2001, CANCER RES, V61, P2169; Goentzel BJ, 2006, BIOCHEM J, V396, P347, DOI 10.1042/BJ20051782; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOSKINS WJ, 1993, CANCER, V71, P1534, DOI 10.1002/cncr.2820710420; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1998, TRENDS GLYCOSCI GLYC, V10, P23, DOI 10.4052/tigg.10.23; Kosaki R, 1999, CANCER RES, V59, P1141; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIAO HX, 1995, J IMMUNOL, V155, P3938; Liu NF, 2001, CANCER RES, V61, P5207; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Mullegger J, 2003, BIOL CHEM, V384, P175, DOI 10.1515/BC.2003.019; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pasonen-Seppanen S, 2003, J INVEST DERMATOL, V120, P1038, DOI 10.1046/j.1523-1747.2003.12249.x; Pegues JC, 1999, INT J ONCOL, V14, P1169; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Riese DJ, 1996, ONCOGENE, V12, P345; Rilla K, 2005, J BIOL CHEM, V280, P31890, DOI 10.1074/jbc.M504736200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Soltes L, 2006, BIOMACROMOLECULES, V7, P659, DOI 10.1021/bm050867v; Spicer AP, 1999, BIOCHEM SOC T, V27, P109, DOI 10.1042/bst0270109; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Stern R, 2006, CHEM REV, V106, P818, DOI 10.1021/cr050247k; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Sugiyama Y, 1998, J INVEST DERMATOL, V110, P116, DOI 10.1046/j.1523-1747.1998.00093.x; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; TOOLE BP, 1991, CELL BIOL EXTRACELLU, V19, P305; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Udabage L, 2005, CANCER RES, V65, P6139, DOI 10.1158/0008-5472.CAN-04-1622; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vijapurkar U, 2003, EXP CELL RES, V284, P291, DOI 10.1016/S0014-4827(02)00040-X; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 2006, J BIOL CHEM, V281, P36542, DOI 10.1074/jbc.M606529200; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yabushita H, 2004, ONCOL REP, V12, P739; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; ZHANG LR, 1995, CANCER RES, V55, P428; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	95	128	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19426	19441		10.1074/jbc.M610054200	http://dx.doi.org/10.1074/jbc.M610054200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17493932	hybrid			2022-12-25	WOS:000247650600017
J	Eoff, RL; Irimia, A; Angel, KC; Egli, M; Guengerich, P				Eoff, Robert L.; Irimia, Adriana; Angel, Karen C.; Egli, Martin; Guengerich, Peter			Hydrogen bonding of 7,8-dihydro-8-oxodeoxyguanosine with a charged residue in the little finger domain determines miscoding events in Sulfolobus solfataricus DNA polymerase Dpo4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; RAY-DIFFRACTION DATA; STEADY-STATE; CRYSTAL-STRUCTURE; NUCLEOTIDE INCORPORATION; REPLICATION FIDELITY; LESION-BYPASS; ERROR-PRONE; Y-FAMILY; ETA	Sulfolobus solfataricus P2 DNA polymerase IV (Dpo4) has been shown to catalyze bypass of 7,8-dihydro-8-oxodeoxyguanosine (8-oxoG) in a highly efficient and relatively accurate manner. Crystal structures have revealed a potential role for Arg332 in stabilizing the anti conformation of the 8-oxoG template base by means of a hydrogen bond or ion-dipole pair, which results in an increased enzymatic efficiency for dCTP insertion and makes formation of a Hoogsteen pair between 8-oxoG and dATP less favorable. Site-directed mutagenesis was used to replace Arg(332) with Ala, Glu, Leu, or His in order to probe the importance of Arg(332) in accurate and efficient bypass of 8-oxoG. The double mutant Ala(331)Ala(332) was also prepared to address the contribution of Arg(331). Transientstate kinetic results suggest that Glu(332) retains fidelity against bypass of 8-oxoG that is similar to wild type Dpo4, a result that was confirmed by tandem mass spectrometric analysis of full-length extension products. A crystal structure of the Dpo4 Glu(332) mutant and 8-oxoG: C pair revealed water-mediated hydrogen bonds between Glu(332) and the O-8 atom of 8-oxoG. The space normally occupied by Arg(332) side chain is empty in the crystal structures of the Ala(332) mutant. Twoother crystal structures show that a Hoogsteen base pair is formed between 8-oxoG andAin the active site of both Glu(332) and Ala(332) mutants. These results support the view that a bond between Arg(332) and 8-oxoG plays a role in determining the fidelity and efficiency of Dpo4-catalyzed bypass of the lesion.	Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Guengerich, P (corresponding author), Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, 23rd Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NCI NIH HHS [F32 CA119776] Funding Source: Medline; NIEHS NIH HHS [P30 ES000267, R01 ES010375, P01 ES05355] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA119776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005355, R01ES010375, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1979, SCIENCE, V204, P587, DOI 10.1126/science.373122; BOYER PD, 1960, ANNU REV BIOCHEM, V29, P15, DOI 10.1146/annurev.bi.29.070160.000311; Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlson KD, 2005, MOL CELL BIOL, V25, P2169, DOI 10.1128/MCB.25.6.2169-2176.2005; Choi JY, 2006, J BIOL CHEM, V281, P25297, DOI 10.1074/jbc.M605699200; Christian NP, 2001, J AM SOC MASS SPECTR, V12, P744, DOI 10.1016/S1044-0305(01)00228-8; DeLucia AM, 2006, J BIOL CHEM, V281, P27286, DOI 10.1074/jbc.M604393200; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; Eoff RL, 2007, J BIOL CHEM, V282, P1456, DOI 10.1074/jbc.M609661200; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; Freisinger E, 2004, EMBO J, V23, P1494, DOI 10.1038/sj.emboj.7600158; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Friedberg E. C., 2006, DNA REPAIR MUTAGENES; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Hammes-Schiffer S, 2006, ANNU REV BIOCHEM, V75, P519, DOI 10.1146/annurev.biochem.75.103004.142800; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; HOWARD AJ, 2000, CRYSTALLOGRAPHIC COM, V7; Hsu GW, 2004, NATURE, V431, P217, DOI 10.1038/nature02908; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Lowe LG, 1996, BIOCHEMISTRY-US, V35, P9840, DOI 10.1021/bi960485x; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; McElhinny SAN, 2007, J BIOL CHEM, V282, P2324, DOI 10.1074/jbc.M609591200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Rechkoblit O, 2006, PLOS BIOL, V4, P25, DOI 10.1371/journal.pbio.0040011; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Vellieux FMD, 1997, J APPL CRYSTALLOGR, V30, P396, DOI 10.1107/S0021889896012551; Wang YL, 2006, PROTEIN SCI, V15, P135, DOI 10.1110/ps.051726906; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; Yang W, 2003, CURR OPIN STRUC BIOL, V13, P23, DOI 10.1016/S0959-440X(02)00003-9; Zang H, 2006, J BIOL CHEM, V281, P2358, DOI 10.1074/jbc.M510889200; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200	44	61	61	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19831	19843		10.1074/jbc.M702290200	http://dx.doi.org/10.1074/jbc.M702290200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17468100	Green Submitted, hybrid			2022-12-25	WOS:000247650600058
J	Purushothaman, A; Fukuda, J; Mizumoto, S; ten Dam, GB; van Kuppevelt, TH; Kitagawa, H; Mikami, T; Sugahara, K				Purushothaman, Anurag; Fukuda, Junko; Mizumoto, Shuji; ten Dam, Gerdy B.; van Kuppevelt, Toin H.; Kitagawa, Hiroshi; Mikami, Tadahisa; Sugahara, Kazuyuki			Functions of chondroitin sulfate/dermatan sulfate chains in brain development - Critical roles of E and iE disaccharide units recognized by a single chain antibody GD3G7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-ASSOCIATED MOLECULE; OVERSULFATED DERMATAN SULFATE; OUTGROWTH-PROMOTING ACTIVITY; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; EMBRYONIC PIG BRAIN; NEURITE OUTGROWTH; MONOCLONAL-ANTIBODY; ZETA/RPTP-BETA	Chondroitin sulfate (CS) and dermatan sulfate (DS) have been implicated in the processes of neural development in the brain. In this study, we characterized developmentally regulated brain CS/DS chains using a single chain antibody, GD3G7, produced by the phage display technique. Evaluation of the specificity of GD3G7 toward various glycosaminoglycan preparations showed that this antibody specifically reacted with squid CS-E (rich in the GlcUA beta 1-3GalNAc(4,6-O-sulfate) disaccharide unit E), hagfish CS-H (rich in the IdoUA alpha 1-3GalNAc(4,6-Osulfate) unit iE), and shark skin DS (rich in both E and iE units). In situ hybridization for the expression of N-acetylgalactosamine-4-sulfate 6-O-sulfotransferase in the postnatal mouse brain, which is involved in the biosynthesis of CS/DS-E, showed a widespread expression of the transcript in the developing brain except at postnatal day 7, where strong expression was observed in the external granule cell layer in the cerebellum. The expression switched from the external to internal granule cell layer with development. Immunohistochemical localization of GD3G7 in the mouse brain showed that the epitope was relatively abundant in the cerebellum, hippocampus, and olfactory bulb. GD3G7 suppressed the growth of neurites in embryonic hippocampal neurons mediated by CS-E, suggesting that the epitope is embedded in the neurite outgrowth- promoting motif of CS-E. In addition, a CS-E decasaccharide fraction was found to be the critical minimal structure needed for recognition by GD3G7. Four discrete decasaccharide epitopic sequences were identified. The antibody GD3G7 has broad applications in investigations of CS/DS chains during the central nervous system's development and under various pathological conditions.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan; Hokkaido Univ, Frontier Res Ctr Post Genom Sci & Technol, Grad Sch Life Sci, Lab Proteoglycan Signaling & Therapeut,Kita Ku, Sapporo, Hokkaido 0010021, Japan; Radboud Univ Nijmegen, Med Ctr, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Kobe Pharmaceutical University; Hokkaido University; Radboud University Nijmegen	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan.	k-sugar@sci.hokudai.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020; van Kuppevelt, A.H.M.S.M./L-4463-2015; Mizumoto, Shuji/F-8313-2018	Kitagawa, Hiroshi/0000-0002-9307-7079; Mizumoto, Shuji/0000-0002-4641-1505				ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2005, J BIOL CHEM, V280, P23184, DOI 10.1074/jbc.M503036200; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deepa SS, 2007, BIOCHEMISTRY-US, V46, P2453, DOI 10.1021/bi602374m; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Engel M, 1996, J COMP NEUROL, V366, P34; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Ito Y, 2005, GLYCOBIOLOGY, V15, P593, DOI 10.1093/glycob/cwi036; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; LAFONT F, 1992, DEVELOPMENT, V114, P17; LIAW PC, 2001, J BIOL CHEM, V276, P5228; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; Mikami T, 2003, J BIOL CHEM, V278, P36115, DOI 10.1074/jbc.M306044200; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Muller S, 2003, ONCOGENE, V22, P6661, DOI 10.1038/sj.onc.1206763; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nakanishi T, 1997, J BIOCHEM-TOKYO, V121, P197; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Ohtake S, 2001, J BIOL CHEM, V276, P43894, DOI 10.1074/jbc.M104922200; Okuda T, 2000, J BIOCHEM, V128, P763, DOI 10.1093/oxfordjournals.jbchem.a022813; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Pons S, 2000, DEVELOPMENT, V127, P333; Properzi F, 2005, EUR J NEUROSCI, V21, P378, DOI 10.1111/j.1460-9568.2005.03876.x; Rhodes KE, 2004, J ANAT, V204, P33, DOI 10.1111/j.1469-7580.2004.00261.x; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SAIGO K, 1970, J NEUROCHEM, V17, P633, DOI 10.1111/j.1471-4159.1970.tb00543.x; Salinero O, 2000, J NEUROSCI RES, V60, P87, DOI 10.1002/(SICI)1097-4547(20000401)60:1<87::AID-JNR9>3.0.CO;2-C; Schwartz NB, 2004, GLYCOCONJUGATE J, V21, P329, DOI 10.1023/B:GLYC.0000046278.34016.36; Schwartz NB, 2002, GLYCOBIOLOGY, V12, p57R, DOI 10.1093/glycob/12.4.57R; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMETSERS TF, 2004, J INVEST DERMATOL, V122, P202; Sorrell JM, 1999, HISTOCHEM J, V31, P549; SORRELL JM, 1993, MATRIX, V13, P351, DOI 10.1016/S0934-8832(11)80040-5; STALLCUP WB, 1981, DEV BIOL, V83, P154, DOI 10.1016/S0012-1606(81)80018-8; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; Wang VY, 2001, NAT REV NEUROSCI, V2, P484, DOI 10.1038/35081558; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Wu AF, 1997, J NEUROSCI, V17, P4987; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	77	71	72	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19442	19452		10.1074/jbc.M700630200	http://dx.doi.org/10.1074/jbc.M700630200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17500059	hybrid, Green Published			2022-12-25	WOS:000247650600018
J	Zhang, JL; Huang, Y; Qiu, LY; Nickel, J; Sebald, W				Zhang, Jin-Li; Huang, Yi; Qiu, Li-Yan; Nickel, Joachim; Sebald, Walter			von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TWISTED GASTRULATION; BMP RECEPTOR IA; TGF-BETA; MOLECULAR RECOGNITION; CELL-DIFFERENTIATION; STRUCTURAL BASIS; II RECEPTORS; IN-VITRO; CHORDIN; BINDING	Bone morphogenetic protein (BMP) function is regulated in the extracellular space by many modulator proteins, including those containing a von Willebrand factor typeC(VWC) domain. The function of the VWC domain-containing proteins in development and diseases has been extensively studied. The structural basis, however, for the mechanism by which BMP is regulated by these proteins is still poorly understood. By analyzing chordin, CHL2 (chordin-like 2), and CV2 ( crossveinless 2) as well as their individual VWC domains, we show that the VWC domain is a versatile binding module that in its multiple forms and environments can expose a variety of binding specificities. Three of four, two of three, and one of five VWCs from chordin, CHL2, and CV2, respectively, can bind BMPs. Using an array of BMP-2 mutant proteins, it can be demonstrated that the binding competent VWC domains all use a specific subset of BMP-2 binding determinants that overlap with the binding site for the type II receptors (knuckle epitope) or for the type I receptors (wrist epitope). This explains the competition between modulator proteins and receptors for BMP binding and therefore the inhibition of BMP signaling. A subset of VWC domains from CHL2 binds to the Tsg (twisted gastrulation) protein similar to chordin. A stable ternary complex consisting of BMP- 2, CHL2, and Tsg can be formed, thus making CHL2 a more efficient BMP-2 inhibitor. The VWCs of CV2, however, do not interact with Tsg. The present results show that chordin, CHL2, and CV2 regulate BMP-2 signaling by different recognition mechanisms.	Univ Wurzburg, Bioctr, Dept Physiol Chem, D-97074 Wurzburg, Germany	University of Wurzburg	Zhang, JL (corresponding author), Univ Wurzburg, Bioctr, Dept Physiol Chem, D-97074 Wurzburg, Germany.	zhang@biozentrum.uni-wuerzburg.de						Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Armishaw CJ, 2005, CURR PROTEIN PEPT SC, V6, P221, DOI 10.2174/1389203054065437; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Binnerts ME, 2004, BIOCHEM BIOPH RES CO, V315, P272, DOI 10.1016/j.bbrc.2004.01.048; De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124; Eldar A, 2002, NATURE, V419, P304, DOI 10.1038/nature01061; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P3875, DOI 10.1210/en.2005-0053; Gazzerro E, 2006, BONE, V39, P1252, DOI 10.1016/j.bone.2006.06.028; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Harrington AE, 2006, EMBO J, V25, P1035, DOI 10.1038/sj.emboj.7601000; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Harrison CA, 2006, ENDOCRINOLOGY, V147, P2744, DOI 10.1210/en.2006-0131; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan B L, 1996, Harvey Lect, V92, P83; Ikeya M, 2006, DEVELOPMENT, V133, P4463, DOI 10.1242/dev.02647; Jasuja R, 2004, J BIOL CHEM, V279, P51289, DOI 10.1074/jbc.M408129200; Kamimura M, 2004, DEV DYNAM, V230, P434, DOI 10.1002/dvdy.20069; Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Kirsch T, 2000, FEBS LETT, V468, P215, DOI 10.1016/S0014-5793(00)01214-X; Larrain J, 2001, DEVELOPMENT, V128, P4439; Larrain J, 2000, DEVELOPMENT, V127, P821; Larrain J, 2003, EMBO REP, V4, P813, DOI 10.1038/sj.embor.embor902; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Lee HX, 2006, CELL, V124, P147, DOI 10.1016/j.cell.2005.12.018; Lin JM, 2006, MOL CELL BIOL, V26, P4577, DOI 10.1128/MCB.02127-05; Lin JM, 2005, NAT MED, V11, P387, DOI 10.1038/nm1217; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Nakayama N, 2004, DEVELOPMENT, V131, P229, DOI 10.1242/dev.00901; Nosaka T, 2003, MOL CELL BIOL, V23, P2969, DOI 10.1128/MCB.23.8.2969-2980.2003; O'Connor MB, 2006, DEVELOPMENT, V133, P183; O'Leary JM, 2004, J BIOL CHEM, V279, P53857, DOI 10.1074/jbc.M409225200; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Oelgeschlager M, 2003, DEVELOPMENT, V130, P4047, DOI 10.1242/dev.00633; Petryk A, 2004, DEV BIOL, V267, P374, DOI 10.1016/j.ydbio.2003.11.015; Reddi AH, 2005, CYTOKINE GROWTH F R, V16, P249, DOI 10.1016/j.cytogfr.2005.04.003; Rentzsch F, 2006, DEVELOPMENT, V133, P801, DOI 10.1242/dev.02250; Schmidl M, 2006, J BIOL CHEM, V281, P31790, DOI 10.1074/jbc.M603419200; Scott IC, 2000, DEV DYNAM, V217, P449, DOI 10.1002/(SICI)1097-0177(200004)217:4<449::AID-DVDY12>3.0.CO;2-8; Sebald W, 2004, BIOL CHEM, V385, P697, DOI 10.1515/BC.2004.086; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimmi O, 2005, CELL, V120, P873, DOI 10.1016/j.cell.2005.02.009; Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; Tobin JF, 2006, DRUG DISCOV TODAY, V11, P405, DOI 10.1016/j.drudis.2006.03.016; Wang YC, 2005, NATURE, V434, P229, DOI 10.1038/nature03318; Watters MR, 2005, SEMIN NEUROL, V25, P278, DOI 10.1055/s-2005-917664; Weber D, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-6; Wills A, 2006, DEV BIOL, V289, P166, DOI 10.1016/j.ydbio.2005.10.022; Xie J, 2005, DEVELOPMENT, V132, P383, DOI 10.1242/dev.01577; Yu K, 2004, GENETICS, V166, P1323, DOI 10.1534/genetics.166.3.1323; Zakin L, 2004, DEVELOPMENT, V131, P413, DOI 10.1242/dev.00946; Zhang DH, 2002, J BONE MINER RES, V17, P293, DOI 10.1359/jbmr.2002.17.2.293	57	84	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					20002	20014		10.1074/jbc.M700456200	http://dx.doi.org/10.1074/jbc.M700456200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17483092	hybrid			2022-12-25	WOS:000247650600074
J	Kyzer, S; Ha, KS; Landick, R; Palangat, M				Kyzer, Scotty; Ha, Kook Sun; Landick, Robert; Palangat, Murali			Direct versus limited-step reconstitution reveals key features of an RNA hairpin-stabilized paused transcription complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTACTS NASCENT RNA; POLYMERASE-II; ELONGATION COMPLEXES; STRUCTURAL BASIS; DNA HYBRID; TRANSLOCATION; SITE; BUBBLE; PROCESSIVITY; TERMINATION	We have identified minimal nucleic acid scaffolds capable of reconstituting hairpin-stabilized paused transcription complexes when incubated with RNAP either directly or in a limited step reconstitution assay. Direct reconstitution was achieved using a 29-nucleotide (nt) RNA whose 3'-proximal 9-10 nt pair to template DNA within an 11-nt noncomplementary bubble of a 39-bp duplex DNA; the 5'-proximal 18 nt of RNA forms the his pause RNA hairpin. Limited- step reconstitution was achieved on the same DNAs using a 27-nt RNA that can be 3'-labeled during reconstitution and then extended 2 nt past the pause site to assay transcriptional pausing. Paused complexes formed by either method recapitulated key features of a promoter-initiated, hairpin-stabilized paused complex, including a slow rate of pause escape, resistance to transcript cleavage and pyrophosphorolysis, and enhancement of pausing by the elongation factor NusA. These findings establish that RNA upstream from the pause hairpin and pyrophosphate are not essential for pausing and for NusA action. Reconstitution of the his paused transcription complex provides a valuable tool for future studies of protein-nucleic interactions involved in transcriptional pausing.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Landick, R (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53706 USA.	landick@bact.wisc.edu; palangat@facstaff.wisc.edu	Palangat, Murali/AAK-5445-2021	Palangat, Murali/0000-0002-3327-3844	NIGMS NIH HHS [GM38660, T32 GM07215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038660, R01GM038660, R29GM038660, T32GM007215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; Artsimovitch I, 2002, CELL, V109, P193, DOI 10.1016/S0092-8674(02)00724-9; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gong XQ, 2005, MOL CELL, V18, P461, DOI 10.1016/j.molcel.2005.04.011; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Herbert KM, 2006, CELL, V125, P1083, DOI 10.1016/j.cell.2006.04.032; Kashkina E, 2006, NUCLEIC ACIDS RES, V34, P4036, DOI 10.1093/nar/gkl559; Kireeva ML, 2000, J MOL BIOL, V299, P325, DOI 10.1006/jmbi.2000.3755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; Landick R, 1996, ESCHERICHIA COLI SAL, P1263; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LIU K, 1995, J MOL BIOL, V247, P547, DOI 10.1016/S0022-2836(05)80136-6; Milan S, 1999, BIOCHEMISTRY-US, V38, P218, DOI 10.1021/bi9818422; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Palangat M, 1998, MOL CELL, V1, P1033, DOI 10.1016/S1097-2765(00)80103-3; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; Ryder AM, 2003, J MOL BIOL, V334, P205, DOI 10.1016/j.jmb.2003.09.039; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; Temiakov D, 2005, MOL CELL, V19, P655, DOI 10.1016/j.molcel.2005.07.020; Toulokhonov I, 2003, MOL CELL, V12, P1125, DOI 10.1016/S1097-2765(03)00439-8; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; TOULOKHONOV I, 2007, IN PRESS MOL CELL; Toulokhonov I, 2006, J MOL BIOL, V361, P644, DOI 10.1016/j.jmb.2006.06.071; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016; Wilson KS, 1999, J MOL BIOL, V289, P1179, DOI 10.1006/jmbi.1999.2814; Worbs M, 2001, MOL CELL, V7, P1177, DOI 10.1016/S1097-2765(01)00262-3; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5	37	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19020	19028		10.1074/jbc.M701483200	http://dx.doi.org/10.1074/jbc.M701483200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17502377	hybrid			2022-12-25	WOS:000247475300044
J	Pfluger, K; de Lorenzo, V				Pfluger, Katharina; de Lorenzo, Victor			Growth-dependent phosphorylation of the PtsN (EIINtr) protein of Pseudomonas putida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; SIGMA(54) PU PROMOTER; ESCHERICHIA-COLI; TOL PLASMID; ENZYME IIA(NTR); CATABOLITE REPRESSION; GENETIC-EVIDENCE; GENOME SEQUENCE; RNA-POLYMERASE; NITROGEN	The nitrogen-related branch of the phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS) of Pseudomonas putida includes the ptsN gene encoding the EIINtr (PtsN) enzyme. Although the implication of this protein in a variety of cellular functions has been observed in diverse bacteria, the physiological signals that bring about phosphorylation/dephosphorylation of the PtsN protein are not understood. This work documents the phosphorylation status of the EIINtr enzyme of P. putida at various growth stages in distinct media. Culture conditions were chosen to include fructose (the uptake of which is controlled by the PTS) or glucose (a non-PTS sugar in P. putida) in minimal medium with casamino acids, ammonia, or nitrate as alternative nitrogen sources. To quantify the relative ratio of PtsN/PtsN similar to P in live cells, we resorted to the in situ electrophoresis of whole bacteria expressing an E-epitope-tagged EIINtr followed by the fractionation of the thereby released native proteome in a non-denaturing gel. Although the PtsN species phosphorylated in amino acid His(68) was detected under virtually all growth scenarios, the relative levels of the non-phosphorylated form varied dramatically depending on the growth phase and the nutrients available in the medium. The share of phosphorylated PtsN increased along growth in a fashion apparently independent of any trafficking of sugars. The large variations of non-phosphorylated PtsN in different growth conditions, in contrast to the systematic excess of the phosphorylated PtsN form, suggested that the P-free PtsN is the predominant signaling species of the protein.	CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	de Lorenzo, V (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus de Cantoblanco, E-28049 Madrid, Spain.	vdlorenzo@cnb.uam.es		de Lorenzo, Victor/0000-0002-6041-2731				Aranda-Olmedo I, 2005, APPL ENVIRON MICROB, V71, P4191, DOI 10.1128/AEM.71.8.4191-4198.2005; Aranda-Olmedo I, 2006, APPL ENVIRON MICROB, V72, P7418, DOI 10.1128/AEM.01067-06; Barabote RD, 2005, MICROBIOL MOL BIOL R, V69, P608, DOI 10.1128/MMBR.69.4.608-634.2005; Bordo D, 1998, J MOL BIOL, V279, P245, DOI 10.1006/jmbi.1998.1753; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Carmona M, 1999, J BIOL CHEM, V274, P33790, DOI 10.1074/jbc.274.47.33790; Cases I, 2003, ENVIRON MICROBIOL, V5, P1281, DOI 10.1111/j.1462-2920.2003.00528.x; Cases I, 1999, J BIOL CHEM, V274, P15562, DOI 10.1074/jbc.274.22.15562; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; Cases I, 2000, J BACTERIOL, V182, P956, DOI 10.1128/JB.182.4.956-960.2000; Cases I, 2001, J BACTERIOL, V183, P5128, DOI 10.1128/JB.183.17.5128-5133.2001; Cases I, 2001, J BACTERIOL, V183, P1032, DOI 10.1128/JB.183.3.1032-1037.2001; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Deutscher J, 2006, MICROBIOL MOL BIOL R, V70, P939, DOI 10.1128/MMBR.00024-06; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; Jurado P, 2002, J MOL BIOL, V320, P1, DOI 10.1016/S0022-2836(02)00405-9; Klumpp S, 2002, EUR J BIOCHEM, V269, P1067, DOI 10.1046/j.1432-1033.2002.02755.x; KOHLER T, 1994, FEMS MICROBIOL LETT, V115, P177, DOI 10.1016/0378-1097(94)90010-8; Lasker M, 1999, PROTEIN SCI, V8, P2177, DOI 10.1110/ps.8.10.2177; Laurie AD, 2003, J BIOL CHEM, V278, P1494, DOI 10.1074/jbc.M209268200; Lee CR, 2007, P NATL ACAD SCI USA, V104, P4124, DOI 10.1073/pnas.0609897104; Lee CR, 2005, MOL MICROBIOL, V58, P334, DOI 10.1111/j.1365-2958.2005.04834.x; Michiels J, 1998, J BACTERIOL, V180, P1729, DOI 10.1128/JB.180.7.1729-1740.1998; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; Paustian ML, 2002, J BACTERIOL, V184, P6714, DOI 10.1128/JB.184.23.6714-6720.2002; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; Rabus R, 1999, J BIOL CHEM, V274, P26185, DOI 10.1074/jbc.274.37.26185; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; Ren JS, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-13; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Sambrook J., 1989, MOL CLONING LAB MANU, V2; VALLS M, 2004, PSEUDOMONAS VIRULENC, V2, P289; Velazquez F, 2004, J BACTERIOL, V186, P8267, DOI 10.1128/JB.186.24.8267-8275.2004; VELAZQUEZ F, 2007, IN PRESS J BACTERIOL; Wang GS, 2005, PROTEIN SCI, V14, P1082, DOI 10.1110/ps.041232805; Weinel C, 2002, ENVIRON MICROBIOL, V4, P809, DOI 10.1046/j.1462-2920.2002.00331.x	41	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18206	18211		10.1074/jbc.M611110200	http://dx.doi.org/10.1074/jbc.M611110200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17478425	hybrid			2022-12-25	WOS:000247302000027
J	Lamontagne, B; Abou Elela, S				Lamontagne, Bruno; Abou Elela, Sherif			Short RNA Guides Cleavage by Eukaryotic RNase III	PLOS ONE			English	Article							SILENCING IN-VITRO; SACCHAROMYCES-CEREVISIAE; MODEL SYSTEM; YEAST; MECHANISM; U2; DETERMINANTS; RECOGNITION; SUBSTRATE; U5	In eukaryotes, short RNAs guide a variety of enzymatic activities that range from RNA editing to translation repression. It is hypothesized that pre-existing proteins evolved to bind and use guide RNA during evolution. However, the capacity of modern proteins to adopt new RNA guides has never been demonstrated. Here we show that Rnt1p, the yeast orthologue of the bacterial dsRNA-specific RNase III, can bind short RNA transcripts and use them as guides for sequence-specific cleavage. Target cleavage occurred at a constant distance from the Rnt1p binding site, leaving the guide RNA intact for subsequent cleavage. Our results indicate that RNase III may trigger sequence-specific RNA degradation independent of the RNA1 machinery, and they open the road for a new generation of precise RNA silencing tools that do not trigger a dsRNA-mediated immune response.	[Lamontagne, Bruno; Abou Elela, Sherif] Univ Sherbrooke, Fac Med Sci Sante, Dept Microbiol & Infectiol, Lab Genom Fonct,Grp ARN, Sherbrooke, PQ J1K 2R1, Canada	University of Sherbrooke	Abou Elela, S (corresponding author), Univ Sherbrooke, Fac Med Sci Sante, Dept Microbiol & Infectiol, Lab Genom Fonct,Grp ARN, Sherbrooke, PQ J1K 2R1, Canada.	Sherif.Abou.Elela@USherbrooke.ca		Abou Elela, Sherif/0000-0002-0630-3294	Canadian Institutes for Health Research (CIHR); Genome Canada/Genome Quebec Competition III	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Genome Canada/Genome Quebec Competition III(Genome Canada)	This work was supported by funds from the Canadian Institutes for Health Research (CIHR) and Genome Canada/Genome Quebec Competition III. S. A. is a Chercheur-Boursier Senior of the Fonds de la Recherche en Sante du Quebec.	AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; ARES M, 1986, CELL, V47, P49, DOI 10.1016/0092-8674(86)90365-X; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; BARTLETT R, 1990, BIOESSAYS, V12, P457, DOI 10.1002/bies.950121002; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Catala M, 2004, MOL BIOL CELL, V15, P3015, DOI 10.1091/mbc.E04-03-0183; CECH TR, 1989, BIOCHEM INT, V18, P7; Chanfreau C, 2000, P NATL ACAD SCI USA, V97, P3142, DOI 10.1073/pnas.070043997; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; DAVIES J, 1992, CIBA F SYMP, V171, P24; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; Gan JH, 2006, CELL, V124, P355, DOI 10.1016/j.cell.2005.11.034; Ge DL, 2005, CURR BIOL, V15, P140, DOI 10.1016/j.cub.2004.12.001; Ghazal G, 2005, MOL CELL BIOL, V25, P2981, DOI 10.1128/MCB.25.8.2981-2994.2005; Ghazal G, 2006, J MOL BIOL, V363, P332, DOI 10.1016/j.jmb.2006.08.028; Guthrie C, 1991, GUIDE YEAST GENETICS; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Jeffares DC, 1998, J MOL EVOL, V46, P18, DOI 10.1007/PL00006280; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Lafontaine DLJ, 1998, TRENDS BIOCHEM SCI, V23, P383, DOI 10.1016/S0968-0004(98)01260-2; Lamontagne B, 2004, J MOL BIOL, V338, P401, DOI 10.1016/j.jmb.2004.02.059; Lamontagne B, 2004, J BIOL CHEM, V279, P2231, DOI 10.1074/jbc.M309324200; Lamontagne B, 2003, J MOL BIOL, V327, P985, DOI 10.1016/S0022-2836(03)00231-6; Lamontagne B, 2001, Curr Issues Mol Biol, V3, P71; Lamontagne B, 2001, METHOD ENZYMOL, V342, P159, DOI 10.1016/S0076-6879(01)42543-2; Larose S, 2007, J BIOL CHEM, V282, P4373, DOI 10.1074/jbc.M607145200; Lebars I, 2001, EMBO J, V20, P7250, DOI 10.1093/emboj/20.24.7250; Lee A, 2005, MOL CELL, V19, P39, DOI 10.1016/j.molcel.2005.05.021; Lin Shi-Lung, 2006, V342, P295, DOI 10.1385/1-59745-123-1:295; Madeo F, 2002, CURR GENET, V41, P208, DOI 10.1007/s00294-002-0310-2; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; Mattick JS, 2005, HUM MOL GENET, V14, pR121, DOI 10.1093/hmg/ddi101; Murchison EP, 2004, CURR OPIN CELL BIOL, V16, P223, DOI 10.1016/j.ceb.2004.04.003; Poole AM, 1998, J MOL EVOL, V46, P1, DOI 10.1007/PL00006275; RIEDEL N, 1986, P NATL ACAD SCI USA, V83, P8097, DOI 10.1073/pnas.83.21.8097; Rose MD., 1990, METHODS YEAST GENETI; Takei Y, 2002, J BIOL CHEM, V277, P23800, DOI 10.1074/jbc.M112100200; Tijsterman M, 2004, CELL, V117, P1, DOI 10.1016/S0092-8674(04)00293-4; Vickers TA, 2003, J BIOL CHEM, V278, P7108, DOI 10.1074/jbc.M210326200; Wilson HR, 2002, EMBO J, V21, P4154, DOI 10.1093/emboj/cdf395; Wintersberger U, 2001, METHOD ENZYMOL, V341, P414, DOI 10.1016/S0076-6879(01)41167-0; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	42	15	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e472	10.1371/journal.pone.0000472	http://dx.doi.org/10.1371/journal.pone.0000472			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534422	Green Submitted, gold, Green Published			2022-12-25	WOS:000207448800002
J	Arai, Y; Mentis, GZ; Wu, JY; O'Donovan, MJ				Arai, Yoshiyasu; Mentis, George Z.; Wu, Jiang-young; O'Donovan, Michael J.			Ventrolateral Origin of Each Cycle of Rhythmic Activity Generated by the Spinal Cord of the Chick Embryo	PLOS ONE			English	Article								Background. The mechanisms responsible for generating rhythmic motor activity in the developing spinal cord of the chick embryo are poorly understood. Here we investigate whether the activity of motoneurons occurs before other neuronal populations at the beginning of each cycle of rhythmic discharge. Methodology/Principal Findings. The spatiotemporal organization of neural activity in transverse slices of the lumbosacral cord of the chick embryo (E8-E11) was investigated using intrinsic and voltage-sensitive dye (VSD) imaging. VSD signals accompanying episodes of activity comprised a rhythmic decrease in light transmission that corresponded to each cycle of electrical activity recorded from the ipsilateral ventral root. The rhythmic signals were widely synchronized across the cord face, and the largest signal amplitude was in the ventrolateral region where motoneurons are located. In unstained slices we recorded two classes of intrinsic signal. In the first, an episode of rhythmic activity was accompanied by a slow decrease in light transmission that peaked in the dorsal horn and decayed dorsoventrally. Superimposed on this signal was a much smaller rhythmic increase in transmission that was coincident with each cycle of discharge and whose amplitude and spatial distribution was similar to that of the VSD signals. At the onset of a spontaneously occurring episode and each subsequent cycle, both the intrinsic and VSD signals originated within the lateral motor column and spread medially and then dorsally. By contrast, following a dorsal root stimulus, the optical signals originated within the dorsal horn and traveled ventrally to reach the lateral motor column. Conclusions/Significance. These findings suggest that motoneuron activity contributes to the initiation of each cycle of rhythmic activity, and that motoneuron and/or R-interneuron synapses are a plausible site for the activity-dependent synaptic depression that modeling studies have identified as a critical mechanism for cycling within an episode.	[Arai, Yoshiyasu; Mentis, George Z.; Wu, Jiang-young; O'Donovan, Michael J.] NINDS, Neural Control Lab, Sect Dev Neurobiol, NIH, Bethesda, MD 20892 USA; [Wu, Jiang-young] Georgetown Univ, Dept Physiol & Biophys, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Georgetown University	O'Donovan, MJ (corresponding author), NINDS, Neural Control Lab, Sect Dev Neurobiol, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	odonovm@ninds.nih.gov	o'donovan, michael/A-2357-2015	o'donovan, michael/0000-0003-2487-7547	National Institute of Neurological Disorders and Stroke; JSPS [2000]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036447, Z01NS003022] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by the National Institute of Neurological Disorders and Stroke Intramural Research Program, and a JSPS Postdoctoral Fellowships for Research Abroad (to Y. A. 2000).	Arai Y, 1999, J NEUROPHYSIOL, V81, P1889, DOI 10.1152/jn.1999.81.4.1889; ARAI Y, 2001, 31 SOC NEUR; BEKOFF A, 1976, BRAIN RES, V106, P271, DOI 10.1016/0006-8993(76)91025-8; Borodinsky LN, 2004, NATURE, V429, P523, DOI 10.1038/nature02518; Chub N, 2006, J NEUROPHYSIOL, V95, P323, DOI 10.1152/jn.00162.2005; Chub N, 1998, J NEUROSCI, V18, P294; Chub N, 2001, J NEUROPHYSIOL, V85, P2166, DOI 10.1152/jn.2001.85.5.2166; Fayuk D, 2002, J NEUROPHYSIOL, V87, P1924, DOI 10.1152/jn.00231.2001; Gonzalez-Islas C, 2006, NEURON, V49, P563, DOI 10.1016/j.neuron.2006.01.017; Grillner S, 2003, NAT REV NEUROSCI, V4, P573, DOI 10.1038/nrn1137; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hanson MG, 2004, NEURON, V43, P687, DOI 10.1016/j.neuron.2004.08.018; Jin WJ, 2002, J NEUROSCI METH, V115, P13, DOI 10.1016/S0165-0270(01)00511-8; KAMINO K, 1981, NATURE, V290, P595, DOI 10.1038/290595a0; Kiehn O, 2006, ANNU REV NEUROSCI, V29, P279, DOI 10.1146/annurev.neuro.29.051605.112910; LANDMESSER LT, 1984, J PHYSIOL-LONDON, V347, P189, DOI 10.1113/jphysiol.1984.sp015061; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; Marchetti C, 2005, J NEUROSCI, V25, P3601, DOI 10.1523/JNEUROSCI.4290-04.2005; Mentis GZ, 2005, P NATL ACAD SCI USA, V102, P7344, DOI 10.1073/pnas.0502788102; Mochida H, 2001, EUR J NEUROSCI, V14, P809, DOI 10.1046/j.0953-816x.2001.01692.x; Mochida H, 2001, EUR J NEUROSCI, V13, P1547, DOI 10.1046/j.0953-816x.2001.01528.x; Momose-Sato Y, 1998, J NEUROPHYSIOL, V79, P2208, DOI 10.1152/jn.1998.79.4.2208; MOMOSESATO Y, 1995, J MEMBRANE BIOL, V144, P167, DOI 10.1007/bf00232802; Nishimaru H, 2005, P NATL ACAD SCI USA, V102, P5245, DOI 10.1073/pnas.0501331102; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; ODONOVAN M, 1994, J NEUROSCI, V14, P6354; ODONOVAN MJ, 1989, J NEUROSCI, V9, P943; PERRINS R, 1995, J NEUROPHYSIOL, V73, P1013, DOI 10.1152/jn.1995.73.3.1013; Ren J, 2006, J NEUROPHYSIOL, V95, P527, DOI 10.1152/jn.00735.2005; Ritter A, 1999, J NEUROSCI, V19, P3457; Roberts A, 1998, ANN NY ACAD SCI, V860, P19, DOI 10.1111/j.1749-6632.1998.tb09036.x; SALZBERG BM, 1983, NATURE, V306, P36, DOI 10.1038/306036a0; SALZBERG BM, 1985, J GEN PHYSIOL, V86, P395, DOI 10.1085/jgp.86.3.395; Sato K, 1997, NEUROREPORT, V8, P3559, DOI 10.1097/00001756-199711100-00028; Sholomenko GN, 1998, EXP NEUROL, V154, P430, DOI 10.1006/exnr.1998.6944; Tabak J, 2000, J NEUROSCI, V20, P3041; Tabak J, 2001, J NEUROSCI, V21, P8966, DOI 10.1523/JNEUROSCI.21-22-08966.2001; Terni T., 1923, Archivio Italiano di Anatomia e di Embriologia, V20, P433; Wenner P, 2001, J NEUROPHYSIOL, V86, P1481, DOI 10.1152/jn.2001.86.3.1481; Wenner P, 1996, J NEUROSCI METH, V70, P111, DOI 10.1016/S0165-0270(96)00108-2; Wenner P, 1999, J NEUROSCI, V19, P7557, DOI 10.1523/JNEUROSCI.19-17-07557.1999; Wu J.-Y., 1993, FLUORESCENT LUMINESC, P389; Xu HY, 2007, J NEUROPHYSIOL, V97, P2769, DOI 10.1152/jn.01324.2006; Xu HY, 2005, J NEUROPHYSIOL, V93, P2922, DOI 10.1152/jn.01091.2004; Zhang LI, 2001, NAT NEUROSCI, V4, P1207, DOI 10.1038/nn753; Ziskind-Conhaim L, 2005, J NEUROPHYSIOL, V94, P1952, DOI 10.1152/jn.00209.2005	47	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e417	10.1371/journal.pone.0000417	http://dx.doi.org/10.1371/journal.pone.0000417			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17479162	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445700019
J	Scotlandi, K; Zuntini, M; Manara, MC; Sciandra, M; Rocchi, A; Benini, S; Nicoletti, G; Bernard, G; Nanni, P; Lollini, PL; Bernard, A; Picci, P				Scotlandi, K.; Zuntini, M.; Manara, M. C.; Sciandra, M.; Rocchi, A.; Benini, S.; Nicoletti, G.; Bernard, G.; Nanni, P.; Lollini, P-L; Bernard, A.; Picci, P.			CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity	ONCOGENE			English	Article						CD99; splice variants; osteosarcoma; migration; metastases	PROSTATE-CANCER CELLS; EWINGS-SARCOMA CELLS; HUMAN OSTEOSARCOMA CELLS; EXPRESSION; ADHESION; PATHWAY; ENGAGEMENT; APOPTOSIS; MOTILITY; MIC2	CD99 gene encodes two distinct proteins, produced by alternative splicing of CD99 gene transcript. Full- length CD99 isoform ( CD99wt) is formed by an extracellular domain, followed by a transmembrane domain and a 36 amino- acid intracytoplasmic domain, which is partially deleted in the truncated, short form ( CD99sh). A differential expression of these two CD99 molecules can lead to distinct functional outcomes in lymphocytes. To investigate the functional effects of CD99 molecules on malignancy, forced overexpression of the two CD99 isoforms was induced in osteosarcoma and prostate cancer cells. The two isoforms exhibited opposite functions: the major form dramatically inhibits anchorage- independent growth, anoikis resistance, migration and metastasis, whereas the CD99sh remarkably favours the phenomena. A mechanistic analysis of CD99-transfected osteosarcoma cells points to involvement of c-Src family kinase activity in regulating CD99 functions in malignancy. Ser168 residue of CD99 plays a pivotal role in the reversion of the malignant phenotype. Our findings highlight the involvement of CD99 in crucial processes of cancer malignancy, serving as a curtain raiser for this, so far neglected molecule. In addition, a dualistic role for the two CD99 isoforms was shown in agreement with what was observed for other cell adhesion molecules.	Inst Orthoped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy; Hosp Archet, INSERM, UMR 576, Nice, France; Univ Bologna, Dipt Patol Sperimentale, Sez Cancerol, Bologna, Italy	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Bologna	Scotlandi, K (corresponding author), Inst Orthoped Rizzoli, Lab Ric Oncol, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Rocchi, Anna/AAA-7748-2019; Scotlandi, Katia/J-9009-2016; Sciandra, Marika/C-8724-2018; Lollini, Pier Luigi/A-7644-2008; Manara, Maria Cristina/K-3366-2018; Picci, Piero/J-5979-2016; BENINI, STEFANIA/D-1804-2019	Rocchi, Anna/0000-0002-1334-9063; Scotlandi, Katia/0000-0001-6114-9499; Sciandra, Marika/0000-0001-7147-6960; Lollini, Pier Luigi/0000-0003-1702-4108; Manara, Maria Cristina/0000-0001-5686-720X; Picci, Piero/0000-0002-8519-4101; BENINI, STEFANIA/0000-0003-0958-9088; Nanni, Patrizia/0000-0001-5319-0803				Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Ayrapetov MK, 2006, J BIOL CHEM, V281, P23776, DOI 10.1074/jbc.M604219200; Benini S, 1999, INT J CANCER, V80, P581, DOI 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.3.CO;2-F; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; Boyer B, 2002, ONCOGENE, V21, P2347, DOI 10.1038/sj.onc.1205298; Byun HJ, 2006, J BIOL CHEM, V281, P34833, DOI 10.1074/jbc.M605483200; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Dworzak MN, 2004, LEUKEMIA, V18, P703, DOI 10.1038/sj.leu.2403303; Fouchet C, 2000, BLOOD, V95, P1819, DOI 10.1182/blood.V95.5.1819.005k05_1819_1826; Goto A, 2004, HISTOPATHOLOGY, V45, P384, DOI 10.1111/j.1365-2559.2004.01967.x; Hahn JH, 1997, J IMMUNOL, V159, P2250; Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008-5472.CAN-04-3448; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; Jung KC, 2002, J KOREAN MED SCI, V17, P483, DOI 10.3346/jkms.2002.17.4.483; Kim SH, 2000, BLOOD, V95, P294; Kreppel M, 2006, ONCOGENE, V25, P2795, DOI 10.1038/sj.onc.1209300; Maitra A, 2003, CLIN CANCER RES, V9, P5988; Manara MC, 2006, MOL BIOL CELL, V17, P1910, DOI 10.1091/mbc.E05-10-0971; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Recchi I, 2003, EUR J CANCER, V39, P1927, DOI 10.1016/S0959-8049(03)00394-0; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 1996, HUM PATHOL, V27, P408, DOI 10.1016/S0046-8177(96)90115-X; SCOTLANDI K, 1993, INT J ONCOL, V3, P963; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Wijetunge S, 1996, FEBS LETT, V399, P63, DOI 10.1016/S0014-5793(96)01177-5	30	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6604	6618		10.1038/sj.onc.1210481	http://dx.doi.org/10.1038/sj.onc.1210481			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17471235				2022-12-25	WOS:000250081500003
J	Gorfe, AA; Caflisch, A				Gorfe, Alemayehu A.; Caflisch, Amedeo			Ser170 controls the conformational multiplicity of the loop 166-175 in prion proteins: implication for conversion and species barrier	FASEB JOURNAL			English	Article						elk; flexibility; mouse; molecular dynamics; allosteric control	CHRONIC WASTING DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; MOLECULAR-DYNAMICS SIMULATIONS; ROCKY-MOUNTAIN ELK; NMR STRUCTURES; MULE DEER; TRANSGENIC MICE; SCRAPIE PRION; TRANSMISSION; SUSCEPTIBILITY	The self-perpetuating conversion of cellular prion proteins (PrPC) into an aggregated beta-sheet rich conformation is associated with transmissible spongiform encephalopathies (TSE). The loop 166 -175 (L1) in PrPC, which displays sequence and structural variation among species, has been suggested to play a role in species barrier, in particular against transmission of TSE from cervids to domestic and laboratory animals. L1 is ordered in elk PrP, as well as in a mouse/elk hybrid (in which L1 of mouse is replaced by elk) but not in other species such as mice, humans, and bovine. To investigate the source and significance of L1 dynamics, we carried out explicit solvent molecular dynamics simulations (approximate to 0.5 mu s in total) of the mouse prion protein, the mouse/elk hybrid, and control simulations, in which the mouse sequence is reintroduced into the structure of the mouse/elk hybrid. We found that the flexibility of L1 correlates with the backbone dynamics of Ser170. Furthermore, L1 mobility promotes a substantial displacement of Tyr169, rupture of the Asp178-Tyr128 and Asp178-Tyr169 side chain hydrogen bonds, as well as disruption of Tyr169-Phe175 pi-stacking interaction. The simulation results go beyond the available experimental data because they highlight the dependence of this network of interactions on residue 170 and L1 plasticity.	Univ Zurich, Dept Biochem, Zurich, Switzerland	University of Zurich	Gorfe, AA (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Urey Hall,Rm 4218,MC 0365, La Jolla, CA 92093 USA.	abebe@mccammon.ucsd.edu	Caflisch, Amedeo/I-3459-2012					Alonso DOV, 2001, P NATL ACAD SCI USA, V98, P2985, DOI 10.1073/pnas.061555898; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; Armen RS, 2004, P NATL ACAD SCI USA, V101, P11622, DOI 10.1073/pnas.0401781101; Belay ED, 2004, EMERG INFECT DIS, V10, P977, DOI 10.3201/eid1006.031082; Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; Bishop MT, 2006, LANCET NEUROL, V5, P393, DOI 10.1016/S1474-4422(06)70413-6; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; Bruce ME, 2000, NAT MED, V6, P258, DOI 10.1038/73098; Calzolai L, 2000, P NATL ACAD SCI USA, V97, P8340, DOI 10.1073/pnas.97.15.8340; Calzolai L, 2005, P NATL ACAD SCI USA, V102, P651, DOI 10.1073/pnas.0408939102; Dima RI, 2002, BIOPHYS J, V83, P1268, DOI 10.1016/S0006-3495(02)73899-X; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Eghiaian F, 2004, P NATL ACAD SCI USA, V101, P10254, DOI 10.1073/pnas.0400014101; Ferguson N, 2006, P NATL ACAD SCI USA, V103, P16248, DOI 10.1073/pnas.0607815103; Fox KA, 2006, J GEN VIROL, V87, P3451, DOI 10.1099/vir.0.81999-0; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; Goldmann W, 2006, J GEN VIROL, V87, P3741, DOI 10.1099/vir.0.82083-0; Gorfe AA, 2005, STRUCTURE, V13, P1487, DOI 10.1016/j.str.2005.06.015; Gorfe AA, 2002, PROTEINS, V46, P41, DOI 10.1002/prot.10027; Gossert AD, 2005, P NATL ACAD SCI USA, V102, P646, DOI 10.1073/pnas.0409008102; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Gsponer J, 2001, J MOL GRAPH MODEL, V20, P169, DOI 10.1016/S1093-3263(01)00117-6; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Kuwata K, 2003, P NATL ACAD SCI USA, V100, P14790, DOI 10.1073/pnas.2433563100; Laurent M, 1998, BIOPHYS CHEM, V72, P211, DOI 10.1016/S0301-4622(98)00135-5; Lysek DA, 2005, P NATL ACAD SCI USA, V102, P640, DOI 10.1073/pnas.0408937102; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Miller MW, 1998, J WILDLIFE DIS, V34, P532, DOI 10.7589/0090-3558-34.3.532; Miller MW, 2000, J WILDLIFE DIS, V36, P676, DOI 10.7589/0090-3558-36.4.676; Miller MW, 2002, VET REC, V151, P610, DOI 10.1136/vr.151.20.610; Miller MW, 2004, CURR TOP MICROBIOL, V284, P193; Miller MW, 2004, EMERG INFECT DIS, V10, P1003, DOI 10.3201/eid1006.040010; O'Rourke KI, 1999, J GEN VIROL, V80, P2765, DOI 10.1099/0022-1317-80-10-2765; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raymond GJ, 2000, EMBO J, V19, P4425, DOI 10.1093/emboj/19.17.4425; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Ronga L, 2006, CHEM BIOL DRUG DES, V68, P139, DOI 10.1111/j.1747-0285.2006.00427.x; Santini S, 2004, CELL MOL LIFE SCI, V61, P951, DOI 10.1007/s00018-003-3455-3; Scott MR, 2005, J VIROL, V79, P5259, DOI 10.1128/JVI.79.9.5259-5271.2005; Weissmann C, 1996, COLD SPRING HARB SYM, V61, P511; Williams ES, 2002, REV SCI TECH OIE, V21, P305, DOI 10.20506/rst.21.2.1340; Williams ES, 2003, REV SCI TECH OIE, V22, P145, DOI 10.20506/rst.22.1.1385; Windl O, 2005, J VIROL, V79, P14971, DOI 10.1128/JVI.79.23.14971-14975.2005; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	51	29	30	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3279	3287		10.1096/fj.07-8292com	http://dx.doi.org/10.1096/fj.07-8292com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17522379				2022-12-25	WOS:000249781600028
J	Lin, J; Sun, T; Ji, L; Deng, W; Roth, J; Minna, J; Arlinghaus, R				Lin, J.; Sun, T.; Ji, L.; Deng, W.; Roth, J.; Minna, J.; Arlinghaus, R.			Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1	ONCOGENE			English	Article						c-Abl; FUS1; NSCLC; lung cancer; imatinib	HOMOZYGOUS DELETION REGION; EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE; IN-VIVO; PROTEIN; BCR; FAMILY; VITRO; EXON; CRK	In lung cancer, frequent loss of one allele of chromosome 3p is seen in both small cell lung cancer and non-small cell lung cancer (NSCLC), providing evidence of tumor suppressor genes (TSGs) in this chromosomal region. The mechanism of Fus1 tumor suppressor activity is unknown. We have found that a Fus1 peptide inhibits the Ab1 tyrosine kinase in vitro (IC50 35 mu M). The inhibitory Fus1 sequence was derived from a region that was deleted in a mutant FUS1 gene (FUS1 (1-80)) detected in some lung cancer cell lines. Importantly, a stearic acid-modified form of this peptide was required for the inhibition, but stearic acid alone was not inhibitory. Two NSCLC cell lines, which lack expression of wild-type Fus1, contain activated c-Abl. Forced expression of an inducible FUS1 cDNA in H1299 NSCLC cells decreased levels of activated c-Abl and inhibited its tyrosine kinase activity. Similarly, treatment of c-Abl immune complexes with the inhibitory Fus1 peptide also reduced the level of c-Abl in these immune complexes. The size and number of colonies of the NSCLC cell line, H1299, in soft agar was strongly inhibited by the Abl kinase inhibitor imatinib mesylate. Co-expression of FUS1 and c-ABL in COS1 cells blocked activation of c-Abl tyrosine kinase. In contrast, coexpression of mutant FUS1(1-80) with c-ABL had little inhibitory activity against c-Abl. These findings provide strong evidence that c-Abl is a possible target in NSCLC patients that have reduced expression of Fus1 in their tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Arlinghaus, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rarlingh@mdanderson.org			NCI NIH HHS [P50CA70907, P50 CA070907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Buchdunger E, 1996, CANCER RES, V56, P100; Das AK, 2006, CANCER RES, V66, P9601, DOI 10.1158/0008-5472.CAN-06-2627; Dowell JE, 2005, NEW ENGL J MED, V352, P830, DOI 10.1056/NEJMe058033; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Girard L, 2000, CANCER RES, V60, P4894; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Ito I, 2004, CANCER GENE THER, V11, P733, DOI 10.1038/sj.cgt.7700756; Ji L, 2002, CANCER RES, V62, P2715; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Ling XY, 2003, CANCER RES, V63, P298; Liu JX, 1996, CANCER RES, V56, P5120; LIU JX, 1993, ONCOGENE, V8, P101; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Uno F, 2004, CANCER RES, V64, P2969, DOI 10.1158/0008-5472.CAN-03-3702; *US CANC STAT WORK, 2004, UC CANC STAT 2001 IN; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhang M, 2004, ACTA PHARMACOL SIN, V25, P61; Zhang Peilin, 2003, Mol Cancer, V2, P1	29	51	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					6989	6996		10.1038/sj.onc.1210500	http://dx.doi.org/10.1038/sj.onc.1210500			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486070	Green Accepted			2022-12-25	WOS:000250412200004
J	Chen, ZS; Gu, J				Chen, Zhengshan; Gu, Jiang			Immunoglobulin G expression in carcinomas and cancer cell lines	FASEB JOURNAL			English	Article						in situ hybridization; laser microdissection	INDUCED CYTIDINE DEAMINASE; CLASS SWITCH RECOMBINATION; V(D)J RECOMBINATION; IMMUNOLOGICAL ENHANCEMENT; GERMINAL CENTER; TUMOR; AID; GENE; ANTIBODIES; CHAIN	The traditional view that immunoglobulin is produced only by differentiated B lymphocytes has been challenged as immunoglobulin genes have been found to be expressed in nonhematopoietic human cancer cells. However, this phenomenon has not been widely accepted, and knowledge about this newly discovered concept is limited. In this study, we investigated the IgG1 heavy chain (IGHG1) constant region gene and IgG protein expression in 6 cell lines, including epithelial cancer cells, and in tissues from 66 hyperplasias, adenomas, and carcinomas. We also studied the mechanism of IgG production in these cells by examining the expression of RAG1 ( recombination activating gene 1), RAG2, and AID (activation-induced cytidine deaminase). In cancer cell lines, mRNA of the IGHG1 constant region and I gamma-C gamma sterile transcript were detected by nested RT-PCR, and Ig gamma and Ig kappa proteins were detected by immunofluorescence and Western blot. In surgically resected carcinoma tissues, we detected mRNA of the IGHG1 constant region by in situ hybridization, and by laser microdissection-assisted nested RT-PCR. Ig gamma and Ig kappa proteins were detected by immunohistochemistry. The V( D)J recombination of IgH and IgL loci, the S gamma 1/2-S mu switch circle, and the expression of RAG1 and RAG2 were also found in these cancer cell lines. These data suggest that cancer cells are capable of producing IgG. Because of its potential biological and clinical significance, this phenomenon warrants further investigation.-Chen, Z. and Gu, J. Immunoglobulin G expression in carcinomas and cancer cell lines.	Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Pathol, Beijing 100083, Peoples R China	Peking University	Gu, J (corresponding author), Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Pathol, 38 Xueyuan Rd,Haidian Dist, Beijing 100083, Peoples R China.	Jianggu@bjmu.edu.cn	Chen, Zhengshan/J-7499-2014	Gu, Jiang/0000-0002-0706-8329				Babbage G, 2006, CANCER RES, V66, P3996, DOI 10.1158/0008-5472.CAN-05-3704; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Cerutti A, 2002, J IMMUNOL, V169, P6594, DOI 10.4049/jimmunol.169.11.6594; Cerutti A, 1998, J IMMUNOL, V160, P2145; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Gercel-Taylor C, 2001, GYNECOL ONCOL, V81, P71, DOI 10.1006/gyno.2000.6102; Goebel P, 2001, J EXP MED, V194, P645, DOI 10.1084/jem.194.5.645; HELLSTROM I, 1969, P NATL ACAD SCI USA, V62, P362, DOI 10.1073/pnas.62.2.362; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KALISS N, 1958, CANCER RES, V18, P992; Kimoto Y, 1998, GENE CHROMOSOME CANC, V22, P83, DOI 10.1002/(SICI)1098-2264(1998)22:1<83::AID-GCC12>3.0.CO;2-O; Liu HD, 2007, CELL SIGNAL, V19, P419, DOI 10.1016/j.cellsig.2006.07.012; Liu YJ, 1996, IMMUNITY, V4, P241, DOI 10.1016/S1074-7613(00)80432-X; Luborsky JL, 2005, AM J REPROD IMMUNOL, V54, P55, DOI 10.1111/j.1600-0897.2005.00287.x; LYNCH S, 1995, EUR J IMMUNOL, V25, P1143, DOI 10.1002/eji.1830250502; Maizels N, 2005, ANNU REV GENET, V39, P23, DOI 10.1146/annurev.genet.39.073003.110544; Margni RA, 1998, IMMUNOL REV, V163, P77, DOI 10.1111/j.1600-065X.1998.tb01189.x; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Oettinger MA, 1999, CURR OPIN CELL BIOL, V11, P325, DOI 10.1016/S0955-0674(99)80044-1; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Prehn RT, 1996, CANCER RES, V56, P937; PREHN RT, 1994, CANCER RES, V54, P908; Qiu XY, 2003, CANCER RES, V63, P6488; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Schreiber H, 2000, SEMIN CANCER BIOL, V10, P351, DOI 10.1006/scbi.2000.0331; SJOGREN HO, 1971, P NATL ACAD SCI USA, V68, P1372, DOI 10.1073/pnas.68.6.1372; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; SNELL GD, 1957, CANCER RES, V17, P2; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zenclussen AC, 2001, AM J REPROD IMMUNOL, V45, P289, DOI 10.1111/j.8755-8920.2001.450504.x	35	105	116	2	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2931	2938		10.1096/fj.07-8073com	http://dx.doi.org/10.1096/fj.07-8073com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475920				2022-12-25	WOS:000249237500033
J	Kovsan, J; Ben-Romano, R; Souza, SC; Greenberg, AS; Rudich, A				Kovsan, Julia; Ben-Romano, Ronit; Souza, Sandra C.; Greenberg, Andrew S.; Rudich, Assaf			Regulation of adipocyte lipolysis by degradation of the perilipin protein - Nelfinavir enhances lysosome-mediated perilipin proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; DROPLET-ASSOCIATED PROTEINS; NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE; OXIDATIVE STRESS; POSTTRANSLATIONAL REGULATION; MOLECULAR-MECHANISMS; OBESITY RISK; EXPRESSION; AUTOPHAGY	A decrease in the lipid droplet-associated protein perilipin may constitute a mechanism for enhanced adipocyte lipolysis under nonstimulated (basal) conditions, and increased basal lipolysis has been linked to whole body metabolic dysregulation. Here we investigated whether the lipolytic actions of the human immunodeficiency virus protease inhibitor, nelfinavir, are mediated by decreased perilipin protein content and studied the mechanisms by which it occurs. Time course analysis revealed that the decrease in perilipin protein content preceded the increase in lipolysis. A causative relationship was suggested by demonstrating that nelfinavir potently increased lipolysis in adipocytes derived from mouse embryonal fibroblasts expressing perilipin but not in mouse embryonal fibroblast adipocytes devoid of perilipin and that adenoviral mediated overexpression of perilipin in 3T3-L1 adipocytes blocked the lipolytic actions of nelfinavir. Nelfinavir did not alter mRNA content of perilipin but rather decreased perilipin proteins t(1/2) from >70 to 12 h. Protein degradation of perilipin in both control and nelfinavir-treated adipocytes could be prevented by inhibiting lysosomal proteolysis using leupeptin or NH4Cl but not by the proteasome inhibitor MG-132. We propose that proteolysis of perilipin involving the lysosomal protein degradation machinery may constitute a novel mechanism for enhancing adipocyte lipolysis.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84103 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, S Daniel Abraham Ctr Hlth & Nutr, IL-84103 Beer Sheva, Israel; Tufts Univ, Jean Mayer USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA	Ben Gurion University; Ben Gurion University; Tufts University; United States Department of Agriculture (USDA)	Rudich, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84103 Beer Sheva, Israel.	rudich@bgu.ac.il		Rudich, Assaf/0000-0002-1366-1444	NIDDK NIH HHS [DK50647] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050647] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aboulaich N, 2006, J BIOL CHEM, V281, P11446, DOI 10.1074/jbc.C500461200; Adler-Wailes DC, 2005, J CLIN ENDOCR METAB, V90, P3251, DOI 10.1210/jc.2004-2194; Arvidsson E, 2004, J INTERN MED, V255, P595, DOI 10.1111/j.1365-2796.2004.01314.x; Ben-Romano R, 2003, AIDS, V17, P23, DOI 10.1097/00002030-200301030-00005; Ben-Romano R, 2004, DIABETOLOGIA, V47, P1107, DOI 10.1007/s00125-004-1408-5; Ben-Romano R, 2006, ANTIVIR THER, V11, P1051; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Corella D, 2005, J CLIN ENDOCR METAB, V90, P5121, DOI 10.1210/jc.2005-0576; Corella D, 2006, DIABETES CARE, V29, P1313, DOI 10.2337/dc06-0045; Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57; Dice J F, 1990, Semin Cell Biol, V1, P449; Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gross DN, 2006, MOL ENDOCRINOL, V20, P459, DOI 10.1210/me.2005-0323; Hadigan C, 2002, METABOLISM, V51, P1143, DOI 10.1053/meta.2002.34704; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Kern PA, 2004, J CLIN ENDOCR METAB, V89, P1352, DOI 10.1210/jc.2003-031388; Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152; Londos C, 1996, INT J OBESITY, V20, pS97; Majeski AE, 2004, INT J BIOCHEM CELL B, V36, P2435, DOI 10.1016/j.biocel.2004.02.013; Marino G, 2004, CELL MOL LIFE SCI, V61, P1439, DOI 10.1007/s00018-004-4012-4; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Miyoshi H, 2006, J BIOL CHEM, V281, P15837, DOI 10.1074/jbc.M601097200; Moore MN, 2006, MAR ENVIRON RES, V62, pS420, DOI 10.1016/j.marenvres.2006.04.055; Qi L, 2005, J MOL MED, V83, P448, DOI 10.1007/s00109-004-0630-4; Qi L, 2004, OBES RES, V12, P1758, DOI 10.1038/oby.2004.218; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosenstock M, 2001, DIABETOLOGIA, V44, P55, DOI 10.1007/s001250051580; Rudich A, 2001, DIABETES, V50, P1425, DOI 10.2337/diabetes.50.6.1425; Rudich A, 2005, ACTA PHYSIOL SCAND, V183, P75, DOI 10.1111/j.1365-201X.2004.01383.x; Rudich A, 1998, DIABETES, V47, P1562, DOI 10.2337/diabetes.47.10.1562; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tirosh A, 1999, J BIOL CHEM, V274, P10595, DOI 10.1074/jbc.274.15.10595; van der Valk M, 2001, AIDS, V15, P2093, DOI 10.1097/00002030-200111090-00004; Vincent S, 2004, JAIDS-J ACQ IMM DEF, V37, P1556, DOI 10.1097/00126334-200412150-00003; Wang YX, 2003, OBES RES, V11, P930, DOI 10.1038/oby.2003.128; Xu GH, 2006, BBA-MOL CELL BIOL L, V1761, P83, DOI 10.1016/j.bbalip.2005.12.005; Xu GH, 2005, J BIOL CHEM, V280, P42841, DOI 10.1074/jbc.M506569200	44	67	69	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21704	21711		10.1074/jbc.M702223200	http://dx.doi.org/10.1074/jbc.M702223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17488708	hybrid			2022-12-25	WOS:000248196800017
J	Rentz, TJ; Poobalarahi, F; Bornstein, P; Sage, EH; Bradshaw, AD				Rentz, Tyler J.; Poobalarahi, Felicitta; Bornstein, Paul; Sage, E. Helene; Bradshaw, Amy D.			SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRICELLULAR PROTEIN SPARC; EHLERS-DANLOS-SYNDROME; NULL MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; FIBRIL ABNORMALITIES; TARGETED DISRUPTION; BINDING-SITES; III COLLAGENS; HUMAN-SKIN; EXPRESSION	A characterization of the factors that control collagen fibril formation is critical for an understanding of tissue organization and the mechanisms that lead to fibrosis. SPARC (secreted protein acidic and rich in cysteine) is a counter-adhesive protein that binds collagens. Herein we show that collagen fibrils in SPARC-null skin from mice 1 month of age were inefficient in fibril aggregation and accumulated in the diameter range of 60-70 nm, a proposed intermediate in collagen fibril growth. In vitro, procollagen I produced by SPARC-null dermal fibroblasts demonstrated an initial preferential association with cell layers, in comparison to that produced by wild-type fibroblasts. However, the collagen I produced by SPARC-null cells was not efficiently incorporated into detergent-insoluble fractions. Coincident with an initial increase in cell association, greater amounts of total collagen I were present as processed forms in SPARC-null versus wild-type cells. Addition of recombinant SPARC reversed collagen I association with cell layers and decreased the processing of procollagen I in SPARC-null cells. Although collagen fibers formed on the surface of SPARC-null fibroblasts earlier than those on wildtype cells, fibers on SPARC-null fibroblasts did not persist. We conclude that SPARC mediates the association of procollagen I with cells, as well as its processing and incorporation into the extracellular matrix.	Med Univ S Carolina, Dept Med, Charleston, SC 29412 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Benaroya Res Inst Virginia Mason, Hope Heart Program, Seattle, WA 98101 USA	Medical University of South Carolina; University of Washington; University of Washington Seattle; Benaroya Research Institute; Virginia Mason Medical Center	Bradshaw, AD (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, 114 Doughty St, Charleston, SC 29425 USA.	bradshad@musc.edu			NIAMS NIH HHS [AR11248] Funding Source: Medline; NIGMS NIH HHS [K01 GM40711] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR011248, R37AR011248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Birk DE, 1997, DEV DYNAM, V208, P291; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Bradshaw Amy D., 2000, Molecular Cell Biology Research Communications, V3, P345, DOI 10.1006/mcbr.2000.0237; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Delany AM, 2003, ENDOCRINOLOGY, V144, P2588, DOI 10.1210/en.2002-221044; Emerson RO, 2006, J CELL BIOCHEM, V98, P701, DOI 10.1002/jcb.20867; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FLEISCHMAJER R, 1988, J HISTOCHEM CYTOCHEM, V36, P1425, DOI 10.1177/36.11.3049791; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; FRIZELL E, 1995, HEPATOLOGY, V21, P847, DOI 10.1002/hep.1840210335; Gardner H, 1999, J CELL SCI, V112, P263; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KUHN C, 1995, AM J PATHOL, V147, P1759; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANDE SR, 1995, J BIOL CHEM, V270, P17858, DOI 10.1074/jbc.270.30.17858; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; Li SH, 2003, AM J PATHOL, V163, P1045, DOI 10.1016/S0002-9440(10)63464-5; Liaw L, 1998, J CLIN INVEST, V101, P1468; Mao JR, 2002, NAT GENET, V30, P421, DOI 10.1038/ng850; Norose K, 1998, INVEST OPHTH VIS SCI, V39, P2674; Pichler RH, 1996, KIDNEY INT, V50, P1978, DOI 10.1038/ki.1996.520; Prockop D.J., 1994, ASSEMBLY COLLAGEN FI; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Sullivan MM, 2006, J BIOL CHEM, V281, P27621, DOI 10.1074/jbc.M510507200; Takeda U, 2002, J INVEST DERMATOL, V119, P678, DOI 10.1046/j.1523-1747.2002.01863.x; Taneda S, 2003, J AM SOC NEPHROL, V14, P968, DOI 10.1097/01.ASN.0000054498.83125.90; Tasheva ES, 2002, MOL VIS, V8, P407; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; VUORIO T, 1991, J RHEUMATOL, V18, P247; Wang H, 2005, ANAL CHEM, V77, P6765, DOI 10.1021/ac051349d; Watson RB, 1998, J MOL BIOL, V278, P195, DOI 10.1006/jmbi.1998.1680; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Yan Q, 2003, J HISTOCHEM CYTOCHEM, V51, P503, DOI 10.1177/002215540305100412; Yan Q, 2002, J CELL SCI, V115, P2747; Zhou XD, 2006, ARTHRITIS RHEUM-US, V54, P2626, DOI 10.1002/art.21973	50	120	127	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22062	22071		10.1074/jbc.M700167200	http://dx.doi.org/10.1074/jbc.M700167200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17522057	hybrid			2022-12-25	WOS:000248196800053
J	Chen, S; Sanchez-Fernandez, R; Lyver, ER; Dancis, A; Rea, PA				Chen, Sixue; Sanchez-Fernandez, Rocio; Lyver, Elise R.; Dancis, Andrew; Rea, Philip A.			Functional characterization of AtATM1, AtATM2, and AtATM3, a subfamily of Arabidopsis half-molecule ATP-binding cassette transporters implicated in iron homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABC TRANSPORTER; PROTEIN; MUTATION; GENE; MEMBRANE; ATM1P	The functional capabilities of one of the smallest subfamilies of ATP-binding cassette transporters from Arabidopsis thaliana, the AtATMs, are described. Designated AtATM1, AtAATM2, and AtATM3, these half-molecule ABC proteins are homologous to the yeast mitochondrial membrane protein ATM1 (ScATM1), which is clearly implicated in the export of mitochondrially synthesized iron/sulfur clusters. Yeast ATM1-deficient (atm1) mutants grow very slowly (have a petite phenotype), are respiration-deficient, accumulate toxic levels of iron in their mitochondria, and show enhanced compensatory high affinity iron uptake. Of the three Arabidopsis ATMs, AtATM3 bears the closest functional resemblance to ScATM1. Heterologously expressed AtATM3 is not only able to complement the yeast atm1 petite phenotype but is also able to suppress the constitutively high capacity for high affinity iron uptake associated with loss of the chromosomal copy of ScATM1, abrogate intra-mitochondrial iron hyperaccumulation, and restore mitochondrial respiratory function and cytochrome c levels. By comparison, AtATM1 only weakly suppresses the atm1 phenotype, and AtATM2 exerts little or no suppressive action but instead is toxic when expressed in this system. The differences between AtATM3 and AtATM1 are maintained after exchanging their target peptides, and these proteins as well as AtATM2 colocalize with the mitochondrial fluor MitoTracker Red when expressed in yeast as GFP fusions. Although its toxicity when heterologously expressed in yeast, except when fused with GFP, precludes the functional analysis of native AtATM2, a common function, mitochondrial export of Fe/S clusters or their precursors for the assembly of cytosolic Fe/S proteins, is inferred for AtATM3 and AtATM1.	Univ Penn, Carolyn Hoff Lynch Biol Lab, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Rea, PA (corresponding author), Univ Penn, Carolyn Hoff Lynch Biol Lab, Inst Plant Sci, Dept Biol, 433 S Univ Ave, Philadelphia, PA 19104 USA.	parea@sas.upenn.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053953, R01DK053953] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53953] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Babiychuk E, 1997, P NATL ACAD SCI USA, V94, P12722, DOI 10.1073/pnas.94.23.12722; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Garcia O, 2004, J MOL BIOL, V343, P249, DOI 10.1016/j.jmb.2004.07.093; Hanikenne M, 2005, PLANT CELL ENVIRON, V28, P863, DOI 10.1111/j.1365-3040.2005.01335.x; Hansen CH, 2001, J BIOL CHEM, V276, P11078, DOI 10.1074/jbc.M010123200; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Kim DY, 2006, PLANT PHYSIOL, V140, P922, DOI 10.1104/pp.105.074146; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lu YP, 1997, P NATL ACAD SCI USA, V94, P8243, DOI 10.1073/pnas.94.15.8243; Mitsuhashi N, 2000, J BIOL CHEM, V275, P17536, DOI 10.1074/jbc.275.23.17536; MONDAL AK, 1990, BIOCHEM BIOPH RES CO, V170, P1, DOI 10.1016/0006-291X(90)91232-H; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; OGUR M, 1957, SCIENCE, V125, P928, DOI 10.1126/science.125.3254.928; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; REA PA, 2003, ABC PROTEINS BACTERI, P335; Rea PA, 2007, ANNU REV PLANT BIOL, V58, P347, DOI 10.1146/annurev.arplant.57.032905.105406; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Senbongi H, 1999, MOL GEN GENET, V262, P426; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	26	65	78	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21561	21571		10.1074/jbc.M702383200	http://dx.doi.org/10.1074/jbc.M702383200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17517886	hybrid			2022-12-25	WOS:000248047500083
J	Gershater, MC; Cummins, I; Edwards, R				Gershater, Markus C.; Cummins, Ian; Edwards, Robert			Role of a carboxylesterase in herbicide bioactivation in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; ESTERASE-ACTIVITY; PURIFICATION; XENOBIOTICS; HYDROLASE; FAMILY; WHEAT; GLUCOSYLTRANSFERASE; IDENTIFICATION; METABOLISM	Arabidopsis thaliana contains multiple carboxyesterases (AtCXEs) with activities toward xenobiotics, including herbicide esters that are activated to their phytotoxic acids upon hydrolysis. On the basis of their susceptibility to inhibition by organophosphates, these AtCXEs are all serine hydrolases. Using a trifunctional probe bearing a fluorophosphonate together with biotin and rhodamine to facilitate detection and recovery, four dominant serine hydrolases were identified in the proteome of Arabidopsis. Using a combination of protein purification, capture with the trifunctional probe and proteomics, one of these hydrolases, AtCXE12, was shown to be the major carboxyesterase responsible for hydrolyzing the pro-herbicide methyl-2,4-dichlorophenoxyacetate (2,4-D-methyl) to the phytotoxic acid 2,4-dichlorophenoxyacetic acid. Recombinant expression of the other identified hydrolases showed that AtCXE12 was unique in hydrolyzing 2,4-D-methyl. To determine the importance of AtCXE12 in herbicide metabolism and efficacy, the respective tDNA knock-out (atcxe12) plants were characterized and shown to lack expression of AtCXE12 and have greatly reduced levels of 2,4-D-methyl-hydrolyzing activity. Young atcxe12 seedlings were less sensitive than wild type plants to 2,4-D-methyl, confirming a role for the enzyme in herbicide bioactivation in Arabidopsis.	Univ Durham, Ctr Bioact Chem, Durham DH1 3LE, England	Durham University	Edwards, R (corresponding author), Univ Durham, Ctr Bioact Chem, Durham DH1 3LE, England.	Robert.Edwards@durham.ac.uk		Edwards, Robert/0000-0003-0809-5991				Adam GC, 2002, MOL CELL PROTEOMICS, V1, P828, DOI 10.1074/mcp.T200007-MCP200; Akashi T, 2005, PLANT PHYSIOL, V137, P882, DOI 10.1104/pp.104.056747; Baudouin E, 1997, EUR J BIOCHEM, V248, P700, DOI 10.1111/j.1432-1033.1997.t01-1-00700.x; Bowles D, 2005, CURR OPIN PLANT BIOL, V8, P254, DOI 10.1016/j.pbi.2005.03.007; Brazier-Hicks M, 2005, PLANT J, V42, P556, DOI 10.1111/j.1365-313X.2005.02398.x; Brick DJ, 1995, FEBS LETT, V377, P475, DOI 10.1016/0014-5793(95)01405-5; Cummins I, 2004, PLANT J, V39, P894, DOI 10.1111/j.1365-313X.2004.02174.x; Cummins I, 2001, PHYSIOL PLANTARUM, V113, P477, DOI 10.1034/j.1399-3054.2001.1130406.x; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; Edwards R, 2005, ADV BOT RES, V42, P1, DOI 10.1016/S0065-2296(05)42001-7; Evans MJ, 2006, CHEM REV, V106, P3279, DOI 10.1021/cr050288g; Fraser CM, 2005, PLANT PHYSIOL, V138, P1136, DOI 10.1104/pp.104.057950; Haslam R, 2001, PESTIC BIOCHEM PHYS, V71, P178, DOI 10.1006/pest.2001.2575; Hayashi M, 1998, PLANT CELL, V10, P183, DOI 10.1105/tpc.10.2.183; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; Kordic S, 2002, ARCH BIOCHEM BIOPHYS, V399, P232, DOI 10.1006/abbi.2002.2772; KRELL HW, 1984, EUR J BIOCHEM, V143, P57, DOI 10.1111/j.1432-1033.1984.tb08339.x; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Loutre C, 2003, PLANT J, V34, P485, DOI 10.1046/j.1365-313X.2003.01742.x; Marshall SDG, 2003, J MOL EVOL, V57, P487, DOI 10.1007/s00239-003-2492-8; Nandula VK, 2000, PESTIC BIOCHEM PHYS, V68, P148, DOI 10.1006/pest.2000.2508; Oakeshott JG, 1999, BIOESSAYS, V21, P1031; PREISS U, 1988, PESTIC SCI, V23, P13, DOI 10.1002/ps.2780230103; Rea PA, 1998, ANNU REV PLANT PHYS, V49, P727, DOI 10.1146/annurev.arplant.49.1.727; Richmond TA, 1999, PLANT CELL, V11, P1911, DOI 10.1105/tpc.11.10.1911; Ruiz-Santaella JP, 2006, PLANTA, V223, P191, DOI 10.1007/s00425-005-0075-1; Sandermann H, 2004, TRENDS PLANT SCI, V9, P406, DOI 10.1016/j.tplants.2004.06.001; Schuler MA, 1996, CRIT REV PLANT SCI, V15, P235, DOI 10.1080/713608134; Sessions A, 2002, PLANT CELL, V14, P2985, DOI 10.1105/tpc.004630; Tripathi LP, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-200; Waspi U, 1998, EUR J BIOCHEM, V254, P32, DOI 10.1046/j.1432-1327.1998.2540032.x	31	43	47	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21460	21466		10.1074/jbc.M701985200	http://dx.doi.org/10.1074/jbc.M701985200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17519238	hybrid			2022-12-25	WOS:000248047500073
J	Maksumova, L; Wang, YN; Wong, NKY; Le, HT; Pallen, CJ; Johnson, P				Maksumova, Lola; Wang, Yanni; Wong, Nelson K. Y.; Le, Hoa T.; Pallen, Catherine J.; Johnson, Pauline			Differential function of PTP alpha and PTP alpha Y789F in T cells and regulation of PTP alpha phosphorylation at tyr-789 by CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE-ALPHA; SRC-FAMILY KINASES; PROTEIN-KINASE; LIPID RAFTS; PHOSPHOTYROSINE PHOSPHATASE; CYTOPLASMIC DOMAIN; ACTIVATION; LCK; FYN; ADAPTER	CD45 is a major membrane protein tyrosine phosphatase (PTP) expressed in T cells where it regulates the activity of Lck, a Src family kinase important for T cell receptor-mediated activation. PTP alpha is a more widely expressed transmembrane PTP that has been shown to regulate the Src family kinases, Src and Fyn, and is also present in T cells. Here, PTP alpha was phosphorylated at Tyr-789 in CD45(-) T cells but not in CD45(+) T cells suggesting that CD45 could regulate the phosphorylation of PTP alpha at this site. Furthermore, CD45 could directly dephosphorylate PTP alpha in vitro. Expression of PTP alpha and PTP alpha-Y789F in T cells revealed that the mutant had a reduced ability to decrease Fyn and Cbp phosphorylation, to regulate the kinase activity of Fyn, and to restore T cell receptor-induced signaling events when compared with PTP alpha. Conversely, this mutant had an increased ability to prevent Pyk2 phosphorylation and CD44-mediated cell spreading when compared with PTP alpha. These data demonstrate distinct activities of PTP alpha and PTP alpha-Y789F in T cells and identify CD45 as a regulator of PTP alpha phosphorylation at tyrosine 789 in T cells.	Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z3, Canada; Child & Family Res Inst, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; Child & Family Research Institute	Johnson, P (corresponding author), Univ British Columbia, Inst Life Sci, Dept Microbiol & Immunol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	pauline@interchange.ubc.ca	Johnson, Pauline/G-9659-2019; Wong, Nelson/S-5526-2016	Johnson, Pauline/0000-0001-7367-4653; Wong, Nelson/0000-0002-7003-6020; Pallen, Catherine/0000-0002-3576-5295				Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Chen M, 2006, J BIOL CHEM, V281, P11972, DOI 10.1074/jbc.M600561200; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; D'Oro U, 1999, J IMMUNOL, V162, P1879; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; DEANS JP, 1992, EUR J IMMUNOL, V22, P661, DOI 10.1002/eji.1830220308; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; Edmonds SD, 2002, J IMMUNOL, V169, P5036, DOI 10.4049/jimmunol.169.9.5036; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Filipp D, 2004, J IMMUNOL, V172, P4266, DOI 10.4049/jimmunol.172.7.4266; Filipp D, 2003, J EXP MED, V197, P1221, DOI 10.1084/jem.20022112; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JOHNSON P, 2000, MOD ASP IMMUNOBIOL, V1, P156; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Maksumova L, 2005, J IMMUNOL, V175, P7947, DOI 10.4049/jimmunol.175.12.7947; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; Ng DHW, 1997, BIOCHEM J, V327, P867; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; Ostergaard HL, 2005, IMMUNOL RES, V31, P267, DOI 10.1385/IR:31:3:267; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Stone JD, 1997, J IMMUNOL, V158, P5773; SU J, 1994, J BIOL CHEM, V269, P18731; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037	39	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20925	20932		10.1074/jbc.M703157200	http://dx.doi.org/10.1074/jbc.M703157200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17507376	hybrid			2022-12-25	WOS:000248047500018
J	De Lay, NR; Cronan, JE				De lay, Nicholas R.; Cronan, John E.			In vivo functional analyses of the type II Acyl carrier proteins of fatty acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOSPHOPANTETHEINYL TRANSFERASE; PHOSPHOLIPID-SYNTHESIS; PLASMODIUM-FALCIPARUM; GENE-EXPRESSION; SYNTHASE; RESIDUES; BINDING; REVEAL; MUTANT	Acyl carrier protein (ACP) is a key component of the fatty acid synthesis pathways of both type I and type II synthesis systems. A large number of structure-function studies of various type II ACPs have been reported, but all are in vitro studies that assayed function or interaction of mutant ACPs with various enzymes of fatty acid synthesis or transfer. Hence in these studies functional properties of various mutant ACPs were assayed with only a subset of the many ACP-interacting proteins, which may not give an accurate overall view of the function of these proteins in vivo. This is especially so because Escherichia coli ACP has been reported to interact with several proteins that have no known roles in lipid metabolism. We therefore tested a large number of mutant derivatives of E. coli ACP carrying single amino acid substitutions for their abilities to restore growth to an E. coli strain carrying a temperature-sensitive mutation in acpP, the gene that encodes ACP. Many of these mutant proteins had previously been tested in vitro thus providing data for comparison with our results. We found that several mutant ACPs containing substitutions of ACP residues reported previously to be required for ACP function in vitro support normal growth of the acpP mutant strain. However, several mutant proteins reported to be severely defective in vitro failed to support growth of the acpP strain in vivo ( or supported only weak growth). A collection of ACPs from diverse bacteria and from three eukaryotic organelles was also tested. All of the bacterial ACPs tested restored growth to the E. coli acpP mutant strain except those from two related bacteria, Enterococcus faecalis and Lactococcus lactis. Only one of the three eukaryotic organellar ACPs allowed growth. Strikingly the ACP is that of the apicoplast of Plasmodium falciparum ( the protozoan that causes malaria). The fact that an ACP from a such diverse organism can replace AcpP functionin E. coli suggests that some of the protein-protein interactions detected for AcpP may be not be essential for growth of E.	Univ Illinois, Dept Microbiol, B103 Chem & Life Sci Lab, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, B103 Chem & Life Sci Lab, 601 S Goodwin Ave, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Cronan, John/V-6626-2019	De Lay, Nicholas/0000-0003-2249-7073	NIAID NIH HHS [AI 15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEREMAND PD, 1987, ARCH BIOCHEM BIOPHYS, V256, P90, DOI 10.1016/0003-9861(87)90428-0; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Cai L, 2006, NATURE, V440, P358, DOI 10.1038/nature04599; Cronan JE, 2006, NAT CHEM BIOL, V2, P232, DOI 10.1038/nchembio0506-232; Cronan JE, 2006, PLASMID, V55, P152, DOI 10.1016/j.plasmid.2005.07.001; Cronan JE, 2005, FEBS LETT, V579, P4892, DOI 10.1016/j.febslet.2005.07.077; Cronan JE, 2004, CHEM BIOL, V11, P1601, DOI 10.1016/j.chembiol.2004.11.011; CRONAN JE, 1988, GENE, V70, P161, DOI 10.1016/0378-1119(88)90114-X; CRONAN JE, 1982, J BIOL CHEM, V257, P5013; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; De Lay NR, 2006, MOL MICROBIOL, V61, P232, DOI 10.1111/j.1365-2958.2006.05222.x; De Lay NR, 2006, J BACTERIOL, V188, P287, DOI 10.1128/JB.188.1.287-296.2006; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; FELL D, 1996, UNDERSTANDING CONTRO; Flaman AS, 2001, J BIOL CHEM, V276, P35934, DOI 10.1074/jbc.M101849200; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Golding I, 2005, CELL, V123, P1025, DOI 10.1016/j.cell.2005.09.031; Gong H, 2003, BIOCHEM BIOPH RES CO, V302, P35, DOI 10.1016/S0006-291X(03)00108-6; Gong HS, 2007, J BIOL CHEM, V282, P4494, DOI 10.1074/jbc.M608234200; Good L, 2001, NAT BIOTECHNOL, V19, P360, DOI 10.1038/86753; Gully D, 2006, PROTEOMICS, V6, P282, DOI 10.1002/pmic.200500115; Gully D, 2003, FEBS LETT, V548, P90, DOI 10.1016/S0014-5793(03)00746-4; Heinrich R., 1996, REGULATION CELLULAR; HILL RB, 1995, PROTEIN EXPRES PURIF, V6, P394, DOI 10.1006/prep.1995.1052; Jain NU, 2004, J MOL BIOL, V343, P1379, DOI 10.1016/j.jmb.2004.08.103; JENSEN PR, 1993, EUR J BIOCHEM, V211, P181, DOI 10.1111/j.1432-1033.1993.tb19885.x; JONES PJ, 1987, J BIOL CHEM, V262, P8963; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; Khlebnikov A, 2002, BIOTECHNOL PROGR, V18, P672, DOI 10.1021/bp010141k; Kim Y, 2006, BIOCHEM BIOPH RES CO, V341, P776, DOI 10.1016/j.bbrc.2006.01.025; Lu YJ, 2006, MOL CELL, V23, P765, DOI 10.1016/j.molcel.2006.06.030; Lu YJ, 2005, J BIOL CHEM, V280, P30342, DOI 10.1074/jbc.M504637200; MARCH JB, 1989, MOL MICROBIOL, V3, P903, DOI 10.1111/j.1365-2958.1989.tb00239.x; Mofid MR, 1999, ACTA CRYSTALLOGR D, V55, P1098, DOI 10.1107/S0907444999003674; Mootz HD, 2001, J BIOL CHEM, V276, P37289, DOI 10.1074/jbc.M103556200; Nichols BP, 1998, J BACTERIOL, V180, P6408; Park SJ, 2003, J BIOCHEM MOL BIOL, V36, P505; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; Prigge ST, 2003, BIOCHEMISTRY-US, V42, P1160, DOI 10.1021/bi026847k; Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Reed MAC, 2003, ORG BIOMOL CHEM, V1, P463, DOI 10.1039/b208941f; ROCK CO, 1979, J BIOL CHEM, V254, P9778; Rock CO, 2002, BIOCHEM BIOPH RES CO, V292, P1155, DOI 10.1006/bbrc.2001.2022; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Roujeinikova A, 2002, STRUCTURE, V10, P825, DOI 10.1016/S0969-2126(02)00775-X; Roujeinikova A, 2007, J MOL BIOL, V365, P135, DOI 10.1016/j.jmb.2006.09.049; SAUER F, 1964, P NATL ACAD SCI USA, V52, P1360, DOI 10.1073/pnas.52.6.1360; SINGER M, 1989, MICROBIOL REV, V53, P1; Smith S, 2006, SCIENCE, V311, P1251, DOI 10.1126/science.1125411; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Srisailam S, 2006, PROTEINS, V64, P800, DOI 10.1002/prot.21016; VAGELOS PR, 1966, FED PROC, V25, P1485; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; Wang HH, 2004, BIOCHEMISTRY-US, V43, P11782, DOI 10.1021/bi0487600; Wang HH, 2004, J BIOL CHEM, V279, P34489, DOI 10.1074/jbc.M403874200; Wildermuth MC, 2000, GENOME BIOL, V1; Witkowski A, 2004, CHEM BIOL, V11, P1667, DOI 10.1016/j.chembiol.2004.09.016; Worsham LAS, 2003, BIOCHEMISTRY-US, V42, P167, DOI 10.1021/bi0261950; Yu J, 2006, SCIENCE, V311, P1600, DOI 10.1126/science.1119623; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200; Zhang YQ, 2003, J BIOL CHEM, V278, P10417, DOI 10.1074/jbc.M211044200	64	60	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20319	20328		10.1074/jbc.M703789200	http://dx.doi.org/10.1074/jbc.M703789200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17522044	hybrid			2022-12-25	WOS:000247819300035
J	Shi, SL; Ge, CH; Luo, Y; Hou, XH; Haltiwanger, RS; Stanley, P				Shi, Shaolin; Ge, Changhui; Luo, Yi; Hou, Xinghua; Haltiwanger, Robert S.; Stanley, Pamela			The threonine that carries fucose, but not fucose, is required for cripto to facilitate nodal signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-LIKE; THROMBOSPONDIN TYPE-1 REPEATS; MAMMARY EPITHELIAL-CELLS; EMBRYONIC STEM-CELLS; O-LINKED FUCOSE; TGF-BETA SIGNALS; LIGAND-BINDING; MOUSE EMBRYO; PROTEIN O-FUCOSYL-TRANSFERASE-1; VERTEBRATE DEVELOPMENT	Cripto is a membrane-bound co-receptor for Nodal, a member of the transforming growth factor-beta superfamily. Mouse embryos lacking either Cripto or Nodal have the same lethal phenotype at embryonic day 7.5. Previous studies suggest that O-fucosylation of the epidermal growth factor-like (EGF) repeat in Cripto is essential for the facilitation of Nodal signaling. Substitution of Ala for the Thr to which O-fucose is attached led to functional inactivation of both human and mouse Cripto. However, embryos null for protein O-fucosyltransferase 1, the enzyme that adds O-fucose to EGF repeats, do not exhibit a Cripto null phenotype and die at about embryonic day 9.5. This suggested that the loss of O-fucose from the EGF repeat may not have led to the inactivation of Cripto in previous studies. Here we investigate this hypothesis and show the following: 1) protein O-fucosyltransferase 1 is indeed the enzyme that adds O-fucose to Cripto; 2) Pofut1(-/-) embryonic stem cells behave the same as Pofut1(+/+) embryonic stem cells in a Nodal signaling assay; 3) Pofut1(+/+) and Pofut1(+/+) embryoid bodies are indistinguishable in their ability to differentiate into cardiomyocytes; and 4) none of 10 amino acid substitutions at Thr72, including Ser which acquires O-fucose, rescues the activity of mouse Cripto in Nodal signaling assays. Therefore, the Thr to which O-fucose is linked in Cripto plays a key functional role, but O-fucose at Thr72 is not required for Cripto to function in cell-based signaling assays or in vivo. By contrast, we show that O-fucose, and not the Thr to which it is attached, is required in the ligand-binding domain of Notch1 for Notch1 signaling.	Albert Einstein Coll Med, Dept Cell Biol, New York, NY 10461 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Yeshiva University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Stanley, P (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, New York, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747; Shi, Shaolin/0000-0003-2297-6496	NATIONAL CANCER INSTITUTE [R01CA095022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER; NCI NIH HHS [CA 95022] Funding Source: Medline; NIGMS NIH HHS [R01 GM061126, GM 61126] Funding Source: Medline; PHS HHS [P01 13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adamson ED, 2002, J CELL PHYSIOL, V190, P267, DOI 10.1002/jcp.10072; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Bianco C, 2005, CURR TOP DEV BIOL, V67, P85, DOI 10.1016/S0070-2153(05)67003-2; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Brennan J, 2001, NATURE, V411, P965, DOI 10.1038/35082103; Chen CH, 2006, DEVELOPMENT, V133, P319, DOI 10.1242/dev.02210; Chen CH, 2004, CURR BIOL, V14, P618, DOI 10.1016/j.cub.2004.02.042; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Chen W, 2003, GLYCOBIOLOGY, V13, P43, DOI 10.1093/glycob/cwg003; Cheng SK, 2004, PLOS BIOL, V2, P215, DOI 10.1371/journal.pbio.0020030; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; De Santis ML, 1997, CELL GROWTH DIFFER, V8, P1257; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; Ebert AD, 1999, CANCER RES, V59, P4502; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hambleton S, 2004, STRUCTURE, V12, P2173, DOI 10.1016/j.str.2004.09.012; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Kenney NJ, 2004, J MAMMARY GLAND BIOL, V9, P133, DOI 10.1023/B:JOMG.0000037158.91940.1c; Kozma K, 2006, J BIOL CHEM, V281, P36742, DOI 10.1074/jbc.M605912200; Lei L, 2003, DEVELOPMENT, V130, P6411, DOI 10.1242/dev.00883; Li YX, 2003, DEVELOPMENT, V130, P2829, DOI 10.1242/dev.00498; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Minchiotti G, 2002, GENE, V287, P33, DOI 10.1016/S0378-1119(01)00892-7; Minchiotti G, 2000, MECH DEVELOP, V90, P133, DOI 10.1016/S0925-4773(99)00235-X; Minchiotti G, 2001, DEVELOPMENT, V128, P4501; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Parisi S, 2003, J CELL BIOL, V163, P303, DOI 10.1083/jcb.200303010; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Rampal R, 2005, J BIOL CHEM, V280, P42454, DOI 10.1074/jbc.M509552200; Rampal R, 2005, J BIOL CHEM, V280, P32133, DOI 10.1074/jbc.M506104200; RAMPAL R, 2007, IN PRESS CURR MOL ME; Roos C, 2002, J BIOL CHEM, V277, P3168, DOI 10.1074/jbc.m107927200; Sasamura T, 2003, DEVELOPMENT, V130, P4785, DOI 10.1242/dev.00679; Sato T, 2006, GLYCOBIOLOGY, V16, P1194, DOI 10.1093/glycob/cwl035; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schiffer SG, 2001, J BIOL CHEM, V276, P37769; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shen MM, 2003, J CLIN INVEST, V112, P500, DOI 10.1172/JCI200319546; Shi SL, 2005, MOL CELL BIOL, V25, P9503, DOI 10.1128/MCB.25.21.9503-9508.2005; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837; Wobus A M, 2002, Methods Mol Biol, V185, P127; Xu AG, 2005, J BIOL CHEM, V280, P30158, DOI 10.1074/jbc.M505569200; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Xu CH, 1999, DEVELOPMENT, V126, P483; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0	62	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20133	20141		10.1074/jbc.M702593200	http://dx.doi.org/10.1074/jbc.M702593200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17504756	hybrid			2022-12-25	WOS:000247819300014
J	van Kerkhof, P; Putters, J; Strous, GJ				van Kerkhof, Peter; Putters, Joyce; Strous, Ger J.			The ubiquitin ligase SCF(beta TrCP) regulates the degradation of the growth hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; PHOSPHORYLATION-DEPENDENT INTERACTION; BETA-TRCP; INDUCED INTERNALIZATION; DESTRUCTION MOTIF; PROTEIN; ENDOCYTOSIS; BINDING; SYSTEM; PATHWAY	SCF ubiquitin ligases play a pivotal role in the regulation of cell division and various signal transduction pathways, which in turn are involved in cell growth, survival, and transformation. SCF( TrCP) recognizes the double phosphorylated DSG Phi XS destruction motif in beta-catenin and I kappa B. We show that the same ligase drives endocytosis and degradation of the growth hormone receptor (GHR) in a ligand-independent fashion. The F-box protein beta-TrCP binds directly and specifically with its WD40 domain to a novel recognition motif, previously designated as the ubiquitin-dependent endocytosis motif. Receptor degradation requires an active neddylation system, implicating ubiquitin ligase activity. GHR-TrCP binding, but not GHR ubiquitination, is necessary for endocytosis. TrCP2 silencing is more effective on GHR degradation and endocytosis than TrCP1, although overexpression of either isoform restores TrCP function in silenced cells. Together, these findings provide direct evidence for a key role of the SCF( TrCP) in the endocytosis and degradation of an important factor in growth, immunity, and life span regulation.	Univ Utrecht, Med Ctr, Inst Biomembranes, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	Utrecht University	Strous, GJ (corresponding author), Univ Utrecht, Med Ctr, Inst Biomembranes, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	gstrous@umcutrecht.nl		van Kerkhof, Peter/0000-0002-8954-2230				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Besnard-Guerin C, 2004, J BIOL CHEM, V279, P788, DOI 10.1074/jbc.M308068200; Chew EH, 2007, CELL SIGNAL, V19, P1071, DOI 10.1016/j.cellsig.2006.12.002; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; dos Santos GMA, 2001, J BIOL CHEM, V276, P32635, DOI 10.1074/jbc.M103583200; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar KGS, 2003, EMBO J, V22, P5480; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Li Y, 2004, MOL CELL BIOL, V24, P4038, DOI 10.1128/MCB.24.9.4038-4048.2004; Mantovani F, 2003, J BIOL CHEM, V278, P42477, DOI 10.1074/jbc.M302799200; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Peters JM, 2003, MOL CELL, V11, P1420, DOI 10.1016/S1097-2765(03)00233-8; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Schantl JA, 2003, BIOCHEM J, V373, P855, DOI 10.1042/BJ20021591; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strous GJ, 2004, CURR TOP MICROBIOL, V286, P81; Strous GJ, 2002, FEBS LETT, V529, P102, DOI 10.1016/S0014-5793(02)03187-3; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Timsit YE, 2005, BIOCHEM BIOPH RES CO, V328, P550, DOI 10.1016/j.bbrc.2005.01.022; Traub LM, 2007, J CELL SCI, V120, P543, DOI 10.1242/jcs.03385; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; van Kerkhof P, 2002, ENDOCRINOLOGY, V143, P1243, DOI 10.1210/en.143.4.1243; van Kerkhof P, 2001, J BIOL CHEM, V276, P3778, DOI 10.1074/jbc.M007326200; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; WATERS M, 1999, GROWTH HORMONE RECEP, P445; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X	44	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20475	20483		10.1074/jbc.M702610200	http://dx.doi.org/10.1074/jbc.M702610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17500058	hybrid			2022-12-25	WOS:000247819300050
J	Huang, Y; Zhou, YB; Yang, W; Butters, R; Lee, HW; Li, SY; Castiblanco, A; Brown, EM; Yang, JJ				Huang, Yun; Zhou, Yubin; Yang, Wei; Butters, Robert; Lee, Hsiau-Wei; Li, Shunyi; Castiblanco, Adriana; Brown, Edward M.; Yang, Jenny J.			Identification and dissection of Ca2+-binding sites in the extracellular domain of Ca2+-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; METABOTROPIC GLUTAMATE-RECEPTOR; EF-HAND PROTEINS; BINDING SITES; LANTHANIDE AFFINITY; STRUCTURAL BASIS; CA2+ BINDING; MUTATIONS; CALMODULIN; DESIGN	Ca2+-sensing receptors (CaSRs) represent a class of receptors that respond to changes in the extracellular Ca2+ concentration ([Ca2+](o)) and activate multiple signaling pathways. A major barrier to advancing our understanding of the role of Ca2+ in regulating CaSRs is the lack of adequate information about their Ca2+-binding locations, which is largely hindered by the lack of a solved three-dimensional structure and rapid off rates due to low Ca2+-binding affinities. In this paper, we have reported the identification of three potential Ca2+-binding sites in a modeled CaSR structure using computational algorithms based on the geometric description and surface electrostatic potentials. Mutation of the predicted ligand residues in the full-length CaSR caused abnormal responses to [Ca2+] o, similar to those observed with naturally occurring activating or inactivating mutations of the CaR, supporting the essential role of these predicted Ca2+-binding sites in the sensing capability of the CaSR. In addition, to probe the intrinsic Ca2+-binding properties of the predicted sequences, we engineered two predicted continuous Ca2+-binding sequences individually into a scaffold protein provided by a non-Ca2+-binding protein, CD2. We report herein the estimation of the metal-binding affinities of these predicted sites in the CaSR by monitoring aromatic-sensitized Tb3+ fluorescence energy transfer. Removing the predicted Ca2+-binding ligands resulted in the loss of or significantly weakened cation binding. The potential Ca2+-binding residues were shown to be involved in Ca2+/Ln(3+) binding by high resolution NMR and site-directed mutagenesis, further validating our prediction of Ca2+-binding sites within the extracellular domain of the CaSR.	Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA; Georgia State Univ, Ctr Biotechnol & Drug Design, Dept Chem, Atlanta, GA 30303 USA; Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA	University System of Georgia; Georgia State University; University System of Georgia; Georgia State University; Harvard University; Brigham & Women's Hospital	Yang, JJ (corresponding author), Georgia State Univ, Dept Chem, Univ Plaza, Atlanta, GA 30303 USA.	chejjy@langate.gsu.edu	Zhou, Yubin/D-4748-2011; LEE, HSIAU-WEI/A-1415-2012	Zhou, Yubin/0000-0001-7962-0517; Huang, Yun/0000-0001-5950-9168; Lee, Hsiau-Wei/0000-0002-6060-6341	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052005, R01DK067155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM070555, R01GM062999] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52005, DK67155] Funding Source: Medline; NIGMS NIH HHS [GM62999-1, R21 GM070555, R01 GM062999-05, R01 GM062999, GM070555] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKKE M, 1995, J MOL BIOL, V252, P102, DOI 10.1006/jmbi.1995.0478; Bai M, 1999, INT J MOL MED, V4, P115; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 2004, CELL CALCIUM, V35, P197, DOI 10.1016/j.ceca.2003.10.018; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Breitwieser GE, 2004, CELL CALCIUM, V35, P209, DOI 10.1016/j.ceca.2003.10.013; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Cetani F, 2003, CLIN ENDOCRINOL, V58, P199, DOI 10.1046/j.1365-2265.2003.01696.x; Chang WH, 2004, CELL CALCIUM, V35, P183, DOI 10.1016/j.ceca.2003.10.012; Deng H, 2006, PROTEINS, V64, P34, DOI 10.1002/prot.20973; DRISCOLL PC, 1993, BIOCHEM SOC T, V21, P947, DOI 10.1042/bst0210947; Dudev T, 2005, J AM CHEM SOC, V127, P4091, DOI 10.1021/ja044404t; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; Feske S, 2003, BIOCHEM BIOPH RES CO, V311, P1117, DOI 10.1016/j.bbrc.2003.09.174; Francesconi A, 2004, J NEUROSCI RES, V75, P472, DOI 10.1002/jnr.10853; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Handford PA, 2000, BBA-MOL CELL RES, V1498, P84, DOI 10.1016/S0167-4889(00)00085-9; HELLINGA HW, 1991, J MOL BIOL, V222, P763, DOI 10.1016/0022-2836(91)90510-D; Higgins D G, 1994, Methods Mol Biol, V25, P307; HIRAOKI T, 1987, J CARDIOVASC PHARM, V10, pS14, DOI 10.1097/00005344-198710001-00004; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hu JX, 2004, J BONE MINER RES, V19, P578, DOI 10.1359/JBMR.040106; Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043-2760(03)00104-8; Ikura M, 2002, BIOESSAYS, V24, P625, DOI 10.1002/bies.10105; Jingami H, 2003, CURR OPIN NEUROBIOL, V13, P271, DOI 10.1016/S0959-4388(03)00067-9; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Maki M, 2002, BBA-PROTEINS PROTEOM, V1600, P51, DOI 10.1016/S1570-9639(02)00444-2; Malmberg NJ, 2004, BIOCHEMISTRY-US, V43, P16320, DOI 10.1021/bi0482405; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Maurer P, 1996, CURR OPIN CELL BIOL, V8, P609, DOI 10.1016/S0955-0674(96)80101-3; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Mun HC, 2004, J BIOL CHEM, V279, P51739, DOI 10.1074/jbc.M406164/200; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Pidcock E, 2001, J BIOL INORG CHEM, V6, P479, DOI 10.1007/s007750100214; Quinn SJ, 2004, J BIOL CHEM, V279, P37241, DOI 10.1074/jbc.M404520200; Sayer JA, 2003, CLIN ENDOCRINOL, V59, P419, DOI 10.1046/j.1365-2265.2003.01869.x; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Silve C, 2005, J BIOL CHEM, V280, P37917, DOI 10.1074/jbc.M506263200; Suzuki Y, 2004, J BIOL CHEM, V279, P35526, DOI 10.1074/jbc.M404831200; TEPLYAKOV AV, 1990, J MOL BIOL, V214, P261, DOI 10.1016/0022-2836(90)90160-N; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Tu CL, 2004, CELL CALCIUM, V35, P265, DOI 10.1016/j.ceca.2003.10.019; Vetter T, 2002, CURR OPIN NEPHROL HY, V11, P403, DOI 10.1097/00041552-200207000-00006; Yang W, 2002, PROTEINS, V47, P344, DOI 10.1002/prot.10093; Yang W, 2005, BIOCHEMISTRY-US, V44, P8267, DOI 10.1021/bi050463n; Yang W, 2005, J AM CHEM SOC, V127, P2085, DOI 10.1021/ja0431307; Yang W, 2003, J AM CHEM SOC, V125, P6165, DOI 10.1021/ja034724x; Ye YM, 2005, J INORG BIOCHEM, V99, P1376, DOI 10.1016/j.jinorgbio.2005.03.011; Ye YM, 2005, J AM CHEM SOC, V127, P3743, DOI 10.1021/ja042786x; Ye YM, 2003, PROTEIN ENG, V16, P429, DOI 10.1093/protein/gzg051; Ye YM, 2001, PROTEIN ENG, V14, P1001, DOI 10.1093/protein/14.12.1001; Zhang XC, 2001, BIOCHEM J, V360, P395, DOI 10.1042/0264-6021:3600395; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200; Zonta M, 2003, J PHYSIOL-LONDON, V553, P407, DOI 10.1113/jphysiol.2003.046706	62	81	81	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19000	19010		10.1074/jbc.M701096200	http://dx.doi.org/10.1074/jbc.M701096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17478419	Green Accepted, hybrid			2022-12-25	WOS:000247475300042
J	Tsai, YC; Qi, HY; Liu, LF				Tsai, Yuan-Chin; Qi, Haiyan; Liu, Leroy F.			Protection of DNA ends by telomeric 3 ' G-tail sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; IN-VITRO; QUADRUPLEX STRUCTURE; MAMMALIAN TELOMERES; TUMOR-CELLS; YEAST; POT1; CHROMOSOMES; OVERHANG	The extreme ends of eukaryotic chromosomes contain 3' extensions in the form of single-stranded G-rich repeats, referred to as telomeric 3' G-tails or overhangs. Increasing evidence has suggested that telomeric 3' G-tails can adopt a G-quadruplex conformation both in vitro and in vivo. However, the role of G-quadruplexes on the structure and function of telomeric 3' G-tails remains unclear. In the current study, we showed that the human telomeric 3' G-tail sequence protected the duplex DNA ends in cis from being recognized as double strand breaks. This protection is dependent on the G-quadruplex conformation of the 3' G-tail sequence. These results suggest that the ability of telomeric 3' G-tails to adopt the end-protecting G-quadruplex conformation may be one of the reasons for the existence of the evolutionarily conserved G-stretch motifs in telomeric DNA sequences.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, LF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	lliu@umdnj.edu		Liu, Leroy/0000-0001-9396-763X	NATIONAL CANCER INSTITUTE [R01CA102463, R01CA039662] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662, CA102463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2004, DNA REPAIR, V3, P225, DOI 10.1016/j.dnarep.2003.10.013; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Chang CC, 2006, ANAL CHEM, V78, P2810, DOI 10.1021/ac052218f; Chang CC, 2004, ANAL CHEM, V76, P4490, DOI 10.1021/ac049510s; Churikov D, 2006, MOL CELL BIOL, V26, P6971, DOI 10.1128/MCB.01011-06; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Ghosal G, 2005, NUCLEIC ACIDS RES, V33, P4692, DOI 10.1093/nar/gki777; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; Gomez D, 2006, J BIOL CHEM, V281, P38721, DOI 10.1074/jbc.M605828200; Gomez D, 2006, CANCER RES, V66, P6908, DOI 10.1158/0008-5472.CAN-06-1581; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hayashi N, 2002, MOL GENET GENOMICS, V267, P806, DOI 10.1007/s00438-002-0712-3; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Knight ZA, 2004, BIOORGAN MED CHEM, V12, P4749, DOI 10.1016/j.bmc.2004.06.022; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Qi HY, 2006, CANCER RES, V66, P11808, DOI 10.1158/0008-5472.CAN-06-1225; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; Schaffitzel C, 2001, P NATL ACAD SCI USA, V98, P8572, DOI 10.1073/pnas.141229498; Stansel RM, 2001, EMBO J, V20, P5532; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; Sun H, 2001, P NATL ACAD SCI USA, V98, P12444, DOI 10.1073/pnas.231479198; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; Yu HQ, 2006, J AM CHEM SOC, V128, P15461, DOI 10.1021/ja064536h; YU HQ, 2006, NUCL ACIDS S SER OXF, V50, P207; Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200	38	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18786	18792		10.1074/jbc.M702171200	http://dx.doi.org/10.1074/jbc.M702171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17483095	hybrid			2022-12-25	WOS:000247475300017
J	Veerman, ECI; Valentijn-Benz, M; Nazmi, K; Ruissen, ALA; Walgreen-Weterings, E; van Marle, J; Doust, AB; van't Hof, W; Bolscher, JGM; Amerongen, AVN				Veerman, Enno C. I.; Valentijn-Benz, Marianne; Nazmi, Kamran; Ruissen, Anita L. A.; Walgreen-Weterings, Els; van Marle, Jan; Doust, Alexander B.; van't Hof, Wim; Bolscher, Jan G. M.; Amerongen, Arie V. Nieuw			Energy depletion protects candida albicans against antimicrobial peptides by rigidifying its cell membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; FLUORESCENCE POLARIZATION; ACTIN POLYMERIZATION; ATP DEPLETION; HISTATIN 5; YEAST; PROTEINS; TARGET; SUSCEPTIBILITY; TRANSLOCATION	Inhibitors of the energy metabolism, such as sodium azide and valinomycin, render yeast cells completely resistant against the killing action of a number of cationic antimicrobial peptides, including the salivary antimicrobial peptide Histatin 5. In this study the Histatin 5-mediated killing of the opportunistic yeast Candida albicans was used as a model system to comprehensively investigate the molecular basis underlying this phenomenon. Using confocal and electron microscopy it was demonstrated that the energy poison azide reversibly blocked the entry of Histatin 5 at the level of the yeast cell wall. Azide treatment hardly induced depolarization of the yeast cell membrane potential, excluding it as a cause of the lowered sensitivity. In contrast, the diminished sensitivity to Histatin 5 of energy-depleted C. albicans was restored by increasing the fluidity of the membrane using the membrane fluidizer benzyl alcohol. Furthermore, rigidification of the membrane by incubation at low temperature or in the presence of the membrane rigidifier Me2SO increased the resistance against Histatin 5, while not affecting the energy charge of the cell. In line, azide induced alterations in the physical state of the interior of the lipid bilayer. These data demonstrate that changes in the physical state of the membrane underlie the increased resistance to antimicrobial peptides.	Acad Ctr Dent Amsterdam, Dept Oral Biochem, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Acad Ctr Dent, Dept Oral Biochem, NL-1081 BT Amsterdam, Netherlands; Acad Med Ctr, Cent Elect Microscopy, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands; Vrije Univ Amsterdam, Dept Phys & Astron, Biophys Sect, NL-1105 AZ Amsterdam, Netherlands	Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Veerman, ECI (corresponding author), Acad Ctr Dent Amsterdam, Dept Oral Biochem, Van der Boechorstr 7, NL-1081 BT Amsterdam, Netherlands.	eci.veerman@vumc.nl	Bolscher, Jan/ABF-6102-2021	Bolscher, Jan/0000-0001-5669-6164				Aspedon A, 1996, MICROBIOL-SGM, V142, P3389, DOI 10.1099/13500872-142-12-3389; BEAUVOIT B, 1991, BIOCHEMISTRY-US, V30, P11212, DOI 10.1021/bi00111a004; Belmont LD, 1998, J CELL BIOL, V142, P1289, DOI 10.1083/jcb.142.5.1289; Bernstein BW, 2003, J NEUROSCI, V23, P1; Bikker FJ, 2006, CHEM BIOL DRUG DES, V68, P148, DOI 10.1111/j.1747-0285.2006.00424.x; Braet F, 2003, HEPATOLOGY, V38, P394, DOI 10.1053/jhep.2003.50347; Brun S, 2003, ANTIMICROB AGENTS CH, V47, P847, DOI 10.1128/AAC.47.3.847-853.2003; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Dai JW, 1999, BIOPHYS J, V77, P3363, DOI 10.1016/S0006-3495(99)77168-7; den Hertog AL, 2004, BIOCHEM J, V379, P665, DOI 10.1042/BJ20031785; Doctor RB, 1997, AM J PHYSIOL-CELL PH, V272, pC439, DOI 10.1152/ajpcell.1997.272.2.C439; EDDY AA, 1985, BIOCHEM J, V231, P291, DOI 10.1042/bj2310291; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; FLORINECASTEEL K, 1991, FASEB J, V5, P2078, DOI 10.1096/fasebj.5.7.2010060; Gaskova D, 1999, INT J BIOCHEM CELL B, V31, P575, DOI 10.1016/S1357-2725(99)00002-3; Gaskova D, 1998, YEAST, V14, P1189, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1189::AID-YEA320>3.3.CO;2-B; GINSBURG I, 1984, INFLAMMATION, V8, P1, DOI 10.1007/BF00918349; Gonzalez B, 1997, YEAST, V13, P1347, DOI 10.1002/(SICI)1097-0061(199711)13:14<1347::AID-YEA176>3.0.CO;2-O; Gyurko C, 2001, ANTON LEEUW INT J G, V79, P297, DOI 10.1023/A:1012070600340; Haidekker MA, 2004, ANN BIOMED ENG, V32, P531, DOI 10.1023/B:ABME.0000019172.12700.b8; Helmerhorst EJ, 1999, J BIOL CHEM, V274, P7286, DOI 10.1074/jbc.274.11.7286; Hochmuth RM, 1996, BIOPHYS J, V70, P358, DOI 10.1016/S0006-3495(96)79577-2; Hui EKW, 2001, VIROLOGY, V290, P329, DOI 10.1006/viro.2001.1181; KOMOR E, 1979, P NATL ACAD SCI USA, V76, P1814, DOI 10.1073/pnas.76.4.1814; KORDEL M, 1988, J BACTERIOL, V170, P84, DOI 10.1128/jb.170.1.84-88.1988; Korobov VP, 2005, MICROBIOLOGY+, V74, P136, DOI 10.1007/s11021-005-0042-7; Koshlukova SE, 1999, J BIOL CHEM, V274, P18872, DOI 10.1074/jbc.274.27.18872; KOVAC L, 1982, BIOCHIM BIOPHYS ACTA, V721, P341, DOI 10.1016/0167-4889(82)90088-X; KUHRY JG, 1985, BIOCHIM BIOPHYS ACTA, V845, P60, DOI 10.1016/0167-4889(85)90055-2; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Li XWS, 2006, J BIOL CHEM, V281, P22453, DOI 10.1074/jbc.M604064200; Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P9799, DOI 10.1021/bi970588v; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; Murata Y, 2003, J BIOL CHEM, V278, P33185, DOI 10.1074/jbc.M300450200; Nurko S, 1996, AM J PHYSIOL-RENAL, V270, pF39, DOI 10.1152/ajprenal.1996.270.1.F39; OBRENOVITCH A, 1978, FEBS LETT, V88, P187, DOI 10.1016/0014-5793(78)80170-7; OLSON VL, 1977, CAN J MICROBIOL, V23, P166, DOI 10.1139/m77-024; Orvar BL, 2000, PLANT J, V23, P785, DOI 10.1046/j.1365-313x.2000.00845.x; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; Patra D., 2004, Journal of Applied Spectroscopy, V71, P334, DOI 10.1023/B:JAPS.0000039958.98539.45; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; Ruissen ALA, 2002, PEPTIDES, V23, P1391, DOI 10.1016/S0196-9781(02)00076-1; Ruissen ALA, 2001, BIOCHEM J, V356, P361, DOI 10.1042/0264-6021:3560361; Sheikh S, 1997, BIOCHEM BIOPH RES CO, V238, P910, DOI 10.1006/bbrc.1997.7407; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; Takeshima K, 2003, J BIOL CHEM, V278, P1310, DOI 10.1074/jbc.M208762200; van der Kraan MIA, 2005, PEPTIDES, V26, P1537, DOI 10.1016/j.peptides.2005.02.011; VANBLITTERSWIJK WJ, 1988, BIOCHIM BIOPHYS ACTA, V644, P323; Veerman ECI, 2004, BIOCHEM J, V381, P447, DOI 10.1042/BJ20040208; White TC, 1998, CLIN MICROBIOL REV, V11, P382, DOI 10.1128/CMR.11.2.382; Yun DJ, 1997, P NATL ACAD SCI USA, V94, P7082, DOI 10.1073/pnas.94.13.7082	53	68	68	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18831	18841		10.1074/jbc.M610555200	http://dx.doi.org/10.1074/jbc.M610555200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17485465	hybrid			2022-12-25	WOS:000247475300022
J	Mikkelson, GM; Gonzalez, A; Peterson, GD				Mikkelson, Gregory M.; Gonzalez, Andrew; Peterson, Garry D.			Economic Inequality Predicts Biodiversity Loss	PLOS ONE			English	Article								Human activity is causing high rates of biodiversity loss. Yet, surprisingly little is known about the extent to which socioeconomic factors exacerbate or ameliorate our impacts on biological diversity. One such factor, economic inequality, has been shown to affect public health, and has been linked to environmental problems in general. We tested how strongly economic inequality is related to biodiversity loss in particular. We found that among countries, and among US states, the number of species that are threatened or declining increases substantially with the Gini ratio of income inequality. At both levels of analysis, the connection between income inequality and biodiversity loss persists after controlling for biophysical conditions, human population size, and per capita GDP or income. Future research should explore potential mechanisms behind this equality-biodiversity relationship. Our results suggest that economic reforms would go hand in hand with, if not serving as a prerequisite for, effective conservation.	[Mikkelson, Gregory M.; Gonzalez, Andrew; Peterson, Garry D.] McGill Sch Environm, Montreal, PQ, Canada; [Mikkelson, Gregory M.] McGill Univ, Dept Philosophy, Montreal, PQ, Canada; [Gonzalez, Andrew] McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; [Peterson, Garry D.] McGill Univ, Dept Geog, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Mikkelson, GM (corresponding author), McGill Sch Environm, Montreal, PQ, Canada.	gregory.mikkelson@mcgill.ca	Peterson, Garry D/C-1309-2008; Gonzalez, Andrew/F-2247-2010	Peterson, Garry D/0000-0003-0173-0112; Gonzalez, Andrew/0000-0001-6075-8081	McGill School of Environment for a collaborative research; Canada Research Chair program	McGill School of Environment for a collaborative research; Canada Research Chair program(Canada Research Chairs)	We are grateful to the McGill School of Environment for a collaborative research grant, and to the Canada Research Chair program for support to A. G. and G. D. P.	Baland JM, 1999, WORLD DEV, V27, P773, DOI 10.1016/S0305-750X(99)00026-1; BERGSTROM T, 1986, J PUBLIC ECON, V29, P25, DOI 10.1016/0047-2727(86)90024-1; BOYCE JK, 1994, ECOL ECON, V11, P169, DOI 10.1016/0921-8009(94)90198-8; Burnham K.P., 2002, MODEL SELECTION MULT, DOI 10.1007/b97636; Carpenter SR, 2006, SCIENCE, V314, P257, DOI 10.1126/science.1131946; Dayton-Johnson J, 2002, ECON J, V112, P577, DOI 10.1111/1468-0297.00731; *DEP EC SOC AFF UN, 2005, WORLD POP PROSP 2004; *DEV DAT GROUP WOR, 2006, WORLD DEV IND 2006 O; Diaz S, 2006, PLOS BIOL, V4, P1300, DOI 10.1371/journal.pbio.0040277; *EARTH CHART INT, 2006, EARTH CHART; Itaya J, 1997, ECON LETT, V57, P289, DOI 10.1016/S0165-1765(97)00179-1; Magnani E, 2000, ECOL ECON, V32, P431, DOI 10.1016/S0921-8009(99)00115-9; Millennium Ecosystem Assessment, 2005, EC HUM WELL BEING BI; NAESS A, 2006, DEEP ECOLOGY PLATFOR; Naidoo R, 2001, CONSERV BIOL, V15, P1021, DOI 10.1046/j.1523-1739.2001.0150041021.x; Olson M., 1965, LOGIC COLLECTIVE ACT; Pitt Inequality Project, 2006, STAND INC DISTR DAT; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Sauer J. R., 2005, N AM BREEDING BIRD S; U.S. Bureau of the Census, 2005, TABL S4 GIN RAT STAT; U. S. Census Bureau, 2002, DEM TRENDS 20 CENT; *UN ENV PROGR WORL, 2005, KNOWN THREAT SPEC; *US BUR CENS, 2005, TABL S3 PER CAP INC; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Wilcove DS, 1998, BIOSCIENCE, V48, P607, DOI 10.2307/1313420; Wilkinson RG, 2006, SOC SCI MED, V62, P1768, DOI 10.1016/j.socscimed.2005.08.036; York R, 2003, AM SOCIOL REV, V68, P279, DOI 10.2307/1519769	27	84	85	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e444	10.1371/journal.pone.0000444	http://dx.doi.org/10.1371/journal.pone.0000444			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505535	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445900004
J	Narasimhan, S; DePonte, K; Marcantonio, N; Liang, XP; Royce, TE; Nelson, KF; Booth, CJ; Koski, B; Anderson, JF; Kantor, F; Fikrig, E				Narasimhan, Sukanya; DePonte, Kathleen; Marcantonio, Nancy; Liang, Xianping; Royce, Thomas E.; Nelson, Kenneth F.; Booth, Carmen J.; Koski, Benjamin; Anderson, John F.; Kantor, Fred; Fikrig, Erol			Immunity against Ixodes scapularis Salivary Proteins Expressed within 24 Hours of Attachment Thwarts Tick Feeding and Impairs Borrelia Transmission	PLOS ONE			English	Article							HUMAN GRANULOCYTIC EHRLICHIOSIS; LYME-DISEASE; RICINUS L; RHIPICEPHALUS-APPENDICULATUS; ACQUIRED-RESISTANCE; PASSIVE TRANSFER; AMPLIFIED RNA; GUINEA-PIGS; ANTIGENS; BURGDORFERI	In North America, the black-legged tick, Ixodes scapularis, an obligate haematophagus arthropod, is a vector of several human pathogens including Borrelia burgdorferi, the Lyme disease agent. In this report, we show that the tick salivary gland transcriptome and proteome is dynamic and changes during the process of engorgement. We demonstrate, using a guinea pig model of I. scapularis feeding and B. burgdorferi transmission, that immunity directed against salivary proteins expressed in the first 24 h of tick attachment - and not later - is sufficient to evoke all the hallmarks of acquired tick-immunity, to thwart tick feeding and also to impair Borrelia transmission. Defining this subset of proteins will promote a mechanistic understanding of novel I. scapularis proteins critical for the initiation of tick feeding and for Borrelia transmission.	[Narasimhan, Sukanya; Liang, Xianping; Koski, Benjamin; Fikrig, Erol] Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, New Haven, CT 06510 USA; [DePonte, Kathleen; Marcantonio, Nancy; Kantor, Fred] Yale Univ, Sch Med, Dept Internal Med, Sect Allergy & Clin Immunol, New Haven, CT 06510 USA; [Royce, Thomas E.] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA; [Nelson, Kenneth F.] Yale Univ, Dept Biochem & Biophys, New Haven, CT USA; [Booth, Carmen J.] Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06510 USA; [Anderson, John F.] Connecticut Agr Expt Stn, Dept Entomol, New Haven, CT 06504 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Connecticut Agricultural Experiment Station	Fikrig, E (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, New Haven, CT 06510 USA.	erol.fikrig@yale.edu			NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI065583] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the NIH	Aljamali MN, 2002, EXP APPL ACAROL, V28, P89, DOI 10.1023/A:1025346131903; ALLEN J R, 1973, International Journal for Parasitology, V3, P195, DOI 10.1016/0020-7519(73)90024-6; ALLEN JR, 1989, EXP APPL ACAROL, V7, P5, DOI 10.1007/BF01200448; Almazan C, 2005, VACCINE, V23, P4403, DOI 10.1016/j.vaccine.2005.04.012; Anguita J, 2002, IMMUNITY, V16, P849, DOI 10.1016/S1074-7613(02)00325-4; ASKENASE PW, 1982, IMMUNOLOGY, V45, P501; BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006; Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29; BELL JF, 1979, AM J TROP MED HYG, V28, P876, DOI 10.4269/ajtmh.1979.28.876; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BROSSARD M, 1979, EXPERIENTIA, V35, P1395, DOI 10.1007/BF01964030; BROSSARD M, 1982, PARASITOLOGY, V85, P583, DOI 10.1017/S0031182000056365; Burke GS, 2005, EMERG INFECT DIS, V11, P36; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Das S, 2001, J INFECT DIS, V184, P1056, DOI 10.1086/323351; de la Fuente J, 2006, VACCINE, V24, P4082, DOI 10.1016/j.vaccine.2006.02.046; DESILVA AM, 1995, AM J TROP MED HYG, V53, P397, DOI 10.4269/ajtmh.1995.53.397; DHARAMPAUL S, 1993, J MED ENTOMOL, V30, P262, DOI 10.1093/jmedent/30.1.262; DIZIJ A, 1995, PARASITE IMMUNOL, V17, P177, DOI 10.1111/j.1365-3024.1995.tb00887.x; DVORAK HF, 1970, J EXP MED, V132, P558, DOI 10.1084/jem.132.3.558; Francischetti IMB, 2002, BLOOD, V99, P3602, DOI 10.1182/blood-2001-12-0237; Francischetti NMB, 2004, THROMB HAEMOSTASIS, V91, P886, DOI 10.1160/TH03-11-0715; Gillespie RD, 2001, J IMMUNOL, V166, P4319, DOI 10.4049/jimmunol.166.7.4319; Gillespie RD, 2000, PARASITE IMMUNOL, V22, P319, DOI 10.1046/j.1365-3024.2000.00309.x; GORDON JR, 1987, PARASITE IMMUNOL, V9, P337, DOI 10.1111/j.1365-3024.1987.tb00512.x; Hannier S, 2004, IMMUNOLOGY, V113, P401, DOI 10.1111/j.1365-2567.2004.01975.x; Hill CA, 2005, TRENDS PARASITOL, V21, P151, DOI 10.1016/j.pt.2005.02.004; Hodzic E, 1998, J CLIN MICROBIOL, V36, P3574, DOI 10.1128/JCM.36.12.3574-3578.1998; Labuda M, 2006, PLOS PATHOG, V2, P251, DOI 10.1371/journal.ppat.0020027; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MATHER TN, 1990, EXP PARASITOL, V70, P55, DOI 10.1016/0014-4894(90)90085-Q; Montgomery RR, 2007, INFECT IMMUN, V75, P613, DOI 10.1128/IAI.00685-06; Mulenga A, 2000, MICROBES INFECT, V2, P1353, DOI 10.1016/S1286-4579(00)01289-2; Narasimhan S, 2002, INSECT MOL BIOL, V11, P641, DOI 10.1046/j.1365-2583.2002.00375.x; Nazario S, 1998, AM J TROP MED HYG, V58, P780, DOI 10.4269/ajtmh.1998.58.780; Nuttall PA, 2006, PARASITE IMMUNOL, V28, P155, DOI 10.1111/j.1365-3024.2006.00806.x; Nuttall PA, 2004, PARASITOLOGY, V129, pS177, DOI 10.1017/S0031182004005633; Park JY, 2004, BIOCHEM BIOPH RES CO, V325, P1346, DOI 10.1016/j.bbrc.2004.10.151; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; Ramamoorthi N, 2005, NATURE, V436, P573, DOI 10.1038/nature03812; Ribeiro JMC, 1998, EXP PARASITOL, V89, P213, DOI 10.1006/expr.1998.4296; Ribeiro JMC, 2006, INSECT BIOCHEM MOLEC, V36, P111, DOI 10.1016/j.ibmb.2005.11.005; Sauer J. R., 1986, MORPHOLOGY PHYSL BEH; SHAPIRO SZ, 1986, J PARASITOL, V72, P454, DOI 10.2307/3281686; Sonenshine DE., 1991, BIOL TICKS; Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209; Telford SR, 1997, EMERG INFECT DIS, V3, P165, DOI 10.3201/eid0302.970209; Thomas V, 2001, INFECT IMMUN, V69, P3359, DOI 10.1128/IAI.69.5.3359-3371.2001; TRAGER WILLIAM, 1939, JOUR PARASITOL, V25, P57, DOI 10.2307/3272160; Trimnell AR, 2005, VACCINE, V23, P4329, DOI 10.1016/j.vaccine.2005.03.041; Valenzuela JG, 2000, J BIOL CHEM, V275, P18717, DOI 10.1074/jbc.M001486200; Valenzuela JG, 2002, J EXP BIOL, V205, P2843; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wang H, 1999, PARASITOLOGY, V119, P143, DOI 10.1017/S0031182099004540; Wang H, 2001, MED VET ENTOMOL, V15, P403, DOI 10.1046/j.0269-283x.2001.00328.x; WHEELER CM, 1991, J PARASITOL, V77, P965, DOI 10.2307/3282751; WHELEN AC, 1986, J PARASITOL, V72, P155, DOI 10.2307/3281809; WHELEN AC, 1993, J PARASITOL, V79, P908, DOI 10.2307/3283729; WIKEL SK, 1988, VET PARASITOL, V29, P235, DOI 10.1016/0304-4017(88)90127-6; WIKEL SK, 1986, VET PARASITOL, V20, P149, DOI 10.1016/0304-4017(86)90098-1; Wikel SK, 1997, INFECT IMMUN, V65, P335, DOI 10.1128/IAI.65.1.335-338.1997; WIKEL SK, 1976, IMMUNOLOGY, V30, P311; Wikel SK, 1996, ANNU REV ENTOMOL, V41, P1, DOI 10.1146/annurev.en.41.010196.000245; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Willadsen P, 1999, PARASITOL TODAY, V15, P258, DOI 10.1016/S0169-4758(99)01472-6; Willadsen P, 1980, Adv Parasitol, V18, P293, DOI 10.1016/S0065-308X(08)60402-9	67	75	76	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e451	10.1371/journal.pone.0000451	http://dx.doi.org/10.1371/journal.pone.0000451			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505544	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445900010
J	Epstein, JM; Goedecke, DM; Yu, F; Morris, RJ; Wagener, DK; Bobashev, GV				Epstein, Joshua M.; Goedecke, D. Michael; Yu, Feng; Morris, Robert J.; Wagener, Diane K.; Bobashev, Georgiy V.			Controlling Pandemic Flu: The Value of International Air Travel Restrictions	PLOS ONE			English	Article							TRANSPORTATION NETWORK; SPREAD; INFLUENZA; STRATEGIES	Background. Planning for a possible influenza pandemic is an extremely high priority, as social and economic effects of an unmitigated pandemic would be devastating. Mathematical models can be used to explore different scenarios and provide insight into potential costs, benefits, and effectiveness of prevention and control strategies under consideration. Methods and Findings. A stochastic, equation-based epidemic model is used to study global transmission of pandemic flu, including the effects of travel restrictions and vaccination. Economic costs of intervention are also considered. The distribution of First Passage Times (FPT) to the United States and the numbers of infected persons in metropolitan areas worldwide are studied assuming various times and locations of the initial outbreak. International air travel restrictions alone provide a small delay in FPT to the U. S. When other containment measures are applied at the source in conjunction with travel restrictions, delays could be much longer. If in addition, control measures are instituted worldwide, there is a significant reduction in cases worldwide and specifically in the U. S. However, if travel restrictions are not combined with other measures, local epidemic severity may increase, because restriction-induced delays can push local outbreaks into high epidemic season. The per annum cost to the U. S. economy of international and major domestic air passenger travel restrictions is minimal: on the order of 0.8% of Gross National Product. Conclusions. International air travel restrictions may provide a small but important delay in the spread of a pandemic, especially if other disease control measures are implemented during the afforded time. However, if other measures are not instituted, delays may worsen regional epidemics by pushing the outbreak into high epidemic season. This important interaction between policy and seasonality is only evident with a global-scale model. Since the benefit of travel restrictions can be substantial while their costs are minimal, dismissal of travel restrictions as an aid in dealing with a global pandemic seems premature.	[Epstein, Joshua M.] Brookings Inst, Econ Studies Program, Washington, DC 20036 USA; [Goedecke, D. Michael; Yu, Feng; Morris, Robert J.; Bobashev, Georgiy V.] RTI Int, Stat & Epidemiol, Res Triangle Pk, NC USA; [Wagener, Diane K.] RTI Int, Stat & Epidemiol, Rockville, MD USA	Brookings Institution; Research Triangle Institute; Research Triangle Institute	Epstein, JM (corresponding author), Brookings Inst, Econ Studies Program, Washington, DC 20036 USA.	jepstein@brookings.edu			NIGMS [1 U01 GM070698]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM070698] Funding Source: NIH RePORTER	NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by the Pilot Studies of Modeling of Infectious Disease Agents Study (MIDAS) cooperative agreement from NIGMS, (1 U01 GM070698).	ANDERSON R M, 1991; BAROYAN OV, 1981, PROGRAMMING COMPUT S, V6, P272; BRINKHOFF T, 2005, MATO GROSSO CITY POP; Brownstein JS, 2006, PLOS MED, V3, P1826, DOI 10.1371/journal.pmed.0030401; *BUR TRANSP STAT, 2002, AIR CARR FIN STAT; Colizza V, 2006, B MATH BIOL, V68, P1893, DOI 10.1007/s11538-006-9077-9; Colizza V, 2006, P NATL ACAD SCI USA, V103, P2015, DOI 10.1073/pnas.0510525103; Colizza V, 2007, PLOS MED, V4, P95, DOI 10.1371/journal.pmed.0040013; Cooper BS, 2006, PLOS MED, V3, P845, DOI 10.1371/journal.pmed.0030212; *DEP EC SOC AFF UN, 2004, WORLD URB PROSP I003; *ESRI, 2005, ARCGIS 9 WORLD EUR C; Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103; Grais R F, 2004, Health Care Manag Sci, V7, P127, DOI 10.1023/B:HCMS.0000020652.38181.da; Grais RF, 2003, EUR J EPIDEMIOL, V18, P1065, DOI 10.1023/A:1026140019146; Guimera R, 2005, P NATL ACAD SCI USA, V102, P7794, DOI 10.1073/pnas.0407994102; HELDERS S, 2005, WORLD GAZETTER; Hollingsworth TD, 2006, NAT MED, V12, P497, DOI 10.1038/nm0506-497; Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717; *MONG COM, 2004, WORLD POP FIG; RVACHEV LA, 1985, MATH BIOSCI, V75, P3, DOI 10.1016/0025-5564(85)90064-1; *US BUR CENS POP D, 2004, CBSAEST200401 US BUR; *US DEP COMM, 2005, SURV CURR BUS, V85; *US SEN JOINT EC C, 2001, ASS LOSS AIRL IND IT	25	195	204	1	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e401	10.1371/journal.pone.0000401	http://dx.doi.org/10.1371/journal.pone.0000401			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476323	Green Published, gold			2022-12-25	WOS:000207445700003
J	Rennemeier, C; Hammerschmidt, S; Niemann, S; Inamura, S; Zahringer, U; Kehrel, BE				Rennemeier, Claudia; Hammerschmidt, Sven; Niemann, Silke; Inamura, Seiichi; Zaehringer, Ulrich; Kehrel, Beate E.			Thrombospondin-1 promotes cellular adherence of Gram-positive pathogens via recognition of peptidoglycan	FASEB JOURNAL			English	Article						colonization; platelet lectin; pneumococci; staphylococci; host tissue cells	STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; LIPOTEICHOIC ACID; MENINGEAL INFLAMMATION; VITRONECTIN RECEPTOR; WALL COMPONENTS; SURFACE PROTEIN; VIRULENCE GENES; CELLS; BINDING	Thrombospondin-1 (TSP1) is a matricellular glycoprotein that has key roles in interactions between human cells and components of the extracellular matrix. Here we report a novel role for the lectin TSP1 in pathogen-host interactions. Binding assays and flow cytometric analysis demonstrate that Streptococcus pneumoniae and other Gram-positive pathogens including S. pyogenes, Staphylococcus aureus, and Listeria monocytogenes interact specifically with human TSP1. We also show for the first time that host cell-bound TSP1 promotes adherence of Gram-positive pathogens to human epithelial and endothelial cell lines. Pretreatment of bacteria with sodium periodate but not Pronase E substantially reduced TSP1-mediated bacterial adherence to host cells, suggesting that a glycoconjugate on the bacterial cell surface functions as the receptor for TSP1. Lipoteichoic acids did not affect TSP1-mediated adherence of S. pneumoniae to host cells. In contrast, attachment of S. pneumoniae and other Gram-positive pathogens to host cells via TSP1 was blocked by soluble peptidoglycan, indicating recognition of bacterial peptidoglycan by TSP1. In conclusion, our results demonstrate that recognition of Gram-positive pathogens by TSP1 promotes bacterial colonization of host tissue cells. In this scenario, peptidoglycan functions as adhesin and TSP1 acts as a molecular bridge linking Gram-positive bacteria with receptors on the host cell.	Univ Wurzburg, Res Ctr Infect Dis, Wurzburg, Germany; Univ Hosp Muenster, Dept Anaesthesiol & Intens Care, Munster, Germany; Res Ctr Borstel, Leibniz Ctr Med & Biosci, Borstel, Germany	University of Wurzburg; University of Munster; Forschungszentrum Borstel	Hammerschmidt, S (corresponding author), Univ Munich, Max Von Pettenkofer Inst Hyg & Microbiol, Pettenkoferstr 9A, D-80336 Munich, Germany.	hammerschmidt@mvp.uni-muenchen.de	Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681				Adams J, 2004, INT J BIOCHEM CELL B, V36, P960, DOI 10.1016/j.biocel.2004.02.009; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; AGBANYO FR, 1993, J CLIN INVEST, V92, P288, DOI 10.1172/JCI116563; Armstrong LC, 2003, MATRIX BIOL, V22, P63, DOI 10.1016/S0945-053X(03)00005-2; BERGER H, 1982, J BACTERIOL, V152, P1241; Bergmann S, 2003, MOL MICROBIOL, V49, P411, DOI 10.1046/j.1365-2958.2003.03557.x; Boneca IG, 2005, CURR OPIN MICROBIOL, V8, P46, DOI 10.1016/j.mib.2004.12.008; Bubert A, 1999, MOL GEN GENET, V261, P323, DOI 10.1007/s004380050973; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; CHUGH TD, 1990, INFECT IMMUN, V58, P315, DOI 10.1128/IAI.58.2.315-319.1990; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Draing C, 2006, J BIOL CHEM, V281, P33849, DOI 10.1074/jbc.M602676200; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Dziarski R, 2006, CELL MICROBIOL, V8, P1059, DOI 10.1111/j.1462-5822.2006.00726.x; Elzie CA, 2004, INT J BIOCHEM CELL B, V36, P1090, DOI 10.1016/j.biocel.2003.12.012; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Grimbert P, 2006, J IMMUNOL, V177, P3534, DOI 10.4049/jimmunol.177.6.3534; Hammerschmidt S, 2006, CURR OPIN MICROBIOL, V9, P12, DOI 10.1016/j.mib.2005.11.001; Hammerschmidt S, 2005, INFECT IMMUN, V73, P4653, DOI 10.1128/IAI.73.8.4653-4667.2005; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hermans PWM, 2006, J BIOL CHEM, V281, P968, DOI 10.1074/jbc.M510014200; HERRMANN M, 1991, INFECT IMMUN, V59, P279, DOI 10.1128/IAI.59.1.279-288.1991; Hughes J, 1997, J IMMUNOL, V158, P4389; Inamura S, 2006, ORG BIOMOL CHEM, V4, P232, DOI 10.1039/b511866b; Isenberg JS, 2006, J BIOL CHEM, V281, P26069, DOI 10.1074/jbc.M605040200; JAFFE EA, 1982, NATURE, V295, P246, DOI 10.1038/295246a0; Jansen WTM, 1998, CLIN DIAGN LAB IMMUN, V5, P703, DOI 10.1128/CDLI.5.5.703-710.1998; JEPRAS RI, 1985, J HYG-CAMBRIDGE, V95, P29, DOI 10.1017/S0022172400062252; Jurk K, 2003, FASEB J, V17, P1490, DOI 10.1096/fj.02-0830fje; KEHREL B, 1991, BIOCHEM BIOPH RES CO, V179, P985, DOI 10.1016/0006-291X(91)91915-Y; Kolberg J, 2006, MICROBIOL-SGM, V152, P1307, DOI 10.1099/mic.0.28747-0; Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; McNicol A, 2006, THROMB HAEMOSTASIS, V95, P288, DOI 10.1160/TH05-07-0491; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Molinari G, 1998, J INFECT DIS, V177, P1600, DOI 10.1086/515310; Nadesalingam J, 2005, J IMMUNOL, V175, P1785, DOI 10.4049/jimmunol.175.3.1785; Narizhneva NV, 2005, FASEB J, V19, P1158, DOI 10.1096/fj.04-3310fje; Niemann S, 2004, CIRCULATION, V110, P193, DOI 10.1161/01.CIR.0000134486.93030.E7; Orr AW, 2004, J BIOL CHEM, V279, P48983, DOI 10.1074/jbc.M404881200; Pearce BJ, 2002, RES MICROBIOL, V153, P243, DOI 10.1016/S0923-2508(02)01312-8; Polissi A, 1998, INFECT IMMUN, V66, P5620, DOI 10.1128/IAI.66.12.5620-5629.1998; Pracht D, 2005, INFECT IMMUN, V73, P2680, DOI 10.1128/IAI.73.5.2680-2689.2005; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; Rietschel ET, 1998, MICROB DRUG RESIST, V4, P37, DOI 10.1089/mdr.1998.4.37; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHELD WM, 1978, J CLIN INVEST, V61, P1394, DOI 10.1172/JCI109057; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Sjobring U, 2002, BLOOD, V100, P4470, DOI 10.1182/blood-2002-01-0069; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Talay Susanne R., 2005, V12, P90, DOI 10.1159/000081691; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Travassos LH, 2005, J BIOL CHEM, V280, P36714, DOI 10.1074/jbc.M501649200; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; Unkmeir A, 2002, MOL MICROBIOL, V46, P933, DOI 10.1046/j.1365-2958.2002.03222.x; Vollmer W, 2000, J BIOL CHEM, V275, P20496, DOI 10.1074/jbc.M910189199; Weber JR, 1995, J NEUROIMMUNOL, V63, P63; Weber JR, 2003, IMMUNITY, V19, P269, DOI 10.1016/S1074-7613(03)00205-X; Weidenmaier C, 2004, NAT MED, V10, P243, DOI 10.1038/nm991; WILCOX KW, 1975, J BACTERIOL, V122, P443, DOI 10.1128/JB.122.2.443-453.1975; Yoshimura A, 2000, J ENDOTOXIN RES, V6, P407, DOI 10.1177/09680519000060050201; Yoshimura A, 1999, J IMMUNOL, V163, P1	64	69	70	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3118	3132		10.1096/fj.06-7992com	http://dx.doi.org/10.1096/fj.06-7992com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17507668				2022-12-25	WOS:000249781600013
J	Dairkee, SH; Nicolau, M; Sayeed, A; Champion, S; Ji, Y; Moore, DH; Yong, B; Meng, Z; Jeffrey, SS				Dairkee, S. H.; Nicolau, M.; Sayeed, A.; Champion, S.; Ji, Y.; Moore, D. H.; Yong, B.; Meng, Z.; Jeffrey, S. S.			Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome	ONCOGENE			English	Article						primary tumor culture; telomerase ( hTERT); gene expression	GENE-EXPRESSION SIGNATURE; LENS EPITHELIAL-CELLS; HUMAN FIBROBLASTS; TELOMERASE; GROWTH; HTERT; APOPTOSIS; PATTERNS; RECEPTOR; BINDING	An improved understanding of cell immortalization and its manifestation in clinical tumors could facilitate novel therapeutic approaches. However, only rare tumor cells, which maintain telomerase expression in vitro, immortalize spontaneously. By expression-profiling analyses of limited-life primary breast tumor cultures pre- and post-hTERT transduction, and spontaneously immortalized breast cancer cell lines, we identified a common signature characteristic of tumor cell immortalization. A predominant feature of this immortalization signature ( ImmSig) was the significant overexpression of oxidoreductase genes. In contrast to epithelial cells derived from low histologic grade primary tumors, which required hTERT transduction for the acquisition of ImmSig, spontaneously immortalizing high-grade tumor cultures displayed similar molecular changes independent of exogenous hTERT. Silencing the hTERT gene reversed ImmSig expression, increased cellular reactive oxygen species levels, altered mitochondrial membrane potential and induced apoptotic and proliferation changes in immortalized cells. In clinical breast cancer samples, cell-proliferation-pathway genes were significantly associated with ImmSig. In these cases, ImmSig expression itself was inversely correlated with patient survival ( P = 0), and was particularly relevant to the outcome of estrogen receptor-positive tumors. Our data support the notion that ImmSig assists in surmounting normal barriers related to oxidative and replicative stress response. Targeting a subset of aggressive breast cancers by reversing ImmSig components could be a practical therapeutic strategy.	Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA; Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; Stanford University	Dairkee, SH (corresponding author), Calif Pacific Med Ctr, Res Inst, 475 Brannan St, San Francisco, CA 94107 USA.	dairkes@sutterhealth.org; ssj@stanford.edu	Dairkee, Shanaz Hashmi/D-6743-2012	Jeffrey, Stefanie/0000-0003-4478-2764; Dairkee, Shanaz/0000-0002-2073-9684	NCI NIH HHS [R01 CA109325, U01 CA85129] Funding Source: Medline; NHGRI NIH HHS [K01 HG00030] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085129, R01CA109325] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K01HG000030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAIRKEE SH, 1995, CANCER RES, V55, P2516; Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47; Dairkee SH, 1997, CANCER RES, V57, P1590; Dudognon C, 2004, ONCOGENE, V23, P7469, DOI 10.1038/sj.onc.1208029; Elkak A E, 2005, J Carcinog, V4, P17, DOI 10.1186/1477-3163-4-17; Kurz DJ, 2004, J CELL SCI, V117, P2417, DOI 10.1242/jcs.01097; Li Z, 1998, CANCER RES, V58, P5271; Liang XS, 1998, MOL CELL ENDOCRINOL, V146, P151, DOI 10.1016/S0303-7207(98)00161-0; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; MICHIELS C, 1990, J CELL PHYSIOL, V144, P295, DOI 10.1002/jcp.1041440216; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shami PJ, 1998, LEUKEMIA, V12, P1461, DOI 10.1038/sj.leu.2401131; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje	35	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6269	6279		10.1038/sj.onc.1210452	http://dx.doi.org/10.1038/sj.onc.1210452			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17471242				2022-12-25	WOS:000249583300003
J	Evron, T; Geyer, BC; Cherni, I; Muralidharan, M; Kilbourne, J; Fletcher, SP; Soreq, H; Mor, TS				Evron, Tama; Geyer, Brian C.; Cherni, Irene; Muralidharan, Mrinalini; Kilbourne, Jacquelyn; Fletcher, Samuel P.; Soreq, Hermona; Mor, Tsafrir S.			Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath	FASEB JOURNAL			English	Article						paraoxon intoxication; neuromuscular junction; transgenic plants; long-term protection; bioscavenger	RECOMBINANT HUMAN ACETYLCHOLINESTERASE; HUMAN BUTYRYLCHOLINESTERASE; READTHROUGH ACETYLCHOLINESTERASE; EXPRESSION; PURIFICATION; ANTIDOTE; PYRIDOSTIGMINE; TRANSCRIPTS; REVEALS; PROTEIN	Therapeutically valuable proteins are often rare and/or unstable in their natural context, calling for production solutions in heterologous systems. A relevant example is that of the stress-induced, normally rare, and naturally unstable "read-through" human acetylcholinesterase variant, AChE-R. AChE-R shares its active site with the synaptic AChE-S variant, which is the target of poisonous organophosphate anticholinesterase insecticides such as the parathion metabolite paraoxon. Inherent AChE-R overproduction under organophosphate intoxication confers both short-term protection ( as a bioscavenger) and long-term neuromuscular damages ( as a regulator). Here we report the purification, characterization, and testing of human, endoplasmic reticulumretained AChE-RER produced from plant-optimized cDNA in Nicotiana benthamiana plants. AChE-RER purified to homogeneity showed indistinguishable biochemical properties, with IC50 = 10(-7) M for the organophosphate paraoxon, similar to mammalian cell culture-derived AChE. In vivo titration showed dose-dependent protection by intravenously injected AChE-RER of FVB/N male mice challenged with a lethal dose of paraoxon, with complete elimination of short-term clinical symptoms at near molar equivalence. By 10 days postexposure, AChE-R prophylaxis markedly limited postexposure increases in plasma murine AChE-R levels while minimizing the organophosphate-induced neuromuscular junction dismorphology. Our findings present plant-produced AChE-RER as a bimodal agent, conferring both short- and long- term protection from organophosphate intoxication.-Evron, T., Geyer, B. C., Cherni, I., Muralidharan, M., Kilbourne, J., Fletcher, S. P., Soreq, H., Mor, T. S. Plant- derived human acetylcholinesterase- R provides protection from lethal organophosphate poisoning and its chronic aftermath.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; Arizona State Univ, Biodesign Inst, Tempe, AZ 85287 USA; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Hebrew University of Jerusalem	Soreq, H (corresponding author), Arizona State Univ, Sch Life Sci, POB 874501, Tempe, AZ 85287 USA.	soreq@cc.huji.ac.il; tsafrir.mor@asu.edu	mor, tsafrir/E-9422-2013	Soreq, Hermona/0000-0002-0955-526X	NINDS NIH HHS [U54 NS058183-010005] Funding Source: Medline; PHS HHS [U54N5058183-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS058183] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashani Y, 2000, DRUG DEVELOP RES, V50, P298, DOI 10.1002/1098-2299(200007/08)50:3/4<298::AID-DDR13>3.3.CO;2-O; Birikh KR, 2003, P NATL ACAD SCI USA, V100, P283, DOI 10.1073/pnas.0135647100; Brenner T, 2003, FASEB J, V17, P214, DOI 10.1096/fj.02-0609com; Cerasoli DM, 2005, CHEM-BIOL INTERACT, V157, P363, DOI 10.1016/j.cbi.2005.10.052; Chan RYY, 1998, J BIOL CHEM, V273, P9727, DOI 10.1074/jbc.273.16.9727; Cohen O, 2004, BIOCHEM J, V378, P117, DOI 10.1042/BJ20031305; Cohen O, 2003, J MOL NEUROSCI, V21, P199, DOI 10.1385/JMN:21:3:199; Darreh-Shori T, 2004, J NEUROCHEM, V88, P1102, DOI 10.1046/j.1471-4159.2003.02230.x; Dharmani Chandrabhan, 2005, Reviews on Environmental Health, V20, P215; Doctor BP, 2005, CHEM-BIOL INTERACT, V157, P167, DOI 10.1016/j.cbi.2005.10.024; Farchi N, 2003, J PHYSIOL-LONDON, V546, P165, DOI 10.1113/jphysiol.2002.030841; Fletcher SP, 2004, PLANT MOL BIOL, V55, P33, DOI 10.1007/s11103-004-0394-9; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; Geyer BC, 2005, CHEM-BIOL INTERACT, V157, P331, DOI 10.1016/j.cbi.2005.10.097; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; Gomord V, 2004, CURR OPIN PLANT BIOL, V7, P171, DOI 10.1016/j.pbi.2004.01.015; Greenfield RA, 2002, AM J MED SCI, V323, P326, DOI 10.1097/00000441-200206000-00005; Grisaru D, 2006, J IMMUNOL, V176, P27, DOI 10.4049/jimmunol.176.1.27; Grunwald J, 1997, J BIOCHEM BIOPH METH, V34, P123, DOI 10.1016/S0165-022X(97)01208-6; Jurgens G, 2004, ANNU REV CELL DEV BI, V20, P481, DOI 10.1146/annurev.cellbio.20.082503.103057; Kaplan D, 2001, BIOCHEMISTRY-US, V40, P7433, DOI 10.1021/bi010181x; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; Kronman C, 2000, J BIOL CHEM, V275, P29488, DOI 10.1074/jbc.M004298200; Kronvang B, 2005, WATER SCI TECHNOL, V51, P55, DOI 10.2166/wst.2005.0575; Lee EC, 2003, JAMA-J AM MED ASSOC, V290, P659, DOI 10.1001/jama.290.5.659; Lenz DE, 2005, CHEM-BIOL INTERACT, V157, P205, DOI 10.1016/j.cbi.2005.10.025; Lev-Lehman E, 2000, J MOL NEUROSCI, V14, P93, DOI 10.1385/JMN:14:1-2:093; London L, 2005, AM J IND MED, V47, P308, DOI 10.1002/ajim.20147; Marchot P, 1996, PROTEIN SCI, V5, P672; MAXWELL DM, 1993, J PHARMACOL EXP THER, V264, P1085; Meshorer E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Mor TS, 2001, BIOTECHNOL BIOENG, V75, P259, DOI 10.1002/bit.10012; Nijholt I, 2004, MOL PSYCHIATR, V9, P174, DOI 10.1038/sj.mp.4001446; Pick M, 2006, BLOOD, V107, P3397, DOI 10.1182/blood-2005-08-3240; RAVEH L, 1993, BIOCHEM PHARMACOL, V45, P2465, DOI 10.1016/0006-2952(93)90228-O; Saxena A, 1998, MOL PHARMACOL, V53, P112, DOI 10.1124/mol.53.1.112; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Sklan EH, 2004, P NATL ACAD SCI USA, V101, P5512, DOI 10.1073/pnas.0307659101; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Taylor P., 1996, GOODMAN GILMANS PHAR, P161; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100	49	29	31	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2961	2969		10.1096/fj.07-8112com	http://dx.doi.org/10.1096/fj.07-8112com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475919	Green Accepted			2022-12-25	WOS:000249237500036
J	Fu, P; Thompson, JA; Bach, LA				Fu, Ping; Thompson, Julian A.; Bach, Leon A.			Promotion of cancer cell migration - An insulin-like growth factor (IGF)-independent action of IGF-binding protein-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-3; HEPATIC STELLATE CELLS; N-TERMINAL DOMAIN; P38 MAP KINASE; ALPHA-5-BETA-1 INTEGRIN; AMINO-ACIDS; ACTIVATION; ERK; EXPRESSION; NEUROBLASTOMA	A family of six high affinity IGF-binding proteins (IGFBPs 1-6) plays an important role in modulating IGF activities. Recent studies suggest that some IGFBPs may have IGF-independent effects, including induction of apoptosis and modulation of cell migration. However, very little is known about possible IGF-independent actions of IGFBP-6. We have generated a non-IGF-binding IGFBP-6 mutant by substituting Ala for four amino acid residues (Pro(93)/Leu(94)/Leu(97)/Leu(98)) in its N-domain IGF-binding site. A > 10,000-fold loss of binding affinity for IGF-I and IGF-II was observed using charcoal solution binding assay, BIAcore biosensor, and ligand blotting. Wild-type and mutant IGFBP-6, as well as IGF-II, induced cell migration in RD rhabdomyosarcoma and LIM 1215 colon cancer cells. Cell migration was mediated by the C-domain of IGFBP-6. Transient p38 phosphorylation was observed in RD cells after treatment with IGFBP-6, whereas no change was seen in phospho-ERK1/2 levels. Phospho-JNK was not detected. IGFBP-6-induced cell migration was inhibited by SB203580, an inhibitor of p38 MAPK, and PD98059, an inhibitor of ERK1/2MAPK activation. In contrast, SP600125, a JNK MAPK inhibitor, had no effect on migration. Knockdown of p38 MAPK using short interfering RNA blocked IGFBP-6-induced migration of RD cells. These results indicate that p38 MAPK is involved in IGFBP-6-induced IGF-independent RD cell migration.	Monash Univ, Alfred Med Res & Educ Precinct, Fac Med Nursing & Hlth Sci, Dept Med,Cent & Eastern Clin Sch, Prahran, Vic 3181, Australia; Alfred Hosp, Dept Endocrinol & Diabet, Melbourne, Vic 3004, Australia	Monash University; Florey Institute of Neuroscience & Mental Health	Fu, P (corresponding author), Monash Univ, Alfred Med Res & Educ Precinct, Fac Med Nursing & Hlth Sci, Dept Med,Cent & Eastern Clin Sch, Prahran, Vic 3181, Australia.	ping.fu@med.monash.edu.au		Bach, Leon/0000-0002-9062-1518				Abrass CK, 1997, AM J PHYSIOL-RENAL, V273, pF899, DOI 10.1152/ajprenal.1997.273.6.F899; Bach LA, 2005, TRENDS ENDOCRIN MET, V16, P228, DOI 10.1016/j.tem.2005.05.005; Bach LA, 2005, GROWTH HORM IGF RES, V15, P185, DOI 10.1016/j.ghir.2005.04.001; BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; Berfield AK, 2000, KIDNEY INT, V57, P1991, DOI 10.1046/j.1523-1755.2000.00049.x; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P4943, DOI 10.1210/jc.86.10.4943; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Dake BL, 2004, ENDOCRINOLOGY, V145, P3369, DOI 10.1210/en.2003-1667; Duan CM, 1998, J BIOL CHEM, V273, P16836, DOI 10.1074/jbc.273.27.16836; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; Fehrenbach H, 2001, HEPATOLOGY, V34, P943, DOI 10.1053/jhep.2001.28788; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Fitsialos G, 2007, J BIOL CHEM, V282, P15090, DOI 10.1074/jbc.M606094200; Fu P, 2007, J CELL BIOCHEM, V100, P58, DOI 10.1002/jcb.20984; Gallicchio MA, 2003, J CELL PHYSIOL, V197, P131, DOI 10.1002/jcp.10352; Gallicchio MA, 2001, INT J CANCER, V94, P645, DOI 10.1002/ijc.1519; Gleeson LM, 2001, J CLIN ENDOCR METAB, V86, P2484, DOI 10.1210/jc.86.6.2484; Grellier P, 1998, CANCER RES, V58, P1670; Headey SJ, 2004, FEBS LETT, V568, P19, DOI 10.1016/j.febslet.2004.04.091; Headey SJ, 2004, J MOL ENDOCRINOL, V33, P377, DOI 10.1677/jme.1.01547; Headey SJ, 2004, MOL ENDOCRINOL, V18, P2740, DOI 10.1210/me.2004-0248; Holt KH, 1996, MOL CELL BIOL, V16, P577; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; Houliston RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1266, DOI 10.1152/ajpcell.2001.281.4.C1266; Hsieh T, 2003, J BIOL CHEM, V278, P42886, DOI 10.1074/jbc.M303835200; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; James PL, 1996, J CELL BIOL, V133, P683, DOI 10.1083/jcb.133.3.683; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jiang Q, 2006, J OCUL PHARMACOL TH, V22, P93, DOI 10.1089/jop.2006.22.93; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Keeton AB, 2002, J BIOL CHEM, V277, P48565, DOI 10.1074/jbc.M207837200; Kim EJ, 2002, J CELL PHYSIOL, V190, P92, DOI 10.1002/jcp.10045; Kim MS, 2003, CANCER RES, V63, P5454; Lee OH, 2000, BRIT J CANCER, V82, P385; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Lewthwaite JC, 2006, J BIOL CHEM, V281, P11011, DOI 10.1074/jbc.M510680200; Marinaro JA, 2000, EUR J BIOCHEM, V267, P5378, DOI 10.1046/j.1432-1327.2000.01575.x; Mauro A, 2002, J CELL SCI, V115, P3587, DOI 10.1242/jcs.00037; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Neumann GM, 1999, J BIOL CHEM, V274, P14587, DOI 10.1074/jbc.274.21.14587; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Popov Y, 2006, J BIOL CHEM, V281, P15090, DOI 10.1074/jbc.M600030200; Puri PL, 2000, GENE DEV, V14, P574; Russo VC, 2005, ENDOCRINOLOGY, V146, P4445, DOI 10.1210/en.2005-0467; Scholl FA, 2005, CANCER LETT, V230, P1, DOI 10.1016/j.canlet.2004.12.013; Seurin D, 2002, EUR J CANCER, V38, P2058, DOI 10.1016/S0959-8049(02)00240-X; Silha JV, 2006, ENDOCRINOLOGY, V147, P2112, DOI 10.1210/en.2005-1270; Sitar T, 2006, P NATL ACAD SCI USA, V103, P13028, DOI 10.1073/pnas.0605652103; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; Tremblay PL, 2006, ONCOGENE, V25, P6563, DOI 10.1038/sj.onc.1209664; Wang LJ, 2001, J BIOL CHEM, V276, P32670, DOI 10.1074/jbc.M102776200; Xie LF, 2005, MOL CELL PROTEOMICS, V4, P1273, DOI 10.1074/mcp.M500032-MCP200; Yan T, 2001, GROWTH HORM IGF RES, V11, P368, DOI 10.1054/ghir.2001.0249; Yan XL, 2004, J BIOL CHEM, V279, P53232, DOI 10.1074/jbc.M409345200; Zeslawski W, 2001, EMBO J, V20, P3638, DOI 10.1093/emboj/20.14.3638	58	54	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22298	22306		10.1074/jbc.M703066200	http://dx.doi.org/10.1074/jbc.M703066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17519236	hybrid			2022-12-25	WOS:000248354200007
J	Xin, MG; Gao, FQ; May, WS; Flagg, T; Deng, XM				Xin, Meiguo; Gao, Fengqin; May, W. Stratford; Flagg, Tammy; Deng, Xingming			Protein kinase C zeta abrogates the proapoptotic function of bax through phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; PKC-ZETA; PROMOTES SURVIVAL; RAT ADIPOCYTES; APOPTOSIS; ACTIVATION; MITOCHONDRIA; MEMBRANE; TRANSLOCATION; INSULIN	Protein kinase C zeta (PKC zeta) is an atypical PKC isoform that plays an important role in supporting cell survival but the mechanism(s) involved is not fully understood. Bax is a major member of the Bcl-2 family that is required for apoptotic cell death. Because Bax is extensively co-expressed with PKC zeta in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cells, it is possible that Bax may act as the downstream target of PKC zeta in regulating survival and chemosensitivity of lung cancer cells. Here we discovered that treatment of cells with nicotine not only enhances PKC zeta activity but also results in Bax phosphorylation and prolonged cell survival, which is suppressed by a PKC zeta specific inhibitor (a myristoylated PKC zeta pseudosubstrate peptide). Purified, active PKC zeta directly phosphorylates Bax in vitro. Overexpression of wild type or the constitutively active A119D but not the dominant negative K281W PKC zeta mutant results in Bax phosphorylation at serine 184. PKC zeta co-localizes and interacts with Bax at the BH3 domain. Specific depletion of PKC zeta by RNA interference blocks nicotine-stimulated Bax phosphorylation and enhances apoptotic cell death. Intriguingly, forced expression of wild type or A119D but not K281W PKC zeta mutant results in accumulation of Bax in cytoplasm and prevents Bax from undergoing a conformational change with prolonged cell survival. Purified PKC zeta can directly dissociate Bax from isolated mitochondria of C2-ceramide-treated cells. Thus, PKC zeta may function as a physiological Bax kinase to directly phosphorylate and interact with Bax, which leads to sequestration of Bax in cytoplasm and abrogation of the proapoptotic function of Bax.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), 1376 Mowry Rd,Canc Genet Res Complex,Rm 262,POB 1, Gainesville, FL 32610 USA.	xdeng@ufl.edu			NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; Ding L, 2002, J BIOL CHEM, V277, P35305, DOI 10.1074/jbc.M201460200; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Gonzalez-Guerrico AM, 2005, J BIOCHEM MOL BIOL, V38, P639; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim JH, 2005, MOL CELL BIOL, V25, P3194, DOI 10.1128/MCB.25.8.3194-3208.2005; Krajewska M, 1997, CANCER RES, V57, P1605; Lasfer M, 2006, FEBS LETT, V580, P2547, DOI 10.1016/j.febslet.2006.03.089; LaVallie ER, 2006, J BIOL CHEM, V281, P24124, DOI 10.1074/jbc.M601905200; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Plo I, 2002, J BIOL CHEM, V277, P31407, DOI 10.1074/jbc.M204654200; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Saxena A, 2004, AM J HEMATOL, V75, P22, DOI 10.1002/ajh.10453; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xin MG, 2006, J BIOL CHEM, V281, P18859, DOI 10.1074/jbc.M512543200; Xin MG, 2005, J BIOL CHEM, V280, P10781, DOI 10.1074/jbc.M500084200; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	46	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21268	21277		10.1074/jbc.M701613200	http://dx.doi.org/10.1074/jbc.M701613200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17525161	hybrid			2022-12-25	WOS:000248047500055
J	Hua, GQ; Zhang, QX; Fan, ZS				Hua, Guoqiang; Zhang, Qixiang; Fan, Zusen			Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; ACTIVATED DNASE; MITOCHONDRIA; DEATH; PROTEASE; EXPRESSION; INTERACTS; DISTINCT; FAMILY; HSP90	Natural killer (NK) cells play an important role in innate immunity against virally infected or transformed cells as the first defense line. GranzymeM(GzmM) is an orphan granzyme that is constitutively highly expressed in NK cells and is consistent with NK cell-mediated cytolysis. We recently demonstrated that GzmM induces caspase-dependent apoptosis with DNA fragmentation through direct cleavage of inhibitor of caspase-activated DNase ( ICAD). However, the molecular mechanisms for GzmM-induced apoptosis are unclear. We found GzmM causes mitochondrial swelling and loss of mitochondrial transmembrane potential. Moreover, GzmM initiates reactive oxygen species (ROS) generation and cytochrome c release. Heat shock protein 75 (HSP75, also known as TRAP1) acts as an antagonist of ROS and protects cells from GzmM-mediated apoptosis. GzmM cleaves TRAP1 and abolishes its antagonistic function to ROS, resulting in ROS accumulation. Silencing TRAP1 through RNA interference increases ROS accumulation, whereas TRAP1 overexpression attenuates ROS production. ROS accumulation is in accordance with the release of cytochrome c from mitochondria and enhances GzmM-mediated apoptosis.	Chinese Acad Sci, Inst Biophys, Ctr Infect & Immun, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Fan, ZS (corresponding author), Chinese Acad Sci, Inst Biophys, Ctr Infect & Immun, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	fanz@moon.ibp.ac.cn						Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Bots M, 2006, J CELL SCI, V119, P5011, DOI 10.1242/jcs.03239; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2006, BLOOD, V107, P1342, DOI 10.1182/blood-2005-08-3485; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fan ZS, 2005, CELL MOL IMMUNOL, V2, P259; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Grossman WJ, 2003, CURR OPIN IMMUNOL, V15, P544, DOI 10.1016/S0952-7915(03)00099-2; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Heibein JA, 1999, J IMMUNOL, V163, P4683; Im CN, 2007, J CELL BIOCHEM, V100, P474, DOI 10.1002/jcb.21064; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Johnson H, 2003, BLOOD, V101, P3093, DOI 10.1182/blood-2002-08-2485; Kelly JM, 2004, J BIOL CHEM, V279, P22236, DOI 10.1074/jbc.M401670200; Kempaiah RK, 2006, J NUTR BIOCHEM, V17, P471, DOI 10.1016/j.jnutbio.2005.09.005; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lee YJ, 2005, ONCOGENE, V24, P3715, DOI 10.1038/sj.onc.1208440; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Lu HX, 2006, J IMMUNOL, V177, P1171, DOI 10.4049/jimmunol.177.2.1171; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; Masuda Y, 2004, J BIOL CHEM, V279, P42503, DOI 10.1074/jbc.M404256200; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Sayers TJ, 2001, J IMMUNOL, V166, P765, DOI 10.4049/jimmunol.166.2.765; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Suck G, 2005, EXP HEMATOL, V33, P1160, DOI 10.1016/j.exphem.2005.06.024; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; WATERHOUSE J, 2006, CELL DEATH DIFFER, V17, P471; Zhao TB, 2007, J BIOL CHEM, V282, P12104, DOI 10.1074/jbc.M611006200	40	152	157	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20553	20560		10.1074/jbc.M703196200	http://dx.doi.org/10.1074/jbc.M703196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17513296	hybrid			2022-12-25	WOS:000247819300058
J	Sheng, SH; Maarouf, AB; Bruns, JB; Hughey, RP; Kleyman, TR				Sheng, Shaohu; Maarouf, Ahmad B.; Bruns, James B.; Hughey, Rebecca P.; Kleyman, Thomas R.			Functional role of extracellular loop cysteine residues of the epithelial Na+ channel in Na+ self-inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; ALPHA-SUBUNIT; CELL-SURFACE; MUTATIONAL ANALYSIS; HISTIDINE-RESIDUES; DISULFIDE BONDS; GAMMA-SUBUNIT; PORE REGION; YEAST SCO1; AMILORIDE	The epithelial Na+ channel (ENaC) is typically formed by three homologous subunits (alpha, beta, and gamma) that possess a characteristic large extracellular loop (ECL) containing 16 conserved cysteine (Cys) residues. We investigated the functional role of these Cys residues in Na+ self- inhibition, an allosteric inhibition of ENaC activity by extracellular Na+. All 16 Cys residues within alpha and gamma ECLs and selected beta ECL Cys residues were individually mutated to alanine or serine residues. The Na+ self- inhibition response of wild type and mutant channels expressed in Xenopus oocytes was determined by whole cell voltage clamp. Individual mutation of eight alpha (Cys-1, - 4, - 5, - 6, - 7, - 10, - 13, or - 16), one beta (Cys- 7), and nine gamma (Cys-3, - 4, - 6, - 7, - 10, - 11, - 12, - 13, or - 16) residues significantly reduced the magnitude of Na+ self- inhibition. Na+ self- inhibition was eliminated by simultaneous mutations of either the last three alpha ECL Cys residues (Cys- 14, - 15, and - 16) or Cys- 7 within both alpha and gamma ECLs. By analyzing the Na+ self-inhibition responses and the effects of a methanethiosulfonate reagent on channel currents in single and double Cys mutants, we identified five Cys pairs within the alpha ECL (alpha Cys- 1/alpha Cys- 6, alpha Cys-4/zeta Cys-5, alpha Cys-7/alpha Cys-16, alpha Cys-10/alpha Cys-13, and alpha Cys-11/alpha Cys-12) and one pair within the gamma ECL (gamma Cys-7/gamma Cys-16) that likely form intrasubunit disulfide bonds. We conclude that approximately half of the ECL Cys residues in the alpha and gamma ENaC subunits are required to establish the tertiary structure that ensures a proper Na+ self-inhibition response, likely by formation of multiple intrasubunit disulfide bonds.	Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sheng, SH (corresponding author), Univ Pittsburgh, Div Renal & Electrolyte, 3550 Terrace St, Pittsburgh, PA 15261 USA.	shaohu@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702	NIDDK NIH HHS [DK 054354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abajian C, 2006, J BIOL INORG CHEM, V11, P459, DOI 10.1007/s00775-006-0096-7; Arolas JL, 2006, TRENDS BIOCHEM SCI, V31, P292, DOI 10.1016/j.tibs.2006.03.005; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Carattino MD, 2006, J BIOL CHEM, V281, P18901, DOI 10.1074/jbc.M604109200; Chen L, 2004, AM J PHYSIOL-RENAL, V286, pF1202, DOI 10.1152/ajprenal.00352.2003; Chraibi A, 2003, PFLUG ARCH EUR J PHY, V447, P316, DOI 10.1007/s00424-003-1178-9; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; Clyne JD, 2002, J NEUROSCI, V22, P3873, DOI 10.1523/JNEUROSCI.22-10-03873.2002; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Firsov D, 1999, J BIOL CHEM, V274, P2743, DOI 10.1074/jbc.274.5.2743; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; Hogg PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI 10.1016/S0968-0004(03)00057-4; Horisberger Jean-Daniel, 2004, Nephron, V96, pp37, DOI 10.1159/000076406; Hughey RP, 2004, J BIOL CHEM, V279, P48491, DOI 10.1074/jbc.C400460200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kellenberger S, 2005, J BIOL CHEM, V280, P7739, DOI 10.1074/jbc.M409955200; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kelly O, 2003, AM J PHYSIOL-RENAL, V285, pF1279, DOI 10.1152/ajprenal.00094.2003; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Li JQ, 2003, J BIOL CHEM, V278, P13867, DOI 10.1074/jbc.M300149200; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Petersen MTN, 1999, PROTEIN ENG, V12, P535, DOI 10.1093/protein/12.7.535; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Sheng S, 2006, AM J PHYSIOL-RENAL, V290, pF1488, DOI 10.1152/ajprenal.00439.2005; Sheng SH, 2004, J BIOL CHEM, V279, P31687, DOI 10.1074/jbc.M405224200; Sheng SH, 2004, J BIOL CHEM, V279, P9743, DOI 10.1074/jbc.M311952200; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Sine SM, 2006, NATURE, V440, P448, DOI 10.1038/nature04708; Sitar T, 2006, P NATL ACAD SCI USA, V103, P13028, DOI 10.1073/pnas.0605652103; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Tarran R, 2006, ANNU REV PHYSIOL, V68, P543, DOI 10.1146/annurev.physiol.68.072304.112754; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; TURNHEIM K, 1991, PHYSIOL REV, V71, P429, DOI 10.1152/physrev.1991.71.2.429; VANDRIESSCHE W, 1985, PHYSIOL REV, V65, P833, DOI 10.1152/physrev.1985.65.4.833; Volk T, 2004, PFLUG ARCH EUR J PHY, V447, P884, DOI 10.1007/s00424-003-1193-x	45	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20180	20190		10.1074/jbc.M611761200	http://dx.doi.org/10.1074/jbc.M611761200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17522058	hybrid			2022-12-25	WOS:000247819300019
J	Strube, K; de Vries, S; Cramm, R				Strube, Katja; de Vries, Simon; Cramm, Rainer			Formation of a dinitrosyl iron complex by NorA, a nitric oxide-binding Di-iron protein from Ralstonia eutropha H16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALCALIGENES-EUTROPHUS; RIBONUCLEOTIDE REDUCTASE; S-NITROSOTHIOLS; R2 SUBUNIT; SITE; GENES; OXO; DERIVATIVES; RESISTANCE	In Ralstonia eutropha H16, two genes, norA and norB, form a dicistronic operon that is controlled by the NO-responsive transcriptional regulator NorR. NorB has been identified as a membrane-bound NO reductase, but the physiological function of NorA is unknown. We found that, in a NorA deletion mutant, the promoter activity of the norAB operon was increased 3-fold, indicating that NorA attenuates activation of NorR. NorA shows limited sequence similarity to the oxygen carrier hemerythrin, which contains a di-iron center. Indeed, optical and EPR spectroscopy of purified NorA revealed the presence of a di-iron center, which binds oxygen in a similar way as hemerythrin. Diferrous NorA binds two molecules of NO maximally. Unexpectedly, binding of NO to the diferrous NorA required an external reductant. Two different NorA-NO species could be resolved. A minor species ( up to 20%) showed an S = (1)/(2) EPR signal with g(perpendicular to) = 2.041, and g(parallel to) = 2.018, typical of a paramagnetic dinitrosyl iron complex. The major species was EPR-silent, showing characteristic signals at 420nmand 750nmin the optical spectrum. This species is proposed to represent a novel dinitrosyl iron complex of the form Fe2+ -[NO](2)(2-), i.e. NO is bound as NO-. The NO binding capacity of NorA in conjunction with its high cytoplasmic concentration (20 mu M) suggests that NorA regulates transcription by lowering the free cytoplasmic concentration of NO.	Humboldt Univ, Inst Biol Mikrobiol, D-10115 Berlin, Germany; Delft Univ Technol, Dept Biotechnol, NL-2628 BC Delft, Netherlands	Humboldt University of Berlin; Delft University of Technology	Cramm, R (corresponding author), Humboldt Univ, Inst Biol Mikrobiol, Chausseestr 117, D-10115 Berlin, Germany.	rainer.cramm@rz.hu-berlin.de		Cramm, Rainer/0000-0002-3630-3885				Andersson K. K., 1995, ADV INORG CHEM, V43, P359; ATTA M, 1994, J AM CHEM SOC, V116, P6429, DOI 10.1021/ja00093a051; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bodenmiller DM, 2006, J BACTERIOL, V188, P874, DOI 10.1128/JB.188.3.874-881.2006; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Choi PS, 2006, APPL ENVIRON MICROB, V72, P2200, DOI 10.1128/AEM.72.3.2200-2205.2006; Costanzo S, 2001, INORG CHIM ACTA, V318, P1, DOI 10.1016/S0020-1693(01)00402-9; Cramm R, 1997, J BACTERIOL, V179, P6769, DOI 10.1128/jb.179.21.6769-6777.1997; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; D'Autreaux B, 2005, NATURE, V437, P769, DOI 10.1038/nature03953; D'Autreaux B, 2004, J AM CHEM SOC, V126, P6005, DOI 10.1021/ja031671a; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; ENEMARK JH, 1974, COORDIN CHEM REV, V13, P339, DOI 10.1016/S0010-8545(00)80259-3; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; GARBETT K, 1969, ARCH BIOCHEM BIOPHYS, V135, P419, DOI 10.1016/0003-9861(69)90559-1; Gomes CM, 2000, BIOCHEMISTRY-US, V39, P16230, DOI 10.1021/bi001844y; GUPTA N, 1995, BIOCHEMISTRY-US, V34, P3310, DOI 10.1021/bi00010a021; Han JY, 1996, INORG CHEM, V35, P4629, DOI 10.1021/ic9515012; HASKIN CJ, 1995, BIOCHEMISTRY-US, V34, P11090, DOI 10.1021/bi00035a014; HUBNER P, 1991, J BACTERIOL, V173, P2993; Justino MC, 2007, J BIOL CHEM, V282, P10352, DOI 10.1074/jbc.M610656200; Justino MC, 2006, FEMS MICROBIOL LETT, V257, P278, DOI 10.1111/j.1574-6968.2006.00179.x; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; Kim CC, 2003, INFECT IMMUN, V71, P3196, DOI 10.1128/IAI.71.6.3196-3205.2003; Klink A, 2007, J BACTERIOL, V189, P2743, DOI 10.1128/JB.01865-06; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; LENZ O, 1994, J BACTERIOL, V176, P4385, DOI 10.1128/jb.176.14.4385-4393.1994; LOWE RH, 1964, BIOCHIM BIOPHYS ACTA, V85, P377, DOI 10.1016/0926-6569(64)90301-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK JM, 1991, J AM CHEM SOC, V113, P9066, DOI 10.1021/ja00024a007; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; Miller JH., 1972, EXPT MOL GENETICS; Mizoguchi TJ, 2001, INORG CHEM, V40, P4662, DOI 10.1021/ic010076b; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; Pohlmann A, 2000, MOL MICROBIOL, V38, P626, DOI 10.1046/j.1365-2958.2000.02157.x; Raner GM, 1997, BIOCHEMISTRY-US, V36, P7037, DOI 10.1021/bi963041+; REEM RC, 1989, J AM CHEM SOC, V111, P4688, DOI 10.1021/ja00195a024; Richardson AR, 2006, MOL MICROBIOL, V61, P927, DOI 10.1111/j.1365-2958.2006.05290.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rodionov DA, 2005, PLOS COMPUT BIOL, V1, P415, DOI 10.1371/journal.pcbi.0010055; Schwartz E, 1998, J BACTERIOL, V180, P3197, DOI 10.1128/JB.180.12.3197-3204.1998; Serres RG, 2004, J AM CHEM SOC, V126, P5138, DOI 10.1021/ja030645+; SHIEMKE AK, 1984, J AM CHEM SOC, V106, P4951, DOI 10.1021/ja00329a054; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STENKAMP RE, 1994, CHEM REV, V94, P715, DOI 10.1021/cr00027a008; Vanin AF, 2004, NITRIC OXIDE-BIOL CH, V10, P60, DOI 10.1016/j.niox.2004.02.005; Vanin AF, 1998, BIOCHEMISTRY-MOSCOW+, V63, P782; Vollack KU, 2001, J BACTERIOL, V183, P2516, DOI 10.1128/JB.183.8.2516-2526.2001; VONWACHENFELDT C, 1994, FEBS LETT, V340, P109, DOI 10.1016/0014-5793(94)80182-7; Wang PG, 2002, CHEM REV, V102, P1091, DOI 10.1021/cr000040l; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8; WEIHS V, 1989, ARCH MICROBIOL, V151, P546, DOI 10.1007/BF00454873; Xiong JJ, 2000, BIOCHEMISTRY-US, V39, P5117, DOI 10.1021/bi992796o; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMER D, 1995, J BACTERIOL, V177, P2373, DOI 10.1128/jb.177.9.2373-2380.1995; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZUMFT WG, 1992, EUR J BIOCHEM, V208, P31, DOI 10.1111/j.1432-1033.1992.tb17156.x; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	60	38	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20292	20300		10.1074/jbc.M702003200	http://dx.doi.org/10.1074/jbc.M702003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17507380	hybrid			2022-12-25	WOS:000247819300032
J	Pedersen, SF; King, SA; Nygaard, EB; Rigor, RR; Cala, PM				Pedersen, Stine F.; King, Scott A.; Nygaard, Eva B.; Rigor, Robert R.; Cala, Peter M.			NHE1 inhibition by amiloride- and benzoylguanidine-type compounds - Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; NA+/H+ EXCHANGER NHE1; VOLUME REGULATION; OSMOTIC SHRINKAGE; PH REGULATION; ANTIPORTER; ISOFORM; AFFINITY; DOMAINS; CLONING	The interaction of the ubiquitous Na+/H+ exchanger, NHE1, with its commonly used inhibitors, amiloride- and benzoylguanidine ( Hoechst type inhibitor ( HOE))-type compounds, is incompletely understood. We previously cloned NHE1 from Amphiuma tridactylum (AtNHE1) and Pleuronectes americanus (PaNHE1). Although highly homologous to the amiloride- and HOE-sensitive human NHE1 (hNHE1), AtNHE1 is insensitive to HOE-type and PaNHE1 to both amiloride- and HOE-type compounds. Here we generated chimeras to "knock in" amiloride and HOE sensitivity to PaNHE1, and we thereby identified several NHE1 regions involved in inhibitor interaction. The markedly different inhibitor sensitivities of hNHE1, AtNHE1, and PaNHE1 could not be accounted for by differences in transmembrane (TM) region 9. Replacing TM10 through the C-terminal tail of PaNHE1 with the corresponding region of AtNHE1 partially restored sensitivity to amiloride and the related compound 5'-(N-ethyl-N-isopropyl) amiloride (EIPA) but not to HOE694. This effect was not due to the tail region, but it was dependent on TM10-11, because replacing only this region with that of AtNHE1 also partially restored amiloride and EIPA but not HOE sensitivity. The converse mutant (TM10-11 of AtNHE1 replaced with those of PaNHE1) exhibited even higher amiloride and EIPA sensitivity and was also HOE-sensitive. Replacing an LFFFY motif in TM region 4 of PaNHE1 with the corresponding residues of hNHE1 (VFFLF) or AtNHE1 (TFFLF) greatly increased sensitivity to both amiloride- and HOE-type compounds, despite the fact that AtNHE1 is HOE694- insensitive. Gain of amiloride sensitivity appeared to correlate with increased Na+/H+ exchange rates. It is concluded that regions within TM4 and TM10-11 contribute to amiloride and HOE sensitivity, with both regions imparting partial inhibitor sensitivity to NHE1.	Univ Calif Davis, Sch Med, Dept Physiol & Membrane Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA; Univ Copenhagen, Dept Mol Biol, DK-2100 Copenhagen, Denmark	University of California System; University of California Davis; University of California System; University of California Davis; University of Copenhagen	Cala, PM (corresponding author), Univ Calif Davis, Sch Med, Dept Physiol & Membrane Biol, One Shields Ave, Davis, CA 95616 USA.	pmcala@ucdavis.edu	Pedersen, Stine Falsig/O-1133-2019; Pedersen, Stine Falsig/M-8347-2014	Pedersen, Stine Falsig/0000-0002-3044-7714; Pedersen, Stine Falsig/0000-0002-3044-7714; Rigor, Robert/0000-0001-6234-1992	NHLBI NIH HHS [HL-21179] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021179, R37HL021179] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON SE, 1990, AM J PHYSIOL, V259, pC940, DOI 10.1152/ajpcell.1990.259.6.C940; Baumgarth M, 1997, J MED CHEM, V40, P2017, DOI 10.1021/jm960768n; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BURCKHARDT G, 2002, J NEPHROL, V15, P3; CALA PM, 1977, J GEN PHYSIOL, V69, P537, DOI 10.1085/jgp.69.5.537; CALA PM, 1994, J GEN PHYSIOL, V103, P1035, DOI 10.1085/jgp.103.6.1035; CALA PM, 1980, J GEN PHYSIOL, V76, P683, DOI 10.1085/jgp.76.6.683; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; Counillon L, 1997, BIOCHEMISTRY-US, V36, P2951, DOI 10.1021/bi9615405; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; Holt MEV, 2006, CELL BIOCHEM BIOPHYS, V45, P1, DOI 10.1385/CBB:45:1:1; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; Khadilkar A, 2001, J BIOL CHEM, V276, P43792, DOI 10.1074/jbc.M106659200; King SA, 2005, FASEB J, V19, pA1585; KINSELLA JL, 1981, AM J PHYSIOL, V241, P374; Lagana A, 2000, J CELL SCI, V113, P3649; Masereel B, 2003, EUR J MED CHEM, V38, P547, DOI 10.1016/S0223-5234(03)00100-4; McLean LA, 1999, AM J PHYSIOL-CELL PH, V276, pC1025, DOI 10.1152/ajpcell.1999.276.5.C1025; McLean LA, 2000, AM J PHYSIOL-CELL PH, V278, pC676, DOI 10.1152/ajpcell.2000.278.4.C676; Murphy E, 1999, CIRC RES, V84, P1469; Murtazina R, 2001, EUR J BIOCHEM, V268, P4674, DOI 10.1046/j.1432-1327.2001.02391.x; Noel J, 2003, BIOCHEMISTRY-US, V42, P15361, DOI 10.1021/bi035296a; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; Pedersen SF, 2004, J EXP ZOOL PART A, V301A, P569, DOI 10.1002/jez.a.47; Pedersen SF, 2003, AM J PHYSIOL-CELL PH, V284, pC1561, DOI 10.1152/ajpcell.00562.2002; Pedersen SF, 2006, PFLUG ARCH EUR J PHY, V452, P249, DOI 10.1007/s00424-006-0044-y; PEDESIN BK, 1991, INT J SPORTS MED, V1, P25; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Touret N, 2001, BIOCHEMISTRY-US, V40, P5095, DOI 10.1021/bi0025464; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; YUN CHC, 1993, BIOCHEM BIOPH RES CO, V193, P532, DOI 10.1006/bbrc.1993.1656	36	41	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19716	19727		10.1074/jbc.M701637200	http://dx.doi.org/10.1074/jbc.M701637200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17493937	hybrid			2022-12-25	WOS:000247650600047
J	Estecio, MRH; Gharibyan, V; Shen, LL; Ibrahim, AEK; Doshi, K; He, R; Jelinek, J; Yang, AS; Yan, PS; Huang, THM; Tajara, EH; Issa, JPJ				Estecio, Marcos R. H.; Gharibyan, Vazganush; Shen, Lanlan; Ibrahim, Ashraf E. K.; Doshi, Ketan; He, Rong; Jelinek, Jaroslav; Yang, Allen S.; Yan, Pearlly S.; Huang, Tim H-M.; Tajara, Eloiza H.; Issa, Jean-Pierre J.			LINE-1 Hypomethylation in Cancer Is Highly Variable and Inversely Correlated with Microsatellite Instability	PLOS ONE			English	Article								Background. Alterations in DNA methylation in cancer include global hypomethylation and gene-specific hypermethylation. It is not clear whether these two epigenetic errors are mechanistically linked or occur independently. This study was performed to determine the relationship between DNA hypomethylation, hypermethylation and microsatellite instability in cancer. Methodology/Principal Findings. We examined 61 cancer cell lines and 60 colorectal carcinomas and their adjacent tissues using LINE-1 bisulfite-PCR as a surrogate for global demethylation. Colorectal carcinomas with sporadic microsatellite instability (MSI), most of which are due to a CpG island methylation phenotype (CIMP) and associated MLH1 promoter methylation, showed in average no difference in LINE-1 methylation between normal adjacent and cancer tissues. Interestingly, some tumor samples in this group showed increase in LINE-1 methylation. In contrast, MSI-showed a significant decrease in LINE-1 methylation between normal adjacent and cancer tissues (P<0.001). Microarray analysis of repetitive element methylation confirmed this observation and showed a high degree of variability in hypomethylation between samples. Additionally, unsupervised hierarchical clustering identified a group of highly hypomethylated tumors, composed mostly of tumors without microsatellite instability. We extended LINE-1 analysis to cancer cell lines from different tissues and found that 50/61 were hypomethylated compared to peripheral blood lymphocytes and normal colon mucosa. Interestingly, these cancer cell lines also exhibited a large variation in demethylation, which was tissue-specific and thus unlikely to be resultant from a stochastic process. Conclusion/Significance. Global hypomethylation is partially reversed in cancers with microsatellite instability and also shows high variability in cancer, which may reflect alternative progression pathways in cancer.	[Estecio, Marcos R. H.; Gharibyan, Vazganush; Shen, Lanlan; He, Rong; Jelinek, Jaroslav; Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Ibrahim, Ashraf E. K.] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; [Doshi, Ketan] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Yang, Allen S.] Univ So Calif, Dept Med, Los Angeles, CA USA; [Yan, Pearlly S.; Huang, Tim H-M.] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; [Tajara, Eloiza H.] Fac Med Sao Jose Rio Preto FAMERP, Dept Mol Biol, Sao Paulo, Brazil	University of Texas System; UTMD Anderson Cancer Center; University of Cambridge; University of Minnesota System; University of Minnesota Twin Cities; University of Southern California; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Issa, JPJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.	jissa@mdanderson.org	Tajara, Eloiza H/G-7586-2012; Yan, Pearlly S/E-4339-2011; Jelinek, Jaroslav/D-2282-2012; Jelinek, Jaroslav/O-6876-2019	Tajara, Eloiza H/0000-0002-2603-2057; Yan, Pearlly S/0000-0003-1965-4920; Jelinek, Jaroslav/0000-0002-2533-0220; Issa, Jean-Pierre/0000-0003-2258-5030; Estecio, Marcos/0000-0002-6874-7413	National Institutes of Health (USA) [CA098006, CA100632, CA105346]; FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil) [99/09368-1, 00/12361-8]; NATIONAL CANCER INSTITUTE [P50CA100632, R01CA105346, R01CA098006] Funding Source: NIH RePORTER	National Institutes of Health (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (USA) grants CA098006, CA100632 and CA105346 (J-P.J.I.) and from FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil) grants 99/09368-1 (M. R. H. E.) and 00/12361-8 (E. H. T.)	BAYLIN SB, 1986, CANCER RES, V46, P2917; BAYLIN SB, 1987, BLOOD, V70, P412; Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137; Deng GR, 2006, INT J CANCER, V118, P2999, DOI 10.1002/ijc.21740; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; Ehrlich M, 2006, ONCOGENE, V25, P2636, DOI 10.1038/sj.onc.1209145; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Frigola J, 2005, HUM MOL GENET, V14, P319, DOI 10.1093/hmg/ddi028; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gonzalgo ML, 1997, CANCER RES, V57, P594; Holm TM, 2005, CANCER CELL, V8, P275, DOI 10.1016/j.ccr.2005.09.007; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LU LJW, 1983, CANCER LETT, V19, P231, DOI 10.1016/0304-3835(83)90159-3; Matsuzaki K, 2005, CLIN CANCER RES, V11, P8564, DOI 10.1158/1078-0432.CCR-05-0859; Piotrowski A, 2006, GENE CHROMOSOME CANC, V45, P656, DOI 10.1002/gcc.20331; Smiraglia DJ, 2002, ONCOGENE, V21, P5414, DOI 10.1038/sj.onc.1205608; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016; Toyota M, 1999, CANCER RES, V59, P2307; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Toyota M, 2005, SEMIN ONCOL, V32, P521, DOI 10.1053/j.seminoncol.2005.07.003; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; WALKER MS, 1981, CANCER BIOCHEM BIOPH, V5, P169; Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032	30	211	224	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e399	10.1371/journal.pone.0000399	http://dx.doi.org/10.1371/journal.pone.0000399			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476321	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445700001
J	Charette, ST; McCance, DJ				Charette, S. T.; McCance, D. J.			The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner	ONCOGENE			English	Article						Akt; cervical cancer; HPV-16; migration; p27; RhoA	CELL-MIGRATION; EXPRESSION; P27(KIP1); P27; PROGRESSION; ARREST	Cyclin-dependent kinase inhibitor p27(kip1) (p27) has recently been implicated as a positive regulator of cellular motility and is a marker of poor prognosis in several forms of cancer when localized to the cytoplasm. Cytoplasmic p27 exerts its effect on migration by binding to and inhibiting the activation of the small GTPase and cytoskeletal organizer RhoA, consequentially loosening cell substrate grip and enhancing movement. Using DNA damage as a p27 nuclear import signal, we found that the E7 oncoprotein from human papillomavirus type 16 (HPV-16), the etiological agent of cervical cancer, enhanced both the cytoplasmic retention of p27 and the migration of human foreskin keratinocytes (HFKs) in a phosphoinositide-3 kinase (PI3K)/Akt-dependent manner using a standard wound assay. Increased migration in E7-expressing HFKs correlated with an Akt-regulated downregulation of RhoA activity through p27 binding under conditions where a p27 nuclear import signal is given (that is, DNA damage). Under these conditions, inhibition of the downstream RhoA effector ROCK enhanced control cell migration, whereas relatively unaffecting E7-expressing cells, further implicating that the inhibitory effect of E7 on RhoA positively regulates migration. We believe that the E7 protein from HPV-16 can modulate the cytoplasmic localization of p27 and may in turn regulate tumor metastasis/aggressiveness through the PI3K/Akt pathway.	Univ Rochester, Dept Microbiol & Immunol, Rochester, NY USA; Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA	University of Rochester; University of Rochester	McCance, DJ (corresponding author), Queens Univ, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast BTQ 7BL, Antrim, North Ireland.	d.mccance@qub.ac.uk			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM068411] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI030798, AI030798] Funding Source: Medline; NIGMS NIH HHS [T32 GM068411, GM068411] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baseman JG, 2005, J CLIN VIROL, V32, pS16, DOI 10.1016/j.jcv.2004.12.008; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Dellas A, 1998, ANTICANCER RES, V18, P3991; Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369; Fiedler M, 2004, FASEB J, V18, P1120, DOI 10.1096/fj.03-1332fje; Hudelist G, 2004, GYNECOL ONCOL, V92, P873, DOI 10.1016/j.ygyno.2003.11.035; Incassati A, 2006, ONCOGENE, V25, P2444, DOI 10.1038/sj.onc.1209276; Li R, 2006, J UROLOGY, V175, P528, DOI 10.1016/S0022-5347(05)00151-5; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Menges CW, 2006, CANCER RES, V66, P5555, DOI 10.1158/0008-5472.CAN-06-0499; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shiozawa T, 2001, CANCER, V92, P3005, DOI 10.1002/1097-0142(20011215)92:12<3005::AID-CNCR10153>3.0.CO;2-6; Vasko V, 2004, J MED GENET, V41, P161, DOI 10.1136/jmg.2003.015339; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Watanabe J, 2002, BRIT J CANCER, V87, P81, DOI 10.1038/sj.bjc.6600434; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; WU S, 1960, CLIN CANCER RES, V12, P2032	20	61	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7386	7390		10.1038/sj.onc.1210541	http://dx.doi.org/10.1038/sj.onc.1210541			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533372	Green Accepted			2022-12-25	WOS:000250955700011
J	Tang, X; Milyavsky, M; Goldfinger, N; Rotter, V				Tang, X.; Milyavsky, M.; Goldfinger, N.; Rotter, V.			Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress	ONCOGENE			English	Article						p53; APLP1; transcription; apoptosis; senescence; neuroblastoma and Alzheimer's disease	ALZHEIMERS-DISEASE; P53-INDUCED APOPTOSIS; NEURONAL APOPTOSIS; FAMILY-MEMBERS; MOUSE-BRAIN; EXPRESSION; CARCINOMA; CLEAVAGE; DENSITY; IMPAIRS	The tumor suppressor p53 is a key modulator of the cellular stress response, inducing cell-cycle arrest, apoptosis, senescence and cell differentiation. To evaluate further the molecular mechanism underlying p53 function, the transcriptional profiles of proliferating and senescent WI-38 cells, both wild-type p53 expressers and counterparts with an inactivated p53, were compared by DNA microarray analysis. In particular, the amyloid-beta precursor-like protein 1 (APLP1) is induced in senescent cells in a p53-dependent manner. APLP1 was confirmed to be a novel transcriptional target of p53 by in vivo and in vitro characterization of a p53 responsive element found in the first intron of the APLP1 gene locus. APLP1 knockdown experiments demonstrate that APLP1 is required for the proliferation of fibroblastic and epithelial cells. Moreover, depletion of APLP1 expression diminishes stress-induced apoptosis of neural cells, whereas ectopic APLP1 expression augments apoptosis. Based on these data, a mechanism is proposed whereby p53-dependent induction of APLP1 is involved in neural cell death, and which may exacerbate neuronal cell loss in some acute or chronic neurodegenerative disorders.	Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Milyavsky, Michael/E-8306-2011					Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Attardi LD, 2000, GENE DEV, V14, P704; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Bayer TA, 1997, ACTA NEUROPATHOL, V94, P519, DOI 10.1007/s004010050745; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cregan SP, 1999, J NEUROSCI, V19, P7860; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Heber S, 2000, J NEUROSCI, V20, P7951; KIM TW, 1995, MOL BRAIN RES, V32, P36, DOI 10.1016/0169-328X(95)00328-P; Ko SY, 2004, INT J CANCER, V111, P727, DOI 10.1002/ijc.20328; LaFerla FM, 1996, J CLIN INVEST, V98, P1626, DOI 10.1172/JCI118957; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; LORENT K, 1995, NEUROSCIENCE, V65, P1009, DOI 10.1016/0306-4522(94)00555-J; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McNamara MJ, 1998, BRAIN RES, V804, P45, DOI 10.1016/S0006-8993(98)00653-2; Meng JY, 2001, INT J CANCER, V92, P31, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1155>3.3.CO;2-8; Milyavsky M, 2005, CANCER RES, V65, P4530, DOI 10.1158/0008-5472.CAN-04-3880; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Morrison RS, 2000, CELL DEATH DIFFER, V7, P868, DOI 10.1038/sj.cdd.4400741; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pietrzik CU, 1998, P NATL ACAD SCI USA, V95, P1770, DOI 10.1073/pnas.95.4.1770; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Stambolsky P, 2006, CELL DEATH DIFFER, V13, P2140, DOI 10.1038/sj.cdd.4401965; Takahashi M, 2000, NEURON, V28, P461, DOI 10.1016/S0896-6273(00)00125-2; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Ward MW, 2004, J BIOENERG BIOMEMBR, V36, P295, DOI 10.1023/B:JOBB.0000041756.23918.11; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758	37	24	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7302	7312		10.1038/sj.onc.1210542	http://dx.doi.org/10.1038/sj.onc.1210542			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533371				2022-12-25	WOS:000250955700002
J	Oxford, G; Smith, SC; Hampton, G; Theodorescu, D				Oxford, G.; Smith, S. C.; Hampton, G.; Theodorescu, D.			Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector	ONCOGENE			English	Article						GTPases; bladder neoplasms; biomarker; metastasis	GTPASES; CARCINOMA; ACTIVATION; PROTEIN; KINASE; GROWTH; RLIP76; PROLIFERATION; METASTASIS; CONTRIBUTE	Although the monomeric GTPases RalA and RalB have been shown to regulate a variety of transcription factors, little is known regarding the differences or similarities in transcriptional programs regulated by RalA compared to RalB. Further, the association of these transcriptional pathways to human carcinogenesis and progression remains unclear. Here, we studied the role of RalA and/or RalB in transcriptional regulation by combining short interfering RNA depletion of Ral with gene expression pro. ling via microarray in the human bladder cancer cell line, UMUC-3. A large number of genes were found to be similarly modulated in cells with RalA and RalB depletion, suggesting that RalA and RalB impinge on overlapping transcriptional signaling pathways. However, smaller sets of genes were modulated by depletion of RalA or RalB, indicating that these closely related proteins also regulate nonoverlapping transcriptional pathways. Computational analysis of upstream sequences of genes modulated by Ral depletion identified Ras-responsive element-binding protein ( RREB)-1, as a putative Ral transcriptional target, which we verified experimentally. Importantly, as a group, Ral-regulated probe sets identified here were disproportionally represented among those differentially expressed as a function of human bladder transformation. Taken together, these data strongly suggest that Ral family members mediate both common and specific transcriptional programs that are associated with human cancer and identify RREB-1 as a novel transcriptional effector of Ral.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Genom Inst Novartis Res Fdn, San Diego, CA USA	University of Virginia; Novartis	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu	Smith, Steven Christopher/S-9375-2019; Smith, Steven/HDM-9496-2022	Smith, Steven Christopher/0000-0003-0982-4607; 	NCI NIH HHS [R01 CA075115, P01CA104106, CA075115, CA009109-29] Funding Source: Medline; NIGMS NIH HHS [T32GM007267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075115, R29CA075115, P01CA104106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; Awasthi S, 2003, INT J CANCER, V106, P635, DOI 10.1002/ijc.11260; Bigler D, 2003, ONCOGENE, V22, P1261, DOI 10.1038/sj.onc.1206242; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Gildea JJ, 2002, CANCER RES, V62, P982; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Haverty PM, 2004, NUCLEIC ACIDS RES, V32, pW213, DOI 10.1093/nar/gkh402; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Lebreton S, 2004, MECH DEVELOP, V121, P1481, DOI 10.1016/j.mod.2004.07.008; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855; Thiagalingam A, 1996, MOL CELL BIOL, V16, P5335; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wu X, 2004, BJU INT, V93, P143, DOI 10.1111/j.1464-410X.2004.04574.x; Zhang SL, 2003, ONCOGENE, V22, P2285, DOI 10.1038/sj.onc.1206257	31	17	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7143	7152		10.1038/sj.onc.1210521	http://dx.doi.org/10.1038/sj.onc.1210521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496927				2022-12-25	WOS:000250715000008
J	Di Maira, G; Brustolon, F; Bertacchini, J; Tosoni, K; Marmiroli, S; Pinna, LA; Ruzzene, M				Di Maira, G.; Brustolon, F.; Bertacchini, J.; Tosoni, K.; Marmiroli, S.; Pinna, L. A.; Ruzzene, M.			Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level	ONCOGENE			English	Article						CK2; MDR; CEM cells; inhibitors; casein kinase 2; CKII	INDUCED APOPTOSIS; CASEIN KINASE-2; P-GLYCOPROTEIN; CANCER-CELLS; II-ALPHA; IN-VIVO; 4,5,6,7-TETRABROMOBENZOTRIAZOLE; PHOSPHORYLATES; EXPRESSION; AKT/PKB	Protein kinase CK2 is an ubiquitous and constitutively active kinase, which phosphorylates many cellular proteins and is implicated in the regulation of cell survival, proliferation and transformation. We investigated its possible involvement in the multidrug resistance phenotype (MDR) by analysing its level in two variants of CEM cells, namely S-CEM and R.-CEM, normally sensitive or resistant to chemical apoptosis, respectively. We found that, while the CK2 regulatory subunit beta was equally expressed in the two cell variants, CK2 alpha catalytic subunit was higher in R-CEM and this was accompanied by a higher phosphorylation of endogenous protein substrates. Pharmacological downregulation of CK2 activity by a panel of specific inhibitors, or knockdown of CK2 alpha expression by RNA interference, were able to induce cell death in R-CEM. CK2 inhibitors could promote an increased uptake of chemotherapeutic drugs inside the cells and sensitize them to drug-induced apoptosis in a co-operative manner. CK2 blockade was also effective in inducing cell death of a different MDR line (U2OS). We therefore conclude that inhibition of CK2 can be considered as a promising tool to revert the MDR phenotype.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Univ Padua, Inst Neurosci, CNR, Padua, Italy; VIMM, Padua, Italy; Univ Modena & Reggio Emilia, Dept Anat & Histol, Modena, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Veneto Institute Molecular Medicine; Universita di Modena e Reggio Emilia	Ruzzene, M (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.	maria.ruzzene@unipd.it	BERTACCHINI, JESSIKA/F-4382-2017; Marmiroli, Sandra/J-5242-2016	BERTACCHINI, JESSIKA/0000-0001-9218-9215; Marmiroli, Sandra/0000-0001-5545-9319; Di Maira, Giovanni/0000-0003-2041-6022; Ruzzene, Maria/0000-0001-8712-8151; Pinna, Lorenzo A./0000-0002-8856-4956				Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001; Ahmad KA, 2007, MOL CANCER THER, V6, P1006, DOI 10.1158/1535-7163.MCT-06-0491; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Allende CC, 1998, J CELL BIOCHEM, P129; Borst P, 1997, SEMIN CANCER BIOL, V8, P131, DOI 10.1006/scbi.1997.0072; Cenni V, 2004, INT J ONCOL, V25, P1599; De Moliner E, 2003, J BIOL CHEM, V278, P1831, DOI 10.1074/jbc.M209367200; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; Dupuis ML, 2003, CHEMOTHERAPY, V49, P8, DOI 10.1159/000069782; Filhol O, 2004, EMBO REP, V5, P351, DOI 10.1038/sj.embor.7400115; Giovannetti E, 2004, CLIN CANCER RES, V10, P2936, DOI 10.1158/1078-0432.CCR-03-0520; Glavy JS, 1997, J BIOL CHEM, V272, P5909, DOI 10.1074/jbc.272.9.5909; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Guo CH, 2001, J BIOL CHEM, V276, P5992, DOI 10.1074/jbc.M004862200; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Klumpp S, 2004, NEUROCHEM INT, V45, P747, DOI 10.1016/j.neuint.2004.02.006; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Matsumoto Y, 2001, JPN J CANCER RES, V92, P778, DOI 10.1111/j.1349-7006.2001.tb01161.x; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Meggio F, 2004, BIOCHEMISTRY-US, V43, P12931, DOI 10.1021/bi048999g; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pagano MA, 2004, J MED CHEM, V47, P6239, DOI 10.1021/jm049854a; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Salvi M, 2006, FEBS LETT, V580, P3948, DOI 10.1016/j.febslet.2006.06.031; Sarno S, 2005, BBA-PROTEINS PROTEOM, V1754, P263, DOI 10.1016/j.bbapap.2005.07.043; Sarno S, 2005, MOL CELL BIOCHEM, V274, P69, DOI 10.1007/s11010-005-3079-z; Sarno S, 2003, BIOCHEM J, V374, P639, DOI 10.1042/BJ20030674; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Sawicka M, 2004, J PHARM PHARMACOL, V56, P1067, DOI 10.1211/0022357044265; Seeber S, 2005, APOPTOSIS, V10, P875, DOI 10.1007/s10495-005-0380-y; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SZYSZKA R, 1995, BIOCHEM BIOPH RES CO, V208, P418, DOI 10.1006/bbrc.1995.1354; Tapia JC, 2006, P NATL ACAD SCI USA, V103, P15079, DOI 10.1073/pnas.0606845103	37	70	71	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6915	6926		10.1038/sj.onc.1210495	http://dx.doi.org/10.1038/sj.onc.1210495			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486073				2022-12-25	WOS:000250188400007
J	Cantero, AV; Portero-Otin, M; Ayala, V; Auge, N; Sanson, M; Elbaz, M; Thiers, JC; Pamplona, R; Salvayre, R; Negre-Salvayre, A				Cantero, Anne-Valerie; Portero-Otin, Manuel; Ayala, Victoria; Auge, Nathalie; Sanson, Marie; Elbaz, Meyer; Thiers, Jean-Claude; Pamplona, Reinald; Salvayre, Robert; Negre-Salvayre, Anne			Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis	FASEB JOURNAL			English	Article						oxidative stress; growth arrest; MGO; wound healing; apoptosis	GROWTH-FACTOR; CARDIOVASCULAR-DISEASE; ACCELERATED ATHEROSCLEROSIS; MAILLARD REACTION; MESANGIAL CELLS; PROTEINS; COMPLICATIONS; ACTIVATION; N-EPSILON-(CARBOXYMETHYL)LYSINE; GLYCOXIDATION	Purpose: Low molecular weight carbonyl compounds, such as the alpha-ketoaldehydes methylglyoxal (MGO) and glyoxal (GO), are formed under hyperglycemic conditions and behave as advanced glycation end product (AGE) precursors. They form adducts on proteins, thereby inducing cellular dysfunctions involved in chronic complications of diabetes. Methods and main findings: Nontoxic concentrations of GO or MGO altered the PDGF-induced PDGFR beta-phosphorylation, ERK1/ 2-activation, and nuclear translocation, and the subsequent proliferation of mesenchymal cells (smooth muscle cells and skin fibroblasts). This resulted mainly from inhibition of the intrinsic tyrosine kinase of PDGFR beta and in part from altered PDGF-BB binding to PDGFR beta. Concomitantly, the formation of AGE adducts (N-epsilon carboxymethyl-ly-sine and N-epsilon carboxyethyl-lysine) was observed on immunoprecipitated PDGFR beta. Arginine and aminoguanidine, used as carbonyl scavengers, reversed the inhibitory effect and the formation of AGE adducts on PDGFR beta. AGE-PDGFR beta adducts were also detected by anti-AGE antibodies in PDGFR beta immunopurified from aortas of diabetic (streptozotocin-treated) compared to nondiabetic apolipoprotein E-null mice. Mass spectrometry analysis of aortas demonstrated increased AGE formation in diabetic specimens. Conclusions: these data indicate that MGO and GO induce desensitization of PDGFR beta that helps to reduce mesenchymal cell proliferation.	Univ Toulouse 3, CHU Rangueil, IFR 31, INSERM,U466, F-31059 Toulouse 9, France; Univ Toulouse 3, CHU Rangueil, IFR 31, Dept Biochem, F-31059 Toulouse 9, France; Univ Lleida, Dept Basic Med Sci, Metab Pathophysiol Res Grp, Lleida, Spain	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universitat de Lleida	Negre-Salvayre, A (corresponding author), Univ Toulouse 3, CHU Rangueil, IFR 31, INSERM,U466, F-31059 Toulouse 9, France.	salvayre@toulouse.inserm.fr	Portero-Otin, Manuel/B-7122-2009; Pamplona, Reinald/A-7359-2010; Ayala, Maria Victoria/A-7391-2010	Portero-Otin, Manuel/0000-0002-1823-0299; Pamplona, Reinald/0000-0003-4337-6107; Ayala, Maria Victoria/0000-0002-1496-966X; ELBAZ, Meyer/0000-0002-3520-7883; Negre-Salvayre, Anne/0000-0003-2136-5706; Auge, Nathalie/0000-0003-2088-7211				Askari B, 2002, HISTOL HISTOPATHOL, V17, P1317, DOI 10.14670/HH-17.1317; Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Betsholtz C, 2004, CURR OPIN NEPHROL HY, V13, P45, DOI 10.1097/00041552-200401000-00007; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Escargueil-Blanc I, 2001, CIRCULATION, V104, P1814, DOI 10.1161/hc4001.097179; Ferreira AEN, 2003, BIOCHEM J, V376, P109, DOI 10.1042/BJ20030496; Forbes JM, 2004, DIABETES, V53, P1813, DOI 10.2337/diabetes.53.7.1813; Hedin U, 2004, CURR OPIN LIPIDOL, V15, P559, DOI 10.1097/00041433-200410000-00010; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Jia XM, 2006, FASEB J, V20, P1555, DOI 10.1096/fj.05-5478fje; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; Kolodgie FD, 2001, CURR OPIN CARDIOL, V16, P285, DOI 10.1097/00001573-200109000-00006; Koveker GB, 2000, INT J CLIN PRACT, V54, P590; Laakso M, 1999, PRIMARY CARE, V26, P829, DOI 10.1016/S0095-4543(05)70133-0; Lapolla A, 2005, MOL NUTR FOOD RES, V49, P685, DOI 10.1002/mnfr.200400093; Lieuw-A-Fa MLM, 2004, NEPHROL DIAL TRANSPL, V19, P631, DOI 10.1093/ndt/gfg619; Liu BF, 2003, KIDNEY INT, V63, P947, DOI 10.1046/j.1523-1755.2003.00829.x; Lu CY, 2004, P NATL ACAD SCI USA, V101, P11767, DOI 10.1073/pnas.0401588101; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Margolis DJ, 2005, WOUND REPAIR REGEN, V13, P531, DOI 10.1111/j.1524-475X.2005.00074.x; Metz TO, 2003, J BIOL CHEM, V278, P42012, DOI 10.1074/jbc.M304292200; Morgan PE, 2002, ARCH BIOCHEM BIOPHYS, V403, P259, DOI 10.1016/S0003-9861(02)00222-9; Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Passarelli M, 2005, DIABETES, V54, P2198, DOI 10.2337/diabetes.54.7.2198; Portero-Otin M, 2002, DIABETES, V51, P1535, DOI 10.2337/diabetes.51.5.1535; Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004; Randell E. W., 2005, Journal of Pharmacological and Toxicological Methods, V51, P153, DOI 10.1016/j.vascn.2004.08.005; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Requena JR, 2001, P NATL ACAD SCI USA, V98, P69, DOI 10.1073/pnas.011526698; Riboulet-Chavey A, 2006, DIABETES, V55, P1289, DOI 10.2337/db05-0857; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakamoto H, 2002, J BIOL CHEM, V277, P45770, DOI 10.1074/jbc.M207485200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seki N, 2003, METABOLISM, V52, P1558, DOI 10.1016/j.metabol.2003.07.010; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Thomas MC, 2005, CURR DRUG TARGETS, V6, P453, DOI 10.2174/1389450054021873; Thornalley PJ, 1996, GEN PHARMACOL-VASC S, V27, P565, DOI 10.1016/0306-3623(95)02054-3; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Thorpe SR, 2003, AMINO ACIDS, V25, P275, DOI 10.1007/s00726-003-0017-9; Vindis C, 2006, CIRC RES, V98, P785, DOI 10.1161/01.RES.0000216288.93234.c3; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D; Yao DC, 2006, CELL, V124, P275, DOI 10.1016/j.cell.2005.11.024	49	102	107	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3096	3106		10.1096/fj.06-7536com	http://dx.doi.org/10.1096/fj.06-7536com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17504976				2022-12-25	WOS:000249781600011
J	Goldberg, A; Parolini, M; Chin, BY; Czismadia, E; Otterbein, LE; Bach, FH; Wang, HJ				Goldberg, Alyssa; Parolini, Margherita; Chin, Beek Y.; Czismadia, Eva; Otterbein, Leo E.; Bach, Fritz H.; Wang, Hongjun			Toll-like receptor 4 suppression leads to islet allograft survival	FASEB JOURNAL			English	Article						islet transplantation; carbon monoxide; inflammation; type 1 diabetes	HEME OXYGENASE-1 GENE; CARBON-MONOXIDE PRODUCTION; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; NITRIC-OXIDE; KAPPA-B; EXPRESSION; APOPTOSIS; MICE; ACTIVATION	Carbon monoxide ( CO) exposure of an islet donor frequently leads to islet allograft long- term survival and tolerance in recipients. We show here that CO confers its protective effects at least in part by suppressing Toll- like receptor 4 ( TLR4) up- regulation in pancreatic beta cells. TLR4 is normally up- regulated in islets during the isolation procedure; donor treatment with CO suppresses TLR4 expression in isolated islets as well as in transplanted grafts. TLR4 up- regulation allows initiation of inflammation, which leads to islet allograft rejection; islet grafts from TLR4- deficient mice survive indefinitely in BALB/ c recipients and show significantly less inflammation at various days after transplantation compared with grafts from a control donor. Isolated islets preinfected with a TLR4 dominant negative virus before transplantation demonstrated prolonged survival in recipients. Despite the salutary effects of TLR4 suppression, HO- 1 expression is still needed in the recipient for islet survival: TLR4deficient islets were rejected promptly after being transplanted into recipients in which HO- 1 activity was blocked. In addition, incubation of an insulinoma cell line, beta TC3, with an anti- TLR4 antibody protects those cells from cytokine- induced apoptosis. Our data suggest that TLR4 induction in beta cells is involved in beta cell death and graft rejection after transplantation. CO exposure protects islets from rejection by blocking TLR4 up- regulation.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA; Univ Milan, Milan, Italy	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Milan	Wang, HJ (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, 99 Brookline Ave, Boston, MA 02215 USA.	hwang3@bidmc.harvard.edu	Wang, Hongjun/AAA-1319-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL077721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alcaraz MJ, 2003, CURR PHARM DESIGN, V9, P2541, DOI 10.2174/1381612033453749; Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Appelberg R, 2000, INFECT IMMUN, V68, P19, DOI 10.1128/IAI.68.1.19-23.2000; AUAUJO JA, 2003, J IMMUNOL, V171, P1572; Bellocchio S, 2004, J IMMUNOL, V173, P7406, DOI 10.4049/jimmunol.173.12.7406; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; CHOI SY, 1996, J PARODONTOL IMPLANT, V15, P19; Davalli AM, 1996, DIABETES, V45, P1161, DOI 10.2337/diabetes.45.9.1161; Dunzendorfer S, 2004, FASEB J, V18, P1117, DOI 10.1096/fj.03-1263fje; Durante W, 1997, AM J PHYSIOL-HEART C, V273, pH317, DOI 10.1152/ajpheart.1997.273.1.H317; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Flodstrom M, 1997, ENDOCRINOLOGY, V138, P2747, DOI 10.1210/en.138.7.2747; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; Goldstein DR, 2003, J CLIN INVEST, V111, P1571, DOI 10.1172/JCI200317573; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Gunther L, 2002, DIABETES, V51, P994, DOI 10.2337/diabetes.51.4.994; Hohmeier HE, 2003, INT J OBESITY, V27, pS12, DOI 10.1038/sj.ijo.0802493; Hollestelle SCG, 2004, CIRCULATION, V109, P393, DOI 10.1161/01.CIR.0000109140.51366.72; Johansson U, 2003, BIOCHEM BIOPH RES CO, V308, P474, DOI 10.1016/S0006-291X(03)01392-5; Katori M, 2002, TRANSPLANTATION, V74, P905, DOI 10.1097/00007890-200210150-00001; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kumagai N, 2002, TRANSPLANTATION, V74, P1223, DOI 10.1097/00007890-200211150-00005; Kushida T, 2002, BIOCHEM BIOPH RES CO, V291, P68, DOI 10.1006/bbrc.2002.6403; Lamhamedi-Cherradi SE, 2003, DIABETES, V52, P2274, DOI 10.2337/diabetes.52.9.2274; Li XW, 2003, INFECT IMMUN, V71, P4414, DOI 10.1128/IAI.71.8.4414-4420.2003; MAINES MD, 1986, J BIOL CHEM, V261, P411; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Methe H, 2004, TRANSPLANTATION, V78, P1324, DOI 10.1097/01.TP.0000137930.40597.03; Molano RD, 2003, DIABETES, V52, P957, DOI 10.2337/diabetes.52.4.957; O'Brien GC, 2005, J IMMUNOL, V174, P1020, DOI 10.4049/jimmunol.174.2.1020; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Otterbein L, 1997, AM J PHYSIOL-LUNG C, V272, pL268; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84; Palmer SM, 2006, CLIN TRANSPLANT, V20, P30, DOI 10.1111/j.1399-0012.2005.00436.x; Pileggi A, 2001, DIABETES, V50, P1983, DOI 10.2337/diabetes.50.9.1983; Pileggi A, 2005, CELL TRANSPLANT, V14, P85, DOI 10.3727/000000005783983160; Poltorak A, 2001, J IMMUNOL, V167, P2106, DOI 10.4049/jimmunol.167.4.2106; Qureshi ST, 1999, TRENDS GENET, V15, P291, DOI 10.1016/S0168-9525(99)01782-5; RICORDI C, 1990, ACTA DIABETOL LAT, V27, P185, DOI 10.1007/BF02581331; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; Satoh M, 2004, LAB INVEST, V84, P173, DOI 10.1038/labinvest.3700031; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; Thornley TB, 2006, J IMMUNOL, V176, P1561, DOI 10.4049/jimmunol.176.3.1561; Vaidya SA, 2003, CURR OPIN IMMUNOL, V15, P402, DOI 10.1016/S0952-7915(03)00070-0; Vives-Pi M, 2003, CLIN EXP IMMUNOL, V133, P208, DOI 10.1046/j.1365-2249.2003.02211.x; Wang HJ, 2006, ENDOCRINOLOGY, V147, P762, DOI 10.1210/en.2005-0632; Wang HJ, 2005, DIABETES, V54, P1400, DOI 10.2337/diabetes.54.5.1400; Wassef A, 2004, HISTOL HISTOPATHOL, V19, P1201, DOI 10.14670/HH-19.1201; Weatherill AR, 2005, J IMMUNOL, V174, P5390, DOI 10.4049/jimmunol.174.9.5390; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Woo J, 2000, TRANSPLANTATION, V69, P623, DOI 10.1097/00007890-200002270-00026; Yang LM, 1999, AM J PHYSIOL-LUNG C, V277, pL127, DOI 10.1152/ajplung.1999.277.1.L127; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; Zhai Y, 2004, J IMMUNOL, V173, P7115, DOI 10.4049/jimmunol.173.12.7115; Zhou CG, 2005, J HIGH ENERGY PHYS	60	55	61	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2840	2848		10.1096/fj.06-7910com	http://dx.doi.org/10.1096/fj.06-7910com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475921				2022-12-25	WOS:000249237500025
J	Cook, VM; deHaseth, PL				Cook, Victoria M.; deHaseth, Pieter L.			Strand opening-deficient Escherichia coli RNA polymerase facilitates investigation of closed complexes with promoter DNA - Effects of DNA sequence and temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-R PROMOTER; TRANSCRIPTION INITIATION; CONFORMATIONAL-CHANGES; -35 REGIONS; SPACER DNA; START SITE; RECOGNITION; BINDING; HOLOENZYME; ELEMENT	Formation of the strand-separated, open complex between RNA polymerase and a promoter involves several intermediates, the first being the closed complex in which the DNA is fully base-paired. This normally short lived complex has been difficult to study. We have used a mutant Escherichia coli RNA polymerase, deficient in promoter DNA melting, and variants of the P-R promoter of bacteriophage lambda to model the closed complex intermediate at physiologically relevant temperatures. Our results indicate that in the closed complex, RNA polymerase recognizes base pairs as double-stranded DNA even in the region that becomes single-stranded in the open complex. Additionally, a particular base pair in the -35 region engages in an important interaction with the RNA polymerase, and a DNase I-hypersensitive site, pronounced in the promoter DNA of the open complex, was not present. The effect of temperature on closed complex formation was found to be small over the temperature range from 15 to 37 degrees C. This suggests that low temperature complexes of wild type RNA polymerase and promoter DNA may adequately model the closed complex.	Case Western Reserve Univ, Ctr RNA Mol Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	deHaseth, PL (corresponding author), Case Western Reserve Univ, Ctr RNA Mol Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	pld2@case.edu			NIGMS NIH HHS [GM31808] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031808] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYERS DG, 1989, J MOL BIOL, V207, P749, DOI 10.1016/0022-2836(89)90241-6; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Burr T, 2000, NUCLEIC ACIDS RES, V28, P1864, DOI 10.1093/nar/28.9.1864; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Feklistov A, 2006, MOL CELL, V23, P97, DOI 10.1016/j.molcel.2006.06.010; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Haugen SP, 2006, CELL, V125, P1069, DOI 10.1016/j.cell.2006.04.034; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; Lew CM, 2004, BIOCHEMISTRY-US, V43, P12660, DOI 10.1021/bi0492814; Li XY, 1998, J BIOL CHEM, V273, P23549, DOI 10.1074/jbc.273.36.23549; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; Liu MF, 2004, P NATL ACAD SCI USA, V101, P6911, DOI 10.1073/pnas.0401929101; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; McKane M, 2000, J MOL BIOL, V299, P337, DOI 10.1006/jmbi.2000.3757; MELANCON P, 1983, BIOCHEMISTRY-US, V22, P5169, DOI 10.1021/bi00291a017; MOYLE H, 1991, J BACTERIOL, V173, P1944, DOI 10.1128/jb.173.6.1944-1950.1991; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Niedziela-Majka A, 2005, J BIOL CHEM, V280, P38219, DOI 10.1074/jbc.M507984200; OZOLINE ON, 1995, NUCLEIC ACIDS RES, V23, P4533, DOI 10.1093/nar/23.22.4533; Panaghie G, 2000, J MOL BIOL, V299, P1217, DOI 10.1006/jmbi.2000.3808; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; Roy S, 2004, J MOL BIOL, V344, P609, DOI 10.1016/j.jmb.2004.09.070; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; Schroeder LA, 2005, J BIOL CHEM, V280, P17422, DOI 10.1074/jbc.M501281200; Sen R, 2000, J BIOL CHEM, V275, P10899, DOI 10.1074/jbc.275.15.10899; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; Sun L, 2004, J MOL BIOL, V343, P1171, DOI 10.1016/j.jmb.2004.09.025; SZOKE PA, 1987, BIOCHEMISTRY-US, V26, P6188, DOI 10.1021/bi00393a035; Tsujikawa L, 2002, P NATL ACAD SCI USA, V99, P3493, DOI 10.1073/pnas.062487299; WARNE SE, 1993, BIOCHEMISTRY-US, V32, P6134, DOI 10.1021/bi00075a003; Zhang X, 1996, J MOL BIOL, V258, P14, DOI 10.1006/jmbi.1996.0230; Zhi HJ, 2003, METHOD ENZYMOL, V370, P174	40	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21319	21326		10.1074/jbc.M702232200	http://dx.doi.org/10.1074/jbc.M702232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17507375	hybrid			2022-12-25	WOS:000248047500060
J	Isaacson, RL; Pye, VE; Simpson, P; Meyer, HH; Zhang, XD; Freemont, PS; Matthews, S				Isaacson, Rivka L.; Pye, Valerie E.; Simpson, Peter; Meyer, Hemmo H.; Zhang, Xiaodong; Freemont, Paul S.; Matthews, Steve			Detailed structural insights into the p97-Npl4-Ufd1 interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AAA ATPASE P97/VCP; CONFORMATIONAL-CHANGES; TRANSCRIPTION FACTOR; MEMBRANE-FUSION; UBIQUITIN; PROTEIN; P97; COMPLEX; P47; DOMAIN	The AAA ATPase, p97, achieves its versatility through binding to a wide range of cofactor proteins that adapt it to different cellular functions. The heterodimer UN (comprising Ufd1 and Npl4) is an adaptor complex that recruits p97 for numerous tasks, many of which involve the ubiquitin pathway. Insights into the structural specificity of p97 for its UN adaptor are currently negligible. Here, we present the solution structure of the Npl4 "ubiquitin-like" domain (UBD), which adopts a beta-grasp fold with a 3(10) helical insert. Moreover we performed a chemical shift perturbation analysis of its binding surface with the p97 N domain. We assigned the backbone amides of the p97 N domain and probed both its reciprocal binding surface with Npl4 UBD and its interaction with the p97-binding region of Ufd1. NMR data recorded on a 400-kDa full-length UN-hexamer p97 complex reveals an identical mode of interaction. We calculated a structural model for the p97 N-Npl4 UBD complex, and a comparison with the p97-p47 adaptor complex reveals subtle differences in p97 adaptor recognition and specificity.	Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; ETH Honggerberg HPM, Inst Biochem, Swiss Fed Sch Technol ETH, CH-8093 Zurich, Switzerland	Imperial College London; Swiss Federal Institutes of Technology Domain; ETH Zurich	Matthews, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, Biochem Bldg, London SW7 2AZ, England.	s.j.matthews@imperial.ac.uk	Meyer, Hemmo/GNH-5784-2022	Meyer, Hemmo/0000-0003-1883-1796; Zhang, Xiaodong/0000-0001-9786-7038; Isaacson, Rivka Leah/0000-0002-9978-8904; Matthews, Steve/0000-0003-0676-0927; Pye, Valerie E/0000-0001-9616-2992; Freemont, Paul/0000-0002-5658-8486; Simpson, Pete/0000-0002-2679-9303	Wellcome Trust [085464, 073908] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beuron F, 2006, EMBO J, V25, P1967, DOI 10.1038/sj.emboj.7601055; Bruderer RM, 2004, J BIOL CHEM, V279, P49609, DOI 10.1074/jbc.M408695200; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Davies JM, 2005, STRUCTURE, V13, P183, DOI 10.1016/j.str.2004.11.014; DeLaBarre B, 2005, J MOL BIOL, V347, P437, DOI 10.1016/j.jmb.2005.01.060; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Dreveny I, 2004, BIOCHEM SOC T, V32, P715, DOI 10.1042/BST0320715; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; Hartmann-Petersen R, 2004, CURR BIOL, V14, P824, DOI 10.1016/j.cub.2004.04.029; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Huyton T, 2003, J STRUCT BIOL, V144, P337, DOI 10.1016/j.jsb.2003.10.007; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; McNeill H, 2004, BIOCHEM J, V384, P391, DOI 10.1042/BJ20041498; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Park S, 2005, STRUCTURE, V13, P995, DOI 10.1016/j.str.2005.04.013; Pye VE, 2007, P NATL ACAD SCI USA, V104, P467, DOI 10.1073/pnas.0603408104; Pye VE, 2006, J STRUCT BIOL, V156, P12, DOI 10.1016/j.jsb.2006.03.003; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Song EJ, 2005, MOL CELL BIOL, V25, P2511, DOI 10.1128/MCB.25.6.2511-2524.2005; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Uchiyama K, 2006, DEV CELL, V11, P803, DOI 10.1016/j.devcel.2006.10.016; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Weihl CC, 2006, HUM MOL GENET, V15, P189, DOI 10.1093/hmg/ddi426; Ye YH, 2006, J STRUCT BIOL, V156, P29, DOI 10.1016/j.jsb.2006.01.005; Yuan XM, 2001, J MOL BIOL, V311, P255, DOI 10.1006/jmbi.2001.4864; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	33	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21361	21369		10.1074/jbc.M610069200	http://dx.doi.org/10.1074/jbc.M610069200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17491009	hybrid, Green Accepted			2022-12-25	WOS:000248047500064
J	Schreiter, ER; Rodriguez, MM; Weichsel, A; Montfort, WR; Bonaventura, J				Schreiter, Eric R.; Rodriguez, Maria M.; Weichsel, Andrzej; Montfort, William R.; Bonaventura, Joseph			S-nitrosylation-induced conformational change in blackfin tuna myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-FLOW REGULATION; NITRIC-OXIDE; RESOLUTION STRUCTURES; CRYSTAL-STRUCTURES; YELLOWFIN TUNA; NITROSOHEMOGLOBIN; IDENTIFICATION; NITROSATION; COMPLEXES; IRON	S-Nitrosylation is a post-translational protein modification that can alter the function of a variety of proteins. Despite the growing wealth of information that this modification may have important functional consequences, little is known about the structure of the moiety or its effect on protein tertiary structure. Here we report high-resolution x-ray crystal structures of S-nitrosylated and unmodified blackfin tuna myoglobin, which demonstrate that in vitro S-nitrosylation of this protein at the surface-exposed Cys-10 directly causes a reversible conformational change by "wedging" apart a helix and loop. Furthermore, we have demonstrated in solution and in a single crystal that reduction of the S-nitrosylated myoglobin with dithionite results in NO cleavage from the sulfur of Cys-10 and rebinding to the reduced heme iron, showing the reversibility of both the modification and the conformational changes. Finally, we report the 0.95-angstrom structure of ferrous nitrosyl myoglobin, which provides an accurate structural view of the NO coordination geometry in the context of a globin heme pocket.	Univ Puerto Rico, Prot Res Ctr, Dept Chem, Mayaguez, PR 00681 USA; Rutgers State Univ, New Brunswick, NJ USA	University of Puerto Rico; University of Puerto Rico Mayaguez; Rutgers State University New Brunswick	Schreiter, ER (corresponding author), Univ Puerto Rico, Prot Res Ctr, Dept Chem, Mayaguez, PR 00681 USA.	eric_sch@mit.edu	Schreiter, Eric/B-2641-2009	Schreiter, Eric/0000-0002-2864-7469	NCRR NIH HHS [5P20RR016439-05] Funding Source: Medline; NHLBI NIH HHS [HL62969] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016439] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062969] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BIRNBAUM GI, 1994, ACTA CRYSTALLOGR D, V50, P283, DOI 10.1107/S0907444993014271; Chan NL, 2004, BIOCHEMISTRY-US, V43, P118, DOI 10.1021/bi030172j; Chan NL, 1998, BIOCHEMISTRY-US, V37, P16459, DOI 10.1021/bi9816711; Cook JA, 1996, ANAL BIOCHEM, V238, P150, DOI 10.1006/abio.1996.0268; Copeland DM, 2006, J INORG BIOCHEM, V100, P1413, DOI 10.1016/j.jinorgbio.2006.04.011; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Greco TM, 2006, P NATL ACAD SCI USA, V103, P7420, DOI 10.1073/pnas.0600729103; GREISS JP, 1879, CHEM BER, V12, P426; Hao G, 2006, P NATL ACAD SCI USA, V103, P1012, DOI 10.1073/pnas.0508412103; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; JAFFREY SR, 2001, SCI STKE PL1; Jentzen W, 1997, J PHYS CHEM B, V101, P1684, DOI 10.1021/jp963142h; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; LANE P, 2001, SCI STKE RE1; Lipton SA, 2002, TRENDS NEUROSCI, V25, P474, DOI 10.1016/S0166-2236(02)02245-2; Maes EM, 2005, BIOCHEMISTRY-US, V44, P12690, DOI 10.1021/bi0506573; Mannick JB, 2002, ARCH BIOCHEM BIOPHYS, V408, P1, DOI 10.1016/S0003-9861(02)00490-3; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Marcinek DJ, 2001, AM J PHYSIOL-REG I, V280, pR1123, DOI 10.1152/ajpregu.2001.280.4.R1123; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; Matsumoto A, 2003, SCIENCE, V301, P657, DOI 10.1126/science.1079319; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; Nims Raymond W., 1995, Methods (Orlando), V7, P48, DOI 10.1006/meth.1995.1007; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JKJ, 1997, ANAL BIOCHEM, V249, P61, DOI 10.1006/abio.1997.2159; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; POULOS TL, 2006, CURR OPIN STRUC BIOL, V16, P1; Rayner BS, 2005, J BIOL CHEM, V280, P9985, DOI 10.1074/jbc.M410564200; Roberts SA, 2001, BIOCHEMISTRY-US, V40, P11327, DOI 10.1021/bi0109257; Rovira C, 1997, J PHYS CHEM A, V101, P8914, DOI 10.1021/jp9722115; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Singel DJ, 2005, ANNU REV PHYSIOL, V67, P99, DOI 10.1146/annurev.physiol.67.060603.090918; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; WATTS DA, 1980, J BIOL CHEM, V255, P916; Weichsel A, 2005, P NATL ACAD SCI USA, V102, P594, DOI 10.1073/pnas.0406549102; Weichsel A, 2007, BIOCHEMISTRY-US, V46, P1219, DOI 10.1021/bi061878r; Williams D. L. H., 2004, NITROSATION REACTION; Williams JG, 2003, P NATL ACAD SCI USA, V100, P6376, DOI 10.1073/pnas.1037299100; Witting PK, 2001, J BIOL CHEM, V276, P3991, DOI 10.1074/jbc.M005758200; Wyllie GRA, 2003, INORG CHEM, V42, P5722, DOI 10.1021/ic034473t; Yi J, 2005, NITRIC OXIDE-BIOL CH, V12, P261, DOI 10.1016/j.niox.2005.03.005; Zhao YL, 2006, J AM CHEM SOC, V128, P1422, DOI 10.1021/ja057097f	49	54	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19773	19780		10.1074/jbc.M701363200	http://dx.doi.org/10.1074/jbc.M701363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17488722	hybrid			2022-12-25	WOS:000247650600052
J	Korber, C; Werner, M; Hoffmann, J; Sager, C; Tietze, M; Schmid, SM; Kott, S; Hollmann, M				Koerber, Christoph; Werner, Markus; Hoffmann, Jutta; Sager, Charlotte; Tietze, Monique; Schmid, Sabine M.; Kott, Sabine; Hollmann, Michael			Stargazin interaction with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors is critically dependent on the amino acid at the narrow constriction of the ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; 2 DISTINCT MECHANISMS; LIGAND-BINDING CORE; GLUTAMATE-RECEPTOR; POINT MUTATION; DESENSITIZATION; SUBUNIT; CYCLOTHIAZIDE; DEACTIVATION; PERMEABILITY	The subunit GluR2 of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subfamily of ionotropic glutamate receptors (GluRs) features a single amino acid at the narrow constriction of the pore loop that is altered from glutamine to arginine by RNA editing. This so-called Q/R site has been shown to play an important role in the determination of the electrophysiological properties of AMPA receptor complexes as well as of trafficking to the plasma membrane. The protein stargazin has also been shown to modulate electrophysiological properties and trafficking to the plasma membrane of AMPA receptors. In this study we examined via a series of mutants of the Q/R site of the AMPA receptor GluR1 whether the amino acid at this position has any influence on the modulatory effects mediated by stargazin. To this end, we analyzed current responses of Q/R site mutants upon application of glutamate and kainate and determined the amount of mutant receptor protein in the plasma membrane in Xenopus oocytes. Desensitization kinetics of several mutants were analyzed in HEK293 cells. We found that the stargazin-mediated decrease in receptor desensitization, the slowing of desensitization kinetics, and the kainate efficacy were all dependent on the amino acid at the Q/R site, whereas the stargazin-mediated increase in trafficking toward the plasma membrane remained independent of this amino acid. We propose that the Q/R site modulates the interaction of stargazin with the transmembrane domains of AMPA receptors via an allosteric mechanism and that this modulation leads to the observed differences in the electrophysiological properties of the receptor.	Ruhr Univ Bochum, Dept Biochem Ireceptor Biochem, D-44780 Bochum, Germany; Int Grad Sch Neurosci, D-44780 Bochum, Germany	Ruhr University Bochum	Hollmann, M (corresponding author), Ruhr Univ Bochum, Dept Biochem Ireceptor Biochem, Bldg NC,Level 6,Room 170, D-44780 Bochum, Germany.	Michael.Hollmann@rub.de		Korber, Christoph/0000-0003-1418-9724				Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Cuadra AE, 2004, J NEUROSCI, V24, P7491, DOI 10.1523/JNEUROSCI.1255-04.2004; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Greger IH, 2003, NEURON, V40, P763, DOI 10.1016/S0896-6273(03)00668-8; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Horning MS, 2004, NEURON, V41, P379, DOI 10.1016/S0896-6273(04)00018-2; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JAKOWEC M, 1995, NEUROSCIENCE, V4, P893; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Nakagawa T, 2006, BIOL CHEM, V387, P179, DOI 10.1515/BC.2006.024; Nakagawa T, 2005, NATURE, V433, P545, DOI 10.1038/nature03328; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Partin KM, 2001, J NEUROSCI, V21, P1939, DOI 10.1523/JNEUROSCI.21-06-01939.2001; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; Priel A, 2005, J NEUROSCI, V25, P2682, DOI 10.1523/JNEUROSCI.4834-04.2005; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Schmidt C, 2006, MOL PHARMACOL, V69, P119, DOI 10.1124/mol.105.016840; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Tomita S, 2005, NATURE, V435, P1052, DOI 10.1038/nature03624; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Tomita S, 2004, SCIENCE, V303, P1508, DOI 10.1126/science.1090262; Tomita S, 2006, P NATL ACAD SCI USA, V103, P10064, DOI 10.1073/pnas.0603128103; Turetsky D, 2005, J NEUROSCI, V25, P7438, DOI 10.1523/JNEUROSCI.1108-05.2005; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; Villmann C, 1999, EUR J NEUROSCI, V11, P1765, DOI 10.1046/j.1460-9568.1999.00594.x; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; YAMADA KA, 1993, J NEUROSCI, V13, P3904; Yelshansky MV, 2004, J NEUROSCI, V24, P4728, DOI 10.1523/JNEUROSCI.0757-04.2004	39	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18758	18766		10.1074/jbc.M611182200	http://dx.doi.org/10.1074/jbc.M611182200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17483093	hybrid			2022-12-25	WOS:000247475300014
J	Fukushima, T; Tezuka, T; Shimomura, T; Nakano, S; Kataoka, H				Fukushima, Tsuyoshi; Tezuka, Tomoaki; Shimomura, Takeshi; Nakano, Shinichi; Kataoka, Hiroaki			Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BINDING; PROGNOSTIC MARKER; CANCER CELLS; PROTEIN-2; PROLIFERATION; MULTIFORME; ACTIVATOR; PATHWAYS; SURVIVAL; INVASION	Glioblastoma multiforme (GBM) is a malignant brain tumor characterized by rapid growth and extensive invasiveness. Overexpression of insulin-like growth factor-binding protein-2 (IGFBP-2) has been reported in GBM. However, it remains to be determined how IGFBP-2 is involved in the progression of GBM. We utilized short hairpin-RNA (shRNA) expression retroviral vectors to inactivate the IGFBP-2 gene permanently in two human GBM cell lines, U251 and YKG-1. The stable knockdown of IGFBP-2 resulted in decreased invasiveness, decreased saturation density of the cells in vitro, and decreased tumorigenicity in nude mice. Transcriptional profiling of both lines revealed several genes that were significantly down-regulated by inactivation of IGFBP-2. One such gene was CD24, which has been implicated in progression of various cancers. Indeed, CD24 was expressed in most GBM cases and the inactivation of CD24 in GBM cells suppressed cellular invasiveness, as was the case for IGFBP-2. Forced overexpression of CD24 led to increased invasiveness of both IGFBP-2-inactivated GBM cell lines and also A172, a human GBM cell line with low endogenous CD24. Further supporting the inter-relationship between IGFBP-2 and CD24, knockdown of IGFBP-2 suppressed the CD24 promoter activity. Moreover, both CD24 promoter activity and in vitro invasiveness were restored in knockdown cells by transfection with an IGFBP-2 expression plasmid. These results indicate that CD24 is modulated by IGFBP-2 and contributes to IGFBP-2 enhanced invasiveness of GBM cells.	Miyazaki Univ, Fac Med, Dept Pathol, Sect Oncopathol & Regenerat Biol, Miyazaki 8891692, Japan; Miyazaki Univ, Fac Med, Dept Neurosurg, Miyazaki 8891692, Japan; Mitsubishi Pharma Corp, Div Pharmaceut Res, Yokohama, Kanagawa 2270033, Japan	University of Miyazaki; University of Miyazaki; Mitsubishi Tanabe Pharma Corporation	Kataoka, H (corresponding author), Miyazaki Univ, Fac Med, Dept Pathol, Sect Oncopathol & Regenerat Biol, Miyazaki 8891692, Japan.	mejina@fc.miyazaki-u.ac.jp	Kallioniemi, Olli P/H-5111-2011; Fukushima, Tsuyoshi/K-4270-2019	Kallioniemi, Olli P/0000-0002-3231-0332; Fukushima, Tsuyoshi/0000-0002-9350-777X				Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Boon K, 2003, ONCOGENE, V22, P7687, DOI 10.1038/sj.onc.1207043; Boulle N, 1998, J CLIN ENDOCR METAB, V83, P1713, DOI 10.1210/jc.83.5.1713; Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; Chakrabarty S, 2006, CANCER BIOL THER, V5, P189, DOI 10.4161/cbt.5.2.2333; Chatterjee S, 2004, INT J UROL, V11, P876, DOI 10.1111/j.1442-2042.2004.00898.x; COHEN P, 1993, J CLIN ENDOCR METAB, V76, P1031, DOI 10.1210/jc.76.4.1031; Elmlinger MW, 2001, ENDOCRINOLOGY, V142, P1652, DOI 10.1210/en.142.4.1652; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Fottner C, 2004, HORM METAB RES, V36, P397, DOI 10.1055/s-2004-814563; Fuller GN, 1999, CANCER RES, V59, P4228; HAHNE M, 1994, J EXP MED, V179, P1391, DOI 10.1084/jem.179.4.1391; Jacob J, 2004, PANCREATOLOGY, V4, P454, DOI 10.1159/000079824; Kibbey MM, 2006, MOL PHARMACOL, V69, P833, DOI 10.1124/mol.105.016998; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Kristiansen G, 2004, J MOL HISTOL, V35, P255; Kristiansen G, 2004, PROSTATE, V58, P183, DOI 10.1002/pros.10324; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Kristiansen G, 2003, BRIT J CANCER, V88, P231, DOI 10.1038/sj.bjc.6600702; Lancaster JM, 2006, INT J GYNECOL CANCER, V16, P1529, DOI 10.1111/j.1525-1438.2006.00623.x; Lee EJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-7; Lefranc F, 2006, EXPERT REV ANTICANC, V6, P719, DOI 10.1586/14737140.6.5.719; Lim SC, 2005, PATHOL RES PRACT, V201, P479, DOI 10.1016/j.prp.2005.05.004; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Mishra L, 1998, GROWTH HORM IGF RES, V8, P473, DOI 10.1016/S1096-6374(98)80300-6; Miyake H, 2005, ONCOL REP, V13, P341; Miyata S, 2005, CANCER LETT, V227, P83, DOI 10.1016/j.canlet.2005.01.010; Nielsen PJ, 1997, BLOOD, V89, P1058, DOI 10.1182/blood.V89.3.1058; Nuki Yoshitsugu, 2004, Hum Cell, V17, P145; Pass MK, 1998, INT J CANCER, V78, P496, DOI 10.1002/(SICI)1097-0215(19981109)78:4<496::AID-IJC17>3.0.CO;2-4; Schostak M, 2006, BMC Urol, V6, P7, DOI 10.1186/1471-2490-6-7; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; Senner V, 1999, J NEUROPATH EXP NEUR, V58, P795, DOI 10.1097/00005072-199908000-00002; Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855; Song SW, 2003, P NATL ACAD SCI USA, V100, P13970, DOI 10.1073/pnas.2332186100; Stupp R, 2006, ONCOLOGIST, V11, P165, DOI 10.1634/theoncologist.11-2-165; Surowiak Pawel, 2005, Polish Journal of Pathology, V56, P69; Uchinokura S, 2006, INT J CANCER, V118, P583, DOI 10.1002/ijc.21362; Wang CC, 2006, CANCER RES, V66, P6756, DOI 10.1158/0008-5472.CAN-06-0185; Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200; Wang H, 2003, CANCER RES, V63, P4315; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhou YH, 2005, NEURO-ONCOLOGY, V7, P485, DOI 10.1215/S1152851704000730	45	74	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18634	18644		10.1074/jbc.M609567200	http://dx.doi.org/10.1074/jbc.M609567200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17475624	hybrid			2022-12-25	WOS:000247302000068
J	Ciucci, F; Putignano, E; Baroncelli, L; Landi, S; Berardi, N; Maffei, L				Ciucci, Francesca; Putignano, Elena; Baroncelli, Laura; Landi, Silvia; Berardi, Nicoletta; Maffei, Lamberto			Insulin-Like Growth Factor 1 (IGF-1) Mediates the Effects of Enriched Environment (EE) on Visual Cortical Development	PLOS ONE			English	Article								Enriched environment (EE) has been recently shown to affect visual cortex development and plasticity, and to prevent dark rearing effects. The factors mediating EE effects on visual cortical development and plasticity are still unclear. We have investigated whether IGF-1 is involved in mediating EE effects on the developing visual cortex. We show that EE increases the number of IGF-1 positive neurons in the visual cortex at P18. Increasing IGF-1 in the visual cortex of non-EE rats by means of osmotic minipumps implanted at P18 mimics EE effects, accelerating visual acuity development, assessed with Visual Evoked Potentials (VEPs). Blocking IGF-1 action in the visual cortex of EE rats by means of the IGF-1 receptor antagonist JB1 from P18 completely blocks EE action on visual acuity development. These results show that IGF-1 is a key factor mediating EE effects on visual cortical development. We then show that IGF-1 affects GAD65 immunoreactivity in perisomatic innervation and the condensation of Chondroitin Sulphate Proteoglycans (CSPGs) in perineuronal nets (PNNs) in the visual cortex. This suggests that IGF-1 action in mediating EE effects could be exerted through the modulation of intracortical inhibitory circuitry and PNN development.	[Ciucci, Francesca; Putignano, Elena; Baroncelli, Laura; Landi, Silvia; Maffei, Lamberto] Scuola Normale Super Pisa, Pisa, Italy; [Berardi, Nicoletta] Univ Florence, Dept Psychol, Florence, Italy; [Berardi, Nicoletta; Maffei, Lamberto] CNR, Inst Neurosci, I-56100 Pisa, Italy	Scuola Normale Superiore di Pisa; University of Florence; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR)	Ciucci, F (corresponding author), Scuola Normale Super Pisa, Pisa, Italy.	francesca.ciucci@in.cnr.it	Landi, Silvia/P-9418-2018; Baroncelli, Laura/K-5823-2016	Landi, Silvia/0000-0001-7999-3452; Baroncelli, Laura/0000-0001-6739-2860; Putignano, Elena/0000-0002-4313-408X	MIUR PRIN	MIUR PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN))	This project was supported by MIUR PRIN to LM.	Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; Bartoletti A, 2004, NAT NEUROSCI, V7, P215, DOI 10.1038/nn1201; BENEVENTO LA, 1995, BRAIN RES, V689, P172, DOI 10.1016/0006-8993(95)00553-3; Berardi N, 2003, TRENDS NEUROSCI, V26, P369, DOI 10.1016/S0166-2236(03)00168-1; Berardi N, 2000, CURR OPIN NEUROBIOL, V10, P138, DOI 10.1016/S0959-4388(99)00047-1; BONDY C, 1992, NEUROSCIENCE, V46, P909, DOI 10.1016/0306-4522(92)90193-6; BONDY CA, 1993, ANN NY ACAD SCI, V692, P33; BONDY CA, 1991, J NEUROSCI, V11, P3442; Camarero G, 2003, DEV BIOL, V262, P242, DOI 10.1016/S0012-1606(03)00387-7; Cancedda L, 2004, J NEUROSCI, V24, P4840, DOI 10.1523/JNEUROSCI.0845-04.2004; Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001; Carro E, 2000, J NEUROSCI, V20, P2926; Chattopadhyaya B, 2004, J NEUROSCI, V24, P9598, DOI 10.1523/JNEUROSCI.1851-04.2004; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; D'Ercole AJ, 2002, NEUROPEPTIDES, V36, P209, DOI 10.1054/npep.2002.0893; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Di Cristo G, 2001, SCIENCE, V292, P2337, DOI 10.1126/science.1059075; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Fernandez AM, 1997, NEUROSCIENCE, V76, P117; Gianfranceschi L, 2003, P NATL ACAD SCI USA, V100, P12486, DOI 10.1073/pnas.1934836100; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Keyvani K, 2004, J NEUROPATH EXP NEUR, V63, P598, DOI 10.1093/jnen/63.6.598; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; Koopmans GC, 2006, EUR J NEUROSCI, V23, P1035, DOI 10.1111/j.1460-9568.2006.04627.x; Lander C, 1997, J NEUROSCI, V17, P1928; Landi S, 2007, FASEB J, V21, P130, DOI 10.1096/fj.06-6083com; Lodovichi C, 2000, J NEUROSCI, V20, P2155; Markowska AL, 1998, NEUROSCIENCE, V87, P559, DOI 10.1016/S0306-4522(98)00143-2; MILLER MW, 1986, DEV BRAIN RES, V25, P271, DOI 10.1016/0165-3806(86)90217-8; Morales B, 2002, J NEUROSCI, V22, P8084; O'Kusky JR, 2000, J NEUROSCI, V20, P8435, DOI 10.1523/JNEUROSCI.20-22-08435.2000; PAXINOS G, 1986, RAT STEREOTAXIC BRAI; Pham TM, 2002, PHARMACOL BIOCHEM BE, V73, P167, DOI 10.1016/S0091-3057(02)00783-9; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Pizzorusso T, 1999, EUR J NEUROSCI, V11, P204, DOI 10.1046/j.1460-9568.1999.00417.x; Pizzorusso T, 2006, P NATL ACAD SCI USA, V103, P8517, DOI 10.1073/pnas.0602657103; Porciatti V, 1999, VISION RES, V39, P3071, DOI 10.1016/S0042-6989(99)00022-X; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; Silver MA, 2000, J COMP NEUROL, V422, P652, DOI 10.1002/1096-9861(20000710)422:4<652::AID-CNE11>3.0.CO;2-1; Tang YP, 2001, NEUROPHARMACOLOGY, V41, P779, DOI 10.1016/S0028-3908(01)00122-8; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; Tropea D, 2006, NAT NEUROSCI, V9, P660, DOI 10.1038/nn1689; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; WOLFF JR, 1984, ADV EXP MED BIOL, V181, P215	60	84	88	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e475	10.1371/journal.pone.0000475	http://dx.doi.org/10.1371/journal.pone.0000475			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534425	Green Published, Green Submitted, gold			2022-12-25	WOS:000207448800005
J	Nabatov, AA; Pollakis, G; Linnemann, T; Paxton, WA; de Baar, MP				Nabatov, Alexey A.; Pollakis, Georgios; Linnemann, Thomas; Paxton, William A.; de Baar, Michel P.			Statins Disrupt CCR5 and RANTES Expression Levels in CD4(+) T Lymphocytes In Vitro and Preferentially Decrease Infection of R5 Versus X4 HIV-1	PLOS ONE			English	Article								Background. Statins have previously been shown to reduce the in vitro infection of human immunodeficiency virus type 1 (HIV-1) through modulation of Rho GTPase activity and lipid raft formation at the cell surface, as well as by disrupting LFA-1 incorporation into viral particles. Principle Findings. Here we demonstrate that treatment of an enriched CD4(+) lymphocyte population with lovastatin (Lov), mevastatin (Mev) and simvastatin (activated and non-activated, Sim(A) and Sim(N), respectively) can reduce the cell surface expression of the CC-chemokine receptor CCR5 (P<0.01 for Sim(A) and Lov). The lowered CCR5 expression was associated with down-regulation of CCR5 mRNA expression. The CC-chemokine RANTES protein and mRNA expression levels were slightly increased in CD4(+) enriched lymphocytes treated with statins. Both R5 and X4 HIV-1 were reduced for their infection of statin-treated cells; however, in cultures where statins were removed and where a decrease in CCR5 expression was observed, there was a preferential inhibition of infection with an R5 versus X4 virus. Conclusions. The results indicate that the modulation of CC-chemokine receptor (CCR5) and CC-chemokine (RANTES) expression levels should be considered as contributing to the anti-viral effects of statins, preferentially inhibiting R5 viruses. This observation, in combination with the immunomodulatory activity exerted by statins, suggests they may possess more potent anti-HIV-1 activity when applied during the early stages of infection or in lowering viral transmission. Alternatively, statin treatment could be considered as a way to modulate immune induction such as during vaccination protocols.	[Nabatov, Alexey A.; Pollakis, Georgios; Linnemann, Thomas; Paxton, William A.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol,Lab Expt Virol, Ctr Infect & Immun Amsterdam CINIMA, NL-1105 AZ Amsterdam, Netherlands; [de Baar, Michel P.] Primagen, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Paxton, WA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol,Lab Expt Virol, Ctr Infect & Immun Amsterdam CINIMA, NL-1105 AZ Amsterdam, Netherlands.	w.a.paxton@amc.uva.nl	Nabatov, Alexey/R-5291-2016; Georgios, Pollakis/Y-2341-2019; paxton, william/R-9747-2019	Nabatov, Alexey/0000-0001-7932-1445; Paxton, William/0000-0001-5200-0801; Pollakis, Georgios/0000-0002-9659-5461; Paxton, William/0000-0002-2654-5186	European Union [QLK2-CT-1999-01321, QLK2-CT-2001-01316]	European Union(European Commission)	This work was supported by grants from the European Union (QLK2-CT-1999-01321 and QLK2-CT-2001-01316 "Eurovac-I and -II").	Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Frauenschuh A, 2004, VACCINE, V23, P546, DOI 10.1016/j.vaccine.2004.06.024; Giguere JF, 2004, J VIROL, V78, P12062, DOI 10.1128/JVI.78.21.12062-12065.2004; HUANG RD, 1996, FINANCIAL MARKETS I, V5, P1; Kim JJ, 1998, J CLIN INVEST, V102, P1112, DOI 10.1172/JCI3986; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Moncunill G, 2005, AIDS, V19, P1697, DOI 10.1097/01.aids.0000183517.60384.db; Nabatov AA, 2004, J VIROL, V78, P524, DOI 10.1128/JVI.78.1.524-530.2004; Negredo E, 2006, AIDS, V20, P619, DOI 10.1097/01.aids.0000210617.90954.0e; Neuhaus O, 2002, NEUROLOGY, V59, P990, DOI 10.1212/WNL.59.7.990; Nguyen DH, 2002, BLOOD, V99, P4298, DOI 10.1182/blood-2001-11-0087; Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121; Paxton WA, 1998, VIROLOGY, V244, P66, DOI 10.1006/viro.1998.9082; Paxton WA, 2001, J INFECT DIS, V183, P1678, DOI 10.1086/320701; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Yoon HA, 2007, IMMUNOLOGY, V120, P182, DOI 10.1111/j.1365-2567.2006.02490.x; Yoshida M, 2001, ARTERIOSCL THROM VAS, V21, P1165, DOI 10.1161/hq0701.092143; Zhang YJ, 1999, J VIROL, V73, P3443, DOI 10.1128/JVI.73.4.3443-3448.1999	28	36	38	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e470	10.1371/journal.pone.0000470	http://dx.doi.org/10.1371/journal.pone.0000470			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520029	Green Published, Green Submitted, gold			2022-12-25	WOS:000207446000018
J	Cavina-Pratesi, C; Goodale, MA; Culham, JC				Cavina-Pratesi, Cristiana; Goodale, Melvyn A.; Culham, Jody C.			FMRI Reveals a Dissociation between Grasping and Perceiving the Size of Real 3D Objects	PLOS ONE			English	Article								Background. Almost 15 years after its formulation, evidence for the neuro-functional dissociation between a dorsal action stream and a ventral perception stream in the human cerebral cortex is still based largely on neuropsychological case studies. To date, there is no unequivocal evidence for separate visual computations of object features for performance of goal-directed actions versus perceptual tasks in the neurologically intact human brain. We used functional magnetic resonance imaging to test explicitly whether or not brain areas mediating size computation for grasping are distinct from those mediating size computation for perception. Methodology/Principal Findings. Subjects were presented with the same real graspable 3D objects and were required to perform a number of different tasks: grasping, reaching, size discrimination, pattern discrimination or passive viewing. As in prior studies, the anterior intraparietal area (AIP) in the dorsal stream was more active during grasping, when object size was relevant for planning the grasp, than during reaching, when object properties were irrelevant for movement planning (grasping > reaching). Activity in AIP showed no modulation, however, when size was computed in the context of a purely perceptual task (size = pattern discrimination). Conversely, the lateral occipital (LO) cortex in the ventral stream was modulated when size was computed for perception (size > pattern discrimination) but not for action (grasping = reaching). Conclusions/Significance. While areas in both the dorsal and ventral streams responded to the simple presentation of 3D objects (passive viewing), these areas were differentially activated depending on whether the task was grasping or perceptual discrimination, respectively. The demonstration of dual coding of an object for the purposes of action on the one hand and perception on the other in the same healthy brains offers a substantial contribution to the current debate about the nature of the neural coding that takes place in the dorsal and ventral streams.	[Cavina-Pratesi, Cristiana; Goodale, Melvyn A.; Culham, Jody C.] Univ Western Ontario, Dept Psychol, London, ON, Canada	Western University (University of Western Ontario)	Culham, JC (corresponding author), Univ Western Ontario, Dept Psychol, London, ON, Canada.	culham@imaging.robarts.ca	Goodale, Melvyn A/M-5907-2013; Culham, Jody C./A-9863-2013	Goodale, Melvyn A/0000-0001-6748-0561; Culham, Jody C./0000-0003-0754-2999	Canadian Institutes of Health Research; Canadian Foundation for Innovation; Canada Research Chairs Program; Medical Research Council [G0401090] Funding Source: researchfish; MRC [G0401090] Funding Source: UKRI	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Canada Research Chairs Program(Canada Research Chairs); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by grants from the Canadian Institutes of Health Research (JCC and MAG), the Canadian Foundation for Innovation (JCC), and the Canada Research Chairs Program (MAG).	Astafiev SV, 2003, J NEUROSCI, V23, P4689; BEGLIOMINI C, 2007, DIFFERENTIAL CORTICA, P1245; Begliomini C, 2007, EUR J NEUROSCI, V25, P1245, DOI 10.1111/j.1460-9568.2007.05365.x; Binkofski F, 1998, NEUROLOGY, V50, P1253, DOI 10.1212/WNL.50.5.1253; Binkofski F, 2003, EXP BRAIN RES, V153, P210, DOI 10.1007/s00221-003-1594-2; Binkofski F, 1999, EXP BRAIN RES, V128, P210, DOI 10.1007/s002210050838; Birn RM, 1999, HUM BRAIN MAPP, V7, P106, DOI 10.1002/(SICI)1097-0193(1999)7:2<106::AID-HBM4>3.0.CO;2-O; Buneo CA, 2002, NATURE, V416, P632, DOI 10.1038/416632a; Cabeza R, 2006, HDB FUNCTIONAL NEURO; CANT JS, 2006, CEREB CORTEX; Cavina-Pratesi C, 2006, J NEUROSCI, V26, P2704, DOI 10.1523/JNEUROSCI.3176-05.2006; Chao LL, 2000, NEUROIMAGE, V12, P478, DOI 10.1006/nimg.2000.0635; Chapman H, 2002, EUR J NEUROSCI, V15, P2037, DOI 10.1046/j.1460-9568.2002.02021.x; Connolly JD, 2003, EXP BRAIN RES, V153, P140, DOI 10.1007/s00221-003-1587-1; Creem-Regehr SH, 2005, COGNITIVE BRAIN RES, V22, P457, DOI 10.1016/j.cogbrainres.2004.10.006; Culham JC, 2003, EXP BRAIN RES, V153, P180, DOI 10.1007/s00221-003-1591-5; Culham JC, 2004, ATTENTION PERFORMANC; CULHAM JC, EMBODIMENT IN PRESS; DAVARE M, 2007, TEMPORAL DISSOCIATIO, P3974; Duvernoy H.M., 1999, HUMAN BRAIN SURFACE; Faillenot I, 1997, CEREB CORTEX, V7, P77, DOI 10.1093/cercor/7.1.77; Faillenot I, 2001, EUR J NEUROSCI, V13, P585, DOI 10.1046/j.1460-9568.2001.01399.x; Field AS, 2000, AM J NEURORADIOL, V21, P1388; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; Freire L, 2001, NEUROIMAGE, V14, P709, DOI 10.1006/nimg.2001.0869; Frey SH, 2005, COGNITIVE BRAIN RES, V23, P397, DOI 10.1016/j.cogbrainres.2004.11.010; GALLESE V, 1994, NEUROREPORT, V5, P1525, DOI 10.1097/00001756-199407000-00029; Galletti C, 2003, EXP BRAIN RES, V153, P158, DOI 10.1007/s00221-003-1589-z; Gardner EP, 2002, BEHAV BRAIN RES, V135, P213, DOI 10.1016/S0166-4328(02)00167-5; Goodale MA, 2004, CURR OPIN NEUROBIOL, V14, P203, DOI 10.1016/j.conb.2004.03.002; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GOODALE MA, 1991, NATURE, V349, P154, DOI 10.1038/349154a0; Graziano MSA, 2000, SCIENCE, V290, P1782, DOI 10.1126/science.290.5497.1782; Grefkes C, 2004, NEUROIMAGE, V23, P1494, DOI 10.1016/j.neuroimage.2004.08.031; Grefkes C, 2002, NEURON, V35, P173, DOI 10.1016/S0896-6273(02)00741-9; Gregoriou GG, 2001, J CEREBR BLOOD F MET, V21, P671, DOI 10.1097/00004647-200106000-00005; Grezes J, 2003, EUR J NEUROSCI, V17, P2735, DOI 10.1046/j.1460-9568.2003.02695.x; Grill-Spector K, 2003, CURR OPIN NEUROBIOL, V13, P159, DOI 10.1016/S0959-4388(03)00040-0; Grill-Spector K, 1999, NEURON, V24, P187, DOI 10.1016/S0896-6273(00)80832-6; Grill-Spector K, 2001, ACTA PSYCHOL, V107, P293, DOI 10.1016/S0001-6918(01)00019-1; Grill-Spector K, 1998, NEURON, V21, P191, DOI 10.1016/S0896-6273(00)80526-7; Grill-Spector K, 2001, VISION RES, V41, P1409, DOI 10.1016/S0042-6989(01)00073-6; Hamilton AFD, 2006, J NEUROSCI, V26, P1133, DOI 10.1523/JNEUROSCI.4551-05.2006; Hasson U, 2003, NEURON, V37, P1027, DOI 10.1016/S0896-6273(03)00144-2; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; James TW, 2003, BRAIN, V126, P2463, DOI 10.1093/brain/awg248; James TW, 2002, NEURON, V35, P793, DOI 10.1016/S0896-6273(02)00803-6; Johnson-Frey SH, 2004, TRENDS COGN SCI, V8, P71, DOI 10.1016/j.tics.2003.12.002; Johnstone T, 2006, HUM BRAIN MAPP, V27, P779, DOI 10.1002/hbm.20219; Kalaska JF, 1996, CAN J PHYSIOL PHARM, V74, P483, DOI 10.1139/cjpp-74-4-483; Klassen LM, 2004, MAGN RESON MED, V51, P881, DOI 10.1002/mrm.20094; Kourtzi Z, 2003, NEURON, V37, P333, DOI 10.1016/S0896-6273(02)01174-1; KROLICZAK G, 2006, SOC NEUR ABSTR; KROLICZAK G, J NEUROPHYS IN PRESS; LE S, 2002, SEEING CHILDHOOD VEN, P58; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; Malach R, 2002, TRENDS COGN SCI, V6, P176, DOI 10.1016/S1364-6613(02)01870-3; Marois R, 2000, NEURON, V25, P717, DOI 10.1016/S0896-6273(00)81073-9; Murata A, 2000, J NEUROPHYSIOL, V83, P2580, DOI 10.1152/jn.2000.83.5.2580; Nakamura K, 2000, J NEUROPHYSIOL, V84, P677, DOI 10.1152/jn.2000.84.2.677; Oakes TR, 2005, NEUROIMAGE, V28, P529, DOI 10.1016/j.neuroimage.2005.05.058; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; ONO M, 1990, ATLAS CEREBRAL SULCI, pR14; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; Prado J, 2005, NEURON, V48, P849, DOI 10.1016/j.neuron.2005.10.010; Rice NJ, 2006, J NEUROSCI, V26, P8176, DOI 10.1523/JNEUROSCI.1641-06.2006; ROBERTSON LC, 1988, J NEUROSCI, V8, P3757; Sakata H, 1997, TRENDS NEUROSCI, V20, P350, DOI 10.1016/S0166-2236(97)01067-9; SAKATA H, 1995, CEREB CORTEX, V5, P429, DOI 10.1093/cercor/5.5.429; SAKATA H, 1992, CONTROL ARM MOVEMENT, P185; Sereno MI, 2001, SCIENCE, V294, P1350, DOI 10.1126/science.1063695; Shikata E, 2003, EUR J NEUROSCI, V17, P1105, DOI 10.1046/j.1460-9568.2003.02540.x; Shikata E, 2001, J NEUROPHYSIOL, V85, P1309, DOI 10.1152/jn.2001.85.3.1309; Shmuelof L, 2005, NEURON, V47, P457, DOI 10.1016/j.neuron.2005.06.034; Stanley DA, 2005, J VISION, V5, P690, DOI 10.1167/5.9.4; Taira M, 2001, NEUROIMAGE, V14, P959, DOI 10.1006/nimg.2001.0895; TAIRA M, 1990, EXP BRAIN RES, V83, P29; Talairach J., 1988, COPLANAR STEREOTAXIC; Tsutsui KI, 2002, SCIENCE, V298, P409, DOI 10.1126/science.1074128; Tunik E, 2005, NAT NEUROSCI, V8, P505, DOI 10.1038/nn1430; Valyear KF, 2006, NEUROPSYCHOLOGIA, V44, P218, DOI 10.1016/j.neuropsychologia.2005.05.004; VALYEAR KF, NEUROIMAGE IN PRESS	83	114	114	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e424	10.1371/journal.pone.0000424	http://dx.doi.org/10.1371/journal.pone.0000424			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487272	gold, Green Accepted, Green Submitted, Green Published			2022-12-25	WOS:000207445800006
J	Mazzoni, A; Broccard, FD; Garcia-Perez, E; Bonifazi, P; Ruaro, ME; Torre, V				Mazzoni, Alberto; Broccard, Frederic D.; Garcia-Perez, Elizabeth; Bonifazi, Paolo; Ruaro, Maria Elisabetta; Torre, Vincent			On the Dynamics of the Spontaneous Activity in Neuronal Networks	PLOS ONE			English	Article							LONG-TERM POTENTIATION; CORTICAL-NEURONS; LEECH; MODULATION; PATTERNS; ORIGIN; MODEL; VARIABILITY; MECHANISMS; AVALANCHES	Most neuronal networks, even in the absence of external stimuli, produce spontaneous bursts of spikes separated by periods of reduced activity. The origin and functional role of these neuronal events are still unclear. The present work shows that the spontaneous activity of two very different networks, intact leech ganglia and dissociated cultures of rat hippocampal neurons, share several features. Indeed, in both networks: i) the inter-spike intervals distribution of the spontaneous firing of single neurons is either regular or periodic or bursting, with the fraction of bursting neurons depending on the network activity; ii) bursts of spontaneous spikes have the same broad distributions of size and duration; iii) the degree of correlated activity increases with the bin width, and the power spectrum of the network firing rate has a 1/f behavior at low frequencies, indicating the existence of long-range temporal correlations; iv) the activity of excitatory synaptic pathways mediated by NMDA receptors is necessary for the onset of the long-range correlations and for the presence of large bursts; v) blockage of inhibitory synaptic pathways mediated by GABA(A) receptors causes instead an increase in the correlation among neurons and leads to a burst distribution composed only of very small and very large bursts. These results suggest that the spontaneous electrical activity in neuronal networks with different architectures and functions can have very similar properties and common dynamics.	[Mazzoni, Alberto; Broccard, Frederic D.; Garcia-Perez, Elizabeth; Bonifazi, Paolo; Ruaro, Maria Elisabetta; Torre, Vincent] Scuola Int Super Studi Avanzati, Trieste, Italy	International School for Advanced Studies (SISSA)	Torre, V (corresponding author), Scuola Int Super Studi Avanzati, Trieste, Italy.	torre@sissa.it	Bonifazi, Paolo/AAA-8035-2020; Mazzoni, Alberto/AGO-5998-2022; Mazzoni, Alberto/C-8523-2009; Mazzoni, Alberto/A-5433-2018; Bonifazi, Paolo/N-9737-2018; Mazzoni, Alberto/N-6960-2016	Bonifazi, Paolo/0000-0001-6374-8997; Mazzoni, Alberto/0000-0002-9632-1831; Mazzoni, Alberto/0000-0002-9632-1831; Bonifazi, Paolo/0000-0001-6374-8997; Mazzoni, Alberto/0000-0002-9632-1831	EU; Italian Government; CIPE/FVG	EU(European Commission); Italian Government; CIPE/FVG	This work was supported by the EU grant NEURO, by a FIRB grant from the Italian Government and by the GRAND grant from CIPE/FVG.	Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Arisi I, 2001, J NEUROPHYSIOL, V86, P2475, DOI 10.1152/jn.2001.86.5.2475; Arnold FJL, 2005, J PHYSIOL-LONDON, V564, P3, DOI 10.1113/jphysiol.2004.077446; Azouz R, 1999, J NEUROSCI, V19, P2209; BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; Baker RE, 2006, BRAIN RES, V1101, P29, DOI 10.1016/j.brainres.2006.05.028; Bedard C, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.118102; Beggs JM, 2004, J NEUROSCI, V24, P5216, DOI 10.1523/JNEUROSCI.0540-04.2004; Beggs JM, 2003, J NEUROSCI, V23, P11167; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bonifazi P, 2005, EUR J NEUROSCI, V22, P2953, DOI 10.1111/j.1460-9568.2005.04464.x; BRODFUEHRER PD, 1986, J NEUROBIOL, V17, P697, DOI 10.1002/neu.480170612; Brodfuehrer PD, 2001, PROG NEUROBIOL, V63, P371, DOI 10.1016/S0301-0082(00)00048-4; Burrell BD, 2004, J NEUROSCI, V24, P4011, DOI 10.1523/JNEUROSCI.0178-04.2004; Butts DA, 2001, J NEUROSCI, V21, P961, DOI 10.1523/JNEUROSCI.21-03-00961.2001; Cacciatore TW, 2000, J NEUROSCI, V20, P1643; CALABRESE RL, 1995, J NEUROBIOL, V27, P390, DOI 10.1002/neu.480270311; Canepari M, 1997, BIOL CYBERN, V77, P153, DOI 10.1007/s004220050376; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; Chiu CY, 2001, J NEUROSCI, V21, P8906, DOI 10.1523/JNEUROSCI.21-22-08906.2001; CLINE HT, 1986, J NEUROSCI, V6, P2848; Crow E.L., 1987, LOGNORMAL DISTRIBUTI; Cymbalyuk GS, 2002, J NEUROSCI, V22, P10580; Destexhe A, 2006, SCIENCE, V314, P85, DOI 10.1126/science.1127241; Egert U, 2002, J NEUROSCI METH, V117, P33, DOI 10.1016/S0165-0270(02)00045-6; Eisenhart FJ, 2000, J COMP PHYSIOL A, V186, P631, DOI 10.1007/s003590000117; Fiser J, 2004, NATURE, V431, P573, DOI 10.1038/nature02907; FRANKLIN JL, 1992, J NEUROSCI, V12, P1726; Freeman WJ, 2004, CLIN NEUROPHYSIOL, V115, P2089, DOI 10.1016/j.clinph.2004.02.028; Gonzalez-Islas C, 2006, NEURON, V49, P563, DOI 10.1016/j.neuron.2006.01.017; Grillner S, 2003, NAT REV NEUROSCI, V4, P573, DOI 10.1038/nrn1137; Haider B, 2006, J NEUROSCI, V26, P4535, DOI 10.1523/JNEUROSCI.5297-05.2006; Hanson MG, 2006, J NEUROSCI, V26, P12769, DOI 10.1523/JNEUROSCI.4170-06.2006; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; Huberman AD, 2006, NEURON, V52, P247, DOI 10.1016/j.neuron.2006.07.028; Jensen H.J., 1998, SELF ORG CRITICALITY; Jones TA, 2000, J NEUROPHYSIOL, V83, P1452, DOI 10.1152/jn.2000.83.3.1452; Koch C., 1999, BIOPHYSICAL COMPUTAT; Krahe R, 2004, NAT REV NEUROSCI, V5, P13, DOI 10.1038/nrn1296; Kristan WB, 2005, PROG NEUROBIOL, V76, P279, DOI 10.1016/j.pneurobio.2005.09.004; Kudela P, 2003, BIOL CYBERN, V88, P276, DOI 10.1007/s00422-002-0381-7; Lee IH, 2003, J NEUROPHYSIOL, V89, P2528, DOI 10.1152/jn.01055.2002; Leinekugel X, 2002, SCIENCE, V296, P2049, DOI 10.1126/science.1071111; Limpert E, 2001, BIOSCIENCE, V51, P341, DOI 10.1641/0006-3568(2001)051[0341:LNDATS]2.0.CO;2; Linkenkaer-Hansen K, 2001, J NEUROSCI, V21, P1370; MAEDA E, 1995, J NEUROSCI, V15, P6834; Maimon G, 2006, J NEUROSCI, V26, P2487, DOI 10.1523/JNEUROSCI.3590-05.2006; Marder E, 1996, PHYSIOL REV, V76, P687, DOI 10.1152/physrev.1996.76.3.687; Marder E, 2002, NEURAL NETWORKS, V15, P479, DOI 10.1016/S0893-6080(02)00043-6; MULLER KJ, 1981, NEUROBIOLOGY LEECH; O'Donovan MJ, 1999, CURR OPIN NEUROBIOL, V9, P94, DOI 10.1016/S0959-4388(99)80012-9; Papoulis A, 1984, PROBABILITY RANDOM V; Raichle ME, 2006, SCIENCE, V314, P1249, DOI 10.1126/science.1134405; Rieke F., 1997, SPIKES EXPLORING NEU; Ruaro ME, 2005, IEEE T BIO-MED ENG, V52, P371, DOI 10.1109/TBME.2004.842975; Segev R, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.118102; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Spitzer NC, 2006, NATURE, V444, P707, DOI 10.1038/nature05300; Staley KJ, 1998, NAT NEUROSCI, V1, P201, DOI 10.1038/651; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; Tateno T, 2005, NEUROSCIENCE, V134, P425, DOI 10.1016/j.neuroscience.2005.04.049; Thorogood MSE, 1995, INVERTEBR NEUROSCI, V1, P223, DOI 10.1007/BF02211024; TRAUB RD, 1994, PROG BRAIN RES, V102, P383; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; van Pelt J, 2004, IEEE T BIO-MED ENG, V51, P2051, DOI 10.1109/TBME.2004.827936; Vespignani A, 1998, PHYS REV E, V57, P6345, DOI 10.1103/PhysRevE.57.6345; Wang XJ, 1999, J NEUROSCI, V19, P9587; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Wu Eric, 2002, Invertebrate Neuroscience, V4, P157, DOI 10.1007/s10158-002-0017-6; ZOHARY E, 1994, NATURE, V370, P140, DOI 10.1038/370140a0	72	184	185	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e439	10.1371/journal.pone.0000439	http://dx.doi.org/10.1371/journal.pone.0000439			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17502919	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445800021
J	Bellanger, S; de Gramont, A; Sobczak-Thepot, J				Bellanger, S.; de Gramont, A.; Sobczak-Thepot, J.			Cyclin B2 suppresses mitotic failure and DNA re-replication in human somatic cells knocked down for both cyclins B1 and B2	ONCOGENE			English	Article						cyclin; mitosis; RNA interference; replication; cell cycle	DEPENDENT KINASES; MAMMALIAN-CELLS; GEMININ BINDING; TUMOR-CELLS; IN-VITRO; PHOSPHORYLATION; MITOSIS; B1; LOCALIZATION; INHIBITOR	Cyclin-dependent kinase 1 (CDK1) plays a crucial role in establishing metaphase and has also been shown to prevent DNA re-replication. Cyclins B1 and B2 are two known activators of CDK1 operating during mitosis in human cells. Little is known about the specific roles of each of these cyclins in CDK1 activation, but cyclin B2 is thought to play a minor role and to be unable to replace cyclin B1 for mitosis completion. In our study, we found that severe reduction by separate RNA interference of either cyclin B1 or cyclin B2 protein levels results in little or no alteration of the cell cycle and, more specifically, of mitosis progression. In contrast, simultaneous depletion of both B-type cyclins leads to massive accumulation of 4N cells, mitotic failure, premature mitosis exit and DNA re-replication. These defects can be corrected by the ectopic expression of a cyclin B2 resistant to the short hairpin RNA. Altogether, these data show that, in cycling human cells, cyclin B2 can compensate for the downregulation of cyclin B1 during mitosis. They also clearly implicate cyclins B1 and B2 as crucial activators of CDK1 in its biological function of DNA re-replication prevention.	Univ Paris 06, CNRS, UMR 7098, Biochim Cellulaire Lab, F-75005 Paris, France; Inst Med Biol, Singapore 138673, Singapore; NIH, NIDDK, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sobczak-Thepot, J (corresponding author), Univ Paris 06, CNRS, UMR 7098, Biochim Cellulaire Lab, F-75005 Paris, France.	Joelle.Sobczak-Thepot@snv.jussieu.fr	Sobczak, Joelle/HHZ-5610-2022	Sobczak, Joelle/0000-0001-7180-2789				Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; JACK DB, 1995, MOL MED TODAY, V1, P2; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Lee YM, 2006, CELL CYCLE, V5, P2110, DOI 10.4161/cc.5.18.3218; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Li CJ, 2004, MOL CELL BIOL, V24, P5875, DOI 10.1128/MCB.24.13.5875-5886.2004; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Niiya F, 2005, J BIOL CHEM, V280, P36502, DOI 10.1074/jbc.M508007200; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Seong YS, 2003, CANCER RES, V63, P7384; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; Zhou Y, 2002, NUCLEIC ACIDS RES, V30, P1664, DOI 10.1093/nar/30.7.1664; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	36	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7175	7184		10.1038/sj.onc.1210539	http://dx.doi.org/10.1038/sj.onc.1210539			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17533373				2022-12-25	WOS:000250955600001
J	Li, XL; Arai, Y; Harada, H; Shima, Y; Yoshida, H; Rokudai, S; Aikawa, Y; Kimura, A; Kitabayashi, I				Li, X-L; Arai, Y.; Harada, H.; Shima, Y.; Yoshida, H.; Rokudai, S.; Aikawa, Y.; Kimura, A.; Kitabayashi, I.			Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1-and p53-mediated transcription	ONCOGENE			English	Article						leukemia; HIPK2; mutation; AML1	INTERACTING PROTEIN KINASE-2; NUCLEAR-PORE COMPLEX; ACUTE LYMPHOBLASTIC-LEUKEMIA; GTPASE-ACTIVATING PROTEIN; FETAL LIVER HEMATOPOIESIS; ACUTE MONOCYTIC LEUKEMIA; SUMO-1 MODIFICATION; HOMEODOMAIN-INTERACTING-PROTEIN-KINASE-2 HIPK2; CHROMOSOME-TRANSLOCATION; AML1/PEBP2-ALPHA-B GENE	The AML1 transcription factor complex is the most frequent target of leukemia-associated chromosomal translocations. Homeodomain-interacting protein kinase 2 (HIPK2) is a part of the AML1 complex and activates AML1-mediated transcription. However, chromosomal translocations and mutations of HIPK2 have not been reported. In the current study, we screened mutations of the HIPK2 gene in 50 cases of acute myeloid leukemia (AML) and in 80 cases of myelodysplastic syndrome (MDS). Results indicated there were two missense mutations ( R868W and N958I) in the speckle-retention signal (SRS) domain of HIPK2. Subcellular localization analyses indicated that the two mutants were largely localized to nuclear regions with conical or ring shapes, and were somewhat diffused in the nucleus, in contrast to the wild type, which were mainly localized in nuclear speckles. The mutations impaired the overlapping localization of AML1 and HIPK2. The mutants showed decreased activities and a dominant-negative function over wild-type protein in AML1- and p53-dependent transcription. These findings suggest that dysfunction of HIPK2 may play a role in the pathogenesis of leukemia.	Natl Canc Ctr, Res Inst, Div Mol Oncol, Chuo Ku, Tokyo 104, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima, Japan	National Cancer Center - Japan; Hiroshima University	Kitabayashi, I (corresponding author), Natl Canc Ctr, Res Inst, Div Mol Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 104, Japan.	ikitabay@gan2.ncc.go.jp	Rokudai, Susumu/O-6771-2018; Kitabayashi, Issay/G-2204-2017	Rokudai, Susumu/0000-0003-0300-0391; Kitabayashi, Issay/0000-0002-8409-0407				Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Duprez E, 1999, J CELL SCI, V112, P381; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Hofmann TG, 2005, J BIOL CHEM, V280, P29224, DOI 10.1074/jbc.M503921200; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kim YH, 2005, FEBS LETT, V579, P6272, DOI 10.1016/j.febslet.2005.10.010; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Moller A, 2003, CANCER RES, V63, P4310; Nguyen LA, 2005, BLOOD, V105, P292, DOI 10.1182/blood-2004-03-1185; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Sung KS, 2005, FEBS LETT, V579, P3001, DOI 10.1016/j.febslet.2005.04.053; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang Y, 2001, BBA-GENE STRUCT EXPR, V1518, P168, DOI 10.1016/S0167-4781(00)00308-0; Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102	62	55	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7231	7239		10.1038/sj.onc.1210523	http://dx.doi.org/10.1038/sj.onc.1210523			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17533375				2022-12-25	WOS:000250955600007
J	Lackey, J; Barnett, J; Davidson, L; Batty, IH; Leslie, NR; Downes, CP				Lackey, J.; Barnett, J.; Davidson, L.; Batty, I. H.; Leslie, N. R.; Downes, C. P.			Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling	ONCOGENE			English	Article						phosphatase; signal transduction; feedback; insulin-like growth factor; phosphoinositide; tumor; suppressor	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; C-ZETA; EXPRESSION; INHIBITION; PATHWAYS; DOWNSTREAM; ACTIVATION; IRS-1	Many tumors have chronically elevated activity of PI 3-kinase-dependent signaling pathways, caused largely by oncogenic mutation of PI 3-kinase itself or loss of the opposing tumor suppressor lipid phosphatase, PTEN. Several PI 3-kinase-dependent feedback mechanisms have been identified that may affect the sensitivity of upstream receptor signaling, but the events required to initiate an inhibited state have not been addressed. We show that in a variety of cell types, loss of PTEN via experimental knockdown or in tumor cell lines correlates with a block in insulin-like growth factor 1 (IGF1)/insulin signaling, without affecting the sensitivity of platelet-derived growth factor or epidermal growth factor signaling. These effects on IGF/insulin signaling include a reduction of up to. veto tenfold in IGF-stimulated PI 3-kinase activation, a failure to activate the ERK kinases and, in some cells, reduced expression of insulin receptor substrate 1, and both IGF1 and insulin receptors. These data indicate that chronically elevated PI 3-kinase-dependent signaling to the degree seen in many tumors causes a selective loss of sensitivity in IGF1/insulin signaling that could significantly reduce the selective advantage of deregulated activation of IGF1/IGF1-R signaling in tumor development.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Coll Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Leslie, NR (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Physiol, Coll Life Sci, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk	Leslie, Nicholas/D-2699-2009	LESLIE, Nicholas/0000-0001-5131-0541	MRC [G9403619] Funding Source: UKRI; Medical Research Council [G9403619(67505), G9403619] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Batty IH, 2004, BIOCHEM J, V379, P641, DOI 10.1042/BJ20031700; Board R, 2005, DRUG RESIST UPDATE, V8, P75, DOI 10.1016/j.drup.2005.03.004; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Cutillas PR, 2006, P NATL ACAD SCI USA, V103, P8959, DOI 10.1073/pnas.0602101103; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Darragh J, 2005, BIOCHEM J, V390, P749, DOI 10.1042/BJ20050196; Fisher TL, 2004, CURR BIOL, V14, pR1005, DOI 10.1016/j.cub.2004.11.024; Foukas LC, 2006, NATURE, V441, P366, DOI 10.1038/nature04694; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hellawell GO, 2002, CANCER RES, V62, P2942; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Keeton AB, 2005, ENDOCRINOLOGY, V146, P2716, DOI 10.1210/en.2004-1662; Kiepe D, 2005, ENDOCRINOLOGY, V146, P3096, DOI 10.1210/en.2005-0324; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; LAM K, 1994, J BIOL CHEM, V269, P20648; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Mise-Omata S, 2005, BIOCHEM BIOPH RES CO, V328, P1034, DOI 10.1016/j.bbrc.2005.01.066; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Natarajan M, 2006, NAT CELL BIOL, V8, P571, DOI 10.1038/ncb1418; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shelton JG, 2005, EXPERT OPIN THER TAR, V9, P1009, DOI 10.1517/14728222.9.5.1009; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Vivekanand P, 2006, ANNU REV GENET, V40, P139, DOI 10.1146/annurev.genet.40.110405.090555; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001	40	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7132	7142		10.1038/sj.onc.1210520	http://dx.doi.org/10.1038/sj.onc.1210520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486056	Green Accepted			2022-12-25	WOS:000250715000007
J	Darwiche, N; Ryscavage, A; Perez-Lorenzo, R; Wright, L; Bae, DS; Hennings, H; Yuspa, SH; Glick, AB				Darwiche, N.; Ryscavage, A.; Perez-Lorenzo, R.; Wright, L.; Bae, D-S; Hennings, H.; Yuspa, S. H.; Glick, A. B.			Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion	ONCOGENE			English	Article						skin carcinogenesis; microarray; squamous cell carcinoma; tumor immunology	MOUSE SKIN; EPITHELIAL-CELLS; MESSENGER-RNA; IN-VIVO; CARCINOGENESIS; TUMORS; INFLAMMATION; SURVEILLANCE; PROGRESSION; RECEPTORS	Chemical induction of squamous tumors in the mouse skin induces multiple benign papillomas: high-frequency terminally benign low-risk papillomas and low-frequency high-risk papillomas, the putative precursor lesions to squamous cell carcinoma (SCC). We have compared the gene expression profile of twenty different early low- and high-risk papillomas with normal skin and SCC. Unsupervised clustering of 514 differentially expressed genes (P<0.001) showed that 9/10 high-risk papillomas clustered with SCC, while 1/10 clustered with low-risk papillomas, and this correlated with keratin markers of tumor progression. Prediction analysis for microarrays (PAM) identified 87 genes that distinguished the two papilloma classes, and a majority of these had a similar expression pattern in both high-risk papillomas and SCC. Additional classifier algorithms generated a gene list that correctly classified unknown benign tumors as low- or high-risk concordant with promotion protocol and keratin profiling. Reduced expression of immune function genes characterized the high-risk papillomas and SCC. Immunohistochemistry confirmed reduced T-cell number in high-risk papillomas, suggesting that reduced adaptive immunity defines papillomas that progress to SCC. These results demonstrate that murine premalignant lesions can be segregated into subgroups; by gene expression patterns that correlate with risk for malignant conversion, and suggest a paradigm for generating diagnostic biomarkers for human premalignant lesions with unknown individual risk for malignant conversion.	Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16801 USA; Amer Univ Beirut, Dept Biol, Beirut, Lebanon; NCI, Lab Canc Biol & Genet, Bethesda, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; American University of Beirut; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Glick, AB (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16801 USA.	abg11@psu.edu		Perez-Lorenzo, Rolando/0000-0002-9355-9617; Ryscavage, Andrew/0000-0002-4156-6903; Darwiche, Nadine/0000-0002-1862-5426	NATIONAL CANCER INSTITUTE [Z01BC005445, R01CA117957] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [CA117957] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Callen JP, 1997, J AM ACAD DERMATOL, V36, P650, DOI 10.1016/S0190-9622(97)70265-2; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Darwiche N, 1996, CANCER RES, V56, P4942; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Dong G, 1997, J CELL BIOCHEM, P90; Dooley TP, 2003, BIOCHEM BIOPH RES CO, V306, P1026, DOI 10.1016/S0006-291X(03)01099-4; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Girardi M, 2003, J EXP MED, V198, P747, DOI 10.1084/jem.20021282; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; Hummerich L, 2006, ONCOGENE, V25, P111, DOI 10.1038/sj.onc.1209016; Juric D, 2005, P NATL ACAD SCI USA, V102, P17763, DOI 10.1073/pnas.0509082102; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Morris RJ, 1997, CANCER RES, V57, P3436; Morris RJ, 2000, CANCER RES, V60, P226; Nambiar PR, 2004, CANCER RES, V64, P6394, DOI 10.1158/0008-5472.CAN-04-0933; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Nishimura H, 1998, J IMMUNOL, V160, P936; Ozaki K, 2004, NATURE, V429, P72, DOI 10.1038/nature02502; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Peyssonnaux C, 2006, BLOOD, V107, P3727, DOI 10.1182/blood-2005-06-2259; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ridd K, 2006, CARCINOGENESIS, V27, P1556, DOI 10.1093/carcin/bgl007; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Serewko MM, 2002, CANCER RES, V62, P3759; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	38	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6885	6895		10.1038/sj.onc.1210491	http://dx.doi.org/10.1038/sj.onc.1210491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17525749				2022-12-25	WOS:000250188400004
J	Chang, WP; Downs, D; Huang, XP; Da, H; Fung, KM; Tang, J				Chang, Wan-Pin; Downs, Deborah; Huang, Xiang-Ping; Da, Huining; Fung, Kar-Ming; Tang, Jordan			Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization	FASEB JOURNAL			English	Article						immunotherapy; Alzheimer's disease; BACE1	ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MOUSE MODEL; KNOCKOUT MICE; BACE1; BRAIN; GENERATION; INHIBITORS; THERAPEUTICS; PEPTIDES	Memapsin 2 (beta-secretase, BACE1) is the protease that initiates cleavage of beta-amyloid precursor protein leading to the production of amyloid-beta (A beta) and the onset of Alzheimer's disease (AD). Reducing A beta by targeting memapsin 2 is a major strategy in developing new AD therapy. Here, in a proof-of-concept study, we show that immunization of transgenic AD mice (Tg2576) with memapsin 2 resulted in A beta reduction and cognitive improvement. To study the basis of this therapy, we demonstrated that anti-memapsin 2 (anti-M2) antibodies were rapidly internalized and reduced A beta production in cultured cells. These antibodies also effectively crossed the blood-brain barrier to reach the brain. Two-and 10-month Tg2576 mice were immunized and monitored over 10 and 6 months, respectively. We observed a significant decrease of plasma and brain A beta(40) and A beta(42) (similar to 35%) in the immunized mice as compared to controls. Immunized mice also showed better cognitive performance than controls in both cohorts. Brain histological analyses found no evidence of T cell/microglia/astrocyte activation in the immunized mice, suggesting the absence of inflammatory responses. These results suggest that memapsin 2 immunization in Tg2576 was effective in reducing A beta production and improving cognitive function and that the current approach warrants further investigation as a therapy for AD.	Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Chang, WP (corresponding author), Oklahoma Med Res Fdn, Prot Studies Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	wanpin-chang@omrf.ouhsc.edu			NCRR NIH HHS [P20 RR 15577-07] Funding Source: Medline; NIA NIH HHS [AG-18933] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018933] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arbel M, 2005, P NATL ACAD SCI USA, V102, P7718, DOI 10.1073/pnas.0502427102; Barten Donna M, 2006, Drugs R D, V7, P87, DOI 10.2165/00126839-200607020-00003; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chang WP, 2004, J NEUROCHEM, V89, P1409, DOI 10.1111/j.1471-4159.2004.02452.x; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P16263, DOI 10.1021/bi005122i; Ghosh AK, 2005, CURR TOP MED CHEM, V5, P1609, DOI 10.2174/156802605775009711; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P646, DOI 10.1016/S1044-7431(03)00227-6; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Hoe HS, 2005, MOL CELL BIOL, V25, P9259, DOI 10.1128/MCB.25.21.9259-9268.2005; Huang XP, 2004, J BIOL CHEM, V279, P37886, DOI 10.1074/jbc.M402130200; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; John V, 2006, CURR TOP MED CHEM, V6, P569, DOI 10.2174/156802606776743084; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kawooya JK, 2003, ANAL BIOCHEM, V323, P103, DOI 10.1016/j.ab.2003.08.027; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lee EB, 2005, FEBS LETT, V579, P2564, DOI 10.1016/j.febslet.2005.03.070; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LIN XL, 1994, METHOD ENZYMOL, V241, P195; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Seyfert S, 2004, J NEUROL, V251, P355, DOI 10.1007/s00415-004-0334-2; Shen J, 2007, P NATL ACAD SCI USA, V104, P403, DOI 10.1073/pnas.0608332104; Sidor MM, 2005, J NEUROIMMUNOL, V165, P104, DOI 10.1016/j.jneuroim.2005.04.022; Siemers ER, 2006, NEUROLOGY, V66, P602, DOI 10.1212/01.WNL.0000198762.41312.E1; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sun AY, 2002, EXP NEUROL, V175, P10, DOI 10.1006/exnr.2002.7875; TRIGUERO D, 1989, P NATL ACAD SCI USA, V86, P4761, DOI 10.1073/pnas.86.12.4761; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Wiltfang J, 2001, J BIOL CHEM, V276, P42645, DOI 10.1074/jbc.M102790200; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	51	34	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3184	3196		10.1096/fj.06-7993com	http://dx.doi.org/10.1096/fj.06-7993com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17494994				2022-12-25	WOS:000249781600019
J	Wang, CS; Leger, RJS				Wang, Chengshu; Leger, Raymond J. St.			The Metarhizium anisopliae perilipin homolog MPL1 regulates lipid metabolism, appressorial turgor pressure, and virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE LIPOLYSIS; MAGNAPORTHE-GRISEA; DROPLETS; EXPRESSION; PHOSPHORYLATION; MECHANISMS; GENERATION; DROSOPHILA; RESPONSES; PROTEINS	Cells store lipids in droplets. Studies addressing how mammals controllipid-based energy homeostasis have implicated proteins of the PAT domain family, such as perilipin that surrounds the lipid droplets. Perilipin knock-out mice are lean and resistant to obesity. Factors that mediate lipid storage in fungi are still unknown. Here we describe a gene (Mpl1) in the economically important insect fungal pathogen Metarhizium anisopliae that has structural similarities to mammalian perilipins. Consistent with a role in lipid storage, Mpl1 is predominantly expressed when M. anisopliae is engaged in accumulating lipids and ectopically expressed green fluorescent protein-tagged MPL1(Metarhizium perilipin-like protein) localized to lipid droplets. Mutant M. anisopliae lacking MPL1 have thinner hyphae, fewer lipid droplets, particularly in appressoria (specialized infection structures at the end of germ tubes), and a decrease in total lipids. Mpl1 therefore acts in a perilipin-like manner suggesting an evolutionary conserved function in lipid metabolism. However, reflecting general differences between animal and fungal lineages, these proteins have also been selected to cope with different tasks. Thus, turgor generation by Delta Mpl1 appressoria is dramatically reduced indicating that lipid droplets are required for solute accumulation. This was linked with the reduced ability to breach insect cuticle so that Mpl1 is a pathogenicity determinant. Blast searches of fungal genomes revealed that perilipin homologs are found only in pezizomycotinal ascomycetes and occur as single copy genes. Expression of Mpl1 in yeast cells, a fungus that lacks a perilipin-like gene, blocked their ability to mobilize lipids during starvation conditions.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Plant Physiol & Ecol, Shanghai 200032, Peoples R China; Univ Maryland, Dept Entomol, College Pk, MD 20742 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University System of Maryland; University of Maryland College Park	Wang, CS (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Plant Physiol & Ecol, Shanghai 200032, Peoples R China.	cswang@sibs.ac.cn; stleger@umd.edu	Wang, Chengshu/A-1656-2011; St. Leger, Raymond/N-3219-2013	Wang, Chengshu/0000-0003-1477-1466; 				Beckman M, 2006, SCIENCE, V311, P1232, DOI 10.1126/science.311.5765.1232; Blanford S, 2005, SCIENCE, V308, P1638, DOI 10.1126/science.1108423; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; DiDonato D, 2003, J HISTOCHEM CYTOCHEM, V51, P773, DOI 10.1177/002215540305100608; Garcia A, 2004, J BIOL CHEM, V279, P8409, DOI 10.1074/jbc.M311198200; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; HOWARD RJ, 1991, P NATL ACAD SCI USA, V88, P11281, DOI 10.1073/pnas.88.24.11281; HWANG CS, 1995, PLANT CELL, V7, P183, DOI 10.1105/tpc.7.2.183; Izard J, 2003, J MICROBIOL METH, V55, P411, DOI 10.1016/S0167-7012(03)00193-3; Marcinkiewicz A, 2006, J BIOL CHEM, V281, P11901, DOI 10.1074/jbc.M600171200; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Miyoshi H, 2006, J BIOL CHEM, V281, P15837, DOI 10.1074/jbc.M601097200; Qi L, 2004, CLIN GENET, V66, P299, DOI 10.1111/j.1399-0004.2004.00309.x; StLeger RJ, 1996, P NATL ACAD SCI USA, V93, P6349, DOI 10.1073/pnas.93.13.6349; Subramanian V, 2004, J LIPID RES, V45, P1983, DOI 10.1194/jlr.M400291-JLR200; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Teixeira L, 2003, MECH DEVELOP, V120, P1071, DOI 10.1016/S0925-4773(03)00158-8; Thines E, 2000, PLANT CELL, V12, P1703, DOI 10.1105/tpc.12.9.1703; Wang C, 2006, P NATL ACAD SCI USA, V103, P6647, DOI 10.1073/pnas.0601951103; Wang CS, 2005, MICROBIOL-SGM, V151, P3223, DOI 10.1099/mic.0.28148-0; Wang CS, 2005, FUNGAL GENET BIOL, V42, P704, DOI 10.1016/j.fgb.2005.04.006; Wang CS, 2005, EUKARYOT CELL, V4, P937, DOI 10.1128/EC.4.5.937-947.2005; Wang ZY, 2005, BIOCHEM SOC T, V33, P384, DOI 10.1042/BST0330384; Weber RWS, 2001, PROTOPLASMA, V216, P101, DOI 10.1007/BF02680137; Welte MA, 2005, CURR BIOL, V15, P1266, DOI 10.1016/j.cub.2005.06.062; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	30	144	161	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21110	21115		10.1074/jbc.M609592200	http://dx.doi.org/10.1074/jbc.M609592200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17526497	hybrid			2022-12-25	WOS:000248047500037
J	Matsukuma, KE; Wang, L; Bennett, MK; Osborne, TF				Matsukuma, Karen E.; Wang, Li; Bennett, Mary K.; Osborne, Timothy F.			A key role for orphan nuclear receptor liver receptor homologue-1 in activation of fatty acid synthase promoter by liver X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; SMALL HETERODIMER PARTNER; CHICK-EMBRYO HEPATOCYTES; TRANSCRIPTIONAL REGULATION; FEEDBACK-REGULATION; STEROL REGULATION; THYROID-HORMONE; DIFFERENTIAL REGULATION; GENE-TRANSCRIPTION; RESPONSE PATHWAY	Liver X receptor (LXR) activates fatty acid synthase (FAS) gene expression through binding to a DR-4 element in the promoter. We show that a distinct nuclear receptor half-site 21 bases downstream of the DR-4 element is also critical for the response of FAS to LXR but is not involved in LXR binding to DNA. This half-site specifically binds liver receptor homologue-1 (LRH-1) in vitro and in vivo, and we show LRH-1 is required for maximal LXR responsiveness of the endogenous FAS gene as well as from promoter reporter constructs. We also demonstrate that LRH-1 stimulation of the FAS LXR response is blocked by the addition of small heterodimer partner (SHP) and that FAS mRNA is overexpressed in SHP knock-out animals, providing evidence that FAS is an in vivo target of SHP repression. Taken together, these findings identify the first direct lipogenic gene target of LRH-1/SHP repression and provide a mechanistic explanation for bile acid repression of FAS and lipogenesis recently reported by others.	Univ Calif Irvine, Sch Biol Sci, Ctr Diabet Res & Treatment, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Kansas, Med Ctr, Dept Med & Pharmacol, Kansas City, KS 66160 USA	University of California System; University of California Irvine; University of Kansas; University of Kansas Medical Center	Osborne, TF (corresponding author), Univ Calif Irvine, Sch Biol Sci, Ctr Diabet Res & Treatment, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	tim.osborne@uci.edu			NHLBI NIH HHS [HL 48044] Funding Source: Medline; NIDDK NIH HHS [DK 71021] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071021] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Bennett MK, 2004, J BIOL CHEM, V279, P37360, DOI 10.1074/jbc.M404693200; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; Chen WL, 2007, CELL METAB, V5, P73, DOI 10.1016/j.cmet.2006.11.012; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; Datta S, 2006, J BIOL CHEM, V281, P807, DOI 10.1074/jbc.M511050200; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, MOL ENDOCRINOL, V17, P386, DOI 10.1210/me.2002-0246; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu Z, 2001, BBA-MOL CELL BIOL L, V1532, P213, DOI 10.1016/S1388-1981(01)00135-4; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Luo Y, 2001, J BIOL CHEM, V276, P24767, DOI 10.1074/jbc.M100912200; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; Matsukuma KE, 2006, J LIPID RES, V47, P2754, DOI 10.1194/jlr.M600342-JLR200; Moschetta A, 2004, NAT MED, V10, P1352, DOI 10.1038/nm1138; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Oskouian B, 1996, BIOCHEM J, V317, P257, DOI 10.1042/bj3170257; Pare JF, 2004, J BIOL CHEM, V279, P21206, DOI 10.1074/jbc.M401523200; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rolland V, 1996, J BIOL CHEM, V271, P21297, DOI 10.1074/jbc.271.35.21297; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Venteclef N, 2006, MOL CELL BIOL, V26, P6799, DOI 10.1128/MCB.00579-06; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Wang L, 2003, J BIOL CHEM, V278, P44475, DOI 10.1074/jbc.M305258200; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; WILSON SB, 1986, J BIOL CHEM, V261, P5179; Xiong SB, 1998, P NATL ACAD SCI USA, V95, P12260, DOI 10.1073/pnas.95.21.12260; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102	45	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20164	20171		10.1074/jbc.M702895200	http://dx.doi.org/10.1074/jbc.M702895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17522048	hybrid			2022-12-25	WOS:000247819300017
J	Tittle, RK; Power, JM; Hume, RI				Tittle, Rachel K.; Power, Jamila M.; Hume, Richard I.			A histidine scan to probe the flexibility of the rat P2X(2) receptor zinc-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; ATP-BINDING; MOLECULAR-PROPERTIES; CYSTEINE RESIDUES; AGONIST BINDING; CALCIUM-ENTRY; MODULATION; SUBUNIT; IDENTIFICATION; PURINOCEPTOR	The response of P2X(2) receptors to submaximal concentrations of ATP is potentiated by low levels of extracellular zinc. Histidines 120 and 213 have previously been shown to be essential in binding zinc across an intersubunit binding site. We tested the flexibility of the zinc-binding site by making mutations that had the effect of shifting the two essential histidines up to 13 residues upstream or downstream from their original positions and then testing the ability of the mutated receptors to respond to zinc. Using this method, we were able to explore potential orientations of the two regions relative to one another. Our data are consistent with a moderately flexible zinc-binding site and inconsistent with parallel and anti-parallel orientations of the regions surrounding histidines 120 and 213.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Hume, RI (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	rhume@umich.edu	, Richard/AAI-5000-2020	Hume, Richard/0000-0001-9807-112X	NINDS NIH HHS [R01-NS039196, R01 NS039196-07, F31 NS051001] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039196, F31NS051001] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; BRANDEN C, 1998, INTRO PROTEIN STRUCT, P13; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Clyne JD, 2003, NEUROPHARMACOLOGY, V44, P403, DOI 10.1016/S0028-3908(02)00406-9; Clyne JD, 2002, J PHYSIOL-LONDON, V539, P347, DOI 10.1113/jphysiol.2001.013244; Clyne JD, 2002, J NEUROSCI, V22, P3873, DOI 10.1523/JNEUROSCI.22-10-03873.2002; Cockayne DA, 2005, J PHYSIOL-LONDON, V567, P621, DOI 10.1113/jphysiol.2005.088435; Ennion S, 2000, J BIOL CHEM, V275, P35656; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Finger TE, 2005, SCIENCE, V310, P1495, DOI 10.1126/science.1118435; Freist W, 1998, FEBS LETT, V434, P61, DOI 10.1016/S0014-5793(98)00958-2; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Kanjhan R, 1999, J COMP NEUROL, V407, P11; Liang LH, 2005, AM J PHYSIOL-CELL PH, V289, pC388, DOI 10.1152/ajpcell.00491.2004; Marquez-Klaka B, 2007, J NEUROSCI, V27, P1456, DOI 10.1523/JNEUROSCI.3105-06.2007; Nagaya N, 2005, J BIOL CHEM, V280, P25982, DOI 10.1074/jbc.M504545200; Nakazawa K, 2004, EUR J PHARMACOL, V483, P29, DOI 10.1016/j.ejphar.2003.10.026; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ren JH, 2003, J PHYSIOL-LONDON, V552, P809, DOI 10.1113/jphysiol.2003.047944; Roberts JA, 2004, J BIOL CHEM, V279, P9043, DOI 10.1074/jbc.M308964200; Roberts JA, 2007, J NEUROSCI, V27, P4072, DOI 10.1523/JNEUROSCI.2310-06.2007; Roberts JA, 2006, PFLUG ARCH EUR J PHY, V452, P486, DOI 10.1007/s00424-006-0073-6; Rong WF, 2003, J NEUROSCI, V23, P11315; Sigel H, 2005, CHEM SOC REV, V34, P875, DOI 10.1039/b505986k; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; Vial C, 2004, TRENDS PHARMACOL SCI, V25, P487, DOI 10.1016/j.tips.2004.07.008; Wildman SS, 1998, BRIT J PHARMACOL, V123, P1214, DOI 10.1038/sj.bjp.0701717; Wilkinson WJ, 2006, MOL PHARMACOL, V70, P1159, DOI 10.1124/mol.106.026658; Yan ZH, 2005, MOL PHARMACOL, V67, P1078, DOI 10.1124/mol.104.010108; Yan ZH, 2006, J BIOL CHEM, V281, P32649, DOI 10.1074/jbc.M512791200; Zhou Z, 1998, J PHYSIOL-LONDON, V507, P353, DOI 10.1111/j.1469-7793.1998.353bt.x; Zsembery A, 2004, J BIOL CHEM, V279, P10720, DOI 10.1074/jbc.M313391200	33	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19526	19533		10.1074/jbc.M701604200	http://dx.doi.org/10.1074/jbc.M701604200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17517890	hybrid			2022-12-25	WOS:000247650600027
J	Grybko, MJ; Bartnik, JP; Wurth, GA; Pores-Fernando, AT; Zweifach, A				Grybko, Michael J.; Bartnik, Jakub P.; Wurth, Georjeana A.; Pores-Fernando, Arun T.; Zweifach, Adam			Calcineurin activation is only one calcium-dependent step in cytotoxic T lymphocyte granule exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CYCLOSPORINE-A; CELLS; DEGRANULATION; MECHANISMS; EXPRESSION; INHIBITOR; RECEPTOR; DEPHOSPHORYLATION; IDENTIFICATION	We have tested the idea that calcineurin, a calcium-dependent phosphatase that is critical for activating cytokine gene expression in helper T cells, plays a role in lytic granule exocytosis in cytotoxic T lymphocytes (CTLs). We used TALL-104 human leukemic CTLs as a model. Our results confirm an earlier report (Dutz, J. P., Fruman, D. A., Burakoff, S. J., and Bierer, B. E. (1993) J. Immunol. 150, 2591-2598) that immunosuppressive drugs inhibit exocytosis in CTLs stimulated either via the T cell receptor (TCR) or via TCR-independent soluble agents. Of the two recently reported alternate targets of immunosuppressive drugs (Matsuda, S., Shibasaki, F., Takehana, K., Mori, H., Nishida, E., and Koyasu, S. (2000) EMBO Rep. 1,428-434 and Matsuda, S., and Koyasu, S. (2000) Immunopharmacology 47, 119-125), JNK is not required for lytic granule exocytosis, but we were not able to exclude a role for P38. Exocytosis could be inhibited by expressing GFP fused to a C-terminal fragment of CAIN (cabin 1), but not by expressing VIVIT-GFP. Finally, expressing either full-length or truncated constitutively active mutant calcineurin A enhanced lytic granule exocytosis. However, the mutant calcineurin was unable to support exocytosis when cells were stimulated in the absence of Ca2+ influx. Taken together, our results support the idea that activation of calcineurin is required for lytic granule exocytosis but suggest that it is not the sole Ca(2+-)dependent step.	Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06268 USA	University of Connecticut	Zweifach, A (corresponding author), Univ Connecticut, Dept Mol & Cell Biol, Unit 3125, 91 N Eagleville Rd, Storrs, CT 06268 USA.	adam.zweifach@uconn.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054839] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI054839] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Berg NN, 1998, J IMMUNOL, V161, P2919; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BERREBI G, 1987, P NATL ACAD SCI USA, V84, P1364, DOI 10.1073/pnas.84.5.1364; Betts MR, 2004, METHOD CELL BIOL, V75, P497; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; CESANO A, 1992, IN VITRO CELL DEV-AN, V28A, P648; Dell'Acqua ML, 2002, J BIOL CHEM, V277, P48796, DOI 10.1074/jbc.M207833200; Dieter B, 2002, PFLUG ARCH EUR J PHY, V443, P333, DOI 10.1007/s00424-001-0742-4; Donelan MJ, 2002, J BIOL CHEM, V277, P24232, DOI 10.1074/jbc.M203345200; DUTZ JP, 1993, J IMMUNOL, V150, P2591; Fierro AF, 2004, J BIOL CHEM, V279, P25646, DOI 10.1074/jbc.M400296200; Fowler KT, 2007, J IMMUNOL, V178, P1498, DOI 10.4049/jimmunol.178.3.1498; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; GRIFFITHS GM, 1995, CURR OPIN IMMUNOL, V7, P343, DOI 10.1016/0952-7915(95)80108-1; Groblewski GE, 1998, J BIOL CHEM, V273, P22738, DOI 10.1074/jbc.273.35.22738; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; Grybko MJ, 2007, J LEUKOCYTE BIOL, V81, P509, DOI 10.1189/jlb.0206109; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; Im SH, 2004, MOL CELLS, V18, P1; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LANCKI DW, 1987, J IMMUNOL, V138, P3646; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Lyubchenko TA, 2001, IMMUNITY, V15, P847, DOI 10.1016/S1074-7613(01)00233-3; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Matsuda S, 2000, EMBO REP, V1, P428, DOI 10.1093/embo-reports/kvd090; Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2; Oliveria SF, 2003, J CELL BIOL, V160, P101, DOI 10.1083/jcb.200209127; Pardo J, 2003, INT IMMUNOL, V15, P1441, DOI 10.1093/intimm/dxg141; Pores-Fernando AT, 2005, J PHYSIOL-LONDON, V567, P891, DOI 10.1113/jphysiol.2005.089565; Puente LG, 2000, J IMMUNOL, V165, P6865, DOI 10.4049/jimmunol.165.12.6865; Puente LG, 2006, EUR J IMMUNOL, V36, P1009, DOI 10.1002/eji.200535277; Puente LG, 2005, MOL IMMUNOL, V42, P1177, DOI 10.1016/j.molimm.2004.11.012; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Raufman JP, 1997, BBA-MOL CELL RES, V1357, P73, DOI 10.1016/S0167-4889(97)00023-2; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Shin DW, 2002, BIOPHYS J, V83, P2539, DOI 10.1016/S0006-3495(02)75265-X; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; TAKAYAMA H, 1987, J IMMUNOL METHODS, V104, P183, DOI 10.1016/0022-1759(87)90502-3; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725	46	14	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18009	18017		10.1074/jbc.M702222200	http://dx.doi.org/10.1074/jbc.M702222200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17478429	hybrid			2022-12-25	WOS:000247302000007
J	Chang, YF; Martin, SS; Baldwin, EP; Carman, GM				Chang, Yu-Fang; Martin, Shelley S.; Baldwin, Enoch P.; Carman, George M.			Phosphorylation of human CTP synthetase 1 by protein kinase C - Identification of Ser(462) and Thr(455) as major sites of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE-TRIPHOSPHATE-SYNTHETASE; AFRICAN SLEEPING SICKNESS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CYCLOPENTENYL CYTOSINE; PHOSPHATIDYLCHOLINE SYNTHESIS; 5'-TRIPHOSPHATE SYNTHETASE; LYMPHOBLASTIC-LEUKEMIA; GENE-PRODUCT; MUTATOR GENE	Phosphorylation of human CTP synthetase 1 by mammalian protein kinase C was examined. Using purified Escherichia coli-expressed CTP synthetase 1 as a substrate, protein kinase C activity was time- and dose-dependent and dependent on the concentrations of ATP and CTP synthetase 1. The protein kinase C phosphorylation of the recombinant enzyme was accompanied by a 95-fold increase in CTP synthetase 1 activity. Phosphopeptide mapping and phosphoamino acid analyses showed that CTP synthetase 1 was phosphorylated on multiple serine and threonine residues. The induction of PKC1(R398A)-encoded protein kinase C resulted in a 50% increase for human CTP synthetase 1 phosphorylation in the Saccharomyces cerevisiae ura7 Delta ura8 Delta mutant lacking yeast CTP synthetase activity. Synthetic peptides that contain the protein kinase C motif for Ser(462) and Thr(455) were substrates for mammalian protein kinase C, and S462A and T455A mutations resulted in decreases in the extent of CTP synthetase 1 phosphorylation that occurred in vivo. Phosphopeptide mapping analysis of S. cerevisiae-expressed CTP synthetase 1 mutant enzymes phosphorylated with mammalian protein kinase C confirmed that Ser(462) and Thr(455) were phosphorylation sites. The S. cerevisiae-expressed and purified S462A mutant enzyme exhibited a 2-fold reduction in CTP synthetase 1 activity, whereas the purified T455A mutant enzyme exhibited a 2-fold elevation in CTP synthetase 1 activity ( Choi, M.- G., and Carman, G. M. ( 2006) J. Biol. Chem. 282, 5367-5377). These data indicated that protein kinase C phosphorylation at Ser(462) stimulates human CTP synthetase 1 activity, whereas phosphorylation at Thr(455) inhibits activity.	Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA; Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	Rutgers State University New Brunswick; University of California System; University of California Davis; University of California System; University of California Davis	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu		Baldwin, Enoch/0000-0002-1472-0944	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063109, R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-63109, GM-50679, R01 GM050679-14, R01 GM050679, R01 GM063109] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; ARONOW B, 1984, J BIOL CHEM, V259, P9035; ARONOW B, 1987, J BIOL CHEM, V262, P5106; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choi MG, 2007, J BIOL CHEM, V282, P5367, DOI 10.1074/jbc.M610993200; Choi MG, 2003, J BIOL CHEM, V278, P23610, DOI 10.1074/jbc.M303337200; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; CULBERTSON MR, 1975, GENETICS, V80, P23; Dereuddre-Bosquet N, 2004, ANTIVIR RES, V61, P67, DOI 10.1016/j.antiviral.2003.08.002; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; Endrizzi JA, 2005, BIOCHEMISTRY-US, V44, P13491, DOI 10.1021/bi051282o; Endrizzi JA, 2004, BIOCHEMISTRY-US, V43, P6447, DOI 10.1021/bi0496945; Fijolek A, 2007, J BIOL CHEM, V282, P11858, DOI 10.1074/jbc.M611580200; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goto M, 2004, STRUCTURE, V12, P1413, DOI 10.1016/j.str.2004.05.013; HAID A, 1983, METHOD ENZYMOL, V96, P192; Han GS, 2005, J BIOL CHEM, V280, P38328, DOI 10.1074/jbc.M509622200; Hatch GM, 1996, J BIOL CHEM, V271, P25810, DOI 10.1074/jbc.271.42.25810; HINDENBURG AA, 1985, CANCER RES, V45, P3048; Hofer A, 2001, P NATL ACAD SCI USA, V98, P6412, DOI 10.1073/pnas.111139498; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KANG GJ, 1989, J BIOL CHEM, V264, P713; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; KIZAKI H, 1980, CANCER RES, V40, P3921; Kursula P, 2006, ACTA CRYSTALLOGR F, V62, P613, DOI 10.1107/S1744309106018136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1969, P NATL ACAD SCI USA, V62, P1121, DOI 10.1073/pnas.62.4.1121; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3365, DOI 10.1021/bi00794a008; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LEWIS DA, 1989, BIOCHEMISTRY-US, V28, P8454, DOI 10.1021/bi00447a027; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Mackay HJ, 2003, ENDOCR-RELAT CANCER, V10, P389, DOI 10.1677/erc.0.0100389; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; Pappas A, 1998, J BIOL CHEM, V273, P15954, DOI 10.1074/jbc.273.26.15954; Pappas A, 1999, BIOCHEMISTRY-US, V38, P16671, DOI 10.1021/bi9920127; Park TS, 2003, J BIOL CHEM, V278, P20785, DOI 10.1074/jbc.M301394200; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POLITI PM, 1995, CANCER CHEMOTH PHARM, V36, P513, DOI 10.1007/BF00685802; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; VANDENBERG AA, 1995, EUR J CANCER, V31A, P108, DOI 10.1016/0959-8049(94)00442-8; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; Verschuur AC, 1998, ADV EXP MED BIOL, V431, P667; Verschuur AC, 2000, EUR J CANCER, V36, P627, DOI 10.1016/S0959-8049(00)00021-6; Verschuur AC, 2000, BRIT J HAEMATOL, V110, P161, DOI 10.1046/j.1365-2141.2000.02136.x; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; Wadskov-Hansen SLL, 2001, J BIOL CHEM, V276, P38002; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; Weber G, 1978, Adv Enzyme Regul, V17, P1; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983; ZHANG H, 1993, CANCER RES, V53, P5714	77	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17613	17622		10.1074/jbc.M702799200	http://dx.doi.org/10.1074/jbc.M702799200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17463002	hybrid, Green Accepted			2022-12-25	WOS:000247084500033
J	Wolff, T; Guinto, JB; Rawls, AS				Wolff, Tanya; Guinto, Jake B.; Rawls, Amy S.			Screen for Genetic Modifiers of stbm Reveals that Photoreceptor Fate and Rotation Can Be Genetically Uncoupled in the Drosophila Eye	PLOS ONE			English	Article							PLANAR CELL POLARITY; TISSUE POLARITY; OMMATIDIAL ROTATION; PROTEIN; PRICKLE; NOTCH; POLARIZATION; INFORMATION; STRABISMUS; ACTIVATION	Background. Polarity of the Drosophila compound eye arises primarily as a consequence of two events that are tightly linked in time and space: fate specification of two photoreceptor cells, R3 and R4, and the subsequent directional movement of the unit eyes of the compound eye, or ommatidia. While it is thought that these fates dictate the direction of ommatidial rotation, the phenotype of mutants in the genes that set up this polarity led to the hypothesis that these two events could be uncoupled. Methodology/Principal Findings. To definitively demonstrate these events are genetically separable, we conducted a dominant modifier screen to determine if genes, when misexpressed, could selectively enhance subclasses of mutant ommatidia in which the direction of rotation does not follow the R3/R4 cell fates, yet not affect the number of ommatidia in which rotation follows the R3/R4 cell fates. We identified a subset of P element lines that exhibit this selective enhancement. We also identified lines that behave in the opposite manner: They enhance the number of ommatidia that rotate in the right direction, but do not alter the number of ommatidia that rotate incorrectly with respect to the R3/R4 fates. Conclusions/Significance. These results indicate that fate and direction of rotation can be genetically separated, and that there are genes that act between R3/R4 fate specification and direction of ommatidial rotation. These data affirm what has been a long-standing assumption about the genetic control of ommatidial polarity.	[Wolff, Tanya; Guinto, Jake B.; Rawls, Amy S.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL)	Wolff, T (corresponding author), Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.	twolff@genetics.wustl.edu			Lucille P. Markey Pathway fellowship; NIH [R01 EY13136]; NATIONAL EYE INSTITUTE [R01EY013136] Funding Source: NIH RePORTER	Lucille P. Markey Pathway fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by a Lucille P. Markey Pathway fellowship to ASR and NIH grant R01 EY13136 to TW. Funders did not contribute to the design or conduct of the study, nor the collection, analysis, or interpretation of the data, nor in the preparation, review or approval of the manuscript.	Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Brown KE, 2003, DEVELOPMENT, V130, P5401, DOI 10.1242/dev.00773; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; Chou YH, 2002, DEV CELL, V3, P839, DOI 10.1016/S1534-5807(02)00362-3; Cooper MTD, 1999, NATURE, V397, P526, DOI 10.1038/17395; Das G, 2004, DEVELOPMENT, V131, P4467, DOI 10.1242/dev.01317; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; Feiguin F, 2001, DEV CELL, V1, P93, DOI 10.1016/S1534-5807(01)00010-7; Gaengel K, 2003, DEVELOPMENT, V130, P5413, DOI 10.1242/dev.00759; Gubb D, 1999, GENE DEV, V13, P2315, DOI 10.1101/gad.13.17.2315; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; HAY BA, 1994, DEVELOPMENT, V120, P2121; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Lopez-Schier H, 2006, P NATL ACAD SCI USA, V103, P18615, DOI 10.1073/pnas.0608536103; Mlodzik M, 2005, AD DEV BIOL, V14, P1; Rawls AS, 2002, CURR BIOL, V12, P1021, DOI 10.1016/S0960-9822(02)00893-X; Rawls AS, 2003, DEVELOPMENT, V130, P1877, DOI 10.1242/dev.00411; Strutt H, 2003, CURR BIOL, V13, P1451, DOI 10.1016/S0960-9822(03)00545-1; Taylor J, 1998, GENETICS, V150, P199; THEISEN H, 1994, DEVELOPMENT, V120, P347; Tomlinson A, 1999, DEVELOPMENT, V126, P5725; Tree DRP, 2002, SEMIN CELL DEV BIOL, V13, P217, DOI 10.1016/S1084-9521(02)00042-3; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wolff T, 1993, DEV DROSOPHILA MELAN; ZHENG L, 1995, DEVELOPMENT, V121, P3045	29	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e453	10.1371/journal.pone.0000453	http://dx.doi.org/10.1371/journal.pone.0000453			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505545	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445900012
J	Elmqvist, T; Pyykonen, M; Tengo, M; Rakotondrasoa, F; Rabakonandrianina, E; Radimilahy, C				Elmqvist, Thomas; Pyykonen, Markku; Tengo, Maria; Rakotondrasoa, Fanambinantsoa; Rabakonandrianina, Elisabeth; Radimilahy, Chantal			Patterns of Loss and Regeneration of Tropical Dry Forest in Madagascar: The Social Institutional Context	PLOS ONE			English	Article								Loss of tropical forests and changes in land-use/land-cover are of growing concern worldwide. Although knowledge exists about the institutional context in which tropical forest loss is embedded, little is known about the role of social institutions in influencing regeneration of tropical forests. In the present study we used Landsat images from southern Madagascar from three different years (1984, 1993 and 2000) and covering 5500 km(2), and made a time-series analysis of three distinct large-scale patterns: 1) loss of forest cover, 2) increased forest cover, and 3) stable forest cover. Institutional characteristics underlying these three patterns were analyzed, testing the hypothesis that forest cover change is a function of strength and enforcement of local social institutions. The results showed a minor decrease of 7% total forest cover in the study area during the whole period 1984-2000, but an overall net increase of 4% during the period 1993-2000. The highest loss of forest cover occurred in a low human population density area with long distances to markets, while a stable forest cover occurred in the area with highest population density and good market access. Analyses of institutions revealed that loss of forest cover occurred mainly in areas characterized by insecure property rights, while areas with well-defined property rights showed either regenerating or stable forest cover. The results thus corroborate our hypothesis. The large-scale spontaneous regeneration dominated by native endemic species appears to be a result of a combination of changes in precipitation, migration and decreased human population and livestock grazing pressure, but under conditions of maintained and well-defined property rights. Our study emphasizes the large capacity of a semi-arid system to spontaneously regenerate, triggered by decreased pressures, but where existing social institutions mitigate other drivers of deforestation and alternative land-use.	[Elmqvist, Thomas; Pyykonen, Markku; Tengo, Maria] Stockholm Univ, Dept Syst Ecol, S-10691 Stockholm, Sweden; [Elmqvist, Thomas] Stockholm Resilience Ctr, Stockholm, Sweden; [Rakotondrasoa, Fanambinantsoa; Rabakonandrianina, Elisabeth] Univ Antananarivo, Dept Biol & Plant Ecol, Antananarivo, Madagascar; [Radimilahy, Chantal] Univ Antananarivo, Museum Art & Archaeol, Antananarivo, Madagascar	Stockholm University; Stockholm University; University Antananarivo; University Antananarivo	Elmqvist, T (corresponding author), Stockholm Univ, Dept Syst Ecol, S-10691 Stockholm, Sweden.	thomase@ecology.su.se	Elmqvist, Thomas/AAY-6344-2021; Tengö, Maria/AAC-5698-2020	Elmqvist, Thomas/0000-0002-4617-6197; Tengö, Maria/0000-0002-4776-3748	Sida/Sarec; Formas	Sida/Sarec; Formas(Swedish Research Council Formas)	Grant from Sida/Sarec and Formas. No role in design and conduct of the study.	Achard F, 2002, SCIENCE, V297, P999, DOI 10.1126/science.1070656; Barrett CB, 2001, BIOSCIENCE, V51, P497, DOI 10.1641/0006-3568(2001)051[0497:CTBAWI]2.0.CO;2; BATTISTINI R, 1972, BIOGEOGRAPHY ECOLOGY; Bawa KS, 1998, CONSERV BIOL, V12, P46, DOI 10.1046/j.1523-1739.1998.96480.x; Berkes F., 2003, NAVIGATING SOCIAL EC, V1, P30; Berkes F., 1998, LINKING SOCIAL ECOLO, DOI DOI 10.1017/CBO9780511541957; BERTRAND A, 1999, GESTION CONTRACTUELL; Brown KA, 2004, P NATL ACAD SCI USA, V101, P6045, DOI 10.1073/pnas.0401456101; Casse T, 2004, FOREST POLICY ECON, V6, P33, DOI 10.1016/S1389-9341(02)00084-9; Chazdon RL, 1998, SCIENCE, V281, P1295, DOI 10.1126/science.281.5381.1295; Clark CD, 1998, INT J REMOTE SENS, V19, P1461, DOI 10.1080/014311698215298; Cohen WB, 2004, BIOSCIENCE, V54, P535, DOI 10.1641/0006-3568(2004)054[0535:LRIEAO]2.0.CO;2; Dewar RE, 1999, J CLIMATE, V12, P3457, DOI 10.1175/1520-0442(1999)012<3457:GPOIRV>2.0.CO;2; Dietz T, 2003, SCIENCE, V302, P1907, DOI 10.1126/science.1091015; Dunn RR, 2004, CONSERV BIOL, V18, P302, DOI 10.1111/j.1523-1739.2004.00151.x; ELMQVIST T, 2004, PLANT TALK, V35, P29; Fairhead J., 1996, Misreading the African landscape: society and ecology in a forest-savanna mosaic.; Fenn M, 2003, NATURAL HIST MADAGAS; Gibson C.C., 2000, PEOPLE FORESTS COMMU, P1; Gibson CC, 2005, WORLD DEV, V33, P273, DOI 10.1016/j.worlddev.2004.07.013; Grau HR, 2003, BIOSCIENCE, V53, P1159, DOI 10.1641/0006-3568(2003)053[1159:TECOSA]2.0.CO;2; GREEN GM, 1990, SCIENCE, V248, P212, DOI 10.1126/science.248.4952.212; Guariguata MR, 2001, FOREST ECOL MANAG, V148, P185, DOI 10.1016/S0378-1127(00)00535-1; HANNA SS, 1996, RIGHTS NATURE; Henderson P.A., 2003, PRACTICAL METHODS EC; Heurtebize G., 1986, HIST AFOMAROLAHY EXT; Holmgren M, 2001, ECOSYSTEMS, V4, P151, DOI 10.1007/s100210000065; Horning N.R., 2003, NATURAL HIST MADAGAS; Kaufmann J.C., 2006, CONSERV SOC, V4, P231; Kiefer R.W., 1994, REMOTE SENSING IMAGE; Koechlin J., 1972, BIOGEOGRAPHY ECOLOGY; Kull C., 2004, ISLE FIRE POLITICAL; Kvale S., 1996, INTERVIEWS INTRO QUA; Lambin EF, 2001, GLOBAL ENVIRON CHANG, V11, P261, DOI 10.1016/S0959-3780(01)00007-3; Lambin EF, 2003, ANNU REV ENV RESOUR, V28, P205, DOI 10.1146/annurev.energy.28.050302.105459; Leach M, 1999, WORLD DEV, V27, P225, DOI 10.1016/S0305-750X(98)00141-7; LOCATELLI B, 2004, TROPICAL DEFORESTATI, P135; Luck GW, 2004, P NATL ACAD SCI USA, V101, P182, DOI 10.1073/pnas.2237148100; McConnell WJ, 2002, ENVIRONMENT, V44, P10, DOI 10.1080/00139157.2002.10544685; McGarigal K., 2000, MULTIVARIATE STAT WI; Olson DM, 2002, ANN MO BOT GARD, V89, P199, DOI 10.2307/3298564; Ostrom E., 1990, GOVERNING COMMONS EV; Ostrom E, 2006, P NATL ACAD SCI USA, V103, P19224, DOI 10.1073/pnas.0607962103; Pascarella JB, 2000, ECOSYSTEMS, V3, P217, DOI 10.1007/s100210000021; RABESANDRATANA R, 1984, MADAGASCAR, P55; Raharison L.-J.R., 1997, CACHIERS SECHERESSE, V8, P129; Ramirez OA, 2002, ENVIRON RESOUR ECON, V21, P23, DOI 10.1023/A:1014533310664; Richard AF, 2002, J ZOOL, V256, P421, DOI 10.1017/S0952836902000468; Rouse Jr. J.W., 1974, MONITORING VERNAL AD; Rudel TK, 2005, GLOBAL ENVIRON CHANG, V15, P23, DOI 10.1016/j.gloenvcha.2004.11.001; *SAP, 2002, DONN STRUCT CONC SEC; Seddon N, 2000, ORYX, V34, P287, DOI 10.1017/S0030605300031355; SHEPERD G, 1992, MANAGING AFRICAS TRO; Silver WL, 1996, CONSERV BIOL, V10, P17, DOI 10.1046/j.1523-1739.1996.10010017.x; Sussman Robert W., 2003, Primate Conservation, V19, P32; SUSSMAN RW, 1994, HUM ECOL, V22, P333, DOI 10.1007/BF02168856; SUSSMAN RW, 1994, BIOTROPICA, V26, P241, DOI 10.2307/2388845; Swift J., 1996, The lie of the land: challenging received wisdom on the African environment., P73; Tengo M., 2004, THESIS STOCKHOLM U S; Tiffen M., 1994, MORE PEOPLE LESS ERO; Tucker C., 2005, CONSERV SOC, V3, P174; Turner IM, 1996, TRENDS ECOL EVOL, V11, P330, DOI 10.1016/0169-5347(96)10046-X; Watson RT, 2000, LAND USE LAND USE CH; WESTOBY M, 1989, J RANGE MANAGE, V42, P266, DOI 10.2307/3899492; Willis KJ, 2004, SCIENCE, V304, P402, DOI 10.1126/science.1093991	65	55	55	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e402	10.1371/journal.pone.0000402	http://dx.doi.org/10.1371/journal.pone.0000402			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476324	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445700004
J	Pinyol, R; Haeckel, A; Ritter, A; Qualmann, B; Kessels, MM				Pinyol, Roser; Haeckel, Akvile; Ritter, Anett; Qualmann, Britta; Kessels, Michael Manfred			Regulation of N-WASP and the Arp2/3 Complex by Abp1 Controls Neuronal Morphology	PLOS ONE			English	Article							ALDRICH-SYNDROME PROTEIN; ACTIN-DEPOLYMERIZING PROTEIN; BINDING-PROTEIN; MEDIATED ENDOCYTOSIS; SYNDAPIN-I; CYTOSKELETON; ACTIVATION; WAVE; LINKS; REARRANGEMENT	Polymerization and organization of actin filaments into complex superstructures is indispensable for structure and function of neuronal networks. We here report that knock down of the F-actin-binding protein Abp1, which is important for endocytosis and synaptic organization, results in changes in axon development virtually identical to Arp2/3 complex inhibition, i.e., a selective increase of axon length. Our in vitro and in vivo experiments demonstrate that Abp1 interacts directly with N-WASP, an activator of the Arp2/3 complex, and releases the autoinhibition of N-WASP in cooperation with Cdc42 and thereby promotes N-WASP-triggered Arp2/3 complex-mediated actin polymerization. In line with our mechanistical studies and the colocalization of Abp1, N-WASP and Arp2/3 at sites of actin polymerization in neurons, we reveal an essential role of Abp1 and its cooperativity with Cdc42 in N-WASP-induced rearrangements of the neuronal cytoskeleton. We furthermore show that introduction of N-WASP mutants lacking the ability to bind Abp1 or Cdc42, Arp2/3 complex inhibition, Abp1 knock down, N-WASP knock down and Arp3 knock down, all cause identical neuromorphological phenotypes. Our data thus strongly suggest that these proteins and their complex formation are important for cytoskeletal processes underlying neuronal network formation.	[Pinyol, Roser; Haeckel, Akvile; Ritter, Anett; Kessels, Michael Manfred] Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, Res Grp Membrane Trafficking & Cytoskeleton, Magdeburg, Germany; [Pinyol, Roser; Haeckel, Akvile; Qualmann, Britta] Leibniz Inst Neurobiol, Res Grp Cell Biol, Magdeburg, Germany	Leibniz Institut fur Neurobiologie (LIN); Leibniz Institut fur Neurobiologie (LIN)	Kessels, MM (corresponding author), Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, Res Grp Membrane Trafficking & Cytoskeleton, Magdeburg, Germany.	kessels@ifn-magde-burg.de	Pinyol, Roser/AAA-4404-2019	Pinyol, Roser/0000-0002-0288-6314	La Caixa/DAAD; Kultusministerium Land Sachsen-Anhalt [XN3571A/0504M]; Deutsche Forschungsgemeinschaft [QU116/4-1, QU116/3-1, KE685/2-1]	La Caixa/DAAD(Deutscher Akademischer Austausch Dienst (DAAD)); Kultusministerium Land Sachsen-Anhalt; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by a La Caixa/DAAD fellowship (to RP) and the Kultusministerium Land Sachsen-Anhalt XN3571A/0504M (to BQ) as well as by Deutsche Forschungsgemeinschaft grants QU116/4-1 (to BQ), QU116/3-1 and 3-2 (to BQ and MMK) as well as KE685/2-1, 2-2 and 2-3 (to MMK).	Benesch S, 2005, J CELL SCI, V118, P3103, DOI 10.1242/jcs.02444; Braun A, 2005, MOL BIOL CELL, V16, P3642, DOI 10.1091/mbc.E05-01-0076; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Connert S, 2006, EMBO J, V25, P1611, DOI 10.1038/sj.emboj.7601053; D'Agostino JL, 2005, GENETICS, V171, P35, DOI 10.1534/genetics.105.040634; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Dillon C, 2005, ANNU REV NEUROSCI, V28, P25, DOI 10.1146/annurev.neuro.28.061604.135757; Fucini RV, 2002, MOL BIOL CELL, V13, P621, DOI 10.1091/mbc.01-11-0547; Fukuoka M, 2001, J CELL BIOL, V152, P471, DOI 10.1083/jcb.152.3.471; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Innocenti M, 2005, NAT CELL BIOL, V7, P969, DOI 10.1038/ncb1304; Kakimoto T, 2006, J BIOL CHEM, V281, P29042, DOI 10.1074/jbc.M604025200; Kaksonen M, 2005, CELL, V123, P305, DOI 10.1016/j.cell.2005.09.024; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Merrifield CJ, 2004, EUR J CELL BIOL, V83, P13, DOI 10.1078/0171-9335-00356; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Mise-Omata S, 2003, BIOCHEM BIOPH RES CO, V301, P704, DOI 10.1016/S0006-291X(02)02972-8; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Otsuki M, 2003, J BIOL CHEM, V278, P6461, DOI 10.1074/jbc.M207433200; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2004, J NEUROSCI, V24, P2481, DOI 10.1523/JNEUROSCI.5479-03.2004; Qualmann B, 2002, INT REV CYTOL, V220, P93; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; QUALMANN B, 2003, REGULATION ENDOCYTIC; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Soulard A, 2002, MOL CELL BIOL, V22, P7889, DOI 10.1128/MCB.22.22.7889-7906.2002; Steffen A, 2006, MOL BIOL CELL, V17, P2581, DOI 10.1091/mbc.E05-11-1088; Stradal TEB, 2004, TRENDS CELL BIOL, V14, P303, DOI 10.1016/j.tcb.2004.04.007; Strasser GA, 2004, NEURON, V43, P81, DOI 10.1016/j.neuron.2004.05.015; Suetsugu S, 2003, INT REV CYTOL, V229, P245, DOI 10.1016/S0074-7696(03)29006-9; Takenawa T, 2001, J CELL SCI, V114, P1801; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; WELCH MD, 2002, BIOCHEM J, V371, P233; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076	46	65	68	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e400	10.1371/journal.pone.0000400	http://dx.doi.org/10.1371/journal.pone.0000400			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476322	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445700002
J	Li, W; Xiao, C; Vonderhaar, BK; Deng, CX				Li, W.; Xiao, C.; Vonderhaar, B. K.; Deng, C-X			A role of estrogen/ER alpha signaling in BRCA1-associated tissue-specific tumor formation	ONCOGENE			English	Article						ERK1/2; cyclin D1; ER alpha; BRCA1; mammary tumors	BREAST-CANCER; CELL-CYCLE; BRCA2 MUTATIONS; OVARIAN-CANCER; RECEPTOR; SUSCEPTIBILITY; WOMEN; MICE; TUMORIGENESIS; OOPHORECTOMY	Estrogen and its receptor alpha (ER alpha) have been implicated in the tissue-specific tumorigenesis associated with BRCA1 mutations. However, the majority of breast cancers developed in human BRCA1 mutation carriers are ER alpha-negative, challenging the link between BRCA1 and estrogen/ER alpha in breast cancer formation. Using a mouse model lacking the full-length form of BRCA1, here we show that ERa is highly expressed in the premalignant mammary gland and initiation stages of tumorigenesis, although its expression is gradually diminished during mammary tumor progression. We demonstrate that the absence of full-length BRCA1 increases sensitivity of cells to estrogen-induced extracellular signal-regulated kinase 1/2 phosphorylation and cyclin D1 expression. The absence of BRCA1 turns the proliferation of ER alpha-positive cells from a paracrine fashion to an autocrine or endocrine fashion. Consequently, BRCA1-mutant cells are sensitized to estrogen-induced cell proliferation in vitro and mammary tumorigenesis in vivo. These findings illustrate a molecular mechanism for estrogen/ER alpha signals in BRCA1-associated tissue-specific tumor formation, and identify several key elements in the estrogen/ER alpha-signaling cascade that can serve as potential therapeutic targets for BRCA1-associated tumorigenesis.	Natl Inst Hlth, NIDDK, Genet Dev & Dis Branch, Bethesda, MD 20892 USA; Natl Inst Hlth, Natl Canc Inst, Mammary Biol & Tumorigen Lab, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX (corresponding author), Natl Inst Hlth, NIDDK, Genet Dev & Dis Branch, 10-9N105, 10 Ctr Dr, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		NATIONAL CANCER INSTITUTE [ZIABC008226, Z01BC008226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056008] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003; Bachelier R, 2005, ONCOL REP, V14, P1117; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Calderon-Margalit R, 2004, INT J CANCER, V112, P357, DOI 10.1002/ijc.20429; Chodankar R, 2005, CURR BIOL, V15, P561, DOI 10.1016/j.cub.2005.01.052; Clarke RB, 1997, CANCER RES, V57, P4987; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082; Eisinger F, 1999, CANCER-AM CANCER SOC, V85, P2291, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2291::AID-CNCR26>3.0.CO;2-9; Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492; Hu YF, 2005, ONCOGENE, V24, P8343, DOI 10.1038/sj.onc.1208985; Huo ZM, 2002, RADIOLOGY, V225, P519, DOI 10.1148/radiol.2252010845; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Lane D., 1995, COMPLEXITY, V1, P9; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 2003, TRENDS GENET, V19, P312, DOI 10.1016/S0168-9525(03)00110-0; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Trauernicht Amy M, 2003, Breast Dis, V18, P11; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	34	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7204	7212		10.1038/sj.onc.1210527	http://dx.doi.org/10.1038/sj.onc.1210527			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17496925				2022-12-25	WOS:000250955600004
J	Sexton, A; McDonald, M; Cayla, C; Thiemermann, C; Ahluwalia, A				Sexton, Alison; McDonald, Michelle; Cayla, Cecile; Thiemermann, Chris; Ahluwalia, Amrita			12-Lipoxygenase-derived eicosanoids protect against myocardial ischemia/reperfusion injury via activation of neuronal TRPV1	FASEB JOURNAL			English	Article						coronary vasodilation; channel activation; capsaicin receptor	GENE-RELATED PEPTIDE; IMPAIRS POSTISCHEMIC RECOVERY; ISOLATED RAT HEARTS; ARACHIDONIC-ACID; VANILLOID RECEPTOR; CORONARY VASODILATION; CAPSAICIN RECEPTORS; REPERFUSION INJURY; SENSORY NEURONS; PAIN PATHWAY	Recent evidence implicates the neuronal transient receptor potential vanilloid receptor 1 ( TRPV1), expressed on sensory C- fibers, as playing an important endogenous protective role in limiting the damaging effects of myocardial I/ R injury. In neurons the 12- lipoxygenase ( 12- LOX) arachidonic acid ( AA) metabolite, 12( S)- HpETE, has been proposed as the endogenous ligand for TRPV1. However, whether 12( S)- HpETE underlies TRPV1 channel activation during I/ R is unknown. Treatment of isolated Langendorff rat hearts with a 12- LOX/ AA cocktail significantly attenuated I/ R injury ( similar to 40% inhibition of infarct size), an effect reversed by the 12- LOX inhibitor baicalein or after chemical desensitization of local sensory C- fiber afferents using capsaicin. Both 12( S)- HpETE and AA caused dose- dependent coronary vasodilatation ( similar to EC50s of 6 X 10 - 19 and 1 X 10 - 7, respectively) that was profoundly suppressed by the TRPV1 antagonist capsazepine, in hearts of TRPV1 knockout mice compared with wild- type mice, or by treatment with a CGRP antagonist. In addition, I/ R itself stimulates up- regulation of TRPV1 expression in both the cell bodies located within the dorsal root ganglia and locally within the myocardium. Together, our data identify a novel 12- LOX/ AA/ TRPV1 pathway activated and up- regulated during I/ R injury, providing an endogenous damage- limiting mechanism whose targeting may prove useful in treating myocardial infarction.	Queen Mary Univ London, Barts & London Med Sch, William Harvey Res Inst, London EC1M 6BQ, England	University of London; Queen Mary University London	Ahluwalia, A (corresponding author), Queen Mary Univ London, Barts & London Med Sch, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	a.ahluwalia@qmul.ac.uk		AHLUWALIA, Amrita/0000-0001-7626-6399; Goddard, Alison/0000-0003-1916-4737; Thiemermann, Christoph/0000-0003-4228-9722				Amaya F, 2003, BRAIN RES, V963, P190, DOI 10.1016/S0006-8993(02)03972-0; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Biro T, 2006, J INVEST DERMATOL, V126, P1909, DOI 10.1038/sj.jid.5700321; Carlton SM, 2001, NEUROSCI LETT, V310, P53, DOI 10.1016/S0304-3940(01)02093-6; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chai WX, 2006, EUR J PHARMACOL, V531, P246, DOI 10.1016/j.ejphar.2005.12.039; Chang YZ, 2000, J PHARMACOL EXP THER, V294, P147; Chen W, 1999, AM J PHYSIOL-HEART C, V276, pH2094, DOI 10.1152/ajpheart.1999.276.6.H2094; CHIBA T, 1989, AM J PHYSIOL, V256, pE331, DOI 10.1152/ajpendo.1989.256.2.E331; Cortright DN, 2004, EUR J BIOCHEM, V271, P1814, DOI 10.1111/j.1432-1033.2004.04082.x; EMONDSALT X, 1993, EUR J PHARMACOL, V250, P403, DOI 10.1016/0014-2999(93)90027-F; Faraci FM, 2001, AM J PHYSIOL-REG I, V281, pR246, DOI 10.1152/ajpregu.2001.281.1.R246; Gabel SA, 2001, AM J PHYSIOL-HEART C, V280, pH1963, DOI 10.1152/ajpheart.2001.280.5.H1963; GAMSE R, 1982, N-S ARCH PHARMACOL, V320, P205, DOI 10.1007/BF00510129; GRYGLEWSKI R, 1972, BRIT J PHARMACOL, V46, P449, DOI 10.1111/j.1476-5381.1972.tb08142.x; HOLZER P, 1991, PHARMACOL REV, V43, P143; Hoover DB, 2000, JPN J PHARMACOL, V84, P367, DOI 10.1254/jjp.84.367; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Kallner G, 1998, J CARDIOVASC PHARM, V32, P500, DOI 10.1097/00005344-199809000-00023; Kaplan BB, 2004, ANN NY ACAD SCI, V1018, P244, DOI 10.1196/annals.1296.029; Koenig E, 2000, J NEUROSCI, V20, P8390, DOI 10.1523/JNEUROSCI.20-22-08390.2000; Li YJ, 1996, EUR J PHARMACOL, V311, P163, DOI 10.1016/0014-2999(96)00426-8; MAGGI CA, 1995, PROG NEUROBIOL, V45, P1, DOI 10.1016/0301-0082(94)E0017-B; MAGGI CA, 1988, NEUROSCIENCE, V26, P233, DOI 10.1016/0306-4522(88)90140-6; McLean PG, 2002, CIRC RES, V90, P465, DOI 10.1161/hh0402.105372; McLean PG, 1999, BRIT J PHARMACOL, V128, P275, DOI 10.1038/sj.bjp.0702743; Miller AW, 2003, J PHARMACOL EXP THER, V304, P139, DOI 10.1124/jpet.102.041780; Moens AL, 2005, INT J CARDIOL, V100, P179, DOI 10.1016/j.ijcard.2004.04.013; MURPHY E, 1995, CIRC RES, V76, P457, DOI 10.1161/01.RES.76.3.457; Nishiyama M, 1998, EUR J PHARMACOL, V341, P57, DOI 10.1016/S0014-2999(97)01353-8; PREIBISZ JJ, 1993, AM J HYPERTENS, V6, P434, DOI 10.1093/ajh/6.5.434; Rubino A, 1996, CARDIOVASC RES, V31, P467; Schicho R, 2004, EUR J NEUROSCI, V19, P1811, DOI 10.1111/j.1460-9568.2004.03290.x; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Starkopf J, 1998, CARDIOVASC RES, V37, P66, DOI 10.1016/S0008-6363(97)00240-X; Strecker T, 2005, CARDIOVASC RES, V65, P405, DOI 10.1016/j.cardiores.2004.10.013; Tohda C, 2001, J NEUROCHEM, V76, P1628, DOI 10.1046/j.1471-4159.2001.00193.x; USTINOVA EE, 1995, CARDIOVASC RES, V30, P55, DOI 10.1016/0008-6363(95)00010-0; Verma S, 2002, CIRCULATION, V105, P2332, DOI 10.1161/01.CIR.0000016602.96363.36; Wang DH, 2005, ACTA PHARMACOL SIN, V26, P286, DOI 10.1111/j.1745-7254.2005.00057.x; Wang LH, 2005, CIRCULATION, V112, P3617, DOI 10.1161/CIRCULATIONAHA.105.556274; Webb A, 2004, P NATL ACAD SCI USA, V101, P13683, DOI 10.1073/pnas.0402927101; Wolfrum S, 2005, REGUL PEPTIDES, V127, P217, DOI 10.1016/j.regpep.2004.12.008; Yellon DM, 2000, HEART, V83, P381, DOI 10.1136/heart.83.4.381; Zink MH, 2001, AM J PHYSIOL-HEART C, V280, pH693, DOI 10.1152/ajpheart.2001.280.2.H693	47	57	63	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2695	2703		10.1096/fj.06-7828com	http://dx.doi.org/10.1096/fj.06-7828com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17470568				2022-12-25	WOS:000249237500011
J	Takaine, M; Mabuchi, I				Takaine, Masak; Mabuchi, Issei			Properties of actin from the fission yeast Schizosaccharomyces pombe and interaction with fission yeast profilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; F-ACTIN; ARP2/3 COMPLEX; DICTYOSTELIUM-DISCOIDEUM; CAPPING PROTEIN; DEPOLYMERIZING PROTEIN; MODULATING PROTEINS; THIN-FILAMENTS; FORMIN CDC12P; MYOSIN-I	The fission yeast Schizosaccharomyces pombe serves as a model system for studying role of actin cytoskeleton, since it has simple actin cytoskeletons and is genetically tractable. In contrast, biochemical approaches using this organism are still developing; fission yeast actin has so far not been isolated in its native form and characterized, and therefore, biochemical assays of fission yeast actin-binding proteins (ABPs) or myosin have been performed using rabbit skeletal muscle actin that may interact with the fission yeast ABPs in a manner different from fission yeast actin. Here, we report a novel method for isolating functionally active actin from fission yeast cells. The highly purified fission yeast actin polymerized with kinetics somewhat different from those of muscle actin and forms filaments that are structurally indistinguishable from skeletal muscle actin filaments. The fission yeast actin was a significantly weaker activator of Mg2+-ATPase of HMM of skeletal muscle myosin than muscle actin. The fission yeast profilin Cdc3 suppressed polymerization of fission yeast actin more effectively than that of muscle actin and showed an affinity for fission yeast actin higher than for muscle actin. The establishment of purification of fission yeast actin will enable reconstruction of physiologically relevant interactions between the actin and fission yeast ABPs or myosins and contribute to clarification of function of actin cytoskeleton in various cellular activities.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Div Biol,Meguro Ku, Tokyo 1538902, Japan	University of Tokyo; University of Tokyo	Mabuchi, I (corresponding author), Gakushuin Univ, Sch Sci, Inst Biomol Sci, Dept Chem,Toshima Ku, 1-5-1 Mejiro, Tokyo 1718588, Japan.	issei.mabuchi@gakushuin.ac.jp	Takaine, Masakatsu/U-1277-2019	Takaine, Masakatsu/0000-0002-1279-9505				Arai R, 2002, J CELL SCI, V115, P887; Arai R, 1998, EUR J CELL BIOL, V76, P288, DOI 10.1016/S0171-9335(98)80007-1; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BOOYSE FM, 1973, J BIOL CHEM, V248, P4083; BRENNER SL, 1979, J BIOL CHEM, V254, P9982; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; CHANG F, 1997, J CELL BIOL, V137, P69; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; CRAIG R, 1980, J MOL BIOL, V140, P35, DOI 10.1016/0022-2836(80)90355-1; De La Cruz EM, 1996, BIOCHEMISTRY-US, V35, P14054, DOI 10.1021/bi961047t; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; GORDON DJ, 1977, J BIOL CHEM, V252, P8300; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; Hanson J., 1963, Journal of Molecular Biology, V6, P46; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Kim E, 1996, BIOCHEMISTRY-US, V35, P16566, DOI 10.1021/bi9623892; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Kovar DR, 2005, MOL BIOL CELL, V16, P2313, DOI 10.1091/mbc.E04-09-0781; KRON SJ, 1992, P NATL ACAD SCI USA, V89, P4466, DOI 10.1073/pnas.89.10.4466; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL AA, 1985, J BIOL CHEM, V260, P132; Lee WL, 2000, J CELL BIOL, V151, P789, DOI 10.1083/jcb.151.4.789; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Lindberg U, 1979, Methods Achiev Exp Pathol, V8, P143; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; LOAD M, 2004, J CELL BIOL, V167, P315; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu J, 2001, MOL BIOL CELL, V12, P1161, DOI 10.1091/mbc.12.4.1161; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MABUCHI I, 1985, J CELL BIOL, V100, P375, DOI 10.1083/jcb.100.2.375; MABUCHI I, 1982, J BIOCHEM-TOKYO, V92, P1439, DOI 10.1093/oxfordjournals.jbchem.a134068; MABUCHI I, 1982, BIOMED RES-TOKYO, V3, P465, DOI 10.2220/biomedres.3.465; MABUCHI I, 1980, J BIOCHEM-TOKYO, V87, P785, DOI 10.1093/oxfordjournals.jbchem.a132808; MABUCHI I, 1981, BIOMED RES, V1, P417; MARKS J, 1985, EUR J CELL BIOL, V39, P27; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; MERTINS P, 1987, NUCLEIC ACIDS RES, V15, P7369, DOI 10.1093/nar/15.18.7369; Morrell JL, 1999, MOL BIOL CELL, V10, P4201, DOI 10.1091/mbc.10.12.4201; Mossakowska M, 1996, J MUSCLE RES CELL M, V17, P383, DOI 10.1007/BF00123355; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Nakano K, 2006, MOL BIOL CELL, V17, P1933, DOI 10.1091/mbc.E05-09-0900; Nakano K, 2001, MOL BIOL CELL, V12, P3515, DOI 10.1091/mbc.12.11.3515; NEFSKY B, 1992, EUR J BIOCHEM, V206, P949, DOI 10.1111/j.1432-1033.1992.tb17005.x; Nitsch M, 1998, NAT STRUCT BIOL, V5, P855, DOI 10.1038/2296; OBRIEN EJ, 1975, J MOL BIOL, V99, P461, DOI 10.1016/S0022-2836(75)80138-0; Oda T, 2005, BIOPHYS J, V88, P2727, DOI 10.1529/biophysj.104.047753; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKAMOTO Y, 1985, J BIOCHEM-TOKYO, V98, P1143, DOI 10.1093/oxfordjournals.jbchem.a135365; Orlova A, 1997, J MOL BIOL, V271, P235, DOI 10.1006/jmbi.1997.1163; OZAKI K, 1984, J CELL BIOL, V98, P1919, DOI 10.1083/jcb.98.6.1919; PERELROIZEN I, 1994, BIOCHEMISTRY-US, V33, P8472, DOI 10.1021/bi00194a011; Ren HY, 1997, PLANT CELL, V9, P1445, DOI 10.1105/tpc.9.8.1445; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; Sirotkin V, 2005, J CELL BIOL, V170, P637, DOI 10.1083/jcb.200502053; SPUDICH JA, 1974, J BIOL CHEM, V249, P6013; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SPUDICH JA, 1972, COLD SPRING HARB SYM, V37, P585; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P435, DOI 10.1021/bi00350a024; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; Toya M, 2001, GENES CELLS, V6, P187, DOI 10.1046/j.1365-2443.2001.00414.x; TSENG PCH, 1982, J CELL BIOL, V94, P213, DOI 10.1083/jcb.94.1.213; UYEMURA DG, 1978, J BIOL CHEM, V253, P9088; Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0; Wen KK, 2003, J BIOL CHEM, V278, P48386, DOI 10.1074/jbc.M308980200; WOOLLEY DE, 1972, ARCH BIOCHEM BIOPHYS, V150, P519, DOI 10.1016/0003-9861(72)90070-7; YOUNG DM, 1964, J BIOL CHEM, V239, P2822; ZECHEL K, 1980, EUR J BIOCHEM, V110, P343, DOI 10.1111/j.1432-1033.1980.tb04873.x	72	17	17	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21683	21694		10.1074/jbc.M611371200	http://dx.doi.org/10.1074/jbc.M611371200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17533155	hybrid			2022-12-25	WOS:000248196800015
J	Martens, GA; Vervoort, A; Van de Casteele, M; Stange, G; Hellemans, K; Van Thi, HV; Schuit, F; Pipeleers, D				Martens, Geert A.; Vervoort, Annelies; Van de Casteele, Mark; Stange, Geert; Hellemans, Karine; Van Thi, Hong Vien; Schuit, Frans; Pipeleers, Daniel			Specificity in beta cell expression of (L)-3-Hydroxyacyl-CoA dehydrogenase, short chain, and potential role in down-regulating insulin release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE; SECRETION; OXIDATION; COA; HYPERINSULINISM; DEFICIENCY; ISLETS; ENZYME; L-3-HYDROXYACYL-COENZYME; ADAPTATION	A loss-of-function mutation of the mitochondrial beta-oxidation enzyme L-3-hydroxyacyl-CoA dehydrogenase, short chain (HADHSC), has been associated with hyperinsulinemic hypoglycemia in man. It is still unclear whether loss of glucose homeostasis in these patients (partly) results from a dysregulation of beta cells. This study examines HADHSC expression in purified rat beta cells and investigates whether its selective suppression elevates insulin release. Beta cells expressed the highest levels of HADHSC mRNA and protein of all examined tissues, including those with high rates of mitochondrial beta-oxidation. On the other hand, beta cells expressed relatively low levels of other beta-oxidation enzymes (acyl-CoA dehydrogenase short, medium, and long chain and acetyl-coenzyme A acyltransferase 2). HADHSC expression was sequence-specifically silenced by RNA interference, and the effects were examined on glucose-stimulated insulin secretion following 48-72 h of suppression. In both rat beta cells and in the beta cell line INS1 832-13, HADHSC silencing resulted in elevated insulin release at low and at high glucose concentrations, which appeared not to be caused by increased rates of glucose metabolism or an inhibition in fatty acid oxidation. These data indicate that the normal beta cell phenotype is characterized by a high expression of HADHSC and a low expression of other beta-oxidation enzymes. Down-regulation of HADHSC causes an elevated secretory activity suggesting that this enzyme protects against inappropriately high insulin levels and hypoglycemia.	Free Univ Brussels VUB, Diabet Res Ctr, B-1090 Brussels, Belgium; Free Univ Brussels ULB, Brugmann Hosp, Pediat Lab, B-1020 Brussels, Belgium; Katholieke Univ Leuven, Dept Mol Cell Biol, Gene Express Unit, B-3000 Louvain, Belgium	Vrije Universiteit Brussel; Universite Libre de Bruxelles; KU Leuven	Pipeleers, D (corresponding author), Free Univ Brussels VUB, Diabet Res Ctr, Laarbeeklaan 103, B-1090 Brussels, Belgium.	Daniel.Pipeleers@vub.ac.be	Hellemans, Karine/B-7573-2013; Martens, Geert A./F-6920-2015; Martens, Geert/ABA-6297-2020; stange, geert m/C-1092-2009	Hellemans, Karine/0000-0001-9306-4369; Martens, Geert A./0000-0003-1208-6289; Martens, Geert/0000-0003-1208-6289; stange, geert m/0000-0003-3148-1372; Pipeleers, Daniel/0000-0002-6440-2485; Van De Casteele, mark/0000-0002-8594-9260				AGREN A, 1977, DIABETES METAB, V3, P169; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; Bennett MJ, 1996, PEDIATR RES, V39, P185, DOI 10.1203/00006450-199601000-00031; Bennett MJ, 1999, PEDIATR DEVEL PATHOL, V2, P337, DOI 10.1007/s100249900132; Cavedon CT, 2005, CLIN CHEM, V51, P745, DOI 10.1373/clinchem.2004.043646; Clayton PT, 2001, BIOCHEM SOC T, V29, P298, DOI 10.1042/BST0290298; Clayton PT, 2001, J CLIN INVEST, V108, P457; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; Eaton S, 2002, PROG LIPID RES, V41, P197, DOI 10.1016/S0163-7827(01)00024-8; Gloyn AL, 2003, DIABETES, V52, P2433, DOI 10.2337/diabetes.52.9.2433; Gregersen N, 2004, EUR J BIOCHEM, V271, P470, DOI 10.1046/j.1432-1033.2003.03949.x; Gremlich S, 2005, ENDOCRINOLOGY, V146, P375, DOI 10.1210/en.2004-0667; Hardy OT, 2007, MOL ENDOCRINOL, V21, P765, DOI 10.1210/me.2006-0411; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hussain K, 2005, J PEDIATR-US, V146, P706, DOI 10.1016/j.jpeds.2005.01.032; Ivarsson R, 2005, DIABETES, V54, P2132, DOI 10.2337/diabetes.54.7.2132; Lalloyer F, 2006, DIABETES, V55, P1605, DOI 10.2337/db06-0016; Lantz KA, 2004, J CLIN INVEST, V114, P512, DOI 10.1172/JCI200421149; Lehtihet M, 2003, AM J PHYSIOL-ENDOC M, V285, pE438, DOI 10.1152/ajpendo.00057.2003; Liang X, 2001, BIOCHEM SOC T, V29, P279, DOI 10.1042/BST0290279; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; MacDonald MJ, 2007, J BIOL CHEM, V282, P6043, DOI 10.1074/jbc.M606652200; Martens GA, 2006, ENDOCRINOLOGY, V147, P5196, DOI 10.1210/en.2006-0580; Martens GA, 2005, J BIOL CHEM, V280, P20389, DOI 10.1074/jbc.M411869200; Matschinsky FM, 2002, DIABETES, V51, pS394, DOI 10.2337/diabetes.51.2007.S394; Molven A, 2004, DIABETES, V53, P221, DOI 10.2337/diabetes.53.1.221; Papeleu Peggy, 2006, Methods Mol Biol, V320, P229; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rinaldo P, 2002, ANNU REV PHYSIOL, V64, P477, DOI 10.1146/annurev.physiol.64.082201.154705; Roduit R, 2004, DIABETES, V53, P1007, DOI 10.2337/diabetes.53.4.1007; Rubi B, 2002, BIOCHEM J, V364, P219, DOI 10.1042/bj3640219; SCHUIT FC, 1991, BIOCHEM BIOPH RES CO, V178, P1182, DOI 10.1016/0006-291X(91)91017-7; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Tordjman K, 2002, J LIPID RES, V43, P936; VANSCHRAVENDIJK CFH, 1992, J BIOL CHEM, V267, P21344; Vredendaal PJCM, 1996, BIOCHEM BIOPH RES CO, V223, P718, DOI 10.1006/bbrc.1996.0961; Yuan BB, 2004, NUCLEIC ACIDS RES, V32, pW130, DOI 10.1093/nar/gkh366	41	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21134	21144		10.1074/jbc.M700083200	http://dx.doi.org/10.1074/jbc.M700083200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17491019	hybrid			2022-12-25	WOS:000248047500040
J	Andriopoulos, B; Hegedusch, S; Mangin, J; Riedel, HD; Hebling, U; Wang, J; Pantopoulos, K; Mueller, S				Andriopoulos, Bill; Hegeduesch, Stephan; Mangin, Julia; Riedel, Hans-Dieter; Hebling, Ulrike; Wang, Jian; Pantopoulos, Kostas; Mueller, Sebastian			Sustained hydrogen peroxide induces iron uptake by transferrin receptor-1 independent of the iron regulatory protein/iron-responsive element network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC VIRAL-HEPATITIS; OXIDATIVE STRESS; GENE-MUTATIONS; K562 CELLS; INFLAMMATION; TRANSLATION; ACTIVATION; PHOSPHORYLATION; METABOLISM; HEPCIDIN	Local and systemic inflammatory conditions are characterized by the intracellular deposition of excess iron, which may promote tissue damage via Fenton chemistry. Because the Fenton reactant H2O2 is continuously released by inflammatory cells, a tight regulation of iron homeostasis is required. Here, we show that exposure of cultured cells to sustained low levels of H2O2 that mimic its release by inflammatory cells leads to upregulation of transferrin receptor 1 (TfR1), the major iron uptake protein. The increase in TfR1 results in increased transferrin-mediated iron uptake and cellular accumulation of the metal. Although iron regulatory protein 1 is transiently activated by H2O2, this response is not sufficient to stabilize TfR1 mRNA and to repress the synthesis of the iron storage protein ferritin. The induction of TfR1 is also independent of transcriptional activation via hypoxia-inducible factor 1 alpha or significant protein stabilization. In contrast, pulse experiments with S-35-labeled methionine/cysteine revealed an increased rate of TfR1 synthesis in cells exposed to sustained low H2O2 levels. Our results suggest a novel mechanism of iron accumulation by sustained H2O2, based on the translational activation of TfR1, which could provide an important (patho) physiological link between iron metabolism and inflammation.	Harvard Univ, Sch Med, Beth Israel Med Ctr, Boston, MA 02115 USA; Univ Heidelberg, Salem Med Ctr, Dept Internal Med, D-69121 Heidelberg, Germany; Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Ruprecht Karls University Heidelberg; Lady Davis Institute; McGill University; McGill University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Mueller, S (corresponding author), Harvard Univ, Sch Med, Beth Israel Med Ctr, 330 Brookline Ave, Boston, MA 02115 USA.	smueller@bidmc.harvard.edu	Pantopoulos, Kostas/A-9668-2008	Pantopoulos, Kostas/0000-0002-2305-0057				BelAiba RS, 2004, BIOL CHEM, V385, P249, DOI 10.1515/BC.2004.019; Bonkovsky HL, 2003, ALCOHOL, V30, P137, DOI 10.1016/S0741-8329(03)00127-7; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; Caltagirone A, 2001, J BIOL CHEM, V276, P19738, DOI 10.1074/jbc.M100245200; CARTWRIGHT GE, 1946, J CLIN INVEST, V25, P65, DOI 10.1172/JCI101690; Casano LM, 2001, PLANT PHYSIOL, V125, P1450, DOI 10.1104/pp.125.3.1450; Cobelens PM, 2007, CELL SIGNAL, V19, P269, DOI 10.1016/j.cellsig.2006.06.009; Coronella-Wood J, 2004, J BIOL CHEM, V279, P33567, DOI 10.1074/jbc.M404013200; FREIREICH EJ, 1957, BLOOD, V12, P972, DOI 10.1182/blood.V12.11.972.972; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Haque S, 1996, HUM PATHOL, V27, P1277, DOI 10.1016/S0046-8177(96)90337-8; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HIRAYAMA M, 1993, HEPATOLOGY, V18, P874, DOI 10.1002/hep.1840180420; Kang KR, 2001, EXP MOL MED, V33, P198, DOI 10.1038/emm.2001.33; Kasvosve I, 2006, CLIN CHIM ACTA, V371, P130, DOI 10.1016/j.cca.2006.02.034; Katschinski DM, 2002, J BIOL CHEM, V277, P9262, DOI 10.1074/jbc.M110377200; Kazemi-Shirazi L, 1999, GASTROENTEROLOGY, V116, P127, DOI 10.1016/S0016-5085(99)70236-2; Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102; KONDO H, 1988, HEPATOLOGY, V8, P32, DOI 10.1002/hep.1840080108; KONIJN AM, 1994, BAIL CL HAE, V7, P829, DOI 10.1016/S0950-3536(05)80127-1; Kotamraju S, 2002, J BIOL CHEM, V277, P17179, DOI 10.1074/jbc.M111604200; LASKEY J, 1988, EXP CELL RES, V176, P87, DOI 10.1016/0014-4827(88)90123-1; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; LUCIANI N, 1995, BIOCHIMIE, V77, P182, DOI 10.1016/0300-9084(96)88123-5; MacCallum PR, 2006, J GEN VIROL, V87, P3251, DOI 10.1099/vir.0.82051-0; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; Mueller S, 2000, CANCER RES, V60, P156; Mueller S, 1997, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P338; Mueller S, 2000, FREE RADICAL BIO MED, V29, P410, DOI 10.1016/S0891-5849(00)00261-6; Mueller S, 2005, BIOFACTORS, V24, P171, DOI 10.1002/biof.5520240121; MUELLER S, 1995, J BIOLUM CHEMILUM, V10, P229, DOI 10.1002/bio.1170100406; Mueller S, 1997, BLOOD, V90, P4973, DOI 10.1182/blood.V90.12.4973.4973_4973_4978; Mueller S, 2002, METHOD ENZYMOL, V348, P324, DOI 10.1016/S0076-6879(02)48651-X; Mueller S, 2001, J BIOL CHEM, V276, P23192, DOI 10.1074/jbc.M100654200; Mueller S, 2006, GASTROENTEROLOGY, V130, P2229, DOI 10.1053/j.gastro.2006.05.006; Mutze S, 2003, J BIOL CHEM, V278, P40542, DOI 10.1074/jbc.M307159200; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; O'Loghlen A, 2003, ARCH BIOCHEM BIOPHYS, V417, P194, DOI 10.1016/S0003-9861(03)00368-0; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Piperno A, 1998, HEPATOLOGY, V28, P1105, DOI 10.1002/hep.510280427; QUASTEL MR, 1966, BLOOD-J HEMATOL, V28, P738, DOI 10.1182/blood.V28.5.738.738; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; Riedel HD, 1999, BLOOD, V94, P3915, DOI 10.1182/blood.V94.11.3915.423k27_3915_3921; Riggio O, 1997, AM J GASTROENTEROL, V92, P1298; Rost D, 2007, J HEPATOL, V46, P482, DOI 10.1016/j.jhep.2006.09.025; Roy CN, 2005, CURR OPIN HEMATOL, V12, P107, DOI 10.1097/00062752-200503000-00001; Roy CN, 2004, NAT GENET, V36, P481, DOI 10.1038/ng1350; SCHAFER KH, 1942, Z GES EXP MED, V110, P678; Shenberger JS, 2002, AM J RESP CELL MOL, V27, P250, DOI 10.1165/ajrcmb.27.2.4785; Sureda A, 2005, FREE RADICAL RES, V39, P817, DOI 10.1080/10715760500164045; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; Upton RL, 2003, EUR RESPIR J, V22, P335, DOI 10.1183/09031936.03.00075302; VOLLAND W, 1940, KLIN WOCHENSCHR, V19, P1242; Wang J, 2005, BIOCHEM J, V392, P383, DOI 10.1042/BJ20050492; Zhang AX, 1998, EMBO J, V17, P6061, DOI 10.1093/emboj/17.20.6061; [No title captured]	62	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20301	20308		10.1074/jbc.M702463200	http://dx.doi.org/10.1074/jbc.M702463200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17517884	hybrid			2022-12-25	WOS:000247819300033
J	Kitatani, K; Idkowiak-Baldys, J; Hannun, YA				Kitatani, Kazuyuki; Idkowiak-Baldys, Jolanta; Hannun, Yusuf A.			Mechanism of inhibition of sequestration of protein kinase C alpha/beta II by ceramide - Roles of ceramide-activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C alpha/beta II on threonine 638/641	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; PHOSPHOLIPASE-D; BETA-II; RECYCLING ENDOSOMES; SIGNAL-TRANSDUCTION; SR PROTEINS; IN-VIVO; DEPHOSPHORYLATION; PHOSPHORYLATION; AUTOPHOSPHORYLATION	Sustained activation of protein kinase C (PKC) isoenzymes alpha and beta II leads to their translocation to a perinuclear region and to the formation of the pericentrion, a PKC-dependent subset of recycling endosomes. In MCF-7 human breast cancer cells, the action of the PKC activator 4 beta-phorbol-12-myristate-13-acetate (PMA) evokes ceramide formation, which in turn prevents PKC alpha/beta II translocation to the pericentrion. In this study we investigated the mechanisms by which ceramide negatively regulates this translocation of PKC alpha/beta II. Upon PMA treatment, HEK-293 cells displayed dual phosphorylation of PKC alpha/beta II at carboxyl-terminal sites (Thr638/641 and Ser-657/660), whereas in MCF-7 cells PKC alpha/beta II were phosphorylated at Ser-657/660 but not Thr-638/641. Inhibition of ceramide synthesis by fumonisin B1 overcame the defect in PKC phosphorylation and restored translocation of PKC alpha/beta II to the pericentrion. To determine the involvement of ceramide-activated protein phosphatases in PKC regulation, we employed small interference RNA to silence individual Ser/Thr protein phosphatases. Knockdown of isoforms alpha or beta of the catalytic subunits of protein phosphatase 1 not only increased phosphorylation of PKC alpha/beta II at Thr-638/641 but also restored PKC alpha/beta II translocation to the pericentrion. Mutagenesis approaches in HEK-293 cells revealed that mutation of either Thr-641 or Ser-660 to Ala in PKC beta II abolished sequestration of PKC, implying the indispensable roles of phosphorylation of PKC alpha/beta II at those sites for their translocation to the pericentrion. Reciprocally, a point mutation of Thr-641 to Glu, which mimics phosphorylation, in PKC beta II overcame the inhibitory effects of ceramide on PKC translocation in PMA-stimulated MCF-7 cells. Therefore, the results demonstrate a novel role for carboxyl-terminal phosphorylation of PKC alpha/beta II in the translocation of PKC to the pericentrion, and they disclose specific regulation of PKC autophosphorylation by ceramide through the activation of specific isoforms of protein phosphatase 1.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,PO Box 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becker KP, 2005, J BIOL CHEM, V280, P2606, DOI 10.1074/jbc.M409066200; Becker KP, 2004, J BIOL CHEM, V279, P28251, DOI 10.1074/jbc.M400770200; Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chalfant CE, 2004, J LIPID RES, V45, P496, DOI 10.1194/jlr.M300347-JLR200; Chen CC, 2001, MOL PHARMACOL, V59, P493, DOI 10.1124/mol.59.3.493; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Galadari S, 2001, EXP MOL MED, V33, P240, DOI 10.1038/emm.2001.39; Garzotto M, 1998, CANCER RES, V58, P2260; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Hu TH, 2004, J BIOL CHEM, V279, P35702, DOI 10.1074/jbc.M402372200; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Idkowiak-Baldys J, 2006, J BIOL CHEM, V281, P22321, DOI 10.1074/jbc.M512540200; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; Jenkins GM, 2002, J BIOL CHEM, V277, P42572, DOI 10.1074/jbc.M207346200; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kitatani K, 2004, CELL SIGNAL, V16, P967, DOI 10.1016/j.cellsig.2004.02.003; Kitatani K, 2001, ARCH BIOCHEM BIOPHYS, V395, P208, DOI 10.1006/abbi.2001.2573; Kitatani K, 2006, J BIOL CHEM, V281, P36793, DOI 10.1074/jbc.M608137200; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kowluru A, 1997, FEBS LETT, V418, P179, DOI 10.1016/S0014-5793(97)01379-3; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lesage B, 2005, FEBS LETT, V579, P5626, DOI 10.1016/j.febslet.2005.09.033; Levade T, 2001, CIRC RES, V89, P957, DOI 10.1161/hh2301.100350; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mora A, 2002, CELL SIGNAL, V14, P557, DOI 10.1016/S0898-6568(01)00282-0; Nakamura Y, 1996, J IMMUNOL, V156, P256; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; ORR JW, 1994, J BIOL CHEM, V269, P27715; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; Prevostel C, 2000, J CELL SCI, V113, P2575; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Shanmugam M, 1999, MOL CELL ENDOCRINOL, V148, P109, DOI 10.1016/S0303-7207(98)00229-9; Suchard SJ, 1997, BLOOD, V89, P2139, DOI 10.1182/blood.V89.6.2139; Venable ME, 1996, J BIOL CHEM, V271, P24800, DOI 10.1074/jbc.271.40.24800; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	65	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20647	20656		10.1074/jbc.M609162200	http://dx.doi.org/10.1074/jbc.M609162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17504762	hybrid			2022-12-25	WOS:000247819300067
J	Kosoy, A; Calonge, TM; Outwin, EA; O'Connell, MJ				Kosoy, Ana; Calonge, Teresa M.; Outwin, Emily A.; O'Connell, Matthew J.			Fission yeast Rnf4 homologs are required for DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER PROTEIN; DAMAGE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; KINASE CHK1; RECOMBINATION; PHOSPHORYLATION; HELICASE; SNURF; CDC2	We describe two RING finger proteins in the fission yeast Schizosaccharomyces pombe, Rfp1 and Rfp2. Weshow that these proteins function redundantly in DNA repair. Rfp1 was isolated as a Chk1-interacting protein in a two-hybrid screen and has high amino acid sequence similarity to Rfp2. Deletion of either gene does not cause a phenotype, but a double deletion ( rfp1 Delta rfp2 Delta) showed poor viability and defects in cell cycle progression. These cells are also sensitive to DNA-damaging agents, although they maintained normal checkpoint signaling to Chk1. Rfp1 and Rfp2 are most closely related to human Rnf4, and we showed that Rnf4 can substitute functionally for Rfp1 and/or Rfp2. The double mutants also showed significantly increased levels of protein SUMOylation, and we identified an S. pombe Ulp2/Smt4 homolog that, when overexpressed, reduced SUMO levels and suppressed the DNA damage sensitivity of rfp1 Delta rfp2 Delta cells.	Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	O'Connell, MJ (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.	matthew.oconnell@mssm.edu			NATIONAL CANCER INSTITUTE [R01CA100076, R56CA100076] Funding Source: NIH RePORTER; NCI NIH HHS [CA 100076] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1995, J CELL SCI, V108, P475; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bylebyl GR, 2003, J BIOL CHEM, V278, P44113, DOI 10.1074/jbc.M308357200; Calonge TM, 2006, GENETICS, V174, P113, DOI 10.1534/genetics.106.060970; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; den Elzen NR, 2004, EMBO J, V23, P908, DOI 10.1038/sj.emboj.7600105; Doe CL, 2004, NUCLEIC ACIDS RES, V32, P5570, DOI 10.1093/nar/gkh853; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; Frampton J, 2006, MOL BIOL CELL, V17, P2976, DOI 10.1091/mbc.e05-11-1008; Friedberg EC, 2005, NAT REV MOL CELL BIO, V6, P943, DOI 10.1038/nrm1781; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Haghnazari E, 2004, NUCLEIC ACIDS RES, V32, P4257, DOI 10.1093/nar/gkh717; Hakli M, 2004, FEBS LETT, V560, P56, DOI 10.1016/S0014-5793(04)00070-5; Hakli M, 2001, J BIOL CHEM, V276, P23653, DOI 10.1074/jbc.M009891200; Harvey SH, 2004, MOL CELL BIOL, V24, P662, DOI 10.1128/MCB.24.2.662-674.2004; Ho JCY, 2001, NUCLEIC ACIDS RES, V29, P4179, DOI 10.1093/nar/29.20.4179; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; Jacquiau HR, 2005, J BIOL CHEM, V280, P23566, DOI 10.1074/jbc.M500947200; James P, 1996, GENETICS, V144, P1425; Krien MJE, 1998, J CELL SCI, V111, P967; Krien MJE, 2002, EMBO J, V21, P1713, DOI 10.1093/emboj/21.7.1713; Latif C, 2004, J CELL SCI, V117, P3489, DOI 10.1242/jcs.01204; Lee KM, 2006, DNA REPAIR, V5, P138, DOI 10.1016/j.dnarep.2005.08.003; LEHMANN AR, 1991, MUTAT RES, V250, P205, DOI 10.1016/0027-5107(91)90177-P; Liu HY, 2002, J BIOL CHEM, V277, P2637, DOI 10.1074/jbc.M109016200; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Lyngso C, 2000, J BIOL CHEM, V275, P26144, DOI 10.1074/jbc.M003405200; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morishita T, 2005, MOL CELL BIOL, V25, P8074, DOI 10.1128/MCB.25.18.8074-8083.2005; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Osman F, 2005, MOL CELL BIOL, V25, P8084, DOI 10.1128/MCB.25.18.8084-8096.2005; PERO R, 2001, J BIOL CHEM; Raleigh JM, 2000, J CELL SCI, V113, P1727; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Saville B, 2002, J BIOL CHEM, V277, P2485, DOI 10.1074/jbc.M109021200; Strunnikov AV, 2001, GENETICS, V158, P95; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Verkade HM, 1999, MOL BIOL CELL, V10, P2905, DOI 10.1091/mbc.10.9.2905; Verkade HM, 1998, MOL GEN GENET, V260, P426, DOI 10.1007/s004380050913; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Watts FZ, 2006, DNA REPAIR, V5, P399, DOI 10.1016/j.dnarep.2005.11.002	48	62	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20388	20394		10.1074/jbc.M702652200	http://dx.doi.org/10.1074/jbc.M702652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17502373	hybrid			2022-12-25	WOS:000247819300041
J	Cai, SQ; Sesti, F				Cai, Shi-Qing; Sesti, Federico			A new mode of regulation of N-type inactivation in a Caenorhabditis elegans voltage-gated potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-TYPE POTASSIUM; C-TYPE INACTIVATION; SHAKER K-CHANNELS; BETA-SUBUNIT; METHIONINE OXIDATION; IK(A) CHANNELS; PHOSPHORYLATION; DOMAIN; PORE; ELIMINATION	N-type inactivation in voltage-gated K+ (Kv) channels is a widespread means to modulate neuronal excitability and signaling. Here we have shown a novel mechanism of N-type inactivation in a Caenorhabditis elegans Kv channel. The N-terminal sequence of KVS-1 contains a domain of 22 amino acids that resembles the inactivation ball in A-type channels, which is preceded by a domain of eighteen amino acids. Wild type KVS-1 currents can be described as A-type; however, their kinetics are significantly ( similar to 5-fold) slower. When the putative inactivation ball is deleted, the current becomes non-inactivating. Inactivation is restored in non-inactivating channels by diffusion of the missing inactivation domain in the cytoplasm. Deletion of the domain in front of the ball speeds inactivation kinetics similar to 5-fold. We conclude that KVS-1 is the first example of a novel type of Kv channel simultaneously possessing an N-inactivating ball preceded by an N inactivation regulatory domain (NIRD) that acts to slow down inactivation through steric mechanisms.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Sesti, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.	sestife@UMDNJ.EDU			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068581] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM68581-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amberg GC, 2003, AM J PHYSIOL-CELL PH, V284, pC583, DOI 10.1152/ajpcell.00301.2002; Antz C, 1999, NAT STRUCT BIOL, V6, P146; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Cai SQ, 2005, NAT NEUROSCI, V8, P1503, DOI 10.1038/nn1557; Ciorba MA, 1999, FEBS LETT, V442, P48, DOI 10.1016/S0014-5793(98)01616-0; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; Fawcett GL, 2006, J BIOL CHEM, V281, P30725, DOI 10.1074/jbc.M605814200; Finol-Urdaneta RK, 2006, J GEN PHYSIOL, V128, P133, DOI 10.1085/jgp.200609498; HAGIWARA S, 1961, J PHYSIOL-LONDON, V155, P470, DOI 10.1113/jphysiol.1961.sp006640; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Kondoh S, 1997, J BIOL CHEM, V272, P19333, DOI 10.1074/jbc.272.31.19333; Kwak YG, 1999, J BIOL CHEM, V274, P13928, DOI 10.1074/jbc.274.20.13928; Leicher T, 1998, J BIOL CHEM, V273, P35095, DOI 10.1074/jbc.273.52.35095; Li Y, 2006, NEUROSCIENTIST, V12, P199, DOI 10.1177/1073858406287717; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; Nitabach MN, 2002, J NEUROSCI, V22, P7913; Ogielska EM, 1995, BIOPHYS J, V69, P2449, DOI 10.1016/S0006-3495(95)80114-1; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; Rasmusson RL, 1997, ADV EXP MED BIOL, V430, P29; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Roeper J, 1998, NATURE, V391, P390, DOI 10.1038/34916; RUDY B, 1988, NEURON, V1, P649, DOI 10.1016/0896-6273(88)90164-X; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; TSENGCRANK J, 1993, J GEN PHYSIOL, V102, P1057, DOI 10.1085/jgp.102.6.1057; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	38	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18597	18601		10.1074/jbc.M702079200	http://dx.doi.org/10.1074/jbc.M702079200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17488718	hybrid			2022-12-25	WOS:000247302000064
J	Sadis, C; Teske, G; Stokman, G; Kubjak, C; Claessen, N; Moore, F; Loi, P; Diallo, B; Barvais, L; Goldman, M; Florquin, S; Le Moine, A				Sadis, Claude; Teske, Gwen; Stokman, Geurt; Kubjak, Carole; Claessen, Nike; Moore, Fabrice; Loi, Patrizia; Diallo, Bilo; Barvais, Luc; Goldman, Michel; Florquin, Sandrine; Le Moine, Alain			Nicotine Protects Kidney from Renal Ischemia/Reperfusion Injury through the Cholinergic Anti-Inflammatory Pathway	PLOS ONE			English	Article								Kidney ischemia/reperfusion injury (I/R) is characterized by renal dysfunction and tubular damages resulting from an early activation of innate immunity. Recently, nicotine administration has been shown to be a powerful inhibitor of a variety of innate immune responses, including LPS-induced toxaemia. This cholinergic anti-inflammatory pathway acts via the alpha 7 nicotinic acetylcholine receptor (alpha 7nAChR). Herein, we tested the potential protective effect of nicotine administration in a mouse model of renal I/R injury induced by bilateral clamping of kidney arteries. Renal function, tubular damages and inflammatory response were compared between control animals and mice receiving nicotine at the time of ischemia. Nicotine pretreatment protected mice from renal dysfunction in a dose-dependent manner and through the alpha 7nAChR, as attested by the absence of protection in alpha 7nAChR-deficient mice. Additionally, nicotine significantly reduced tubular damages, prevented neutrophil infiltration and decreased productions of the CXC-chemokine KC, TNF-alpha and the proinflammatory high-mobility group box 1 protein. Reduced tubular damage in nicotine pre-treated mice was associated with a decrease in tubular cell apoptosis and proliferative response as attested by the reduction of caspase-3 and Ki67 positive cells, respectively. All together, these data highlight that nicotine exerts a protective anti-inflammatory effect during kidney I/R through the cholinergic alpha 7nAChR pathway. In addition, this could provide an opportunity to overcome the effect of surgical cholinergic denervation during kidney transplantation.	[Sadis, Claude; Kubjak, Carole; Moore, Fabrice; Loi, Patrizia; Goldman, Michel; Le Moine, Alain] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium; [Teske, Gwen; Stokman, Geurt; Claessen, Nike; Florquin, Sandrine] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Sadis, Claude; Barvais, Luc] Univ Libre Bruxelles, Dept Anesthesiol, Erasme Hosp, Brussels, Belgium; [Diallo, Bilo] Biovallee, Gosselies, Belgium	Universite Libre de Bruxelles; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Le Moine, A (corresponding author), Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium.	alemoine@ulb.ac.be	Florquin, Sandrine/B-8242-2012		Walloon Region; FNRS-Belgium; GlaxoSmithKline Biologicals (Rixensart, Belgium)	Walloon Region; FNRS-Belgium(Fonds de la Recherche Scientifique - FNRS); GlaxoSmithKline Biologicals (Rixensart, Belgium)(GlaxoSmithKline)	C.S. is a research fellow at the Fondation Erasme. A.L. is a Research Associate of the FNRS-Belgium. This work was funded by research grants of the Walloon Region and the FNRS-Belgium. The Institute for Medical Immunology is supported by GlaxoSmithKline Biologicals (Rixensart, Belgium) and the government of the Walloon Region.	Bonventre JV, 2004, KIDNEY INT, V66, P480, DOI 10.1111/j.1523-1755.2004.761_2.x; Boros P, 2006, AM J TRANSPLANT, V6, P652, DOI 10.1111/j.1600-6143.2005.01228.x; Crockett ET, 2006, BMC CLIN PATHOL, V6, DOI 10.1186/1472-6890-6-3; Daemen MARC, 2001, TRANSPLANTATION, V71, P1007; Dasgupta P, 2006, P NATL ACAD SCI USA, V103, P6332, DOI 10.1073/pnas.0509313103; Gill N, 2005, CHEST, V128, P2847, DOI 10.1378/chest.128.4.2847; Izuishi K, 2006, J IMMUNOL, V176, P7154, DOI 10.4049/jimmunol.176.12.7154; Joosten SA, 2005, KIDNEY INT, V68, P1, DOI 10.1111/j.1523-1755.2005.00376.x; Leemans JC, 2005, J CLIN INVEST, V115, P2894, DOI 10.1172/JCI22832; Lieberthal W, 2000, AM J PHYSIOL-RENAL, V278, pF1, DOI 10.1152/ajprenal.2000.278.1.F1; Lien YHH, 2003, LIFE SCI, V74, P543, DOI 10.1016/j.lfs.2003.08.001; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Metz CN, 2005, NAT IMMUNOL, V6, P756, DOI 10.1038/ni0805-756; Qin SX, 2006, J EXP MED, V203, P1637, DOI 10.1084/jem.20052203; Rouschop KMA, 2005, J AM SOC NEPHROL, V16, P2034, DOI 10.1681/ASN.2005010054; Saeed RW, 2005, J EXP MED, V201, P1113, DOI 10.1084/jem.20040463; Sener G, 2005, PHARMACOLOGY, V74, P37, DOI 10.1159/000083245; Serobyan N, 2005, BRIT J HAEMATOL, V129, P257, DOI 10.1111/j.1365-2141.2005.05446.x; Thomas GAO, 2005, NAT CLIN PRACT GASTR, V2, P536, DOI 10.1038/ncpgasthep0316; Toborek M, 2007, J CELL BIOCHEM, V100, P279, DOI 10.1002/jcb.21013; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Ulloa L, 2005, NAT REV DRUG DISCOV, V4, P673, DOI 10.1038/nrd1797; Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053/j.gastro.2006.02.022; van Westerloo DJ, 2005, J INFECT DIS, V191, P2138, DOI 10.1086/430323; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; YANG D, 2006, J LEUKOC BIOL; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82	31	106	117	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e469	10.1371/journal.pone.0000469	http://dx.doi.org/10.1371/journal.pone.0000469			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520028	Green Published, gold, Green Submitted			2022-12-25	WOS:000207446000017
J	Boucher, P; Li, WP; Matz, RL; Takayama, Y; Auwerx, J; Anderson, RGW; Herz, J				Boucher, Philippe; Li, Wei-Ping; Matz, Rachel L.; Takayama, Yoshiharu; Auwerx, Johan; Anderson, Richard G. W.; Herz, Joachim			LRP1 Functions as an Atheroprotective Integrator of TGF beta and PDGF Signals in the Vascular Wall: Implications for Marfan Syndrome	PLOS ONE			English	Article								Background. The multifunctional receptor LRP1 controls expression, activity and trafficking of the PDGF receptor-beta in vascular smooth muscle cells (VSMC). LRP1 is also a receptor for TGF beta 1 and is required for TGF beta mediated inhibition of cell proliferation. Methods and Principal Findings. We show that loss of LRP1 in VSMC (smLRP(-)) in vivo results in a Marfan-like syndrome with nuclear accumulation of phosphorylated Smad2/3, disruption of elastic layers, tortuous aorta, and increased expression of the TGFb target genes thrombospondin-1 (TSP1) and PDGFR beta in the vascular wall. Treatment of smLRP1(-) animals with the PPAR gamma agonist rosiglitazone abolished nuclear pSmad accumulation, reversed the Marfan-like phenotype, and markedly reduced smooth muscle proliferation, fibrosis and atherosclerosis independent of plasma cholesterol levels. Conclusions and Significance. Our findings are consistent with an activation of TGF beta signals in the LRP1-deficient vascular wall. LRP1 may function as an integrator of proliferative and anti-proliferative signals that control physiological mechanisms common to the pathogenesis of Marfan syndrome and atherosclerosis, and this is essential for maintaining vascular wall integrity.	[Boucher, Philippe; Takayama, Yoshiharu; Herz, Joachim] Univ Texas SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; [Boucher, Philippe; Matz, Rachel L.] Inst Gilbert Laustriat, UMR 7175, LC 1, Dept Pharmacol, Illkirch Graffenstaden, France; [Li, Wei-Ping; Anderson, Richard G. W.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Auwerx, Johan] Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Herz, J (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA.	joachim.herz@utsouthwestern.edu	Takayama, Yoshiharu/M-8826-2019; 黎, 伟/GXM-4040-2022; li, wj/HGD-7322-2022; Auwerx, Johan/ABE-9307-2021; Takayama, Yoshiharu/E-3662-2010	Takayama, Yoshiharu/0000-0003-4532-7114; Takayama, Yoshiharu/0000-0003-4532-7114; Auwerx, Johan/0000-0002-5065-5393; MATZ, Rachel/0000-0001-5832-7063; Boucher, Philippe/0000-0002-3928-9812	Fondation pour la Recherche Medicale, Fondation de France; Conseil Scientifique de l'Universite Louis Pasteur de Strasbourg; National Institutes of Health [HL20948, HL63762, NS43408]; Perot Family Foundation; Humboldt Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	Fondation pour la Recherche Medicale, Fondation de France(Fondation de FranceFondation pour la Recherche Medicale); Conseil Scientifique de l'Universite Louis Pasteur de Strasbourg; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Perot Family Foundation; Humboldt Foundation(Alexander von Humboldt Foundation); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from, Fondation pour la Recherche Medicale, Fondation de France, Conseil Scientifique de l'Universite Louis Pasteur de Strasbourg, the National Institutes of Health (HL20948, HL63762, NS43408), and the Perot Family Foundation. J.H. is an Established Investigator of the American Heart Association and Parke-Davis and is the recipient of a Wolfgang-Paul Award from the Humboldt Foundation. None of the sponsors has placed any restrictions on the work or its publication.	BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Boileau C, 2005, CURR OPIN CARDIOL, V20, P194, DOI 10.1097/01.hco.0000162398.21972.cd; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dietz HC, 2005, AM J MED GENET C, V139C, P4, DOI 10.1002/ajmg.c.30068; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Emonard H, 2004, J BIOL CHEM, V279, P54944, DOI 10.1074/jbc.M406792200; Fan WH, 2000, EUR J CELL BIOL, V79, P915, DOI 10.1078/0171-9335-00122; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; Gao BB, 2006, BIOCHEM J, V397, P337, DOI 10.1042/BJ20060095; Ghosh AK, 2004, ARTHRITIS RHEUM-US, V50, P1305, DOI 10.1002/art.20104; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Ikuno Y, 2002, INVEST OPHTH VIS SCI, V43, P41; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Kaartinen V, 2003, NAT GENET, V33, P331, DOI 10.1038/ng0303-331; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Mizuguchi T, 2004, NAT GENET, V36, P855, DOI 10.1038/ng1392; Morosetti R, 2004, INT J ONCOL, V25, P493; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Pannu H, 2005, CIRCULATION, V112, P513, DOI 10.1161/CIRCULATIONAHA.105.537340; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Ruiz-Ortega M, 2007, CARDIOVASC RES, V74, P196, DOI 10.1016/j.cardiores.2007.02.008; Takayama Y, 2005, J BIOL CHEM, V280, P18504, DOI 10.1074/jbc.M410265200; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; Tseng WF, 2004, FEBS LETT, V562, P71, DOI 10.1016/S0014-5793(04)00185-1; Yu Q, 2000, GENE DEV, V14, P163; Zirlik A, 2004, THROMB HAEMOSTASIS, V91, P674, DOI 10.1160/TH03-06-0384	45	93	94	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e448	10.1371/journal.pone.0000448	http://dx.doi.org/10.1371/journal.pone.0000448			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505534	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445900008
J	Maye, A; Hsieh, CH; Sugihara, G; Brembs, B				Maye, Alexander; Hsieh, Chih-Hao; Sugihara, George; Brembs, Bjoern			Order in Spontaneous Behavior	PLOS ONE			English	Article							VISUAL FLIGHT ORIENTATION; DROSOPHILA-MELANOGASTER; NONLINEAR DYNAMICS; DECISION-MAKING; TIME-SERIES; PRISONERS-DILEMMA; OPERANT-BEHAVIOR; SEARCH PATTERNS; YAW TORQUE; FRUIT-FLY	Brains are usually described as input/output systems: they transform sensory input into motor output. However, the motor output of brains (behavior) is notoriously variable, even under identical sensory conditions. The question of whether this behavioral variability merely reflects residual deviations due to extrinsic random noise in such otherwise deterministic systems or an intrinsic, adaptive indeterminacy trait is central for the basic understanding of brain function. Instead of random noise, we find a fractal order (resembling Levy flights) in the temporal structure of spontaneous flight maneuvers in tethered Drosophila fruit flies. Levy-like probabilistic behavior patterns are evolutionarily conserved, suggesting a general neural mechanism underlying spontaneous behavior. Drosophila can produce these patterns endogenously, without any external cues. The fly's behavior is controlled by brain circuits which operate as a nonlinear system with unstable dynamics far from equilibrium. These findings suggest that both general models of brain function and autonomous agents ought to include biologically relevant nonlinear, endogenous behavior-initiating mechanisms if they strive to realistically simulate biological brains or out-compete other agents.	[Brembs, Bjoern] Free Univ Berlin, Inst Biol Neurobiol, D-1000 Berlin, Germany; [Maye, Alexander] Univ Klinikum Hamburg Eppendorf, Zentrum Expt Med, Inst Neurophysiol & Pathophysiol, Hamburg, Germany; [Hsieh, Chih-Hao; Sugihara, George] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	Free University of Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of California System; University of California San Diego; Scripps Institution of Oceanography	Brembs, B (corresponding author), Free Univ Berlin, Inst Biol Neurobiol, D-1000 Berlin, Germany.	bjoern@brembs.net	Hsieh, Chih-hao/B-3797-2008; Brembs, Björn/A-9970-2008	Hsieh, Chih-hao/0000-0001-5935-7272; Brembs, Björn/0000-0001-7824-7650	DFG [BR 1893/3-2]	DFG(German Research Foundation (DFG))	Supported by the DFG (BR 1893/3-2)	Abbott A, 2007, NATURE, V445, P250, DOI 10.1038/445250a; Ashwin P, 2005, NATURE, V436, P36, DOI 10.1038/436036b; Barabasi AL, 2005, NATURE, V435, P207, DOI 10.1038/nature03459; Barinaga M, 1996, SCIENCE, V274, P344, DOI 10.1126/science.274.5286.344; Bartumeus F, 2003, P NATL ACAD SCI USA, V100, P12771, DOI 10.1073/pnas.2137243100; Bassettt DS, 2006, P NATL ACAD SCI USA, V103, P19518, DOI 10.1073/pnas.0606005103; Belanger JH, 1996, ADAPT BEHAV, V4, P217, DOI 10.1177/105971239600400302; Boeddeker N, 2005, J EXP BIOL, V208, P1563, DOI 10.1242/jeb.01558; Boeddeker N, 2003, P ROY SOC B-BIOL SCI, V270, P1971, DOI 10.1098/rspb.2003.2463; Bongard J, 2006, SCIENCE, V314, P1118, DOI 10.1126/science.1133687; Brembs B, 1996, OIKOS, V76, P14, DOI 10.2307/3545744; Brembs B, 2002, SCIENCE, V296, P1706, DOI 10.1126/science.1069434; Brembs B, 2006, LEARN MEMORY, V13, P618, DOI 10.1101/lm.318606; Brembs B, 2006, LEARN MEMORY, V13, P629, DOI 10.1101/lm.319406; Briggman KL, 2005, SCIENCE, V307, P896, DOI 10.1126/science.1103736; Brockmann D, 2006, NATURE, V439, P462, DOI 10.1038/nature04292; BULTHOFF H, 1979, NATURE, V278, P636, DOI 10.1038/278636a0; COLE BJ, 1995, ANIM BEHAV, V50, P1317, DOI 10.1016/0003-3472(95)80047-6; COX DR, 1955, J ROY STAT SOC B, V17, P129; Cox DR, 1980, MONOGRAPHS APPL PROB; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; Darbin O, 2006, BRAIN RES, V1118, P84, DOI 10.1016/j.brainres.2006.08.027; DICKINSON A, 1985, PHILOS T ROY SOC B, V308, P67, DOI 10.1098/rstb.1985.0010; Dixon PA, 1999, SCIENCE, V283, P1528, DOI 10.1126/science.283.5407.1528; Faure P, 2001, CR ACAD SCI III-VIE, V324, P773, DOI 10.1016/S0764-4469(01)01377-4; Keller EF, 2007, NATURE, V445, P603, DOI 10.1038/445603a; Franceschini N, 2007, CURR BIOL, V17, P329, DOI 10.1016/j.cub.2006.12.032; Fry SN, 2003, SCIENCE, V300, P495, DOI 10.1126/science.1081944; Frye MA, 2004, CURR OPIN NEUROBIOL, V14, P729, DOI 10.1016/j.conb.2004.10.004; Garland B., 2004, NEUROSCIENCE LAW BRA; Glimcher PW, 2005, ANNU REV PSYCHOL, V56, P25, DOI 10.1146/annurev.psych.55.090902.141429; Glimcher PW, 2004, SCIENCE, V306, P447, DOI 10.1126/science.1102566; GOTZ KG, 1964, KYBERNETIK, V2, P77, DOI 10.1007/BF00288561; GRASSBERGER P, 1983, PHYSICA D, V9, P189, DOI 10.1016/0167-2789(83)90298-1; Greene J, 2004, PHILOS T R SOC B, V359, P1775, DOI 10.1098/rstb.2004.1546; Greenspan RJ, 2005, CURR BIOL, V15, pR671, DOI 10.1016/j.cub.2005.08.018; Guo A, 1996, LEARN MEMORY, V3, P49, DOI 10.1101/lm.3.1.49; Heisenberg M, 2001, LEARN MEMORY, V8, P1, DOI 10.1101/lm.8.1.1; HEISENBERG M, 1988, J COMP PHYSIOL A, V163, P373, DOI 10.1007/BF00604013; Heisenberg M., 1993, Reviews of Oculomotor Research, V5, P265; Heisenberg M., 1994, Life Sciences Research Report, V55, P147; HEISENBERG M, 1979, J COMP PHYSIOL, V130, P113, DOI 10.1007/BF00611046; Heisenberg M., 1984, VISION DROSOPHILA GE, P1; Heisenberg W., 1930, PHYS PRINCIPLES QUAN; Hsieh CH, 2005, NATURE, V435, P336, DOI 10.1038/nature03553; Jablonski PG, 2001, BRAIN BEHAV EVOLUT, V58, P218, DOI 10.1159/000057565; Korn H, 2005, NEURON, V47, P13, DOI 10.1016/j.neuron.2005.05.019; Krechevsky I, 1937, J COMP PSYCHOL, V23, P139, DOI 10.1037/h0056131; Krichmar JL, 2005, P NATL ACAD SCI USA, V102, P2111, DOI 10.1073/pnas.0409792102; LAND MF, 1974, J COMP PHYSIOL, V89, P331, DOI 10.1007/BF00695351; Laplace P., 1825, ESSAI PHILOS PROBABI; Leopold DA, 1999, TRENDS COGN SCI, V3, P254, DOI 10.1016/S1364-6613(99)01332-7; Li JS, 2002, REV NEUROSCIENCE, V13, P31; LOWEN SB, 1991, PHYS REV A, V43, P4192, DOI 10.1103/PhysRevA.43.4192; Lowen SB, 2001, METHODS, V24, P377, DOI 10.1006/meth.2001.1207; Lum CS, 2005, J NEUROPHYSIOL, V94, P2427, DOI 10.1152/jn.00280.2005; Ma WJ, 2006, NAT NEUROSCI, V9, P1432, DOI 10.1038/nn1790; Malescio G, 2005, NATURE, V434, P1073, DOI 10.1038/4341073a; MANTEGNA RN, 1995, NATURE, V376, P46, DOI 10.1038/376046a0; Marder E, 2006, NAT REV NEUROSCI, V7, P563, DOI 10.1038/nrn1949; Martin JR, 2001, J NEUROGENET, V15, P205, DOI 10.3109/01677060109167377; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Mauk MD, 2000, NAT NEUROSCI, V3, P649, DOI 10.1038/76606; MAYER M, 1988, J COMP PHYSIOL A, V163, P389, DOI 10.1007/BF00604014; McNamara JM, 2004, NATURE, V428, P745, DOI 10.1038/nature02432; Miller G. F., 1997, MACHIAVELLIAN INTELL, P312, DOI [10.1017/CBO9780511525636.013, DOI 10.1017/CBO9780511525636.013]; Mobbs D, 2007, PLOS BIOL, V5, P693, DOI 10.1371/journal.pbio.0050103; Nepomnyashchikh VA, 2003, ADAPT BEHAV, V11, P245, DOI 10.1177/1059712303114002; Oliveira JG, 2005, NATURE, V437, P1251, DOI 10.1038/4371251a; Osborne LC, 2005, NATURE, V437, P412, DOI 10.1038/nature03961; Pavlov I.P., 1927, CONDITIONED REFLEXES; Platt ML, 2004, NAT NEUROSCI, V7, P319, DOI 10.1038/nn0404-319; Raichle ME, 2006, SCIENCE, V314, P1249, DOI 10.1126/science.1134405; Reynolds AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000354; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Schrodinger E, 1944, WHAT IS LIFE; Segev R, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.118102; Shannon C.E., 1963, MATH THEORY COMMUNIC; Shultz S, 2006, BIOL LETTERS, V2, P505, DOI 10.1098/rsbl.2006.0519; Skinner B. F, 1974, BEHAVIORISM, V1st; Smolen P, 2000, NEURON, V26, P567, DOI 10.1016/S0896-6273(00)81194-0; Stein RB, 2005, NAT REV NEUROSCI, V6, P389, DOI 10.1038/nrn1668; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; Sugihara G, 1999, P NATL ACAD SCI USA, V96, P14210, DOI 10.1073/pnas.96.25.14210; SUGIHARA G, 1990, PHILOS T R SOC B, V330, P235, DOI 10.1098/rstb.1990.0195; Tammero LF, 2002, J EXP BIOL, V205, P327; Teich MC, 2000, IEEE J SEL TOP QUANT, V6, P1450, DOI 10.1109/2944.902200; Todorov E, 2004, NAT NEUROSCI, V7, P907, DOI 10.1038/nn1309; Tu SJ, 2005, INT J MOD PHYS C, V16, P281, DOI 10.1142/S0129183105007091; vanSteveninck RRD, 1997, SCIENCE, V275, P1805, DOI 10.1126/science.275.5307.1805; Viswanathan GM, 1996, NATURE, V381, P413, DOI 10.1038/381413a0; Viswanathan GM, 1999, NATURE, V401, P911, DOI 10.1038/44831; Viswanathan GM, 2001, PHYSICA A, V295, P85, DOI 10.1016/S0378-4371(01)00057-7; Viswanathan GM, 2001, BRAZ J PHYS, V31, P102, DOI 10.1590/S0103-97332001000100018; WALES DJ, 1991, NATURE, V350, P485, DOI 10.1038/350485a0; Webb B, 2002, NATURE, V417, P359, DOI 10.1038/417359a; WOLF R, 1990, J COMP PHYSIOL A, V167, P269, DOI 10.1007/BF00188119; WOLF R, 1991, J COMP PHYSIOL A, V169, P699; [No title captured]; [No title captured]; [No title captured]; [No title captured]	102	162	162	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e443	10.1371/journal.pone.0000443	http://dx.doi.org/10.1371/journal.pone.0000443			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505542	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445900003
J	Yang, JM; Chen, YF; Tu, YY; Yen, KR; Yang, YL				Yang, Jinn-Moon; Chen, Yan-Fu; Tu, Yu-Yin; Yen, Kuei-Rong; Yang, Yun-Liang			Combinatorial Computational Approaches to Identify Tetracycline Derivatives as Flavivirus Inhibitors	PLOS ONE			English	Article							GENERIC EVOLUTIONARY METHOD; VIRUS ENVELOPE PROTEIN; WEST-NILE-VIRUS; ENCEPHALITIS-VIRUS; MOLECULAR-BIOLOGY; STRUCTURAL BASIS; NEUROVIRULENCE; EPIDEMIOLOGY; ANTIBIOTICS; INFECTIONS	Limited structural information of drug targets, cellular toxicity possessed by lead compounds, and large amounts of potential leads are the major issues facing the design-oriented approach of discovering new leads. In an attempt to tackle these issues, we have developed a process of virtual screening based on the observation that conformational rearrangements of the dengue virus envelope protein are essential for the mediation of viral entry into host cells via membrane fusion. Screening was based solely on the structural information of the Dengue virus envelope protein and was focused on a target site that is presumably important for the conformational rearrangements necessary for viral entry. To circumvent the issue of lead compound toxicity, we performed screening based on molecular docking using structural databases of medical compounds. To enhance the identification of hits, we further categorized and selected candidates according to their novel structural characteristics. Finally, the selected candidates were subjected to a biological validation assay to assess inhibition of Dengue virus propagation in mammalian host cells using a plaque formation assay. Among the 10 compounds examined, rolitetracycline and doxycycline significantly inhibited plaque formation, demonstrating their inhibitory effect on dengue virus propagation. Both compounds were tetracycline derivatives with IC(50)s estimated to be 67.1 mu M and 55.6 mu M, respectively. Their docked conformations displayed common hydrophobic interactions with critical residues that affected membrane fusion during viral entry. These interactions will therefore position the tetracyclic ring moieties of both inhibitors to bind firmly to the target and, subsequently, disrupt conformational rearrangement and block viral entry. This process can be applied to other drug targets in which conformational rearrangement is critical to function.	[Yang, Jinn-Moon; Chen, Yan-Fu; Tu, Yu-Yin; Yen, Kuei-Rong; Yang, Yun-Liang] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan; [Yang, Jinn-Moon] Natl Chiao Tung Univ, Inst Bioinformat, Hsinchu, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Yang, YL (corresponding author), Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan.	yyang@mail.nctu.edu.tw	Yang, Jinn-Moon/AAU-4400-2021; Yang, Jinn-Moon/E-8287-2011	Yang, Jinn-Moon/0000-0002-3205-4391	National Chiao Tung University [95W821]; Academia Sinica [AS91IMB7PP]; National Science Council; University System at Taiwan-Veteran General Hospital	National Chiao Tung University; Academia Sinica(Academia Sinica - Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); University System at Taiwan-Veteran General Hospital	Y.-L. Yang, Y.-Y. Tu, and K.-R. Yen, are supported by National Chiao Tung University under the MoE ATU plan, grant 95W821, and Academia Sinica under grant AS91IMB7PP. J.-M. Yang and Y.-F. Chen are both supported by the National Science Council and a grant from the University System at Taiwan-Veteran General Hospital.	[Anonymous], FIELDS VIROLOGY; Beasley DWC, 2001, VIROLOGY, V279, P447, DOI 10.1006/viro.2000.0721; Bissantz C, 2000, J MED CHEM, V43, P4759, DOI 10.1021/jm001044l; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Chiu MW, 2003, BIOCHEM BIOPH RES CO, V309, P672, DOI 10.1016/j.bbrc.2003.08.053; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; Connell SR, 2003, ANTIMICROB AGENTS CH, V47, P3675, DOI 10.1128/AAC.47.12.3675-3681.2003; Ghosh S, 2006, CURR OPIN CHEM BIOL, V10, P194, DOI 10.1016/j.cbpa.2006.04.002; Gubler DJ, 2014, DENGUE AND DENGUE HEMORRHAGIC FEVER, 2ND EDITION, P1, DOI 10.1079/9781845939649.0001; Guirakhoo F, 2004, J VIROL, V78, P9998, DOI 10.1128/JVI.78.18.9998-10008.2004; Hayes EB, 2006, ANNU REV MED, V57, P181, DOI 10.1146/annurev.med.57.121304.131418; Hurrelbrink RJ, 2001, J VIROL, V75, P7692, DOI 10.1128/JVI.75.16.7692-7702.2001; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kramer B, 1999, PROTEINS, V37, P228, DOI 10.1002/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8; Laurie ATR, 2005, BIOINFORMATICS, V21, P1908, DOI 10.1093/bioinformatics/bti315; Lee E, 1997, VIROLOGY, V232, P281, DOI 10.1006/viro.1997.8570; Leyssen P, 2000, CLIN MICROBIOL REV, V13, P67, DOI 10.1128/CMR.13.1.67-82.2000; Lyne PD, 2002, DRUG DISCOV TODAY, V7, P1047, DOI 10.1016/S1359-6446(02)02483-2; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Monath TP, 2002, J VIROL, V76, P1932, DOI 10.1128/JVI.76.4.1932-1943.2002; Orth P, 2000, NAT STRUCT BIOL, V7, P215; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Serafin IL, 2001, ARCH VIROL, V146, P2469, DOI 10.1007/s007050170017; Shen M, 2002, J MED CHEM, V45, P2811, DOI 10.1021/jm010488u; Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197; Shoichet BK, 2002, CURR OPIN CHEM BIOL, V6, P439, DOI 10.1016/S1367-5931(02)00339-3; Yang JM, 2005, J CHEM INF MODEL, V45, P1134, DOI 10.1021/ci050034w; Yang JM, 2005, PROTEINS, V59, P205, DOI 10.1002/prot.20387; Yang JM, 2004, LECT NOTES COMPUT SC, V3102, P481; Yang JM, 2004, PROTEINS, V55, P288, DOI 10.1002/prot.20035; Yang JM, 2004, J COMPUT CHEM, V25, P843, DOI 10.1002/jcc.20013	34	75	78	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e428	10.1371/journal.pone.0000428	http://dx.doi.org/10.1371/journal.pone.0000428			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17502914	Green Submitted, gold, Green Published			2022-12-25	WOS:000207445800010
J	Ebauer, M; Wachtel, M; Niggli, FK; Schaefer, BW				Ebauer, M.; Wachtel, M.; Niggli, F. K.; Schaefer, B. W.			Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR	ONCOGENE			English	Article						alveolar RMS; chimeric transcription factor; expression profiling; TFAP2B; PAX3/FKHR	PAX3-FKHR FUSION PROTEIN; ALVEOLAR RHABDOMYOSARCOMA; TRANSCRIPTION FACTOR; PAX3; MICE; TRANSLOCATION; POTENT; CELLS; MET	The chromosomal translocation t(2;13), characteristic for the aggressive childhood cancer alveolar rhabdomyosarcoma (aRMS), generates the chimeric transcription factor PAX3/FKHR with a well known oncogenic role. However, the molecular mechanisms mediating essential pathophysiological functions remain poorly defined. Here, we used comparative expression pro. ling of PAX3/FKHR silencing in vitro and PAX3/FKHR-specific gene signatures in vivo to identify physiologically important target genes. Hereby, 51 activated genes, both novel and known, were identified. We also found repression of skeletal muscle-specific genes suggesting that PAX3/FKHR blocks further differentiation of aRMS cells. Importantly, TFAP2B was validated as direct target gene mediating the anti-apoptotic function of PAX3/FKHR. Hence, we developed a pathophysiologically relevant transcriptional profile of PAX3/FKHR and identified a critical target gene for aRMS development.	Univ Zurich, Childrens Hosp, Dept Oncol, CH-8032 Zurich, Switzerland	University Children's Hospital Zurich; University of Zurich	Schaefer, BW (corresponding author), Univ Zurich, Childrens Hosp, Dept Oncol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	beat.schaefer@kispi.unizh.ch	Niggli, Felix/L-6547-2017	Niggli, Felix/0000-0002-7553-3712; Wachtel, Marco/0000-0002-6077-3692; Schafer, Beat/0000-0001-5988-2915				Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Ayyanathan K, 2000, CANCER RES, V60, P5803; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; EDELMAN GM, 1995, PHILOS T R SOC B, V349, P305, DOI 10.1098/rstb.1995.0118; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Ginsberg JP, 1998, CANCER RES, V58, P3542; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Khan J, 1998, CANCER RES, V58, P5009; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lang D, 2005, NATURE, V433, P884, DOI 10.1038/nature03292; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 2003, LAB INVEST, V83, P571, DOI 10.1097/01.LAB.0000064703.92382.50; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Tomescu O, 2004, LAB INVEST, V84, P1060, DOI 10.1038/labinvest.3700125; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Xia SJJ, 2004, ONCOGENE, V23, P6864, DOI 10.1038/sj.onc.1207850; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958	28	67	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7267	7281		10.1038/sj.onc.1210525	http://dx.doi.org/10.1038/sj.onc.1210525			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525748				2022-12-25	WOS:000250955600011
J	Zheng, S; Ei-Naggar, AK; Kim, ES; Kurie, JM; Lozano, G				Zheng, S.; Ei-Naggar, A. K.; Kim, E. S.; Kurie, J. M.; Lozano, G.			A genetic mouse model for metastatic lung cancer with gender differences in survival	ONCOGENE			English	Article						p53; K-ras; mesotheliomas	RAS ONCOGENE ACTIVATION; CLINICAL-SIGNIFICANCE; P53 GENE; MESOTHELIOMA; MUTATIONS; ADENOCARCINOMA; ABNORMALITIES; PATHOGENESIS; PROGRESSION; XENOGRAFTS	Lung cancer is a devastating disease with poor prognosis. The design of better therapies for lung cancer patients would be greatly aided by good mouse models that closely resemble the human disease. Unfortunately, current models for lung adenocarcinoma are inadequate due to the absence of metastases. In this study, we incorporated both K-ras and p53 missense mutations into the mouse genome and established a more faithful genetic model for human lung adenocarcinoma, the most common type of lung cancer. Mice with both mutations developed advanced lung adenocarcinomas that were highly aggressive and metastasized to multiple intrathoracic and extrathoracic sites in a pattern similar to that of human lung cancer. These mice also showed a gender difference in cancer-related death. Additionally, the presence of both mutations induced pleural mesotheliomas in 23% of these mice. This mouse model recapitulates the metastatic nature of human lung cancer and will be invaluable to further probe the molecular basis of metastatic lung cancer and for translational studies.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Unit 1010, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Unit 1010, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abutaily AS, 2002, J CLIN PATHOL, V55, P662, DOI 10.1136/jcp.55.9.662; Bach PB, 2003, JNCI-J NATL CANCER I, V95, P470, DOI 10.1093/jnci/95.6.470; Bain C, 2004, JNCI-J NATL CANCER I, V96, P826, DOI 10.1093/jnci/djh143; Becher O. J., 2006, CANCER RES, V66, P3358; Becher OJ, 2006, CANCER RES, V66, P3355, DOI 10.1158/0008-5472.CAN-05-3827; Belinsky SA, 2003, CANCER RES, V63, P7089; BELINSKY SA, 1993, CANCER RES, V53, P410; CASTONGUAY A, 1991, EXP LUNG RES, V17, P485, DOI 10.3109/01902149109064434; CHIBA I, 1990, ONCOGENE, V5, P1603; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HECHT SS, 1991, EXP LUNG RES, V17, P501, DOI 10.3109/01902149109064435; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jaurand MC, 2005, PATHOL BIOL, V53, P41, DOI 10.1016/j.patbio.2003.10.005; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; KERR KM, 1992, THORAX, V47, P337, DOI 10.1136/thx.47.5.337; Kitamura H, 1999, AM J CLIN PATHOL, V111, P610; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; MALKINSON AM, 1994, MOL CARCINOGEN, V10, P61, DOI 10.1002/mc.2940100202; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Olak J, 2004, J THORAC CARDIOV SUR, V128, P346, DOI 10.1016/j.jtcvs.2004.05.025; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ordonez NG, 2003, AM J SURG PATHOL, V27, P1031, DOI 10.1097/00000478-200308000-00001; Payne S, 2001, SOC SCI MED, V53, P1067, DOI 10.1016/S0277-9536(00)00402-0; Quint LE, 1996, ANN THORAC SURG, V62, P246, DOI 10.1016/0003-4975(96)00220-2; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; Sadikot RT, 1997, SOUTH MED J, V90, P1063, DOI 10.1097/00007611-199710000-00021; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sausville E.A., 2006, CANCER RES, V66; Sausville EA, 2006, CANCER RES, V66, P3351, DOI 10.1158/0008-5472.CAN-05-3627; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAMURA A, 1992, CANCER, V70, P437, DOI 10.1002/1097-0142(19920715)70:2<437::AID-CNCR2820700211>3.0.CO;2-L; Toyooka S, 2003, HUM MUTAT, V21, P229, DOI 10.1002/humu.10177; Vahakangas KH, 2001, CANCER RES, V61, P4350; Wang Y, 2006, ONCOGENE, V25, P1277, DOI 10.1038/sj.onc.1209182; Wang Y, 2006, ONCOGENE, V25, P1320, DOI 10.1038/sj.onc.1209180; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183	42	74	74	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6896	6904		10.1038/sj.onc.1210493	http://dx.doi.org/10.1038/sj.onc.1210493			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486075	Bronze			2022-12-25	WOS:000250188400005
J	Steensberg, A; Keller, C; Hillig, T; Frosig, C; Wojtaszewski, JFP; Pedersen, BK; Pilegaard, H; Sander, M				Steensberg, Adam; Keller, Charlotte; Hillig, Thore; Frosig, Christian; Wojtaszewski, Jorgen F. P.; Pedersen, Bente Klarlund; Pilegaard, Henriette; Sander, Mikael			Nitric oxide production is a proximal signaling event controlling exercise-induced mRNA expression in human skeletal muscle	FASEB JOURNAL			English	Article						interleukin; NO; AMP-activated kinase; nuclear factor kappa B	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; ALPHA-ADRENERGIC VASOCONSTRICTION; HUMAN ENDOTHELIAL-CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; INTERLEUKIN-6 RELEASE; EXHAUSTIVE EXERCISE; CYTOKINE RESPONSE; GLUCOSE-INGESTION	Previous studies have described the magnitude and time course by which several genes are regulated within exercising skeletal muscle. These include interleukin- 6 ( IL- 6), interleukin- 8 ( IL- 8), heme oxygenase1 ( HO- 1), and heat shock protein- 72 ( HSP72), which are involved in secondary signaling and preservation of intracellular environment. However, the primary signaling mechanisms coupling contraction to transcription are unknown. We hypothesized that exercise- induced nitric oxide ( NO) production is an important signaling event for IL- 6, IL- 8, HO- 1, and HSP72 expression in muscle. Twenty healthy males participated in the study. By realtime PCR, mRNA levels for 11 genes were determined in thigh muscle biopsies obtained 1) before and after 2 h knee extensor exercise without ( control) and with concomitant NO synthase inhibition ( nitro- L- arginine methyl ester, L- NAME, 5 mg center dot kg (-1)); or 2) before and after 2 h femoral artery infusion of the NO donor nitroglycerin ( NTG, 1.5 mu g center dot kg(-1) center dot min (-1)). L- NAME caused marked reductions in exercise- induced expression of 4 of 11 mRNAs including IL- 6, IL- 8, and HO- 1. IL- 6 protein release from the study leg to the circulation increased in the control but not in the L- NAME trial. NTG infusion significantly augmented expression of the mRNAs attenuated by L- NAME. These findings advance the novel concept that NO production contributes to regulation of gene expression in muscle during exercise. Subsequently, we sought evidence for involvement of AMP- activated kinase or nuclear factor kappa B, but found none.	Natl Hosp, Dept Cardiol, Copenhagen Muscle Res Ctr & Aviat Med, Dept Infect Dis,Ctr Inflammat & Metab, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Dept Mol Biol, Copenhagen, Denmark; Univ Copenhagen, Dept Exercise & Sport Sci, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen	Sander, M (corresponding author), Natl Hosp, Dept Cardiol, Copenhagen Muscle Res Ctr & Aviat Med, Dept Infect Dis,Ctr Inflammat & Metab, Sect 7522,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	sanders@dadlnet.dk	Wojtaszewski, Jørgen FP/P-6583-2014; Frøsig, Christian/A-3750-2015; Pilegaard, Henriette/M-2315-2014; Pedersen, Bente Klarlund/AGR-3217-2022	Wojtaszewski, Jørgen FP/0000-0001-9785-6830; Frøsig, Christian/0000-0001-9302-9328; Pilegaard, Henriette/0000-0002-1071-0327; Pedersen, Bente Klarlund/0000-0001-6508-6288; wojtaszewski, jorgen/0000-0001-8185-3408; Hillig, Thore/0000-0002-2085-5183				Akerstrom T, 2005, J PHYSIOL-LONDON, V563, P507, DOI 10.1113/jphysiol.2004.077610; ANDERSEN P, 1985, J APPL PHYSIOL, V59, P1647, DOI 10.1152/jappl.1985.59.5.1647; Baeza-Raja B, 2004, MOL BIOL CELL, V15, P2013, DOI 10.1091/mbc.E03-08-0585; BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; Birk JB, 2006, J PHYSIOL-LONDON, V577, P1021, DOI 10.1113/jphysiol.2006.120972; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Chan MHS, 2004, FASEB J, V18, P1785, DOI 10.1096/fj.03-1039fje; Civitarese AE, 2005, AM J PHYSIOL-ENDOC M, V289, pE1023, DOI 10.1152/ajpendo.00193.2005; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Dinenno FA, 2003, J PHYSIOL-LONDON, V553, P281, DOI 10.1113/jphysiol.2003.049940; Du JH, 2005, BIOCHEM BIOPH RES CO, V337, P1139, DOI 10.1016/j.bbrc.2005.09.174; Febbraio MA, 2003, J PHYSIOL-LONDON, V549, P607, DOI 10.1113/jphysiol.2003.042374; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Febbraio MA, 2004, DIABETES, V53, P1643, DOI 10.2337/diabetes.53.7.1643; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055, DOI 10.1152/jappl.2000.89.3.1055; Frandsen U, 2001, J PHYSIOL-LONDON, V531, P257, DOI 10.1111/j.1469-7793.2001.0257j.x; Frandsen U, 1996, BIOCHEM BIOPH RES CO, V227, P88, DOI 10.1006/bbrc.1996.1472; Grange RW, 2001, PHYSIOL GENOMICS, V5, P35, DOI 10.1152/physiolgenomics.2001.5.1.35; Haapanen N, 1997, INT J EPIDEMIOL, V26, P739, DOI 10.1093/ije/26.4.739; Hemish J, 2003, J BIOL CHEM, V278, P42321, DOI 10.1074/jbc.M308192200; Higaki Y, 2001, DIABETES, V50, P241, DOI 10.2337/diabetes.50.2.241; Hiscock N, 2004, FASEB J, V18, P992, DOI 10.1096/fj.03-1259fje; Hiscock N, 2003, AM J PHYSIOL-HEART C, V285, pH1759, DOI 10.1152/ajpheart.00150.2003; Ho RC, 2005, AM J PHYSIOL-CELL PH, V289, pC794, DOI 10.1152/ajpcell.00632.2004; Jensen L, 2004, AM J PHYSIOL-REG I, V287, pR397, DOI 10.1152/ajpregu.00071.2004; Ji LL, 2004, FASEB J, V18, P1499, DOI 10.1096/fj.04-1846com; Jorgensen SB, 2006, J PHYSIOL-LONDON, V574, P17, DOI 10.1113/jphysiol.2006.109942; Jung JE, 2004, NEUROSCI LETT, V354, P197, DOI 10.1016/j.neulet.2003.10.012; Kalra D, 2000, CIRCULATION, V102, P1302, DOI 10.1161/01.CIR.102.11.1302; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; Koulmann N, 2006, PFLUG ARCH EUR J PHY, V452, P125, DOI 10.1007/s00424-005-0030-9; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Lau KS, 2000, PHYSIOL GENOMICS, V2, P21, DOI 10.1152/physiolgenomics.2000.2.1.21; Lei BA, 2005, P NATL ACAD SCI USA, V102, P6966, DOI 10.1073/pnas.0500768102; Lundby C, 2006, EUR J APPL PHYSIOL, V96, P363, DOI 10.1007/s00421-005-0085-5; Lundby C, 2003, TOXICOLOGY, V192, P229, DOI 10.1016/S0300-483X(03)00328-7; Maass DL, 2005, CRIT CARE MED, V33, P2794, DOI 10.1097/01.CCM.0000189747.97541.59; MacDonald C, 2003, J APPL PHYSIOL, V95, P2273, DOI 10.1152/japplphysiol.00242.2003; MALYSHEV IY, 1995, FEBS LETT, V370, P159, DOI 10.1016/0014-5793(95)00801-F; Miki C, 1999, CYTOKINE, V11, P244, DOI 10.1006/cyto.1998.0419; Nieman DC, 2005, MED SCI SPORT EXER, V37, P1283, DOI 10.1249/01.mss.0000175054.99588.b1; Nieman DC, 1998, MED SCI SPORT EXER, V30, P671, DOI 10.1097/00005768-199805000-00005; NORTHOFF H, 1991, INT J SPORTS MED S1, V12, P9; Ostrowski K, 1998, J PHYSIOL-LONDON, V513, P889, DOI 10.1111/j.1469-7793.1998.889ba.x; Pae HO, 2005, ENDOCRINOLOGY, V146, P2229, DOI 10.1210/en.2004-1431; PEDERSEN BK, 2000, SCAND J MED SCI S S1, V16, P3; Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje; Pilegaard H, 2004, P NUTR SOC, V63, P221, DOI 10.1079/PNS2004345; Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Pilz RB, 2005, FRONT BIOSCI-LANDMRK, V10, P1239, DOI 10.2741/1616; Plomgaard P, 2005, EXERC IMMUNOL REV, V11, P53; Radegran G, 1999, AM J PHYSIOL-HEART C, V276, pH1951, DOI 10.1152/ajpheart.1999.276.6.H1951; Roberts CK, 1999, AM J PHYSIOL-ENDOC M, V277, pE390, DOI 10.1152/ajpendo.1999.277.2.E390; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Sander M, 1999, HYPERTENSION, V33, P937, DOI 10.1161/01.HYP.33.4.937; Silveira LR, 2003, FREE RADICAL BIO MED, V35, P455, DOI 10.1016/S0891-5849(03)00271-5; Smolka MB, 2000, AM J PHYSIOL-REG I, V279, pR1539, DOI 10.1152/ajpregu.2000.279.5.R1539; Starkie R, 2003, FASEB J, V17, P884, DOI 10.1096/fj.02-0670fje; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; Stoppani J, 2002, AM J PHYSIOL-ENDOC M, V283, pE1239, DOI 10.1152/ajpendo.00278.2002; Suzuki K, 2002, EXERC IMMUNOL REV, V8, P6; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Umansky V, 1998, EUR J IMMUNOL, V28, P2276, DOI 10.1002/(SICI)1521-4141(199808)28:08<2276::AID-IMMU2276>3.0.CO;2-H; van Hall G, 2003, J CLIN ENDOCR METAB, V88, P3005, DOI 10.1210/jc.2002-021687; Vesely MJJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1087, DOI 10.1152/ajpcell.1998.275.4.C1087; VILLARETE LH, 1995, BIOCHEM BIOPH RES CO, V211, P671, DOI 10.1006/bbrc.1995.1864; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Wojtaszewski JFP, 1997, DIABETES, V46, P1775, DOI 10.2337/diabetes.46.11.1775; Wray DW, 2004, J PHYSIOL-LONDON, V555, P545, DOI 10.1113/jphysiol.2003.054650; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	75	63	65	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2683	2694		10.1096/fj.06-7477com	http://dx.doi.org/10.1096/fj.06-7477com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17470570				2022-12-25	WOS:000249237500010
J	Sitachitta, N; Lopanik, NB; Mao, Y; Sherman, DH				Sitachitta, Namthip; Lopanik, Nicole B.; Mao, Yingqing; Sherman, David H.			Analysis of a parallel branch in the mitomycin biosynthetic pathway involving the mitN-encoded aziridine N-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYCOLATOPSIS-MEDITERRANEI S699; GENE-CLUSTER; STREPTOMYCES-VERTICILLATUS; O-METHYLTRANSFERASE; MOLECULAR ANALYSIS; KINETIC MECHANISM; ESCHERICHIA-COLI; PURIFICATION; INDOLOCARBAZOLE; ANTIBIOTICS	Mitomycin C is a natural product with potent alkylating activity, and it is an important anticancer drug and antibiotic. mitN, one of three genes with high similarity to methyltransferases, is located within the mitomycin biosynthetic gene cluster. An inframe deletion in mitN of the mitomycin biosynthetic pathway was generated in Streptomyces lavendulae to produce the DHS5373 mutant strain. Investigation of DHS5373 revealed continued production of mitomycin A and mitomycin C in addition to the accumulation of a new mitomycin analog, 9-epi-mitomycin C. The mitN gene was overexpressed in Escherichia coli, and the histidine-tagged protein (MitN) was purified to homogeneity. Reaction of 9-epi-mitomycin C with MitN in the presence of S-adenosylmethionine yielded mitomycin E showing that the enzyme functions as an aziridine N-methyltransferase. Likewise, MitN was also shown to convert mitomycin A to mitomycin F under the same reaction conditions. We conclude that MitN plays an important role in a parallel biosynthetic pathway leading to the subclass of mitomycins with 9 alpha-stereochemistry but is not involved directly in the biosynthesis of mitomycins A and C.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Minnesota, Microbiol & Biotechnol Inst, Minneapolis, MN 55455 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	Sherman, DH (corresponding author), Univ Michigan, Inst Life Sci, 210 Washtenaw Ave, Ann Arbor, MI 48109 USA.	davidhs@lsi.umich.edu			NATIONAL CANCER INSTITUTE [R01CA081172, F32CA110636] Funding Source: NIH RePORTER; NCI NIH HHS [5F32CA110636, CA/GM81172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlert J, 2002, SCIENCE, V297, P1173, DOI 10.1126/science.1072105; ANDERSON MG, 1980, J CHEM SOC CHEM COMM, P1277, DOI 10.1039/c39800001277; August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; BALTZ RH, 1980, DEV IND MICROBIOL, V21, P43; BAUER NJ, 1988, J BIOL CHEM, V263, P15619; BEZANSON GS, 1971, CAN J BIOCHEM CELL B, V49, P911, DOI 10.1139/o71-131; Bradner WT, 2001, CANCER TREAT REV, V27, P35, DOI 10.1053/ctrv.2000.0202; CARTER SK, 1979, MITOMYCIN C CURRENT; DENIS F, 1992, GENE, V111, P115, DOI 10.1016/0378-1119(92)90611-R; Dhar K, 2000, APPL ENVIRON MICROB, V66, P4877, DOI 10.1128/AEM.66.11.4877-4882.2000; Gao QJ, 2006, CHEM BIOL, V13, P733, DOI 10.1016/j.chembiol.2006.05.009; Gruschow S, 2007, J AM CHEM SOC, V129, P6470, DOI 10.1021/ja0700193; HATA T, 1956, J ANTIBIOT, V9, P141; Hong YS, 2001, BIOTECHNOL LETT, V23, P1765, DOI 10.1023/A:1012496317299; HORNEMAN.U, 1974, J AM CHEM SOC, V96, P320, DOI 10.1021/ja00808a087; HORNEMANN U, 1975, J ANTIBIOT, V28, P841, DOI 10.7164/antibiotics.28.841; HORNEMANN U, 1985, J ORG CHEM, V50, P1301, DOI 10.1021/jo00208a031; Ikeda H, 1999, P NATL ACAD SCI USA, V96, P9509, DOI 10.1073/pnas.96.17.9509; KASAI M, 1995, EXPERT OPIN THER PAT, V5, P757; KONO M, 1990, J ANTIBIOT, V43, P383, DOI 10.7164/antibiotics.43.383; KREUZMAN AJ, 1988, J BIOL CHEM, V263, P15626; LACALLE RA, 1991, GENE, V109, P55, DOI 10.1016/0378-1119(91)90588-3; Lavid N, 2002, PLANT PHYSIOL, V129, P1899, DOI 10.1104/pp.005330; LEFEMINE DV, 1962, J AM CHEM SOC, V84, P3184, DOI 10.1021/ja00875a031; MAO Y, 2000, THESIS U MINNESOTA M, P191; Mao YQ, 1999, CHEM BIOL, V6, P251, DOI 10.1016/S1074-5521(99)80040-4; Mao YQ, 1999, J BACTERIOL, V181, P2199, DOI 10.1128/JB.181.7.2199-2208.1999; MAZODIER P, 1989, J BACTERIOL, V171, P3583, DOI 10.1128/jb.171.6.3583-3585.1989; Meyers CLF, 2004, ANGEW CHEM INT EDIT, V43, P67, DOI 10.1002/anie.200352626; MORTON GO, 1970, J AM CHEM SOC, V92, P2588, DOI 10.1021/ja00711a085; NISHIKOHRI K, 1975, EUR J APPL MICROBIOL, V2, P129; Nishizawa T, 2005, J BACTERIOL, V187, P2084, DOI 10.1128/JB.187.6.2084-2092.2005; Oliynyk M, 2003, MOL MICROBIOL, V49, P1179, DOI 10.1046/j.1365-2958.2003.03571.x; Pacholec M, 2005, BIOCHEMISTRY-US, V44, P14969, DOI 10.1021/bi051599o; SHAFIEE A, 1994, EUR J BIOCHEM, V225, P755, DOI 10.1111/j.1432-1033.1994.00755.x; Spanswick VJ, 1998, GEN PHARMACOL-VASC S, V31, P539, DOI 10.1016/S0306-3623(98)00055-X; TOMASZ M, 1995, CHEM BIOL, V2, P575, DOI 10.1016/1074-5521(95)90120-5; Varoglu M, 2001, J AM CHEM SOC, V123, P6712, DOI 10.1021/ja015646l; Verweij J, 1990, Cancer Chemother Biol Response Modif, V11, P67; WAKAKI S., 1958, ANTIBIOT AND CHEMOTHER, V8, P228; Wang JH, 1999, ARCH BIOCHEM BIOPHYS, V368, P172, DOI 10.1006/abbi.1999.1304; Xu J, 2003, ARCH BIOCHEM BIOPHYS, V411, P277, DOI 10.1016/S0003-9861(03)00004-3; Zhang C, 2006, CHEMBIOCHEM, V7, P795, DOI 10.1002/cbic.200500504	43	13	14	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20941	20947		10.1074/jbc.M702456200	http://dx.doi.org/10.1074/jbc.M702456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17507379	hybrid			2022-12-25	WOS:000248047500020
J	Galloux, M; Libersou, S; Morellet, N; Bouaziz, S; Da Costa, B; Ouldali, M; Lepault, J; Delmas, B				Galloux, Marie; Libersou, Sonia; Morellet, Nelly; Bouaziz, Serge; Da Costa, Bruno; Ouldali, Malika; Lepault, Jean; Delmas, Bernard			Infectious bursal disease virus, a non-enveloped virus, possesses a capsid-associated peptide that deforms and perforates biological membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; MATURATION PROCESS; PROTEIN VP3; REOVIRUS; POLYMORPHISM; MICROSCOPY; PARTICLES; PH	Double-stranded RNA (dsRNA) virions constitute transcriptionally competent machines that must translocate across cell membranes to function within the cytoplasm. The entry mechanism of such non-enveloped viruses is not well described. Birnaviruses are unique among dsRNA viruses because they possess a single shell competent for entry. We hereby report how infectious bursal disease virus, an avian birnavirus, can disrupt cell membranes and enter into its target cells. One of its four structural peptides, pep46 (a 46-amino acid amphiphilic peptide) deforms synthetic membranes and induces pores visualized by electron cryomicroscopy, having a diameter of less than 10 nm. Using both biological and synthetic membranes, the pore-forming domain of pep46 was identified as its N terminus moiety (pep22). The N and C termini of pep22 are shown to be accessible during membrane destabilization and pore formation. NMR studies show that pep46 inserted into micelles displays a cis-trans proline isomerization at position 16 that we propose to be associated to the pore formation process. Reverse genetic experiments confirm that the amphiphilicity and proline isomerization of pep46 are both essential to the viral cycle. Furthermore, we show that virus infectivity and its membrane activity ( probably because of the release of pep46 from virions) are controlled differently by calcium concentration, suggesting that entry is performed in two steps, endocytosis followed by endosome permeabilization. Our findings reveal a possible entry pathway of infectious bursal disease virus: in endosomes containing viruses, the lowering of the calcium concentration promotes the release of pep46 that induces the formation of pores in the endosomal membrane.	INRA, Unite Virol Immunol Mol, UR892, F-78350 Jouy En Josas, France; CNRS, INRA, IFR 115, Lab Virol Mol Struct,UMR 2472,UMR 1157, F-91198 Gif Sur Yvette, France; CNRS, INSERM, Unite Pharmacol Chim Genet, U640,UMR 8151, F-75006 Paris, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); INRAE; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Lepault, J (corresponding author), INRA, Unite Virol Immunol Mol, UR892, F-78350 Jouy En Josas, France.	jean.lepault@vms.cnrs-gif.fr; bernard.delmas@jouy.inra.fr	Lepault, Jean/AAN-8859-2020; bouaziz, serge/C-1401-2014; Bouaziz, Serge/ABA-8712-2020; Ouldali, Malika/AAN-7157-2020	Bouaziz, Serge/0000-0001-7792-8307; Ouldali, Malika/0000-0002-7601-6397; morellet, nelly/0000-0001-5076-8884				ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; Agosto MA, 2006, P NATL ACAD SCI USA, V103, P16496, DOI 10.1073/pnas.0605835103; Birghan C, 2000, EMBO J, V19, P114, DOI 10.1093/emboj/19.1.114; Bong DT, 1999, CHEM BIOL, V6, P473, DOI 10.1016/S1074-5521(99)80065-9; Bottcher B, 1997, J VIROL, V71, P325; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bubeck D, 2005, NAT STRUCT MOL BIOL, V12, P615, DOI 10.1038/nsmb955; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Chandran K, 2003, TRENDS MICROBIOL, V11, P374, DOI 10.1016/S0966-842X(03)00178-1; Chevalier C, 2005, J VIROL, V79, P12253, DOI 10.1128/JVI.79.19.12253-12263.2005; Chevalier C, 2002, J VIROL, V76, P2384, DOI 10.1128/JVI.76.5.2384-2392.2002; Coulibaly F, 2005, CELL, V120, P761, DOI 10.1016/j.cell.2005.01.009; Da Costa B, 2002, J VIROL, V76, P2393, DOI 10.1128/JVI.76.5.2393-2402.2002; DELMAS B, 2005, BIRNAVIRIDAE; Gerasimenko JV, 1998, CURR BIOL, V8, P1335, DOI 10.1016/S0960-9822(07)00565-9; Gerasimenko O, 2005, CELL CALCIUM, V38, P201, DOI 10.1016/j.ceca.2005.06.025; Heldwein EE, 2006, SCIENCE, V313, P217, DOI 10.1126/science.1126548; Hogle JM, 2002, ANNU REV MICROBIOL, V56, P677, DOI 10.1146/annurev.micro.56.012302.160757; Janshoff A, 1999, BIOCHEMISTRY-US, V38, P5328, DOI 10.1021/bi982976i; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lombardo E, 1999, J VIROL, V73, P6973, DOI 10.1128/JVI.73.8.6973-6983.1999; LUZZATI V, 1968, NATURE, V217, P1028, DOI 10.1038/2171028a0; Maia LF, 2006, J BIOL CHEM, V281, P29278, DOI 10.1074/jbc.M604689200; NANDI P, 1992, J VIROL, V66, P3363, DOI 10.1128/JVI.66.6.3363-3367.1992; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pous J, 2005, J GEN VIROL, V86, P2339, DOI 10.1099/vir.0.80942-0; Roche S, 2006, SCIENCE, V313, P187, DOI 10.1126/science.1127683; Saugar I, 2005, STRUCTURE, V13, P1007, DOI 10.1016/j.str.2005.04.012; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Tacken MGJ, 2002, J VIROL, V76, P11301, DOI 10.1128/JVI.76.22.11301-11311.2002; WERY JP, 1994, J MOL BIOL, V235, P565, DOI 10.1006/jmbi.1994.1014; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; Zhang L, 2006, J VIROL, V80, P12367, DOI 10.1128/JVI.01343-06	35	53	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20774	20784		10.1074/jbc.M701048200	http://dx.doi.org/10.1074/jbc.M701048200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17488723	Green Published, hybrid			2022-12-25	WOS:000247819300079
J	Watanabe, H; Shionyu, M; Kimura, T; Kimata, K; Watanabe, H				Watanabe, Hiroki; Shionyu, Masafumi; Kimura, Tomoatsu; Kimata, Koji; Watanabe, Hideto			Splicing factor 3b subunit 4 binds BMPR-IA and inhibits osteochondral cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; BONE MORPHOGENETIC PROTEINS; SPLICEOSOME-ASSOCIATED PROTEIN; ATDC5 CELLS; RECEPTOR; IDENTIFICATION; CHONDROGENESIS; DEGRADATION; SMAD2; P38	Bone morphogenetic protein (BMP)-2/4 play critical roles in early embryogenesis and skeletal development. BMP-2/4 signals conduct into cells via two types of serine/threonine kinase receptors, known as BMPR-I (IA and IB) and BMPR-II. Here we identified splicing factor 3b subunit 4 (SF3b4) as a molecule that interacts with BMPR-IA, using a yeast two-hybrid screening with a human fetal brain cDNA library. Co-immunoprecipitation/ immunoblot analysis confirmed their interaction in mammalian cells. By separation of the cell components, SF3b4 was present in the cell membrane fraction with BMPR-IA as well as in the nucleus. Overexpression of SF3b4 inhibited BMP-2-mediated osteogenic and chondrocytic differentiation of C2C12 and ATDC5 cells, respectively, and the endogenous expression level of SF3b4 decreased during differentiation in ATDC5 cells. By reporter gene assay, SF3b4 suppressed Id reporter gene activity, specific to the Smad1/5/8 pathway, but not TGF beta-mediated reporter gene activity. Biotin labeling of the cell surface proteins followed by their immunoblot revealed that SF3b4 decreased the cell surface BMPRI-A levels. Further analysis by molecular modeling of the intracellular domain of BMPR-IA, coupled with binding studies of its several mutants, indicated that the site(s) for SF3b4 binding is not directly associated with the C-terminal lobe and the activation segment. Taken together, these results suggest that SF3b4, known to be localized in the nucleus and involved in RNA splicing, binds BMPR-IA and specifically inhibits BMP-mediated osteochondral cell differentiation.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Toyama Univ, Fac Med, Dept Orthopaed Surg, Toyama 9300194, Japan; Nagahama Inst Biosci & Technol, Fac Biosci, Shiga 5260829, Japan	Aichi Medical University; University of Toyama	Watanabe, H (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	wannabee@aichi-med-u.ac.jp		Shionyu, Masafumi/0000-0002-0431-3456; Watanabe, Hideto/0000-0001-5291-0696				Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; Charng MJ, 1998, J BIOL CHEM, V273, P9365, DOI 10.1074/jbc.273.16.9365; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Isono K, 2005, GENE DEV, V19, P536, DOI 10.1101/gad.1284605; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kielkopf CL, 2004, GENE DEV, V18, P1513, DOI 10.1101/gad.1206204; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishanian TG, 2004, BIOCHEM BIOPH RES CO, V323, P91, DOI 10.1016/j.bbrc.2004.08.060; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pizette S, 2000, DEV BIOL, V219, P237, DOI 10.1006/dbio.2000.9610; RuizLozano P, 1997, DEV DYNAM, V208, P482, DOI 10.1002/(SICI)1097-0177(199704)208:4<482::AID-AJA4>3.0.CO;2-E; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Tsumaki N, 2005, CYTOKINE GROWTH F R, V16, P279, DOI 10.1016/j.cytogfr.2005.04.001; WAN M, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI DOI 10.1016/J.BBRC.2004.11.067; Warner DR, 2003, FEBS LETT, V539, P167, DOI 10.1016/S0014-5793(03)00155-8; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Zhang JW, 2005, DEV BIOL, V284, P1, DOI 10.1016/j.ydbio.2005.05.009	40	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20728	20738		10.1074/jbc.M703292200	http://dx.doi.org/10.1074/jbc.M703292200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17513295	hybrid			2022-12-25	WOS:000247819300075
J	Zoudilova, M; Kumar, P; Ge, L; Wang, P; Bokoch, GM; Defea, KA				Zoudilova, Maria; Kumar, Puneet; Ge, Lan; Wang, Ping; Bokoch, Gary M.; Defea, Kathryn A.			beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ACTIN DYNAMICS; PHOSPHATIDYLINOSITOL 3-KINASE; PARACELLULAR PERMEABILITY; FILAMENT TURNOVER; MAPK ACTIVATION; FACTOR VIIA; LIM-KINASE; ADF/COFILIN; BETA-ARRESTIN-1	beta-Arrestins are pleiotropic molecules that mediate signal desensitization, G-protein-independent signaling, scaffolding of signaling molecules, and chemotaxis. Protease-activated receptor-2 (PAR-2), a G alpha(q/11)-coupled receptor, which has been proposed as a therapeutic target for inflammation and cancer, requires the scaffolding function of beta-arrestins for chemotaxis. We hypothesized that PAR-2 can trigger specific responses by differential activation of two pathways, one through classic G alpha(q)/Ca2+ signaling and one through beta-arrestins, and we proposed that the latter involves scaffolding of proteins involved in cell migration and actin assembly. Here we demonstrate the following. (a) PAR-2 promotes beta-arrestin-dependent dephosphorylation and activation of the actin filament-severing protein (cofilin) independently of G alpha(q)/Ca2+ signaling. (b) PAR-2-evoked cofilin dephosphorylation requires both the activity of a recently identified cofilin-specific phosphatase (chronophin) and inhibition of LIM kinase ( LIMK) activity. ( c) beta-Arrestins can interact with cofilin, LIMK, and chronophin and colocalize with them in membrane protrusions, suggesting that beta-arrestins may spatially regulate their activities. These findings identify cofilin as a novel target of beta-arrestin-dependent scaffolding and suggest that many PAR-2-induced processes may be independent of G alpha(q/11)-protein coupling.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Cell Mol & Dev Biol Program, Riverside, CA 92521 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; Scripps Research Institute	Defea, KA (corresponding author), Univ Calif Riverside, Div Biomed Sci, B605 Stat Rd, Riverside, CA 92521 USA.	kathryn.defea@ucr.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428, R01GM066151] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 066151, R01 GM 44428, R01 GM066151-04, R01 GM066151] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Al-Ani B, 2002, J PHARMACOL EXP THER, V300, P702, DOI 10.1124/jpet.300.2.702; Andrianantoandro E, 2006, MOL CELL, V24, P13, DOI 10.1016/j.molcel.2006.08.006; Bailly M, 1998, EXP CELL RES, V241, P285, DOI 10.1006/excr.1998.4031; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200; Bernstein BW, 2000, CELL MOTIL CYTOSKEL, V47, P319, DOI 10.1002/1097-0169(200012)47:4<319::AID-CM6>3.0.CO;2-I; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; Bolton SJ, 2003, J LEUKOCYTE BIOL, V74, P60, DOI 10.1189/jlb.0702351; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Cenac N, 2003, J IMMUNOL, V170, P4296, DOI 10.4049/jimmunol.170.8.4296; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Chan AY, 2000, J CELL BIOL, V148, P531, DOI 10.1083/jcb.148.3.531; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; COOPER J A, 1992, P47; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; Cuffe JE, 2002, J PHYSIOL-LONDON, V539, P209, DOI 10.1113/jphysiol.2001.013159; Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Gohla A, 2002, CURR BIOL, V12, P1704, DOI 10.1016/S0960-9822(02)01184-3; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hjortoe GM, 2004, BLOOD, V103, P3029, DOI 10.1182/blood-2003-10-3417; Hunt RA, 1999, HYPERTENSION, V34, P603, DOI 10.1161/01.HYP.34.4.603; Hunton DL, 2005, MOL PHARMACOL, V67, P1229, DOI 10.1124/mol.104.006270; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; Jacob C, 2005, J BIOL CHEM, V280, P31936, DOI 10.1074/jbc.M506338200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; KUMAR P, 2007, IN PRESS AM J PHYSL; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McGuire JJ, 2004, J PHARMACOL EXP THER, V309, P1124, DOI 10.1124/jpet.103.064584; Miki Mari, 2003, Journal of Medical Investigation, V50, P95; Moffatt JD, 2002, AM J RESP CELL MOL, V26, P680, DOI 10.1165/ajrcmb.26.6.4693; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; MUKAI H, 1992, J BIOL CHEM, V267, P16237; Nagata-Ohashi K, 2004, J CELL BIOL, V165, P465, DOI 10.1083/jcb.200401136; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Stalheim L, 2005, MOL PHARMACOL, V67, P78, DOI 10.1124/mol.104.006072; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Usui I, 2004, MOL CELL BIOL, V24, P8929, DOI 10.1128/MCB.24.20.8929-8937.2004; Wang P, 2006, BIOCHEMISTRY-US, V45, P9374, DOI 10.1021/bi0602617; Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100	65	113	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20634	20646		10.1074/jbc.M701391200	http://dx.doi.org/10.1074/jbc.M701391200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17500066	hybrid			2022-12-25	WOS:000247819300066
J	Bekker-Jensen, S; Fugger, K; Danielsen, JR; Gromova, I; Sehested, M; Celis, J; Bartek, J; Lukas, J; Mailand, N				Bekker-Jensen, Simon; Fugger, Kasper; Danielsen, Jannie Rendtlew; Gromova, Irina; Sehested, Maxwell; Celis, Julio; Bartek, Jiri; Lukas, Jiri; Mailand, Niels			Human Xip1 (C2orf13) is a novel regulator of cellular responses to DNA strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FHA DOMAIN; POLYMERASE-BETA; REPAIR; XRCC1; DAMAGE; POLY(ADP-RIBOSE); CHECKPOINTS; RECOGNITION; MECHANISMS; RETENTION	DNA strand breaks arise continuously as the result of intracellular metabolism and in response to a multitude of genotoxic agents. To overcome such challenges to genomic stability, cells have evolved genome surveillance pathways that detect and repair damaged DNA in a coordinated fashion. Here we identify the previously uncharacterized human protein Xip1 (C2orf13) as a novel component of the checkpoint response to DNA strand breaks. Green fluorescent protein-tagged Xip1 was rapidly recruited to sites of DNA breaks, and this accumulation was dependent on a novel type of zinc finger motif located in the C terminus of Xip1. The initial recruitment kinetics of Xip1 closely paralleled that of XRCC1, a central organizer of single strand break (SSB) repair, and its accumulation was both delayed and sustained when the detection of SSBs was abrogated by inhibition of PARP-1. Xip1 and XRCC1 stably interacted through recognition of CK2 phosphorylation sites in XRCC1 by the Forkhead-associated (FHA) domain of Xip1, and XRCC1 was required to maintain steady-state levels of Xip1. Moreover, Xip1 was phosphorylated on Ser-116 by ataxia telangiectasia-mutated in response to ionizing radiation, further underscoring the potential importance of Xip1 in the DNA damage response. Finally, depletion of Xip1 significantly decreased the clonogenic survival of cells exposed to DNA SSB- or double strand break-inducing agents. Collectively, these findings implicate Xip1 as a new regulator of genome maintenance pathways, which may function to organize DNA strand break repair complexes at sites of DNA damage.	Inst Canc Biol, Ctr Genotox Stress Res, Danish Canc Soc, DK-2100 Copenhagen, Denmark; Inst Canc Biol, Dept Proteom Canc, Danish Canc Soc, DK-2100 Copenhagen, Denmark; Univ Hosp, Dept Pathol, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Danish Cancer Society	Lukas, J (corresponding author), Inst Canc Biol, Ctr Genotox Stress Res, Danish Canc Soc, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	jil@cancer.dk	Fugger, Kasper/J-1231-2014; Bartek, Jiri/G-5870-2014	Fugger, Kasper/0000-0001-9811-3983; Lukas, Jiri/0000-0001-9087-506X; Bekker-Jensen, Simon/0000-0002-7308-4597; Gromova, Irina/0000-0003-4357-5958				Almeida KH, 2007, DNA REPAIR, V6, P695, DOI 10.1016/j.dnarep.2007.01.009; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Brem R, 2005, NUCLEIC ACIDS RES, V33, P2512, DOI 10.1093/nar/gki543; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Caldecott KW, 2004, DNA REPAIR, V3, P875, DOI 10.1016/j.dnarep.2004.04.011; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	21	62	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19638	19643		10.1074/jbc.C700060200	http://dx.doi.org/10.1074/jbc.C700060200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17507382	hybrid			2022-12-25	WOS:000247650600038
J	Reyes-Moreno, C; Sharif-Askari, E; Girouard, J; Leveille, C; Jundi, M; Akoum, A; Lapointe, R; Darveau, A; Mourad, W				Reyes-Moreno, Carlos; Sharif-Askari, Ehssan; Girouard, Julie; Leveille, Claire; Jundi, Malek; Akoum, Ali; Lapointe, Rejean; Darveau, Andre; Mourad, Walid			Requirement of oxidation-dependent CD40 homodimers for CD154/CD40 bidirectional signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-CELL; LIPID-RAFTS; DENDRITIC CELLS; MEMBRANE RAFTS; RECEPTOR; LIGAND; DOMAIN; CYSTEINE; TRANSLOCATION; STIMULATION	It is well established that the CD154/CD40 interaction is required for T cell-dependent B cell differentiation and maturation. However, the early molecular and structural mechanisms that orchestrate CD154 and CD40 signaling at the T cell/APC contact site are not well understood. We demonstrated that CD40 engagement induces the formation of disulfide-linked (dl) CD40 homodimers that predominantly associate with detergentresistant membrane microdomains. Mutagenesis and biochemical analyses revealed that (a) the integrity of the detergentresistant membranes is necessary for dl-CD40 homodimer formation, (b) the cytoplasmic Cys238 of CD40 is the target for the de novo disulfide oxidation induced by receptor oligomerization, and (c) dl-CD40 homodimer formation is required for CD40-induced interleukin-8 secretion. Stimulation of CD154-positive T cells with staphylococcal enterotoxin E superantigen that mimics nominal antigen in initiating cognate T cell/APC interaction revealed that dl- CD40 homodimer formation is required for interleukin- 2 production by T cells. These findings indicate that dl-CD40 homodimer formation has a physiological role in regulating bidirectional signaling.	Univ Laval, Ctr Hosp, Ctr Rech & Rheumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Montreal, Hop St Luc, Ctr Hosp, Lab Immunol Cellular & Mol, Montreal, PQ H2X 1P1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Quebec Trois Rivieres, Dept Biol Chem, Trois Rivieres, PQ G9A 5H7, Canada; Univ Laval, Ctr Rech & Endocrinol Reprod, Quebec City, PQ G1V 4G2, Canada; Univ Montreal, Hop Notre Dame de Bon Secours, Ctr Hosp, Montreal, PQ H2L 4M1, Canada; Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Universite de Montreal; Universite de Montreal; University of Quebec; University of Quebec Trois Rivieres; Laval University; Universite de Montreal; Laval University	Mourad, W (corresponding author), Univ Montreal, Ctr Hosp, Ctr Rech, 264 Blvd Rene Levesque Est, Montreal, PQ H2X 1P1, Canada.	MW.Mourad@umontreal.ca		Mourad, Walid/0000-0002-1859-9387				Akoum A, 2001, MOL HUM REPROD, V7, P859, DOI 10.1093/molehr/7.9.859; Bajorath J, 1997, PROTEINS, V27, P59; Bock J, 2003, FEBS LETT, V534, P169, DOI 10.1016/S0014-5793(02)03784-5; Bouillon M, 2003, J BIOL CHEM, V278, P7099, DOI 10.1074/jbc.M211566200; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; Brenner B, 1997, FEBS LETT, V417, P301, DOI 10.1016/S0014-5793(97)01306-9; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cheng PC, 2001, J IMMUNOL, V166, P3693, DOI 10.4049/jimmunol.166.6.3693; Chevion M, 2000, FREE RADICAL RES, V33, pS99; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Ellmark P, 2003, IMMUNOLOGY, V108, P452, DOI 10.1046/j.1365-2567.2003.01622.x; Eren E, 2006, SCAND J IMMUNOL, V63, P7, DOI 10.1111/j.1365-3083.2006.01700.x; Girouard J, 2005, MOL IMMUNOL, V42, P773, DOI 10.1016/j.molimm.2004.07.048; Giurisato E, 2003, J BIOL CHEM, V278, P6771, DOI 10.1074/jbc.M210758200; Grammer A C, 2000, Adv Immunol, V76, P61; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2002, J BIOL CHEM, V277, P30289, DOI 10.1074/jbc.M200494200; GRAZIOLI L, 1994, J BIOL CHEM, V269, P22304; Jones MD, 1997, BIOCHEMISTRY-US, V36, P14914, DOI 10.1021/bi971696k; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kovacs B, 2005, J IMMUNOL, V175, P7848, DOI 10.4049/jimmunol.175.12.7848; KRONING H, 1991, HYBRIDOMA, V10, P651, DOI 10.1089/hyb.1991.10.651; Lee JR, 2003, MOL CELL BIOCHEM, V252, P1, DOI 10.1023/A:1025529704480; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Reyes-Moreno C, 2004, J BIOL CHEM, V279, P7799, DOI 10.1074/jbc.M313168200; Sadra A, 2004, P NATL ACAD SCI USA, V101, P11422, DOI 10.1073/pnas.0403792101; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Stadtman ER, 2002, HUM EXP TOXICOL, V21, P83, DOI 10.1191/0960327102ht215oa; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Wollman EE, 1997, BIOCHEM BIOPH RES CO, V230, P602, DOI 10.1006/bbrc.1996.6015; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YELLIN MJ, 1991, J IMMUNOL, V147, P3389; Zeyda M, 2006, PROG LIPID RES, V45, P187, DOI 10.1016/j.plipres.2006.01.002	37	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19473	19480		10.1074/jbc.M701076200	http://dx.doi.org/10.1074/jbc.M701076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17504764	hybrid			2022-12-25	WOS:000247650600021
J	Sal-Man, N; Gerber, D; Bloch, I; Shai, Y				Sal-Man, Neta; Gerber, Doron; Bloch, Itai; Shai, Yechiel			Specificity in transmembrane helix-helix interactions mediated by aromatic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMERIZATION MOTIF; MEMBRANE-PROTEINS; ALPHA-HELICES; DRIVE ASSOCIATION; AMINO-ACIDS; GXXXG MOTIF; PI-STACKING; IN-VIVO; MODEL; OLIGOMERIZATION	Aromatic residues have been previously shown to mediate the self-assembly of different soluble proteins through pi-pi interactions ( McGaughey, G. B., Gagne, M., and Rappe, A. K. ( 1998) J. Biol. Chem. 273, 15458-15463). However, their role in transmembrane (TM) assembly is not yet clear. In this study, we performed statistical analysis of the frequency of occurrence of aromatic pairs in a bacterial TM data base that provided an initial indication that the appearance of a specific aromatic pattern, Aromatic-XX-Aromatic, is not coincidental, similar to the well characterized QXXS motif. The QXXS motif was previously shown to be both critical and sufficient for stabilizing TM self-assembly. Using the ToxR system, we monitored the dimerization propensities of TM domains that contain mutations of interacting residues to aromatic amino acids and demonstrated that aromatic residues can adequately stabilize self-association. Importantly, we have provided an example of a natural TM domain, the cholera toxin secretion protein EpsM, whose TM self-assembly is mediated by an aromatic motif (WXXW). This is, in fact, the first evidence that aromatic residues are involved in the dimerization of a wild type TM domain. The association mediated by aromatic residues was found to be sensitive to the TM sequence, suggesting that aromatic residue motifs can provide a general means for specificity in TM assembly. Molecular dynamics provided a structural explanation for this backbone sequence sensitivity.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il		Sal-Man, Neta/0000-0002-1109-479X				Abendroth J, 2004, J MOL BIOL, V338, P585, DOI 10.1016/j.jmb.2004.01.064; Arkin IT, 2002, BBA-BIOMEMBRANES, V1565, P347, DOI 10.1016/S0005-2736(02)00580-1; Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Belbeoc'h S, 2004, EUR J BIOCHEM, V271, P1476, DOI 10.1111/j.1432-1033.2004.04052.x; Brosig B, 1998, PROTEIN SCI, V7, P1052; Campbell K S, 1994, Semin Immunol, V6, P393, DOI 10.1006/smim.1994.1049; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; KOLMAR H, 1994, BIOL CHEM H-S, V375, P61; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; Li R, 2004, BIOCHEM SOC T, V32, P412, DOI 10.1042/BST0320412; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; Ramachandran R, 2004, NAT STRUCT MOL BIOL, V11, P697, DOI 10.1038/nsmb793; Ridder A, 2005, J MOL BIOL, V354, P894, DOI 10.1016/j.jmb.2005.09.084; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sal-Man N, 2005, J BIOL CHEM, V280, P27449, DOI 10.1074/jbc.M503095200; Sal-Man N, 2004, BIOCHEMISTRY-US, V43, P2309, DOI 10.1021/bi0356294; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Sun S, 1996, J PHYS CHEM-US, V100, P13348, DOI 10.1021/jp960739o; Tsang S, 1996, J COMPUT BIOL, V3, P185, DOI 10.1089/cmb.1996.3.185; von Heijne G, 1999, Q REV BIOPHYS, V32, P285, DOI 10.1017/S0033583500003541; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	33	91	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19753	19761		10.1074/jbc.M610368200	http://dx.doi.org/10.1074/jbc.M610368200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17488729	hybrid			2022-12-25	WOS:000247650600050
J	Veiga, P; Bulbarela-Sampieri, C; Furlan, S; Maisons, A; Chapot-Chartier, MP; Erkelenz, M; Mervelet, P; Noirot, P; Frees, D; Kuipers, OP; Kok, J; Gruss, A; Buist, G; Kulakauskas, S				Veiga, Patrick; Bulbarela-Sampieri, Carmen; Furlan, Sylviane; Maisons, Aurelie; Chapot-Chartier, Marie-Pierre; Erkelenz, Michael; Mervelet, Peggy; Noirot, Philippe; Frees, Dorte; Kuipers, Oscar P.; Kok, Jan; Gruss, Alexandra; Buist, Girbe; Kulakauskas, Saulius			SpxB regulates O-acetylation-dependent resistance of Lactococcus lactis peptidoglycan to hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; CELL-WALL; N-ACETYLGLUCOSAMINIDASE; STAPHYLOCOCCUS-AUREUS; LYSOZYME-RESISTANCE; BACILLUS-SUBTILIS; STRESS TOLERANCE; GENE-EXPRESSION; IDENTIFICATION; PROTEINS	Endogenous peptidoglycan (PG)-hydrolyzing enzymes, the autolysins, are needed to relax the rigid PG sacculus to allow bacterial cell growth and separation. PGs of pathogens and commensal bacteria may also be degraded by hydrolases of animal origin (lysozymes), which act as antimicrobials. The genetic mechanisms regulating PG resistance to hydrolytic degradation were dissected in the Gram-positive bacterium Lactococcus lactis. We found that the ability of L. lactis to counteract PG hydrolysis depends on the degree of acetylation. Overexpression of PG O-acetylase (encoded by oatA) led to bacterial growth arrest, indicating the potential lethality of oatA and a need for its tight regulation. A novel regulatory factor, SpxB (previously denoted as YneH), exerted a positive effect on oatA expression. Our results indicate that SpxB binding to RNA polymerase constitutes a previously missing link in the multistep response to cell envelope stress, provoked by PG hydrolysis with lysozyme. We suggest that the two-component system CesSR responds to this stress by inducing SpxB, thus favoring its interactions with RNA polymerase. Induction of PGO-acetylation by this cascade renders it resistant to hydrolysis.	INRA, Unit Bacteria Lact & Pathogenes Opportun, F-78352 Jouy En Josas, France; INRA, Unit Biochem Bacteria, F-78352 Jouy En Josas, France; Royal Vet & Agr Univ, Dept Vet Pathobiol, DK-1870 Frederiksberg, Denmark; Univ Groningen, Biomol Sci & Biotechnol Inst, Dept Mol Genet, NL-9751 NN Groningen, Netherlands	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Copenhagen; University of Groningen	Kulakauskas, S (corresponding author), INRA, Unit Bacteria Lact & Pathogenes Opportun, F-78352 Jouy En Josas, France.	saulius.kulakauskas@jouy.inra.fr	Kuipers, Oscar/B-6752-2009; Veiga, Patrick/A-9862-2011; Kok, Jan/C-9972-2012	Kuipers, Oscar/0000-0001-5596-7735; Veiga, Patrick/0000-0001-6318-8547; Frees, Dorte/0000-0003-4946-2890; Gruss, Alexandra/0000-0001-7426-5229; Chapot-Chartier, Marie-Pierre/0000-0002-4947-0519				ARTHUR M, 1995, GENE, V54, P87; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bera A, 2005, MOL MICROBIOL, V55, P778, DOI 10.1111/j.1365-2958.2004.04446.x; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRUMFITT W, 1958, NATURE, V181, P1783, DOI 10.1038/1811783a0; BUIST G, 1995, J BACTERIOL, V177, P1554, DOI 10.1128/jb.177.6.1554-1563.1995; CLARKE AJ, 1992, CAN J MICROBIOL, V38, P85, DOI 10.1139/m92-014; Courtin P, 2006, J BACTERIOL, V188, P5293, DOI 10.1128/JB.00285-06; Crisostomo MI, 2006, MOL MICROBIOL, V61, P1497, DOI 10.1111/j.1365-2958.2006.05340.x; Darst SA, 2001, CURR OPIN STRUC BIOL, V11, P155; Delcour J, 1999, ANTON LEEUW INT J G, V76, P159, DOI 10.1023/A:1002089722581; Dubnau D, 2006, MOL MICROBIOL, V61, P564, DOI 10.1111/j.1365-2958.2006.05249.x; Duwat P, 1999, MOL MICROBIOL, V31, P845, DOI 10.1046/j.1365-2958.1999.01222.x; Foster S.J., 2002, BACILLUS SUBTILIS IT, P21; Frees D, 2001, MOL MICROBIOL, V41, P93, DOI 10.1046/j.1365-2958.2001.02503.x; Fukushima T, 2005, J BACTERIOL, V187, P1287, DOI 10.1128/JB.187.4.1287-1292.2005; Gaspar P, 2004, APPL ENVIRON MICROB, V70, P1466, DOI 10.1128/AEM.70.3.1466-1474.2004; GASSON MJ, 1983, J BACTERIOL, V154, P1; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; Guedon E, 2005, MICROBIOL-SGM, V151, P3895, DOI 10.1099/mic.0.28186-0; Huard C, 2004, APPL ENVIRON MICROB, V70, P3493, DOI 10.1128/AEM.70.6.3493-3499.2004; Huard C, 2003, MICROBIOL-SGM, V149, P695, DOI 10.1099/mic.0.25875-0; Iwamoto K, 2005, MAR BIOTECHNOL, V7, P407, DOI 10.1007/s10126-005-0029-4; James P, 1996, GENETICS, V144, P1425; Jordan S, 2006, J BACTERIOL, V188, P5153, DOI 10.1128/JB.00310-06; Kets EPW, 1996, J BACTERIOL, V178, P6665, DOI 10.1128/jb.178.23.6665-6670.1996; Kramer NE, 2006, ANTIMICROB AGENTS CH, V50, P1753, DOI 10.1128/AAC.50.5.1753-1761.2006; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Kuroda M, 2003, MOL MICROBIOL, V49, P807, DOI 10.1046/j.1365-2958.2003.03599.x; LAW J, 1995, J BACTERIOL, V177, P7011, DOI 10.1128/jb.177.24.7011-7018.1995; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Leloup L, 1997, APPL ENVIRON MICROB, V63, P2117, DOI 10.1128/AEM.63.6.2117-2123.1997; Lepeuple AS, 1998, APPL ENVIRON MICROB, V64, P4142; MAGUIN E, 1992, J BACTERIOL, V174, P5633, DOI 10.1128/JB.174.17.5633-5638.1992; Mascher T, 2006, FEMS MICROBIOL LETT, V264, P133, DOI 10.1111/j.1574-6968.2006.00444.x; Masschalck B, 2003, CRIT REV MICROBIOL, V29, P191, DOI 10.1080/713610448; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; McAleese F, 2006, J BACTERIOL, V188, P1120, DOI 10.1128/JB.188.3.1120-1133.2006; Mercier C, 2002, MOL MICROBIOL, V46, P235, DOI 10.1046/j.1365-2958.2002.03160.x; Mukamolova GV, 2006, MOL MICROBIOL, V59, P84, DOI 10.1111/j.1365-2958.2005.04930.x; Nakano S, 2002, J BACTERIOL, V184, P3664, DOI 10.1128/JB.184.13.3664-3670.2002; Nakano S, 2003, P NATL ACAD SCI USA, V100, P4233, DOI 10.1073/pnas.0637648100; Noirot-Gros MF, 2002, MOL GENET GENOMICS, V267, P391, DOI 10.1007/s00438-002-0670-9; O'Connell-Motherway M, 2000, MICROBIOL-SGM, V146, P935, DOI 10.1099/00221287-146-4-935; Pamp SJ, 2006, J BACTERIOL, V188, P4861, DOI 10.1128/JB.00194-06; Pfeffer JM, 2006, J BACTERIOL, V188, P902, DOI 10.1128/JB.188.3.902-908.2006; Psylinakis E, 2005, J BIOL CHEM, V280, P30856, DOI 10.1074/jbc.M407426200; Shelburne SA, 2005, P NATL ACAD SCI USA, V102, P16037, DOI 10.1073/pnas.0505839102; Shockman GD, 1996, MICROB DRUG RESIST, V2, P95, DOI 10.1089/mdr.1996.2.95; Shockman GD, 1994, NEW COMPREHENSIVE BI, P131; Smits WK, 2006, NAT REV MICROBIOL, V4, P259, DOI 10.1038/nrmicro1381; Sperandio B, 2005, J BACTERIOL, V187, P3762, DOI 10.1128/JB.187.11.3762-3778.2005; Steen A, 2005, FEBS J, V272, P2854, DOI 10.1111/j.1742-4658.2005.04706.x; TAN PST, 1992, FEBS LETT, V306, P9, DOI 10.1016/0014-5793(92)80827-4; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Telkov MV, 2006, BIOCHEMISTRY-MOSCOW+, V71, P414, DOI 10.1134/S0006297906040092; Utaida S, 2003, MICROBIOL-SGM, V149, P2719, DOI 10.1099/mic.0.26426-0; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; van Hijum SAFT, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-77; Veiga P, 2006, MOL MICROBIOL, V62, P1713, DOI 10.1111/j.1365-2958.2006.05474.x; Vollmer W, 2000, J BIOL CHEM, V275, P20496, DOI 10.1074/jbc.M910189199; Weadge JT, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-49; Wegmann U, 2007, J BACTERIOL, V189, P3256, DOI 10.1128/JB.01768-06; Zuber P, 2004, J BACTERIOL, V186, P1911, DOI 10.1128/JB.186.7.1911-1918.2004	66	81	82	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19342	19354		10.1074/jbc.M611308200	http://dx.doi.org/10.1074/jbc.M611308200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17485463	hybrid			2022-12-25	WOS:000247650600009
J	Yamashita, T; Yao, ZQ; Li, F; Zhang, Q; Badell, IR; Schwarz, EM; Takeshita, S; Wagner, EF; Noda, M; Matsuo, K; Xing, LP; Boyce, BF				Yamashita, Teruhito; Yao, Zhenqiang; Li, Fang; Zhang, Qian; Badell, I. Raul; Schwarz, Edward M.; Takeshita, Sunao; Wagner, Erwin F.; Noda, Masaki; Matsuo, Koichi; Xing, Lianping; Boyce, Brendan F.			NF-kappa B p50 and p52 regulate receptor activator of NF-kappa B ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID-ARTHRITIS; T-CELLS; BONE HOMEOSTASIS; KEY REGULATOR; INFLAMMATORY OSTEOLYSIS; OSTEOPROTEGERIN LIGAND; LYMPHOCYTE DEVELOPMENT; GENE-EXPRESSION; NUCLEAR FACTOR; IN-VITRO	Postmenopausal osteoporosis and rheumatoid joint destruction result from increased osteoclast formation and bone resorption induced by receptor activator of NF-kappa B ligand (RANKL) and tumor necrosis factor (TNF). Osteoclast formation induced by these cytokines requires NF-kappa B p50 and p52, c-Fos, and NFATc1 expression in osteoclast precursors. c-Fos induces NFATc1, but the relationship between NF-kappa B and these other transcription factors in osteoclastogenesis remains poorly understood. We report that RANKL and TNF can induce osteoclast formation directly from NF-kappa B p50/p52 double knockout (dKO) osteoclast precursors when either c-Fos or NFATc1 is expressed. RANKL- or TNF-induced c-Fos up-regulation and activation are abolished in dKO cells and in wild-type cells treated with an NF-kappa B inhibitor. c-Fos expression requires concomitant RANKL or TNF treatment to induce NFATc1 activation in the dKO cells. Furthermore, c-Fos expression increases the number and resorptive capacity of wild-type osteoclasts induced by TNF in vitro. We conclude that NF-kappa B controls early osteoclast differentiation from precursors induced directly by RANKL and TNF, leading to activation of c-Fos followed by NFATc1. Inhibition of NF-kappa B should prevent RANKL- and TNF-induced bone resorption.	Univ Rochester, Med Ctr, Dept Pathol, Lab Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA; Natl Ctr Geriat & Gerontol, Res Inst, D0pt Bone & Joint Dis, Obu 4748522, Japan; Res Inst Mol Pathol, A-1030 Vienna, Austria; Tokyo Med & Dent Univ, Tokyo 1010062, Japan; Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 1608582, Japan	University of Rochester; University of Rochester; National Center for Geriatrics & Gerontology; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Tokyo Medical & Dental University (TMDU); Keio University	Boyce, BF (corresponding author), Dept Pathol, Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	Brendan_Boyce@urmc.rochester.edu	Matsuo, Koichi/K-5695-2012	Matsuo, Koichi/0000-0002-1490-8955; Wagner, Erwin F/0000-0001-7872-0196	NIAMS NIH HHS [AR48697, AR43510] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043510, R01AR048697] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023; Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223-002-1049-y; Goldring SR, 2003, RHEUMATOLOGY, V42, P11, DOI 10.1093/rheumatology/keg327; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320; Jimi E, 1996, J BIOL CHEM, V271, P4605; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225; Kaplan C, 2003, FRONT BIOSCI-LANDMRK, V8, pD1018, DOI 10.2741/1102; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440-1711.1999.00815.x; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; OKeefe RJ, 1997, LAB INVEST, V76, P457; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ray N, 2006, INT IMMUNOL, V18, P671, DOI 10.1093/intimm/dxl004; RICH GM, 1992, J HEART LUNG TRANSPL, V11, P950; Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Suda T, 2001, Novartis Found Symp, V232, P235; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109-004-0612-6; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tanabe N, 2005, LIFE SCI, V77, P615, DOI 10.1016/j.lfs.2004.10.079; Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857; Teitelbaum SL, 2000, J BONE MINER METAB, V18, P344, DOI 10.1007/s007740070007; Tobe M, 2003, BIOORGAN MED CHEM, V11, P3869, DOI 10.1016/S0968-0896(03)00438-3; Udagawa N, 2002, ARTHRITIS RES, V4, P281, DOI 10.1186/ar431; Urushibara M, 2004, ARTHRITIS RHEUM-US, V50, P794, DOI 10.1002/art.20206; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Xing LP, 2005, CURR RHEUMATOL REV, V1, P21, DOI 10.2174/1573397052954127; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yamashita T, 2002, J BONE MINER RES, V17, pS131; Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200; Zhu LL, 2005, BIOCHEM BIOPH RES CO, V326, P131, DOI 10.1016/j.bbrc.2004.10.212	71	315	331	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18245	18253		10.1074/jbc.M610701200	http://dx.doi.org/10.1074/jbc.M610701200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17485464	hybrid			2022-12-25	WOS:000247302000031
J	Oleinik, NV; Krupenko, NI; Krupenko, SA				Oleinik, N. V.; Krupenko, N. I.; Krupenko, S. A.			Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway	ONCOGENE			English	Article						apoptosis; FDH; jun kinases; p53; RNAi	CELL-CYCLE PROGRESSION; PROTEIN-KINASE INHIBITORS; PHOSPHORYLATED IN-VITRO; C-JUN KINASE; 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; CANCER-CELLS; SIGNAL-TRANSDUCTION; STRESS; IDENTIFICATION; VIVO	FDH (10-formyltetrahydrofolate dehydrogenase) is strongly downregulated in tumors while its elevation suppresses proliferation of cancer cells and induces p53-dependent apoptosis. We have previously shown that FDH induces phosphorylation of p53 at Ser6, which is a required step in the activation of apoptosis. In the present study, we report that FDH-induced p53 phosphorylation is carried out by JNK1 and JNK2 (c-Jun N-terminal kinases) working in concert. We have demonstrated that FDH induces phosphorylation of JNK1 and JNK2, while treatment of FDH-expressing cells with JNK inhibitor SP600125, as well as knockdown of JNK1 or JNK2 by siRNA, prevents phosphorylation of p53 at Ser6 and protects cells from apoptosis. Interestingly, the knockdown of JNK1 abolished phosphorylation of JNK2 in response to FDH, while knockdown of JNK2 did not prevent JNK1 phosphorylation. Pull-down assay with the p53-specific antibody has shown that JNK2, but not JNK1, is physically associated with p53. Our studies revealed a novel mechanism in which phosphorylation of JNK2 is mediated by JNK1 before phosphorylation of p53, and then p53 is directly phosphorylated by JNK2 at Ser6.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Rm 512-B BSB, Charleston, SC 29425 USA.	Krupenko@musc.edu			NATIONAL CANCER INSTITUTE [R01CA095030] Funding Source: NIH RePORTER; NCI NIH HHS [CA95030] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anguera MC, 2006, J BIOL CHEM, V281, P18335, DOI 10.1074/jbc.M510623200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bost F, 1999, MOL CELL BIOL, V19, P1938; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CHAMPION KM, 1994, P NATL ACAD SCI USA, V91, P11338, DOI 10.1073/pnas.91.24.11338; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fogarty MP, 2003, BIOCHEM J, V371, P789, DOI 10.1042/BJ20021660; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Krupenko SA, 2002, CELL GROWTH DIFFER, V13, P227; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; Oleinik NV, 2005, BIOCHEM J, V391, P503, DOI 10.1042/BJ20050533; Oleinik NV, 2003, MOL CANCER RES, V1, P577; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Tafolla E, 2005, J BIOL CHEM, V280, P19992, DOI 10.1074/jbc.M500331200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	43	99	103	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7222	7230		10.1038/sj.onc.1210526	http://dx.doi.org/10.1038/sj.onc.1210526			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525747				2022-12-25	WOS:000250955600006
J	Mizutani, K; Ito, H; Iwamoto, I; Morishita, R; Deguchi, T; Nozawa, Y; Asano, T; Nagata, KI				Mizutani, K.; Ito, H.; Iwamoto, I.; Morishita, R.; Deguchi, T.; Nozawa, Y.; Asano, T.; Nagata, K-I			Essential roles of ERK-mediated phosphorylation of vinexin in cell spreading, migration and anchorage-independent growth	ONCOGENE			English	Article						ERK; vinexin; adaptor protein; cytokeleton; phosphorylation	ADHESION PROTEIN VINEXIN; SIGNAL-REGULATED KINASE; CYTOSKELETAL ORGANIZATION; ADAPTER PROTEIN; ACTIVATION; EXPRESSION; INTERACTS; VINCULIN; COMPLEX; GAMMA	Vinexin is an adaptor protein supposed to play pivotal roles in various cellular events such as cell adhesion, cytoskeletal organization, signa ling and gene expression. Despite the possible importance, physiological functions and regulatory mechanisms of vinexin are largely unknown. In addition, although vinexin was reported to be phosphorylated by extracellular signal-regulated kinase ( ERK), physiological significance of the phosphorylation remains to be elucidated. Here we carried out characterization of endogenous vinexin and found that it was enriched at the leading edge of migrating cells and focal adhesions of spread cells. In the analyses using ERK-phosphorylated vinexin-specific antibody, the phosphorylation signal was also detected at the leading edges of migrating cells and at cell periphery of spreading cells, whereas only faint signal was observed at focal adhesions of well-spread cells. We then established LNCaP cell lines stably expressing GFP-fused vinexin beta or two mutants at Ser189 that mimic the ERK-phosphorylated or -unphosphorylated vinexinb. Based on the analyses using the lines, the phosphorylation was likely to inhibit the cell spreading and migration. On the other hand, anchorage-independent cell growth was inhibited by unphosphorylated vinexin beta. Taken together, ERK-mediated phosphorylation of vinexinb is strongly suggested to occur in a spatio-temporally regulated manner and play important roles in cell spreading, migration and anchorage-independent growth.	Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, Kasugai, Aichi 4800392, Japan; Gifu Univ, Sch Med, Dept Urol, Gifu 500, Japan; Gifu Int Inst Biotechnol, Gifu, Japan	Gifu University	Nagata, KI (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, 713-8 Kamiya, Kasugai, Aichi 4800392, Japan.	knagata@inst-hsc.jp		Ito, Hidenori/0000-0002-6527-477X				Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Bour G, 2005, J BIOL CHEM, V280, P17027, DOI 10.1074/jbc.M501344200; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Ito H, 2007, J NEUROCHEM, V100, P545, DOI 10.1111/j.1471-4159.2006.04222.x; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Matsuyama M, 2005, GENES CELLS, V10, P421, DOI 10.1111/j.1365-2443.2005.00844.x; Mitsushima M, 2006, GENES CELLS, V11, P281, DOI 10.1111/j.1365-2443.2006.00932.x; Mitsushima M, 2004, J BIOL CHEM, V279, P34570, DOI 10.1074/jbc.M402304200; Nagata K, 2004, J BIOL CHEM, V279, P55895, DOI 10.1074/jbc.M406153200; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; Takahashi H, 2005, BIOCHEM BIOPH RES CO, V336, P239, DOI 10.1016/j.bbrc.2005.08.064; Tujague M, 2004, J BIOL CHEM, V279, P9255, DOI 10.1074/jbc.M312160200	13	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7122	7131		10.1038/sj.onc.1210512	http://dx.doi.org/10.1038/sj.onc.1210512			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486060				2022-12-25	WOS:000250715000006
J	Flinterman, MB; Mymryk, JS; Klanrit, P; Yousef, AF; Lowe, SW; Caldas, C; Gaken, J; Farzaneh, F; Tavassoli, M				Flinterman, M. B.; Mymryk, J. S.; Klanrit, P.; Yousef, A. F.; Lowe, S. W.; Caldas, C.; Gaken, J.; Farzaneh, F.; Tavassoli, M.			p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing	ONCOGENE			English	Article						p400; EGFR; E1A; apoptosis; head and neck cancer	GROWTH-FACTOR RECEPTOR; SIMIAN ADENOVIRUSES; SEQUENCE-ANALYSIS; E1A PROTEINS; TYPE-5 E1A; APOPTOSIS; P53; INDUCTION; BINDING; CANCER	We have recently shown that E1A protein of human adenovirus downregulates epidermal growth factor receptor (EGFR) expression and induces apoptosis in head and neck (HNSCC) and lung cancer cells independently of their p53 status. E1A has five isoforms of which the major ones E1A12S and E1A13S regulate transcription of cellular genes by binding to transcriptional modulators such as pRB, CtBP, p300 and p400. In this study, we have identified E1A12S isoform to) have the highest effect on EGFR suppression and induction of apoptosis in HNSCC cells. Similar to Ad5, E1A12S from human adenovirus types 2, 3, 9 and 12 suppressed EGFR, whereas E1A12S of adenovirus types 4 and 40 had no effect on EGFR expression. Using deletion mutants of E1A12S we have shown that interaction of E1A with p400, but not p300 or pRB, is required for EGFR suppression and apoptosis. Inhibition of p400 by short hairpin RNA confirmed that HNSCC cells with reduced p400 expression were less sensitive to E1A-induced suppression of EGFR and apoptosis. p300 function was shown to be dispensable, as cells expressing E1A mutants that are unable to bind p300, or p300 knockout cells., remained sensitive to E1A-induced apoptosis. In summary, this study identifies p400 as an important mediator of E1A-induced downregulation of EGFR and apoptosis.	Kings Coll London, Guys Kings & St Thomass Hosp, Inst Dent, Head & Neck Oncol Grp, London SE5 9NU, England; Univ Western Ontario, London Reg Canc Ctr, Dept Oncol & Microbiol, London, ON, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Immunol, London, ON, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Cambridge, Hutchison MRC Res Ctr, Canc Genom Program, Dept Oncol, Cambridge, England; Kings Coll London, Dept Haematol & Mol Med, London WC2R 2LS, England	University of London; King's College London; Western University (University of Western Ontario); Western University (University of Western Ontario); Cold Spring Harbor Laboratory; University of Cambridge; University of London; King's College London	Tavassoli, M (corresponding author), Kings Coll London, Guys Kings & St Thomass Hosp, Inst Dent, Head & Neck Oncol Grp, 123 Coldharbour Lane, London SE5 9NU, England.	mahvash.tavassoli@kcl.ac.uk	Caldas, Carlos/U-7250-2019; Farzaneh, Farzin/B-4902-2009; Caldas, Carlos/A-7543-2008	Caldas, Carlos/0000-0003-3547-1489; Farzaneh, Farzin/0000-0002-9275-2415; Yousef, Ahmed F./0000-0001-5734-489X	NCI NIH HHS [P01 CA013106, P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; BARBEAU D, 1994, ONCOGENE, V9, P359; Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Flinterman M, 2003, ONCOGENE, V22, P1965, DOI 10.1038/sj.onc.1206190; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1998, NUCLEIC ACIDS RES, V26, P292, DOI 10.1093/nar/26.1.292; PATERSON IC, 1995, BRIT J CANCER, V72, P922, DOI 10.1038/bjc.1995.434; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Samuelson AV, 2005, J BIOL CHEM, V280, P21915, DOI 10.1074/jbc.M414564200; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; YAN DH, 1991, ONCOGENE, V6, P343; Yu DH, 1998, CANCER METAST REV, V17, P195, DOI 10.1023/A:1006054421970	35	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6863	6874		10.1038/sj.onc.1210497	http://dx.doi.org/10.1038/sj.onc.1210497			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486071	Green Accepted			2022-12-25	WOS:000250188400002
J	Herrmann, A; Fleischer, K; Czajkowska, H; Muller-Newen, G; Becker, W				Herrmann, Andreas; Fleischer, Katrin; Czajkowska, Hanna; Mueller-Newen, Gerhard; Becker, Walter			Characterization of cyclin L1 as an immobile component of the splicing factor compartment	FASEB JOURNAL			English	Article						nuclear speckles; photobleaching; arginineserine-rich domain; mobility	SR PROTEINS; RS DOMAIN; SUBNUCLEAR LOCALIZATION; NUCLEAR SPECKLES; RNA; KINASE; PHOSPHORYLATION; TRANSCRIPTION; ORGANIZATION; EXPRESSION	Cyclin L1 and cyclin L2 are two closely related members of the cyclin family that contain C-terminal arginine-and serine-rich (RS) domains and are localized in the splicing factor compartment (nuclear speckles). Here we applied photobleaching techniques to show that a green fluorescent protein (GFP) fusion protein of cyclin L1, in contrast to cyclin L2, was not mobile within the nucleus of living COS7 cells. The objectives of this study were to 1) characterize the intranuclear localization and mobility properties of cyclin L1 in different cellular states, and 2) dissect the structural elements required for immobilization of cyclin L1. Transcriptional arrest by actinomycin D caused accumulation of GFP-cyclin L2 in rounded and enlarged nuclear speckles but did not affect the sub-nuclear pattern of distribution of GFP-cyclin L1. Although immobile in most phases of the cell cycle, GFP-cyclin L1 was diffusely distributed and highly mobile in the cytoplasm of metaphase cells. By analysis of a series of chimeras, deletion constructs, and a point mutant, a segment within the RS domain of cyclin L1 was identified to be necessary for the immobility of the protein in nuclear speckles. This study provides the first characterization of an immobile component of nuclear speckles.	Univ Aachen, Fak Med, Rhein Westfal TH Aachen, Inst Biochem, D-52074 Aachen, Germany	RWTH Aachen University	Becker, W (corresponding author), Univ Aachen, Fak Med, Inst Pharmakol & Toxikol, Rhein Westfal TH Aachen, Wendlingweg 2, D-52074 Aachen, Germany.	wbecker@ukaachen.de	Becker, Walter/B-8889-2008	Becker, Walter/0000-0002-0347-4768				Berke JD, 2001, NEURON, V32, P277, DOI 10.1016/S0896-6273(01)00465-2; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Boucher L, 2001, RNA, V7, P1693; Bubulya PA, 2004, EXP CELL RES, V296, P4, DOI 10.1016/j.yexcr.2004.03.018; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cazalla D, 2002, MOL CELL BIOL, V22, P6871, DOI 10.1128/MCB.22.19.6871-6882.2002; Chen HH, 2006, MOL CELL BIOL, V26, P2736, DOI 10.1128/MCB.26.7.2736-2745.2006; Cmarko D, 1999, MOL BIOL CELL, V10, P211, DOI 10.1091/mbc.10.1.211; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; de Graaf K, 2004, J BIOL CHEM, V279, P4612, DOI 10.1074/jbc.M310794200; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; Duncan PI, 1998, EXP CELL RES, V241, P300, DOI 10.1006/excr.1998.4083; Fang YD, 2004, MOL BIOL CELL, V15, P2664, DOI 10.1091/mbc.E04-02-0100; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; Ko TK, 2001, J CELL SCI, V114, P2591; Kruhlak MJ, 2000, J CELL BIOL, V150, P41, DOI 10.1083/jcb.150.1.41; Lai MC, 2003, BIOCHEM J, V371, P937, DOI 10.1042/BJ20021827; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; Loyer P, 2005, CELL SIGNAL, V17, P1033, DOI 10.1016/j.cellsig.2005.02.005; Maris C, 2005, FEBS J, V272, P2118, DOI 10.1111/j.1742-4658.2005.04653.x; Martin RM, 2005, CYTOM PART A, V67A, P45, DOI 10.1002/cyto.a.20172; Misteli T, 2001, J CELL BIOL, V155, P181, DOI 10.1083/jcb.200108110; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Politz JCR, 2006, MOL BIOL CELL, V17, P1239, DOI 10.1091/mbc.E05-10-0952; Prasanth KV, 2003, MOL BIOL CELL, V14, P1043, DOI 10.1091/mbc.E02-10-0669; Rabut G., 2005, LIVE CELL IMAGING LA, P101; Sacco-Bubulya P, 2002, J CELL BIOL, V156, P425, DOI 10.1083/jcb.200107017; Shin C, 2005, MOL CELL BIOL, V25, P8334, DOI 10.1128/MCB.25.18.8334-8343.2005; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Yang LJ, 2004, J BIOL CHEM, V279, P11639, DOI 10.1074/jbc.M312895200; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; ZHANG GH, 1994, NATURE, V372, P809; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500	43	15	16	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3142	3152		10.1096/fj.07-8377com	http://dx.doi.org/10.1096/fj.07-8377com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17494991				2022-12-25	WOS:000249781600015
J	Yuan, HT; Venkatesha, S; Chan, B; Deutsch, U; Mammoto, T; Sukhatme, VP; Woolf, AS; Karumanchi, SA				Yuan, Hai Tao; Venkatesha, Shivalingappa; Chan, Barden; Deutsch, Urban; Mammoto, Tadanori; Sukhatme, Vikas P.; Woolf, Adrian S.; Karumanchi, S. Ananth			Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival	FASEB JOURNAL			English	Article						angiopoietin; apoptosis; embryo; endothelial cells; tie receptors	GROWTH-FACTOR RECEPTOR-1; TYROSINE KINASES TIE-1; PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOPOIETIN-1; ANGIOGENESIS; EXPRESSION; INTEGRITY; RELEASE; LIGANDS; FLT-1	A critical role for Tie1, an orphan endothelial receptor, in blood vessel morphogenesis has emerged from mutant mouse studies. Moreover, it was recently demonstrated that certain angiopoietin (Ang) family members can activate Tie1. We report here that Ang1 induces Tie1 phosphorylation in endothelial cells. Tie1 phosphorylation was, however, Tie2 dependent because 1) Ang1 failed to induce Tie1 phosphorylation when Tie2 was down-regulated in endothelial cells; 2) Tie1 phosphorylation was induced in the absence of Ang1 by either a constitutively active form of Tie2 or a Tie2 agonistic antibody; 3) in HEK 293 cells Ang1 phosphorylated a form of Tie1 without kinase activity when coexpressed with Tie2, and Ang1 failed to phosphorylate Tie1 when coexpressed with kinase-defective Tie2. Ang1-mediated AKT and 42/44MAPK phosphorylation is predominantly Tie2 mediated, and Tie1 down-regulates this pathway. Finally, based on a battery of in vitro and in vivo data, we show that a main role for Tie1 is to modulate blood vessel morphogenesis by virtue of its ability to down-regulate Tie2-driven signaling and endothelial survival. Our new observations help to explain why Tie1 null embryos have increased capillary densities in several organ systems. The experiments also constitute a paradigm for how endothelial integrity is fine-tuned by the interplay between closely related receptors by a single growth factor.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Mol & Vasc Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Div, Boston, MA 02215 USA; Univ Bern, Theodor Kocher Inst, Bern, Switzerland; UCL Inst Child Hlth, Nephrourol Unit, London, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Bern; University of London; University College London	Yuan, HT (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Mol & Vasc Med, 330 Brookline Ave,RW663, Boston, MA 02215 USA.	hyuan@bidmc.harvard.edu	Karumanchi, Subbian Ananth/AAI-1694-2021; Sukhatme, Vikas/W-2776-2019; Woolf, Adrian S./AAZ-1075-2020	Woolf, Adrian S./0000-0001-5541-1358; Deutsch, Urban/0000-0003-4265-6262				Ahmed A, 1997, LAB INVEST, V76, P779; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Daly C, 2006, P NATL ACAD SCI USA, V103, P15491, DOI 10.1073/pnas.0607538103; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Dunk C, 2001, AM J PATHOL, V158, P265, DOI 10.1016/S0002-9440(10)63965-X; Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Goede V, 1998, LAB INVEST, V78, P1385; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Kearney JB, 2002, BLOOD, V99, P2397, DOI 10.1182/blood.V99.7.2397; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontos CD, 2002, MOL CELL BIOL, V22, P1704, DOI 10.1128/MCB.22.6.1704-1713.2002; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Lee HJ, 2004, FASEB J, V18, P1200, DOI 10.1096/fj.03-1466com; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Marron MB, 2000, J BIOL CHEM, V275, P39741, DOI 10.1074/jbc.M007189200; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; McCarthy MJ, 1998, FEBS LETT, V423, P334, DOI 10.1016/S0014-5793(98)00122-7; Niu Q, 2004, CANCER BIOL THER, V3, P402, DOI 10.4161/cbt.3.4.735; Patan S, 1998, MICROVASC RES, V56, P1, DOI 10.1006/mvre.1998.2081; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Porat RM, 2004, CIRC RES, V94, P394, DOI 10.1161/01.RES.0000111803.92923.D6; Puri MC, 1999, DEVELOPMENT, V126, P4569; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Rodewald HR, 1996, ONCOGENE, V12, P397; Saharinen P, 2005, J CELL BIOL, V169, P239, DOI 10.1083/jcb.200411105; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takahashi A, 1999, BIOCHEM BIOPH RES CO, V257, P855, DOI 10.1006/bbrc.1999.0465; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yabkowitz R, 1997, BLOOD, V90, P706, DOI 10.1182/blood.V90.2.706.706_706_715; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yuan HT, 1999, J AM SOC NEPHROL, V10, P1722; Yuan HT, 2002, KIDNEY INT, V61, P2078, DOI 10.1046/j.1523-1755.2002.00381.x	45	79	84	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3171	3183		10.1096/fj.07-8487com	http://dx.doi.org/10.1096/fj.07-8487com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17504972				2022-12-25	WOS:000249781600018
J	Zhang, M; Mal, N; Kiedrowski, M; Chacko, M; Askari, AT; Popovic, ZB; Koc, ON; Penn, MS				Zhang, Ming; Mal, Niladri; Kiedrowski, Matthew; Chacko, Matthews; Askari, Arman T.; Popovic, Zoran B.; Koc, Omer N.; Penn, Marc S.			SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction	FASEB JOURNAL			English	Article						HSC; cardiac regeneration; transplantation; SDF-1-based therapy	BONE-MARROW; VENTRICULAR-FUNCTION; MIGRATION; HEART; GROWTH; CXCR4; NEOVASCULARIZATION; TRANSPLANTATION; REGENERATION; PROGENITORS	Stem cell transplantation at the time of acute myocardial infarction (AMI) improves cardiac function. Whether the improved cardiac function results from regeneration of cardiac myocytes, modulation of remodeling, or preservation of injured tissue through paracrine mechanisms is actively debated. Because no specific stem cell population has been shown to be optimal, we investigated whether the benefit of stem cell transplantation could be attributed to a trophic effect on injured myocardium. Mesenchymal stem cells secrete SDF-1 and the interaction of SDF-1 with its receptor, CXCR4, increases survival of progenitor cells. Therefore, we compared the effects of MSC and MSC engineered to overexpress SDF-1 on cardiac function after AMI. Tail vein infusion of syngeneic MSC and MSC: SDF-1 1 day after AMI in the Lewis rat led to improved cardiac function by echocardiography by 70.7% and 238.8%, respectively, compared with saline controls 5 wk later. The beneficial effects of MSC and MSC: SDF-1 transplantation were mediated primarily through preservation, not regeneration of cardiac myocytes within the infarct zone. The direct effect of SDF-1 on cardiac myocytes was due to the observation that, between 24 and 48 h after AMI, SDF-1-expressing MSC increased cardiac myocyte survival, vascular density (18.2 +/- 4.0 vs. 7.6 +/- 2.3 vessels/mm(2), P<0.01; SDF-1: MSC vs. MSC), and cardiac myosin-positive area (MSC: 49.5%; mSC: SDF-1: 162.1%) within the infarct zone. There was no evidence of cardiac regeneration by the infused MSC or endogenous cardiac stem cells based on lack of evidence for cardiac myocytes being derived from replicating cells. These results indicate that stem cell transplantation may have significant beneficial effects on injured organ function independent of tissue regeneration and identify SDF-1: CXCR4 binding as a novel target for myocardial preservation.	Cleveland Clin Fdn, Dept Cardiovasc Med, Bakken Heart Brain Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Div Hematol & Oncol, Cleveland, OH 44106 USA; Ctr Stem Cell & Regenerat Med, Cleveland, OH USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Penn, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Bakken Heart Brain Inst, 9500 Euclid Ave,NC10,NE30, Cleveland, OH 44195 USA.	pennm@ccf.org	Mordwinkin, Nicholas M/A-4347-2010	popovic, zoran/0000-0001-5692-2299	PHS HHS [1R01-74400] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Askari A, 2004, J AM COLL CARDIOL, V43, P1908, DOI 10.1016/j.jacc.2003.12.045; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Broxmeyer HE, 2003, J IMMUNOL, V170, P421, DOI 10.4049/jimmunol.170.1.421; Damas JK, 2000, CARDIOVASC RES, V47, P778, DOI 10.1016/S0008-6363(00)00142-5; Hodgson DM, 2004, AM J PHYSIOL-HEART C, V287, pH471, DOI 10.1152/ajpheart.01247.2003; Itescu S, 2003, J MOL MED, V81, P288, DOI 10.1007/s00109-003-0432-0; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Kahn J, 2004, BLOOD, V103, P2942, DOI 10.1182/blood-2003-07-2607; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kayali AG, 2003, J CELL BIOL, V163, P859, DOI 10.1083/jcb.200304153; Koc ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349; Lee RJ, 2000, CIRCULATION, V102, P898; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; MILLS WR, 2006, IN PRESS J MOL CELL; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; NAGAYA, 2004, AM J PHYSIOL, V287, pH2670; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Ratajczak MZ, 2003, STEM CELLS, V21, P363, DOI 10.1634/stemcells.21-3-363; Rota M, 2005, CIRC RES, V97, P1332, DOI 10.1161/01.RES.0000196568.11624.ae; Schenk S, 2007, STEM CELLS, V25, P245, DOI 10.1634/stemcells.2006-0293; Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003-4975(02)03517-8; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Suzuki K, 2001, CIRCULATION, V104, pI207; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; von Degenfeld G, 2003, BRIT J PHARMACOL, V140, P620, DOI 10.1038/sj.bjp.0705492; Vulliet PR, 2004, LANCET, V363, P783, DOI 10.1016/S0140-6736(04)15695-X; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22	36	360	394	1	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3197	3207		10.1096/fj.06-6558com	http://dx.doi.org/10.1096/fj.06-6558com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17496162				2022-12-25	WOS:000249781600020
J	Hubert, P; Herman, L; Maillard, C; Caberg, JH; Nikkels, A; Pierard, G; Foidart, JM; Noel, A; Boniver, J; Delvenne, P				Hubert, Pascale; Herman, Ludivine; Maillard, Catherine; Caberg, Jean-Hubert; Nikkels, Arjen; Pierard, Gerald; Foidart, Jean-Marie; Noel, Agnes; Boniver, Jacques; Delvenne, Philippe			Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre) neoplastic lesions formed in vitro and transplanted in vivo	FASEB JOURNAL			English	Article						alpha and beta defensins; antigen presenting cells; HPV; cervical lesions; migration	SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN NEUTROPHIL PEPTIDE-1; COLONY-STIMULATING FACTOR; LANGERHANS CELLS; ALPHA-DEFENSINS; UTERINE CERVIX; HUMAN SKIN; TRANSFORMED KERATINOCYTES; (PRE)NEOPLASTIC LESIONS; PRENEOPLASTIC LESIONS	In addition to their direct antimicrobial activity, defensins might also influence adaptive immunity by attracting immature dendritic cells ( DC). As these cells have been shown to be deficient in uterine cervix carcinogenesis, we evaluated the ability of alpha- defensin ( HNP- 2, human neutrophil defensin 2) and alpha- defensin ( H beta D2, human beta defensin 2) to stimulate their migration in human papillomavirus ( HPV)associated ( pre) cancers. We first observed, using RTPCR and immunohistology, that H beta D2 is absent in HPV- transformed keratinocytes and that it is weakly expressed in cervical ( pre) neoplastic lesions in comparison with normal keratinocytes. We next demonstrated that defensins exert a chemotactic activity for DC in a Boyden Chamber assay and stimulate their infiltration in an in vitro- formed ( pre) neoplastic epithelium ( organotypic culture of HPV- transformed keratinocytes). To evaluate the ability of defensins also to recruit DC in vivo, we developed a model of immunodeficient mice grafted with organotypic cultures of HPV + keratinocytes, which form an epithelium similar to a high- grade neoplastic lesion, with tumoral invasion and neovascularization. Intravenously injected human DC were able to infiltrate grafts of HPV + keratinocytes after administration of HNP- 2 in the transplantation chamber. Taken together, these results suggest that defensins could reverse a frequent immune alteration observed in cancer development.	CHU Sart Tilman, Univ Hosp Liege, Dept Pathol, B-4000 Liege, Belgium; CHU Sart Tilman, Univ Hosp Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; CHU Sart Tilman, Univ Hosp Liege, Dept Dermatol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Hubert, P (corresponding author), Univ Liege, Dept Pathol B35, CHU Sart Tilman, B-4000 Liege, Belgium.	P.hubert@ulg.ac.be		Noel, Agnes/0000-0002-7670-6179; Nikkels, Arjen/0000-0001-5240-4806				Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Al-Saleh W, 1998, J PATHOL, V184, P283, DOI 10.1002/(SICI)1096-9896(199803)184:3<283::AID-PATH25>3.0.CO;2-K; Ali RS, 2001, J INVEST DERMATOL, V117, P106; Andrade W, 1996, J IMMUNOL METHODS, V194, P181, DOI 10.1016/0022-1759(96)00083-X; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bosch FX, 2002, VIRUS RES, V89, P183, DOI 10.1016/S0168-1702(02)00187-9; Buck CB, 2006, P NATL ACAD SCI USA, V103, P1516, DOI 10.1073/pnas.0508033103; Calore EE, 2001, GYNECOL OBSTET INVES, V51, P51, DOI 10.1159/000052891; Chadebech P, 2003, CELL BIOL TOXICOL, V19, P313, DOI 10.1023/B:CBTO.0000004975.36521.c8; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; Chavakis T, 2004, FASEB J, V18, P1306, DOI 10.1096/fj.03-1009fje; Chen HQ, 2006, PEPTIDES, V27, P931, DOI 10.1016/j.peptides.2005.08.018; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; DELVENNE P, 1995, AM J PATHOL, V146, P589; Duits LA, 2002, IMMUNOLOGY, V106, P517, DOI 10.1046/j.1365-2567.2002.01430.x; Economopoulou M, 2005, BLOOD, V106, P3831, DOI 10.1182/blood-2005-03-0889; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Giannini SL, 1998, CLIN EXP IMMUNOL, V113, P183; Giannini SL, 2002, INT J CANCER, V97, P654, DOI 10.1002/ijc.10084; Grutkoski PS, 2003, ANTIMICROB AGENTS CH, V47, P2666, DOI 10.1128/AAC.47.8.2666-2668.2003; Havard L, 2005, VIROLOGY, V331, P357, DOI 10.1016/j.virol.2004.10.030; Hubert P, 2005, J PATHOL, V206, P346, DOI 10.1002/path.1771; Hubert P, 2005, EXP DERMATOL, V14, P469, DOI 10.1111/j.0906-6705.2005.00299.x; Hubert P, 2001, FASEB J, V15, P2521, DOI 10.1096/fj.00-0872fje; Hubert P, 1999, AM J PATHOL, V154, P775, DOI 10.1016/S0002-9440(10)65324-2; Hubert P, 1998, CANCER IMMUNOL IMMUN, V47, P81, DOI 10.1007/s002620050507; HUGHES RG, 1988, J CLIN PATHOL, V41, P253, DOI 10.1136/jcp.41.3.253; Josien R, 1997, J EXP MED, V186, P467, DOI 10.1084/jem.186.3.467; KAPLAN G, 1992, J EXP MED, V175, P1717, DOI 10.1084/jem.175.6.1717; Lillard JW, 1999, P NATL ACAD SCI USA, V96, P651, DOI 10.1073/pnas.96.2.651; Lundy FT, 2004, ORAL ONCOL, V40, P139, DOI 10.1016/S1368-8375(03)00142-8; Mallow EB, 1996, J BIOL CHEM, V271, P4038; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; Matthews K, 2003, J VIROL, V77, P8378, DOI 10.1128/JVI.77.15.8378-8385.2003; McKeown STW, 2006, ORAL ONCOL, V42, P685, DOI 10.1016/j.oraloncology.2005.11.005; MEMAR OM, 1995, J INVEST DERMATOL, V105, pS99, DOI 10.1111/1523-1747.ep12316241; Mizukawa N, 2000, ANTICANCER RES, V20, P1125; Muller CA, 2002, AM J PATHOL, V160, P1311, DOI 10.1016/S0002-9440(10)62558-8; Noel A, 2004, J CLIN PATHOL, V57, P577, DOI 10.1136/jcp.2003.014472; Papo N, 2005, CELL MOL LIFE SCI, V62, P784, DOI 10.1007/s00018-005-4560-2; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; Renard I, 2002, AM J PATHOL, V160, P113, DOI 10.1016/S0002-9440(10)64355-6; Sorensen OE, 2005, J IMMUNOL, V174, P4870, DOI 10.4049/jimmunol.174.8.4870; THIVOLET J, 1982, INT J DERMATOL, V21, P94, DOI 10.1111/j.1365-4362.1982.tb00510.x; van Wetering S, 2002, INFLAMM RES, V51, P8, DOI 10.1007/PL00000282; Wang W, 2004, J IMMUNOL, V173, P515, DOI 10.4049/jimmunol.173.1.515; Weinberg A, 2006, Adv Dent Res, V19, P42; Yang D, 2000, J LEUKOCYTE BIOL, V68, P9; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	51	58	63	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2765	2775		10.1096/fj.06-7646com	http://dx.doi.org/10.1096/fj.06-7646com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17470569				2022-12-25	WOS:000249237500018
J	Kopriva, S; Fritzemeier, K; Wiedemann, G; Reski, R				Kopriva, Stanislav; Fritzemeier, Kai; Wiedemann, Gertrud; Reski, Ralf			The putative moss 3 '-phosphoadenosine-5 '-phosphosulfate reductase is a novel form of adenosine-5 '-phosphosulfate reductase without an iron-sulfur cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 5'-PHOSPHOSULFATE REDUCTASE; PREDICTING SUBCELLULAR-LOCALIZATION; PHYSCOMITRELLA-PATENS; SULFATE REDUCTASE; PAPS REDUCTASE; APS REDUCTASE; ASSIMILATION; METABOLISM	Sulfate assimilation provides reduced sulfur for synthesis of the amino acids cysteine and methionine and for a range of other metabolites. Sulfate has to be activated prior to reduction by adenylation to adenosine 5'-phosphosulfate (APS). In plants, algae, and many bacteria, this compound is reduced to sulfite by APS reductase (APR); in fungi and some cyanobacteria and gamma-proteobacteria, a second activation step, phosphorylation to 3'-phosphoadenosine 5'-phosphosulfate ( PAPS), is necessary before reduction to sulfite by PAPS reductase (PAPR). We found previously that the moss Physcomitrella patens is unique among these organisms in possessing orthologs of both APR and PAPR genes (Koprivova, A., Meyer, A. J., Schween, G., Herschbach, C., Reski, R., and Kopriva, S. ( 2002) J. Biol. Chem. 277, 32195-32201). To assess the function of the two enzymes, we compared their biochemical properties by analysis of purified recombinant proteins. APR from Physcomitrella is very similar to the well characterized APRs from seed plants. On the other hand, we found that the putative PAPR preferentially reduces APS. Sequence analysis, analysis of UV-visible spectra, and determination of iron revealed that this new APR, named PpAPR-B, does not contain the FeS cluster, which was previously believed to determine the substrate specificity of the otherwise relatively similar enzymes. The lack of the FeS cluster in PpAPR-B catalysis is connected with a lower turnover rate but higher stability of the protein. These findings show that APS reduction without the FeS cluster is possible and that plant sulfate assimilation is predominantly dependent on reduction of APS.	John Innes Inst, Dept Metab Biol, Norwich NR4 7UH, Norfolk, England; Univ Freiburg, Fac Biol, Plant Biochem Sect, D-79104 Freiburg, Germany; Univ Freiburg, Fac Biol, Plant Biotechnol Sect, D-79104 Freiburg, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Freiburg; University of Freiburg	Kopriva, S (corresponding author), John Innes Inst, Dept Metab Biol, Coloney Lane, Norwich NR4 7UH, Norfolk, England.	stanislav.kopriva@bbsrc.ac.uk	Reski, Ralf/A-8817-2008; Kopriva, Stanislav/C-7401-2013	Kopriva, Stanislav/0000-0002-7416-6551; Wiedemann, Gertrud/0000-0002-2259-1011; Reski, Ralf/0000-0002-5496-6711				Berndt C, 2004, J BIOL CHEM, V279, P7850, DOI 10.1074/jbc.M309332200; Bick JA, 1998, P NATL ACAD SCI USA, V95, P8404, DOI 10.1073/pnas.95.14.8404; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carroll KS, 2005, PLOS BIOL, V3, P1418, DOI 10.1371/journal.pbio.0030250; Carroll KS, 2005, BIOCHEMISTRY-US, V44, P14647, DOI 10.1021/bi051344a; Chartron J, 2006, J MOL BIOL, V364, P152, DOI 10.1016/j.jmb.2006.08.080; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; Guindon S, 2005, NUCLEIC ACIDS RES, V33, pW557, DOI 10.1093/nar/gki352; HOGLUND A, 2006, P PAC S BIOC, V11, P16; Hohe A, 2002, PLANT CELL REP, V20, P1135, DOI 10.1007/s00299-002-0463-y; Horton P, 2006, P 4 AS PAC BIOINF C; Kiessling J, 2000, J CELL BIOL, V151, P945, DOI 10.1083/jcb.151.4.945; Kim SK, 2004, BIOCHEMISTRY-US, V43, P13478, DOI 10.1021/bi048811t; Kim SK, 2007, BIOCHEMISTRY-US, V46, P591, DOI 10.1021/bi0618971; Kircher S, 1999, PLANT CELL, V11, P1445, DOI 10.1105/tpc.11.8.1445; Kopriva S, 2004, J EXP BOT, V55, P1775, DOI 10.1093/jxb/erh185; Kopriva S, 2006, ANN BOT-LONDON, V97, P479, DOI 10.1093/aob/mcl006; Kopriva S, 2002, J BIOL CHEM, V277, P21786, DOI 10.1074/jbc.M202152200; Kopriva S, 2001, J BIOL CHEM, V276, P42881, DOI 10.1074/jbc.M107424200; Koprivova A, 2002, J BIOL CHEM, V277, P32195, DOI 10.1074/jbc.M204971200; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lang D, 2005, PLANT BIOLOGY, V7, P238, DOI 10.1055/s-2005-837578; Leustek T, 2000, ANNU REV PLANT PHYS, V51, P141, DOI 10.1146/annurev.arplant.51.1.141; LI JY, 1991, BIOCHEM J, V274, P355, DOI 10.1042/bj2740355; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lu Z, 2004, BIOINFORMATICS, V20, P547, DOI 10.1093/bioinformatics/btg447; Penning TM, 2001, CHEM REV, V101, P3027, DOI 10.1021/cr000049n; RESKI R, 1985, PLANTA, V165, P354, DOI 10.1007/BF00392232; ROTHER S, 1994, J PLANT PHYSIOL, V143, P72, DOI 10.1016/S0176-1617(11)82099-7; Savage H, 1997, STRUCTURE, V5, P895, DOI 10.1016/S0969-2126(97)00244-X; SCHWENN JD, 1988, ARCH MICROBIOL, V150, P313, DOI 10.1007/BF00408300; Stumpe M, 2006, BBA-MOL CELL BIOL L, V1761, P301, DOI 10.1016/j.bbalip.2006.03.008; Tomita T, 2006, BIOSCI BIOTECH BIOCH, V70, P2230, DOI 10.1271/bbb.60170; Weber M, 2000, EUR J BIOCHEM, V267, P3647, DOI 10.1046/j.1432-1327.2000.01394.x	35	31	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22930	22938		10.1074/jbc.M702522200	http://dx.doi.org/10.1074/jbc.M702522200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17519237	hybrid			2022-12-25	WOS:000248354200070
J	Wei, F; Scholer, HR; Atchison, ML				Wei, Fang; Schoeler, Hans R.; Atchison, Michael L.			Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; POU DIMER CONFIGURATION; TRANSCRIPTION FACTOR; SUMO-1 MODIFICATION; MAMMALIAN EMBRYO; PROTEIN SUMO-1; UBIQUITIN; GENE; OCT-3/4; DOMAIN	Transcription factor Oct4 is a master regulator affecting the fate of pluripotent stem cells and germ cell precursors. Oct4 expression is tightly regulated, and small changes in expression level can have dramatic effects on differentiation or oncogenesis. Post-translational modifications including phosphorylation and ubiquitination have been reported to regulate Oct4 transcriptional activity. Here we show that Oct4 is a target for small ubiquitin-related modifier (SUMO)-1 modification in vivo and in vitro. Sumoylation of Oct4 occurs at a single lysine, Lys(118), located at the end of the amino-terminal transactivation domain and next to the Pit1-Oct-Unc86 (POU) DNA binding domain. SUMO-1 and Oct4 colocalize at several promoter sequences in vivo, and a fraction of Oct4 molecules colocalized with SUMO-1 in nuclear aggregates. Sumoylation of Oct4 led to significantly increased Oct4 stability and increased DNA binding. In addition, SUMO-1 cotransfection led to augmented Oct4 transactivation potential that was reduced when the Oct4 sumoylation target site was mutated. Therefore, sumoylation of Oct4 results in increased stability, DNA binding, and transactivation and provides an important mechanism to regulate Oct4 activity.	Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Dept Anim Biol, Philadelphia, PA 19104 USA; Max Planck Inst Mol Biomed, D-48149 Munster, Germany	University of Pennsylvania; Max Planck Society	Atchison, ML (corresponding author), Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	atchison@vet.upenn.edu	, HS/AAB-4434-2019	, HS/0000-0003-2643-5136	NICHD NIH HHS [HD042011] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042011] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hodawadekar S, 2006, J IMMUNOL, V177, P6165, DOI 10.4049/jimmunol.177.9.6165; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Ihara M, 2005, MOL CELL BIOL, V25, P3506, DOI 10.1128/MCB.25.9.3506-3518.2005; Kehler J, 2004, EMBO REP, V5, P1078, DOI 10.1038/sj.embor.7400279; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Nordhoff V, 2001, MAMM GENOME, V12, P309, DOI 10.1007/s003350010279; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; Okumura-Nakanishi S, 2005, J BIOL CHEM, V280, P5307, DOI 10.1074/jbc.m410015200; Ovitt CE, 1998, MOL HUM REPROD, V4, P1021, DOI 10.1093/molehr/4.11.1021; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Tomilin A, 2000, CELL, V103, P853, DOI 10.1016/S0092-8674(00)00189-6; Xu HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200; Yeom YI, 1996, DEVELOPMENT, V122, P881; YEOM YI, 1991, MECH DEVELOP, V35, P171	38	136	141	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21551	21560		10.1074/jbc.M611041200	http://dx.doi.org/10.1074/jbc.M611041200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17525163	hybrid			2022-12-25	WOS:000248047500082
J	Gand, A; Antoine, M; Boschi-Muller, S; Branlant, G				Gand, Adeline; Antoine, Mathias; Boschi-Muller, Sandrine; Branlant, Guy			Characterization of the amino acids involved in substrate specificity of methionine sulfoxide reductase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NEISSERIA-MENINGITIDIS; CATALYTIC MECHANISM; KINETIC CHARACTERIZATION; CRYSTAL-STRUCTURE; OXIDATION; ENZYME; MSRA	Methionine sulfoxide reductases (Msrs) are ubiquitous enzymes that catalyze the thioredoxin-dependent reduction of methionine sulfoxide ( MetSO) back to methionine. In vivo, Msrs are essential in protecting cells against oxidative damages on proteins and in the virulence of some bacteria. There exists two structurally unrelated classes of Msrs. MsrAs are stereo-specific toward the S epimer on the sulfur of the sulfoxide, whereas MsrBs are specific toward the R isomer. Both classes of Msrs display a similar catalytic mechanism of sulfoxide reduction by thiols via the sulfenic acid chemistry and a better affinity for protein-bound MetSO than for free MetSO. Recently, the role of the amino acids implicated in the catalysis of the reductase step of Neisseria meningitidis MsrA was determined. In the present study, the invariant amino acids potentially involved in substrate binding, i.e. Phe-52, Trp-53, Asp-129, His-186, Tyr-189, and Tyr-197, were substituted. The catalytic parameters under steady-state conditions and of the reductase step of the mutated MsrAs were determined and compared with those of the wild type. Altogether, the results support the presence of at least two binding subsites. The first one, whose contribution is major in the efficiency of the reductase step and in which the is an element of-methyl group of MetSO binds, is the hydrophobic pocket formed by Phe-52 and Trp-53, the position of the indole ring being stabilized by interactions with His-186 and Tyr-189. The second subsite composed of Asp-129 and Tyr-197 contributes to the binding of the main chain of the substrate but to a lesser extent.	Nancy Univ, Fac Sci & Tech, CNRS, UHP 7567, F-54506 Vandoeuvre Les Nancy, France; Nancy Univ, Fac Sci & Tech, Unite Mixte Rech, F-54506 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Universite de Lorraine	Branlant, G (corresponding author), Nancy Univ, Fac Sci & Tech, CNRS, UHP 7567, Bld des Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	Guy.Branlant@maem.uhp-nancy.fr		Boschi, Sandrine/0000-0001-8962-4749				Antoine M, 2003, J BIOL CHEM, V278, P45352, DOI 10.1074/jbc.M307471200; Antoine M, 2006, J BIOL CHEM, V281, P39062, DOI 10.1074/jbc.M608844200; Balta B, 2006, J PHYS CHEM A, V110, P7628, DOI 10.1021/jp0573036; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; Boschi-Muller S, 2005, BBA-PROTEINS PROTEOM, V1703, P231, DOI 10.1016/j.bbapap.2004.09.016; Boschi-Muller S, 2001, PROTEIN SCI, V10, P2272, DOI 10.1110/ps.10701; CHIPOT C, 1993, J PHYS CHEM-US, V97, P9788, DOI 10.1021/j100140a042; Coudevylle N, 2007, J MOL BIOL, V366, P193, DOI 10.1016/j.jmb.2006.11.042; Ezraty B, 2005, BBA-PROTEINS PROTEOM, V1703, P221, DOI 10.1016/j.bbapap.2004.08.017; Gruez A, 2004, J MOL BIOL, V343, P29, DOI 10.1016/j.jmb.2004.08.030; Guillot R, 2001, ACTA CRYSTALLOGR B, V57, P567, DOI 10.1107/S0108768101007212; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Moskovitz J, 2005, BBA-PROTEINS PROTEOM, V1703, P213, DOI 10.1016/j.bbapap.2004.09.003; Mossner E, 1998, PROTEIN SCI, V7, P1233; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; Neiers F, 2004, J BIOL CHEM, V279, P42462, DOI 10.1074/jbc.M407464200; Olry A, 2004, BIOCHEMISTRY-US, V43, P11616, DOI 10.1021/bi049306z; Olry A, 2002, J BIOL CHEM, V277, P12016, DOI 10.1074/jbc.M112350200; Rouhier N, 2007, J BIOL CHEM, V282, P3367, DOI 10.1074/jbc.M605007200; Schoneich C, 2005, BBA-PROTEINS PROTEOM, V1703, P111, DOI 10.1016/j.bbapap.2004.09.009; Taylor AB, 2003, J BACTERIOL, V185, P4119, DOI 10.1128/JB.185.14.4119-4126.2003; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8; Tsou LK, 2002, J AM CHEM SOC, V124, P14917, DOI 10.1021/ja026721a; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; Weissbach H, 2005, BBA-PROTEINS PROTEOM, V1703, P203, DOI 10.1016/j.bbapap.2004.10.004	25	13	14	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20484	20491		10.1074/jbc.M702350200	http://dx.doi.org/10.1074/jbc.M702350200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17500063	Green Published, hybrid			2022-12-25	WOS:000247819300051
J	Tang, GL; Cheng, YQ; Shen, B				Tang, Gong-Li; Cheng, Yi-Qiang; Shen, Ben			Chain initiation in the leinamycin-producing hybrid nonribosomal peptide/polyketide synthetase from streptomyces atroolivaceus S-140 - Discrete, monofunctional adenylation enzyme and peptidyl carrier protein that directly load D-Alanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC GENE-CLUSTER; IN-VITRO RECONSTITUTION; POLYKETIDE SYNTHASE; CYCLIC PEPTIDE; BIOCHEMICAL-CHARACTERIZATION; VERTICILLUS ATCC15003; NATURAL-PRODUCTS; VIBRIO-CHOLERAE; IDENTIFICATION; SIDEROPHORE	Nonribosomal peptide natural products are biosynthesized from amino acid precursors by nonribosomal peptide synthetases (NRPSs), which are organized into modules. For a typical NRPS initiation module, an adenylation (A) domain activates an amino acid and installs it onto a peptidyl carrier protein (PCP) domain as a thioester; an elongation module, which has a condensation (C) domain located between every consecutive pair of A and PCP domains, catalyzes the formation of the peptide bond between the upstream aminoacyl/peptidyl-S-PCP and the free amino group of the downstream aminoacyl-S-PCP. D-Amino acid constituents in peptide natural products usually arise from the L-enantiomers through the action of integral epimerization (E) domains of an NRPS. The biosynthetic gene cluster for leinamycin, a hybrid nonribosomal peptide/polyketide containing a D-alanine moiety, does not encode a typical NRPS initiation module with the expected A-PCP-E domains; instead, it has only an A protein (LnmQ) and a PCP (LnmP), both of which are encoded by separate genes. Here we show the results of biochemical experiments as follows: (i) we demonstrate that LnmQ directly activates D-alanine as D-alaninyl-AMP and installs it onto LnmP to generate a D-alaninyl-S-PCP intermediate; (ii) we confirm that aminoacylation of LnmP by LnmQ in trans is the result of specific communication between the separate A and PCP proteins; and (iii) we reveal that leinamycin production can be improved by supplementation of exogenous D-alanine in the fermentation broth of Streptomyces atroolivaceous S-140. These findings unveil an unprecedented NRPS initiation module structure that is characterized by a discrete D-alanine-specific A protein and a PCP.	Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53705 USA; Univ Wisconsin, Div Pharmaceut Sci, Natl Cooperat Drug Discovery Grp, Madison, WI 53705 USA; Univ Wisconsin, Dept Chem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Shen, B (corresponding author), Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, 777 Highland Ave, Madison, WI 53705 USA.	bshen@pharmacy.wisc.edu		Cheng, Eric/0000-0001-9336-2593	NATIONAL CANCER INSTITUTE [U19CA113297, R01CA106150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051687] Funding Source: NIH RePORTER; NCI NIH HHS [CA 106150, CA 113297, U19 CA113297] Funding Source: Medline; NIAID NIH HHS [AI 51687] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belshaw PJ, 1999, SCIENCE, V284, P486, DOI 10.1126/science.284.5413.486; Billman-Jacobe H, 1999, MOL MICROBIOL, V33, P1244, DOI 10.1046/j.1365-2958.1999.01572.x; Chang ZX, 2002, GENE, V296, P235, DOI 10.1016/S0378-1119(02)00860-0; Chen HW, 2001, BIOCHEMISTRY-US, V40, P11651, DOI 10.1021/bi0115434; Chen HW, 2001, CHEM BIOL, V8, P899, DOI 10.1016/S1074-5521(01)00064-3; Cheng YQ, 2000, J BIOL CHEM, V275, P4906, DOI 10.1074/jbc.275.7.4906; Cheng YQ, 2002, J BACTERIOL, V184, P7013, DOI 10.1128/JB.184.24.7013-7024.2002; Cheng YQ, 2003, P NATL ACAD SCI USA, V100, P3149, DOI 10.1073/pnas.0537286100; Chiu HT, 2001, P NATL ACAD SCI USA, V98, P8548, DOI 10.1073/pnas.151246498; Christiansen G, 2003, J BACTERIOL, V185, P564, DOI 10.1128/JB.185.2.564-572.2003; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; Doekel S, 2000, CHEM BIOL, V7, P373, DOI 10.1016/S1074-5521(00)00118-6; Du LC, 2000, CHEM BIOL, V7, P623, DOI 10.1016/S1074-5521(00)00011-9; Du LC, 1999, CHEM BIOL, V6, P507, DOI 10.1016/S1074-5521(99)80083-0; Du LH, 2001, METAB ENG, V3, P78, DOI 10.1006/mben.2000.0171; Duitman EH, 1999, P NATL ACAD SCI USA, V96, P13294, DOI 10.1073/pnas.96.23.13294; Ehmann DE, 2000, P NATL ACAD SCI USA, V97, P2509, DOI 10.1073/pnas.040572897; Fischbach MA, 2006, CHEM REV, V106, P3468, DOI 10.1021/cr0503097; Gaitatzis N, 2001, P NATL ACAD SCI USA, V98, P11136, DOI 10.1073/pnas.201167098; Gehring AM, 1997, BIOCHEMISTRY-US, V36, P8495, DOI 10.1021/bi970453p; HARA M, 1989, J ANTIBIOT, V42, P333, DOI 10.7164/antibiotics.42.333; HOFFMANN K, 1994, J BIOL CHEM, V269, P12710; Hubbard BK, 2003, ANGEW CHEM INT EDIT, V42, P730, DOI 10.1002/anie.200390202; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; Jiang WL, 2003, J AM CHEM SOC, V125, P1877, DOI 10.1021/ja0212314; Keating TA, 2000, BIOCHEMISTRY-US, V39, P15513, DOI 10.1021/bi001651a; Keating TA, 2000, BIOCHEMISTRY-US, V39, P15522, DOI 10.1021/bi0016523; Linne U, 2004, METHOD ENZYMOL, V388, P293; Lombo F, 2006, CHEMBIOCHEM, V7, P366, DOI 10.1002/cbic.200500325; Marsden AFA, 1998, SCIENCE, V279, P199, DOI 10.1126/science.279.5348.199; May JJ, 2001, J BIOL CHEM, V276, P7209, DOI 10.1074/jbc.M009140200; Miao V, 2005, MICROBIOL-SGM, V151, P1507, DOI 10.1099/mic.0.27757-0; Miller DA, 2002, CHEM BIOL, V9, P333, DOI 10.1016/S1074-5521(02)00115-1; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Mootz HD, 2002, CHEMBIOCHEM, V3, P490, DOI 10.1002/1439-7633(20020603)3:6<490::AID-CBIC490>3.0.CO;2-N; Patel HM, 2001, BIOCHEMISTRY-US, V40, P9023, DOI 10.1021/bi010519n; Pootoolal J, 2002, P NATL ACAD SCI USA, V99, P8962, DOI 10.1073/pnas.102285099; Quadri LEN, 1998, CHEM BIOL, V5, P631, DOI 10.1016/S1074-5521(98)90291-5; RUSNAK F, 1989, BIOCHEMISTRY-US, V28, P6827, DOI 10.1021/bi00443a008; Sambrook J, 2001, MOL CLONING LAB MANU; Sanchez C, 2001, CHEM BIOL, V8, P725, DOI 10.1016/S1074-5521(01)00047-3; Schmoock G, 2005, J BIOL CHEM, V280, P4339, DOI 10.1074/jbc.M411026200; Schoenafinger G, 2006, J AM CHEM SOC, V128, P7406, DOI 10.1021/ja0611240; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; Sieber SA, 2005, CHEM REV, V105, P715, DOI 10.1021/cr0301191; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Tang GL, 2006, J NAT PROD, V69, P387, DOI 10.1021/np050467t; Tang GL, 2004, CHEM BIOL, V11, P33, DOI 10.1016/j.chembiol.2003.12.014; Tao MF, 2007, MOL BIOSYST, V3, P60, DOI 10.1039/b615284h; Thomas MG, 2002, CHEM BIOL, V9, P171, DOI 10.1016/S1074-5521(02)00100-X; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; Walsh CT, 2002, CHEMBIOCHEM, V3, P125; Watanabe K, 2006, NAT CHEM BIOL, V2, P423, DOI 10.1038/nchembio803; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; Xia ZP, 2001, J ORG CHEM, V66, P3459, DOI 10.1021/jo005783l	55	44	49	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20273	20282		10.1074/jbc.M702814200	http://dx.doi.org/10.1074/jbc.M702814200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17502372	hybrid			2022-12-25	WOS:000247819300030
J	Hong, J; Doebele, RC; Lingen, MW; Quilliam, LA; Tang, WJ; Rosner, MR				Hong, Jia; Doebele, Robert C.; Lingen, Mark W.; Quilliam, Lawrence A.; Tang, Wei-Jen; Rosner, Marsha Rich			Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; CYCLIC-AMP; LETHAL FACTOR; BARRIER FUNCTION; ANGIOGENESIS; EXPRESSION; KINASE; ACTIVATION; RECEPTOR; PATHWAY	Angiogenesis involves the assembly of endothelial cells into capillaries from a pre-existing vasculature. Because abnormal angiogenesis is a hallmark of many cancers, it is critical to find factors that control this process. Endothelial cells are enriched in the anthrax receptor; we therefore determined the effect of anthrax edema toxin ( ET), an adenylyl cyclase, on chemotaxis. cAMP generated by ET does not block proliferation or survival but causes cytoskeletal changes and inhibits chemotaxis by primary human microvascular endothelial cells (HMVECs). These effects are due to the action of a downstream cAMP effector, Epac, a guanine nucleotide exchange-activating protein for Rap1 (RAP1-GEF). ET induces transcription of Epac-related activators of Rap1, Epac2 (RapGEF4), and MR-GEF/RapGEF5. Similar to ET, activated Epac or Rap1 induces cytoskeletal changes and blocks chemotaxis in human endothelial cells. These results identify Epac and Rap1 as key regulators of signaling cascades leading to endothelial cell chemotaxis.	Univ Chicago, Gordon Ctr Integrat Sci, Dept Canc Res, Chicago, IL 60637 USA; Univ Chicago, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Rosner, MR (corresponding author), Univ Chicago, Gordon Ctr Integrat Sci, Dept Canc Res, 929 E 57th St, Chicago, IL 60637 USA.	m-rosner@uchicago.edu	Doebele, Robert C./I-8230-2019; Quilliam, Lawrence/Q-4987-2019; Quilliam, Lawrence/B-6447-2015	Doebele, Robert C./0000-0001-6728-6857; Tang, Wei-Jen/0000-0002-8267-8995	NCI NIH HHS [CA108647, R01 CA108647, R01 CA108647-03, CA112310, CA109278] Funding Source: Medline; NHLBI NIH HHS [HL-07605] Funding Source: Medline; NIGMS NIH HHS [GM53459, GM62548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112310, R01CA109278, R01CA108647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062548, R01GM053459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Cline EI, 2002, CANCER RES, V62, P7143; Cullere X, 2005, BLOOD, V105, P1950, DOI 10.1182/blood-2004-05-1987; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dodge-Kafka KL, 2005, NATURE, V437, P574, DOI 10.1038/nature03966; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005; Gupta K, 2005, POSTGRAD MED J, V81, P236, DOI 10.1136/pgmj.2004.023309; Hong J, 2005, BIOCHEM BIOPH RES CO, V335, P850, DOI 10.1016/j.bbrc.2005.07.132; HOOVER DL, 1994, INFECT IMMUN, V62, P4432, DOI 10.1128/IAI.62.10.4432-4439.1994; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Khodarev NN, 2003, J CELL SCI, V116, P1013, DOI 10.1242/jcs.00281; Kirby JE, 2004, INFECT IMMUN, V72, P430, DOI 10.1128/IAI.72.1.430-439.2004; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; Kuo WL, 2004, J BIOL CHEM, V279, P23073, DOI 10.1074/jbc.M313696200; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Li Y, 2006, J BIOL CHEM, V281, P2506, DOI 10.1074/jbc.M508165200; Lingen MW, 2003, METH MOLEC MED, V78, P337; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Nor JE, 2000, J VASC RES, V37, P209, DOI 10.1159/000025733; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rehmann H, 2003, J BIOL CHEM, V278, P38548, DOI 10.1074/jbc.M306292200; Reinhart-King CA, 2005, BIOPHYS J, V89, P676, DOI 10.1529/biophysj.104.054320; Ribatti D, 2005, BRIT J HAEMATOL, V128, P303, DOI 10.1111/j.1365-2141.2004.05291.x; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Soelaiman S, 2003, J BIOL CHEM, V278, P25990, DOI 10.1074/jbc.M301232200; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Volpert OV, 2000, CANCER METAST REV, V19, P87, DOI 10.1023/A:1026560618302; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006; Wittchen ES, 2005, J BIOL CHEM, V280, P11675, DOI 10.1074/jbc.M412595200	39	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19781	19787		10.1074/jbc.M700128200	http://dx.doi.org/10.1074/jbc.M700128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17491018	hybrid			2022-12-25	WOS:000247650600053
J	Taurin, S; Hogarth, K; Sandbo, N; Yau, DM; Dulin, NO				Taurin, Sebastien; Hogarth, Kyle; Sandbo, Nathan; Yau, Douglas M.; Dulin, Nickolai O.			G beta gamma-mediated prostacyclin production and cAMP-dependent protein kinase activation by endothelin-1 promotes vascular smooth muscle cell hypertrophy through inhibition of glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHOSPHOLIPASE-C; RECEPTOR; GENE; EXPRESSION; SUBUNITS; RELEASE; PATHWAY; PKA; STIMULATION	Endothelin-1 (ET1) is a vasoactive peptide that stimulates hypertrophy of vascular smooth muscle cells (VSMC) through diverse signaling pathways mediated by G(q)/G(i)/G(13) heterotrimeric G proteins. We have found that ET1 stimulates the activity of cAMP-dependent protein kinase (PKA) in VSMC as profoundly as the G(s)-linked beta-adrenergic agonist, isoproterenol (ISO), but in a transient manner. PKA activation by ET1 was mediated by type-A ET1 receptors (ETA) and recruited an autocrine signaling mechanism distinct from that of ISO, involving G(i)-coupled beta gamma subunits of heterotrimeric G proteins, extracellular signal-regulated kinases ERK1/2, cyclooxygenase COX-1 ( but not COX-2) and prostacyclin receptors. In the functional studies, inhibition of PKA or COX-1 attenuated ET1-induced VSMC hypertrophy, suggesting the positive role of PKA in this response to ET1. Furthermore, we found that ET1 stimulates a G beta gamma-mediated, PKA-dependent phosphorylation and inactivation of glycogen synthase kinase-3 (GSK3), an enzyme that regulates cell growth. Together, this study describes that (i) PKA can be transiently activated by G(i)-coupled agonists such as ET1 by an autocrine mechanism involving G beta gamma/calcium/ERK/COX1/prostacyclin signaling, and (ii) this PKA activation promotes VSMC hypertrophy, at least in part, through PKA-dependent phosphorylation and inhibition of GSK3.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Dulin, NO (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	ndulin@medicine.bsd.uchicago.edu		Taurin, Sebastien/0000-0003-2167-5253	NHLBI NIH HHS [HL071755] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071755] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI M, 1991, BIOCHEM BIOPH RES CO, V180, P1265, DOI 10.1016/S0006-291X(05)81332-4; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; CHUA BHL, 1992, AM J PHYSIOL, V262, pE412, DOI 10.1152/ajpendo.1992.262.4.E412; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis A, 2003, CELL SIGNAL, V15, P597, DOI 10.1016/S0898-6568(02)00148-1; Demoliou-Mason CD, 1998, BIOL SIGNAL RECEPT, V7, P90; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Dulin NO, 2001, J BIOL CHEM, V276, P20827, DOI 10.1074/jbc.C100195200; Dulin NO, 2001, BIOCHEM J, V357, P587, DOI 10.1042/0264-6021:3570587; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FILEP JG, 1991, BIOCHEM BIOPH RES CO, V177, P171, DOI 10.1016/0006-291X(91)91964-E; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Goubaeva F, 2003, J BIOL CHEM, V278, P19634, DOI 10.1074/jbc.M300052200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; GRIENDLING KK, 1989, J BIOL CHEM, V264, P8237; Hogarth DK, 2004, AM J PHYSIOL-CELL PH, V287, pC449, DOI 10.1152/ajpcell.00547.2003; IIJIMA K, 1991, J CARDIOVASC PHARM, V17, pS146, DOI 10.1097/00005344-199100177-00040; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lum H, 1999, AM J PHYSIOL-CELL PH, V277, pC580, DOI 10.1152/ajpcell.1999.277.3.C580; MIURA K, 1989, EUR J PHARMACOL, V170, P91, DOI 10.1016/0014-2999(89)90139-8; MORELAND S, 1994, BRIT J PHARMACOL, V112, P704, DOI 10.1111/j.1476-5381.1994.tb13133.x; RAKUGI H, 1989, BIOCHEM BIOPH RES CO, V160, P924, DOI 10.1016/0006-291X(89)92523-0; RESINK TJ, 1988, BIOCHEM BIOPH RES CO, V157, P1360, DOI 10.1016/S0006-291X(88)81025-8; Roberts NA, 2005, BRIT J PHARMACOL, V145, P477, DOI 10.1038/sj.bjp.0706210; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; Schneider MP, 2007, ANNU REV PHARMACOL, V47, P731, DOI 10.1146/annurev.pharmtox.47.120505.105134; Shajahan AN, 2004, J BIOL CHEM, V279, P48055, DOI 10.1074/jbc.M405837200; Soltow QA, 2006, MED SCI SPORT EXER, V38, P840, DOI 10.1249/01.mss.0000218142.98704.66; WAGNERMANN C, 1991, AM J PHYSIOL, V260, pC763, DOI 10.1152/ajpcell.1991.260.4.C763; Wu R, 2005, HYPERTENSION, V45, P1139, DOI 10.1161/01.HYP.0000164572.92049.29; Yamboliev IA, 1998, PULM PHARMACOL THER, V11, P205, DOI 10.1006/pupt.1998.0139; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	43	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19518	19525		10.1074/jbc.M702655200	http://dx.doi.org/10.1074/jbc.M702655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17513863	hybrid			2022-12-25	WOS:000247650600026
J	Baldock, PA; Allison, SJ; Lundberg, P; Lee, NJ; Slack, K; Lin, EJD; Enriquez, RF; McDonald, MM; Zhang, L; During, MJ; Little, DG; Eisman, JA; Gardiner, EM; Yulyaningsih, E; Lin, S; Sainsbury, A; Herzog, H				Baldock, Paul A.; Allison, Susan J.; Lundberg, Pernilla; Lee, Nicola J.; Slack, Katy; Lin, En-Ju D.; Enriquez, Ronaldo F.; McDonald, Michelle M.; Zhang, Lei; During, Matthew J.; Little, David G.; Eisman, John A.; Gardiner, Edith M.; Yulyaningsih, Ernie; Lin, Shu; Sainsbury, Amanda; Herzog, Herbert			Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOTHALAMIC Y2 RECEPTORS; NEUROPEPTIDE-Y; INSULIN-SECRETION; ADIPOSE-TISSUE; KNOCKOUT MICE; NORMAL RATS; CYCLIC-AMP; LEPTIN; CELLS; MASS	The importance of neuropeptide Y (NPY) and Y2 receptors in the regulation of bone and energy homeostasis has recently been demonstrated. However, the contributions of the other Y receptors are less clear. Here we show that Y1 receptors are expressed on osteoblastic cells. Moreover, bone and adipose tissue mass are elevated in Y1(-/-) mice with a generalized increase in bone formation on cortical and cancellous surfaces. Importantly, the inhibitory effects of NPY on bone marrow stromal cells in vitro are absent in cells derived from Y1(-/-) mice, indicating a direct action of NPY on bone cells via this Y receptor. Interestingly, in contrast to Y2 receptor or germ line Y1 receptor deletion, conditional deletion of hypothalamic Y1 receptors in adult mice did not alter bone homeostasis, food intake, or adiposity. Furthermore, deletion of both Y1 and Y2 receptors did not produce additive effects in bone or adiposity. Thus Y1 receptor pathways act powerfully to inhibit bone production and adiposity by nonhypothalamic pathways, with potentially direct effects on bone tissue through a single pathway with Y2 receptors.	Univ Queensland, Sch Med, Brisbane, Qld 4000, Australia; St Vincents Hosp, Garvan Inst Med Res, Bone & Mineral Program, Neurosci Res Program, Sydney, NSW 2010, Australia; Umea Univ, Dept Oral Cell Biol, S-90187 Umea, Sweden; Childrens Hosp Westmead, Dept Orthopaed Res & Biotechnol, Sydney, NSW 2000, Australia; Univ Auckland, Dept Mol Med & Pathol, Auckland 1001, New Zealand; Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Brisbane, Qld 4102, Australia	University of Queensland; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Umea University; University of Sydney; University of Auckland; University of Queensland	Herzog, H (corresponding author), Univ Lund Hosp, Stem Cell Inst, Lab Neural Stem Cell Biol, S-22184 Lund, Sweden.	h.herzog@garvan.org.au	/B-2038-2013; /A-4361-2010; /E-2900-2010; /A-6021-2011; McDonald, Michelle/AAD-4760-2019; Herzog, Herbert/B-8294-2008; /B-6258-2012; During, Matthew/AAC-1388-2020; Eisman, John A/C-2886-2014; Salis, Amanda/A-3187-2011; Baldock, Paul/B-3840-2012	/0000-0001-7766-6095; /0000-0003-2110-2017; McDonald, Michelle/0000-0002-3928-2506; Salis, Amanda/0000-0001-9176-1574; lin, shu/0000-0002-4239-2028; , Herbert/0000-0002-1713-1029				Baldock PA, 2005, J BONE MINER RES, V20, P1851, DOI 10.1359/JBMR.050523; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Baldock PA, 2006, J BONE MINER RES, V21, P1618, DOI 10.1359/JBMR.060714; Baldock PA, 2006, J BONE MINER RES, V21, P1600, DOI 10.1359/JBMR.060705; BJURHOLM A, 1992, J BONE MINER RES, V7, P1011; BJURHOLM A, 1988, ACTA PHYSIOL SCAND, V134, P451, DOI 10.1111/j.1748-1716.1988.tb08515.x; BOONEKAMP PM, 1984, P K NED AKAD B PHYS, V87, P371; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CUSIN I, 1990, ENDOCRINOLOGY, V127, P3246, DOI 10.1210/endo-127-6-3246; DUMONT Y, 1990, EUR J PHARMACOL, V191, P501, DOI 10.1016/0014-2999(90)94189-5; Elefteriou F, 2004, P NATL ACAD SCI USA, V101, P3258, DOI 10.1073/pnas.0308744101; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; Gardiner EM, 2000, FASEB J, V14, P1908, DOI 10.1096/fj.99-1075com; Howell OW, 2005, J NEUROCHEM, V93, P560, DOI 10.1111/j.1471-4159.2005.03057.x; INSEL TR, 1989, PHYSIOL BEHAV, V45, P1033, DOI 10.1016/0031-9384(89)90234-5; Iyengar S, 1999, J PHARMACOL EXP THER, V289, P1031; Kalariti N, 2004, IN VIVO, V18, P621; Koteja P, 2003, PHYSIOL BEHAV, V80, P375, DOI 10.1016/j.physbeh.2003.09.001; Kushi A, 1998, P NATL ACAD SCI USA, V95, P15659, DOI 10.1073/pnas.95.26.15659; Lundberg P, 2007, J BIOL CHEM, V282, P19082, DOI 10.1074/jbc.M609629200; MOLTZ JH, 1985, PEPTIDES, V6, P1155, DOI 10.1016/0196-9781(85)90443-7; Morgan DG, 1998, DIABETOLOGIA, V41, P1482, DOI 10.1007/s001250051095; MURZI E, 1991, BRAIN RES BULL, V26, P321, DOI 10.1016/0361-9230(91)90001-Z; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; Parker RMC, 1999, EUR J NEUROSCI, V11, P1431, DOI 10.1046/j.1460-9568.1999.00553.x; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; PETTERSSON M, 1987, CELL TISSUE RES, V248, P43, DOI 10.1007/BF01239960; Pralong FP, 2002, FASEB J, V16, P712, DOI 10.1096/fj.01-0754fje; Sainsbury A, 2006, DIABETES, V55, P19; Sainsbury A, 1997, DIABETES, V46, P209, DOI 10.2337/diabetes.46.2.209; Sainsbury A, 2003, MOL CELL BIOL, V23, P5225, DOI 10.1128/MCB.23.15.5225-5233.2003; Sainsbury A, 1997, DIABETOLOGIA, V40, P1269, DOI 10.1007/s001250050820; Sainsbury A, 2002, P NATL ACAD SCI USA, V99, P8938, DOI 10.1073/pnas.132043299; Sainsbury A, 2002, DIABETES, V51, P3420, DOI 10.2337/diabetes.51.12.3420; Siu WS, 2003, J BONE MINER METAB, V21, P316, DOI 10.1007/s00774-003-0427-5; Standridge M, 2000, FASEB J, V14, P455, DOI 10.1096/fasebj.14.3.455; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7	39	153	166	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19092	19102		10.1074/jbc.M700644200	http://dx.doi.org/10.1074/jbc.M700644200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17491016	hybrid, Green Published			2022-12-25	WOS:000247475300051
J	Delaine, C; Alvino, CL; McNeil, KA; Mulhern, TD; Gauguin, L; De Meyts, P; Jones, EY; Brown, J; Wallace, JC; Forbes, BE				Delaine, Carlie; Alvino, Clair L.; McNeil, Kerrie A.; Mulhern, Terrance D.; Gauguin, Lisbeth; De Meyts, Pierre; Jones, E. Yvonne; Brown, James; Wallace, John C.; Forbes, Briony E.			A novel binding site for the human insulin-like growth factor-II (IGF-II)/mannose 6-phosphate receptor on IGF-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION; FUSION PROTEINS; LIGAND-BINDING; CROSS-LINKING; LOW-AFFINITY; B-DOMAIN; EXPRESSION; LOCALIZATION; MUTATIONS; RESIDUES	The mammalian insulin-like growth factor (IGF)-II/cation-independent mannose 6-phosphate receptor (IGF2R) binds IGF-II with high affinity. By targeting IGF-II to lysosomal degradation, it plays a role in the maintenance of correct IGF-II levels in the circulation and in target tissues. Loss of IGF2R function is associated with tumor progression; therefore, the IGF2R is often referred to as a tumor suppressor. The interaction between IGF2R and IGF-II involves domains 11 and 13 of the 15 extracellular domains of the receptor. Recently, a hydrophobic binding region was identified on domain 11 of the IGF2R. In contrast, relatively little is known about the residues of IGF-II that are involved in IGF2R binding and the determinants of IGF2R specificity for IGF-II over the structurally related IGF-I. Using a series of novel IGF-II analogues and surface plasmon resonance assays, this study revealed a novel binding surface on IGF-II critical for IGF2R binding. The hydrophobic residues Phe19 and Leu53 are critical for IGF2R binding, as are residues Thr16 and Asp52. Furthermore, Thr16 was identified as playing a major role in determining why IGF-II, but not IGF-I, binds with high affinity to the IGF2R.	Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia; Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Dept Biochem, Melbourne, Vic 3010, Australia; Hagedorn Res Lab, Receptor Syst Biol Lab, DK-2820 Gentofte, Denmark; Univ Oxford, Canc Res UK Receptor Struct Res Grp, Div Struct Biol, Oxford, England	University of Adelaide; University of Melbourne; Novo Nordisk; Hagedorn Research Institute; Cancer Research UK; University of Oxford	Forbes, BE (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	briony.forbes@adelaide.edu.au	Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016; , John/AAP-5150-2020; Mulhern, Terrence/A-1206-2007; Forbes, Briony/R-1838-2019	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Mulhern, Terrence/0000-0002-1609-7498; Forbes, Briony/0000-0003-4360-9927; De Meyts, Pierre/0000-0001-6214-0824	NCRR NIH HHS [P41 RR-01081] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brown J, 2002, EMBO J, V21, P1054, DOI 10.1093/emboj/21.5.1054; Brzozowski AM, 2002, BIOCHEMISTRY-US, V41, P9389, DOI 10.1021/bi020084j; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DAVIS SJ, 1990, J MOL BIOL, V213, P7, DOI 10.1016/S0022-2836(05)80116-0; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Denley A, 2004, MOL ENDOCRINOL, V18, P2502, DOI 10.1210/me.2004-0183; Denley A, 2005, MOL ENDOCRINOL, V19, P711, DOI 10.1210/me.2004-0409; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Devi GR, 1999, CANCER RES, V59, P4314; Forbes BE, 2001, GROWTH FACTORS, V19, P163, DOI 10.3109/08977190109001084; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Gill R, 1999, PROTEIN ENG, V12, P297, DOI 10.1093/protein/12.4.297; Hancock MK, 2002, J BIOL CHEM, V277, P47205, DOI 10.1074/jbc.M208534200; Hancock MK, 2002, J BIOL CHEM, V277, P11255, DOI 10.1074/jbc.M109855200; HODGSON DR, 1995, EUR J BIOCHEM, V233, P299, DOI 10.1111/j.1432-1033.1995.299_1.x; Killian JK, 2000, MOL CELL, V5, P707, DOI 10.1016/S1097-2765(00)80249-X; KING R, 1992, J MOL ENDOCRINOL, V8, P29, DOI 10.1677/jme.0.0080029; Lien S, 2001, BIOTECHNOL BIOENG, V74, P335, DOI 10.1002/bit.1124; Linnell J, 2001, J BIOL CHEM, V276, P23986, DOI 10.1074/jbc.M100700200; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Mazor O, 2002, ANAL BIOCHEM, V301, P75, DOI 10.1006/abio.2001.5475; MILNER SJ, 1995, BIOCHEM J, V308, P865, DOI 10.1042/bj3080865; OH Y, 1991, BIOCHEM J, V278, P249, DOI 10.1042/bj2780249; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; Raussens V, 2003, ANAL BIOCHEM, V319, P114, DOI 10.1016/S0003-2697(03)00285-9; Reddy ST, 2004, J BIOL CHEM, V279, P38658, DOI 10.1074/jbc.M407474200; Roche P, 2006, PROTEINS, V64, P758, DOI 10.1002/prot.21035; ROTH BV, 1991, BIOCHEM BIOPH RES CO, V181, P907, DOI 10.1016/0006-291X(91)91277-J; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; Scott CD, 2004, HORM METAB RES, V36, P261, DOI 10.1055/s-2004-814477; Shooter GK, 1996, J MOL ENDOCRINOL, V17, P237, DOI 10.1677/jme.0.0170237; SOOS MA, 1992, J BIOL CHEM, V267, P12955; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; Walenkamp MJE, 2005, J CLIN ENDOCR METAB, V90, P2855, DOI 10.1210/jc.2004-1254; Wan ZL, 2005, BIOCHEMISTRY-US, V44, P5000, DOI 10.1021/bi047585k; Yandell CA, 1999, J BIOL CHEM, V274, P27076, DOI 10.1074/jbc.274.38.27076; Zaccheo OJ, 2006, J MOL BIOL, V359, P403, DOI 10.1016/j.jmb.2006.03.046	41	29	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18886	18894		10.1074/jbc.M700531200	http://dx.doi.org/10.1074/jbc.M700531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17475626	hybrid			2022-12-25	WOS:000247475300029
J	Haacke, A; Hartl, FU; Breuer, P				Haacke, Annette; Hartl, F. Ulrich; Breuer, Peter			Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE; TRANSGENIC MICE; CELL-DEATH; CASPASE CLEAVAGE; NEURODEGENERATIVE DISORDERS; INTRANUCLEAR INCLUSIONS; PROTEIN AGGREGATION; MUTANT HUNTINGTIN; WILD-TYPE; FRAGMENTS	The formation of intraneuronal inclusions is a common feature of neurodegenerative polyglutamine disorders, including Spinocerebellar ataxia type 3. The mechanism that triggers inclusion formation in these typically late onset diseases has remained elusive. However, there is increasing evidence that proteolytic fragments containing the expanded polyglutamine segment are critically required to initiate the aggregation process. We analyzed ataxin-3 proteolysis in neuroblastoma cells and in vitro and show that calcium-dependent calpain proteases generate aggregation-competent ataxin-3 fragments. Co-expression of the highly specific cellular calpain inhibitor calpastatin abrogated fragmentation and the formation of inclusions in cells expressing pathological ataxin-3. These findings suggest a critical role of calpains in the pathogenesis of Spinocerebellar ataxia type 3.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society	Hartl, FU (corresponding author), Max Planck Inst Biochem, Am Klopferspitz 18, D-82152 Martinsried, Germany.	u.hartl@biochem.mpg.de; breuer@biochem.mpg.de	Hartl, F. Ulrich/Y-8206-2019					Berke SJS, 2004, J NEUROCHEM, V89, P908, DOI 10.1111/j.1471-4159.2004.02369.x; Cemal CK, 2002, HUM MOL GENET, V11, P1075, DOI 10.1093/hmg/11.9.1075; Chan EYW, 2002, HUM MOL GENET, V11, P1939, DOI 10.1093/hmg/11.17.1939; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Goffredo D, 2002, J BIOL CHEM, V277, P39594, DOI 10.1074/jbc.C200353200; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Goti D, 2004, J NEUROSCI, V24, P10266, DOI 10.1523/JNEUROSCI.2734-04.2004; Haacke A, 2006, HUM MOL GENET, V15, P555, DOI 10.1093/hmg/ddi472; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Kim MH, 2003, EXP NEUROL, V183, P109, DOI 10.1016/S0014-4886(03)00132-8; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; LIU CM, 1978, J BIOL CHEM, V253, P5892; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Miyashita T, 1997, J BIOL CHEM, V272, P29238, DOI 10.1074/jbc.272.46.29238; MouattPrigent A, 1996, NEUROSCIENCE, V73, P979, DOI 10.1016/0306-4522(96)00100-5; Namura S, 2002, NEUROBIOL DIS, V11, P147, DOI 10.1006/nbdi.2002.0532; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Samara C, 2003, AGEING RES REV, V2, P451, DOI 10.1016/S1568-1637(03)00032-1; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Vig PJS, 2000, J NEUROL SCI, V174, P100, DOI 10.1016/S0022-510X(00)00262-8; Villa PG, 1998, J CELL SCI, V111, P713; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wootz H, 2006, EXP CELL RES, V312, P1890, DOI 10.1016/j.yexcr.2006.02.021; Yadavalli R, 2004, J BIOL CHEM, V279, P21948, DOI 10.1074/jbc.M400793200	40	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18851	18856		10.1074/jbc.M611914200	http://dx.doi.org/10.1074/jbc.M611914200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17488727	hybrid			2022-12-25	WOS:000247475300024
J	Paul, S; Gable, K; Dunn, TM				Paul, Shilpi; Gable, Kenneth; Dunn, Teresa M.			A six-membrane-spanning topology for yeast and arabidopsis Tsc13p, the enoyl reductases of the microsomal fatty acid elongating system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; TRANSMEMBRANE TOPOLOGY; LIPID RAFTS; GENE FAMILY; IDENTIFICATION; GLYCOSYLATION; BIOSYNTHESIS; SUPPRESSORS; COMPONENT; ENCODES	The very long chain fatty acids are crucial building blocks of essential lipids, most notably the sphingolipids. These elongated fatty acids are synthesized by a system of enzymes that are organized in a complex within the endoplasmic reticulum membrane. Although several of the components of the elongase complex have recently been identified, little is known about how these proteins are organized within the membrane or about how they interact with one another during fatty acid elongation. In this study the topology of Tsc13p, the enoyl reductase of the elongase system, was investigated. The N and C termini of Tsc13p reside in the cytoplasm, and six putative membrane-spanning domains were identified by insertion of glycosylation and factor Xa cleavage sites at various positions. The N-terminal domain including the first membrane-spanning segment contains sufficient information for targeting to the endoplasmic reticulum membrane. Studies of the Arabidopsis Tsc13p protein revealed a similar topology. Highly conserved domains of the Tsc13p proteins that are likely to be important for enzymatic activity lie on the cytosolic face of the endoplasmic reticulum, possibly partially embedded within the membrane.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20184 USA	Uniformed Services University of the Health Sciences - USA	Dunn, TM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20184 USA.	tdunn@usuhs.mil		PAUL, SHILPI/0000-0001-5075-2081				Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; Beaudoin F, 2002, J BIOL CHEM, V277, P11481, DOI 10.1074/jbc.M111441200; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Gable K, 2004, J EXP BOT, V55, P543, DOI 10.1093/jxb/erh061; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Han GS, 2002, J BIOL CHEM, V277, P35440, DOI 10.1074/jbc.M205620200; Han GS, 2004, J BIOL CHEM, V279, P53707, DOI 10.1074/jbc.M410014200; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Kim H, 2006, P NATL ACAD SCI USA, V103, P11142, DOI 10.1073/pnas.0604075103; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lee S, 2006, NUCLEIC ACIDS RES, V34, pW99, DOI 10.1093/nar/gkl351; Miller JP, 2005, P NATL ACAD SCI USA, V102, P12123, DOI 10.1073/pnas.0505482102; Moon YA, 2003, J BIOL CHEM, V278, P7335, DOI 10.1074/jbc.M211684200; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Paul S, 2006, J BIOL CHEM, V281, P9018, DOI 10.1074/jbc.M507723200; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; Romano JD, 2001, MOL BIOL CELL, V12, P1957, DOI 10.1091/mbc.12.7.1957; Sherman F., 1986, METHODS YEAST GENETI; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Xu XJ, 2002, PLANT PHYSIOL, V128, P924, DOI 10.1104/pp.010621; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Zhang XM, 2003, MOL VIS, V9, P301; ZHAO C, 1994, J BIOL CHEM, V269, P21480; Zheng HQ, 2005, PLANT CELL, V17, P1467, DOI 10.1105/tpc.104.030155	36	16	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19237	19246		10.1074/jbc.M701774200	http://dx.doi.org/10.1074/jbc.M701774200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17463005	hybrid			2022-12-25	WOS:000247475300064
J	Robin, E; Guzy, RD; Loor, G; Iwase, H; Waypa, GB; Marks, JD; Hoek, TLV; Schumacker, PT				Robin, Emmanuel; Guzy, Robert D.; Loor, Gabriel; Iwase, Hirotaro; Waypa, Gregory B.; Marks, Jeremy D.; Hoek, Terry L. Vanden; Schumacker, Paul T.			Oxidant stress during simulated ischemia primes cardiomyocytes for cell death during reperfusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; REDOX GENE-THERAPY; MYOCARDIAL-ISCHEMIA; FLUORESCENT PROTEIN; CARDIAC MYOCYTES; RABBIT HEART; NITRIC-OXIDE; COMPLEX-III; OXYGEN; INJURY	Ischemia-reperfusion injury induces oxidant stress, and the burst of reactive oxygen species (ROS) production after reperfusion of ischemic myocardium is sufficient to induce cell death. Mitochondrial oxidant production may begin during ischemia prior to reperfusion because reducing equivalents accumulate and promote superoxide production. We utilized a ratiometric redox-sensitive protein sensor (heat shock protein 33 fluorescence resonance energy transfer (HSP-FRET)) to assess oxidant stress in cardiomyocytes during simulated ischemia. HSP-FRET consists of the cyan and yellow fluorescent protein fluorophores linked by the cysteine-containing regulatory domain from bacterial HSP-33. During ischemia, ROS-mediated oxidation of HSP-FRET was observed, along with a decrease in cellular reduced glutathione levels. These findings were corroborated by measurements using redox-sensitive green fluorescent protein, another protein thiol ratiometric sensor, which became 93% oxidized by the end of simulated ischemia. However, cell death did not occur during ischemia, indicating that this oxidant stress is not sufficient to induce death before reperfusion. However, interventions that attenuate ischemic oxidant stress, including antioxidants or scavengers of residual O-2 that attenuate/prevent ROS generation during ischemia, abrogated cell death during simulated reperfusion. These findings reveal that, in isolated cardiomyocytes, sublethal H2O2 generation during simulated ischemia regulates cell death during simulated reperfusion, which is mediated by the reperfusion oxidant burst.	Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA	Northwestern University; University of Chicago; University of Chicago	Schumacker, PT (corresponding author), Northwestern Univ, Dept Pediat, 303 E Chicago Ave, Chicago, IL 60611 USA.	p-schumacker@northwestern.edu	Marks, Jeremy/W-2087-2019	Marks, Jeremy/0000-0002-2644-5257; Robin, Emmanuel/0000-0003-3422-5622; Waypa, Gregory/0000-0002-6179-4209; Guzy, Robert/0000-0001-8420-6177; Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [R01 HL079650, HL079650, HL35440, HL66315, R01 HL066315, HL32646] Funding Source: Medline; NINDS NIH HHS [R01 NS056313-01A1, R01 NS056313] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL032646, R01HL079650, R01HL032646, R01HL035440, R01HL066315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS056313] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Argaud L, 2005, CIRCULATION, V111, P194, DOI 10.1161/01.CIR.0000151290.04952.3B; Bai JX, 2001, J BIOL CHEM, V276, P4315, DOI 10.1074/jbc.M008895200; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; Chen ZY, 2000, FREE RADICAL BIO MED, V29, P589, DOI 10.1016/S0891-5849(00)00363-4; DEBOER LWV, 1983, P NATL ACAD SCI-BIOL, V80, P5784, DOI 10.1073/pnas.80.18.5784; Dooley CT, 2004, J BIOL CHEM, V279, P22284, DOI 10.1074/jbc.M312847200; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Eaton P, 2002, J MOL CELL CARDIOL, V34, P1549, DOI 10.1006/jmcc.2002.2108; Graf PCF, 2004, J BIOL CHEM, V279, P20529, DOI 10.1074/jbc.M401764200; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hanson GT, 2004, J BIOL CHEM, V279, P13044, DOI 10.1074/jbc.M312846200; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Jain M, 2004, CIRCULATION, V109, P898, DOI 10.1161/01.CIR.0000112605.43318.CA; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Janssens S, 2004, CIRC RES, V94, P1256, DOI 10.1161/01.RES.0000126497.38281.23; Lesnefsky EJ, 2004, AM J PHYSIOL-HEART C, V287, pH258, DOI 10.1152/ajpheart.00348.2003; Lesnefsky EJ, 2001, AM J PHYSIOL-HEART C, V280, pH2770; Levraut J, 2003, AM J PHYSIOL-HEART C, V284, pH549, DOI 10.1152/ajpheart.00708.2002; Liochev SI, 2001, J BIOL CHEM, V276, P35253, DOI 10.1074/jbc.M104237200; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; McDonald MC, 1999, FREE RADICAL BIO MED, V27, P493, DOI 10.1016/S0891-5849(99)00100-8; MISRA HP, 1972, J BIOL CHEM, V247, P188; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; REIMER KA, 1979, LAB INVEST, V40, P633; SCHONHEIT K, 1995, BBA-MOL BASIS DIS, V1271, P335, DOI 10.1016/0925-4439(95)00052-6; Shao ZH, 2007, AM J PHYSIOL-HEART C, V292, pH1995, DOI 10.1152/ajpheart.01312.2005; Swift LM, 2000, AM J PHYSIOL-HEART C, V278, pH982, DOI 10.1152/ajpheart.2000.278.3.H982; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Van den Berg A, 2000, INT J CANCER, V86, P548, DOI 10.1002/(SICI)1097-0215(20000515)86:4<548::AID-IJC17>3.0.CO;2-A; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Vanden Hoek TL, 2003, AM J PHYSIOL-HEART C, V284, pH141, DOI 10.1152/ajpheart.00132.2002; VandenHoek TL, 1996, AM J PHYSIOL-HEART C, V270, pH1334, DOI 10.1152/ajpheart.1996.270.4.H1334; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Vergely C, 2003, ARCH BIOCHEM BIOPHYS, V420, P209, DOI 10.1016/j.abb.2003.07.007; Vergely C, 2001, FREE RADICAL RES, V35, P475, DOI 10.1080/10715760100301491; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Zhao HT, 2005, P NATL ACAD SCI USA, V102, P5727, DOI 10.1073/pnas.0501719102; Zhao KS, 2004, J BIOL CHEM, V279, P34682, DOI 10.1074/jbc.M402999200; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698; Zwacka RM, 1998, HUM GENE THER, V9, P1381, DOI 10.1089/hum.1998.9.9-1381; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; Zweier JL, 1998, TRANSPL P, V30, P4228, DOI 10.1016/S0041-1345(98)01399-2	47	115	119	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19133	19143		10.1074/jbc.M701917200	http://dx.doi.org/10.1074/jbc.M701917200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17488710	hybrid			2022-12-25	WOS:000247475300055
J	Wakamatsu, K; Ogita, H; Okabe, N; Irie, K; Tanaka-Okamoto, M; Ishizaki, H; Ishida-Yamamoto, A; Iizuka, H; Miyoshi, J; Takai, Y				Wakamatsu, Kotaro; Ogita, Hisakazu; Okabe, Noriko; Irie, Kenji; Tanaka-Okamoto, Miki; Ishizaki, Hiroyuki; Ishida-Yamamoto, Akemi; Iizuka, Hajime; Miyoshi, Jun; Takai, Yoshimi			Up-regulation of loricrin expression by cell adhesion molecule nectin-1 through Rap1-ERK signaling in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTIONS; BARRIER FUNCTION; ECTODERMAL DYSPLASIA; ADHERENS JUNCTIONS; EPIDERMAL BARRIER; CLEFT LIP/PALATE; E-CADHERIN; PROTEIN; SKIN; ROLES	Nectin is an immunoglobulin-like cell-cell adhesion molecule, which plays essential roles in the initial step of formation of adherens junctions and tight junctions. We demonstrate here the role of nectin-1 in the epidermis using nectin-1(-/-) mice. Newborn nectin-1(-/-) pups showed shiny and slightly reddish skin; the amount of loricrin, one of the differentiation markers and also a major component of cornified cell envelopes, was markedly reduced in the epidermis of nectin-1(-/-) mice. The amounts of repetin and SPRRP, other components of cornified cell envelopes, were markedly elevated probably due to a compensatory mechanism to overcome the impaired expression of loricrin. However, cornified cells from nectin-1(-/-) mice were sensitive to mechanical stress. Moreover, Ca2+ induced activation of ERK through Rap1 and expression of loricrin were reduced in primary cultured nectin-1(-/-) keratinocytes; in turn, the inhibition of ERK activation reduced the amount of loricrin in wild-type keratinocytes. These results indicate that nectin-1 plays a key role in the expression of loricrin in the epidermis.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Mol Biol, Osaka 5378511, Japan; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan	Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Asahikawa Medical College	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Wakamatsu, Kazumasa/AAZ-5877-2020; Ogita, Hisakazu/AAE-4416-2020	Wakamatsu, Kazumasa/0000-0003-1748-9001; Tanaka-Okamoto, Miki/0000-0002-6429-7662; Ogita, Hisakazu/0000-0001-6750-1668				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; ELIAS PM, 1977, ANAT RECORD, V189, P577, DOI 10.1002/ar.1091890404; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Inagaki M, 2005, DEVELOPMENT, V132, P1525, DOI 10.1242/dev.01697; Inagaki M, 2006, GENES CELLS, V11, P1125, DOI 10.1111/j.1365-2443.2006.01006.x; Jarnik M, 2002, J INVEST DERMATOL, V118, P102, DOI 10.1046/j.0022-202x.2001.01661.x; Kobayashi T, 1998, J DERMATOL SCI, V17, P108, DOI 10.1016/S0923-1811(97)00081-9; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Lane EB, 2004, J PATHOL, V204, P355, DOI 10.1002/path.1643; Matsushima H, 2003, BRIT J DERMATOL, V148, P755, DOI 10.1046/j.1365-2133.2003.05225.x; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Mueller S, 2003, BIOL REPROD, V69, P1330, DOI 10.1095/biolreprod.102.014670; Ogita H, 2006, IUBMB LIFE, V58, P334, DOI 10.1080/15216540600719622; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okabe N, 2004, DEV BIOL, V273, P244, DOI 10.1016/j.ydbio.2004.05.034; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; Sakai S, 2003, J INVEST DERMATOL, V120, P79, DOI 10.1046/j.1523-1747.2003.12006.x; Sakamoto Y, 2006, J BIOL CHEM, V281, P19631, DOI 10.1074/jbc.M600301200; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Seo HR, 2004, EXP MOL MED, V36, P292, DOI 10.1038/emm.2004.40; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Sozen MA, 2001, NAT GENET, V29, P141, DOI 10.1038/ng740; STEVEN AC, 1994, J CELL SCI, V107, P693; Suzuki K, 1998, AM J HUM GENET, V63, P1102, DOI 10.1086/302072; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tinkle CL, 2004, P NATL ACAD SCI USA, V101, P552, DOI 10.1073/pnas.0307437100; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2002, CURR OPIN CELL BIOL, V14, P531, DOI 10.1016/S0955-0674(02)00362-9; Tunggal JA, 2005, EMBO J, V24, P1146, DOI 10.1038/sj.emboj.7600605; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; Yamada A, 2006, ONCOGENE, V25, P5085, DOI 10.1038/sj.onc.1209525	45	23	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18173	18181		10.1074/jbc.M611159200	http://dx.doi.org/10.1074/jbc.M611159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17472964	hybrid			2022-12-25	WOS:000247302000023
J	Wood, VHJ; O'Neil, JD; Wei, W; Stewart, SE; Dawson, CW; Young, LS				Wood, V. H. J.; O'Neil, J. D.; Wei, W.; Stewart, S. E.; Dawson, C. W.; Young, L. S.			Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGF beta signaling pathways	ONCOGENE			English	Article						EBV; EBNA1; STAT1; TGF beta 1; SMAD2	GROWTH-FACTOR-BETA; NUCLEAR ANTIGEN 1; NASOPHARYNGEAL CARCINOMA; KAPOSIS-SARCOMA; LYMPHOMA-CELLS; KAPPA-B; EXPRESSION; CANCER; PROTEIN; PROMOTER	The Epstein-Barr virus (EBV)-encoded EBNA1 protein is expressed in all virus-associated tumors where it plays an essential role in the maintenance, replication and transcription of the EBV genome. Transcriptional pro. ling of EBNA1-expressing carcinoma cells demonstrated that EBNA1 also influences the expression of a range of cellular genes including those involved in translation, transcription and cell signaling. Of particular interest was the ability of EBNA1 to enhance expression of STAT1 and sensitize cells to interferon-induced STAT1 activation with resultant enhancement of major histocompatibility complex expression. A negative effect of EBNA1 on the expression of TGF beta 1-responsive beta ig-h3 and PAI-1 genes was confirmed at the protein level in EBV-infected carcinoma cells. This effect resulted from the ability of EBNA1 to repress TGFb1-induced transcription via a reduction in the interaction of SMAD2 with SMAD4. More detailed analysis revealed that EBNA1 induces a lower steady-state level of SMAD2 protein as a consequence of increased protein turnover. These data show that EBNA1 can influence cellular gene transcription resulting in effects that may contribute to the development of EBV-associated tumors.	Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	L.S.Young@bham.ac.uk	Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298; Wei, Wenbin/0000-0003-1288-6999				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Cao WP, 2006, BLOOD, V107, P2777, DOI 10.1182/blood-2005-05-1803; Chen HL, 2003, J VIROL, V77, P4139, DOI 10.1128/JVI.77.7.4139-4148.2003; Chen HL, 1999, P NATL ACAD SCI USA, V96, P9339, DOI 10.1073/pnas.96.16.9339; Chen HL, 2001, J VIROL, V75, P2929, DOI 10.1128/JVI.75.6.2929-2937.2001; Choi SH, 2006, J BIOL CHEM, V281, P7468, DOI 10.1074/jbc.M512438200; Chow LSN, 2006, ONCOGENE, V25, P310, DOI 10.1038/sj.onc.1209001; Chuang TC, 2002, FEBS LETT, V532, P135, DOI 10.1016/S0014-5793(02)03658-X; Debonneville C, 2004, MOL CELL BIOL, V24, P2397, DOI 10.1128/MCB.24.6.2397-2409.2004; Fakhari FD, 2006, J CLIN INVEST, V116, P735, DOI 10.1172/JCI26190; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Harn HJ, 2002, ORAL ONCOL, V38, P23, DOI 10.1016/S1368-8375(01)00008-2; Holowaty MN, 2003, J BIOL CHEM, V278, P29987, DOI 10.1074/jbc.M303977200; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Humme S, 2003, P NATL ACAD SCI USA, V100, P10989, DOI 10.1073/pnas.1832776100; Kang MS, 2005, P NATL ACAD SCI USA, V102, P820, DOI 10.1073/pnas.0408774102; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; Kennedy G, 2003, P NATL ACAD SCI USA, V100, P14269, DOI 10.1073/pnas.2336099100; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Komano J, 1998, J VIROL, V72, P9150, DOI 10.1128/JVI.72.11.9150-9156.1998; Kovacic B, 2006, CANCER CELL, V10, P77, DOI 10.1016/j.ccr.2006.05.025; Kube D, 1999, J VIROL, V73, P1630, DOI 10.1128/JVI.73.2.1630-1636.1999; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Lee CY, 2004, IEEE T EVOLUT COMPUT, V8, P1, DOI 10.1109/TEVC.2003.816583; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Liang CL, 2000, VIROLOGY, V277, P184, DOI 10.1006/viro.2000.0582; Liang CL, 2002, J BIOL CHEM, V277, P23345, DOI 10.1074/jbc.M107420200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Mori N, 2003, INT J CANCER, V105, P661, DOI 10.1002/ijc.11146; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Nam JO, 2005, CANCER RES, V65, P4153, DOI 10.1158/0008-5472.CAN-04-2705; Oh JE, 2005, J BIOL CHEM, V280, P21629, DOI 10.1074/jbc.m412293200; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Renne C, 2006, AM J PATHOL, V169, P655, DOI 10.2353/ajpath.2006.060020; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Saridakis V, 2005, MOL CELL, V18, P25, DOI 10.1016/j.molcel.2005.02.029; Seo TG, 2005, CANCER RES, V65, P1738, DOI 10.1158/0008-5472.CAN-04-2374; Shao GZ, 2006, CANCER RES, V66, P4566, DOI 10.1158/0008-5472.CAN-05-2130; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Sheu LF, 1996, J PATHOL, V180, P243, DOI 10.1002/(SICI)1096-9896(199611)180:3<243::AID-PATH655>3.0.CO;2-7; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; Stewart S, 2004, P NATL ACAD SCI USA, V101, P15730, DOI 10.1073/pnas.0402135101; Tellam J, 2004, J EXP MED, V199, P1421, DOI 10.1084/jem.20040191; Tsimbouri P, 2002, ONCOGENE, V21, P5182, DOI 10.1038/sj.onc.1205490; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Voo KS, 2004, J EXP MED, V199, P459, DOI 10.1084/jem.20031219; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	60	96	103	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4135	4147		10.1038/sj.onc.1210496	http://dx.doi.org/10.1038/sj.onc.1210496			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17486072				2022-12-25	WOS:000247252700009
J	Meyers, JH; Justement, JS; Hallahan, CW; Blair, ET; Sun, YMA; O'Shea, MA; Roby, G; Kottilil, S; Moir, S; Kovacs, CM; Chun, TW; Fauci, AS				Meyers, Jennifer Hartt; Justement, J. Shawn; Hallahan, Claire W.; Blair, Eric T.; Sun, Yongming A.; O'Shea, M. Angeline; Roby, Gregg; Kottilil, Shyam; Moir, Susan; Kovacs, Colin M.; Chun, Tae-Wook; Fauci, Anthony S.			Impact of HIV on Cell Survival and Antiviral Activity of Plasmacytoid Dendritic Cells	PLOS ONE			English	Article								Plasmacytoid dendritic cells (pDCs) are important mediators of innate immunity that act mainly through secretion of interferon (IFN)-alpha. Previous studies have found that these cells can suppress HIV in vitro; additionally, pDCs have been shown to be severely reduced in the peripheral blood of HIV-infected individuals. In the present study, we sought to determine the ability of pDCs to directly suppress viral replication ex vivo and to delineate the potential mechanisms whereby pDCs are depleted in HIV-infected individuals. We demonstrate that activated pDCs strongly suppress HIV replication in autologous CD4(+) T cells via a mechanism involving IFN-alpha as well as other antiviral factors. Of note, unstimulated pDCs from infected individuals who maintain low levels of plasma viremia without antiretroviral therapy were able to suppress HIV ex vivo via a mechanism requiring cell-to-cell contact. Our data also demonstrate that death of pDCs by both apoptosis and necrosis is induced by fusion of HIV with pDCs. Taken together, our data suggest that pDCs play an important role in the control of HIV replication and that high levels of viral replication in vivo are associated with pDC cell death via apoptosis and necrosis. Elucidation of the mechanism by which pDCs suppress HIV replication in vivo may have clinically relevant implications for future therapeutic strategies.	[Meyers, Jennifer Hartt; Justement, J. Shawn; O'Shea, M. Angeline; Roby, Gregg; Kottilil, Shyam; Moir, Susan; Chun, Tae-Wook; Fauci, Anthony S.] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; [Blair, Eric T.; Sun, Yongming A.] Appl Biosyst Inc, Foster City, CA 94404 USA; [Hallahan, Claire W.] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA; [Kovacs, Colin M.] Univ Toronto, Dept Med, Toronto, ON, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Thermo Fisher Scientific; Applied Biosystems; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Toronto	Chun, TW (corresponding author), NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	twchun@nih.gov	Chun, Tae-Wook/W-9187-2019; Moir, Susan/AAC-3676-2020; Kottilil, Shyam/ABF-7605-2021; Chun, Tae-Wook/AAC-3101-2020	Chun, Tae-Wook/0000-0001-5153-7340; 	National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000825, Z01AI000885, Z01AI000886, Z01AI000390, ZIAAI000825, ZIAAI000886, ZIAAI000390, Z01AI000851, ZIAAI000851] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Almeida M, 2006, JAIDS-J ACQ IMM DEF, V41, P405, DOI 10.1097/01.qai.0000209896.82255.d3; Barron MA, 2003, J INFECT DIS, V187, P26, DOI 10.1086/345957; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Bjorndal A, 1997, J VIROL, V71, P7478; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bosinger SE, 2004, J IMMUNOL, V173, P6858, DOI 10.4049/jimmunol.173.11.6858; Chehimi J, 2002, J IMMUNOL, V168, P4796, DOI 10.4049/jimmunol.168.9.4796; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Del Corno M, 2005, J VIROL, V79, P12597, DOI 10.1128/JVI.79.19.12597-12601.2005; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574; Donaghy H, 2003, BLOOD, V101, P4505, DOI 10.1182/blood-2002-10-3189; FAKRUDDIN JM, 2006, BLOOD; Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711; Feldman S, 2001, CLIN IMMUNOL, V101, P201, DOI 10.1006/clim.2001.5111; Finke JS, 2004, J CLIN IMMUNOL, V24, P647, DOI 10.1007/s10875-004-6250-5; Fong L, 2002, J VIROL, V76, P11033, DOI 10.1128/JVI.76.21.11033-11041.2002; Fonteneau JF, 2004, J VIROL, V78, P5223, DOI 10.1128/JVI.78.10.5223-5232.2004; Groot F, 2006, BLOOD, V108, P1957, DOI 10.1182/blood-2006-03-010918; Gurney KB, 2004, J IMMUNOL, V173, P7269, DOI 10.4049/jimmunol.173.12.7269; Kamga I, 2005, J INFECT DIS, V192, P303, DOI 10.1086/430931; Killian MS, 2006, AIDS, V20, P1247, DOI 10.1097/01.aids.0000232231.34253.bd; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Letvin NL, 2003, NAT MED, V9, P861, DOI 10.1038/nm0703-861; MATTHEWS TJ, 1987, P NATL ACAD SCI USA, V84, P5424, DOI 10.1073/pnas.84.15.5424; McKenna K, 2005, J VIROL, V79, P17, DOI 10.1128/JVI.79.1.17-27.2005; Moir S, 1999, J VIROL, V73, P7972, DOI 10.1128/JVI.73.10.7972-7980.1999; Muller-Trutwin M, 2005, IMMUNOL CELL BIOL, V83, P578, DOI 10.1111/j.1440-1711.2005.01394.x; Patterson Bruce K., 2002, Current Molecular Medicine (Hilversum), V2, P713, DOI 10.2174/1566524023361817; Patterson S, 2001, J VIROL, V75, P6710, DOI 10.1128/JVI.75.14.6710-6713.2001; Rothenfusser S, 2002, HUM IMMUNOL, V63, P1111, DOI 10.1016/S0198-8859(02)00749-8; Schmid Gunther, 2006, SOCIO-ECON REV, V4, P1, DOI DOI 10.1093/SER/MWJ029; Schmidt B, 2004, VIROLOGY, V329, P280, DOI 10.1016/j.virol.2004.08.016; Schmidt B, 2005, VIROLOGY, V343, P256, DOI 10.1016/j.virol.2005.09.059; Smed-Sorensen A, 2005, J VIROL, V79, P8861, DOI 10.1128/JVI.79.14.8861-8869.2005; Soumelis V, 2001, BLOOD, V98, P906, DOI 10.1182/blood.V98.4.906; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Yonezawa A, 2003, J VIROL, V77, P3777, DOI 10.1128/JVI.77.6.3777-3784.2003	40	64	65	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e458	10.1371/journal.pone.0000458	http://dx.doi.org/10.1371/journal.pone.0000458			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520017	Green Published, gold, Green Submitted			2022-12-25	WOS:000207446000006
J	Baysal, BE				Baysal, Bora E.			A Recurrent Stop-Codon Mutation in Succinate Dehydrogenase Subunit B Gene in Normal Peripheral Blood and Childhood T-Cell Acute Leukemia	PLOS ONE			English	Article								Background. Somatic cytidine mutations in normal mammalian nuclear genes occur during antibody diversification in B lymphocytes and generate an isoform of apolipoprotein B in intestinal cells by RNA editing. Here, I describe that succinate dehydrogenase (SDH; mitochondrial complex II) subunit B gene (SDHB) is somatically mutated at a cytidine residue in normal peripheral blood mononuclear cells (PBMCs) and T-cell acute leukemia. Germ line mutations in the SDHB, SDHC or SDHD genes cause hereditary paraganglioma (PGL) tumors which show constitutive activation of homeostatic mechanisms induced by oxygen deprivation (hypoxia). Principal Findings. To determine the prevalence of a mutation identified in the SDHB mRNA, 180 samples are tested. An SDHB stop-codon mutation c.136C>T (R46X) is present in a significant fraction (average = 5.8%, range = less than 1 to 30%, n = 52) of the mRNAs obtained from PBMCs. In contrast, the R46X mutation is present in the genomic DNA of PBMCs at very low levels. Examination of the PBMC cell-type subsets identifies monocytes and natural killer (NK) cells as primary sources of the mutant transcript, although lesser contributions also come from B and T lymphocytes. Transcript sequence analyses in leukemic cell lines derived from monocyte, NK, T and B cells indicate that the mutational mechanism targeting SDHB is operational in T-cell acute leukemia. Accordingly, substantial levels (more than 3%) of the mutant SDHB transcripts are detected in five of 20 primary childhood T-cell acute lymphoblastic leukemia (T-ALL) bone marrow samples, but in none of 20 B-ALL samples. In addition, distinct heterozygous SDHB missense DNA mutations are identified in Jurkat and TALL-104 cell lines which are derived from T-ALLs. Conclusions. The identification of a recurrent, inactivating stop-codon mutation in the SDHB gene in normal blood cells suggests that SDHB is targeted by a cytidine deaminase enzyme. The SDHB mutations in normal PBMCs and leukemic T cells might play a role in cellular pre-adaptation to hypoxia.	[Baysal, Bora E.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA; [Baysal, Bora E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Baysal, BE (corresponding author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA.	baysalb@mwri.magee.edu			NIH [CA11236, CA98543, CA114766]; NATIONAL CANCER INSTITUTE [U24CA114766, U10CA098543] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants (CA11236 to B. E. B, CA98543 and CA114766 to Children's Oncology Group). The funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	ALBERTINI RJ, 1990, ANNU REV GENET, V24, P305; Amrani N, 2006, NAT REV MOL CELL BIO, V7, P415, DOI 10.1038/nrm1942; Arezi B, 2007, ANAL BIOCHEM, V360, P84, DOI 10.1016/j.ab.2006.10.009; Astrom K, 2003, HUM GENET, V113, P228, DOI 10.1007/s00439-003-0969-6; Bayley JP, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-39; Baysal B.E., 2005, DIS MECH, V2, P247; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Baysal BE, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-12; CHADWICK DJ, 2006, NOV FDN S; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Gabay C, 1999, EUR J HAEMATOL, V63, P180; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; LING PD, 2005, CURRENT PROTOCOLS MO; Mukhopadhyay D, 2002, AM J HUM GENET, V70, P38, DOI 10.1086/337952; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Neuberger MS, 2007, J EXP MED, V204, P7, DOI 10.1084/jem.20062409; Piruat JI, 2004, MOL CELL BIOL, V24, P10933, DOI 10.1128/MCB.24.24.10933-10940.2004; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Stenmark KR, 2005, J APPL PHYSIOL, V98, P715, DOI 10.1152/japplphysiol.00840.2004; Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4	23	37	38	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e436	10.1371/journal.pone.0000436	http://dx.doi.org/10.1371/journal.pone.0000436			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487275	Green Accepted, Green Published, gold			2022-12-25	WOS:000207445800018
J	Powilleit, F; Breinig, T; Schmitt, MJ				Powilleit, Frank; Breinig, Tanja; Schmitt, Manfred J.			Exploiting the Yeast L-A Viral Capsid for the In Vivo Assembly of Chimeric VLPs as Platform in Vaccine Development and Foreign Protein Expression	PLOS ONE			English	Article								A novel expression system based on engineered variants of the yeast (Saccharomyces cerevisiae) dsRNA virus L-A was developed allowing the in vivo assembly of chimeric virus-like particles (VLPs) as a unique platform for a wide range of applications. We show that polypeptides fused to the viral capsid protein Gag self-assemble into isometric VLP chimeras carrying their cargo inside the capsid, thereby not only effectively preventing proteolytic degradation in the host cell cytosol, but also allowing the expression of a per se cytotoxic protein. Carboxyterminal extension of Gag by T cell epitopes from human cytomegalovirus pp65 resulted in the formation of hybrid VLPs that strongly activated antigen-specific CD8(+) memory T cells ex vivo. Besides being a carrier for polypeptides inducing antigen-specific immune responses in vivo, VLP chimeras were also shown to be effective in the expression and purification of (i) a heterologous model protein (GFP), (ii) a per se toxic protein (K28 alpha-subunit), and (iii) a particle-associated and fully recyclable biotechnologically relevant enzyme (esterase A). Thus, yeast viral Gag represents a unique platform for the in vivo assembly of chimeric VLPs, equally attractive and useful in vaccine development and recombinant protein production.	[Powilleit, Frank; Schmitt, Manfred J.] Univ Saarland, Saarbrucken, Germany; [Breinig, Tanja] Univ Saarland, Inst Virol, Homburg, Germany	Saarland University; Saarland University	Schmitt, MJ (corresponding author), Univ Saarland, Saarbrucken, Germany.	mjs@microbiol.uni-sb.de	Schmitt, Manfred J/AAA-5070-2022		Aventis Research & Technologies (Frankfurt Hoechst) [DE-102004032888]	Aventis Research & Technologies (Frankfurt Hoechst)	This research was supported by a grant from Aventis Research & Technologies (Frankfurt Hoechst) to MJS and is part of German patent number DE-102004032888.	Ackerman AL, 2004, NAT IMMUNOL, V5, P678, DOI 10.1038/ni1082; Ausubel F.M., 1998, CURRENT PROTOCOLS MO; Breinig F, 2003, FEMS IMMUNOL MED MIC, V38, P231, DOI 10.1016/S0928-8244(03)00148-2; Breinig F, 2006, APPL ENVIRON MICROB, V72, P7140, DOI 10.1128/AEM.00503-06; Breinig T, 2006, METHODS, V38, P77, DOI 10.1016/j.ymeth.2005.09.016; Brown JT, 2000, RNA, V6, P449, DOI 10.1017/S1355838200991787; Burns Nigel R., 1994, Molecular Biotechnology, V1, P137, DOI 10.1007/BF02921554; Chang HC, 2005, J MOL BIOL, V353, P397, DOI 10.1016/j.jmb.2005.08.052; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; FUJIMURA T, 1992, NATURE, V359, P746, DOI 10.1038/359746a0; GILMOUR JEM, 1989, AIDS, V3, P717, DOI 10.1097/00002030-198911000-00005; Gyulai Z, 2000, J INFECT DIS, V181, P1537, DOI 10.1086/315445; Hansson M, 2000, BIOTECHNOL APPL BIOC, V32, P95, DOI 10.1042/BA20000034; Heiligenstein S, 2006, EMBO J, V25, P4717, DOI 10.1038/sj.emboj.7601350; HENSING MCM, 1995, ANTON LEEUW INT J G, V67, P261, DOI 10.1007/BF00873690; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Huang DG, 2006, APPL ENVIRON MICROB, V72, P7748, DOI 10.1128/AEM.01403-06; ICHO T, 1989, J BIOL CHEM, V264, P6716; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; Kern F, 2002, J INFECT DIS, V185, P1709, DOI 10.1086/340637; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; Kost TA, 1999, CURR OPIN BIOTECH, V10, P428, DOI 10.1016/S0958-1669(99)00005-1; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Kruger DH, 1999, BIOL CHEM, V380, P275, DOI 10.1515/BC.1999.037; MCLAUGHLINTAYLOR E, 1994, J MED VIROL, V43, P103, DOI 10.1002/jmv.1890430119; Moron VG, 2003, J IMMUNOL, V171, P2242, DOI 10.4049/jimmunol.171.5.2242; Naitow H, 2002, NAT STRUCT BIOL, V9, P725, DOI 10.1038/nsb844; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; RABINOVICH NR, 1994, SCIENCE, V265, P1401, DOI 10.1126/science.7521064; Rai M, 2001, CURR SCI INDIA, V80, P1121; Reinisch KM, 2002, NAT STRUCT BIOL, V9, P714, DOI 10.1038/nsb1002-714; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHIRMBECK R, 1995, EUR J IMMUNOL, V25, P1063, DOI 10.1002/eji.1830250431; Schlacher A, 1998, J BIOTECHNOL, V62, P47, DOI 10.1016/S0168-1656(98)00042-X; Schleiss Mark, 2005, Herpes, V12, P66; Schultheiss E, 2002, J MOL CATAL B-ENZYM, V18, P89, DOI 10.1016/S1381-1177(02)00063-2; Solache A, 1999, J IMMUNOL, V163, P5512; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; Tsunetsugu-Yokota Y, 2003, J VIROL, V77, P10250, DOI 10.1128/JVI.77.19.10250-10259.2003; Ulmer JB, 2006, NAT BIOTECHNOL, V24, P1377, DOI 10.1038/nbt1261; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; WIDNER WR, 1993, MOL CELL BIOL, V13, P4331, DOI 10.1128/MCB.13.7.4331; Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996	48	10	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e415	10.1371/journal.pone.0000415	http://dx.doi.org/10.1371/journal.pone.0000415			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476337	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445700017
J	Zhong, JM; Jasinskas, A; Barbour, AG				Zhong, Jianmin; Jasinskas, Algimantas; Barbour, Alan G.			Antibiotic Treatment of the Tick Vector Amblyomma americanum Reduced Reproductive Fitness	PLOS ONE			English	Article								Background. The lone star tick Amblyomma americanum is a common pest and vector of infectious diseases for humans and other mammals in the southern and eastern United States. A Coxiella sp. bacterial endosymbiont was highly prevalent in both laboratory-reared and field-collected A. americanum. The Coxiella sp. was demonstrated in all stages of tick and in greatest densities in nymphs and adult females, while a Rickettsia sp. was less prevalent and in lower densities when present. Methodology/Principal Findings. We manipulated the numbers of both bacterial species in laboratory-reared A. americanum by injecting engorged nymphs or engorged, mated females with single doses of an antibiotic (rifampin or tetracycline) or buffer alone. Burdens of the bacteria after molting or after oviposition were estimated by quantitative polymerase chain reaction with primers and probes specific for each bacterial species or, as an internal standard, the host tick. Post-molt adult ticks that had been treated with rifampin or tetracycline had lower numbers of the Coxiella sp. and Rickettsia sp. and generally weighed less than ticks that received buffer alone. Similarly, after oviposition, females treated previously with either antibiotic had lower burdens of both bacterial species in comparison to controls. Treatment of engorged females with either antibiotic was associated with prolonged time to oviposition, lower proportions of ticks that hatched, lower proportions of viable larvae among total larvae, and lower numbers of viable larvae per tick. These fitness estimators were associated with reduced numbers of the Coxiella sp. but not the Rickettsia sp. Conclusion/Significance. The findings indicate that the Coxiella sp. is a primary endosymbiont, perhaps provisioning the obligately hematophagous parasites with essential nutrients. The results also suggest that antibiotics could be incorporated into an integrated pest management plan for control of these and other tick vectors of disease.	[Zhong, Jianmin; Jasinskas, Algimantas; Barbour, Alan G.] Univ Calif Irvine, Dept Med, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA; [Zhong, Jianmin; Jasinskas, Algimantas; Barbour, Alan G.] Univ Calif Irvine, Pacific SW Ctr Biodefense & Emerging Infect, Irvine, CA USA; [Zhong, Jianmin] Humboldt State Univ, Dept Biol Sci, Arcata, CA 95521 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; California State University System; California State Polytechnic University, Humboldt	Barbour, AG (corresponding author), Univ Calif Irvine, Dept Med, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA.	abarbour@uci.edu	Zhong, Jianmin/AAO-9401-2020	Zhong, Jianmin/0000-0002-4746-8458	Ellison Medical Foundation	Ellison Medical Foundation(Lawrence Ellison Foundation)	Senior Scholar in Global Infectious Diseases Program of the Ellison Medical Foundation (A. G. B.) and unrestricted patent royalties (A. G. B.). The study sponsor had no role in study design, the collection, analysis, and interpretation of data, the writing of the paper, or the decision to submit the manuscript for publication.	Bandi C, 1999, INT J PARASITOL, V29, P357, DOI 10.1016/S0020-7519(98)00200-8; BARBOUR A G, 1988, Clinical Microbiology Reviews, V1, P399; Barbour AG, 1996, J INFECT DIS, V173, P403, DOI 10.1093/infdis/173.2.403; BAUMANN P, 1995, ANNU REV MICROBIOL, V49, P55, DOI 10.1146/annurev.mi.49.100195.000415; Boulos A, 2004, INT J ANTIMICROB AG, V23, P169, DOI 10.1016/j.ijantimicag.2003.07.007; Brennan RE, 2003, J CLIN MICROBIOL, V41, P1869, DOI 10.1128/JCM.41.5.1869-1874.2003; BRESSAC C, 1993, J INVERTEBR PATHOL, V61, P226, DOI 10.1006/jipa.1993.1044; Bunikis J, 2004, EMERG INFECT DIS, V10, P1661, DOI 10.3201/eid1009.040236; Childs JE, 2003, ANNU REV ENTOMOL, V48, P307, DOI 10.1146/annurev.ento.48.091801.112728; Dale C, 2001, INT J PARASITOL, V31, P628, DOI 10.1016/S0020-7519(01)00151-5; Fenollar F, 2003, ANTIMICROB AGENTS CH, V47, P1665, DOI 10.1128/AAC.47.5.1665-1671.2003; Ginsberg HS, 2005, TICK-BORNE DISEASES OF HUMANS, P65; Goethert HK, 2005, J MED ENTOMOL, V42, P502, DOI 10.1603/0022-2585(2005)042[0502:ANFBFI]2.0.CO;2; HARINGTON JS, 1960, PARASITOLOGY, V50, P279, DOI 10.1017/S0031182000025373; Heddi A, 1999, P NATL ACAD SCI USA, V96, P6814, DOI 10.1073/pnas.96.12.6814; Jasinskas A, 2005, J MED ENTOMOL, V42, P359, DOI 10.1603/0022-2585(2005)042[0359:TFFMTU]2.0.CO;2; Jasinskas A, 2007, APPL ENVIRON MICROB, V73, P334, DOI 10.1128/AEM.02009-06; Jaworski DC, 2001, INSECT MOL BIOL, V10, P323, DOI 10.1046/j.0962-1075.2001.00271.x; KASHLYAEVA TK, 1983, ANTIBIOT MED BIOTEK, V28, P285; Kazragis RJ, 1996, ANTIMICROB AGENTS CH, V40, P2632, DOI 10.1128/AAC.40.11.2632; Labruna MB, 2004, J MED ENTOMOL, V41, P1073, DOI 10.1603/0022-2585-41.6.1073; Long SW, 2003, J MED ENTOMOL, V40, P1000, DOI 10.1603/0022-2585-40.6.1000; Mixson TR, 2006, J MED ENTOMOL, V43, P1261, DOI 10.1603/0022-2585(2006)43[1261:POEBAR]2.0.CO;2; Moran NA, 2000, CURR OPIN MICROBIOL, V3, P270, DOI 10.1016/S1369-5274(00)00088-6; Moran NA, 2003, P NATL ACAD SCI USA, V100, P14543, DOI 10.1073/pnas.2135345100; Moran NA, 2000, TRENDS ECOL EVOL, V15, P321, DOI 10.1016/S0169-5347(00)01902-9; Munderloh UG, 2005, TICK-BORNE DISEASES OF HUMANS, P37; NDIAYE M, 1995, J SUBMICR CYTOL PATH, V27, P557; Niebylski ML, 1997, APPL ENVIRON MICROB, V63, P3933, DOI 10.1128/AEM.63.10.3933-3940.1997; Noda H, 1997, APPL ENVIRON MICROB, V63, P3926, DOI 10.1128/AEM.63.10.3926-3932.1997; Oliver KM, 2003, P NATL ACAD SCI USA, V100, P1803, DOI 10.1073/pnas.0335320100; PORTARO JK, 1975, J MED ENTOMOL, V12, P265, DOI 10.1093/jmedent/12.2.265; RAOULT D, 1989, EUR J EPIDEMIOL, V5, P432, DOI 10.1007/BF00140135; RAOULT D, 1987, J INFECT DIS, V155, P1059, DOI 10.1093/infdis/155.5.1059; Reeves WK, 2006, EXP APPL ACAROL, V39, P321, DOI 10.1007/s10493-006-9012-7; Roux V, 1997, INT J SYST BACTERIOL, V47, P252, DOI 10.1099/00207713-47-2-252; Schulze TL, 2005, J MED ENTOMOL, V42, P450, DOI 10.1603/0022-2585(2005)042[0450:REFAPO]2.0.CO;2; Scoles GA, 2004, J MED ENTOMOL, V41, P277, DOI 10.1603/0022-2585-41.3.277; SILVA PMFE, 1994, J EUKARYOT MICROBIOL, V41, P55, DOI 10.1111/j.1550-7408.1994.tb05934.x; Simser JA, 2001, APPL ENVIRON MICROB, V67, P546, DOI 10.1128/AEM.67.2.546-552.2001; Thompson HA, 2005, TICK-BORNE DISEASES OF HUMANS, P328; Tsao JI, 2004, P NATL ACAD SCI USA, V101, P18159, DOI 10.1073/pnas.0405763102; Weeks AR, 2004, P ROY SOC B-BIOL SCI, V271, pS193, DOI 10.1098/rsbl.2003.0137; ZCHORIFEIN E, 1995, INSECT MOL BIOL, V4, P173, DOI 10.1111/j.1365-2583.1995.tb00023.x; Zientz E, 2006, APPL ENVIRON MICROB, V72, P6027, DOI 10.1128/AEM.00933-06	45	152	156	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e405	10.1371/journal.pone.0000405	http://dx.doi.org/10.1371/journal.pone.0000405			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476327	Green Published, gold			2022-12-25	WOS:000207445700007
J	Coutinho, EL; Andrade, LNDS; Chammas, R; Morganti, L; Schor, N; Bellini, MH				Coutinho, Enia Lucia; Andrade, Luciana Nogueira de Sousa; Chammas, Roger; Morganti, Ligia; Schor, Nestor; Bellini, Maria Helena			Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma	FASEB JOURNAL			English	Article						gene therapy; cancer; bioassay; antiangiogenesis	ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; IN-VITRO; ANGIOGENESIS; CANCER; THERAPY; EXPRESSION; INHIBITION; GALECTIN-3; ANTIANGIOGENESIS	We investigated whether transfer of the gene encoding the angiogenesis inhibitor endostatin into the NIH/3T3 fibroblast cell line could inhibit renal tumor growth in vivo. NIH/3T3 cells were transduced with retroviral vectors containing the murine endostatin (ES) gene. SCID mice bearing CaKi-1 derived tumors were given a subcutaneous injection of either ES-transduced cells or control cells and were monitored for tumor growth. At the end of the in vivo experiment, the mean tumor volume of treated mice was 51.6 +/- 2.4 mm(3), while the tumor volume of control was 234.5 +/- 14.8 mm(3). Microvascular density was significantly decreased on treatment (control 9.79 vs. ES 2.53%, < 0.001) accompanied by a 23-fold increase in intraturmoral necrotic area and a 2.94-fold increase in the apoptotic index, determined by immunohistochemistry with anti- activated caspase-3. Apoptotic cells were found in foci enriched in infiltrating leukocytes. In conclusion, retroviral endostatin gene transfer led to secretion of functional endostatin that was sufficiently active to inhibit tumor angiogenesis and tumor growth. A second mechanism may also be implied in endostatin-dependent tumor regression, associated with tumor infiltration of leukocytes. Besides its antiangiogenic properties, endostatin may be a promising adjuvant to immunotherapy.	IPEN CNEN SP, BR-05508900 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Med, Div Nephrol, Sao Paulo, Brazil; CEPID FAPESP, Ctr Terapia Celular, Sao Paulo, Brazil; Univ Sao Paulo, Fac Med, Dept Radiol, Expt Oncol Lab, Sao Paulo, Brazil	Comissao Nacional de Energia Nuclear (CNEN); Instituto de Pesquisas Energeticas e Nucleares (IPEN); Universidade Federal de Sao Paulo (UNIFESP); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Universidade de Sao Paulo	Bellini, MH (corresponding author), IPEN CNEN SP, Cidade Univ IPEN-CNEN-SP,Av Lineu Prestes 2242, BR-05508900 Sao Paulo, Brazil.	mhmarumo@terra.com.br	Schor, Nestor/K-4364-2013; Morganti, Ligia/K-4352-2014; Chammas, Roger/A-8004-2011; Andrade, Luciana/P-4604-2017; Batista, Marcelo/K-4305-2013	Morganti, Ligia/0000-0002-7870-1793; Chammas, Roger/0000-0003-0342-8726; Andrade, Luciana/0000-0002-5481-4355; Andrade, Luciana/0000-0003-2735-1217				Bellini MH, 2003, FASEB J, V17, P2322, DOI 10.1096/fj.03-0018fje; Brammer RD, 2005, BRIT J CANCER, V93, P1024, DOI 10.1038/sj.bjc.6602835; BROWN LF, 1993, AM J PATHOL, V143, P1255; Chow WH, 1999, JAMA-J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628; Cristofanilli M, 2002, NAT REV DRUG DISCOV, V1, P415, DOI 10.1038/nrd819; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; DHANABAL M, 1999, BIOCHEM BIOPH RES CO, V258, P260; Ding I, 2001, CANCER RES, V61, P526; Dirix LY, 1997, BRIT J CANCER, V76, P238, DOI 10.1038/bjc.1997.368; Dirkx AEM, 2006, FASEB J, V20, P621, DOI 10.1096/fj.05-4493com; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Feldman AL, 2002, CANCER-AM CANCER SOC, V95, P1637, DOI 10.1002/cncr.10845; Feldman AL, 2001, J NATL CANCER I, V93, P1014, DOI 10.1093/jnci/93.13.1014; Feldman AL, 2000, CLIN CANCER RES, V6, P4628; Figlin RA, 1999, J UROLOGY, V161, P381, DOI 10.1016/S0022-5347(01)61897-4; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1998, P NATL ACAD SCI USA, V95, P9064, DOI 10.1073/pnas.95.16.9064; Folkman J., 2006, SCI STKE, V354, P35; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; Gleave ME, 1998, NEW ENGL J MED, V338, P1265, DOI 10.1056/NEJM199804303381804; Gordower L, 1999, NEUROPATH APPL NEURO, V25, P319; Jacobsen J, 2000, J UROLOGY, V163, P343, DOI 10.1016/S0022-5347(05)68049-4; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kleinman HK, 2001, JNCI-J NATL CANCER I, V93, P965, DOI 10.1093/jnci/93.13.965; Kurdow R, 2003, LANGENBECK ARCH SURG, V388, P401, DOI 10.1007/s00423-003-0400-8; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Mulders P, 2003, UROL CLIN N AM, V30, P455, DOI 10.1016/S0094-0143(03)00024-7; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parkkila S, 2000, P NATL ACAD SCI USA, V97, P2220, DOI 10.1073/pnas.040554897; Pulkkanen KJ, 2002, CANCER GENE THER, V9, P908, DOI 10.1038/sj.cgt.7700519; Sabo E, 2001, CLIN CANCER RES, V7, P533; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Scappaticci FA, 2001, MOL THER, V3, P186, DOI 10.1006/mthe.2000.0243; STREIT M, 2004, CANCER RES, V62, P2004; Szary J, 2001, INT J CANCER, V91, P835, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1123>3.3.CO;2-K; TAKAHASHI A, 1994, CANCER RES, V54, P4233; Tomisawa M, 1999, EUR J CANCER, V35, P133, DOI 10.1016/S0959-8049(98)00278-0; TOMOHARU F, 2002, UROLOGY, V59, P973; TOMOHARU F, 2002, UROLOGY, V59, P6; van Wijngaarden J, 2004, LAB INVEST, V84, P1472, DOI 10.1038/labinvest.3700157; Wen W, 1999, CANCER RES, V59, P6052; WILFRED TV, 1994, BLOOD, V84, P780; YAGODA A, 1989, UROL INT, V44, P338, DOI 10.1159/000281537; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yamanaka R, 2001, CANCER GENE THER, V8, P796, DOI 10.1038/sj.cgt.7700367; Yokoyama Y, 2000, CANCER RES, V60, P2190; Young RC, 1998, NEW ENGL J MED, V338, P1305, DOI 10.1056/NEJM199804303381811	54	21	23	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3153	3161		10.1096/fj.07-8412com	http://dx.doi.org/10.1096/fj.07-8412com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17513560				2022-12-25	WOS:000249781600016
J	Egozi, D; Shapira, M; Paor, G; Ben-Izhak, O; Skorecki, K; Hershko, DD				Egozi, Dana; Shapira, Maanit; Paor, Galit; Ben-Izhak, Ofer; Skorecki, Karl; Hershko, Dan D.			Regulation of the cell cycle inhibitor p27 and its ubiquitin ligase Skp2 in differentiation of human embryonic stem cells	FASEB JOURNAL			English	Article						tumorigenesis; cyclin-dependent kinase; hESc differentiation; F-box protein; ubiquitin system	DEPENDENT KINASE INHIBITORS; HUMAN PROSTATE-CANCER; SUBUNIT SKP2; HUMAN BREAST; P27(KIP1); DEGRADATION; EXPRESSION; PROTEIN; GROWTH; TRANSCRIPTION	Embryonic stem cells combine the features of robust proliferation with precise differentiation capacity. p27 is a cell cycle inhibitor that is involved in the regulation of proliferation and differentiation in many developing tissues. Recent studies in murine embryonic stem cells have suggested that p27 is involved in the progression of normal differentiation programs in these cells. However, the expression and regulation of p27 and its role in the differentiation of human embryonic stem cells ( hESc) has not been previously explored. Herein we show that p27 expression was low in undifferentiated hESc, but increased markedly in differentiated cells. The expression of Skp2, the ubiquitin ligase that targets p27 for degradation, was inversely related to p27 expression. Moreover, embryoid bodies ( EBs) with low p27 expression and high Skp2/ p27 ratio showed poorer differentiation than those with high p27 expression. Modulation of Skp2 expression is mainly regulated by its rate of degradation. In contrast to somatic cells, which have high levels of Skp2 mainly in S and G2/ M, in undifferentiated hESc Skp2 levels were also high in G1. These results point to a potentially important role for p27 regulation in hESc.	Technion Israel Inst Technol, Rambam Med Ctr, Dept Surg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Dept Plast Surg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Dept Nephrol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rambam Med Ctr, Dept Pathol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Res Inst, IL-31096 Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology	Hershko, DD (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Dept Surg, IL-31096 Haifa, Israel.	d_hershko@rambam.health.gov.il						Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bryja V, 2005, STEM CELLS, V23, P965, DOI 10.1634/stemcells.2004-0174; Bryja V, 2004, CELL MOL LIFE SCI, V61, P1384, DOI 10.1007/s00018-004-4081-4; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Fujii-Yamamoto H, 2005, J BIOL CHEM, V280, P12976, DOI 10.1074/jbc.M412224200; GRANA X, 1995, ONCOGENE, V11, P211; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Hershko DD, 2006, CANCER-AM CANCER SOC, V107, P668, DOI 10.1002/cncr.22073; Imaki H, 2003, CANCER RES, V63, P4607; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REED M, 1994, SPILL SCI TECHNOL B, V1, P69, DOI 10.1016/1353-2561(94)90009-4; SALVATIER P, 1994, ONCOGENE, V9, P809; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shapiro S, 2005, J NEUROSURG-SPINE, V2, P1; Sherr C. J., 1993, CELL, V48, P981; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tzukerman M, 2003, P NATL ACAD SCI USA, V100, P13507, DOI 10.1073/pnas.2235551100; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yang G, 2002, CLIN CANCER RES, V8, P3419; ZHANG J, 1995, FINITE ELEM ANAL DES, V19, P45, DOI 10.1016/0168-874X(94)00056-L	47	52	59	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2807	2817		10.1096/fj.06-7758com	http://dx.doi.org/10.1096/fj.06-7758com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475922				2022-12-25	WOS:000249237500022
J	Mason, JM; Hagemann, UB; Arndt, KM				Mason, Jody M.; Hagemann, Urs B.; Arndt, Katja M.			Improved stability of the Jun-Fos activator protein-1 coiled coil motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOW CIRCULAR-DICHROISM; FREE-ENERGY CHANGES; LEUCINE-ZIPPER; EMPIRICAL PARAMETERS; TRANSITION-STATES; FOLDING PROBLEM; IN-VIVO; LINEAR EXTRAPOLATION; 2-STATE TRANSITION; ESCHERICHIA-COLI	Two c-Jun leucine zipper variants that bind with high affinity to c-Fos have been selected using semirational design combined with protein-fragment complementation assays (JunW) or phage display selection (JunW(Ph1)). Enriched winners differ from each other in only two of ten semi-randomized positions, with Delta Tm values of 28 degrees C and 37 degrees C over wild-type. cFos-JunW, cFos-JunW(Ph1), and two intermediate mutants (cFos-JunW(Q21R) and cFos-JunW(E23K)) display biphasic kinetics in the folding direction, indicating the existence of a folding intermediate. The first reaction phase is fast and concentration-dependent, showing that the intermediate is readily populated and dimeric. The second phase is independent of concentration and is exponential. In contrast, in the unfolding direction, all molecules display two-state kinetics. Collectively this implies a transition state between unfolded helices and dimeric intermediate that is readily traversed in both directions. We demonstrate that the added stability of cFos-JunW(Ph1) relative to cFos-JunW is achieved via a combination of kinetic rate changes; cFos-JunW(E23K) has an increased initial dimerization rate, prior to the major transition state barrier while cFos-JunW(Q21R) displays a decreased unfolding rate. The former implies that improved hydrophobic burial and helix-stabilizing mutations exert their effect on the initial, rapid, monomer-collision event. In contrast, electrostatic interactions exert their effect late in the folding pathway. Although our focus is the leucine zipper region of the oncogenic transcription factor Activator Protein-1, coiled coils are ubiquitous and highly specific in their recognition of partners. Consequently, generating kinetic-based rules to predict and engineer their stability is of major significance in peptide-based drug design and nano-biotechnology.	Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	University of Freiburg	Mason, JM (corresponding author), Univ Freiburg, Inst Biol 3, Schaenzlestr 1, D-79104 Freiburg, Germany.	jody@biologie.uni-freiburg.de; katja@biologie.uni-freiburg.de	Mason, Jody/W-8204-2019; Mason, Jody/A-9329-2011	Mason, Jody/0000-0002-4118-1958; Mason, Jody/0000-0002-4118-1958; Arndt, Katja/0000-0001-9220-0920				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Arndt KM, 2002, STRUCTURE, V10, P1235, DOI 10.1016/S0969-2126(02)00838-9; Arndt KM, 2000, J MOL BIOL, V295, P627, DOI 10.1006/jmbi.1999.3352; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; Bosshard HR, 2001, BIOCHEMISTRY-US, V40, P3544, DOI 10.1021/bi002161l; Bunagan MR, 2006, BIOCHEMISTRY-US, V45, P10981, DOI 10.1021/bi0606142; Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; Capaldi AP, 2001, NAT STRUCT BIOL, V8, P68; Cheung MS, 2002, P NATL ACAD SCI USA, V99, P685, DOI 10.1073/pnas.022387699; Dragan AI, 2002, J MOL BIOL, V321, P891, DOI 10.1016/S0022-2836(02)00699-X; Du H, 1998, PHOTOCHEM PHOTOBIOL, V68, P141, DOI 10.1562/0031-8655(1998)068<0141:PACADA>2.3.CO;2; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Ibarra-Molero B, 2004, J MOL BIOL, V336, P989, DOI 10.1016/j.jmb.2003.12.069; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; Jelesarov I, 1998, BIOCHEMISTRY-US, V37, P7539, DOI 10.1021/bi972977v; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Knappenberger JA, 2002, J MOL BIOL, V321, P1, DOI 10.1016/S0022-2836(02)00592-2; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; Leventhal C, 1969, MOSSBAUER SPECTROSCO, P22; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Lu CH, 2005, ONCOGENE, V24, P6516, DOI 10.1038/sj.onc.1208905; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; MANN CJ, 1993, BIOCHEMISTRY-US, V32, P5282, DOI 10.1021/bi00071a002; Mason JM, 2005, J BIOL CHEM, V280, P40494, DOI 10.1074/jbc.M509281200; Mason JM, 2002, BIOCHEMISTRY-US, V41, P12093, DOI 10.1021/bi026398o; Mason JM, 2007, BIOCHEMISTRY-US, V46, P4804, DOI 10.1021/bi602506p; Mason JM, 2006, P NATL ACAD SCI USA, V103, P8989, DOI 10.1073/pnas.0509880103; Meisner WK, 2004, P NATL ACAD SCI USA, V101, P15639, DOI 10.1073/pnas.0404895101; Meisner WK, 2004, P NATL ACAD SCI USA, V101, P13478, DOI 10.1073/pnas.0404057101; MILLA ME, 1994, BIOCHEMISTRY-US, V33, P1125, DOI 10.1021/bi00171a011; MO JM, 1991, P NATL ACAD SCI USA, V88, P916, DOI 10.1073/pnas.88.3.916; Moran LB, 1999, P NATL ACAD SCI USA, V96, P10699, DOI 10.1073/pnas.96.19.10699; MUNOZ V, 1995, J MOL BIOL, V245, P297, DOI 10.1006/jmbi.1994.0024; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; Myers JK, 1999, J MOL BIOL, V289, P205, DOI 10.1006/jmbi.1999.2747; PACE CN, 1979, BIOCHEMISTRY-US, V18, P288, DOI 10.1021/bi00569a008; Parker MJ, 1998, BIOCHEMISTRY-US, V37, P2538, DOI 10.1021/bi972459k; Pelletier JN, 1999, NAT BIOTECHNOL, V17, P683, DOI 10.1038/10897; Ryadnov MG, 2003, NAT MATER, V2, P329, DOI 10.1038/nmat885; Ryadnov MG, 2003, J AM CHEM SOC, V125, P9388, DOI 10.1021/ja0352045; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P4901, DOI 10.1021/bi00135a022; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sosnick TR, 1996, PROTEINS, V24, P427; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; Wang T, 2005, BIOPHYS J, V89, P4180, DOI 10.1529/biophysj.105.068809; WENDT H, 1994, J AM CHEM SOC, V116, P6973, DOI 10.1021/ja00094a077; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; WILLIAMS RW, 1987, BIOCHIM BIOPHYS ACTA, V916, P200, DOI 10.1016/0167-4838(87)90109-9; ZITZEWITZ JA, 1995, BIOCHEMISTRY-US, V34, P12812, DOI 10.1021/bi00039a042	54	36	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23015	23024		10.1074/jbc.M701828200	http://dx.doi.org/10.1074/jbc.M701828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17483489	hybrid			2022-12-25	WOS:000248577500004
J	Kremer, W; Kachel, N; Kuwata, K; Akasaka, K; Kalbitzer, HR				Kremer, Werner; Kachel, Norman; Kuwata, Kazuo; Akasaka, Kazuyuki; Kalbitzer, Hans Robert			Species-specific differences in the intermediate states of human and Syrian hamster prion protein detected by high pressure NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVITY SAPPHIRE CELLS; CONFORMATION; REVEALS; SHIFTS	Human (huPrP) and Syrian hamster (ShaPrP) prion proteins have barriers for mutual infectivity, although they fold into almost an identical structure. The pressure responses of huPrP and ShaPrP characterized by high pressure NMR spectroscopy show differences in their excited states, as monitored by pressure-induced chemical shifts and intensity changes of individual residues in the N-15/H-1 HSQC spectra. Both proteins fluctuate rapidly between two well folded (native) conformations N-1 and N-2 and less frequently between N and the excited states I-1 and I-2 with local disorder that may present structural intermediates on the way to PrPSc. These four structural states can be observed in the hamster and human PrP. At ambient pressure, less than 5 molecules of 10,000 are in the intermediate state I-2. From the structural point of view, the different states are mutually different, particularly in positions strategically important for generating species barriers for infection. The results point to the notion that excited state conformers are important for infection and that their structural differences may crucially determine species barriers for infection.	Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; Gifu Univ, Ctr Emerging Infect Dis, Gifu 5008705, Japan; Kinki Univ, Sch Biol Oriented Sci & Technol, Dept Biotechnol Sci, Wakayama 6496493, Japan	University of Regensburg; Gifu University; Kindai University (Kinki University)	Kalbitzer, HR (corresponding author), Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany.	hans-robert.kalbitzer@biologie.uni-regensburg.de		Kalbitzer, Hans Robert/0000-0002-6514-2355				Akasaka K, 1999, PROTEIN SCI, V8, P1946, DOI 10.1110/ps.8.10.1946; Akasaka K, 2001, BIOCHEMISTRY-US, V40, P8665, DOI 10.1021/bi010312u; Akasaka K, 2006, CHEM REV, V106, P1814, DOI 10.1021/cr040440z; Arnold MR, 2003, J MAGN RESON, V161, P127, DOI 10.1016/S1090-7807(02)00179-9; Arnold MR, 2002, BIOPHYS CHEM, V96, P129, DOI 10.1016/S0301-4622(02)00018-2; Calzolai L, 2003, J BIOL CHEM, V278, P35592, DOI 10.1074/jbc.M303005200; Chen SG, 2002, NEURON, V34, P854, DOI 10.1016/S0896-6273(02)00736-5; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Foguel D, 2003, P NATL ACAD SCI USA, V100, P9831, DOI 10.1073/pnas.1734009100; Garcia FL, 2000, P NATL ACAD SCI USA, V97, P8334, DOI 10.1073/pnas.97.15.8334; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; Kachel N, 2006, BMC STRUCT BIOL, V6, DOI 10.1186/1472-6807-6-16; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kremer W, 2004, SPECTROSC-INT J, V18, P271, DOI 10.1155/2004/407619; Kuwata K, 2002, BIOCHEMISTRY-US, V41, P12277, DOI 10.1021/bi026129y; Li H, 1998, BIOCHEMISTRY-US, V37, P1167, DOI 10.1021/bi972288j; Maurer T, 2004, J BACTERIOL, V186, P5906, DOI 10.1128/JB.186.17.5906-5918.2004; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Price WE, 1997, PRACT APPR CHEM SER, P225; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Vanik DL, 2004, MOL CELL, V14, P139, DOI 10.1016/S1097-2765(04)00155-8; Weissmann C, 2002, P NATL ACAD SCI USA, V99, P16378, DOI 10.1073/pnas.172403799; YAMADA H, 1974, REV SCI INSTRUM, V45, P640, DOI 10.1063/1.1686703; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1999, Q REV BIOPHYS, V32, P309, DOI 10.1017/S0033583500003553	31	22	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22689	22698		10.1074/jbc.M701884200	http://dx.doi.org/10.1074/jbc.M701884200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17519231	hybrid			2022-12-25	WOS:000248354200046
J	Kashkina, E; Anikin, M; Brueckner, F; Lehmann, E; Kochetkov, SN; McAllister, WT; Cramer, P; Temiakov, D				Kashkina, Ekaterina; Anikin, Michael; Brueckner, Florian; Lehmann, Elisabeth; Kochetkov, Sergey N.; McAllister, William T.; Cramer, Patrick; Temiakov, Dmitry			Multisubunit RNA polymerases melt only a single DNA base pair downstream of the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II ELONGATION COMPLEX; STRUCTURAL BASIS; NUCLEOTIDE INCORPORATION; 2-AMINOPURINE FLUORESCENCE; TEMPLATE-STRAND; TRANSCRIPTION; INITIATION; BUBBLE; NTP; TRANSLOCATION	To extend the nascent transcript, RNA polymerases must melt the DNA duplex downstream from the active site to expose the next acceptor base for substrate binding and incorporation. A number of mechanisms have been proposed to account for the manner in which the correct substrate is selected, and these differ in their predictions as to how far the downstream DNA is melted. Using fluorescence quenching experiments, we provide evidence that cellular RNA polymerases from bacteria and yeast melt only one DNA base pair downstream from the active site. These data argue against a model in which multiple NTPs are lined up downstream of the active site.	Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Cell Biol, Stratford, NJ 08084 USA; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Univ Munich, Gene Ctr Munich, D-81377 Munich, Germany; Univ Munich, Ctr Integrated Prot Sci, Dept Chem & Biochem, D-81377 Munich, Germany	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Munich; University of Munich	Temiakov, D (corresponding author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Cell Biol, Stratford, NJ 08084 USA.	d.temiakov@umdnj.edu	Kochetkov, Sergey N./O-1065-2013	Kochetkov, Sergey/0000-0002-7443-6961	NIGMS NIH HHS [GM38147, R01 GM038147-15A1, R01 GM038147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Batada NN, 2004, P NATL ACAD SCI USA, V101, P17361, DOI 10.1073/pnas.0408168101; Datta K, 2006, J MOL BIOL, V360, P800, DOI 10.1016/j.jmb.2006.05.053; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gong XQ, 2005, MOL CELL, V18, P461, DOI 10.1016/j.molcel.2005.04.011; Hariharan C, 2006, BIOCHEMISTRY-US, V45, P2836, DOI 10.1021/bi051644s; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Kashkina E, 2006, MOL CELL, V24, P257, DOI 10.1016/j.molcel.2006.10.001; Kashkina E, 2006, NUCLEIC ACIDS RES, V34, P4036, DOI 10.1093/nar/gkl559; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; Landick R, 2005, TRENDS BIOCHEM SCI, V30, P651, DOI 10.1016/j.tibs.2005.10.001; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Mandal SS, 2002, BIOCHEMISTRY-US, V41, P4399, DOI 10.1021/bi015723p; Martin CT, 2003, METHOD ENZYMOL, V371, P13; Nudler E, 2003, METHOD ENZYMOL, V371, P160; Pomerantz RT, 2006, MOL CELL, V24, P245, DOI 10.1016/j.molcel.2006.08.014; Purohit V, 2003, BIOCHEMISTRY-US, V42, P10200, DOI 10.1021/bi0341206; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Temiakov D, 2003, ACTA CRYSTALLOGR D, V59, P185, DOI 10.1107/S0907444902019777; Temiakov D, 2002, J BIOL CHEM, V277, P47035, DOI 10.1074/jbc.M208923200; Thompson AA, 2007, J MOL BIOL, V366, P1459, DOI 10.1016/j.jmb.2006.11.070; Wang D, 2006, CELL, V127, P941, DOI 10.1016/j.cell.2006.11.023; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	27	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21578	21582		10.1074/jbc.C700098200	http://dx.doi.org/10.1074/jbc.C700098200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17526498	hybrid			2022-12-25	WOS:000248196800002
J	Mullany, LK; Nelsen, CJ; Hanse, EA; Goggin, MM; Anttila, CK; Peterson, M; Bitterman, PB; Raghavan, A; Crary, GS; Albrecht, JH				Mullany, Lisa K.; Nelsen, Christopher J.; Hanse, Eric A.; Goggin, Melissa M.; Anttila, Chelsea K.; Peterson, Mark; Bitterman, Peter B.; Raghavan, Arvind; Crary, Gretchen S.; Albrecht, Jeffrey H.			Akt-mediated liver growth promotes induction of cyclin E through a novel translational mechanism and a p21-mediated cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P21; RIBOSOMAL-PROTEIN S6; HEPATOCYTE PROLIFERATION; SIGNALING PATHWAY; IN-VIVO; REGENERATING LIVER; ENDOTHELIAL-CELLS; GENE-EXPRESSION; ORGAN GROWTH; PROGRESSION	The control of hepatocyte growth is relevant to the processes of liver regeneration, development, metabolic homeostasis, and cancer. A key component of growth control is the protein kinase Akt, which acts downstream of mitogens and nutrients to affect protein translation and cell cycle progression. In this study, we found that transient transfection of activated Akt triggered a 3-4-fold increase in liver size within days but only minimal hepatocyte proliferation. Akt-induced liver growth was associated with marked up-regulation of cyclin E but not cyclin D1. Analysis of liver polyribosomes demonstrated that the post-transcriptional induction of cyclin E was associated with increased translational efficiency of this mRNA, suggesting that cell growth promotes expression of this protein through a translational mechanism that is distinct from the cyclin D-E2F pathway. Treatment of Akt-transfected mice with rapamycin only partially inhibited liver growth and did not prevent the induction of cyclin E protein, indicating that target of rapamycin activity is not necessary for this response. In the enlarged livers, cyclin E-Cdk2 complexes were present in high abundance but were inactive due to increased binding of p21 to these complexes. Akt transfection of p21(-/-) mice promoted liver growth, activation of Cdk2, and enhanced hepatocyte proliferation. In conclusion, growth promotes cyclin E expression through a novel translational mechanism in the liver, suggesting a new link between cell growth and the cell cycle machinery. Furthermore, p21 suppresses proliferation in the overgrown livers and may play a role in preventing cell cycle progression in response to organ size homeostatic mechanisms.	Hennepin Cty Med Ctr G5, Div Gastroenterol, Minneapolis, MN 55415 USA; Minneapolis Med Res Fdn Inc, Minneapolis, MN 55404 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN 55415 USA	Hennepin County Medical Center; Minneapolis Medical Research Foundation; University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center	Albrecht, JH (corresponding author), Hennepin Cty Med Ctr G5, Div Gastroenterol, 701 Pk Ave, Minneapolis, MN 55415 USA.	albre010@umn.edu		BITTERMAN, PETER/0000-0002-7995-7117; Raghavan, Arvind/0000-0002-2959-3626; Hanse, Eric/0000-0002-1234-0198	NIDDK NIH HHS [DK54921] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054921] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Boylan JM, 2001, J BIOL CHEM, V276, P44457, DOI 10.1074/jbc.M103457200; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Crary GS, 1998, HEPATOLOGY, V28, P738, DOI 10.1002/hep.510280320; Derenzini M, 2005, J CELL PHYSIOL, V202, P483, DOI 10.1002/jcp.20144; Edgar Bruce A., 2004, VVolume 42, P23; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Fausto N, 2003, MECH DEVELOP, V120, P117, DOI 10.1016/S0925-4773(02)00338-6; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; FRANCAVILLA A, 1992, HEPATOLOGY, V15, P871, DOI 10.1002/hep.1840150520; FRANCAVILLA A, 1992, TRANSPLANTATION, V53, P496; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Garcia Z, 2006, EMBO J, V25, P655, DOI 10.1038/sj.emboj.7600967; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Goggin MM, 2004, HEPATOLOGY, V40, P537, DOI 10.1002/hep.20338; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hui TT, 2002, AM J SURG, V183, P457, DOI 10.1016/S0002-9610(02)00822-X; Jaime M, 2002, HEPATOLOGY, V35, P1063, DOI 10.1053/jhep.2002.32678; Jiang YP, 2001, J BIOL CHEM, V276, P10943, DOI 10.1074/jbc.M007758200; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; Larsson O, 2006, NUCLEIC ACIDS RES, V34, P4375, DOI 10.1093/nar/gkl558; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Luedde T, 2003, HEPATOLOGY, V37, P833, DOI 10.1053/jhep.2003.50136; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Morita Tomoyuki, 2002, J Hepatobiliary Pancreat Surg, V9, P352, DOI 10.1007/s005340200039; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nelsen CJ, 2003, J BIOL CHEM, V278, P25853, DOI 10.1074/jbc.M302360200; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Nelsen CJ, 2001, CANCER RES, V61, P8564; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Ono H, 2003, DIABETES, V52, P2905, DOI 10.2337/diabetes.52.12.2905; Prober DA, 2001, CURR OPIN GENET DEV, V11, P19, DOI 10.1016/S0959-437X(00)00151-9; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Saucedo LJ, 2002, CURR OPIN GENET DEV, V12, P565, DOI 10.1016/S0959-437X(02)00341-6; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Tapon N, 2001, CURR OPIN CELL BIOL, V13, P731, DOI 10.1016/S0955-0674(00)00284-2; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Torbenson M, 2002, AM J PATHOL, V161, P155, DOI 10.1016/S0002-9440(10)64167-3; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wagayama H, 2001, DIGEST DIS SCI, V46, P2074, DOI 10.1023/A:1011977923941; Wells WA, 2002, J CELL BIOL, V158, P1156, DOI 10.1083/jcb.200209042; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zhang H, 2007, MOL CELL, V25, P175, DOI 10.1016/j.molcel.2007.01.008	62	42	45	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21244	21252		10.1074/jbc.M702110200	http://dx.doi.org/10.1074/jbc.M702110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17517888	hybrid			2022-12-25	WOS:000248047500052
J	Bharadwaj, AG; Rector, K; Simpson, MA				Bharadwaj, Alamelu G.; Rector, Katherine; Simpson, Melanie A.			Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; HYAL1 HYALURONIDASE; CARCINOMA-CELLS; PERICELLULAR MATRIX; EXPRESSION; CANCER; CD44; ACID; GENE; INHIBITION	Prostate cancer progression can be predicted in human tumor biopsies by abundant hyaluronan ( HA) and its processing enzyme, the hyaluronidase HYAL1. Accumulation of HA is dictated by the balance between expression levels of HA synthases, the enzymes that produce HA polymers, and hyaluronidases, which process polymers to oligosaccharides. Aggressive prostate tumor cells express 20-fold higher levels of the hyaluronan synthase HAS3, but the mechanistic relevance of this correlation has not been determined. We stably overexpressed HAS3 in prostate tumor cells. Adhesion to extracellular matrix and cellular growth kinetics in vitro were significantly reduced. Slow growth in culture was restored either by exogenous addition of hyaluronidase or by stable HYAL1 coexpression. Coexpression did not improve comparably slow growth in mice, however, suggesting that excess hyaluronan production by HAS3 may alter the balance required for induced tumor growth. To address this, we used a tetracycline-inducible HAS3 expression system in which hyaluronan production could be experimentally controlled. Adjusting temporal parameters of hyaluronan production directly affected growth rate of the cells. Relief from growth suppression in vitro but not in vivo by enzymatic removal of HA effectively uncoupled the respective roles of hyaluronan in growth and angiogenesis, suggesting that growth mediation is less critical to establishment of the tumor than early vascular development. Collectively results also imply that HA processing by elevated HYAL1 expression in invasive prostate cancer is a requirement for progression.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Simpson, MA (corresponding author), Univ Nebraska, Dept Biochem, N241 Beadle Ctr,1901 Vine St, Lincoln, NE 68588 USA.	msimpson2@unl.edu			NATIONAL CANCER INSTITUTE [R01CA106584] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 106584] Funding Source: Medline; NCRR NIH HHS [P20 RR 018759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aaltomaa S, 2002, UROL INT, V69, P266, DOI 10.1159/000066123; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Asteriou T, 2006, MATRIX BIOL, V25, P166, DOI 10.1016/j.matbio.2005.11.005; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; Bullard KM, 2003, INT J CANCER, V107, P739, DOI 10.1002/ijc.11475; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Csoka TB, 1998, GENOMICS, V48, P63, DOI 10.1006/geno.1997.5158; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; DEKLERK DP, 1984, J UROLOGY, V131, P1008, DOI 10.1016/S0022-5347(17)50750-8; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; Dube B, 2001, BBA-MOL CELL RES, V1538, P283, DOI 10.1016/S0167-4889(01)00079-9; Ekici S, 2004, INT J CANCER, V112, P121, DOI 10.1002/ijc.20368; Enegd B, 2002, NEUROSURGERY, V50, P1311, DOI 10.1097/00006123-200206000-00023; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; FEINBERG RN, 1983, SCIENCE, V220, P1177, DOI 10.1126/science.6857242; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Frost GI, 1997, ANAL BIOCHEM, V251, P263, DOI 10.1006/abio.1997.2262; FUJIMOTO T, 1989, J PEDIATR SURG, V24, P550, DOI 10.1016/S0022-3468(89)80504-4; Gakunga P, 1997, DEVELOPMENT, V124, P3987; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Harada H, 2007, J BIOL CHEM, V282, P5597, DOI 10.1074/jbc.M608358200; Hughes C, 2005, J CLIN PATHOL, V58, P673, DOI 10.1136/jcp.2002.003954; Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098; Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200; Itano N, 1999, CANCER RES, V59, P2499; Kosaki R, 1999, CANCER RES, V59, P1141; Kovar JL, 2006, AM J PATHOL, V169, P1415, DOI 10.2353/ajpath.2006.060324; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Laurent T. C., 1996, IMMUNOL CELL BIOL, V74, pA1, DOI [10.1038/icb.1996.32, DOI 10.1038/ICB.1996.32]; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; LEES VC, 1995, LAB INVEST, V73, P259; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lesley J, 2000, J BIOL CHEM, V275, P26967; Lipponen P, 2001, EUR J CANCER, V37, P849, DOI 10.1016/S0959-8049(00)00448-2; Liu NF, 2001, CANCER RES, V61, P5207; Lokeshwar VB, 2005, CANCER RES, V65, P7782, DOI 10.1158/0008-5472.CAN-05-1022; Lokeshwar VB, 2005, CANCER RES, V65, P2243, DOI 10.1158/0008-5472.CAN-04-2805; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Lokeshwar VB, 1996, CANCER RES, V56, P651; Lopez MV, 2006, MOL CANCER THER, V5, P2503, DOI 10.1158/1535-7163.MCT-06-0286; Mio K, 2002, MATRIX BIOL, V21, P31, DOI 10.1016/S0945-053X(01)00185-8; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nardini M, 2004, GENE EXPR PATTERNS, V4, P303, DOI 10.1016/j.modgep.2003.10.006; Patel S, 2002, INT J CANCER, V97, P416, DOI 10.1002/ijc.1638; Posey JT, 2003, CANCER RES, V63, P2638; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Simpson MA, 2002, AM J PATHOL, V161, P849, DOI 10.1016/S0002-9440(10)64245-9; Simpson MA, 2002, J BIOL CHEM, V277, P10050, DOI 10.1074/jbc.M110069200; Simpson MA, 2001, J BIOL CHEM, V276, P17949, DOI 10.1074/jbc.M010064200; Simpson MA, 2006, AM J PATHOL, V169, P247, DOI 10.2353/ajpath.2006.060032; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Stern R, 2005, PATHOL BIOL, V53, P372, DOI 10.1016/j.patbio.2004.12.021; Stern R, 2004, EUR J CELL BIOL, V83, P317, DOI 10.1078/0171-9335-00392; Stern R, 2006, EUR J CELL BIOL, V85, P699, DOI 10.1016/j.ejcb.2006.05.009; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; Triggs-Raine B, 1999, P NATL ACAD SCI USA, V96, P6296, DOI 10.1073/pnas.96.11.6296; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Udabage L, 2005, CANCER RES, V65, P6139, DOI 10.1158/0008-5472.CAN-04-1622; van Bokhoven A, 2001, CANCER RES, V61, P6340; Ward JA, 2003, AM J PATHOL, V162, P1403, DOI 10.1016/S0002-9440(10)64273-3; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WELSH CF, 1995, J CELL PHYSIOL, V164, P605, DOI 10.1002/jcp.1041640319; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; Wingo PA, 2003, CANCER-AM CANCER SOC, V97, P3133, DOI 10.1002/cncr.11380; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200; Zeng CX, 1998, INT J CANCER, V77, P396; ZHANG LR, 1995, CANCER RES, V55, P428	79	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20561	20572		10.1074/jbc.M702964200	http://dx.doi.org/10.1074/jbc.M702964200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17502371	hybrid			2022-12-25	WOS:000247819300059
J	Maskrey, BH; Bermudez-Fajardo, A; Morgan, AH; Stewart-Jones, E; Dioszeghy, V; Taylor, GW; Baker, PRS; Coles, B; Coffey, MJ; Kuhn, H; O'Donnell, VB				Maskrey, Benjamin H.; Bermudez-Fajardo, Alexandra; Morgan, Alwena H.; Stewart-Jones, Esther; Dioszeghy, Vincent; Taylor, Graham W.; Baker, Paul R. S.; Coles, Barbara; Coffey, Marcus J.; Kuehn, Hartmut; O'Donnell, Valerie B.			Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER EPITHELIAL-CELLS; 15-HYDROXYEICOSATETRAENOIC ACID; 12(S)-HYDROXYEICOSATETRAENOIC ACID; SELECTIVE INCORPORATION; SIGNALING PATHWAY; GLYCOPROTEIN-VI; RECEPTOR-GAMMA; KNOCKOUT MICE; FATTY-ACIDS; PHOSPHOLIPIDS	12/15-Lipoxygenase (LOX) mediates immune-regulatory activities not accounted for by its known free acid eicosanoids, suggesting that additional lipids may be generated by activated cells. To characterize novel LOX-derived lipids, a lipidomic approach was utilized. Ionophore-activated interleukin-4-treated human peripheral monocytes generated up to 10-fold more esterified 15-hydroxyeicosatetraenoic acid (15-HETE) than free in a phosphatidylinositol 3-kinase- and protein kinase C-sensitive manner. Precursor scanning electrospray ionization/tandem spectroscopy form/z 319 ( HETE, [M-H](-)) showed 4 ions at m/z 738, 764, 766, and 782 that were identified using tandem spectroscopy and MS3 as specific diacyl and plasmalogen 15-HETE phosphatidylethanolamines. Using (H2O)-O-18 water, the compounds were shown to form by direct oxidation of endogenous phosphatidylethanolamine (PE) by 15-LOX, with PE being the preferred phospholipid pool containing 15-HETE. Similarly, human platelets generated 4 analogous PE lipids that contained 12-HETE and increased significantly in response to ionophore, collagen, or convulxin. These products were retained in the cells, in contrast to free acids, which are primarily secreted. Precursor scanning of platelet extracts for the major platelet-derived prostanoid, thromboxane B2 (m/z 369.2), did not reveal PE esters, indicating that this modification is restricted to the LOX pathway. In summary, we show formation of PE-esterified HETEs in immune cells that may contribute to LOX signaling in inflammation.	Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales; UCL Royal Free Univ, Sch Med, Ctr Amyloidosis & Acute Phase Proteins, London NW3 2PF, England; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Humboldt Univ, Inst Biochem, D-10117 Berlin, Germany	Cardiff University; University of London; University College London; UCL Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Humboldt University of Berlin	O'Donnell, VB (corresponding author), Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	o-donnellvb@cardiff.ac.uk	O'Donnell, Valerie/C-6948-2012; Taylor, Graham Walter/R-4811-2019	Taylor, Graham Walter/0000-0002-9672-8463; Bermudez-Fajardo, Alexandra/0000-0001-8889-5635; /0000-0003-4089-8460	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALPERT SE, 1993, AM J RESP CELL MOL, V8, P273, DOI 10.1165/ajrcmb/8.3.273; Anning PB, 2005, AM J PATHOL, V166, P653, DOI 10.1016/S0002-9440(10)62287-0; Arai M, 1997, EUR J BIOCHEM, V244, P513, DOI 10.1111/j.1432-1033.1997.00513.x; Berry KAZ, 2004, J AM SOC MASS SPECTR, V15, P1499, DOI 10.1016/j.jasms.2004.07.009; Bleich D, 1999, J CLIN INVEST, V103, P1431, DOI 10.1172/JCI5241; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; BRASH AR, 1986, PROSTAG LEUKOTR ESS, V23, P149, DOI 10.1016/0262-1746(86)90178-2; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; Coffey MJ, 2004, FEBS LETT, V576, P165, DOI 10.1016/j.febslet.2004.09.007; Coffey MJ, 2004, CIRC RES, V94, P1598, DOI 10.1161/01.RES.0000132281.78948.65; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; DUGAN LL, 1986, J CHROMATOGR, V378, P317, DOI 10.1016/S0378-4347(00)80728-8; GIRTON RA, 1994, KIDNEY INT, V45, P972, DOI 10.1038/ki.1994.131; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; KENNETT FF, 1984, BIOCHIM BIOPHYS ACTA, V804, P301, DOI 10.1016/0167-4889(84)90133-2; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; KUHN H, 1994, J LIPID RES, V35, P1749; KUHN H, 1987, EUR J BIOCHEM, V169, P593, DOI 10.1111/j.1432-1033.1987.tb13650.x; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; Legrand AB, 1996, BBA-LIPID LIPID MET, V1301, P150, DOI 10.1016/0005-2760(96)00015-X; MARINETTI GV, 1982, CHEM PHYS LIPIDS, V31, P169, DOI 10.1016/0009-3084(82)90042-1; Middleton MK, 2006, J IMMUNOL, V176, P265, DOI 10.4049/jimmunol.176.1.265; Miller YI, 2001, J BIOL CHEM, V276, P19431, DOI 10.1074/jbc.M011276200; Murphy R. C, 2002, MASS SPECTROMETRY PH; Pace-Asciak CR, 1999, ADV EXP MED BIOL, V447, P123; PAPAYIANNI A, 1995, KIDNEY INT, V47, P1295, DOI 10.1038/ki.1995.184; PAWLOWSKI NA, 1982, J EXP MED, V155, P1653, DOI 10.1084/jem.155.6.1653; Profita M, 1999, AM J RESP CELL MOL, V20, P61, DOI 10.1165/ajrcmb.20.1.3151; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SERHAN CN, 1991, ADV PROSTAG THROMB L, V21, P105; Shankaranarayanan P, 2003, J IMMUNOL, V170, P887, DOI 10.4049/jimmunol.170.2.887; Shappell SB, 2001, CANCER RES, V61, P497; SHEN XY, 1988, BIOCHEMISTRY-US, V27, P996, DOI 10.1021/bi00403a024; STENSON WF, 1983, PROSTAGLANDINS, V26, P253, DOI 10.1016/0090-6980(83)90093-X; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; URSINI F, 1995, METHOD ENZYMOL, V252, P28; Vernhet L, 1997, LIFE SCI, V61, P1667, DOI 10.1016/S0024-3205(97)00772-8; Vernhet L, 1996, J LIPID MEDIAT CELL, V13, P233, DOI 10.1016/0929-7855(95)00050-X; WALLUKAT G, 1994, J BIOL CHEM, V269, P29055; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhao L, 2002, J BIOL CHEM, V277, P35350, DOI 10.1074/jbc.M205738200	44	113	114	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20151	20163		10.1074/jbc.M611776200	http://dx.doi.org/10.1074/jbc.M611776200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17519227	hybrid			2022-12-25	WOS:000247819300016
J	Nakanishi-Matsui, M; Kashiwagi, S; Ubukata, T; Iwamoto-Kihara, A; Wada, Y; Futai, M				Nakanishi-Matsui, Mayumi; Kashiwagi, Sachiko; Ubukata, Toshiharu; Iwamoto-Kihara, Atsuko; Wada, Yoh; Futai, Masamitsu			Rotational catalysis of Escherichia coli ATP synthase F-1 sector - Stochastic fluctuation and a key domain of the beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; TORQUE GENERATION; EPSILON-SUBUNIT; GAMMA-SUBUNIT; F-ATPASE; C-RING; F-1-ATPASE; MUTANT; F1-ATPASE; SITE	A complex of gamma, is an element of, and c subunits rotates in ATP synthase (FoF(1)) coupled with proton transport. A gold bead connected to the gamma subunit of the Escherichia coli F-1 sector exhibited stochastic rotation, confirming a previous study (Nakanishi-Matsui, M., Kashiwagi, S., Hosokawa, H., Cipriano, D. J., Dunn, S. D., Wada, Y., and Futai, M. (2006) J. Biol. Chem. 281, 4126 - 4131). A similar approach was taken for mutations in the beta subunit key region; consistent with its bulk phase ATPase activities, F1 with the Ser-174 to Phe substitution (beta S174F) exhibited a slower single revolution time ( time required for 360 degree revolution) and paused almost 10 times longer than the wild type at one of the three 120 positions during the stepped revolution. The pause positions were probably not at the "ATP waiting" dwell but at the "ATP hydrolysis/ product release" dwell, since the ATP concentration used for the assay was similar to 30-fold higher than the Km value for ATP. A beta Gly-149 to Ala substitution in the phosphate binding P-loop suppressed the defect of beta S174F. The revertant (beta G149A/beta S174F) exhibited similar rotation to the wild type, except that it showed long pauses less frequently. Essentially the same results were obtained with the Ser-174 to Leu substitution and the corresponding revertant beta G149A/beta S174L. These results indicate that the domain between beta-sheet 4 (beta Ser-174) and P-loop (beta Gly-149) is important to drive rotation.	Microbial Chem Res Ctr, Microbial Chem Res Fdn, Futai Special Lab, Tokyo 1410021, Japan; Iwate Med Univ, Fac Pharmaceut Sci, Dept Biochem, Iwate 0283694, Japan; Nagahama Inst Biosci & Technol, Dept Biosci, Shiga 5260829, Japan; Osaka Univ, Inst Sci, Dept Biol Sci, Ibaraki 5670041, Japan	Iwate Medical University; Osaka University	Futai, M (corresponding author), Microbial Chem Res Ctr, Microbial Chem Res Fdn, Futai Special Lab, Tokyo 1410021, Japan.	futaim@iwate-med.ac.jp						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Adachi K, 2000, P NATL ACAD SCI USA, V97, P7243, DOI 10.1073/pnas.120174297; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; Futai M., 2004, HDB ATPASES BIOCH CE, P237; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; Hosokawa H, 2005, J BIOL CHEM, V280, P23797, DOI 10.1074/jbc.M502650200; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Iko Y, 2001, J BIOL CHEM, V276, P47508, DOI 10.1074/jbc.M108803200; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; KANAZAWA H, 1980, J BIOCHEM-TOKYO, V88, P695, DOI 10.1093/oxfordjournals.jbchem.a133022; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Masaike T, 2000, J EXP BIOL, V203, P1; Nakanishi-Matsui M, 2006, J BIOL CHEM, V281, P4126, DOI 10.1074/jbc.M510090200; Nakanishi-Matsui M, 2006, IUBMB LIFE, V58, P318, DOI 10.1080/15216540600702255; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Nishizaka T, 2004, NAT STRUCT MOL BIOL, V11, P142, DOI 10.1038/nsmb721; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OMOTE H, 1994, J BIOL CHEM, V269, P10265; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Shimabukuro K, 2003, P NATL ACAD SCI USA, V100, P14731, DOI 10.1073/pnas.2434983100; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; Ueno H, 2005, P NATL ACAD SCI USA, V102, P1333, DOI 10.1073/pnas.0407857102; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Zimmermann B, 2005, EMBO J, V24, P2053, DOI 10.1038/sj.emboj.7600682	35	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20698	20704		10.1074/jbc.M700551200	http://dx.doi.org/10.1074/jbc.M700551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17517893	hybrid			2022-12-25	WOS:000247819300072
J	Henriksson, LM; Unge, T; Carlsson, J; Aqvist, J; Mowbray, SL; Jones, TA				Henriksson, Lena M.; Unge, Torsten; Carlsson, Jens; Aqvist, Johan; Mowbray, Sherry L.; Jones, T. Alwyn			Structures of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase provide new insights into catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-MEVALONATE PATHWAY; 5-PHOSPHATE REDUCTOISOMERASE; ISOPRENOID BIOSYNTHESIS; CRYSTAL-STRUCTURE; NONMEVALONATE PATHWAY; 2-C-METHYL-D-ERYTHRITOL 4-PHOSPHATE; ISOPENTENYL DIPHOSPHATE; FOSMIDOMYCIN; ENZYME; BOND	Isopentenyl diphosphate is the precursor of various isoprenoids that are essential to all living organisms. It is produced by the mevalonate pathway in humans but by an alternate route in plants, protozoa, and many bacteria. 1-Deoxy-D-xylulose-5-phosphate reductoisomerase catalyzes the second step of this non-mevalonate pathway, which involves an NADPH-dependent rearrangement and reduction of 1-deoxy-D-xylulose 5-phosphate to form 2-C-methyl-D-erythritol 4-phosphate. The use of different pathways, combined with the reported essentiality of the enzyme makes the reductoisomerase a highly promising target for drug design. Here we present several high resolution structures of the Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate reductoisomerase, representing both wild type and mutant enzyme in various complexes with Mn2+, NADPH, and the known inhibitor fosmidomycin. The asymmetric unit corresponds to the biological homodimer. Although crystal contacts stabilize an open active site in the B molecule, the A molecule displays a closed conformation, with some differences depending on the ligands bound. An inhibition study with fosmidomycin resulted in an estimated IC50 value of 80 nM. The double mutant enzyme (D151N/E222Q) has lost its ability to bind the metal and, thereby, also its activity. Our structural information complemented with molecular dynamics simulations and free energy calculations provides the framework for the design of new inhibitors and gives new insights into the reaction mechanism. The conformation of fosmidomycin bound to the metal ion is different from that reported in a previously published structure and indicates that a rearrangement of the intermediate is not required during catalysis.	Uppsala Univ, Biomed Ctr, Dept Mol & Cell Biol, S-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Biomed Ctr, Dept Mol Biol, S-75124 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences	Jones, TA (corresponding author), Uppsala Univ, Biomed Ctr, Dept Mol & Cell Biol, S-75124 Uppsala, Sweden.	Alwyn@xray.bmc.uu.se	Mowbray, Sherry L/D-2141-2013	Carlsson, Jens/0000-0003-4623-2977				AQVIST J, 1993, CHEM REV, V93, P2523, DOI 10.1021/cr00023a010; AQVIST J, 1909, COMPUTATIONAL APPROA, P341; Argyrou A, 2004, BIOCHEMISTRY-US, V43, P4375, DOI 10.1021/bi049974k; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bjelic S, 2006, BIOCHEMISTRY-US, V45, P7709, DOI 10.1021/bi060131y; Boucher Y, 2000, MOL MICROBIOL, V37, P703, DOI 10.1046/j.1365-2958.2000.02004.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Dhiman RK, 2005, J BACTERIOL, V187, P8395, DOI 10.1128/JB.187.24.8395-8402.2005; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Haemers T, 2006, BIOORG MED CHEM LETT, V16, P1888, DOI 10.1016/j.bmcl.2005.12.082; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; Henriksson LM, 2006, ACTA CRYSTALLOGR D, V62, P807, DOI 10.1107/S0907444906019196; Hoeffler JF, 2002, EUR J BIOCHEM, V269, P4446, DOI 10.1046/j.1432-1033.2002.03150.x; Holmberg N, 1999, PROTEIN ENG, V12, P851, DOI 10.1093/protein/12.10.851; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Kuzuyama T, 2000, J BIOL CHEM, V275, P19928, DOI 10.1074/jbc.M001820200; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P4509, DOI 10.1016/S0040-4039(98)00802-8; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lell B, 2003, ANTIMICROB AGENTS CH, V47, P735, DOI 10.1128/AAC.47.2.735-738.2003; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Mac Sweeney A, 2005, J MOL BIOL, V345, P115, DOI 10.1016/j.jmb.2004.10.030; MACKERELL AD, 1995, J AM CHEM SOC, V117, P11946, DOI 10.1021/ja00153a017; Marelius J, 1998, J MOL GRAPH MODEL, V16, P213, DOI 10.1016/S1093-3263(99)00012-1; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Missinou MA, 2002, LANCET, V360, P1941, DOI 10.1016/S0140-6736(02)11860-5; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Proteau PJ, 1999, ORG LETT, V1, P921, DOI 10.1021/ol990839n; Radykewicz T, 2000, FEBS LETT, V465, P157, DOI 10.1016/S0014-5793(99)01743-3; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reuter K, 2002, J BIOL CHEM, V277, P5378, DOI 10.1074/jbc.M109500200; Ricagno S, 2004, BBA-PROTEINS PROTEOM, V1698, P37, DOI 10.1016/j.bbapap.2003.10.006; Rodriguez-Concepcion M, 2000, FEBS LETT, V473, P328, DOI 10.1016/S0014-5793(00)01552-0; Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Sem DS, 2004, CHEM BIOL, V11, P185, DOI 10.1016/j.chembio.2004.02.012; SHIGI Y, 1989, J ANTIMICROB CHEMOTH, V24, P131, DOI 10.1093/jac/24.2.131; Spurgeon SL, 1981, BIOSYNTHESIS ISOPREN, P1; Steinbacher S, 2003, J BIOL CHEM, V278, P18401, DOI 10.1074/jbc.M300993200; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; Warshel A, 1991, COMPUTER MODELING CH; Yajima S, 2004, J AM CHEM SOC, V126, P10824, DOI 10.1021/ja040126m; Yajima S, 2002, J BIOCHEM, V131, P313, DOI 10.1093/oxfordjournals.jbchem.a003105; Zeidler J, 1998, Z NATURFORSCH C, V53, P980	59	69	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19905	19916		10.1074/jbc.M701935200	http://dx.doi.org/10.1074/jbc.M701935200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17491006	hybrid			2022-12-25	WOS:000247650600065
J	Arrecubieta, C; Lee, MH; Macey, A; Foster, TJ; Lowy, FD				Arrecubieta, Carlos; Lee, Mei-Ho; Macey, Alistair; Foster, Timothy J.; Lowy, Franklin D.			SdrF, a Staphylococcus epidermidis surface protein, binds type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; FOREIGN-BODY INFECTIONS; CELL-SURFACE; EXTRACELLULAR-MATRIX; LACTOCOCCUS-LACTIS; MOLECULAR-BASIS; CLUMPING FACTOR; AUREUS; FIBRONECTIN; ADHERENCE	Staphylococcus epidermidis is the leading cause of device-related infections. These infections require an initial colonization step in which S. epidermidis adheres to the implanted material. This process is usually mediated by specific bacterial surface proteins and host factors coating the foreign device. Some of these surface proteins belong to the serine-aspartate repeat (Sdr) family, which includes adhesins from Staphyloccus aureus and S. epidermidis. Using a heterologous expression system in Lactococcus lactis to overcome possible staphylococcal adherence redundancy we observed that one of these Sdr proteins, SdrF, mediates binding to type I collagen when present on the lactococcal cell surface. We used lactococcal recombinant strains, a protein-protein interaction assay and Western ligand blot analysis to demonstrate that this process occurs via the B domain of SdrF and both the alpha 1 and alpha 2 chains of type I collagen. It was also found that a single B domain repeat of S. epidermidis 9491 retains the capacity to bind to type I collagen. We demonstrated that the putative ligand binding N-terminal A domain does not bind to collagen which suggests that SdrF might be a multiligand adhesin. Antibodies directed against the B domain significantly reduce in vitro adherence of S. epidermidis to immobilized collagen.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Med, Div Infect Dis, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland	Columbia University; Columbia University; Columbia University; Trinity College Dublin	Lowy, FD (corresponding author), Trinity Coll Dublin, Moyne Inst Prevent Med, Dublin 2, Ireland.	fl189@columbia.edu	Lee, Mei-Ho/ABA-1514-2021	Lee, Mei-Ho/0000-0001-9206-6805	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077096] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 077096-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acil Y, 1997, J CHROMATOGR A, V758, P313, DOI 10.1016/S0021-9673(96)00729-7; Andreola F, 2004, J BIOL CHEM, V279, P3434, DOI 10.1074/jbc.M305832200; Bowden MG, 2005, MICROBIOL-SGM, V151, P1453, DOI 10.1099/mic.0.27534-0; Bowden MG, 2002, J BIOL CHEM, V277, P43017, DOI 10.1074/jbc.M207921200; Davis SL, 2001, J BIOL CHEM, V276, P27799, DOI 10.1074/jbc.M103873200; Deivanayagam CCS, 2000, STRUCTURE, V8, P67, DOI 10.1016/S0969-2126(00)00081-2; DICKINSON GM, 1989, ANTIMICROB AGENTS CH, V33, P597, DOI 10.1128/AAC.33.5.597; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Francois P, 1998, ANN VASC SURG, V12, P34, DOI 10.1007/s100169900112; Gotz F, 2002, MOL MICROBIOL, V43, P1367, DOI 10.1046/j.1365-2958.2002.02827.x; Hartford O, 1997, MOL MICROBIOL, V25, P1065, DOI 10.1046/j.1365-2958.1997.5291896.x; Heilmann C, 2003, MICROBIOL-SGM, V149, P2769, DOI 10.1099/mic.0.26527-0; Heilmann C, 1997, MOL MICROBIOL, V24, P1013, DOI 10.1046/j.1365-2958.1997.4101774.x; Heimberger T S, 1989, Infect Dis Clin North Am, V3, P221; HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693; Hussain M, 2001, J BACTERIOL, V183, P6778, DOI 10.1128/JB.183.23.6778-6786.2001; Ingham KC, 2004, J BIOL CHEM, V279, P42945, DOI 10.1074/jbc.M406984200; Josefsson E, 1998, J BIOL CHEM, V273, P31145, DOI 10.1074/jbc.273.47.31145; Josefsson E, 1998, MICROBIOL-UK, V144, P3387, DOI 10.1099/00221287-144-12-3387; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; KRISTINSSON KG, 1989, J MED MICROBIOL, V28, P249, DOI 10.1099/00222615-28-4-249; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9; McCrea KW, 2000, MICROBIOL-SGM, V146, P1535, DOI 10.1099/00221287-146-7-1535; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; NI ED, 1998, MOL MICROBIOL, V30, P245; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Pei L, 1999, INFECT IMMUN, V67, P4525, DOI 10.1128/IAI.67.9.4525-4530.1999; PETERS G, 1988, J ANTIMICROB CHEMOTH, V21, P139, DOI 10.1093/jac/21.suppl_C.139; PETERS G, 1982, J INFECT DIS, V146, P479, DOI 10.1093/infdis/146.4.479; PREVOST G, 1995, INFECT IMMUN, V63, P4121; Que YA, 2000, INFECT IMMUN, V68, P3516, DOI 10.1128/IAI.68.6.3516-3522.2000; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; Schwarz-Linek U, 2004, MOL MICROBIOL, V52, P631, DOI 10.1111/j.1365-2958.2004.04027.x; Simon D, 2005, CLIN INFECT DIS, V40, P1108, DOI 10.1086/428728; von Eiff C, 1999, INFECTION, V27, pS7, DOI 10.1007/BF02561610; von Eiff C, 2002, LANCET INFECT DIS, V2, P677, DOI 10.1016/S1473-3099(02)00438-3; WELLS JM, 1993, J APPL BACTERIOL, V74, P629, DOI 10.1111/j.1365-2672.1993.tb05195.x; Williams RJ, 2002, INFECT IMMUN, V70, P6805, DOI 10.1128/IAI.70.12.6805-6810.2002; Zong YN, 2005, EMBO J, V24, P4224, DOI 10.1038/sj.emboj.7600888	42	64	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18767	18776		10.1074/jbc.M610940200	http://dx.doi.org/10.1074/jbc.M610940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17472965	hybrid			2022-12-25	WOS:000247475300015
J	Guizzetti, M; Chen, J; Oram, JF; Tsuji, R; Dao, K; Moller, T; Costa, LG				Guizzetti, Marina; Chen, Jing; Oram, John F.; Tsuji, Ryozo; Dao, Khoi; Moeller, Thomas; Costa, Lucio G.			Ethanol induces cholesterol efflux and up-regulates ATP-binding cassette cholesterol transporters in fetal astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED PHOSPHOINOSITIDE METABOLISM; LEMLI-OPITZ-SYNDROME; APOLIPOPROTEIN-E; ALCOHOL SYNDROME; SONIC HEDGEHOG; CELL-DEATH; DEVELOPMENTAL NEUROTOXICITY; MUSCARINIC RECEPTORS; NEURITE OUTGROWTH; RETINOIC ACID	Cholesterol plays an important role during brain development, since it is involved in glial cell proliferation, neuronal survival and differentiation, and synaptogenesis. Astrocytes produce large amounts of brain cholesterol and produce and release lipoproteins containing apoE that can extract cholesterol from CNS cells for elimination. We hypothesized that some of the deleterious effects of ethanol in the developing brain may be due to the disruption of cholesterol homeostasis in astrocytes. This study investigates the effect of ethanol on cholesterol efflux mediated by ATP-binding cassette (ABC) cholesterol transporters. In fetal rat astrocytes in culture, ethanol caused a concentration-dependent increase in cholesterol efflux and increased the levels of ABCA1 starting at 25mM. Similar effects of ethanol on cholesterol efflux and ABCA1 were also observed in fetal human astrocytes. In addition, ABCA1 levels were increased in the brains of 7-day-old pups treated for 3 days with 2, 4, or 6 g/kg ethanol. Ethanol also increased apoE release from fetal rat astrocytes, and conditioned medium prepared from ethanol-treated astrocytes extracted more cholesterol than conditioned medium from untreated cells. In addition, ethanol increased the levels of another cholesterol transporter, ABCG1. Ethanol did not affect cholesterol synthesis and reduced the levels of intracellular cholesterol in rat astrocytes. Retinoic acid, which induces teratogenic effects similarly to ethanol, also caused up-regulation of ABCA1 and ABCG1.	Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98105 USA; Univ Washington, Dept Med, Seattle, WA 98105 USA; Univ Washington, Dept Neurol, Seattle, WA 98105 USA; Sumitomo Chem Co Ltd, Environm Hlth Lab, Osaka 554, Japan; Univ Parma, Dept Human Anat Pharmacol & Forens Med, I-43100 Parma, Italy	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Sumitomo Chem Co Ltd; University of Parma	Guizzetti, M (corresponding author), Univ Washington, Dept Environm & Occupat Hlth Sci, 4225 Roosevelt Way NE No100, Seattle, WA 98105 USA.	marinag@u.washington.edu			NIAAA NIH HHS [AA015443, AA08154] Funding Source: Medline; NICHD NIH HHS [HD00836] Funding Source: Medline; NIEHS NIH HHS [P30ES07033] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD000836] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD000836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA015443, R01AA008154] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200; Ahlgren SC, 2002, P NATL ACAD SCI USA, V99, P10476, DOI 10.1073/pnas.162356199; Astley SJ, 2000, ALCOHOL ALCOHOLISM, V35, P400, DOI 10.1093/alcalc/35.4.400; Astley SJ, 1999, TERATOLOGY, V59, P163, DOI 10.1002/(SICI)1096-9926(199903)59:3<163::AID-TERA8>3.0.CO;2-8; BALDUINI W, 1989, J PHARMACOL EXP THER, V250, P541; BALDUINI W, 1990, BRAIN RES, V512, P248, DOI 10.1016/0006-8993(90)90633-M; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Blader P, 1998, DEV BIOL, V201, P185, DOI 10.1006/dbio.1998.8995; BOCHELEN D, 1995, J NEUROCHEM, V65, P2194; CASTELLI WP, 1977, LANCET, V2, P153; Cohen MM, 2002, AM J MED GENET, V109, P1, DOI 10.1002/ajmg.10258; Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399; Cooper MK, 2003, NAT GENET, V33, P508, DOI 10.1038/ng1134; Costet P, 2003, MOL CELL BIOL, V23, P7756, DOI 10.1128/MCB.23.21.7756-7766.2003; DAVIES DL, 1981, NEUROSCI LETT, V26, P49, DOI 10.1016/0304-3940(81)90424-9; Dehart DB, 1997, AM J MED GENET, V68, P328, DOI 10.1002/(SICI)1096-8628(19970131)68:3<328::AID-AJMG15>3.0.CO;2-V; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Fan QW, 2002, J NEUROCHEM, V80, P178, DOI 10.1046/j.0022-3042.2001.00686.x; Guizzetti M, 2005, MED HYPOTHESES, V64, P563, DOI 10.1016/j.mehy.2004.05.019; Guizzetti M, 2004, J NEUROCHEM, V90, P646, DOI 10.1111/j.1471-4159.2004.02541.x; Guizzetti M, 1996, J NEUROCHEM, V67, P2236; Guizzetti M, 1996, EUR J PHARMACOL, V297, P265, DOI 10.1016/0014-2999(95)00746-6; Guizzetti M, 2001, NEUROREPORT, V12, P1639, DOI 10.1097/00001756-200106130-00025; Guizzetti Marina, 1997, Frontiers in Bioscience, V2, pE93; Helms JA, 1997, DEV BIOL, V187, P25, DOI 10.1006/dbio.1997.8589; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; INOMATA K, 1987, INT J DEV NEUROSCI, V5, P455, DOI 10.1016/0736-5748(87)90023-2; Jurevics HA, 1997, J LIPID RES, V38, P723; Karten B, 2006, J BIOL CHEM, V281, P4049, DOI 10.1074/jbc.M508915200; Kim WS, 2007, J BIOL CHEM, V282, P2851, DOI 10.1074/jbc.M607831200; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Kotter K, 1999, J NEUROCHEM, V73, P2517, DOI 10.1046/j.1471-4159.1999.0732517.x; KUGE T, 1993, ENVIRON RES, V62, P99, DOI 10.1006/enrs.1993.1094; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lanoue L, 1997, AM J MED GENET, V73, P24; Lusa S, 2003, J BIOL CHEM, V278, P19844, DOI 10.1074/jbc.M212503200; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Michikawa M, 1999, J NEUROCHEM, V72, P2278, DOI 10.1046/j.1471-4159.1999.0722278.x; Nowaczyk MJM, 1999, CAN MED ASSOC J, V161, P165; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2005, PHYSIOL REV, V85, P1343, DOI 10.1152/physrev.00005.2005; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; Porter FD, 2003, CURR OPIN PEDIATR, V15, P607, DOI 10.1097/00008480-200312000-00011; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Soscia SJ, 2006, CELL MOL LIFE SCI, V63, P2039, DOI 10.1007/s00018-006-6208-2; SRIVASTAVA LM, 1994, ALCOHOL ALCOHOLISM, V29, P11; STREISSGUTH AP, 1991, JAMA-J AM MED ASSOC, V265, P1961, DOI 10.1001/jama.265.15.1961; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; SULIK KK, 1988, DEVELOPMENT, V103, P213; Tachikawa M, 2005, J NEUROCHEM, V95, P294, DOI 10.1111/j.1471-4159.2005.03369.x; Tsuji R, 2003, NEUROREPORT, V14, P1395, DOI 10.1097/01.wnr.0000071763.92388.41; Vaughan AM, 2006, J LIPID RES, V47, P2433, DOI 10.1194/jlr.M600218-JLR200; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wang YT, 2005, J BIOL CHEM, V280, P35896, DOI 10.1074/jbc.M506210200; Yagle K, 2001, GLIA, V35, P111, DOI 10.1002/glia.1076; Yanni PA, 2000, DEV BRAIN RES, V120, P233, DOI 10.1016/S0165-3806(00)00015-8	61	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18740	18749		10.1074/jbc.M702398200	http://dx.doi.org/10.1074/jbc.M702398200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17478430	hybrid			2022-12-25	WOS:000247475300012
J	Yaghmur, A; Laggner, P; Zhang, SG; Rappolt, M				Yaghmur, Anan; Laggner, Peter; Zhang, Shuguang; Rappolt, Michael			Tuning Curvature and Stability of Monoolein Bilayers by Designer Lipid-Like Peptide Surfactants	PLOS ONE			English	Article							PHASE-BEHAVIOR; CUBIC PHASES; MEMBRANE-PROTEIN; NONBILAYER LIPIDS; LIQUID-CRYSTALS; FORM NANOTUBES; FUSION PEPTIDE; WATER SYSTEMS; X-RAY; CRYSTALLIZATION	This study reports the effect of loading four different charged designer lipid-like short anionic and cationic peptide surfactants on the fully hydrated monoolein (MO)-based Pn3m phase (Q(224)). The studied peptide surfactants comprise seven amino acid residues, namely A(6)D, DA(6), A(6)K, and KA(6). D (aspartic acid) bears two negative charges, K (lysine) bears one positive charge, and A (alanine) constitutes the hydrophobic tail. To elucidate the impact of these peptide surfactants, the ternary MO/peptide/water system has been investigated using small-angle X-ray scattering (SAXS), within a certain range of peptide concentrations (R<0.2) and temperatures (25 to 70 degrees C). We demonstrate that the bilayer curvature and the stability are modulated by: i) the peptide/lipid molar ratio, ii) the peptide molecular structure (the degree of hydrophobicity, the type of the hydrophilic amino acid, and the headgroup location), and iii) the temperature. The anionic peptide surfactants, A(6)D and DA(6), exhibit the strongest surface activity. At low peptide concentrations (R = 0.01), the Pn3m structure is still preserved, but its lattice increases due to the strong electrostatic repulsion between the negatively charged peptide molecules, which are incorporated into the interface. This means that the anionic peptides have the effect of enlarging the water channels and thus they serve to enhance the accommodation of positively charged water-soluble active molecules in the Pn3m phase. At higher peptide concentration (R = 0.10), the lipid bilayers are destabilized and the structural transition from the Pn3m to the inverted hexagonal phase (H-2) is induced. For the cationic peptides, our study illustrates how even minor modifications, such as changing the location of the headgroup (A(6)K vs. KA(6)), affects significantly the peptide's effectiveness. Only KA(6) displays a propensity to promote the formation of H-2, which suggests that KA(6) molecules have a higher degree of incorporation in the interface than those of A(6)K.	[Yaghmur, Anan; Laggner, Peter; Rappolt, Michael] Austrian Acad Sci, Inst Biophys & Nanosyst Res, Graz, Austria; [Zhang, Shuguang] MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA	Austrian Academy of Sciences; Massachusetts Institute of Technology (MIT)	Yaghmur, A (corresponding author), Austrian Acad Sci, Inst Biophys & Nanosyst Res, Graz, Austria.	anan.yaghmur@oeaw.ac.at	Yaghmur, Anan/AGU-9381-2022	Yaghmur, Anan/0000-0003-1608-773X; Rappolt, Michael/0000-0001-9942-3035; Zhang, Shuguang/0000-0002-3856-3752				Almsherqi ZA, 2006, J CELL BIOL, V173, P839, DOI 10.1083/jcb.200603055; Andersson AS, 1998, BIOPHYS J, V75, P2877, DOI 10.1016/S0006-3495(98)77730-6; Angelova A, 2005, J PHYS CHEM B, V109, P3089, DOI 10.1021/jp044216p; Barauskas J, 2005, LANGMUIR, V21, P2569, DOI 10.1021/la047590p; Basanez G, 1998, BIOCHEMISTRY-US, V37, P3901, DOI 10.1021/bi9728497; Bechinger B, 2006, BBA-BIOMEMBRANES, V1758, P1529, DOI 10.1016/j.bbamem.2006.07.001; Borne J, 2000, LANGMUIR, V16, P10044, DOI 10.1021/la000619e; Borne J, 2001, LANGMUIR, V17, P7742, DOI 10.1021/la010650w; Briggs J, 1996, J PHYS II, V6, P723, DOI 10.1051/jp2:1996208; Caboi F, 2001, CHEM PHYS LIPIDS, V109, P47, DOI 10.1016/S0009-3084(00)00200-0; Caboi F, 2002, LANGMUIR, V18, P7916, DOI 10.1021/la0259959; Caboi F, 1997, LANGMUIR, V13, P5476, DOI 10.1021/la9702188; Caffrey M, 2003, J STRUCT BIOL, V142, P108, DOI 10.1016/S1047-8477(03)00043-1; Caffrey M, 2000, CURR OPIN STRUC BIOL, V10, P486, DOI 10.1016/S0959-440X(00)00119-6; Chernik GG, 1999, CURR OPIN COLLOID IN, V4, P381, DOI 10.1016/S1359-0294(00)00023-6; CHUNG H, 1994, NATURE, V368, P224, DOI 10.1038/368224a0; Chupin V, 2003, BIOPHYS J, V84, P2373, DOI 10.1016/S0006-3495(03)75043-7; Colotto A, 1996, BIOCHEMISTRY-US, V35, P980, DOI 10.1021/bi951991+; Colotto A, 1997, BIOCHEMISTRY-US, V36, P7644, DOI 10.1021/bi970382u; de Campo L, 2004, LANGMUIR, V20, P5254, DOI 10.1021/la0499416; deKruijff B, 1997, NATURE, V386, P129, DOI 10.1038/386129a0; Deng YR, 2002, PROTOPLASMA, V219, P160, DOI 10.1007/s007090200017; Drummond CJ, 1999, CURR OPIN COLLOID IN, V4, P449, DOI 10.1016/S1359-0294(00)00020-0; Duesing PM, 1997, LANGMUIR, V13, P351, DOI 10.1021/la960602p; ELLENS H, 1989, BIOCHEMISTRY-US, V28, P3692, DOI 10.1021/bi00435a011; Epand RM, 1997, CURR TOP MEMBR, V44, P237; Garab G, 2000, TRENDS PLANT SCI, V5, P489, DOI 10.1016/S1360-1385(00)01767-2; Gustafsson J, 1996, LANGMUIR, V12, P4611, DOI 10.1021/la960318y; Gustafsson J, 1997, LANGMUIR, V13, P6964, DOI 10.1021/la970566+; Harper PE, 2000, EUR PHYS J E, V2, P217, DOI 10.1007/PL00013660; HYDE S, 1997, ELSEVIER BOOK SERIES; Hyde S. T., 2001, HDB APPL SURFACE COL, P299; Hyde ST, 1996, CURR OPIN SOLID ST M, V1, P653, DOI 10.1016/S1359-0286(96)80047-7; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; Kamo T, 2006, J PHYS CHEM B, V110, P24987, DOI 10.1021/jp064988g; Killian JA, 2006, CURR OPIN STRUC BIOL, V16, P473, DOI 10.1016/j.sbi.2006.06.007; KOZLOV MM, 1994, BIOPHYS J, V67, P1603, DOI 10.1016/S0006-3495(94)80633-2; LAGGNER P, 1992, NUCL INSTRUM METH A, V323, P86, DOI 10.1016/0168-9002(92)90273-7; Landau EM, 1997, J PHYS CHEM B, V101, P1935, DOI 10.1021/jp963347q; LANDH T, 1994, J PHYS CHEM-US, V98, P8453, DOI 10.1021/j100085a028; Larsson K, 2000, CURR OPIN COLLOID IN, V5, P64, DOI 10.1016/S1359-0294(00)00040-6; LARSSON K, 1989, J PHYS CHEM-US, V93, P7304, DOI 10.1021/j100358a010; LARSSON K, 1983, NATURE, V304, P664, DOI 10.1038/304664c0; Lewis RNAH, 1997, CURR TOP MEMBR, V44, P25; Li SJ, 2001, BIOPHYS J, V81, P983, DOI 10.1016/S0006-3495(01)75756-6; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LINDBLOM G, 1979, J AM CHEM SOC, V101, P5465, DOI 10.1021/ja00513a002; Liu F, 2001, BIOCHEMISTRY-US, V40, P760, DOI 10.1021/bi001942j; LUTTON ES, 1965, J AM OIL CHEM SOC, V42, P1068, DOI 10.1007/BF02636909; Luzzati V, 1997, CURR OPIN STRUC BIOL, V7, P661, DOI 10.1016/S0959-440X(97)80075-9; Lynch ML, 2003, J COLLOID INTERF SCI, V260, P404, DOI 10.1016/S0021-9797(02)00016-4; Masum SM, 2005, LANGMUIR, V21, P5290, DOI 10.1021/la0469607; Masum SM, 2003, LANGMUIR, V19, P4745, DOI 10.1021/la026847l; Misquitta Y, 2001, BIOPHYS J, V81, P1047, DOI 10.1016/S0006-3495(01)75762-1; Morein S, 2000, BIOPHYS J, V78, P2475, DOI 10.1016/S0006-3495(00)76792-0; NILSSON A, 1994, CHEM PHYS LIPIDS, V71, P119, DOI 10.1016/0009-3084(94)90065-5; PATTON JS, 1979, SCIENCE, V204, P145, DOI 10.1126/science.432636; Qiu H, 1998, J PHYS CHEM B, V102, P4819, DOI 10.1021/jp980553k; Qiu H, 2000, BIOMATERIALS, V21, P223, DOI 10.1016/S0142-9612(99)00126-X; Qiu H, 1999, CHEM PHYS LIPIDS, V100, P55, DOI 10.1016/S0009-3084(99)00040-7; Rappolt M, 2006, EUROPHYS LETT, V75, P267, DOI 10.1209/epl/i2006-10104-y; RAPPOLT M, 2006, ELSEVIER BOOK SERIES, V5, P253; Rummel G, 1998, J STRUCT BIOL, V121, P82, DOI 10.1006/jsbi.1997.3952; Sagalowicz L, 2006, J MICROSC-OXFORD, V221, P110, DOI 10.1111/j.1365-2818.2006.01544.x; Santoso S, 2002, NANO LETT, V2, P687, DOI 10.1021/n1025563i; Seddon JM, 1996, BER BUNSEN PHYS CHEM, V100, P380, DOI 10.1002/bbpc.19961000324; Shearman GC, 2006, J PHYS-CONDENS MAT, V18, pS1105, DOI 10.1088/0953-8984/18/28/S01; Siegel DP, 2006, BIOPHYS J, V90, P200, DOI 10.1529/biophysj.105.070466; Siegel DP, 1999, BIOPHYS J, V76, P291, DOI 10.1016/S0006-3495(99)77197-3; Simidjiev I, 2000, P NATL ACAD SCI USA, V97, P1473, DOI 10.1073/pnas.97.4.1473; Spicer PT., 2004, DEKKER ENCY NANOSCIE, P881; Staudegger E, 2000, BBA-BIOMEMBRANES, V1468, P213, DOI 10.1016/S0005-2736(00)00260-1; TATE MW, 1989, BIOCHEMISTRY-US, V28, P4245, DOI 10.1021/bi00436a019; Vauthey S, 2002, P NATL ACAD SCI USA, V99, P5355, DOI 10.1073/pnas.072089599; von Maltzahn G, 2003, LANGMUIR, V19, P4332, DOI 10.1021/la026526+; WIESLANDER A, 1995, EUR J BIOCHEM, V227, P734, DOI 10.1111/j.1432-1033.1995.tb20196.x; Yaghmur A, 2006, LANGMUIR, V22, P517, DOI 10.1021/la052109w; Yaghmur A, 2005, LANGMUIR, V21, P569, DOI 10.1021/la0482711; Yaghmur A, 2006, LANGMUIR, V22, P9919, DOI 10.1021/la061303v; Yang SJ, 2006, SUPRAMOL CHEM, V18, P389, DOI 10.1080/10615800600658586; Yeh JI, 2005, BIOCHEMISTRY-US, V44, P16912, DOI 10.1021/bi051357o; Zhao XJ, 2006, P NATL ACAD SCI USA, V103, P17707, DOI 10.1073/pnas.0607167103; Zhao XJ, 2006, CHEM SOC REV, V35, P1105, DOI 10.1039/b511336a	83	95	97	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e479	10.1371/journal.pone.0000479	http://dx.doi.org/10.1371/journal.pone.0000479			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534429	Green Published, Green Submitted, gold			2022-12-25	WOS:000207448800009
J	Andrianifahanana, M; Singh, AP; Nemos, C; Ponnusamy, MP; Moniaux, N; Mehta, PP; Varshney, GC; Batra, SK				Andrianifahanana, M.; Singh, A. P.; Nemos, C.; Ponnusamy, M. P.; Moniaux, N.; Mehta, P. P.; Varshney, G. C.; Batra, S. K.			IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response	ONCOGENE			English	Article						IFN-gamma; MUC4; STAT-1; pancreatic cancer; regulation	INTERFERON-GAMMA; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION; UNPHOSPHORYLATED STAT1; GENE-EXPRESSION; GROWTH; ALPHA; ASSOCIATION; INHIBITION; INDUCTION	MUC4 is a transmembrane mucin, which is aberrantly expressed in pancreatic adenocarcinoma with no detectable expression in the normal pancreas. Here, we present a novel mechanism of IFN-gamma-induced expression of MUC4 in pancreatic cancer cells. Our studies highlight the upregulation of STAT-1 as a basis for MUC4 induction and demonstrate that its activation and upregulation by IFN-gamma are two distinct, albeit temporally integrated, signalling events that drive the selective induction of IRF-1 and MUC4, respectively, within a single cell system. The pro. le of interferon regulatory factor (IRF)-1 gene induction by IFN-gamma is consistent with its rapid transactivation by phospho-Y701-STAT-1. In contrast, the induction of the MUC4 mucin gene expression is relatively delayed, and occurs only in response to an increase in STAT-1 expression. A progressive binding of STAT-1 to various gamma-interferon-activated sequences (GAS) in the MUC4 promoter is observed in chromatin immuno-precipitation assay, indicating its direct association. Stimulation of STAT-1 expression by double-stranded polynucleotides or ectopic expression is shown to induce MUC4 expression, without Y701 phosphorylation of STAT-1. This effect is abrogated by short interfering RNA (siRNA)-mediated inhibition of STAT-1 expression, supporting further the relevance of STAT-1 in MUC4 regulation. In conclusion, our findings identify a novel mechanism for MUC4 regulation in pancreatic cancer cells and unfold new perspectives on the foundation of IFN-gamma-dependent gene regulation.	Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE USA; Inst Microbial Technol, Chandigarh, India	University of Nebraska System; University of Nebraska Medical Center; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Mad Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018; Singh, Ajay/AAF-4414-2020	Moniaux, Nicolas/0000-0001-9718-1386; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X; Singh, Ajay/0000-0003-3492-6330	NCI NIH HHS [CA78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Guo GG, 2002, J INTERF CYTOK RES, V22, P555, DOI 10.1089/10799900252982034; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Lagow EL, 2002, J CELL BIOCHEM, V86, P759, DOI 10.1002/jcb.10261; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Suzuki K, 1999, P NATL ACAD SCI USA, V96, P2285, DOI 10.1073/pnas.96.5.2285; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Yang J, 2005, CANCER RES, V65, P939; Zhou YH, 2001, ONCOLOGY-BASEL, V60, P330, DOI 10.1159/000058529	25	40	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7251	7261		10.1038/sj.onc.1210532	http://dx.doi.org/10.1038/sj.onc.1210532			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525742				2022-12-25	WOS:000250955600009
J	Ito, TK; Ishii, G; Chiba, H; Ochiai, A				Ito, T-K; Ishii, G.; Chiba, H.; Ochiai, A.			The VEGF angiogenic switch of. broblasts is regulated by MMP-7 from cancer cells	ONCOGENE			English	Article						broblasts; angiogenesis; VEGF; MMP-7; CTGF	ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; TUMOR ANGIOGENESIS; FIBROBLASTS; BINDING; CARCINOGENESIS; MATRILYSIN; TUMORIGENESIS; MACROPHAGES; FIBRONECTIN	Vascular endothelial growth factor (VEGF) production by stromal fibroblasts plays an important role in tumor angiogenesis. However, VEGF is also expressed by normal tissue fibroblasts, raising the question of how the VEGF activity of fibroblasts is regulated. Here we report that the latent VEGF angiogenic activity of fibroblasts is activated by cancer cells, resulting in tumor-selective utilization of fibroblast-derived VEGF. Through the production of VEGF, human VA-13 fibroblasts promote angiogenesis in and growth of human pancreas cancer Capan-1 xenograft tumors, whereas VA-13 fibroblasts alone do not show significant angiogenesis. Treatment of VA-13 fibroblast supernatant with matrix metalloproteinase-7 (MMP- 7), an extracellular proteinase characteristically expressed by cancer cells, elicits endothelial tube formation. This effect is abrogated by anti-VEGF antibody or connective tissue growth factor (CTGF), which was previously reported to sequester VEGF and be degraded by MMP-7. Suppression of MMP-7 in Capan-1 cells abrogates the tumor angiogenic activity of VA-13 fibroblasts, which is restored by suppression of CTGF in VA-13 fibroblasts. We further show that these molecular mechanisms that trigger angiogenesis are effective in human primary fibroblasts and human colorectal tissue. These data suggest that fibroblasts may store VEGF in a latent state in the extracellular environment for urgent use in angiogenesis.	Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, Kashiwa, Chiba 2778577, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Canc Biol Lab, Kashiwa, Chiba, Japan	National Cancer Center - Japan; University of Tokyo	Ochiai, A (corresponding author), Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, 6-5-1 Kashiwanoba, Kashiwa, Chiba 2778577, Japan.	aochiai@east.ncc.go.jp	Ishii, Genichiro/E-2913-2012					Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen YL, 2004, MOL BIOL CELL, V15, P5635, DOI 10.1091/mbc.E04-06-0490; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Crawford HC, 2002, J CLIN INVEST, V109, P1437, DOI 10.1172/JCI200215051; Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; HLATKY L, 1994, CANCER RES, V54, P6083; Huo N, 2002, CANCER LETT, V177, P95, DOI 10.1016/S0304-3835(01)00772-8; Ichikawa Y, 2006, ONCOL REP, V15, P311; Ii M, 2006, EXP BIOL MED, V231, P20; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Ishii G, 2005, INT J CANCER, V117, P212, DOI 10.1002/ijc.21199; Jang HS, 2004, MOL THER, V9, P464, DOI 10.1016/j.ymthe.2003.12.002; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; McCarthy M, 2003, LANCET, V361, P1959, DOI 10.1016/S0140-6736(03)13603-3; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Roy R, 2006, EXP CELL RES, V312, P608, DOI 10.1016/j.yexcr.2005.11.022; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Zanetta L, 2000, INT J CANCER, V85, P281, DOI 10.1002/(SICI)1097-0215(20000115)85:2<281::AID-IJC21>3.0.CO;2-3	39	86	93	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7194	7203		10.1038/sj.onc.1210535	http://dx.doi.org/10.1038/sj.onc.1210535			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525740				2022-12-25	WOS:000250955600003
J	Migliaccio, A; Varricchio, L; De Falco, A; Castoria, G; Arra, C; Yamaguchi, H; Ciociola, A; Lombardi, M; Di Stasio, R; Barbieri, A; Baldi, A; Barone, MV; Appella, E; Auricchio, F				Migliaccio, A.; Varricchio, L.; De Falco, A.; Castoria, G.; Arra, C.; Yamaguchi, H.; Ciociola, A.; Lombardi, M.; Di Stasio, R.; Barbieri, A.; Baldi, A.; Barone, M. V.; Appella, E.; Auricchio, F.			Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth	ONCOGENE			English	Article						androgen receptor; estrogen receptor; receptor antagonist; Src; xenografts	PROSTATE-CANCER CELLS; ESTRADIOL-RECEPTOR; ESTROGEN-RECEPTOR; FACTOR-I; ACTIVATION; PATHWAY; PROTEIN; BREAST; PHOSPHORYLATION; COMPLEX	In human mammary and prostate cancer cells, steroid hormones or epidermal growth factor ( EGF) trigger association of the androgen receptor ( AR)- estradiol receptor ( ER) (alpha or beta) complex with Src. This interaction activates Src and affects the G1 to S cell cycle progression. In this report, we identify the sequence responsible for the AR/ Src interaction and describe a 10 amino- acid peptide that inhibits this interaction. Treatment of the human prostate or mammary cancer cells ( LNCaP or MCF- 7, respectively) with nanomolar concentrations of this peptide inhibits the androgen- or estradiol- induced association between the AR or the ER and Src the Src/ Erk pathway activation, cyclin D1 expression and DNA synthesis, without interfering in the receptor- dependent transcriptional activity. Similarly, the peptide prevents the S phase entry of LNCaP and MCF- 7 cells treated with EGF as well as mouse embryo fibroblasts stimulated with androgen or EGF. Interestingly, the peptide does not inhibit the S phase entry and cytoskeletal changes induced by EGF or serum treatment of AR- negative prostate cancer cell lines. The peptide is the first example of a specific inhibitor of steroid receptor-dependent signal transducing activity. The importance of these results is highlighted by the finding that the peptide strongly inhibits the growth of LNCaP xenografts established in nude mice.	Univ Naples 2, Fac Med & Chirurg, Dipartimento Patol Gen, I-80138 Naples, Italy; NCI, NIH, Cell Biol Lab, Bethesda, MD 20892 USA; Inst Cura Tumori Fdn, Naples, Italy; Univ Naples 2, Sez Anat Patol, Dipartimento Biochim & Biofis, Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Pediat, Naples, Italy	Universita della Campania Vanvitelli; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universita della Campania Vanvitelli; University of Naples Federico II	Auricchio, F (corresponding author), Univ Naples 2, Fac Med & Chirurg, Dipartimento Patol Gen, Via L Crecchio 7, I-80138 Naples, Italy.	ferdinando.auricchio@unina2.it	Barbieri, Antonio/AAG-8961-2019; Migliaccio, Antimo/AAB-3376-2019; Baldi, Alfonso/ABG-2397-2021; Castoria, Gabriella/I-3349-2019	Barbieri, Antonio/0000-0002-7788-6167; Castoria, Gabriella/0000-0002-0576-4494; Migliaccio, Antimo/0000-0002-4197-2055; Baldi, Alfonso/0000-0002-8693-3842; BARONE, Maria Vittoria/0000-0001-6190-4917; Arra, Claudio/0000-0003-3162-2091	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bonaccorsi L, 2000, ENDOCRINOLOGY, V141, P3172, DOI 10.1210/en.141.9.3172; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Castoria G, 2004, MOL CELL BIOL, V24, P7643, DOI 10.1128/MCB.24.17.7643-7653.2004; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CULIG Z, 1994, CANCER RES, V54, P5474; Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x; Gururaj AE, 2006, CLIN CANCER RES, V12, p1001S, DOI 10.1158/1078-0432.CCR-05-2110; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Marquez DC, 2001, ENDOCRINE, V16, P73, DOI 10.1385/ENDO:16:2:073; Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Singer CA, 1999, J NEUROSCI, V19, P2455; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	30	74	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6619	6629		10.1038/sj.onc.1210487	http://dx.doi.org/10.1038/sj.onc.1210487			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486077				2022-12-25	WOS:000250081500004
J	Azoitei, N; Brey, A; Busch, T; Fulda, S; Adler, G; Seufferlein, T				Azoitei, N.; Brey, A.; Busch, T.; Fulda, S.; Adler, G.; Seufferlein, T.			Thirty-eight-negative kinase 1 (TNK1) facilitates TNF alpha-induced apoptosis by blocking NF-kappa B activation	ONCOGENE			English	Article						apoptosis; NF-kappa B; p65 transactivation; TNF alpha; TNK1	TUMOR-NECROSIS-FACTOR; PROTEIN-TYROSINE KINASE; GENE-EXPRESSION; P65 SUBUNIT; RECEPTOR; PHOSPHORYLATION; CELLS; TRANSCRIPTION; DEATH	Thirty-eight-negative kinase 1 (TNK1) is a member of the ACK-family of nonreceptor tyrosine kinases and was originally cloned from CD34+/Lin-/CD38-hematopoietic stem/progenitor cells. The signaling pathways induced by TNK1 are largely unknown. Here, we report that expression and consequent activation of TNK1 enables tumor necrosis factor a (TNF alpha)-induced apoptosis by selectively inhibiting TNF alpha-induced activation of nuclear factor-kappa B (NF-kappa B). TNK1 has no effect on NF-kappa B DNA binding or the composition of the NF-kappa B complex; however, the kinase markedly prevents TNFa-induced NF-kappa B transactivation. TNK1 therefore acts as a novel molecular switch that can determine the properties of TNFa signaling and therefore cell death.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Childrens Hosp, Ulm, Germany	Ulm University; Ulm University	Seufferlein, T (corresponding author), Univ Ulm, Dept Internal Med 1, Robert Koch St 8, D-89081 Ulm, Germany.	thomas.seufferlein@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Seufferlein, Thomas TW/P-7147-2018	Fulda, Simone/0000-0002-0459-6417				Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; BEG AA, 1996, SCIENCE, V274, P784; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Eickhoff B, 2000, BIOL CHEM, V381, P1127, DOI 10.1515/BC.2000.138; Felschow DM, 2000, BIOCHEM BIOPH RES CO, V273, P294, DOI 10.1006/bbrc.2000.2887; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; Hoehn GT, 1996, ONCOGENE, V12, P903; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Mukhopadhyay A, 2002, J BIOL CHEM, V277, P30622, DOI 10.1074/jbc.M204748200; Navakauskiene R, 2004, PROTEOMICS, V4, P1029, DOI 10.1002/pmic.200300671; Neumann B, 1996, J EXP MED, V184, P259, DOI 10.1084/jem.184.1.259; Pasparakis M, 2000, CELL IMMUNOL, V201, P33, DOI 10.1006/cimm.2000.1636; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Taghiyev AF, 2005, CANCER BIOL THER, V4, P382; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	28	22	23	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	45					6536	6545		10.1038/sj.onc.1210476	http://dx.doi.org/10.1038/sj.onc.1210476			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471239				2022-12-25	WOS:000249919800007
J	Kumaran, J; Wei, L; Kotra, LP; Fish, EN				Kumaran, Jyothi; Wei, Lianhu; Kotra, Lakshmi P.; Fish, Eleanor N.			A structural basis for interferon-alpha-receptor interactions	FASEB JOURNAL			English	Article						interferon; interferon receptor; homology modeling; docking	CRYSTAL-STRUCTURE; BINDING; EXPRESSION; CLONING; BETA	Interferon (IFN)-alpha subtypes exhibit differences in biological potencies based on their affinity interactions with the IFN receptor subunits, IFNAR1 and IFNAR2. Using available three-dimensional structural information and computational biology, homology models of human IFN-alpha 1, human IFN-alpha 8, IFN alfacon-1, and murine IFN-alpha 4 were derived and docked with the extracellular region of human IFNAR2 to evaluate the behavior of potential interacting residue pairs and characterize the nature of the IFN-IFNAR2 binding interfaces. The data suggest that IFN afacon-1 has 9 optimal interactions with IFNAR2, comprising hydrophobic, electrostatic, and hydrogen bonding. Human IFN-alpha 2 exhibits 8 optimal interactions, human IFN-alpha 1, 7, and murine IFN-alpha 4 exhibits the least number of optimal interactions, at 5. A model of IFNAR1 was generated, taking into consideration the IFNAR1 extracellular domain interaction with cell surface glycosphingolipids, putative ligand interaction residues, and residues stabilizing the structural integrity of IFNAR. IFNAR1 was then docked with the various IFN-IFNAR2 complexes to describe the complete extracellular receptor pocket with bound IFN. These data provide insights into the species specificity of IFN-alpha s: residues in murine IFN-alpha 4 that preclude strong affinity interactions with human IFNAR because of steric crowding and residues in human IFN-alpha 8 that resemble a receptor interactive domain in murine IFN-alpha 4, are described.	Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Pharmaceut Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University of Toronto	Fish, EN (corresponding author), Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, 67 Coll St,Rm 424, Toronto, ON M5G 2M1, Canada.	en.fish@utoronto.ca		Kotra, Lakshmi P./0000-0002-7071-4637				Blatt LM, 1996, J INTERF CYTOK RES, V16, P489, DOI 10.1089/jir.1996.16.489; Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845; Chill JH, 2002, BIOCHEMISTRY-US, V41, P3575, DOI 10.1021/bi011778f; Cutrone EC, 1997, FEBS LETT, V404, P197, DOI 10.1016/S0014-5793(97)00129-4; Cutrone EC, 2001, J BIOL CHEM, V276, P17140, DOI 10.1074/jbc.M009663200; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; EID P, 2005, EUR CYTOKINE NEWS EU, V11, P560; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FISH EN, 1989, J INTERFERON RES, V9, P97, DOI 10.1089/jir.1989.9.97; GAJEANFEROLDI C, 2004, BIOCHEMISTRY-US, V43, P12498; Gavutis M, 2006, BIOPHYS J, V90, P3345, DOI 10.1529/biophysj.105.072546; GHISLAIN J, 1994, J IMMUNOL, V153, P3655; Gol'dshtein V, 1998, COMBUST THEOR MODEL, V2, P1; Karpusas M, 1997, P NATL ACAD SCI USA, V94, P11813, DOI 10.1073/pnas.94.22.11813; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; Lamken P, 2004, J MOL BIOL, V341, P303, DOI 10.1016/j.jmb.2004.05.059; Mitsui Y, 1997, J INTERF CYTOK RES, V17, P319, DOI 10.1089/jir.1997.17.319; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Quadt-Akabayov SR, 2006, PROTEIN SCI, V15, P2656, DOI 10.1110/ps.062283006; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; Radhakrishnan R, 1999, J MOL BIOL, V286, P151, DOI 10.1006/jmbi.1998.2480; Roisman LC, 2001, P NATL ACAD SCI USA, V98, P13231, DOI 10.1073/pnas.221290398; SALI A, 2001, MODELLER; Slutzki M, 2006, J MOL BIOL, V360, P1019, DOI 10.1016/j.jmb.2006.05.069; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; *TRIP INC, SYBYL 7 0; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z	30	35	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3288	3296		10.1096/fj.07-8585com	http://dx.doi.org/10.1096/fj.07-8585com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17517919				2022-12-25	WOS:000249781600029
J	Meur, G; Parker, AKT; Gergely, FV; Taylor, CW				Meur, Gargi; Parker, Andrew K. T.; Gergely, Fanni V.; Taylor, Colin W.			Targeting and retention of type 1 ryanodine receptors to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; MEMBRANE RETENTION; PROTEIN; TOPOLOGY; EXPRESSION; SIGNAL; ASSOCIATION; REGION	Most ryanodine receptors and their relatives, inositol 1,4,5-trisphosphate receptors, are expressed in the sarcoplasmic or endoplasmic reticulum (ER), where they mediate Ca2+ release. We expressed fragments of ryanodine receptor type 1 (RyR1) in COS cells alone or fused to intercellular adhesion molecule-1 (ICAM-1), each tagged with yellow fluorescent protein, and used confocal imaging and glycoprotein analysis to identify the determinants of ER targeting and retention. Single transmembrane domains (TMD) of RyR1 taken from the first (TMD1-TMD2) or last (TMD5-TMD6) pair were expressed in the ER membrane. TMD3-TMD4 was expressed in the outer mitochondrial membrane. The TMD outer pairs (TMD1-TMD2 and TMD5-TMD6) retained ICAM-1, a plasma membrane-targeted protein, within the ER membrane. TMD1 alone provided a strong ER retention signal and TMD6 a weaker signal, but the other single TMD were unable to retain ICAM-1 in the ER. We conclude that TMD1 provides the first and sufficient signal for ER targeting of RyR1. The TMD outer pairs include redundant ER retention signals, with TMD1 providing the strongest signal.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Taylor, CW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	cwt1000@cam.ac.uk	; Taylor, Colin/G-2447-2010	Meur, Gargi/0000-0002-8466-2997; Taylor, Colin/0000-0001-7771-1044; Gergely, Fanni/0000-0002-2441-8095	Biotechnology and Biological Sciences Research Council [BB/C005201/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Balshaw D, 1999, P NATL ACAD SCI USA, V96, P3345, DOI 10.1073/pnas.96.7.3345; Bhat MB, 2002, J BIOL CHEM, V277, P8597, DOI 10.1074/jbc.M107609200; Brickley K, 2005, J BIOL CHEM, V280, P14723, DOI 10.1074/jbc.M409095200; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; Dalbey R.E., 2002, PROTEIN TARGETING TR; Dellis O, 2006, SCIENCE, V313, P229, DOI 10.1126/science.1125203; Du GG, 2002, P NATL ACAD SCI USA, V99, P16725, DOI 10.1073/pnas.012688999; Du GG, 2004, J BIOL CHEM, V279, P37566, DOI 10.1074/jbc.M406637200; Du GG, 2001, J BIOL CHEM, V276, P31760, DOI 10.1074/jbc.M102751200; Dulhunty AF, 2003, CLIN EXP PHARMACOL P, V30, P713, DOI 10.1046/j.1440-1681.2003.03904.x; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; George CH, 2004, MOL BIOL CELL, V15, P2627, DOI 10.1091/mbc.E03-09-0688; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; High S, 2004, BIOCHEM SOC T, V32, P659, DOI 10.1042/BST0320659; Huh YH, 2005, FEBS LETT, V579, P2597, DOI 10.1016/j.febslet.2005.03.076; LEE HC, 2002, CYCLIC ADPRIBOSE NAA; LEE S, 2000, JPL OPTICAL COMMUNIC, V2000, P1; Ludtke SJ, 2005, STRUCTURE, V13, P1203, DOI 10.1016/j.str.2005.06.005; Ma JJ, 2004, CELL BIOCHEM BIOPHYS, V40, P207, DOI 10.1385/CBB:40:2:207; Marius P, 2006, CELL CALCIUM, V39, P65, DOI 10.1016/j.ceca.2005.09.010; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Moonga BS, 2002, AM J PHYSIOL-RENAL, V282, pF921, DOI 10.1152/ajprenal.00045.2000; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Papadopoulos S, 2004, J BIOL CHEM, V279, P44046, DOI 10.1074/jbc.M405317200; Parker AKT, 2004, J BIOL CHEM, V279, P23797, DOI 10.1074/jbc.M402098200; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Samso M, 2005, NAT STRUCT MOL BIOL, V12, P539, DOI 10.1038/nsmb938; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; Serysheva I, 2005, J MOL BIOL, V345, P427, DOI 10.1016/j.jmb.2004.10.073; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Treves S, 2002, CELL CALCIUM, V31, P1, DOI 10.1054/ceca.2001.0252; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Williams AJ, 2001, Q REV BIOPHYS, V34, P61, DOI 10.1017/S0033583501003675; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Xiao BL, 2002, J BIOL CHEM, V277, P41778, DOI 10.1074/jbc.M208210200; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	47	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23096	23103		10.1074/jbc.M702457200	http://dx.doi.org/10.1074/jbc.M702457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17526491	hybrid			2022-12-25	WOS:000248577500012
J	Lee, GH; Kim, HK; Chae, SW; Kim, DS; Ha, KC; Cuddy, M; Kress, C; Reed, JC; Kim, HR; Chae, HJ				Lee, Geum-Hwa; Kim, Hyun-Kyung; Chae, Soo-Wan; Kim, Do-Sung; Ha, Ki-Chan; Cuddy, Mike; Kress, Christina; Reed, John C.; Kim, Hyung-Ryong; Chae, Han-Jung			Bax inhibitor-1 regulates endoplasmic reticulum stress-associated reactive oxygen species and heme oxygenase-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; PANCREATIC BETA-CELLS; INDUCED APOPTOSIS; OXIDATIVE STRESS; GENE-EXPRESSION; YEAST; RAT; ER; PROTECTION; INDUCTION	The Bax inhibitor-1 ( BI-1) is an anti-apoptotic protein that is located in endoplasmic reticulum (ER) membranes and protects cells from ER stress-induced apoptosis. The ER is associated with generation of reactive oxygen species (ROS) through oxidative protein folding. This study examined the role of BI-1 in the regulation of ER stress-induced accumulation of ROS and expression of unfolded protein response-associated proteins. BI-1 reduced the expression levels of glucose response protein 78, C/EBP homologous protein, phospho-eukaryotic initiation factor 2 alpha, IRE1 alpha, XBP-1, and phospho-JNK and inhibited the cleavage of ATF-6 alpha p-90, leading to the inhibition of ROS. Although ROS scavengers offer some protection against ER stress-induced apoptosis, the expression of pro-apoptotic ER stress proteins was not affected. This study shows that the response of unfolded proteins is followed by ROS accumulation under ER stress, which is regulated in BI-1 cells. The mechanism for these BI-1-associated functions involves the expression of heme oxygenase-1 (HO-1) through nuclear factor erythroid 2-related factor 2. In BI-1 cells, the transfection of HO-1 small interfering RNA completely abolished the BI-1-induced protection. The endogenous expression of HO-1 through ER stress-initiated ROS is believed to be as a protection signal. In conclusion, these observations suggest that BI-1 can inhibit the ER stress proteins as well as the accumulation of ROS, thereby protecting the cells. Moreover, HO-1 plays an important role in the BI-1-associated protection against ER stress.	Wonkwang Univ, Sch Dent, Dept Dent Pharmacol, Iksan 570749, Chonbuk, South Korea; Wonkwang Univ, Sch Dent, Wonkwang Biomat Implant Res Inst, Iksan 570749, Chonbuk, South Korea; Chonbuk Natl Univ, Sch Med, Dept Pharmacol, Jeonju 561182, Chonbuk, South Korea; Chonbuk Natl Univ, Sch Med, Inst Cardiovasc Res, Jeonju 561182, Chonbuk, South Korea; Chonbuk Hosp, Clin Trial Ctr Funct Foods, Jeonju, Chonbuk, South Korea; Burnham Inst Med Res, La Jolla, CA USA	Wonkwang University; Wonkwang University; Jeonbuk National University; Jeonbuk National University; Sanford Burnham Prebys Medical Discovery Institute	Chae, HJ (corresponding author), Wonkwang Univ, Sch Dent, Dept Dent Pharmacol, Iksan 570749, Chonbuk, South Korea.	hjchae@chonbuk.ac.kr		Chae, Han-Jung/0000-0003-4190-9889				Ahmad A, 2005, J BIOL CHEM, V280, P32090, DOI 10.1074/jbc.M501426200; Bailly-Maitre B, 2006, P NATL ACAD SCI USA, V103, P2809, DOI 10.1073/pnas.0506854103; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chae HJ, 2003, GENE, V323, P101, DOI 10.1016/j.gene.2003.09.011; Chae HJ, 2000, ENDOCRINOLOGY, V141, P2904, DOI 10.1210/en.141.8.2904; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Clark JE, 2000, BIOCHEM J, V348, P615, DOI 10.1042/0264-6021:3480615; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gavilan MP, 2006, NEUROBIOL AGING, V27, P973, DOI 10.1016/j.neurobiolaging.2005.05.010; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; Hoetzel A, 2001, HEPATOLOGY, V33, P925, DOI 10.1053/jhep.2001.23431; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JANSCO G, 2007, ANN NY ACAD SCI, V1095, P251; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kessel D, 2005, CELL DEATH DIFFER, V12, P502, DOI 10.1038/sj.cdd.4401579; Kim DS, 2005, BIOCHEM PHARMACOL, V70, P1066, DOI 10.1016/j.bcp.2005.06.026; Ladiges WC, 2005, DIABETES, V54, P1074, DOI 10.2337/diabetes.54.4.1074; Liu XM, 2005, J BIOL CHEM, V280, P872, DOI 10.1074/jbc.M410413200; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; OWUER ED, 2002, BIOCHEM PHARMACOL, V64, P765; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Schuliga M, 2002, TOXICOL SCI, V70, P183, DOI 10.1093/toxsci/70.2.183; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Ueda K, 2005, EUR J ENDOCRINOL, V153, P167, DOI 10.1530/eje.1.01945; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	34	88	94	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21618	21628		10.1074/jbc.M700053200	http://dx.doi.org/10.1074/jbc.M700053200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17526500	hybrid			2022-12-25	WOS:000248196800008
J	Banuelos, S; Omaetxebarria, MJ; Ramos, I; Larsen, MR; Arregi, I; Jensen, ON; Arizmendi, JM; Prado, A; Muga, A				Banuelos, Sonia; Omaetxebarria, Miren J.; Ramos, Isbaal; Larsen, Martin R.; Arregi, Igor; Jensen, Ole N.; Arizmendi, Jesus M.; Prado, Adelina; Muga, Arturo			Phosphorylation of both nucleoplasmin domains is required for activation of its chromatin decondensation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; HISTONE CHAPERONES; NUCLEAR CHAPERONES; CRYSTAL-STRUCTURE; SPERM CHROMATIN; PROTEINS; DNA; BINDING; CORE; CONFORMATION	Nucleoplasmin (NP) is a histone chaperone involved in nucleosome assembly, chromatin decondensation at fertilization, and apoptosis. To carry out these activities NP has to interact with different types of histones, an interaction that is regulated by phosphorylation. Here we have identified a number of phosphorylated residues by mass spectrometry and generated mutants in which these amino acids are replaced by Asp to mimic the effect of phosphorylation. Our results show that, among the eight phosphoryl groups experimentally detected, four are located at the flexible N terminus, and the rest are found at the tail domain, flanking the nuclear localization signal. Phosphorylation-mimicking mutations render a recombinant protein as active in chromatin decondensation as hyperphosphorylated NP isolated from Xenopus laevis eggs. Comparison of mutants in which the core and tail domains of the protein were independently or simultaneously "activated" indicates that activation or phosphorylation of both protein domains is required for NP to efficiently extract linker-type histones from chromatin.	Univ Basque Country, CSIC, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Fac Ciencias & Tecnol, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; University of Southern Denmark	Muga, A (corresponding author), Univ Basque Country, CSIC, Unidad Biofis, POB 644, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Muga, Arturo/N-1174-2014; Jensen, Ole N/J-1763-2012; Bañuelos, Sonia/N-9128-2019; Omaetxebarria, Miren Josu/AAB-5667-2019; Larsen, Martin Rossel/F-1411-2015	Muga, Arturo/0000-0003-0345-6882; Jensen, Ole N/0000-0003-1862-8528; Bañuelos, Sonia/0000-0002-1399-381X; Larsen, Martin Rossel/0000-0001-6203-0123; Arizmendi, Jesus M/0000-0002-1412-4042				Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Banuelos S, 2003, J MOL BIOL, V334, P585, DOI 10.1016/j.jmb.2003.09.067; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; COTTEN M, 1986, BIOCHEMISTRY-US, V25, P5063, DOI 10.1021/bi00366a014; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; Dingwall C, 1990, Semin Cell Biol, V1, P11; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; Dutta S, 2001, MOL CELL, V8, P841, DOI 10.1016/S1097-2765(01)00354-9; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; Gillespie PJ, 2000, NUCLEIC ACIDS RES, V28, P472, DOI 10.1093/nar/28.2.472; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; Haushalter KA, 2003, NAT REV MOL CELL BIO, V4, P613, DOI 10.1038/nrm1177; Hierro A, 2002, BIOCHEMISTRY-US, V41, P6408, DOI 10.1021/bi020002r; Hierro A, 2001, EUR J BIOCHEM, V268, P1739; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Kepert JF, 2005, J BIOL CHEM, V280, P34063, DOI 10.1074/jbc.M507322200; Kjellstrom S, 2004, ANAL CHEM, V76, P5109, DOI 10.1021/ac0400257; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; Leno GH, 1996, J BIOL CHEM, V271, P7253, DOI 10.1074/jbc.271.13.7253; Lohka MJ, 1998, METHOD CELL BIOL, V53, P367; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Lu ZG, 2005, P NATL ACAD SCI USA, V102, P2778, DOI 10.1073/pnas.0405374102; Matsumoto K, 1999, MOL CELL BIOL, V19, P6940; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Namboodiri VMH, 2004, STRUCTURE, V12, P2149, DOI 10.1016/j.str.2004.09.017; Namboodiri VMH, 2003, STRUCTURE, V11, P175, DOI 10.1016/S0969-2126(03)00007-8; Park YJ, 2006, BIOCHEM CELL BIOL, V84, P549, DOI 10.1139/O06-088; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; Prado A, 2004, BIOCHEM CELL BIOL, V82, P437, DOI 10.1139/O04-042; Ramos I, 2005, BIOCHEMISTRY-US, V44, P8274, DOI 10.1021/bi050386w; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shintomi K, 2005, P NATL ACAD SCI USA, V102, P8210, DOI 10.1073/pnas.0500822102; Tamada H, 2006, MOL CELL BIOL, V26, P1259, DOI 10.1128/MCB.26.4.1259-1271.2006; Tholey A, 1999, BIOPHYS J, V76, P76, DOI 10.1016/S0006-3495(99)77179-1; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; VANCUROVA I, 1995, J CELL SCI, V108, P779; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	39	29	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21213	21221		10.1074/jbc.M702842200	http://dx.doi.org/10.1074/jbc.M702842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17510054	hybrid			2022-12-25	WOS:000248047500048
J	Huang, MS; Morony, S; Lu, JX; Zhang, Z; Bezouglaia, O; Tseng, W; Tetradis, S; Demer, LL; Tintut, Y				Huang, Michael S.; Morony, Sean; Lu, Jinxiu; Zhang, Zina; Bezouglaia, Olga; Tseng, Wendy; Tetradis, Sotirios; Demer, Linda L.; Tintut, Yin			Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN; LOW-DENSITY-LIPOPROTEIN; MARROW STROMAL CELLS; NF-KAPPA-B; OXIDIZED PHOSPHOLIPIDS; IN-VIVO; VASCULAR CALCIFICATION; POSTMENOPAUSAL WOMEN; DIFFERENTIATION; ERK	Cardiovascular disease, such as atherosclerosis, has been associated with reduced bone mineral density and fracture risk. A major etiologic factor in atherogenesis is believed to be oxidized phospholipids. We previously found that these phospholipids inhibit spontaneous osteogenic differentiation of marrow stromal cells, suggesting that they may account for the clinical link between atherosclerosis and osteoporosis. Currently, anabolic agents that promote bone formation are increasingly used as a new treatment for osteoporosis. It is not known, however, whether atherogenic phospholipids alter the effects of bone anabolic agents, such as bone morphogenetic protein (BMP)-2 and parathyroid hormone (PTH). Therefore we investigated the effects of oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (ox-PAPC) on osteogenic signaling induced by BMP-2 and PTH in MC3T3-E1 cells. Results showed that ox-PAPC attenuated BMP-2 induction of osteogenic markers alkaline phosphatase and osteocalcin. Ox-PAPC also inhibited both spontaneous and BMP-induced expression of PTH receptor. Consistently, pretreatment of cells with ox-PAPC inhibited PTH-induced cAMP production and expression of immediate early genes Nurr1 and IL-6. Results from immunofluorescence and Western blot analyses showed that inhibitory effects of ox-PAPC on BMP-2 signaling were associated with inhibition of SMAD 1/5/8 but not p38-MAPK activation. These effects appear to be due to ox-PAPC activation of the ERK pathway, as the ERK inhibitor PD98059 reversed ox-PAPC inhibitory effects on BMP-2-induced alkaline phosphatase activity, osteocalcin expression, and SMAD activation. These results suggest that atherogenic lipids inhibit osteogenic signaling induced by BMP-2 and PTH, raising the possibility that hyperlipidemia and atherogenic phospholipids may interfere with anabolic therapy.	Univ Calif Los Angeles, Sch Dent, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Dept Mol Cellular Integrat Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 90095 USA; Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Amgen	Tintut, Y (corresponding author), Univ Calif Los Angeles, Sch Dent, Dept Med, CHS BH 307,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	ytintut@mednet.ucla.edu	Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK076009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065823] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL081202, R01 HL081202] Funding Source: Medline; NIDDK NIH HHS [DK076009-01, R21 DK076009, R21 DK076009-01, R21 DK076009-02] Funding Source: Medline; NIGMS NIH HHS [T32 GM065823] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abedin M, 2006, CIRC RES, V98, P727, DOI 10.1161/01.RES.0000216009.68958.e6; Bagger YZ, 2006, J INTERN MED, V259, P598, DOI 10.1111/j.1365-2796.2006.01640.x; Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073; Barengolts EI, 1998, CALCIFIED TISSUE INT, V62, P209, DOI 10.1007/s002239900419; Chae HJ, 2002, IMMUNOPHARM IMMUNOT, V24, P31, DOI 10.1081/IPH-120003401; Chan GK, 2003, ENDOCRINOLOGY, V144, P5511, DOI 10.1210/en.2003-0273; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Date T, 2004, J ORTHOP SCI, V9, P503, DOI 10.1007/s00776-004-0815-2; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Furnkranz A, 2005, ARTERIOSCL THROM VAS, V25, P633, DOI 10.1161/01.ATV.0000153106.03644.a0; Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785; Iida-Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270; Jie KSG, 1996, CALCIFIED TISSUE INT, V59, P352, DOI 10.1007/s002239900139; JOHNSON EE, 1988, CLIN ORTHOP RELAT R, P257; Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889; Kadl A, 2002, VASC PHARMACOL, V38, P219, DOI 10.1016/S1537-1891(02)00172-6; Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018; Kono SJ, 2007, BONE, V40, P68, DOI 10.1016/j.bone.2006.07.024; Kronke G, 2003, J BIOL CHEM, V278, P51006, DOI 10.1074/jbc.M304103200; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; MA YF, 1995, J BONE MINER RES, V10, P496; Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891-5849(01)00610-4; Orozco P, 2004, EUR J EPIDEMIOL, V19, P1105, DOI 10.1007/s10654-004-1706-8; Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005-0303; Parhami F, 1999, J BONE MINER RES, V14, P2067, DOI 10.1359/jbmr.1999.14.12.2067; Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680; Parhami F, 2001, J BONE MINER RES, V16, P182, DOI 10.1359/jbmr.2001.16.1.182; Pirih FQ, 2003, BIOCHEM BIOPH RES CO, V306, P144, DOI 10.1016/S0006-291X(03)00931-8; Pirih FQ, 2005, BIOCHEM BIOPH RES CO, V332, P494, DOI 10.1016/j.bbrc.2005.04.132; RODAN GA, 1992, BONE S1, V13, P3; Shao JS, 2003, J BIOL CHEM, V278, P50195, DOI 10.1074/jbc.M308825200; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Tintut Y, 2004, ARTERIOSCL THROM VAS, V24, pE6, DOI 10.1161/01.ATV.0000112023.62695.7f; Tintut Y, 2002, J BIOL CHEM, V277, P14221, DOI 10.1074/jbc.M111551200; Urist MR, 1997, CONNECT TISSUE RES, V36, P9, DOI 10.3109/03008209709160210; Velardez MO, 2001, MOL CELL ENDOCRINOL, V172, P7, DOI 10.1016/S0303-7207(00)00399-3; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Yamaguchi T, 2002, ENDOCR J, V49, P211, DOI 10.1507/endocrj.49.211	42	32	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21237	21243		10.1074/jbc.M701341200	http://dx.doi.org/10.1074/jbc.M701341200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17522049	hybrid, Green Accepted			2022-12-25	WOS:000248047500051
J	Zhang, W; Zitron, E; Homme, MK; Kihm, L; Morath, C; Scherer, D; Hegge, S; Thomas, D; Schmitt, CP; Zeier, M; Katus, H; Karle, C; Schwenger, V				Zhang, Wei; Zitron, Edgar; Hoemme, Meike; Kihm, Lars; Morath, Christian; Scherer, Daniel; Hegge, Stephan; Thomas, Dierk; Schmitt, Claus P.; Zeier, Martin; Katus, Hugo; Karle, Christoph; Schwenger, Vedat			Aquaporin-1 channel function is positively regulated by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; WATER PERMEABILITY; IN-VITRO; ALPHA; PROLONGATION; ACTIVATION	Aquaporin-1 (AQP1) channels contribute to osmotically induced water transport in several organs including the kidney and serosal membranes such as the peritoneum and the pleura. In addition, AQP1 channels have been shown to conduct cationic currents upon stimulation by cyclic nucleotides. To date, the short term regulation of AQP1 function by other major intracellular signaling pathways has not been studied. In the present study, we therefore investigated the regulation of AQP1 by protein kinase C. AQP1 wild type channels were expressed in Xenopus oocytes. Water permeability was assessed by hypotonic challenges. Activation of protein kinase C (PKC) by 1-oleoyl-2-acetyl-sn-glycerol (OAG) induced a marked increase of AQP1-dependent water permeability. This regulation was abolished in mutated AQP1 channels lacking both consensus PKC phosphorylation sites Thr(157) and Thr(239) (termed AQP1 Delta PKC). AQP1 cationic currents measured with double-electrode voltage clamp were markedly increased after pharmacological activation of PKC by either OAG or phorbol 12-myristate 13-acetate. Deletion of either Thr(157) or Thr(239) caused a marked attenuation of PKC-dependent current increases, and deletion of both phosphorylation sites in AQP1 Delta PKC channels abolished the effect. In vitro phosphorylation studies with synthesized peptides corresponding to amino acids 154-168 and 236-250 revealed that both Thr(157) and Thr(239) are phosphorylated by PKC. Upon stimulation by cyclic nucleotides, AQP1 wild type currents exhibited a strong activation. This regulation was not affected after deletion of PKC phosphorylation sites in AQP1 Delta PKC channels. In conclusion, this is the first study to show that PKC positively regulates both water permeability and ionic conductance of AQP1 channels. This new pathway of AQP1 regulation is independent of the previously described cyclic nucleotide pathway and may contribute to the PKC stimulation of AQP1-modulated processes such as endothelial permeability, angiogenesis, and urine concentration.	Univ Heidelberg Hosp, Dept Cardiol, D-69120 Heidelberg, Germany; Univ Heidelberg Hosp, Dept Paediat, D-69120 Heidelberg, Germany; Univ Heidelberg Hosp, Dept Nephrol, D-69120 Heidelberg, Germany; Univ Heidelberg Hosp, Dept Parasitol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Zitron, E (corresponding author), Med Univ Hosp Heidelberg, Dept Cardiol, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	edgar.zitron@med.uni-heidelberg.de	Thomas, Dierk/ABA-4706-2021; Morath, Christian/ABC-5091-2021; Thomas, Dierk/V-3940-2017	Thomas, Dierk/0000-0002-5687-7843; 				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Anthony TL, 2000, MOL PHARMACOL, V57, P576, DOI 10.1124/mol.57.3.576; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Belge H, 2006, NEPHROL DIAL TRANSPL, V21, P2069, DOI 10.1093/ndt/gfl162; Boassa D, 2006, J NEUROSCI, V26, P7811, DOI 10.1523/JNEUROSCI.0525-06.2006; Boassa Daniela, 2003, BMC Physiol, V3, P12, DOI 10.1186/1472-6793-3-12; Bokhari SM, 2006, J INVEST DERMATOL, V126, P460, DOI 10.1038/sj.jid.5700071; Chang YS, 2000, MICROVASC RES, V59, P265, DOI 10.1006/mvre.1999.2225; Dang L, 2005, CLIN EXP PHARMACOL P, V32, P771, DOI 10.1111/j.1440-1681.2005.04266.x; Devuyst O, 2005, BIOL CELL, V97, P667, DOI 10.1042/BC30040132; GARCIA NH, 1994, J CLIN INVEST, V93, P2572, DOI 10.1172/JCI117268; Han ZQ, 1998, J BIOL CHEM, V273, P6001, DOI 10.1074/jbc.273.11.6001; Hara-Chikuma M, 2006, J AM SOC NEPHROL, V17, P39, DOI 10.1681/ASN.2005080846; Karle CA, 2002, CIRCULATION, V106, P1493, DOI 10.1161/01.CIR.0000029747.53262.5C; Kiesecker C, 2006, J MOL MED, V84, P46, DOI 10.1007/s00109-005-0707-8; Ni J, 2006, KIDNEY INT, V69, P1518, DOI 10.1038/sj.ki.5000285; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Saparov SM, 2001, J BIOL CHEM, V276, P31515, DOI 10.1074/jbc.M104267200; Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002; Tsunoda SP, 2004, J BIOL CHEM, V279, P11364, DOI 10.1074/jbc.M310881200; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; Wang AH, 2002, CIRC RES, V90, P609, DOI 10.1161/01.RES.0000012503.30315.E8; Ware JA, 1999, ANGIOGENESIS AND CARDIOVASCULAR DISEASE, P30; Witchel HJ, 2002, J PHARMACOL TOX MET, V48, P65, DOI 10.1016/S1056-8719(03)00041-8; Yao LJ, 2004, AM J PHYSIOL-RENAL, V287, pF299, DOI 10.1152/ajprenal.00274.2003; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; Yool AJ, 2002, NEWS PHYSIOL SCI, V17, P68, DOI 10.1152/nips.01372.2001; Yu J, 2006, STRUCTURE, V14, P1411, DOI 10.1016/j.str.2006.07.006; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zitron E, 2005, CIRCULATION, V111, P835, DOI 10.1161/01.CIR.0000155617.54749.09; Zitron E, 2004, CARDIOVASC RES, V63, P520, DOI 10.1016/j.cardiores.2004.02.015	34	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20933	20940		10.1074/jbc.M703858200	http://dx.doi.org/10.1074/jbc.M703858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17522053	hybrid			2022-12-25	WOS:000248047500019
J	Oshiro, N; Takahashi, R; Yoshino, KI; Tanimura, K; Nakashima, A; Eguchi, S; Miyamoto, T; Hara, K; Takehana, K; Avruch, J; Kikkawa, U; Yonezawa, K				Oshiro, Noriko; Takahashi, Rinako; Yoshino, Ken-ichi; Tanimura, Keiko; Nakashima, Akio; Eguchi, Satoshi; Miyamoto, Takafumi; Hara, Kenta; Takehana, Kenji; Avruch, Joseph; Kikkawa, Ushio; Yonezawa, Kazuyoshi			The proline-rich akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; REPRESSOR PHAS-I; PROTEIN-KINASE; TUBEROUS SCLEROSIS; SIGNALING PATHWAYS; BINDING PARTNER; CELL-SURVIVAL; GROWTH-FACTOR; EIF-4E BP1; AMINO-ACID	The proline-rich Akt substrate of 40 kilodaltons (PRAS40) was identified as a raptor-binding protein that is phosphorylated directly by mammalian target of rapamycin ( mTOR) complex 1 (mTORC1) but not mTORC2 in vitro, predominantly at PRAS40 (Ser(183)). The binding of S6K1 and 4E-BP1 to raptor requires a TOR signaling (TOS) motif, which contains an essential Phe followed by four alternating acidic and small hydrophobic amino acids. PRAS40 binding to raptor was severely inhibited by mutation of PRAS40 (Phe(129) to Ala). Immediately carboxyl-terminal to Phe(129) are two small hydrophobic amino acid followed by two acidic residues. PRAS40 binding to raptor was also abolished by mutation of the majormTORC1phosphorylation site, Ser(183), to Asp. PRAS40 (Ser(183)) was phosphorylated in intact cells; this phosphorylation was inhibited by rapamycin, by 2- deoxyglucose, and by overexpression of the tuberous sclerosis complex heterodimer. PRAS40 ( Ser183) phosphorylation was also inhibited reversibly by withdrawal of all or of only the branched chain amino acids; this inhibition was reversed by overexpression of the Rheb GTPase. Over-expressed PRAS40 suppressed the phosphorylation of S6K1 and 4E-BP1 at their rapamycin-sensitive phosphorylation sites, and reciprocally, overexpression of S6K1 or 4E-BP1 suppressed phosphorylation of PRAS40 (Ser(183)) and its binding to raptor. RNA interference-induced depletion of PRAS40 enhanced the amino acid-stimulated phosphorylation of both S6K1 and 4E-BP1. These results establish PRAS40 as a physiological mTORC1 substrate that contains a variant TOS motif. Moreover, they indicate that the ability of raptor to bind endogenous substrates is limiting for the activity of mTORC1 in vivo and is therefore a potential locus of regulation.	Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; Kobe Univ, Sch Med, Dept Internal & Geriatr Med, Kobe, Hyogo 6500017, Japan; Ajinomoto Co Inc, Pharmaceut Res Labs, Kawasaki, Kanagawa 2108681, Japan; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Dept Mol Biol & Diabet Unit, Boston, MA 02114 USA	Kobe University; Kobe University; Ajinomoto Co Inc; Harvard University; Harvard Medical School; Massachusetts General Hospital	Avruch, J (corresponding author), Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan.	avruch@molbio.mgh.harvard.edu	Miyamoto, Takafumi/T-6950-2019	Miyamoto, Takafumi/0000-0001-9363-2864	NCI NIH HHS [R01 CA073818, CA 73818] Funding Source: Medline; NIDDK NIH HHS [P30 DK040561, P30 DK040561-12, R37 DK017776, DK 17776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, R37DK017776, R01DK017776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chern JJ, 2002, DEVELOPMENT, V129, P4005; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DUMONT FJ, 1990, J IMMUNOL, V144, P251; Ess KC, 2004, GLIA, V46, P28, DOI 10.1002/glia.10324; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Harthill JE, 2002, BIOCHEM J, V368, P565, DOI 10.1042/BJ20020838; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Huang B, 2005, ACTA PHARMACOL SIN, V26, P1253, DOI 10.1111/j.1745-7254.2005.00184.x; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; Nascimento EBM, 2006, DIABETES, V55, P3221, DOI 10.2337/db05-1390; Nishiuma T, 1998, BIOCHEM BIOPH RES CO, V252, P440, DOI 10.1006/bbrc.1998.9671; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Saito A, 2006, STROKE, V37, P513, DOI 10.1161/01.STR.0000198826.56611.a2; Saito A, 2004, J NEUROSCI, V24, P1584, DOI 10.1523/JNEUROSCI.5209-03.2004; Sakakibara K, 2005, J BIOL CHEM, V280, P15029, DOI 10.1074/jbc.M410538200; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shah OJ, 2005, CELL CYCLE, V4, P46, DOI 10.4161/cc.4.1.1343; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Singh A, 2006, DEVELOPMENT, V133, P4771, DOI 10.1242/dev.02686; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wang LF, 2006, J BIOL CHEM, V281, P24293, DOI 10.1074/jbc.M603566200; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yamaguchi Y, 2006, J BIOL CHEM, V281, P31627, DOI 10.1074/jbc.M606992200; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	49	251	259	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20329	20339		10.1074/jbc.M702636200	http://dx.doi.org/10.1074/jbc.M702636200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17517883	Green Accepted, hybrid			2022-12-25	WOS:000247819300036
J	Oueslati, M; Hermosilla, R; Schonenberger, E; Oorschot, V; Beyermann, M; Wiesner, B; Schmidt, A; Klumperman, J; Rosenthal, W; Schulein, R				Oueslati, Morad; Hermosilla, Ricardo; Schoenenberger, Eva; Oorschot, Viola; Beyermann, Michael; Wiesner, Burkhard; Schmidt, Antje; Klumperman, Judith; Rosenthal, Walter; Schuelein, Ralf			Rescue of a nephrogenic diabetes insipidus-causing vasopressin V-2 receptor mutant by cell-penetrating peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; V2 RECEPTOR; SURFACE EXPRESSION; SECRETORY PATHWAY; INTERMEDIATE COMPARTMENT; INTRACELLULAR-TRANSPORT; EPITHELIAL-CELLS; PROTEIN; DEGRADATION	Mutant membrane proteins are frequently retained in the early secretory pathway by a quality control system, thereby causing disease. An example are mutants of the vasopressin V-2 receptor (V2R) leading to nephrogenic diabetes insipidus. Transport-defective V(2)Rs fall into two classes: those retained exclusively in the endoplasmic reticulum ( ER) and those reaching post-ER compartments such as the ER/Golgi intermediate compartment. Although numerous chemical or pharmacological chaperones that rescue the transport of ER-retained membrane proteins are known, substances acting specifically in post-ER compartments have not been described as yet. Using the L62P (ER-retained) and Y205C ( reaching post-ER compartments) mutants of the V2R as a model, we show here that the cell-penetrating peptide penetratin and its synthetic analog KLAL rescue the transport of the Y205C mutant. In contrast, the location of the L62P mutant is not influenced by either peptide because the peptides are unable to enter the ER. We also show data indicating that the peptide-mediated transport rescue is associated with an increase in cytosolic Ca2+ concentrations. Thus, we describe a new class of substances influencing protein transport specifically in post-ER compartments.	Leibniz Inst Mol Pharmakol, D-13125 Berlin, Germany; Charite Univ Med Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Med Ctr, Biomembrane Inst, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Utrecht University; Utrecht University Medical Center	Schulein, R (corresponding author), Leibniz Inst Mol Pharmakol, Robert-Rossle-Strasse 10, D-13125 Berlin, Germany.	schuelein@fmp-berlin.de	Horstmann, Britta/C-2154-2008					Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Beyermann M, 1996, J MED CHEM, V39, P3324, DOI 10.1021/jm960116z; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hauri HP, 2000, J CELL SCI, V113, P587; Hermosilla R, 2004, TRAFFIC, V5, P993, DOI 10.1111/j.1600-0854.2004.00239.x; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Klussmann E, 2000, REV PHYSIOL BIOCH P, V141, P33, DOI 10.1007/BFb0119577; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lorenz D, 2003, EMBO REP, V4, P88, DOI 10.1038/sj.embor.embor711; Lotti LV, 1996, EXP CELL RES, V227, P323, DOI 10.1006/excr.1996.0281; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; Robben JH, 2006, MOL BIOL CELL, V17, P379, DOI 10.1091/mbc.E05-06-0579; Saliba RS, 2002, J CELL SCI, V115, P2907; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulein R, 1996, J BIOL CHEM, V271, P28844, DOI 10.1074/jbc.271.46.28844; Schulein R, 2004, REV PHYSIOL BIOCH P, V151, P45, DOI 10.1007/s10254-004-0022-8; Schulein R, 2000, FEBS LETT, V466, P101, DOI 10.1016/S0014-5793(99)01764-0; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Schulein R, 2001, J BIOL CHEM, V276, P8384, DOI 10.1074/jbc.M007045200; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Van Baelen K, 2004, BBA-MOL CELL RES, V1742, P103, DOI 10.1016/j.bbamcr.2004.08.018; Wuller S, 2004, J BIOL CHEM, V279, P47254, DOI 10.1074/jbc.M408154200; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558	38	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20676	20685		10.1074/jbc.M611530200	http://dx.doi.org/10.1074/jbc.M611530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17491025	hybrid			2022-12-25	WOS:000247819300070
J	Shahid, G; Hussain, T				Shahid, Gulnar; Hussain, Tahir			GRK2 negatively regulates glycogen synthesis in mouse liver FL83B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; HUMAN INSULIN-RECEPTOR; PLASMA-MEMBRANES; SKELETAL-MUSCLE; PHOSPHORYLATION; KINASE; SUBSTRATE-1; TRANSLOCATION; ADIPOCYTES; ACTIVATION	G-protein-coupled receptor (GPCR) kinases (GRKs) are serine/threonine kinases that desensitize agonist-occupied classical GPCRs. Although the insulin receptor (IR) is a tyrosine kinase receptor, the IR also couples to G-proteins and utilizes G-protein signaling components. The present study was designed to test the hypothesis that GRK2 negatively regulates IR signaling. FL83B cells, derived from mouse liver, were treated with insulin and membrane translocation of GRK2 was determined using immunofluoresecence and Western blotting. Insulin caused an increase in the translocation of GRK-2 from cytosol to the plasma membrane. To determine the role of GRK2 in IR signaling, GRK2 was selectively down-regulated (similar to by 90%) in FL83B cells using a small interfering RNA technique. Basal as well as insulin-induced glycogen synthesis ( measured by D-[(UC)-C-14] glucose incorporation) was increased in GRK2-deficient cells compared with control cells. Similarly, GRK2 deficiency increased the basal and insulin-stimulated phosphorylation of Ser(21) in glycogen synthase kinase-3 alpha. Insulin-induced tyrosine phosphorylation of the IR was similar in control and GRK2-deficient cells. Basal and insulin-stimulated phosphorylation of Tyr(612) in insulin receptor subunit 1 was significantly increased while phosphorylation of Ser(307) was decreased in GRK2-deficient FL83B cells compared with control cells. Chronic insulin treatment ( 24 h) in control cells caused an increase in GRK2 (56%) and a decrease in IR (50%) expression associated with the absence of an increase in glycogen synthesis, suggesting impairment of IR function. However, chronic insulin treatment (24 h) did not decrease IR expression or impair IR effects on glycogen synthesis in GRK2-deficient cells. We conclude that (i) GRK2 negatively regulates basal and insulin-stimulated glycogen synthesis via a post-IR signaling mechanism, and (ii) GRK2 may contribute to reduced IR expression and function during chronic insulin exposure.	Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA	University of Houston System; University of Houston	Hussain, T (corresponding author), Univ Houston, Sci & Res Bldg 2,4800 Calhoun, Houston, TX 77204 USA.	thussain2@uh.edu						Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Esposito DL, 2001, ENDOCRINOLOGY, V142, P2833, DOI 10.1210/en.142.7.2833; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Green A, 1997, AM J PHYSIOL-ENDOC M, V273, pE254, DOI 10.1152/ajpendo.1997.273.2.E254; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; Iaccarino G, 2003, ASSAY DRUG DEV TECHN, V1, P347, DOI 10.1089/154065803321204484; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; KASUGA M, 1982, J BIOL CHEM, V257, P9891; Korsheninnikova E, 2002, DIABETES-METAB RES, V18, P209, DOI 10.1002/dmrr.272; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Liberman Z, 2005, J BIOL CHEM, V280, P4422, DOI 10.1074/jbc.M410610200; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Penela P, 2006, CARDIOVASC RES, V69, P46, DOI 10.1016/j.cardiores.2005.09.011; PILCH PF, 1980, J BIOL CHEM, V255, P1722; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; Tennagels N, 2001, BIOCHEM BIOPH RES CO, V282, P387, DOI 10.1006/bbrc.2001.4589; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Trivedi M, 2005, AM J PHYSIOL-RENAL, V289, pF298, DOI 10.1152/ajprenal.00362.2004; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Usui I, 2004, EMBO J, V23, P2821, DOI 10.1038/sj.emboj.7600297; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609	33	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20612	20620		10.1074/jbc.M700744200	http://dx.doi.org/10.1074/jbc.M700744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17517892	hybrid			2022-12-25	WOS:000247819300064
J	Tran, TH; Andreka, P; Rodrigues, CO; Webster, KA; Bishopric, NH				Tran, Thanh H.; Andreka, Peter; Rodrigues, Claudia O.; Webster, Keith A.; Bishopric, Nanette H.			Jun kinase delays caspase-9 activation by interaction with the apoptosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; CARDIAC MYOCYTE APOPTOSIS; DEATH PROTEASE CASPASE-9; CYTOCHROME-C RELEASE; HEAT-SHOCK-PROTEIN; T-CELL-ACTIVATION; APAF-1 APOPTOSOME; OXIDATIVE STRESS; NITRIC-OXIDE; MEDIATED OLIGOMERIZATION	Activation of c-Jun N-terminal kinase 1/2 (JNK) can delay oxidant-induced cell death, but the mechanism is unknown. We found that oxidant stress of cardiac myocytes activated both JNK and mitochondria-dependent apoptosis and that expression of JNK inhibitory mutants accelerated multiple steps in this pathway, including the cleavage and activation of caspases-3 and -9 and DNA internucleosomal cleavage, without affecting the rate of cytochrome c release; JNK inhibition also increased caspase-3 and -9 cleavage in a cell-free system. On activation by GSNO or H2O2, JNK formed a stable association with oligomeric Apaf-1 in a similar to 1.4-2.0 mDa pre-apoptosome complex. Formation of this complex could be triggered by addition of cytochrome c and ATP to the cell-free cytosol. JNK inhibition abrogated JNK-Apaf-1 association and accelerated the association of procaspase-9 and Apaf-1 in both intact cells and cell-free extracts. We conclude that oxidant-activated JNK associates with Apaf-1 and cytochrome c in a catalytically inactive complex. We propose that this interaction delays formation of the active apoptosome, promoting cell survival during short bursts of oxidative stress.	Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Gottsegen Hungarian Inst Cardiol, Budapest, Hungary; Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Med & Pediat, Miami, FL 33136 USA	University of Miami; University of Miami	Bishopric, NH (corresponding author), Dept Mol & Cellular Pharmacol, PO Box 016189, Miami, FL 33101 USA.	n.bishopric@miami.edu		Webster, Keith A/0000-0002-6431-3642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044578, R01HL071094] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 71094, R01 HL 44578] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Andreka P, 2001, CIRC RES, V88, P305, DOI 10.1161/01.RES.88.3.305; Angelastro JM, 2001, J BIOL CHEM, V276, P12190, DOI 10.1074/jbc.M009523200; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Beem E, 2004, AM J PHYSIOL-CELL PH, V287, pC664, DOI 10.1152/ajpcell.00232.2003; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Bishopric Nanette H., 2001, Current Opinion in Pharmacology, V1, P141, DOI 10.1016/S1471-4892(01)00032-7; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boluyt MO, 2003, AM J PHYSIOL-HEART C, V285, pH2639, DOI 10.1152/ajpheart.00596.2003; Borutaite V, 2003, FREE RADICAL BIO MED, V35, P1457, DOI 10.1016/j.freeradbiomed.2003.08.003; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Brecht S, 2005, EUR J NEUROSCI, V21, P363, DOI 10.1111/j.1460-9568.2005.03857.x; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Clerk A, 2002, BIOCHEM J, V368, P101, DOI 10.1042/BJ20021083; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; Communal C, 2002, J CARD FAIL, V8, P86, DOI 10.1054/jcaf.2002.32755; Czerski L, 2004, J MOL CELL CARDIOL, V37, P643, DOI 10.1016/j.yjmcc.2004.04.016; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; Dreskin SC, 2001, J IMMUNOL, V166, P5646, DOI 10.4049/jimmunol.166.9.5646; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Engelbrecht A-M, 2004, BASIC RES CARDIOL, V99, P338, DOI 10.1007/s00395-004-0478-3; Ferrandi C, 2004, BRIT J PHARMACOL, V142, P953, DOI 10.1038/sj.bjp.0705873; Flesch M, 2001, CIRCULATION, V104, P2273, DOI 10.1161/hc4401.099449; Han H, 2004, AM J PHYSIOL-HEART C, V286, pH2169, DOI 10.1152/ajpheart.00199.2003; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Hreniuk D, 2001, MOL PHARMACOL, V59, P867, DOI 10.1124/mol.59.4.867; Ing DJ, 1999, CIRC RES, V84, P21; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Kaiser RA, 2005, J BIOL CHEM, V280, P32602, DOI 10.1074/jbc.M500684200; Kevin LG, 2003, AM J PHYSIOL-HEART C, V284, pH566, DOI 10.1152/ajpheart.00711.2002; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Krumenacker JS, 2005, AM J PHYSIOL-CELL PH, V289, pC778, DOI 10.1152/ajpcell.00057.2005; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martin MC, 2005, J BIOL CHEM, V280, P15449, DOI 10.1074/jbc.M414325200; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Nishitai G, 2004, J BIOL CHEM, V279, P1621, DOI 10.1074/jbc.M310335200; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Park JH, 2001, J CELL BIOCHEM, V82, P326, DOI 10.1002/jcb.1163; Petrich BG, 2004, J BIOL CHEM, V279, P15330, DOI 10.1074/jbc.M314142200; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Pinsky DJ, 1997, CIRC RES, V81, P372, DOI 10.1161/01.RES.81.3.372; Pop C, 2006, MOL CELL, V22, P269, DOI 10.1016/j.molcel.2006.03.009; Remondino A, 2003, CIRC RES, V92, P136, DOI 10.1161/01.RES.0000054624.03539.B4; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Sanna MG, 2002, J BIOL CHEM, V277, P30454, DOI 10.1074/jbc.M203312200; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Seye CI, 2004, CARDIOVASC RES, V64, P144, DOI 10.1016/j.cardiores.2004.05.016; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Tachibana H, 2006, BIOCHEM BIOPH RES CO, V343, P1060, DOI 10.1016/j.bbrc.2006.03.065; Takatani T, 2004, AM J PHYSIOL-CELL PH, V287, pC949, DOI 10.1152/ajpcell.00042.2004; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Twiddy D, 2004, J BIOL CHEM, V279, P19665, DOI 10.1074/jbc.M311388200; Ueda Ryuji, 2003, Medical Electron Microscopy, V36, P41, DOI 10.1007/s007950300005; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	90	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20340	20350		10.1074/jbc.M702210200	http://dx.doi.org/10.1074/jbc.M702210200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17483091	hybrid			2022-12-25	WOS:000247819300037
J	Gusarova, V; Seo, J; Sullivan, ML; Watkins, SC; Brodsky, JL; Fisher, EA				Gusarova, Viktoria; Seo, Jeongmin; Sullivan, Mara L.; Watkins, Simon C.; Brodsky, Jeffrey L.; Fisher, Edward A.			Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SUBCELLULAR-LOCALIZATION; PHYSIOLOGICAL RELEVANCE; TRANSFER PROTEIN; RAT HEPATOCYTES; APO-B; SECRETION; TRIGLYCERIDE; OCCURS; TRIACYLGLYCEROL	The major protein component in secreted very low density lipoproteins (VLDL) is apoB, and it is established that these particles can reach sizes approaching 100 nm. We previously employed a cell-free system to investigate the nature of the vesicles in which this large cargo exits the endoplasmic reticulum (ER) (Gusarova, V., Brodsky, J. L., and Fisher, E. A. (2003) J. Biol. Chem. 278, 48051-48058). We found that apoB-containing lipoproteins exit the ER as dense lipid-protein complexes regardless of the final sizes of the particles and that further expansion occurs via post-ER lipidation. Here, we focused on maturation in the Golgi apparatus. In three separate approaches, we found that VLDL maturation (as assessed by changes in buoyant density) was associated with conformational changes in apoB. In addition, as the size of VLDL expanded, apoE concentrated in a subclass of Golgi microsomes or Golgi-derived vesicles that co-migrated with apoB-containing microsomes or vesicles, respectively. A relationship between apoB and apoE was further confirmed in co-localization studies by immunoelectron microscopy. These combined results are consistent with previous suggestions that apoE is required for VLDL maturation. To our surprise, however, we observed robust secretion of mature VLDL when apoE synthesis was inhibited in either rat hepatoma cells or apoE(-/-) mouse primary hepatocytes. We conclude that VLDL maturation in the Golgi involves apoB conformational changes and that the expansion of the lipoprotein does not require apoE; rather, the increase in VLDL surface area favors apoE binding.	NYU, Sch Med, Dept Med, Leon Charney Div Cardiol, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, Marc & Bell Program Vasc Biol, New York, NY 10016 USA; Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	New York University; New York University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fisher, EA (corresponding author), NYU, Sch Med, Dept Med, 550 1St Ave, New York, NY 10016 USA.	edward.fisher@med.nyu.edu	Watkins, Simon/ABG-2590-2021; Adiels, Martin/C-9278-2011; Fisher, Edward/ABE-7469-2020	Watkins, Simon/0000-0003-4092-1552; Fisher, Edward/0000-0001-9802-143X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58541] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BAMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1994, J BIOL CHEM, V269, P25879; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; FAZIO S, 1995, ARTERIOSCL THROM VAS, V15, P593, DOI 10.1161/01.ATV.15.5.593; Fazio S, 2000, TRENDS CARDIOVAS MED, V10, P23, DOI 10.1016/S1050-1738(00)00033-5; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fromme JC, 2005, CURR OPIN CELL BIOL, V17, P345, DOI 10.1016/j.ceb.2005.06.004; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; Gusarova V, 2003, J BIOL CHEM, V278, P48051, DOI 10.1074/jbc.M306898200; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; HAMILTON RL, 1990, J LIPID RES, V31, P1589; Hasty AH, 1999, J LIPID RES, V40, P1529; HAVEL RJ, 2001, METABOLIC MOL BASES, P2705; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Kummrow E, 2002, J LIPID RES, V43, P2155, DOI 10.1194/jlr.M200249-JLR200; Mancias JD, 2005, TRAFFIC, V6, P278, DOI 10.1111/j.1600-0854.2005.00279.x; Maugeais C, 2000, J LIPID RES, V41, P1673; Mensenkamp AR, 1999, J BIOL CHEM, V274, P35711, DOI 10.1074/jbc.274.50.35711; Olofsson SO, 2005, J INTERN MED, V258, P395, DOI 10.1111/j.1365-2796.2005.01556.x; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; Stagg SM, 2006, NATURE, V439, P234, DOI 10.1038/nature04339; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Sullivan ML, 2003, J HISTOCHEM CYTOCHEM, V51, P545, DOI 10.1177/002215540305100417; Swift LL, 2003, J LIPID RES, V44, P1841, DOI 10.1194/jlr.M300276-JLR200; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; SWIFT LL, 1980, J CLIN INVEST, V66, P415, DOI 10.1172/JCI109871; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Wientgen H, 2004, ARTERIOSCL THROM VAS, V24, P1460, DOI 10.1161/01.ATV.0000134297.61979.3c; WILCOX HG, 1987, J LIPID RES, V28, P351; Yamaguchi J, 2003, J BIOL CHEM, V278, P42643, DOI 10.1074/jbc.M306920200; Zhu MY, 2005, METABOLISM, V54, P1309, DOI 10.1016/j.metabol.2005.04.019	48	51	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19453	19462		10.1074/jbc.M700475200	http://dx.doi.org/10.1074/jbc.M700475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17500069	hybrid			2022-12-25	WOS:000247650600019
J	Franchi, L; Kanneganti, TD; Dubyak, GR; Nunez, G				Franchi, Luigi; Kanneganti, Thirumala-Devi; Dubyak, George R.; Nunez, Gabriel			Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P2X(7) RECEPTOR; IL-1-BETA-CONVERTING ENZYME; IL-1-BETA SECRETION; MICE DEFICIENT; INTERLEUKIN-1-BETA; ATP; RELEASE; INFLAMMASOME; MATURATION; INFECTION	Interleukin-1 beta (IL-1 beta) is a pro-inflammatory cytokine that plays an important role in host defense and inflammatory diseases. The maturation and secretion of IL-1 beta are mediated by caspase-1, a protease that processes pro-IL-1 beta into biologically active IL-1 beta. The activity of caspase-1 is controlled by the inflammasome, a multiprotein complex formed by NLR proteins and the adaptor ASC, that induces the activation of caspase-1. The current model proposes that changes in the intracellular concentration of K+ potentiate caspase-1 activation induced by the recognition of bacterial products. However, the roles of P2X7 receptor and intracellular K+ in IL-1 beta secretion induced by bacterial infection remain unknown. Here we show that, in response to Toll-like receptor agonists such as lipopolysaccharide or infection with extracellular bacteria Staphylococcus aureus and Escherichia coli, efficient caspase-1 activation is only triggered by addition of ATP, a signal that promotes caspase-1 activation through depletion of intracellular K+ caused by stimulation of the purinergic P2X7 receptor. In contrast, activation of caspase-1 that relies on cytosolic sensing of flagellin or intracellular bacteria did not require ATP stimulation or depletion of cytoplasmic K+. Consistently, caspase-1 activation induced by intracellular Salmonella or Listeria was unimpaired in macrophages deficient in P2X7 receptor. These results indicate that, unlike caspase-1 induced by Toll-like receptor agonists and ATP, activation of the inflammasome by intracellular bacteria and cytosolic flagellin proceeds normally in the absence of P2X7 receptor-mediated cytoplasmic K+ perturbations.	Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Case Western Reserve University	Nunez, G (corresponding author), Univ Michigan, Sch Med, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	bclx@umich.ed	Nuñez, Gabriel/A-7160-2014; Kanneganti, Thirumala-Devi/Y-2503-2019; Kanneganti, Thirumala-Devi/M-9435-2018	Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Kanneganti, Thirumala-Devi/0000-0002-6395-6443; Dubyak, George/0000-0001-9720-4226	NIAID NIH HHS [AI063331, AI064748] Funding Source: Medline; NIAMS NIH HHS [AR051790] Funding Source: Medline; NIGMS NIH HHS [GM36387] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063331, R37AI063331, R56AI063331, R01AI064748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Amer A, 2006, J BIOL CHEM, V281, P35217, DOI 10.1074/jbc.M604933200; Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101; Birmingham CL, 2006, J BIOL CHEM, V281, P11374, DOI 10.1074/jbc.M509157200; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; Burns K, 2003, CURR OPIN IMMUNOL, V15, P26, DOI 10.1016/S0952-7915(02)00017-1; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Cheneval D, 1998, J BIOL CHEM, V273, P17846, DOI 10.1074/jbc.273.28.17846; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Cornelis GR, 2006, NAT REV MICROBIOL, V4, P811, DOI 10.1038/nrmicro1526; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Franchi L, 2006, J IMMUNOL, V177, P3507, DOI 10.4049/jimmunol.177.6.3507; Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346; Gavrilin MA, 2006, P NATL ACAD SCI USA, V103, P141, DOI 10.1073/pnas.0504271103; Gurcel L, 2006, CELL, V126, P1135, DOI 10.1016/j.cell.2006.07.033; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Kahlenberg JM, 2005, J IMMUNOL, V175, P7611, DOI 10.4049/jimmunol.175.11.7611; Kahlenberg JM, 2004, AM J PHYSIOL-CELL PH, V286, pC1100, DOI 10.1152/ajpcell.00494.2003; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Kawamura H, 2006, J IMMUNOL, V176, P2152, DOI 10.4049/jimmunol.176.4.2152; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Laliberte RE, 1997, J LEUKOCYTE BIOL, V62, P227, DOI 10.1002/jlb.62.2.227; Laliberte RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/jbc.274.52.36944; Laliberte RE, 2003, J BIOL CHEM, V278, P16567, DOI 10.1074/jbc.M211596200; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Mariathasan S, 2005, J EXP MED, V202, P1043, DOI 10.1084/jem.20050977; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; McCaffrey RL, 2004, P NATL ACAD SCI USA, V101, P11386, DOI 10.1073/pnas.0403215101; Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344; O'Riordan M, 2002, P NATL ACAD SCI USA, V99, P13861, DOI 10.1073/pnas.202476699; Ozoren N, 2006, J IMMUNOL, V176, P4337, DOI 10.4049/jimmunol.176.7.4337; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 1998, AM J PHYSIOL-CELL PH, V275, pC1538, DOI 10.1152/ajpcell.1998.275.6.C1538; Perregaux DG, 1996, J BIOL CHEM, V271, P29830, DOI 10.1074/jbc.271.47.29830; Perregaux DG, 2000, J IMMUNOL, V165, P4615, DOI 10.4049/jimmunol.165.8.4615; Portnoy DA, 2002, J CELL BIOL, V158, P409, DOI 10.1083/jcb.200205009; Sanz JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/jimmunol.164.9.4893; Scott AM, 2007, CELL DEATH DIFFER, V14, P23, DOI 10.1038/sj.cdd.4402026; Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Yamamoto M, 2004, GENES CELLS, V9, P1055, DOI 10.1111/j.1365-2443.2004.00789.x; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273	52	256	259	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18810	18818		10.1074/jbc.M610762200	http://dx.doi.org/10.1074/jbc.M610762200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17491021	hybrid			2022-12-25	WOS:000247475300020
J	Sousa, JC; Costa, MJ; Palha, JA				Sousa, Joao Carlos; Costa, Manuel Joao; Palha, Joana Almeida			Hormone-Mediated Gene Regulation and Bioinformatics: Learning One from the Other	PLOS ONE			English	Article								The ability to manage the constantly growing clinically relevant information in genetics available on the internet is becoming crucial in medical practice. Therefore, training students in teaching environments that develop bioinformatics skills is a particular challenge to medical schools. We present here an instructional approach that potentiates learning of hormone/vitamin mechanisms of action in gene regulation with the acquisition and practice of bioinformatics skills. The activity is integrated within the study of the Endocrine System module. Given a nucleotide sequence of a hormone or vitamin-response element, students use internet databases and tools to find the gene to which it belongs. Subsequently, students search how the corresponding hormone/vitamin influences the expression of that particular gene and how a dysfunctional interaction might cause disease. This activity was presented for four consecutive years to cohorts of 50-60 students/year enrolled in the 2(nd) year of the medical degree. 90% of the students developed a better understanding of the usefulness of bioinformatics and 98% intend to use web-based resources in the future. Since hormones and vitamins regulate genes of all body organ systems, this activity successfully integrates the whole body physiology of the medical curriculum.	[Sousa, Joao Carlos; Costa, Manuel Joao; Palha, Joana Almeida] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal	Universidade do Minho	Sousa, JC (corresponding author), Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Campus Gualtar, Braga, Portugal.		Sousa, João C/C-1048-2009; Costa, Manuel Joao/C-3900-2009; Palha, Joana Almeida/C-2745-2009; Sousa, João/T-6628-2019	Sousa, João C/0000-0003-3249-0035; Costa, Manuel Joao/0000-0001-5255-4257; Palha, Joana Almeida/0000-0002-8866-368X; Sousa, João/0000-0003-3249-0035				*ASS AM MED COLL, 2006, CONT ISS MED BAS SCI; Boron W. F., 2003, MED PHYSL; Brenner S, 2003, SCIENCE, V302, P533, DOI 10.1126/science.302.5645.533; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Haga SB, 2006, NAT REV GENET, V7, P223, DOI 10.1038/nrg1803; Magee J, 2001, ACAD MED, V76, P852, DOI 10.1097/00001888-200108000-00022; Sansom CE, 2000, BIOCHEM EDUC, V28, P127, DOI 10.1016/S0307-4412(99)00142-9; Waggoner DJ, 2006, GENET MED, V8, P379, DOI 10.1097/01.gim.0000223543.63104.5a; Waters MJ, 2006, J ENDOCRINOL, V190, P11, DOI 10.1677/joe.1.06843; Wheeler DL, 2006, NUCLEIC ACIDS RES, V34, pD173, DOI 10.1093/nar/gkj158	10	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e481	10.1371/journal.pone.0000481	http://dx.doi.org/10.1371/journal.pone.0000481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534431	Green Published, gold, Green Submitted			2022-12-25	WOS:000207448800011
J	Malhi, RS; Sickler, B; Lin, DW; Satkoski, J; Tito, RY; George, D; Kanthaswamy, S; Smith, DG				Malhi, Ripan S.; Sickler, Brad; Lin, Dawei; Satkoski, Jessica; Tito, Raul Y.; George, Debbie; Kanthaswamy, Sreetharan; Smith, David Glenn			MamuSNP: A Resource for Rhesus Macaque (Macaca mulatta) Genomics	PLOS ONE			English	Article								We developed a novel method for identifying SNPs widely distributed throughout the coding and non-coding regions of a genome. The method uses large-scale parallel pyrosequencing technology in combination with bioinformatics tools. We used this method to generate approximately 23,000 candidate SNPs throughout the Macaca mulatta genome. We estimate that over 60% of the SNPs will be of high frequency and useful for mapping QTLs, genetic management, and studies of individual relatedness, whereas other less frequent SNPs may be useful as population specific markers for ancestry identification. We have created a web resource called MamuSNP to view the SNPs and associated information online. This resource will also be useful for researchers using a wide variety of Macaca species in their research.	[Malhi, Ripan S.; Tito, Raul Y.] Univ Illinois, Dept Anthropol, Urbana, IL 61801 USA; [Malhi, Ripan S.] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; [Kanthaswamy, Sreetharan; Smith, David Glenn] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; [Satkoski, Jessica; George, Debbie; Smith, David Glenn] Univ Calif Davis, Dept Anthropol, Davis, CA 95616 USA; [Sickler, Brad; Lin, Dawei] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Malhi, RS (corresponding author), Univ Illinois, Dept Anthropol, 109 Davenport Hall, Urbana, IL 61801 USA.	malhi@uiuc.edu	Tito, Raul/CAG-3546-2022	Tito Tadeo, Raul Yhossef/0000-0001-9660-7621; Malhi, Ripan/0000-0002-1484-0292; Trask, Jessica/0000-0002-9902-8753	NIH [RR05090]; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR005090] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	NIH grant RR05090 to DGS	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Doxiadis GGM, 2006, IMMUNOGENETICS, V58, P259, DOI 10.1007/s00251-006-0083-8; Ferguson B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-43; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; GRAUR D, 2000, FUNDAMENTALS MOL EVO; Hernandez RD, 2007, SCIENCE, V316, P240, DOI 10.1126/science.1140462; Kanthaswamy S, 2006, AM J PRIMATOL, V68, P73, DOI 10.1002/ajp.20207; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Noonan JP, 2006, SCIENCE, V314, P1113, DOI 10.1126/science.1131412; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; SATKOSKI JA, J MED PRIMA IN PRESS; Smith DG, 2007, AM J PRIMATOL, V69, P182, DOI 10.1002/ajp.20337	12	37	37	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e438	10.1371/journal.pone.0000438	http://dx.doi.org/10.1371/journal.pone.0000438			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487284	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445800020
J	Bressler, D; Spotswood, N; Whitney, D				Bressler, David; Spotswood, Nicole; Whitney, David			Negative BOLD fMRI Response in the Visual Cortex Carries Precise Stimulus-Specific Information	PLOS ONE			English	Article							FUNCTIONAL MRI; ATTENTIONAL MODULATION; SELECTIVE ATTENTION; NEURAL MECHANISMS; BLOOD-FLOW; AREAS; SUPPRESSION; SEPARATION; STRIATE; FIELD	Sustained positive BOLD (blood oxygen level-dependent) activity is employed extensively in functional magnetic resonance imaging (fMRI) studies as evidence for task or stimulus-specific neural responses. However, the presence of sustained negative BOLD activity (i.e., sustained responses that are lower than the fixation baseline) has remained more difficult to interpret. Some studies suggest that it results from local "blood stealing'' wherein blood is diverted to neurally active regions without a concomitant change of neural activity in the negative BOLD regions. However, other evidence suggests that negative BOLD is a result of local neural suppression. In both cases, regions of negative BOLD response are usually interpreted as carrying relatively little, if any, stimulus-specific information (hence the predominant reliance on positive BOLD activity in fMRI). Here we show that the negative BOLD response resulting from visual stimulation can carry high information content that is stimulus-specific. Using a general linear model (GLM), we contrasted standard flickering stimuli to a fixation baseline and found regions of the visual cortex that displayed a sustained negative BOLD response, consistent with several previous studies. Within these negative BOLD regions, we compared patterns of fMRI activity generated by flickering Gabors that were systematically shifted in position. As the Gabors were shifted further from each other, the correlation in the spatial pattern of activity across a population of voxels (such as the population of V1 voxels that displayed a negative BOLD response) decreased significantly. Despite the fact that the BOLD signal was significantly negative (lower than fixation baseline), these regions were able to discriminate objects separated by less than 0.5 deg (at similar to 10 deg eccentricity). The results suggest that meaningful, stimulus-specific processing occurs even in regions that display a strong negative BOLD response.	[Whitney, David] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Mind & Brain, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Whitney, D (corresponding author), Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA.	dwhitney@ucdavis.edu			National Eye Institute (NEI), NIH; NATIONAL EYE INSTITUTE [R01EY018216] Funding Source: NIH RePORTER	National Eye Institute (NEI), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This study was supported by the National Eye Institute (NEI), NIH.	BECK J, 1985, VISION RES, V25, P1105, DOI 10.1016/0042-6989(85)90099-9; Brefczynski JA, 1999, NAT NEUROSCI, V2, P370, DOI 10.1038/7280; Chen CC, 2005, NEUROIMAGE, V24, P802, DOI 10.1016/j.neuroimage.2004.09.021; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd ed., DOI DOI 10.4324/9780203771587; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Devor A, 2005, P NATL ACAD SCI USA, V102, P3822, DOI 10.1073/pnas.0407789102; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; DRIVER J, 1989, J EXP PSYCHOL HUMAN, V15, P448, DOI 10.1037/0096-1523.15.3.448; Gazzaley A, 2005, J COGNITIVE NEUROSCI, V17, P507, DOI 10.1162/0898929053279522; Gazzaley A, 2005, NAT NEUROSCI, V8, P1298, DOI 10.1038/nn1543; Harel N, 2002, J CEREBR BLOOD F MET, V22, P908, DOI 10.1097/00004647-200208000-00002; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Kastner S, 1999, NEURON, V22, P751, DOI 10.1016/S0896-6273(00)80734-5; LEVI DM, 1988, VISION RES, V28, P597, DOI 10.1016/0042-6989(88)90109-5; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; Macmillan N.A., 2004, DETECTION THEORY USE, DOI DOI 10.4324/9781410611147; Maunsell JHR, 2002, PHILOS T ROY SOC B, V357, P1063, DOI 10.1098/rstb.2002.1107; MCKEE SP, 1984, VISION RES, V24, P25, DOI 10.1016/0042-6989(84)90140-8; MCKEE SP, 1986, VISION RES, V26, P609, DOI 10.1016/0042-6989(86)90009-X; MCKEE SP, 1981, VISION RES, V21, P491, DOI 10.1016/0042-6989(81)90095-X; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; Muller NG, 2005, VISION RES, V45, P1129, DOI 10.1016/j.visres.2004.11.003; Muller NG, 2004, NEUROREPORT, V15, P977, DOI 10.1097/01.wnr.000012504766941.17; Ogawa S, 2000, P NATL ACAD SCI USA, V97, P11026, DOI 10.1073/pnas.97.20.11026; POSNER MI, 1980, J EXP PSYCHOL GEN, V109, P160, DOI 10.1037/0096-3445.109.2.160; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Regan David, 2000, HUMAN PERCEPTION OBJ; Reynolds JH, 2004, ANNU REV NEUROSCI, V27, P611, DOI 10.1146/annurev.neuro.26.041002.131039; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shmuel A, 2006, NAT NEUROSCI, V9, P569, DOI 10.1038/nn1675; Shmuel A, 2002, NEURON, V36, P1195, DOI 10.1016/S0896-6273(02)01061-9; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Slotnick SD, 2003, NEUROIMAGE, V19, P1602, DOI 10.1016/S1053-8119(03)00187-3; Smith AT, 2004, HUM BRAIN MAPP, V21, P213, DOI 10.1002/hbm.20017; Smith AT, 2000, NEUROREPORT, V11, P271, DOI 10.1097/00001756-200002070-00010; Somers DC, 1999, P NATL ACAD SCI USA, V96, P1663, DOI 10.1073/pnas.96.4.1663; Tootell RBH, 1998, NEURON, V21, P1409, DOI 10.1016/S0896-6273(00)80659-5; Tootell RBH, 1998, P NATL ACAD SCI USA, V95, P811, DOI 10.1073/pnas.95.3.811; Tootell RBH, 1998, P NATL ACAD SCI USA, V95, P818, DOI 10.1073/pnas.95.3.818; Tootell RBH, 1997, J NEUROSCI, V17, P7060; TREISMAN AM, 1969, PSYCHOL REV, V76, P282, DOI 10.1037/h0027242; Wandell BA, 2005, PHILOS T R SOC B, V360, P693, DOI 10.1098/rstb.2005.1628; WATT RJ, 1985, VISION RES, V25, P1661, DOI 10.1016/0042-6989(85)90138-5; WESTHEIMER G, 1977, VISION RES, V17, P89, DOI 10.1016/0042-6989(77)90206-1; Whitaker D, 1996, VISION RES, V36, P2957, DOI 10.1016/0042-6989(96)00031-4; Whitaker D, 1998, VISION RES, V38, P3591, DOI 10.1016/S0042-6989(98)00032-7; Whitaker D, 1997, VISION RES, V37, P2207, DOI 10.1016/S0042-6989(97)00030-8; WHITE JM, 1992, VISION RES, V32, P513, DOI 10.1016/0042-6989(92)90243-C; Woolsey TA, 1996, CEREB CORTEX, V6, P647, DOI 10.1093/cercor/6.5.647; YAP YL, 1989, VISION RES, V29, P789, DOI 10.1016/0042-6989(89)90091-6; Yeshurun Y, 1998, NATURE, V396, P72, DOI 10.1038/23936	52	58	58	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e410	10.1371/journal.pone.0000410	http://dx.doi.org/10.1371/journal.pone.0000410			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476332	gold, Green Published			2022-12-25	WOS:000207445700012
J	Rapisarda, A; Melillo, G				Rapisarda, A.; Melillo, G.			UVC inhibits HIF-1 alpha protein translation by a DNA damage- and topoisomerase I-independent pathway	ONCOGENE			English	Article						HIF-1; topoisomerase; UVC; translation; DNA damage; cancer therapeutics	HYPOXIA-INDUCIBLE FACTOR-1; RNA-POLYMERASE-II; XERODERMA-PIGMENTOSUM; ULTRAVIOLET-LIGHT; CANCER-THERAPY; TUMOR-GROWTH; HIF-ALPHA; TRANSCRIPTION; ACTIVATION; ATR	Hypoxia inducible factor 1 (HIF-1) is a key player in cancer progression and an attractive target for cancer therapy. Several small molecule inhibitors of HIF-1 alpha also induce a DNA damage response. However, whether or not DNA damage is required for or associated with the inhibition of HIF-1 alpha protein accumulation is poorly understood. In this report we investigated the effects of distinct DNA damaging conditions on the hypoxic induction of HIF-1 alpha protein in cancer cell lines. We demonstrate that in addition to topotecan (TPT), a known inhibitor of HIF-1 alpha, UVC, but not other DNA damaging agents (cisplatin, ionizing radiation and doxorubicin), inhibited HIF-1 alpha protein accumulation in a dose-dependent, p53-independent fashion. Low doses UVC decreased HIF-1 alpha translation without affecting global protein synthesis. Inhibition of HIF-1 alpha by UVC required ongoing RNA transcription, but not DNA replication. Moreover, a functional ATR was required for the activation of DNA damage-dependent responses by both UVC and TPT, but was dispensable for the inhibition of HIF-1 alpha protein. Notably, unlike TPT, inhibition of HIF-1 alpha protein by UVC did not require topoisomerase 1, suggesting a similar yet distinct mode of action. Our data reveal that UVC is a novel signal associated with inhibition of HIF-1 alpha protein accumulation, and they uncouple the DNA damage-dependent signaling pathway exerted by UVC and TPT from HIF-1 alpha inhibition.	Natl Canc Inst, SAIC Frederick Inc, DTP Tumor Hypoxia Lab, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Melillo, G (corresponding author), Natl Canc Inst, SAIC Frederick Inc, DTP Tumor Hypoxia Lab, 1050 Boyles St,Bldg 432,Room 218, Ft Detrick, MD 21702 USA.	melillog@ncifcff.gov			NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brown JM, 1998, CANCER RES, V58, P1408; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Furuta T, 2002, CANCER RES, V62, P4899; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Laine JP, 2006, TRENDS GENET, V22, P430, DOI 10.1016/j.tig.2006.06.006; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Ljungman M, 2005, MUTAT RES-FUND MOL M, V577, P203, DOI 10.1016/j.mrfmmm.2005.02.014; MAYNE LV, 1982, CANCER RES, V42, P1473; Mazan-Mamczarz K, 2006, MOL CELL BIOL, V26, P2716, DOI 10.1128/MCB.26.7.2716-2727.2006; Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235; Mellon I, 2005, MUTAT RES-FUND MOL M, V577, P155, DOI 10.1016/j.mrfmmm.2005.03.016; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Proietti-De-Santis L, 2006, EMBO J, V25, P1915, DOI 10.1038/sj.emboj.7601071; Rapisarda A, 2004, CELL CYCLE, V3, P172; Rapisarda A, 2004, CANCER RES, V64, P6845, DOI 10.1158/0008-5472.CAN-04-2116; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Rapisarda A, 2002, CANCER RES, V62, P4316; Semenza GL, 2006, EXPERT OPIN THER TAR, V10, P267, DOI 10.1517/14728222.10.2.267; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Soe K, 2004, DNA REPAIR, V3, P387, DOI 10.1016/j.dnarep.2003.12.003; Tornaletti S, 2005, MUTAT RES-FUND MOL M, V577, P131, DOI 10.1016/j.mrfmmm.2005.03.014; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	38	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6875	6884		10.1038/sj.onc.1210489	http://dx.doi.org/10.1038/sj.onc.1210489			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17496931				2022-12-25	WOS:000250188400003
J	Wang, Q; Williamson, M; Bott, S; Brookman-Amissah, N; Freeman, A; Nariculam, J; Hubank, MJF; Ahmed, A; Masters, JR				Wang, Q.; Williamson, M.; Bott, S.; Brookman-Amissah, N.; Freeman, A.; Nariculam, J.; Hubank, M. J. F.; Ahmed, A.; Masters, J. R.			Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer	ONCOGENE			English	Article						cancer; epigenetics; prostate; WNT5A; S100P; CRIP1	TRANSCRIPTION FACTOR AP-2; C-MYB; ABERRANT EXPRESSION; OVARIAN-CARCINOMA; GENE-EXPRESSION; UP-REGULATION; CELL-LINES; ALPHA GENE; V-MYB; METHYLATION	Oligoarray analysis of a matched pair of prostate cancer and normal cell lines derived from the same radical prostatectomy specimen identified 113 candidate hypo-methylated genes that were overexpressed in the cancer cells and contained CpG islands. Hypomethylation of wingless-related MMTV integration site 5A (WNT5A), S100 calcium-binding protein P (S100P) and cysteine-rich protein 1(CRIP1) was confirmed in the cancer cells by bisulfate sequencing. Treatment of the corresponding normal prostate epithelial cells 1542-NPTX with the DNA methyltransferase inhibitor 5-Aza-2 '-deoxycytidine (5-aza-CdR) induced higher levels of mRNA expression and partial loss of methylation on these genes. Primary prostate cancers were tested using methylation-specific polymerase chain reaction. WNT5A was hypomethylated in 11/17 (65%) tumors, S100P in 8/16 (50%) and CRIP1 in 13/20 ( 65%). Bisulfate sequencing of a section of the 50 untranslated region (UTR) of WNT5A revealed that three CpG sites ( 15, 24 and 35) were consistently methylated (93%) in the normal cell line and normal tissues, but not in the prostate cancer cell line and eight primary prostate cancers. Multiple putative binding sites for the transcription factors SP1 and AP-2 were found adjacent to CpG sites 15 and 24. A putative c-Myb binding site was located within the CpG site 35. Anti-c-Myb antibody co-precipitation with WNT5A was methylation- sensitive in 1542-NPTX cells. It is likely that an epigenetic mechanism regulates WNT5A expression in prostate cancer.	UCL, Prostate Canc Res Ctr, Inst Urol & Nephrol, London W1W 7EJ, England; UCL Hosp Trust, Dept Histopathol, London, England; UCL, Gene Microarray Ctr, Inst Child Hlth, London, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London	Masters, JR (corresponding author), UCL, Prostate Canc Res Ctr, Inst Urol & Nephrol, 3rd Floor,67 Riding House St, London W1W 7EJ, England.	j.masters@ucl.ac.uk	Masters, John R/C-5694-2011; Hubank, Michael JF/C-1837-2008	Hubank, Michael JF/0000-0002-2901-0742; Williamson, Magali/0000-0002-7183-7495; Ahmed, Aamir/0000-0001-7405-5336	MRC [G0100116] Funding Source: UKRI; Medical Research Council [G0100116] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Bright RK, 1997, CANCER RES, V57, P995; Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004; Cho M, 2001, BRIT J CANCER, V85, P563, DOI 10.1054/bjoc.2001.1951; Esteller M, 2001, CANCER RES, V61, P3225; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gibadulinova A, 2005, ONCOL REP, V14, P575; Gupta A, 2003, CANCER RES, V63, P664; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; IOZZO RV, 1995, CANCER RES, V55, P3495; Ishii Y, 2005, BBA-MOL CELL RES, V1745, P156, DOI 10.1016/j.bbamcr.2005.01.005; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KLEMPNAUER KH, 1993, ONCOGENE, V8, P111; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; LEVENSON CW, 1993, P NATL ACAD SCI USA, V90, P712, DOI 10.1073/pnas.90.2.712; Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mousses S, 2002, CURR OPIN CHEM BIOL, V6, P97, DOI 10.1016/S1367-5931(01)00283-6; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Ording E, 1996, ONCOGENE, V13, P1043; Oshimo Y, 2003, INT J ONCOL, V23, P1663; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269; Sato N, 2003, CANCER RES, V63, P4158; Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	41	113	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	45					6560	6565		10.1038/sj.onc.1210472	http://dx.doi.org/10.1038/sj.onc.1210472			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17486081				2022-12-25	WOS:000249919800009
J	Liu, YL; Li, M; Warburton, RR; Hill, NS; Fanburg, BL				Liu, Yinglin; Li, Min; Warburton, Rod R.; Hill, Nicholas S.; Fanburg, Barry L.			The 5-HT transporter transactivates the PDGF beta receptor in pulmonary artery smooth muscle cells	FASEB JOURNAL			English	Article						serotonin; pulmonary hypertension	PROTEIN-TYROSINE PHOSPHATASES; GROWTH-FACTOR; SEROTONIN TRANSPORTER; SIGNALING PATHWAY; COUPLED RECEPTORS; MESANGIAL CELLS; IN-VITRO; HYPERTENSION; ACTIVATION; HYPERPLASIA	Serotonin ( 5- HT) stimulates smooth muscle cell growth through 5- HT receptors and the 5- HT transporter ( 5- HTT), and has been associated with pulmonary hypertension ( PH). Platelet- derived growth factor receptors ( PDGFR) have also been associated with PH. We present evidence for the first time that 5- HT transactivates PDGFR beta through the 5- HTT in pulmonary artery ( PA) SMCs. Inhibition of PDGFR kinase with imatinib or AG1296 blocks 5- HT- stimulated PDGFR beta phosphorylation. 5- HTT inhibitors and the Na +/ K +- ATPase inhibitor ouabain, but not 5- HT2 and 5- HT1B/ 1D receptor inhibitors, block PDGFR beta activation by 5- HT. Notably, 5- HTT binds the PDGFR beta upon 5- HT stimulation and the 5- HTT inhibitor fluoxetine blocks both the binding and PDGDR beta activation. Activation of PDGFR beta may occur through oxidation of a catalytic cysteine of tyrosine phosphatase. 5- HT- activated PDGFR beta phosphorylation is blocked by the antioxidant N- acetyl- L- cysteine and the NADPH oxidase inhibitor, DPI. Inhibition of PDGFR kinase with imatinib or AG1296 significantly inhibits SMC proliferation and migration induced by 5- HT in vitro. Infusion of 5- HT by miniosmotic pumps enhances PDGFR beta activation in mouse lung in vivo. In summary, these results demonstrate that 5- HT transactivates PDGFR beta in PASMCs leading to SMC proliferation and migration, and may be an important signaling pathway in the production of PH in vivo.	Tufts Univ, New England Med Ctr, Pulm Crit Care & Sleep Div, Tupper Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Fanburg, BL (corresponding author), Tufts Univ, New England Med Ctr, Pulm Crit Care & Sleep Div, Tupper Res Inst, 750 Washington St,257, Boston, MA 02111 USA.	bfanburg@tufts-nemc.org			NHLBI NIH HHS [R01 HL32723] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balasubramaniam V, 2003, AM J PHYSIOL-LUNG C, V284, pL826, DOI 10.1152/ajplung.00199.2002; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOSIN TR, 1990, BIOCHEM PHARMACOL, V40, P723, DOI 10.1016/0006-2952(90)90307-7; Buchdunger E, 2002, EUR J CANCER, V38, pS28, DOI 10.1016/S0959-8049(02)80600-1; Chen CH, 2006, MOL PHARMACOL, V69, P1347, DOI 10.1124/mol.105.017558; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Choudhury GG, 2006, CELL SIGNAL, V18, P1854, DOI 10.1016/j.cellsig.2006.02.003; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Day RM, 2006, BIOCHEM PHARMACOL, V71, P386, DOI 10.1016/j.bcp.2005.10.035; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; Eddahibi S, 1999, CIRC RES, V84, P329, DOI 10.1161/01.RES.84.3.329; Eddahibi S, 2003, CIRCULATION, V108, P1839, DOI 10.1161/01.CIR.0000091409.53101.E8; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; FANBURG BL, 1997, AM J PHYSIOL, V272, P795; Gooz M, 2006, J BIOL CHEM, V281, P21004, DOI 10.1074/jbc.M512096200; Groen A, 2005, J BIOL CHEM, V280, P10298, DOI 10.1074/jbc.M412424200; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Lampugnani MG, 1999, METH MOL B, V96, P177; LEE SL, 1991, CIRC RES, V68, P1362, DOI 10.1161/01.RES.68.5.1362; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; Lee SL, 1998, FREE RADICAL BIO MED, V24, P855, DOI 10.1016/S0891-5849(97)00359-6; Liu YL, 2006, AM J RESP CELL MOL, V34, P182, DOI 10.1165/rcmb.2005-0163OC; Liu YL, 2004, CIRC RES, V95, P579, DOI 10.1161/01.RES.0000141428.53262.a4; Long L, 2006, CIRC RES, V98, P818, DOI 10.1161/01.RES.0000215809.47923.fd; Lowes VL, 2002, NEUROSIGNALS, V11, P5, DOI 10.1159/000057317; Marcos E, 2004, CIRC RES, V94, P1263, DOI 10.1161/01.RES.0000126847.27660.69; Meng TC, 2005, METHODS, V35, P28, DOI 10.1016/j.ymeth.2004.07.005; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Olivares-Reyes JA, 2005, MOL PHARMACOL, V68, P356, DOI 10.1124/mol.104.010637; Ormond J, 2004, NEURON, V44, P715, DOI 10.1016/j.neuron.2004.11.001; Popescu LM, 2006, EUR J PHARMACOL, V546, P177, DOI 10.1016/j.ejphar.2006.06.068; RAMMAOORTHY S, 1999, SCIENCE, V285, P763; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Simon AR, 2005, CELL BIOCHEM BIOPHYS, V42, P263, DOI 10.1385/CBB:42:3:263; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Zanatta LM, 2001, BRAZ J MED BIOL RES, V34, P1265, DOI 10.1590/S0100-879X2001001000005	38	62	64	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2725	2734		10.1096/fj.06-8058com	http://dx.doi.org/10.1096/fj.06-8058com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17504974				2022-12-25	WOS:000249237500014
J	Omerovic, J; Santangelo, L; Puggioni, EMR; Marrocco, J; Dall'Armi, C; Palumbo, C; Belleudi, F; Di Marcotullio, L; Frati, L; Torrisi, MR; Cesareni, G; Gulino, A; Alimandi, M				Omerovic, Jasminka; Santangelo, Laura; Puggioni, Eleonora Maria-Rosaria; Marrocco, Jordan; Dall'Armi, Claudia; Palumbo, Camilla; Belleudi, Francesca; Di Marcotullio, Lucia; Frati, Luigi; Torrisi, Maria-Rosaria; Cesareni, Gianni; Gulino, Alberto; Alimandi, Maurizio			The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation	FASEB JOURNAL			English	Article						negative regulators; ubiquitin ligase; nuclear translocation	GROWTH-FACTOR RECEPTOR; WW DOMAIN; TYROSINE KINASES; PROTEIN LIGASE; ITCH; P73; UBIQUITYLATION; ENDOCYTOSIS; ISOFORM; GENE	The ErbB- 4 receptors are unique in the EGFR/ ErbB family for the ability to associate with WW domain- containing proteins. To identify new ligands of the cytoplasmic tail of ErbB- 4, we panned a brain cDNA phage library with ErbB- 4 peptides containing sequence motifs corresponding to putative docking sites for class- I WW domains. This approach led to identification of AIP4/ Itch, a member of the Nedd4- like family of E3 ubiquitin protein ligases, as a protein that specifically interacts with and ubiquitinates ErbB- 4 in vivo. Interaction with the ErbB- 4 receptors occurs via the WW domains of AIP4/ Itch. Functional analyses demonstrate that AIP4/ Itch is recruited to the ErbB- 4 receptor to promote its polyubiquitination and degradation, thereby regulating stability of the receptor and access of receptor intracellular domains to the nuclear compartment. These findings expand our understanding of the mechanisms contributing to the integrity of the ErbB signaling network and mechanistically link the cellular ubiquitination pathway of AIP4/ Itch to the ErbB- 4 receptor.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy; Neuromed Inst, Isernia, Italy; Azienda Ospedaliera Sant Andrea, Rome, Italy; IRCCS, Ist Dermatol Sant Maria & San Gallicano, Rome, Italy; Ist Regina Elena, Ctr Ric Sperimentale, I-00161 Rome, Italy	Sapienza University Rome; University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Neuromed; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Alimandi, M (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Viale Regina Elena 324, I-00161 Rome, Italy.	maurizio.alimandi@uniroma1.it	Omerovic, Jasminka/D-4998-2017; Cesareni, Gianni/AAW-1382-2020; Frati, Luigi/ABI-7437-2020; Alimandi, Maurizio/AAG-9246-2019	Alimandi, Maurizio/0000-0002-1409-6803; Marrocco, Jordan/0000-0001-8357-5288; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178; Palumbo, Camilla/0000-0001-5087-7140				Angers A, 2004, J BIOL CHEM, V279, P11471, DOI 10.1074/jbc.M309934200; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Baulida J, 1996, J BIOL CHEM, V271, P5251; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Ferretti E, 2006, ONCOGENE, V25, P7267, DOI 10.1038/sj.onc.1209716; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Gallo RM, 2006, BIOCHEM BIOPH RES CO, V349, P372, DOI 10.1016/j.bbrc.2006.08.055; Gilbertson R, 2001, GENE CHROMOSOME CANC, V31, P288, DOI 10.1002/gcc.1146; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Rubin C, 2005, CELL RES, V15, P66, DOI 10.1038/sj.cr.7290268; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155	39	62	62	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2849	2862		10.1096/fj.06-7925com	http://dx.doi.org/10.1096/fj.06-7925com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17463226				2022-12-25	WOS:000249237500026
J	Patel, HH; Zhang, S; Murray, F; Suda, RYS; Head, BP; Yokoyama, U; Swaney, JS; Niesman, IR; Schermuly, RT; Pullamsetti, SS; Thistlethwaite, PA; Miyanohara, A; Farquhar, MG; Yuan, JXJ; Insel, PA				Patel, Hemal H.; Zhang, Shen; Murray, Fiona; Suda, Ryan Y. S.; Head, Brian P.; Yokoyama, Utako; Swaney, James S.; Niesman, Ingrid R.; Schermuly, Ralph T.; Pullamsetti, Soni Savai; Thistlethwaite, Patricia A.; Miyanohara, Atsushi; Farquhar, Marilyn G.; Yuan, Jason X. -J.; Insel, Paul A.			Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension	FASEB JOURNAL			English	Article						statins; calcium; primary pulmonary hypertension; secondary pulmonary hypertension	NITRIC-OXIDE SYNTHASE; PROTEIN-COUPLED RECEPTOR; P42/44 MAP KINASE; PLASMA-MEMBRANE; CHOLESTEROL DEPLETION; SIGNAL-TRANSDUCTION; LIPID RAFTS; NULL MICE; IN-VIVO; DOMAIN	Vasoconstriction and vascular medial hypertrophy, resulting from increased intracellular [Ca2+] in pulmonary artery smooth muscle cells (PASMC), contribute to elevated vascular resistance in patients with idiopathic pulmonary arterial hypertension (IPAH). Caveolae, microdomains within the plasma membrane, contain the protein caveolin, which binds certain signaling molecules. We tested the hypothesis that PASMC from IPAH patients express more caveolin-1 (Cav-1) and caveolae, which contribute to increased capacitative Ca2+ entry (CCE) and DNA synthesis. Immunohistochemistry showed increased expression of Cav-1 in smooth muscle cells but not endothelial cells of pulmonary arteries from patients with IPAH. Subcellular fractionation and electron microscopy confirmed the increase in Cav-1 and caveolae expression in IPAH-PASMC. Treatment of IPAHPASMC with agents that deplete membrane cholesterol (methyl-beta-cyclodextrin or lovastatin) disrupted caveolae, attenuated CCE, and inhibited DNA synthesis of IPAH-PASMC. Increasing Cav-1 expression of normal PASMC with a Cav-1-encoding adenovirus increased caveolae formation, CCE, and DNA synthesis; treatment of IPAH-PASMC with siRNA targeted to Cav-1 produced the opposite effects. Treatments that down-regulate caveolin/caveolae expression, including cholesterol-lowering drugs, reversed the increased CCE and DNA synthesis in IPAH-PASMC. Increased caveolin and caveolae expression thus contribute to IPAHPASMC pathophysiology. The close relationship between caveolin/caveolae expression and altered cell physiology in IPAH contrast with previous results obtained in various animal models, including caveolin-knockout mice, thus emphasizing unique features of the human disease. The results imply that disruption of caveolae in PASMC may provide a novel therapeutic approach to attenuate disease manifestations of IPAH.-Patel, H. H., Zhang, S., Murray, F., Suda, R. Y. S., Head, B. P., Yokoyama, U., Swaney, J. S., Niesman, I. R., Schermuly, R. T., Savai Pullamsetti, S., Thistlethwaite, P. A., Miyanohara, A., Farquhar, M. G., Yuan, J. X.-J., Insel, P. A. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Gene Therapy Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Giessen, Lung Ctr, Med Clin 2 5, Giessen, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Justus Liebig University Giessen	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,BSB 3076, La Jolla, CA 92093 USA.	pinsel@ucsd.edu	Yokoyama, Utako/AAD-1404-2022; Patel, Hemal/C-7325-2019	Yokoyama, Utako/0000-0003-1803-0155; Schermuly, Ralph/0000-0002-5167-6970; Patel, Hemal/0000-0001-6722-9625; Murray, Fiona/0000-0002-5572-4810; Suda, Ryan/0000-0002-1115-4561; Niesman, Ingrid/0000-0001-9767-6629; Pullamsetti, Soni Savai/0000-0003-0440-8831	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066941, F32HL074625, R01HL066012, R01HL064945] Funding Source: NIH RePORTER; NCI NIH HHS [CA10076] Funding Source: Medline; NHLBI NIH HHS [R01 HL066012, HL66012, HL74625, HL66941, HL64945] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achcar ROD, 2006, CHEST, V129, P696, DOI 10.1378/chest.129.3.696; Bayer-Garner I, 2002, MODERN PATHOL, V15, P1, DOI 10.1038/modpathol.3880481; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Campian ME, 2006, N-S ARCH PHARMACOL, V373, P391, DOI 10.1007/s00210-006-0087-9; Capozza F, 2005, AM J PHYSIOL-CELL PH, V288, pC677, DOI 10.1152/ajpcell.00232.2004; Christian AE, 1997, J LIPID RES, V38, P2264; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Dudzinski DM, 2006, ANNU REV PHARMACOL, V46, P235, DOI 10.1146/annurev.pharmtox.44.101802.121844; Eddahibi S, 2002, EUR RESPIR J, V20, P1559, DOI 10.1183/09031936.02.00081302; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Farber HW, 2004, NEW ENGL J MED, V351, P1655, DOI 10.1056/NEJMra035488; Feron O, 2006, CARDIOVASC RES, V69, P788, DOI 10.1016/j.cardiores.2005.12.014; Feron O, 2001, CIRC RES, V88, P129; Feron O, 1998, J BIOL CHEM, V273, P30249, DOI 10.1074/jbc.273.46.30249; Fine SW, 2001, AM J CLIN PATHOL, V115, P719; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gaine S, 2000, JAMA-J AM MED ASSOC, V284, P3160, DOI 10.1001/jama.284.24.3160; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Geraci MW, 2001, CIRC RES, V88, P555, DOI 10.1161/01.RES.88.6.555; Girgis RE, 2003, AM J PHYSIOL-HEART C, V285, pH938, DOI 10.1152/ajpheart.01097.2002; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; Hardin CD, 2006, CARDIOVASC RES, V69, P808, DOI 10.1016/j.cardiores.2005.11.024; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Humbert M, 2004, NEW ENGL J MED, V351, P1425, DOI 10.1056/NEJMra040291; Insel PA, 2007, BRIT J PHARMACOL, V150, P251, DOI 10.1038/sj.bjp.0706981; Jasmin JF, 2006, CIRCULATION, V114, P912, DOI 10.1161/CIRCULATIONAHA.106.634709; Jasmin JF, 2004, CARDIOVASC RES, V63, P747, DOI 10.1016/j.cardiores.2004.05.018; Jones KA, 2004, EXP CELL RES, V295, P512, DOI 10.1016/j.yexcr.2004.01.022; Kamoun WS, 2006, HEPATOLOGY, V43, P182, DOI 10.1002/hep.20940; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li LK, 2001, CANCER RES, V61, P4386; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Machado RD, 2001, AM J HUM GENET, V68, P92, DOI 10.1086/316947; Mathew R, 2004, CIRCULATION, V110, P1499, DOI 10.1161/01.CIR.0000141576.39579.23; McLaughlin VV, 2006, CIRCULATION, V114, P1417, DOI 10.1161/CIRCULATIONAHA.104.503540; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Nishimura T, 2003, CIRCULATION, V108, P1640, DOI 10.1161/01.CIR.0000087592.47401.37; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Peng Y, 2004, MOL BIOL CELL, V15, P384, DOI 10.1091/mbc.e03-06-0445; Raikar LS, 2006, J CELL BIOCHEM, V98, P861, DOI 10.1002/jcb.20732; Rajjayabun PH, 2001, UROLOGY, V58, P811, DOI 10.1016/S0090-4295(01)01337-1; Ramos M, 2006, VASC PHARMACOL, V44, P50, DOI 10.1016/j.vph.2005.09.007; Razani B, 2001, J BIOL CHEM, V276, P38121; Rong JX, 2003, P NATL ACAD SCI USA, V100, P13531, DOI 10.1073/pnas.1735526100; Rubin LJ, 2002, AM J RESP CRIT CARE, V166, P1308, DOI 10.1164/rccm.2208008; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Yang G, 2000, CLIN CANCER RES, V6, P3430; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	66	94	101	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2970	2979		10.1096/fj.07-8424com	http://dx.doi.org/10.1096/fj.07-8424com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17470567				2022-12-25	WOS:000249237500037
J	Yamada, S; Tomoeda, M; Ozawa, Y; Yoneda, S; Terashima, Y; Ikezawa, K; Ikegawa, S; Saito, M; Toyosawa, S; Murakami, S				Yamada, Satoru; Tomoeda, Miki; Ozawa, Yasuhiro; Yoneda, Shinya; Terashima, Yoshimitsu; Ikezawa, Kazuhiko; Ikegawa, Shiro; Saito, Masahiro; Toyosawa, Satoru; Murakami, Shinya			PLAP-1/asporin, a novel negative regulator of periodontal ligament mineralization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; LEUCINE-RICH REPEATS; GROWTH-FACTOR-BETA; OSTEOBLAST DIFFERENTIATION; MATRIX MINERALIZATION; DECORIN-BINDING; CELLS; BIGLYCAN; EXPRESSION; ASPORIN	Periodontal ligament-associated protein-1 (PLAP-1)/asporin is a recently identified novel member of the small leucine-rich repeat proteoglycan family. PLAP-1/asporin is involved in chondrogenesis, and its involvement in the pathogenesis of osteoarthritis has been suggested. We report that PLAP-1/asporin is also expressed specifically and predominantly in the periodontal ligament (PDL) and that it negatively regulates the mineralization of PDL cells. In situ hybridization analysis revealed that PLAP-1/asporin was expressed specifically not only in the PDL of an erupted tooth but also in the dental follicle, which is the progenitor tissue of the PDL during tooth development. Overexpression of PLAP-1/asporin in mouse PDL-derived clone cells interfered with both naturally and bone morphogenetic protein 2 (BMP-2)-induced mineralization of the PDL cells. On the other hand, knockdown of PLAP-1/asporin transcript levels by RNA interference enhanced BMP-2-induced differentiation of PDL cells. Furthermore co-immuno-precipitation assays showed a direct interaction between PLAP1/asporin and BMP- 2 in vitro, and immunohistochemistry staining revealed the co-localization of PLAP-1/asporin and BMP- 2 at the cellular level. These results suggest that PLAP-1/asporin plays a specific role(s) in the periodontal ligament as a negative regulator of cytodifferentiation and mineralization probably by regulating BMP- 2 activity to prevent the periodontal ligament from developing non-physiological mineralization such as ankylosis.	Osaka Univ, Grad Sch Dent, Dept Periodontol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Dent, Dept Oral Pathol, Suita, Osaka 5650871, Japan; RIKEN, Single Nucleotide Polymorphisms Res Ctr, Lab Bone & Joint Dis, Minato Ku, Tokyo 1088639, Japan; Kanagawa Dent Coll, Div Operat Dent & Endodont, Dept Oral Med, Yokosuka, Kanagawa 2388580, Japan	Osaka University; Osaka University; RIKEN; Kanagawa Dental College	Murakami, S (corresponding author), Osaka Univ, Grad Sch Dent, Dept Periodontol, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	ipshinya@dent.osaka-u.ac.jp	Ikegawa, Shiro/N-6895-2015	Ikegawa, Shiro/0000-0003-0316-2147; Murakami, Shinya/0000-0002-5230-452X				ARCEO N, 1991, J PERIODONTOL, V62, P499, DOI 10.1902/jop.1991.62.8.499; Bartold PM, 2006, PERIODONTOL 2000, V40, P164, DOI 10.1111/j.1600-0757.2005.00139.x; Beertsen W, 1997, PERIODONTOL 2000, V13, P20, DOI 10.1111/j.1600-0757.1997.tb00094.x; BESSEY OA, 1946, J BIOL CHEM, V164, P321; Bosshardt DD, 1996, ANAT RECORD, V245, P267; Chen XD, 2004, FASEB J, V18, P948, DOI 10.1096/fj.03-0899com; CHO MI, 1992, CALCIFIED TISSUE INT, V50, P459, DOI 10.1007/BF00296778; DAHL LK, 1952, P SOC EXP BIOL MED, V80, P474, DOI 10.3181/00379727-80-19661; Duarte WR, 2003, J BONE MINER RES, V18, P493, DOI 10.1359/jbmr.2003.18.3.493; Duarte WR, 1999, BIOCHEM BIOPH RES CO, V255, P416, DOI 10.1006/bbrc.1999.0214; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Iida A, 2006, J HUM GENET, V51, P151, DOI 10.1007/s10038-005-0337-6; Ikegawa S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1992; Ishihara K, 1999, BBA-MOL CELL RES, V1451, P48, DOI 10.1016/S0167-4889(99)00090-7; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; Kobayashi M, 1999, J DENT RES, V78, P1624, DOI 10.1177/00220345990780100701; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lekic P, 1996, ANAT REC, V245, P327; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; Mochida Y, 2003, BIOCHEM BIOPH RES CO, V305, P6, DOI 10.1016/S0006-291X(03)00693-4; Parisuthiman D, 2005, J BONE MINER RES, V20, P1878, DOI 10.1359/JBMR.050612; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Saito M, 2005, J BONE MINER RES, V20, P50, DOI 10.1359/jbmr.041006; Saito Y, 2002, J CELL SCI, V115, P4191, DOI 10.1242/jcs.00098; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Sulochana KN, 2005, J BIOL CHEM, V280, P27935, DOI 10.1074/jbc.M414320200; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017; Yamada S, 2006, J DENT RES, V85, P447, DOI 10.1177/154405910608500510; Yamada S, 2001, GENE, V275, P279, DOI 10.1016/S0378-1119(01)00683-7; Yoshizawa T, 2004, MOL CELL BIOL, V24, P3460, DOI 10.1128/MCB.24.8.3460-3472.2004; Zhao M, 2002, J BONE MINER RES, V17, P1441, DOI 10.1359/jbmr.2002.17.8.1441	37	148	155	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23070	23080		10.1074/jbc.M611181200	http://dx.doi.org/10.1074/jbc.M611181200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17522060	hybrid			2022-12-25	WOS:000248577500009
J	Kobayashi, S; Mao, K; Zheng, HQ; Wang, XJ; Patterson, C; O'Connell, TD; Liang, QR				Kobayashi, Satoru; Mao, Kai; Zheng, Hanqiao; Wang, Xuejun; Patterson, Cam; O'Connell, Timothy D.; Liang, Qiangrong			Diminished GATA4 protein levels contribute to hyperglycemia-induced cardiomyocyte injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC CARDIOMYOPATHY; INDUCED APOPTOSIS; CELL-DEATH; VENTRICULAR MYOCYTES; CARDIAC MYOCYTES; UBIQUITIN LIGASE; GENE-EXPRESSION; VITAMIN-E; IN-VITRO; HYPERTROPHY	Hyperglycemia is an independent risk factor for diabetic heart failure. However, the mechanisms that mediate hyperglycemia-induced cardiac damage remain poorly understood. The transcription factor GATA4 is essential for cardiac homeostasis, and its protein levels are dramatically reduced in the heart in response to diverse pathologic stresses. In this study, we investigated if hyperglycemia affects GATA4 expression in cardiomyocytes and if enhancing GATA4 signaling could attenuate hyperglycemia-induced cardiomyocyte injury. In cultured rat cardiomyocytes, high glucose (HG, 25 or 40 mM) markedly reduced GATA4 protein levels as compared with normal glucose (NG, 5.5 mM). Equal amount of mannitol did not affect GATA4 protein expression (NG, 100 +/- 12%; mannitol, 97 +/- 8%, versus HG, 43 +/- 16%, p < 0.05). The GATA4 mRNA content, either steady-state or polysome-associated, remained unchanged. HG-induced GATA4 reduction was reversed by MG262, a specific proteasome inhibitor. HG did not activate the ubiquitin proteasome system (UPS) in cardiomyocytes as indicated by a UPS reporter, nor did it increase the peptidase activities or protein expression of the proteasomal subunits. However, the mRNA levels of ubiquitin-protein isopeptide ligase (E3) carboxyl terminus of Hsp70-interacting protein (CHIP) were markedly increased in HG-treated cardiomyocytes. CHIP overexpression promoted GATA4 protein degradation, whereas small interfering RNA-mediated CHIP knockdown prevented HG-induced GATA4 depletion. Moreover, overexpression of GATA4 blocked HG-induced cardiomyocyte death. Also, GATA4 protein levels were diminished in the hearts of streptozotocin and db/db diabetic mice (44 +/- 7% and 67 +/- 13% of control, p < 0.05), which correlated with increased CHIPmRNA abundance. In summary, increased GATA4 protein degradation may be an important mechanism that contributes to hyperglycemic cardiotoxicity.	Univ S Dakota Sanford Sch Med, Sanford Res, Inst Cardiovasc Res, Sioux Falls, SD 57105 USA; Univ N Carolina, Sch Med, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA	Sanford Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Liang, QR (corresponding author), Univ S Dakota Sanford Sch Med, Sanford Res, Inst Cardiovasc Res, Sioux Falls, SD 57105 USA.	qliang@usd.edu	Wang, Xuejun/AAT-9490-2021; Wang, Xuejun/K-8874-2013; O'Connell, Timothy/D-5048-2013	Wang, Xuejun/0000-0001-9267-1343; Wang, Xuejun/0000-0001-9267-1343; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017662] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072166] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR017662] Funding Source: Medline; NHLBI NIH HHS [R01 HL085629, R01 HL072166] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aasum E, 2003, DIABETES, V52, P434, DOI 10.2337/diabetes.52.2.434; Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Arya R, 2004, J CELL BIOL, V167, P1147, DOI 10.1083/jcb.200402033; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BELL DSH, 1995, DIABETES CARE, V18, P708, DOI 10.2337/diacare.18.5.708; Cai L, 2002, DIABETES, V51, P1938, DOI 10.2337/diabetes.51.6.1938; Chagnon F, 2005, CIRC RES, V96, P1095, DOI 10.1161/01.RES.0000168327.22888.4d; Cooper ME, 2004, AM J HYPERTENS, V17, p31S, DOI 10.1016/j.amjhyper.2004.08.021; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Dong X, 2004, AM J PHYSIOL-HEART C, V287, pH1417, DOI 10.1152/ajpheart.01233.2003; Fiordaliso F, 2004, J MOL CELL CARDIOL, V37, P959, DOI 10.1016/j.yjmcc.2004.07.008; Fiordaliso F, 2000, LAB INVEST, V80, P513, DOI 10.1038/labinvest.3780057; Fiordaliso F, 2001, DIABETES, V50, P2363, DOI 10.2337/diabetes.50.10.2363; Frustaci A, 2000, CIRC RES, V87, P1123, DOI 10.1161/01.RES.87.12.1123; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Idris I, 2001, DIABETOLOGIA, V44, P659, DOI 10.1007/s001250051675; Kakita T, 2001, CIRC RES, V88, P1239, DOI 10.1161/hh1201.091794; Kobayashi S, 2006, FASEB J, V20, P800, DOI 10.1096/fj.05-5426fje; Kumarapeli ARK, 2005, FASEB J, V19, P2051, DOI 10.1096/fj.05-3973fje; Kuzman JA, 2005, J MOL CELL CARDIOL, V39, P841, DOI 10.1016/j.yjmcc.2005.07.019; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; Li LH, 2006, CIRCULATION, V113, P535, DOI 10.1161/CIRCULATIONAHA.105.568402; Li YW, 2006, LAB INVEST, V86, P32, DOI 10.1038/labinvest.3700367; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2002, DIABETES, V51, P174, DOI 10.2337/diabetes.51.1.174; Lonn E, 2002, DIABETES CARE, V25, P1919, DOI 10.2337/diacare.25.11.1919; Malhotra A, 2005, AM J PHYSIOL-HEART C, V289, pH1343, DOI 10.1152/ajpheart.01200.2004; Malhotra A, 2005, MOL CELL BIOCHEM, V268, P169, DOI 10.1007/s11010-005-3858-6; Maulik N, 1999, CIRCULATION, V100, P369; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Oka T, 2006, CIRC RES, V98, P837, DOI 10.1161/01.RES.0000215985.18538.c4; Peng HM, 2004, J BIOL CHEM, V279, P52970, DOI 10.1074/jbc.M406926200; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Pierce GN, 1997, CARDIOVASC RES, V34, P41, DOI 10.1016/S0008-6363(97)00010-2; Poornima IG, 2006, CIRC RES, V98, P596, DOI 10.1161/01.RES.0000207406.94146.c2; Qian SB, 2006, NATURE, V440, P551, DOI 10.1038/nature04600; ROSSINI AA, 1977, P NATL ACAD SCI USA, V74, P2485, DOI 10.1073/pnas.74.6.2485; Sacco M, 2003, DIABETES CARE, V26, P3264, DOI 10.2337/diacare.26.12.3264; Shizukuda Y, 2002, AM J PHYSIOL-HEART C, V282, pH1625, DOI 10.1152/ajpheart.00783.2001; Suzuki YJ, 2004, J MOL CELL CARDIOL, V37, P1195, DOI 10.1016/j.yjmcc.2004.09.009; Ye G, 2004, DIABETES, V53, P1336, DOI 10.2337/diabetes.53.5.1336; Zhang CL, 2005, AM J PHYSIOL-HEART C, V288, pH2836, DOI 10.1152/ajpheart.01122.2004	42	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21945	21952		10.1074/jbc.M703048200	http://dx.doi.org/10.1074/jbc.M703048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17525155	hybrid			2022-12-25	WOS:000248196800042
J	Wayne, GJ; Deng, SJ; Amour, A; Borman, S; Matico, R; Carter, HL; Murphy, G				Wayne, Gareth J.; Deng, Su-Jun; Amour, Augustin; Borman, Satty; Matico, Rosalie; Carter, H. Luke; Murphy, Gillian			TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-RELATED-CHANGES; EXTRACELLULAR-MATRIX; CHONDROITIN SULFATE; ARTICULAR-CARTILAGE; TISSUE INHIBITOR; KERATAN SULFATE; METALLOPROTEINASES; CLEAVAGE; FAMILY; BINDING	ADAMTS-4 (aggrecanase-1) is a glutamyl endopeptidase capable of generating catabolic fragments of aggrecan analogous to those released from articular cartilage during degenerative joint diseases such as osteoarthritis. Efficient aggrecanase activity requires the presence of sulfated glycosaminoglycans attached to the aggrecan core protein, implying the contribution of substrate recognition/binding site(s) to ADAMTS-4 activity. In this study, we developed a sensitive fluorescence resonance energy transfer peptide assay with a K-m in the 10 mu M range and utilized this assay to demonstrate that inhibition of full-length ADAMTS-4 by full-length TIMP-3 (a physiological inhibitor of metalloproteinases) is enhanced in the presence of aggrecan. Our data indicate that this interaction is mediated largely through the binding of glycosaminoglycans (specifically chondroitin 6-sulfate) of aggrecan to binding sites in the thrombospondin type 1 motif and spacer domains of ADAMTS-4 to form a complex with an improved binding affinity for TIMP-3 over free ADAMTS-4. The results of this study therefore indicate that the cartilage environment can modulate the function of enzyme-inhibitor systems and could have relevance for therapeutic approaches to aggrecanase modulation.	Univ Cambridge, Dept Oncol, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England; GlaxoSmithKline Inc, Harlow CM19 5AW, Essex, England; GlaxoSmithKline Inc, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline Inc, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline Inc, King Of Prussia, PA 19406 USA	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Murphy, G (corresponding author), Univ Cambridge, Dept Oncol, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England.	gm290@cam.ac.uk		Matico, Rosalie/0000-0003-2341-3767				Alvarez-Iglesias M, 2005, LAB INVEST, V85, P1440, DOI 10.1038/labinvest.3700340; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Brown GM, 1998, J BIOL CHEM, V273, P26408, DOI 10.1074/jbc.273.41.26408; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; Deng SJ, 2004, J VIROL, V78, P2637, DOI 10.1128/JVI.78.5.2637-2641.2003; Deng SJ, 2000, J BIOL CHEM, V275, P31422, DOI 10.1074/jbc.M004538200; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Lauder RM, 2001, BIOCHEM J, V358, P523, DOI 10.1042/0264-6021:3580523; Liu YY, 1999, ANAL BIOCHEM, V267, P331, DOI 10.1006/abio.1998.3014; MACPHERSON JL, 1997, J MED CHEM, V40, P2525; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Poon CJ, 2005, J BIOL CHEM, V280, P23615, DOI 10.1074/jbc.M412145200; POPE A, 2001, DRUG DISCOV TODAY, V4, P350; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; Roughley PJ, 2001, ARTHRITIS RES, V3, P342, DOI 10.1186/ar326; Segel I. H., 1993, ENZYME KINETICS, P793; Struglics A, 2006, OSTEOARTHR CARTILAGE, V14, P101, DOI 10.1016/j.joca.2005.07.018; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	29	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20991	20998		10.1074/jbc.M610721200	http://dx.doi.org/10.1074/jbc.M610721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17470431	hybrid			2022-12-25	WOS:000248047500025
J	Gunawardena, RW; Fox, SR; Siddiqui, H; Knudsen, ES				Gunawardena, Ranjaka W.; Fox, Sejal R.; Siddiqui, Hasan; Knudsen, Erik S.			SWI/SNF activity is required for the repression of deoxyribonucleotide triphosphate metabolic enzymes via the recruitment of mSin3B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; CHROMATIN REMODELING FACTOR; CELL-CYCLE CONTROL; TRANSCRIPTIONAL REPRESSION; POCKET PROTEINS; DNA-DAMAGE; IN-VIVO; E2F; FAMILY; COMPLEXES	The SWI/SNF chromatin remodeling complex plays a critical role in the coordination of gene expression with physiological stimuli. The synthetic enzymes ribonucleotide reductase, dihydrofolate reductase, and thymidylate synthase are coordinately regulated to ensure appropriate deoxyribonucleotide triphosphate levels. Particularly, these enzymes are actively repressed as cells exit the cell cycle through the action of E2F transcription factors and the retinoblastoma tumor suppressor/p107/p130 family of pocket proteins. This process is found to be highly dependent on SWI/SNF activity as cells deficient in BRG-1 and Brm subunits fail to repress these genes with activation of pocket proteins, and this deficit in repression can be complemented, via the ectopic expression of BRG-1. The failure to repress transcription does not involve a blockade in the association of E2F or pocket proteins p107 and p130 with promoter elements. Rather, the deficit in repression is due to a failure to mediate histone deacetylation of ribonucleotide reductase, dihydrofolate reductase, and thymidylate synthase promoters in the absence of SWI/SNF activity. The basis for this is found to be a failure to recruit mSin3B and histone deacetylase proteins to promoters. Thus, the coordinate repression of deoxyribonucleotide triphosphate metabolic enzymes is dependent on the action of SWI/SNF in facilitating the assembly of repressor complexes at the promoter.	Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), 3125 Eden Ave, Cincinnati, OH 45267 USA.	erik.Knudsen@uc.edu			NCI NIH HHS [CA 104213] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Angus SP, 2003, MOL CELL BIOL, V23, P8172, DOI 10.1128/MCB.23.22.8172-8188.2003; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005; Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; Belotserkovskaya R, 1999, CRIT REV EUKAR GENE, V9, P221, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.70; Bilodeau S, 2006, GENE DEV, V20, P2871, DOI 10.1101/gad.1444606; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dror V, 2004, MOL CELL BIOL, V24, P8227, DOI 10.1128/MCB.24.18.8227-8235.2004; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Henderson A, 2004, MOL CELL BIOL, V24, P389, DOI 10.1128/MCB.24.1.389-397.2004; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Imbalzano AN, 2005, CANCER CELL, V7, P294, DOI 10.1016/j.ccr.2005.04.001; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; KASAHARA Y, 1993, MUTAT RES, V319, P143, DOI 10.1016/0165-1218(93)90073-M; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; Lee SI, 2006, P NATL ACAD SCI USA, V103, P14062, DOI 10.1073/pnas.0601852103; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427; Nakayama Norisuke, 2006, Gastric Cancer, V9, P185, DOI 10.1007/s10120-006-0371-x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ni ZY, 2005, P NATL ACAD SCI USA, V102, P14611, DOI 10.1073/pnas.0503070102; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Ooi L, 2006, J BIOL CHEM, V281, P38974, DOI 10.1074/jbc.M605370200; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Rastogi S, 2006, MOL CELL BIOL, V26, P4161, DOI 10.1128/MCB.02142-05; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Reisman DN, 2003, CANCER RES, V63, P560; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Ross S, 2006, EMBO J, V25, P4490, DOI 10.1038/sj.emboj.7601332; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Takahashi Y, 2000, GENE DEV, V14, P804; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Un F, 2006, ANTICANCER RES, V26, P2761; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yang L, 2003, BIOCHEM J, V369, P651, DOI 10.1042/BJ20020854	72	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20116	20123		10.1074/jbc.M701406200	http://dx.doi.org/10.1074/jbc.M701406200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17510060	hybrid			2022-12-25	WOS:000247819300012
J	Meesapyodsuk, D; Reed, DW; Covello, PS; Qiu, X				Meesapyodsuk, Dauenpen; Reed, Darwin W.; Covello, Patrick S.; Qiu, Xiao			Primary structure, regioselectivity, and evolution of the membrane-bound fatty acid desaturases of Claviceps purpurea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE; ACYL-LIPID DESATURASE; SACCHAROMYCES-CEREVISIAE; HISTIDINE-RESIDUES; GENE; EXPRESSION; TOPOLOGY; SPECIFICITY; IDENTIFICATION; PREDICTION	Two cDNAs with sequence similarity to fatty acid desaturase genes were isolated from the phytopathogenic fungus, Claviceps purpurea. The predicted amino acid sequences of the corresponding genes, named CpDes12 and CpDesX, share 87% identity. Phylogenetic analysis indicates that CpDes12 and CpDesX arose by gene duplication of an ancestral Delta(12)-desaturase gene after the divergence of Nectriaceae and Clavicipitaceae. Functional expression of CpDes12 and CpDesX in yeast ( Saccharomyces cerevisiae) indicated that CpDes12 is primarily a "Delta(12)"-desaturase, whereas CpDesX is a novel desaturase catalyzing "Delta(12)," "Delta(15)," and "omega(3)" types of desaturation with omega(3) activity predominating. CpDesX sequentially desaturates both 16:1-9c and 18:1-9c to give 16: 3-9c, 12c, 15c and 18: 3-9c, 12c, 15c, respectively. In addition, it could also act as an omega(3)-desaturase converting omega(6)-polyunsaturates 18: 3-6c, 9c, 12c, 20: 3-8c, 11c, 14c, and 20: 4-5c, 8c, 11c, 14c to their omega(3) counterparts 18: 4 - 6c, 9c, 12c, 15c, 20: 4 8c, 11c, 14c, 17c, and 20: 5 - 5c, 8c, 11c, 14c, 17c, respectively. By using reciprocal site-directed mutagenesis, we demonstrated that two residues (isoleucine at 152 and alanine at 206) are critical in defining the catalytic specificity of these enzymes and the C-terminal amino acid sequence (residues 302 - 477) was also found to be important. These data provide insights into the nature of regio-selectivity in membrane-bound fatty acid desaturases and the relevant structural determinants. The authors suggest that the regio-selectivity of such enzymes may be best understood by considering the relative importance of more than one regioselective preference. In this view, CpDesX is designated as a v + 3(omega(3)) desaturase, which primarily references an existing double bond (v + 3 regioselectivity) and secondarily shows preference for omega(3) desaturation.	Univ Saskatchewan, Dept Appl Microbiol & Food Sci, Saskatoon, SK S7N 5A8, Canada; Bioriginal Food & Sci Corp, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada	University of Saskatchewan	Qiu, X (corresponding author), Univ Saskatchewan, Dept Appl Microbiol & Food Sci, 51 Campus Dr, Saskatoon, SK S7N 5A8, Canada.	xiao.qiu@usask.ca		Reed, Darwin/0000-0001-8038-8647				Arai M, 2004, NUCLEIC ACIDS RES, V32, pW390, DOI 10.1093/nar/gkh380; AVELANGEMACHEREL MH, 1995, FEBS LETT, V361, P111, DOI 10.1016/0014-5793(95)00163-4; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Broadwater JA, 2002, J BIOL CHEM, V277, P15613, DOI 10.1074/jbc.M200231200; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Cahoon EB, 2004, J BIOL CHEM, V279, P12495, DOI 10.1074/jbc.M314329200; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Covello PS, 1996, PLANT PHYSIOL, V111, P223, DOI 10.1104/pp.111.1.223; Damude HG, 2006, P NATL ACAD SCI USA, V103, P9446, DOI 10.1073/pnas.0511079103; Diaz AR, 2002, J BIOL CHEM, V277, P48099, DOI 10.1074/jbc.M208960200; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fujimori K, 1997, FEBS LETT, V413, P226, DOI 10.1016/S0014-5793(97)00846-6; Heilmann I, 2004, P NATL ACAD SCI USA, V101, P10266, DOI 10.1073/pnas.0402200101; HITZ WD, 1994, PLANT PHYSIOL, V105, P635, DOI 10.1104/pp.105.2.635; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Libisch B, 2000, BIOCHEM BIOPH RES CO, V279, P779, DOI 10.1006/bbrc.2000.4023; Los DA, 1998, BBA-LIPID LIPID MET, V1394, P3, DOI 10.1016/S0005-2760(98)00091-5; LUTHRIA DL, 1993, LIPIDS, V28, P561, DOI 10.1007/BF02536089; MANTLE PG, 1976, J GEN MICROBIOL, V93, P321, DOI 10.1099/00221287-93-2-321; Meesapyodsuk D, 2000, BIOCHEMISTRY-US, V39, P11948, DOI 10.1021/bi000756a; Mey G, 2002, MOL PLANT MICROBE IN, V15, P303, DOI 10.1094/MPMI.2002.15.4.303; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Reed DW, 2000, PLANT PHYSIOL, V122, P715, DOI 10.1104/pp.122.3.715; Sakuradani E, 2005, APPL MICROBIOL BIOT, V66, P648, DOI 10.1007/s00253-004-1760-x; Sayanova O, 2006, J BIOL CHEM, V281, P36533, DOI 10.1074/jbc.M605158200; Schwartzbeck JL, 2001, PHYTOCHEMISTRY, V57, P643, DOI 10.1016/S0031-9422(01)00081-4; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Sperling P, 2003, PROSTAG LEUKOTR ESS, V68, P73, DOI 10.1016/S0952-3278(02)00258-2; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; YADAV NS, 1993, PLANT PHYSIOL, V103, P467, DOI 10.1104/pp.103.2.467; Zhang S, 2007, FEBS LETT, V581, P315, DOI 10.1016/j.febslet.2006.12.031	36	47	57	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20191	20199		10.1074/jbc.M702196200	http://dx.doi.org/10.1074/jbc.M702196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17510052	hybrid			2022-12-25	WOS:000247819300020
J	Shi, XH; Ma, YQ; Tu, Y; Chen, K; Wu, S; Fukuda, K; Qin, J; Plow, EF; Wu, CY				Shi, Xiaohua; Ma, Yan-Qing; Tu, Yizeng; Chen, Ka; Wu, Shan; Fukuda, Koichi; Qin, Jun; Plow, Edward F.; Wu, Chuanyue			The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; INTEGRIN ACTIVATION; CYTOPLASMIC DOMAIN; FIBRONECTIN RECEPTOR; SHAPE MODULATION; BINDING-PROTEIN; FOCAL ADHESIONS; TALIN; MIGRATION; MIGFILIN	Integrin-mediated cell-matrix adhesion plays an important role in control of cell behavior. We report here that MIG-2, a widely expressed focal adhesion protein, interacts with beta 1 and beta 3 integrin cytoplasmic domains. Integrin binding is mediated by a single site within the MIG-2 FERM domain. Functionally, the MIG-2/integrin interaction recruits MIG-2 to focal adhesions. Furthermore, using alpha IIb beta 3 integrin-expressing Chinese hamster ovary cells, a well described model system for integrin activation, we show that MIG-2 promotes integrin activation and enhances cell-extracellular matrix adhesion. Although MIG-2 is expressed in many cell types, it is deficient in certain colon cancer cells. Expression of MIG-2, but not of an integrin binding-defective MIG-2 mutant, in MIG-2-null colon cancer cells strengthened cell-matrix adhesion, promoted focal adhesion formation, and reduced cell motility. These results suggest that the MIG-2/integrin interaction is an important element in the cellular control of integrin-mediated cell-matrix adhesion and that loss of this interaction likely contributes to high motility of colon cancer cells.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cleveland Clinic Foundation	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, 707B Scaife Hall, 3550 Terrace St, Pittsburgh, PA 15261 USA.	carywu@pitt.edu	Qin, Jun/D-5559-2009	Qin, Jun/0000-0002-2647-9270	NHLBI NIH HHS [HL 073311] Funding Source: Medline; NIDDK NIH HHS [DK 54639] Funding Source: Medline; NIGMS NIH HHS [GM 65188] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL073311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; Critchley DR, 2005, BIOCHEM SOC T, V33, P1308, DOI 10.1042/BST0331308; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gkretsi V, 2005, J CELL SCI, V118, P697, DOI 10.1242/jcs.01638; Guo L, 2002, FASEB J, V16, P1298, DOI 10.1096/fj.02-0089fje; Hemler M E, 1995, Curr Opin Hematol, V2, P61; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kloeker S, 2004, J BIOL CHEM, V279, P6824, DOI 10.1074/jbc.M307978200; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li J, 1999, J CELL BIOL, V147, P1391, DOI 10.1083/jcb.147.7.1391; Liu SC, 2000, J CELL SCI, V113, P3563; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; Ma YQ, 2006, BIOCHEMISTRY-US, V45, P6656, DOI 10.1021/bi060279h; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; MCCLAY DR, 2003, CURRENT PROTOCOLS CE, V1; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; Qin J, 2004, PLOS BIOL, V2, P726, DOI 10.1371/journal.pbio.0020169; Rogalski TM, 2000, J CELL BIOL, V150, P253, DOI 10.1083/jcb.150.1.253; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; ROUSSEL A, 1991, TURBO FRUDO SILICON; Schaller MD, 2000, J CELL BIOL, V150, pF9, DOI 10.1083/jcb.150.1.F9; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Su AI, 2001, CANCER RES, V61, P7388; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Vinogradova O, 2004, P NATL ACAD SCI USA, V101, P4094, DOI 10.1073/pnas.0400742101; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wegener KL, 2007, CELL, V128, P171, DOI 10.1016/j.cell.2006.10.048; Wu CY, 2005, TRENDS CELL BIOL, V15, P460, DOI 10.1016/j.tcb.2005.07.002; Wu CY, 2005, J CELL SCI, V118, P659, DOI 10.1242/jcs.01639; YAMADA KM, 2003, CURRENT PROTOCOLS CE, V1; Zhang YJ, 2006, J BIOL CHEM, V281, P12397, DOI 10.1074/jbc.M512107200; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	51	141	145	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20455	20466		10.1074/jbc.M611680200	http://dx.doi.org/10.1074/jbc.M611680200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17513299	hybrid			2022-12-25	WOS:000247819300048
J	Ikegami, A; Yoshimura, N; Motohashi, K; Takahashi, S; Romano, PGN; Hisabori, T; Takamiya, K; Masuda, T				Ikegami, Akinori; Yoshimura, Naho; Motohashi, Ken; Takahashi, Shigekazu; Romano, Patrick G. N.; Hisabori, Toru; Takamiya, Ken-ichiro; Masuda, Tatsuru			The CHLI1 subunit of Arabidopsis thaliana magnesium chelatase is a target protein of the chloroplast thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING CUCUMBER CHLOROPLASTS; MG-CHELATASE; ATPASE ACTIVITY; RHODOBACTER-SPHAEROIDES; PLASTIDIAL THIOREDOXINS; CHLOROPHYLL SYNTHESIS; ESCHERICHIA-COLI; EXPRESSION; SYSTEM; ENZYME	Insertion of magnesium into protoporphyrin IX by magnesium chelatase is a key step in the chlorophyll biosynthetic pathway, which takes place in plant chloroplasts. ATP hydrolysis by the CHLI subunit of magnesium chelatase is an essential component of this reaction, and the activity of this enzyme is a primary determinant of the rate of magnesium insertion into the chlorophyll molecule ( tetrapyrrole ring). Higher plant CHLI contains highly conserved cysteine residues and was recently identified as a candidate protein in a proteomic screen of thioredoxin target proteins (Balmer, Y., Koller, A., del Val, G., Manieri, W., Schurmann, P., and Buchanan, B. B.( 2003) Proc. Natl. Acad. Sci. U. S. A. 100,370-375). To study the thioredoxin-dependent regulation of magnesium chelatase, we first investigated the effect of thioredoxin on the ATPase activity of CHLI1, a major isoform of CHLI in Arabidopsis thaliana. The ATPase activity of recombinant CHLI1 was found to be fully inactivated by oxidation and easily recovered by thioredoxin-assisted reduction, suggesting that CHLI1 is a target protein of thioredoxin. Moreover, we identified one crucial disulfide bond located in the C-terminal helical domain of CHLI1 protein, which may regulate the binding of the nucleotide to the N-terminal catalytic domain. The redox state of CHLI was also found to alter in a light-dependent manner in vivo. Moreover, we successfully observed stimulation of the magnesium chelatase activity in isolated chloroplasts by reduction. Our findings strongly suggest that chlorophyll biosynthesis is subject to chloroplast biogenesis regulation networks to coordinate them with the photosynthetic pathways in chloroplasts.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Japan Sci & Technol Corp, ATP Syst Project, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Univ Tokyo, Grad Sch Arts & Sci, Tokyo 153, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Tokyo Institute of Technology; University of Tokyo	Masuda, T (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan.	ctmasuda@mail.ecc.u-tokyo.ac.jp	Masuda, Tatsuru/E-7942-2013; Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Masuda, Tatsuru/0000-0002-1585-5832; Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; Buchanan BB, 2005, ANNU REV PLANT BIOL, V56, P187, DOI 10.1146/annurev.arplant.56.032604.144246; Collin V, 2004, PLANT PHYSIOL, V136, P4088, DOI 10.1104/pp.104.052233; Collin V, 2003, J BIOL CHEM, V278, P23747, DOI 10.1074/jbc.M302077200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fodje MN, 2001, J MOL BIOL, V311, P111, DOI 10.1006/jmbi.2001.4834; FUESLER T P, 1984, Plant Physiology (Rockville), V74, P928; FUESLER TP, 1984, PLANT PHYSIOL, V75, P662, DOI 10.1104/pp.75.3.662; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; Gelhaye E, 2005, CELL MOL LIFE SCI, V62, P24, DOI 10.1007/s00018-004-4296-4; Gibson LCD, 1999, BIOCHEM J, V337, P243, DOI 10.1042/0264-6021:3370243; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; Gibson LCD, 1996, PLANT PHYSIOL, V111, P61, DOI 10.1104/pp.111.1.61; GLAZER AN, 1975, CHEM MODIFICATION PR, P21; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; Hisabori T, 2005, J EXP BOT, V56, P1463, DOI 10.1093/jxb/eri170; Hosoya-Matsuda N, 2005, J BIOL CHEM, V280, P840, DOI 10.1074/jbc.M411493200; Jensen PE, 2000, BIOCHEM J, V352, P435, DOI 10.1042/0264-6021:3520435; Jensen PE, 1999, BIOCHEM J, V339, P127, DOI 10.1042/0264-6021:3390127; Jensen PE, 1996, MOL GEN GENET, V250, P383; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; KONCZ C, 1990, EMBO J, V9, P1337, DOI 10.1002/j.1460-2075.1990.tb08248.x; Larkin RM, 2003, SCIENCE, V299, P902, DOI 10.1126/science.1079978; Matsumoto F, 2004, PLANT PHYSIOL, V135, P2379, DOI 10.1104/pp.104.042408; Meyer Y, 2005, PHOTOSYNTH RES, V86, P419, DOI 10.1007/s11120-005-5220-y; Mochizuki N, 2001, P NATL ACAD SCI USA, V98, P2053, DOI 10.1073/pnas.98.4.2053; Motohashi K, 2003, J BIOL CHEM, V278, P31848, DOI 10.1074/jbc.M304258200; Motohashi K, 1997, FEBS LETT, V412, P633, DOI 10.1016/S0014-5793(97)00847-8; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Motohashi K, 2006, J BIOL CHEM, V281, P35039, DOI 10.1074/jbc.M605938200; Nakayama M, 1998, PLANT CELL PHYSIOL, V39, P275, DOI 10.1093/oxfordjournals.pcp.a029368; NAKAYAMA M, 1995, BIOCHEM BIOPH RES CO, V215, P422, DOI 10.1006/bbrc.1995.2481; Neuwald AF, 1999, GENOME RES, V9, P27; Papenbrock J, 1997, PLANT J, V12, P981, DOI 10.1046/j.1365-313X.1997.12050981.x; Reid JD, 2003, BIOCHEMISTRY-US, V42, P6912, DOI 10.1021/bi034082q; Reid JD, 2004, J BIOL CHEM, V279, P26893, DOI 10.1074/jbc.M400958200; Rissler HM, 2002, PLANT PHYSIOL, V128, P770, DOI [10.1104/pp.010625, 10.1104/pp0010625]; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALKER CJ, 1991, P NATL ACAD SCI USA, V88, P5789, DOI 10.1073/pnas.88.13.5789; WALKER CJ, 1991, PLANT PHYSIOL, V95, P1189, DOI 10.1104/pp.95.4.1189; Willows RD, 1996, EUR J BIOCHEM, V235, P438, DOI 10.1111/j.1432-1033.1996.00438.x; Yano H, 2001, P NATL ACAD SCI USA, V98, P4794, DOI 10.1073/pnas.071041998	45	109	116	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19282	19291		10.1074/jbc.M703324200	http://dx.doi.org/10.1074/jbc.M703324200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17472958	hybrid			2022-12-25	WOS:000247650600003
J	Brusselmans, K; Timmermans, L; Van de Sande, T; Van Veldhoven, PP; Guan, GM; Shechter, I; Claessens, F; Verhoeven, G; Swinnen, JV				Brusselmans, Koen; Timmermans, Leen; Van de Sande, Tine; Van Veldhoven, Paul P.; Guan, Guimin; Shechter, Ishaiahu; Claessens, Frank; Verhoeven, Guido; Swinnen, Johannes V.			Squalene synthase, a determinant of raft-associated cholesterol and modulator of cancer cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; LOVASTATIN-INDUCED APOPTOSIS; LIPOGENIC GENE-EXPRESSION; LIPID RAFTS; PROTEIN GERANYLGERANYLATION; TRANSCRIPTIONAL REGULATION; SEQUENCE ELEMENTS; INHIBITION; GROWTH; ANDROGENS	Several cues for cell proliferation, migration, and survival are transmitted through lipid rafts, membrane microdomains enriched in sphingolipids and cholesterol. Cells obtain cholesterol from the circulation but can also synthesize cholesterol de novo through the mevalonate/ isoprenoid pathway. This pathway, however, has several branches and also produces non-sterol isoprenoids. Squalene synthase (SQS) is the enzyme that determines the switch toward sterol biosynthesis. Here we demonstrate that in prostate cancer cells SQS expression is enhanced by androgens, channeling intermediates of the mevalonate/ isoprenoid pathway toward cholesterol synthesis. Interestingly, the resulting increase in de novo synthesis of cholesterol mainly affects the cholesterol content of lipid rafts, while leaving non-raft cholesterol levels unaffected. Conversely, RNA interference-mediated SQS inhibition results in a decrease of raft-associated cholesterol. These data show that SQS activity and de novo cholesterol synthesis are determinants of membrane microdomain-associated cholesterol in cancer cells. Remarkably, SQS knock down also attenuates proliferation and induces death of prostate cancer cells. Similar effects are observed when cancer cells are treated with the chemical SQS inhibitor zaragozic acid A. Importantly, although the anti-tumor effect of statins has previously been attributed to inhibition of protein isoprenylation, the present study shows that specific inhibition of the cholesterol biosynthesis branch of the mevalonate/isoprenoid pathway also induces cancer cell death. These findings significantly underscore the importance of de novo cholesterol synthesis for cancer cell biology and suggest that SQS is a potential novel target for antineoplastic intervention.	LEGENDO, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Mol Cell Biol, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Div Pharmacol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Div Biochem, B-3000 Louvain, Belgium; Uniformed Serv Univ Hlth Sci, Sch Med, Dept Surg, Bethesda, MD 20814 USA	KU Leuven; KU Leuven; KU Leuven; KU Leuven; Uniformed Services University of the Health Sciences - USA	Swinnen, JV (corresponding author), LEGENDO, Herestr 49,bos 902, B-3000 Louvain, Belgium.	Johan.Swinnen@med.kuleuven.be	, Van Veldhoven Paul/U-6359-2019; Claessens, Frank/M-8565-2016; Swinnen, Johannes V/AAA-2214-2022	, Van Veldhoven Paul/0000-0002-4478-2564; Claessens, Frank/0000-0002-8676-7709; Swinnen, Johannes V/0000-0002-7720-5077				Andela VB, 2003, CLIN ORTHOP RELAT R, pS59, DOI 10.1097/01.blo.0000093846.72468.66; Bang B, 2005, EXP DERMATOL, V14, P266, DOI 10.1111/j.0906-6705.2005.00283.x; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; Bosland M C, 2000, J Natl Cancer Inst Monogr, P39; BROWN MS, 1973, FED PROC, V32, P2168; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Brusselmans K, 2003, INT J CANCER, V106, P856, DOI 10.1002/ijc.11317; De Schrijver E, 2003, CANCER RES, V63, P3799; Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; Guan GM, 1997, J BIOL CHEM, V272, P10295; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HAEFFNER EW, 1984, CANCER RES, V44, P2668; Hager MH, 2006, CURR OPIN CLIN NUTR, V9, P379, DOI 10.1097/01.mco.0000232896.66791.62; Hancock JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Heemers HV, 2006, MOL ENDOCRINOL, V20, P2265, DOI 10.1210/me.2005-0479; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Khanzada UK, 2006, ONCOGENE, V25, P877, DOI 10.1038/sj.onc.1209117; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; Marcelli M, 1998, CANCER RES, V58, P76; Marques RB, 2005, INT J CANCER, V117, P221, DOI 10.1002/ijc.21201; Muck AO, 2004, INT J CLIN PHARM TH, V42, P695; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; Sato R, 1995, CELL STRUCT FUNCT, V20, P421, DOI 10.1247/csf.20.421; Sebti SM, 2005, CANCER CELL, V7, P297, DOI 10.1016/j.ccr.2005.04.005; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SPECTOR AA, 1985, J LIPID RES, V26, P1015; SUMI S, 1992, GASTROENTEROLOGY, V103, P982, DOI 10.1016/0016-5085(92)90032-T; Swinnen JV, 2004, J STEROID BIOCHEM, V92, P273, DOI 10.1016/j.jsbmb.2004.10.013; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Swinnen JV, 2003, BIOCHEM BIOPH RES CO, V302, P898, DOI 10.1016/S0006-291X(03)00265-1; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; Swinnen JV, 1997, CANCER RES, V57, P1086; Tansey TR, 2000, BBA-MOL CELL BIOL L, V1529, P49, DOI 10.1016/S1388-1981(00)00137-2; Ukomadu C, 2003, J BIOL CHEM, V278, P43586, DOI 10.1074/jbc.M307194200; Willard NR, 2002, CELL MOL LIFE SCI, V59, P1771, DOI 10.1007/PL00012505; Xia Z, 2001, LEUKEMIA, V15, P1398, DOI 10.1038/sj.leu.2402196; Zhong WB, 2003, ENDOCRINOLOGY, V144, P3852, DOI 10.1210/en.2003-0098; Zhuang LY, 2005, J CLIN INVEST, V115, P959	49	77	80	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18777	18785		10.1074/jbc.M611763200	http://dx.doi.org/10.1074/jbc.M611763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17483544	hybrid			2022-12-25	WOS:000247475300016
J	Lundberg, P; Allison, SJ; Lee, NJ; Baldock, PA; Brouard, N; Rost, S; Enriquez, RF; Sainsbury, A; Lamghari, M; Simmons, P; Eisman, JA; Gardiner, EM; Herzog, H				Lundberg, Pernilla; Allison, Susan J.; Lee, Nicola J.; Baldock, Paul A.; Brouard, Nathalie; Rost, Stephanie; Enriquez, Ronaldo F.; Sainsbury, Amanda; Lamghari, Meriem; Simmons, Paul; Eisman, John A.; Gardiner, Edith M.; Herzog, Herbert			Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; MOUSE CALVARIAL OSTEOBLASTS; BETA-ADRENERGIC RECEPTORS; MARROW STROMAL CELLS; GENE-RELATED PEPTIDE; NEUROPEPTIDE-Y; TYROSINE-HYDROXYLASE; OSTEOGENIC CELLS; MESSENGER-RNAS; SUBSTANCE-P	Germ line or hypothalamus-specific deletion of Y2 receptors in mice results in a doubling of trabecular bone volume. However, the specific mechanism by which deletion of Y2 receptors increases bone mass has not yet been identified. Here we show that cultured adherent bone marrow stromal cells from Y2(-/-) mice also demonstrate increased mineralization in vitro. Isolation of two populations of progenitor cell types, an immature mesenchymal stem cell population and a more highly differentiated population of progenitor cells, revealed a greater number of the progenitor cells within the bone of Y2(-/-) mice. Analysis of Y receptor transcripts in cultured stromal cells from wild-type mice revealed high levels of Y1 but not Y2, Y4, Y5, or y6 receptor mRNA. Interestingly, germ line Y2 receptor deletion causes Y1 receptor down-regulation in stromal cells and bone tissue possibly due to the lack of feedback inhibition of NPY release and subsequent overstimulation of Y1 receptors. Furthermore, deletion of Y1 receptors resulted in increased bone mineral density in mice. Together, these findings indicate that the greater number of mesenchymal progenitors and the altered Y1 receptor expression within bone cells in the absence of Y2 receptors are a likely mechanism for the greater bone mineralization in vivo and in vitro, opening up potential new treatment avenues for osteoporosis.	St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, Darlinghurst, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, Bone & Mineral Res Program, Darlinghurst, NSW 2010, Australia; Peter MacCallum Canc Inst, Stem Cell Res Lab, Melbourne, Vic 8006, Australia; Univ Queensland, Princess Alexandra Hosp, Diamantina, Brisbane, Qld 4102, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Peter Maccallum Cancer Center; University of Queensland	Lundberg, P (corresponding author), Umea Univ, Dept Odontol, Sect Oral Cell Biol, S-90187 Umea, Sweden.	pernilla.lundberg@odont.umu.se; h.herzog@garvan.org.au	Lamghari, Meriem/K-2159-2013; Baldock, Paul/B-3840-2012; Herzog, Herbert/B-8294-2008; /E-2900-2010; /B-2038-2013; Salis, Amanda/A-3187-2011; Eisman, John A/C-2886-2014	Lamghari, Meriem/0000-0002-2500-4548; /0000-0001-7766-6095; Salis, Amanda/0000-0001-9176-1574; , Herbert/0000-0002-1713-1029				AHMED M, 1994, REGUL PEPTIDES, V51, P179, DOI 10.1016/0167-0115(94)90063-9; AHMED M, 1993, SPINE, V18, P268, DOI 10.1097/00007632-199302000-00016; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Baldock PA, 2005, J BONE MINER RES, V20, P1851, DOI 10.1359/JBMR.050523; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200; Baldock PA, 2006, J BONE MINER RES, V21, P1600, DOI 10.1359/JBMR.060705; BERESFORD JN, 1992, J CELL SCI, V102, P341; BJURHOLM A, 1991, INT ORTHOP, V15, P325; BJURHOLM A, 1992, J BONE MINER RES, V7, P1011; BJURHOLM A, 1988, J AUTONOM NERV SYST, V25, P119, DOI 10.1016/0165-1838(88)90016-1; Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100; Bradfute SB, 2005, EXP HEMATOL, V33, P836, DOI 10.1016/j.exphem.2005.04.001; Cornish J, 1999, J BONE MINER RES, V14, P1302, DOI 10.1359/jbmr.1999.14.8.1302; Denes A, 2005, NEUROSCIENCE, V134, P947, DOI 10.1016/j.neuroscience.2005.03.060; ERICSSON A, 1987, P NATL ACAD SCI USA, V84, P5585, DOI 10.1073/pnas.84.16.5585; Goto T, 1998, CELL TISSUE RES, V293, P87, DOI 10.1007/s004410051100; HILL EL, 1991, NEUROSCIENCE, V44, P747, DOI 10.1016/0306-4522(91)90094-5; Howell OW, 2003, J NEUROCHEM, V86, P646, DOI 10.1046/j.1471-4159.2003.01895.x; Ito CY, 2003, BLOOD, V101, P517, DOI 10.1182/blood-2002-06-1918; Kellenberger S, 1998, BONE, V22, P471, DOI 10.1016/S8756-3282(98)00026-X; King PJ, 2000, EUR J PHARMACOL, V396, pR1, DOI 10.1016/S0014-2999(00)00230-2; Kitano Y, 2000, EXP HEMATOL, V28, P1460, DOI 10.1016/S0301-472X(00)00551-8; Lin S, 2005, NEUROPEPTIDES, V39, P21, DOI 10.1016/j.npep.2004.10.002; LINDBLAD BE, 1994, ACTA ORTHOP SCAND, V65, P629, DOI 10.3109/17453679408994619; Lundberg P, 1999, REGUL PEPTIDES, V85, P47, DOI 10.1016/S0167-0115(99)00069-5; Lundberg P, 2000, BONE, V27, P803, DOI 10.1016/S8756-3282(00)00394-X; Lundberg P, 2001, ENDOCRINOLOGY, V142, P339, DOI 10.1210/en.142.1.339; Miura Y, 2005, P NATL ACAD SCI USA, V102, P14022, DOI 10.1073/pnas.0409397102; MOORE RE, 1993, BONE MINER, V23, P301, DOI 10.1016/S0169-6009(08)80105-5; Mori T, 1999, BIOCHEM BIOPH RES CO, V262, P418, DOI 10.1006/bbrc.1999.1220; MULLINS MW, 1993, REGUL PEPTIDES, V49, P65, DOI 10.1016/0167-0115(93)90385-L; Nuttall ME, 1998, J BONE MINER RES, V13, P371, DOI 10.1359/jbmr.1998.13.3.371; Parker RMC, 1999, EUR J NEUROSCI, V11, P1431, DOI 10.1046/j.1460-9568.1999.00553.x; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Sainsbury A, 2003, MOL CELL BIOL, V23, P5225, DOI 10.1128/MCB.23.15.5225-5233.2003; Sainsbury A, 2002, P NATL ACAD SCI USA, V99, P8938, DOI 10.1073/pnas.132043299; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007; Sisask G, 1996, J AUTONOM NERV SYST, V59, P27, DOI 10.1016/0165-1838(95)00139-5; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Togari A, 1997, NEUROSCI LETT, V233, P125, DOI 10.1016/S0304-3940(97)00649-6; VANVLASSELAER P, 1994, BLOOD, V84, P753, DOI 10.1182/blood.V84.3.753.bloodjournal843753; Wieczorek G, 2003, CELL TISSUE RES, V311, P227, DOI 10.1007/s00441-002-0671-3	46	114	125	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19082	19091		10.1074/jbc.M609629200	http://dx.doi.org/10.1074/jbc.M609629200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17491022	Green Published, hybrid			2022-12-25	WOS:000247475300050
J	Shukla, K; Kim, J; Blundell, J; Powell, CM				Shukla, Kajal; Kim, James; Blundell, Jacqueline; Powell, Craig M.			Learning-induced glutamate receptor phosphorylation resembles that induced by long term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY FRACTION; DEPENDENT PROTEIN-KINASE; SYNAPTIC PLASTICITY; AMPA RECEPTORS; GLUR1 SUBUNIT; MICE LACKING; REGULATORY PHOSPHORYLATION; FIELD POTENTIALS; RAT FOREBRAIN; MUTANT MICE	Long term potentiation and long term depression of synaptic responses in the hippocampus are thought to be critical for certain forms of learning and memory, although until recently it has been difficult to demonstrate that long term potentiation or long term depression occurs during hippocampus-dependent learning. Induction of long term potentiation or long term depression in hippocampal slices in vitro modulates phosphorylation of the alpha-amino-3-hydrozy-5-methylisoxazole-4-propionic acid subtype of glutamate receptor subunit GluR1 at distinct phosphorylation sites. In long term potentiation, GluR1 phosphorylation is increased at the Ca2+/calmodulin-dependent protein kinase and protein kinase C site serine 831, whereas in long term depression, phosphorylation of the protein kinase A site serine 845 is decreased. Indeed, phosphorylation of one or both of these sites is required for long term synaptic plasticity and for certain forms of learning and memory. Here we demonstrate that training in a hippocampus-dependent learning task, contextual fear conditioning is associated with increased phosphorylation of GluR1 at serine 831 in the hippocampal formation. This increased phosphorylation is specific to learning, has a similar time course to that in long term potentiation, and like memory and long term potentiation, is dependent on N-methyl-D- aspartate receptor activation during training. Furthermore, the learning-induced increase in serine 831 phosphorylation is present at synapses and is in heteromeric complexes with the glutamate receptor subunit GluR2. These data indicate that a biochemical correlate of long term potentiation occurs at synapses in receptor complexes in a final, downstream, postsynaptic effector of long term potentiation during learning in vivo, further strengthening the link between long term potentiation and memory.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Powell, CM (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	craig.powell@utsouthwestern.edu		Powell, Craig/0000-0001-5451-2165	NIMH NIH HHS [K08 MH065975-03, K08 MH065975-04, K08 MH065975, MH65975, K08 MH065975-05] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH065975] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; Andersen P, 1996, J PHYSIOLOGY-PARIS, V90, P349, DOI 10.1016/S0928-4257(97)87917-X; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; BANNERMAN DM, 1994, J NEUROSCI, V14, P7404; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bevilaqua LR, 2005, NEUROSCIENCE, V136, P397, DOI 10.1016/j.neuroscience.2005.08.007; Boehm J, 2005, BIOCHEM SOC T, V33, P1354, DOI 10.1042/BST0331354; Bordi F, 1996, NEUROPHARMACOLOGY, V35, P1557, DOI 10.1016/S0028-3908(96)00101-3; Cammarota M, 1998, EUR J NEUROSCI, V10, P2669, DOI 10.1046/j.1460-9568.1998.t01-1-00254.x; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; Chen XB, 2005, P NATL ACAD SCI USA, V102, P11551, DOI 10.1073/pnas.0505359102; Cheng DM, 2006, MOL CELL PROTEOMICS, V5, P1158, DOI 10.1074/mcp.D500009-MCP200; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREEN EJ, 1990, J NEUROSCI, V10, P1455; GREEN EJ, 1986, J NEUROPHYSIOL, V55, P739, DOI 10.1152/jn.1986.55.4.739; Gu YH, 2002, J NEUROSCI, V22, P2753, DOI 10.1523/JNEUROSCI.22-07-02753.2002; Hall J, 2000, NAT NEUROSCI, V3, P533, DOI 10.1038/75698; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YY, 2005, P NATL ACAD SCI USA, V102, P9365, DOI 10.1073/pnas.0503777102; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Hunt CA, 1996, J NEUROSCI, V16, P1380; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Jouvenceau A, 2003, EUR J NEUROSCI, V18, P1279, DOI 10.1046/j.1460-9568.2003.02831.x; Jun KS, 1998, LEARN MEMORY, V5, P317; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; Kjoller C, 2000, NEUROCHEM INT, V37, P7, DOI 10.1016/S0197-0186(00)00008-5; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; Ling DSF, 2002, NAT NEUROSCI, V5, P295, DOI 10.1038/nn829; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Malinow R, 2003, PHILOS T ROY SOC B, V358, P707, DOI 10.1098/rstb.2002.1233; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; Matynia A, 2002, ANNU REV GENET, V36, P687, DOI 10.1146/annurev.genet.36.062802.091007; Mayford M, 1997, CURR BIOL, V7, pR580, DOI 10.1016/S0960-9822(06)00287-9; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P563; Meiri N, 1998, P NATL ACAD SCI USA, V95, P15037, DOI 10.1073/pnas.95.25.15037; Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; MITSUNO K, 1994, PHYSIOL BEHAV, V55, P633, DOI 10.1016/0031-9384(94)90037-X; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; Moser EI, 1998, SCIENCE, V281, P2038, DOI 10.1126/science.281.5385.2038; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Norman ED, 2000, J NEUROCHEM, V74, P192, DOI 10.1046/j.1471-4159.2000.0740192.x; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; Oh MC, 2006, J BIOL CHEM, V281, P752, DOI 10.1074/jbc.M509677200; Oh MC, 2005, NAT NEUROSCI, V8, P853, DOI 10.1038/nn1476; Otmakhova NA, 2000, J NEUROSCI, V20, P4446, DOI 10.1523/JNEUROSCI.20-12-04446.2000; Pavlov I, 2002, MOL CELL NEUROSCI, V20, P330, DOI 10.1006/mcne.2002.1104; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Powell CM, 2004, NEURON, V42, P143, DOI 10.1016/S0896-6273(04)00146-1; POWELL CM, 1994, J BIOL CHEM, V269, P27958; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Shapiro ML, 1999, HIPPOCAMPUS, V9, P365, DOI 10.1002/(SICI)1098-1063(1999)9:4<365::AID-HIPO4>3.3.CO;2-K; SHARP PE, 1985, BRAIN RES, V339, P361, DOI 10.1016/0006-8993(85)90105-2; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, COLD SPRING HARB SYM, V57, P527, DOI 10.1101/SQB.1992.057.01.058; Soderling TR, 1996, NEUROCHEM INT, V28, P359, DOI 10.1016/0197-0186(95)00098-4; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Song I, 2002, TRENDS NEUROSCI, V25, P578, DOI 10.1016/S0166-2236(02)02270-1; Sweatt JD, 2001, CURR BIOL, V11, pR391, DOI 10.1016/S0960-9822(01)00216-0; Sweatt JD, 1999, LEARN MEMORY, V6, P399, DOI 10.1101/lm.6.5.399; Sweatt JD, 2003, MECH MEMORY; Thiels E, 2000, J NEUROSCI, V20, P7199; Tonegawa S, 1996, COLD SPRING HARB SYM, V61, P225; Villacres EC, 1998, J NEUROSCI, V18, P3186; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Walther T, 1998, J BIOL CHEM, V273, P11867, DOI 10.1074/jbc.273.19.11867; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805	97	18	20	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18100	18107		10.1074/jbc.M702906200	http://dx.doi.org/10.1074/jbc.M702906200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17472959	hybrid, Green Accepted			2022-12-25	WOS:000247302000016
J	Tian, C; Chikayama, E; Tsuboi, Y; Kuromori, T; Shinozaki, K; Kikuchi, J; Hirayama, T				Tian, Chunjie; Chikayama, Eisuke; Tsuboi, Yuuri; Kuromori, Takashi; Shinozaki, Kazuo; Kikuchi, Jun; Hirayama, Takashi			Top-down phenomics of Arabidopsis thaliana - Metabolic profiling by one- and two-dimensional nuclear magnetic resonance spectroscopy and transcriptome analysis of albino mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMICS; NONMEVALONATE PATHWAY; GENE-EXPRESSION; DRAFT SEQUENCE; NITROGEN; BIOSYNTHESIS; CYTOKININ; REVEALS; SYSTEMS; LEAVES	Elucidating the function of each gene in a genome is important for understanding the whole organism. We previously constructed 4000 disruptant mutants of Arabidopsis by insertion of Ds transposons. Here, we describe a top-down phenomics approach based on metabolic profiling that uses one-dimensional H-1 and two-dimensional H-1, C-13 NMR analyses and transcriptome analysis of albino mutant lines of Arabidopsis. One-dimensional H-1 NMR metabolic fingerprinting revealed global metabolic changes in the albino mutants, notably a decrease in aromatic metabolites and changes in aliphatic metabolites. NMRmeasurements of plants fed with C-13(6)-glucose showed that the albino lines had dramatically different C-13-labeling patterns and increased levels of several (am)ino acids, especially Asn and Gln. Microarray analysis of one of the albino lines revealed a unique expression profile and showed that changes in the expression of genes encoding metabolic enzymes did not correspond with changes in the levels of metabolites. Collectively, these results suggest that albino mutants lose the normal carbon/nitrogen balance, presumably mainly through lack ofphotosynthesis. Our study offers an idea of how much the metabolite network is affected by chloroplast function in plants and shows the effectiveness of NMR-based metabolic analysis for metabolite profiling. On the basis of these findings, we propose that future investigations of plant systems biology combine transcriptomic, metabolomic, and phenomic analyses of gene disruptant lines.	RIKEN, Wako Inst, Lab Environm Mol Biol, Wako, Saitama 351, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2300045, Japan; RIKEN, Plant Sci Ctr, Gene Discovery Res Grp, Yokohama, Kanagawa 230, Japan; CREST, Japan Sci & Technol Agcy, Kawaguchi 3320012, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 464, Japan	RIKEN; Yokohama City University; RIKEN; Japan Science & Technology Agency (JST); Nagoya University	Kikuchi, J (corresponding author), RIKEN, Yokohama Inst, 1-7-22 Suehiro, Yokohama, Kanagawa 2300045, Japan.	kikuchi@psc.riken.jp; hirayama@gsc.riken.jp	HIRAYAMA, Takashi/B-2496-2011; Kuromori, Takashi/G-7862-2013; Kikuchi, Jun/O-4725-2019; Shinozaki, Kazuo/G-4202-2013; Kikuchi, Jun/M-5512-2015	HIRAYAMA, Takashi/0000-0002-3868-2380; Kuromori, Takashi/0000-0003-3232-7262; Kikuchi, Jun/0000-0002-6809-394X; Shinozaki, Kazuo/0000-0002-6317-9867; Kikuchi, Jun/0000-0002-6809-394X				Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Allen J, 2003, NAT BIOTECHNOL, V21, P692, DOI 10.1038/nbt823; Alonso JM, 2006, NAT REV GENET, V7, P524, DOI 10.1038/nrg1893; Bi YM, 2005, PLANT J, V44, P680, DOI 10.1111/j.1365-313X.2005.02568.x; Blasing OE, 2005, PLANT CELL, V17, P3257, DOI 10.1105/tpc.105.035261; Coruzzi GM, 2001, CURR OPIN PLANT BIOL, V4, P247, DOI 10.1016/S1369-5266(00)00168-0; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deuschle K, 2001, PLANT J, V27, P345, DOI 10.1046/j.1365-313X.2001.01101.x; Dixon RA, 2006, J AGR FOOD CHEM, V54, P8984, DOI 10.1021/jf061218t; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; Fellermeier M, 2001, EUR J BIOCHEM, V268, P6302, DOI 10.1046/j.0014-2956.2001.02585.x; Fong SS, 2004, NAT GENET, V36, P1056, DOI 10.1038/ng1432; Fritz C, 2006, PLANT CELL ENVIRON, V29, P2055, DOI 10.1111/j.1365-3040.2006.01580.x; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Glawischnig E, 2001, PLANT PHYSIOL, V125, P1178, DOI 10.1104/pp.125.3.1178; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; Hirai MY, 2004, P NATL ACAD SCI USA, V101, P10205, DOI 10.1073/pnas.0403218101; Hsieh MH, 2006, PLANTA, V223, P779, DOI 10.1007/s00425-005-0140-9; Hsieh MH, 2005, PLANT PHYSIOL, V138, P641, DOI 10.1104/pp.104.058735; Hughes TR, 2004, CURR OPIN MICROBIOL, V7, P546, DOI 10.1016/j.mib.2004.08.015; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Ishii N, 2005, METABOLOMICS, V1, P29, DOI 10.1007/s11306-005-1105-5; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Kaiser WM, 2000, PLANTA, V210, P801, DOI 10.1007/s004250050682; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kikuchi J, 2006, BIOTECH AGR FOREST, V57, P93; Kikuchi J, 2004, PLANT CELL PHYSIOL, V45, P1099, DOI 10.1093/pcp/pch117; KIKUCHI J, 2006, METABOLOMICS METHODS, P273; Kolbe A, 2006, PLANT PHYSIOL, V141, P412, DOI 10.1104/pp.106.081208; Kuromori T, 2004, PLANT J, V37, P897, DOI 10.1111/j.1365.313X.2004.02009.x; Kuromori T, 2006, PLANT J, V47, P640, DOI 10.1111/j.1365-313X.2006.02808.x; LAM HM, 1995, PLANT CELL, V7, P887, DOI 10.1105/tpc.7.7.887; Lawlor DW, 2002, J EXP BOT, V53, P773, DOI 10.1093/jexbot/53.370.773; Liang YS, 2006, PHYTOCHEMISTRY, V67, P2503, DOI 10.1016/j.phytochem.2006.08.018; Morgenthal K, 2006, BIOSYSTEMS, V83, P108, DOI 10.1016/j.biosystems.2005.05.017; Mori H, 2004, J BIOCHEM MOL BIOL, V37, P83; Muskett PR, 2003, PLANT PHYSIOL, V132, P506, DOI 10.1104/pp.102.016535; Oliver SG, 2006, PHILOS T R SOC B, V361, P477, DOI 10.1098/rstb.2005.1805; Oswald O, 2001, P NATL ACAD SCI USA, V98, P2047, DOI 10.1073/pnas.021449998; Pfalz J, 2006, PLANT CELL, V18, P176, DOI 10.1105/tpc.105.036392; Raamsdonk LM, 2001, NAT BIOTECHNOL, V19, P45, DOI 10.1038/83496; Rastogi R, 1997, PLANT MOL BIOL, V34, P465, DOI 10.1023/A:1005842812321; Ratcliffe RG, 2001, ANNU REV PLANT PHYS, V52, P499, DOI 10.1146/annurev.arplant.52.1.499; Ratcliffe RG, 2006, PLANT J, V45, P490, DOI 10.1111/j.1365-313X.2005.02649.x; Roberts JKM, 2000, TRENDS PLANT SCI, V5, P30, DOI 10.1016/S1360-1385(99)01515-0; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sakakibara H, 2006, TRENDS PLANT SCI, V11, P440, DOI 10.1016/j.tplants.2006.07.004; Sasaki T, 2002, NATURE, V420, P312, DOI 10.1038/nature01184; Scheible WR, 2004, PLANT PHYSIOL, V136, P2483, DOI 10.1104/pp.104.047019; SEKIYAMA Y, 2007, IN PRESS PHYTOCHEMIS; Sherameti I, 2002, J BIOL CHEM, V277, P46594, DOI 10.1074/jbc.M202924200; Smith D, 1996, PLANT J, V10, P721, DOI 10.1046/j.1365-313X.1996.10040721.x; Sriram G, 2004, PLANT PHYSIOL, V136, P3043, DOI 10.1104/pp.104.050625; Stitt M, 2002, J EXP BOT, V53, P959, DOI 10.1093/jexbot/53.370.959; Sweetlove LJ, 2003, PLANT PHYSIOL, V132, P420, DOI 10.1104/pp.103.022004; Takei K, 2004, PLANT CELL PHYSIOL, V45, P1053, DOI 10.1093/pcp/pch119; Takei K, 2001, PLANT CELL PHYSIOL, V42, P85, DOI 10.1093/pcp/pce009; Thiele I, 2005, J BACTERIOL, V187, P5818, DOI 10.1128/JB.187.16.5818-5830.2005; Thiele I, 2005, J BIOL CHEM, V280, P11683, DOI 10.1074/jbc.M409072200; Thimm O, 2004, PLANT J, V37, P914, DOI 10.1111/j.1365-313X.2004.02016.x; Verbruggen N, 1996, P NATL ACAD SCI USA, V93, P8787, DOI 10.1073/pnas.93.16.8787; Wagner A, 2001, P ROY SOC B-BIOL SCI, V268, P1803, DOI 10.1098/rspb.2001.1711; Ward JL, 2003, PHYTOCHEMISTRY, V62, P949, DOI 10.1016/S0031-9422(02)00705-7; Weckwerth W, 2003, ANNU REV PLANT BIOL, V54, P669, DOI 10.1146/annurev.arplant.54.031902.135014; Wettenhall JM, 2006, BIOINFORMATICS, V22, P897, DOI 10.1093/bioinformatics/btl025; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037	68	46	51	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18532	18541		10.1074/jbc.M700549200	http://dx.doi.org/10.1074/jbc.M700549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17468106	hybrid			2022-12-25	WOS:000247302000058
J	Jack, AI; Patel, GH; Astafiev, SV; Snyder, AZ; Akbudak, E; Shulman, GL; Corbetta, M				Jack, Anthony I.; Patel, Gaurav H.; Astafiev, Serguei V.; Snyder, Abraham Z.; Akbudak, Erbil; Shulman, Gordon L.; Corbetta, Maurizio			Changing Human Visual Field Organization from Early Visual to Extra-Occipital Cortex	PLOS ONE			English	Article							LATERAL INTRAPARIETAL AREA; POSTERIOR PARIETAL CORTEX; FRONTAL EYE FIELDS; SPATIAL ATTENTION; RETINOTOPIC ORGANIZATION; TOPOGRAPHIC ORGANIZATION; MACAQUE MONKEYS; CORTICAL AREA; MAPS; REPRESENTATION	Background. The early visual areas have a clear topographic organization, such that adjacent parts of the cortical surface represent distinct yet adjacent parts of the contralateral visual field. We examined whether cortical regions outside occipital cortex show a similar organization. Methodology/Principal Findings. The BOLD responses to discrete visual field locations that varied in both polar angle and eccentricity were measured using two different tasks. As described previously, numerous occipital regions are both selective for the contralateral visual field and show topographic organization within that field. Extra-occipital regions are also selective for the contralateral visual field, but possess little ( or no) topographic organization. A regional analysis demonstrates that this weak topography is not due to increased receptive field size in extra-occipital areas. Conclusions/Significance. A number of extra-occipital areas are identified that are sensitive to visual field location. Neurons in these areas corresponding to different locations in the contralateral visual field do not demonstrate any regular or robust topographic organization, but appear instead to be intermixed on the cortical surface. This suggests a shift from processing that is predominately local in visual space, in occipital areas, to global, in extra-occipital areas. Global processing fits with a role for these extra-occipital areas in selecting a spatial locus for attention and/or eye-movements.	[Jack, Anthony I.; Patel, Gaurav H.; Astafiev, Serguei V.; Snyder, Abraham Z.; Akbudak, Erbil; Shulman, Gordon L.; Corbetta, Maurizio] Washington Univ, Sch Med, St Louis, MO 63130 USA	Washington University (WUSTL)	Corbetta, M (corresponding author), Washington Univ, Sch Med, St Louis, MO 63130 USA.	mau@npg.wustl.edu	Patel, Gaurav/AAW-3195-2021; Astafiev, Serguei/A-9734-2014; Jack, Anthony Ian/AAJ-7153-2021; Corbetta, Maurizio/AAZ-5219-2020; Jack, Anthony/A-8929-2008	Patel, Gaurav/0000-0003-0028-2098; Jack, Anthony Ian/0000-0001-9613-3964; Jack, Anthony/0000-0001-9613-3964; CORBETTA, MAURIZIO/0000-0001-8295-3304; Astafiev, Serguei/0000-0003-3736-7095	National Institutes of Health; National Eye Institute Institutional National Research Service Award [5-T32EY13360-04]; National Institute of Mental Health [R01 MH71920-06]; National Institute of Neurological Disorders and Stroke [R01 NS48013]; NATIONAL EYE INSTITUTE [T32EY013360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH071920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048013] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Eye Institute Institutional National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This investigation was supported by National Institutes of Health, National Eye Institute Institutional National Research Service Award 5-T32EY13360-04, National Institute of Mental Health R01 MH71920-06, National Institute of Neurological Disorders and Stroke R01 NS48013. The authors declare no conflicts of interest.	Arguin M, 2000, NEUROPSYCHOLOGIA, V38, P283, DOI 10.1016/S0028-3932(99)00077-9; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; Beauchamp MS, 2001, NEUROIMAGE, V14, P310, DOI 10.1006/nimg.2001.0788; Ben Hamed S, 2001, EXP BRAIN RES, V140, P127, DOI 10.1007/s002210100785; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; Brett M, 2002, NAT REV NEUROSCI, V3, P243, DOI 10.1038/nrn756; Brewer AA, 2005, NAT NEUROSCI, V8, P1102, DOI 10.1038/nn1507; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; Chklovskii DB, 2004, ANNU REV NEUROSCI, V27, P369, DOI 10.1146/annurev.neuro.27.070203.144226; Claeys KG, 2003, NEURON, V40, P631, DOI 10.1016/S0896-6273(03)00590-7; Constantinidis C, 2001, J NEUROSCI, V21, P3646, DOI 10.1523/JNEUROSCI.21-10-03646.2001; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; Engel SA, 1997, CEREB CORTEX, V7, P181, DOI 10.1093/cercor/7.2.181; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fize D, 2003, J NEUROSCI, V23, P7395; Hadjikhani N, 1998, NAT NEUROSCI, V1, P235, DOI 10.1038/681; Hagler DJ, 2006, NEUROIMAGE, V29, P567, DOI 10.1016/j.neuroimage.2005.08.058; Hasson U, 2002, NEURON, V34, P479, DOI 10.1016/S0896-6273(02)00662-1; Hines RJ, 2002, NEUROPSYCHOLOGIA, V40, P1804, DOI 10.1016/S0028-3932(02)00032-5; Huk AC, 2002, J NEUROSCI, V22, P7195; Koyama M, 2004, NEURON, V41, P795, DOI 10.1016/S0896-6273(04)00047-9; Kraft A, 2005, NEUROIMAGE, V28, P453, DOI 10.1016/j.neuroimage.2005.05.050; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Macaluso E, 2003, CURR BIOL, V13, P990, DOI 10.1016/S0960-9822(03)00377-4; Macaluso E, 2002, CEREB CORTEX, V12, P357, DOI 10.1093/cercor/12.4.357; McLaughlin T, 2005, ANNU REV NEUROSCI, V28, P327, DOI 10.1146/annurev.neuro.28.061604.135714; Medendorp WP, 2006, J NEUROPHYSIOL, V95, P1645, DOI 10.1152/jn.00905.2005; Medendorp WP, 2003, J NEUROSCI, V23, P6209; Merriam EP, 2003, NEURON, V39, P361, DOI 10.1016/S0896-6273(03)00393-3; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; Petit L, 1997, J NEUROPHYSIOL, V77, P3386, DOI 10.1152/jn.1997.77.6.3386; Pitzalis S, 2006, J NEUROSCI, V26, P7962, DOI 10.1523/JNEUROSCI.0178-06.2006; Platt ML, 1998, EXP BRAIN RES, V121, P65, DOI 10.1007/s002210050438; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sawaguchi T, 2001, J NEUROPHYSIOL, V86, P2041, DOI 10.1152/jn.2001.86.4.2041; Schluppeck D, 2005, J NEUROPHYSIOL, V94, P1372, DOI 10.1152/jn.01290.2004; Schluppeck D, 2006, J NEUROSCI, V26, P5098, DOI 10.1523/JNEUROSCI.5330-05.2006; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Sereno MI, 2001, SCIENCE, V294, P1350, DOI 10.1126/science.1063695; Silver MA, 2005, J NEUROPHYSIOL, V94, P1358, DOI 10.1152/jn.01316.2004; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Sommer MA, 2000, J NEUROPHYSIOL, V83, P1979, DOI 10.1152/jn.2000.83.4.1979; STANTON GB, 1995, J COMP NEUROL, V353, P291, DOI 10.1002/cne.903530210; SUZUKI H, 1983, EXP BRAIN RES, V53, P47; Tootell RBH, 1998, NEURON, V21, P1409, DOI 10.1016/S0896-6273(00)80659-5; Tootell RBH, 1998, P NATL ACAD SCI USA, V95, P818, DOI 10.1073/pnas.95.3.818; Tootell RBH, 1997, J NEUROSCI, V17, P7060; Wade AR, 2002, PHILOS T R SOC B, V357, P963, DOI 10.1098/rstb.2002.1108; Yantis S, 2002, NAT NEUROSCI, V5, P995, DOI 10.1038/nn921	52	38	38	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e452	10.1371/journal.pone.0000452	http://dx.doi.org/10.1371/journal.pone.0000452			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505546	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445900011
J	Cusack, MP; Thibert, B; Bredesen, DE; del Rio, G				Cusack, Michael P.; Thibert, Boris; Bredesen, Dale E.; del Rio, Gabriel			Efficient Identification of Critical Residues Based Only on Protein Structure by Network Analysis	PLOS ONE			English	Article							PREDICTION; SITES	Despite the increasing number of published protein structures, and the fact that each protein's function relies on its three-dimensional structure, there is limited access to automatic programs used for the identification of critical residues from the protein structure, compared with those based on protein sequence. Here we present a new algorithm based on network analysis applied exclusively on protein structures to identify critical residues. Our results show that this method identifies critical residues for protein function with high reliability and improves automatic sequence-based approaches and previous network-based approaches. The reliability of the method depends on the conformational diversity screened for the protein of interest. We have designed a web site to give access to this software at http://bis.ifc.unam.mx/jamming/. In summary, a new method is presented that relates critical residues for protein function with the most traversed residues in networks derived from protein structures. A unique feature of the method is the inclusion of the conformational diversity of proteins in the prediction, thus reproducing a basic feature of the structure/function relationship of proteins.	[del Rio, Gabriel] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Bioquim, Mexico City 04510, DF, Mexico; [Bredesen, Dale E.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Cusack, Michael P.; Bredesen, Dale E.] Buck Inst Age Res, Novato, CA USA; [Thibert, Boris] Lab Modelisat & Calcul LMC IMAG, Grenoble, France	Universidad Nacional Autonoma de Mexico; University of California System; University of California San Francisco; Buck Institute for Research on Aging	del Rio, G (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Bioquim, Mexico City 04510, DF, Mexico.	gdelrio@ifc.unam.mx			Glenn Foundation; CoNaCyT [SEP-2004-C01-47399/A-1, PAPIIT IN210705-3]; Macroproyecto UNAM Tecnologias para la Universidad de la Informacion y la Computacion	Glenn Foundation; CoNaCyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Macroproyecto UNAM Tecnologias para la Universidad de la Informacion y la Computacion	The first author, Michael P. Cusack, was supported by a grant from the Glenn Foundation that supports students during summer research. This work was supported in part by three grants to the corresponding author, Gabriel del Rio, CoNaCyT SEP-2004-C01-47399/A-1, PAPIIT IN210705-3 and Macroproyecto UNAM Tecnologias para la Universidad de la Informacion y la Computacion.	Amitai G, 2004, J MOL BIOL, V344, P1135, DOI 10.1016/j.jmb.2004.10.055; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Christendat D, 2000, NAT STRUCT BIOL, V7, P903; del Sol A, 2005, PROTEINS, V58, P672, DOI 10.1002/prot.20348; Devos D, 2000, PROTEINS, V41, P98, DOI 10.1002/1097-0134(20001001)41:1<98::AID-PROT120>3.3.CO;2-J; Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282; Eisenberg D, 2000, NATURE, V405, P823, DOI 10.1038/35015694; Elcock AH, 2001, J MOL BIOL, V312, P885, DOI 10.1006/jmbi.2001.5009; George RA, 2005, P NATL ACAD SCI USA, V102, P12299, DOI 10.1073/pnas.0504833102; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; Mattos C, 1996, NAT BIOTECHNOL, V14, P595, DOI 10.1038/nbt0596-595; Mesa AD, 2003, J MOL BIOL, V326, P1289, DOI 10.1016/S0022-2836(02)01451-1; Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964; Pal D, 2005, STRUCTURE, V13, P121, DOI 10.1016/j.str.2004.10.015; Pazos F, 2004, P NATL ACAD SCI USA, V101, P14754, DOI 10.1073/pnas.0404569101; PHILIPPSEN M, 1997, PRACTICE EXPERIENCE, V9, P1225; POTEETE AR, 1992, PROTEINS, V13, P38, DOI 10.1002/prot.340130104; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; Sadreyev RI, 2006, BMC STRUCT BIOL, V6, DOI 10.1186/1472-6807-6-6; Suhre K, 2004, NUCLEIC ACIDS RES, V32, pW610, DOI 10.1093/nar/gkh368; Thibert B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-213; Thornton JM, 2000, NAT STRUCT BIOL, V7, P991, DOI 10.1038/80784; Vendruscolo M, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.061910; WEISS M, 1999, DATA STRUCTURES ALGO, P291	28	23	23	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e421	10.1371/journal.pone.0000421	http://dx.doi.org/10.1371/journal.pone.0000421			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17502913	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445800003
J	Sundvall, M; Peri, L; Maatta, JA; Tvorogov, D; Paatero, I; Savisalo, M; Silvennoinen, O; Yarden, Y; Elenius, K				Sundvall, M.; Peri, L.; Maatta, J. A.; Tvorogov, D.; Paatero, I.; Savisalo, M.; Silvennoinen, O.; Yarden, Y.; Elenius, K.			Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains	ONCOGENE			English	Article						cancer; gamma-secretase; HER; neuregulin; nuclear shuttling; ubiquitin	GROWTH-FACTOR RECEPTOR; GAMMA-SECRETASE CLEAVAGE; BREAST-CANCER CELLS; TYROSINE KINASE; ESTROGEN-RECEPTOR; ISOFORM; ACTIVATION; PHOSPHORYLATION; TRANSACTIVATION; UBIQUITYLATION	Cleavable isoforms of the ErbB4 receptor tyrosine kinase release a soluble intracellular domain (ICD) that may translocate to the nucleus and regulate signaling. However, ErbB4 gene is alternatively spliced generating CYT-1 and CYT-2 isoforms with different cytoplasmic tails. Here, we addressed whether the two alternative ErbB4 ICDs of either CYT4 (ICD1) or CYT-2 (ICD2) type differ in signaling to the nucleus. Confocal microscopy and extraction of nuclear cell fractions indicated that significantly more ICD2 translocated to the nuclei when compared to ICD1. Unlike the membrane-anchored 80 kDa fragments derived from full-length ErbB4 isoforms, the two ICDs did not differ from each other in metabolic stability or ubiquitylation. However, ICD2 was phosphorylated at tyrosine residues to a higher extent and demonstrated greater in vitro kinase activity than ICDI. Mutating the ATP-binding site within ICD2 kinase domain (ICD2 K751R) blocked its tyrosine phosphorylation and significantly reduced its nuclear translocation. When expressed in the context of full-length ErbB4, ICD2 was also more efficient than ICD1 in promoting transcriptional activation of the STAT5 target gene beta-casein. These findings indicate that the two alternative ICDs of ErbB4 differ in their nuclear accumulation, and that the mechanism involves differential kinase activity but not ubiquitin-regulated ICD stability.	Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Univ Turku, Medicity Res Lab, Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, Turku, Finland; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Clin Microbiol, Tampere, Finland; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Turku Univ, Cent Hosp, Dept Oncol, Turku, Finland	University of Turku; University of Turku; University of Turku; Tampere University; Tampere University; Tampere University Hospital; Weizmann Institute of Science; University of Turku	Elenius, K (corresponding author), Univ Turku, Dept Med Biochem & Mol Biol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021; YARDEN, YOSEF/K-1467-2012; Paatero, Ilkka/A-6391-2009; Paatero, Ilkka/AAE-7542-2019	Elenius, Klaus/0000-0001-5700-0827; Paatero, Ilkka/0000-0001-5926-2396; Maatta, Jorma/0000-0001-8752-6862; Tvorogov, Denis/0000-0002-2009-1347; Sundvall, Maria H/0000-0002-0494-2965				Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Srinivasan R, 2000, CANCER RES, V60, P1483; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397	36	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6905	6914		10.1038/sj.onc.1210501	http://dx.doi.org/10.1038/sj.onc.1210501			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486069				2022-12-25	WOS:000250188400006
J	Evangelisti, C; Tazzari, PL; Riccio, M; Fiume, R; Hozumi, Y; Fala, F; Goto, K; Manzoli, L; Cocco, L; Martelli, AM				Evangelisti, Camilla; Tazzari, Pier Luigi; Riccio, Massimo; Fiume, Roberta; Hozumi, Yasukazu; Fala, Federica; Goto, Kaoru; Manzoli, Lucia; Cocco, Lucio; Martelli, Alberto M.			Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts	FASEB JOURNAL			English	Article						nucleus; lipid-dependent signaling pathways; siRNA; phosphorylated pRB	RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; SKELETAL-MUSCLE DIFFERENTIATION; C-ALPHA; PHOSPHATIDIC-ACID; SWISS 3T3-CELLS; PHOSPHOLIPASE-C; DNA-REPLICATION; SITES; PROLIFERATION; LOCALIZATION	The nucleus contains diacylglycerol kinases ( DGKs), i.e., the enzymes that, by converting diacylglycerol ( DG) into phosphatidic acid, terminate DG-dependent events. It has been demonstrated that nuclear DGK-zeta interferes with cell cycle progression. We previously reported that nuclear DGK-zeta expression increased during myogenic differentiation, whereas its down-regulation impaired differentiation. Here, we evaluated the possible involvement of nuclear DGK-zeta in cell cycle progression of C2C12 myoblasts. Overexpression of a wild-type DGK-zeta, which mainly localized to the nucleus ( but not of a kinase dead mutant or of a mutant that did not enter the nucleus), blocked the cells in the G(1) phase of the cell cycle, as demonstrated by in situ analysis of biotinylated-16-dUTP incorporated into newly synthesized DNA and by flow cytometry. In contrast, down-regulation of endogenous DGK-zeta by short interfering RNA ( siRNA) increased the number of cells in both the S and G(2)/M phases of the cell cycle. Cell cycle arrest of cells overexpressing wild-type DGK-zeta was accompanied by decreased levels of retinoblastoma protein phosphorylated on Ser-807/811. Down-regulation of endogenous DGK-zeta, using siRNA, prevented the cell cycle block characterizing C2C12 cell myogenic differentiation. Overall, our results identify nuclear DGK-zeta as a key determinant of cell cycle progression and differentiation of C2C12 cells. -Evangelisti, C., Tazzari, P. L., Riccio, M., Fiume, R., Hozumi, Y., Fala, F., Goto, K., Manzoli, L., Cocco, L., Martelli, A. M. Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts.	Univ Bologna, Dipartimento Sci Anat Umane & Fisiopatol Apparato, Cell Signaling Lab, Sez Anat, I-40126 Bologna, Italy; Policlin S Orsola Malphigi, Serv Immunoematol & Trasfus, Bologna, Italy; Univ Modena & Reggio Emilia, Dipartimento Anat & Istol, Modena, Italy; Yamagata Univ, Sch Med, Dept Anat & Cell Biol, Yamagata 99023, Japan; IOR, CNR, IGM, Bologna, Italy	University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Universita di Modena e Reggio Emilia; Yamagata University; Consiglio Nazionale delle Ricerche (CNR)	Martelli, AM (corresponding author), Univ Bologna, Dipartimento Sci Anat Umane & Fisiopatol Apparato, Cell Signaling Lab, Sez Anat, Via Irnerio 48, I-40126 Bologna, Italy.	alberto.martelli@unibo.it	Hozumi, Yasukazu/AAO-6439-2020; TAZZARI, PIER LUIGI/HGC-8394-2022; Cocco, Lucio/AAI-2206-2020; Evangelisti, Camilla/C-6977-2019	TAZZARI, PIER LUIGI/0000-0002-8789-657X; Cocco, Lucio/0000-0002-9206-8277; Evangelisti, Camilla/0000-0003-3531-9540; Hozumi, Yasukazu/0000-0002-9102-5419; FIUME, ROBERTA/0000-0001-7757-4000				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; Berezney R, 2005, ADV ENZYME REGUL, V45, P17, DOI 10.1016/j.advenzreg.2005.02.013; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Brantey MA, 2000, CANCER RES, V60, P4320; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Cardenas C, 2004, J BIOL CHEM, V279, P39122, DOI 10.1074/jbc.M401044200; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Drexler HCA, 2003, CELL CYCLE, V2, P438, DOI 10.4161/cc.2.5.461; Driscoll B, 1999, J BIOL CHEM, V274, P9463, DOI 10.1074/jbc.274.14.9463; Evangelisti C, 2006, EUR J HISTOCHEM, V50, P9; Evangelisti C, 2006, J CELL PHYSIOL, V209, P370, DOI 10.1002/jcp.20744; Faenza I, 2007, ENDOCRINOLOGY, V148, P1108, DOI 10.1210/en.2006-1003; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Goto K, 2006, ADV ENZYME REGUL, V46, P192, DOI 10.1016/j.advenzreg.2006.01.005; Goto K, 2006, BBA-MOL CELL BIOL L, V1761, P535, DOI 10.1016/j.bbalip.2006.04.001; Grossel MJ, 2006, J CELL BIOCHEM, V97, P485, DOI 10.1002/jcb.20712; Hozumi Y, 2003, EUR J NEUROSCI, V18, P1448, DOI 10.1046/j.1460-9568.2003.02871.x; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; Los AP, 2006, J BIOL CHEM, V281, P858, DOI 10.1074/jbc.M502693200; LOS AP, 2006, BIOCHIM BIOPHYS ACTA, V1773, P352; Ma H, 1998, J CELL BIOL, V143, P1415, DOI 10.1083/jcb.143.6.1415; Markiewicz E, 2005, J CELL SCI, V118, P409, DOI 10.1242/jcs.01630; Martelli AM, 2006, BBA-MOL CELL BIOL L, V1761, P542, DOI 10.1016/j.bbalip.2006.02.009; Martelli AM, 2004, CELL MOL LIFE SCI, V61, P1143, DOI 10.1007/s00018-004-3414-7; Martelli AM, 2005, J CELL BIOCHEM, V96, P285, DOI 10.1002/jcb.20527; Martelli AM, 2000, CANCER RES, V60, P815; Martelli AM, 2002, CELL MOL LIFE SCI, V59, P1129, DOI 10.1007/s00018-002-8492-9; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Neri LM, 1998, J BIOL CHEM, V273, P29738, DOI 10.1074/jbc.273.45.29738; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Topham MK, 2006, J CELL BIOCHEM, V97, P474, DOI 10.1002/jcb.20704; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Trinkle-Mulcahy L, 2003, MOL BIOL CELL, V14, P107, DOI 10.1091/mbc.E02-07-0376; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; ZHOU W, 1993, J BIOL CHEM, V268, P23041	43	35	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3297	3307		10.1096/fj.07-8336com	http://dx.doi.org/10.1096/fj.07-8336com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17488950				2022-12-25	WOS:000249781600030
J	Paul, S; Singh, C; Mishra, S; Chaudhuri, TK				Paul, Subhankar; Singh, Chanpreet; Mishra, Saroj; Chaudhuri, Tapan K.			The 69 kDa Escherichia coli maltodextrin glucosidase does not get encapsulated underneath GroES and folds through trans mechanism during GroEL/GroES-assisted folding	FASEB JOURNAL			English	Article						in vivo and in vitro folding; large substrate protein; trans folding mechanism	BACTERIAL CHAPERONIN GROEL; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; SINGLE-RING; IN-VITRO; PROTEIN; POLYPEPTIDE; INTERMEDIATE; ATP; COMPLEX	Escherichia coli chaperonin GroEL and GroES assist in folding of a wide variety of substrate proteins in the molecular mass range of similar to 50 kDa, using cis mechanism, but limited information is available on how they assist in folding of larger proteins. Considering that the central cavity of GroEL can accommodate a non- native protein of similar to 60 kDa, it is important to study the GroEL- GroES- assisted folding of substrate proteins that are large enough for cis encapsulation. In this study, we have reported the mechanism of GroEL/ GroES- assisted in vivo and in vitro folding of a 69 kDa monomeric E. coli protein maltodextrin glucosidase ( MalZ). Coexpression of GroEL and GroES in E. coli causes a 2- fold enhancement of exogenous MalZ activity in vivo. In vitro, GroEL and GroES in the presence of ATP give rise to a 7- fold enhancement in MalZ refolding. Neither GroEL nor single ring GroEL ( SR1) in the presence or absence of ATP could enhance the in vitro folding of MalZ. GroES could not encapsulate GroELbound MalZ. All these experimental findings suggested that GroEL/ GroES- assisted folding of MalZ followed trans mechanism, whereas denatured MalZ and GroES bound to the opposite rings of a GroEL molecule.	Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi 110016, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi	Chaudhuri, TK (corresponding author), Indian Inst Technol, Dept Biochem Engn & Biotechnol, Haus Khas, New Delhi 110016, India.	tapan@dbeb.iitd.ac.in	Singh, Chanpreet/ABD-7407-2020	Singh, Chanpreet/0000-0002-2697-3033				Bhattacharyya AM, 2002, BIOCHEMISTRY-US, V41, P422, DOI 10.1021/bi011726q; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chaudhuri TK, 2001, CELL, V107, P235, DOI 10.1016/S0092-8674(01)00523-2; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Chuang JL, 1999, J BIOL CHEM, V274, P10395, DOI 10.1074/jbc.274.15.10395; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Farr GW, 2003, EMBO J, V22, P3220, DOI 10.1093/emboj/cdg313; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; Feltham JL, 2000, CELL, V100, P193, DOI 10.1016/S0092-8674(00)81557-3; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; Horwich AL, 1998, METHOD ENZYMOL, V290, P141, DOI 10.1016/S0076-6879(98)90013-1; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Huang YS, 1999, J BIOL CHEM, V274, P10405, DOI 10.1074/jbc.274.15.10405; Ikura T, 2000, J MOL BIOL, V297, P791, DOI 10.1006/jmbi.2000.3580; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; Lin Z, 2006, CRIT REV BIOCHEM MOL, V41, P211, DOI 10.1080/10409230600760382; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Motojima F, 2004, P NATL ACAD SCI USA, V101, P15005, DOI 10.1073/pnas.0406132101; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Song JL, 2000, J BIOL CHEM, V275, P22305, DOI 10.1074/jbc.M002038200; Song JL, 2003, J BIOL CHEM, V278, P2515, DOI 10.1074/jbc.M209705200; TAPIO S, 1991, J BIOL CHEM, V266, P19450; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	40	27	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2874	2885		10.1096/fj.06-7958com	http://dx.doi.org/10.1096/fj.06-7958com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17494995				2022-12-25	WOS:000249237500028
J	Jones, PM; George, AM				Jones, Peter M.; George, Anthony M.			Nucleotide-dependent allostery within the ABC transporter ATP-binding cassette - A computational study of the MJ0796 dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; ACTIVE-SITE; CONFORMATIONAL-CHANGES; DOMAIN MOVEMENTS; MOTOR DOMAIN; PROTEINS; SUBUNIT; ARCHITECTURE	ATP-binding cassette transporters perform energy-dependent transmembrane solute trafficking in all organisms. These proteins often mediate cellular resistance to therapeutic drugs and are involved in a range of human genetic diseases. Enzymological studies have implicated a helical subdomain within the ATP-binding cassette nucleotide-binding domain in coupling ATP hydrolysis to solute transport in the transmembrane domains. Consistent with this, structural and computational analyses have indicated that the helical subdomain undergoes nucleotide-dependent movement relative to the core of the nucleotide-binding domain fold. Here we use theoretical methods to examine the allosteric nucleotide dependence of helical subdomain transitions to further elucidate its role in interactions between the transmembrane and nucleotide-binding domains. Unrestrained 30-ns molecular dynamics simulations of the ATP-bound, ADP-bound, and apo states of the MJ0796 monomer support the idea that interaction of a conserved glutamine residue with the catalytic metal mediates the rotation of the helical subdomain in response to nucleotide binding and hydrolysis. Simulations of the nucleotide-binding domain dimer revealed that ATP hydrolysis induces a large transition of one helical subdomain, resulting in an asymmetric conformation of the dimer not observed previously. A coarse-grained elastic network analysis supports this finding, revealing the existence of corresponding dynamic modes intrinsic to the contact topology of the protein. The implications of these findings for the coupling of ATP hydrolysis to conformational changes in the transmembrane domains required for solute transport are discussed in light of recent whole transporter structures.	Univ Technol Sydney, Fac Sci, Dept Med & Mol Biosci, Broadway, NSW 2007, Australia	University of Technology Sydney	George, AM (corresponding author), Univ Technol Sydney, Fac Sci, Dept Med & Mol Biosci, POB 123, Broadway, NSW 2007, Australia.	tony.george@uts.edu.au		George, Anthony/0000-0003-4691-8960				AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Ambudkar SV, 2006, FEBS LETT, V580, P1049, DOI 10.1016/j.febslet.2005.12.051; Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2; Bianchet MA, 1997, J BIOENERG BIOMEMBR, V29, P503, DOI 10.1023/A:1022443209010; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Campbell JD, 2005, FEBS LETT, V579, P4193, DOI 10.1016/j.febslet.2005.06.027; Campbell JD, 2004, BIOPHYS J, V87, P3703, DOI 10.1529/biophysj.104.046870; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Haliloglu T, 1997, PHYS REV LETT, V79, P3090, DOI 10.1103/PhysRevLett.79.3090; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Jones PM, 2002, P NATL ACAD SCI USA, V99, P12639, DOI 10.1073/pnas.152439599; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kurashima-Ito K, 2006, J BIOMOL NMR, V35, P53, DOI 10.1007/s10858-006-9000-6; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Liao JL, 2004, BIOPHYS J, V87, P1369, DOI 10.1529/biophysj.103.038653; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Liu PQ, 1999, J BIOL CHEM, V274, P18310, DOI 10.1074/jbc.274.26.18310; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Lu WC, 2006, PROTEINS, V62, P152, DOI 10.1002/prot.20743; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mazumder-Shivakumar D, 2004, P NATL ACAD SCI USA, V101, P14379, DOI 10.1073/pnas.0406002101; Ose T, 2004, PROTEINS, V57, P635, DOI 10.1002/prot.20206; Pinkett HW, 2007, SCIENCE, V315, P373, DOI 10.1126/science.1133488; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schmitt L, 2003, J MOL BIOL, V330, P333, DOI 10.1016/S0022-2836(03)00592-8; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang CY, 2004, J MOL BIOL, V342, P525, DOI 10.1016/j.jmb.2004.07.001; Wriggers W, 1997, PROTEINS, V29, P1; Yang LW, 2005, BIOINFORMATICS, V21, P2978, DOI 10.1093/bioinformatics/bti469; Yang LW, 2005, STRUCTURE, V13, P893, DOI 10.1016/j.str.2005.03.015; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zaitseva J, 2005, EMBO J, V24, P1901, DOI 10.1038/sj.emboj.7600657; Zaitseva J, 2006, EMBO J, V25, P3432, DOI 10.1038/sj.emboj.7601208	55	60	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22793	22803		10.1074/jbc.M700809200	http://dx.doi.org/10.1074/jbc.M700809200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17485460	hybrid			2022-12-25	WOS:000248354200057
J	Lee, WS; Choi, KS; Riddell, J; Ip, C; Ghosh, D; Park, JH; Park, YM				Lee, WeonSup; Choi, Kyoung-Soo; Riddell, Jonah; Ip, Clement; Ghosh, Debashis; Park, Jong-Hoon; Park, Young-Mee			Human peroxiredoxin 1 and 2 are not duplicate proteins - The unique presence of Cys(83) in Prx1 underscores the structural and functional differences between Prx1 and Prx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER CELLS; 2-CYS PEROXIREDOXIN; OXIDATIVE STRESS; THIOREDOXIN PEROXIDASE; CRYSTAL-STRUCTURE; SITE CYSTEINE; I EXPRESSION; ANTIOXIDANT; FAMILY; PAG	Human peroxiredoxins 1 and 2, also known as Prx1 and Prx2, are more than 90% homologous in their amino acid sequences. Prx1 and Prx2 are elevated in various cancers and are shown to influence diverse cellular processes. Although their growth regulatory role has traditionally been attributed to the peroxidase activity, the physiological significance of this function is unclear because the proteins are highly susceptible to inactivation by H2O2. A chaperone activity appears to emerge when their peroxidase activity is lost. Structural studies suggest that they may form a homodimer or doughnut-shaped homodecamer. However, little information is available whether human Prx1 and Prx2 are duplicative in structure and function. We noted that Prx1 contains a cysteine (Cys(83)) at the putative dimer-dimer interface, which is absent in Prx2. We studied the role of Cys(83) in regulating the peroxidase and chaperone activities of Prx1, because the redox status of Cys(83) might influence the oligomeric structure and consequently the functions of Prx1. We show that Prx1 is more efficient as a molecular chaperone, whereas Prx2 is better suited as a peroxidase enzyme. Substituting Cys(83) with Ser(83) (Prx1C83S) results in dramatic changes in the structural and functional characteristics of Prx1 in a direction similar to those of Prx2. Here we also report the first crystal structure of human Prx1 and the presence of the Cys(83)-Cys(83) bond at the dimer-dimer interface of decameric Prx1. These findings are consistent with the hypothesis that human Prx1 and Prx2 possess unique functions and regulatory mechanisms and that Cys(83) bestows a distinctive identity to Prx1.	Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Prevent, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharmaol & Therapeut, Buffalo, NY 14263 USA; Hauptman Woodward Med Res Inst, Dept Biol Struct, Buffalo, NY 14203 USA; Sookmyung Womens Univ, Dept Biol Sci, Seoul 140742, South Korea	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Hauptman Woodward Medical Research Institute; Sookmyung Women's University	Park, YM (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA.	young-mee.park@roswellpark.org			NATIONAL CANCER INSTITUTE [R01CA105500, P30CA016056, R01CA111846, R01CA109480] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY009412, R01EY009412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062794] Funding Source: NIH RePORTER; NCI NIH HHS [CA109480, CA111846, CA16056, CA105500] Funding Source: Medline; NEI NIH HHS [EY09412] Funding Source: Medline; NIGMS NIH HHS [GM62794] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Chang JW, 2005, FEBS LETT, V579, P2873, DOI 10.1016/j.febslet.2005.04.028; Chang JW, 2001, BIOCHEM BIOPH RES CO, V289, P507, DOI 10.1006/bbrc.2001.5989; Chen MF, 2006, INT J RADIAT ONCOL, V64, P581, DOI 10.1016/j.ijrobp.2005.10.012; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Chung YM, 2001, ANTICANCER RES, V21, P1129; Delano W. L., 2003, PYMOL MOL GENETICS G; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Ghosh D, 2001, J BIOL CHEM, V276, P11159, DOI 10.1074/jbc.M008831200; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; ISHII T, 1993, J BIOL CHEM, V268, P18633; Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078; Jang HH, 2006, FEBS LETT, V580, P351, DOI 10.1016/j.febslet.2005.12.030; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; Karihtala P, 2003, CLIN CANCER RES, V9, P3418; KAWAI S, 1994, J BIOCHEM-TOKYO, V115, P641, DOI 10.1093/oxfordjournals.jbchem.a124388; Kim HJ, 2003, CELL BIOL TOXICOL, V19, P285, DOI 10.1023/B:CBTO.0000004952.07979.3d; Kim JA, 2005, ANAL BIOCHEM, V338, P216, DOI 10.1016/j.ab.2004.12.008; Kim YJ, 2006, CANCER RES, V66, P7136, DOI 10.1158/0008-5472.CAN-05-4446; Kinnula VL, 2004, FEBS LETT, V569, P1, DOI 10.1016/j.febslet.2004.05.045; Kinnula VL, 2002, J PATHOL, V196, P316, DOI 10.1002/path.1042; Lee K, 2002, BIOCHEM BIOPH RES CO, V296, P337, DOI 10.1016/S0006-291X(02)00801-X; Lee TH, 2003, BLOOD, V101, P5033, DOI 10.1182/blood-2002-08-2548; Lehtonen ST, 2004, INT J CANCER, V111, P514, DOI 10.1002/ijc.20294; Moon JC, 2005, J BIOL CHEM, V280, P28775, DOI 10.1074/jbc.M505362200; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Noh DY, 2001, ANTICANCER RES, V21, P2085; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SH, 2000, CLIN CANCER RES, V6, P4915; Parsonage D, 2005, BIOCHEMISTRY-US, V44, P10583, DOI 10.1021/bi050448i; Pasta SY, 2004, MOL VIS, V10, P655; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Qi YJ, 2005, PROTEOMICS, V5, P2960, DOI 10.1002/pmic.200401175; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Sarafian TA, 1999, J NEUROSCI RES, V56, P206, DOI 10.1002/(SICI)1097-4547(19990415)56:2<206::AID-JNR1>3.0.CO;2-X; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; SHAU HY, 1994, BIOCHEM BIOPH RES CO, V199, P83, DOI 10.1006/bbrc.1994.1197; Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; Trujillo M, 2006, J BIOL CHEM, V281, P20555, DOI 10.1074/jbc.M601008200; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Wagner E, 2002, BIOCHEM J, V366, P777, DOI 10.1042/BJ20020525; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yanagawa T, 2000, CANCER LETT, V156, P27, DOI 10.1016/S0304-3835(00)00434-1; Yanagawa T, 1999, CANCER LETT, V145, P127, DOI 10.1016/S0304-3835(99)00243-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Yoo YD, 2002, EXP MOL MED, V34, P273, DOI 10.1038/emm.2002.38; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	53	116	126	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22011	22022		10.1074/jbc.M610330200	http://dx.doi.org/10.1074/jbc.M610330200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17519234	hybrid			2022-12-25	WOS:000248196800048
J	Lu, JI; Qian, J; Keppler, D; Cardoso, WV				Lue, Jining; Qian, Jun; Keppler, Daniel; Cardoso, Wellington V.			Cathespin H is an Fgf10 target involved in Bmp4 degradation during lung branching morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-B; CATHEPSIN-H; CYSTEINE PROTEINASES; EPITHELIAL-CELLS; MICE DEFICIENT; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; INHIBITION; PROTEASES	During lung development, signaling by Fgf10 (fibroblast growth factor 10) and its receptor Fgfr2b is critical for induction of a gene network that controls proliferation, differentiation, and branching of the epithelial tubules. The downstream events triggered by Fgf10-Fgfr2b signaling during this process are still poorly understood. In a global screen for transcriptional targets of Fgf10, we identified Ctsh (cathepsin H), a gene encoding a lysosomal cysteine protease of the papain family, highly up-regulated in the developing lung epithelium. Here we show that among other cathepsin genes present in the lung, Ctsh is the only family member selectively induced by Fgf10 in the lung epithelium. We provide evidence that, during branching morphogenesis, epithelial expression of Ctsh overlaps temporally and spatially with that of Bmp4 (bone morphogenetic protein 4), another target of Fgf10. Moreover, we show that Ctsh controls the availability of mature Bmp4 protein in the embryonic lung and that inhibiting Ctsh activity leads to a marked accumulation of Bmp4 protein and disruption of branching morphogenesis. Tightly controlled levels of Bmp4 signaling are critical for patterning of the distal lung epithelium. Our study suggests a potentially novel posttranscriptional mechanism in which Ctsh rapidly removes Bmp4 from forming buds to limit Bmp4 action. The presence of both Ctsh and Bmp4 or Bmp4 signaling activity in other developing structures, such as the kidney, yolk sac, and choroid plexus, suggests a possible general role of Ctsh in regulating Bmp4 proteolysis in different morphogenetic events.	Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Sch Med, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Boston University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Cardoso, WV (corresponding author), Boston Univ, Sch Med, Ctr Pulm, 715 Albany St, Boston, MA 02118 USA.	wcardoso@bu.edu	Keppler, Daniel/B-4309-2012	Cardoso, Wellington/0000-0002-2550-3697	NHLBI NIH HHS [R01 HL67129, P01 HL47049] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067129, P01HL047049] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGLIKER H, 1989, BIOCHEM J, V262, P63, DOI 10.1042/bj2620063; AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Brasch F, 2002, AM J RESP CELL MOL, V26, P659, DOI 10.1165/ajrcmb.26.6.4744; Buhling F, 2002, DEV DYNAM, V225, P14, DOI 10.1002/dvdy.10134; Cardoso WV, 2006, DEVELOPMENT, V133, P1611, DOI 10.1242/dev.02310; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Constam DB, 2000, GENE DEV, V14, P1146; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Cui YZ, 2001, GENE DEV, V15, P2797; Desai TJ, 2004, DEV BIOL, V273, P402, DOI 10.1016/j.ydbio.2004.04.039; Eblaghie MC, 2006, DEV BIOL, V291, P67, DOI 10.1016/j.ydbio.2005.12.006; Flentke GR, 2004, DEV DYNAM, V229, P886, DOI 10.1002/dvdy.10489; Friedrichs B, 2003, J CLIN INVEST, V111, P1733, DOI 10.1172/JCI200315990; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Guttentag S, 2003, AM J RESP CELL MOL, V28, P69, DOI 10.1165/rcmb.2002-0111OC; Hyatt BA, 2002, DEV DYNAM, V225, P153, DOI 10.1002/dvdy.10145; ISHII Y, 1991, J HISTOCHEM CYTOCHEM, V39, P461, DOI 10.1177/39.4.2005374; Jortikka L, 1997, CELL SIGNAL, V9, P47, DOI 10.1016/S0898-6568(96)00094-0; KOMINAMI E, 1988, FEBS LETT, V231, P225, DOI 10.1016/0014-5793(88)80736-1; Lebeche D, 1999, MECH DEVELOP, V86, P125, DOI 10.1016/S0925-4773(99)00124-0; Lopes SMCD, 2004, GENE DEV, V18, P1838, DOI 10.1101/gad.294004; Lu J, 2004, DEV BIOL, V273, P418, DOI 10.1016/j.ydbio.2004.05.035; Lu JN, 2005, J BIOL CHEM, V280, P4834, DOI 10.1074/jbc.M410714200; Malpel S, 2000, DEVELOPMENT, V127, P3057; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V260, P712, DOI 10.1016/0003-9861(88)90500-0; Nomura Y, 1999, BIOCHEM BIOPH RES CO, V254, P388, DOI 10.1006/bbrc.1998.9941; Ohuchi H, 2000, BIOCHEM BIOPH RES CO, V277, P643, DOI 10.1006/bbrc.2000.3721; Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SAN SB, 1986, FEBS LETT, V201, P251; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; SHAW E, 1994, METHOD ENZYMOL, V244, P649; Toomes C, 1999, NAT GENET, V23, P421, DOI 10.1038/70525; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Ueno T, 2004, J BIOL CHEM, V279, P16178, DOI 10.1074/jbc.M312029200; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; VRLJICAK P, 2004, AM J PHYSIOL, V286, pF265; Waghray A, 2002, J BIOL CHEM, V277, P11533, DOI 10.1074/jbc.M109557200; Weaver M, 2000, DEVELOPMENT, V127, P2695; Weaver M, 1999, DEVELOPMENT, V126, P4005; WILCOX D, 1992, BIOCHEM J, V285, P495, DOI 10.1042/bj2850495; Wolters P J, 2000, Respir Res, V1, P170, DOI 10.1186/rr29; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Yayoi Y, 2001, ARCH HISTOL CYTOL, V64, P89, DOI 10.1679/aohc.64.89; Zhang T, 2000, IMMUNOLOGY, V100, P13, DOI 10.1046/j.1365-2567.2000.00000.x; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	55	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22176	22184		10.1074/jbc.M700063200	http://dx.doi.org/10.1074/jbc.M700063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17500053	hybrid			2022-12-25	WOS:000248196800063
J	Um, JH; Yang, ST; Yamazaki, S; Kang, H; Viollet, B; Foretz, M; Chung, JH				Um, Jee Hyun; Yang, Shutong; Yamazaki, Shin; Kang, Hyeog; Viollet, Benoit; Foretz, Marc; Chung, Jay H.			Activation of 5 '-AMP-activated kinase with diabetes drug metformin induces casein kinase I epsilon (CKI epsilon)-dependent degradation of clock protein mPer2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCADIAN GENE-EXPRESSION; PHOSPHORYLATION; FIBROBLASTS; MAMMALS; FAMILY; LIVER; MICE; TAU; CKI	Metformin is one of the most commonly used first line drugs for type II diabetes. Metformin lowers serum glucose levels by activating 5'-AMP-activated kinase (AMPK), which maintains energy homeostasis by directly sensing the AMP/ATP ratio. AMPK plays a central role in food intake and energy metabolism through its activities in central nervous system and peripheral tissues. Since food intake and energy metabolism is synchronized to the light-dark (LD) cycle of the environment, we investigated the possibility that AMPK may affect circadian rhythm. We discovered that the circadian period of Rat-1 fibroblasts treated with metformin was shortened by 1 h. One of the regulators of the period length is casein kinase I epsilon (CKI epsilon), which by phosphorylating and inducing the degradation of the circadian clock component, mPer2, shortens the period length. AMPK phosphorylates Ser-389 of CKI epsilon, resulting in increased CKI epsilon activity and degradation of mPer2. In peripheral tissues, injection of metformin leads to mPer2 degradation and a phase advance in the circadian expression pattern of clock genes in wild-type mice but not in AMPK alpha 2 knock-out mice. We conclude that metformin and AMPK have a previously unrecognized role in regulating the circadian rhythm.	NHLBI, Natl Inst Hlth, Lab Biochem Genet, Bethesda, MD 20892 USA; Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA; Inst Cochin, Dept Endocrinol Metab & Canc, F-75014 Paris, France; INSERM, U567, F-75014 Paris, France; CNRS, UMR 8104, F-75014 Paris, France; Univ Paris 05, Fac Med Rene Descartes, UM 3, F-75014 Paris, France; Univ Paris 05, Inst Cochin, CNRS, UMR 8104, F-75014 Paris, France	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Vanderbilt University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chung, JH (corresponding author), NHLBI, Natl Inst Hlth, Lab Biochem Genet, Bldg 10,Rm 7D14,10 Ctr Dr, Bethesda, MD 20892 USA.	chungj@nhlbi.nih.gov	Viollet, Benoit/O-6927-2017; FORETZ, Marc/O-7334-2017; Viollet, Benoit/N-2397-2019	Viollet, Benoit/0000-0002-0121-0224; FORETZ, Marc/0000-0001-7017-9032; Viollet, Benoit/0000-0002-0121-0224; kang, hyeog/0000-0001-8935-1103	Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002243, ZIAHL002243] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balsalobre A, 2000, CURR BIOL, V10, P1291, DOI 10.1016/S0960-9822(00)00758-2; Camacho F, 2001, FEBS LETT, V489, P159, DOI 10.1016/S0014-5793(00)02434-0; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Consoli A, 2004, DIABETES METAB, V30, P509, DOI 10.1016/S1262-3636(07)70148-9; Eide EJ, 2005, MOL CELL BIOL, V25, P2795, DOI 10.1128/MCB.25.7.2795-2807.2005; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Gallego M, 2006, P NATL ACAD SCI USA, V103, P10618, DOI 10.1073/pnas.0604511103; GAO G, 1995, BBA-MOL CELL RES, V1266, P73, DOI 10.1016/0167-4889(94)00222-Z; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Izumo M, 2003, P NATL ACAD SCI USA, V100, P16089, DOI 10.1073/pnas.2536313100; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; JUNIEN JL, 1979, ARCH INT PHARMACOD T, V241, P165; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Laposky AD, 2006, AM J PHYSIOL-REG I, V290, pR894, DOI 10.1152/ajpregu.00304.2005; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Yamazaki S, 2005, METHOD ENZYMOL, V393, P288, DOI 10.1016/S0076-6879(05)93012-7; Yoo SH, 2005, P NATL ACAD SCI USA, V102, P2608, DOI 10.1073/pnas.0409763102; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	27	159	164	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20794	20798		10.1074/jbc.C700070200	http://dx.doi.org/10.1074/jbc.C700070200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17525164	hybrid			2022-12-25	WOS:000248047500003
J	Lin, WJ; Duffy, A; Chen, CY				Lin, Wei-Jye; Duffy, Aaron; Chen, Ching-Yi			Localization of AU-rich element-containing mRNA in cytoplasmic granules containing exosome subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCESSING BODIES; DECAPPING ENZYME; POLY(A)-BINDING PROTEIN; MAMMALIAN EXOSOME; BINDING PROTEIN; GENE-EXPRESSION; MEDIATED DECAY; GW BODIES; DEGRADATION; TURNOVER	Eukaryotic mRNAs can be degraded in either decapping/5'-to-3' or 3'-to-5' direction after deadenylation. In yeast and mammalian cells, decay factors involved in the 5'-to-3' decay pathway are concentrated in cytoplasmic processing bodies (P bodies). The mechanistic steps and localization of mammalianm RNA decay are still not completely understood. Here, we investigate functions of human mRNA decay enzymes in AU-rich element (ARE)-mediated mRNA decay (AMD) and find that the deadenylase, poly(A) ribonuclease PARN, and enzymes involved in the 5'-to-3' and 3'-to-5' decay pathways are required for AMD. The ARE-containing reporter mRNA accumulates in discrete cytoplasmic granular structures, which are distinct from P bodies and stress granules. These granules consist of poly(A)-specific ribonuclease, exosome subunits, and decay-promoting ARE-binding proteins. Inhibition of AMD increases accumulation of ARE-mRNA in these granules. We refer to these structures as cytoplasmic exosome granules and suggest that some AMD may occur in these granules.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, CY (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.	cchen@uab.edu	Lin, Wei-Jye/AGW-1054-2022	Lin, Wei-Jye/0000-0002-6057-7325	NIGMS NIH HHS [GM68758] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068758] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Bakheet T, 2003, NUCLEIC ACIDS RES, V31, P421, DOI 10.1093/nar/gkg023; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Bashkirov VI, 1997, J CELL BIOL, V136, P761, DOI 10.1083/jcb.136.4.761; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Brengues M, 2005, SCIENCE, V310, P486, DOI 10.1126/science.1115791; Brouwer R, 2001, J BIOL CHEM, V276, P6177, DOI 10.1074/jbc.M007603200; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Chou CF, 2006, MOL CELL BIOL, V26, P3695, DOI 10.1128/MCB.26.10.3695-3706.2006; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Eystathioy T, 2003, RNA, V9, P1171, DOI 10.1261/rna.5810203; Franks TM, 2007, GENE DEV, V21, P719, DOI 10.1101/gad.1494707; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Graham AC, 2006, MOL BIOL CELL, V17, P1399, DOI 10.1091/mbc.e05-08-0805; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lejeune F, 2003, MOL CELL, V12, P675, DOI 10.1016/S1097-2765(03)00349-6; Liu QS, 2006, CELL, V127, P1223, DOI 10.1016/j.cell.2006.10.037; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Murray EL, 2007, MOL CELL BIOL, V27, P2791, DOI 10.1128/MCB.01445-06; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Raijmakers R, 2003, J BIOL CHEM, V278, P30698, DOI 10.1074/jbc.M302488200; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Stoecklin G, 2006, EMBO REP, V7, P72, DOI 10.1038/sj.embor.7400572; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uchida N, 2004, J BIOL CHEM, V279, P1383, DOI 10.1074/jbc.M309125200; Unterholzner L, 2004, MOL CELL, V16, P587, DOI 10.1016/j.molcel.2004.10.013; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016; Yang Z, 2004, J CELL SCI, V117, P5567, DOI 10.1242/jcs.01477	46	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19958	19968		10.1074/jbc.M702281200	http://dx.doi.org/10.1074/jbc.M702281200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17470429	hybrid			2022-12-25	WOS:000247650600070
J	Vincent, C; Maridonneau-Parini, I; Le Clainche, C; Gounon, P; Labrousse, A				Vincent, Claire; Maridonneau-Parini, Isabelle; Le Clainche, Christophe; Gounon, Pierre; Labrousse, Arnaud			Activation of p61Hck triggers WASp- and Arp2/3-dependent actin-comet tail biogenesis and accelerates lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT BARBED ENDS; N-WASP; TYROSINE KINASE; PLASMA-MEMBRANE; ENDOSOMAL MEMBRANES; SECRETORY GRANULES; HUMAN MACROPHAGES; ARP2/3 COMPLEX; F-ACTIN; MOTILITY	Secretory lysosomes exist in few cell types, but various mechanisms are involved to ensure their mobilization within the cytoplasm. In phagocytes, lysosome exocytosis is a regulated phenomenon at least in part under the control of the phagocyte-specific and lysosome-associated Src-kinase p61Hck (hematopoietic cell kinase). We show here that p61Hck activation triggered polymerization of actin at the membrane of lysosomes, which resulted in F-actin structures similar to comet tails observed on endocytic vesicles. We correlated this actin-comet biogenesis to a 35% acceleration of p61Hck-lysosomes in cells, which was dependent on actin polymerization and required an intact microtubular network. It was possible to initiate the formation of actin tails on p61Hck-positive lysosomes and on p61Hck-associated latex beads incubated in human phagocyte cytosolic extracts. The in vitro reconstitution on beads indicated that other lysosomal proteins were dispensable in this mechanism. The de novo actin polymerization process was functionally dependent on the kinase activity of Hck, WASp, the Arp2/3 complex, and Cdc42 but not Rac or Rho. Thus, we identified p61Hck as the first lysosomal protein able to recruit the molecular machinery responsible for actin tail formation. Altogether, our results suggest a new mechanism for lysosome motility involving p61Hck, actin-comet tail biogenesis, and the microtubule network.	Inst Pharmacol & Biol Struct, CNRS, UMR5089, F-31077 Toulouse, France; CNRS, Lab Enzymol & Biochem Struct, F-91198 Gif Sur Yvette, France; Fac Sci, Ctr Commun Microscopy, F-06108 Nice, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Maridonneau-Parini, I (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UMR5089, 205 Route de Narbonne, F-31077 Toulouse, France.	Isabelle.Maridonneau-Parini@ipbs.fr	Le Clainche, Christophe/A-4782-2015; Maridonneau-Parini, Isabelle/F-1985-2011	Le Clainche, Christophe/0000-0001-5659-677X; Labrousse, Arnaud/0000-0002-6525-6627; Maridonneau-Parini, Isabelle/0000-0003-0189-0976				Astarie-Dequeker C, 2002, J CELL SCI, V115, P81; Astarie-Dequeker C, 1999, INFECT IMMUN, V67, P469, DOI 10.1128/IAI.67.2.469-477.1999; Barral DC, 2004, PIGM CELL RES, V17, P111, DOI 10.1111/j.1600-0749.2004.00138.x; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; Boldogh IR, 2006, BBA-MOL CELL RES, V1763, P450, DOI 10.1016/j.bbamcr.2006.02.014; Bompard G, 2004, J CELL BIOL, V166, P957, DOI 10.1083/jcb.200403127; Bossi G, 2002, IMMUNOL REV, V189, P152, DOI 10.1034/j.1600-065X.2002.18913.x; Boyer L, 2006, J CELL BIOL, V173, P809, DOI 10.1083/jcb.200509009; Carreno S, 2000, J BIOL CHEM, V275, P36223, DOI 10.1074/jbc.M003901200; Carreno S, 2002, J BIOL CHEM, V277, P21007, DOI 10.1074/jbc.M201212200; Cordonnier MN, 2001, MOL BIOL CELL, V12, P4013, DOI 10.1091/mbc.12.12.4013; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; Cougoule C, 2005, TRAFFIC, V6, P682, DOI 10.1111/j.1600-0854.2005.00307.x; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; Fehrenbacher KL, 2003, TRENDS CELL BIOL, V13, P472, DOI 10.1016/S0962-8924(03)00174-0; Fernandez-Borja M, 2005, J CELL SCI, V118, P2661, DOI 10.1242/jcs.02384; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Goding CR, 2007, INT J BIOCHEM CELL B, V39, P275, DOI 10.1016/j.biocel.2006.10.003; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; GOUNON P, 2002, MOL CELLULAR MICROBI, P531; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Helfer E, 2006, EMBO J, V25, P1184, DOI 10.1038/sj.emboj.7601019; Kaksonen M, 2000, J CELL SCI, V113, P4421; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kjeken R, 2004, MOL BIOL CELL, V15, P345, DOI 10.1091/mbc.e03-05-0334; Le Cabec V, 2002, J IMMUNOL, V169, P2003, DOI 10.4049/jimmunol.169.4.2003; Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Ma L, 1998, J CELL BIOL, V140, P1125; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Newsome TP, 2004, SCIENCE, V306, P124, DOI 10.1126/science.1101509; Park SJ, 2005, EMBO J, V24, P1557, DOI 10.1038/sj.emboj.7600586; Poincloux R, 2006, EUR J CELL BIOL, V85, P327, DOI 10.1016/j.ejcb.2005.09.012; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; Welch H, 1997, J BIOL CHEM, V272, P102; Zhang FL, 2002, CELL MOTIL CYTOSKEL, V53, P81, DOI 10.1002/cm.10058	51	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19565	19574		10.1074/jbc.M701501200	http://dx.doi.org/10.1074/jbc.M701501200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17500055	hybrid			2022-12-25	WOS:000247650600031
J	Vos, A; Dekker, N; Distel, B; Leunissen, JAM; Hochstenbach, F				Vos, Alina; Dekker, Nick; Distel, Ben; Leunissen, Jack A. M.; Hochstenbach, Frans			Role of the synthase domain of Ags1p in cell wall alpha-glucan biosynthesis in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; COLI GLYCOGEN-SYNTHASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BACTERIAL GLYCOGEN; SCHIZOSACCHAROMYCES-POMBE; ASPERGILLUS-FUMIGATUS; PHYLOGENETIC TREES; CRYSTAL-STRUCTURE; CHITIN SYNTHASE	The cell wall is important for maintenance of the structural integrity and morphology of fungal cells. Besides beta-glucan and chitin, alpha-glucan is a major polysaccharide in the cell wall of many fungi. In the fission yeast Schizosaccharomyces pombe, cell wall alpha-glucan is an essential component, consisting mainly of (1,3)-alpha-glucan with similar to 10% (1,4)-linked alpha-glucose residues. The multidomain protein Ags1p is required for alpha-glucan biosynthesis and is conserved among cell wall alpha-glucan-containing fungi. One of its domains shares amino acid sequence motifs with (1,4)-alpha-glucan synthases such as bacterial glycogen synthases and plant starch synthases. Whether Ags1p is involved in the synthesis of the (1,4)-alpha-glucan constituent of cell wall alpha-glucan had remained unclear. Here, we show that overexpression of Ags1p in S. pombe cells results in accumulation of (1,4)-alpha-glucan. To determine whether the synthase domain of Ags1p is responsible for this activity, we overexpressed Ags1p-E1526A, which carries a mutation in a putative catalytic residue of the synthase domain, but observed no accumulation of (1,4)-alpha-glucan. Compared with wild-type Ags1p, this mutant Ags1p showed a markedly reduced ability to complement the cell lysis phenotype of the temperature-sensitive ags1-1 mutant. Therefore, we conclude that, in S. pombe, the production of (1,4)-alpha-glucan by the synthase domain of Ags1p is important for the biosynthesis of cell wall alpha-glucan.	Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands; Univ Wageningen & Res Ctr, Lab Bioinformat, NL-6700 ET Wageningen, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Wageningen University & Research	Hochstenbach, F (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	f.hochstenbach@amc.uva.nl	Hochstenbach, Frans/B-5232-2008					Alako BTF, 2006, NUCLEIC ACIDS RES, V34, pW104, DOI 10.1093/nar/gkl171; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BAILEY JM, 1961, J BIOL CHEM, V236, P969; Ball SG, 2003, ANNU REV PLANT BIOL, V54, P207, DOI 10.1146/annurev.arplant.54.031902.134927; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Beauvais A, 2005, APPL ENVIRON MICROB, V71, P1531, DOI 10.1128/AEM.71.3.1531-1538.2005; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; CHENG C, 1995, MOL CELL BIOL, V15, P6632; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; Cid E, 2002, FEBS LETT, V528, P5, DOI 10.1016/S0014-5793(02)03313-6; Cos T, 1998, EUR J BIOCHEM, V256, P419, DOI 10.1046/j.1432-1327.1998.2560419.x; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Dekker N, 2006, FEBS LETT, V580, P3099, DOI 10.1016/j.febslet.2006.04.061; Dijkgraaf GJP, 2002, YEAST, V19, P671, DOI 10.1002/yea.866; Felsenstein J., 2002, PHYLIP PHYLOGENY INF; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FOX J, 1976, BIOCHEMISTRY-US, V15, P849, DOI 10.1021/bi00649a019; FURUKAWA K, 1993, J BIOL CHEM, V268, P23837; FURUKAWA K, 1994, J BIOL CHEM, V269, P868; GRUN CH, 2004, GLYCOBIOLOGY, V15, P1; Hochstenbach F, 1998, P NATL ACAD SCI USA, V95, P9161, DOI 10.1073/pnas.95.16.9161; Horcajada C, 2006, J BIOL CHEM, V281, P2923, DOI 10.1074/jbc.M507394200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES PG, 1990, CARBOHYD RES, V198, P23, DOI 10.1016/0008-6215(90)84273-W; JOHNSTON IR, 1965, BIOCHEM J, V96, P659, DOI 10.1042/bj0960659; Kartsonis NA, 2003, DRUG RESIST UPDATE, V6, P197, DOI 10.1016/S1368-7646(03)00064-5; Katayama S, 1999, J CELL BIOL, V144, P1173, DOI 10.1083/jcb.144.6.1173; Kostova Z, 2003, EUR J BIOCHEM, V270, P4507, DOI 10.1046/j.1432-1033.2003.03844.x; LEVER M, 1972, ANAL BIOCHEM, V47, P273, DOI 10.1016/0003-2697(72)90301-6; Lomako J, 2004, BBA-GEN SUBJECTS, V1673, P45, DOI 10.1016/j.bbagen.2004.03.017; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Maubon D, 2006, FUNGAL GENET BIOL, V43, P366, DOI 10.1016/j.fgb.2006.01.006; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; PALUMBO G, 1987, LIPIDS, V22, P201, DOI 10.1007/BF02537303; Rappleye CA, 2004, MOL MICROBIOL, V53, P153, DOI 10.1111/j.1365-2958.2004.04131.x; Reese AJ, 2003, MOL MICROBIOL, V50, P1401, DOI 10.1046/j.1365-2958.2003.03780.x; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ugalde JE, 2003, P NATL ACAD SCI USA, V100, P10659, DOI 10.1073/pnas.1534787100; Yep A, 2004, J BIOL CHEM, V279, P8359, DOI 10.1074/jbc.M312686200	48	19	21	4	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18969	18979		10.1074/jbc.M605147200	http://dx.doi.org/10.1074/jbc.M605147200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17472966	hybrid			2022-12-25	WOS:000247475300039
J	Reineke, EL; Liu, H; Lam, M; Liu, Y; Kao, HY				Reineke, Erin L.; Liu, Heng; Lam, Minh; Liu, Yu; Kao, Hung-Ying			Aberrant association of promyelocytic leukemia protein-retinoic acid receptor-alpha with coactivators contributes to its ability to regulate gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PML-RAR-ALPHA; NUCLEAR HORMONE-RECEPTORS; LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL COACTIVATOR; FUSION PROTEIN; PML/RAR-ALPHA; RXR-ALPHA; N-COR; MEDIATED TRANSACTIVATION; T(1517) TRANSLOCATION	The aberrant association of promyelocytic leukemia proteinretinoic acid receptor-alpha (PML-RAR alpha) with corepressor complexes is generally thought to contribute to the ability of PML-RAR alpha to regulate transcription. We report here that PML-RAR alpha acquires aberrant association with coactivators. We show that endogenous PML-RAR alpha interacts with the histone acetyltransferases CBP, p300, and SRC-1 in a hormone-independent manner, an association not seen for RAR alpha. This hormone-independent coactivator binding activity requires an intact ligand-binding domain and the NR box of the coactivators. Confocal microscopy studies demonstrate that exogenous PML-RAR alpha sequesters and colocalizes with coactivators. These observations correlate with the ability of PML-RAR alpha to attenuate the transcription activation of the Notch signaling downstream effector, CBF1, and of the glucocorticoid receptor. This includes attenuation of the glucocorticoid-induced leucine zipper (GILZ) and FLJ25390 target genes of the endogenous glucocorticoid receptor. Furthermore, treatment of NB4 cells with all-trans-retinoic acid, which promotes PML-RAR alpha degradation, resulted in increased activation of GILZ. On the basis of these findings, we propose a model in which the hormone-independent association between PML-RAR alpha and coactivators contributes to its ability to regulate gene expression.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Ctr Comprehens Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	Kao, HY (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	hxk43@cwru.edu			NCI NIH HHS [P30 CA43703-12, T32 CA059366-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, T32CA059366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chan IT, 2006, BLOOD, V108, P1708, DOI 10.1182/blood-2006-04-015040; Chattopadhyay A, 2006, ONCOGENE, V25, P2223, DOI 10.1038/sj.onc.1209252; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DANIEL MT, 1993, BLOOD, V82, P1858; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dong S, 2003, ONCOGENE, V22, P858, DOI 10.1038/sj.onc.1206182; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; Hayashi R, 2004, EUR J PHARMACOL, V500, P51, DOI 10.1016/j.ejphar.2004.07.011; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG SM, 1989, CANCER RES, V49, pS2292; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; Jones PL, 2001, J BIOL CHEM, V276, P8807, DOI 10.1074/jbc.C000879200; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2003, J BIOL CHEM, V278, P7366, DOI 10.1074/jbc.M207569200; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Khan MM, 2004, J BIOL CHEM, V279, P11814, DOI 10.1074/jbc.M312121200; Kogan SC, 2000, BLOOD, V95, P1541, DOI 10.1182/blood.V95.5.1541.005k28_1541_1550; LAVAU C, 1994, LEUKEMIA, V8, P1615; Lengfelder E, 2005, CRIT REV ONCOL HEMAT, V56, P261, DOI 10.1016/j.critrevonc.2004.08.009; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Liu H, 2004, J BIOL CHEM, V279, P45208, DOI 10.1074/jbc.M408033200; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Meani N, 2005, ONCOGENE, V24, P3358, DOI 10.1038/sj.onc.1208498; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Ng APP, 2006, CANCER RES, V66, P9903, DOI 10.1158/0008-5472.CAN-06-0002; ONATE SA, 1995, SCIENCE, V270, P1354; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Park DJ, 2003, BLOOD, V102, P3727, DOI 10.1182/blood-2003-02-0412; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2006, ONCOGENE, V25, P1974, DOI 10.1038/sj.onc.1209216; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	63	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18584	18596		10.1074/jbc.M700330200	http://dx.doi.org/10.1074/jbc.M700330200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17475621	hybrid			2022-12-25	WOS:000247302000063
J	Tchurikov, NA; Kretova, OV				Tchurikov, Nickolai A.; Kretova, Olga V.			Suffix-specific RNAi Leads to Silencing of F Element in Drosophila melanogaster	PLOS ONE			English	Article							DOUBLE-STRANDED-RNA; 3 ENDS; TRANSCRIPTION; INTERFERENCE; EXPRESSION; EVOLUTION; SEQUENCE; ORIGIN; FAMILY; GENE	Separate conserved copies of suffix, a short interspersed Drosophila retroelement (SINE), and also divergent copies in the 3' untranslated regions of the three genes, have already been described. Suffix has also been identified on the 3' end of the Drosophila non-LTR F element, where it forms the last conserved domain of the reverse transcriptase (RT). In our current study, we show that the separate copies of suffix are far more actively transcribed than their counterparts on the F element. Transcripts from both strands of suffix are present in RNA preparations during all stages of Drosophila development, providing the potential for the formation of double-stranded RNA and the initiation of RNA interference (RNAi). Using in situ RNA hybridization analysis, we have detected the expression of both sense and antisense suffix transcripts in germinal cells. These sense and antisense transcripts are colocalized in the primary spermatocytes and in the cytoplasm of the nurse cells, suggesting that they form double-stranded RNA. We performed further analyses of suffix-specific small RNAs using northern blotting and SI nuclease protection assays. Among the total RNA preparations isolated from embryos, larvae, pupae and flies, suffix-specific small interfering RNAs (siRNAs) were detected only in pupae. In wild type ovaries, both the siRNAs and longer suffix-specific Piwi-interacting RNAs (piRNAs) were observed, whereas in ovaries of the Dicer-2 mutant, only piRNAs were detected. We further found by 3' RACE that in pupae and ovaries, F element transcripts lacking the suffix sequence are also present. Our data provide direct evidence that suffix-specific RNAi leads to the silencing of the relative LINE (long interspersed element), F element, and suggests that SINE-specific RNA interference could potentially downregulate a set of genes possessing SINE stretches in their 5' or 3' non-coding regions. These data also suggest that double stranded RNAs possessing suffix are processed by both RNAi and an additional silencing mechanism.	[Tchurikov, Nickolai A.; Kretova, Olga V.] Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Tchurikov, NA (corresponding author), Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow, Russia.	tchurikov@eimb.ru	Tchurikov, Nickolai A./R-4850-2016		Russian Academy of Sciences; Russian Ministry of Education and Science [02.512.11.2066]; Russian Foundation for Basic Research [05-04-48256-?]	Russian Academy of Sciences(Russian Academy of Sciences); Russian Ministry of Education and Science(Ministry of Education and Science, Russian Federation); Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR))	This work was supported by grants from the Molecular and Cellular Biology Program of the Russian Academy of Sciences, Russian Ministry of Education and Science, 02.512.11.2066 and Russian Foundation for Basic Research, 05-04-48256-?.	Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; DINOCERA PP, 1987, P NATL ACAD SCI USA, V84, P5843; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fuller Margaret T., 1993, P71; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Kerber B, 1996, MOL CELL BIOL, V16, P2998; Kretova O. V., 2002, Genetika, V38, P1090; Lau NC, 2006, SCIENCE, V313, P363, DOI 10.1126/science.1130164; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Li TH, 2001, GENE, V276, P135, DOI 10.1016/S0378-1119(01)00637-0; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; MINCHIOTTI G, 1994, MOL GEN GENET, V245, P152, DOI 10.1007/BF00283262; Nikaido M, 1999, P NATL ACAD SCI USA, V96, P10261, DOI 10.1073/pnas.96.18.10261; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Ohshima K, 1996, MOL CELL BIOL, V16, P3756; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148; Rubin CM, 2002, NUCLEIC ACIDS RES, V30, P3253, DOI 10.1093/nar/gkf419; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; Shiu PKT, 2002, GENETICS, V161, P1483; Siol O, 2006, MOL CELL BIOL, V26, P8242, DOI 10.1128/MCB.01348-06; TCHURIKOV NA, 1986, EMBO J, V5, P2341, DOI 10.1002/j.1460-2075.1986.tb04502.x; TCHURIKOV NA, 1982, CELL, V28, P365, DOI 10.1016/0092-8674(82)90354-3; TCHURIKOV NA, 1996, TSITOL GENET+, V30, P14; TCHURIKOV NA, 1998, DOKL AKAD NAUK, V360, P124; Tuschl T, 2003, NATURE, V421, P220, DOI 10.1038/421220a; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333; Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Yigit E, 2006, CELL, V127, P747, DOI 10.1016/j.cell.2006.09.033; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	34	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e476	10.1371/journal.pone.0000476	http://dx.doi.org/10.1371/journal.pone.0000476			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534426	Green Published, gold, Green Submitted			2022-12-25	WOS:000207448800006
J	Zhang, YHP; Evans, BR; Mielenz, JR; Hopkins, RC; Adams, MWW				Zhang, Y. -H. Percival; Evans, Barbara R.; Mielenz, Jonathan R.; Hopkins, Robert C.; Adams, Michael W. W.			High-Yield Hydrogen Production from Starch and Water by a Synthetic Enzymatic Pathway	PLOS ONE			English	Article								Background. The future hydrogen economy offers a compelling energy vision, but there are four main obstacles: hydrogen production, storage, and distribution, as well as fuel cells. Hydrogen production from inexpensive abundant renewable biomass can produce cheaper hydrogen, decrease reliance on fossil fuels, and achieve zero net greenhouse gas emissions, but current chemical and biological means suffer from low hydrogen yields and/or severe reaction conditions. Methodology/Principal Findings. Here we demonstrate a synthetic enzymatic pathway consisting of 13 enzymes for producing hydrogen from starch and water. The stoichiometric reaction is C(6)H(10)O(5) (l)+7 H(2)O (l)-> 12 H(2) (g)+ 6 CO(2) (g). The overall process is spontaneous and unidirectional because of a negative Gibbs free energy and separation of the gaseous products with the aqueous reactants. Conclusions. Enzymatic hydrogen production from starch and water mediated by 13 enzymes occurred at 30 degrees C as expected, and the hydrogen yields were much higher than the theoretical limit (4 H(2)/glucose) of anaerobic fermentations. Significance. The unique features, such as mild reaction conditions (30 degrees C and atmospheric pressure), high hydrogen yields, likely low production costs ($similar to 2/kg H(2)), and a high energy-density carrier starch (14.8 H(2)-based mass%), provide great potential for mobile applications. With technology improvements and integration with fuel cells, this technology also solves the challenges associated with hydrogen storage, distribution, and infrastructure in the hydrogen economy.	[Zhang, Y. -H. Percival] Virginia Tech, Dept Biol Syst Engn, Blacksburg, VA 24061 USA; [Evans, Barbara R.] Oak Ridge Natl Lab, Div Chem Sci, Oak Ridge, TN USA; [Mielenz, Jonathan R.] Oak Ridge Natl Lab, Biosci Div, Oak Ridge, TN USA; [Hopkins, Robert C.; Adams, Michael W. W.] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Virginia Polytechnic Institute & State University; United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University System of Georgia; University of Georgia	Zhang, YHP (corresponding author), Virginia Tech, Dept Biol Syst Engn, Blacksburg, VA 24061 USA.	ypzhang@vt.edu		Adams, Michael/0000-0002-9796-5014	Southeastern Sun Grant Center, USDA-CSREES [2006-38909-03484]; Oak Ridge Associated Universities; Oak Ridge National Laboratory; Department of Energy [DE-FG02-05ER15710, DE-AC05-00OR22725, FWP CEEB06]; U.S. Department of Energy Office of Energy Efficiency and Renewable Energy	Southeastern Sun Grant Center, USDA-CSREES(United States Department of Agriculture (USDA)National Institute of Food and Agriculture); Oak Ridge Associated Universities; Oak Ridge National Laboratory(United States Department of Energy (DOE)); Department of Energy(United States Department of Energy (DOE)); U.S. Department of Energy Office of Energy Efficiency and Renewable Energy(United States Department of Energy (DOE))	We are grateful for financial support from the Southeastern Sun Grant Center, USDA-CSREES (2006-38909-03484), and Oak Ridge Associated Universities to YHPZ. JRM was supported by Oak Ridge National Laboratory. RCH and MWWA were supported by a grant (DE-FG02-05ER15710) from the Department of Energy under contract DE-AC05-00OR22725. Previous research at Oak Ridge National Laboratory was funded by the U.S. Department of Energy Office of Energy Efficiency and Renewable Energy under FWP CEEB06. Oak Ridge National Laboratory is managed by UT-Battelle, LLC, for the U.S. Department of Energy under contract DE-AC05-00OR22725.	Adams MWW, 1998, SCIENCE, V282, P1842, DOI 10.1126/science.282.5395.1842; Allain EJ, 2007, J CHEM TECHNOL BIOT, V82, P117, DOI 10.1002/jctb.1649; Antal MJ, 2000, IND ENG CHEM RES, V39, P4040, DOI 10.1021/ie0003436; Atkins PW, 2005, ELEMENTS PHYS CHEM, P605; Benner SA, 2005, NAT REV GENET, V6, P533, DOI 10.1038/nrg1637; Berg J.M., 2002, BIOCHEMISTRY-US, P380; Blennow A, 2002, TRENDS PLANT SCI, V7, P445, DOI 10.1016/S1360-1385(02)02332-4; Cortright RD, 2002, NATURE, V418, P964, DOI 10.1038/nature01009; Das D, 2001, INT J HYDROGEN ENERG, V26, P13, DOI 10.1016/S0360-3199(00)00058-6; Deluga GA, 2004, SCIENCE, V303, P993, DOI 10.1126/science.1093045; *DOE, 2004, BAS RES NEEDS HYDR E; Donahue JL, 2000, J BACTERIOL, V182, P5624, DOI 10.1128/JB.182.19.5624-5627.2000; Endy D, 2005, NATURE, V438, P449, DOI 10.1038/nature04342; Farrell AE, 2006, SCIENCE, V311, P506, DOI 10.1126/science.1121416; Glass JI, 2006, P NATL ACAD SCI USA, V103, P425, DOI 10.1073/pnas.0510013103; Hallenbeck PC, 2002, INT J HYDROGEN ENERG, V27, P1185, DOI 10.1016/S0360-3199(02)00131-3; Hoffert MI, 2002, SCIENCE, V298, P981, DOI 10.1126/science.1072357; Huber GW, 2003, SCIENCE, V300, P2075, DOI 10.1126/science.1085597; Jung GY, 2004, SCIENCE, V304, P428, DOI 10.1126/science.1096920; Lynd LR, 1999, BIOTECHNOL PROGR, V15, P777, DOI 10.1021/bp990109e; Lynd LR, 2002, MICROBIOL MOL BIOL R, V66, P506, DOI 10.1128/MMBR.66.3.506-577.2002; MA K, 1993, P NATL ACAD SCI USA, V90, P5341, DOI 10.1073/pnas.90.11.5341; MA KS, 1994, FEMS MICROBIOL LETT, V122, P245, DOI 10.1016/0378-1097(94)00330-0; Matsumura Y, 2005, BIOMASS BIOENERG, V29, P269, DOI 10.1016/j.biombioe.2005.04.006; Millsaps JF, 2001, PHOTOCHEM PHOTOBIOL, V73, P630, DOI 10.1562/0031-8655(2001)073<0630:NPPPOH>2.0.CO;2; Moore RB, 1998, INT J HYDROGEN ENERG, V23, P617, DOI 10.1016/S0360-3199(97)00061-X; Morris D, 2006, J SCI FOOD AGR, V86, P1743, DOI 10.1002/jsfa.2561; MUIR M, 1985, J BACTERIOL, V163, P1237, DOI 10.1128/JB.163.3.1237-1242.1985; Ohno A, 2000, J ORG CHEM, V65, P6381, DOI 10.1021/jo000262j; Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736; Ramos A, 1997, APPL ENVIRON MICROB, V63, P4020, DOI 10.1128/AEM.63.10.4020-4025.1997; Salge JR, 2006, SCIENCE, V314, P801, DOI 10.1126/science.1131244; Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634; SMIL V, 1999, ENERGIES ILLUSTRATED, P1; Steele BCH, 2001, NATURE, V414, P345, DOI 10.1038/35104620; Stephanopoulos G., 1998, METAB ENG; *US DEP EN HYDR PR, 2005, DOE ANN NEW HYDR COS; Wheals AE, 1999, TRENDS BIOTECHNOL, V17, P482, DOI 10.1016/S0167-7799(99)01384-0; Woodward J, 2000, NATURE, V405, P1014, DOI 10.1038/35016633; Zhang YHP, 2006, BIOTECHNOL ADV, V24, P452, DOI 10.1016/j.biotechadv.2006.03.003; Zhang YHP, 2005, P NATL ACAD SCI USA, V102, P7321, DOI 10.1073/pnas.0408734102; Zhang YHP, 2004, BIOTECHNOL BIOENG, V88, P797, DOI 10.1002/bit.20282; Zhang YHP, 2004, APPL ENVIRON MICROB, V70, P1563, DOI 10.1128/AEM.70.3.1563-1569.2004	43	202	223	3	80	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e456	10.1371/journal.pone.0000456	http://dx.doi.org/10.1371/journal.pone.0000456			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520015	Green Published, gold			2022-12-25	WOS:000207446000004
J	Janniere, L; Canceill, D; Suski, C; Kanga, S; Dalmais, B; Lestini, R; Monnier, AF; Chapuis, J; Bolotin, A; Marina, T; Le Chatelier, E; Ehrlich, SD				Janniere, Laurent; Canceill, Danielle; Suski, Catherine; Kanga, Sophie; Dalmais, Berengere; Lestini, Roxane; Monnier, Anne-Francoise; Chapuis, Jerome; Bolotin, Alexander; Marina, Titok; Le Chatelier, Emmanuelle; Ehrlich, S. Dusko			Genetic Evidence for a Link Between Glycolysis and DNA Replication	PLOS ONE			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; INITIATION FREQUENCY; STRINGENT RESPONSE; CELL-DIVISION; PROTEIN; TRANSCRIPTION; COMPLEX; CHROMOSOME; MUTANTS	Background. A challenging goal in biology is to understand how the principal cellular functions are integrated so that cells achieve viability and optimal fitness in a wide range of nutritional conditions. Methodology/Principal Findings. We report here a tight link between glycolysis and DNA synthesis. The link, discovered during an analysis of suppressors of thermosensitive replication mutants in bacterium Bacillus subtilis, is very strong as some metabolic alterations fully restore viability to replication mutants in which a lethal arrest of DNA synthesis otherwise occurs at a high, restrictive, temperature. Full restoration of viability by such alterations was limited to cells with mutations in three elongation factors ( the lagging strand DnaE polymerase, the primase and the helicase) out of a large set of thermosensitive mutants affected in most of the replication proteins. Restoration of viability resulted, at least in part, from maintenance of replication protein activity at high temperature. Physiological studies suggested that this restoration depended on the activity of the three-carbon part of the glycolysis/gluconeogenesis pathway and occurred in both glycolytic and gluconeogenic regimens. Restoration took place abruptly over a narrow range of expression of genes in the three-carbon part of glycolysis. However, the absolute value of this range varied greatly with the allele in question. Finally, restoration of cell viability did not appear to be the result of a decrease in growth rate or an induction of major stress responses. Conclusions/Significance. Our findings provide the first evidence for a genetic system that connects DNA chain elongation to glycolysis. Its role may be to modulate some aspect of DNA synthesis in response to the energy provided by the environment and the underlying mechanism is discussed. It is proposed that related systems are ubiquitous.	[Janniere, Laurent; Canceill, Danielle; Suski, Catherine; Kanga, Sophie; Dalmais, Berengere; Lestini, Roxane; Monnier, Anne-Francoise; Chapuis, Jerome; Bolotin, Alexander; Marina, Titok; Le Chatelier, Emmanuelle; Ehrlich, S. Dusko] INRA, Lab Genet Microbienne, Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Janniere, L (corresponding author), INRA, Lab Genet Microbienne, Jouy En Josas, France.	laurent.janniere@jouy.inra.fr	LE CHATELIER, Emmanuelle/O-1243-2017; Lestini, Roxane/R-9285-2017; Ehrlich, S./Y-2423-2019; Bolotine, Alexandre/AAW-1156-2020	LE CHATELIER, Emmanuelle/0000-0002-2724-0536; Lestini, Roxane/0000-0001-7377-4734; Ehrlich, S./0000-0002-7563-4046; Bolotine, Alexandre/0000-0002-5878-8270; Titok, Marina/0000-0002-8623-5083; Suski Grabowski, Catherine/0000-0002-4892-6633; Janniere, Laurent/0000-0003-2353-3160				Barry ER, 2006, MICROBIOL MOL BIOL R, V70, P876, DOI 10.1128/MMBR.00029-06; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blinkova A, 2003, J BACTERIOL, V185, P3583, DOI 10.1128/JB.185.12.3583-3595.2003; BOYLAN SA, 1993, J BACTERIOL, V175, P7931, DOI 10.1128/JB.175.24.7931-7937.1993; Bruck I, 2000, J BIOL CHEM, V275, P28971, DOI 10.1074/jbc.M003565200; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; Canback B, 2002, P NATL ACAD SCI USA, V99, P6097, DOI 10.1073/pnas.082112499; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Chang VK, 2004, MOL CELL BIOL, V24, P6514, DOI 10.1128/MCB.24.14.6514-6524.2004; Chang VK, 2003, J BIOL CHEM, V278, P6093, DOI 10.1074/jbc.M209827200; Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708; CHEN YR, 1995, MOL CELL BIOL, V15, P4631; Cho YH, 2006, CELL, V127, P579, DOI 10.1016/j.cell.2006.09.028; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Dauner M, 2001, J BACTERIOL, V183, P7308, DOI 10.1128/JB.183.24.7308-7317.2001; Dervyn E, 2001, SCIENCE, V294, P1716, DOI 10.1126/science.1066351; Doan T, 2003, MOL MICROBIOL, V47, P1709, DOI 10.1046/j.1365-2958.2003.03404.x; Erbse A, 2004, BIOCHEM SOC T, V32, P617, DOI 10.1042/BST0320617; Eymann C, 2002, J BACTERIOL, V184, P2500, DOI 10.1128/JB.184.9.2500-2520.2002; Fillinger S, 2000, J BIOL CHEM, V275, P14031, DOI 10.1074/jbc.275.19.14031; Fitch MJ, 2003, J BIOL CHEM, V278, P25408, DOI 10.1074/jbc.M300699200; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; Foti JJ, 2005, MOL CELL, V17, P549, DOI 10.1016/j.molcel.2005.01.012; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Giraldo R, 2003, FEMS MICROBIOL REV, V26, P533, DOI 10.1111/j.1574-6976.2003.tb00629.x; Gon S, 2006, EMBO J, V25, P1137, DOI 10.1038/sj.emboj.7600990; Guzman EC, 2002, MOL MICROBIOL, V43, P487, DOI 10.1046/j.1365-2958.2002.02761.x; Hardy CD, 2005, MOL MICROBIOL, V57, P1636, DOI 10.1111/j.1365-2958.2005.04799.x; Hartl B, 2001, J BACTERIOL, V183, P2696, DOI 10.1128/JB.183.8.2696-2699.2001; HARWOOD CR, MOL BIOL METHODS BAC; HELMSTETTER CE, 1996, ESCHERICHIA COLI SAL, P1627; HENSON JM, 1979, GENETICS, V92, P1041; JINDAL HK, 1990, J BIOL CHEM, V265, P6540; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Kaguni JM, 2006, ANNU REV MICROBIOL, V60, P351, DOI 10.1146/annurev.micro.60.080805.142111; Katayama T, 2001, MOL MICROBIOL, V41, P9, DOI 10.1046/j.1365-2958.2001.02483.x; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005; Klevecz RR, 2004, P NATL ACAD SCI USA, V101, P1200, DOI 10.1073/pnas.0306490101; Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Laschet JJ, 2004, J NEUROSCI, V24, P7614, DOI 10.1523/JNEUROSCI.0868-04.2004; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; Le Chatelier E, 2004, J BIOL CHEM, V279, P1757, DOI 10.1074/jbc.M310719200; LEVINE A, 1991, J MOL BIOL, V219, P605, DOI 10.1016/0022-2836(91)90657-R; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; MAHER M, 1995, MOL CELL BIOL, V15, P3129; Mai B, 2002, MOL CELL BIOL, V22, P430, DOI 10.1128/MCB.22.2.430-441.2002; MAINE GT, 1984, GENETICS, V106, P365; MATHEWS CK, 1993, PROG NUCLEIC ACID RE, V44, P167, DOI 10.1016/S0079-6603(08)60220-2; McHenry CS, 2003, MOL MICROBIOL, V49, P1157, DOI 10.1046/j.1365-2958.2003.03645.x; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Michelsen O, 2003, MICROBIOL-SGM, V149, P1001, DOI 10.1099/mic.0.26058-0; Mijakovic I, 2006, NUCLEIC ACIDS RES, V34, P1588, DOI 10.1093/nar/gkj514; Molina F, 2004, MOL MICROBIOL, V52, P1597, DOI 10.1111/j.1365-2958.2004.04097.x; Moreno MS, 2001, MOL MICROBIOL, V39, P1366, DOI 10.1046/j.1365-2958.2001.02328.x; Noirot-Gros MF, 2002, P NATL ACAD SCI USA, V99, P8342, DOI 10.1073/pnas.122040799; Norris V, 2007, MICROBIOL MOL BIOL R, V71, P230, DOI 10.1128/MMBR.00035-06; Ortenberg R, 2004, P NATL ACAD SCI USA, V101, P7439, DOI 10.1073/pnas.0401965101; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; Peter BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-r87; Petersen C, 2000, J BIOL CHEM, V275, P3931, DOI 10.1074/jbc.275.6.3931; PETIT MA, 1990, J BACTERIOL, V172, P6736, DOI 10.1128/jb.172.12.6736-6740.1990; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; REEVE JN, 1970, J BACTERIOL, V104, P1052, DOI 10.1128/JB.104.3.1052-1064.1970; RICARD M, 1973, J BACTERIOL, V116, P314, DOI 10.1128/JB.116.1.314-322.1973; Riedinger HJ, 2001, J BIOL CHEM, V276, P47122, DOI 10.1074/jbc.M106938200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; Schneider DA, 2004, J BIOL CHEM, V279, P8262, DOI 10.1074/jbc.M311996200; SCHREIBER G, 1995, CURR MICROBIOL, V30, P27, DOI 10.1007/BF00294520; SCHUMANN W, FUNCTIONAL ANAL BACT; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Skovgaard O, 2005, MICROBIOL-SGM, V151, P963, DOI 10.1099/mic.0.27630-0; Sutera VA, 2006, MOL MICROBIOL, V60, P229, DOI 10.1111/j.1365-2958.2006.05093.x; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Titok M, 2006, MICROBIOL-SGM, V152, P1471, DOI 10.1099/mic.0.28693-0; Tu BP, 2005, SCIENCE, V310, P1152, DOI 10.1126/science.1120499; Tuominen F W, 1975, Methods Enzymol, V42, P157; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; Velten M, 2003, MOL CELL, V11, P1009, DOI 10.1016/S1097-2765(03)00130-8; WALKER JR, 1982, P NATL ACAD SCI-BIOL, V79, P3340, DOI 10.1073/pnas.79.10.3340; Walker JR, 2006, BIOCHIMIE, V88, P1, DOI 10.1016/j.biochi.2005.08.009; Wegrzyn G, 2002, MICROB CELL FACT, V1, DOI 10.1186/1475-2859-1-2; Westers H, 2003, MOL BIOL EVOL, V20, P2076, DOI 10.1093/molbev/msg219; Yao DC, 2006, CELL, V124, P275, DOI 10.1016/j.cell.2005.11.024; Zeghouf M, 2004, J PROTEOME RES, V3, P463, DOI 10.1021/pr034084x; Zhang SY, 2005, J BACTERIOL, V187, P7554, DOI 10.1128/JB.187.22.7554-7560.2005; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	96	56	57	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e447	10.1371/journal.pone.0000447	http://dx.doi.org/10.1371/journal.pone.0000447			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505547	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445900007
J	Smolen, P				Smolen, Paul			A Model of Late Long-Term Potentiation Simulates Aspects of Memory Maintenance	PLOS ONE			English	Article								Late long-term potentiation (L-LTP) denotes long-lasting strengthening of synapses between neurons. L-LTP appears essential for the formation of long-term memory, with memories at least partly encoded by patterns of strengthened synapses. How memories are preserved for months or years, despite molecular turnover, is not well understood. Ongoing recurrent neuronal activity, during memory recall or during sleep, has been hypothesized to preferentially potentiate strong synapses, preserving memories. This hypothesis has not been evaluated in the context of a mathematical model representing ongoing activity and biochemical pathways important for L-LTP. In this study, ongoing activity was incorporated into two such models - a reduced model that represents some of the essential biochemical processes, and a more detailed published model. The reduced model represents synaptic tagging and gene induction simply and intuitively, and the detailed model adds activation of essential kinases by Ca(2+). Ongoing activity was modeled as continual brief elevations of Ca(2+). In each model, two stable states of synaptic strength/weight resulted. Positive feedback between synaptic weight and the amplitude of ongoing Ca(2+) transients underlies this bistability. A tetanic or theta-burst stimulus switches a model synapse from a low basal weight to a high weight that is stabilized by ongoing activity. Bistability was robust to parameter variations in both models. Simulations illustrated that prolonged periods of decreased activity reset synaptic strengths to low values, suggesting a plausible forgetting mechanism. However, episodic activity with shorter inactive intervals maintained strong synapses. Both models support experimental predictions. Tests of these predictions are expected to further understanding of how neuronal activity is coupled to maintenance of synaptic strength. Further investigations that examine the dynamics of activity and synaptic maintenance can be expected to help in understanding how memories are preserved for up to a lifetime in animals including humans.	Univ Texas Med Sch Houston, WM Keck Ctr Neurobiol Learning & Memory, Dept Neurobiol & Anat, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston	Smolen, P (corresponding author), Univ Texas Med Sch Houston, WM Keck Ctr Neurobiol Learning & Memory, Dept Neurobiol & Anat, Houston, TX USA.	Paul.D.Smolen@uth.tmc.edu			National Institutes of Health [P01 NS038310]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS038310] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by National Institutes of Health grant P01 NS038310	Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; ABELES M, 1993, J NEUROPHYSIOL, V70, P1624; Abraham WC, 2002, J NEUROSCI, V22, P9626; Bhalla US, 2004, BIOPHYS J, V87, P745, DOI 10.1529/biophysj.104.040501; Bhalla US, 2002, BIOPHYS J, V83, P740, DOI 10.1016/S0006-3495(02)75205-3; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Blitzer RD, 2005, BIOL PSYCHIAT, V57, P113, DOI 10.1016/j.biopsych.2004.02.031; Bradshaw JM, 2003, P NATL ACAD SCI USA, V100, P10512, DOI 10.1073/pnas.1932759100; Buckby LE, 2006, MOL CELL NEUROSCI, V31, P805, DOI 10.1016/j.mcn.2006.01.009; Burrone J, 2003, CURR OPIN NEUROBIOL, V13, P560, DOI 10.1016/j.conb.2003.09.007; Chen HX, 2001, J NEUROPHYSIOL, V85, P1368, DOI 10.1152/jn.2001.85.4.1368; Cui ZZ, 2005, EUR J NEUROSCI, V22, P755, DOI 10.1111/j.1460-9568.2005.04257.x; Cui ZZ, 2004, NEURON, V41, P781, DOI 10.1016/S0896-6273(04)00072-8; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; Fenton AA, 1998, P NATL ACAD SCI USA, V95, P3182, DOI 10.1073/pnas.95.6.3182; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Frey U, 1998, NEUROPHARMACOLOGY, V37, P545, DOI 10.1016/S0028-3908(98)00040-9; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Fusi S, 2000, NEURAL COMPUT, V12, P2227, DOI 10.1162/089976600300014917; Fusi S, 2005, NEURON, V45, P599, DOI 10.1016/j.neuron.2005.02.001; Govindarajan A, 2006, NAT REV NEUROSCI, V7, P575, DOI 10.1038/nrn1937; Hayer A, 2005, PLOS COMPUT BIOL, V1, P137, DOI 10.1371/journal.pcbi.0010020; Hayon G, 2005, J COMPUT NEUROSCI, V18, P41, DOI 10.1007/s10827-005-5479-1; Horn D, 1998, NETWORK-COMP NEURAL, V9, P577, DOI 10.1088/0954-898X/9/4/011; Horn D, 1998, NEURAL COMPUT, V10, P1, DOI 10.1162/089976698300017863; Ikegaya Y, 2004, SCIENCE, V304, P559, DOI 10.1126/science.1093173; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Jacobs J, 2007, J NEUROSCI, V27, P3839, DOI 10.1523/JNEUROSCI.4636-06.2007; Kalitzin S, 2000, BIOL CYBERN, V83, P139, DOI 10.1007/s004220000157; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Karpova A, 2006, NEUROSCIENCE, V137, P833, DOI 10.1016/j.neuroscience.2005.10.012; Kauderer BS, 2000, P NATL ACAD SCI USA, V97, P13342, DOI 10.1073/pnas.97.24.13342; KAVANAU JL, 1994, BEHAV BRAIN RES, V63, P111; Kavanau JL, 1997, NEUROSCIENCE, V79, P7, DOI 10.1016/S0306-4522(96)00610-0; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Kikuchi S, 2003, NEURAL NETWORKS, V16, P1389, DOI 10.1016/j.neunet.2003.09.002; Krishna S, 2006, P NATL ACAD SCI USA, V103, P10840, DOI 10.1073/pnas.0604085103; Lee AK, 2002, NEURON, V36, P1183, DOI 10.1016/S0896-6273(02)01096-6; Lestienne R, 2001, PROG NEUROBIOL, V65, P545, DOI 10.1016/S0301-0082(01)00019-3; Levy WB, 2005, NEURAL NETWORKS, V18, P1242, DOI 10.1016/j.neunet.2005.08.005; Ling DSF, 2006, HIPPOCAMPUS, V16, P443, DOI 10.1002/hipo.20171; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Manahan-Vaughan D, 2000, J NEUROSCI, V20, P8572, DOI 10.1523/JNEUROSCI.20-22-08572.2000; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Martin SJ, 2002, HIPPOCAMPUS, V12, P609, DOI 10.1002/hipo.10107; Molter C, 2007, HIPPOCAMPUS, V17, P201, DOI 10.1002/hipo.20258; Montgomery JM, 2002, NEURON, V33, P765, DOI 10.1016/S0896-6273(02)00606-2; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Park CS, 2006, J BIOL CHEM, V281, P30195, DOI 10.1074/jbc.M605876200; Pastalkova E, 2006, SCIENCE, V313, P1141, DOI 10.1126/science.1128657; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; Press W., 1992, NUMERICAL RECIPES FO; Rubin J, 2001, PHYS REV LETT, V86, P364, DOI 10.1103/PhysRevLett.86.364; Sabatini BL, 2002, NEURON, V33, P439, DOI 10.1016/S0896-6273(02)00573-1; Sajikumar S, 2004, NEUROBIOL LEARN MEM, V82, P12, DOI 10.1016/j.nlm.2004.03.003; Sakagami H, 2005, EUR J NEUROSCI, V22, P2697, DOI 10.1111/j.1460-9568.2005.04463.x; Schmitt JM, 2005, J NEUROSCI, V25, P1281, DOI 10.1523/JNEUROSCI.4086-04.2005; Seliger P, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.011905; Serrano P, 2005, J NEUROSCI, V25, P1979, DOI 10.1523/JNEUROSCI.5132-04.2005; Shimizu E, 2000, SCIENCE, V290, P1170, DOI 10.1126/science.290.5494.1170; Simpson RE, 2006, J BIOL CHEM, V281, P17379, DOI 10.1074/jbc.M510992200; Smolen P, 2006, BIOPHYS J, V90, P2760, DOI 10.1529/biophysj.105.072470; SORRA KE, 1993, J NEUROSCI, V13, P3736; Tsokas P, 2005, J NEUROSCI, V25, P5833, DOI 10.1523/JNEUROSCI.0599-05.2005; Vickers CA, 2005, J PHYSIOL-LONDON, V568, P803, DOI 10.1113/jphysiol.2005.092924; Wang HM, 2006, PROG NEUROBIOL, V79, P123, DOI 10.1016/j.pneurobio.2006.06.004; Washbourne P, 2002, NAT NEUROSCI, V5, P751, DOI 10.1038/nn883; Whitlock JR, 2006, SCIENCE, V313, P1093, DOI 10.1126/science.1128134; Wittenberg GM, 2002, HIPPOCAMPUS, V12, P637, DOI 10.1002/hipo.10102; Wong ST, 1999, NEURON, V23, P787, DOI 10.1016/S0896-6273(01)80036-2; Woo NH, 2000, J NEUROPHYSIOL, V84, P2739, DOI 10.1152/jn.2000.84.6.2739; Yasuda R, 2006, NAT NEUROSCI, V9, P283, DOI 10.1038/nn1635; Yeung LC, 2004, P NATL ACAD SCI USA, V101, P14943, DOI 10.1073/pnas.0405555101; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002; Young JZ, 2006, EUR J NEUROSCI, V23, P1784, DOI 10.1111/j.1460-9568.2006.04707.x	81	11	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e445	10.1371/journal.pone.0000445	http://dx.doi.org/10.1371/journal.pone.0000445			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505541	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445900005
J	Lin, B; Malanoski, AP; Wang, Z; Blaney, KM; Ligler, AG; Rowley, RK; Hanson, EH; von Rosenvinge, E; Ligler, FS; Kusterbeck, AW; Metzgar, D; Barrozo, CP; Russell, KL; Tibbetts, C; Schnur, JM; Stenger, DA				Lin, Baochuan; Malanoski, Anthony P.; Wang, Zheng; Blaney, Kate M.; Ligler, Adam G.; Rowley, Robb K.; Hanson, Eric H.; von Rosenvinge, Erik; Ligler, Frances S.; Kusterbeck, Anne W.; Metzgar, David; Barrozo, Christopher P.; Russell, Kevin L.; Tibbetts, Clark; Schnur, Joel M.; Stenger, David A.			Application of Broad-Spectrum, Sequence-Based Pathogen Identification in an Urban Population	PLOS ONE			English	Article								A broad spectrum detection platform that provides sequence level resolution of target regions would have a significant impact in public health, case management, and means of expanding our understanding of the etiology of diseases. A previously developed respiratory pathogen microarray (RPM v.1) demonstrated the capability of this platform for this purpose. This newly developed RPM v.1 was used to analyze 424 well-characterized nasal wash specimens from patients presenting with febrile respiratory illness in the Washington, D. C. metropolitan region. For each specimen, the RPM v.1 results were compared against composite reference assay (viral and bacterial culture and, where appropriate, RT-PCR/PCR) results. Across this panel, the RPM assay showed >= 98% overall agreement for all the organisms detected compared with reference methods. Additionally, the RPM v.1 results provide sequence information which allowed phylogenetic classification of circulating influenza A viruses in similar to 250 clinical specimens, and allowed monitoring the genetic variation as well as antigenic variability prediction. Multiple pathogens (2-4) were detected in 58 specimens (13.7%) with notably increased abundances of respiratory colonizers (esp. S. pneumoniae) during viral infection. This first-ever comparison of a broad-spectrum viral and bacterial identification technology of this type against a large battery of conventional "gold standard'' assays confirms the utility of the approach for both medical surveillance and investigations of complex etiologies of illness caused by respiratory co-infections.	[Lin, Baochuan; Malanoski, Anthony P.; Ligler, Frances S.; Kusterbeck, Anne W.; Schnur, Joel M.; Stenger, David A.] USN, Res Lab, Ctr Bio Mol Sci & Engn, Washington, DC 20375 USA; [Wang, Zheng; Blaney, Kate M.; Ligler, Adam G.] NOVA Res Inc, Alexandria, VA USA; [Rowley, Robb K.; Hanson, Eric H.; Tibbetts, Clark] Headquarters USAF Surg Gen, Falls Church, VA USA; [von Rosenvinge, Erik] Malcolm Grow USAF Med Ctr, Andrews AFB, MD USA; [Metzgar, David; Barrozo, Christopher P.; Russell, Kevin L.] Naval Hlth Res Ctr, Ctr Deployment Hlth Res, Dept Def, San Diego, CA USA	United States Department of Defense; United States Navy; Naval Research Laboratory; Nova Research, Inc.; United States Department of Defense; United States Air Force; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC)	Lin, B (corresponding author), USN, Res Lab, Ctr Bio Mol Sci & Engn, Code 6900, Washington, DC 20375 USA.	baochuan.lin@nrl.navy.mil	Lin, Baochuan/A-8390-2009; Malanoski, Anthony/P-6975-2019; Hanson, Eric H/B-7367-2009; Malanoski, Anthony P/C-7814-2011	Lin, Baochuan/0000-0002-9484-0785; Malanoski, Anthony/0000-0001-6192-888X; Malanoski, Anthony P/0000-0001-6192-888X; von Rosenvinge, Erik C./0000-0002-1862-7288	NRL; Office of Naval Research	NRL; Office of Naval Research(Office of Naval Research)	The funding for this research is provided by the NRL base program and the Office of Naval Research. This project would not be possible without the support from the Air Force Surgeon General Office, the Joint Program Executive Office and Defense Threat Reduction Agency during the Silent Guardian Demonstration Project.	Bellau-Pujol S, 2005, J VIROL METHODS, V126, P53, DOI 10.1016/j.jviromet.2005.01.020; Briese T, 2005, EMERG INFECT DIS, V11, P310, DOI 10.3201/eid1102.040492; Davignon L, 2005, J CLIN MICROBIOL, V43, P5690, DOI 10.1128/JCM.43.11.5690-5695.2005; Dunbar SA, 2006, CLIN CHIM ACTA, V363, P71, DOI 10.1016/j.cccn.2005.06.023; Ecker DJ, 2005, P NATL ACAD SCI USA, V102, P8012, DOI 10.1073/pnas.0409920102; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lazarus R, 2001, BMC PUBLIC HEALTH, V1, DOI 10.1186/1471-2458-1-9; Lewis MD, 2002, AM J PREV MED, V23, P180, DOI 10.1016/S0749-3797(02)00490-7; LIN B, 2006, J CLIN MICROBIO; Lin BC, 2007, J CLIN MICROBIOL, V45, P443, DOI 10.1128/JCM.01870-06; Lin BC, 2006, GENOME RES, V16, P527, DOI 10.1101/gr.4337206; Lin BC, 2004, J CLIN MICROBIOL, V42, P3232, DOI 10.1128/JCM.42.7.3232-3239.2004; Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077; Malanoski AP, 2006, NUCLEIC ACIDS RES, V34, P5300, DOI 10.1093/nar/gkl565; Peltola VT, 2004, PEDIATR INFECT DIS J, V23, pS87, DOI 10.1097/01.inf.0000108197.81270.35; Vora GJ, 2006, EMERG INFECT DIS, V12, P921, DOI 10.3201/eid1206.050245; Vora GJ, 2005, P NATL ACAD SCI USA, V102, P19109, DOI 10.1073/pnas.0505033102; Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699; Wang D, 2003, PLOS BIOL, V1, P257, DOI 10.1371/journal.pbio.0000002; Wang Z, 2006, EMERG INFECT DIS, V12, P638, DOI 10.3201/eid1204.051441; Wilson KH, 2002, APPL ENVIRON MICROB, V68, P2535, DOI 10.1128/AEM.68.5.2535-2541.2002; Wilson WJ, 2002, MOL CELL PROBE, V16, P119, DOI 10.1006/mcpr.2001.0397	23	27	28	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e419	10.1371/journal.pone.0000419	http://dx.doi.org/10.1371/journal.pone.0000419			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17502915	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445800001
J	Pauleau, AL; Larochette, N; Giordanetto, F; Scholz, SR; Poncet, D; Zamzami, N; Goldmacher, VS; Kroemer, G				Pauleau, A-L; Larochette, N.; Giordanetto, F.; Scholz, S. R.; Poncet, D.; Zamzami, N.; Goldmacher, V. S.; Kroemer, G.			Structure-function analysis of the interaction between Bax and the cytomegalovirus-encoded protein vMIA	ONCOGENE			English	Article						cytomegalovirus; vMIA; mitochondria; Bak; Bax; apoptosis	CELL-DEATH; INDUCED APOPTOSIS; BCL-XL; MITOCHONDRIA; INHIBITOR; INFECTION; CANCER; LOCALIZATION; RECOGNITION; ACTIVATION	The viral mitochondrial inhibitor of apoptosis ( vMIA) encoded by the human cytomegalovirus exerts cytopathic effects and neutralizes the proapoptotic endogenous Bcl-2 family member Bax by recruiting it to mitochondria, inducing its oligomerization and membrane insertion. Using a combination of computational modeling and mutational analyses, we addressed the structure-function relationship of the molecular interaction between the protein Bax and the viral antiapoptotic protein vMIA. We propose a model in which vMIA exhibits an overall fold similar to Bcl-X-L. In contrast to Bcl-X-L, however, this predicted conformation of vMIA does not bind to the BH3 domain of Bax and rather engages in electrostatic interactions that involve a stretch of amino acids between the BH3 and BH2 domains of Bax and an alpha-helical domain located within the previously defined Bax-binding domain of vMIA, between the putative BH1-like and BH2-like domains. According to this model, vMIA is likely to bind Bax preferentially in its membrane-inserted conformation. The capacity of vMIA to cause fragmentation of the mitochondrial network and disorganization of the actin cytoskeleton is independent of its Bax-binding function. We found that Delta 131-147 vMIA mutant, which lacks both the Bax-binding function and cell-death suppression but has intact mitochondria-targeting capacity, is similar to vMIA in its ability to disrupt the mitochondrial network and to disorganize the actin cytoskeleton. vMIA Delta 131-147 is a dominant-negative inhibitor of the antiapoptotic function of wild-type vMIA. Our experiments with vMIA Delta 131-147 suggest that vMIA forms homo-oligomers, which may engage in cooperative and/or multivalent interactions with Bax, leading to its functional neutralization.	Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; Univ Paris 11, Fac Med, Villejuif, France; AstraZeneca R&D, Lead Generat, Molndal, Sweden; ImmunoGen Inc, Cambridge, MA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; AstraZeneca; ImmunoGen, Inc.	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; Poncet, Delphine A/A-7190-2016; KROEMER, Guido/B-4263-2013; LAROCHETTE, Nathanael/R-4298-2017; Giordanetto, Fabrizio/E-2811-2012	Poncet, Delphine A/0000-0003-0446-5262; KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Goldmakher, Viktor/0000-0001-6130-4436				ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnoult D, 2004, P NATL ACAD SCI USA, V101, P7988, DOI 10.1073/pnas.0401897101; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Day CL, 2005, J BIOL CHEM, V280, P4738, DOI 10.1074/jbc.M411434200; Froberg MK, 2004, ANN CLIN LAB SCI, V34, P123; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Goldmacher VS, 2005, APOPTOSIS, V10, P251, DOI 10.1007/s10495-005-0800-z; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8; Hassan M, 1996, MOL DIVERS, V2, P64, DOI 10.1007/BF01718702; Hayajneh WA, 2001, VIROLOGY, V279, P233, DOI 10.1006/viro.2000.0726; Hoever G, 2005, BIOCHEM BIOPH RES CO, V326, P395, DOI 10.1016/j.bbrc.2004.11.042; Huang JH, 2005, CIRCULATION, V112, P76, DOI 10.1161/CIRCULATIONAHA.105.535740; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; Jurak I, 2006, EMBO J, V25, P2634, DOI 10.1038/sj.emboj.7601133; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lang-Rollin I, 2005, APOPTOSIS, V10, P809, DOI 10.1007/s10495-005-0378-5; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mavinakere MS, 2006, J VIROL, V80, P6771, DOI 10.1128/JVI.00492-06; McCormick AL, 2005, J VIROL, V79, P12205, DOI 10.1128/JVI.79.19.12205-12217.2005; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McMartin C, 1997, J COMPUT AID MOL DES, V11, P333, DOI 10.1023/A:1007907728892; Michelson S, 2004, HUM IMMUNOL, V65, P465, DOI 10.1016/j.humimm.2004.02.002; Moont G, 1999, PROTEINS, V35, P364, DOI 10.1002/(SICI)1097-0134(19990515)35:3<364::AID-PROT11>3.0.CO;2-4; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Poncet D, 2006, J CELL BIOL, V174, P985, DOI 10.1083/jcb.200604069; Reboredo M, 2004, J GEN VIROL, V85, P3555, DOI 10.1099/vir.0.80379-0; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Samanta M, 2003, J UROLOGY, V170, P998, DOI 10.1097/01.ju.0000080263.46164.97; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Skaletskaya A, 2001, P NATL ACAD SCI USA, V98, P7829, DOI 10.1073/pnas.141108798; Smith MS, 2004, J LEUKOCYTE BIOL, V76, P65, DOI 10.1189/jlb.1203621; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Terrasson J, 2005, CANCER RES, V65, P2787, DOI 10.1158/0008-5472.CAN-04-2019; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281	47	44	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7067	7080		10.1038/sj.onc.1210511	http://dx.doi.org/10.1038/sj.onc.1210511			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496930				2022-12-25	WOS:000250715000001
J	Ku, SY; Yip, P; Cornell, KA; Riscoe, MK; Behr, JB; Guillerm, G; Howell, PL				Ku, Shao-Yang; Yip, Patrick; Cornell, Kenneth A.; Riscoe, Michael K.; Behr, Jean-Bernard; Guillerm, Georges; Howell, P. Lynne			Structures of 5-methylthioribose kinase reveal substrate specificity and unusual mode of nucleotide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SALVAGE PATHWAY; CRYSTAL-STRUCTURE; METHYLTHIORIBOSE KINASE; PROTEIN; ENZYME; PHOSPHATE; 5-METHYLTHIOADENOSINE; REFINEMENT; MECHANISMS; ALIGNMENT	The methionine salvage pathway is ubiquitous in all organisms, but metabolic variations exist between bacteria and mammals. 5-Methylthioribose (MTR) kinase is a key enzyme in methionine salvage in bacteria and the absence of a mammalian homolog suggests that it is a good target for the design of novel antibiotics. The structures of the apo-form of Bacillus subtilis MTR kinase, as well as its ADP, ADP-PO4, AMPPCP, and AMPPCP-MTR complexes have been determined. MTR kinase has a bilobal eukaryotic protein kinase fold but exhibits a number of unique features. The protein lacks the DFG motif typically found at the beginning of the activation loop and instead coordinates magnesium via a DXE motif (Asp(250)-Glu(252)). In addition, the glycine-rich loop of the protein, analogous to the "Gly triad" in protein kinases, does not interact extensively with the nucleotide. The MTR substrate binding site consists of Asp(233) of the catalytic HGD motif, a novel twin arginine motif (Arg(340)/Arg(341)), and a semi-conserved W-loop, which appears to regulate MTR binding specificity. No lobe closure is observed for MTR kinase upon substrate binding. This is probably because the enzyme lacks the lobe closure/inducing interactions between the C-lobe of the protein and the ribosyl moiety of the nucleotide that are typically responsible for lobe closure in protein kinases. The current structures suggest that MTR kinase has a dissociative mechanism.	Hosp Sick Children, Res Inst, Program Mol Struct & Funct, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A8, Canada; Boise State Univ, Dept Chem, Boise, ID 83725 USA; Portland State Univ, Dept Chem, Portland, OR 97207 USA; Vet Affairs Med Ctr, Med Res Serv, Portland, OR 97201 USA; Univ Reims, CNRS, UMR URCA 6519, F-51687 Reims 2, France	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Idaho; Boise State University; Portland State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Howell, PL (corresponding author), Hosp Sick Children, Res Inst, Program Mol Struct & Funct, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	howell@sickkids.ca						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Breton C, 1998, J BIOCHEM, V123, P1000; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burk DL, 2001, BIOCHEMISTRY-US, V40, P8756, DOI 10.1021/bi010504p; Cleland WW, 2006, CHEM REV, V106, P3252, DOI 10.1021/cr050287o; Cornell KA, 1996, BIOCHEM J, V317, P285, DOI 10.1042/bj3170285; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FERRO AJ, 1978, J BIOL CHEM, V253, P6021; FERRO AJ, 1983, METHOD ENZYMOL, V94, P361; Fraternali F, 2002, NUCLEIC ACIDS RES, V30, P2950, DOI 10.1093/nar/gkf373; GIANOTTI AJ, 1990, J BIOL CHEM, V265, P831; GURANOWSKI A, 1983, PLANT PHYSIOL, V71, P932, DOI 10.1104/pp.71.4.932; Hayward S, 2004, J MOL BIOL, V339, P1001, DOI 10.1016/j.jmb.2004.04.004; Hemmer W, 1997, J BIOL CHEM, V272, P16946, DOI 10.1074/jbc.272.27.16946; Henrick K, 1998, TRENDS BIOCHEM SCI, V23, P358, DOI 10.1016/S0968-0004(98)01253-5; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; Kannan N, 2005, J MOL BIOL, V351, P956, DOI 10.1016/j.jmb.2005.06.057; Ku SY, 2007, ACTA CRYSTALLOGR D, V63, P493, DOI 10.1107/S0907444907006592; Ku SY, 2004, ACTA CRYSTALLOGR D, V60, P116, DOI 10.1107/S0907444903022042; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li JG, 2001, GLYCOBIOLOGY, V11, P217, DOI 10.1093/glycob/11.3.217; Lodowski DT, 2006, J BIOL CHEM, V281, P16785, DOI 10.1074/jbc.M601327200; Malito E, 2006, J MOL BIOL, V364, P136, DOI 10.1016/j.jmb.2006.08.084; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murphy BA, 2002, J BACTERIOL, V184, P2314, DOI 10.1128/JB.184.8.2314-2318.2002; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parang K, 2001, NAT STRUCT BIOL, V8, P37; PEGG AE, 1969, BIOCHEM J, V115, P241, DOI 10.1042/bj1150241; Peisach D, 2003, STRUCTURE, V11, P703, DOI 10.1016/S0969-2126(03)00094-7; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; RISCOE MK, 1988, ANTIMICROB AGENTS CH, V32, P1904, DOI 10.1128/AAC.32.12.1904; Sauter M, 2004, PLANT PHYSIOL, V136, P4061, DOI 10.1104/pp.104.053587; SCHLENK F, 1973, BIOCHIM BIOPHYS ACTA, V320, P357, DOI 10.1016/0304-4165(73)90316-4; Sekowska A, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-9; Sekowska A, 2001, BMC Microbiol, V1, P15, DOI 10.1186/1471-2180-1-15; Sekowska A, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-8; SUFRIN JR, 1995, ANTIMICROB AGENTS CH, V39, P2511, DOI 10.1128/AAC.39.11.2511; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson PR, 2002, BIOCHEMISTRY-US, V41, P7001, DOI 10.1021/bi0256680; TOWER PA, 1993, J GEN MICROBIOL, V139, P1027, DOI 10.1099/00221287-139-5-1027; Weeks CM, 2002, Z KRISTALLOGR, V217, P686, DOI 10.1524/zkri.217.12.686.20659; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Ye YZ, 2003, BIOINFORMATICS, V19, pII246, DOI 10.1093/bioinformatics/btg1086; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423	56	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22195	22206		10.1074/jbc.M611045200	http://dx.doi.org/10.1074/jbc.M611045200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17522047	hybrid			2022-12-25	WOS:000248196800065
J	Fialcowitz-White, EJ; Brewer, BY; Ballin, JD; Willis, CD; Toth, EA; Wilson, GM				Fialcowitz-White, Elizabeth J.; Brewer, Brandy Y.; Ballin, Jeff D.; Willis, Chris D.; Toth, Eric A.; Wilson, Gerald M.			Specific protein domains mediate cooperative assembly of HuR oligomers on AU-rich mRNA-destabilizing sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; FLUORESCENCE ANISOTROPY; ESCHERICHIA-COLI; DNA INTERACTIONS; MAMMALIAN-CELLS; GENE-EXPRESSION; POLY(A) TAIL; ELEMENTS; STABILITY; ALPHA	The RNA-binding factor HuR is a ubiquitously expressed member of the Hu protein family that binds and stabilizes mRNAs containing AU-rich elements (AREs). Huproteins share a common domain organization of two tandemly arrayed RNA recognition motifs (RRMs) near the N terminus, followed by a basic hinge domain and a third RRM near the C terminus. In this study, we engineered recombinant wild-type and mutant HuR proteins lacking affinity tags to characterize their ARE-binding properties. Using combinations of electrophoretic mobility shift and fluorescence anisotropy-based binding assays, we show that HuR can bind ARE substrates as small as 13 nucleotides with low nanomolar affinity, but forms cooperative oligomeric protein complexes on ARE substrates of at least 18 nucleotides in length. Analyses of deletion mutant proteins indicated that RRM3 does not contribute to high affinity recognition of ARE substrates, but is required for cooperative assembly of HuR oligomers on RNA. Finally, the hinge domain between RRM2 and RRM3 contributes significant binding energy to HuR center dot ARE complex formation in an ARE length-dependent manner. The hinge does not enhance RNA-binding activity by increased ion pair formation despite extensive positive charge within this region, and it does not thermodynamically stabilize protein folding. Together, the results define distinct roles for the HuR hinge and RRM3 domains in formation of cooperative HuR center dot ARE complexes in solution.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Wilson, GM (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	gwils001@umaryland.edu	Wilson, Gerald/AAF-3874-2019; Ballin, Jeff D/AAC-3869-2022; Ballin, Jeff/D-3752-2011	Ballin, Jeff D/0000-0002-2712-130X; Ballin, Jeff/0000-0002-2712-130X; Willis, Chris/0000-0002-6639-6568; Wilson, Gerald/0000-0002-1273-7507	NCI NIH HHS [R01 CA102428-04, R01 CA102428] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102428] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Brewer BY, 2004, J BIOL CHEM, V279, P27870, DOI 10.1074/jbc.M402551200; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; Bujalowski W., 2000, SPECTROPHOTOMETRY SP, P141; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; de Silanes IL, 2005, MOL CELL BIOL, V25, P9520, DOI 10.1128/MCB.25.21.9520-9531.2005; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fialcowitz EJ, 2005, J BIOL CHEM, V280, P22406, DOI 10.1074/jbc.M500618200; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Gouble A, 2000, ONCOGENE, V19, P5377, DOI 10.1038/sj.onc.1203910; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Inoue M, 2000, NUCLEIC ACIDS RES, V28, P1743, DOI 10.1093/nar/28.8.1743; Jancarik J, 2004, ACTA CRYSTALLOGR D, V60, P1670, DOI 10.1107/S0907444904010972; Keller RW, 2000, J MOL BIOL, V297, P569, DOI 10.1006/jmbi.2000.3572; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; Lu JY, 2006, GENE DEV, V20, P3174, DOI 10.1101/gad.1467606; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Manyusa S, 1999, BIOCHEMISTRY-US, V38, P9533, DOI 10.1021/bi990550d; Meisner NC, 2004, CHEMBIOCHEM, V5, P1432, DOI 10.1002/cbic.200400219; MISRA VK, 1995, P NATL ACAD SCI USA, V92, P4691, DOI 10.1073/pnas.92.10.4691; Mobarak CD, 2000, MOL BIOL CELL, V11, P3191, DOI 10.1091/mbc.11.9.3191; Nabors LB, 2001, CANCER RES, V61, P2154; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Tudyka T, 1997, PROTEIN SCI, V6, P2180; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; Wilson GM, 2005, REV FLUORESCENCE, V2, P223; Wilson GM, 2003, J BIOL CHEM, V278, P33039, DOI 10.1074/jbc.M305775200; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Zou TT, 2006, J BIOL CHEM, V281, P19387, DOI 10.1074/jbc.M602344200	55	75	77	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20948	20959		10.1074/jbc.M701751200	http://dx.doi.org/10.1074/jbc.M701751200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17517897	hybrid, Green Accepted			2022-12-25	WOS:000248047500021
J	Laxalt, AM; Raho, N; ten Have, A; Lamattina, L				Laxalt, Ana M.; Raho, Nicolas; ten Have, Arjen; Lamattina, Lorenzo			Nitric Oxide is critical for inducing phosphatidic acid accumulation in xylanase-elicited tomato cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PLANT-DISEASE RESISTANCE; LATERAL ROOT-FORMATION; CULTURED RICE CELLS; PHOSPHOLIPASE-D; ABSCISIC-ACID; HYDROGEN-PEROXIDE; SIGNALING PATHWAYS; OXIDATIVE BURST; NADPH OXIDASE	Nitric Oxide (NO) is a second messenger related to development and (a) biotic stress responses in plants. We have studied the role of NO in signaling during plant defense responses upon xylanase elicitation. Treatment of tomato cell cultures with the fungal elicitor xylanase resulted in a rapid and dose-dependent NO accumulation. We have demonstrated that NO is required for the production of the lipid second messenger phosphatidic acid (PA) via the activation of the phospholipase C (PLC) and diacylglycerol kinase (DGK) pathway. Defense-related responses downstream of PA were studied. PA and, correspondingly, xylanase were shown to induce reactive oxygen species production. Scavenging of NO or inhibition of either the PLC or the DGK enzyme diminished xylanase-induced reactive oxygen species production. Xylanase-induced PLD beta 1 and PR1 mRNA levels decreased when NO or PA production were compromised. Finally, we have shown that NO and PA are involved in the induction of cell death by xylanase. Treatment with NO scavenger cPTIO, PLC inhibitor U73122, or DGK inhibitor R59022 diminished xylanase-induced cell death. On the basis of biochemical and pharmacological experimental results, we have shown that PLC/DGK-derived PA represents a novel downstream component of NO signaling cascade during plant defense.	Univ Nacl Mar del Plata, Inst Invest Biol, RA-7600 Mar Del Plata, Argentina	National University of Mar del Plata	Laxalt, AM (corresponding author), Univ Nacl Mar del Plata, Inst Invest Biol, CC 1245, RA-7600 Mar Del Plata, Argentina.	amlaxalt@mdp.edu.ar	Have, Arjen ten/J-2524-2014; Have, Arjen ten/N-3934-2019	Have, Arjen ten/0000-0001-6210-5017; Have, Arjen ten/0000-0001-6210-5017				Andersson MX, 2006, PLANT J, V47, P947, DOI 10.1111/j.1365-313X.2006.02844.x; Anthony RG, 2004, EMBO J, V23, P572, DOI 10.1038/sj.emboj.7600068; Anthony RG, 2006, J BIOL CHEM, V281, P37536, DOI 10.1074/jbc.M607341200; BAILEY BA, 1990, PLANT PHYSIOL, V94, P1849, DOI 10.1104/pp.94.4.1849; Bargmann BOR, 2006, PLANT J, V45, P358, DOI 10.1111/j.1365-313X.2005.02631.x; Bright J, 2006, PLANT J, V45, P113, DOI 10.1111/j.1365-313X.2005.02615.x; Broillet MC, 1999, CELL MOL LIFE SCI, V55, P1036, DOI 10.1007/s000180050354; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Chen J, 2007, PROTOPLASMA, V230, P13, DOI 10.1007/s00709-006-0195-x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clark D, 2000, MOL PLANT MICROBE IN, V13, P1380, DOI 10.1094/MPMI.2000.13.12.1380; Clementi E, 1998, BIOCHEM PHARMACOL, V55, P713, DOI 10.1016/S0006-2952(97)00375-4; CLEMENTI E, 1995, MOL PHARMACOL, V47, P517; Correa-Aragunde N, 2006, J EXP BOT, V57, P581, DOI 10.1093/jxb/erj045; Correa-Aragunde N, 2004, PLANTA, V218, P900, DOI 10.1007/s00425-003-1172-7; Creus CM, 2005, PLANTA, V221, P297, DOI 10.1007/s00425-005-1523-7; de Jong CF, 2004, PLANT J, V39, P1, DOI 10.1111/j.1365-313X.2004.02110.x; de Pinto MC, 2006, PLANT J, V48, P784, DOI 10.1111/j.1365-313X.2006.02919.x; de Pinto MC, 2002, PLANT PHYSIOL, V130, P698, DOI 10.1104/pp.005629; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; Del Rio LA, 2004, PHYTOCHEMISTRY, V65, P783, DOI 10.1016/j.phytochem.2004.02.001; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Delledonne M, 2001, P NATL ACAD SCI USA, V98, P13454, DOI 10.1073/pnas.231178298; Durner J, 1998, P NATL ACAD SCI USA, V95, P10328, DOI 10.1073/pnas.95.17.10328; Durner J, 1999, CURR OPIN PLANT BIOL, V2, P369, DOI 10.1016/S1369-5266(99)00007-2; Elbaz M, 2002, CELL DEATH DIFFER, V9, P726, DOI 10.1038/sj.cdd.4401030; Farmer PK, 1999, BBA-PROTEIN STRUCT M, V1434, P6, DOI 10.1016/S0167-4838(99)00166-1; FELIX G, 1991, PLANT PHYSIOL, V97, P19, DOI 10.1104/pp.97.1.19; Garcia-Mata C, 2003, P NATL ACAD SCI USA, V100, P11116, DOI 10.1073/pnas.1434381100; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; Gerber Isak B, 2003, Methods Cell Sci, V25, P115; Itoh Y, 2000, ANAL BIOCHEM, V287, P203, DOI 10.1006/abio.2000.4859; Kojima H, 1998, CHEM PHARM BULL, V46, P373; Kumar D, 2000, MOL PLANT MICROBE IN, V13, P347, DOI 10.1094/MPMI.2000.13.3.347; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lamotte O, 2004, PLANT PHYSIOL, V135, P516, DOI 10.1104/pp.104.038968; Lanteri ML, 2006, J EXP BOT, V57, P1341, DOI 10.1093/jxb/erj109; Laxalt AM, 2002, CURR OPIN PLANT BIOL, V5, P332, DOI 10.1016/S1369-5266(02)00268-6; Laxalt AM, 2001, PLANT J, V26, P237, DOI 10.1046/j.1365-313X.2001.01023.x; Lee S, 2001, PLANT J, V26, P479, DOI 10.1046/j.1365-313x.2001.01037.x; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Lum HK, 2002, NITRIC OXIDE-BIOL CH, V6, P205, DOI 10.1006/niox.2001.0395; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Mishra G, 2006, SCIENCE, V312, P264, DOI 10.1126/science.1123769; Moise AR, 2002, J VIROL, V76, P1578, DOI 10.1128/JVI.76.4.1578-1587.2002; Mou Z, 2003, CELL, V113, P935, DOI 10.1016/S0092-8674(03)00429-X; Mueller-Roeber B, 2002, PLANT PHYSIOL, V130, P22, DOI 10.1104/pp.004770; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; Munnik T, 1998, BBA-LIPID LIPID MET, V1389, P222, DOI 10.1016/S0005-2760(97)00158-6; Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5; Neill SJ, 2002, J EXP BOT, V53, P1237, DOI 10.1093/jexbot/53.372.1237; Neill SJ, 2002, PLANT PHYSIOL, V128, P13, DOI 10.1104/pp.010707; Pagnussat GC, 2004, PLANT PHYSIOL, V135, P279, DOI 10.1104/pp.103.038554; Pagnussat GC, 2003, PLANT PHYSIOL, V132, P1241, DOI 10.1104/pp.103.022228; Pagnussat GC, 2002, PLANT PHYSIOL, V129, P954, DOI 10.1104/pp.004036; Palicz A, 2001, J BIOL CHEM, V276, P3090, DOI 10.1074/jbc.M007759200; Park J, 2004, PLANT PHYSIOL, V134, P129, DOI 10.1104/pp.103.031393; Regier DS, 2000, J BIOL CHEM, V275, P28406, DOI 10.1074/jbc.M004703200; Rentel MC, 2004, NATURE, V427, P858, DOI 10.1038/nature02353; Romero-Puertas MC, 2004, CELL MICROBIOL, V6, P795, DOI 10.1111/j.1462-5822.2004.00428.x; Ron M, 2004, PLANT CELL, V16, P1604, DOI 10.1105/tpc.022475; Sang YM, 2001, PLANT PHYSIOL, V126, P1449, DOI 10.1104/pp.126.4.1449; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Testerink C, 2004, PLANT J, V39, P527, DOI 10.1111/j.1365-313X.2004.02152.x; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; Torres MA, 2005, NAT GENET, V37, P1130, DOI 10.1038/ng1639; Torres MA, 2002, P NATL ACAD SCI USA, V99, P517, DOI 10.1073/pnas.012452499; van der Luit AH, 2000, PLANT PHYSIOL, V123, P1507, DOI 10.1104/pp.123.4.1507; VANKAN JAL, 1992, PLANT MOL BIOL, V20, P513, DOI 10.1007/BF00040610; Walia M, 2003, AM J PHYSIOL-CELL PH, V284, pC649, DOI 10.1152/ajpcell.00405.2002; Yamaguchi T, 2005, PLANT CELL PHYSIOL, V46, P579, DOI 10.1093/pcp/pci065; Yamaguchi T, 2004, PLANT CELL PHYSIOL, V45, P1261, DOI 10.1093/pcp/pch150; Yano A, 1998, MOL PLANT MICROBE IN, V11, P115, DOI 10.1094/MPMI.1998.11.2.115; Zhang WH, 2005, BBA-MOL CELL BIOL L, V1736, P1, DOI 10.1016/j.bbalip.2005.07.004; Zhang WH, 2004, P NATL ACAD SCI USA, V101, P9508, DOI 10.1073/pnas.0402112101; Zonia Laura, 2006, V39, P207	79	92	96	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21160	21168		10.1074/jbc.M701212200	http://dx.doi.org/10.1074/jbc.M701212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17491015	hybrid			2022-12-25	WOS:000248047500042
J	Goto, K; Kamiya, Y; Imamura, T; Miyazono, K; Miyazawa, K				Goto, Kouichiro; Kamiya, Yuto; Imamura, Takeshi; Miyazono, Kohei; Miyazawa, Keiji			Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; GERMLINE MUTATIONS; SIGNAL-TRANSDUCTION; JUVENILE POLYPOSIS; CRYSTAL-STRUCTURE; C2C12 MYOBLASTS; FAMILY-MEMBERS; MESSENGER-RNA; DOMAIN; IDENTIFICATION	The inhibitory Smads, Smad6 and Smad7, play pivotal roles in negative regulation of transforming growth factor-beta (TGF-beta) family signaling as feedback molecules as well as mediators of cross-talk with other signaling pathways. Whereas Smad7 acts as a ubiquitous inhibitor of Smad signaling, Smad6 has been shown to effectively inhibit bone morphogenetic protein (BMP) signaling but only weakly TGF-beta/activin signaling. In the present study, we have found that Smad6 inhibits signaling from the activin receptor-like kinase (ALK)-3/6 subgroup in preference to that from the ALK-1/2 subgroup of BMP type I receptors. The difference is attributable to the interaction of Smad6 with these BMP type I receptors. The amino acid residues responsible for Smad6 sensitivity of ALK-3 were identified as Arg-238, Phe-264, Thr-265, and Ala-269, which map to the N-terminal lobe of the ALK-3 kinase domain. Although Smad6 regulates BMP signaling through multiple mechanisms, our findings suggest that interaction with type I receptors is a critical step in the function of Smad6.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Koto Ku, Tokyo 1358550, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp	MIYAZAWA, KEIJI/I-9713-2014					Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Aoki H, 2001, J CELL SCI, V114, P1483; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Bitzer M, 2000, GENE DEV, V14, P187; Brown MA, 2005, J BIOL CHEM, V280, P25111, DOI 10.1074/jbc.M503328200; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; Ebisawa T, 1999, J CELL SCI, V112, P3519; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Lehmann K, 2003, P NATL ACAD SCI USA, V100, P12277, DOI 10.1073/pnas.2133476100; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Ma LJ, 2005, DEVELOPMENT, V132, P5601, DOI 10.1242/dev.02156; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Mochizuki T, 2004, J BIOL CHEM, V279, P31568, DOI 10.1074/jbc.M313977200; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Song LY, 2007, DEV BIOL, V301, P276, DOI 10.1016/j.ydbio.2006.08.004; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yu PB, 2005, J BIOL CHEM, V280, P24443, DOI 10.1074/jbc.M502825200; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703	48	111	115	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20603	20611		10.1074/jbc.M702100200	http://dx.doi.org/10.1074/jbc.M702100200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17493940	hybrid			2022-12-25	WOS:000247819300063
J	Jang, SI; Lee, EJ; Hart, PS; Ramaswami, M; Pallos, D; Hart, TC				Jang, Shyh-Ing; Lee, Eun-Jin; Hart, P. Suzanne; Ramaswami, Mukundhan; Pallos, Debora; Hart, Thomas C.			Germ line gain of function with SOS1 mutation in hereditary gingival fibromatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; EARLY GENE-PRODUCTS; MAP KINASE; SIGNAL-TRANSDUCTION; EGF RECEPTOR; PC12 CELLS; NUCLEAR TRANSLOCATION; TRANSCRIPTION FACTORS	Mutation of human SOS1 is responsible for hereditary gingival fibromatosis type 1, a benign overgrowth condition of the gingiva. Here, we investigated molecular mechanisms responsible for the increased rate of cell proliferation in gingival fibroblasts caused by mutant SOS1 in vitro. Using ectopic expression of wild-type and mutant SOS1 constructs, we found that truncated SOS1 could localize to the plasma membrane, without growth factor stimuli, leading to sustained activation of Ras/MAPK signaling. Additionally, we observed an increase in the magnitude and duration of ERK signaling in hereditary gingival fibromatosis gingival fibroblasts that was associated with phosphorylation of retinoblastoma tumor suppressor protein and the up-regulation of cell cycle regulators, including cyclins C, D, and E and the E2F/DP transcription factors. These factors promote cell cycle progression from G1 to S phase, and their up-regulation may underlie the increased gingival fibroblast proliferation observed. Selective depletion of wild-type and mutant SOS1 through small interfering RNA demonstrates the link between mutation of SOS1, ERK signaling, cell proliferation rate, and the expression levels of Egr-1 and proliferating cell nuclear antigen. These findings elucidate the mechanisms for gingival overgrowth mediated by SOS1 gene mutation in humans.	NIH, NIDCR, Sect Human & Craniofacial Genet, Bethesda, MD 20892 USA; NHGRI, NIH, Bethesda, MD 20892 USA; Univ Taubate, Dept Dent, Periodont Res & Grad Studies Div, BR-12020 Sao Paulo, Brazil	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Universidade de Taubate	Hart, TC (corresponding author), NIH, NIDCR, Sect Human & Craniofacial Genet, Bldg 10, Bethesda, MD 20892 USA.	thart@mail.nih.gov	Pallos, Debora/AAW-5258-2021; Pallos, Debora/H-7844-2012	Pallos, Debora/0000-0001-7426-1041; Lee, Eun-Jin/0000-0001-5718-542X	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000711, Z01DE000711] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Gorlin RJ, 2001, SYNDROMES HEAD NECK, P847; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Guerrero C, 1996, ONCOGENE, V12, P1097; Hart TC, 2002, AM J HUM GENET, V70, P943, DOI 10.1086/339689; Hart TC, 1998, AM J HUM GENET, V62, P876, DOI 10.1086/301797; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Jang SI, 2005, J CELL SCI, V118, P781, DOI 10.1242/jcs.01647; Jang SI, 2002, J BIOL CHEM, V277, P42268, DOI 10.1074/jbc.M205593200; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee EJ, 2006, J DENT RES, V85, P1050, DOI 10.1177/154405910608501115; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Liu W, 1999, J CELL SCI, V112, P2409; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NIMNUAL A, 2002, SCI STKE, pPE36, DOI DOI 10.1126/STKE.2002.145; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Roberts AE, 2007, NAT GENET, V39, P70, DOI 10.1038/ng1926; Rojas JM, 1996, ONCOGENE, V12, P2291; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Tartaglia M, 2007, NAT GENET, V39, P75, DOI 10.1038/ng1939; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WITKOP C J JR, 1971, Birth Defects Original Article Series, V7, P210	57	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20245	20255		10.1074/jbc.M701609200	http://dx.doi.org/10.1074/jbc.M701609200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17510059	hybrid			2022-12-25	WOS:000247819300027
J	Geyer, J; Doring, B; Meerkamp, K; Ugele, B; Bakhiya, N; Fernandes, CF; Godoy, JR; Glatt, H; Petzinger, E				Geyer, Joachim; Doering, Barbara; Meerkamp, Kerstin; Ugele, Bernhard; Bakhiya, Nadiya; Fernandes, Carla F.; Godoy, Jose R.; Glatt, Hansruedi; Petzinger, Ernst			Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID COTRANSPORTER; STEROID-HORMONE BIOSYNTHESIS; MEMBRANE-PROTEIN STRUCTURE; SUBSTRATE-SPECIFICITY; TOPOLOGY PREDICTION; RAT; ILEAL; IDENTIFICATION; LOCALIZATION; EXPRESSION	We have cloned human sodium-dependent organic anion transporter ( SOAT) cDNA, which consists of 1502 bp and encodes a 377-amino acid protein. SOAT shows 42% sequence identity to the ileal apical sodium-dependent bile acid transporter ASBT and 33% sequence identity to the hepatic Na+/taurocholate- cotransporting polypeptide NTCP. Immunoprecipitation of a SOAT-FLAG-tagged protein revealed a glycosylated form at 46 kDa that decreased to 42 kDa after PNGase F treatment. SOAT exhibits a seven-transmembrane domain topology with an outside-to-inside orientation of the N-terminal and C-terminal ends. SOAT mRNA is most highly expressed in testis. Relatively high SOAT expression was also detected in placenta and pancreas. We established a stable SOAT-HEK293 cell line that showed sodium-dependent transport of dehydroepiandrosterone sulfate, estrone-3-sulfate, and pregnenolone sulfate with apparent Km values of 28.7, 12.0, and 11.3 mu M, respectively. Although bile acids, such as taurocholic acid, cholic acid, and chenodeoxycholic acid, were not substrates of SOAT, the sulfoconjugated bile acid taurolithocholic acid-3-sulfate was transported by SOAT-HEK293 cells in a sodium-dependent manner and showed competitive inhibition of SOAT transport with an apparent K-i value of 0.24 mu M. Several nonsteroidal organosulfates also strongly inhibited SOAT, including 1-(omega-sulfooxyethyl) pyrene, bromosulfophthalein, 2- and 4-sulfooxymethylpyrene, and alpha-naphthylsulfate. Among these inhibitors, 2- and 4-sulfooxymethylpyrene were competitive inhibitors of SOAT, with apparent Ki values of 4.3 and 5.5 mu M, respectively, and they were also transported by SOAT-HEK293 cells.	Univ Giessen, Inst Pharmacol & Toxicol, D-35392 Giessen, Germany; Univ Munich, Univ Hosp, D-80337 Munich, Germany; German Inst Human Nutr, Dept Nutr Toxicol, D-14558 Nuthetal, Germany	Justus Liebig University Giessen; University of Munich; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Geyer, J (corresponding author), Univ Giessen, Inst Pharmacol & Toxicol, Frankfurter Str 107, D-35392 Giessen, Germany.	joachim.m.geyer@vetmed.uni-giessen.de	Godoy, Jose/ABF-3804-2020; Geyer, Joachim/AAQ-4593-2021	Glatt, Hansruedi/0000-0001-6053-0562				ALBRECHT ED, 1990, ENDOCR REV, V11, P124, DOI 10.1210/edrv-11-1-124; ALCALAY M, 1988, NUCLEIC ACIDS RES, V16, P9527, DOI 10.1093/nar/16.20.9527; ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; Bakhiya N, 2006, J AM SOC NEPHROL, V17, P1414, DOI 10.1681/ASN.2005080801; Banerjee A, 2006, BIOCHEMISTRY-US, V45, P943, DOI 10.1021/bi052202j; Baringhaus KH, 1999, J LIPID RES, V40, P2158; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; Dawson Paul A., 1995, Current Opinion in Lipidology, V6, P109, DOI 10.1097/00041433-199504000-00009; DEPERETTI E, 1983, J CLIN ENDOCR METAB, V57, P550, DOI 10.1210/jcem-57-3-550; Enders N., 1993, POLYCYCLIC AROMATIC, V3, P887; Engst W, 1999, CARCINOGENESIS, V20, P1777, DOI 10.1093/carcin/20.9.1777; Geyer J, 2006, N-S ARCH PHARMACOL, V372, P413, DOI 10.1007/s00210-006-0043-8; Geyer J, 2004, BIOCHEM BIOPH RES CO, V316, P300, DOI 10.1016/j.bbrc.2004.02.048; Glatt H, 2000, CHEM-BIOL INTERACT, V129, P141, DOI 10.1016/S0009-2797(00)00202-7; Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P566, DOI 10.1007/s00424-003-1130-z; Hagenbuch B, 1996, SEMIN LIVER DIS, V16, P129, DOI 10.1055/s-2007-1007226; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hata S, 2003, AM J PHYSIOL-GASTR L, V285, pG829, DOI 10.1152/ajpgi.00352.2002; Hess Rex A, 2003, Reprod Biol Endocrinol, V1, P52, DOI 10.1186/1477-7827-1-52; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kobayashi Y, 2005, J BIOL CHEM, V280, P32332, DOI 10.1074/jbc.M504246200; Kramer W, 2006, CURR MED CHEM, V13, P997, DOI 10.2174/092986706776361003; Kramer W, 1999, J LIPID RES, V40, P1604; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUSS E, 1994, EXP CLIN ENDOCRINOL, V102, P135, DOI 10.1055/s-0029-1211276; Labrie F, 2001, FRONT NEUROENDOCRIN, V22, P185, DOI 10.1006/frne.2001.0216; Lazaridis KN, 2000, P NATL ACAD SCI USA, V97, P11092, DOI 10.1073/pnas.200325297; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mareninova O, 2005, BIOCHEMISTRY-US, V44, P13702, DOI 10.1021/bi051291x; Marin Jose J G, 2005, Ann Hepatol, V4, P70; Miller WL, 1998, CLIN PERINATOL, V25, P799, DOI 10.1016/S0095-5108(18)30084-8; NAKAGAWA M, 1990, J LIPID RES, V31, P1089; Pasquier C, 1999, PROTEIN ENG, V12, P631, DOI 10.1093/protein/12.8.631; Persson B, 1996, PROTEIN SCI, V5, P363; Reed MJ, 2005, ENDOCR REV, V26, P171, DOI 10.1210/er.2004-0003; Schroeder A, 1998, AM J PHYSIOL-GASTR L, V274, pG370, DOI 10.1152/ajpgi.1998.274.2.G370; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; Srivastava A, 2004, CANCER EPIDEM BIOMAR, V13, P49, DOI 10.1158/1055-9965.EPI-03-0133; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; Strauss JF, 1996, BIOL REPROD, V54, P303, DOI 10.1095/biolreprod54.2.303; Suzuki T, 2003, MOL ENDOCRINOL, V17, P1203, DOI 10.1210/me.2002-0304; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Ugele B, 1999, J STEROID BIOCHEM, V71, P203, DOI 10.1016/S0960-0760(99)00138-7; Ugele B, 2003, AM J PHYSIOL-ENDOC M, V284, pE390, DOI 10.1152/ajpendo.00257.2002; WATKINS JB, 1983, J PEDIATR GASTR NUTR, V2, P365, DOI 10.1097/00005176-198305000-00027; Weinman SA, 1998, J BIOL CHEM, V273, P34691, DOI 10.1074/jbc.273.52.34691; Weinman SA, 1997, YALE J BIOL MED, V70, P331; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; WONG MH, 1994, J BIOL CHEM, V269, P1340; Zhang EY, 2004, BIOCHEMISTRY-US, V43, P11380, DOI 10.1021/bi049270a	55	76	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19728	19741		10.1074/jbc.M702663200	http://dx.doi.org/10.1074/jbc.M702663200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17491011	hybrid			2022-12-25	WOS:000247650600048
J	Gross, SA; Wissenbach, U; Philipp, SE; Freichel, M; Cavalie, A; Flockerzi, V				Gross, Stefan Alfred; Wissenbach, Ulrich; Philipp, Stephan Ernst; Freichel, Marc; Cavalie, Adolfo; Flockerzi, Veit			Murine ORAI2 splice variants form functional Ca2+ release-activated Ca2+ (CRAC) channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORE; STIM1; SUBUNIT; IDENTIFICATION; MODULATION; TERMINUS; PROTEIN; SENSOR; GENES; PORE	The stimulation of membrane receptors coupled to the phopholipase C pathway leads to activation of the Ca2+ release-activated Ca2+ ( CRAC) channels. Recent evidence indicates that ORAI1 is an essential pore subunit of CRAC channels. STIM1 is additionally required for CRAC channel activation. The present study focuses on the genomic organization, tissue expression pattern, and functional properties of the murine ORAI2. Additionally, we report the cloning of the murine ORAI1, ORAI3, and STIM1. Two chromosomal loci were identified for the murine orai2 gene, one containing an intronless gene and a second locus that gives rise to the splice variants ORAI2 long (ORAI2L) and ORAI2 short (ORAI2S). Northern blots revealed a prominent expression of the ORAI2 variants in the brain, lung, spleen, and intestine, while ORAI1, ORAI3, and STIM1 appeared to be near ubiquitously expressed in mice tissues. Specific antibodies detected ORAI2 in RBL 2H3 but not in HEK 293 cells, whereas both cell lines appeared to express ORAI1 and STIM1 proteins. Co-expression experiments with STIM1 and either ORAI1 or ORAI2 variants showed that ORAI2L and ORAI2S enhanced substantially CRAC current densities in HEK 293 but were ineffective in RBL 2H3 cells, whereas ORAI1 strongly amplified CRAC currents in both cell lines. Thus, the capability of ORAI2 variants to form CRAC channels depends strongly on the cell background. Additionally, CRAC channels formed by ORAI2S were strongly sensitive to inactivation by internal Ca2+. When co-expressed with STIM1 and ORAI1, ORAI2S apparently plays a negative dominant role in the formation of CRAC channels.	Univ Saarland, Inst Expt & Klin Pharmacol & Toxicol, D-66421 Homburg, Germany	Saarland University	Cavalie, A (corresponding author), Univ Saarland, Campus Homburg,bldg 46, D-66421 Homburg, Germany.	ptacav@uks.eu	Philipp, Stephan/AAR-7519-2020	Philipp, Stephan/0000-0003-1959-9167				Aneiros E, 2005, J IMMUNOL, V174, P119, DOI 10.4049/jimmunol.174.1.119; BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2005, J EXP MED, V202, P651, DOI 10.1084/jem.20050687; GRUSKIN KD, 1987, P NATL ACAD SCI USA, V84, P1605, DOI 10.1073/pnas.84.6.1605; GWACK Y, 2007, IN PRESS J BIOL CHEM, V282; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; Held B, 2002, J PHYSIOL-LONDON, V539, P459, DOI 10.1113/jphysiol.2001.012745; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Kang MG, 2003, J BIOL CHEM, V278, P21315, DOI 10.1074/jbc.R300004200; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Soboloff J, 2006, CURR BIOL, V16, P1465, DOI 10.1016/j.cub.2006.05.051; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Takahashi Y, 2007, BIOCHEM BIOPH RES CO, V356, P45, DOI 10.1016/j.bbrc.2007.02.107; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	29	84	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19375	19384		10.1074/jbc.M701962200	http://dx.doi.org/10.1074/jbc.M701962200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17463004	hybrid			2022-12-25	WOS:000247650600012
J	Leng, YM; Cao, C; Ren, J; Huang, L; Chen, DS; Ito, M; Kufe, D				Leng, Yumei; Cao, Cheng; Ren, Jian; Huang, Lei; Chen, Dongshu; Ito, Masaki; Kufe, Donald			Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; BETA-CATENIN; APOPTOTIC RESPONSE; GENE-TRANSCRIPTION; SURVIVAL RESPONSE; OXIDATIVE STRESS; TANDEM REPEATS; PROTEIN IMPORT; PORE COMPLEX	The MUC1 heterodimeric transmembrane protein is aberrantly overexpressed by most human carcinomas. The MUC1 C-terminal subunit (MUC1-C) is devoid of a classical nuclear localization signal and is targeted to the nucleus by an unknown mechanism. The present results demonstrate that MUC1-C associates with importin beta and not importin alpha. The results also show that, like importin beta, MUC1-C binds to Nup62 ( nucleoporin p62). MUC1-C binds directly to the Nup62 central domain and indirectly to the Nup62 C-terminal alpha-helical coiled-coil domain. We demonstrate that MUC1-C forms oligomers and that oligomerization is necessary for binding to Nup62. The MUC1-C cytoplasmic domain contains a CQC motif that when mutated to AQA abrogates oligomerization and binding to Nup62. Stable expression of MUC1 with the CQC -> AQA mutations was associated with targeting to the cell membrane and cytosol and attenuation of nuclear localization. The results further show that expression of MUC1(CQC-AQA) attenuates MUC1-induced (i) transcriptional coactivation, (ii) anchorage-independent growth, and (iii) tumorigenicity. These findings indicate that the MUC1-C oncoprotein is imported to the nucleus by a pathway involving Nup62.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu	Cao, Cheng/GNP-6156-2022	Huang, Lei/0000-0002-4851-4807	NATIONAL CANCER INSTITUTE [R01CA097098] Funding Source: NIH RePORTER; NCI NIH HHS [CA97098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1989, CANCER RES, V49, P2834; Angeline M, 2003, VIROLOGY, V317, P13, DOI 10.1016/j.virol.2003.08.024; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; CORDES V, 1991, EUR J CELL BIOL, V55, P31; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang L, 2003, CANCER BIOL THER, V2, P702; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Kinlough CL, 2006, J BIOL CHEM, V281, P12112, DOI 10.1074/jbc.M512996200; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Le Rouzic E, 2002, J BIOL CHEM, V277, P45091, DOI 10.1074/jbc.M207439200; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; MERLO GR, 1989, CANCER RES, V49, P6966; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Pemberton LF, 1996, J BIOL CHEM, V271, P2332, DOI 10.1074/jbc.271.4.2332; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; STARR CM, 1991, BIOESSAYS, V13, P145, DOI 10.1002/bies.950130309; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; Suh EK, 2003, EXP CELL RES, V290, P447, DOI 10.1016/S0014-4827(03)00370-7; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yin L, 2004, J BIOL CHEM, V279, P45721, DOI 10.1074/jbc.M408027200; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; ZRIHANLICHT S, 1994, EUR J BIOCHEM, V224, P787, DOI 10.1111/j.1432-1033.1994.00787.x	52	113	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19321	19330		10.1074/jbc.M703222200	http://dx.doi.org/10.1074/jbc.M703222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17500061	hybrid			2022-12-25	WOS:000247650600007
J	Sharma, N; Lopez, DI; Nyborg, JK				Sharma, Neelam; Lopez, Dinaida I.; Nyborg, Jennifer K.			DNA binding and phosphorylation induce conformational alterations in the kinase-inducible domain of CREB - Implications for the mechanism of transcription function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-RESPONSE ELEMENT; VIRUS TYPE-1 PROMOTER; GENOME-WIDE ANALYSIS; PROTEIN CREB; KIX DOMAIN; TAX TRANSACTIVATION; MOLECULAR-MECHANISM; ACTIVATION DOMAINS; COMPLEX-FORMATION; CYCLIC-AMP	CREB-mediated activation of target gene transcription is stimulated by protein kinase A (PKA) phosphorylation at serine 133. This is followed by recruitment of the coactivators CREB-binding protein (CBP) or p300. Conversely, the decline in expression during the attenuation phase is linked to CREB dephosphorylation by nuclear phosphatases. The CREB bZIP domain, which promotes dimerization and promoter binding, as well as the kinase-inducible domain (KID), which interacts with the KIX domain of CBP/p300, are both largely unstructured in solution and become more structured once bound to their respective ligands. In this study, we biochemically characterize DNA- and phosphorylation-induced conformational alterations in CREB that may play a role in its transcriptionally poised, activated state. We find that sequence-specific DNA binding of pCREB renders the protein resistant to serine 133 dephosphorylation by protein phosphatase 1. Paradoxically, CREB bound to DNA and chromatin is efficiently phosphorylated by PKA, indicating that the KID region exists in a different conformation depending on its phosphorylation state. Consistent with this observation, we find that phosphorylation of DNA-bound CREB promotes an alternate conformation characterized by an apparent increase in the size or asymmetry of the complex and a qualitative change in proteolytic sensitivity. Together, our data indicate that DNA binding promotes a global conformational change in CREB that alters the structure of KID. PKA phosphorylation of KID in the DNA-bound state induces a phosphatase-resistant conformation that may prolong transcriptional activity.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	Jennifer.Nyborg@ColoState.edu			NCI NIH HHS [R01 CA080002-09, CA 80002, R01 CA080002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BULGER M, 1994, GENE CHROMOSOME ANAL, V5; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHEN P, 1989, J BIOL CHEM, V264, P21435; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; Euskirchen G, 2004, MOL CELL BIOL, V24, P3804, DOI 10.1128/MCB.24.9.3804-3814.2004; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Fyodorov DV, 2003, METHOD ENZYMOL, V371, P499; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; Goto NK, 2002, J BIOL CHEM, V277, P43168, DOI 10.1074/jbc.M207660200; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Johnson KM, 2004, METHOD ENZYMOL, V380, P207; Konesky KL, 2006, J VIROL, V80, P10542, DOI 10.1128/JVI.00631-06; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Mayr BM, 2005, J BIOL CHEM, V280, P15103, DOI 10.1074/jbc.M414144200; MERINO A, 1989, J BIOL CHEM, V264, P21266; Mestas SP, 1999, NAT STRUCT BIOL, V6, P613; Mick JE, 2000, AIDS RES HUM RETROV, V16, P1597, DOI 10.1089/08892220050193010; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Parker D, 1996, MOL CELL BIOL, V16, P694; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SANTIAGORIVERA ZI, 1993, PROTEIN SCI, V2, P1461, DOI 10.1002/pro.5560020910; SCHONTHAL AH, 1998, FRONT BIOSCI, V3, P1262; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; Smal C, 2004, BIOCHEM PHARMACOL, V68, P95, DOI 10.1016/j.bcp.2004.02.031; Usukura J, 2000, GENES CELLS, V5, P515, DOI 10.1046/j.1365-2443.2000.00345.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Votavova H, 1997, J BIOMOL STRUCT DYN, V15, P587, DOI 10.1080/07391102.1997.10508968; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Wu XL, 1998, J BIOL CHEM, V273, P20820, DOI 10.1074/jbc.273.33.20820; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zor T, 2002, J BIOL CHEM, V277, P42241, DOI 10.1074/jbc.M207361200	58	24	32	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19872	19883		10.1074/jbc.M701435200	http://dx.doi.org/10.1074/jbc.M701435200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17491014	hybrid			2022-12-25	WOS:000247650600062
J	Cao, W; Xi, XY; Hao, ZY; Li, WJ; Kong, Y; Cui, LX; Ma, C; Ba, DN; He, W				Cao, Wei; Xi, Xueyan; Hao, Zhiyong; Li, Wenjing; Kong, Yan; Cui, Lianxian; Ma, Chi; Ba, Denian; He, Wei			RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-RELATED MOLECULES; CD8(+) T-CELLS; NKG2D RECEPTOR; MALIGNANT DISEASES; GLYCOPROTEIN UL16; CUTTING EDGE; LIGANDS; ENGAGEMENT; EXPRESSION; MICA	UL16-binding proteins (ULBPs, also termed as retinoic acid early transcripts, encoded by RAET1 genes), a family of ligands for NKG2D in humans, are frequently expressed by tumor cells and mediate cytotoxicities of natural killer (NK) cells and CD8(+) alpha beta T cells to tumor cells. ULBP1, ULBP2, ULBP3, and RAET1L link to membrane through glycosylphosphatidylinositol, whereas RAET1E and RAET1G contain transmembrane and cytoplasmic domains. Proteolytic cleavage of ULBP2 produces truncated and soluble forms that may counteract NKG2D-mediated tumor immune surveillance. In this study, we report that RAET1E can produce a soluble, 35-kDa protein (termed as RAET1E2) lacking the transmembrane region by selective splicing in tumor cells. The expressions of both RAET1E2 transcripts and protein can be found in different tumor cells and tissues. Preincubation of NK-92 cells, a human NK cell line, with culture supernatants from tumor cell lines expressing RAET1E2 or RAET1E2 gene-transfected COS-7 cells resulted in decreased expression of NKG2D on NK-92 cells. Furthermore, incubation of NK-92 cells with recombinant RAET1E2 protein also decreased the surface expression of NKG2D and resulted in marked reduction in cytotoxicities to MGC-803, HepG2, or K562 tumor cells. Taken together, our data provide strong evidence for an immune escape mechanism of tumors via alternative splicing of ULBP RNA to generate a free soluble ULBP protein, RAET1E2, that may impair NKG2D-mediated NK cell cytotoxicity to tumors.	Chinese Acad Med Sci, Peking Union Med Coll, Sch Basic Med, Inst Basic Med Sci,Dept Immunol,Natl Key Lab MMB, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS	He, W (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Sch Basic Med, Inst Basic Med Sci,Dept Immunol,Natl Key Lab MMB, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	heweiimu@public.bta.net.cn	Li, Wenjing/G-3551-2012					Bacon L, 2004, J IMMUNOL, V173, P1078, DOI 10.4049/jimmunol.173.2.1078; Cao W, 2004, IMMUNOBIOLOGY, V209, P283, DOI 10.1016/j.imbio.2004.04.008; Cao We, 2007, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V23, P242; Cerboni C, 2007, J GEN VIROL, V88, P242, DOI 10.1099/vir.0.82125-0; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(09)00098-3; Das H, 2001, IMMUNITY, V15, P83, DOI 10.1016/S1074-7613(01)00168-6; Dhanji S, 2004, BLOOD, V104, P2116, DOI 10.1182/blood-2004-01-0150; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205; Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Holdenrieder S, 2006, INT J CANCER, V118, P684, DOI 10.1002/ijc.21382; Holdenrieder S, 2006, CANCER IMMUNOL IMMUN, V55, P1584, DOI 10.1007/s00262-006-0167-1; JAN CN, 2003, BIOCHEM BIOPH RES CO, V305, P129; Kubin M, 2001, EUR J IMMUNOL, V31, P1428, DOI 10.1002/1521-4141(200105)31:5<1428::AID-IMMU1428>3.0.CO;2-4; Maasho K, 2005, J IMMUNOL, V174, P4480, DOI 10.4049/jimmunol.174.8.4480; Maccalli C, 2003, EUR J IMMUNOL, V33, P2033, DOI 10.1002/eji.200323909; Marten A, 2006, INT J CANCER, V119, P2359, DOI 10.1002/ijc.22186; Markiewicz MA, 2005, J IMMUNOL, V175, P2825, DOI 10.4049/jimmunol.175.5.2825; Meresse B, 2004, IMMUNITY, V21, P357, DOI 10.1016/j.immuni.2004.06.020; Nitahara A, 2006, J INVEST DERMATOL, V126, P1052, DOI 10.1038/sj.jid.5700112; Radosavljevic M, 2002, GENOMICS, V79, P114, DOI 10.1006/geno.2001.6673; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Rincon-Orozco B, 2005, J IMMUNOL, V175, P2144, DOI 10.4049/jimmunol.175.4.2144; Rolle A, 2003, J IMMUNOL, V171, P902, DOI 10.4049/jimmunol.171.2.902; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; Song H, 2006, CELL IMMUNOL, V239, P22, DOI 10.1016/j.cellimm.2006.03.002; Spreu J, 2006, J IMMUNOL, V177, P3143, DOI 10.4049/jimmunol.177.5.3143; Sutherland CL, 2002, J IMMUNOL, V168, P671, DOI 10.4049/jimmunol.168.2.671; Sutherland CL, 2001, IMMUNOL REV, V181, P185, DOI 10.1034/j.1600-065X.2001.1810115.x; Sutherland CL, 2006, BLOOD, V108, P1313, DOI 10.1182/blood-2005-11-011320; Vales-Gomez Mar, 2003, BMC Immunol, V4, P4, DOI 10.1186/1471-2172-4-4; Verneris MR, 2004, BLOOD, V103, P3065, DOI 10.1182/blood-2003-06-2125; Waldhauer I, 2006, CANCER RES, V66, P2520, DOI 10.1158/0008-5472.CAN-05-2520; Welte SA, 2003, EUR J IMMUNOL, V33, P194, DOI 10.1002/immu.200390022; Yokoyama WM, 2002, NATURE, V419, P679, DOI 10.1038/419679a; Zhou H, 2006, BLOOD, V107, P3251, DOI 10.1182/blood-2005-10-4231; Zhou H, 2005, P NATL ACAD SCI USA, V102, P10846, DOI 10.1073/pnas.0502208102	41	60	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18922	18928		10.1074/jbc.M702504200	http://dx.doi.org/10.1074/jbc.M702504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17470428	hybrid			2022-12-25	WOS:000247475300033
J	Goenka, S; Cho, SH; Boothby, M				Goenka, Shreevrat; Cho, Sung Hoon; Boothby, Mark			Collaborator of stat6 (CoaSt6)-associated poly(ADP-ribose) polymerase activity modulates stat6-dependent gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL LYMPHOMAS; ACTIVATION; COACTIVATOR; EXPRESSION; PARP-1; DNA; IDENTIFICATION; SPECIFICITY; INHIBITION; MECHANISM	The transcription factor Stat6 plays a critical role in interleukin-4-dependent gene activation. To mediate this function, Stat6 recruits canonical transcriptional co-activators including the histone acetyl transferases CREB-binding protein and NCoA-1 and other proteins such as a p100 co-factor. However, much remains unknown regarding the constituents of Stat6 enhancer complexes, and the exact molecular events that modulate Stat6-dependent gene activation are not fully understood. Recently, we identified a novel co-factor, CoaSt6 (collaborator of Stat6), which associates with Stat6 and enhances its transcriptional activity. Sequence homologies place CoaSt6 in a superfamily of poly(ADP-ribosyl) polymerase (PARP)-like proteins. We have demonstrated here that PARP enzymatic activity is associated with CoaSt6, and this function of CoaSt6 can append ADP-ribose to itself and p100. Further, we show that a catalytically inactive mutant of CoaSt6 was unable to enhance Stat6-mediated transcription of a test promoter. Consistent with these findings, chemical inhibition of PARP activity blocked interleukin-4-dependent transcription from target promoters in vivo. Taken together, we have identified a CoaSt6-associated PARP activity and provided evidence for a role of poly(ADP ribosyl)ation in Stat-mediated transcriptional responses involving a novel PARP.	Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Div Rheumatol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Goenka, S (corresponding author), Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37232 USA.	shreevrat.goenka@vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071735] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM071735] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguiar RCT, 2005, J BIOL CHEM, V280, P33756, DOI 10.1074/jbc.M505408200; Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Amiri KI, 2006, ONCOGENE, V25, P7714, DOI 10.1038/sj.onc.1209751; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Goenka S, 1999, J IMMUNOL, V163, P4663; Goenka S, 2006, P NATL ACAD SCI USA, V103, P4210, DOI 10.1073/pnas.0506981103; Goenka S, 2003, J BIOL CHEM, V278, P50362, DOI 10.1074/jbc.M305854200; Guiter C, 2004, BLOOD, V104, P543, DOI 10.1182/blood-2003-10-3545; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2003, J BIOL CHEM, V278, P45145, DOI 10.1074/jbc.M307957200; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Juszczynski P, 2006, MOL CELL BIOL, V26, P5348, DOI 10.1128/MCB.02351-05; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Lu XQ, 2005, BLOOD, V105, P2924, DOI 10.1182/blood-2004-10-3820; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; MATHIS G, 1987, BIOCHEM BIOPH RES CO, V143, P1049, DOI 10.1016/0006-291X(87)90358-5; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; PEHRSON JR, 1992, SCIENCE, V257, P1398; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; REALINI CA, 1992, J BIOL CHEM, V267, P18858; Ruf A, 1998, J MOL BIOL, V278, P57, DOI 10.1006/jmbi.1998.1673; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; TONG X, 1995, MOL CELL BIOL, V15, P4735; Yang J, 2002, EMBO J, V21, P4950, DOI 10.1093/emboj/cdf463	38	64	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18732	18739		10.1074/jbc.M611283200	http://dx.doi.org/10.1074/jbc.M611283200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17478423	hybrid			2022-12-25	WOS:000247475300011
J	Tampellini, D; Magrane, J; Takahashi, RH; Li, F; Lin, MT; Almeida, CG; Gouras, GK				Tampellini, Davide; Magrane, Jordi; Takahashi, Reisuke H.; Li, Feng; Lin, Michael T.; Almeida, Claudia G.; Gouras, Gunnar K.			Internalized antibodies to the A beta domain of APP reduce neuronal A beta and protect against synaptic alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-PRECURSOR-PROTEIN; INTRANEURONAL A-BETA-42 ACCUMULATION; ALZHEIMERS-DISEASE; INTRACELLULAR ACCUMULATION; TRANSGENIC MODEL; PLAQUE-FORMATION; MEMORY LOSS; IMMUNIZATION; PEPTIDE; ENDOCYTOSIS	Immunotherapy against beta-amyloid peptide (A beta) is a leading therapeutic direction for Alzheimer disease (AD). Experimental studies in transgenic mouse models of AD have demonstrated that A beta immunization reduces A beta plaque pathology and improves cognitive function. However, the biological mechanisms by which A beta antibodies reduce amyloid accumulation in the brain remain unclear. We provide evidence that treatment of AD mutant neuroblastoma cells or primary neurons with A beta antibodies decreases levels of intracellular A beta. Antibody-mediated reduction in cellular A beta appears to require that the antibody binds to the extracellular A beta domain of the amyloid precursor protein (APP) and be internalized. In addition, treatment with A beta antibodies protects against synaptic alterations that occur in APP mutant neurons.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA	Cornell University	Gouras, GK (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 525 E 68th St, New York, NY 10021 USA.	gkgouras@med.cornell.edu	de Almeida, Cláudia Guimas/AAN-8935-2020; Gouras, Gunnar/B-3021-2010; Magrané, Jordi/AAJ-2967-2020	de Almeida, Cláudia Guimas/0000-0001-9384-2896; Gouras, Gunnar/0000-0002-5500-6325; Magrané, Jordi/0000-0002-6785-2166; Tampellini, Davide/0000-0003-3188-0293	NIA NIH HHS [AG028174] Funding Source: Medline; NINDS NIH HHS [NS045677] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K02AG028174] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Almeida CG, 2006, J NEUROSCI, V26, P4277, DOI 10.1523/JNEUROSCI.5078-05.2006; Almeida CG, 2005, NEUROBIOL DIS, V20, P187, DOI 10.1016/j.nbd.2005.02.008; Arbel M, 2005, P NATL ACAD SCI USA, V102, P7718, DOI 10.1073/pnas.0502427102; Bacskai BJ, 2002, J NEUROSCI, V22, P7873; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; Carey RM, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-30; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; Das P, 2003, J NEUROSCI, V23, P8532; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; Goldsbury C, 2006, TRAFFIC, V7, P873, DOI 10.1111/j.1600-0854.2006.00434.x; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Gouras GK, 2005, NEUROBIOL AGING, V26, P1235, DOI 10.1016/j.neurobiolaging.2005.05.022; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Holtzman DM, 2002, ADV DRUG DELIVER REV, V54, P1603, DOI 10.1016/S0169-409X(02)00158-8; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Lemere CA, 2003, NEUROBIOL DIS, V14, P10, DOI 10.1016/S0969-9961(03)00044-5; Levites Y, 2006, J CLIN INVEST, V116, P193, DOI 10.1172/JCI25410; Lord A, 2006, NEUROBIOL AGING, V27, P67, DOI 10.1016/j.neurobiolaging.2004.12.007; Lorenzo A, 2000, NAT NEUROSCI, V3, P460, DOI 10.1038/74833; Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Mori C, 2002, AMYLOID, V9, P88, DOI 10.3109/13506120208995241; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Netzer WJ, 2003, P NATL ACAD SCI USA, V100, P12444, DOI 10.1073/pnas.1534745100; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Oddo S, 2006, AM J PATHOL, V168, P184, DOI 10.2353/ajpath.2006.050593; Paganetti P, 2005, J CELL BIOL, V168, P863, DOI 10.1083/jcb.200410047; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Saura CA, 2005, J NEUROSCI, V25, P6755, DOI 10.1523/JNEUROSCI.1247-05.2005; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shaked GM, 2006, FASEB J, V20, P1254, DOI 10.1096/fj.05-5032fje; Sheng JG, 2003, NEUROBIOL DIS, V14, P133, DOI 10.1016/S0969-9961(03)00069-X; Shie FS, 2003, NEUROREPORT, V14, P123, DOI 10.1097/00001756-200301200-00023; Solomon Beka, 2004, Current Alzheimer Research, V1, P149, DOI 10.2174/1567205043332126; Tabira T, 2002, FRONT BIOSCI-LANDMRK, V7, pA44, DOI 10.2741/tabira; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200; Weiner HL, 2006, NAT REV IMMUNOL, V6, P404, DOI 10.1038/nri1843; Wilcock DM, 2004, NEUROBIOL DIS, V15, P11, DOI 10.1016/j.nbd.2003.09.015; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Yamazaki T, 1996, J CELL SCI, V109, P999; Yang AJ, 1999, J BIOL CHEM, V274, P20650, DOI 10.1074/jbc.274.29.20650	63	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18895	18906		10.1074/jbc.M700373200	http://dx.doi.org/10.1074/jbc.M700373200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17468102	hybrid			2022-12-25	WOS:000247475300030
J	Wright, DC; Geiger, PC; Han, DH; Jones, TE; Holloszy, JO				Wright, David C.; Geiger, Paige C.; Han, Dong-Ho; Jones, Terry E.; Holloszy, John O.			Calcium induces increases in peroxisome proliferator-activated receptor gamma coactivator-1 alpha and mitochondrial biogenesis by a pathway leading to p38 mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; TRANSCRIPTIONAL COACTIVATOR; BIOCHEMICAL ADAPTATIONS; GENE-EXPRESSION; EXERCISE; PGC-1-ALPHA; NUCLEAR; PGC-1; ALPHA	Previous studies have shown that raising cytosolic calcium in myotubes induces increases in peroxisome proliferator-activated receptor gamma coactivator-1 alpha expression and mitochondrial biogenesis. This finding suggests that the increases in cytosolic calcium in skeletal muscle during exercise may mediate the exercise-induced increase in mitochondria. The initial aim of this study was to determine whether raising calcium in skeletal muscle induces the same adaptations as in myotubes. We found that treatment of rat epitrochlearis muscles with a concentration of caffeine that raises cytosolic calcium to a concentration too low to cause contraction induces increases in peroxisome proliferator-activated receptor gamma coactivator-1 alpha expression and mitochondrial biogenesis. Our second aim was to elucidate the pathway by which calcium induces these adaptations. Raising cytosolic calcium has been shown to activate calcium/calmodulin-dependent protein kinase in muscle. In the present study raising cytosolic calcium resulted in increases in phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor-2, which were blocked by the calcium/calmodulin-dependent protein kinase inhibitor KN93 and by the p38 mitogen-activated protein kinase inhibitor SB202190. The increases in peroxisome proliferator-activated receptor gamma coactivator-1 alpha expression and mitochondrial biogenesis were also prevented by inhibiting p38 activation. We interpret these findings as evidence that p38 mitogen-activated protein kinase is downstream of calcium/calmodulin-dependent protein kinase in a signaling pathway by which increases in cytosolic calcium lead to increases in peroxisome proliferator-activated receptor gamma coactivator-1 alpha expression and mitochondrial biogenesis in muscle.	Washington Univ, Sch Med, Div Geriatr & Nutr Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Div Geriatr & Nutr Sci, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jhollosz@im.wustl.edu		Wright, David/0000-0003-3867-8901	NIA NIH HHS [AG00425, AG00078] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-06, DK070425, P30 DK056341, P30 DK056341-07] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, F32DK070425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG000425, R56AG000425, R37AG000425] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; BALDWIN KM, 1972, AM J PHYSIOL, V222, P373, DOI 10.1152/ajplegacy.1972.222.2.373; BIANCHI CP, 1961, J GEN PHYSIOL, V44, P845, DOI 10.1085/jgp.44.5.845; BOOTH FW, 1977, J BIOL CHEM, V252, P416; BOOTH FW, 1997, HDB PHYSL 12, P1075; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Chan MHS, 2004, FASEB J, V18, P1785, DOI 10.1096/fj.03-1039fje; Chin ER, 2004, P NUTR SOC, V63, P279, DOI 10.1079/PNS2004335; CONSTABLE SH, 1987, AM J PHYSIOL, V253, pC316, DOI 10.1152/ajpcell.1987.253.2.C316; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; Elzi DJ, 2001, AM J PHYSIOL-CELL PH, V281, pC350; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305; Geiger PC, 2005, AM J PHYSIOL-ENDOC M, V288, pE782, DOI 10.1152/ajpendo.00477.2004; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; LAWRENCE JC, 1983, AM J PHYSIOL, V244, pC348, DOI 10.1152/ajpcell.1983.244.5.C348; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V283, pE1040, DOI 10.1152/ajpendo.00242.2002; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; RODNICK KJ, 1992, AM J PHYSIOL, V262, pC9, DOI 10.1152/ajpcell.1992.262.1.C9; Rose AJ, 2006, J PHYSIOL-LONDON, V574, P889, DOI 10.1113/jphysiol.2006.111757; Rose AJ, 2003, J PHYSIOL-LONDON, V553, P303, DOI 10.1113/jphysiol.2003.054171; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Terada S, 2006, AM J PHYSIOL-ENDOC M, V290, pE607, DOI 10.1152/ajpendo.00430.2005; Terada S, 2003, J APPL PHYSIOL, V94, P1813, DOI 10.1152/japplphysiol.00780.2002; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Wright DC, 2007, J BIOL CHEM, V282, P194, DOI 10.1074/jbc.M606116200; Wright DC, 2004, AM J PHYSIOL-ENDOC M, V287, pE305, DOI 10.1152/ajpendo.00082.2004; Wright DC, 2004, DIABETES, V53, P330, DOI 10.2337/diabetes.53.2.330; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; YOUN JH, 1991, AM J PHYSIOL, V260, pC555, DOI 10.1152/ajpcell.1991.260.3.C555; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	62	207	216	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18793	18799		10.1074/jbc.M611252200	http://dx.doi.org/10.1074/jbc.M611252200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17488713	hybrid			2022-12-25	WOS:000247475300018
J	Yang, WY; Devaiah, SP; Pan, XQ; Isaac, G; Welti, R; Wang, XM				Yang, Wenyu; Devaiah, Shivakumar P.; Pan, Xiangqing; Isaac, Giorgis; Welti, Ruth; Wang, Xuemin			AtPLAI is an acyl hydrolase involved in basal jasmonic acid production and Arabidopsis resistance to Botrytis cinerea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOUND-INDUCED ACCUMULATION; PHOSPHOLIPASE D-ALPHA; LEUCINE-RICH REPEAT; METHYL JASMONATE; PROTEINASE-INHIBITORS; SALICYLIC-ACID; TOBACCO-LEAVES; PATATIN; EXPRESSION; GENE	Intracellular phospholipase A(2) (PLA(2)) plays an important role in regulating oxylipin biosynthesis in mammals, but the molecular and biochemical nature of intracellular PLA2 is not well understood in plants. Arabidopsis thaliana gene At1g61850 (AtPLAI) encodes a 140-kDa protein that is most similar to mammalian calcium-independent PLA(2), and additionally contains leucine-rich repeats and Armadillo repeats. AtPLAI hydrolyzes phospholipids at both the sn-1 and sn-2 positions, but prefers galactolipids to phospholipids as substrates. Profiling of lipid species altered in response to the necrotrophic fungus Botrytis cinerea revealed decreases in the levels of phosphatidylglycerol and digalactosyldiacylglycerol, suggesting that hydrolysis of plastidic polar lipids might provide precursors for pathogen-induced jasmonic acid (JA) production. Disruption of AtPLAI by T-DNA insertion reduced the basal level of JA, but did not impede pathogen-induced production of JA, free linolenic acid, or hydrolysis of plastidic lipids. Still, AtPLAI-deficient plants exhibited more damage than wild type plants after B. cinerea infection, and pretreatment of plants with methyl jasmonate alleviated pathogen damage to the mutant plants. The study shows that AtPLAI is an acyl hydrolase, rather than a specific phospholipase A. AtPLAI is involved in basal JA production and Arabidopsis resistance to the necrotrophic fungus B. cinerea.	Univ Missouri, Dept Biol, St Louis, MO 63121 USA; Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; Kansas State Univ, Div Biol, Kansas Lipodom Res Ctr, Manhattan, KS 66506 USA	University of Missouri System; University of Missouri Saint Louis; Donald Danforth Plant Science Center; Kansas State University	Wang, XM (corresponding author), Univ Missouri, Dept Biol, 8001 Nat Bridge Rd, St Louis, MO 63121 USA.	wangxue@umsl.edu	Wang, Xuemin/M-2853-2013	wang, xuemin/0000-0002-6251-6745; Welti, Ruth/0000-0003-4373-2538	NCRR NIH HHS [P20RR16475] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016475] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; Balboa MA, 2006, BBA-MOL CELL BIOL L, V1761, P385, DOI 10.1016/j.bbalip.2006.03.014; Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; Buseman CM, 2006, PLANT PHYSIOL, V142, P28, DOI 10.1104/pp.106.082115; Chandra S, 1996, PLANT PHYSIOL, V110, P979, DOI 10.1104/pp.110.3.979; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Coates JC, 2003, TRENDS CELL BIOL, V13, P463, DOI 10.1016/S0962-8924(03)00167-3; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; CREELMAN RA, 1992, P NATL ACAD SCI USA, V89, P4938, DOI 10.1073/pnas.89.11.4938; Devaiah SP, 2006, PHYTOCHEMISTRY, V67, P1907, DOI 10.1016/j.phytochem.2006.06.005; Dhondt S, 2000, PLANT J, V23, P431, DOI 10.1046/j.1365-313x.2000.00802.x; Dhondt S, 2002, PLANT J, V32, P749, DOI 10.1046/j.1365-313X.2002.01465.x; DOARES SH, 1995, PLANT PHYSIOL, V108, P1741, DOI 10.1104/pp.108.4.1741; Ellis J, 2000, CURR OPIN PLANT BIOL, V3, P278, DOI 10.1016/S1369-5266(00)00080-7; Enkhbayar P, 2004, PROTEINS, V54, P394, DOI 10.1002/prot.10605; Fan L, 1997, PLANT CELL, V9, P2183, DOI 10.1105/tpc.9.12.2183; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; Farmer EE, 2003, CURR OPIN PLANT BIOL, V6, P372, DOI 10.1016/S1369-5266(03)00045-1; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; GUNDLACH H, 1992, P NATL ACAD SCI USA, V89, P2389, DOI 10.1073/pnas.89.6.2389; Harms K, 1998, PLANT PHYSIOL, V118, P1057, DOI 10.1104/pp.118.3.1057; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; He YH, 2002, PLANT PHYSIOL, V128, P876, DOI 10.1104/pp.010843; Hirschberg HJHB, 2001, EUR J BIOCHEM, V268, P5037, DOI 10.1046/j.0014-2956.2001.02411.x; Hisamatsu Y, 2005, J NAT PROD, V68, P600, DOI 10.1021/np0495938; Holk A, 2002, PLANT PHYSIOL, V130, P90, DOI 10.1104/pp.006288; Howe GA, 2002, CURR OPIN PLANT BIOL, V5, P230, DOI 10.1016/S1369-5266(02)00250-9; Ishiguro S, 2001, PLANT CELL, V13, P2191, DOI 10.1105/tpc.13.10.2191; KAUSS H, 1986, PLANT PHYSIOL, V80, P7, DOI 10.1104/pp.80.1.7; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; La Camera S, 2005, PLANT J, V44, P810, DOI 10.1111/j.1365-313X.2005.02578.x; Liavonchanka A, 2006, J PLANT PHYSIOL, V163, P348, DOI 10.1016/j.jplph.2005.11.006; LIECHTI R, 2006, SCI STKE, V322; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; Maleck K, 1999, TRENDS PLANT SCI, V4, P215, DOI 10.1016/S1360-1385(99)01415-6; MASON HS, 1992, PLANT PHYSIOL, V98, P859, DOI 10.1104/pp.98.3.859; MASON HS, 1990, PLANT CELL, V2, P569, DOI 10.1105/tpc.2.6.569; Mueller MJ, 1997, PHYSIOL PLANTARUM, V100, P653, DOI 10.1034/j.1399-3054.1997.1000329.x; Narusaka Y, 2003, PLANT CELL PHYSIOL, V44, P1246, DOI 10.1093/pcp/pcg138; Narvaez-Vasquez J, 1999, PLANT CELL, V11, P2249, DOI 10.1105/tpc.11.11.2249; Pappan K, 2004, J BIOL CHEM, V279, P47833, DOI 10.1074/jbc.M402789200; Pieterse CMJ, 2006, MULTIGENIC AND INDUCED SYSTEMIC RESISTANCE IN PLANTS, P166, DOI 10.1007/0-387-23266-4_8; Prins TW, 2000, FUNGAL PATHOLOGY, P33; Rietz S, 2004, PLANTA, V219, P743, DOI 10.1007/s00425-004-1275-9; ROY S, 1995, PLANT SCI, V107, P17, DOI 10.1016/0168-9452(95)04086-A; Rydel TJ, 2003, BIOCHEMISTRY-US, V42, P6696, DOI 10.1021/bi027156r; Ryu SB, 2004, TRENDS PLANT SCI, V9, P229, DOI 10.1016/j.tplants.2004.03.004; Ryu SB, 1998, BBA-LIPID LIPID MET, V1393, P193, DOI 10.1016/S0005-2760(98)00048-4; Seo HS, 2001, P NATL ACAD SCI USA, V98, P4788, DOI 10.1073/pnas.081557298; Stelmach BA, 2001, J BIOL CHEM, V276, P28628; Stelmach BA, 2001, J BIOL CHEM, V276, P12832, DOI 10.1074/jbc.M010743200; Stenzel I, 2003, PLANT MOL BIOL, V51, P895, DOI 10.1023/A:1023049319723; Thomma BPHJ, 1998, P NATL ACAD SCI USA, V95, P15107, DOI 10.1073/pnas.95.25.15107; Viehweger K, 2002, PLANT CELL, V14, P1509, DOI 10.1105/tpc.002329; Viehweger K, 2006, PLANT CELL, V18, P1510, DOI 10.1105/tpc.105.035121; Wang CX, 2000, PLANT CELL, V12, P2237, DOI 10.1105/tpc.12.11.2237; Wanjie SW, 2005, LIPIDS, V40, P773, DOI 10.1007/s11745-005-1439-4; Welti R, 2002, J BIOL CHEM, V277, P31994, DOI 10.1074/jbc.M205375200; Welti R, 2005, FUNCTIONAL LIPIDOMIC, P307; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; Young ND, 2000, CURR OPIN PLANT BIOL, V3, P285, DOI 10.1016/S1369-5266(00)00081-9; Zien CA, 2001, BBA-MOL CELL BIOL L, V1530, P236, DOI 10.1016/S1388-1981(01)00091-9	65	102	104	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18116	18128		10.1074/jbc.M700405200	http://dx.doi.org/10.1074/jbc.M700405200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17475618	hybrid, Green Published			2022-12-25	WOS:000247302000018
J	Ignoul, S; Simaels, J; Hermans, D; Annaert, W; Eggermont, J				Ignoul, Sofie; Simaels, Jeannine; Hermans, Diane; Annaert, Wim; Eggermont, Jan			Human ClC-6 Is a Late Endosomal Glycoprotein that Associates with Detergent-Resistant Lipid Domains	PLOS ONE			English	Article							LYSOSOMAL STORAGE DISEASE; CHLORIDE CHANNEL; N-GLYCOSYLATION; CELL-SURFACE; BETA-SUBUNIT; TRANSPORT; EXPRESSION; LOCALIZATION; KIDNEY; LEADS	Background. The mammalian CLC protein family comprises nine members (ClC-1 to -7 and ClC-Ka, -Kb) that function either as plasma membrane chloride channels or as intracellular chloride/proton antiporters, and that sustain a broad spectrum of cellular processes, such as membrane excitability, transepithelial transport, endocytosis and lysosomal degradation. In this study we focus on human ClC-6, which is structurally most related to the late endosomal/lysomal ClC-7. Principal Findings. Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422 and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be simultaneously N-glycosylated. In a differentiated human neuroblastoma cell line (SH-SY5Y), endogenous ClC-6 colocalizes with LAMP-1, a late endosomal/lysosomal marker, but not with early/recycling endosomal markers such as EEA-1 and transferrin receptor. In contrast, when transiently expressed in COS-1 or HeLa cells, human ClC-6 mainly overlaps with markers for early/recycling endosomes (transferrin receptor, EEA-1, Rab5, Rab4) and not with late endosomal/lysosomal markers (LAMP1, Rab7). Analogously, overexpression of human ClC-6 in SH-SY5Y cells also leads to an early/recycling endosomal localization of the exogenously expressed ClC-6 protein. Finally, in transiently transfected COS-1 cells, ClC-6 copurifies with detergent-resistant membrane fractions, suggesting its partitioning in lipid rafts. Mutating a juxtamembrane string of basic amino acids (amino acids 71-75: KKGRR) disturbs the association with detergent-resistant membrane fractions and also affects the segregation of ClC-6 and ClC-7 when cotransfected in COS-1 cells. Conclusions. We conclude that human ClC-6 is an endosomal glycoprotein that partitions in detergent resistant lipid domains. The differential sorting of endogenous (late endosomal) versus overexpressed (early and recycling endosomal) ClC-6 is reminiscent of that of other late endosomal/lysosomal membrane proteins (e. g. LIMP II), and is consistent with a rate-limiting sorting step for ClC-6 between early endosomes and its final destination in late endosomes.	[Ignoul, Sofie; Simaels, Jeannine; Hermans, Diane; Eggermont, Jan] Univ Louvain, Dept Mol Cell Biol, Lab Membrane Transport, Louvain, Belgium; [Annaert, Wim] Univ Louvain, Dept Human Genet, Lab Membrane Trafficking, Louvain, Belgium; [Annaert, Wim] VIB 11, Louvain, Belgium	Flanders Institute for Biotechnology (VIB)	Eggermont, J (corresponding author), Univ Louvain, Dept Mol Cell Biol, Lab Membrane Transport, Louvain, Belgium.	Jan.Eggermont@med.kuleuven.be	Ignoul, Sofie/AAF-4758-2019	Ignoul, Sofie/0000-0002-4154-785X; Eggermont, Jan/0000-0002-8497-1159	Forton Foundation (Koning Boudewijn Stichting, Belgium); Fund for Scientific Research-Flanders (FWO-Vlaanderen) [G. 0243.04, G. 0217.03]; Bijzonder Onderzoeksfonds [OT/03/42]	Forton Foundation (Koning Boudewijn Stichting, Belgium); Fund for Scientific Research-Flanders (FWO-Vlaanderen)(FWO); Bijzonder Onderzoeksfonds	Research in the authors' laboratory is supported by the Forton Foundation (Koning Boudewijn Stichting, Belgium), the Fund for Scientific Research-Flanders (FWO-Vlaanderen; G. 0243.04 to WA and G. 0217.03 to JE) and the Bijzonder Onderzoeksfonds (BOF; OT/03/42 to JE) of the K. U. Leuven.	Accardi A, 2005, J GEN PHYSIOL, V126, P563, DOI 10.1085/jgp.200509417; Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; Bonifacino JS, 2006, NAT REV MOL CELL BIO, V7, P568, DOI 10.1038/nrm1985; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Buyse G, 1998, BIOCHEM J, V330, P1015, DOI 10.1042/bj3301015; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; Bykova EA, 2006, NAT STRUCT MOL BIOL, V13, P1115, DOI 10.1038/nsmb1176; Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683; Christensen EI, 2003, P NATL ACAD SCI USA, V100, P8472, DOI 10.1073/pnas.1432873100; de Wit H, 2001, MOL BIOL CELL, V12, P3703, DOI 10.1091/mbc.12.11.3703; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Dowland LK, 2000, J BIOL CHEM, V275, P37765, DOI 10.1074/jbc.M004840200; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hinzpeter A, 2007, J BIOL CHEM, V282, P2423, DOI 10.1074/jbc.M608251200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Ignoul S, 2005, AM J PHYSIOL-CELL PH, V289, pC1369, DOI 10.1152/ajpcell.00282.2005; Jentsch TJ, 2005, ANNU REV PHYSIOL, V67, P779, DOI 10.1146/annurev.physiol.67.032003.153245; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jones J, 2005, BBA-GEN SUBJECTS, V1726, P121, DOI 10.1016/j.bbagen.2005.07.003; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Kuronita T, 2002, J CELL SCI, V115, P4117, DOI 10.1242/jcs.00075; Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Poet M, 2006, P NATL ACAD SCI USA, V103, P13854, DOI 10.1073/pnas.0606137103; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Sakamoto H, 1999, AM J PHYSIOL-RENAL, V277, pF957, DOI 10.1152/ajprenal.1999.277.6.F957; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; Schmieder S, 2001, BIOCHEM BIOPH RES CO, V286, P635, DOI 10.1006/bbrc.2001.5407; Schmieder S, 2007, J CELL PHYSIOL, V210, P479, DOI 10.1002/jcp.20882; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Suzuki T, 2006, J CELL PHYSIOL, V206, P792, DOI 10.1002/jcp.20516; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; Trouet D, 2001, AM J PHYSIOL-CELL PH, V281, pC248, DOI 10.1152/ajpcell.2001.281.1.C248; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; Voets T, 1996, J PHYSIOL-LONDON, V495, P441, DOI 10.1113/jphysiol.1996.sp021605; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200	53	22	24	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e474	10.1371/journal.pone.0000474	http://dx.doi.org/10.1371/journal.pone.0000474			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534424	Green Submitted, gold, Green Published			2022-12-25	WOS:000207448800004
J	Kentsis, A; Gindin, T; Mezei, M; Osman, R				Kentsis, Alex; Gindin, Tatyana; Mezei, Mihaly; Osman, Roman			Calculation of the Free Energy and Cooperativity of Protein Folding	PLOS ONE			English	Article								Calculation of the free energy of protein folding and delineation of its pre-organization are of foremost importance for understanding, predicting and designing biological macromolecules. Here, we introduce an energy smoothing variant of parallel tempering replica exchange Monte Carlo (REMS) that allows for efficient configurational sampling of flexible solutes under the conditions of molecular hydration. Its usage to calculate the thermal stability of a model globular protein, Trp cage TC5b, achieves excellent agreement with experimental measurements. We find that the stability of TC5b is attained through the coupled formation of local and non-local interactions. Remarkably, many of these structures persist at high temperature, concomitant with the origin of native-like configurations and mesostates in an otherwise macroscopically disordered unfolded state. Graph manifold learning reveals that the conversion of these mesostates to the native state is structurally heterogeneous, and that the cooperativity of their formation is encoded largely by the unfolded state ensemble. In all, these studies establish the extent of thermodynamic and structural pre-organization of folding of this model globular protein, and achieve the calculation of macromolecular stability ab initio, as required for ab initio structure prediction, genome annotation, and drug design.	[Kentsis, Alex; Gindin, Tatyana; Mezei, Mihaly; Osman, Roman] NYU, Mt Sinai Sch Med, Dept Mol Physiol & Biophys, New York, NY USA	Icahn School of Medicine at Mount Sinai; New York University	Kentsis, A (corresponding author), Harvard Univ, Sch Med, Dept Med, Childrens Hosp Boston, Boston, MA 02115 USA.	alex.kentsis@childrens.harvard.edu			National Institutes of Health Medical Scientist Training Program [DK 43046]	National Institutes of Health Medical Scientist Training Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	National Institutes of Health Medical Scientist Training Program, Grant DK 43046.	ABKEVICH VI, 1995, J MOL BIOL, V252, P460, DOI 10.1006/jmbi.1995.0511; Ahmed Z, 2005, J AM CHEM SOC, V127, P10943, DOI 10.1021/ja050664e; Andrec M, 2005, P NATL ACAD SCI USA, V102, P6801, DOI 10.1073/pnas.0408970102; Bai YW, 2001, PROTEIN SCI, V10, P1056, DOI 10.1110/ps.00601; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; Biswas P, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2062047; Brown S, 2003, J COMPUT CHEM, V24, P68, DOI 10.1002/jcc.10181; Bunagan MR, 2006, J PHYS CHEM B, V110, P3759, DOI 10.1021/jp055288z; Chen JH, 2006, J AM CHEM SOC, V128, P3728, DOI 10.1021/ja057216r; Cheng XL, 2005, J PHYS CHEM B, V109, P8220, DOI 10.1021/jp045437y; Cheung MS, 2003, J PHYS CHEM B, V107, P11193, DOI 10.1021/jp034441r; Daggett V, 2003, TRENDS BIOCHEM SCI, V28, P18, DOI 10.1016/S0968-0004(02)00012-9; Dyson HJ, 2005, METHOD ENZYMOL, V394, P299, DOI 10.1016/S0076-6879(05)94011-1; Faisca PFN, 2005, PROTEINS, V60, P712, DOI 10.1002/prot.20521; Feig M, 2004, J MOL GRAPH MODEL, V22, P377, DOI 10.1016/j.jmgm.2003.12.005; Geney R, 2006, J CHEM THEORY COMPUT, V2, P115, DOI 10.1021/ct050183l; GEYER CJ, 1995, J AM STAT ASSOC, V90, P909, DOI 10.1080/01621459.1995.10476590; GO N, 1978, P NATL ACAD SCI USA, V75, P559, DOI 10.1073/pnas.75.2.559; Hansmann UHE, 1997, CHEM PHYS LETT, V281, P140, DOI 10.1016/S0009-2614(97)01198-6; Hukushima K, 1996, J PHYS SOC JPN, V65, P1604, DOI 10.1143/JPSJ.65.1604; HUNENBERGER PH, 1995, J MOL BIOL, V252, P492, DOI 10.1006/jmbi.1995.0514; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KARPEN ME, 1993, BIOCHEMISTRY-US, V32, P412, DOI 10.1021/bi00053a005; Kentsis A, 2005, PROTEINS, V61, P769, DOI 10.1002/prot.20655; Kentsis A, 2004, PROTEINS, V55, P493, DOI 10.1002/prot.20051; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Kortemme T, 2000, J MOL BIOL, V297, P1217, DOI 10.1006/jmbi.2000.3618; Krantz BA, 2004, J MOL BIOL, V337, P463, DOI 10.1016/j.jmb.2004.01.018; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Liu P, 2005, P NATL ACAD SCI USA, V102, P13749, DOI 10.1073/pnas.0506346102; LOGAN TM, 1994, J MOL BIOL, V236, P637, DOI 10.1006/jmbi.1994.1173; Lwin TZ, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2161202; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mezei M, 2004, PROTEINS, V55, P502, DOI 10.1002/prot.20050; Mezei M, 2003, J CHEM PHYS, V118, P3874, DOI 10.1063/1.1539839; Mitsutake A, 2004, J CHEM PHYS, V121, P2491, DOI 10.1063/1.1766015; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; Neirotti JP, 2000, J CHEM PHYS, V112, P10340, DOI 10.1063/1.481671; NERI D, 1992, SCIENCE, V257, P1559, DOI 10.1126/science.1523410; Neuweiler H, 2005, P NATL ACAD SCI USA, V102, P16650, DOI 10.1073/pnas.0507351102; Nikiforovich GV, 2003, PROTEINS, V52, P292, DOI 10.1002/prot.10409; Nymeyer H, 2004, METHOD ENZYMOL, V383, P119; Opps SB, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.056701; Pitera JW, 2003, P NATL ACAD SCI USA, V100, P7587, DOI 10.1073/pnas.1330954100; Prompers JJ, 2002, PROTEINS, V46, P177, DOI 10.1002/prot.10025; Qiu LL, 2002, J AM CHEM SOC, V124, P12952, DOI 10.1021/ja0279141; Rao F, 2004, J MOL BIOL, V342, P299, DOI 10.1016/j.jmb.2004.06.063; Roweis ST, 2000, SCIENCE, V290, P2323, DOI 10.1126/science.290.5500.2323; SAUL LK, 2005, SEMISUPERVISED LEARN; Schueler-Furman O, 2005, SCIENCE, V310, P638, DOI 10.1126/science.1112160; Schug A, 2004, EUROPHYS LETT, V67, P307, DOI 10.1209/epl/i2004-10056-2; Schwalbe H, 1997, BIOCHEMISTRY-US, V36, P8977, DOI 10.1021/bi970049q; Shi ZS, 2002, P NATL ACAD SCI USA, V99, P9190, DOI 10.1073/pnas.112193999; Shoemaker BA, 1997, P NATL ACAD SCI USA, V94, P777, DOI 10.1073/pnas.94.3.777; Singhal N, 2004, J CHEM PHYS, V121, P415, DOI 10.1063/1.1738647; Sosnick TR, 1996, PROTEINS, V24, P413; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Sugita Y, 1999, CHEM PHYS LETT, V314, P141, DOI 10.1016/S0009-2614(99)01123-9; Ulmschneider JP, 2004, J AM CHEM SOC, V126, P1849, DOI 10.1021/ja0378862; Zhou RH, 2002, P NATL ACAD SCI USA, V99, P12777, DOI 10.1073/pnas.142430099; Zhou RH, 2003, P NATL ACAD SCI USA, V100, P13280, DOI 10.1073/pnas.2233312100	63	21	21	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2007	2	5							e446	10.1371/journal.pone.0000446	http://dx.doi.org/10.1371/journal.pone.0000446			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DY	17505540	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445900006
J	Cushion, MT; Smulian, AG; Slaven, BE; Sesterhenn, T; Arnold, J; Staben, C; Porollo, A; Adamczak, R; Meller, J				Cushion, Melanie T.; Smulian, A. George; Slaven, Bradley E.; Sesterhenn, Tom; Arnold, Jonathan; Staben, Chuck; Porollo, Aleksey; Adamczak, Rafal; Meller, Jarek			Transcriptome of Pneumocystis carinii during Fulminate Infection: Carbohydrate Metabolism and the Concept of a Compatible Parasite	PLOS ONE			English	Article								Members of the genus Pneumocystis are fungal pathogens that cause pneumonia in a wide variety of mammals with debilitated immune systems. Little is known about their basic biological functions, including life cycle, since no species can be cultured continuously outside the mammalian lung. To better understand the pathological process, about 4500 ESTS derived from sequencing of the poly(A) tail ends of P. carinii mRNAs during fulminate infection were annotated and functionally characterized as unassembled reads, and then clustered and reduced to a unigene set with 1042 members. Because of the presence of sequences from other microbial genomes and the rat host, the analysis and compression to a unigene set was necessarily an iterative process. BLASTx analysis of the unassembled reads (UR) vs. the Uni-Prot and TREMBL databases revealed 56% had similarities to existing polypeptides at E values of <= 10(-6), with the remainder lacking any significant homology. The most abundant transcripts in the UR were associated with stress responses, energy production, transcription and translation. Most (70%) of the UR had similarities to proteins from filamentous fungi (e. g., Aspergillus, Neurospora) and existing P. carinii gene products. In contrast, similarities to proteins of the yeast-like fungi, Schizosaccharomyces pombe and Saccharomyces cerevisiae, predominated in the unigene set. Gene Ontology analysis using BLAST2GO revealed P. carinii dedicated most of its transcripts to cellular and physiological processes (similar to 80%), molecular binding and catalytic activities (similar to 70%), and were primarily derived from cell and organellar compartments (similar to 80%). KEGG Pathway mapping showed the putative P. carinii genes represented most standard metabolic pathways and cellular processes, including the tricarboxylic acid cycle, glycolysis, amino acid biosynthesis, cell cycle and mitochondrial function. Several gene homologs associated with mating, meiosis, and sterol biosynthesis in fungi were identified. Genes encoding the major surface glycoprotein family (MSG), heat shock (HSP70), and proteases (PROT/KEX) were the most abundantly expressed of known P. carinii genes. The apparent presence of many metabolic pathways in P. carinii, sexual reproduction within the host, and lack of an invasive infection process in the immunologically intact host suggest members of the genus Pneumocystis may be adapted parasites and have a compatible relationship with their mammalian hosts. This study represents the first characterization of the expressed genes of a non-culturable fungal pathogen of mammals during the infective process.	[Cushion, Melanie T.; Smulian, A. George; Slaven, Bradley E.; Sesterhenn, Tom] Univ Cincinnati, Coll Med, Dept Internal Med, Div Infect Dis, Cincinnati, OH 45221 USA; [Arnold, Jonathan] Univ Georgia, Dept Genet, Athens, GA 30602 USA; [Staben, Chuck] Univ Kentucky, Lexington, KY USA; [Cushion, Melanie T.] Cincinnati Vet Adm Med Ctr, Cincinnati, OH USA; [Porollo, Aleksey; Adamczak, Rafal; Meller, Jarek] Childrens Hosp Res Fdn, Div Biomed Informat, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Georgia; University of Georgia; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Cushion, MT (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Infect Dis, Cincinnati, OH 45221 USA.	melanie.cushion@uc.edu	Meller, Jaroslaw/A-1971-2011; Adamczak, Rafal/F-2965-2014; Staben, Charles/C-1562-2013	Meller, Jaroslaw/0000-0002-1162-8253; Adamczak, Rafal/0000-0002-0261-8184; Cushion, Melanie T./0000-0001-6621-2784; Porollo, Alexey/0000-0002-3202-5099; arnold, jonathan/0000-0001-5845-1048	NIH [R01 AI44651, R21]; Veterans Administration; UGA College of Agricultural and Environmental Sciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044651] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Administration(US Department of Veterans Affairs); UGA College of Agricultural and Environmental Sciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	NIH: R01 AI44651 (M. T. C., A. G. S., J.A., C. S.) and R21 (J.M., A. G. S.); the Veterans Administration (Medical Research Equipment Grant) (A. G. S., M. T. C.). The NIH or the VA had no role in the design or conduct etc. of the study. They provided funds to execute the studies after award of grants (NIH) or equipment (VA). We also thank the UGA College of Agricultural and Environmental Sciences for their support.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barelle CJ, 2006, CELL MICROBIOL, V8, P961, DOI 10.1111/j.1462-5822.2005.00676.x; Batzoglou S, 2002, GENOME RES, V12, P177, DOI 10.1101/gr.208902; BECK JM, 1991, AM J RESP CELL MOL, V5, P186, DOI 10.1165/ajrcmb/5.2.186; Bozdech Z, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-17; Calderon E, 2004, EUR J CLIN MICROBIOL, V23, P545, DOI 10.1007/s10096-004-1151-3; Conesa A, 2005, BIOINFORMATICS, V21, P3674, DOI 10.1093/bioinformatics/bti610; Crothers K, 2005, AIDS, V19, P801, DOI 10.1097/01.aids.0000168974.67090.70; Cushion M.T., 2006, TOPLEY WILSONS MED M, P763; Cushion MT, 2005, MYCOLOGIA, V97, P268, DOI 10.3852/mycologia.97.1.268; Cushion MT, 2004, MYCOLOGIA, V96, P429, DOI 10.2307/3762163; Cushion MT, 2004, TRENDS MICROBIOL, V12, P243, DOI 10.1016/j.tim.2004.03.005; Cushion MT, 2004, J EUKARYOT MICROBIOL, V51, P30, DOI 10.1111/j.1550-7408.2004.tb00158.x; CUSHION MT, 1993, INFECT IMMUN, V61, P4801, DOI 10.1128/IAI.61.11.4801-4813.1993; Cushion MT, 1997, J EUKARYOT MICROBIOL, V44, p7S, DOI 10.1111/j.1550-7408.1997.tb05737.x; CUSHION MT, 1984, INFECT IMMUN, V44, P245, DOI 10.1128/IAI.44.2.245-251.1984; Cushion MT, 1997, INFECT IMMUN, V65, P4365, DOI 10.1128/IAI.65.10.4365-4365.1997; Dei-Cas E, 2006, FEMS MICROBIOL REV, V30, P853, DOI 10.1111/j.1574-6976.2006.00037.x; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; Enyenihi AH, 2003, GENETICS, V163, P47; Eschrich D, 2002, FEMS YEAST RES, V2, P315, DOI 10.1016/S1567-1356(02)00087-9; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FELDMANN H, 2005, SHORT COMPENDIUM BAS; Fisk DT, 2003, CLIN INFECT DIS, V36, P70, DOI 10.1086/344951; Flores CL, 2000, FEMS MICROBIOL REV, V24, P507, DOI 10.1111/j.1574-6976.2000.tb00553.x; Frenkel J K, 1976, Natl Cancer Inst Monogr, V43, P13; Frenkel JK, 1999, J EUKARYOT MICROBIOL, V46, p89S; FURLONG ST, 1994, ANTIMICROB AGENTS CH, V38, P2534, DOI 10.1128/AAC.38.11.2534; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401; Huang L, 2004, EMERG INFECT DIS, V10, P1721, DOI 10.3201/eid1010.030994; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Icenhour CR, 2002, EUKARYOT CELL, V1, P414, DOI 10.1128/EC.1.3.414-419.2002; Icenhour CR, 2001, J CLIN MICROBIOL, V39, P3437, DOI 10.1128/JCM.39.10.3437-3441.2001; JOFFRION T, 2006, J EUKARYOTI IN PRESS; Kaneshiro ES, 2000, ANTIMICROB AGENTS CH, V44, P1630, DOI 10.1128/AAC.44.6.1630-1638.2000; KANESHIRO ES, 1994, J EUKARYOT MICROBIOL, V41, P78, DOI 10.1111/j.1550-7408.1994.tb05938.x; Kaneshiro ES, 2002, MOL MICROBIOL, V44, P989, DOI 10.1046/j.1365-2958.2002.02932.x; Kazanjian P, 2001, J INFECT DIS, V183, P819, DOI 10.1086/318835; Kazanjian PH, 2004, J INFECT DIS, V189, P1684, DOI 10.1086/382957; Keely SP, 2004, MICROBIOL-SGM, V150, P1153, DOI 10.1099/mic.0.26921-0; Keely SP, 2003, INFECT IMMUN, V71, P47, DOI 10.1128/IAI.71.1.47-60.2003; Kovacs JA, 2001, JAMA-J AM MED ASSOC, V286, P2450, DOI 10.1001/jama.286.19.2450; LANGRETH SG, 1994, J EUKARYOT MICROBIOL, V41, pS95; Larochelle M, 2006, MOL CELL BIOL, V26, P6690, DOI 10.1128/MCB.02450-05; Lee JG, 2000, J BIOCHEM-TOKYO, V128, P1059, DOI 10.1093/oxfordjournals.jbchem.a022834; LI J, 1994, J EUKARYOT MICROBIOL, V41, pS97; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIMPER AH, 1993, INFECT IMMUN, V61, P4302, DOI 10.1128/IAI.61.10.4302-4309.1993; Liu YJ, 2004, P NATL ACAD SCI USA, V101, P4507, DOI 10.1073/pnas.0400938101; Lorenz MC, 2002, EUKARYOT CELL, V1, P657, DOI 10.1128/EC.1.5.657-662.2002; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; MATSUMOTO Y, 1984, J PROTOZOOL, V31, P420, DOI 10.1111/j.1550-7408.1984.tb02989.x; Milla P, 2002, LIPIDS, V37, P1171, DOI 10.1007/s11745-002-1017-9; Morales IJ, 2003, AM J RESP CELL MOL, V29, P232, DOI 10.1165/rcmb.2003-0012OC; Morris A, 2004, EMERG INFECT DIS, V10, P1713, DOI 10.3201/eid1010.030985; Morris A, 2004, AM J RESP CRIT CARE, V170, P408, DOI 10.1164/rccm.200401-094OC; O'Connell RJ, 2006, NEW PHYTOL, V171, P699, DOI 10.1111/j.1469-8137.2006.01829.x; PARK YU, 2006, EUKARYOT CELL; PIFER LL, 1978, PEDIATRICS, V61, P35; PIXLEY FJ, 1991, MOL MICROBIOL, V5, P1347, DOI 10.1111/j.1365-2958.1991.tb00781.x; POTTRATZ ST, 1994, J LAB CLIN MED, V123, P273; POTTRATZ ST, 1995, EXP CELL RES, V221, P357, DOI 10.1006/excr.1995.1385; REDHEAD S, 2005, J EUKARYOT IN PRESS; Rozen S, 2000, Methods Mol Biol, V132, P365; Sakurai M, 2004, FEMS YEAST RES, V4, P649, DOI 10.1016/j.femsyr.2003.12.009; Sharma SK, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-52; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Smulian AG, 2006, MOLECULAR PRINCIPLES OF FUNGAL PATHOGENESIS, P347; Smulian AG, 2001, GENETICS, V157, P991; Solomon PS, 2004, MOL MICROBIOL, V53, P1065, DOI 10.1111/j.1365-2958.2004.04178.x; STRINGER SL, 1989, EXP PARASITOL, V68, P450, DOI 10.1016/0014-4894(89)90130-6; Tatebe H, 2003, MOL CELL BIOL, V23, P5132, DOI 10.1128/MCB.23.15.5132-5142.2003; Teixeira MC, 2006, FEMS YEAST RES, V6, P230, DOI 10.1111/j.1567-1364.2006.00041.x; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Vidal S, 2006, CLIN MICROBIOL INFEC, V12, P231, DOI 10.1111/j.1469-0691.2005.01337.x; Vohra PK, 2004, BIOCHEM BIOPH RES CO, V319, P193, DOI 10.1016/j.bbrc.2004.04.154; WISNIOWSKI P, 1995, J LAB CLIN MED, V125, P38; Zar HJ, 2004, CLIN INFECT DIS, V39, P1047, DOI 10.1086/424010	80	45	46	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e423	10.1371/journal.pone.0000423	http://dx.doi.org/10.1371/journal.pone.0000423			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487271	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445800005
J	Ricaud, L; Proux, C; Renou, JP; Pichon, O; Fochesato, S; Ortet, P; Montane, MH				Ricaud, Lilian; Proux, Caroline; Renou, Jean-Pierre; Pichon, Olivier; Fochesato, Sylvain; Ortet, Philippe; Montane, Marie-Helene			ATM-Mediated Transcriptional and Developmental Responses to gamma-rays in Arabidopsis	PLOS ONE			English	Article							STRAND BREAK REPAIR; CELL-CYCLE CHECKPOINT; DNA-DAMAGE RESPONSE; DEPENDENT PROTEIN-KINASE; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; GENE-EXPRESSION; ATAXIA-TELANGIECTASIA; S-PHASE; HISTONE ACETYLATION	ATM (Ataxia Telangiectasia Mutated) is an essential checkpoint kinase that signals DNA double-strand breaks in eukaryotes. Its depletion causes meiotic and somatic defects in Arabidopsis and progressive motor impairment accompanied by several cell deficiencies in patients with ataxia telangiectasia (AT). To obtain a comprehensive view of the ATM pathway in plants, we performed a time-course analysis of seedling responses by combining confocal laser scanning microscopy studies of root development and genome-wide expression profiling of wild-type (WT) and homozygous ATM-deficient mutants challenged with a dose of gamma-rays (IR) that is sublethal for WT plants. Early morphologic defects in meristematic stem cells indicated that AtATM, an Arabidopsis homolog of the human ATM gene, is essential for maintaining the quiescent center and controlling the differentiation of initial cells after exposure to IR. Results of several microarray experiments performed with whole seedlings and roots up to 5 h post-IR were compiled in a single table, which was used to import gene information and extract gene sets. Sequence and function homology searches; import of spatio-temporal, cell cycling, and mutant-constitutive expression characteristics; and a simplified functional classification system were used to identify novel genes in all functional classes. The hundreds of radiomodulated genes identified were not a random collection, but belonged to functional pathways such as those of the cell cycle; cell death and repair; DNA replication, repair, and recombination; and transcription; translation; and signaling, indicating the strong cell reprogramming and double-strand break abrogation functions of ATM checkpoints. Accordingly, genes in all functional classes were either down or up-regulated concomitantly with downregulation of chromatin deacetylases or upregulation of acetylases and methylases, respectively. Determining the early transcriptional indicators of prolonged S-G2 phases that coincided with cell proliferation delay, or an anticipated subsequent auxin increase, accelerated cell differentiation or death, was used to link IR-regulated hallmark functions and tissue phenotypes after IR. The transcription burst was almost exclusively AtATM-dependent or weakly AtATR-dependent, and followed two major trends of expression in atm: (i)-loss or severe attenuation and delay, and (ii)-inverse and/or stochastic, as well as specific, enabling one to distinguish IR/ATM pathway constituents. Our data provide a large resource for studies on the interaction between plant checkpoints of the cell cycle, development, hormone response, and DNA repair functions, because IR-induced transcriptional changes partially overlap with the response to environmental stress. Putative connections of ATM to stem cell maintenance pathways after IR are also discussed.	[Ricaud, Lilian; Fochesato, Sylvain; Ortet, Philippe; Montane, Marie-Helene] CEA, DSV, Inst Biol Environm & Biotechnol, SBVME, Cadarache, St Paul Lez Dur, France; [Proux, Caroline; Renou, Jean-Pierre; Pichon, Olivier] UEVE, Unite Rech Genom Vegetale, CNRS 8114, UMR INRA 1165, Evry, France	CEA; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Montane, MH (corresponding author), CEA, DSV, Inst Biol Environm & Biotechnol, SBVME, Cadarache, St Paul Lez Dur, France.	marie-helene.montane@cea.fr	ORTET, Philippe/T-8172-2018	ORTET, Philippe/0000-0002-2648-8978	GENOPLANTE [AF2001051]	GENOPLANTE	This work was supported by a GENOPLANTE contract (AF2001051).	Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Ahlfors R, 2004, PLANT CELL, V16, P1925, DOI 10.1105/tpc.021832; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Aplan PD, 2006, TRENDS GENET, V22, P46, DOI 10.1016/j.tig.2005.10.002; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Aylon Y, 2004, EMBO J, V23, P4868, DOI 10.1038/sj.emboj.7600469; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barber LJ, 2005, MOL CELL BIOL, V25, P2297, DOI 10.1128/MCB.25.6.2297-2309.2005; Barroco RM, 2005, PLANT PHYSIOL, V137, P127, DOI 10.1104/pp.104.049361; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bleuyard JY, 2006, DNA REPAIR, V5, P1, DOI 10.1016/j.dnarep.2005.08.017; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; Boisnard-Lorig C, 2001, PLANT CELL, V13, P495, DOI 10.1105/tpc.13.3.495; Bonatto D, 2005, BRAZ J MED BIOL RES, V38, P321, DOI 10.1590/S0100-879X2005000300002; Boyes DC, 2001, PLANT CELL, V13, P1499, DOI 10.1105/tpc.13.7.1499; Boyko A, 2006, PLANT CELL PHYSIOL, V47, P736, DOI 10.1093/pcp/pcj045; Brown EJ, 2000, GENE DEV, V14, P397; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Carballo JA, 2006, BIOL RES, V39, P331, DOI 10.4067/S0716-97602006000200015; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Cebolla A, 1999, EMBO J, V18, P4476, DOI 10.1093/emboj/18.16.4476; Chang MS, 2000, BIOCHEM BIOPH RES CO, V279, P732, DOI 10.1006/bbrc.2000.3992; Chen IP, 2003, PLANT J, V35, P771, DOI 10.1046/j.1365-313X.2003.01847.x; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Colon-Carmona A, 1999, PLANT J, V20, P503, DOI 10.1046/j.1365-313x.1999.00620.x; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Criqui MC, 2000, PLANT J, V24, P763, DOI 10.1111/j.1365-313X.2000.t01-1-.x; Crowe ML, 2003, NUCLEIC ACIDS RES, V31, P156, DOI 10.1093/nar/gkg071; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; Culligan K, 2004, PLANT CELL, V16, P1091, DOI 10.1105/tpc.018903; Culligan KM, 2006, PLANT J, V48, P947, DOI 10.1111/j.1365-313X.2006.02931.x; Da Costa M, 2006, PLANT CELL, V18, P1426, DOI 10.1105/tpc.105.040485; Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936-9948.2005; De Schutter K, 2007, PLANT CELL, V19, P211, DOI 10.1105/tpc.106.045047; Deveaux Y, 2000, RADIAT RES, V154, P355, DOI 10.1667/0033-7587(2000)154[0355:MCADEO]2.0.CO;2; Ding YH, 2006, PLANT CELL, V18, P815, DOI 10.1105/tpc.105.039495; Doerner P, 1996, NATURE, V380, P520, DOI 10.1038/380520a0; Doerner P, 2006, CURR BIOL, V16, pR199, DOI 10.1016/j.cub.2006.02.027; Doutriaux MP, 1998, MOL GEN GENET, V257, P283, DOI 10.1007/s004380050649; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Duque P, 2003, PLANT J, V35, P787, DOI 10.1046/j.1365-313X.2003.01848.x; Elkon R, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-5-r43; Ellis CM, 2005, DEVELOPMENT, V132, P4563, DOI 10.1242/dev.02012; Endo M, 2006, EMBO J, V25, P5579, DOI 10.1038/sj.emboj.7601434; Esmon CA, 2006, P NATL ACAD SCI USA, V103, P236, DOI 10.1073/pnas.0507127103; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Ferreira MG, 2004, GENE DEV, V18, P2249, DOI 10.1101/gad.315804; Fleming AJ, 2006, J PLANT RES, V119, P31, DOI 10.1007/s10265-005-0240-4; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Frame FM, 2006, ONCOGENE, V25, P3258, DOI 10.1038/sj.onc.1209352; Friedberg EC, 2005, NAT REV MOL CELL BIO, V6, P943, DOI 10.1038/nrm1781; Friesner JD, 2005, MOL BIOL CELL, V16, P2566, DOI 10.1091/mbc.E04-10-0890; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085; Fritsch O, 2004, MOL CELL, V16, P479, DOI 10.1016/j.molcel.2004.09.034; Fu Z, 2005, MOL CELL BIOL, V25, P6047, DOI 10.1128/MCB.25.14.6047-6064.2005; Fulop K, 2005, CELL CYCLE, V4, P1084; Garber PM, 2005, TRENDS BIOCHEM SCI, V30, P63, DOI 10.1016/j.tibs.2004.12.004; Garcia V, 2003, PLANT CELL, V15, P119, DOI 10.1105/tpc.006577; Garcia V, 2000, NUCLEIC ACIDS RES, V28, P1692, DOI 10.1093/nar/28.8.1692; Garcia-Ortiz MV, 2004, PLANT J, V39, P84, DOI 10.1111/j.1365-313X.2004.02112.x; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; GUO C, 2007, CELLULAR SIGNALLING, V3, P504; Hamant O, 2006, ANNU REV PLANT BIOL, V57, P267, DOI 10.1146/annurev.arplant.57.032905.105255; He SS, 2004, PLANT MOL BIOL, V56, P171, DOI 10.1007/s11103-004-2748-8; Hefner E, 2006, DNA REPAIR, V5, P102, DOI 10.1016/j.dnarep.2005.08.013; Hefner E, 2003, J EXP BOT, V54, P669, DOI 10.1093/jxb/erg069; Hilson P, 2004, GENOME RES, V14, P2176, DOI 10.1101/gr.2544504; Hirayama T, 1996, P NATL ACAD SCI USA, V93, P13371, DOI 10.1073/pnas.93.23.13371; Hu QH, 2006, NUCLEIC ACIDS RES, V34, P6272, DOI 10.1093/nar/gkl801; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Inagaki S, 2006, PLANT CELL, V18, P879, DOI 10.1105/tpc.105.036798; Innes CL, 2006, MOL CANCER RES, V4, P197, DOI 10.1158/1541-7786.MCR-05-0154; Inze D, 2006, ANNU REV GENET, V40, P77, DOI 10.1146/annurev.genet.40.110405.090431; Ishimi Y, 2004, J STRUCT BIOL, V146, P234, DOI 10.1016/j.jsb.2003.11.027; Ismail IH, 2005, J BIOL CHEM, V280, P4649, DOI 10.1074/jbc.M411588200; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Iwakawa H, 2006, PLANT J, V45, P819, DOI 10.1111/j.1365-313X.2005.02643.x; Iwanaga R, 2006, ONCOGENE, V25, P1786, DOI 10.1038/sj.onc.1209210; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jeggo PA, 2006, DNA REPAIR, V5, P1192, DOI 10.1016/j.dnarep.2006.05.011; Kandasamy MK, 2005, PLANT J, V41, P845, DOI 10.1111/j.1365-313X.2005.02345.x; Kaplun L, 2005, MOL CELL BIOL, V25, P5355, DOI 10.1128/MCB.25.13.5355-5362.2005; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kats ES, 2006, P NATL ACAD SCI USA, V103, P3710, DOI 10.1073/pnas.0511102103; Khidr L, 2006, ONCOGENE, V25, P5210, DOI 10.1038/sj.onc.1209612; Kimura S, 2006, CHEM REV, V106, P753, DOI 10.1021/cr040482n; Kirik A, 2006, PLANT CELL, V18, P2431, DOI 10.1105/tpc.106.045088; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Krizek BA, 2006, PLANTA, V224, P612, DOI 10.1007/s00425-006-0253-9; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lafarge S, 2003, NUCLEIC ACIDS RES, V31, P1148, DOI 10.1093/nar/gkg202; Lawrence RJ, 2004, MOL CELL, V13, P599, DOI 10.1016/S1097-2765(04)00064-4; Le Roy F, 2005, NAT STRUCT MOL BIOL, V12, P505, DOI 10.1038/nsmb944; Lee BH, 2005, PLANT CELL, V17, P3155, DOI 10.1105/tpc.105.035568; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li CX, 2005, P NATL ACAD SCI USA, V102, P12978, DOI 10.1073/pnas.0504039102; Lin WC, 2001, GENE DEV, V15, P1833; Lobrich M, 2005, RADIOTHER ONCOL, V76, P112, DOI 10.1016/j.radonc.2005.06.027; Lobrich M, 2005, DNA REPAIR, V4, P749, DOI 10.1016/j.dnarep.2004.12.008; Long JA, 2006, SCIENCE, V312, P1520, DOI 10.1126/science.1123841; Lu X, 2006, CANCER RES, V66, P1052, DOI 10.1158/0008-5472.CAN-05-3459; Ludwig AA, 2005, P NATL ACAD SCI USA, V102, P10736, DOI 10.1073/pnas.0502954102; Lurin C, 2004, PLANT CELL, V16, P2089, DOI 10.1105/tpc.104.022236; Lydall D, 2005, DNA REPAIR, V4, P1195, DOI 10.1016/j.dnarep.2005.06.007; Matei IR, 2006, IMMUNOL REV, V209, P142, DOI 10.1111/j.0105-2896.2006.00361.x; McGarry RC, 2003, PLANT CELL, V15, P1605, DOI 10.1105/tpc.012120; McGuinness BE, 2005, PLOS BIOL, V3, P433, DOI 10.1371/journal.pbio.0030086; Menges M, 2006, PLANT CELL, V18, P893, DOI 10.1105/tpc.105.039636; Menges M, 2005, PLANT J, V41, P546, DOI 10.1111/j.1365-313X.2004.02319.x; Menges M, 2002, J BIOL CHEM, V277, P41987, DOI 10.1074/jbc.M207570200; Mercer SE, 2006, CELL BIOCHEM BIOPHYS, V45, P303, DOI 10.1385/CBB:45:3:303; Mercier G, 2001, MUTAT RES-DNA REPAIR, V487, P157, DOI 10.1016/S0921-8777(01)00116-1; Mischo HE, 2005, J BIOL CHEM, V280, P9586, DOI 10.1074/jbc.M411444200; Mizukami Y, 2001, CURR OPIN PLANT BIOL, V4, P533, DOI 10.1016/S1369-5266(00)00212-0; Molinier J, 2005, MUTAT RES-FUND MOL M, V571, P235, DOI 10.1016/j.mrfmmm.2004.09.016; Molinier J, 2004, PLANT CELL, V16, P1633, DOI 10.1105/tpc.021378; Morikawa H, 2004, MOL CELL BIOL, V24, P9401, DOI 10.1128/MCB.24.21.9401-9413.2004; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nakai T, 2006, FEBS LETT, V580, P336, DOI 10.1016/j.febslet.2005.12.018; Ng DWK, 2006, PLANT CELL, V18, P119, DOI 10.1105/tpc.105.037010; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Nicolai M, 2006, PLANT PHYSIOL, V141, P663, DOI 10.1104/pp.106.079418; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; Nole-Wilson S, 2006, PLANT PHYSIOL, V141, P977, DOI 10.1104/pp.106.076604; O'Brien PJ, 2006, CHEM REV, V106, P720, DOI 10.1021/cr040481v; Ohno T, 2004, BIOCHEM BIOPH RES CO, V317, P925, DOI 10.1016/j.bbrc.2004.03.131; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Patel JH, 2006, J BIOL CHEM, V281, P3283, DOI 10.1074/jbc.M513038200; PICCOLI GD, 2006, NAT CELL BIOL, V8, P1032; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Post SM, 2003, NUCLEIC ACIDS RES, V31, P5568, DOI 10.1093/nar/gkg765; Preuss SB, 2003, GENETICS, V164, P323; Rieger KE, 2004, NUCLEIC ACIDS RES, V32, P4786, DOI 10.1093/nar/gkh783; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Saintigny Y, 2007, ONCOGENE, V26, P2769, DOI 10.1038/sj.onc.1210075; Sanchez-Moran E, 2005, CYTOGENET GENOME RES, V109, P181, DOI 10.1159/000082398; Sano T, 2006, FEBS LETT, V580, P597, DOI 10.1016/j.febslet.2005.12.074; Scheible WR, 2004, PLANT PHYSIOL, V136, P2483, DOI 10.1104/pp.104.047019; Schindler K, 2003, MOL CELL BIOL, V23, P8718, DOI 10.1128/MCB.23.23.8718-8728.2003; Schonrock N, 2006, J BIOL CHEM, V281, P9560, DOI 10.1074/jbc.M513426200; Schwaiger M, 2006, CURR OPIN GENET DEV, V16, P177, DOI 10.1016/j.gde.2006.02.007; Sedgwick C, 2006, BIOCHEM J, V399, P151, DOI 10.1042/BJ20060363; Shechter D, 2005, CELL CYCLE, V4, P235; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Shiloh Y, 2004, NAT CELL BIOL, V6, P923, DOI 10.1038/ncb1004-923; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Shimotohno A, 2006, PLANT J, V47, P701, DOI 10.1111/j.1365-313X.2006.02820.x; Shukla A, 2005, BIOCHEM BIOPH RES CO, V329, P1240, DOI 10.1016/j.bbrc.2005.02.106; Siaud N, 2004, EMBO J, V23, P1392, DOI 10.1038/sj.emboj.7600146; Sonoda E, 2006, DNA REPAIR, V5, P1021, DOI 10.1016/j.dnarep.2006.05.022; Stankovic T, 2004, BLOOD, V103, P291, DOI 10.1182/blood-2003-04-1161; Stoynova-Bakalova E, 2004, NEW PHYTOL, V162, P471, DOI 10.1111/j.1469-8137.2004.01031.x; Summers MK, 2005, ONCOGENE, V24, P2589, DOI 10.1038/sj.onc.1208428; Sutherland BM, 2000, BIOCHEMISTRY-US, V39, P8026, DOI 10.1021/bi9927989; Takeda S, 2004, GENE DEV, V18, P782, DOI 10.1101/gad.295404; Takemura M, 2002, BIOSYSTEMS, V65, P139, DOI 10.1016/S0303-2647(02)00007-2; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Thareau V, 2003, BIOINFORMATICS, V19, P2191, DOI 10.1093/bioinformatics/btg286; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tonkin ET, 2004, NAT GENET, V36, P636, DOI 10.1038/ng1363; Tremousaygue D, 2003, PLANT J, V33, P957, DOI 10.1046/j.1365-313X.2003.01682.x; Trenz K, 2006, EMBO J, V25, P1764, DOI 10.1038/sj.emboj.7601045; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tzafrir I, 2004, PLANT PHYSIOL, V135, P1206, DOI 10.1104/pp.104.045179; Umeda M, 2000, P NATL ACAD SCI USA, V97, P13396, DOI 10.1073/pnas.240458997; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; Vandepoele K, 2005, PLANT PHYSIOL, V139, P316, DOI 10.1104/pp.105.066290; Vernoux T, 2005, CURR OPIN GENET DEV, V15, P388, DOI 10.1016/j.gde.2005.06.008; Weingartner M, 2004, PLANT CELL, V16, P643, DOI 10.1105/tpc.020057; West CE, 2000, PLANT J, V24, P67, DOI 10.1046/j.1365-313x.2000.00856.x; West CE, 2004, BIOCHEM SOC T, V32, P964, DOI 10.1042/BST0320964; Wildwater M, 2005, CELL, V123, P1337, DOI 10.1016/j.cell.2005.09.042; Wu KQ, 2003, PLANT J, V34, P241, DOI 10.1046/j.1365-313X.2003.01714.x; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yamanaka T, 2002, J VIROL, V76, P2491, DOI 10.1128/JVI.76.5.2491-2497.2002; Yang ZB, 1998, CURR OPIN PLANT BIOL, V1, P525, DOI 10.1016/S1369-5266(98)80046-0; Yao JL, 2001, J BIOL CHEM, V276, P13517, DOI 10.1074/jbc.M007006200; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Zhang CQ, 2005, PLANT METHODS, V1, DOI 10.1186/1746-4811-1-7; Zhang NX, 2005, J BIOL CHEM, V280, P40559, DOI 10.1074/jbc.M508453200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	196	82	83	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e430	10.1371/journal.pone.0000430	http://dx.doi.org/10.1371/journal.pone.0000430			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487278	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445800012
J	Fujita, M; Takeshita, H; Sawa, H				Fujita, Masaki; Takeshita, Hisako; Sawa, Hitoshi			Cyclin E and CDK2 Repress the Terminal Differentiation of Quiescent Cells after Asymmetric Division in C. elegans	PLOS ONE			English	Article								Coordination between cell proliferation and differentiation is important in normal development and oncogenesis. These processes usually have an antagonistic relationship, in that differentiation is blocked in proliferative cells, and terminally differentiated cells do not divide. In some instances, cyclins, cyclin-dependent kinases (CDKs) and their inhibitors (CKIs) play important roles in this antagonistic regulation. However, it is unknown whether CKIs and cyclin/CDKs regulate the uncommitted state in quiescent cells where CDK activities are likely to be low. Here, we show in C. elegans that cye-1/cyclin E and cdk-2/CDK2 repress terminal differentiation in quiescent cells. In cye-1 mutants and cdk-2(RNAi) animals, after asymmetric division, certain quiescent cells adopted their sister cells' phenotype and differentiated at some frequency. In contrast, in cki-1(RNAi) animals, these cells underwent extra divisions, while, in cki-1(RNAi); cdk-2( RNAi) or cki-1(RNAi); cye-1 animals, they remained quiescent or differentiated. Therefore, in wild-type animals, CKI-1/CKI in these cells maintained quiescence by inhibiting CYE-1/CDK-2, while sufficient CYE-1/CDK-2 remained to repress the terminal differentiation. The difference between sister cells is regulated by the Wnt/MAP kinase pathway, which causes asymmetric expression of CYE-1 and CKI-1. Our results suggest that the balance between the levels of CKI and cyclin E determines three distinct cell states: terminally differentiated, quiescent and uncommitted, and proliferating.	[Fujita, Masaki; Takeshita, Hisako; Sawa, Hitoshi] Ctr Dev Biol, RIKEN, Lab Cell Fate Decis, Kobe, Hyogo, Japan; [Sawa, Hitoshi] Kobe Univ, Dept Biol, Grad Sch Sci, Kobe, Hyogo 657, Japan	RIKEN; Kobe University	Sawa, H (corresponding author), Ctr Dev Biol, RIKEN, Lab Cell Fate Decis, Kobe, Hyogo, Japan.	sawa@cdb.riken.jp		Sawa, Hitoshi/0000-0001-9774-7976	Japanese Ministry of Education, Culture, Sports, Science and Technology	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology.	Berger C, 2005, NAT CELL BIOL, V7, P56, DOI 10.1038/ncb1203; Blelloch R, 1999, DEV BIOL, V216, P382, DOI 10.1006/dbio.1999.9491; Boxem M, 1999, DEVELOPMENT, V126, P2227; Boxem M, 2001, DEVELOPMENT, V128, P4349; BRENNER S, 1974, GENETICS, V77, P71; Brodigan TM, 2003, DEV BIOL, V254, P102, DOI 10.1016/S0012-1606(02)00032-5; Chen P, 2003, NAT CELL BIOL, V5, P422, DOI 10.1038/ncb976; Chen S.-C., 2000, KLUW INT S ADV DATA, V21; Chen Z, 2001, DEVELOPMENT, V128, P4911; Cheng T, 2004, ONCOGENE, V23, P7256, DOI 10.1038/sj.onc.1207945; Fay DS, 2000, DEVELOPMENT, V127, P4049; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; Fukuyama M, 2003, DEV BIOL, V260, P273, DOI 10.1016/S0012-1606(03)00239-2; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hong Y, 1998, DEVELOPMENT, V125, P3585; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; Koppen M, 2001, NAT CELL BIOL, V3, P983, DOI 10.1038/ncb1101-983; Kostic I, 2003, DEV BIOL, V263, P242, DOI 10.1016/S0012-1606(03)00452-4; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; Nakamura K, 2005, GENE DEV, V19, P1749, DOI 10.1101/gad.1323705; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; Saito RM, 2004, NAT CELL BIOL, V6, P777, DOI 10.1038/ncb1154; Sawa H, 2000, MOL CELL, V6, P617, DOI 10.1016/S1097-2765(00)00060-5; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Siegfried KR, 2002, DEVELOPMENT, V129, P443; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Takeshita H, 2005, GENE DEV, V19, P1743, DOI 10.1101/gad.1322805; Terns RM, 1997, GENETICS, V146, P185; Thorpe CJ, 2000, TRENDS CELL BIOL, V10, P10, DOI 10.1016/S0962-8924(99)01672-4; Tilmann C, 2005, DEV CELL, V9, P489, DOI 10.1016/j.devcel.2005.09.004; Wang MQ, 2000, DEVELOPMENT, V127, P5047; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	38	17	26	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e407	10.1371/journal.pone.0000407	http://dx.doi.org/10.1371/journal.pone.0000407			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476329	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445700009
J	Zhang, X; Leung, YK; Ho, SM				Zhang, X.; Leung, Y-K; Ho, S-M			AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells	ONCOGENE			English	Article						epigenetics; promoter analysis; non-canonical; cis-element; tumor suppressor; gene regulation	ER-BETA; ACTIVATOR PROTEIN-2-ALPHA; GENE-EXPRESSION; BREAST-CANCER; BINDING; CLONING; FAMILY; DNA; CARCINOGENESIS; CARCINOMA	We reported previously that the loss of expression of estrogen receptor (ER)-beta during the development of prostate cancer (PCa) is associated with methylation of a CpG island located in the 5'-flanking sequence of the 0N promoter. Three methylation hotspots, referred to as centers 1, 2 and 3, were identified in the CpG island. In this study, we demonstrated that a 581-bp region with these three centers within it is sufficient for the promoter activity in PCa cells. Deletion analyses indicated that center 1 ( 16 bp), with a putative activator protein-2 (AP-2) binding site, is essential for gene transactivation. Chromatin immunoprecipitation assays showed that AP-2 alpha occupies a short sequence containing center 1. Forced expression of AP-2 alpha or -2 gamma, but not -2 beta, increased activity of the ER beta 0N promoter and the accumulation of mRNA. Conversely, siRNA-mediated AP-2 alpha and -2 gamma knockdown reduced levels of ERb transcript and promoter activity. Quantitative reverse transcription - PCR showed that AP-2 alpha and -2 gamma are the predominant transcripts expressed in PCa cells, and levels of ERb transcript correlate with levels of these AP-2 transcripts among different PCa cell lines. These results provide the first evidence that ERb is an AP-2-regulated gene. They also support the hypothesis that certain cis-acting elements are methylation hotspots susceptible to epigenetic modi. cations during cancer progression.	Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Ho, SM (corresponding author), Univ Cincinnati, Coll Med, Dept Environm Hlth, 130 Kettering,3223 Eden Ave,PO Box 670056, Cincinnati, OH 45267 USA.	shuk-mei.ho@uc.edu	Zhang, Xiang/D-3632-2009; Leung, Ricky/H-5958-2019	Leung, Ricky/0000-0003-2063-277X	NIDDK NIH HHS [DK061084] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061084] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bosher JM, 1996, ONCOGENE, V13, P1701; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Comhaire F, 2004, Aging Male, V7, P155; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; HERMANN R, 1991, FEBS LETT, V281, P191, DOI 10.1016/0014-5793(91)80391-F; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hirata S, 2001, J STEROID BIOCHEM, V78, P33, DOI 10.1016/S0960-0760(01)00071-1; Ho SM, 2006, ANN NY ACAD SCI, V1089, P177, DOI 10.1196/annals.1386.005; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Horvath LG, 2001, CANCER RES, V61, P5331; Imamov O, 2005, BIOL REPROD, V73, P866, DOI 10.1095/biolreprod.105.043497; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lai JS, 2004, UROLOGY, V64, P814, DOI 10.1016/j.urology.2004.05.036; Lau KM, 2000, CANCER RES, V60, P3175; Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002-9440(10)61676-8; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216; Mitchell DC, 2006, J BIOL CHEM, V281, P51, DOI 10.1074/jbc.M506245200; Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760; Nieto M, 2007, INT J BIOCHEM CELL B, V39, P1562, DOI 10.1016/j.biocel.2007.01.005; Ockrim J, 2006, NAT CLIN PRACT ONCOL, V3, P552, DOI 10.1038/ncponc0602; Pellikainen JM, 2007, INT J CANCER, V120, P2061, DOI 10.1002/ijc.22648; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; Shoda T, 2002, J STEROID BIOCHEM, V82, P201, DOI 10.1016/S0960-0760(02)00186-3; Signoretti S, 2001, AM J PATHOL, V159, P13, DOI 10.1016/S0002-9440(10)61666-5; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200; ZHU X, 2004, AM J PATHOL, V546, P17	30	35	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7346	7354		10.1038/sj.onc.1210537	http://dx.doi.org/10.1038/sj.onc.1210537			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17525739				2022-12-25	WOS:000250955700006
J	Cordes, N; Frickz, S; Brunner, TB; Pilarsky, C; Grutzmann, R; Siposs, B; Kloppels, G; McKenna, WG; Bernhard, EJ				Cordes, N.; Frickz, S.; Brunner, T. B.; Pilarsky, C.; Gruetzmann, R.; Siposs, B.; Kloeppels, G.; McKenna, W. G.; Bernhard, E. J.			Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1	ONCOGENE			English	Article						caveolin-1; ionizing radiation; beta 1-integrin; FAK; pancreatic cancer	LUNG-CANCER CELLS; INDUCED GENOTOXIC INJURY; P42/44 MAP KINASE; EXTRACELLULAR-MATRIX; DOWN-REGULATION; DUCTAL ADENOCARCINOMA; EXPRESSION; SURVIVAL; ADHESION; GROWTH	Caveolin-1 (Cav-1) is an integral transmembrane protein and a critical component in interactions of integrin receptors with cytoskeleton-associated and signaling molecules. Since integrin-mediated cell adhesion generates signals conferring radiation resistance, we examined the effects of small interfering RNA-mediated knockdown of Cav-1 alone or in combination with beta 1-integrin or focal adhesion kinase (FAK) on radiation survival and proliferation of pancreatic carcinoma cell lines. Irradiation induced Cav-1 expression in PATU8902, MiaPaCa2 and Panel cell lines. The cell lines showed significant radio-sensitization after knockdown of Cav-1, beta 1-integrin or FAK and cholesterol depletion by beta-cyclodextrin relative to nonspecific controls. Under knockdown conditions, proliferation of non-irradiated and irradiated cells was significantly attenuated relative to controls. These findings correlated with changes in expression or phosphorylation of Akt, glycogen synthase kinase 3 beta, Paxillin, Src, c-Jun N-terminal kinase and mitogen-activated protein kinase. Analysis of DNA microarray data revealed a Cav-1 overexpression in a subset of pancreatic ductal adenocarcinoma samples. The data presented show, for the first time, that disruption of interactions of Cav-1 with beta 1-integrin or FAK affects radiation survival and proliferation of pancreatic carcinoma cells and suggest that Cav-1 is critical to these processes.. These results indicate that strategies targeting Cav-1 may be useful as an approach to improve conventional therapies, including radiotherapy, for pancreatic cancer.	Tech Univ Dresden, Med Fac Carl Gustav Carus, OncoRay Ctr Radiat Res Oncol, D-01307 Dresden, Germany; Bundeswehr Inst Radiobiol, Munich, Germany; Univ Erlangen Nurnberg, Erlangen, Germany; Univ Hosp Dresden, Dept Visceral Thorac, Dresden, Germany; Univ Hosp Dresden, Dept Vasc Surg, Dresden, Germany; Univ Hosp Kiel, Dept Pathol, Kiel, Germany; Univ Oxford, Churchill Hosp, Radiobiol Res Inst, Oxford, England	Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Erlangen Nuremberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Oxford	Cordes, N (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, OncoRay Ctr Radiat Res Oncol, Fetscherstasse 74-PF, D-01307 Dresden, Germany.	nils.cordes@oncoray.de		Cordes, Nils/0000-0001-5684-629X; Pilarsky, Christian/0000-0002-7968-3283	Medical Research Council [G0700730] Funding Source: Medline; NCI NIH HHS [R01 CA73820] Funding Source: Medline; MRC [G0700730] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA073820] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belanger MM, 2004, CANCER BIOL THER, V3, P954, DOI 10.4161/cbt.3.10.1112; Buttery RC, 2004, INT J BIOCHEM CELL B, V36, P1154, DOI 10.1016/S1357-2725(03)00261-9; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Cherubini A, 2005, MOL BIOL CELL, V16, P2972, DOI 10.1091/mbc.E04-10-0940; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Eke I, 2006, RADIOTHER ONCOL, V80, P178, DOI 10.1016/j.radonc.2006.07.028; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Estrugo D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000269; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fritz G, 2003, INT J RADIAT BIOL, V79, P601, DOI 10.1080/09553000310001609233; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Grutzmann R, 2004, NEOPLASIA, V6, P611, DOI 10.1593/neo.04295; Grutzmann R, 2005, ONCOGENE, V24, P5079, DOI 10.1038/sj.onc.1208696; Grutzmann R, 2003, VIRCHOWS ARCH, V443, P508, DOI 10.1007/s00428-003-0884-1; Hailstones D, 1998, J LIPID RES, V39, P369; Hayashi K, 2001, CANCER RES, V61, P2361; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Hess F, 2007, ONCOGENE, V26, P1372, DOI 10.1038/sj.onc.1209947; Hodkinson PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li JW, 2005, CELL CYCLE, V4, P1817, DOI 10.4161/cc.4.12.2199; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Regina A, 2004, J NEUROSCI RES, V75, P291, DOI 10.1002/jnr.10865; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shatz M, 2004, LEUKEMIA RES, V28, P907, DOI 10.1016/j.leukres.2004.03.013; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; Suzuoki M, 2002, BRIT J CANCER, V87, P1140, DOI 10.1038/sj.bjc.6600619; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Willcox M, 2004, TRA HERB, V4, P279; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Yacoub A, 2007, MOL PHARMACOL, V71, P259, DOI 10.1124/mol.106.031153	43	95	100	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6851	6862		10.1038/sj.onc.1210498	http://dx.doi.org/10.1038/sj.onc.1210498			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17471232				2022-12-25	WOS:000250188400001
J	Banerjee, S; Brooks, WS; Crawford, DF				Banerjee, S.; Brooks, W. S.; Crawford, D. F.			Inactivation of the ubiquitin conjugating enzyme UBE2Q2 causes a prophase arrest and enhanced apoptosis in response to microtubule inhibiting agents	ONCOGENE			English	Article						UBE2Q2; checkpoint; mitosis; microtubule; inhibiting agents (MIAs); apoptosis; antephase	MITOTIC STRESS CHECKPOINT; CELL-CYCLE; KAPPA-B; SPINDLE CHECKPOINT; CHFR; DELAYS; DEGRADATION; EXPRESSION; METAPHASE; GENE	A putative ubiquitin conjugating enzyme known as UBE2Q2 was previously identified in a microarray screen for mitotic regulatory proteins. UBE2Q2 is very similar to another human protein, UBE2Q1 and orthologs from other higher eukaryotic species. In these studies, we demonstrate that UBE2Q2 can covalently bind ubiquitin on the active site cysteine in vitro and show that inhibition of this protein in vivo causes an early mitotic arrest and increased cytotoxicity when cells are treated with microtubule inhibiting agents (MIAs). Changes in cell cycle progression and viability are not observed in the absence of MIA treatment, indicating that UBE2Q2 is involved in the response to MIAs rather than performing a more general function in mitosis. Inhibition of the UBE2Q2 protein causes cells to undergo a prolonged prophase arrest suggesting that UBE2Q2 normally functions to antagonize an early mitotic checkpoint. Furthermore, UBE2Q2 inhibition sensitizes cells to the cytotoxic effects of MIAs through caspase-mediated apoptosis that is correlated with PARP-1 cleavage. These data provide insights into the cellular response to MIAs and demonstrate that inhibition of UBE2Q2 protein function may be useful in the treatment of malignancies.	Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Crawford, DF (corresponding author), Univ Alabama, Dept Pediat & Cell Biol, 1600 7th Ave S,ACC 512, Birmingham, AL 35233 USA.	dfc@uab.edu			NCI NIH HHS [5K08CA86941-5] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA086941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Baker DJ, 2005, CURR OPIN CELL BIOL, V17, P583, DOI 10.1016/j.ceb.2005.09.011; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; CHEN C, 1987, MOL CELL BIOL, V7, P27; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; Gu HD, 2003, P NATL ACAD SCI USA, V100, P8963, DOI 10.1073/pnas.1533420100; Huang Y, 2004, MOL CANCER THER, V3, P271; Koh DW, 2005, PHARMACOL RES, V52, P5, DOI 10.1016/j.phrs.2005.02.011; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; Liu Q, 2006, INVEST OPHTH VIS SCI, V47, P1302, DOI 10.1167/iovs.05-0935; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; Melner MH, 2004, BIOL REPROD, V70, P406, DOI 10.1095/biolreprod.103.020719; Melner MH, 2006, BIOL REPROD, V75, P395, DOI 10.1095/biolreprod.106.051458; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Pallardy M, 1999, METHODS, V19, P36, DOI 10.1006/meth.1999.0825; Pati D, 1999, MOL CELL BIOL, V19, P5001; PINKERTON CR, 1988, CANCER CHEMOTH PHARM, V22, P271, DOI 10.1007/BF00273423; Pray TR, 2002, DRUG RESIST UPDATE, V5, P249, DOI 10.1016/S1368-7646(02)00121-8; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1992, J CELL SCI, V102, P387; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Schulze E, 2003, BIOCHEM BIOPH RES CO, V305, P691, DOI 10.1016/S0006-291X(03)00824-6; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Seghatoleslam A, 2006, BIOCHEM BIOPH RES CO, V339, P422, DOI 10.1016/j.bbrc.2005.11.026; Skerra A, 1999, BIOMOL ENG, V16, P79, DOI 10.1016/S1050-3862(99)00033-9; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; WEISSMAN AM, 2001, NAT REV MOL CELL BIO, V21, P3445; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	40	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6509	6517		10.1038/sj.onc.1210471	http://dx.doi.org/10.1038/sj.onc.1210471			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471241				2022-12-25	WOS:000249919800004
J	Egger, M; Schgoer, W; Beer, AGE; Jeschke, J; Leierer, J; Theurl, M; Frauscher, S; Tepper, OM; Niederwanger, A; Ritsch, A; Kearney, M; Wanschitz, J; Gurtner, GC; Fischer-Colbrie, R; Weiss, G; Piza-Katzer, H; Losordo, DW; Patsch, JR; Schratzberger, P; Kirchmair, R				Egger, Margot; Schgoer, Wilfried; Beer, Arno G. E.; Jeschke, Johannes; Leierer, Johannes; Theurl, Markus; Frauscher, Silke; Tepper, Oren M.; Niederwanger, Andreas; Ritsch, Andreas; Kearney, Marianne; Wanschitz, Julia; Gurtner, Geoffrey C.; Fischer-Colbrie, Reiner; Weiss, Guenter; Piza-Katzer, Hildegunde; Losordo, Douglas W.; Patsch, Josef R.; Schratzberger, Peter; Kirchmair, Rudolf			Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1 alpha- and basic FGF-dependent pathway in muscle cells	FASEB JOURNAL			English	Article						vascular biology; neuropeptides; ischemia	ENDOTHELIAL GROWTH-FACTOR; VEGF GENE-TRANSFER; SECRETOGRANIN-II; NEUROPEPTIDE SECRETONEURIN; PROHORMONE CONVERTASES; PERIPHERAL NEUROPATHY; INDUCIBLE FACTOR-1; CHROMOGRANIN-A; TUMOR-GROWTH; IN-VITRO	Expression of angiogenic cytokines like vascular endothelial growth factor is enhanced by hypoxia. We tested the hypothesis that decreased oxygen levels up-regulate the angiogenic factor secretoneurin. In vivo, muscle cells of mouse ischemic hind limbs showed increased secretoneurin expression, and inhibition of secretoneurin by a neutralizing antibody impaired the angiogenic response in this ischemia model. In a mouse soft tissue model of hypoxia, secretoneurin was increased in subcutaneous muscle fibers. In vitro, secretoneurin mRNA and protein were up-regulated in L6 myoblast cells after exposure to low oxygen levels. The hypoxia-dependent regulation of secretoneurin was tissue specific and was not observed in endothelial cells, vascular smooth muscle cells, or AtT20 pituitary tumor cells. The hypoxia-dependent induction of secretoneurin in L6 myoblasts is regulated by hypoxia-inducible factor-1 alpha, since inhibition of this factor using si-RNA inhibited up-regulation of secretoneurin. Induction of secretoneurin by hypoxia was dependent on basic fibroblast growth factor in vivo and in vitro, and inhibition of this regulation by heparinase suggests an involvement of low-affinity basic fibroblast growth factor binding sites. In summary, our data show that the angiogenic cytokine secretoneurin is up-regulated by hypoxia in muscle cells by hypoxia-inducible factor-1 alpha- and basic fibroblast growth factor-dependent mechanisms.-Egger, M., Schgoer, W., Beer, A. G. E., Jeschke, J., Leierer, J., Theurl, M., Frauscher, S., Tepper, O. M., Niederwanger, A., Ritsch, A., Kearney, M., Wanschitz, J., Gurtner, G. C., Fischer-Colbrie, R., Weiss, G., Piza-Katzer, H., Losordo, D. W., Patsch, J. R., Schratzberger, P., Kirchmair, R. Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1 alpha- and basic FGF-dependent pathway in muscle cells.	Univ Innsbruck, Dept Internal Med, A-6020 Innsbruck, Austria; Med Univ Innsbruck, Gen Internal Med, Dept Internal Med, Innsbruck, Austria; Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; Med Univ Innsbruck, Dept Plast Surg, Innsbruck, Austria; Med Univ Innsbruck, Dept Pharmacol, Innsbruck, Austria; NYU, Med Ctr, Lab Microvasc Res, New York, NY 10016 USA; NYU, Med Ctr, Vasc Tissue Engn, New York, NY 10016 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02111 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Vasc Med, Boston, MA 02111 USA	University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; New York University; New York University; New York University Tandon School of Engineering; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University	Kirchmair, R (corresponding author), Univ Innsbruck, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.	rudolf.kirchmair@uibk.ac.at	Losordo, Douglas W/F-9782-2011	Losordo, Douglas/0000-0002-6857-7506; Ritsch, Andreas/0000-0002-0417-5161; Weiss, Guenter/0000-0003-0709-2158; Leierer, Johannes/0000-0002-7884-9827; Theurl, Markus/0000-0002-3609-9730				Bauer R, 2000, EUR J NEUROSCI, V12, P2746, DOI 10.1046/j.1460-9568.2000.00157.x; Calvani M, 2006, BLOOD, V107, P2705, DOI 10.1182/blood-2005-09-3541; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Emanueli C, 2002, CIRCULATION, V106, P2257, DOI 10.1161/01.CIR.0000033971.56802.C5; Fischer-Colbrie R, 2005, CURR PROTEIN PEPT SC, V6, P373, DOI 10.2174/1389203054546334; FISCHERCOLBRIE R, 1995, PROG NEUROBIOL, V46, P49, DOI 10.1016/0301-0082(94)00060-U; HOFLEHNER J, 1995, FEBS LETT, V360, P294, DOI 10.1016/0014-5793(95)00127-U; Iimuro S, 2004, CIRC RES, V95, P415, DOI 10.1161/01.RES.0000138018.61065.d1; Isner JM, 2000, J CLIN INVEST, V106, P615, DOI 10.1172/JCI10961; Jogi A, 2003, CANCER LETT, V197, P145, DOI 10.1016/S0304-3835(03)00095-8; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Kirchmair R, 2005, CIRCULATION, V111, P2662, DOI 10.1161/CIRCULATIONAHA.104.470849; Kirchmair R, 2004, CIRCULATION, V110, P1121, DOI 10.1161/01.CIR.0000139884.81390.56; Kirchmair R, 2004, CIRCULATION, V109, P777, DOI 10.1161/01.CIR.0000112574.07422.C1; KIRCHMAIR R, 1993, NEUROSCIENCE, V53, P359, DOI 10.1016/0306-4522(93)90200-Y; Krishnamachary B, 2003, CANCER RES, V63, P1138; Laslop A, 1998, J NEUROCHEM, V70, P374; Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929; Li J, 2002, J CELL SCI, V115, P1951; Marti E, 2001, ACTA NEUROPATHOL, V101, P159; Medhurst AD, 2001, NEUROSCIENCE, V105, P353, DOI 10.1016/S0306-4522(01)00190-7; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; Pruneri G, 1998, PROSTATE, V34, P113, DOI 10.1002/(SICI)1097-0045(19980201)34:2<113::AID-PROS5>3.0.CO;2-L; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Stockmann C, 2006, CLIN EXP PHARMACOL P, V33, P968, DOI 10.1111/j.1440-1681.2006.04474.x; Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187	35	56	60	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2906	2917		10.1096/fj.06-7440com	http://dx.doi.org/10.1096/fj.06-7440com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17504977				2022-12-25	WOS:000249237500031
J	Lundberg, P; El-Andaloussi, S; Sutlu, T; Johansson, H; Langel, U				Lundberg, Pontus; El-Andaloussi, S.; Sutlu, T.; Johansson, H.; Langel, U.			Delivery of short interfering RNA using endosomolytic cell-penetrating peptides	FASEB JOURNAL			English	Article						CPP; gene silencing; siRNA; oligonucleotides; RNA interference	MAMMALIAN-CELLS; NUCLEIC-ACIDS; TAT; OLIGONUCLEOTIDES; MACROPINOCYTOSIS; PROTEINS; ENHANCE; CARRIER; ESCAPE; VECTOR	Cell- penetrating peptides ( CPPs) are peptides able to promote uptake of various cargos, including proteins and plasmids. Advances in recent years imply the uptake to be endocytic, where the current hurdle for efficient intracellular delivery is material being retained in the endosomes. In this study we wanted to compare the ability of various established CPPs to deliver siRNA and induce gene silencing of luciferase, with a novel designed penetratin analog having endosomolytic properties, using a noncovalent strategy. In principal, the penetratin analog EB1 will, upon protonation in the early- late endosomes, be able to form an amphipathic alpha helix resulting in permeabilization of the endosomal membrane. We demonstrate that even though all CPPs evaluated in this study can form complexes with siRNA, there is not a direct relationship between the complex formation ability and delivery efficacy. More important, although all CPPs significantly promote siRNA uptake, in some cases no gene silencing effect can be observed unless endosomal escape is induced. We find the designed endosomolytic peptide EB1 to be far more effective both in forming complexes and transporting biologically active siRNA than its parent peptide penetratin. We believe that developing CPPs with increased endosomolytical properties is a necessary step toward achieving biological effects at low concentrations for future in vivo applications.	Stockholm Univ, Dept Neurochem, S-10691 Stockholm, Sweden	Stockholm University	Lundberg, P (corresponding author), Stockholm Univ, Dept Neurochem, Svante Arrhenius Vag 21A, S-10691 Stockholm, Sweden.	pontus@neurochem.su.se	Johansson, Henrik J/O-3363-2014; Sutlu, Tolga/E-1190-2012	Johansson, Henrik J/0000-0003-4729-4205; Sutlu, Tolga/0000-0002-7813-8734; Langel, Ulo/0000-0001-6107-0844				Davidson BL, 2004, LANCET NEUROL, V3, P145, DOI 10.1016/S1474-4422(04)00678-7; Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004; El-Andaloussi S, 2005, J CONTROL RELEASE, V110, P189, DOI 10.1016/j.jconrel.2005.09.012; El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796; El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Goncalves C, 2004, MOL THER, V10, P373, DOI 10.1016/j.ymthe.2004.05.023; Kang SH, 1998, BIOCHEMISTRY-US, V37, P6235, DOI 10.1021/bi980300h; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Magzoub M, 2005, BIOCHEMISTRY-US, V44, P14890, DOI 10.1021/bi051356w; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510; Petersen H, 2002, BIOMACROMOLECULES, V3, P926, DOI 10.1021/bm025539z; Shiraishi T, 2005, CHEM BIOL, V12, P923, DOI 10.1016/j.chembiol.2005.06.009; Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385; Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P27, DOI 10.1093/nar/gki142; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996	20	246	283	1	70	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2664	2671		10.1096/fj.06-6502com	http://dx.doi.org/10.1096/fj.06-6502com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17463227				2022-12-25	WOS:000249237500008
J	Yoshida, Y; Hachiya, A; Sriwiriyanont, P; Ohuchi, A; Kitahara, T; Takema, Y; Visscher, MO; Boissy, RE				Yoshida, Yasuko; Hachiya, Akira; Sriwiriyanont, Penkanok; Ohuchi, Atsushi; Kitahara, Takashi; Takema, Yoshinori; Visscher, Marty O.; Boissy, Raymond E.			Functional analysis of keratinocytes in skin color using a human skin substitute model composed of cells derived from different skin pigmentation types	FASEB JOURNAL			English	Article						race; melanocytes; melanization; complexion	HUMAN MELANOCYTES; EPIDERMAL HYPERPIGMENTATION; DISTRIBUTION PATTERNS; IN-VIVO; TYROSINASE; ENDOTHELIN-1; ACTIVATION; EXPRESSION; MELANOSOMES; INHIBITION	Skin color is one of the most distinct features in the human race. To assess the mechanisms of skin color variation, human skin substitutes ( HSS) were constructed by grafting mixtures of cultured keratinocytes and melanocytes from a combination of donor skin types, together with light skin derived fibroblasts, into chambers inserted onto the back skin of severe combined immunodeficient ( SCID) mice. The resulting complexion coloration of the HSS was relatively darker and lighter when dark and light skin derived keratinocytes, respectively, were combined with melanocytes derived from either light or dark skin. The melanin content in the epidermis and the maturation stage of melanosomes in basal keratinocytes were significantly increased in the HSS composed of dark compared to light skin derived keratinocytes. In addition, the ratio of individual/ clustered melanosomes in recipient keratinocytes was increased in the former as opposed to the latter HSS. The genetic expression of endothelin- 1, proopiomelanocortin, microphthalmia-associated transcription factor, tyrosinase, GP100, and MART1 were increased in HSS composed of dark vs. light skin derived keratinocytes. These data suggest that our HSS is a promising melanogenic model that demonstrates the role of the keratinocyte in regulating in part both melanogenesis and distribution of transferred melanosomes.	Univ Cincinnati, Coll Med, Dept Dermatol, Cincinnati, OH 45267 USA; Kao Biol Sci Labs, Haga, Tochigi, Japan; Tokyo Med Univ, Dept Dermatol, Shinjyuku Ku, Tokyo, Japan; Cincinnati Childrens Hosp, Res Fdn, Skin Sci Inst, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; Tokyo Medical University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Boissy, RE (corresponding author), Univ Cincinnati, Coll Med, Dept Dermatol, 231 Albert Sabin Way ML 592, Cincinnati, OH 45267 USA.	boissyre@ucmail.uc.edu						ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; Babiarz-Magee L, 2004, PIGM CELL RES, V17, P241, DOI 10.1111/j.1600-0749.2004.00133.x; BARTELT RN, 1984, Z HAUTKRANKHEITEN, V59, P1053; Bessou S, 1997, BRIT J DERMATOL, V137, P890, DOI 10.1046/j.1365-2133.1997.19822084.x; BIOSSY RE, 2006, PIGMENTARY SYSTEM, P155; Boissy RE, 2004, PIGM CELL RES, V17, P208, DOI 10.1111/j.1600-0749.2004.00130.x; Byers H.R, 2006, PIGMENTARY SYSTEM PH, P181; Cario-Andre M, 2006, PIGM CELL RES, V19, P434, DOI 10.1111/j.1600-0749.2006.00326.x; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; COOPER ML, 1991, J INVEST DERMATOL, V97, P649, DOI 10.1111/1523-1747.ep12483707; Diamond J, 2005, NATURE, V435, P283, DOI 10.1038/435283a; Evans RR, 1996, AM J CARDIOL, V78, P486, DOI 10.1016/S0002-9149(96)00344-X; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; Hachiya A, 2005, J INVEST DERMATOL, V125, P364, DOI 10.1111/j.0022-202X.2005.23832.x; Hachiya A, 2001, J INVEST DERMATOL, V116, P578, DOI 10.1046/j.1523-1747.2001.01290.x; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; Hedley SJ, 2002, PIGM CELL RES, V15, P49, DOI 10.1034/j.1600-0749.2002.00067.x; Hoath SB, 2003, J INVEST DERMATOL, V121, P1440, DOI 10.1046/j.1523-1747.2003.12606.x; HUNT G, 1994, PIGM CELL RES, V7, P217, DOI 10.1111/j.1600-0749.1994.tb00052.x; Im SB, 1998, CANCER RES, V58, P47; Imokawa G, 1997, PIGM CELL RES, V10, P218, DOI 10.1111/j.1600-0749.1997.tb00488.x; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; IWATA M, 1990, J INVEST DERMATOL, V95, P9, DOI 10.1111/1523-1747.ep12872677; Jablonski NG, 2000, J HUM EVOL, V39, P57, DOI 10.1006/jhev.2000.0403; Kihira C, 1999, J DERMATOL SCI, V20, P72, DOI 10.1016/S0923-1811(98)00077-2; KONRAD K, 1973, ARCH DERMATOL, V107, P853; Maeda K, 1997, J DERMATOL SCI, V14, P199, DOI 10.1016/S0923-1811(96)00575-0; Minwalla L, 2001, J INVEST DERMATOL, V117, P341, DOI 10.1046/j.0022-202x.2001.01411.x; MONTAGNA W, 1991, J AM ACAD DERMATOL, V24, P929, DOI 10.1016/0190-9622(91)70148-U; Okazaki M, 2003, BRIT J DERMATOL, V148, P689, DOI 10.1046/j.1365-2133.2003.05283.x; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; Paine C, 2001, J INVEST DERMATOL, V116, P587, DOI 10.1046/j.1523-1747.2001.01291.x; Passeron T, 2005, J AUTOIMMUN, V25, P63, DOI 10.1016/j.jaut.2005.10.001; POMERANTZ SH, 1975, J CLIN INVEST, V55, P1127, DOI 10.1172/JCI108014; Quevedo WCJ, 2006, PIGMENTARY SYSTEM, P63; Scott G, 2001, J INVEST DERMATOL, V117, P1412, DOI 10.1046/j.0022-202x.2001.01575.x; Scott G.A, 2006, PIGMENTARY SYSTEM, P171; Seiberg M, 2000, J INVEST DERMATOL, V115, P162, DOI 10.1046/j.1523-1747.2000.00035.x; Seiberg M, 2000, EXP CELL RES, V254, P25, DOI 10.1006/excr.1999.4692; Seiberg M, 2001, PIGM CELL RES, V14, P236, DOI 10.1034/j.1600-0749.2001.140402.x; Sharlow ER, 2000, J CELL SCI, V113, P3093; Spritz RA, 2006, J DERMATOL SCI, V41, P3, DOI 10.1016/j.jdermsci.2005.10.001; SZABO G, 1969, NATURE, V222, P1082, DOI 10.1038/2221081a0; Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x; Thong HY, 2003, BRIT J DERMATOL, V149, P498, DOI 10.1046/j.1365-2133.2003.05473.x; Treiber FA, 2000, HYPERTENSION, V35, P722, DOI 10.1161/01.HYP.35.3.722; Yamamoto T, 1998, DERMATOLOGY, V197, P109, DOI 10.1159/000017979; Yang F, 2000, J INVEST DERMATOL, V114, P157, DOI 10.1046/j.1523-1747.2000.00836.x	49	50	54	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2829	2839		10.1096/fj.06-6845com	http://dx.doi.org/10.1096/fj.06-6845com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17475923				2022-12-25	WOS:000249237500024
J	Panee, J; Stoytcheva, ZR; Liu, W; Berry, MJ				Panee, Jun; Stoytcheva, Zoia R.; Liu, Wanyu; Berry, Marla J.			Selenoprotein H is redox-sensing high mobility group family DNA-binding protein that up-regulates genes involved in glutathione synthesis and phase II detoxification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; TARGET TISSUES; SUBUNIT GENE; CELL-DEATH; SELENIUM; EXPRESSION; ASSAY	Selenoprotein His a recently identified member of the selenoprotein family whose function is not fully known. Previous studies from our laboratory and others showed that Drosophila melanogaster selenoprotein H is essential for viability and antioxidant defense. In this study we investigated the function of human selenoprotein H in murine hippocampal HT22 cells engineered to stably overexpress the protein. After treatment of cells with L-buthionine-(S, R)-sulfoximine to deplete glutathione, selenoprotein H-overexpressing cells exhibited higher levels of total glutathione, total antioxidant capacities, and glutathione peroxidase enzymatic activity than did vector control cells. Overexpression of selenoprotein H also up-regulated the mRNA levels of endogenous selenoprotein H, glutamylcysteine synthetase heavy and light chains, and glutathione S-transferases Alpha 2, Alpha 4, and Omega 1. The amino acid sequence of selenoprotein H contains four putative nuclear localization sequences and an AT-hook motif, a small DNA-binding domain first identified in high mobility group proteins. Chromatin immunoprecipitation using a green fluorescent protein-selenoprotein H fusion revealed binding to sequences containing heat shock and/or stress response elements. Thus, selenoprotein His a redox-responsive DNA-binding protein of the AT-hook family and functions in regulating expression levels of genes involved in de novo glutathione synthesis and phase II detoxification in response to redox status.	Univ Hawaii, John A Burns Sch Med, Dept Cell & Mol Biol, Honolulu, HI 96813 USA	University of Hawaii System	Berry, MJ (corresponding author), 651 Ilalo St,BSB 222, Honolulu, HI 96813 USA.	mberry@hawaii.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040302] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS40302] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Ben Jilani KE, 2007, INT J BIOL SCI, V3, P198; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kwon SY, 2003, MOL CELL BIOL, V23, P8495, DOI 10.1128/MCB.23.23.8495-8504.2003; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Morozova N, 2003, GENES CELLS, V8, P963, DOI 10.1046/j.1365-2443.2003.00687.x; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Novoselov SV, 2007, J BIOL CHEM, V282, P11960, DOI 10.1074/jbc.M701605200; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pellegrini N, 1999, METHOD ENZYMOL, V299, P379; Prior RL, 2005, J AGR FOOD CHEM, V53, P4290, DOI 10.1021/jf0502698; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; Takamura Y, 2006, AM J PHYSIOL-CELL PH, V290, pC554, DOI 10.1152/ajpcell.00398.2005; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Zafar KS, 2003, J NEUROCHEM, V84, P438, DOI 10.1046/j.1471-4159.2003.01531.x	21	83	84	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2007	282	33					23759	23765		10.1074/jbc.M702267200	http://dx.doi.org/10.1074/jbc.M702267200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	199HK	17526492	hybrid			2022-12-25	WOS:000248686600004
J	Bartoov-Shifman, R; Ridner, G; Bahar, K; Rubins, N; Walker, MD				Bartoov-Shifman, Reut; Ridner, Gabriela; Bahar, Keren; Rubins, Nir; Walker, Michael D.			Regulation of the gene encoding GPR40, a fatty acid receptor expressed selectively in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; BINDING PROTEINS; PROMOTER; TRANSCRIPTION; LINE; TUMOR; MICE; PDX1	GPR40 is a G protein-coupled receptor expressed preferentially in pancreatic beta cells. It is activated by long-chain fatty acids and has been implicated in mediating physiological and pathological effects of long-chain fatty acids on beta cells. We mapped the GPR40 transcription start site to a location 1044 bp upstream of the translation start site. This permitted definition of the GPR40 core promoter and the organization of the gene, which comprises a 24-bp non-coding exon, a 698-bp intron and a 4402-bp second exon, containing the entire protein coding sequence. Sequence analysis of the GPR40 locus revealed three evolutionarily conserved regions upstream to the translation start site (HR1-HR3). DNase I-hypersensitive sites were present in the HR2 and HR3 regions in beta cells but not in non-beta cells. The 5 '-flanking region of the GPR40 gene was capable of directing transcriptional activity selectively in beta cells. An important component of this is attributable to the HR2 region, which showed strong beta cell-specific enhancer activity. Systematic mutagenesis of HR2 revealed several important sub-regions. Mutagenesis of sub-regions 4-5, and 9 reduced transcriptional activity by similar to 60 and 40%, respectively. These sub-regions can bind the beta cellspecific transcription factors PDX1 and BETA2, respectively, both in vitro and in vivo. Thus, cell-specific expression of the GPR40 gene involves a characteristic chromatin organization of the locus and is controlled at the transcriptional level through HR2, a potent beta cell-specific enhancer.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Walker, MD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, POB 26, IL-76100 Rehovot, Israel.	m.walker@weizmann.ac.il						Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2005, DNA CELL BIOL, V24, P54, DOI 10.1089/dna.2005.24.54; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Deryckere F, 1996, GENE, V175, P35, DOI 10.1016/0378-1119(96)00117-5; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Flodgren E, 2007, BIOCHEM BIOPH RES CO, V354, P240, DOI 10.1016/j.bbrc.2006.12.193; Fujiwara K, 2005, AM J PHYSIOL-ENDOC M, V289, pE670, DOI 10.1152/ajpendo.00035.2005; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Henquin JC, 2003, EUR J CLIN INVEST, V33, P742, DOI 10.1046/j.1365-2362.2003.01207.x; HUTTON JC, 1990, BIOCHEM SOC T, V18, P122, DOI 10.1042/bst0180122; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kotarsky K, 2003, BIOCHEM BIOPH RES CO, V301, P406, DOI 10.1016/S0006-291X(02)03064-4; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; Liberzon A, 2004, NUCLEIC ACIDS RES, V32, P54, DOI 10.1093/nar/gkh156; Moller DE, 2005, ANNU REV MED, V56, P45, DOI 10.1146/annurev.med.56.082103.104751; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Nilsson NE, 2003, BIOCHEM BIOPH RES CO, V303, P1047, DOI 10.1016/S0006-291X(03)00488-1; PARK CW, 1992, J BIOL CHEM, V267, P15642; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Poe JC, 2004, NAT IMMUNOL, V5, P1078, DOI 10.1038/ni1121; Poitout V, 2003, TRENDS ENDOCRIN MET, V14, P201, DOI 10.1016/S1043-2760(03)00086-9; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; Rutter GA, 2003, CURR BIOL, V13, pR403, DOI 10.1016/S0960-9822(03)00322-1; Salehi A, 2005, CELL TISSUE RES, V322, P207, DOI 10.1007/s00441-005-0017-z; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; Shapiro H, 2005, BIOCHEM BIOPH RES CO, V335, P97, DOI 10.1016/j.bbrc.2005.07.042; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Sosinsky A, 2000, GENOMICS, V70, P49, DOI 10.1006/geno.2000.6363; Steneberg R, 2005, CELL METAB, V1, P245, DOI 10.1016/j.cmet.2005.03.007; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Yaney GC, 2003, DIABETOLOGIA, V46, P1297, DOI 10.1007/s00125-003-1207-4; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	42	34	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23561	23571		10.1074/jbc.M702115200	http://dx.doi.org/10.1074/jbc.M702115200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17525159	hybrid			2022-12-25	WOS:000248577500058
J	Choi, CS; Savage, DB; Kulkarni, A; Yu, XX; Liu, ZX; Morino, K; Kim, S; Distefano, A; Samuel, VT; Neschen, S; Zhang, DY; Wang, A; Zhang, XM; Kahn, M; Cline, GW; Pandey, SK; Geisler, JG; Bhanot, S; Monia, BP; Shulman, GI				Choi, Cheol Soo; Savage, David B.; Kulkarni, Ameya; Yu, Xing Xian; Liu, Zhen-Xiang; Morino, Katsutaro; Kim, Sheene; Distefano, Alberto; Samuel, Varman T.; Neschen, Susanne; Zhang, Dongyan; Wang, Amy; Zhang, Xian-Man; Kahn, Mario; Cline, Gary W.; Pandey, Sanjay K.; Geisler, John G.; Bhanot, Sanjay; Monia, Brett P.; Shulman, Gerald I.			Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; GLUCOSE-METABOLISM; MONOACYLGLYCEROL ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; TRIGLYCERIDE SYNTHESIS; RECEPTOR SUBSTRATE-1; OBESITY RESISTANCE; TREATMENT STRATEGY; LIVER	Nonalcoholic fatty liver disease (NAFLD) is a major contributing factor to hepatic insulin resistance in type 2 diabetes. Diacylglycerol acyltransferase (Dgat), of which there are two iso-forms (Dgat1 and Dgat2), catalyzes the final step in triglyceride synthesis. We evaluated the metabolic impact of pharmacological reduction of DGAT1 and -2 expression in liver and fat using antisense oligonucleotides (ASOs) in rats with diet-induced NAFLD. Dgat1 and Dgat2 ASO treatment selectively reduced DGAT1 and DGAT2 mRNA levels in liver and fat, but only Dgat2 ASO treatment significantly reduced hepatic lipids (diacylglycerol and triglyceride but not long chain acyl CoAs) and improved hepatic insulin sensitivity. Because Dgat catalyzes triglyceride synthesis from diacylglycerol, and because we have hypothesized that diacylglycerol accumulation triggers fat-induced hepatic insulin resistance through protein kinase C-is an element of activation, we next sought to understand the paradoxical reduction in diacylglycerol in Dgat2 ASO-treated rats. Within 3 days of starting Dgat2 ASO therapy in high fat-fed rats, plasma fatty acids increased, whereas hepatic lysophosphatidic acid and diacylglycerol levels were similar to those of control rats. These changes were associated with reduced expression of lipogenic genes (SREBP1c, ACC1, SCD1, and mtGPAT) and increased expression of oxidative/thermogenic genes ( CPT1 and UCP2). Taken together, these data suggest that knocking down Dgat2 protects against fat-induced hepatic insulin resistance by paradoxically lowering hepatic diacylglycerol content and protein kinase C-is an element of activation through decreased SREBP1c-mediated lipogenesis and increased hepatic fatty acid oxidation.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Isis Pharmaceut, Carlsbad, CA 92008 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Yale University; Isis Pharmaceuticals Inc; Howard Hughes Medical Institute; Yale University	Shulman, GI (corresponding author), Yale Univ, Sch Med, TAC S269,POB 9812, New Haven, CT 06536 USA.	gerald.shulman@yale.edu	MORINO, KATSUTARO/I-3207-2019; O'Rahilly, Stephen/ABF-6509-2020; Adiels, Martin/C-9278-2011; Distefano, Alberto/AAD-8638-2019; Shulman, Gerald I./P-7176-2019	MORINO, KATSUTARO/0000-0003-2420-3817; O'Rahilly, Stephen/0000-0003-2199-4449; Distefano, Alberto/0000-0003-2842-9119; Shulman, Gerald I./0000-0003-1529-5668; Savage, David Bousfield/0000-0002-7857-7032	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, P30DK045735] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, P30 DK-45735, R01 DK-40936] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Cao JS, 2007, J LIPID RES, V48, P583, DOI 10.1194/jlr.M600331-JLR200; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2003, J CLIN INVEST, V111, P1715, DOI [10.1172/JCI15859, 10.1172/JCI200315859]; Chen HC, 2005, ARTERIOSCL THROM VAS, V25, P482, DOI 10.1161/01.ATV.0000151874.81059.ad; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2938, DOI 10.1172/JCI118001; Cooney GJ, 2002, ANN NY ACAD SCI, V967, P196; Crooke RM, 2005, J LIPID RES, V46, P872, DOI 10.1194/jlr.M400492-JLR200; Dentin R, 2005, J CLIN INVEST, V115, P2843, DOI 10.1172/JCI25256; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Ishigaki Y, 2005, DIABETES, V54, P322, DOI 10.2337/diabetes.54.2.322; Jandacek RJ, 2004, GASTROENTEROLOGY, V127, P139, DOI 10.1053/j.gastro.2004.04.007; Jump DB, 2005, J NUTR, V135, P2503, DOI 10.1093/jn/135.11.2503; JUMP DB, 1994, J LIPID RES, V35, P1076; Kim HJ, 2004, ARCH INTERN MED, V164, P2169, DOI 10.1001/archinte.164.19.2169; Kim JK, 2004, J CLIN INVEST, V113, P756, DOI 10.1172/JCI200418917; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; LEHNER R, 1993, J BIOL CHEM, V268, P8781; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Neschen S, 2005, CELL METAB, V2, P55, DOI 10.1016/j.cmet.2005.06.006; Neschen S, 2002, AM J PHYSIOL-ENDOC M, V282, pE395, DOI 10.1152/ajpendo.00414.2001; OHSHIMA K, 1984, AM J PHYSIOL, V246, pE193, DOI 10.1152/ajpendo.1984.246.2.E193; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Petersen KF, 2006, AM J MED, V119, p10S, DOI 10.1016/j.amjmed.2006.01.009; Petersen KF, 2005, DIABETES, V54, P603, DOI 10.2337/diabetes.54.3.603; Qu X, 1999, J ENDOCRINOL, V162, P207, DOI 10.1677/joe.0.1620207; Reznick RM, 2006, J PHYSIOL-LONDON, V574, P33, DOI 10.1113/jphysiol.2006.109512; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; Samuel VT, 2007, J CLIN INVEST, V117, P739, DOI 10.1172/JCI30400; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Savage DB, 2006, J CLIN INVEST, V116, P817, DOI 10.1172/JCI27300; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; SHMUELI E, 1993, J INTERN MED, V234, P397, DOI 10.1111/j.1365-2796.1993.tb00761.x; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Streeper RS, 2006, AM J PHYSIOL-ENDOC M, V291, pE388, DOI 10.1152/ajpendo.00621.2005; Watts LM, 2005, DIABETES, V54, P1846, DOI 10.2337/diabetes.54.6.1846; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; YOUN JH, 1993, DIABETES, V42, P757, DOI 10.2337/diabetes.42.5.757; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yu XX, 2005, HEPATOLOGY, V42, P362, DOI 10.1002/hep.20783	50	282	302	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22678	22688		10.1074/jbc.M704213200	http://dx.doi.org/10.1074/jbc.M704213200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17526931	hybrid			2022-12-25	WOS:000248354200045
J	Jin, MH; Yuan, Q; Li, SH; Travis, GH				Jin, Minghao; Yuan, Quan; Li, Songhua; Travis, Gabriel H.			Role of LRAT on the retinoid isomerase activity and membrane association of Rpe65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE VISUAL CYCLE; PIGMENT EPITHELIUM; PROTEIN PALMITOYLATION; VITAMIN-A; LECITHIN; ACYLTRANSFERASE; ESTERS; ISOMEROHYDROLASE; SUBSTRATE; ISOMERIZATION	Absorption of a photon by a vertebrate opsin pigment induces 11-cis to all-trans isomerization of its retinaldehyde chromophore. Restoration of light sensitivity to the bleached opsin requires chemical re-isomerization of the chromophore via an enzyme pathway called the visual cycle. The retinoid isomerase in this pathway is Rpe65, a membrane-associated protein in the retinal pigment epithelium (RPE) with no predicted membrane-spanning segments. It has been suggested that Rpe65 is S-palmitoylated by lecithin: retinol acyl transferase (LRAT) on Cys(231), Cys(329), and Cys(330), and that this palmitoylation is required for isomerase activity and the association of Rpe65 with membranes. Here we show that the affinity of Rpe65 for membranes is similar in wild-type and lrat(-/-) mice. The isomerase activity of Rpe65 is also similar in both strains when all-trans-retinyl palmitate is used as substrate. With all-trans-retinol substrate, isomerase activity is present in wild-type but undetectable in RPE homogenates from lrat(-/-) mice. Substitution of Cys231, Cys(329), and Cys(330) with Ser or Ala did not affect the affinity of Rpe65 for membranes. Further, these Cys residues are not palmitoylated in Rpe65 by mass spectrometric analysis. Global inhibition of protein palmitoylation by 2-bromopalmitate did not affect the solubility or isomerase activity of Rpe65. Finally, we show that soluble and membrane-associated Rpe65 possesses similar isomerase specific activities. These results indicate that LRAT is not required for isomerase activity beyond synthesis of retinyl-ester substrate, and that the association of Rpe65 with membranes is neither dependent upon LRAT nor the result of S-palmitoylation. The affinity of Rpe65 for membranes is probably an intrinsic feature of this protein.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Travis, GH (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Dept Biol Chem, Los Angeles, CA 90095 USA.	travis@jsei.ucla.edu	Travis, Gabriel Harvey/AIF-1062-2022; yuan, quan/GZM-5597-2022	Travis, Gabriel Harvey/0000-0003-4020-9493; 	NEI NIH HHS [R01 EY011713-14, R01 EY015844, R01 EY011713, R01 EY011713-15, R01 EY011713-16, R01 EY015844-04] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011713, R01EY015844] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; Felius J, 2002, ARCH OPHTHALMOL-CHIC, V120, P55; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P11824, DOI 10.1021/bi035227w; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; Guo H, 2006, J THEOR BIOL, V242, P117, DOI 10.1016/j.jtbi.2006.02.005; HO MTP, 1989, J BIOL CHEM, V264, P17759; Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110; JACKSON CS, 2002, CURRENT PROTOCOLS PR, V2; JIMENEZ CR, 2002, CURRENT PROTOCOLS PR, V2; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; Liu LM, 2005, J BIOL CHEM, V280, P40226, DOI 10.1074/jbc.M509643200; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Resh MD, 2006, METHODS, V40, P191, DOI 10.1016/j.ymeth.2006.04.013; Ruegg U T, 1977, Methods Enzymol, V47, P111; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1993, BIOCHEM J, V291, P697, DOI 10.1042/bj2910697; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xue LL, 2006, BIOCHEMISTRY-US, V45, P10710, DOI 10.1021/bi060897y; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016	31	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20915	20924		10.1074/jbc.M701432200	http://dx.doi.org/10.1074/jbc.M701432200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17504753	Green Accepted, hybrid			2022-12-25	WOS:000248047500017
J	Payne, VA; Au, WS; Gray, SL; Nora, ED; Rahman, SM; Sanders, R; Hadaschik, D; Friedman, JE; O'Rahilly, S; Rochford, JJ				Payne, Victoria A.; Au, Wo-Shing; Gray, Sarah L.; Nora, Edoardo Dalla; Rahman, Shaikh M.; Sanders, Rebecca; Hadaschik, Dirk; Friedman, Jacob E.; O'Rahilly, Stephen; Rochford, Justin J.			Sequential regulation of diacylglycerol acyltransferase 2 expression by CAAT/Enhancer-binding protein ss(C/EBP ss) and C/EBP alpha during adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; MICE LACKING; 3T3-L1 PREADIPOCYTES; HEPATIC STEATOSIS; GENE-EXPRESSION; ADIPOSE-TISSUE; PPAR-GAMMA; IN-VITRO; BETA; ACTIVATION	Diacylglycerol acyltransferase 2 (DGAT2) catalyzes the final step of triacylglycerol (TG) synthesis. Despite the existence of an alternative acyltransferase (DGAT1), mice lacking DGAT2 have a severe deficiency of TG in adipose tissue, indicating a nonredundant role for this enzyme in adipocyte TG synthesis. We have studied the regulation of DGAT2 expression during adipogenesis. In both isolated murine preadipocytes and 3T3-L1 cells the temporal pattern of DGAT2 expression closely mimicked that of genes whose expression is regulated by CAAT/enhancer-binding protein beta (C/EBP beta). Inhibition of C/EBP beta expression in differentiating preadipocytes reduced DGAT2 expression, and electrophoretic mobility shift assay and chromatin immunoprecipitation experiments identified a promoter element in the DGAT2 gene that is likely to mediate this effect. The importance of C/EBP beta in adipocyte expression of DGAT2 was confirmed by the finding of reduced DGAT2 expression in the adipose tissue of C/EBP beta-null animals. However, DGAT2 expression is maintained at high levels during the later stages of adipogenesis, when C/EBP beta levels decline. We show that, at these later stages of differentiation, C/EBP alpha is capable of substituting for C/EBP beta at the same promoter element. These observations provide novel insight into the transcriptional regulation of DGAT2 expression. Moreover, they further refine the complex and serial roles of the C/EBP family of transcription factors in inducing and maintaining the metabolic properties of mature adipocytes.	Univ Cambridge, Dept Clin Biochem, Addenbrookes Hosp, Cambridge CB2 2QR, England; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Rochford, JJ (corresponding author), Univ Cambridge, Dept Clin Biochem, Addenbrookes Hosp, Box 232,Level 4,Hills Rd, Cambridge CB2 2QR, England.	jjr30@cam.ac.uk	O'Rahilly, Stephen/ABF-6509-2020; Rahman, Shaikh Mizanoor/GLN-7518-2022; Nora, Edoardo Dalla/AAA-8938-2019	O'Rahilly, Stephen/0000-0003-2199-4449; Rahman, Shaikh Mizanoor/0000-0002-4879-2663; dalla nora, edoardo/0000-0003-2583-4776; Rochford, Justin/0000-0002-5020-4939	British Heart Foundation [FS/05/092/19519] Funding Source: Medline; NIDDK NIH HHS [R01 DK059767, DK059767] Funding Source: Medline; Wellcome Trust Funding Source: Medline; Medical Research Council [G0600717B] Funding Source: researchfish; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059767] Funding Source: NIH RePORTER	British Heart Foundation(British Heart Foundation); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal AK, 2002, NAT GENET, V31, P21, DOI 10.1038/ng880; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; Camp HS, 2002, TRENDS MOL MED, V8, P442, DOI 10.1016/S1471-4914(02)02396-1; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Chen Z, 2005, CELL METAB, V1, P93, DOI 10.1016/j.cmet.2004.12.009; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Gale SE, 2006, J BIOL CHEM, V281, P11082, DOI 10.1074/jbc.M509612200; Gustafson B, 2003, BIOCHEM BIOPH RES CO, V308, P933, DOI 10.1016/S0006-291X(03)01518-3; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Jitrapakdee S, 2005, J BIOL CHEM, V280, P27466, DOI 10.1074/jbc.M503836200; Lane MD, 1996, INT J OBESITY, V20, pS91; Laudes M, 2004, J BIOL CHEM, V279, P11711, DOI 10.1074/jbc.M310240200; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Magre J, 2003, DIABETES, V52, P1573, DOI 10.2337/diabetes.52.6.1573; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Peterfy M, 2005, J BIOL CHEM, V280, P32883, DOI 10.1074/jbc.M503885200; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Rochford JJ, 2004, MOL CELL BIOL, V24, P9863, DOI 10.1128/MCB.24.22.9863-9872.2004; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Schroeder-Gloeckler JM, 2007, J BIOL CHEM, V282, P15717, DOI 10.1074/jbc.M701329200; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 2000, P NATL ACAD SCI USA, V97, P12446, DOI 10.1073/pnas.220425597; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; Williams LJS, 2000, J BIOL CHEM, V275, P30232, DOI 10.1074/jbc.M001286200; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yamamoto H, 2002, J CELL SCI, V115, P3601, DOI 10.1242/jcs.00044; Yu XX, 2005, HEPATOLOGY, V42, P362, DOI 10.1002/hep.20783; Zuo Y, 2006, J BIOL CHEM, V281, P7960, DOI 10.1074/jbc.M510682200	44	49	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21005	21014		10.1074/jbc.M702871200	http://dx.doi.org/10.1074/jbc.M702871200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17504763	Green Accepted, hybrid			2022-12-25	WOS:000248047500027
J	Sandelin, E; Nordlund, A; Andersen, PM; Marklund, SSL; Oliveberg, M				Sandelin, Erik; Nordlund, Anna; Andersen, Peter M.; Marklund, Stefan S. L.; Oliveberg, Mikael			Amyotrophic lateral sclerosis-associated copper/zinc superoxide dismutase mutations preferentially reduce the repulsive charge of the proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALS-LINKED SOD1; CU,ZN-SUPEROXIDE DISMUTASE; AGGREGATION; MUTANTS; DISEASE; DATABASE; DESTABILIZATION; STABILITY; RESIDUES; DEFECTS	We provide bioinformatical evidence that protein charge plays a key role in the disease mechanism of amyotrophic lateral sclerosis (ALS). Analysis of 100 ALS-associated mutations in copper/zinc superoxide dismutase (SOD1) shows that these are site-selective with a preference to decrease the proteins' net repulsive charge. For each SOD1 monomer this charge is normally -6. Because biomolecules as a rule maintain net negative charge to assure solubility in the cellular interior, the result lends support to the hypothesis of protein aggregation as an initiating event in the ALS pathogenesis. The strength of the preferential reduction of repulsive charge is higher in SOD1 associated ALS than in other inherited protein disorders.	Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden	Stockholm University	Oliveberg, M (corresponding author), Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	mikael.oliveberg@dbb.su.se						Andersen PM, 2004, ANN NEUROL, V55, P298, DOI 10.1002/ana.10850; Andersen PM, 2003, AMYOTROPH LATERAL SC, V4, P62, DOI 10.1080/14660820310011700; Antonarakis SE, 2000, EUR J PEDIATR, V159, pS173, DOI 10.1007/PL00014395; Assfalg M, 2003, J MOL BIOL, V330, P145, DOI 10.1016/S0022-2836(03)00533-3; Baglioni S, 2006, J NEUROSCI, V26, P8160, DOI 10.1523/JNEUROSCI.4809-05.2006; Bairoch A, 2005, NUCLEIC ACIDS RES, V33, pD154, DOI 10.1093/nar/gki070; Bendotti C, 2004, J NEUROPATH EXP NEUR, V63, P113, DOI 10.1093/jnen/63.2.113; Brown A, 1998, NUCLEIC ACIDS RES, V26, P259, DOI 10.1093/nar/26.1.259; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chung J, 2003, BIOCHEM BIOPH RES CO, V312, P873, DOI 10.1016/j.bbrc.2003.11.008; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DiDonato M, 2003, J MOL BIOL, V332, P601, DOI 10.1016/S0022-2836(03)00889-1; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012; Fokkema IFAC, 2005, HUM MUTAT, V26, P63, DOI 10.1002/humu.20201; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Gunasekaran K, 1996, J MOL BIOL, V264, P191, DOI 10.1006/jmbi.1996.0633; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Jonsson PA, 2006, BRAIN, V129, P451, DOI 10.1093/brain/awh704; Jonsson PA, 2004, BRAIN, V127, P73, DOI 10.1093/brain/awh005; Khare SD, 2006, P NATL ACAD SCI USA, V103, P3147, DOI 10.1073/pnas.0511266103; Kwok CJ, 2002, HUM MUTAT, V19, P217, DOI 10.1002/humu.10036; Lindberg M, 2002, NAT STRUCT BIOL, V9, P818, DOI 10.1038/nsb847; Lindberg MJ, 2005, P NATL ACAD SCI USA, V102, P9754, DOI 10.1073/pnas.0501957102; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; Lindberg MJ, 2004, P NATL ACAD SCI USA, V101, P15893, DOI 10.1073/pnas.0403979101; Liochev SI, 2003, FREE RADICAL BIO MED, V34, P1383, DOI 10.1016/S0891-5849(03)00153-9; Miller MP, 2001, HUM MOL GENET, V10, P2319, DOI 10.1093/hmg/10.21.2319; Morrison BM, 1998, J COMP NEUROL, V391, P64, DOI 10.1002/(SICI)1096-9861(19980202)391:1<64::AID-CNE6>3.0.CO;2-P; Nordlund A, 2006, P NATL ACAD SCI USA, V103, P10218, DOI 10.1073/pnas.0601696103; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otzen DE, 2000, P NATL ACAD SCI USA, V97, P9907, DOI 10.1073/pnas.160086297; Parrini C, 2005, STRUCTURE, V13, P1143, DOI 10.1016/j.str.2005.04.022; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; Rodriguez JA, 2005, P NATL ACAD SCI USA, V102, P10516, DOI 10.1073/pnas.0502515102; Rousseau F, 2006, CURR OPIN STRUC BIOL, V16, P118, DOI 10.1016/j.sbi.2006.01.011; Scriver CR, 2003, HUM MUTAT, V21, P333, DOI 10.1002/humu.10200; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Stathopulos PB, 2006, J BIOL CHEM, V281, P6184, DOI 10.1074/jbc.M509496200; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212; Thirumalai D, 2003, CURR OPIN STRUC BIOL, V13, P146, DOI 10.1016/S0959-440X(03)00032-0; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200	49	58	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21230	21236		10.1074/jbc.M700765200	http://dx.doi.org/10.1074/jbc.M700765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17513298	hybrid			2022-12-25	WOS:000248047500050
J	Benanti, EL; Chivers, PT				Benanti, Erin L.; Chivers, Peter T.			The N-terminal arm of the Helicobacter pylori Ni2+-dependent transcription factor NikR is required for specific DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI NIKR; NICKEL-RESPONSIVE REGULATOR; CRYSTAL-STRUCTURE; HYDROGENASE ISOENZYMES; OPERATOR COMPLEX; ACID RESISTANCE; UREASE ACTIVITY; MNT REPRESSOR; METAL-BINDING; BETA-SHEETS	The Ni2+-dependent transcription factor NikR is widespread among microbes. The two experimentally characterized NikR orthologs, from Helicobacter pylori and Escherichia coli, display vastly different regulatory capabilities in response to increased intracellular Ni2+. Here, we demonstrate that the nine-residue N-terminal arm present in H. pylori NikR plays a critical role in the expanded regulatory capabilities of this NikR family member. Specifically, the N-terminal arm is required to inhibit NikR binding to low affinity and nonspecific DNA sequences and is also linked to a cation requirement for NikR binding to the nixA promoter. Site-directed mutagenesis and arm-truncation variants of NikR indicate that two residues, Asp-7 and Asp-8, are linked to the cation requirement for binding. Pro-4 and Lys-6 are required for maximal DNA binding affinity of the full-length protein to both the nixA and ureA promoters. The N-terminal arm is highly variable among NikR family members, and these results suggest that it is an adaptable structural feature that can tune the regulatory capabilities of NikR to the nickel physiology of the microbe in which it is found.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Chivers, PT (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA.	chivers@wustl.edu		Chivers, Peter/0000-0002-8779-1452				Abraham LO, 2006, J INORG BIOCHEM, V100, P1005, DOI 10.1016/j.jinorgbio.2005.10.014; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; Bauerfeind P, 1997, GUT, V40, P25, DOI 10.1136/gut.40.1.25; Belzer C, 2005, MICROBIOL-SGM, V151, P3989, DOI 10.1099/mic.0.28188-0; Berggrun A, 2000, J MOL BIOL, V301, P959, DOI 10.1006/jmbi.2000.4007; Berggrun A, 2001, P NATL ACAD SCI USA, V98, P2301, DOI 10.1073/pnas.041612198; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; Bloom SL, 2004, BIOCHEMISTRY-US, V43, P10029, DOI 10.1021/bi049404k; Brown NL, 2003, FEMS MICROBIOL REV, V27, P145, DOI 10.1016/S0168-6445(03)00051-2; Bury-Mone S, 2004, MOL MICROBIOL, V53, P623, DOI 10.1111/j.1365-2958.2004.04137.x; Carrington PE, 2003, NAT STRUCT BIOL, V10, P126, DOI 10.1038/nsb890; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P14985, DOI 10.1021/bi970071j; Chivers PT, 1999, PROTEIN SCI, V8, P2494, DOI 10.1110/ps.8.11.2494; Chivers PT, 2005, J MOL BIOL, V348, P597, DOI 10.1016/j.jmb.2005.03.017; Chivers PT, 2000, J BIOL CHEM, V275, P19735, DOI 10.1074/jbc.M002232200; Chivers PT, 2002, CHEM BIOL, V9, P1141, DOI 10.1016/S1074-5521(02)00241-7; Contreras M, 2003, MOL MICROBIOL, V49, P947, DOI 10.1046/j.1365-2958.2003.03621.x; Cowan JA, 1998, CHEM REV, V98, P1067, DOI 10.1021/cr960436q; Davis GS, 2006, INFECT IMMUN, V74, P6811, DOI 10.1128/IAI.01188-06; De Pina K, 1999, J BACTERIOL, V181, P670, DOI 10.1128/JB.181.2.670-674.1999; Delany I, 2005, J BACTERIOL, V187, P7703, DOI 10.1128/JB.187.22.7703-7715.2005; Dian C, 2006, J MOL BIOL, V361, P715, DOI 10.1016/j.jmb.2006.06.058; Dias AV, 2005, J BIOL INORG CHEM, V10, P605, DOI 10.1007/s00775-005-0008-2; Dosanjh NS, 2007, BIOCHEMISTRY-US, V46, P2520, DOI 10.1021/bi062092w; EATON KA, 1991, INFECT IMMUN, V59, P2470, DOI 10.1128/IAI.59.7.2470-2475.1991; Ernst FD, 2005, INFECT IMMUN, V73, P7252, DOI 10.1128/IAI.73.11.7252-7258.2005; Ernst FD, 2006, INFECT IMMUN, V74, P6821, DOI 10.1128/IAI.01196-06; FOX JG, 1990, GASTROENTEROLOGY, V99, P352, DOI 10.1016/0016-5085(90)91016-Y; FOX JG, 1994, J CLIN MICROBIOL, V32, P1238, DOI 10.1128/JCM.32.5.1238-1245.1994; Grant GA, 2006, J BIOL CHEM, V281, P33825, DOI 10.1074/jbc.R600024200; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Iwig JS, 2006, MOL MICROBIOL, V62, P252, DOI 10.1111/j.1365-2958.2006.05369.x; KNIGHT KL, 1989, P NATL ACAD SCI USA, V86, P797, DOI 10.1073/pnas.86.3.797; Leitch S, 2007, J AM CHEM SOC, V129, P5085, DOI 10.1021/ja068505y; Maier RJ, 2007, BIOMETALS, V20, P655, DOI 10.1007/s10534-006-9061-8; Maroney MJ, 1999, CURR OPIN CHEM BIOL, V3, P188, DOI 10.1016/S1367-5931(99)80032-5; MeyerRosberg K, 1996, GASTROENTEROLOGY, V111, P886, DOI 10.1016/S0016-5085(96)70056-2; Mulrooney SB, 2003, FEMS MICROBIOL REV, V27, P239, DOI 10.1016/S0168-6445(03)00042-1; Nguyen CC, 1995, FEBS LETT, V377, P98, DOI 10.1016/0014-5793(95)01344-X; Olson JW, 2001, MOL MICROBIOL, V39, P176, DOI 10.1046/j.1365-2958.2001.02244.x; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Pennella MA, 2005, BIOMETALS, V18, P413, DOI 10.1007/s10534-005-3716-8; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; RAUMANN BE, 1995, NAT STRUCT BIOL, V2, P1115, DOI 10.1038/nsb1295-1115; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; RAUMANN BE, 1994, CURR OPIN STRUC BIOL, V4, P36, DOI 10.1016/S0959-440X(94)90057-4; Rigali S, 2002, J BIOL CHEM, V277, P12507, DOI 10.1074/jbc.M110968200; Rowe JL, 2005, J BACTERIOL, V187, P6317, DOI 10.1128/JB.187.18.6317-6323.2005; SAWERS RG, 1985, J BACTERIOL, V164, P1324, DOI 10.1128/JB.164.3.1324-1331.1985; Schauer K, 2007, MOL MICROBIOL, V63, P1054, DOI 10.1111/j.1365-2958.2006.05578.x; Schreiter ER, 2003, NAT STRUCT BIOL, V10, P794, DOI 10.1038/nsb985; Schreiter ER, 2006, P NATL ACAD SCI USA, V103, P13676, DOI 10.1073/pnas.0606247103; Scott DR, 2002, GASTROENTEROLOGY, V123, P187, DOI 10.1053/gast.2002.34218; Scott DR, 1998, GASTROENTEROLOGY, V114, P58, DOI 10.1016/S0016-5085(98)70633-X; SEGAL ED, 1992, INFECT IMMUN, V60, P1883, DOI 10.1128/IAI.60.5.1883-1889.1992; Shirai M, 1999, GENE, V239, P351, DOI 10.1016/S0378-1119(99)00389-3; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Stingl K, 2005, INT J MED MICROBIOL, V295, P307, DOI 10.1016/j.ijmm.2005.06.006; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; van Vliet AHM, 2004, INFECT IMMUN, V72, P766, DOI 10.1128/IAI.72.2.766-773.2004; van Vliet AHM, 2002, INFECT IMMUN, V70, P2846, DOI 10.1128/IAI.70.6.2846-2852.2002; VERSHON AK, 1987, J MOL BIOL, V195, P311, DOI 10.1016/0022-2836(87)90652-8; Wang SC, 2004, BIOCHEMISTRY-US, V43, P10018, DOI 10.1021/bi049405c; WARD JM, 1994, JNCI-J NATL CANCER I, V86, P1222, DOI 10.1093/jnci/86.16.1222; WU LF, 1989, MOL MICROBIOL, V3, P1709, DOI 10.1111/j.1365-2958.1989.tb00156.x; WU LF, 1991, GENE, V107, P37; ZINONI F, 1984, ARCH MICROBIOL, V139, P299, DOI 10.1007/BF00408370	68	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20365	20375		10.1074/jbc.M702982200	http://dx.doi.org/10.1074/jbc.M702982200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17522054	hybrid			2022-12-25	WOS:000247819300039
J	Fries, T; Betz, C; Sohn, K; Caesar, S; Schlenstedt, G; Bailer, SM				Fries, Thomas; Betz, Christian; Sohn, Kai; Caesar, Stefanie; Schlenstedt, Gabriel; Bailer, Susanne M.			A novel conserved nuclear localization signal is recognized by a group of yeast importins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEINS; MAMMALIAN-CELLS; TRANSPORT; EXPORT; BETA; HISTONES; RECEPTOR; KARYOPHERINS; COMPLEXES; PATHWAY	Nucleo-cytoplasmic transport of proteins is mostly mediated by specific interaction between transport receptors of the importin beta family and signal sequences present in their cargo. While several signal sequences, in particular the classical nuclear localization signal (NLS) recognized by the heterodimeric importin alpha/beta complex are well known, the signals recognized by other importin beta-like transport receptors remain to be characterized in detail. Here we present the systematic analysis of the nuclear import of Saccharomyces cerevisiae Asr1p, a nonessential alcohol-responsive Ring/PHD finger protein that shuttles between nucleus and cytoplasm but accumulates in the nucleus upon alcohol stress. Nuclear import of Asr1p is constitutive and mediated by its C-terminal domain. A short sequence comprising residues 243-280 is sufficient and necessary for active targeting to the nucleus. Moreover, the nuclear import signal is conserved from yeast to mammals. In vitro, the nuclear localization signal of Asr1p directly interacts with the importins Kap114p, Kap95p, Pse1p, Kap123p, or Kap104p, interactions that are sensitive to the presence of RanGTP. In vivo, these importins cooperate in nuclear import. Interestingly, the same importins mediate nuclear transport of histone H2A. Based on mutational analysis and sequence comparison with a region mediating nuclear import of histone H2A, we identified a ;novel type of NLS with the consensus sequence R/KxxL(x)(n)V/YxxV/IxK/RxxxK/R that is recognized by five yeast importins and connects them into a highly efficient network for nuclear import of proteins.	Univ Saarland, D-66421 Homburg, Germany; Fraunhofer Inst Grenzflachen & Bioverfahrenstech, D-70569 Stuttgart, Germany	Saarland University; Fraunhofer Gesellschaft	Bailer, SM (corresponding author), Univ Saarland, D-66421 Homburg, Germany.	dr.susanne.bailer@med-rz.uni-saarland.de						Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; Betz C, 2004, J BIOL CHEM, V279, P28174, DOI 10.1074/jbc.M401595200; Caesar S, 2006, MOL CELL BIOL, V26, P3170, DOI 10.1128/MCB.26.8.3170-3180.2006; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Daigle N, 2001, J CELL BIOL, V154, P71, DOI 10.1083/jcb.200101089; Greiner M, 2004, EUR J CELL BIOL, V83, P511, DOI 10.1078/0171-9335-00418; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Kunzler M, 2000, MOL CELL BIOL, V20, P4295, DOI 10.1128/MCB.20.12.4295-4308.2000; Lee BJ, 2006, CELL, V126, P543, DOI 10.1016/j.cell.2006.05.049; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; Madrid AS, 2006, CHROMOSOMA, V115, P98, DOI 10.1007/s00412-005-0043-3; Matsuura Y, 2004, NATURE, V432, P872, DOI 10.1038/nature03144; Maurer P, 2001, MOL BIOL CELL, V12, P539, DOI 10.1091/mbc.12.3.539; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Mosammaparast N, 2001, J CELL BIOL, V153, P251, DOI 10.1083/jcb.153.2.251; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Strom AC, 2001, GENOME BIOL, V2; Sullivan SA, 2000, NUCLEIC ACIDS RES, V28, P320, DOI 10.1093/nar/28.1.320; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207	30	22	23	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19292	19301		10.1074/jbc.M700217200	http://dx.doi.org/10.1074/jbc.M700217200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17485461	hybrid			2022-12-25	WOS:000247650600004
J	Maa, MC; Lee, JC; Chen, YJ; Chen, YJ; Lee, YC; Wang, ST; Huang, CC; Chow, NH; Leu, TH				Maa, Ming-Chei; Lee, Jenq-Chang; Chen, Yen-Jen; Chen, Yun-Ju; Lee, Yuch-Ching; Wang, Shan-Tair; Huang, Ching-Chung; Chow, Nan-Haw; Leu, Tzeng-Horng			EPS8 facilitates cellular growth and motility of colon cancer cells by increasing the expression and activity of focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT3 ACTIVATION; MAXIMAL ACTIVATION; FACTOR RECEPTOR; C-SRC; PROTEIN; TYROSINE; PHOSPHORYLATION; BINDING; OVEREXPRESSION; TRANSFORMATION	In an attempt to study the role of Eps8 in human carcinogenesis, we observe that ectopic overexpression of Eps8 in SW480 cells (low Eps8 expression) increases cell proliferation. By contrast, expressing eps8 small interference RNA in SW620 and WiDr cells (high Eps8 expression) reduces their proliferation rate. Interestingly, attenuation of Eps8 decreases Src Pi-Tyr-416, Shc Pi-Tyr-317, and serum-induced FAK Pi-Tyr-397 and Pi-Tyr-861. Remarkably, by virtue of mammalian target of rapamycin/STAT3 Pi-Ser-727, Eps8 modulates FAK expression required for cell proliferation. Within 62% of colorectal tumor specimens examined, > 2-fold enhancement of Eps8 as compared with their normal counterparts is observed, especially for those from the advanced stage. In agreement with the modulation of FAK by Eps8, the concomitant expression of these two proteins in tumor specimens is observed. Notably, Eps8 attenuation also impedes the motility of SW620 and WiDr cells, which can be rescued by ectopically expressed FAK. This finding discloses the indispensability of Eps8 and FAK in cell locomotion. These results provide a novel mechanism for Eps8-mediated FAK expression and activation in colon cancer cells.	China Med Univ, Inst Med Sci, Taichung 40402, Taiwan; Natl Cheng Kung Univ, Dept Surg, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Inst Basic Med Sci, Dept Pharmacol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Inst Basic Med Sci, Dept Publ Hlth, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pathol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Tainan 70101, Taiwan	China Medical University Taiwan; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Leu, TH (corresponding author), China Med Univ, Inst Med Sci, Taichung 40402, Taiwan.	tzengleu@mail.ncku.edu.tw						Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Baisden JM, 2001, ONCOGENE, V20, P6607, DOI 10.1038/sj.onc.1204802; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; DEVOR BB, 1993, BIOCHEM BIOPH RES CO, V190, P1084, DOI 10.1006/bbrc.1993.1160; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Funato Y, 2004, CANCER RES, V64, P5237, DOI 10.1158/0008-5472.CAN-04-0327; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Lee JC, 2005, MOL CARCINOGEN, V43, P207, DOI 10.1002/mc.20117; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Leu TH, 2004, J BIOL CHEM, V279, P9875, DOI 10.1074/jbc.M309884200; Leu TH, 2003, FRONT BIOSCI-LANDMRK, V8, pS28, DOI 10.2741/980; Leu TH, 2002, ONCOGENE, V21, P6992, DOI 10.1038/sj.onc.1205904; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Maa MC, 2001, ONCOGENE, V20, P106, DOI 10.1038/sj.onc.1204069; Matoskova B, 1996, ONCOGENE, V12, P2679; OWENS LV, 1995, CANCER RES, V55, P2752; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamamoto D, 2003, CELL SIGNAL, V15, P575, DOI 10.1016/S0898-6568(02)00142-0; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeh HH, 2006, ONCOGENE, V25, P4300, DOI 10.1038/sj.onc.1209464; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	49	62	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19399	19409		10.1074/jbc.M610280200	http://dx.doi.org/10.1074/jbc.M610280200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17496330	hybrid			2022-12-25	WOS:000247650600014
J	Hou, ZB; Li, Q; He, LS; Lim, HY; Fu, XR; Cheung, NS; Qi, DX; Qi, RZ				Hou, Zhibo; Li, Qing; He, Lisheng; Lim, Hui-Ying; Fu, Xinrong; Cheung, Nam Sang; Qi, Donna X.; Qi, Robert Z.			Microtubule association of the neuronal p35 activator of Cdk5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHORYLATION; IDENTIFICATION; CLEAVAGE; DEFECTS; P25	Cdk5 and its neuronal activator p35 play an important role in neuronal migration and proper development of the brain cortex. We show that p35 binds directly to alpha/beta-tubulin and microtubules. Microtubule polymers but not the alpha/beta-tubulin heterodimer block p35 interaction with Cdk5 and therefore inhibit Cdk5-p35 activity. p25, a neurotoxin-induced and truncated form of p35, does not have tubulin and microtubule binding activities, and Cdk5-p25 is inert to the inhibitory effect of microtubules. p35 displays strong activity in promoting microtubule assembly and inducing formation of microtubule bundles. Furthermore, microtubules stabilized by p35 are resistant to cold-induced disassembly. In cultured cortical neurons, a significant proportion of p35 localizes to microtubules. When microtubules were isolated from rat brain extracts, p35 co-assembled with microtubules, including cold-stable microtubules. Together, these findings suggest that p35 is a microtubule-associated protein that modulates microtubule dynamics. Also, microtubules play an important role in the control of Cdk5 activation.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Qi, RZ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	qirz@ust.hk		Lim, Hui-Ying/0000-0001-8084-6337				Andrieux A, 2002, GENE DEV, V16, P2350, DOI 10.1101/gad.223302; BAAS PW, 1994, J CELL SCI, V107, P135; Bosc C, 2003, BIOCHEMISTRY-US, V42, P12125, DOI 10.1021/bi0352163; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Ching YP, 2002, J BIOL CHEM, V277, P15237, DOI 10.1074/jbc.C200032200; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Fu XR, 2006, J BIOL CHEM, V281, P39014, DOI 10.1074/jbc.M512663200; GASKIN F, 1982, METHOD ENZYMOL, V85, P433; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lim ACB, 2004, J BIOL CHEM, V279, P4433, DOI 10.1074/jbc.M310563200; Lim ACB, 2004, J BIOL CHEM, V279, P46668, DOI 10.1074/jbc.M404760200; Lim ACB, 2003, NEUROSIGNALS, V12, P230, DOI 10.1159/000074625; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Qi Z, 1998, FEBS LETT, V423, P227, DOI 10.1016/S0014-5793(98)00096-9; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; Tanaka T, 2004, NEURON, V41, P215, DOI 10.1016/S0896-6273(03)00852-3; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; TURNER PF, 1984, J CELL BIOL, V99, P940, DOI 10.1083/jcb.99.3.940; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6	28	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18666	18670		10.1074/jbc.C700052200	http://dx.doi.org/10.1074/jbc.C700052200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17491008	hybrid, Green Published			2022-12-25	WOS:000247475300003
J	Shalbuyeva, N; Brustovetsky, T; Brustovetsky, N				Shalbuyeva, Natalia; Brustovetsky, Tatiana; Brustovetsky, Nickolay			Lithium desensitizes brain mitochondria to calcium, antagonizes permeability transition, and diminishes cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CEREBELLAR GRANULE CELLS; CA-2&-INDUCED MEMBRANE TRANSITION; GLYCOGEN-SYNTHASE KINASE-3; CYCLOSPORINE-A; CYCLOPHILIN-D; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; STRIATAL NEURONS; GLUTAMATE EXCITOTOXICITY	Among the numerous effects of lithium on intracellular targets, its possible action on mitochondria remains poorly explored. In the experiments with suspension of isolated brain mitochondria, replacement of KCl by LiCl suppressed mitochondrial swelling, depolarization, and a release of cytochrome c induced by a single Ca2+ bolus. Li+ robustly protected individual brain mitochondria loaded with rhodamine 123 against Ca2+- induced depolarization. In the experiments with slow calcium infusion, replacement of KCl by LiCl in the incubation medium increased resilience of synaptic and nonsynaptic brain mitochondria as well as resilience of liver and heart mitochondria to the deleterious effect of Ca2+. In LiCl medium, mitochondria accumulated larger amounts of Ca2+ before they lost the ability to sequester Ca2+. However, lithium appeared to be ineffective if mitochondria were challenged by Sr2+ instead of Ca2+. Cyclosporin A, sanglifehrin A, and Mg2+, inhibitors of the mitochondrial permeability transition (mPT), increased mitochondrial Ca2+ capacity in KCl medium but failed to do so in LiCl medium. This suggests that the mPT might be a common target for Li+ and mPT inhibitors. In addition, lithium protected mitochondria against high Ca2+ in the presence of ATP, where cyclosporin A was reported to be ineffective. SB216763 and SB415286, inhibitors of glycogen synthase kinase-3 beta, which is implicated in regulating reactive oxygen species-induced mPT in cardiac mitochondria, did not increase Ca2+ capacity of brain mitochondria. Altogether, these findings suggest that Li+ desensitizes mitochondria to elevated Ca2+ and diminishes cytochrome c release from brain mitochondria by antagonizing the Ca2+-induced mPT.	Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Brustovetsky, N (corresponding author), Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, 635 Barnhill Dr,Med Sci Bldg,Rm 549, Indianapolis, IN 46202 USA.	nbrous@iupui.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050131] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 050131] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bambrick LL, 2006, J BIOENERG BIOMEMBR, V38, P43, DOI 10.1007/s10863-006-9004-7; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1982, FEBS LETT, V139, P9, DOI 10.1016/0014-5793(82)80475-4; Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAGADIN M, 1979, BIOCHEMISTRY-US, V18, P5972, DOI 10.1021/bi00593a033; Brocard JB, 2001, J PHYSIOL-LONDON, V531, P793, DOI 10.1111/j.1469-7793.2001.0793h.x; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; BROWN MR, 2006, J BIOL CHEM; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Brustovetsky T, 2005, J PHYSIOL-LONDON, V568, P47, DOI 10.1113/jphysiol.2005.091199; Brustovetsky T, 2005, J NEUROCHEM, V94, P980, DOI 10.1111/j.1471-4159.2005.03248.x; CADE JFJ, 1949, MED J AUSTRALIA, V2, P349, DOI 10.5694/j.1326-5377.1949.tb36912.x; CARAFOLI E, 1965, BIOCHIM BIOPHYS ACTA, V97, P88, DOI 10.1016/0304-4165(65)90272-2; Castilho RF, 1998, J NEUROSCI, V18, P10277; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chinopoulos C, 2004, J NEUROCHEM, V91, P471, DOI 10.1111/j.1471-4159.2004.02732.x; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Czyz A, 2002, J NEUROCHEM, V81, P379, DOI 10.1046/j.1471-4159.2002.00851.x; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; GEAR ARL, 1968, J BIOL CHEM, V243, P3953; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; HUTSON SM, 1976, J BIOL CHEM, V251, P5251; Isaev NK, 1996, FEBS LETT, V392, P143, DOI 10.1016/0014-5793(96)00804-6; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Karkanias NB, 1999, J NEUROPHYSIOL, V81, P1506, DOI 10.1152/jn.1999.81.4.1506; KHODOROV B, 1995, FEBS LETT, V371, P249, DOI 10.1016/0014-5793(95)00894-F; Kiedrowski L, 1999, MOL PHARMACOL, V56, P619, DOI 10.1124/mol.56.3.619; KIEDROWSKI L, 1992, MOL PHARMACOL, V41, P779; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Layden BT, 2005, BBA-MOL BASIS DIS, V1741, P339, DOI 10.1016/j.bbadis.2005.07.004; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; Mansson R, 2007, NEUROBIOL DIS, V25, P198, DOI 10.1016/j.nbd.2006.09.008; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; MURPHY SN, 1987, J NEUROSCI, V7, P4145; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; ROTTENBERG H, 1989, FEBS LETT, V247, P483, DOI 10.1016/0014-5793(89)81396-1; Sarti Paolo, 2003, Ital J Biochem, V52, P37; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Sattler R, 1998, J NEUROCHEM, V71, P2349; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Shalbuyeva N, 2006, J BIOL CHEM, V281, P37547, DOI 10.1074/jbc.M607263200; SHERMAN WR, 1981, J NEUROCHEM, V36, P1947, DOI 10.1111/j.1471-4159.1981.tb10819.x; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Srinivasan C, 1999, LIPIDS, V34, P1211, DOI 10.1007/s11745-999-0474-5; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TSUZUKI K, 1994, MOL BRAIN RES, V26, P37, DOI 10.1016/0169-328X(94)90071-X; Vercesi AE, 1997, BIOSCIENCE REP, V17, P43, DOI 10.1023/A:1027335217774; Vergun O, 2005, BBA-BIOENERGETICS, V1709, P127, DOI 10.1016/j.bbabio.2005.07.006; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Vergun O, 2003, BIOPHYS J, V85, P3358, DOI 10.1016/S0006-3495(03)74755-9; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; WERTH JL, 1994, J NEUROSCI, V14, P348; White RJ, 1996, J NEUROSCI, V16, P5688; YAMAGUCHI K, 1990, J PHYSIOL-LONDON, V420, P185, DOI 10.1113/jphysiol.1990.sp017907; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	84	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18057	18068		10.1074/jbc.M702134200	http://dx.doi.org/10.1074/jbc.M702134200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17485418	hybrid			2022-12-25	WOS:000247302000012
J	Chipoy, C; Brounais, B; Trichet, V; Battaglia, S; Berreur, M; Oliver, L; Juin, P; Redini, F; Heymann, D; Blanchard, F				Chipoy, C.; Brounais, B.; Trichet, V.; Battaglia, S.; Berreur, M.; Oliver, L.; Juin, P.; Redini, F.; Heymann, D.; Blanchard, F.			Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53	ONCOGENE			English	Article						osteosarcoma; osteoblast; oncostatin M; STAT5; p53; apoptosis	SIGNAL TRANSDUCER; OSTEOBLAST DIFFERENTIATION; MITOCHONDRIAL-MEMBRANE; HEMATOPOIETIC-CELLS; GROWTH-HORMONE; DNA-DAMAGE; T-CELLS; GENE; PROTEIN; BAX	Oncostatin M ( OSM), a cytokine of the interleukin- 6 family, induces growth arrest and differentiation of osteoblastic cells into glial- like/ osteocytic cells. Here, we asked whether OSM regulates apoptosis of normal or transformed ( osteosarcoma) osteoblasts. We show that OSM sensitizes cells to apoptosis induced by various death inducers such as staurosporine, ultraviolet or tumor necrosis factor-alpha. Apoptosis is mediated by the mitochondrial pathway, with release of cytochrome c from the mitochondria to the cytosol and activation of caspases- 9 and - 3. DNA micro-arrays revealed that OSM modulates the expression of Bax, Bad, Bnip3, Bcl- 2 and Mcl- 1. Pharmacological inhibitors, dominant- negative signal transducer and activator of transcriptions ( STATs), stable RNA interference and knockout cells indicated that the transcription factors p53 and STAT5, which are activated by OSM, are implicated in the sensitization to apoptosis, being responsible for Bax induction and Bcl- 2 reduction, respectively. These results indicate that, in addition to growth arrest and induced differentiation, OSM also sensitizes normal and transformed osteoblasts to apoptosis by a mechanism implicating ( i) activation and nuclear translocation of STAT5 and p53 and ( ii) an increased Bax/ Bcl- 2 ratio. Therefore, association of OSM with kinase inhibitors such as Sts represents new therapeutic opportunities for wild- type p53 osteosarcoma.	Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, F-44035 Nantes 1, France; INSERM, ER17, Nantes, France; INSERM, U601, Nantes, France	Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Chipoy, C (corresponding author), Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, 1 Rue Gaston Veil, F-44035 Nantes 1, France.	celine.chipoy@univ-nantes.fr	Heymann, Dominique/AAC-6014-2019; JUIN, Philippe/Q-1338-2019; ROYER, Bénédicte BROUNAIS-LE/AAY-8894-2020; Blanchard, Frederic/AAS-1930-2021; BATTAGLIA, Severine/K-8715-2015; Oliver, Lisa/L-3070-2015	Heymann, Dominique/0000-0001-7777-0669; JUIN, Philippe/0000-0002-4997-3888; ROYER, Bénédicte BROUNAIS-LE/0000-0002-4556-9853; Blanchard, Frederic/0000-0003-1055-2573; Oliver, Lisa/0000-0002-5588-7564; Trichet, Valerie/0000-0003-4183-9032				Auernhammer CJ, 2004, J ENDOCRINOL, V180, P479, DOI 10.1677/joe.0.1800479; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Baumann H, 2000, J BIOL CHEM, V275, P22014, DOI 10.1074/jbc.M002830200; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; Bellini MH, 1998, J ENDOCRINOL INVEST, V21, P1; Buitenhuis M, 2004, INT J BIOCHEM CELL B, V36, P2120, DOI 10.1016/j.biocel.2003.11.008; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CASEY G, 1991, ONCOGENE, V6, P1791; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen SH, 2004, CYTOKINE GROWTH F R, V15, P379, DOI 10.1016/j.cytogfr.2004.06.002; Chipoy C, 2004, J BONE MINER RES, V19, P1850, DOI 10.1359/JBMR.040817; Debierre-Grockiego F, 2004, APOPTOSIS, V9, P717, DOI 10.1023/B:APPT.0000045785.65546.a2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Heath C, 2004, J BIOL CHEM, V279, P6666, DOI 10.1074/jbc.M308743200; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; Le Meur N, 2004, NUCLEIC ACIDS RES, V32, P5349, DOI 10.1093/nar/gkh870; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Trichet V, 2006, J IMMUNOL, V177, P6129, DOI 10.4049/jimmunol.177.9.6129; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106; Wei QZ, 2005, J BIOL CHEM, V280, P37790, DOI 10.1074/jbc.M502974200	38	39	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2007	26	46					6653	6664		10.1038/sj.onc.1210492	http://dx.doi.org/10.1038/sj.onc.1210492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17471233				2022-12-25	WOS:000250081500007
J	Reef, S; Shifman, O; Oren, M; Kimchi, A				Reef, S.; Shifman, O.; Oren, M.; Kimchi, A.			The autophagic inducer smARF interacts with and is stabilized bythe mitochondrial p32 protein	ONCOGENE			English	Article							TYPE-1 TAT TRANSACTIVATOR; IN-VITRO INTERACTION; CELLULAR-PROTEIN; BINDING-PROTEIN; SPLICING FACTOR; MOLECULAR-CLONING; ACTIVATION DOMAIN; GLOBULAR HEADS; VIRUS; RECEPTOR	The alternative reading frame ( ARF) mRNA encodes two pro- death proteins, the nucleolar p19ARF and a shorter mitochondrial isoform, named smARF ( hsmARF in human). While p19ARF can inhibit cell growth by causing cell cycle arrest or type I apoptotic cell death, smARF is able to induce type II autophagic cell death. Inappropriate proliferative signals generated by proto-oncogenes, such as c-Myc and E2F1, can elevate both p19ARF and smARF proteins. Here, we reveal a novel means of regulation of smARF protein steady state levels through its interactions with the mitochondrial p32. The p32 protein physically interacts with both human and murine smARF, and colocalizes with these short isoforms to the mitochondria. Remarkably, knocking down p32 protein levels significantly reduced the steady state levels of smARF by increasing its turn over. As a consequence, the ability of ectopically expressed smARF to induce autophagy and to cause mitochondrial membrane dissipation was significantly reduced. In contrast, the protein levels of full- length p19ARF, which mainly resides in the nucleolus, were not influenced by p32 depletion, suggesting that p32 exclusively stabilizes the mitochondrial smARF protein. Thus the interaction with p32 provides a means of specifically regulating the expression of the recently identified autophagic inducer, smARF, and adds yet another layer of complexity to the multifaceted regulation of the ARF gene.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Belfer 209, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il		Oren, Moshe/0000-0003-4311-7172				Brokstad KA, 2001, BIOCHEM BIOPH RES CO, V281, P1161, DOI 10.1006/bbrc.2001.4473; Bruni R, 1996, P NATL ACAD SCI USA, V93, P10423, DOI 10.1073/pnas.93.19.10423; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; Dedio J, 1998, J IMMUNOL, V160, P3534; DESAI K, 1991, P NATL ACAD SCI USA, V88, P8875, DOI 10.1073/pnas.88.20.8875; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Granot Z, 2003, MOL ENDOCRINOL, V17, P2461, DOI 10.1210/me.2003-0074; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Lim BL, 1996, J BIOL CHEM, V271, P26739, DOI 10.1074/jbc.271.43.26739; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Sunayama J, 2004, CELL DEATH DIFFER, V11, P771, DOI 10.1038/sj.cdd.4401418; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995	25	43	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2007	26	46					6677	6683		10.1038/sj.onc.1210485	http://dx.doi.org/10.1038/sj.onc.1210485			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486078				2022-12-25	WOS:000250081500009
J	Davies, WL; Cowing, JA; Carvalho, LS; Potter, IC; Trezise, AEO; Hunt, DM; Collin, SP				Davies, Wayne L.; Cowing, Jill A.; Carvalho, Livia S.; Potter, Ian C.; Trezise, Ann E. O.; Hunt, David M.; Collin, Shaun P.			Functional characterization, tuning, and regulation of visual pigment gene expression in an anadromous lamprey	FASEB JOURNAL			English	Article						color vision; lifecycle; recombinant protein	SOUTHERN-HEMISPHERE LAMPREY; COLOR-VISION; MOLECULAR EVOLUTION; RHODOPSIN; MORPHOLOGY; ACTIVATION; PHYLOGENY; KINASE; OPSIN	Lampreys are one of the two surviving groups of jawless vertebrates, whose ancestors arose more than 540 million years ago. Some species, such as Geotria australis, are anadromous, commencing life as ammocoetes in rivers, migrating downstream to the sea, and migrating back into rivers to spawn. Five photoreceptor types and five retinal cone opsin genes ( LWS, SWS1, SWS2, RhA, and RhB) have previously been identified in G. australis. This implies that the ancestral vertebrates possessed photopic or cone- based vision with the potential for pentachromacy. Changes in the morphology of photoreceptors and their spectral sensitivity are encountered during differing aquatic phases of the lamprey lifecycle. To understand the molecular basis for these changes, we characterized the visual pigments and measured the relative levels of opsin expression over two lifecycle phases that are accompanied by contrasting ambient light environments. By expressing recombinant opsins in vitro, we show that SWS1, SWS2, RhA, and RhB visual pigments possess lambda max values of 359, 439, 497, and 492 nm respectively. For the LWS visual pigment, we predict a lambda max value of 560 nm based on key spectral tuning sites in other vertebrate LWS opsins. Quantitative reverse transcriptasepolymerase chain reaction reveals that the retinal opsin genes of G. australis are differentially regulated such that the visual system switches from a broad sensitivity across a wide spectral range to a much narrower sensitivity centered around 490 - 500 nm on transition from marine to riverine conditions. These quantitative changes in visual pigment expression throughout the lifecycle may directly result from changes in the lighting conditions of the surrounding milieu.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; UCL Inst Ophthalmol, London, England; Murdoch Univ, Sch Biol Sci & Biotechnol, Murdoch, WA 6150, Australia	University of Queensland; University of London; University College London; Murdoch University	Collin, SP (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	s.collin@uq.edu.au	Collin, Shaun/K-8827-2012; Hunt, David M/K-6024-2012; Davies, Wayne/I-1547-2014; Carvalho, Livia/B-4984-2013	Collin, Shaun/0000-0001-6236-0771; Hunt, David M/0000-0002-9264-3948; Davies, Wayne/0000-0003-0232-1812; Carvalho, Livia/0000-0002-3909-5778				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Collin Shaun P, 2004, Clin Exp Optom, V87, P217; Collin SP, 2003, CURR BIOL, V13, pR864, DOI 10.1016/j.cub.2003.10.044; Collin SP, 2003, VISUAL NEUROSCI, V20, P119, DOI 10.1017/S0952523803202030; Collin SP, 1999, BRAIN BEHAV EVOLUT, V54, P96, DOI 10.1159/000006616; Cowing JA, 2002, BIOCHEM J, V367, P129, DOI 10.1042/BJ20020483; Davies WL, 2004, BIOCHEM BIOPH RES CO, V319, P410, DOI 10.1016/j.bbrc.2004.05.008; Davies WL, 2004, J BIOL CHEM, V279, P15877, DOI 10.1074/jbc.M313628200; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; Gill HS, 2003, COPEIA, P687, DOI 10.1643/IA02-085.1; Govardovskii VI, 2000, VISUAL NEUROSCI, V17, P509, DOI 10.1017/S0952523800174036; HAROSI FI, 1994, VISION RES, V34, P1359, DOI 10.1016/0042-6989(94)90134-1; HAROSI FI, 1993, VISUAL NEUROSCI, V10, P711, DOI 10.1017/S0952523800005411; Hisatomi O, 1997, PHOTOCHEM PHOTOBIOL, V66, P792, DOI 10.1111/j.1751-1097.1997.tb03226.x; Hunt DM, 2004, PHOTOCH PHOTOBIO SCI, V3, P713, DOI 10.1039/b314693f; Hunt DM, 2001, J EXP BIOL, V204, P3333; Hunt DM, 2001, CELL MOL LIFE SCI, V58, P1583, DOI 10.1007/PL00000798; Janz JM, 2001, BIOCHEMISTRY-US, V40, P7219, DOI 10.1021/bi002937i; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Lythgoe J.N., 1979, ECOLOGY VISION; McDowall R.M., 1988, DIADROMY FISHES; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; POTTER I C, 1979, Environmental Biology of Fishes, V4, P65, DOI 10.1007/BF00005929; POTTER IC, 1983, J ZOOL, V200, P1; POTTER IC, 1980, CAN J FISH AQUAT SCI, V37, P1595, DOI 10.1139/f80-207; POTTER IC, 1980, J ZOOL, V190, P405, DOI 10.1111/j.1469-7998.1980.tb01435.x; POTTER IC, 1987, J ZOOL, V212, P713, DOI 10.1111/j.1469-7998.1987.tb05966.x; Renaud CB, 1997, J APPL ICHTHYOL, V13, P143, DOI 10.1111/j.1439-0426.1997.tb00114.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SAKMAR TP, 1996, J CHEM, V35, P325; Shu DG, 2003, NATURE, V421, P526, DOI 10.1038/nature01264; Shu DG, 1999, NATURE, V402, P42, DOI 10.1038/46965; Takahashi Y, 2003, BIOCHEMISTRY-US, V42, P6025, DOI 10.1021/bi020629+; Wagner HJ, 2005, PROG RETIN EYE RES, V24, P521, DOI 10.1016/j.preteyeres.2005.01.002; WHITMORE AV, 1989, J COMP PHYSIOL A, V166, P103; Yokoyama S, 2000, PROG RETIN EYE RES, V19, P385, DOI 10.1016/S1350-9462(00)00002-1; Yokoyama S, 1999, P NATL ACAD SCI USA, V96, P6279, DOI 10.1073/pnas.96.11.6279; Yokoyama S, 2002, GENE, V300, P69, DOI 10.1016/S0378-1119(02)00845-4; Yokoyama S, 2003, GENE, V306, P91, DOI 10.1016/S0378-1119(03)00424-4; Yokoyama S, 2001, GENETICS, V158, P1697; YOUSON JH, 1980, CAN J FISH AQUAT SCI, V37, P1687, DOI 10.1139/f80-216; Zhao XY, 1997, VISUAL NEUROSCI, V14, P225, DOI 10.1017/S0952523800011366	51	62	63	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2713	2724		10.1096/fj.06-8057com	http://dx.doi.org/10.1096/fj.06-8057com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17463225				2022-12-25	WOS:000249237500013
J	Nicolae, C; Ko, YP; Miosge, N; Niehoff, A; Studer, D; Enggist, L; Hunziker, EB; Paulsson, M; Wagener, R; Aszodi, A				Nicolae, Claudia; Ko, Ya-Ping; Miosge, Nicolai; Niehoff, Anja; Studer, Daniel; Enggist, Lukas; Hunziker, Ernst B.; Paulsson, Mats; Wagener, Raimund; Aszodi, Attila			Abnormal collagen fibrils in cartilage of matrilin-1/matrilin-3-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; MULTIPLE EPIPHYSEAL DYSPLASIA; HUMAN ARTICULAR-CARTILAGE; EXTRACELLULAR-MATRIX; A-DOMAIN; MATRILIN-3 MUTATION; MOLECULAR-STRUCTURE; TISSUE DISTRIBUTION; EXPRESSION; SKELETAL	Matrilins are oligomeric extracellular matrix adaptor proteins mediating interactions between collagen fibrils and other matrix constituents. All four matrilins are expressed in cartilage and mutations in the human gene encoding matrilin-3 (MATN3) are associated with different forms of chondrodysplasia. Surprisingly, however, Matn3-null as well as Matn1-and Matn2-null mice do not show an overt skeletal phenotype, suggesting a dominant negative pathomechanism for the human disorders and redundancy/compensation among the family members in the knock-out situation. Here, we show that mice lacking both matrilin-1 and matrilin-3 develop an apparently normal skeleton, but exhibit biochemical and ultrastructural abnormalities of the knee joint cartilage. At the protein level, an altered SDS-PAGE band pattern and a clear up-regulation of the homotrimeric form of matrilin-4 were evident in newborn Matn1/Matn3 and Matn1 knock-out mice, but not in Matn3-null mice. The ultrastructure of the cartilage matrix after conventional chemical fixation was grossly normal; however, electron microscopy of high pressure frozen and freeze-substituted samples, revealed two consistent observations: 1) moderately increased collagen fibril diameters throughout the epiphysis and the growth plate in both single and double mutants; and 2) increased collagen volume density in Matn1(-/-)/Matn3(-/-) and Matn3(-/-) mice. Taken together, our results demonstrate that matrilin-1 and matrilin-3 modulate collagen fibrillogenesis in cartilage and provide evidence that biochemical compensation might exist between matrilins.	Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Univ Gottingen, Dept Prosthodont, D-37075 Gottingen, Germany; German Sport Univ Cologne, Inst Biomech & Orthopaed, D-50933 Cologne, Germany; Univ Bern, Dept Anat, CH-3010 Bern, Switzerland; Univ Bern, ITI Res Inst Dental & Skeletal Biol, CH-3010 Bern, Switzerland	Max Planck Society; University of Cologne; University of Cologne; University of Gottingen; German Sport University Cologne; University of Bern; University of Bern	Aszodi, A (corresponding author), Max Planck Inst Biochem, Dept Mol Med, Klopferspitz 18A, D-82152 Martinsried, Germany.	aszodi@biochem.mpg.de	Studer, Daniel/F-8581-2012; Niehoff, Anja/K-6626-2015; Miosge, Nicolai/E-3244-2010; Hunziker, Ernst B/GYA-1015-2022	Niehoff, Anja/0000-0002-4165-0929; Nicolae, Claudia/0000-0003-4933-5496				Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Aszodi A, 1999, MOL CELL BIOL, V19, P7841; Aszodi A, 1998, J CELL BIOL, V143, P1399, DOI 10.1083/jcb.143.5.1399; Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003; Aszodi A, 1996, EUR J BIOCHEM, V236, P970, DOI 10.1111/j.1432-1033.1996.00970.x; ASZODI A, 1994, MATRIX BIOL, V14, P181, DOI 10.1016/0945-053X(94)90007-8; Bengtsson T, 2005, J CELL SCI, V118, P929, DOI 10.1242/jcs.01678; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; Borochowitz ZU, 2004, J MED GENET, V41, P366, DOI 10.1136/jmg.2003.013342; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; Budde B, 2005, MOL CELL BIOL, V25, P10465, DOI 10.1128/MCB.25.23.10465-10478.2005; Chapman KL, 2001, NAT GENET, V28, P393, DOI 10.1038/ng573; Cotterill SL, 2005, HUM MUTAT, V26, P557, DOI 10.1002/humu.20263; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Frank S, 2002, J BIOL CHEM, V277, P19071, DOI 10.1074/jbc.M202146200; GLUER CC, 1995, EUR J RADIOL, V20, P173, DOI 10.1016/0720-048X(95)00651-6; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Hagg R, 1997, J BIOL CHEM, V272, P20650, DOI 10.1074/jbc.272.33.20650; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Huang XM, 1999, DEV DYNAM, V216, P434, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<434::AID-DVDY11>3.3.CO;2-O; HUNZIKER EB, 1989, J PHYSIOL-LONDON, V414, P55, DOI 10.1113/jphysiol.1989.sp017676; Hunziker EB, 1997, MICROSC RES TECHNIQ, V37, P271; Jackson GC, 2004, J MED GENET, V41, P52, DOI 10.1136/jmg.2003.011429; Klatt AR, 2000, J BIOL CHEM, V275, P3999, DOI 10.1074/jbc.275.6.3999; Klatt AR, 2002, MATRIX BIOL, V21, P289, DOI 10.1016/S0945-053X(02)00006-9; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; Ko YP, 2004, MOL CELL BIOL, V24, P1691, DOI 10.1128/MCB.24.4.1691-1699.2004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loughlin J, 2000, ARTHRITIS RHEUM, V43, P1423, DOI 10.1002/1529-0131(200006)43:6<1423::AID-ANR31>3.0.CO;2-4; LOUGHLIN J, 1994, HUM GENET, V94, P698; Mabuchi Akihiko, 2004, Hum Mutat, V24, P439, DOI 10.1002/humu.9286; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; Mates L, 2004, MATRIX BIOL, V23, P195, DOI 10.1016/j.matbio.2004.05.003; Meulenbelt I, 1997, ARTHRITIS RHEUM, V40, P1760, DOI 10.1002/art.1780401006; Min JL, 2006, ANN RHEUM DIS, V65, P1060, DOI 10.1136/ard.2005.045153; Miosge N, 1999, LAB INVEST, V79, P1591; Mostert AK, 2003, AM J MED GENET A, V120A, P490, DOI 10.1002/ajmg.a.20034; Okimura A, 1997, ARTHRITIS RHEUM, V40, P1029, DOI 10.1002/art.1780400606; Opolka A, 2007, MATRIX BIOL, V26, P85, DOI 10.1016/j.matbio.2006.09.010; Otten C, 2005, J MED GENET, V42, P774, DOI 10.1136/jmg.2004.029462; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; Pullig O, 2007, ANN RHEUM DIS, V66, P279, DOI 10.1136/ard.2006.058263; Pullig O, 2002, OSTEOARTHR CARTILAGE, V10, P253, DOI 10.1053/joca.2001.0508; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Stefansson SE, 2003, AM J HUM GENET, V72, P1448, DOI 10.1086/375556; Svensson L, 2002, MOL CELL BIOL, V22, P4366, DOI 10.1128/MCB.22.12.4366-4371.2002; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; van der Weyden L, 2006, AM J PATHOL, V169, P515, DOI 10.2353/ajpath.2006.050981; Wagener R, 1998, FEBS LETT, V438, P165, DOI 10.1016/S0014-5793(98)01293-9; Wagener R, 2005, FEBS LETT, V579, P3323, DOI 10.1016/j.febslet.2005.03.018; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307	55	53	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22163	22175		10.1074/jbc.M610994200	http://dx.doi.org/10.1074/jbc.M610994200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17502381	hybrid			2022-12-25	WOS:000248196800062
J	Nascimento, FD; Hayashi, MAF; Kerkis, A; Oliveira, V; Oliveira, EB; Radis-Baptista, G; Nader, HB; Yamane, T; Tersariol, ILD; Kerkis, I				Nascimento, Fabio Dupart; Hayashi, Mirian A. F.; Kerkis, Alexandre; Oliveira, Vitor; Oliveira, Eduardo B.; Radis-Baptista, Gandhi; Nader, Helena Bonciani; Yamane, Tetsuo; Tersariol, Ivarne Luis dos Santos; Kerkis, Irina			Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENETRATING PEPTIDES; INTRACELLULAR DELIVERY; PROTEIN TRANSDUCTION; ENDOTHELIAL-CELLS; HELA-CELLS; CHLORIDE; TRANSLOCATION; TAT; MECHANISM; ENDOCYTOSIS	Recently we have shown that crotamine, a toxin from the South American rattlesnake Crotalus durissus terrificus venom, belongs to the family of cell-penetrating peptides. Moreover, crotamine was demonstrated to be a marker of centrioles, of cell cycle, and of actively proliferating cells. Herein we show that this toxin at non-toxic concentrations is also capable of binding electrostatically to plasmid DNA forming DNA-peptide complexes whose stabilities overcome the need for chemical conjugation for carrying nucleic acids into cells. Interestingly, crotamine demonstrates cell specificity and targeted delivery of plasmid DNA into actively proliferating cells both in vitro and in vivo, which distinguishes crotamine from other known natural cell-penetrating peptides. The mechanism of crotamine penetration and cargo delivery into cells was also investigated, showing the involvement of heparan sulfate proteoglycans in the uptake phase, which is followed by endocytosis and peptide accumulation within the acidic endosomal vesicles. Finally, the permeabilization of endosomal membranes induced by crotamine results in the leakage of the vesicles contents to the cell cytosol.	Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, BR-08780210 Mogi Das Cruzes, SP, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Dept Bioquim, BR-04044020 Sao Paulo, Brazil; Inst Butantan, Ctr Toxinol Aplicada, BR-05503900 Sao Paulo, Brazil; Clin & Ctr Pesquisa Reprod Humana Roger Abdelmass, BR-01431000 Sao Paulo, Brazil; Univ Cidade Sao Paulo, Lab Neurociencias, BR-03071000 Sao Paulo, Brazil; Univ Sao Paulo, Dept Bioquim & Imunol, BR-14049900 Ribeirao Preto, Brazil; Univ Fed Pernambuco, Ctr Ciencias Biol, BR-50732970 Recife, PE, Brazil; Univ Sao Paulo, IPEN CNEN SP, BR-05508000 Sao Paulo, Brazil; Inst Butantan, Genet Lab, BR-05503900 Sao Paulo, Brazil	Universidade de Mogi das Cruzes; Universidade Federal de Sao Paulo (UNIFESP); Instituto Butantan; Universidade Cidade de Sao Paulo; Universidade de Sao Paulo; Universidade Federal de Pernambuco; Comissao Nacional de Energia Nuclear (CNEN); Instituto de Pesquisas Energeticas e Nucleares (IPEN); Universidade de Sao Paulo; Instituto Butantan	Tersariol, ILD (corresponding author), Univ Mogi das Cruzes, Ctr Interdisciplinar Invest Bioquim, Predio I,Sala 1S-15,Av Dr Candido Xavier de Almei, BR-08780210 Mogi Das Cruzes, SP, Brazil.	ivarne@umc.br; ikerkis@butantan.gov.br	Nascimento, Fabio Dupart/ABB-8295-2020; Nascimento, Fabio D/A-5115-2010; Oliveira, Vitor/L-3709-2013; Kerkis, Irina/AAD-1006-2019; Hayashi, Mirian/ABG-2663-2020; Nader, Helena Bonciani/D-9253-2012; RADIS-BAPTISTA, GANDHI/J-4991-2019; Dos Santos Tersariol, Ivarne Luis/G-4042-2012; Hayashi, Mirian/C-7458-2012; Oliveira, Vitor/AAT-5981-2020; RADIS-BAPTISTA, GANDHI/H-9574-2016	Nascimento, Fabio Dupart/0000-0001-6672-3373; Nascimento, Fabio D/0000-0001-6672-3373; Oliveira, Vitor/0000-0002-4662-1377; RADIS-BAPTISTA, GANDHI/0000-0001-9210-092X; Dos Santos Tersariol, Ivarne Luis/0000-0002-8399-4535; Hayashi, Mirian/0000-0001-6437-4923; RADIS-BAPTISTA, GANDHI/0000-0001-9210-092X; NADER, HELENA/0000-0002-7569-2166				ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Brockstedt U, 2002, EXP CELL RES, V274, P235, DOI 10.1006/excr.2002.5477; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; Coeytaux E, 2003, J BIOL CHEM, V278, P18110, DOI 10.1074/jbc.M300248200; Conrad H. E., 1998, HEPARIN BINDING PROT; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Erdal H, 2005, P NATL ACAD SCI USA, V102, P192, DOI 10.1073/pnas.0408592102; Fadel V, 2005, TOXICON, V46, P759, DOI 10.1016/j.toxicon.2005.07.018; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476; Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+; Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x; Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P1241, DOI 10.1074/jbc.M407030200; Henriques ST, 2005, BIOCHEMISTRY-US, V44, P10189, DOI 10.1021/bi0502644; HEWLETT LJ, 1994, J CELL BIOL, V124, P689, DOI 10.1083/jcb.124.5.689; Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9; Jentsch TJ, 2007, J PHYSIOL-LONDON, V578, P633, DOI 10.1113/jphysiol.2006.124719; Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101; KENZIE DL, 2000, J BIOL CHEM, V275, P9970; Kerkis A, 2006, IUBMB LIFE, V58, P7, DOI 10.1080/15216540500494508; Kerkis A, 2004, FASEB J, V18, P1407, DOI 10.1096/fj.03-1459fje; Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006; LAURE CJ, 1975, H-S Z PHYSIOL CHEM, V356, P213; Letoha T, 2003, J MOL RECOGNIT, V16, P272, DOI 10.1002/jmr.637; LEWIS RS, 1988, TRENDS NEUROSCI, V11, P214, DOI 10.1016/0166-2236(88)90129-4; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Magzoub M, 2005, BIOCHEMISTRY-US, V44, P14890, DOI 10.1021/bi051356w; McKenzie DL, 2000, BIOCONJUGATE CHEM, V11, P901, DOI 10.1021/bc000056i; Moreira CR, 2004, BBA-GEN SUBJECTS, V1673, P178, DOI 10.1016/j.bbagen.2004.04.014; MOZHAEVA G N, 1973, Neuroscience and Behavioral Physiology, V6, P228, DOI 10.1007/BF01190346; Neuringer IP, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-6; Nicastro G, 2003, EUR J BIOCHEM, V270, P1969, DOI 10.1046/j.1432-1033.2003.03563.x; OLSON ST, 1991, J BIOL CHEM, V266, P6353; Pellegrin P, 1997, FEBS LETT, V418, P101, DOI 10.1016/S0014-5793(97)01339-2; Pimenta DC, 2002, BIOCHEM J, V366, P435, DOI 10.1042/BJ20020023; Porcionatto MA, 1998, J CELL BIOCHEM, V70, P563, DOI 10.1002/(SICI)1097-4644(19980915)70:4<563::AID-JCB12>3.0.CO;2-I; Pusch M, 1999, J PHYSIOL-LONDON, V515, P341, DOI 10.1111/j.1469-7793.1999.341ac.x; Radis-Baptista G, 1999, TOXICON, V37, P973, DOI 10.1016/S0041-0101(98)00226-8; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; ROBBINS E, 1963, J CELL BIOL, V18, P237, DOI 10.1083/jcb.18.2.237; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Smith A, 2001, COLD SPRING HARBOR M, P205; Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200; Suda T, 2005, TRENDS IMMUNOL, V26, P426, DOI 10.1016/j.it.2005.06.006; Sukoyan MA, 2002, BRAZ J MED BIOL RES, V35, P535, DOI 10.1590/S0100-879X2002000500004; Tang DG, 2000, J CELL BIOL, V148, P971, DOI 10.1083/jcb.148.5.971; Tkachenko E, 2004, J CELL SCI, V117, P3189, DOI 10.1242/jcs.01190; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032; WHITAKER M, 1990, DEVELOPMENT, V108, P525; Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604; Zimmermann P, 2005, DEV CELL, V9, P721, DOI 10.1016/j.devcel.2005.10.011; Zimmermann P, 2005, DEV CELL, V9, P377, DOI 10.1016/j.devcel.2005.07.011; Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010	72	83	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21349	21360		10.1074/jbc.M604876200	http://dx.doi.org/10.1074/jbc.M604876200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17491023	hybrid			2022-12-25	WOS:000248047500063
J	Ashibe, B; Hirai, T; Higashi, K; Sekimizu, K; Motojima, K				Ashibe, Bunichiro; Hirai, Toshitake; Higashi, Kyoichiro; Sekimizu, Kazuhisa; Motojima, Kiyoto			Dual subcellular localization in the endoplasmic reticulum and peroxisomes and a vital role in protecting against oxidative stress of fatty aldehyde dehydrogenase are achieved by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-ALPHA; SJOGREN-LARSSON-SYNDROME; PHYTANIC ACID; RAT-LIVER; MAMMALIAN PEROXISOMES; MOLECULAR-CLONING; HUMAN FIBROBLASTS; GENE-EXPRESSION; PPAR-ALPHA; METABOLISM	Fatty aldehyde dehydrogenase ( FALDH, ALDH3A2) is thought to be involved in the degradation of phytanic acid, a saturated branched chain fatty acid derived from chlorophyll. However, the identity, subcellular distribution, and physiological roles of FALDH are unclear because several variants produced by alternative splicing are present in varying amounts at different subcellular locations. Subcellular fractionation experiments do not provide a clear-cut conclusion because of the incomplete separation of organelles. We established human cell lines heterologously expressing mouse FALDH from each cDNA without tagging under the control of an inducible promoter and detected the variant FALDH proteins using a mouse FALDH specific antibody. One variant, FALDH-V, was exclusively detected in peroxisomal membranes. Human FALDH-V with an amino-terminal Myc sequence also localized to peroxisomes. The most dominant form, FALDH-N, and other variants examined, however, were distributed in the endoplasmic reticulum. A gas chromatography-mass spectrometry-based analysis of metabolites in FALDH-expressing cells incubated with phytol or phytanic acid showed that FALDH-V, not FALDH-N, is the key aldehyde dehydrogenase in the degradation pathway and that it protects peroxisomes from oxidative stress. In contrast, both FALDHs had a protective effect against oxidative stress induced by a model aldehyde for lipid peroxidation, dodecanal. These results suggest that FALDH variants are produced by alternative splicing and share an important role in protecting against oxidative stress in an organelle-specific manner.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Microbiol Lab, Bunkyo Ku, Tokyo 1130033, Japan	Meiji Pharmaceutical University; University of Tokyo	Motojima, K (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, Noshio 2-522-1, Tokyo 2048588, Japan.	motojima@my-pharm.ac.jp						ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Chai ZL, 2003, ENDOCRINOLOGY, V144, P2084, DOI 10.1210/en.2002-221030; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; DeLaurenzi V, 1996, NAT GENET, V12, P52; Demozay D, 2004, J BIOL CHEM, V279, P6261, DOI 10.1074/jbc.M312062200; Foulon V, 1999, P NATL ACAD SCI USA, V96, P10039, DOI 10.1073/pnas.96.18.10039; FOWLER ME, 1983, J WILDLIFE DIS, V19, P34, DOI 10.7589/0090-3558-19.1.34; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI21625]; GHOSH MK, 1986, ANAL BIOCHEM, V159, P169, DOI 10.1016/0003-2697(86)90323-4; Gloerich J, 2007, J LIPID RES, V48, P77, DOI 10.1194/jlr.M600050-JLR200; Gloerich J, 2006, MOL GENET METAB, V89, P111, DOI 10.1016/j.ymgme.2006.05.009; Goto T, 2005, BIOCHEM BIOPH RES CO, V337, P440, DOI 10.1016/j.bbrc.2005.09.077; Heim M, 2002, FASEB J, V16, P718, DOI 10.1096/fj.01-0816fje; Hirota Morihiko, 2006, Journal of Toxicological Sciences, V31, P149, DOI 10.2131/jts.31.149; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; Jansen GA, 2001, BIOCHEM BIOPH RES CO, V283, P674, DOI 10.1006/bbrc.2001.4835; Kelson TL, 1997, BBA-GEN SUBJECTS, V1335, P99, DOI 10.1016/S0304-4165(96)00126-2; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Komen JC, 2004, J LIPID RES, V45, P1341, DOI 10.1194/jlr.M400064-JLR200; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Legakis JE, 2002, MOL BIOL CELL, V13, P4243, DOI 10.1091/mbc.E02-06-0322; Lin ZL, 2000, MOL GENET METAB, V71, P496, DOI 10.1006/mgme.2000.3084; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; Mindnich R, 2004, MOL CELL ENDOCRINOL, V218, P7, DOI 10.1016/j.mce.2003.12.006; MITCHELL DY, 1989, ARCH BIOCHEM BIOPHYS, V269, P11, DOI 10.1016/0003-9861(89)90081-7; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; Motojima K, 2006, FEBS J, V273, P292, DOI 10.1111/j.1742-4658.2005.05060.x; Motojima K, 2004, EUR J BIOCHEM, V271, P4141, DOI 10.1111/j.1432-1033.2004.04352.x; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Mount AS, 2004, SCIENCE, V304, P297, DOI 10.1126/science.1090506; OWEN JB, 1992, J AGR SCI, V119, P151, DOI 10.1017/S0021859600014052; Rizzo WB, 2005, HUM MUTAT, V26, P1, DOI 10.1002/humu.20181; Rizzo WB, 2001, CHEM-BIOL INTERACT, V130, P297, DOI 10.1016/S0009-2797(00)00273-8; Rizzo WB, 2000, BBA-MOL BASIS DIS, V1535, P1, DOI 10.1016/S0925-4439(00)00077-6; Schrader M, 2004, HISTOCHEM CELL BIOL, V122, P383, DOI 10.1007/s00418-004-0673-1; van den Brink DM, 2006, CELL MOL LIFE SCI, V63, P1752, DOI 10.1007/s00018-005-5463-y; van den Brink DM, 2005, J BIOL CHEM, V280, P26838, DOI 10.1074/jbc.M501861200; Vasiliou V, 1996, DNA CELL BIOL, V15, P235, DOI 10.1089/dna.1996.15.235; Vasiliou V, 2000, PHARMACOLOGY, V61, P192, DOI 10.1159/000028400; Verhoeven NM, 1998, FEBS LETT, V429, P225, DOI 10.1016/S0014-5793(98)00574-2; Vizeacoumar FJ, 2006, J BIOL CHEM, V281, P14805, DOI 10.1074/jbc.M601808200; Wanders RJA, 2006, ANNU REV BIOCHEM, V75, P295, DOI 10.1146/annurev.biochem.74.082803.133329; Willemsen MAAP, 2001, J NEUROL SCI, V183, P61, DOI 10.1016/S0022-510X(00)00474-3; Zomer AWM, 2000, J LIPID RES, V41, P1801	45	58	58	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20763	20773		10.1074/jbc.M611853200	http://dx.doi.org/10.1074/jbc.M611853200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17510064	hybrid			2022-12-25	WOS:000247819300078
J	Clausen, JD; McIntosh, DB; Anthonisen, AN; Woolley, DG; Vilsen, B; Andersen, JP				Clausen, Johannes D.; McIntosh, David B.; Anthonisen, Anne Nyholm; Woolley, David G.; Vilsen, Bente; Andersen, Jens Peter			ATP-binding modes and functionally important interdomain bonds of sarcoplasmic reticulum Ca2+-ATPase revealed by mutation of glycine 438, glutamate 439, and arginine 678	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED PHOSPHORYLATION LOOP; ALKALI-METAL SALTS; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; CATALYTIC SITE; ACTIVE-SITE; REACTION-MECHANISM; CRYSTAL-STRUCTURE; KINETIC EVIDENCE; DOMAIN RESIDUES	ATP binds to sarcoplasmic reticulum Ca2+-ATPase both in a phosphorylating ( catalytic) mode and in a nonphosphorylating ( modulatory) mode, the latter leading to acceleration of phosphoenzyme turnover (Ca2E1P -> E2P and E2P -> E-2 reactions) and Ca2+ binding (E-2 -> Ca2E1). In some of the Ca2+-ATPase crystal structures, Arg(678) and Glu(439) seem to be involved in the binding of nucleotide or an associated Mg2+ ion. We have replaced Arg(678), Glu(439), and Gly(438) with alanine to examine their importance for the enzyme cycle and the modulatory effects of ATP and MgATP. The results point to the key role of Arg678 in nucleotide binding and to the importance of interdomain bonds Glu(439)-Ser(186) and Arg(678)-Asp(203) in stabilizing the E2P and E-2 intermediates, respectively. Mutation of Arg(678) had conspicuous effects on ATP/MgATP binding to the E-1 form and ADP binding to Ca2E1P, as well as ATP/MgATP binding in modulatory modes to E2P and E-2, whereas the effects on ATP/MgATPacceleration of the Ca2E1P -> E2P transition were small, suggesting that the nucleotide that accelerates Ca2E1P -> E2P binds differently from that modulating the E2P -> E-2 and E-2 -> Ca2E1 reactions. Mutation of Glu(439) hardly affected nucleotide binding to E-1, Ca2E1P, and E-2, but it led to disruption of the modulatory effect of ATP on E2P 3 E2 and acceleration of the latter reaction, indicating that ATP normally modulates E2P -> E-2 by interfering with the interaction between Glu(439) and Ser(186). Gly(438) seems to be important for this interaction as well as for nucleotide binding, probably because of its role in formation of the helix containing Glu(439) and Thr(441).	Univ Aarhus, Inst Physiol & Biophys, Dept Physiol, DK-8000 Aarhus C, Denmark; Univ Cape Town, Fac Hlth Sci, Div Chem Pathol, ZA-7925 Cape Town, South Africa	Aarhus University; University of Cape Town	Andersen, JP (corresponding author), Univ Aarhus, Inst Physiol & Biophys, Dept Physiol, Ole Worms Alle 1160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk		Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Clausen JD, 2006, J BIOL CHEM, V281, P9471, DOI 10.1074/jbc.M512371200; Clausen JD, 2004, J BIOL CHEM, V279, P54426, DOI 10.1074/jbc.M410204200; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; COLL RJ, 1991, BIOCHEMISTRY-US, V30, P1456, DOI 10.1021/bi00220a002; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Dode L, 2003, J BIOL CHEM, V278, P47877, DOI 10.1074/jbc.M306784200; FORGE V, 1993, J BIOL CHEM, V268, P10953; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Jensen AML, 2006, EMBO J, V25, P2305, DOI 10.1038/sj.emboj.7601135; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LUND S, 1988, J BIOL CHEM, V263, P1654; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; McIntosh DB, 2004, J BIOL CHEM, V279, P32515, DOI 10.1074/jbc.M403242200; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2357; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; Moncoq K, 2007, J BIOL CHEM, V282, P9748, DOI 10.1074/jbc.M611653200; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; ROSS DC, 1987, J BIOL CHEM, V262, P2042; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1458; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; Strugatsky D, 2005, BIOCHEMISTRY-US, V44, P15961, DOI 10.1021/bi051921v; Strugatsky D, 2003, J BIOL CHEM, V278, P46064, DOI 10.1074/jbc.M308303200; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VERJOVSKIALMEIDA S, 1979, J BIOL CHEM, V254, P18; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762	56	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20686	20697		10.1074/jbc.M702365200	http://dx.doi.org/10.1074/jbc.M702365200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17504757	hybrid			2022-12-25	WOS:000247819300071
J	Nagano, Y; Mavrakis, KJ; Lee, KL; Fujii, T; Koinuma, D; Sase, H; Yuki, K; Isogaya, K; Saitoh, M; Imamura, T; Episkopou, V; Miyazono, K; Miyazawa, K				Nagano, Yoshiko; Mavrakis, Konstantinos J.; Lee, Kian Leong; Fujii, Tomoko; Koinuma, Daizo; Sase, Hitoshi; Yuki, Keiko; Isogaya, Kazunobu; Saitoh, Masao; Imamura, Takeshi; Episkopou, Vasso; Miyazono, Kohei; Miyazawa, Keiji			Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; ANAPHASE-PROMOTING COMPLEX; SMAD PROTEINS; TRANSCRIPTIONAL REPRESSION; PROGNOSTIC MARKER; UBIQUITIN LIGASE; TGF; EXPRESSION; RECEPTOR; GENE	Transforming growth factor-beta (TGF-beta) signaling is controlled by a variety of regulators that target either signaling receptors or activated Smad complexes. Among the negative regulators, Smad7 antagonizes TGF-beta signaling mainly through targeting the signaling receptors, whereas SnoN and c-Ski repress signaling at the transcriptional level through inactivation of Smad complexes. We previously found that Arkadia is a positive regulator of TGF-beta signaling that induces ubiquitin-dependent degradation of Smad7 through its C-terminal RING domain. We report here that Arkadia induces degradation of SnoN and c-Ski in addition to Smad7. Arkadia interacts with SnoN and c-Ski in their free forms as well as in the forms bound to Smad proteins, and constitutively down-regulates levels of their expression. Arkadia thus appears to effectively enhance TGF-beta signaling through simultaneous down-regulation of two distinct types of negative regulators, Smad7 and SnoN/c-Ski, and may play an important role in determining the intensity of TGF-beta family signaling in target cells.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; Imperial Coll Sch Med, Hammersmith Hosp, Mammalian Neurogenesis Med Res Council, London W12 0NN, England; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Tokyo 1358550, Japan	University of Tokyo; Imperial College London; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp	LEE, Kian Leong/E-3584-2013; MIYAZAWA, KEIJI/I-9713-2014; Episkopou, Vasso/E-2952-2010; Koinuma, Daizo/Y-8716-2018	LEE, Kian Leong/0000-0002-0443-2746; Koinuma, Daizo/0000-0001-5611-2122; FUJII, Tomoko/0000-0003-3854-4081	MRC [MC_U120074332] Funding Source: UKRI; Medical Research Council [MC_U120074332] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Briones-Orta MA, 2006, BIOCHEM BIOPH RES CO, V341, P889, DOI 10.1016/j.bbrc.2006.01.041; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buess M, 2004, NEOPLASIA, V6, P207, DOI 10.1593/neo.03442; da Graca LS, 2004, DEVELOPMENT, V131, P435, DOI 10.1242/dev.00922; Denissova NG, 2004, J BIOL CHEM, V279, P28143, DOI 10.1074/jbc.M404961200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Episkopou V, 2001, NATURE, V410, P825, DOI 10.1038/35071095; Fukasawa H, 2004, P NATL ACAD SCI USA, V101, P8687, DOI 10.1073/pnas.0400035101; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; He J, 2003, J BIOL CHEM, V278, P30540, DOI 10.1074/jbc.M304016200; Hsu YHR, 2006, J BIOL CHEM, V281, P33008, DOI 10.1074/jbc.M604380200; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kobayashi N, 2007, GENES CELLS, V12, P375, DOI 10.1111/j.1365-2443.2007.01052.x; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Kollias HD, 2006, MOL CELL BIOL, V26, P6248, DOI 10.1128/MCB.00384-06; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Luo KX, 2004, CURR OPIN GENET DEV, V14, P65, DOI 10.1016/j.gde.2003.11.003; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mavrakis KJ, 2007, PLOS BIOL, V5, P586, DOI 10.1371/journal.pbio.0050067; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; MIYAZONO K, 2006, SMAD SIGNAL TRANSDUC, V5, P277; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Nagata M, 2006, GENES CELLS, V11, P1267, DOI 10.1111/j.1365-2443.2006.01018.x; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Niederlander C, 2001, NATURE, V410, P830, DOI 10.1038/35071103; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Reed JA, 2001, CANCER RES, V61, P8074; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Shinagawa T, 2001, ONCOGENE, V20, P8100, DOI 10.1038/sj.onc.1204987; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Suzuki H, 2004, ONCOGENE, V23, P5068, DOI 10.1038/sj.onc.1207690; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tewari M, 2004, MOL CELL, V13, P469, DOI 10.1016/S1097-2765(04)00033-4; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zhang F, 2003, CANCER RES, V63, P5005; Zhang ST, 2006, CELL CYCLE, V5, P2787, DOI 10.4161/cc.5.23.3523; Zhu QW, 2007, MOL CELL BIOL, V27, P324, DOI 10.1128/MCB.01394-06	61	126	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20492	20501		10.1074/jbc.M701294200	http://dx.doi.org/10.1074/jbc.M701294200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17510063	hybrid			2022-12-25	WOS:000247819300052
J	Pedmale, UV; Liscum, E				Pedmale, Ullas V.; Liscum, Emmanuel			Regulation of phototropic signaling in Arabidopsis via phosphorylation state changes in the phototropin 1-interacting protein NPH3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-LIGHT; PHOSPHATASE 2A; OKADAIC ACID; CELL-CYCLE; UBIQUITIN LIGASES; GUARD-CELLS; KINASE; DOMAIN; BINDING; TRANSDUCTION	Phototropism, or the directional growth ( curvature) of various organs toward or away from incident light, represents a ubiquitous adaptive response within the plant kingdom. This response is initiated through the sensing of directional blue light (BL) by a small family of photoreceptors known as the phototropins. Of the two phototropins present in the model plant Arabidopsis thaliana, phot1 (phototropin 1) is the dominant receptor controlling phototropism. Absorption of BL by the sensory portion of phot1 leads, as in other plant phototropins, to activation of a C-terminal serine/threonine protein kinase domain, which is tightly coupled with phototropic responsiveness. Of the five phot1-interacting proteins identified to date, only one, NPH3 (non-phototropic hypocotyl 3), is essential for all phot1-dependent phototropic responses, yet little is known about how phot1 signals through NPH3. Here, we show that, in dark-grown seedlings, NPH3 exists as a phosphorylated protein and that BL stimulates its dephosphorylation. phot1 is necessary for this response and appears to regulate the activity of a type 1 protein phosphatase that catalyzes the reaction. The abrogation of both BL-dependent dephosphorylation of NPH3 and development of phototropic curvatures by protein phosphatase inhibitors further suggests that this post-translational modification represents a crucial event in phot1-dependent phototropism. Given that NPH3 may represent a core component of a CUL3-based ubiquitin-protein ligase (E3), we hypothesize that the phosphorylation state of NPH3 determines the functional status of such an E3 and that differential regulation of this E3 is required for normal phototropic responsiveness.	Univ Missouri, Christopher S Bond Life Sci Ctr, Div Biol Sci, Columbus, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Liscum, E (corresponding author), Univ Missouri, Christopher S Bond Life Sci Ctr, Div Biol Sci, Columbus, MO 65211 USA.	liscume@missouri.edu		Liscum, Emmanuel/0000-0002-8672-9315				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Allende-Vega N, 2005, MOL CELL BIOCHEM, V274, P85, DOI 10.1007/s11010-005-3074-4; Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Ardley HC, 2005, ESSAYS BIOCHEM, V41, P15, DOI 10.1042/EB0410015; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Bouly JP, 2003, EUR J BIOCHEM, V270, P2921, DOI 10.1046/j.1432-1033.2003.03691.x; Celaya RB, 2005, PHOTOCHEM PHOTOBIOL, V81, P73, DOI 10.1562/2004-08-22-IR-282.1; Chen M, 2004, ANNU REV GENET, V38, P87, DOI 10.1146/annurev.genet.38.072902.092259; Christie JM, 2002, PLANT J, V32, P205, DOI 10.1046/j.1365-313X.2002.01415.x; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Christie JM, 2007, ANNU REV PLANT BIOL, V58, P21, DOI 10.1146/annurev.arplant.58.032806.103951; Christopher DA, 1997, PLANT PHYSIOL, V113, P1273, DOI 10.1104/pp.113.4.1273; Cohen PTW, 2002, J CELL SCI, V115, P241; DeLong A, 2006, CURR OPIN PLANT BIOL, V9, P470, DOI 10.1016/j.pbi.2006.07.015; Deruere J, 1999, PLANT J, V20, P389, DOI 10.1046/j.1365-313x.1999.00607.x; Emi T, 2005, PLANT PHYSIOL, V138, P1615, DOI 10.1104/pp.104.052639; ERDODI F, 1995, AM J PHYSIOL-CELL PH, V269, pC1176, DOI 10.1152/ajpcell.1995.269.5.C1176; Esmon CA, 2005, INT J DEV BIOL, V49, P665, DOI 10.1387/ijdb.052028ce; Esmon CA, 2006, P NATL ACAD SCI USA, V103, P236, DOI 10.1073/pnas.0507127103; Fankhauser C, 2000, SEMIN CELL DEV BIOL, V11, P467, DOI 10.1006/scdb.2000.0201; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Folta KM, 2001, PLANT J, V26, P471, DOI 10.1046/j.1365-313x.2001.01038.x; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Haga K, 2005, PLANT CELL, V17, P103, DOI 10.1105/tpc.104.028357; Harper SM, 2004, BIOCHEMISTRY-US, V43, P16184, DOI 10.1021/bi048092i; Harper SM, 2003, SCIENCE, V301, P1541, DOI 10.1126/science.1086810; Harper SM, 2004, J AM CHEM SOC, V126, P3390, DOI 10.1021/ja038224f; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Iino M, 2001, PHOTOMOVEMENT, V1, P659, DOI DOI 10.1016/S1568-461X(01)80027-2; Inada S, 2004, PLANT CELL, V16, P887, DOI 10.1105/tpc.019901; Jackson LP, 2006, MOL CELL BIOL, V26, P2456, DOI 10.1128/MCB.26.6.2456-2466.2006; Kagawa T, 2001, SCIENCE, V291, P2138, DOI 10.1126/science.291.5511.2138; Kim DH, 2002, PLANT CELL, V14, P3043, DOI 10.1105/tpc.005306; Kimura M, 2006, CURR OPIN PLANT BIOL, V9, P503, DOI 10.1016/j.pbi.2006.07.003; Kinoshita T, 1997, PLANT CELL PHYSIOL, V38, P1281, DOI 10.1093/oxfordjournals.pcp.a029117; Kinoshita T, 2003, PLANT PHYSIOL, V133, P1453, DOI 10.1104/pp.103.029629; Kong SG, 2006, PLANT J, V45, P994, DOI 10.1111/j.1365-313X.2006.02667.x; Krek W, 2003, NAT CELL BIOL, V5, P950, DOI 10.1038/ncb1103-950; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lariguet P, 2006, P NATL ACAD SCI USA, V103, P10134, DOI 10.1073/pnas.0603799103; Lasceve G, 1999, PLANT PHYSIOL, V120, P605, DOI 10.1104/pp.120.2.605; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; LI YM, 1993, BIOCHEM PHARMACOL, V46, P1435, DOI 10.1016/0006-2952(93)90109-A; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; Liscum E, 1996, PLANT PHYSIOL, V112, P291, DOI 10.1104/pp.112.1.291; LISCUM E, 2002, ARABIDOPSIS BOOK, P1; Loyet KM, 2005, MOL CELL PROTEOMICS, V4, P235, DOI 10.1074/mcp.R400011-MCP200; Luan S, 2003, ANNU REV PLANT BIOL, V54, P63, DOI 10.1146/annurev.arplant.54.031902.134743; Matsuoka D, 2005, P NATL ACAD SCI USA, V102, P13337, DOI 10.1073/pnas.0506402102; Matsuoka D, 2007, PHOTOCHEM PHOTOBIOL, V83, P122, DOI 10.1562/2006-03-29-RA-861; McCluskey Adam, 2001, Mini-Reviews in Medicinal Chemistry, V1, P43, DOI 10.2174/1389557013407205; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Mizoguchi T, 2006, INT REV CYTOL, V250, P47, DOI 10.1016/S0074-7696(06)50002-6; Moller SG, 2003, PLANT CELL, V15, P1111, DOI 10.1105/tpc.008649; Motchoulski A, 1999, SCIENCE, V286, P961, DOI 10.1126/science.286.5441.961; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nuhse TS, 2004, PLANT CELL, V16, P2394, DOI 10.1105/tpc.104.023150; Ozgur S, 2006, BIOCHEMISTRY-US, V45, P13369, DOI 10.1021/bi061556n; Phee BK, 2006, PROTEOMICS, V6, P3671, DOI 10.1002/pmic.200500222; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Rawn DFK, 2005, J CHROMATOGR A, V1080, P148, DOI 10.1016/j.chroma.2005.05.035; Ryu JS, 2005, CELL, V120, P395, DOI 10.1016/j.cell.2004.12.019; Sakai T, 2000, PLANT CELL, V12, P225, DOI 10.1105/tpc.12.2.225; Sakai T, 2001, P NATL ACAD SCI USA, V98, P6969, DOI 10.1073/pnas.101137598; Sakamoto K, 2002, PLANT CELL, V14, P1723, DOI 10.1105/tpc.003293; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; Salomon M, 2003, BIOCHEMISTRY-US, V42, P4217, DOI 10.1021/bi027324f; Shalitin D, 2003, PLANT CELL, V15, P2421, DOI 10.1105/tpc.013011; Shalitin D, 2002, NATURE, V417, P763, DOI 10.1038/nature00815; SHEEN J, 1993, EMBO J, V12, P3497, DOI 10.1002/j.1460-2075.1993.tb06024.x; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Smith RD, 1996, ANNU REV PLANT PHYS, V47, P101, DOI 10.1146/annurev.arplant.47.1.101; Stogios PJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r82; Stowe-Evans EL, 2001, PLANT PHYSIOL, V126, P826, DOI 10.1104/pp.126.2.826; Stowe-Evans EL, 1998, PLANT PHYSIOL, V118, P1265, DOI 10.1104/pp.118.4.1265; Takemiya A, 2006, P NATL ACAD SCI USA, V103, P13549, DOI 10.1073/pnas.0602503103; van den Heuvel S, 2004, CURR BIOL, V14, pR59, DOI 10.1016/j.cub.2003.12.044; Wang HY, 2005, CURR TOP DEV BIOL, V68, P227, DOI 10.1016/S0070-2153(05)68008-8; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Whippo CW, 2004, PLANT CELL ENVIRON, V27, P1223, DOI 10.1111/j.1365-3040.2004.01227.x; Whippo CW, 2003, PLANT PHYSIOL, V132, P1499, DOI 10.1104/pp.102.018481; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Winter M, 2004, BIOCHEMISTRY-US, V43, P16356, DOI 10.1021/bi0489255; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; ZHUO S, 1993, J BIOL CHEM, V268, P17754	92	112	125	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19992	20001		10.1074/jbc.M702551200	http://dx.doi.org/10.1074/jbc.M702551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17493935	hybrid			2022-12-25	WOS:000247650600073
J	Medel, YFF; Gardner, PD				Fuentes Medel, Yuly F.; Gardner, Paul D.			Transcriptional repression by a conserved intronic sequence in the nicotinic receptor alpha 3 subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CENTRAL-NERVOUS-SYSTEM; FRONTAL-LOBE EPILEPSY; MESSENGER-RNA LEVELS; 4 SUBUNIT GENE; ACETYLCHOLINE-RECEPTOR; REGULATORY ELEMENTS; ALPHA-3 GENE; FUNCTIONAL-CHARACTERIZATION; DIFFERENTIAL REGULATION	The genes encoding the nicotinic acetylcholine receptor alpha 3, alpha 5, and beta 4 subunits are genomically clustered. These genes are co-expressed in a variety of cells in the peripheral and central nervous systems. Their gene products assemble in a number of stoichiometries to generate several nicotinic receptor subtypes that have distinct pharmacological and physiological properties. Signaling through these receptors is critical for a variety of fundamental biological processes. Despite their importance, the transcriptional mechanisms underlying their coordinated expression remain to be completely elucidated. By using a bioin-formatics approach, we identified a highly conserved intronic sequence within the fifth intron of the alpha 3 subunit gene. Reporter gene analysis demonstrated that this sequence, termed "alpha 3 intron 5," inhibits the transcriptional activities of the alpha 3 and beta 4 subunit gene promoters. This repressive activity is position- and orientation-independent. Importantly, repression occurs in a cell type-specific manner, being present in cells that do not express the receptor genes or expresses them at very low levels. Electrophoretic mobility shift assays demonstrate that nuclear proteins specifically interact with alpha 3 intron 5 at two distinct sites. We propose that this intronic repressor element is important for the restricted expression patterns of the nicotinic receptor alpha 3 and beta 4 subunit genes.	Univ Massachusetts, Sch Med, Brudnick Neuropsychiat Res Inst, Dept Psychiat, Worcester, MA 01604 USA	University of Massachusetts System; University of Massachusetts Worcester	Gardner, PD (corresponding author), Univ Massachusetts, Sch Med, Brudnick Neuropsychiat Res Inst, 303 Belmont St, Worcester, MA 01604 USA.	paul.gardner@umassmed.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030243] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30243] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benfante R, 2007, J BIOL CHEM, V282, P13290, DOI 10.1074/jbc.M608616200; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1996, J BIOL CHEM, V271, P32842, DOI 10.1074/jbc.271.51.32842; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Boyd RT, 1996, NEUROSCI LETT, V208, P73, DOI 10.1016/0304-3940(96)12561-1; Boyd RT, 1997, CRIT REV TOXICOL, V27, P299, DOI 10.3109/10408449709089897; BOYD RT, 1994, J NEUROBIOL, V25, P960, DOI 10.1002/neu.480250806; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Dani JA, 2001, NEURON, V31, P349, DOI 10.1016/S0896-6273(01)00379-8; De Fusco M, 2000, NAT GENET, V26, P275; DEVAY P, 1994, DEV BIOL, V162, P56, DOI 10.1006/dbio.1994.1066; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Ebihara M, 2002, GENE, V298, P101, DOI 10.1016/S0378-1119(02)00925-3; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798; Fedorova L, 2003, GENETICA, V118, P123, DOI 10.1023/A:1024145407467; FINKBEINER S, 2001, SCI STKE, pPE1; Flora A, 2000, EUR J PHARMACOL, V393, P85, DOI 10.1016/S0014-2999(00)00040-6; Flores CM, 1996, J NEUROSCI, V16, P7892; Flores GV, 2000, CELL, V103, P75, DOI 10.1016/S0092-8674(00)00106-9; Fornasari D, 1997, MOL PHARMACOL, V51, P250, DOI 10.1124/mol.51.2.250; FORNASARI D, 1998, NEURONAL NICOTINIC R, P25; Francis N, 2002, J BIOL CHEM, V277, P6511, DOI 10.1074/jbc.M105616200; Francis NJ, 1999, ANNU REV NEUROSCI, V22, P541, DOI 10.1146/annurev.neuro.22.1.541; FRANK E, 1993, NEURON, V10, P779, DOI 10.1016/0896-6273(93)90194-V; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; Fyodorov D, 1998, J NEUROBIOL, V34, P151, DOI 10.1002/(SICI)1097-4695(19980205)34:2<151::AID-NEU5>3.0.CO;2-1; Genzen JR, 2001, J NEUROPHYSIOL, V86, P1773, DOI 10.1152/jn.2001.86.4.1773; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Groves AK, 1999, CURR TOP DEV BIOL, V43, P221; HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M; HU MJ, 1995, J BIOL CHEM, V270, P4497, DOI 10.1074/jbc.270.19.11619; Isacson O, 2002, TRENDS NEUROSCI, V25, P79, DOI 10.1016/S0166-2236(02)02037-4; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Jones S, 1999, TRENDS NEUROSCI, V22, P555, DOI 10.1016/S0166-2236(99)01471-X; King SL, 2003, J NEUROSCI, V23, P3837; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; Laviolette SR, 2004, NAT REV NEUROSCI, V5, P55, DOI 10.1038/nrn1298; Lee SK, 2001, NAT NEUROSCI, V4, P1183, DOI 10.1038/nn750; Lena C, 1997, CURR OPIN NEUROBIOL, V7, P674, DOI 10.1016/S0959-4388(97)80088-8; LEVEY MS, 1995, NEURON, V14, P153, DOI 10.1016/0896-6273(95)90249-X; LIPTON SA, 1988, SCIENCE, V239, P1293, DOI 10.1126/science.3344435; Liu Q, 1999, J NEUROSCI, V19, P9747; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Lustig LR, 2001, GENOMICS, V73, P272, DOI 10.1006/geno.2000.6503; Ma QF, 2006, J PHYSIOL-LONDON, V575, P379, DOI 10.1113/jphysiol.2006.113449; Matter JM, 1998, J PHYSIOLOGY-PARIS, V92, P245, DOI 10.1016/S0928-4257(98)80027-2; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; MCCONNELL SK, 1995, J NEUROSCI, V15, P6987; McDonough J, 1997, J NEUROSCI, V17, P2273; McDonough J, 2000, J BIOL CHEM, V275, P28962, DOI 10.1074/jbc.M004181200; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Melnikova IN, 2000, NEUROPHARMACOLOGY, V39, P2615, DOI 10.1016/S0028-3908(00)00125-8; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Milton NGN, 1996, BIOCHEM J, V317, P419, DOI 10.1042/bj3170419; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; Perl O, 2003, FASEB J, V17, P1948, DOI 10.1096/fj.03-0104fje; Perry EK, 2001, ALCOHOL, V24, P63, DOI 10.1016/S0741-8329(01)00130-6; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Picciotto MR, 2002, J NEUROSCI, V22, P3338; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Record M T Jr, 1985, Adv Biophys, V20, P109; Richardson CE, 2001, GASTROENTEROLOGY, V121, P350, DOI 10.1053/gast.2001.26320; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; RUST G, 1994, EUR J NEUROSCI, V6, P478, DOI 10.1111/j.1460-9568.1994.tb00290.x; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Schuller HM, 2000, EUR J PHARMACOL, V393, P265, DOI 10.1016/S0014-2999(00)00094-7; Sher E, 1998, ANN NY ACAD SCI, V841, P606, DOI 10.1111/j.1749-6632.1998.tb10993.x; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Teaktong T, 2003, GLIA, V41, P207, DOI 10.1002/glia.10132; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200; Thiel G, 2004, EUR J BIOCHEM, V271, P2855, DOI 10.1111/j.1432-1033.2004.04174.x; Valor LM, 2003, J BIOL CHEM, V278, P37249, DOI 10.1074/jbc.M307043200; Valor LM, 2002, J BIOL CHEM, V277, P8866, DOI 10.1074/jbc.M110454200; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; Wang NS, 2002, PROG NEUROBIOL, V68, P341, DOI 10.1016/S0301-0082(02)00106-5; Watkins S S, 2000, Nicotine Tob Res, V2, P19; WHITEHOUSE PJ, 1988, ARCH NEUROL-CHICAGO, V45, P722, DOI 10.1001/archneur.1988.00520310028012; WinzerSerhan UH, 1997, J COMP NEUROL, V386, P540, DOI 10.1002/(SICI)1096-9861(19971006)386:4<540::AID-CNE2>3.0.CO;2-2; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; Xu XH, 2006, MOL CELL BIOL, V26, P5636, DOI 10.1128/MCB.00456-06; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; Yang XD, 1997, J NEUROBIOL, V32, P311, DOI 10.1002/(SICI)1097-4695(199703)32:3<311::AID-NEU5>3.0.CO;2-A; Zhou YF, 1998, J NEUROBIOL, V34, P164, DOI 10.1002/(SICI)1097-4695(19980205)34:2<164::AID-NEU6>3.0.CO;2-0; Zoli M, 1998, J NEUROSCI, V18, P4461	97	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19062	19070		10.1074/jbc.M702354200	http://dx.doi.org/10.1074/jbc.M702354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17504758	hybrid			2022-12-25	WOS:000247475300048
J	Yabuta, N; Okada, N; Ito, A; Hosomi, T; Nishihara, S; Sasayama, Y; Fujimori, A; Okuzaki, D; Zhao, H; Ikawa, M; Okabe, M; Nojima, H				Yabuta, Norikazu; Okada, Nobuhiro; Ito, Akihiko; Hosomi, Toshiya; Nishihara, Souichi; Sasayama, Yuya; Fujimori, Azumi; Okuzaki, Daisuke; Zhao, Hanjun; Ikawa, Masahito; Okabe, Masaru; Nojima, Hiroshi			Lats2 is an essential mitotic regulator required for the coordination of cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA TUMOR-SUPPRESSOR; PUTATIVE PROTEIN-KINASE; AURORA-A KINASE; CENTROSOME DUPLICATION; BUDDING YEAST; HUMAN HOMOLOG; PROMOTES APOPTOSIS; TETRAPLOIDY CHECKPOINT; DOWN-REGULATION; MOB1 PROTEIN	Tumor suppressor Lats2 is a member of the conserved Dbf2 kinase family. It localizes to the centrosome and has been implicated in regulation of the cell cycle and apoptosis. However, the in vivo function of this kinase remains unclear. Here, we show that complete disruption of the gene encoding Lats2 in mice causes developmental defects in the nervous system and embryonic lethality. Furthermore, mutant cells derived from total LATS2-knock-out embryos exhibit mitotic defects including centrosome fragmentation and cytokinesis defects, followed by nuclear enlargement and multinucleation. We show that the Mob1 family, a regulator of mitotic exit, associates with Lats2 to induce its activation. We also show that the complete LATS2-knock-out cells exhibit an acceleration of exit from mitosis and marked down-regulation of critical mitotic regulators. These results suggest that Lats2 plays an essential mitotic role in coordinating accurate cytokinesis completion, governing the stabilization of other mitotic regulators.	Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, Suita, Osaka 5650871, Japan; Kobe Univ, Grad Sch Med, Div Surg Pathol, Chuo Ku, Kobe, Hyogo 650, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan	Osaka University; Kobe University; Osaka University	Nojima, H (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	snj-0212@biken.osaka-u.ac.jp	Okuzaki, Daisuke/AAN-5641-2020; ikawa, masahito/A-5315-2009; Okabe, Masaru/B-6917-2015	Okuzaki, Daisuke/0000-0002-4552-783X; ikawa, masahito/0000-0001-9859-6217; Okada, Nobuhiro/0000-0002-0434-6039; Okabe, Masaru/0000-0002-0803-9044				Abe Y, 2006, FEBS LETT, V580, P782, DOI 10.1016/j.febslet.2005.12.096; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Beisson J, 2003, CURR OPIN CELL BIOL, V15, P96, DOI 10.1016/S0955-0674(02)00017-0; Bichsel SJ, 2004, J BIOL CHEM, V279, P35228, DOI 10.1074/jbc.M404542200; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bosl WJ, 2005, CELL, V121, P325, DOI 10.1016/j.cell.2005.04.006; Bothos J, 2005, CANCER RES, V65, P6568, DOI 10.1158/0008-5472.CAN-05-0862; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Devroe E, 2004, J BIOL CHEM, V279, P24444, DOI 10.1074/jbc.M401999200; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Frenz LM, 2000, J CELL SCI, V113, P3399; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hay BA, 2003, DEV CELL, V5, P361, DOI 10.1016/S1534-5807(03)00270-3; Hergovich A, 2006, NAT REV MOL CELL BIO, V7, P253, DOI 10.1038/nrm1891; Hergovich A, 2006, BIOCHEM BIOPH RES CO, V345, P50, DOI 10.1016/j.bbrc.2006.03.244; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; Hou MC, 2004, MOL CELL BIOL, V24, P3262, DOI 10.1128/MCB.24.8.3262-3276.2004; Hou MC, 2003, J CELL SCI, V116, P125, DOI 10.1242/jcs.00206; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kamikubo Y, 2003, J BIOL CHEM, V278, P17609, DOI 10.1074/jbc.M211974200; Ke HN, 2004, EXP CELL RES, V298, P329, DOI 10.1016/j.yexcr.2004.04.031; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Kramer A, 2004, CELL CYCLE, V3, P1390, DOI 10.4161/cc.3.11.1252; Kuninaka S, 2007, ONCOGENE, V26, P2395, DOI 10.1038/sj.onc.1210042; Kuninaka S, 2005, ONCOGENE, V24, P5287, DOI 10.1038/sj.onc.1208682; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; McPherson JP, 2004, EMBO J, V23, P3677, DOI 10.1038/sj.emboj.7600371; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mrkobrada S, 2006, J MOL BIOL, V362, P430, DOI 10.1016/j.jmb.2006.07.007; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Ponchon L, 2004, J MOL BIOL, V337, P167, DOI 10.1016/j.jmb.2004.01.010; Queralt E, 2006, CELL, V125, P719, DOI 10.1016/j.cell.2006.03.038; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Saavedra HI, 2003, CANCER CELL, V3, P333, DOI 10.1016/S1535-6108(03)00083-7; Salimova E, 2000, J CELL SCI, V113, P1695; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Seshan A, 2004, CURR OPIN CELL BIOL, V16, P41, DOI 10.1016/j.ceb.2003.11.003; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sparks CA, 1999, J CELL BIOL, V146, P777, DOI 10.1083/jcb.146.4.777; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stavridi ES, 2003, STRUCTURE, V11, P1163, DOI 10.1016/S0969-2126(03)00182-5; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Stewart S, 2005, CANCER RES, V65, P8730, DOI 10.1158/0008-5472.CAN-05-1500; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; TOYN JH, 1991, GENE, V104, P63, DOI 10.1016/0378-1119(91)90465-N; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Visintin R, 2003, MOL BIOL CELL, V14, P4486, DOI 10.1091/mbc.E03-02-0095; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang Q, 2006, P NATL ACAD SCI USA, V103, P6512, DOI 10.1073/pnas.0601682103; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU TA, 1995, DEVELOPMENT, V121, P1053; Xu ZX, 2005, MOL CELL, V17, P721, DOI 10.1016/j.molcel.2005.02.014; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817	85	123	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19259	19271		10.1074/jbc.M608562200	http://dx.doi.org/10.1074/jbc.M608562200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17478426	hybrid			2022-12-25	WOS:000247475300066
J	Watson, LE; Kuo, SR; Katki, K; Dang, TY; Park, SK; Dostal, DE; Tang, WJ; Leppla, SH; Frankel, AE				Watson, Linley E.; Kuo, Shu-ru; Katki, Khurshed; Dang, Tongyun; Park, Seong Kyu; Dostal, David E.; Tang, Wei-jen; Leppla, Stephen H.; Frankel, Arthur E.			Anthrax Toxins Induce Shock in Rats by Depressed Cardiac Ventricular Function	PLOS ONE			English	Article								Anthrax infections are frequently associated with severe and often irreversible hypotensive shock. The isolated toxic proteins of Bacillus anthracis produce a non-cytokine-mediated hypotension in rats by unknown mechanisms. These observations suggest the anthrax toxins have direct cardiovascular effects. Here, we characterize these effects. As a first step, we administered systemically anthrax lethal toxin (LeTx) and edema toxin (EdTx) to cohorts of three to twelve rats at different doses and determined the time of onset, degree of hypotension and mortality. We measured serum concentrations of the protective antigen (PA) toxin component at various time points after infusion. Peak serum levels of PA were in the mg/mL range with half-lives of 10-20 minutes. With doses that produced hypotension with delayed lethality, we then gave bolus intravenous infusions of toxins to groups of four to six instrumented rats and continuously monitored blood pressure by telemetry. Finally, the same doses used in the telemetry experiments were given to additional groups of four rats, and echocardiography was performed pretreatment and one, two, three and twenty-four hours post-treatment. LeTx and EdTx each produced hypotension. We observed a doubling of the velocity of propagation and 20% increases in left ventricular diastolic and systolic areas in LeTx-treated rats, but not in EdTx-treated rats. EdTx-but not LeTx-treated rats showed a significant increase in heart rate. These results indicate that LeTx reduced left ventricular systolic function and EdTx reduced preload. Uptake of toxins occurs readily into tissues with biological effects occurring within minutes to hours of serum toxin concentrations in the mu g/mL range. LeTx and EdTx yield an irreversible shock with subsequent death. These findings should provide a basis for the rational design of drug interventions to reduce the dismal prognosis of systemic anthrax infections.	[Watson, Linley E.] Scott & White Mem Hosp & Clin, Div Cardiol, Scott Sherwood & Brindley Fdn, Temple, TX 76508 USA; [Watson, Linley E.; Katki, Khurshed; Dostal, David E.; Frankel, Arthur E.] Texas A&M Univ Syst, Hlth Sci Ctr, Coll Med, Dept Med, Temple, TX USA; [Kuo, Shu-ru; Dang, Tongyun; Park, Seong Kyu; Frankel, Arthur E.] Scott & White Canc Res Inst, Temple, TX USA; [Watson, Linley E.; Dostal, David E.] Texas A&M Univ Syst, Div Mol Cardiol, Hlth Sci Ctr, Coll Med, Temple, TX USA; [Watson, Linley E.; Dostal, David E.] Cent Texas Vet Hlth Care Syst, Temple, TX USA; [Tang, Wei-jen] Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; [Leppla, Stephen H.] NIAID, Bacterial Toxins & Therapeut Sect, Bethesda, MD 20892 USA	Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Frankel, AE (corresponding author), Scott & White Mem Hosp & Clin, Div Cardiol, Scott Sherwood & Brindley Fdn, Temple, TX 76508 USA.	AFRANKEL@swmail.sw.org		Tang, Wei-Jen/0000-0002-8267-8995	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001032, ZIAAI000929, Z01AI001032, Z01AI000929] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abi-Habib RJ, 2005, MOL CANCER THER, V4, P1303, DOI 10.1158/1535-7163.MCT-05-0145; Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; Baines CP, 2005, J MOL CELL CARDIOL, V38, P47, DOI 10.1016/j.yjmcc.2004.11.004; Borio L, 2001, JAMA-J AM MED ASSOC, V286, P2554, DOI 10.1001/jama.286.20.2554; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Cui XZ, 2007, J INFECT DIS, V195, P572, DOI 10.1086/510856; Cui XZ, 2005, J INFECT DIS, V191, P422, DOI 10.1086/427189; Cui XZ, 2004, AM J PHYSIOL-REG I, V286, pR699, DOI 10.1152/ajpregu.00593.2003; Culley NC, 2005, INFECT IMMUN, V73, P7006, DOI 10.1128/IAI.73.10.7006-7010.2005; DIPETTE DJ, 1989, AM J MED SCI, V297, P65, DOI 10.1097/00000441-198902000-00001; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; EZZELL JW, 1984, INFECT IMMUN, V45, P761, DOI 10.1128/IAI.45.3.761-767.1984; Firoved AM, 2007, INFECT IMMUN, V75, P2120, DOI 10.1128/IAI.01781-06; Firoved AM, 2005, AM J PATHOL, V167, P1309, DOI 10.1016/S0002-9440(10)61218-7; Hong J, 2005, BIOCHEM BIOPH RES CO, V335, P850, DOI 10.1016/j.bbrc.2005.07.132; Kobiler D, 2006, INFECT IMMUN, V74, P5871, DOI 10.1128/IAI.00792-06; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Mabry R, 2006, CLIN VACCINE IMMUNOL, V13, P671, DOI 10.1128/CVI.00023-06; Marcus H, 2004, INFECT IMMUN, V72, P3471, DOI 10.1128/IAI.72.6.3471-3477.2004; Mayer TA, 2001, JAMA-J AM MED ASSOC, V286, P2549, DOI 10.1001/jama.286.20.2549; Mina B, 2002, JAMA-J AM MED ASSOC, V287, P858, DOI 10.1001/jama.287.7.858; Moayeri M, 2005, INFECT IMMUN, V73, P4238, DOI 10.1128/IAI.73.7.4238-4244.2005; Moayeri M, 2003, J CLIN INVEST, V112, P670, DOI [10.1172/JCI200317991, 10.1172/JCI17991]; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; Ogawa Toshihiro, 2005, Cardiovasc Ultrasound, V3, P24, DOI 10.1186/1476-7120-3-24; OH JK, 1999, ECHO MANUAL; Paccani SR, 2005, J EXP MED, V201, P325, DOI 10.1084/jem.20041557; Park S, 2000, PROTEIN EXPRES PURIF, V18, P293, DOI 10.1006/prep.2000.1208; Plehm Ralph, 2006, V129, P115; Rainey GJA, 2005, P NATL ACAD SCI USA, V102, P13278, DOI 10.1073/pnas.0505865102; Ramirez DM, 2002, J IND MICROBIOL BIOT, V28, P232, DOI 10.1038/sj/jim/700239; Rosovitz MJ, 2003, J BIOL CHEM, V278, P30936, DOI 10.1074/jbc.M301154200; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Scobie HM, 2006, PLOS PATHOG, V2, P949, DOI 10.1371/journal.ppat.0020111; Soelaiman S, 2003, J BIOL CHEM, V278, P25990, DOI 10.1074/jbc.M301232200; Trujillo C, 2006, NEUROTOX RES, V9, P63, DOI 10.1007/BF03033924; Watson LE, 2004, J AM SOC ECHOCARDIOG, V17, P161, DOI 10.1016/j.echo.2003.10.010	37	48	49	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e466	10.1371/journal.pone.0000466	http://dx.doi.org/10.1371/journal.pone.0000466			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520025	Green Published, gold, Green Submitted			2022-12-25	WOS:000207446000014
J	Kaneko, K				Kaneko, Kunihiko			Evolution of Robustness to Noise and Mutation in Gene Expression Dynamics	PLOS ONE			English	Article								Phenotype of biological systems needs to be robust against mutation in order to sustain themselves between generations. On the other hand, phenotype of an individual also needs to be robust against fluctuations of both internal and external origins that are encountered during growth and development. Is there a relationship between these two types of robustness, one during a single generation and the other during evolution? Could stochasticity in gene expression have any relevance to the evolution of these types of robustness? Robustness can be defined by the sharpness of the distribution of phenotype; the variance of phenotype distribution due to genetic variation gives a measure of 'genetic robustness', while that of isogenic individuals gives a measure of 'developmental robustness'. Through simulations of a simple stochastic gene expression network that undergoes mutation and selection, we show that in order for the network to acquire both types of robustness, the phenotypic variance induced by mutations must be smaller than that observed in an isogenic population. As the latter originates from noise in gene expression, this signifies that the genetic robustness evolves only when the noise strength in gene expression is larger than some threshold. In such a case, the two variances decrease throughout the evolutionary time course, indicating increase in robustness. The results reveal how noise that cells encounter during growth and development shapes networks' robustness to stochasticity in gene expression, which in turn shapes networks' robustness to mutation. The necessary condition for evolution of robustness, as well as the relationship between genetic and developmental robustness, is derived quantitatively through the variance of phenotypic fluctuations, which are directly measurable experimentally.	[Kaneko, Kunihiko] Univ Tokyo, Dept Pure & Appl Sci, Tokyo, Japan; [Kaneko, Kunihiko] Japan Sci & Technol Agcy, Exploratory Res Adv Technol ERATO, Complex Syst Biol Project, Tokyo, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Kaneko, K (corresponding author), Univ Tokyo, Dept Pure & Appl Sci, Tokyo, Japan.	kaneko@complex.c.u-tokyo.ac.jp						ABE H, 1980, I FORMULATION BIOPOL, P1013; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Ancel LW, 2000, THEOR POPUL BIOL, V58, P307, DOI 10.1006/tpbi.2000.1484; ANCEL LW, 2002, J EXPT ZOOLOGY, P242; Ao P, 2005, PHYS LIFE REV, V2, P117, DOI 10.1016/j.plrev.2005.03.002; Bar-Even A, 2006, NAT GENET, V38, P636, DOI 10.1038/ng1807; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Callahan HS, 1997, BIOESSAYS, V19, P519, DOI 10.1002/bies.950190611; CILIBERTI S, 2007, PLOS COMPUTATIONAL B, pE15; de Visser JAGM, 2003, EVOLUTION, V57, P1959, DOI 10.1554/02-750R; EDWARDS AWF, 2000, FDN MATH GENETICS; Eigen M, 1979, HYPERCYCLE; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Fisher R.A., 1930, GENETICAL THEORY NAT; Furusawa Chikara, 2005, Biophysics (Nagoya-shi), V1, P25, DOI 10.2142/biophysics.1.25; Futuyma DJ, 1986, EVOL BIOL; GLASS L, 1973, J THEOR BIOL, V39, P103, DOI 10.1016/0022-5193(73)90208-7; GOMPERTS BD, 2002, SIGNAL TRANSDUCTION; Hasty J, 2000, P NATL ACAD SCI USA, V97, P2075, DOI 10.1073/pnas.040411297; Hertz JA, 2018, INTRO THEORY NEURAL; ISHIHARA S, 2004, PHYS REV LETT; JNONUCHIC JN, 1995, P NATL ACAD SCI USA, P3626; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Kaneko K, 1999, J THEOR BIOL, V199, P243, DOI 10.1006/jtbi.1999.0952; Kaneko K, 2006, LIFE INTRO COMPLEX S; Kaneko K, 2006, J THEOR BIOL, V240, P78, DOI 10.1016/j.jtbi.2005.08.029; Kashiwagi A, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000049; KIRSCHNER MW, 2005, PLAUSBILITY LIFE; Kubo R., 1985, STAT PHYS, V2; LI F, 2004, P NATL ACAD SCI USA, P10040; Mayo AE, 2006, PLOS BIOL, V4, P555, DOI 10.1371/journal.pbio.0040045; Mezard M., 1987, SPIN GLASS THEORY IN; MJOLSNESS E, 1991, J THEOR BIOL, V152, P429, DOI 10.1016/S0022-5193(05)80391-1; Nishimori H., 2001, STAT PHYS SPIN GLASS; Saito S, 1997, P NATL ACAD SCI USA, V94, P11324, DOI 10.1073/pnas.94.21.11324; Salazar-Ciudad I, 2000, J THEOR BIOL, V205, P587, DOI 10.1006/jtbi.2000.2092; Salazar-Ciudad I, 2001, EVOL DEV, V3, P84, DOI 10.1046/j.1525-142x.2001.003002084.x; Sato K, 2003, P NATL ACAD SCI USA, V100, P14086, DOI 10.1073/pnas.2334996100; Sawai S, 2005, NATURE, V433, P323, DOI 10.1038/nature03228; Schmalhausen II, 1949, FACTORS EVOLUTION TH; Siegal ML, 2002, P NATL ACAD SCI USA, V99, P10528, DOI 10.1073/pnas.102303999; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Ueda M, 2001, SCIENCE, V294, P864, DOI 10.1126/science.1063951; Waddington C., 1957, STRATEGY GENES; WAGNER A, 2000, NAT GENET, P355; WAGNER GP, 1997, POPULATION GENETIC T, P329; West-Eberhard Mary Jane, 2003, pi	47	103	103	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e434	10.1371/journal.pone.0000434	http://dx.doi.org/10.1371/journal.pone.0000434			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17502916	Green Submitted, gold, Green Published			2022-12-25	WOS:000207445800016
J	Craft, CS; Romero, D; Vary, CPH; Bergan, RC				Craft, C. S.; Romero, D.; Vary, C. P. H.; Bergan, R. C.			Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway	ONCOGENE			English	Article						transforming growth factor beta; prostate cancer; motility; endoglin; smad1; ALK2	GROWTH-FACTOR-BETA; MATRIX-METALLOPROTEINASE TYPE-2; HUMAN ENDOTHELIAL-CELLS; RECEPTOR-LIKE KINASE-2; TGF-BETA; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSES; EPITHELIAL-CELLS; II RECEPTORS; ACTIVIN	Endoglin is a transforming growth factor beta (TGF beta) superfamily auxiliary receptor. We had previously shown that it suppressed prostate cancer (PCa) cell motility, and that its expression was lost during PCa progression. The mechanism by which endoglin inhibits PCa cell motility is unknown. Here we demonstrate that endoglin abrogates TGF beta-mediated cell motility, but does not alter cell surface binding of TGF beta. By measuring Smad-specific phosphorylation and Smad-responsive promoter activity, endoglin was shown to constitutively activate Smad1, with little-to-no effect upon Smad3. Knockdown of Smad1 increased motility and abrogated endoglin's effects. As type I activin receptor-like kinases (ALKs) are necessary for Smad activation, we went on to show that knockdown of ALK2, but not TGF beta RI (ALK5), abrogated endoglin-mediated decreases in cell motility and constitutively active ALK2 was sufficient to restore a low-motility phenotype in endoglin deficient cells. These findings provide the first evidence that endoglin decreases PCa cell motility through activation of the ALK2-Smad1 pathway.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Maine Medical Center	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Olson 8321, 710 N Fairbanks, Chicago, IL 60611 USA.	r-bergan@northwestern.edu	Romero, Diana/GWU-9250-2022		NATIONAL CANCER INSTITUTE [T32CA009560, P50CA090386] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083151] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA090386, T32 CA009560, CA90386, T32CA09560] Funding Source: Medline; NCRR NIH HHS [P20 RR015555-076459, P20 RR015555, P20 RR015555-076465] Funding Source: Medline; NHLBI NIH HHS [R01 HL083151, R01 HL083151-01A2S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Blanco FJ, 2005, J CELL PHYSIOL, V204, P574, DOI 10.1002/jcp.20311; CARROLL PR, 2001, CANC PRINCIPLES PRAC, P1418; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Desgrosellier JS, 2005, DEV BIOL, V280, P201, DOI 10.1016/j.ydbio.2004.12.037; Ding Y, 2006, PROSTATE CANCER P D, V9, P379, DOI 10.1038/sj.pcan.4500888; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Jovanovic B D, 2001, Am J Pharmacogenomics, V1, P145, DOI 10.2165/00129785-200101020-00007; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Monteiro RM, 2004, J CELL SCI, V117, P4653, DOI 10.1242/jcs.01337; Pece-Barbara N, 2005, J BIOL CHEM, V280, P27800, DOI 10.1074/jbc.M503471200; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Ward SM, 2002, J BIOL CHEM, V277, P50183, DOI 10.1074/jbc.M209668200; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337	37	53	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7240	7250		10.1038/sj.onc.1210533	http://dx.doi.org/10.1038/sj.onc.1210533			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17496924	Green Accepted			2022-12-25	WOS:000250955600008
J	Aarabi, S; Bhatt, KA; Shi, Y; Paterno, J; Chang, EI; Loh, SA; Holmes, JW; Longaker, MT; Yee, H; Gurtner, GC				Aarabi, Shahram; Bhatt, Kirit A.; Shi, Yubin; Paterno, Josemaria; Chang, Edward I.; Loh, Shang A.; Holmes, Jeffrey W.; Longaker, Michael T.; Yee, Herman; Gurtner, Geoffrey C.			Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis	FASEB JOURNAL			English	Article						hypertrophic scar; wound healing; fibrosis; scarring	BCL-2 EXPRESSION; MANAGEMENT; AKT; FIBROBLASTS; ADHESION; PROTEIN; CELLS; MECHANOTRANSDUCTION; CONTRACTURES; VERSATILITY	Hypertrophic scars occur following cutaneous wounding and result in severe functional and esthetic defects. The pathophysiology of this process remains unknown. Here, we demonstrate for the first time that mechanical stress applied to a healing wound is sufficient to produce hypertrophic scars in mice. The resulting scars are histopathologically identical to human hypertrophic scars and persist for more than six months following a brief (one-week) period of augmented mechanical stress during the proliferative phase of wound healing. Resulting scars are structurally identical to human hypertrophic scars and showed dramatic increases in volume (20-fold) and cellular density (20-fold). The increased cellularity is accompanied by a four-fold decrease in cellular apoptosis and increased activation of the prosurvival marker Akt. To clarify the importance of apoptosis in hypertrophic scar formation, we examine the effects of mechanical loading on cutaneous wounds of animals with altered pathways of cellular apoptosis. In p53-null mice, with down-regulated cellular apoptosis, we observe significantly greater scar hypertrophy and cellular density. Conversely, scar hypertrophy and cellular density are significantly reduced in proapoptotic BclII-null mice. We conclude that mechanical loading early in the proliferative phase of wound healing produces hypertrophic scars by inhibiting cellular apoptosis through an Akt-dependent mechanism.	Stanford Univ, PSRL, Sch Med, Dept Surg, Stanford, CA 94305 USA; Columbia Univ, Dept Biomed Engn, New York, NY USA; NYU, Sch Med, Dept Pathol, New York, NY USA	Stanford University; Columbia University; New York University	Gurtner, GC (corresponding author), Stanford Univ, PSRL, Sch Med, Dept Surg, GK-210,257 Campus Dr, Stanford, CA 94305 USA.	ggurtner@stanford.edu		Holmes, Jeffrey/0000-0001-9125-7220	NHLBI NIH HHS [R01 HL-075639] Funding Source: Medline; NIA NIH HHS [R01 AG-021494] Funding Source: Medline; NIDDK NIH HHS [R01 DK067771] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK067771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021494] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALENGHAT FJ, 2002, SCI STKE; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Bao G, 2003, NAT MATER, V2, P715, DOI 10.1038/nmat1001; Borer JS, 2002, CIRCULATION, V105, P1837, DOI 10.1161/01.CIR.0000014419.71706.85; Brissett A E, 2001, Facial Plast Surg, V17, P263, DOI 10.1055/s-2001-18827; Burke M, 1998, Aust Fam Physician, V27, P275; Clark JA, 1996, BURNS, V22, P443, DOI 10.1016/0305-4179(96)00038-1; Colwell AS, 2003, FRONT BIOSCI-LANDMRK, V8, pS1240, DOI 10.2741/1183; Costa AMA, 1999, AM J PATHOL, V155, P1671, DOI 10.1016/S0002-9440(10)65482-X; DEITCH EA, 1983, J TRAUMA, V23, P895, DOI 10.1097/00005373-198310000-00009; Edlich R F, 1998, J Emerg Med, V16, P759; EHRLICH HP, 1994, AM J PATHOL, V145, P105; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Greenhalgh DG, 1998, INT J BIOCHEM CELL B, V30, P1019, DOI 10.1016/S1357-2725(98)00058-2; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333; Lee JYY, 2004, AM J DERMATOPATH, V26, P379, DOI 10.1097/00000372-200410000-00006; LINARES HA, 1972, J INVEST DERMATOL, V59, P323, DOI 10.1111/1523-1747.ep12627386; Linge C, 2005, J INVEST DERMATOL, V125, P72, DOI 10.1111/j.0022-202X.2005.23771.x; LONGACRE JJ, 1976, SCAND J PLAST RECONS, V10, P113, DOI 10.3109/02844317609105199; Marneros AG, 2004, J INVEST DERMATOL, V122, P1126, DOI 10.1111/j.0022-202X.2004.22327.x; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Martin P, 2004, DEVELOPMENT, V131, P3021, DOI 10.1242/dev.01253; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Mustoe TA, 2002, PLAST RECONSTR SURG, V110, P560, DOI 10.1097/00006534-200208000-00031; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Reno F, 2003, WOUND REPAIR REGEN, V11, P331, DOI 10.1046/j.1524-475X.2003.11504.x; Riser BL, 2001, AM J PATHOL, V158, P11, DOI 10.1016/S0002-9440(10)63938-7; ROBSON MC, 1992, WORLD J SURG, V16, P87, DOI 10.1007/BF02067119; Santucci M, 2001, VIRCHOWS ARCH, V438, P457, DOI 10.1007/s004280000335; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Sheridan RL, 2000, INT ANESTHESIOL CLIN, V38, P129, DOI 10.1097/00004311-200007000-00009; Sheridan RL, 2004, J AM COLL SURGEONS, V198, P243, DOI 10.1016/j.jamcollsurg.2003.11.007; Sheridan RL, 2003, JAMA-J AM MED ASSOC, V290, P719, DOI 10.1001/jama.290.6.719; SHERRIS DA, 1995, OTOLARYNG CLIN N AM, V28, P1057; Singer AJ, 1997, NEW ENGL J MED, V337, P1142, DOI 10.1056/NEJM199710163371607; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sugden PH, 2003, CIRC RES, V93, P1179, DOI 10.1161/01.RES.0000106132.04301.F5; Suzuki S, 1996, PLAST RECONSTR SURG, V98, P1016, DOI 10.1097/00006534-199611000-00014; Suzuki S, 1998, BRIT J PLAST SURG, V51, P363, DOI 10.1054/bjps.1997.0279; Tuan TL, 1998, MOL MED TODAY, V4, P19, DOI 10.1016/S1357-4310(97)80541-2; Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com; Varedi M, 2000, BIOCHEM CELL BIOL, V78, P427, DOI 10.1139/bcb-78-4-427; Vittal R, 2005, AM J PATHOL, V166, P367, DOI 10.1016/S0002-9440(10)62260-2; Wang JX, 2006, EXP CELL RES, V312, P205, DOI 10.1016/j.yexcr.2005.11.004; Wang Z, 2006, J CELL PHYSIOL, V206, P510, DOI 10.1002/jcp.20486; WHITE CR, 2004, TXB DERMATOPATHOLOGY; Wilson IF, 2000, PLAST RECONSTR SURG, V105, P27, DOI 10.1097/00006534-200001000-00005; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Zhan GD, 2003, NAT MATER, V2, P38, DOI 10.1038/nmat793	53	338	367	4	54	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3250	3261		10.1096/fj.07-8218com	http://dx.doi.org/10.1096/fj.07-8218com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17504973				2022-12-25	WOS:000249781600025
J	Baker, DJ; Wuenschell, G; Xia, LQ; Termini, J; Bates, SE; Riggs, AD; O'Connor, TR				Baker, David J.; Wuenschell, Gerald; Xia, Liqun; Termini, John; Bates, Steven E.; Riggs, Arthur D.; O'Connor, Timothy R.			Nucleotide excision repair eliminates unique DNA-protein cross-links from mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TOPOISOMERASE-I; PYRIMIDINE DIMERS; ACTIVE GENE; FPG PROTEIN; DAMAGE; MECHANISM; METHYLTRANSFERASE; ADDUCT; BASE	DNA- protein cross-links (DPCs) present a formidable obstacle to cellular processes because they are "superbulky" compared with the majority of chemical adducts. Elimination of DPCs is critical for cell survival because their persistence can lead to cell death or halt cell cycle progression by impeding DNA and RNA synthesis. To study DPC repair, we have used DNA methyltransferases to generate unique DPC adducts in oligodeoxyribonucleotides or plasmids to monitor both in vitro excision and in vivo repair. We show that HhaI DNA methyltransferase covalently bound to an oligodeoxyribonucleotide is not efficiently excised by using mammalian cell-free extracts, but protease digestion of the full-length HhaI DNA methyltransferase-DPC yields a substrate that is efficiently removed by a process similar to nucleotide excision repair (NER). To examine the repair of that unique DPC, we have developed two plasmid-based in vivo assays for DPC repair. One assay shows that in nontranscribed regions, DPC repair is greater than 60% in 6 h. The other assay based on host cell reactivation using a green fluorescent protein demonstrates that DPCs in transcribed genes are also repaired. Using Xpg-deficient cells (NER-defective) with the in vivo host cell reactivation assay and a unique DPC indicates that NER has a role in the repair of this adduct. We also demonstrate a role for the 26 S proteasome in DPC repair. These data are consistent with a model for repair in which the polypeptide chain of a DPC is first reduced by proteolysis prior to NER.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	O'Connor, TR (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	toconnor@coh.org		Riggs, Arthur/0000-0002-8184-5288; O'Connor, Timothy/0000-0001-5848-3592	NIGMS NIH HHS [GM59219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; ASUBEL FM, 1992, SHORT PROTOCOLS MOL; BAKER DJ, 1993, BIOCHEM BIOPH RES CO, V196, P864, DOI 10.1006/bbrc.1993.2329; Barker S, 2005, J BIOL CHEM, V280, P33826, DOI 10.1074/jbc.M502477200; Barker S, 2005, ANAL BIOCHEM, V344, P204, DOI 10.1016/j.ab.2005.06.039; Barker S, 2005, MUTAT RES-REV MUTAT, V589, P111, DOI 10.1016/j.mrrev.2004.11.003; Bates SE, 2005, NUCLEIC ACIDS RES, V33, P2475, DOI 10.1093/nar/gki542; Biggerstaff M, 1999, METH MOL B, V113, P357; BLOW DM, 1974, ENZYMES, P185; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; CALDECOTT K, 1991, MUTAT RES, V255, P111, DOI 10.1016/0921-8777(91)90046-R; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHENG X, 1993, COLD SPRING HARB SYM, V58, P331, DOI 10.1101/SQB.1993.058.01.039; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Costa M, 1997, J TOXICOL ENV HEALTH, V50, P433, DOI 10.1080/00984109708984000; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Emri G, 2004, EXP DERMATOL, V13, P305, DOI 10.1111/j.0906-6705.2004.00157.x; ERICKSON LC, 1980, CANCER RES, V40, P4216; FORNACE AJ, 1982, CANCER RES, V42, P145; FORNACE AJ, 1979, CANCER RES, V39, P704; GANTT R, 1984, CANCER RES, V44, P1809; GANTT R, 1987, MUTAT RES, V183, P75, DOI 10.1016/0167-8817(87)90048-4; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; Giri I, 2002, BIOCHEMISTRY-US, V41, P5462, DOI 10.1021/bi012116t; Gowher H, 2004, CANCER BIOL THER, V3, P1062, DOI 10.4161/cbt.3.11.1308; Guengerich FP, 2002, CHEM RES TOXICOL, V15, P793, DOI 10.1021/tx0200055; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; HARRIS TM, 1990, J PHARMACEUT BIOMED, V8, P195, DOI 10.1016/0731-7085(90)80027-M; Hazra TK, 2001, NUCLEIC ACIDS RES, V29, P1967, DOI 10.1093/nar/29.9.1967; Hohl M, 2003, J BIOL CHEM, V278, P19500, DOI 10.1074/jbc.M213155200; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JELINSKY SA, 1995, BIOCHEMISTRY-US, V34, P13545, DOI 10.1021/bi00041a034; Karle IL, 2004, P NATL ACAD SCI USA, V101, P1433, DOI 10.1073/pnas.0307305101; KAYSEN J, 1986, CANCER RES, V46, P4534; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Kohn KW, 2000, CELL BIOCHEM BIOPHYS, V33, P175, DOI 10.1385/CBB:33:2:175; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; Larsen AK, 2001, CANCER RES, V61, P2961; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; McCullough AK, 2001, BIOCHEMISTRY-US, V40, P561, DOI 10.1021/bi002404+; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Merk O, 2000, MUTAT RES-GEN TOX EN, V471, P71, DOI 10.1016/S1383-5718(00)00110-8; Minko IG, 2005, BIOCHEMISTRY-US, V44, P3000, DOI 10.1021/bi0478805; Minko IG, 2002, P NATL ACAD SCI USA, V99, P1905, DOI 10.1073/pnas.042700399; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; Parsons JL, 2005, FEBS J, V272, P5753, DOI 10.1111/j.1742-4658.2005.04962.x; PODDEVIN B, 1993, MOL PHARMACOL, V44, P767; Quievryn G, 2000, CARCINOGENESIS, V21, P1573, DOI 10.1093/carcin/21.8.1573; Raymond AC, 2005, J BIOL CHEM, V280, P22029, DOI 10.1074/jbc.M502148200; Reardon JT, 2006, CELL CYCLE, V5, P1366, DOI 10.4161/cc.5.13.2892; Reardon JT, 2006, P NATL ACAD SCI USA, V103, P4056, DOI 10.1073/pnas.0600538103; Reardon JT, 1997, NUCLEIC ACIDS RES, V25, P1015, DOI 10.1093/nar/25.5.1015; Reardon JT, 2003, GENE DEV, V17, P2539, DOI 10.1101/gad.1131003; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RODRIGUEZ H, 1993, BIOCHEMISTRY-US, V32, P1759, DOI 10.1021/bi00058a009; Sambrook J, 2001, MOL CLONING LAB MANU; Sankpal UT, 2002, CRIT REV BIOCHEM MOL, V37, P167, DOI 10.1080/10409230290771492; Saparbaev M, 2002, ENVIRON MOL MUTAGEN, V39, P10, DOI 10.1002/em.10041; Sastry S, 1998, J BIOL CHEM, V273, P9942, DOI 10.1074/jbc.273.16.9942; Shivji MKK, 1999, METH MOL B, V113, P373; Sidorkina OM, 2000, J BIOL CHEM, V275, P9924, DOI 10.1074/jbc.275.14.9924; Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; Speit G, 2002, MUTAGENESIS, V17, P183, DOI 10.1093/mutage/17.3.183; Speit G, 2000, MUTAGENESIS, V15, P85, DOI 10.1093/mutage/15.1.85; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; Sugasawa K, 2001, GENE DEV, V15, P507, DOI 10.1101/gad.866301; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; Topcu Z, 2001, J CLIN PHARM THER, V26, P405, DOI 10.1046/j.1365-2710.2001.00368.x; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Vladu B, 2000, MOL PHARMACOL, V57, P243; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Wang HX, 2001, MOL BIOTECHNOL, V19, P133, DOI 10.1385/MB:19:2:133; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; ZHAO XD, 1995, BIOCHEMISTRY-US, V34, P1386, DOI 10.1021/bi00004a033; Zhitkovich A, 1998, ENVIRON HEALTH PERSP, V106, P969, DOI 10.2307/3434139; Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9	91	86	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31							22592	10.1074/jbc.M702856200	http://dx.doi.org/10.1074/jbc.M702856200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17507378	hybrid			2022-12-25	WOS:000248354200037
J	Thuerauf, DJ; Marcinko, M; Belmont, PJ; Glembotski, CC				Thuerauf, Donna J.; Marcinko, Marie; Belmont, Peter J.; Glembotski, Christopher C.			Effects of the isoform-specific characteristics of ATF6 alpha and ATF6 beta on endoplasmic reticulum stress response gene expression and cell viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; TRANSCRIPTION FACTOR ATF6; NF-Y CBF; DNA-BINDING; HETEROLOGOUS PROTEINS; IN-VIVO; ELEMENT; ACTIVATION; PROTEOLYSIS; DOMAIN	The endoplasmic reticulum (ER)-transmembrane proteins, ATF6 alpha and ATF6 beta, are cleaved during the ER stress response (ERSR). The resulting N-terminal fragments ( N-ATF6 alpha and N-ATF6 beta) have conserved DNA-binding domains and divergent transcriptional activation domains. N-ATF6 alpha and N-ATF6 beta translocate to the nucleus, bind to specific regulatory elements, and influence expression of ERSR genes, such as glucose-regulated protein 78 (GRP78), that contribute to resolving the ERSR, thus, enhancing cell viability. We previously showed that N-ATF6 alpha is a rapidly degraded, strong transcriptional activator, whereas beta is a slowly degraded, weak activator. In this study we explored the molecular basis and functional impact of these isoform-specific characteristics in HeLa cells. Mutants in the transcriptional activation domain or DNA-binding domain of N-ATF6 alpha exhibited loss of function and increased expression, the latter of which suggested decreased rates of degradation. Fusing N-ATF6 alpha to the mutant estrogen receptor generated N-ATF6 alpha-MER, which, without tamoxifen exhibited loss-of- function and high expression, but in the presence of tamoxifen N-ATF6 alpha- MER exhibited gain-of-function and low expression. N-ATF6 beta conferred loss-of-function and high expression to N-ATF6 alpha, suggesting that ATF6 beta is an endogenous inhibitor of ATF6 alpha. In vitro DNA binding experiments showed that recombinant N-ATF6 beta inhibited the binding of recombinant N-ATF6 alpha to an ERSR element from the GRP78 promoter. Moreover, siRNA-mediated knock-down of endogenous ATF6 beta increased GRP78 promoter activity and GRP78 gene expression, as well as augmenting cell viability. Thus, the relative levels of ATF6 alpha and -beta, may contribute to regulating the strength and duration of ATF6-dependent ERSR gene induction and cell viability.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Heart, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, Dept Biol, 5300 Campanile Dr, San Diego, CA 92182 USA.	cglembotski@sciences.sdsu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL75573] Funding Source: Medline; NINDS NIH HHS [NS025037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Collins GA, 2006, CURR OPIN GENET DEV, V16, P197, DOI 10.1016/j.gde.2006.02.009; Corton JC, 1998, J BIOL CHEM, V273, P13776, DOI 10.1074/jbc.273.22.13776; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu CY, 2003, J CELL SCI, V116, P1861, DOI 10.1242/jcs.00408; Martindale JJ, 2006, CIRC RES, V98, P1186, DOI 10.1161/01.RES.0000220643.65941.8d; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Pal B, 2007, MOL BIOL CELL, V18, P426, DOI 10.1091/mbc.E06-04-0304; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Spear E, 2001, TRAFFIC, V2, P515, DOI 10.1034/j.1600-0854.2001.20801.x; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; Thuerauf DJ, 2004, J BIOL CHEM, V279, P21078, DOI 10.1074/jbc.M400713200; Thuerauf DJ, 2002, J BIOL CHEM, V277, P20734, DOI 10.1074/jbc.M201749200; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Thuerauf DJ, 2006, CIRC RES, V99, P275, DOI 10.1161/01.RES.0000233317.70421.03; Wang Y, 2000, J BIOL CHEM, V275, P27013; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2006, J CELL BIOL, V172, P565, DOI 10.1083/jcb.200508145; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	36	107	116	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22865	22878		10.1074/jbc.M701213200	http://dx.doi.org/10.1074/jbc.M701213200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17522056	hybrid			2022-12-25	WOS:000248354200064
J	Bao, JJ; Ma, XF; Liu, CY; Adelstein, RS				Bao, Jianjun; Ma, Xuefei; Liu, Chengyu; Adelstein, Robert S.			Replacement of nonmuscle myosin II-B with II-A rescues brain but not cardiac defects in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY CHAIN-B; DILATED CARDIOMYOPATHY; MOLECULAR-MECHANISMS; NERVOUS-SYSTEM; HEART-FAILURE; MESSENGER-RNA; CELL-ADHESION; CYTOKINESIS; EXPRESSION; ISOFORMS	The purpose of these studies was to learn whether one isoform of nonmuscle myosin II, specifically nonmuscle myosin II-A, could functionally replace a second one, nonmuscle myosin II-B, in mice. To accomplish this, we used homologous recombination to ablate nonmuscle myosin heavy chain (NMHC) II-B by inserting cDNA encoding green fluorescent protein (GFP)NMHC II-A into the first coding exon of the Myh10 gene, thereby placing GFP-NMHC II-A under control of the endogenous II-B promoter. Similar to B-/B- mice, most B-a*/B-a* mice died late in embryonic development with structural cardiac defects and impaired cytokinesis of the cardiac myocytes. However, unlike B-/B- mice, 15 B-a*/B-a* mice of 172 F2 generation mice survived embryonic lethality but developed a dilated cardiomyopathy as adults. Surprisingly none of the B-a*/B-a* mice showed evidence for hydrocephalus that is always found in B-/B- mice. Rescue of this defect was due to proper localization and function of GFP-NMHC II-A in place of NMHC II-B in a cell-cell adhesion complex in the cells lining the spinal canal. Restoration of the integrity and adhesion of these cells prevents protrusion of the underlying cells into the spinal canal where they block circulation of the cerebral spinal fluid. However, abnormal migration of facial and pontine neurons found in NMHC II-B mutant and ablated mice persisted in B-a*/B-a* mice. Thus, although NMHC II-A can substitute for NMHC II-B to maintain integrity of the spinal canal, NMHC II-B plays an isoform-specific role during cytokinesis in cardiac myocytes and in migration of the facial and pontine neurons.	NIH, Mol Cardiol Lab, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Adelstein, RS (corresponding author), NIH, Mol Cardiol Lab, Bldg 10,Rm 8N202,10 Ctr Dr MSC 1762, Bethesda, MD 20892 USA.	adelster@nhlbi.nih.gov		Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004216, ZIAHL004216] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bao JJ, 2005, J BIOL CHEM, V280, P19594, DOI 10.1074/jbc.M501573200; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; CONRAD AH, 1995, CELL MOTIL CYTOSKEL, V31, P93, DOI 10.1002/cm.970310203; Conti MA, 2004, J BIOL CHEM, V279, P41263, DOI 10.1074/jbc.C400352200; Even-Ram S, 2007, NAT CELL BIOL, V9, P299, DOI 10.1038/ncb1540; Fatkin D, 2002, PHYSIOL REV, V82, P945, DOI 10.1152/physrev.00012.2002; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; Kim KY, 2005, J BIOL CHEM, V280, P22769, DOI 10.1074/jbc.M503488200; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Ma XF, 2004, MOL BIOL CELL, V15, P2568, DOI 10.1091/mbc.E03-11-0836; Ma XF, 2007, MOL BIOL CELL, V18, P2305, DOI 10.1091/mbc.E07-01-0073; Matsumura F, 2005, TRENDS CELL BIOL, V15, P371, DOI 10.1016/j.tcb.2005.05.004; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; Robinson DN, 2004, CURR OPIN CELL BIOL, V16, P182, DOI 10.1016/j.ceb.2004.02.002; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Sellers J. R., 1999, MYOSINS; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; Simerly C, 1998, MOL BIOL CELL, V9, P2509, DOI 10.1091/mbc.9.9.2509; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Takeda K, 2000, CELL MOTIL CYTOSKEL, V46, P59, DOI 10.1002/(SICI)1097-0169(200005)46:1<59::AID-CM6>3.0.CO;2-Q; Takeda K, 2003, CIRC RES, V93, P330, DOI 10.1161/01.RES.0000089256.00309.CB; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; Uren D, 2000, J CLIN INVEST, V105, P663, DOI 10.1172/JCI8199; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617	42	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22102	22111		10.1074/jbc.M702731200	http://dx.doi.org/10.1074/jbc.M702731200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17519229	hybrid			2022-12-25	WOS:000248196800057
J	Geething, NC; Spudich, JA				Geething, Nathan C.; Spudich, James A.			Identification of a minimal myosin Va binding site within an intrinsically unstructured domain of melanophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-GENETIC DISSECTION; NATIVELY UNFOLDED PROTEINS; MELANOSOME DISTRIBUTION; UNCONVENTIONAL MYOSIN; REGION MUTATIONS; DISORDER; RECEPTOR; SLAC2-A/MELANOPHILIN; MELANOCYTES; TRANSPORT	Myosin V is a molecular motor that transports a variety of cellular cargo, including organelles, vesicles, and messenger RNA. The proper peripheral distribution of melanosomes, a dense pigment-containing organelle, is dependent on actin and the activity of myosin Va. The recruitment of myosin Va to the melanosome and proper transport of the melanosome requires melanophilin, which directly binds to myosin Va and is tethered to the melanosome membrane via Rab27a. Here we use highly purified proteins to demonstrate that the globular tail domain of myosin Va binds directly to an intrinsically unstructured domain of melanophilin. The myosin Va binding domain of melanophilin lacks stable secondary structure, and H-1 NMR measurements indicate that the protein is unfolded. This domain is extremely sensitive to mild proteolysis and has a hydrodynamic radius that is consistent with a random coil-like polypeptide. We show that myosin Va binding does not induce the global folding of melanophilin. Truncations of melanophilin were utilized to define a short peptide sequence (26 residues) within melanophilin that is critical for myosin Va binding. We demonstrate that a peptide corresponding to these residues binds directly to the globular tail domain with the same affinity as melanophilin. Wediscuss the possible implications of protein intrinsic disorder in recruitment and maintenance of myosin Va on melanosome membranes.	Stanford Univ, Dept Biochem, Stanford, CA 94041 USA	Stanford University	Spudich, JA (corresponding author), Stanford Univ, Dept Biochem, Stanford, CA 94041 USA.	jspudich@stanford.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033289] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01 AR42895] Funding Source: Medline; NIGMS NIH HHS [R01 GM033289] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin RL, 2000, P NATL ACAD SCI USA, V97, P12391, DOI 10.1073/pnas.97.23.12391; Benison G, 2006, J MOL BIOL, V362, P1082, DOI 10.1016/j.jmb.2006.08.006; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Cheng YG, 2006, BIOCHEMISTRY-US, V45, P10448, DOI 10.1021/bi060981d; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Dosztanyi Z, 2006, J PROTEOME RES, V5, P2985, DOI 10.1021/pr060171o; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Fukuda M, 2004, J BIOL CHEM, V279, P22314, DOI 10.1074/jbc.401791200; Fukuda M, 2004, J CELL SCI, V117, P583, DOI 10.1242/jcs.00891; Gill AC, 2000, EMBO J, V19, P5324, DOI 10.1093/emboj/19.20.5324; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; Huang JD, 1998, GENETICS, V148, P1951; Huang JD, 1998, GENETICS, V148, P1963; Hume AN, 2006, MOL BIOL CELL, V17, P4720, DOI 10.1091/mbc.E06-05-0457; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Lacy ER, 2004, NAT STRUCT MOL BIOL, V11, P358, DOI 10.1038/nsmb746; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Li XD, 2005, J BIOL CHEM, V280, P17815, DOI 10.1074/jbc.M413295200; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Mohan A, 2006, J MOL BIOL, V362, P1043, DOI 10.1016/j.jmb.2006.07.087; Oldfield CJ, 2005, BIOCHEMISTRY-US, V44, P12454, DOI 10.1021/bi050736e; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; Shi ZS, 2006, CHEM REV, V106, P1877, DOI 10.1021/cr040433a; Sivakolundu SG, 2005, J MOL BIOL, V353, P1118, DOI 10.1016/j.jmb.2005.08.074; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Syme CD, 2002, EUR J BIOCHEM, V269, P148, DOI 10.1046/j.0014-2956.2001.02633.x; TANFORD C, 1966, J BIOL CHEM, V241, P1921; Tang FS, 2003, NATURE, V422, P87, DOI 10.1038/nature01453; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Wei Q, 1997, J MUSCLE RES CELL M, V18, P517, DOI 10.1023/A:1018659117569; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Wu XS, 2005, J CELL BIOL, V171, P201, DOI 10.1083/jcb.200503028	46	28	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21518	21528		10.1074/jbc.M701932200	http://dx.doi.org/10.1074/jbc.M701932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17513864	hybrid			2022-12-25	WOS:000248047500079
J	Dang, W; Kagalwala, MN; Bartholomew, B				Dang, Weiwei; Kagalwala, Mohamedi N.; Bartholomew, Blaine			The Dpb4 subunit of ISW2 is anchored to extranucleosomal DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEX; YEAST SWI/SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; HISTONE OCTAMER; POLYMERASE-EPSILON; IN-VIVO; NUCLEOSOME; BINDING; TRANSCRIPTION; DISRUPTION	Histone fold proteins Dpb4 and Dls1 are components of the yeast ISW2 chromatin remodeling complex that resemble the smaller subunits of the CHRAC (Chromatin Accessibility Complex) complex found in Drosophila and humans. DNA photoaffinity labeling found that the Dpb4 subunit contacts extranucleosomal DNA 37-53 bp away from the entry/exit site of the nucleosome. Binding of Dpb4 to Isw2 and Itc2, the two largest subunits of ISW2, was found to require Dls1. Even after remodeling and nucleosome movement, Dpb4 tends to remain bound to its original binding site and likely serves as an anchor point for ISW2 on DNA. In vitro, only minor differences can be detected in the nucleosome binding and mobilization properties of ISW2 with or without Dpb4 and Dls1. Changes in the contacts of the largest subunit Itc1 with extranucleosomal DNA have, however, been found upon deletion of the Dpb4 and Dls1 dimer that may affect the nucleosome spacing properties of ISW2.	So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA; So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University; University of Texas System; UTMD Anderson Cancer Center; Southern Illinois University System; Southern Illinois University	Bartholomew, B (corresponding author), Univ Penn, Wistar Inst, Inst Human Gene Therapy, 3601 Spruce St,Rm 204, Philadelphia, PA 19104 USA.	bbartholomew@siumed.edu		Dang, Weiwei/0000-0002-6931-4636				Asturias FJ, 2006, NAT STRUCT MOL BIOL, V13, P35, DOI 10.1038/nsmb1040; Brachmann CB, 1998, YEAST, V14, P115; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001; Clapier CR, 2002, NUCLEIC ACIDS RES, V30, P649, DOI 10.1093/nar/30.3.649; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Dang WW, 2006, MOL CELL BIOL, V26, P7388, DOI 10.1128/MCB.01159-06; Fazzio TG, 2005, MOL CELL BIOL, V25, P9165, DOI 10.1128/MCB.25.21.9165-9174.2005; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Guschin D, 2000, J BIOL CHEM, V275, P35248, DOI 10.1074/jbc.M006041200; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; Hartlepp KF, 2005, MOL CELL BIOL, V25, P9886, DOI 10.1128/MCB.25.22.9886-9896.2005; Iida T, 2004, MOL CELL BIOL, V24, P217, DOI 10.1128/MCB.24.1.217-227.2004; Kagalwala MN, 2004, EMBO J, V23, P2092, DOI 10.1038/sj.emboj.7600220; Kassabov SR, 2002, MOL CELL BIOL, V22, P7524, DOI 10.1128/MCB.22.21.7524-7534.2002; Kukimoto I, 2004, MOL CELL, V13, P265, DOI 10.1016/S1097-2765(03)00523-9; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; McConnell AD, 2004, MOL CELL BIOL, V24, P2605, DOI 10.1128/MCB.24.7.2605-2613.2004; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ohya T, 2000, NUCLEIC ACIDS RES, V28, P3846, DOI 10.1093/nar/28.20.3846; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Sengupta SM, 1999, METHODS, V19, P434, DOI 10.1006/meth.1999.0880; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Zofall M, 2006, NAT STRUCT MOL BIOL, V13, P339, DOI 10.1038/nsmb1071	35	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19418	19425		10.1074/jbc.M700640200	http://dx.doi.org/10.1074/jbc.M700640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17491017	hybrid			2022-12-25	WOS:000247650600016
J	Hyde, R; Cwiklinski, EL; MacAulay, K; Taylor, PM; Hundal, HS				Hyde, Russell; Cwiklinski, Emma L.; MacAulay, Katrina; Taylor, Peter M.; Hundal, Harinder S.			Distinct sensor pathways in the hierarchical control of SNAT2, a putative amino acid transceptor, by amino acid availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM-A; TRANSPORT SYSTEM; ADAPTIVE REGULATION; GENE-EXPRESSION; PLASMA-MEMBRANE; MECHANISM; ACTIVATION; PERMEASE; CELLS; ATA2	Mammalian nutrient sensors are novel targets for therapeutic intervention in disease states such as insulin resistance and muscle wasting; however, the proteins responsible for this important task are largely uncharacterized. Toaddress this issue we have dissected an amino acid (AA) sensor/effector regulon that controls the expression of the System A amino acid transporter-SNAT2-in mammalian cells, a paradigm nutrient-responsive process, and found evidence for the convergence of at least two sensor/effector pathways. During AA withdrawal, JNK is activated and induces the expression of SNAT2 in L6 myotubes by stimulating an intronic nutrient-sensitive domain. A sensor for large neutral AA (e.g. Tyr, Gln) inhibits JNK activation and SNAT2 up-regulation. Additionally, shRNA and transporter chimeras demonstrate that SNAT2 provides a repressive signal for gene transcription during AA sufficiency, thus echoing AA sensing by transceptor (transporter-receptor) orthologues in yeast (Gap1/Ssy1) and Drosophila (PATH). Furthermore, the SNAT2 protein is stabilized during AA withdrawal.	Univ Dundee, Coll Life Sci, Sir James Black Ctr, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Dundee	Hundal, HS (corresponding author), Univ Dundee, Coll Life Sci, Sir James Black Ctr, Div Mol Physiol, Dundee DD1 5EH, Scotland.	h.s.hundal@dundee.ac.uk	Taylor, Peter M/A-4667-2010; Hundal, Hari/A-8990-2008	Hundal, Hari/0000-0002-7621-4932	Biotechnology and Biological Sciences Research Council [C19477] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Asola MR, 2002, EUR J NUCL MED MOL I, V29, P1485, DOI 10.1007/s00259-002-0921-3; Bain PJ, 2002, J NUTR, V132, P3023, DOI 10.1093/jn/131.10.3023; Baird FE, 2006, BIOCHEM J, V397, P369, DOI 10.1042/BJ20060026; Bevington A, 2002, EUR J CLIN INVEST, V32, P590, DOI 10.1046/j.1365-2362.2002.01038.x; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; BRACY DS, 1986, J BIOL CHEM, V261, P1514; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Donaton MCV, 2003, MOL MICROBIOL, V50, P911, DOI 10.1046/j.1365-2958.2003.03732.x; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Franchi-Gazzola R, 1999, J BIOL CHEM, V274, P28922, DOI 10.1074/jbc.274.41.28922; Gaccioli F, 2006, J BIOL CHEM, V281, P17929, DOI 10.1074/jbc.M600341200; GAZZOLA GC, 1981, J BIOL CHEM, V256, P3191; Gazzola RF, 2001, FEBS LETT, V490, P11; Goberdhan DCI, 2005, DEVELOPMENT, V132, P2365, DOI 10.1242/dev.01821; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hatanaka T, 2006, J BIOL CHEM, V281, P35922, DOI 10.1074/jbc.M606577200; HEATON JH, 1977, J BIOL CHEM, V252, P2900; Holsbeeks I, 2004, TRENDS BIOCHEM SCI, V29, P556, DOI 10.1016/j.tibs.2004.08.010; HUNDAL HS, 1989, J PHYSIOL-LONDON, V408, P93, DOI 10.1113/jphysiol.1989.sp017449; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; Hyde R, 2002, J BIOL CHEM, V277, P13628, DOI 10.1074/jbc.M108609200; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; Iraqui I, 1999, MOL CELL BIOL, V19, P989; Jousse C, 2004, BIOCHEM BIOPH RES CO, V313, P447, DOI 10.1016/j.bbrc.2003.07.020; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; Ling R, 2001, BBA-BIOMEMBRANES, V1512, P15, DOI 10.1016/S0005-2736(01)00310-8; Lopez AB, 2007, BIOCHEM J, V402, P163, DOI 10.1042/BJ20060941; Lopez-Fontanals M, 2003, J GEN PHYSIOL, V122, P5, DOI 10.1085/jgp.200308800; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; MOFFETT J, 1984, MOL CELL BIOL, V4, P799, DOI 10.1128/MCB.4.4.799; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; Nakanishi T, 2001, AM J PHYSIOL-CELL PH, V281, pC1757, DOI 10.1152/ajpcell.2001.281.6.C1757; Palii SS, 2006, BIOCHEM J, V395, P517, DOI 10.1042/BJ20051867; Palii SS, 2004, J BIOL CHEM, V279, P3463, DOI 10.1074/jbc.M310483200; Pan YX, 2007, BIOCHEM J, V401, P299, DOI 10.1042/BJ20061261; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; Rubio-Texeira M, 2006, MOL BIOL CELL, V17, P3031, DOI 10.1091/mbc.E05-07-0669; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; Verrey F, 2003, PFLUG ARCH EUR J PHY, V445, P529, DOI 10.1007/S00424-002-0973-Z; Wu BQ, 2006, J CELL BIOL, V173, P327, DOI 10.1083/jcb.200602089; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200; Zorzano A, 2000, BIOCHEM J, V349, P667, DOI 10.1042/bj3490667	44	91	96	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19788	19798		10.1074/jbc.M611520200	http://dx.doi.org/10.1074/jbc.M611520200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17488712	hybrid			2022-12-25	WOS:000247650600054
J	Su, JL; Yang, CY; Zhao, M; Kuo, ML; Yen, ML				Su, Jen-Liang; Yang, Ching-Yao; Zhao, Ming; Kuo, Min-Liang; Yen, Men-Luh			Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; BREAST-CANCER CELLS; ESTROGEN-RECEPTOR; TRANSCRIPTION FACTOR; IN-VITRO; INHIBITION; PATHWAY; GROWTH; EXPRESSION; APOPTOSIS	Osteoporosis is a major public health problem and the most obvious preventive strategy, hormone replacement therapy, has lost favor due to recent findings of the Women's Health Initiative regarding increased risks of breast cancer and cardiovascular disease. Resveratrol, a naturally occurring compound possessing estrogenic activity, is thought to have considerable potential for therapy of osteoporosis. In the present study, resveratrol was found to exhibit bone-protective effects equivalent to those exerted by ;hormone replacement therapy and decrease the risk of breast cancer in the in vivo and in vitro models. Forkhead proteins were found to be essential for both effects of resveratrol. The bone-protective effect was attributable to induction of bone morphogenetic protein-2 through Src kinase-dependent estrogen receptor activation and FOXA1 is required for resveratrol-induced estrogen receptor-dependent bone morphogenetic protein-2 expression. The tumor suppressive effects of resveratrol were the consequence of Akt inactivation mediated FOXO3a nuclear accumulation and activation. Resveratrol is therefore anticipated to be highly effective in management of postmenopausal osteoporosis without an increased risk of breast cancer.	China Med Univ, Coll Med, Grad Inst Canc Biol, Taichung 404, Taiwan; China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan; Asia Univ, Dept Biotechnol & Bioinformat, Taichung 41354, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Traumatol, Taipei 100, Taiwan; Vanderbilt Univ, Vanderbilt Ctr Bone Biol, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Coll Med, Dept Primary Care Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Vanderbilt University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Yen, ML (corresponding author), Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Primary Hlth Care Med, No 7,Chung Shan S Rd, Taipei, Taiwan.	ntu88447004.tw@yahoo.com.tw	Kuo, Min-Liang/C-4872-2009	YEN, MEN-LUH/0000-0003-3800-3664; YANG, CHING-YAO/0000-0001-6312-3719; KUO, MIN-LIANG/0000-0002-7139-0144				Abrams KL, 2004, J BIOL CHEM, V279, P15916, DOI 10.1074/jbc.M313531200; Anderson HC, 2000, J HISTOCHEM CYTOCHEM, V48, P1493, DOI 10.1177/002215540004801106; Andreou V, 2004, J PERIODONTOL, V75, P939, DOI 10.1902/jop.2004.75.7.939; Aziz MH, 2006, MOL CANCER THER, V5, P1335, DOI 10.1158/1535-7163.MCT-05-0526; Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008-5472.CAN-05-0651; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Couzin J, 2003, SCIENCE, V302, P1136, DOI 10.1126/science.302.5648.1136; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; de la Lastra CA, 2005, MOL NUTR FOOD RES, V49, P405; Delmas D, 2005, MOL NUTR FOOD RES, V49, P377, DOI 10.1002/mnfr.200400098; Delmas D, 2006, CURR DRUG TARGETS, V7, P423, DOI 10.2174/138945006776359331; Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140-6736(02)08827-X; Denu JM, 2005, CURR OPIN CHEM BIOL, V9, P431, DOI 10.1016/j.cbpa.2005.08.010; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Fleet JC, 1996, ENDOCRINOLOGY, V137, P4605, DOI 10.1210/en.137.11.4605; Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kumar R, 2005, CANCER RES, V65, P2511, DOI 10.1158/0008-5472.CAN-05-0189; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lehmann OJ, 2003, TRENDS GENET, V19, P339, DOI 10.1016/S0168-9525(03)00111-2; Li Y, 2006, APPL BIOCHEM BIOTECH, V135, P181, DOI 10.1385/ABAB:135:3:181; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsumoto A, 2001, J PERIODONTAL RES, V36, P175, DOI 10.1034/j.1600-0765.2001.360306.x; Mizutani K, 2000, J NUTR SCI VITAMINOL, V46, P78, DOI 10.3177/jnsv.46.78; Mundy GR, 2006, AM J CLIN NUTR, V83, p427S; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Ray PS, 1999, FREE RADICAL BIO MED, V27, P160, DOI 10.1016/S0891-5849(99)00063-5; Rice R, 2005, DEV DYNAM, V233, P847, DOI 10.1002/dvdy.20430; Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081; Song LH, 2006, TOXICOL IN VITRO, V20, P915, DOI 10.1016/j.tiv.2006.01.016; Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Su JL, 2005, CARCINOGENESIS, V26, P1, DOI 10.1093/carcin/bgh220; Turgeman G, 2002, J CELL BIOCHEM, V86, P461, DOI 10.1002/jcb.10231; Van Der Horst G, 2002, BONE, V31, P661, DOI 10.1016/S8756-3282(02)00903-1; Wietzke JA, 2005, MOL CELL ENDOCRINOL, V230, P59, DOI 10.1016/j.mce.2004.11.001; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yen ML, 2005, MOL PHARMACOL, V68, P1061, DOI 10.1124/mol.104.010082; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012; Zhao M, 2006, MOL CELL BIOL, V26, P6197, DOI 10.1128/MCB.02214-05; Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002-0210	50	86	90	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19385	19398		10.1074/jbc.M702452200	http://dx.doi.org/10.1074/jbc.M702452200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17513867	hybrid			2022-12-25	WOS:000247650600013
J	Cabello-Verrugio, C; Brandan, E				Cabello-Verrugio, Claudio; Brandan, Enrique			A novel modulatory mechanism of transforming growth factor-ss signaling through decorin and LRP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; RECEPTOR-RELATED PROTEIN; HUMAN MESANGIAL CELLS; TGF-BETA SIGNALS; PROTEOGLYCAN DECORIN; TYROSINE PHOSPHORYLATION; MYOBLAST DIFFERENTIATION; EPITHELIAL-CELLS; EXPRESSION; INHIBITION	Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that signals to the nucleus through cell surface transmembrane receptors with serine/threonine kinase activity and cytoplasmic effectors, including Smad proteins. Here we describe two novel modulators of this pathway, lipoprotein-receptor related protein (LRP-1) and decorin. Decorin null (Dcn null) myoblasts showed a diminished TGF-beta response that is restored by decorin re-expression. Importantly, this reactivation occurs without changes in the binding to TGF-beta receptors, Smad protein phosphorylation, or Smad-4 nuclear translocation. In wild type myoblasts, inhibition of decorin binding to LRP-1 and depletion of LRP-1 inhibited TGF-beta response to levels similar to those observed in Dcn null myoblasts. Re-expression of decorin in Dcn null myoblasts cannot restore TGF-beta response if the Smad pathway or phosphatidylinositol 3-kinase activity is inhibited, suggesting that this LRP-1-decorin modulatory pathway requires activation of the Smad pathway by TGF-beta and involves phosphatidylinositol 3-kinase activity. This work unveils a new regulatory mechanism for TGF-beta signaling by decorin and LRP-1.	Pontificia Univ Catolica Chile, Fac Biol Sci, Ctr Regulat Cellular & Pathol, Millinnium Inst Fundamental & Appl Biol, Santiago, Chile	Pontificia Universidad Catolica de Chile	Brandan, E (corresponding author), Pontificia Univ Catolica Chile, Fac Biol Sci, Ctr Regulat Cellular & Pathol, Millinnium Inst Fundamental & Appl Biol, Santiago, Chile.	ebrandan@bio.puc.cl	Cabello-Verrugio, Claudio/AAD-1454-2020; Brandan, Enrique/A-7063-2017	Cabello-Verrugio, Claudio/0000-0001-7273-2102; Brandan, Enrique/0000-0002-6820-5059				Abdel-Wahab N, 2002, BIOCHEM J, V362, P643, DOI 10.1042/0264-6021:3620643; Bernasconi P, 1999, NEUROMUSCULAR DISORD, V9, P28, DOI 10.1016/S0960-8966(98)00093-5; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BRANDAN E, 1991, EUR J CELL BIOL, V55, P209; Brandan E, 1996, EUR J CELL BIOL, V71, P170; Brandan E, 2006, J BIOL CHEM, V281, P31562, DOI 10.1074/jbc.M602919200; Bu GJ, 2000, TRENDS CARDIOVAS MED, V10, P148, DOI 10.1016/S1050-1738(00)00045-1; Casar JC, 2004, DEV BIOL, V268, P358, DOI 10.1016/j.ydbio.2003.12.025; Costacurta A, 2002, J CLIN LAB ANAL, V16, P178, DOI 10.1002/jcla.10038; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Droguett R, 2006, MATRIX BIOL, V25, P332, DOI 10.1016/j.matbio.2006.04.004; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; Gray PC, 2001, MOL CELL ENDOCRINOL, V180, P47, DOI 10.1016/S0303-7207(01)00515-9; Hausser H, 1998, ARCH BIOCHEM BIOPHYS, V349, P363, DOI 10.1006/abbi.1997.0471; HAUSSER H, 1992, J BIOL CHEM, V267, P11559; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hjelmeland MD, 2004, MOL CANCER THER, V3, P737; Huang SS, 2004, FASEB J, V18, P1719, DOI 10.1096/fj.04-1872fje; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Imamichi Y, 2005, BIOL CHEM, V386, P225, DOI 10.1515/BC.2005.028; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Ishitobi M, 2000, NEUROREPORT, V11, P4033, DOI 10.1097/00001756-200012180-00026; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; Larrain J, 1998, J BIOL CHEM, V273, P32288, DOI 10.1074/jbc.273.48.32288; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lien SC, 2006, CELL SIGNAL, V18, P1270, DOI 10.1016/j.cellsig.2005.10.013; Lopez-Casillas F, 2003, J BIOL CHEM, V278, P382, DOI 10.1074/jbc.M208520200; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsumoto-Ida M, 2006, AM J PHYSIOL-HEART C, V290, pH709, DOI 10.1152/ajpheart.00186.2005; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nili N, 2003, AM J PATHOL, V163, P869, DOI 10.1016/S0002-9440(10)63447-5; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Ohashi N, 2005, FEBS LETT, V579, P2557, DOI 10.1016/j.febslet.2005.03.069; Osses N, 2002, AM J PHYSIOL-CELL PH, V282, pC383, DOI 10.1152/ajpcell.00322.2001; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Riquelme C, 2001, J BIOL CHEM, V276, P3589, DOI 10.1074/jbc.M004602200; Rodriguez-Barbero A, 2006, KIDNEY INT, V70, P901, DOI 10.1038/sj.ki.5001626; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Schonherr E, 2005, J BIOL CHEM, V280, P15767, DOI 10.1074/jbc.M500451200; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; Stander M, 1998, GENE THER, V5, P1187, DOI 10.1038/sj.gt.3300709; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; Tseng WF, 2004, FEBS LETT, V562, P71, DOI 10.1016/S0014-5793(04)00185-1; Tufvesson E, 2002, FEBS LETT, V530, P124, DOI 10.1016/S0014-5793(02)03439-7; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	61	101	103	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18842	18850		10.1074/jbc.M700243200	http://dx.doi.org/10.1074/jbc.M700243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17485468	hybrid			2022-12-25	WOS:000247475300023
J	Sun, SY; Liu, XG; Zou, W; Yue, P; Marcus, AI; Khuri, FR				Sun, Shi-Yong; Liu, Xiangguo; Zou, Wei; Yue, Ping; Marcus, Adam I.; Khuri, Fadlo R.			The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL TRANSFERASE INHIBITOR; ENDOPLASMIC-RETICULUM STRESS; SYNTHETIC RETINOID CD437; RECEPTOR-SELECTIVE RETINOIDS; LUNG-CARCINOMA CELLS; DEATH RECEPTORS; UP-REGULATION; PHASE-I; ANTITUMOR-ACTIVITY; TRANSGENIC MICE	Pre-clinical studies have demonstrated that farnesyltransferase inhibitors (FTIs) induce growth arrest or apoptosis in various human cancer cells independently of Ras mutations. However, the underlying mechanism remains unknown. Death receptor 5 (DR5) is a pro-apoptotic protein involved in mediating the extrinsic apoptotic pathway. Its role in FTI-induced apoptosis has not been reported. In this study, we investigated the modulation of DR5 by the FTI lonafarnib and the involvement of DR5 up-regulation in FTI-induced apoptosis. Lonafarnib activated caspase-8 and its downstream caspases, whereas the caspase-8-specific inhibitor benzyloxycarbonyl-Ile-Glu(methoxy)-Thr-Asp(methoxy)-fluoromethyl ketone or small interfering RNA abrogated lonafarnib-induced apoptosis, indicating that lonafarnib induces caspase-8-dependent apoptosis. Lonafarnib up-regulated DR5 expression, increased cell-surface DR5 distribution, and enhanced tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Overexpression of a dominant-negative Fas-associated death domain mutant or silencing of DR5 expression using small interfering RNA attenuated lonafarnib-induced apoptosis. These results indicate a critical role of the DR5-mediated extrinsic apoptotic pathway in lonafarnib-induced apoptosis. By analyzing the DR5 promoter, we found that lonafarnib induced a CCAAT/enhancer-binding protein homologous protein (CHOP)-dependent transactivation of the DR5 promoter. Lonafarnib increased CHOP expression, whereas silencing of CHOP expression abrogated lonafarnib-induced DR5 expression. These results thus indicate that lonafarnib induces CHOP-dependent DR5 up-regulation. We conclude that CHOP-dependent DR5 up-regulation contributes to lonafarnib-induced apoptosis.	Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Sun, SY (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, 1365-C Clifton Rd,C3088, Atlanta, GA 30322 USA.	shi-yong.sun@emoryhealthcare.org	Liu, Xiangguo/G-1091-2010; Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Liu, Xiangguo/0000-0002-1879-3817				Abdelrahim M, 2006, CARCINOGENESIS, V27, P717, DOI 10.1093/carcin/bgi270; Adjei AA, 2000, CANCER RES, V60, P1871; Adjei AA, 2001, CLIN CANCER RES, V7, P1438; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Awada A, 2002, EUR J CANCER, V38, P2272, DOI 10.1016/S0959-8049(02)00379-9; Beaupre DM, 2004, MOL CANCER THER, V3, P179; Beaupre DM, 2003, LEUKEMIA LYMPHOMA, V44, P2123, DOI 10.1080/1042819031000116652; Bohnke A, 2004, INT J RADIAT BIOL, V80, P53, DOI 10.1080/09553000310001642902; Brunner TB, 2003, CANCER RES, V63, P5656; CHINNAIYAN AM, 1995, CELL, V81, P512; Chun KH, 2003, CANCER RES, V63, P4796; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Du W, 1999, CANCER RES, V59, P4208; Edamatsu H, 2000, ONCOGENE, V19, P3059, DOI 10.1038/sj.onc.1203625; Feldkamp MM, 2001, CANCER RES, V61, P4425; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hoover RR, 2002, BLOOD, V100, P1068, DOI 10.1182/blood.V100.3.1068; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Khuri FR, 2004, CLIN CANCER RES, V10, P2968, DOI 10.1158/1078-0432.CCR-03-0412; Kim ES, 2005, CANCER, V104, P561, DOI 10.1002/cncr.21188; Lackner MR, 2005, CANCER CELL, V7, P325, DOI 10.1016/j.ccr.2005.03.024; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Liu M, 1998, CANCER RES, V58, P4947; Liu XG, 2004, JNCI-J NATL CANCER I, V96, P1769, DOI 10.1093/jnci/djh322; Marcus AI, 2006, CANCER RES, V66, P8838, DOI 10.1158/0008-5472.CAN-06-0699; Marzo I, 2004, LEUKEMIA, V18, P1599, DOI 10.1038/sj.leu.2403469; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nakajima A, 2003, MOL CANCER THER, V2, P219; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; Reichert A, 2001, BLOOD, V97, P1399, DOI 10.1182/blood.V97.5.1399; Sebti SM, 2005, CANCER CELL, V7, P297, DOI 10.1016/j.ccr.2005.04.005; Sharma S, 2002, ANN ONCOL, V13, P1067, DOI 10.1093/annonc/mdf173; Sheikh MS, 1998, CANCER RES, V58, P1593; Shi B, 2000, CANCER CHEMOTH PHARM, V46, P387, DOI 10.1007/s002800000170; Smalley KSM, 2003, INT J CANCER, V105, P165, DOI 10.1002/ijc.11064; Sun SY, 2000, CANCER RES, V60, P6537; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Sun SY, 2004, CANCER BIOL THER, V3, P1092, DOI 10.4161/cbt.3.11.1176; Sun SY, 1997, CANCER RES, V57, P4931; Sun SY, 2000, ONCOGENE, V19, P4513, DOI 10.1038/sj.onc.1203810; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wen LP, 1998, CELL DEATH DIFFER, V5, P729, DOI 10.1038/sj.cdd.4400409; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693; Zou W, 2004, CANCER RES, V64, P7570, DOI 10.1158/0008-5472.CAN-04-1238	51	45	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18800	18809		10.1074/jbc.M611438200	http://dx.doi.org/10.1074/jbc.M611438200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17493934	hybrid			2022-12-25	WOS:000247475300019
J	Przewloka, MR; Zhang, W; Costa, P; Archambault, V; D'Avino, PP; Lilley, KS; Laue, ED; McAinsh, AD; Glover, DM				Przewloka, Marcin R.; Zhang, Wei; Costa, Patricia; Archambault, Vincent; D'Avino, Pier Paolo; Lilley, Kathryn S.; Laue, Ernest D.; McAinsh, Andrew D.; Glover, David M.			Molecular Analysis of Core Kinetochore Composition and Assembly in Drosophila melanogaster	PLOS ONE			English	Article							KH-DOMAIN PROTEIN; CENP-A; NDC80 COMPLEX; CENTROMERE FORMATION; OUTER KINETOCHORE; TOPOISOMERASE-II; CELL-CYCLE; HETEROCHROMATIN; CHROMATIN; DNA	Background. Kinetochores are large multiprotein complexes indispensable for proper chromosome segregation. Although Drosophila is a classical model organism for studies of chromosome segregation, little is known about the organization of its kinetochores. Methodology/Principal Findings. We employed bioinformatics, proteomics and cell biology methods to identify and analyze the interaction network of Drosophila kinetochore proteins. We have shown that three Drosophila proteins highly diverged from human and yeast Ndc80, Nuf2 and Mis12 are indeed their orthologues. Affinity purification of these proteins from cultured Drosophila cells identified a further five interacting proteins with weak similarity to subunits of the SPC105/KNL-1, MIND/MIS12 and NDC80 kinetochore complexes together with known kinetochore associated proteins such as dynein/dynactin, spindle assembly checkpoint components and heterochromatin proteins. All eight kinetochore complex proteins were present at the kinetochore during mitosis and MIND/MIS12 complex proteins were also centromeric during interphase. Their down-regulation led to dramatic defects in chromosome congression/segregation frequently accompanied by mitotic spindle elongation. The systematic depletion of each individual protein allowed us to establish dependency relationships for their recruitment onto the kinetochore. This revealed the sequential recruitment of individual members of first, the MIND/MIS12 and then, NDC80 complex. Conclusions/Significance. The Drosophila MIND/MIS12 and NDC80 complexes and the Spc105 protein, like their counterparts from other eukaryotic species, are essential for chromosome congression and segregation, but are highly diverged in sequence. Hierarchical dependence relationships of individual proteins regulate the assembly of Drosophila kinetochore complexes in a manner similar, but not identical, to other organisms.	[Przewloka, Marcin R.; Costa, Patricia; Archambault, Vincent; D'Avino, Pier Paolo; Glover, David M.] Univ Cambridge, Dept Genet, Cell Cycle Genet Res Grp, Canc Res UK, Cambridge CB2 3EH, England; [Zhang, Wei; Lilley, Kathryn S.; Laue, Ernest D.] Univ Cambridge, Dept Biochem, Cambridge CB2 3EH, England; [Lilley, Kathryn S.] Univ Cambridge, Cambridge Ctr Prote, Cambridge CB2 3EH, England; [McAinsh, Andrew D.] Marie Curie Res Inst, Chromosome Segregat Lab, Oxted, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; University of Cambridge	Przewloka, MR (corresponding author), Univ Cambridge, Dept Genet, Cell Cycle Genet Res Grp, Canc Res UK, Downing St, Cambridge CB2 3EH, England.	mrp50@cam.ac.uk; dmg25@cam.ac.uk	McAinsh, Andrew/C-6438-2012; D'Avino, Pier Paolo/AAU-4577-2020; Lilley, Kathryn/ABF-5787-2020; Przewloka, Marcin R./AAA-5137-2020	Lilley, Kathryn/0000-0003-0594-6543; Przewloka, Marcin R./0000-0002-0329-9162; Laue, Ernest/0000-0002-7476-4148; D'Avino, Pier Paolo/0000-0002-4773-6950; McAinsh, Andrew/0000-0001-6808-0711; Glover, David/0000-0003-0956-0103	BBSRC [BB/C508926/1, BB/E011586/1]; EC [HPRN-CT-2006-00260]; Human Frontier Science Program; Cancer Research UK; Marie Curie Cancer Care; MRC [G0501718] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C508926/1, BB/E011586/1] Funding Source: researchfish; Medical Research Council [G0501718] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EC(European CommissionEuropean Commission Joint Research Centre); Human Frontier Science Program(Human Frontier Science Program); Cancer Research UK(Cancer Research UK); Marie Curie Cancer Care; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The work presented here was supported by BBSRC grants BB/C508926/1 and BB/E011586/1. P. C. was supported by funding from the EC FW5 Network "Molecular analysis of Drosophila cell division'' (HPRN-CT-2006-00260). V. A. holds a long-term fellowship from the Human Frontier Science Program. Programme grant support from Cancer Research UK to D. M. G. also helped support this work. A. D. M was supported by Marie Curie Cancer Care.	Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Blower MD, 2001, NAT CELL BIOL, V3, P730, DOI 10.1038/35087045; Carroll CW, 2006, TRENDS CELL BIOL, V16, P70, DOI 10.1016/j.tcb.2005.12.008; Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104; Chen F, 2007, CURR BIOL, V17, P293, DOI 10.1016/j.cub.2007.01.068; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Cortes A, 2000, MOL CELL BIOL, V20, P3860, DOI 10.1128/MCB.20.11.3860-3869.2000; Dawe RK, 2006, TRENDS BIOCHEM SCI, V31, P662, DOI 10.1016/j.tibs.2006.10.004; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Foltz DR, 2006, NAT CELL BIOL, V8, P458, DOI 10.1038/ncb1397; Fujita Y, 2007, DEV CELL, V12, P17, DOI 10.1016/j.devcel.2006.11.002; Furuyama T, 2006, P NATL ACAD SCI USA, V103, P6172, DOI 10.1073/pnas.0601686103; Glover DM, 2005, ONCOGENE, V24, P230, DOI 10.1038/sj.onc.1208279; Goshima G, 1999, GENE DEV, V13, P1664, DOI 10.1101/gad.13.13.1664; Goshima G, 2003, J CELL BIOL, V160, P25, DOI 10.1083/jcb.200210005; Heeger S, 2005, GENE DEV, V19, P2041, DOI 10.1101/gad.347805; Heit R, 2006, BIOCHEM CELL BIOL, V84, P605, DOI 10.1139/O06-080; Huertas D, 2004, CURR BIOL, V14, P1611, DOI 10.1016/j.cub.2004.09.024; Karess R, 2005, TRENDS CELL BIOL, V15, P386, DOI 10.1016/j.tcb.2005.05.003; King JM, 2000, J CELL BIOL, V151, P739, DOI 10.1083/jcb.151.4.739; Kline SL, 2006, J CELL BIOL, V173, P9, DOI 10.1083/jcb.200509158; Liu ST, 2006, J CELL BIOL, V175, P41, DOI 10.1083/jcb.200606020; Liu XK, 2005, EMBO J, V24, P2919, DOI 10.1038/sj.emboj.7600762; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maiato H, 2004, J CELL SCI, V117, P5461, DOI 10.1242/jcs.01536; Maiato H, 2006, CHROMOSOMA, V115, P469, DOI 10.1007/s00412-006-0076-2; May KM, 2006, J CELL SCI, V119, P4139, DOI 10.1242/jcs.03165; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; McAinsh AD, 2006, EMBO J, V25, P4033, DOI 10.1038/sj.emboj.7601293; McCleland ML, 2004, CURR BIOL, V14, P131, DOI 10.1016/j.cub.2003.12.058; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; Meraldi P, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-r23; Morris CA, 2007, CELL, V128, P647, DOI 10.1016/j.cell.2007.02.002; Morrison EE, 2007, CELL MOL LIFE SCI, V64, P307, DOI 10.1007/s00018-007-6360-3; Obuse C, 2004, GENES CELLS, V9, P105, DOI 10.1111/j.1365-2443.2004.00705.x; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Okada M, 2006, NAT CELL BIOL, V8, P446, DOI 10.1038/ncb1396; Pidoux AL, 2005, PHILOS T R SOC B, V360, P569, DOI 10.1098/rstb.2004.1611; Porter ACG, 2004, CHROMOSOME RES, V12, P569, DOI 10.1023/B:CHRO.0000036608.91085.d1; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Salina D, 2003, J CELL BIOL, V162, P991, DOI 10.1083/jcb.200304080; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Tai CY, 2002, J CELL BIOL, V156, P959, DOI 10.1083/jcb.200109046; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tirnauer JS, 2002, MOL BIOL CELL, V13, P4308, DOI 10.1091/mbc.e02-04-0236; Vos LJ, 2006, BIOCHEM CELL BIOL, V84, P619, DOI 10.1139/O06-078; Wei RR, 2005, P NATL ACAD SCI USA, V102, P5363, DOI 10.1073/pnas.0501168102; Worby C A, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.95.pl1; Yucel JK, 2000, J CELL BIOL, V150, P1, DOI 10.1083/jcb.150.1.1	55	105	107	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e478	10.1371/journal.pone.0000478	http://dx.doi.org/10.1371/journal.pone.0000478			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534428	Green Accepted, Green Published, gold, Green Submitted			2022-12-25	WOS:000207448800008
J	Karagiannis, J; Balasubramanian, MK				Karagiannis, Jim; Balasubramanian, Mohan K.			A Cyclin-Dependent Kinase that Promotes Cytokinesis through Modulating Phosphorylation of the Carboxy Terminal Domain of the RNA Pol II Rpb1p Sub-Unit	PLOS ONE			English	Article								In Schizosaccharomyces pombe, the nuclear-localized kinase, Lsk1p, promotes cytokinesis by positively regulating the Septation Initiation Network (SIN). Although a member of the cyclin-dependent kinase (CDK) family, neither a cyclin partner nor a physiological target has been identified. In this report we identify a cyclin, Lsc1p, that physically interacts and co-localizes with Lsk1p. Furthermore, lsk1 Delta, lsc1 Delta, as well as kinase-dead lsk1-K306R mutants, display highly similar cytokinesis defects. Lsk1p is related to CDKs that phosphorylate the carboxy-terminal domain (CTD) of the largest sub-unit of RNA polymerase II (Rpb1p). Interestingly, we find that Lsk1p and Lsc1p are required for phosphorylation of Ser-2 residues found in the heptad repeats of the CTD. To determine if Rpb1p could be a physiological target, we replaced the native rpb1 gene with a synthetic gene encoding a Rpb1p protein in which Ser-2 was substituted with the non-phosphorylatable amino-acid alanine in all heptads. Cells carrying this allele were similar to lsk1 Delta mutants: They were viable, displayed genetic interactions with the SIN, and were unable to complete cytokinesis upon perturbation of the cell division machinery. We conclude that Ser-2 phosphorylation of the CTD heptads plays a novel physiological role in the regulation of cytokinesis.	[Balasubramanian, Mohan K.] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore; [Karagiannis, Jim; Balasubramanian, Mohan K.] Temasek Life Sci Lab, Lab Cell Div, Singapore, Singapore	National University of Singapore	Karagiannis, J (corresponding author), Univ Western Ontario, Dept Biol, London, ON, Canada.	jkaragia@uwo.ca		Karagiannis, Jim/0000-0002-7901-1815; Balasubramanian, Mohan/0000-0002-1292-8602	Temasek Life Sciences Laboratory; Singapore Millennium Foundation	Temasek Life Sciences Laboratory(National University of Singapore); Singapore Millennium Foundation(Singapore Millennium Foundation)	This work was supported by research funds from Temasek Life Sciences Laboratory. JK is a recipient of a Singapore Millennium Foundation post-doctoral fellowship.	Alfa C, 1993, EXPT FISSION YEAST L; Balasubramanian MK, 1997, METHOD ENZYMOL, V283, P494; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chang YW, 2004, MOL CELL, V15, P107, DOI 10.1016/j.molcel.2004.05.021; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Chu YY, 2006, MOL CELL BIOL, V26, P3029, DOI 10.1128/MCB.26.8.3029-3038.2006; Cueille N, 2001, J CELL SCI, V114, P2649; FANKHAUSER C, 1993, EMBO J, V12, P2697, DOI 10.1002/j.1460-2075.1993.tb05931.x; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Howe KJ, 2002, BBA-GENE STRUCT EXPR, V1577, P308, DOI 10.1016/S0167-4781(02)00460-8; Jeong SJ, 2005, J MICROBIOL, V43, P516; Karagiannis J, 2005, MOL BIOL CELL, V16, P358, DOI 10.1091/mbc.E04-06-0502; Keogh MC, 2003, MOL CELL BIOL, V23, P7005, DOI 10.1128/MCB.23.19.7005-7018.2003; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Krapp A, 2004, CURR BIOL, V14, pR722, DOI 10.1016/j.cub.2004.08.049; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Laribee RN, 2005, CURR BIOL, V15, P1487, DOI 10.1016/j.cub.2005.07.028; Larschan E, 2005, MOL CELL BIOL, V25, P114, DOI 10.1128/MCB.25.1.114-123.2005; Le Goff X, 1999, MOL GEN GENET, V262, P163; Lee KM, 2005, MOL BIOL CELL, V16, P2734, DOI 10.1091/mbc.E04-11-0982; Liu JH, 2000, J CELL SCI, V113, P1223; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; Mishra M, 2005, CURR BIOL, V15, P1376, DOI 10.1016/j.cub.2005.06.070; Mishra M, 2004, J CELL SCI, V117, P3897, DOI 10.1242/jcs.01244; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Ostapenko D, 2003, EUKARYOT CELL, V2, P274, DOI 10.1128/EC.2.2.274-283.2003; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; WEST ML, 1995, GENETICS, V140, P1223; Wood A, 2007, MOL CELL BIOL, V27, P709, DOI 10.1128/MCB.01627-06; Yuryev A, 1996, GENETICS, V143, P661	43	30	32	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e433	10.1371/journal.pone.0000433	http://dx.doi.org/10.1371/journal.pone.0000433			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17502918	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445800015
J	Seidel, B; Thomzig, A; Buschmann, A; Groschup, MH; Peters, R; Beekes, M; Terytze, K				Seidel, Bjoern; Thomzig, Achim; Buschmann, Anne; Groschup, Martin H.; Peters, Rainer; Beekes, Michael; Terytze, Konstantin			Scrapie Agent (Strain 263K) Can Transmit Disease via the Oral Route after Persistence in Soil over Years	PLOS ONE			English	Article							CHRONIC WASTING DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; PATHOLOGICAL PRION PROTEIN; CENTRAL-NERVOUS-SYSTEM; CYCLIC AMPLIFICATION; INFECTIOUS PRIONS; SODIUM-HYDROXIDE; E-CADHERIN; MULE DEER; HAMSTERS	The persistence of infectious biomolecules in soil constitutes a substantial challenge. This holds particularly true with respect to prions, the causative agents of transmissible spongiform encephalopathies (TSEs) such as scrapie, bovine spongiform encephalopathy (BSE), or chronic wasting disease (CWD). Various studies have indicated that prions are able to persist in soil for years without losing their pathogenic activity. Dissemination of prions into the environment can occur from several sources, e. g., infectious placenta or amniotic fluid of sheep. Furthermore, environmental contamination by saliva, excrements or non-sterilized agricultural organic fertilizer is conceivable. Natural transmission of scrapie in the field seems to occur via the alimentary tract in the majority of cases, and scrapie-free sheep flocks can become infected on pastures where outbreaks of scrapie had been observed before. These findings point to a sustained contagion in the environment, and notably the soil. By using outdoor lysimeters, we simulated a contamination of standard soil with hamster-adapted 263K scrapie prions, and analyzed the presence and biological activity of the soil-associated PrPSc and infectivity by Western blotting and hamster bioassay, respectively. Our results showed that 263K scrapie agent can persist in soil at least over 29 months. Strikingly, not only the contaminated soil itself retained high levels of infectivity, as evidenced by oral administration to Syrian hamsters, but also feeding of aqueous soil extracts was able to induce disease in the reporter animals. We could also demonstrate that PrPSc in soil, extracted after 21 months, provides a catalytically active seed in the protein misfolding cyclic amplification (PMCA) reaction. PMCA opens therefore a perspective for considerably improving the detectability of prions in soil samples from the field.	[Seidel, Bjoern; Peters, Rainer] Fraunhofer Inst Mol Biol & Appl Ecol IME, Schmallenberg, Germany; [Thomzig, Achim; Beekes, Michael] Robert Koch Inst, Transmissible Spongiform Encephalopathies P24, D-1000 Berlin, Germany; [Terytze, Konstantin] UBA, German Fed Environm Agcy, Dessau, Germany; [Buschmann, Anne; Groschup, Martin H.] Friedrich Loeffler Inst, Inst Novel & Emerging Infect Dis, Insel Riems, Germany	Fraunhofer Gesellschaft; Robert Koch Institute; Friedrich Loeffler Institute	Seidel, B (corresponding author), Fraunhofer Inst Mol Biol & Appl Ecol IME, Schmallenberg, Germany.	bjoern.seidel@ime.fraunhofer.de	Beekes, Michael/S-1975-2018	Beekes, Michael/0000-0002-6454-6657	German Federal Environmental Agency (UBA); EU [QLK-CT 2001-309]	German Federal Environmental Agency (UBA)(University of Buenos Aires); EU(European Commission)	This research project was funded by the German Federal Environmental Agency (UBA). This work was supported by the EU grant QLK-CT 2001-309 and the EU funded Network of Excellence 'NeuroPrion'.	ALPER T, 1966, BIOCHEM BIOPH RES CO, V22, P278, DOI 10.1016/0006-291X(66)90478-5; Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; Beekes M, 1998, J GEN VIROL, V79, P601, DOI 10.1099/0022-1317-79-3-601; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BRADLEY R, 1993, BRIT MED BULL, V49, P932, DOI 10.1093/oxfordjournals.bmb.a072654; BROWN P, 1991, LANCET, V337, P269, DOI 10.1016/0140-6736(91)90873-N; CINDY M, 2007, SCI TECHNOL, V41, P811; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; FOSTER JD, 1992, VET REC, V130, P341, DOI 10.1136/vr.130.16.341; GIBBONS RA, 1967, NATURE, V215, P1041, DOI 10.1038/2151041a0; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; GREIG J. R., 1940, VET JOUR, V96, P203; Gudmundsdottir KB, 2006, ACTA VET SCAND, V48, DOI 10.1186/1751-0147-48-16; HADLOW WJ, 1982, J INFECT DIS, V146, P657, DOI 10.1093/infdis/146.5.657; HATZINGER PB, 1995, ENVIRON SCI TECHNOL, V29, P537, DOI 10.1021/es00002a033; Hoinville LJ, 1996, REV SCI TECH OIE, V15, P827, DOI 10.20506/rst.15.3.959; Johnson CJ, 2006, PLOS PATHOG, V2, P296, DOI 10.1371/journal.ppat.0020032; Kim TY, 2005, J VET MED SCI, V67, P753, DOI 10.1292/jvms.67.753; Lupi O, 2005, MED HYPOTHESES, V65, P47, DOI 10.1016/j.mehy.2005.01.039; Lupi O, 2003, INT J DERMATOL, V42, P425, DOI 10.1046/j.1365-4362.2003.00345.x; Mathiason CK, 2006, SCIENCE, V314, P133, DOI 10.1126/science.1132661; McBride PA, 2001, J VIROL, V75, P9320, DOI 10.1128/JVI.75.19.9320-9327.2001; McBride PA, 1999, NEUROSCI LETT, V265, P135, DOI 10.1016/S0304-3940(99)00223-2; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Menke A, 2001, CANCER RES, V61, P3508; Miller MW, 1998, J WILDLIFE DIS, V34, P532, DOI 10.7589/0090-3558-34.3.532; Miller MW, 2003, NATURE, V425, P35, DOI 10.1038/425035a; Miller MW, 2004, CURR TOP MICROBIOL, V284, P193; Miller MW, 2004, EMERG INFECT DIS, V10, P1003, DOI 10.3201/eid1006.040010; PALLSON P, 1979, SLOW TRANSMISSIBLE D, V1, P357; Post K, 1999, LANCET, V354, P1969, DOI 10.1016/S0140-6736(99)00469-9; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Purdey M, 2000, MED HYPOTHESES, V54, P278, DOI 10.1054/mehy.1999.0836; Purdey M, 1998, MED HYPOTHESES, V50, P91, DOI 10.1016/S0306-9877(98)90194-3; Rigou P, 2006, ENVIRON SCI TECHNOL, V40, P1497, DOI 10.1021/es0516965; Saa P, 2006, J BIOL CHEM, V281, P35245, DOI 10.1074/jbc.M603964200; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Schreuder BEC, 2003, REV SCI TECH OIE, V22, P103, DOI 10.20506/rst.22.1.1387; Scow KM, 1995, ENVIRON HEALTH PERSP, V103, P93, DOI 10.2307/3432488; Scudamore JM, 2002, REV SCI TECH OIE, V21, P699, DOI 10.20506/rst.21.3.1351; Seidel B, 2004, ONCOGENE, V23, P5532, DOI 10.1038/sj.onc.1207718; Shaked GM, 2001, J BIOL CHEM, V276, P31479, DOI 10.1074/jbc.C100278200; SIGURDSSON BJORN, 1954, BRIT VET JOUR, V110, P341; Sohn HJ, 2002, J VET MED SCI, V64, P855, DOI 10.1292/jvms.64.855; TAYLOR DM, 1991, J HOSP INFECT, V18, P141, DOI 10.1016/0195-6701(91)90016-2; TAYLOR DM, 1993, BRIT MED BULL, V49, P810, DOI 10.1093/oxfordjournals.bmb.a072648; Taylor DM, 1996, J GEN VIROL, V77, P811, DOI 10.1099/0022-1317-77-4-811; Taylor DM, 2000, VET J, V159, P10, DOI 10.1053/tvjl.1999.0406; Taylor DM, 1999, VET MICROBIOL, V67, P13, DOI 10.1016/S0378-1135(99)00026-7; Taylor DM, 1997, VET MICROBIOL, V58, P87, DOI 10.1016/S0378-1135(97)00103-X; Thomzig A, 2004, J CLIN INVEST, V113, P1465, DOI 10.1172/JCI200421083; Thomzig A, 2003, EMBO REP, V4, P530, DOI 10.1038/sj.embor.embor827; Tomzig A, 2004, J BIOL CHEM, V279, P33847, DOI 10.1074/jbc.M403730200; Williams E.S., 1992, Revue Scientifique et Technique Office International des Epizooties, V11, P551; Williams ES, 2005, VET PATHOL, V42, P530, DOI 10.1354/vp.42-5-530; Williams ES, 2002, REV SCI TECH OIE, V21, P305, DOI 10.20506/rst.21.2.1340; Wisniewski HM, 1996, LANCET, V347, P1114, DOI 10.1016/S0140-6736(96)90310-4	58	107	108	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e435	10.1371/journal.pone.0000435	http://dx.doi.org/10.1371/journal.pone.0000435			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17502917	Green Published, gold			2022-12-25	WOS:000207445800017
J	Besson, C; Roetynck, S; Williams, F; Orsi, L; Amiel, C; Lependeven, C; Antoni, G; Hermine, O; Brice, P; Ferme, C; Carde, P; Canioni, D; Briere, J; Raphael, M; Nicolas, JC; Clavel, J; Middleton, D; Vivier, E; Abel, L				Besson, Caroline; Roetynck, Sophie; Williams, Fionnuala; Orsi, Laurent; Amiel, Corinne; Lependeven, Catherine; Antoni, Guillemette; Hermine, Olivier; Brice, Pauline; Ferme, Christophe; Carde, Patrice; Canioni, Danielle; Briere, Josette; Raphael, Martine; Nicolas, Jean-Claude; Clavel, Jacqueline; Middleton, Derek; Vivier, Eric; Abel, Laurent			Association of Killer Cell Immunoglobulin-Like Receptor Genes with Hodgkin's Lymphoma in a Familial Study	PLOS ONE			English	Article								Background. Epstein-Barr virus (EBV) is the major environmental factor associated with Hodgkin's lymphoma (HL), a common lymphoma in young adults. Natural killer (NK) cells are key actors of the innate immune response against viruses. The regulation of NK cell function involves activating and inhibitory Killer cell Immunoglobulin-like receptors (KIRs), which are expressed in variable numbers on NK cells. Various viral and virus-related malignant disorders have been associated with the presence/absence of certain KIR genes in case/control studies. We investigated the role of the KIR cluster in HL in a family-based association study. Methodology. We included 90 families with 90 HL index cases (age 16-35 years) and 255 first-degree relatives (parents and siblings). We developed a procedure for reconstructing full genotypic information (number of gene copies) at each KIR locus from the standard KIR gene content. Out of the 90 collected families, 84 were informative and suitable for further analysis. An association study was then carried out with specific family-based analysis methods on these 84 families. Principal Findings. Five KIR genes in strong linkage disequilibrium were found significantly associated with HL. Refined haplotype analysis showed that the association was supported by a dominant protective effect of KIR3DS1 and/or KIR2DS1, both of which are activating receptors. The odds ratios for developing HL in subjects with at least one copy of KIR3DS1 or KIR2DS1 with respect to subjects with neither of these genes were 0.44[95% confidence interval 0.23-0.85] and 0.42[0.21-0.85], respectively. No significant association was found in a tentative replication case/control study of 68 HL cases (age 1871 years). In the familial study, the protective effect of KIR3DS1/KIR2DS1 tended to be stronger in HL patients with detectable EBV in blood or tumour cells. Conclusions. This work defines a template for family-based association studies based on full genotypic information for the KIR cluster, and provides the first evidence that activating KIRs can have a protective role in HL.	[Besson, Caroline; Antoni, Guillemette; Abel, Laurent] INSERM, U550, Lab Genet Humaine Malad Infect, Paris, France; [Besson, Caroline; Antoni, Guillemette; Abel, Laurent] Univ Paris 05, Fac Med Rene Descartes, Paris, France; [Besson, Caroline; Raphael, Martine] CHU Bicetre, AP HP, Serv Hematol & Immunol Biol, Le Kremlin Bicetre, France; [Besson, Caroline; Raphael, Martine; Clavel, Jacqueline] Univ Paris Sud, Fac Med, F-94275 Le Kremlin Bicetre, France; [Roetynck, Sophie; Vivier, Eric] Univ Mediterranee, Ctr Immunol Marseille Luminy, Marseille, France; [Roetynck, Sophie; Vivier, Eric] INSERM, U631, F-13258 Marseille, France; [Roetynck, Sophie; Vivier, Eric] CNRS, UMR6102, Marseille, France; [Williams, Fionnuala; Middleton, Derek] Belfast City Hosp, No Ireland Reg Histocompatibil & Immunogenet Lab, Belfast BT9 7AD, Antrim, North Ireland; [Orsi, Laurent; Clavel, Jacqueline] Univ Paris 11, INSERM, U754, Villejuif, France; [Amiel, Corinne; Lependeven, Catherine; Nicolas, Jean-Claude] Hop Tenon, Virol Lab, F-75970 Paris, France; [Hermine, Olivier] Hop Necker Enfants Malad, Serv Hematol Adultes, Paris, France; [Brice, Pauline] Hop St Louis, Serv Oncohematol, Paris, France; [Ferme, Christophe; Carde, Patrice] Inst Gustave Roussy, Dept Hematol, Villejuif, France; [Canioni, Danielle] Hop Necker Enfants Malad, Serv Anatomopathol, Paris, France; [Briere, Josette] Hop St Louis, Serv Anatomopathol, Paris, France; [Middleton, Derek] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland; [Vivier, Eric] Hop Conception, Assistance Publ Hop Marseille, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Belfast City Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Ulster University; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Abel, L (corresponding author), INSERM, U550, Lab Genet Humaine Malad Infect, Paris, France.	abel@necker.fr	Vivier, Eric/F-8939-2010; Besson, Caroline/H-4648-2018; AMIEL, Corinne/B-7854-2012; Clavel, Jacqueline/Q-2750-2016; Abel, Laurent/H-8888-2017; Hermine, Olivier/Q-7072-2018; Orsi, Laurent/H-7863-2018	Vivier, Eric/0000-0001-7022-8287; Besson, Caroline/0000-0003-4364-7173; AMIEL, Corinne/0000-0002-1144-4868; Clavel, Jacqueline/0000-0002-3616-7676; Abel, Laurent/0000-0001-7016-6493; Orsi, Laurent/0000-0002-9332-3620; Hermine, Olivier/0000-0003-2574-3874	Association pour la Recherche contre le Cancer; Ligue Nationale contre le cancer; Fondation de France European Union FP6 [LSHB-CT-2004-503319-Allostem]; Agence Nationale de la Recherche (Reseau Innovation Biotechnologiesand Microbiologie Immunologie Maladies Emergentes); INSERM; CNRS; Ministeere de l'Enseignement Superieur et de la Recherche; Fondation Schlumberger; Fondation BNP Paribas; Fondation de France; Northern Ireland Histocompatibility and Immunogenetics Laboratory Research Trust Fund	Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale contre le cancer(Ligue nationale contre le cancer); Fondation de France European Union FP6; Agence Nationale de la Recherche (Reseau Innovation Biotechnologiesand Microbiologie Immunologie Maladies Emergentes)(French National Research Agency (ANR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); Ministeere de l'Enseignement Superieur et de la Recherche; Fondation Schlumberger(Schlumberger); Fondation BNP Paribas; Fondation de France(Fondation de France); Northern Ireland Histocompatibility and Immunogenetics Laboratory Research Trust Fund	This work was supported by Association pour la Recherche contre le Cancer, Ligue Nationale contre le cancer (EV : 'Equipe labellisee La Ligue'), Fondation de France European Union FP6, LSHB-CT-2004-503319-Allostem, Agence Nationale de la Recherche (Reseau Innovation Biotechnologiesand Microbiologie Immunologie Maladies Emergentes), INSERM, CNRS and Ministeere de l'Enseignement Superieur et de la Recherche and by donations from the Fondation Schlumberger and Fondation BNP Paribas. CB was supported by Fondation de France. SR was supported in part by Northern Ireland Histocompatibility and Immunogenetics Laboratory Research Trust Fund. The sponsors and funders did not participate with the design, conduct of the study, analysis, interpretation of the data, preparation, review or approval of the manuscript.	Andre P, 2001, NAT IMMUNOL, V2, P661, DOI 10.1038/90589; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; BASHIROVA AA, 2006, ANN REV GENOMICS HUM; Besson C, 2006, J CLIN MICROBIOL, V44, P47, DOI 10.1128/JCM.44.1.47-50.2006; Callan MFC, 2004, MICROBES INFECT, V6, P937, DOI 10.1016/j.micinf.2004.04.014; Carrington M, 2005, J EXP MED, V201, P1069, DOI 10.1084/jem.20042158; Cartwright RA, 2004, HEMATOL ONCOL, V22, P11, DOI 10.1002/hon.723; Crum KA, 2000, TISSUE ANTIGENS, V56, P313, DOI 10.1034/j.1399-0039.2000.560403.x; Denis L, 2005, TISSUE ANTIGENS, V66, P267, DOI 10.1111/j.1399-0039.2005.00473.x; Desrosiers MP, 2005, NAT GENET, V37, P593, DOI 10.1038/ng1564; Diepstra A, 2005, LANCET, V365, P2216, DOI 10.1016/S0140-6736(05)66780-3; Eidenschenk C, 2006, AM J HUM GENET, V78, P721, DOI 10.1086/503269; Ferraris AM, 1997, ANN HEMATOL, V74, P131, DOI 10.1007/s002770050270; French AR, 2003, CURR OPIN IMMUNOL, V15, P45, DOI 10.1016/S095279150200002X; Gandhi MK, 2004, BRIT J HAEMATOL, V125, P267, DOI 10.1111/j.1365-2141.2004.04902.x; Goldin LR, 2005, J MED GENET, V42, P595, DOI 10.1136/jmg.2004.027433; GRUFFERMAN S, 1977, NEW ENGL J MED, V296, P248, DOI 10.1056/NEJM197702032960504; Halfpenny IA, 2004, HUM IMMUNOL, V65, P602, DOI 10.1016/j.humimm.2004.03.003; Harty LC, 2002, BLOOD, V99, P690, DOI 10.1182/blood.V99.2.690; Hjalgrim H, 2003, NEW ENGL J MED, V349, P1324, DOI 10.1056/NEJMoa023141; Hjalgrim H, 2001, LANCET, V358, P297, DOI 10.1016/S0140-6736(01)05498-8; HORS J, 1983, IMMUNOL REV, V70, P167, DOI 10.1111/j.1600-065X.1983.tb00714.x; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Hsu KC, 2002, J IMMUNOL, V169, P5118, DOI 10.4049/jimmunol.169.9.5118; Hsu KC, 2002, IMMUNOL REV, V190, P40, DOI 10.1034/j.1600-065X.2002.19004.x; Knapp M, 1999, AM J HUM GENET, V64, P861, DOI 10.1086/302285; Kovacic MB, 2005, CANCER EPIDEM BIOMAR, V14, P2673, DOI 10.1158/1055-9965.EPI-05-0229; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; Lee SH, 2001, NAT GENET, V28, P42, DOI 10.1038/ng0501-42; Lodoen MB, 2006, CURR OPIN IMMUNOL, V18, P391, DOI 10.1016/j.coi.2006.05.002; Loh J, 2005, J VIROL, V79, P661, DOI 10.1128/JVI.79.1.661-667.2005; Lopez-Vazquez A, 2005, J INFECT DIS, V192, P162, DOI 10.1086/430351; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; Malik S, 2005, P NATL ACAD SCI USA, V102, P12183, DOI 10.1073/pnas.0503368102; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Maxwell LD, 2004, HUM IMMUNOL, V65, P613, DOI 10.1016/j.humimm.2004.02.028; Maxwell LD, 2002, TISSUE ANTIGENS, V60, P254, DOI 10.1034/j.1399-0039.2002.600307.x; MENDEZ AGH, 2006, TISSUE ANTI IN PRESS; MIDDLETON D, 1995, TISSUE ANTIGENS, V45, P232, DOI 10.1111/j.1399-0039.1995.tb02445.x; Middleton D, 2005, TRANSPL IMMUNOL, V14, P135, DOI 10.1016/j.trim.2005.03.002; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; Oudejans JJ, 1996, BLOOD, V87, P3844, DOI 10.1182/blood.V87.9.3844.bloodjournal8793844; Pappworth IY, 2007, J VIROL, V81, P474, DOI 10.1128/JVI.01777-06; Parham P, 2005, NAT REV IMMUNOL, V5, P201, DOI 10.1038/nri1570; Re D, 2005, J CLIN ONCOL, V23, P6379, DOI 10.1200/JCO.2005.55.013; Schaid DJ, 1998, AM J HUM GENET, V63, P1492, DOI 10.1086/302094; Shugart YY, 2000, HUM GENET, V106, P553, DOI 10.1007/s004390050024; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714; Stewart CA, 2005, P NATL ACAD SCI USA, V102, P13224, DOI 10.1073/pnas.0503594102; Thomas RK, 2004, LANCET ONCOL, V5, P11, DOI 10.1016/S1470-2045(03)01319-6; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; Uhrberg M, 2002, IMMUNOGENETICS, V54, P221, DOI 10.1007/s00251-002-0463-7; Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Wall JD, 2003, NAT REV GENET, V4, P587, DOI 10.1038/nrg1123; Williams F, 2004, HUM IMMUNOL, V65, P31, DOI 10.1016/j.humimm.2003.10.009; Williams F, 2002, HUM IMMUNOL, V63, P602, DOI 10.1016/S0198-8859(02)00408-1; Williams H, 2005, BRIT J HAEMATOL, V129, P266, DOI 10.1111/j.1365-2141.2005.05452.x	59	53	57	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e406	10.1371/journal.pone.0000406	http://dx.doi.org/10.1371/journal.pone.0000406			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476328	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445700008
J	Lastowska, M; Viprey, V; Santibanez-Koref, M; Wappler, I; Peters, H; Cullinane, C; Roberts, P; Hall, AG; Tweddle, DA; Pearson, ADJ; Lewis, I; Burchill, SA; Jackson, MS				Lastowska, M.; Viprey, V.; Santibanez-Koref, M.; Wappler, I.; Peters, H.; Cullinane, C.; Roberts, P.; Hall, A. G.; Tweddle, D. A.; Pearson, A. D. J.; Lewis, I.; Burchill, S. A.; Jackson, M. S.			Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data	ONCOGENE			English	Article						neuroblastoma; expression arrays; SNP arrays; candidate genes	HIGH-RESOLUTION ANALYSIS; TUMOR-SUPPRESSOR GENE; N-MYC ONCOGENE; COPY NUMBER; CHROMOSOME 1P; ALLELIC LOSS; 17Q; AMPLIFICATION; CGH; ABNORMALITIES	Identifying genes, whose expression is consistently altered by chromosomal gains or losses, is an important step in defining genes of biological relevance in a wide variety of tumour types. However, additional criteria are needed to discriminate further among the large number of candidate genes identified. This is particularly true for neuroblastoma, where multiple genomic copy number changes of proven prognostic value exist. We have used Affymetrix microarrays and a combination of. fluorescentin situ hybridization and single nucleotide polymorphism (SNP) microarrays to establish expression profiles and delineate copy number alterations in 30 primary neuroblastomas. Correlation of microarray data with patient survival and analysis of expression within rodent neuroblastoma cell lines were then used to define further genes likely to be involved in the disease process. Using this approach, we identify > 1000 genes within eight recurrent genomic alterations (loss of 1p, 3p, 4p, 10q and 11q, 2p gain, 17q gain, and the MYCN amplicon) whose expression is consistently altered by copy number change. Of these, 84 correlate with patient survival, with the minimal regions of 17q gain and 4p loss being enriched significantly for such genes. These include genes involved in RNA and DNA metabolism, and apoptosis. Orthologues of all but one of these genes on 17q are overexpressed in rodent neuroblastoma cell lines. A significant excess of SNPs whose copy number correlates with survival is also observed on proximal 4p in stage 4 tumours, and we find that deletion of 4p is associated with improved outcome in an extended cohort of tumours. These results de. ne the major impact of genomic copy number alterations upon transcription within neuroblastoma, and highlight genes on distal 17q and proximal 4p for downstream analyses. They also suggest that integration of discriminators, such as survival and comparative gene expression, with microarray data be useful in the identification of critical genes within regions of loss or gain in many human cancers.	Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; St James Univ Hosp, Canc Res UK Clin Ctr, Childrens Canc Res Lab, Leeds, W Yorkshire, England; St James Univ Hosp, Dept Pathol, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Dept Cytogenet, Leeds LS9 7TF, W Yorkshire, England; Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Inst Canc Res, Sutton, Surrey, England; St James Univ Hosp, Dept Paediat Oncol & Haematol, Leeds LS9 7TF, W Yorkshire, England	Newcastle University - UK; Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; Saint James's University Hospital; Newcastle University - UK; University of London; Institute of Cancer Research - UK; Saint James's University Hospital	Jackson, MS (corresponding author), Int Ctr Life, Inst Human Genet, Central Parkway, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	m.s.jackson@ncl.ac.uk	Hall, Andrew G/B-3485-2009	Viprey, Virginie/0000-0001-6463-7092; Jackson, Michael/0000-0001-7179-1354; Lastowska, Maria/0000-0003-0632-6995				Ambros PF, 2001, MED PEDIATR ONCOL, V37, P492, DOI 10.1002/mpo.1242; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BOWN NP, 1994, MED PEDIATR ONCOL, V23, P124, DOI 10.1002/mpo.2950230210; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Bussey KJ, 2006, MOL CANCER THER, V5, P853, DOI 10.1158/1535-7163.MCT-05-0155; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Caron H, 1996, HUM GENET, V97, P834; Chen QR, 2006, GENE CHROMOSOME CANC, V45, P856, DOI 10.1002/gcc.20349; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; De Preter K, 2005, J CLIN ONCOL, V23, P3167, DOI 10.1200/JCO.2005.05.346; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Fischer M, 2005, J MOL DIAGN, V7, P89, DOI 10.1016/S1525-1578(10)60013-X; Hackett CS, 2003, CANCER RES, V63, P5266; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Huang Jing, 2004, Human Genomics, V1, P287; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; Lastowska M, 2004, GENE CHROMOSOME CANC, V40, P158, DOI 10.1002/gcc.20031; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Miller MA, 2006, J PEDIAT HEMATOL ONC, V28, P412, DOI 10.1097/01.mph.0000212937.00287.e5; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Popescu NC, 1997, CANCER GENET CYTOGEN, V93, P10, DOI 10.1016/S0165-4608(96)00262-2; Rao CR, 1973, LINEAR STAT INTERFER; Schleiermacher G, 2005, ONCOGENE, V24, P3377, DOI 10.1038/sj.onc.1208486; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SELTZER R, 2005, GENE CHROMOSOME CANC, V44, P305; SLAVC I, 1990, CANCER RES, V50, P1459; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Walker BA, 2006, BLOOD, V108, P1733, DOI 10.1182/blood-2006-02-005496; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weber A, 2004, J CLIN ONCOL, V22, P2681, DOI 10.1200/JCO.2004.07.192	41	65	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7432	7444		10.1038/sj.onc.1210552	http://dx.doi.org/10.1038/sj.onc.1210552			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17533364				2022-12-25	WOS:000251282000005
J	Xu, X; Li, W; Fan, X; Liang, Y; Zhao, M; Zhang, J; Liang, Y; Tong, W; Wang, J; Yang, W; Lu, Y				Xu, X.; Li, W.; Fan, X.; Liang, Y.; Zhao, M.; Zhang, J.; Liang, Y.; Tong, W.; Wang, J.; Yang, W.; Lu, Y.			Identification and characterization of a novel p42.3 gene astumor-s pecific and mitosis phase-dependent expression in gastric cancer	ONCOGENE			English	Article						gastric cancer; p42.3; cell cycle; RNAi	CELL-CYCLE; MOLECULAR-CLONING; PROLIFERATION; CHECKPOINT; PHENOTYPE; PROTEINS	Multiple genetic alterations are attributed to gastric cancer (GC); however, only a few critical genes have been identified so far. In this study, we isolated and characterized a novel gene p42.3, represented as tumor-specific and mitosis phase-dependent expression protein in GC cell line BGC823. Our data showed that the expression of p42.3 was cell cycle-dependent in GC cell lines. Moreover, p42.3 was specifically expressed in primary GC tissues but not in the matched normal mucosa of stomach, and this gene was expressed in diverse embryonic tissues. Furthermore, significant suppression of cell proliferation and tumorigenicity were detected and G(2)/M phase arrest was observed in cell line BGC823 depleted of p42.3 expression by RNAi technique, and we confirmed the expression changes of cyclin B1 and Chk2 following the silence of p42.3. Taken together, we cloned and characterized p42.3 gene that was specifically expressed in GC tumors but not in normal gastric mucosa, and the gene was associated with M-phase regulation. Moreover, p42.3 might be involved in cell proliferation and tumorigenesis; therefore, this gene might have potential applications in the diagnosis or treatment of GC.	Peking Univ, Sch Oncol, Inst Canc Res, Oncol Mol Lab, Beijing 100871, Peoples R China; Chinese Acad Sci, Genom Inst, Beijing, Peoples R China; Tsinghua Univ, Natl Engn Res Ctr Biochip Technol, Sch Med, Beijing 100084, Peoples R China	Peking University; Chinese Academy of Sciences; Tsinghua University	Lu, Y (corresponding author), Peking Univ, Sch Oncol, Inst Canc Res, Oncol Mol Lab, Fu-Cheng rd 52,Hai-Dian Dist, Beijing 100871, Peoples R China.	yongylu@public.bta.net.cn						Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cobb JA, 2006, NUCLEIC ACIDS RES, V34, P4106, DOI 10.1093/nar/gkl557; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng H, 2005, BIOCHEM BIOPH RES CO, V326, P274, DOI 10.1016/j.bbrc.2004.11.027; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Herness EA, 2003, CANCER RES, V63, P329; Ji JF, 2002, ONCOGENE, V21, P6549, DOI 10.1038/sj.onc.1205829; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lu M, 2005, CANCER RES, V65, P6159, DOI 10.1158/0008-5472.CAN-04-4016; Murata T, 2004, GENE EXPR PATTERNS, V5, P171, DOI 10.1016/j.modgep.2004.08.007; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Pinto-Santini D, 2005, CANCER EPIDEM BIOMAR, V14, P1853, DOI 10.1158/1055-9965.EPI-04-0784; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Stock M, 2005, GENE, V360, P1, DOI 10.1016/j.gene.2005.06.026; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tang ZB, 2004, ONCOL REP, V11, P333; Toyota M, 1999, CANCER RES, V59, P5438; You Wei Cheng, 2005, Chin J Dig Dis, V6, P149; Zeng JZ, 2002, ONCOGENE, V21, P4932, DOI 10.1038/sj.onc.1205652; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	25	38	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7371	7379		10.1038/sj.onc.1210538	http://dx.doi.org/10.1038/sj.onc.1210538			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17525738				2022-12-25	WOS:000250955700009
J	Garcia-Morales, P; Carrasco-Garcia, E; Ruiz-Rico, P; Martinez-Mira, R; Menendez-Gutierrez, MP; Ferragut, JA; Saceda, M; Martinez-Lacaci, I				Garcia-Morales, P.; Carrasco-Garcia, E.; Ruiz-Rico, P.; Martinez-Mira, R.; Menendez-Gutierrez, M. P.; Ferragut, J. A.; Saceda, M.; Martinez-Lacaci, I.			Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines	ONCOGENE			English	Article						ansamycins; G(2)/M arrest; cdc2; cdc25c; glioblastoma	CYCLE-ARREST; GELDANAMYCIN; APOPTOSIS; CHAPERONE; COMPLEX; AKT; DEGRADATION; PROTEINS; KINASE	Ansamycins exert their effects by binding heat shock protein 90 (Hsp90) and targeting important signalling molecules for degradation via the proteasome pathway. We wanted to study the effect of geldanamycin (GA) and its derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) on glioblastoma cell lines. We show that these cells are growth inhibited by ansamycins by being arrested in G(2)/M and, subsequently, cells undergo apoptosis. The protein levels of cell division cycle 2 (cdc2) kinase and cell division cycle 25c (cdc25c) were downregulated upon GA and 17-AAG treatment and cdc2 kinase activity was inhibited. However, other proteins involved in the G(2)/M checkpoint were not affected. The cdc2 and cdc25c mRNA levels did not show significant differences upon ansamycin treatment, but the stability of cdc2 protein was reduced. The association of cdc2 and cdc25c with p50(cdc37), an Hsp90 cochaperone, decreased, but the interaction of cdc2 and cdc25c with the Hsp70 co-chaperone increased after ansamycin treatment. Proteasome inhibitors were able to rescue the cdc2 downregulation, but not the cdc25c reduction. However, calpain inhibitors were able to rescue the cdc25c downregulation, suggesting that cdc25c is proteolysed by calpains in the presence of ansamycins, and not by the proteasome. We conclude that ansamycins downregulate cdc2 and cdc25c by two different mechanisms.	Univ Miguel Hernandez, Inst Mol & Cellular Biol, E-03202 Alicante, Spain; Hosp Gen Univ Elche, Unidad Invest, Alicante, Spain	Universidad Miguel Hernandez de Elche	Martinez-Lacaci, I (corresponding author), Univ Miguel Hernandez, Inst Mol & Cellular Biol, Edificio Torregaitan, E-03202 Alicante, Spain.	imlacaci@umh.es	Saceda, Miguel/A-1581-2008; Garcia Morales, Pilar/ABD-4362-2021	Saceda, Miguel/0000-0002-1564-3602; 				An WG, 2000, CELL GROWTH DIFFER, V11, P355; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bellocq A, 1999, J BIOL CHEM, V274, P36891, DOI 10.1074/jbc.274.52.36891; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; Demidenko ZN, 2006, CELL DEATH DIFFER, V13, P1434, DOI 10.1038/sj.cdd.4401812; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; Drysdale MJ, 2006, CURR OPIN DRUG DISC, V9, P483; Georgakis GV, 2006, BRIT J HAEMATOL, V135, P68, DOI 10.1111/j.1365-2141.2006.06247.x; Georgakis GV, 2006, CLIN CANCER RES, V12, P584, DOI 10.1158/1078-0432.CCR-05-1194; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Hostein I, 2001, CANCER RES, V61, P4003; Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006; Kim HR, 1999, IUBMB LIFE, V48, P425, DOI 10.1080/152165499306810; McIlwrath AJ, 1996, CANCER CHEMOTH PHARM, V37, P423, DOI 10.1007/s002800050407; MILLER P, 1994, CANCER RES, V54, P2724; Munster PN, 2002, CANCER RES, V62, P3132; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nomura M, 2004, J CELL PHYSIOL, V201, P374, DOI 10.1002/jcp.20090; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Senju M, 2006, J CANCER RES CLIN, V132, P150, DOI 10.1007/s00432-005-0047-7; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stupp R, 2006, ONCOLOGIST, V11, P165, DOI 10.1634/theoncologist.11-2-165; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xiao L, 2006, MINI-REV MED CHEM, V6, P1137, DOI 10.2174/138955706778560166	28	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7185	7193		10.1038/sj.onc.1210534	http://dx.doi.org/10.1038/sj.onc.1210534			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525741				2022-12-25	WOS:000250955600002
J	Taubert, H; Wurl, P; Greither, T; Kappler, M; Bache, M; Bartel, F; Kehlen, A; Lautenschlager, C; Harris, LC; Kaushal, D; Fussel, S; Meye, A; Bohnke, A; Schmidt, H				Taubert, H.; Wuerl, P.; Greither, T.; Kappler, M.; Bache, M.; Bartel, F.; Kehlen, A.; Lautenschlaeger, C.; Harris, L. C.; Kaushal, D.; Fuessel, S.; Meye, A.; Boehnke, A.; Schmidt, H.			Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients	ONCOGENE			English	Article						stem cell-associated genes; soft-tissue sarcoma; prognosis; Hiwi; hTERT; survivin	TUMOR-RELATED DEATH; TELOMERASE ACTIVITY; CANCER; PROTEIN; EXPRESSION; SURVIVIN; HIWI; PROLIFERATION; PATHWAY; HTERT	Cancer stem cells can play an important role in tumorigenesis and tumor progression. However, it is still difficult to detect and isolate cancer stem cells. An alternative approach is to analyse stem cell-associated gene expression. We investigated the coexpression of three stem cell-associated genes, Hiwi, hTERT and survivin, by quantitative real-time-PCR in 104 primary soft-tissue sarcomas (STS). Multivariate Cox's proportional hazards regression analyses allowed correlating gene expression with overall survival for STS patients. Coexpression of all three stem cell-associated genes resulted in a significantly increased risk of tumor-related death. Importantly, tumors of patients with the poorest prognosis were of all four tumor stages, suggesting that their risk is based upon coexpression of stem cell-associated genes rather than on tumor stage.	Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle, Germany; Univ Ulm, Clin Gen & Transplantat Surg, Ulm, Germany; Univ Halle Wittenberg, Dept Radiotherapy, D-06097 Halle, Germany; Univ Halle Wittenberg, Inst Pathol, Junior Res Grp, D-06097 Halle, Germany; Probiodrug AG, Halle, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle, Germany; St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany	Martin Luther University Halle Wittenberg; Ulm University; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Vivoryon Therapeutics; Martin Luther University Halle Wittenberg; St Jude Children's Research Hospital; Technische Universitat Dresden	Taubert, H (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Pathol, Magdeburger Str 14, D-06097 Halle, Germany.	helge.taubert@medizin.uni-halle.de	Greither, Thomas/M-5334-2019; Kappler, Matthias/ABG-9644-2020	Kappler, Matthias/0000-0003-2002-0271				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Endoh T, 2005, EXP CELL RES, V305, P300, DOI 10.1016/j.yexcr.2004.12.014; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Ju ZY, 2006, EUR J CANCER, V42, P1197, DOI 10.1016/j.ejca.2006.01.040; Kirkpatrick KL, 2001, EUR J SURG ONCOL, V27, P754, DOI 10.1053/ejso.2001.1151; Lee JH, 2006, HUM MOL GENET, V15, P201, DOI 10.1093/hmg/ddi430; Lingel A, 2005, CURR OPIN STRUC BIOL, V15, P107, DOI 10.1016/j.sbi.2005.01.010; Liu XY, 2006, INT J CANCER, V118, P1922, DOI 10.1002/ijc.21575; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nguyen HG, 2006, J CELL PHYSIOL, V208, P12, DOI 10.1002/jcp.20565; Pendino F, 2006, CURR CANCER DRUG TAR, V6, P147, DOI 10.2174/156800906776056482; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Qiao D, 2002, ONCOGENE, V21, P3988, DOI 10.1038/sj.onc.1205505; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Soltysova A, 2005, NEOPLASMA, V52, P435; Taubert H, 2007, ONCOGENE, V26, P1098, DOI 10.1038/sj.onc.1209880; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Zhu CQ, 2006, BRIT J CANCER, V94, P1452, DOI 10.1038/sj.bjc.6603110	20	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7170	7174		10.1038/sj.onc.1210530	http://dx.doi.org/10.1038/sj.onc.1210530			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17525744				2022-12-25	WOS:000250715000012
J	Lahdenranta, J; Sidman, RL; Pasqualini, R; Arap, W				Lahdenranta, Johanna; Sidman, Richard L.; Pasqualini, Renata; Arap, Wadih			Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease	FASEB JOURNAL			English	Article						aminopeptidases; angiogenesis; peptide ligand; targeted therapy	ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; PHAGE DISPLAY; HUMAN VASCULATURE; AMINOPEPTIDASE-A; TUMOR; PEPTIDES; ANGIOGENESIS; DELIVERY; RECEPTOR	We have previously identified ligands from combinatorial peptide libraries that target tumor vasculature after in vivo selection. These ligands bind to differentially expressed receptors in angiogenic vasculature such as alpha(v)beta(3)/alpha(v)beta(5) integrins, aminopeptidase N, and aminopeptidase A. We hypothesized that we can use these ligands to target angiogenic vasculature in retinopathies. Pathological retinal angiogenesis in conditions such as diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration is a major cause of blindness for which current treatments are inadequate. Here we tested whether known tumor vasculature targeting peptide ligands displayed on bacteriophage particles would home to the proliferating blood vessels of the retina in a standard mouse model of retinopathy of prematurity. We found that activated retinal blood vessels share many of the endothelial and periendothelial cell receptors expressed in tumor vasculature. Furthermore, these vascular receptors -alpha(v) integrins and aminopeptidases -are accessible through the circulation and mediate phage homing and internalization to endothelial and periendothelial cells. Treatment of mice with a peptide containing alpha(v)beta(3)/alpha(v)beta(5) integrin targeting domain fused to a proapoptotic domain significantly reduced oxygen-induced retinal angiogenesis by selectively inducing activated endothelial cell apoptosis. Targeted proapoptotic peptides may prove useful in the management of angiogenic retinal diseases.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Harvard Inst Med, Boston, MA 02215 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Arap, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rpasqual@mdanderson.org						AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547; ASSMANN KJM, 1992, J EXP MED, V175, P623, DOI 10.1084/jem.175.3.623; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; Brekken RA, 1998, CANCER RES, V58, P1952; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Burg MA, 1999, CANCER RES, V59, P2869; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678; George AJT, 2003, TRENDS BIOTECHNOL, V21, P199, DOI 10.1016/S0167-7799(03)00079-9; Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; Joyce JA, 2003, CANCER CELL, V4, P393, DOI 10.1016/S1535-6108(03)00271-X; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Lahdenranta J, 2001, P NATL ACAD SCI USA, V98, P10368, DOI 10.1073/pnas.181329198; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2004, CURR OPIN HEMATOL, V11, P262, DOI 10.1097/01.moh.0000126936.58889.95; Marchio S, 2004, CANCER CELL, V5, P151, DOI 10.1016/S1535-6108(04)00025-X; Moffatt S, 2005, HUM GENE THER, V16, P57, DOI 10.1089/hum.2005.16.57; Ozerdem Ugur, 2004, Angiogenesis, V7, P269, DOI 10.1007/s10456-004-4182-6; Pasqualini R, 2000, CANCER RES, V60, P722; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Pastorino F, 2003, CANCER RES, V63, P7400; PLATE KH, 1993, CANCER RES, V53, P5822; SCHRAPPE M, 1991, CANCER RES, V51, P4986; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; St Croix B, 2000, SCIENCE, V289, P1197; Trepel M, 2002, CURR OPIN CHEM BIOL, V6, P399, DOI 10.1016/S1367-5931(02)00336-8; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8	44	26	33	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3272	3278		10.1096/fj.07-8273com	http://dx.doi.org/10.1096/fj.07-8273com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17513561				2022-12-25	WOS:000249781600027
J	Brooks, CL; Li, M; Gu, W				Brooks, Christopher L.; Li, Muyang; Gu, Wei			Mechanistic studies of MDM2-mediated ubiquitination in p53 regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; RING-FINGER DOMAIN; C-TERMINAL DOMAIN; NUCLEAR EXPORT; DNA-BINDING; MDM2; DEGRADATION; PROTEIN; MONOUBIQUITINATION; ONCOPROTEIN	As a central regulator for cell cycle arrest, apoptosis, and cellular senescence, p53 requires multiple layers of regulatory control to ensure correct temporal and spatial functions. It is well accepted that Mdm2-mediated ubiquitination plays a crucial role in p53 regulation. In addition to proteasome-mediated degradation, ubiquitination of p53 by Mdm2 acts a key signal for its nuclear export. Nuclear export has previously been thought to require the disassociation of the p53 tetramer and exposure of the intrinsic nuclear export signal. To elucidate the molecular mechanism of degradation-independent repression on p53 by Mdm2, we have developed a two-step approach to purify ubiquitinated forms of p53 induced by Mdm2 from human cells. Surprisingly, however, we found that ubiquitination has no effect on the tetramerization/oligomerization of p53, arguing against this seemingly well accepted model. Moreover, nuclear export of p53 alone is not sufficient to completely abolish p53 activity. Ubiquitination-mediated repression of p53 by Mdm2 acts at least, in part, through inhibiting the sequence-specific DNA binding activity. Thus, our results have important implications regarding the mechanisms by which Mdm2 acts on p53.	Columbia Univ, Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Gu, W (corresponding author), 1130 St Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu		Brooks, Christopher/0000-0003-3487-6644	NCI NIH HHS [R01 CA098821, R01 CA131439, P01 CA097403, R01 CA129627, R01 CA104843, R01 CA085533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085533, P01CA097403, R01CA104843, R01CA131439, R01CA098821, R01CA129627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arva NC, 2005, J BIOL CHEM, V280, P26776, DOI 10.1074/jbc.M505203200; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Caron De Fromentel Claude, 1992, Genes Chromosomes and Cancer, V4, P1; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Ohkubo S, 2006, J BIOL CHEM, V281, P16943, DOI 10.1074/jbc.M601388200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; White DE, 2006, CANCER RES, V66, P3463, DOI 10.1158/0008-5472.CAN-05-1381; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175	49	34	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22804	22815		10.1074/jbc.M700961200	http://dx.doi.org/10.1074/jbc.M700961200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17500067	hybrid, Green Accepted			2022-12-25	WOS:000248354200058
J	Driscoll, WJ; Chaturvedi, S; Mueller, GP				Driscoll, William J.; Chaturvedi, Shalini; Mueller, Gregory P.			Oleamide synthesizing activity from rat kidney - Identification as cytochrome C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID AMIDES; SECRETORY GRANULES; BRAIN LIPIDS; SLEEP; BIOSYNTHESIS; ACYLTRANSFERASE; COMMUNICATION; OLEOYLGLYCINE; CARDIOLIPIN; GENERATION	Oleamide (cis-9-octadecenamide) is the prototype member of an emerging class of lipid signaling molecules collectively known as the primary fatty acid amides. Current evidence suggests that oleamide participates in the biochemical mechanisms underlying the drive to sleep, thermoregulation, and antinociception. Despite the potential importance of oleamide in these physiologic processes, the biochemical pathway for its synthesis in vivo has not been established. We report here the discovery of an oleamide synthetase found in rat tissues using [C-14]oleoyl-CoA and ammonium ion. Hydrogen peroxide was subsequently found to be a required cofactor. The enzyme displayed temperature and pH optima in the physiologic range, a remarkable resistance to proteolysis, and specificity for long-chain acyl-CoA substrates. The reaction demonstrated Michaelis-Menten kinetics with a K-m for oleoyl-CoA of 21 mu M. Proteomic, biochemical, and immunologic analyses were used to identify the source of the oleamide synthesizing activity as cytochrome c. This identification was based upon peptide mass fingerprinting of isolated synthase protein, a tight correlation between enzymatic activity and immunoreactivity for cytochrome c, and identical functional properties shared by the tissue-derived synthetase and commercially obtained cytochrome c. The ability of cytochrome c to catalyze the formation of oleamide experimentally raises the possibility that cytochrome c may mediate oleamide biosynthesis in vivo.	Uniformed Serv Univ Hlth Sci, F Edward Herbert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Mueller, GP (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Herbert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA.	gmueller@usuhs.mil			NINDS NIH HHS [R01 NS38050-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038050] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAFAT ES, 1989, LIFE SCI, V45, P1679, DOI 10.1016/0024-3205(89)90278-6; Barros MH, 2003, FREE RADICAL BIO MED, V35, P179, DOI 10.1016/S0891-5849(03)00307-1; Bisogno T, 1997, BIOCHEM BIOPH RES CO, V239, P473, DOI 10.1006/bbrc.1997.7431; Bisogno T, 2002, CURR PHARM DESIGN, V8, P533, DOI 10.2174/1381612023395655; BISSWANGER H, 2002, ENZYME KINETICS PRIN, P55; Boger DL, 1998, P NATL ACAD SCI USA, V95, P4810, DOI 10.1073/pnas.95.9.4810; Boger DL, 1998, CURR PHARM DESIGN, V4, P303; Chaturvedi S, 2006, PROSTAG OTH LIPID M, V81, P136, DOI 10.1016/j.prostaglandins.2006.09.001; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; DENNIS SC, 1977, BIOCHEM J, V168, P521, DOI 10.1042/bj1680521; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Fedorova I, 2001, J PHARMACOL EXP THER, V299, P332; Garcia-Dorado D, 2002, CARDIOVASC RES, V55, P456, DOI 10.1016/S0008-6363(02)00441-8; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HuidobroToro JP, 1996, P NATL ACAD SCI USA, V93, P8078, DOI 10.1073/pnas.93.15.8078; Huitron-Resendiz S, 2001, EXP NEUROL, V172, P235, DOI 10.1006/exnr.2001.7792; IDE T, 1995, LIPIDS, V30, P755, DOI 10.1007/BF02537803; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016; Kim NH, 2004, B KOREAN CHEM SOC, V25, P1889; LANOUE KF, 1983, J BIOL CHEM, V258, P1726; LERNER RA, 1994, P NATL ACAD SCI USA, V91, P9505, DOI 10.1073/pnas.91.20.9505; Lichtman AH, 2002, J PHARMACOL EXP THER, V302, P73, DOI 10.1124/jpet.302.1.73; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Merkler DJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P430, DOI 10.1006/abbi.1996.0272; Merkler DJ, 2004, BIOCHEMISTRY-US, V43, P12667, DOI 10.1021/bi049529p; Mueller GP, 2007, J BIOL CHEM, V282, P22364, DOI 10.1074/jbc.M701801200; Muth E, 2004, BBA-PROTEINS PROTEOM, V1699, P263, DOI 10.1016/j.bbapap.2004.03.007; Power GW, 1997, LIPIDS, V32, P31, DOI 10.1007/s11745-997-0005-4; Ripps H, 2002, EXP EYE RES, V74, P327, DOI 10.1006/exer.2002.1155; Satriano J, 2004, AMINO ACIDS, V26, P321, DOI 10.1007/s00726-004-0078-4; Soltys BJ, 2001, CELL BIOL INT, V25, P331, DOI 10.1006/cbir.2000.0651; STEWART JM, 2002, BIOCH CELL BIOL, V78, P675; Sugiura T, 1996, BIOCHEM MOL BIOL INT, V40, P931; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; YAMASHIT.S, 1973, EUR J BIOCHEM, V38, P25, DOI 10.1111/j.1432-1033.1973.tb03028.x; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; Zhao YG, 2004, BIOCHEM BIOPH RES CO, V317, P980, DOI 10.1016/j.bbrc.2004.03.144; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200	42	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22353	22363		10.1074/jbc.M610070200	http://dx.doi.org/10.1074/jbc.M610070200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17496328	hybrid			2022-12-25	WOS:000248354200013
J	Li, YW; Wang, ZW; Kong, D; Murthy, S; Dou, QP; Sheng, S; Reddy, GPV; Sarkar, FH				Li, Yiwei; Wang, Zhiwei; Kong, Dejuan; Murthy, Shalini; Dou, Q. Ping; Sheng, Shijie; Reddy, G. Prem Veer; Sarkar, Fazlul H.			Regulation of FOXO3a/beta-catenin/GSK-3 beta signaling by 3,3 '-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ANDROGEN RECEPTOR; BETA-CATENIN; BREAST-CANCER; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; AKT PATHWAY; KAPPA-B; SURVIVAL; PHOSPHORYLATION	Previous studies from our laboratory have shown anti-proliferative and pro-apoptotic effects of 3,3'-diindolylmethane (DIM) through regulation of Akt and androgen receptor (AR) in prostate cancer cells. However, the mechanism by which DIM regulates Akt and AR signaling pathways has not been fully investigated. It has been known that FOXO3a and glycogen synthase kinase-3 beta (GSK-3 beta), two targets of activated Akt, interact with beta-catenin, regulating cell proliferation and apoptotic cell death. More importantly, FOXO3a, GSK-3 beta, and beta-catenin are all AR coregulators and regulate the activity of AR, mediating the development and progression of prostate cancers. Here, we investigated the molecular effects of B-DIM, a formulated DIM with higher bioavailability, on Akt/FOXO3a/GSK-3 beta/beta-catenin/AR signaling in hormone-sensitive LNCaP and hormone-insensitive C4-2B prostate cancer cells. We found that B-DIM significantly inhibited the phosphorylation of Akt and FOXO3a and increased the phosphorylation of beta-catenin, leading to the inhibition of cell growth and induction of apoptosis. We also found that B-DIM significantly inhibited beta-catenin nuclear translocation. By electrophoretic mobility shift and chromatin immunoprecipitation assays, we found that B-DIM inhibited FOXO3a binding to the promoter of AR and promoted FOXO3a binding to the p27(KIP1) promoter, resulting in the alteration of AR and p27(KIP1) expression, the inhibition of cell proliferation, and the induction of apoptosis in both androgen-sensitive and -insensitive prostate cancer cells. These results suggest that B-DIM-induced cell growth inhibition and apoptosis induction are partly mediated through the regulation of Akt/FOXO3a/GSK-3 beta/beta-catenin/AR signaling. Therefore, B-DIM could be a promising non-toxic agent for possible treatment of hormone-sensitive but most importantly hormone-refractory prostate cancers.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; Henry Ford Hosp, Vattikuti Urol Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Henry Ford Health System; Henry Ford Hospital	Sarkar, FH (corresponding author), 740 Hudson Webber Canc Res Ctr, 4100 John Rd, Detroit, MI 48201 USA.	fsarkar@med.wayne.edu	Wang, Zhiwei/A-6809-2011	Murthy, Shalini/0000-0001-5517-9894; Dou, Qingping/0000-0002-6465-1473	NCI NIH HHS [5R01CA108535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108535] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderton MJ, 2004, DRUG METAB DISPOS, V32, P632, DOI 10.1124/dmd.32.6.632; Bhuiyan MMR, 2006, CANCER RES, V66, P10064, DOI 10.1158/0008-5472.CAN-06-2011; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chong ZZ, 2006, CURR NEUROVASC RES, V3, P107, DOI 10.2174/156720206776875830; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Firestone GL, 2003, J NUTR, V133, p2448S, DOI 10.1093/jn/133.7.2448S; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; Hu YY, 2005, MOL BIOL CELL, V16, P3705, DOI 10.1091/mbc.E05-04-0301; Huang Haojie, 2006, Future Oncol, V2, P83, DOI 10.2217/14796694.2.1.83; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kuemmerle JF, 2005, AM J PHYSIOL-GASTR L, V288, pG101, DOI 10.1152/ajpgi.00032.2004; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lee HJ, 2003, CELL MOL LIFE SCI, V60, P1613, DOI 10.1007/s00018-003-2309-3; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Nachshon-Kedmi M, 2003, FOOD CHEM TOXICOL, V41, P745, DOI 10.1016/S0278-6915(03)00004-8; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Prueitt RL, 2007, INT J CANCER, V120, P796, DOI 10.1002/ijc.22336; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Rosas M, 2006, J LEUKOCYTE BIOL, V80, P186, DOI 10.1189/jlb.1105636; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Segrelles C, 2006, ONCOGENE, V25, P1174, DOI 10.1038/sj.onc.1209155; Terry S, 2006, J CELL BIOCHEM, V99, P402, DOI 10.1002/jcb.20983; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Truica CI, 2000, CANCER RES, V60, P4709; Wen Y, 2000, CANCER RES, V60, P6841; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	43	102	105	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21542	21550		10.1074/jbc.M701978200	http://dx.doi.org/10.1074/jbc.M701978200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17522055	hybrid			2022-12-25	WOS:000248047500081
J	Liu, XW; Wu, B; Szary, J; Kofoed, EM; Schaufele, F				Liu, Xiaowei; Wu, Bo; Szary, Jaroslaw; Kofoed, Eric M.; Schaufele, Fred			Functional sequestration of transcription factor activity by repetitive DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-ALPHA; ESTROGEN-RECEPTOR ACTIVATION; PITUITARY-CELL NUCLEUS; GENE-EXPRESSION; C/EBP-ALPHA; CENTROMERIC HETEROCHROMATIN; SATELLITE DNA; LIVING CELLS; PIT-1; LOCALIZATION	Higher eukaryote genomes contain repetitive DNAs, often concentrated in transcriptionally inactive heterochromatin. Although repetitive DNAs are not typically considered as regulatory elements that directly affect transcription, they can contain binding sites for some transcription factors. Here, we demonstrate that binding of the transcription factor CCAAT/enhancer-binding protein alpha (C/EBP alpha) to the mouse major alpha-satellite repetitive DNA sequesters C/EBP alpha in the transcriptionally inert pericentromeric heterochromatin. We find that this sequestration reduces the transcriptional capacity of C/EBP alpha. Functional sequestration of C/EBP alpha was demonstrated by experimentally reducing C/EBP alpha binding to the major alpha-satellite DNA, which elevated the concentration of C/EBP alpha in the non-heterochromatic subcompartment of the cell nucleus. The reduction in C/EBP alpha binding to alpha-satellite DNA was induced by the co-expression of the transcription factor Pit-1, which removes C/EBP alpha from the heterochromatic compartment, and by the introduction of an altered-specificity mutation into C/EBP alpha that reduces binding to alpha-satellite DNA but permits normal binding to sites in some gene promoters. In both cases the loss of alpha-satellite DNA binding coincided with an elevation in the binding of C/EBP alpha to a promoter and an increased transcriptional output from that promoter. Thus, the binding of C/EBP alpha to this highly repetitive DNA reduced the amount of C/EBP alpha available for binding to and regulation of this promoter. The functional sequestration of some transcription factors through binding to repetitive DNAs may represent an underappreciated mechanism controlling transcription output.	Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Schaufele, F (corresponding author), Univ Calif San Francisco, Ctr Diabet, S-1230,513 Parnassus, San Francisco, CA 94143 USA.	freds@diabetes.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054345] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK054345, DK-54345, R01 DK054345-07] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blattes R, 2006, EMBO J, V25, P2397, DOI 10.1038/sj.emboj.7601125; Brown K, 1999, CRIT REV EUKAR GENE, V9, P203, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.50; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Chuang FM, 1997, MOL ENDOCRINOL, V11, P1332, DOI 10.1210/me.11.9.1332; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Corry GN, 2005, BIOCHEM CELL BIOL, V83, P535, DOI 10.1139/O05-062; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Day RN, 2003, MOL ENDOCRINOL, V17, P333, DOI 10.1210/me.2002-0136; Day RN, 2001, METHODS, V25, P4, DOI 10.1006/meth.2001.1211; DeFranco DB, 2002, MOL ENDOCRINOL, V16, P1449, DOI 10.1210/me.16.7.1449; Demarco IA, 2006, MOL CELL BIOL, V26, P8087, DOI 10.1128/MCB.02410-05; Enwright JF, 2003, MOL ENDOCRINOL, V17, P209, DOI 10.1210/me.2001-0222; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Henikoff S, 2005, ANNU REV CELL DEV BI, V21, P133, DOI 10.1146/annurev.cellbio.21.012704.133518; Henikoff S, 2001, SCIENCE, V293, P1098, DOI 10.1126/science.1062939; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Isogai Y, 2003, CURR OPIN CELL BIOL, V15, P296, DOI 10.1016/S0955-0674(03)00052-8; Jacob KK, 1999, ENDOCRINOLOGY, V140, P4542, DOI 10.1210/en.140.10.4542; Janssen S, 2000, MOL CELL, V6, P1013, DOI 10.1016/S1097-2765(00)00100-3; Janssen S, 2000, MOL CELL, V6, P999, DOI 10.1016/S1097-2765(00)00099-X; Jolly C, 2002, J CELL BIOL, V156, P775, DOI 10.1083/jcb.200109018; JOSEPH A, 1989, EXP CELL RES, V183, P494, DOI 10.1016/0014-4827(89)90408-4; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Kosak ST, 2004, GENE DEV, V18, P1371, DOI 10.1101/gad.1209304; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; Lamb JC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-214; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Liu WQ, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-6; Miller M, 2003, J BIOL CHEM, V278, P15178, DOI 10.1074/jbc.M300417200; Misteli T, 2004, CELL, V119, P153, DOI 10.1016/j.cell.2004.09.035; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Perrod S, 2003, CELL MOL LIFE SCI, V60, P2303, DOI 10.1007/s00018-003-3246-x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pilipuk GP, 2003, J BIOL CHEM, V278, P35668, DOI 10.1074/jbc.M305182200; Platero JS, 1998, J CELL BIOL, V140, P1297; Schaufele F, 1999, MOL ENDOCRINOL, V13, P935, DOI 10.1210/me.13.6.935; Schaufele F, 2003, J BIOL CHEM, V278, P10578, DOI 10.1074/jbc.M207466200; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schueler MG, 2001, SCIENCE, V294, P109, DOI 10.1126/science.1065042; Shestakova EA, 2004, NUCLEIC ACIDS RES, V32, P4390, DOI 10.1093/nar/gkh737; STEPHANOVA E, 1988, EXP CELL RES, V179, P545, DOI 10.1016/0014-4827(88)90292-3; Tang QQ, 2000, P NATL ACAD SCI USA, V97, P12446, DOI 10.1073/pnas.220425597; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Yang JQ, 2005, J BIOL CHEM, V280, P38689, DOI 10.1074/jbc.M503486200	52	38	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20868	20876		10.1074/jbc.M702547200	http://dx.doi.org/10.1074/jbc.M702547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17526489	Green Accepted, hybrid			2022-12-25	WOS:000248047500012
J	Mckee, KK; Harrison, D; Capizzi, S; Yurchenco, PD				Mckee, Karen K.; Harrison, David; Capizzi, Stephanie; Yurchenco, Peter D.			Role of laminin terminal globular domains in basement membrane assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIDOGEN-BINDING-SITE; ALPHA-CHAIN; LAMININ-GAMMA-1; AGGREGATION; STABILITY; LETHALITY; ABLATION; NETWORK; IV	Laminins contribute to basement membrane assembly through interactions of their N- and C-terminal globular domains. To further analyze this process, recombinant laminin-111 heterotrimers with deletions and point mutations were generated by recombinant expression and evaluated for their ability to self-assemble, interact with nidogen-1 and type IV collagen, and form extracellular matrices on cultured Schwann cells by immunofluorescence and electron microscopy. Wild-type laminin and laminin without LG domains polymerized in contrast to laminins with deleted alpha 1-, beta 1-, or gamma 1-LN domains or with duplicated beta 1- or alpha 1-LN domains. Laminins with a full complement of LN and LG domains accumulated on cell surfaces substantially above those lacking either LN or LG domains and formed a lamina densa. Accumulation of type IV collagen onto the cell surface was found to require laminin with separate contributions arising from the presence of laminin LN domains, nidogen-1, and the nidogen-binding site in laminin. Collectively, the data support the hypothesis that basement membrane assembly depends on laminin self-assembly through formation of alpha-, beta-, and gamma-LN domain complexes and LG-mediated cell surface anchorage. Furthermore, type IV collagen recruitment into the laminin extracellular matrices appears to be mediated through a nidogen bridge with a lesser contribution arising from a direct interaction with laminin.	Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Yurchenco, PD (corresponding author), Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, 675 Hoes Lane, Piscataway, NJ 08854 USA.	yurchenc@umdnj.edu		Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036425] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK036425, R37-DK36425] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Bader BL, 2005, MOL CELL BIOL, V25, P6846, DOI 10.1128/MCB.25.15.6846-6856.2005; Bose K, 2006, J BIOL CHEM, V281, P39620, DOI 10.1074/jbc.M607886200; Chen ZL, 2003, J CELL BIOL, V163, P889, DOI 10.1083/jcb.200307068; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 1999, CURR BIOL, V9, P1327, DOI 10.1016/S0960-9822(00)80056-1; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FUJIWARA S, 1984, EUR J BIOCHEM, V143, P145, DOI 10.1111/j.1432-1033.1984.tb08353.x; Harrison D, 2007, J BIOL CHEM, V282, P11573, DOI 10.1074/jbc.M610657200; Huang CC, 2003, DEVELOPMENT, V130, P3343, DOI 10.1242/dev.00481; KALB E, 1991, J BIOL CHEM, V266, P19047; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Moll J, 2001, NATURE, V413, P302, DOI 10.1038/35095054; Odenthal U, 2004, J BIOL CHEM, V279, P44504, DOI 10.1074/jbc.M402455200; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; Poschl E, 1996, EMBO J, V15, P5154, DOI 10.1002/j.1460-2075.1996.tb00899.x; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; Ries A, 2001, EUR J BIOCHEM, V268, P5119, DOI 10.1046/j.0014-2956.2001.02437.x; RUBEN GC, 1994, MICROSC RES TECHNIQ, V28, P13, DOI 10.1002/jemt.1070280104; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Tsiper MV, 2002, J CELL SCI, V115, P1005; Willem M, 2002, DEVELOPMENT, V129, P2711; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	36	132	135	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21437	21447		10.1074/jbc.M702963200	http://dx.doi.org/10.1074/jbc.M702963200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17517882	hybrid			2022-12-25	WOS:000248047500071
J	Peng, ZM; Peng, L; Fan, YX; Zandi, E; Shertzer, HG; Xia, Y				Peng, Zhimin; Peng, Li; Fan, Yunxia; Zandi, Ebrahim; Shertzer, Howard G.; Xia, Ying			A critical role for I kappa B kinase beta in metallothionein-1 expression and protection against arsenic toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; DNA-DAMAGE; CELL-LINES; RESPONSIVE ELEMENT; TNF-ALPHA; ACTIVATION; APOPTOSIS; TRIOXIDE; INDUCTION; PROTEIN	Arsenic is a widespread environmental toxic agent that has been shown to cause diverse tissue and cell damage and at the same time to be an effective anti-cancer therapeutic agent. The objective of this study is to explore the signaling mechanisms involved in arsenic toxicity. We show that the I kappa B kinase beta (IKK beta) plays a crucial role in protecting cells from arsenic toxicity. Ikk beta(-/-) mouse 3T3 fibroblasts have decreased expression of antioxidant genes, such as metallothionein 1 (Mt1). In contrast to wild type and IKK beta- reconstituted Ikk beta(-/-) cells, IKK beta-null cells display a marked increase in arsenic-induced reactive oxygen species (ROS) accumulation, which leads to activation of the MKK4-c-Jun NH2-terminal kinase (JNK) pathway, c-Jun phosphorylation, and apoptosis. Pretreatment with the antioxidant N-acetylcysteine (NAC) and expression of MT1 in the Ikk beta(-/-) cells prevented JNK activation; moreover, NAC pretreatment, MT1expression, MKK4 ablation, and JNK inhibition all protected cells from death induced by arsenic. Our data show that two signaling pathways appear to be important for modulating arsenic toxicity. First, the IKK-NF-kappa B pathway is crucial for maintaining cellular metallothionein-1 levels to counteract ROS accumulation, and second, when this pathway fails, excessive ROS leads to activation of the MKK4-JNK pathway, resulting in apoptosis.	Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University System of Ohio; University of Cincinnati; University of Southern California	Xia, Y (corresponding author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, 123 E Shields St, Cincinnati, OH 45267 USA.	xiay@email.uc.edu	peng, zhimin/B-4536-2010		NEI NIH HHS [R01 EY015227] Funding Source: Medline; NIEHS NIH HHS [ES11798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011798] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Andela VB, 2005, FEBS LETT, V579, P6814, DOI 10.1016/j.febslet.2005.11.018; ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bashir S, 2006, BASIC CLIN PHARMACOL, V98, P38, DOI 10.1111/j.1742-7843.2006.pto_170.x; Bi YY, 2004, BIOCHEM J, V380, P695, DOI 10.1042/BJ20031677; Campagne MV, 2000, J NEUROSCI, V20, P5200, DOI 10.1523/JNEUROSCI.20-14-05200.2000; Chen F, 2003, CANCER RES, V63, P7689; Das S, 2005, TOXICOL APPL PHARM, V204, P18, DOI 10.1016/j.taap.2004.08.010; Del Razo LM, 2001, TOXICOL APPL PHARM, V177, P132, DOI 10.1006/taap.2001.9291; Ding W, 2005, MOL CELL BIOCHEM, V279, P105, DOI 10.1007/s11010-005-8227-y; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Felix K, 2005, J BIOCHEM MOL TOXIC, V19, P67, DOI 10.1002/jbt.20062; Gupta S, 2003, MOL CANCER THER, V2, P711; Haas AF, 1998, FREE RADICAL BIO MED, V25, P998, DOI 10.1016/S0891-5849(98)00135-X; Haga N, 2005, CANCER SCI, V96, P825, DOI 10.1111/j.1349-7006.2005.00114.x; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Iwama K, 2001, INT J CANCER, V92, P518, DOI 10.1002/ijc.1220; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kann S, 2005, TOXICOL SCI, V87, P365, DOI 10.1093/toxsci/kfi253; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liao VHC, 2005, BIOMETALS, V18, P519, DOI 10.1007/s10534-005-2996-3; Liu J, 2001, TOXICOL SCI, V61, P314, DOI 10.1093/toxsci/61.2.314; Lynn S, 2000, CIRC RES, V86, P514, DOI 10.1161/01.RES.86.5.514; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Munshi NC, 2002, INT J HEMATOL, V76, P340, DOI 10.1007/BF03165281; Murgo AJ, 2001, ONCOLOGIST, V6, P22, DOI 10.1634/theoncologist.6-suppl_2-22; Nesnow S, 2002, CHEM RES TOXICOL, V15, P1627, DOI 10.1021/tx025598y; Nikaido M, 2003, ENVIRON TOXICOL, V18, P306, DOI 10.1002/tox.10129; Nishigori C, 2004, ANTIOXID REDOX SIGN, V6, P561, DOI 10.1089/152308604773934314; Nishina H, 1999, DEVELOPMENT, V126, P505; NORDENSON I, 1991, HUM HERED, V41, P71, DOI 10.1159/000153979; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Pi JB, 2002, ENVIRON HEALTH PERSP, V110, P331, DOI 10.1289/ehp.02110331; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Santra A, 2000, Indian J Gastroenterol, V19, P112; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; Schuliga M, 2002, TOXICOL SCI, V70, P183, DOI 10.1093/toxsci/70.2.183; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Shi HL, 2004, CHEM RES TOXICOL, V17, P871, DOI 10.1021/tx049939e; Shumilla JA, 1999, J BIOL CHEM, V274, P36207, DOI 10.1074/jbc.274.51.36207; Soignet SL, 2001, ONCOLOGIST, V6, P11; Song L, 2006, J CELL BIOL, V175, P607, DOI 10.1083/jcb.200602149; Sun XC, 2006, TOXICOL IN VITRO, V20, P1139, DOI 10.1016/j.tiv.2006.02.008; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Woo SY, 2006, PEDIATR HEMAT ONCOL, V23, P231, DOI 10.1080/08880010500506818; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yan W, 2007, BIOCHEM BIOPH RES CO, V355, P1038, DOI 10.1016/j.bbrc.2007.02.064; Zhang W, 1998, LEUKEMIA, V12, P1383, DOI 10.1038/sj.leu.2401112; Zheng X, 2005, BIOCHEM BIOPH RES CO, V329, P95, DOI 10.1016/j.bbrc.2005.01.105	52	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21487	21496		10.1074/jbc.M702510200	http://dx.doi.org/10.1074/jbc.M702510200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17526490	hybrid			2022-12-25	WOS:000248047500076
J	Escusa, S; Laporte, D; Massoni, A; Boucherie, H; Dautant, A; Daignan-Fornier, B				Escusa, Stephanie; Laporte, Damien; Massoni, Aurelie; Boucherie, Helian; Dautant, Alain; Daignan-Fornier, Bertrand			Skp1-Cullin-F-box-dependent degradation of Aah1p requires its interaction with the F-box protein Saf1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; UBIQUITIN LIGASES; DEPENDENT DEGRADATION; ADENOSINE-DEAMINASE; ADENINE DEAMINASE; CRYSTAL-STRUCTURE; YEAST; SCF; COMPLEXES; SYSTEM	When yeast cells enter into quiescence in response to nutrient limitation, the adenine deaminase Aah1p is specifically degraded via a process requiring the F-box protein Saf1p and components of the Skp1-Cullin-F-box complex. In this paper, we show that Saf1p interacts with both Aah1p and Skp1p. Interaction with Skp1p, but not with Aah1p, requires the F-box domain of Saf1p. Based on deletion and point mutations, we further demonstrate that the F-box domain of Saf1p is critical for degradation of Aah1p. We also establish that overexpression of Saf1p in proliferating cells is sufficient to trigger the degradation of Aah1p. Using this property and a two-dimensional protein gel approach, we found that Saf1p has a small number of direct targets. Finally, we isolated and characterized several point mutations in Aah1p, which increase its stability during quiescence. The majority of the mutated residues are located in two distinct exposed regions in the Aah1p three-dimensional model structure. Two hybrid experiments strongly suggest that these domains are directly involved in interaction with Saf1p. Importantly, we obtained a mutation in Aah1p that does not affect the protein interaction with Saf1p but abolishes Aah1p degradation. Because this mutated residue is an exposed lysine in the Aah1p three-dimensional model, we propose that it is likely to be a major ubiquitylation site. All together, our data strongly argue for Saf1p being a bona fide Skp1-Cullin-F-box subunit.	Univ Bordeaux 2, CNRS, UMR 5095, Inst Biochim & Genet Cellulaires, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Daignan-Fornier, B (corresponding author), Univ Bordeaux 2, CNRS, UMR 5095, Inst Biochim & Genet Cellulaires, 1 Rue Camille Saint-Saens, F-33076 Bordeaux, France.	B.Daignan-Fornier@ibgc.u-bordeaux2.fr						BOUCHERIE H, 2006, YEAST PROTOCOLS, P47; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Durfee T, 1999, YEAST, V15, P1761, DOI 10.1002/(SICI)1097-0061(199912)15:16<1761::AID-YEA494>3.0.CO;2-C; Escobar-Henriques M, 2006, J CELL BIOL, V173, P645, DOI 10.1083/jcb.200512079; Escusa S, 2006, MOL MICROBIOL, V60, P1014, DOI 10.1111/j.1365-2958.2006.05153.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Louvet O, 1997, BIOTECHNIQUES, V23, P816, DOI 10.2144/97235bm11; Nishimoto T, 1999, BIOCHEM BIOPH RES CO, V262, P571, DOI 10.1006/bbrc.1999.1252; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Perrot M, 1999, ELECTROPHORESIS, V20, P2280, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2280::AID-ELPS2280>3.3.CO;2-H; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Ribard C, 2003, J MOL BIOL, V334, P1117, DOI 10.1016/j.jmb.2003.10.005; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; SIKORSKI RS, 1989, GENETICS, V122, P19; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Ting LM, 2005, J BIOL CHEM, V280, P9547, DOI 10.1074/jbc.M412693200; Wang ZM, 1998, BIOCHEMISTRY-US, V37, P8314, DOI 10.1021/bi980324o; Weihofen WA, 2004, J BIOL CHEM, V279, P43330, DOI 10.1074/jbc.M405001200; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	30	11	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20097	20103		10.1074/jbc.M702425200	http://dx.doi.org/10.1074/jbc.M702425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17517885	hybrid			2022-12-25	WOS:000247819300010
J	Kuwata, H; Fujimoto, C; Yoda, E; Shimbara, S; Nakatani, Y; Hara, S; Murakami, M; Kudo, I				Kuwata, Hiroshi; Fujimoto, Chikako; Yoda, Emiko; Shimbara, Satoko; Nakatani, Yoshihito; Hara, Shuntaro; Murakami, Makoto; Kudo, Ichiro			A novel role of group VIB calcium-independent phospholipase A(2) (iPLA(2)gamma) in the inducible expression of group IIA secretory PLA(2) in rat fibroblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; MECHANISM-BASED DISCRIMINATION; NEUROPATHY TARGET ESTERASE; SMOOTH-MUSCLE-CELLS; GROUP-V; PROSTAGLANDIN PRODUCTION; BROMOENOL LACTONE; MESANGIAL CELLS; GROUP-X; GENE	Group IIA secretory phospholipase A(2) (sPLA(2)-IIA) is a prototypic sPLA(2) enzyme that may play roles in modification of eicosanoid biosynthesis as well as antibacterial defense. In several cell types, inducible expression of sPLA(2) by pro-inflammatory stimuli is attenuated by group IVA cytosolic PLA(2) (cPLA(2)alpha) inhibitors such as arachidonyl trifluoromethylketone, leading to the proposal that prior activation of cPLA(2)alpha is required for de novo induction of sPLA(2). However, because of the broad specificity of several cPLA(2)alpha inhibitors used so far, a more comprehensive approach is needed to evaluate the relevance of this ambiguous pathway. Here, we provide evidence that the induction of sPLA(2)-IIA by pro-inflammatory stimuli requires group VIB calcium-independent PLA(2) (iPLA(2)gamma), rather than cPLA(2)alpha, in rat fibroblastic 3Y1 cells. Results with small interfering RNA unexpectedly showed that the cytokine induction of sPLA2-IIA in cPLA(2)alpha knockdown cells, in which cPLA(2)alpha protein was undetectable, was similar to that in replicate control cells. By contrast, knockdown of iPLA(2)gamma, another arachidonyl trifluoromethyl ketone-sensitive intracellular PLA(2), markedly reduced the cytokine- induced expression of sPLA(2)-IIA. Supporting this finding, the R-enantiomer of bromoenol lactone, an iPLA(2)gamma inhibitor, suppressed the cytokine- induced sPLA2-IIA expression, whereas (S)-bromoenol lactone, an iPLA(2)beta inhibitor, failed to do so. Moreover, lipopolysaccharide- stimulated sPLA(2)-IIA expression was also abolished by knockdown of iPLA(2)gamma. These findings open new insight into a novel regulatory role of iPLA(2)gamma in stimulus- coupled sPLA(2)-IIA expression.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 113, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan	Showa University; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.	ichi-ku@pharm.showa-u.ac.jp						ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bao SZ, 2006, J BIOL CHEM, V281, P20958, DOI 10.1074/jbc.M600075200; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Beck S, 2003, J BIOL CHEM, V278, P29799, DOI 10.1074/jbc.M211763200; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; CROWL RM, 1991, J BIOL CHEM, V266, P2647; Guidet B, 1996, INFECTION, V24, P103, DOI 10.1007/BF01713312; Hamaguchi K, 2003, BBA-MOL CELL BIOL L, V1635, P37, DOI 10.1016/j.bbalip.2003.10.004; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Herbert SP, 2006, J BIOL CHEM, V281, P35709, DOI 10.1074/jbc.M600699200; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kessen UA, 2005, J LIPID RES, V46, P2488, DOI 10.1194/jlr.M500325-JLR200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kinsey GR, 2007, AM J PHYSIOL-RENAL, V292, pF853, DOI 10.1152/ajprenal.00318.2006; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kuhn H, 2002, PROSTAG OTH LIPID M, V68-9, P263, DOI 10.1016/S0090-6980(02)00035-7; Kuwata H, 2000, J IMMUNOL, V165, P4024, DOI 10.4049/jimmunol.165.7.4024; Kuwata H, 2005, J BIOL CHEM, V280, P25830, DOI 10.1074/jbc.M500168200; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Kuwata H, 2004, BBA-MOL CELL BIOL L, V1686, P15, DOI 10.1016/j.bbalip.2004.07.002; Mancuso DJ, 2004, EUR J BIOCHEM, V271, P4709, DOI 10.1111/j.1432-1033.2004.04435.x; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Menschikowski M, 2006, PROSTAG OTH LIPID M, V79, P1, DOI 10.1016/j.prostaglandins.2005.10.005; Menschikowski M, 1995, ATHEROSCLEROSIS, V118, P173, DOI 10.1016/0021-9150(95)05604-1; Morgan NV, 2006, NAT GENET, V38, P752, DOI 10.1038/ng1826; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Murakami M, 2005, J BIOL CHEM, V280, P14028, DOI 10.1074/jbc.M413766200; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; Ni Z, 2006, J BIOL CHEM, V281, P16245, DOI 10.1074/jbc.M513874200; OKA S, 1991, J BIOL CHEM, V266, P9956; OUZUMI N, 1997, NATURE, V390, P618; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Piris-Gimenez A, 2005, J IMMUNOL, V175, P6786, DOI 10.4049/jimmunol.175.10.6786; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Quistad GB, 2003, P NATL ACAD SCI USA, V100, P7983, DOI 10.1073/pnas.1232473100; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Tanaka H, 2000, BIOCHEM BIOPH RES CO, V272, P320, DOI 10.1006/bbrc.2000.2776; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Tay HK, 2004, J BIOL CHEM, V279, P22505, DOI 10.1074/jbc.M308788200; Uozumi N, 2002, PROSTAG OTH LIPID M, V68-9, P59, DOI 10.1016/S0090-6980(02)00021-7; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; WEISS J, 1994, J BIOL CHEM, V269, P26331; Yan W, 2005, J BIOL CHEM, V280, P26669, DOI 10.1074/jbc.M502358200; Yang JY, 2003, FEBS LETT, V546, P247, DOI 10.1016/S0014-5793(03)00581-7; Yoshimoto T, 2002, PROSTAG OTH LIPID M, V68-9, P245, DOI 10.1016/S0163-7827(97)00002-7	64	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20124	20132		10.1074/jbc.M611883200	http://dx.doi.org/10.1074/jbc.M611883200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17475622	hybrid			2022-12-25	WOS:000247819300013
J	Manya, H; Suzuki, T; Akasaka-Manya, K; Ishida, H; Mizuno, M; Suzuki, Y; Inazu, T; Dohmae, N; Endo, T				Manya, Hiroshi; Suzuki, Takehiro; Akasaka-Manya, Keiko; Ishida, Hide-Ki; Mizuno, Mamoru; Suzuki, Yasushi; Inazu, Toshiyuki; Dohmae, Naoshi; Endo, Tamao			Regulation of mammalian protein O-mannosylation - Preferential amino acid sequence for O-mannose modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-DYSTROGLYCAN; C-MANNOSYLATION; GLYCOSYLATION; MUTATIONS; FUCOSE; FUCOSYLATION; REGION; YEAST; POMT1	O-Mannosyl glycans are important in muscle and brain development. Protein O-mannosyltransferase (POMT) catalyzes the initial step of O-mannosyl glycan biosynthesis. To understand which serine (Ser) and threonine (Thr) residues POMT recognizes for mannosylation, we prepared a series of synthetic peptides based on a mucin-like domain in alpha-dystroglycan (alpha-DG), one of the best known O-mannosylated proteins in mammals. In alpha-DG, the mucin-like domain spans amino acid residues 316 to 489. Two similar peptide sequences, corresponding to residues 401-420 and 336-355, respectively, were strongly mannosylated by POMT, whereas other peptides from alpha-DG and peptides of various mucin tandem repeat regions were poorly mannosylated. Peptides 401-420 and 336-355 contained four and six Ser and Thr residues, respectively. Substitution of Ala residues for the Ser or Thr residues showed that Thr-414 of peptide 401-420 and Thr-351 of peptide 336-355 were prominently modified by O-mannosylation. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry and Edman degradation analysis of the mannosylated peptide 401-420 indicated that Thr-414 was the Thr residue that was most prominently modified by O-mannosylation and that O-mannosylation occurred sequentially rather than at random. Based on these results, we propose a preferred amino acid sequence for mammalian O-mannose modification.	Fdn Res Aging & Promot Human Welfare, Tokyo Metropolitan Inst Gerontol, Glycobiol Res Grp, Itabashi Ku, Tokyo 173, Japan; RIKEN, Biomol Characterizat Team, Wako, Saitama 351, Japan; Tokyo Chem Ind Co Ltd, Kita Ku, Tokyo 114, Japan; Noguchi Inst, Res Dept, Itabashi Ku, Tokyo 173, Japan; Tokai Univ, Sch Engn, Inst Glycotechnol, Dept Appl Chem, Kanagawa 2591292, Japan	Tokyo Metropolitan Institute of Gerontology; RIKEN; Tokai University	Endo, T (corresponding author), Fdn Res Aging & Promot Human Welfare, Tokyo Metropolitan Inst Gerontol, Glycobiol Res Grp, Itabashi Ku, 35-2 Sakaecho, Tokyo 173, Japan.	endo@tmig.or.jp	Suzuki, Takehiro/B-3210-2013; Inazu, Toshiyuki/R-1966-2019; Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410; Manya, Hiroshi/0000-0003-1573-9177				Akasaka-Manya K, 2004, BIOCHEM BIOPH RES CO, V325, P75, DOI 10.1016/j.bbrc.2004.10.001; Akasaka-Manya K, 2006, J BIOL CHEM, V281, P19339, DOI 10.1074/jbc.M601091200; Beltran-Valero de Bernabe D, 2002, AM J HUM GENET, V71, P1033, DOI 10.1086/342975; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; Brancaccio A, 1997, EUR J BIOCHEM, V246, P166, DOI 10.1111/j.1432-1033.1997.00166.x; Chiba A, 1997, J BIOL CHEM, V272, P2156; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Endo T, 2004, GLYCOCONJUGATE J, V21, P3, DOI 10.1023/B:GLYC.0000043740.26062.2c; Endo T, 1999, BBA-GEN SUBJECTS, V1473, P237, DOI 10.1016/S0304-4165(99)00182-8; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; Harty C, 2001, MOL BIOL CELL, V12, P1093, DOI 10.1091/mbc.12.4.1093; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Lehle L, 2006, ANGEW CHEM INT EDIT, V45, P6802, DOI 10.1002/anie.200601645; Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200; Manya H, 2004, P NATL ACAD SCI USA, V101, P500, DOI 10.1073/pnas.0307228101; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Nakatsukasa K, 2004, J BIOL CHEM, V279, P49762, DOI 10.1074/jbc.M403234200; Proszynski TJ, 2004, MOL BIOL CELL, V15, P1533, DOI 10.1091/mbc.E03-07-0511; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Takahashi S, 2001, GLYCOBIOLOGY, V11, P37, DOI 10.1093/glycob/11.1.37; Ten Hagen KG, 2003, GLYCOBIOLOGY, V13, p1R, DOI 10.1093/glycob/cwg007; van Reeuwijk J, 2005, J MED GENET, V42, P907, DOI 10.1136/jmg.2005.031963; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yamada H, 1996, J NEUROCHEM, V66, P1518; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3	29	42	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20200	20206		10.1074/jbc.M702369200	http://dx.doi.org/10.1074/jbc.M702369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17502374	hybrid			2022-12-25	WOS:000247819300021
J	Li, J; Pan, GJ; Cui, K; Liu, YW; Xu, SB; Pei, DQ				Li, Jun; Pan, Guangjin; Cui, Kai; Liu, Yuwen; Xu, Shaobin; Pei, Duanqing			A dominant-negative form of mouse SOX2 induces trophectoderm differentiation and progressive polyploidy in mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; PLURIPOTENCY; NANOG; OCT4; ENHANCER; ANOPHTHALMIA; ELEMENTS; RENEWAL; COMPLEX	SOX2 plays an important role in early embryogenesis by cooperating with OCT4 in regulating gene expression in fertilized eggs, yet the precise mechanism through which SOX2 accomplishes this important function remains poorly understood. Here, we describe the identification of two nuclear localization signals (NLS) in SOX2 and the generation of a dominant-negative mutant (Dmu-mSox2) by mutating these two NLS in its high mobility group domain. Characterization of this mutant demonstrated that SOX2 shuttles between the cytoplasm and nucleus using these two NLS. The mutant has lost its ability to interact with OCT4, but remains competent to interact with wild-type SOX2. Functionally, Dmu-mSox2 is inactive and unable to cooperate with OCT4 in transactivating target promoters bearing its binding sites. However, Dmu-mSox2 is able to inhibit the activity of wild- type SOX2 and subsequently suppress the activity of downstream genes such as Oct4 and Nanog. When stably expressed in embryonic stem (ES) cells, DmumSox2 triggered progressive doublings of cell ploidy (> 8N), leading to differentiation into the trophectoderm lineage. Knockdown of Sox2 by small interfering RNA also induced trophectoderm differentiation and polyploid formation in mouse ES cells. These results suggest that SOX2 maintains stem cell pluripotency by shuttling between the nucleus and cytoplasm in cooperation with OCT4 to prevent trophectoderm differentiation and polyploid formation in ES cells.	Tsinghua Univ, Sch Med, Inst Pharmacol, Dept Biol Sci & Biotechnol,State Key Lab Biomembr, Beijing 100084, Peoples R China; Tsinghua Univ, Sch Med, Inst Biomed, Beijing 100084, Peoples R China	Tsinghua University; Tsinghua University	Pei, DQ (corresponding author), Tsinghua Univ, Sch Med, Inst Pharmacol, Dept Biol Sci & Biotechnol,State Key Lab Biomembr, Beijing 100084, Peoples R China.	pei_duanqing@gibh.ac.cn	zhou, xingru/G-4442-2012					Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Catena R, 2004, J BIOL CHEM, V279, P41846, DOI 10.1074/jbc.M405514200; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Constantinescu S, 2003, J CELL MOL MED, V7, P103, DOI 10.1111/j.1582-4934.2003.tb00209.x; Episkopou V, 2005, TRENDS NEUROSCI, V28, P219, DOI 10.1016/j.tins.2005.03.003; Fantes J, 2003, NAT GENET, V33, P461, DOI 10.1038/ng1120; Fraidenraich D, 1998, DEV BIOL, V204, P197, DOI 10.1006/dbio.1998.9053; Kishi M, 2000, DEVELOPMENT, V127, P791; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Niwa H, 2005, CELL, V123, P917, DOI 10.1016/j.cell.2005.08.040; Pan GJ, 2004, J BIOL CHEM, V279, P37013, DOI 10.1074/jbc.M405117200; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Pan GJ, 2006, FASEB J, V20, P1730, DOI 10.1096/fj.05-5543fje; Ragge NK, 2005, AM J MED GENET A, V135A, P1, DOI 10.1002/ajmg.a.30642; Remenyi A, 2003, GENE DEV, V17, P2048, DOI 10.1101/gad.269303; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Smith A, 2005, CELL, V123, P757, DOI 10.1016/j.cell.2005.11.012; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	25	71	75	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19481	19492		10.1074/jbc.M702056200	http://dx.doi.org/10.1074/jbc.M702056200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17507372	hybrid			2022-12-25	WOS:000247650600022
J	Uchida, Y; Nakano, SI; Gomi, F; Takahashi, H				Uchida, Yoko; Nakano, Shun-ichirou; Gomi, Fujiya; Takahashi, Hiroshi			Differential regulation of basic helix-loop-helix factors Mash1 and Olig2 by beta-amyloid accelerates both differentiation and death of cultured neural stem/progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; STEM-CELLS; TRANSCRIPTION FACTOR; PROGENITOR CELLS; HIPPOCAMPAL NEUROGENESIS; ADULT NEUROGENESIS; CORTICAL-NEURONS; MOUSE MODEL; BRAIN	Despite increased neurogenic differentiation markers in the hippocampal CA1 in Alzheimer disease, neurons are not replaced in CA1 and the neocortex in the disease. beta-Amyloid (A beta) might cause deterioration of the brain microenvironment supporting neurogenesis and the survival of immature neurons. To test this possibility, we examined whether A beta alters the expression of cell fate determinants in cerebral cortical cultures and in an Alzheimer disease mouse model (PrP-APPSW). Upregulation of Mash1 and down-regulation of Olig2 were found in cerebral cortical cultures treated with A beta-(1-42). Mash1 was expressed in nestin-positive immature cells. The majority of Mash1-positive cells in untreated cortical culture co-expressed Olig2. A beta increased the proportion of Olig2-negative/Mash1-positive cells. A decrease in Olig2+ cells was also observed in the cerebral cortex of adult PrP-APPSW mice. Cotransfection experiments with Mash1 cDNA and Olig2 siRNA revealed that overexpression of Mash1 in neurosphere cells retaining Olig2 expression enhanced neural differentiation but accelerated death of Olig2-depleted cells. Growth factor deprivation, which down-regulated Olig2, accelerated death of Mash1-overexpressing neurosphere cells. We conclude that cooperation between Mash1 and Olig2 is necessary for neural stem/progenitor cells to develop into fully mature neurons and that downregulation of Olig2 by A beta in Mash1-overexpressing cells switches the cell fate to death. Maintaining Olig2 expression in differentiating cells could have therapeutic potential.	Tokyo Metropolitan Inst Gerontol, Res Team Geriatr Disorders, Gene Express Res Grp, Itabashi Ku, Tokyo 173, Japan; Mitsubishi Kagaku Inst Life Sci, Tokyo 194, Japan	Tokyo Metropolitan Institute of Gerontology; Mitsubishi Kagaku Institute of Life Sciences (MITILS)	Uchida, Y (corresponding author), Tokyo Metropolitan Inst Gerontol, Res Team Geriatr Disorders, Gene Express Res Grp, Itabashi Ku, 35-2 Sakaecho, Tokyo 173, Japan.	57uchida@tmig.or.jp						Becker M, 2007, P NATL ACAD SCI USA, V104, P1691, DOI 10.1073/pnas.0610180104; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Calafiore M, 2006, NEUROBIOL AGING, V27, P606, DOI 10.1016/j.neurobiolaging.2005.03.019; Dong H, 2004, NEUROSCIENCE, V127, P601, DOI 10.1016/j.neuroscience.2004.05.040; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Elliott RC, 2001, NEUROSCIENCE, V106, P79, DOI 10.1016/S0306-4522(01)00198-1; Furusho M, 2006, DEV BIOL, V293, P348, DOI 10.1016/j.ydbio.2006.01.031; Gabay L, 2003, NEURON, V40, P485, DOI 10.1016/S0896-6273(03)00637-8; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; Hack MA, 2005, NAT NEUROSCI, V8, P865, DOI 10.1038/nn1479; Hack MA, 2004, MOL CELL NEUROSCI, V25, P664, DOI 10.1016/j.mcn.2003.12.012; HARDY J, 1997, TRENDS NEUROSCI, V20, P164; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Lopez-Toledano MA, 2004, J NEUROSCI, V24, P5439, DOI 10.1523/JNEUROSCI.0974-04.2004; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mazur-Kolecka B, 2006, NEUROBIOL AGING, V27, P1181, DOI 10.1016/j.neurobiolaging.2005.07.006; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Parras CM, 2004, EMBO J, V23, P4495, DOI 10.1038/sj.emboj.7600447; Pleasure SJ, 2000, J NEUROSCI, V20, P6095, DOI 10.1523/JNEUROSCI.20-16-06095.2000; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Schnell SA, 1999, J HISTOCHEM CYTOCHEM, V47, P719, DOI 10.1177/002215549904700601; Torii MA, 1999, DEVELOPMENT, V126, P443; Uchida Y, 2003, J BIOL CHEM, V278, P366, DOI 10.1074/jbc.M210091200; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Wen PH, 2002, NEUROBIOL DIS, V10, P8, DOI 10.1006/nbdi.2002.0490; Yamamoto S, 2001, J NEUROSCI, V21, P9814, DOI 10.1523/JNEUROSCI.21-24-09814.2001; Yung SY, 2002, P NATL ACAD SCI USA, V99, P16273, DOI 10.1073/pnas.232586699; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	36	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19700	19709		10.1074/jbc.M703099200	http://dx.doi.org/10.1074/jbc.M703099200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17488716	hybrid			2022-12-25	WOS:000247650600045
J	Ginestier, C; Adelaide, J; Goncalves, A; Repellini, L; Sircoulomb, F; Letessier, A; Finetti, P; Geneix, J; Charafe-Jauffret, E; Bertucci, F; Jacquemier, J; Viens, P; Birnbaum, D				Ginestier, C.; Adelaiede, J.; Goncalves, A.; Repellini, L.; Sircoulomb, F.; Letessier, A.; Finetti, P.; Geneix, J.; Charafe-Jauffret, E.; Bertucci, F.; Jacquemier, J.; Viens, P.; Birnbaum, D.			ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines	ONCOGENE			English	Article						herceptin; trastuzumab; ERBB2; breast cancer; phosphorylation; tyrosine kinase	ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; 1ST-LINE TREATMENT; PHASE-II; THERAPY; EXPRESSION; HERCEPTIN; EFFICACY; RESISTANCE; COMPLEX	Breast cancers that overexpress the ERBB2 tyrosine kinase receptor may be treated with the recombinant humanized monoclonal anti-ERBB2 antibody trastuzumab (herceptin). However, resistance to this targeted therapy is frequent. We have determined the response of 18 breast tumor cell lines to trastuzumab and compared it with the ERBB2 phosphorylation status using antibodies directed against tyrosine residue 1248. We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein.	Inst J Paoli I Calmettes, Ctr Rech Cancerol Marseille, INSERM, UMR599,Dept Oncol Mol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Ctr Rech Cancerol Marseille, INSERM, UMR599,Dept Oncol Med, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France; Inst J Paoli I Calmettes, Dept BioPathol, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, Ctr Rech Cancerol Marseille, INSERM, UMR599,Dept Oncol Mol, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	ADELAIDE, José JA/O-4390-2017; Letessier, Anne/M-3431-2017; Ginestier, Christophe/M-8828-2017; Finetti, Pascal/O-8669-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	ADELAIDE, José JA/0000-0003-4364-9857; Letessier, Anne/0000-0002-1894-4072; Ginestier, Christophe/0000-0002-7477-3837; Birnbaum, Daniel/0000-0001-7920-9883; Finetti, Pascal/0000-0002-2674-3123; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; BADACHE A, 2004, NAT CELL BIOL, V6, P515; Baselga J, 2004, SEMIN ONCOL, V31, P51, DOI 10.1053/j.seminoncol.2004.07.022; Baselga J, 2005, J CLIN ONCOL, V23, P2162, DOI 10.1200/JCO.2005.01.014; Bernard-Marty C, 2006, DRUGS, V66, P1577, DOI 10.2165/00003495-200666120-00004; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Emens Leisha A, 2005, Am J Ther, V12, P243; ETHIER SP, 1993, CANCER RES, V53, P627; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Gonzalez-Angulo AM, 2006, ONCOLOGIST, V11, P857, DOI 10.1634/theoncologist.11-8-857; Hudelist G, 2006, INT J CANCER, V118, P1126, DOI 10.1002/ijc.21492; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lee JW, 2006, CLIN CANCER RES, V12, P57, DOI 10.1158/1078-0432.CCR-05-0976; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Mass Robert D, 2005, Clin Breast Cancer, V6, P240, DOI 10.3816/CBC.2005.n.026; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nagy P, 2005, CANCER RES, V65, P473; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Pegram MD, 1999, SEMIN ONCOL, V26, P89; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091; Vogel CL, 2001, ONCOLOGY-BASEL, V61, P37, DOI 10.1159/000055400; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wobus M, 2001, GYNECOL ONCOL, V83, P227, DOI 10.1006/gyno.2001.6369	39	50	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7163	7169		10.1038/sj.onc.1210528	http://dx.doi.org/10.1038/sj.onc.1210528			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17525746				2022-12-25	WOS:000250715000011
J	Shan, X; Chang, YM; Lin, CLG				Shan, Xiu; Chang, Yueming; Lin, Chien-Liang Glenn			Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression	FASEB JOURNAL			English	Article						oxidative stress; oxidative damage; Alzheimer's disease; neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; PROMINENT FEATURE; OXIDIZED RNAS; STRESS; DAMAGE; NEURONS; BRAIN; REPAIR	We previously reported that up to 50% of messenger RNAs ( mRNA) are oxidatively damaged in the affected area of Alzheimer's disease ( AD) brains. The role of RNA oxidation in the cell death process is unknown. In the present study, we used cortical primary dissociated cultures to investigate the relationship between RNA oxidation and neuron degeneration induced by various insults, including hydrogen peroxide, glutamate, and amyloid beta peptide. These insults mediate the production of reactive oxygen species and thus induce oxidative stress. The results showed that RNA oxidation was an early event far preceding cell death, not merely a consequence of dying cells. RNA oxidation occurred primarily in a distinct group of neurons that died later. Identification of oxidized RNA species revealed that significant amounts of mRNAs were oxidized and that some mRNA species were more susceptible to oxidative damage, consistent with findings in the AD brain. The level of protein corresponding to the oxidized mRNA species was significantly decreased. Polyribosome analysis indicated that oxidized bases in mRNAs caused ribosome stalling on the transcripts, which led to a decrease of protein expression. These results suggest that RNA oxidation may be directly associated with neuronal deterioration, rather than harmless epiphenomenona, during the process of neurodegeneration.	Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Lin, CLG (corresponding author), Ohio State Univ, Dept Neurosci, 4198 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	lin.492@osu.edu	Lin, Chien-liang G/E-3513-2011		NATIONAL INSTITUTE ON AGING [R21AG027797] Funding Source: NIH RePORTER; NIA NIH HHS [AG027797] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363; Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; Andreasen N, 2001, ARCH NEUROL-CHICAGO, V58, P373, DOI 10.1001/archneur.58.3.373; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Butterfield DA, 1999, METHOD ENZYMOL, V309, P746; Butterfield DA, 1999, NEUROBIOL AGING, V20, P339; Davies E, 1995, METHOD CELL BIOL, V50, P209, DOI 10.1016/S0091-679X(08)61032-8; del Prete MJ, 2002, FASEB J, V16, P2003, DOI 10.1096/fj.02-0392fje; Dickey LF, 1998, PLANT CELL, V10, P475, DOI 10.1105/tpc.10.3.475; Ding QX, 2005, J NEUROSCI, V25, P9171, DOI 10.1523/JNEUROSCI.3040-05.2005; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; Honda K, 2005, J BIOL CHEM, V280, P20978, DOI 10.1074/jbc.M500526200; HUANG JA, 1995, BRAIN RES, V680, P16, DOI 10.1016/0006-8993(95)00209-9; JENNER P, 1992, ANN NEUROL S, V32, P82; KASAI H, 1991, Journal of Toxicological Sciences, V16, P95; Kikuchi A, 2002, NEUROBIOL DIS, V9, P244, DOI 10.1006/nbdi.2002.0466; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Lovell MA, 1999, J NEUROCHEM, V72, P771, DOI 10.1046/j.1471-4159.1999.0720771.x; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Meiners S, 1997, MOL CELL NEUROSCI, V10, P100, DOI 10.1006/mcne.1997.0643; Nunomura A, 2004, NEUROBIOL DIS, V17, P108, DOI 10.1016/j.nbd.2004.06.003; Nunomura A, 1999, J NEUROSCI, V19, P1959; OKA A, 1993, J NEUROSCI, V13, P1441; Omar Rawhi A., 1999, J Alzheimers Dis, V1, P139; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Pratico D, 2004, J ALZHEIMERS DIS, V6, P171; Ranum LPW, 2002, CURR OPIN GENET DEV, V12, P266, DOI 10.1016/S0959-437X(02)00297-6; Roediger B, 2003, NEUROBIOL DIS, V13, P222, DOI 10.1016/S0969-9961(03)00038-X; Shan X, 2006, NEUROBIOL AGING, V27, P657, DOI 10.1016/j.neurobiolaging.2005.03.022; Shan X, 2003, J NEUROSCI, V23, P4913; SHIFMAN MI, 1995, J NEUROSCI METH, V59, P205, DOI 10.1016/0165-0270(94)00184-I; SIES H, 1991, KLIN WOCHENSCHR, V69, P965, DOI 10.1007/BF01645140; Smith MA, 2006, J ALZHEIMERS DIS, V9, P305; WHITTEMORE ER, 1994, NEUROREPORT, V5, P1485, DOI 10.1097/00001756-199407000-00019; Yatin SM, 1999, NEUROBIOL AGING, V20, P325; Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5; Zhu XW, 2005, MOL NEUROBIOL, V31, P205, DOI 10.1385/MN:31:1-3:205	41	140	144	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2007	21	11					2753	2764		10.1096/fj.07-8200com	http://dx.doi.org/10.1096/fj.07-8200com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17496160				2022-12-25	WOS:000249237500017
J	Yoon, IS; Chen, E; Busse, T; Repetto, E; Lakshmana, MK; Koo, EH; Kang, DE				Yoon, Il-Sang; Chen, Eunice; Busse, Tracy; Repetto, Emanuela; Lakshmana, Madepalli K.; Koo, Edward H.; Kang, David E.			Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway	FASEB JOURNAL			English	Article						Alzheimer's disease; BACE1; secretase; Swedish; siRNA	ONSET ALZHEIMERS-DISEASE; BETA-SECRETASE CLEAVAGE; APOLIPOPROTEIN-E RECEPTOR; GAMMA-SECRETASE; CYTOPLASMIC DOMAIN; MEMBRANE MICRODOMAINS; BIOLOGICAL FUNCTIONS; ALPHA-SECRETASE; LRP; ASSOCIATION	The major defining pathological hallmark of Alzheimer's disease ( AD) is the accumulation of amyloid beta protein ( A beta), a small peptide derived from beta- and gamma- secretase cleavages of the amyloid precursor protein ( APP). Recent studies have shown that beta- and gamma- secretase activities of BACE1 and presenilin, respectively, are concentrated in intracellular lipid raft microdomains. However, the manner in which APP normally traffics to lipid rafts is unknown. In this study, using transient transfection and immuno- precipitation assays, we show that the cytoplasmic domain of low- density lipoprotein receptor- related protein ( LRP) interacts with APP and increases A beta secretion and APP beta- CTF ( C- terminal fragment) generation by promoting BACE1- APP interaction. We also employed discontinuous sucrose density gradient ultracentrifugation to show that the LRP cytoplasmic domain- mediated effect was accompanied by greatly increased localization of APP and BACE1 to lipid raft membranes, where beta- and gamma- secretase activities are highly enriched. Moreover, we provide evidence that endogenous LRP is required for the normal delivery of APP to lipid rafts and A beta generation primarily in the endocytic but not secretory pathway. These results may provide novel insights to block A beta generation by targeting LRP- mediated delivery of APP to raft microdomains.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kang, DE (corresponding author), Univ Calif San Diego, Dept Neurosci, MC0691,Leichtag Biomed Res 380,9500 Gilman Dr, La Jolla, CA 92093 USA.	dekang@ucsd.edu	Kang, David E./E-5234-2012	Kang, David E./0000-0002-7132-821X; REPETTO, EMANUELA/0000-0002-6270-3540	NATIONAL INSTITUTE ON AGING [R01AG012376] Funding Source: NIH RePORTER; NIA NIH HHS [AG-12376] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Cam JA, 2005, J BIOL CHEM, V280, P15464, DOI 10.1074/jbc.M500613200; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; De Strooper B, 2000, J CELL SCI, V113, P1857; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hollenbach E, 1998, NEUROLOGY, V50, P1905, DOI 10.1212/WNL.50.6.1905; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Lambert JC, 1998, LANCET, V351, P1787, DOI 10.1016/S0140-6736(05)78749-3; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Lleo A, 2005, J BIOL CHEM, V280, P27303, DOI 10.1074/jbc.M413969200; Lucero HA, 2004, ARCH BIOCHEM BIOPHYS, V426, P208, DOI 10.1016/j.abb.2004.03.020; Ma L, 2003, J NEUROSCI, V23, P3164; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Narita M, 1997, J NEUROCHEM, V69, P1904; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Steinhilb ML, 2002, J NEUROCHEM, V80, P1019, DOI 10.1046/j.0022-3042.2002.00764.x; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vetrivel KS, 2005, J BIOL CHEM, V280, P25892, DOI 10.1074/jbc.M503570200; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yang DS, 1999, NEUROSCIENCE, V90, P1217, DOI 10.1016/S0306-4522(98)00561-2; Yoon IS, 2005, J BIOL CHEM, V280, P20140, DOI 10.1074/jbc.M413729200	57	61	65	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2007	21	11					2742	2752		10.1096/fj.07-8114com	http://dx.doi.org/10.1096/fj.07-8114com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	207FR	17463224				2022-12-25	WOS:000249237500016
J	Hunter, GA; Zhang, JS; Ferreira, GC				Hunter, Gregory A.; Zhang, Junshun; Ferreira, Gloria C.			Transient kinetic studies support refinements to the chemical and kinetic mechanisms of aminolevulinate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL-PHOSPHATE ENZYMES; 5-AMINOLEVULINATE SYNTHASE; 8-AMINO-7-OXONONANOATE SYNTHASE; REACTION SPECIFICITY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SWISS-MODEL; BIOSYNTHESIS; CATALYSIS; COFACTOR	5-Aminolevulinate synthase catalyzes the pyridoxal 5'- phosphate-dependent condensation of glycine and succinyl-CoA to produce carbon dioxide, CoA, and 5-aminolevulinate, in a reaction cycle involving the mechanistically unusual successive cleavage of two amino acid substrate alpha-carbon bonds. Single and multiple turnover rapid scanning stopped-flow experiments have been conducted from pH 6.8-9.2 and 5-35 degrees C, and the results, interpreted within the framework of the recently solved crystal structures, allow refined characterization of the central kinetic and chemical steps of the reaction cycle. Quinonoid intermediate formation occurs with an apparent pK(a) of 7.7 +/- 0.1, which is assigned to His-207 acid-catalyzed decarboxylation of the alpha-amino-beta-ketoadipate intermediate to form an enol that is in rapid equilibrium with the 5-aminolevulinate-bound quinonoid species. Quinonoid intermediate decay occurs in two kinetic steps, the first of which is acid-catalyzed with a pKa of 8.1 +/- 0.1, and is assigned to protonation of the enol by Lys-313 to generate the product-bound external aldimine. The second step of quinonoid decay defines k(cat) and is relatively pH-independent and is assigned to opening of the active site loop to allow ALA dissociation. The data support important refinements to both the chemical and kinetic mechanisms and indicate that 5-aminolevulinate synthase operates under the stereoelectronic control predicted by Dunathan's hypothesis.	Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Hunter, GA (corresponding author), Univ S Florida, Coll Med, Dept Mol Med, MDC 7, Tampa, FL 33612 USA.	ghunter@health.usf.edu; gferreir@health.usf.edu	Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217	NIDDK NIH HHS [R01 DK063191, DK63191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063191] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKHTAR M, 1976, PHILOS T ROY SOC B, V273, P117, DOI 10.1098/rstb.1976.0005; Alexeev D, 2006, ORG BIOMOL CHEM, V4, P1209, DOI 10.1039/b517922j; Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Astner I, 2005, EMBO J, V24, P3166, DOI 10.1038/sj.emboj.7600792; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bottomley SS, 2004, WINTROBES CLIN HEMAT, P1011; Christen P, 2001, CHEM REC, V1, P436, DOI 10.1002/tcr.10005; COREY EJ, 1956, J AM CHEM SOC, V78, P6269, DOI 10.1021/ja01605a013; DUNATHAN HC, 1971, ADV ENZYMOL RAMB, V35, P79; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Ferreira GC, 2002, CELL MOL BIOL, V48, P827; FERREIRA GC, 1993, J BIOL CHEM, V268, P584; Fogle EJ, 2005, BIOCHEMISTRY-US, V44, P16392, DOI 10.1021/bi051475b; Gong J, 1998, BIOCHEMISTRY-US, V37, P3509, DOI 10.1021/bi9719298; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hunter GA, 1999, BIOCHEMISTRY-US, V38, P3711, DOI 10.1021/bi982390w; Hunter GA, 1999, J BIOL CHEM, V274, P12222, DOI 10.1074/jbc.274.18.12222; Kerbarh O, 2006, CHEM COMMUN, P60, DOI 10.1039/b511837a; KIKUCHI G, 1958, J BIOL CHEM, V233, P1214; MCDONALD IK, 1995, PROTEIN ENG, V8, P217, DOI 10.1093/protein/8.3.217; NANDI DL, 1978, J BIOL CHEM, V253, P8872; Schmidt A, 2001, BIOCHEMISTRY-US, V40, P5151, DOI 10.1021/bi002204y; Schulze JO, 2006, J MOL BIOL, V358, P1212, DOI 10.1016/j.jmb.2006.02.064; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Toney MD, 2005, ARCH BIOCHEM BIOPHYS, V433, P279, DOI 10.1016/j.abb.2004.09.037; TSAI MD, 1978, BIOCHEMISTRY-US, V17, P3183, DOI 10.1021/bi00609a002; WEISS B, 1963, J BIOL CHEM, V238, P1953; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; ZAMAN Z, 1973, BIOCHEM J, V135, P257, DOI 10.1042/bj1350257; Zhang JS, 2002, J BIOL CHEM, V277, P44660, DOI 10.1074/jbc.M203584200	31	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23025	23035		10.1074/jbc.M609330200	http://dx.doi.org/10.1074/jbc.M609330200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17485466	hybrid			2022-12-25	WOS:000248577500005
J	Moin, SM; Panteva, M; Jameel, S				Moin, Syed Mohammad; Panteva, Milena; Jameel, Shahid			The hepatitis E virus Orf3 protein protects cells from mitochondrial depolarization and death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; RAT-BRAIN HEXOKINASE; CYTOCHROME-C RELEASE; RECOMBINANT YEAST MITOCHONDRIA; PERMEABILITY TRANSITION; COLORIMETRIC ASSAY; VIRAL-HEPATITIS; APOPTOSIS; EXPRESSION; BINDING	The biology and pathogenesis of hepatitis E virus are poorly understood due to the lack of an in vitro culture or infection models. The viral Orf3 protein activates the cellular mitogen-activated protein kinase pathway and is likely to modulate the host cell environment for efficient viral replication. We screened for cellular genes whose transcription was differentially up-regulated in an Orf3-expressing stable cell line (ORF3/4). The gene for mitochondrial voltage-dependent anion channel (VDAC) was one such candidate. The up-regulation of VDAC in ORF3/4 cells was confirmed by Northern and Western blotting in various cell lines. Transfection of ORF3/4 cells with an ORF3-specific small interfering RNA led to a reduction in VDAC protein levels. VDAC is a critical mitochondrial outer membrane protein, and its overexpression results in apoptosis. Surprisingly, Orf3-expressing cells were protected against staurosporine-induced cell death by preservation of mitochondrial potential and membrane integrity. A small interfering RNA-mediated reduction in Orf3 and VDAC levels also made cells sensitive to staurosporine. Chemical cross-linking showed Orf3-expressing cells to contain higher levels of oligomeric VDAC. These cells also contained higher levels of hexokinase I that directly interacted with VDAC. This interaction is known to preserve mitochondrial potential and prevent cytochrome c release. We report here the first instance of a viral protein promoting cell survival through such a mechanism.	Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Jameel, S (corresponding author), Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India.	shahid@icgeb.res.in		Mechkarska, Milena/0000-0001-8882-0975; Moin, Syed/0000-0001-8789-9167	Wellcome Trust [063171] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abu-Hamad S, 2006, P NATL ACAD SCI USA, V103, P5787, DOI 10.1073/pnas.0600103103; Aflalo C, 1998, J BIOENERG BIOMEMBR, V30, P245, DOI 10.1023/A:1020544803475; Agrawal N, 2000, CURR SCI INDIA, V79, P711; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; ARORA KK, 1988, J BIOL CHEM, V263, P17422; Azoulay-Zohar H, 2000, EUR J BIOCHEM, V267, P2973; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Bour S, 2000, Adv Pharmacol, V48, P75; Boya P, 2003, BIOCHEM BIOPH RES CO, V304, P575, DOI 10.1016/S0006-291X(03)00630-2; Boya P, 2001, EMBO J, V20, P4325, DOI 10.1093/emboj/20.16.4325; Boya P, 2004, BBA-BIOENERGETICS, V1659, P178, DOI 10.1016/j.bbabio.2004.08.007; Brown GC, 2003, SCIENCE, V299, P838, DOI 10.1126/science.1082028; Bryson JM, 2002, J BIOL CHEM, V277, P11392, DOI 10.1074/jbc.M110927200; CARMICHAEL J, 1987, CANCER RES, V47, P936; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; Downward J, 2003, NATURE, V424, P896, DOI 10.1038/424896a; EMERSON SU, 2004, 8 ICTV, P851; Emerson SU, 2006, J VIROL, V80, P10457, DOI 10.1128/JVI.00892-06; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Graff J, 2005, J VIROL, V79, P6680, DOI 10.1128/JVI.79.11.6680-6689.2005; Graff J, 2006, J VIROL, V80, P5919, DOI 10.1128/JVI.00046-06; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Huang YW, 2007, J VIROL, V81, P3018, DOI 10.1128/JVI.02259-06; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; Korkaya H, 2001, J BIOL CHEM, V276, P42389, DOI 10.1074/jbc.M101546200; KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1002/hep.1840170525; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Mishra RN, 2005, ANAL BIOCHEM, V345, P149, DOI 10.1016/j.ab.2005.07.029; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAYAK NC, 1989, J GASTROEN HEPATOL, V4, P345, DOI 10.1111/j.1440-1746.1989.tb00846.x; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; PURCELL RH, 1988, VIRAL HEPATITIS LIVE, P131; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; RAMALINGASWAMI V, 1988, LANCET, V1, P571; REMPEL A, 1994, BBA-GENE STRUCT EXPR, V1219, P660, DOI 10.1016/0167-4781(94)90225-9; Roy AK, 2004, J BIOL CHEM, V279, P28345, DOI 10.1074/jbc.M400457200; Rucker E, 2004, J VIROL, V78, P12689, DOI 10.1128/JVI.78.22.12689-12693.2004; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Sebastian S, 1997, BIOCHEM BIOPH RES CO, V235, P389, DOI 10.1006/bbrc.1997.6797; Shinohara Y, 2000, EUR J BIOCHEM, V267, P6067, DOI 10.1046/j.1432-1327.2000.01687.x; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Steffens CM, 2001, AIDS, V15, pS21, DOI 10.1097/00002030-200100005-00004; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Tyagi S, 2004, J BIOL CHEM, V279, P29308, DOI 10.1074/jbc.M402017200; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VISTICA DT, 1991, CANCER RES, V51, P2515; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; XIE GC, 1990, ARCH BIOCHEM BIOPHYS, V276, P285, DOI 10.1016/0003-9861(90)90040-6; XIE GC, 1988, ARCH BIOCHEM BIOPHYS, V267, P803, DOI 10.1016/0003-9861(88)90090-2; Zafrullah M, 1997, J VIROL, V71, P9045, DOI 10.1128/JVI.71.12.9045-9053.1997; Zafrullah M, 1999, J VIROL, V73, P4074, DOI 10.1128/JVI.73.5.4074-4082.1999; Zalk R, 2005, BIOCHEM J, V386, P73, DOI 10.1042/BJ20041356; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	65	59	62	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21124	21133		10.1074/jbc.M701696200	http://dx.doi.org/10.1074/jbc.M701696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17488721	Green Accepted, hybrid			2022-12-25	WOS:000248047500039
J	Jia, ZZ; Moulson, CL; Pei, ZT; Miner, JH; Watkins, PA				Jia, Zhenzhen; Moulson, Casey L.; Pei, Zhengtong; Miner, Jeffrey H.; Watkins, Paul A.			Fatty acid transport protein 4 is the principal very long chain fatty Acyl-CoA synthetase in skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR UPTAKE; CLONING; EXPRESSION; PLASMA; ROLES; MOUSE; MECHANISM; RELEVANCE; MAMMALS; FAMILY	Fatty acid transport protein 4 (FATP4) is a fatty acyl-CoA synthetase that preferentially activates very long chain fatty acid substrates, such as C24: 0, to their CoA derivatives. To gain better insight into the physiological functions of FATP4, we established dermal fibroblast cell lines from FATP4-deficient wrinklefree mice and wild type (w.t.) mice. FATP4-/- fibroblasts had no detectable FATP4 protein by Western blot. Compared with w.t. fibroblasts, cells lacking FATP4 had an 83% decrease in C24: 0 activation. Peroxisomal degradation of C24: 0 was reduced by 58%, and rates of C24: 0 incorporation into major phospholipid species (54-64% decrease), triacylglycerol (64% decrease), and cholesterol esters ( 58% decrease) were significantly diminished. Because these lipid metabolic processes take place in different subcellular organelles, we used immunofluorescence and Western blotting of subcellular fractions to investigate the distribution of FATP4 protein and measured enzyme activity in fractions from w.t. and FATP4(-/-) fibroblasts. FATP4 protein and acyl-CoA synthetase activity localized to multiple organelles, including mitochondria, peroxisomes, endoplasmic reticulum, and the mitochondria-associated membrane fraction. We conclude that in murine skin fibroblasts, FATP4 is the major enzyme producing very long chain fatty acid-CoA for lipid metabolic pathways. Although FATP4 deficiency primarily affected very long chain fatty acid metabolism, mutant fibroblasts also showed reduced uptake of a fluorescent long chain fatty acid and reduced levels of long chain polyunsaturated fatty acids. FATP4-deficient cells also contained abnormal neutral lipid droplets. These additional defects indicate that metabolic abnormalities in these cells are not limited to very long chain fatty acids.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Washington University (WUSTL)	Watkins, PA (corresponding author), Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	watkins@kennedykrieger.org		Watkins, Paul A./0000-0002-3246-1405	NIAMS NIH HHS [AR 49269] Funding Source: Medline; NICHD NIH HHS [HD 10981] Funding Source: Medline; NINDS NIH HHS [NS 37355] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Bonen A, 2004, P NUTR SOC, V63, P245, DOI 10.1079/PNS2004331; Bonen A, 2002, MOL CELL BIOCHEM, V239, P181, DOI 10.1023/A:1020511125085; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; CONIGLIO JG, 1994, PROG LIPID RES, V33, P387, DOI 10.1016/0163-7827(94)90024-8; DiDonato D, 2003, J HISTOCHEM CYTOCHEM, V51, P773, DOI 10.1177/002215540305100608; DiRusso CC, 2005, J BIOL CHEM, V280, P16829, DOI 10.1074/jbc.M409598200; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gimeno RE, 2003, J BIOL CHEM, V278, P49512, DOI 10.1074/jbc.M309759200; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; Hajri T, 2002, ANNU REV NUTR, V22, P383, DOI 10.1146/annurev.nutr.22.020402.130846; Hall AM, 2005, J BIOL CHEM, V280, P11948, DOI 10.1074/jbc.M412629200; Hamilton JA, 2002, MOL CELL BIOCHEM, V239, P17, DOI 10.1023/A:1020542220599; Hamilton JA, 2001, J MOL NEUROSCI, V16, P99, DOI 10.1385/JMN:16:2-3:99; Herrmann T, 2003, J CELL BIOL, V161, P1105, DOI 10.1083/jcb.200207080; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagerstedt SA, 2001, MOL GENET METAB, V73, P38, DOI 10.1006/mgme.2001.3170; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mashek DG, 2006, CURR OPIN LIPIDOL, V17, P274, DOI 10.1097/01.mol.0000226119.20307.2b; Milger K, 2006, J CELL SCI, V119, P4678, DOI 10.1242/jcs.03280; MOORE SA, 1995, J LIPID RES, V36, P2433; Morita YS, 2000, SCIENCE, V288, P140, DOI 10.1126/science.288.5463.140; Moser AB, 1999, ANN NEUROL, V45, P100, DOI 10.1002/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U; Moser HW, 1991, TECHNIQUES DIAGNOSTI, P177; Moulson CL, 2003, P NATL ACAD SCI USA, V100, P5274, DOI 10.1073/pnas.0431186100; Pei ZT, 2004, J BIOL CHEM, V279, P54454, DOI 10.1074/jbc.M410091200; Pei ZT, 2003, J BIOL CHEM, V278, P47070, DOI 10.1074/jbc.M310075200; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schmuth M, 2005, J INVEST DERMATOL, V125, P1174, DOI 10.1111/j.0022-202X.2005.23934.x; Sprecher H, 1999, LIPIDS, V34, pS153, DOI 10.1007/BF02562271; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Steinberg SJ, 2000, J BIOL CHEM, V275, P35162, DOI 10.1074/jbc.M006403200; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; STEWART ME, 1991, ADV LIPID RES, V24, P263; Tong FM, 2006, ARCH BIOCHEM BIOPHYS, V447, P46, DOI 10.1016/j.abb.2006.01.005; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; Wanders RJA, 2006, ANNU REV BIOCHEM, V75, P295, DOI 10.1146/annurev.biochem.74.082803.133329; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; WATKINS PA, 1995, AM J HUM GENET, V57, P292; Wertz PW, 2000, ACTA DERM-VENEREOL, P7	49	84	87	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20573	20583		10.1074/jbc.M700568200	http://dx.doi.org/10.1074/jbc.M700568200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17522045	hybrid			2022-12-25	WOS:000247819300060
J	Maruyama, M; Hattori, A; Goto, Y; Ueda, M; Maeda, M; Fujiwara, H; Tsujimoto, M				Maruyama, Masato; Hattori, Akira; Goto, Yoshikuni; Ueda, Masamichi; Maeda, Michiyuki; Fujiwara, Hiroshi; Tsujimoto, Masafumi			Laeverin/aminopeptidase Q, a novel bestatin-sensitive leucine aminopeptidase belonging to the M1 family of aminopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-REGULATED AMINOPEPTIDASE; PROTEIN-COUPLED RECEPTOR; HAMSTER OVARY CELLS; C-TERMINAL DOMAIN; OXYTOCINASE SUBFAMILY; TRIMS PRECURSORS; MATERNAL SERUM; ANGIOTENSIN-IV; EXPRESSION; IDENTIFICATION	Laeverin/aminopeptidase Q (APQ) is a cell surface protein specifically expressed on human embryo-derived extravillous trophoblasts that invades the uterus during placentation. The cDNA cloning of Laeverin/APQ revealed that the sequence encodes a protein with 990 amino acid residues, and Laeverin/APQ contains the HEXXHX18E gluzincin motif, which is characteristic of the M1 family of aminopeptidases, although the exopeptidase motif of the family, GAMEN, is uniquely substituted for the HAMEN sequence. In this study, we expressed a recombinant human Laeverin/APQ using a baculovirus expression system, purified to homogeneity, and characterized its enzymatic properties. It was found that Laeverin/APQ had a broad substrate specificity toward synthetic substrate, although it showed a preference for Leu-4-methylcoumaryl-7-amide. Searching natural substrates, we found that Laeverin/ APQ was able to cleave the N-terminal amino acid of several peptides such as angiotensin III, kisspeptin-10, and endokinin C, which are abundantly expressed in the placenta. In contrast to the case with other M1 aminopeptidases, bestatin inhibited the aminopeptidase activity of Laeverin/ APQ much more effectively than other known aminopeptidase inhibitors. These results indicate that Laeverin/ APQis a novel bestatin-sensitive leucine aminopeptidase and suggest that the enzyme plays important roles in human placentation by regulating biological activity of key peptides at the embryo- maternal interface.	RIKEN, Lab Cellular Biochem, Wako, Saitama 351, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 606, Japan; Redox Biosci Inc, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Fac Med, Dept Obstet & Gynecol, Sakyo Ku, Kyoto 606, Japan	RIKEN; Kyoto University; Kyoto University	Hattori, A (corresponding author), RIKEN, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 351, Japan.	ahattori@riken.jp	FUJIWARA, Hiroshi/J-8401-2015	FUJIWARA, Hiroshi/0000-0003-3098-9406				Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200; Bilban M, 2004, J CELL SCI, V117, P1319, DOI 10.1242/jcs.00971; Chang SC, 2005, P NATL ACAD SCI USA, V102, P17107, DOI 10.1073/pnas.0500721102; CONSTAM DB, 1995, J BIOL CHEM, V270, P26931, DOI 10.1074/jbc.270.45.26931; Cui XL, 2003, J BIOL CHEM, V278, P28677, DOI 10.1074/jbc.M300456200; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; DANIELSEN EM, 1990, BIOCHEMISTRY-US, V29, P305, DOI 10.1021/bi00453a042; Fujiwara H, 2004, BIOCHEM BIOPH RES CO, V313, P962, DOI 10.1016/j.bbrc.2003.12.024; Goto Y, 2006, J BIOL CHEM, V281, P23503, DOI 10.1074/jbc.M603191200; Haas CS, 2006, ARTHRITIS RHEUM-US, V54, P2047, DOI 10.1002/art.21953; Hattori A, 1999, J BIOCHEM-TOKYO, V125, P931, DOI 10.1093/oxfordjournals.jbchem.a022371; Hattori A, 2000, J BIOCHEM-TOKYO, V128, P755, DOI 10.1093/oxfordjournals.jbchem.a022812; HOOPER NM, 1994, FEBS LETT, V31, P1; Ito N, 2004, BIOCHEM BIOPH RES CO, V314, P1008, DOI 10.1016/j.bbrc.2003.12.183; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Laustsen PG, 2001, EUR J BIOCHEM, V268, P98, DOI 10.1046/j.1432-1327.2001.01848.x; Luciani N, 1998, BIOCHEMISTRY-US, V37, P686, DOI 10.1021/bi971705p; Matsumoto H, 2000, EUR J BIOCHEM, V267, P46, DOI 10.1046/j.1432-1327.2000.00949.x; Matsumoto H, 2001, EUR J BIOCHEM, V268, P3259, DOI 10.1046/j.1432-1327.2001.02221.x; Miyashita H, 2002, BLOOD, V99, P3241, DOI 10.1182/blood.V99.9.3241; Nomura S, 2005, BBA-PROTEINS PROTEOM, V1751, P19, DOI 10.1016/j.bbapap.2005.04.006; Ofner LD, 2002, BIOCHEM J, V362, P191, DOI 10.1042/0264-6021:3620191; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; OKUYAMA T, 1991, CLIN CHIM ACTA, V196, P207, DOI 10.1016/0009-8981(91)90074-M; Osada T, 1999, J NEUROSCI, V19, P6068, DOI 10.1523/JNEUROSCI.19-14-06068.1999; Page NM, 2004, CELL MOL LIFE SCI, V61, P1652, DOI 10.1007/s00018-004-4035-x; Page NM, 2003, P NATL ACAD SCI USA, V100, P6245, DOI 10.1073/pnas.0931458100; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Reaux A, 1999, P NATL ACAD SCI USA, V96, P13415, DOI 10.1073/pnas.96.23.13415; Rogi T, 1996, J BIOL CHEM, V271, P56, DOI 10.1074/jbc.271.1.56; Rozenfeld R, 2004, J BIOL CHEM, V279, P43285, DOI 10.1074/jbc.M404369200; SAFAVI A, 1995, J NEUROCHEM, V65, P389; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208; Schomburg L, 1999, EUR J BIOCHEM, V265, P415, DOI 10.1046/j.1432-1327.1999.00753.x; Tanioka T, 2003, J BIOL CHEM, V278, P32275, DOI 10.1074/jbc.M305076200; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; Tobler AR, 1997, J NEUROCHEM, V68, P889; Tsujimoto M, 2005, BBA-PROTEINS PROTEOM, V1751, P9, DOI 10.1016/j.bbapap.2004.09.011; Turner AJ, 2004, HDB PROTEOLYTIC ENZY, V1, P289; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; Vonnahme KA, 2004, BIOL REPROD, V70, P132, DOI 10.1095/biolreprod.103.020412; WATANABE Y, 1995, BIOL CHEM H-S, V376, P397, DOI 10.1515/bchm3.1995.376.7.397; WU Q, 1991, P NATL ACAD SCI USA, V88, P676, DOI 10.1073/pnas.88.2.676; Xia Y, 2002, J BIOL CHEM, V277, P24601, DOI 10.1074/jbc.M201369200; Yamahara N, 2000, LIFE SCI, V66, P1401, DOI 10.1016/S0024-3205(00)00451-3; Yamamoto N, 2002, HUM MUTAT, V19, P251, DOI 10.1002/humu.10047; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	49	34	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20088	20096		10.1074/jbc.M702650200	http://dx.doi.org/10.1074/jbc.M702650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17525158	hybrid			2022-12-25	WOS:000247819300009
J	Rydziel, S; Stadmeyer, L; Zanotti, S; Durant, D; Smerdel-Ramoya, A; Canalis, E				Rydziel, Sheila; Stadmeyer, Lisa; Zanotti, Stefano; Durant, Deena; Smerdel-Ramoya, Anna; Canalis, Ernesto			Nephroblastoma overexpressed (Nov) inhibits osteoblastogenesis and causes osteopenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MORPHOGENETIC-PROTEIN; MARROW STROMAL CELLS; TWISTED-GASTRULATION; SIGNALING PATHWAYS; BMP ANTAGONIST; BETA-CATENIN; TGF-BETA; OSTEOCALCIN GENE; STEM-CELLS; IN-VITRO	Nephroblastoma overexpressed (Nov), a member of the Cyr 61, connective tissue growth factor, Nov (CCN) family of proteins, is expressed by osteoblasts, but its function in cells of the osteoblastic lineage is not known. We investigated the effects of Nov overexpression by transducing murine ST-2 stromal and MC3T3 osteoblastic cells with a retroviral vector where Nov is under the control of the cytomegalovirus promoter. We also examined the skeletal phenotype of transgenic mice expressing Nov under the control of the human osteocalcin promoter. Overexpression of Nov in ST-2 cells inhibited the appearance of mineralized nodules and decreased alkaline phosphatase activity and osteocalcin mRNA levels. Nov overexpression inhibited the effect of bone morphogenetic protein (BMP)-2 on the phosphorylation of Smad 1/5/8; on the transactivation of 12xSBE-Oc-pGL3, a BMP/Smad signaling reporter construct, and of Wnt 3 on cytoplasmic beta-catenin levels; and on the transactivation of the Wnt/beta- catenin signaling reporter construct 16xTCF-Luc. Nov overexpression did not activate Notch or transforming growth factor beta signaling. Glutathione S-transferase pulldown assays demonstrated direct Nov-BMP interactions. Nov transgenic mice exhibited osteopenia. In conclusion, Nov binds BMP-2 and antagonizes BMP-2 and Wnt activity, and its overexpression inhibits osteoblastogenesis and causes osteopenia.	St Francis Hosp & Med Ctr, Med Ctr, Dept Res, Hartford, CT 06105 USA	Saint Francis Hospital & Medical Center	Canalis, E (corresponding author), St Francis Hosp & Med Ctr, Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.	ecanalis@stfranciscare.org	Zanotti, Stefano/C-6006-2009		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR021707, R01AR021707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045227] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR21707, R01 AR021707] Funding Source: Medline; NIDDK NIH HHS [DK45227] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413; Billiard J, 2005, MOL ENDOCRINOL, V19, P90, DOI 10.1210/me.2004-0153; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Calhabeua F, 2006, EXP CELL RES, V312, P1876, DOI 10.1016/j.yexcr.2006.02.027; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chang CB, 2001, NATURE, V410, P483, DOI 10.1038/35068583; DAHL LK, 1952, P SOC EXP BIOL MED, V80, P474, DOI 10.3181/00379727-80-19661; Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200; Frenkel B, 1997, ENDOCRINOLOGY, V138, P2109, DOI 10.1210/en.138.5.2109; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004-0766; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P3875, DOI 10.1210/en.2005-0053; Gazzerro E, 1999, ENDOCRINOLOGY, V140, P562, DOI 10.1210/en.140.2.562; Gazzerro E, 2006, BONE, V39, P1252, DOI 10.1016/j.bone.2006.06.028; Gellhaus A, 2004, J BIOL CHEM, V279, P36931, DOI 10.1074/jbc.M404073200; Ghosh-Choudhury Nandini, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P345; Hagen T, 2002, J BIOL CHEM, V277, P23330, DOI 10.1074/jbc.M201364200; HARRIS SE, 1994, J BONE MINER RES, V9, P389; Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont J, 2005, J BONE MINER RES, V20, P2213, DOI 10.1359/JBMR.050818; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; Latinkic BV, 2003, DEVELOPMENT, V130, P2429, DOI 10.1242/dev.00449; Laurikkala J, 2003, DEV BIOL, V264, P91, DOI 10.1016/j.ydbio.2003.08.011; Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; Lin CG, 2005, J BIOL CHEM, V280, P8229, DOI 10.1074/jbc.M404903200; Liu ZY, 2006, J BIOL CHEM, V281, P17156, DOI 10.1074/jbc.M513812200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, P2089, DOI 10.1093/nar/30.9.2089; Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Nosaka T, 2003, MOL CELL BIOL, V23, P2969, DOI 10.1128/MCB.23.8.2969-2980.2003; Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005-0303; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Parisi MS, 2006, BONE, V38, P671, DOI 10.1016/j.bone.2005.10.005; Pereira RC, 2000, J CELL PHYSIOL, V182, P239, DOI 10.1002/(SICI)1097-4652(200002)182:2<239::AID-JCP13>3.0.CO;2-W; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955-2964.2006; Sims NA, 1997, MOL ENDOCRINOL, V11, P1695, DOI 10.1210/me.11.11.1695; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Su BY, 2001, J CLIN PATHOL-MOL PA, V54, P184, DOI 10.1136/mp.54.3.184; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yanagita M, 2005, CYTOKINE GROWTH F R, V16, P309, DOI 10.1016/j.cytogfr.2005.02.007; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200	70	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19762	19772		10.1074/jbc.M700212200	http://dx.doi.org/10.1074/jbc.M700212200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17500060	hybrid			2022-12-25	WOS:000247650600051
J	Mies, F; Spriet, C; Heliot, L; Sariban-Sohraby, S				Mies, Frederique; Spriet, Corentin; Heliot, Laurent; Sariban-Sohraby, Sarah			Epithelial Na+ channel stimulation by n-3 fatty acids requires proximity to a membrane-bound A-kinase-anchoring protein complexed with protein kinase A and phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; LIVING CELLS; CA2+ CURRENT; CAMP; CURRENTS; ACTIVATION; PHOSPHORYLATION; AQUAPORIN-2; INHIBITION; TRANSPORT	Essential polyunsatured fatty acids have been shown to modulate enzymes, channels and transporters, to interact with lipid bilayers and to affect metabolic pathways. We have previously shown that eicosapentanoic acid (EPA, C20:5, n-3) activates epithelial sodium channels (ENaCs) in a cAMP-dependent manner involving stimulation of cAMP-dependent protein kinase (PKA). In the present study, we explored further the mechanism of EPA stimulation of ENaC in A6 cells. Fluorescence resonance energy transfer experiments confirmed activation of PKA by EPA. Consistent with our previous studies, EPA had no further stimulatory effect on amiloride-sensitive transepithelial current (I-Na) in the presence of CPT-cAMP. Thus, we investigated the effect of EPA on cellular pathways which produce cAMP. EPA did not stimulate adenylate cyclase activity or total cellular cAMP accumulation. However, membrane-bound phosphodiesterase activity was inhibited by EPA from 2.46 pmol/mg of protein/min to 1.3 pmol/mg of protein/min. To investigate the potential role of an A-kinase-anchoring protein (AKAP), we used HT31, an inhibitor of the binding between PKA and AKAPs as well as cerulenin, an inhibitor of myristoylation and palmitoylation. Both agents prevented the stimulatory effect of EPA and CPT-cAMP on I-Na and drastically decreased the amount of PKA in the apical membrane. Colocalization experiments in A6 cells cotransfected with fluorescently labeled ENaC beta subunit and PKA regulatory subunit confirmed the close proximity of the two proteins and the membrane anchorage of PKA. Last, in A6 cells transfected with a dead mutant of Sgk, an enzyme which up-regulates ENaCs, EPA did not stimulate Na+ current. Our results suggest that stimulation of ENaCs by EPA occurs via SGK in membrane-bound compartments containing an AKAP, activated PKA, and a phosphodiesterase.	Univ Libre Bruxelles, Dept Phys, B-1070 Brussels, Belgium; Interdisciplinary Res Inst, Biophoton Cellulaire Fonctionnelle, F-59021 Lille, France	Universite Libre de Bruxelles	Sariban-Sohraby, S (corresponding author), NIH, Bldg 31,Rm 6A22, Bethesda, MD 20892 USA.	sohrabys@nei.nih.gov	Spriet, Corentin/ABE-4215-2021	Spriet, Corentin/0000-0002-5805-3426				Ali S, 1998, P NATL ACAD SCI USA, V95, P10274, DOI 10.1073/pnas.95.17.10274; Barnes AP, 2005, J BIOL CHEM, V280, P7997, DOI 10.1074/jbc.M407521200; Bengrine A, 2007, FASEB J, V21, P1189, DOI 10.1096/fj.06-6046com; Bringmann A, 2001, GRAEF ARCH CLIN EXP, V239, P859, DOI 10.1007/s004170100372; Camuzeaux B, 2005, BIOCHEM BIOPH RES CO, V332, P1107, DOI 10.1016/j.bbrc.2005.05.057; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Ferrier GR, 2002, CARDIOVASC RES, V54, P601, DOI 10.1016/S0008-6363(02)00275-4; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Henn V, 2005, BIOCHEM SOC T, V33, P1316, DOI 10.1042/BST0331316; Henn V, 2004, J BIOL CHEM, V279, P26654, DOI 10.1074/jbc.M312835200; Hill WG, 2002, J BIOL CHEM, V277, P33541, DOI 10.1074/jbc.C200309200; Hong MP, 2004, BRAIN RES, V1008, P81, DOI 10.1016/j.brainres.2004.02.033; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Kahn-Kirby AH, 2004, CELL, V119, P889, DOI 10.1016/j.cell.2004.11.005; Leaf A, 1998, Curr Opin Clin Nutr Metab Care, V1, P225, DOI 10.1097/00075197-199803000-00014; Leaf A, 1999, J NUTR BIOCHEM, V10, P440, DOI 10.1016/S0955-2863(99)00034-0; Liu LW, 2000, J PHYSIOL-LONDON, V525, P391, DOI 10.1111/j.1469-7793.2000.00391.x; MATSUMOTO PS, 1993, AM J PHYSIOL, V264, pC246, DOI 10.1152/ajpcell.1993.264.1.C246; Mies F, 2004, AM J PHYSIOL-RENAL, V287, pF850, DOI 10.1152/ajprenal.00078.2004; Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200; Rychkov GY, 2005, BIOCHEM J, V385, P551, DOI 10.1042/BJ20041604; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schonfeld P, 2004, J BIOENERG BIOMEMBR, V36, P241, DOI 10.1023/B:JOBB.0000031975.72350.c6; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Shlyonsky VG, 2003, AM J PHYSIOL-RENAL, V284, pF182, DOI 10.1152/ajprenal.00216.2002; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; Waharte F, 2006, CYTOM PART A, V69A, P299, DOI 10.1002/cyto.a.20240; WARRIE RS, 2005, AM J PHYSIOL, V289, pC455; Wells J N, 1977, Adv Cyclic Nucleotide Res, V8, P119; Wu P, 2004, P NATL ACAD SCI USA, V101, P17634, DOI 10.1073/pnas.0407649101; Xiao YF, 2004, BIOCHEM BIOPH RES CO, V321, P116, DOI 10.1016/j.bbrc.2004.06.114	39	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18339	18347		10.1074/jbc.M611160200	http://dx.doi.org/10.1074/jbc.M611160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17478424	hybrid			2022-12-25	WOS:000247302000040
J	Vingtdeux, V; Hamdane, M; Loyens, A; Gele, P; Drobeck, H; Begard, S; Galas, MC; Delacourte, A; Beauvillain, JC; Buee, L; Sergeant, N				Vingtdeux, Valerie; Hamdane, Malika; Loyens, Anne; Gele, Patrick; Drobeck, Herve; Begard, Severine; Galas, Marie-Christine; Delacourte, Andre; Beauvillain, Jean-Claude; Buee, Luc; Sergeant, Nicolas			Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE COMPLEX; VACUOLAR H+-ATPASE; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; TERMINAL FRAGMENTS; BETA-SECRETASE; PROTEOMIC ANALYSIS; TRANSGENIC MICE; LIPID RAFTS; EXOSOMES	Amyloid precursor protein (APP) metabolism is central to the pathogenesis of Alzheimer disease. We showed recently that the amyloid intracellular domain (AICD), which is released by gamma-secretase cleavage of APP C-terminal fragments (CTFs), is strongly increased in cells treated with alkalizing drugs (Vingtdeux, V., Hamdane, M., Begard, S., Loyens, A., Delacourte, A., Beauvillain, J.- C., Buee, L., Marambaud, P., and Sergeant, N. (2007) Neurobiol. Dis. 25, 686-696). Herein, we aimed to determine the cell compartment in which AICD accumulates. We show that APP-CTFs and AICD are present in multivesicular structures. Multivesicular bodies contain intraluminal vesicles (known as exosomes) when released in the extracellular space. We demonstrate that APP, APP-CTFs, and AICD are integrated and secreted within exosomes in differentiated neuroblastoma and primary neuronal culture cells. Together with recent data showing that amyloid-beta is also found in exosomes, our data show that multivesicular bodies are essential organelles for APP metabolism and that all APP metabolites can be secreted in the extracellular space.	Univ Lille 2, Ctr Rech Jean Pierre Aubert, INSERM, U837, F-59045 Lille, France; Univ Lille 2, Ctr Rech Jean Pierre Aubert, Inst Med Predict & Rech Rheapeut, Fac Med, F-59045 Lille, France; Univ Lille 1, CNRS, Inst Pasteur, UMR 8161, F-59021 Lille, France; Univ Lille 1, CNRS, Inst Biol, UMR 8161, F-59021 Lille, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Sergeant, N (corresponding author), INSERM, U837, Jean Pierre Auabert Res Ctr, 1,Place de Verdun, F-59045 Lille, France.	sergeant@lille.inserm.fr	Sergeant, Nicolas/O-5467-2017; BUEE, Luc/B-3126-2010; Vingtdeux, Valerie/C-2463-2012; Galas, Marie-Christine/AAL-9812-2020	Sergeant, Nicolas/0000-0003-1448-124X; BUEE, Luc/0000-0002-6261-4230; Vingtdeux, Valerie/0000-0003-4550-503X; Hamdane, Malika/0000-0001-7971-8696; Galas, Marie-Christine/0000-0002-3766-7103				Andrau D, 2003, J BIOL CHEM, V278, P25859, DOI 10.1074/jbc.M302622200; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Casas C, 2004, AM J PATHOL, V165, P1289, DOI 10.1016/S0002-9440(10)63388-3; Chen TY, 2006, BIOCHEM BIOPH RES CO, V342, P266, DOI 10.1016/j.bbrc.2006.01.156; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871; de Gassart A, 2004, TRAFFIC, V5, P896, DOI 10.1111/j.1600-0854.2004.00223.x; Efthimiopoulos S, 1996, P NATL ACAD SCI USA, V93, P8046, DOI 10.1073/pnas.93.15.8046; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Faure J, 2006, MOL CELL NEUROSCI, V31, P642, DOI 10.1016/j.mcn.2005.12.003; Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101; Fevrier B, 2004, CURR OPIN CELL BIOL, V16, P415, DOI 10.1016/j.ceb.2004.06.003; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1995, J BIOL CHEM, V270, P6186, DOI 10.1074/jbc.270.11.6186; Johnstone RM, 2005, BLOOD CELL MOL DIS, V34, P214, DOI 10.1016/j.bcmd.2005.03.002; Kaether C, 2006, TRAFFIC, V7, P408, DOI 10.1111/j.1600-0854.2006.00396.x; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Koh YH, 2005, J BIOL CHEM, V280, P32499, DOI 10.1074/jbc.M506199200; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Langui D, 2004, AM J PATHOL, V165, P1465, DOI 10.1016/S0002-9440(10)63405-0; Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876; Nixon RA, 2005, NEUROBIOL AGING, V26, P373, DOI 10.1016/j.neurobiolaging.2004.09.018; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943; Santiard-Baron D, 2005, J NEUROCHEM, V93, P330, DOI 10.1111/j.1471-4159.2005.03026.x; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P379; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; Segura E, 2005, BLOOD CELL MOL DIS, V35, P89, DOI 10.1016/j.bcmd.2005.05.003; Sergeant N, 2003, J NEUROCHEM, V85, P1581, DOI 10.1046/j.1471-4159.2003.01818.x; Sergeant N, 2002, J NEUROCHEM, V81, P663, DOI 10.1046/j.1471-4159.2002.00901.x; Stoeck A, 2006, BIOCHEM J, V393, P609, DOI 10.1042/BJ20051013; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Tezapsidis N, 1998, BIOCHEMISTRY-US, V37, P1274, DOI 10.1021/bi9714159; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; van der Goot FG, 2006, TRENDS CELL BIOL, V16, P514, DOI 10.1016/j.tcb.2006.08.003; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verbeek MM, 2002, J HISTOCHEM CYTOCHEM, V50, P681, DOI 10.1177/002215540205000509; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vingtdeux V, 2005, NEUROBIOL DIS, V20, P625, DOI 10.1016/j.nbd.2005.05.004; Vingtdeux V, 2007, NEUROBIOL DIS, V25, P686, DOI 10.1016/j.nbd.2006.09.019; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	58	144	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18197	18205		10.1074/jbc.M609475200	http://dx.doi.org/10.1074/jbc.M609475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17468104	hybrid			2022-12-25	WOS:000247302000026
J	Brooks, CL; Li, M; Hu, M; Shi, Y; Gu, W				Brooks, C. L.; Li, M.; Hu, M.; Shi, Y.; Gu, W.			The p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP	ONCOGENE			English	Article						HAUSP; p53; deubiquitination; Mdm2 degradation	MDM2; PATHWAY; DEUBIQUITINATION; UBIQUITINATION; RECOGNITION; CONTRIBUTES; USP7/HAUSP	The ubiquitin-specific protease HAUSP is a critical component of the p53-Mdm2 pathway by acting as a specific deubiquitinase for both p53 and Mdm2. Recent structural studies have indicated that p53 and Mdm2 bind to the N-terminal TRAF-like domain of HAUSP in a mutually exclusive manner. To understand the mechanism of HAUSP-mediated effects, we have created a p53 mutant that lacks HAUSP binding based on the crystal structure analysis. Indeed, this mutant p53 protein can be degraded by Mdm2 but fails to interact with HAUSP both in vitro and in vivo. Surprisingly, however, we have found that direct interaction between HAUSP and p53 is not absolutely required for it to antagonize efficiently Mdm2-mediated ubiquitination of p53 and that HAUSP is capable of enzymatically functioning in trans on p53 by using Mdm2 as a bridge. Further, we show that a trimeric protein complex containing p53, Mdm2 and HAUSP can exist in vivo, despite mutually exclusive binding, with Mdm2 serving as a binding mediator for p53 and HAUSP. These findings reveal the complication of HAUSP-mediated effects in the p53-Mdm2 interplay. It also has important implications for the development of novel chemotherapeutic compounds aimed at blocking this protein-protein interaction.	Columbia Univ, Coll Phys & Surg, Inst Canc Genet, Dept Pathol, New York, NY USA; Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA	Columbia University; Princeton University	Gu, W (corresponding author), Columbia Univ, Coll Phys & Surg, Inst Canc Genet, 1130 Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA098821, R01CA129627, R01CA104843, R01CA131439, R01CA085533, P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA097403, R01 CA098821, R01 CA085533, R01 CA104843, R01 CA131439, R01 CA129627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472	14	105	116	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7262	7266		10.1038/sj.onc.1210531	http://dx.doi.org/10.1038/sj.onc.1210531			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525743	Green Accepted			2022-12-25	WOS:000250955600010
J	Sommer, P; Le Rouzic, P; Gillingham, H; Berry, A; Kayahara, M; Huynh, T; White, A; Ray, DW				Sommer, P.; Le Rouzic, P.; Gillingham, H.; Berry, A.; Kayahara, M.; Huynh, T.; White, A.; Ray, D. W.			Glucocorticoid receptor overexpression exerts an antisurvival effect on human small cell lung cancer cells	ONCOGENE			English	Article						glucocorticoids; glucocorticoid receptor; small cell lung cancer	NF-KAPPA-B; GENE-EXPRESSION; PROOPIOMELANOCORTIN GENE; MICROARRAY ANALYSIS; INDUCED APOPTOSIS; MOLECULAR-BASIS; CYCLE ARREST; DNA-BINDING; GROWTH; DEXAMETHASONE	Small cell lung cancer ( SCLC) is an aggressive tumour with an abysmal prognosis. These cancers are characteristically resistant to glucocorticoid ( Gc) action, owing to impaired expression of the glucocorticoid receptor ( GR). We identified reduced GR expression in human SCLC cell lines, compared to a non-SCLC cell line. The SCLC cells also showed no Gc inhibition of proliferation, in contrast to non-SCLC cells. Retroviral overexpression of GR resulted in significantly increased cell death, which was partially blocked by the GR antagonist, RU486. Indeed, in cells sorted for GR expression, there was rapid, near complete loss of live cells by 72 h, in contrast to control cells that proliferated as expected. Flow cytometry using Annexin V revealed that cell death was by apoptosis. In addition, confocal analysis of fixed cells showed that cells overexpressing GR displayed a significant increase in fragmenting apoptotic nuclei. Microarray studies showed that transgenic GR expression upregulated the proapoptotic genes, BAD and BAX. We have, therefore, identified a profound apoptotic effect of GR in SCLC cells, which may explain the low levels of endogenous GR in SCLC cells. Understanding how GR overexpression leads to apoptotic cell death in SCLC cells may uncover new therapeutic strategies.	Univ Manchester, Fac Med & Human Sci, Dept Med, Ctr Mol Med, Manchester M13 9PT, Lancs, England; Univ Manchester, Endocrine Sci Res Grp, Manchester M13 9PT, Lancs, England; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester; University of Manchester	White, A (corresponding author), Univ Manchester, Fac Med & Human Sci, Dept Med, Ctr Mol Med, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	anne.white@manchester.ac.uk; david.w.ray@manchester.ac.uk	Zeef, Leo/D-6922-2011; White, Anne/G-7717-2015; Sommer, Paula/E-9454-2010; White, Anne/C-3753-2011	White, Anne/0000-0002-7686-2884; Kayahara, Midori/0000-0002-2967-1786; Ray, David/0000-0002-4739-6773; Smethurst, Helen/0000-0003-1234-7936	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BRAUNSCHWEIGER PG, 1983, CANCER RES, V43, P4757; CLARK AJL, 1990, J CLIN ENDOCR METAB, V70, P485, DOI 10.1210/jcem-70-2-485; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; CROSBY SR, 1988, J CLIN ENDOCR METAB, V67, P1272, DOI 10.1210/jcem-67-6-1272; Donn R, 2007, FASEB J, V21, P402, DOI 10.1096/fj.06-7236com; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; FARRELL WE, 1993, J MOL ENDOCRINOL, V10, P25, DOI 10.1677/jme.0.0100025; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; Hernandez J, 2000, CYTOKINE, V12, P791, DOI 10.1006/cyto.1999.0629; Herr I, 2003, CANCER RES, V63, P3112; Hofmann J, 1995, EUR J CANCER, V31A, P2053, DOI 10.1016/0959-8049(95)00431-9; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Kofler R, 2000, HISTOCHEM CELL BIOL, V114, P1; Leis H, 2004, MOL ENDOCRINOL, V18, P303, DOI 10.1210/me.2003-0350; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu YS, 2005, WORLD J GASTROENTERO, V11, P6373, DOI 10.3748/wjg.v11.i40.6373; Mathieu M, 1999, GENE THER, V6, P245, DOI 10.1038/sj.gt.3300814; Minna JD, 2003, CANCER CELL, V4, P163, DOI 10.1016/S1535-6108(03)00221-6; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Mortenson MM, 2005, LUNG CANCER, V49, P163, DOI 10.1016/j.lungcan.2005.01.006; NORMAN J, 1994, J SURG RES, V57, P33, DOI 10.1006/jsre.1994.1105; NORMAN MR, 1977, CANCER RES, V37, P3785; Pang D, 2004, BREAST CANCER RES TR, V88, pS27; RAY DW, 1994, J CLIN INVEST, V93, P1625, DOI 10.1172/JCI117143; Ray DW, 1996, CANCER RES, V56, P3276; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Tamura K, 2002, J HUM GENET, V47, P348, DOI 10.1007/s100380200048; Wang Z, 2003, J BIOL CHEM, V278, P50897, DOI 10.1074/jbc.M310297200; WHITE A, 1990, BAILLIERE CLIN ENDOC, V4, P1, DOI 10.1016/S0950-351X(05)80313-1; WHITE A, 1993, CLIN ENDOCRINOL, V39, P131, DOI 10.1111/j.1365-2265.1993.tb01765.x; Witschi H, 2005, INHAL TOXICOL, V17, P119, DOI 10.1080/08958370590899712; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Zhu XY, 2004, J STEROID BIOCHEM, V92, P375, DOI 10.1016/j.jsbmb.2004.07.010	46	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7111	7121		10.1038/sj.onc.1210524	http://dx.doi.org/10.1038/sj.onc.1210524			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496926				2022-12-25	WOS:000250715000005
J	Kida, A; Kakihana, K; Kotani, S; Kurosu, T; Miura, O				Kida, A.; Kakihana, K.; Kotani, S.; Kurosu, T.; Miura, O.			Glycogen synthase kinase-3 beta and p38 phosphorylate cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent degradation in hematopoietic cells	ONCOGENE			English	Article						cyclin D2; PI3K; GSK3 beta; p38; proteasomal degradation	ERYTHROPOIETIN RECEPTOR; CYCLE PROGRESSION; D2 EXPRESSION; BCR-ABL; D1; PROTEIN; DYSREGULATION; INHIBITION; PROLIFERATION; ACTIVATION	Cyclin D2 plays an important role in regulation of hematopoietic cell proliferation by cytokines and is implicated in oncogenesis of various hematopoietic malignancies. However, mechanisms regulating cyclin D2 stability and its expression level have remained to be known. Here, we demonstrate that interleukin- 3 signaling stabilizes cyclin D2 by inhibition of glycogen synthase kinase-3 beta ( GSK3 beta) through Janus kinase2-dependent activation of phosphatidylinositol 3'-kinase ( PI3K)/Akt signaling pathway in hematopoietic 32Dcl3 cells. On the other hand, osmotic stress was shown to induce a rapid proteasomal degradation of cyclin D2, which was mediated by activation of p38. GSK3 beta and p38 was demonstrated to phosphorylate cyclin D2 on Thr280 in vitro, while a cyclin D2 mutant with this residue substituted with Ala was found to be resistant to ubiquitination and proteasome- dependent degradation in 32Dcl3 cells. Inhibition of the PI3K pathway or induction of osmotic stress also caused a rapid proteasomal degradation of cyclin D2 in primary leukemic or myeloma cells. These results indicate that cyclin D2 expression in normal and malignant hematopoietic cells is regulated by ubiquitin/ proteasome- dependent degradation that is triggered by Thr280 phosphorylation by GSK3 beta or p38, which is induced by inhibition of the PI3K pathway or by osmotic stress, respectively.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Hematol, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Hematol, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Carthon BC, 2005, MOL CELL BIOL, V25, P1081, DOI 10.1128/MCB.25.3.1081-1088.2005; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Casanovas O, 2004, ONCOGENE, V23, P7537, DOI 10.1038/sj.onc.1208040; Chiles TC, 2004, J IMMUNOL, V173, P2901, DOI 10.4049/jimmunol.173.5.2901; Chin H, 1998, BLOOD, V91, P3734; Clappier E, 2006, LEUKEMIA, V20, P82, DOI 10.1038/sj.leu.2404008; Deininger MWN, 2001, CANCER RES, V61, P8005; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; Fox BC, 2005, CELL SIGNAL, V17, P473, DOI 10.1016/j.cellsig.2004.09.004; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Huang W, 2007, ONCOGENE, V26, P2471, DOI 10.1038/sj.onc.1210033; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jena N, 2002, CANCER RES, V62, P535; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Karrman K, 2006, EUR J HAEMATOL, V77, P27, DOI 10.1111/j.0902-4441.2006.t01-1-EJH2553.x; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Kozar K, 2005, CELL CYCLE, V4, P388, DOI 10.4161/cc.4.3.1551; Kurosu T, 2005, APOPTOSIS, V10, P1111, DOI 10.1007/s10495-005-3372-z; Kwak YT, 2005, J BIOL CHEM, V280, P33945, DOI 10.1074/jbc.M506206200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lucet IS, 2006, BLOOD, V107, P176, DOI 10.1182/blood-2005-06-2413; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Naderi S, 2004, J CELL SCI, V117, P3769, DOI 10.1242/jcs.01210; Okabe H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000128; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Radosevic N, 2001, LEUKEMIA, V15, P559, DOI 10.1038/sj.leu.2402092; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Yang GX, 2003, RRD PL CE P, V1, P7	42	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6630	6640		10.1038/sj.onc.1210490	http://dx.doi.org/10.1038/sj.onc.1210490			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486076				2022-12-25	WOS:000250081500005
J	Bondesen, BA; Jones, KA; Glasgow, WC; Pavlath, GK				Bondesen, Brenda A.; Jones, Kristen A.; Glasgow, Wayne C.; Pavlath, Grace K.			Inhibition of myoblast migration by prostacyclin is associated with enhanced cell fusion	FASEB JOURNAL			English	Article						prostaglandins; myogenesis; muscle repair	SKELETAL-MUSCLE REGENERATION; PROTEIN-TURNOVER; CYCLIC-AMP; NFATC2-DEPENDENT PATHWAY; GENE-EXPRESSION; PRECURSOR CELLS; SATELLITE CELLS; COX-2 PATHWAY; IN-VITRO; PROSTAGLANDINS	Satellite cells are stem cells that are critical for the formation and growth of skeletal muscle during myogenesis. To differentiate and fuse, proliferating satellite cells or myoblasts must migrate and establish stable cell-cell contacts. However, the factors that regulate myoblast migration and fusion are not understood completely. We have identified PGI(2) as a novel regulator of myogenesis in vitro. PGI(2) is a member of the family of prostaglandins ( PG), autocrine/paracrine signaling molecules synthesized via the cyclo-oxygenase-1 and -2 pathways. Primary mouse muscle cells both secrete PGI(2) and express the PGI(2) receptor, IP, at various stages of myogenesis. Using genetic and pharmacological approaches, we show that PGI(2) is a negative regulator of myoblast migration that also enhances cell fusion. Thus, PGI(2) may act as a "brake" on migrating cells to facilitate cell-cell contact and fusion. Together, our results highlight the importance of the balance between positive and negative regulators in cell migration and myogenesis. This work may have implications for migration of other populations of adult stem cells and/or cells that undergo fusion. Bondesen, B. A., Jones, K. A., Glasgow, W. C., Pavlath, G. K. Inhibition of myoblast migration by prostacyclin is associated with enhanced cell fusion.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Mercer Univ, Sch Med, Div Basic Med Sci, Macon, GA 31207 USA	Emory University; Mercer University	Pavlath, GK (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rm 5027,OW Rollins Res Bldg, Atlanta, GA 30322 USA.	gpavlat@emory.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052730, R01AR051372, R01AR047314, R01AR048884] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR48884, AR47314, AR052730, AR051372] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; BARACOS V, 1986, AM J PHYSIOL, V250, pE702, DOI 10.1152/ajpendo.1986.250.6.E702; Becciolini L, 2006, BBA-MOL CELL BIOL L, V1761, P43, DOI 10.1016/j.bbalip.2006.01.006; Birchmeier C, 2000, CURR OPIN CELL BIOL, V12, P725, DOI 10.1016/S0955-0674(00)00159-9; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; Blindt R, 2002, EUR J PHARMACOL, V444, P31, DOI 10.1016/S0014-2999(02)01607-2; Bondesen BA, 2006, AM J PHYSIOL-CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005; Bondesen BA, 2004, AM J PHYSIOL-CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004; Bulin C, 2005, ARTERIOSCL THROM VAS, V25, P84, DOI 10.1161/01.ATV.0000146814.81581.68; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Corti S, 2001, EXP CELL RES, V268, P36, DOI 10.1006/excr.2001.5267; DAVID JD, 1981, DEV BIOL, V82, P308, DOI 10.1016/0012-1606(81)90454-1; Dedieu S, 2004, EXP CELL RES, V292, P187, DOI 10.1016/j.yexcr.2003.08.014; Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje; ENTWISTLE A, 1986, J CELL BIOL, V103, P857, DOI 10.1083/jcb.103.3.857; Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085; GOLDBERG AL, 1984, FED PROC, V43, P1301; HASSELGREN PO, 1988, ANN SURG, V207, P399, DOI 10.1097/00000658-198804000-00005; HASSELGREN PO, 1990, BIOCHEM J, V270, P45, DOI 10.1042/bj2700045; Hill E, 2006, P NATL ACAD SCI USA, V103, P2494, DOI 10.1073/pnas.0506004103; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085; Hui AY, 2004, PROSTAG LEUKOTR ESS, V71, P329, DOI 10.1016/j.plefa.2004.04.007; Jansen KM, 2006, J CELL BIOL, V174, P403, DOI 10.1083/jcb.200601102; Kang JS, 2003, P NATL ACAD SCI USA, V100, P3989, DOI 10.1073/pnas.0736565100; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Kawajiri H, 2002, ARCH BIOCHEM BIOPHYS, V398, P51, DOI 10.1006/abbi.2001.2685; KERRY PJ, 1985, PROSTA LEUKOTR MED, V17, P283, DOI 10.1016/0262-1746(85)90117-9; Kohyama T, 2002, AM J PHYSIOL-LUNG C, V283, pL428, DOI 10.1152/ajplung.00432.2001; Kothapalli D, 2003, MOL PHARMACOL, V64, P249, DOI 10.1124/mol.64.2.249; Krauss RS, 2005, J CELL SCI, V118, P2355, DOI 10.1242/jcs.02397; Lindemann S, 2003, BASIC RES CARDIOL, V98, P8, DOI 10.1007/s00395-003-0383-1; MCLENNAN IS, 1991, J ANAT, V174, P115; Mitchell PO, 2004, AM J PHYSIOL-CELL PH, V287, pC1753, DOI 10.1152/ajpcell.00292.2004; Mylona E, 2006, J CELL PHYSIOL, V209, P314, DOI 10.1002/jcp.20724; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NICOLINI FA, 1990, THROMB RES, V59, P669, DOI 10.1016/0049-3848(90)90426-D; NOWAK J, 1983, PROSTA LEUKOTR MED, V11, P269, DOI 10.1016/0262-1746(83)90040-9; Olguin HC, 2003, DEV BIOL, V259, P209, DOI 10.1016/S0012-1606(03)00180-5; Otis JS, 2005, EXP CELL RES, V310, P417, DOI 10.1016/j.yexcr.2005.08.009; ROBERTSON TA, 1993, EXP CELL RES, V207, P321, DOI 10.1006/excr.1993.1199; RODEMANN HP, 1982, J BIOL CHEM, V257, P1632; ROSSI MJ, 1989, J CELL PHYSIOL, V141, P142, DOI 10.1002/jcp.1041410121; SCHUTZLE UB, 1984, BIOCHIM BIOPHYS ACTA, V805, P204, DOI 10.1016/0167-4889(84)90169-1; Shen W, 2006, J APPL PHYSIOL, V101, P1215, DOI 10.1152/japplphysiol.01331.2005; Stewart SA, 2004, J BIOL CHEM, V279, P29109, DOI 10.1074/jbc.M404271200; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Trappe RA, 2002, AM J PHYSIOL-ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001; Trappe TA, 2001, J CLIN ENDOCR METAB, V86, P5067, DOI 10.1210/jc.86.10.5067; VANDENBURGH HH, 1995, J CELL PHYSIOL, V163, P285, DOI 10.1002/jcp.1041630209; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; ZALIN RJ, 1987, EXP CELL RES, V172, P265, DOI 10.1016/0014-4827(87)90386-7; ZALIN RJ, 1977, DEV BIOL, V59, P241, DOI 10.1016/0012-1606(77)90258-5	55	53	54	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3338	3345		10.1096/fj.06-7070com	http://dx.doi.org/10.1096/fj.06-7070com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17488951				2022-12-25	WOS:000249781600034
J	Wu, R; Kausar, H; Johnson, P; Montoya-Durango, DE; Merchant, M; Rane, MJ				Wu, Rui; Kausar, Hina; Johnson, Paul; Montoya-Durango, Diego E.; Merchant, Michael; Rane, Madhavi J.			Hsp27 regulates Akt activation and polymorphonuclear leukocyte apoptosis by scaffolding MK2 to Akt signal complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; C-DEPENDENT ACTIVATION; CELL-SURVIVAL PATHWAY; P38 MAP KINASE; CYTOCHROME-C; ACTIN REORGANIZATION; NEGATIVE REGULATION; APAF-1 APOPTOSOME; HUMAN NEUTROPHILS	We have shown previously that Akt exists in a signal complex with p38 MAPK, MAPK-activated protein kinase-2 (MK2), and heat shock protein 27 (Hsp27) and MK2 phosphorylates Akt on Ser-473. Additionally, dissociation of Hsp27 from Akt, prior to Akt activation, induced polymorphonuclear leukocyte (PMN) apoptosis. However, the role of Hsp27 in regulating Akt activation was not examined. This study tested the hypothesis that Hsp27 regulates Akt activation and promotes cell survival by scaffolding MK2 to the Akt signal complex. Here we show that loss of Akt/Hsp27 interaction by anti-Hsp27 antibody treatment resulted in loss of Akt/MK2 interaction, loss of Akt-Ser-473 phosphorylation, and induced PMN apoptosis. Transfection of myristoylated Akt (AktCA) in HK-11 cells induced Akt-Ser-473 phosphorylation, activation, and Hsp27-Ser-82 phosphorylation. Co-transfection of AktCA with Hsp27 short interfering RNA, but not scrambled short interfering RNA, silenced Hsp27 expression, without altering Akt expression in HK-11 cells. Silencing Hsp27 expression inhibited Akt/MK2 interaction, inhibited Akt phosphorylation and Akt activation, and induced HK-11 cell death. Deletion mutagenesis studies identified acidic linker region (amino acids 117-128) on Akt as an Hsp27 binding region. Deletion of amino acids 117-128 on Akt resulted in loss of its interaction with Hsp27 and MK2 but not with Hsp90 as demonstrated by immunoprecipitation and glutathione S-transferase pulldown studies. Co-transfection studies demonstrated that constitutively activeMK2(MK2EE) phosphorylated Aktwt (wild type) on Ser-473 but failed to phosphorylate Akt(Delta 117-128) mutant in transfixed cells. These studies collectively define a novel role of Hsp27 in regulating Akt activation and cellular apoptosis by mediating interaction between Akt and its upstream activator MK2.	Univ Louisville, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem, Louisville, KY 40202 USA; Univ Louisville, Dept Mol Biol, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville	Rane, MJ (corresponding author), Univ Louisville, Dept Med, 570 S Preston St,Baxter 1 Bldg S 102C, Louisville, KY 40202 USA.	mjrane01@gwise.louisville.edu	Merchant, Michael/F-7109-2013; Merchant, Michael L/N-7444-2013	Merchant, Michael L/0000-0003-4128-4057	NIAID NIH HHS [1 R56 AI059165-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI059165] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Arrigo AP, 2005, ANTIOXID REDOX SIGN, V7, P414, DOI 10.1089/ars.2005.7.414; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Cabane C, 2004, CELL SIGNAL, V16, P1405, DOI 10.1016/j.cellsig.2004.05.003; Cappellini A, 2005, APOPTOSIS, V10, P141, DOI 10.1007/s10495-005-6069-4; Chang-Liao KS, 2001, ELEC SOC S, V2001, P1; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood-2003-05-1417; de Graauw M, 2005, J BIOL CHEM, V280, P29885, DOI 10.1074/jbc.M412708200; Efthymiou CA, 2004, BASIC RES CARDIOL, V99, P392, DOI 10.1007/s00395-004-0483-6; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; Gozal E, 2005, AM J PHYSIOL-CELL PH, V288, pC535, DOI 10.1152/ajpcell.00270.2004; Hansen RK, 2001, BIOCHEM BIOPH RES CO, V282, P186, DOI 10.1006/bbrc.2001.4548; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Khundmiri SJ, 2005, J AM SOC NEPHROL, V16, P2598, DOI 10.1681/ASN.2004121049; Klein JB, 2001, CELL SIGNAL, V13, P335, DOI 10.1016/S0898-6568(01)00151-6; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee YJ, 2005, J BIOL CHEM, V280, P18108, DOI 10.1074/jbc.M501131200; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Morissette MR, 2006, CIRC RES, V99, P15, DOI 10.1161/01.RES.0000231290.45676.d4; Nakajima K, 2005, LIFE SCI, V77, P96, DOI 10.1016/j.lfs.2004.12.017; Okamoto CT, 1999, AM J PHYSIOL-CELL PH, V277, pC1029; Oya-Ito T, 2006, J CELL BIOCHEM, V99, P279, DOI 10.1002/jcb.20781; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Piotrowicz RS, 1998, FASEB J, V12, P1481, DOI 10.1096/fasebj.12.14.1481; Pivovarova AV, 2005, BIOCHEM BIOPH RES CO, V331, P1548, DOI 10.1016/j.bbrc.2005.04.077; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schepers H, 2005, EXP HEMATOL, V33, P660, DOI 10.1016/j.exphem.2005.03.009; Sheth K, 2001, J SURG RES, V99, P129, DOI 10.1006/jsre.2000.6100; Shiue H, 2005, J BIOL CHEM, V280, P1688, DOI 10.1074/jbc.M409471200; Son GH, 2005, BIOCHEM BIOPH RES CO, V338, P1751, DOI 10.1016/j.bbrc.2005.10.152; Souza K, 2001, MOL MED, V7, P767, DOI 10.1007/BF03401967; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; VENKATAKRISHNAN CD, 2006, AM J PHYSIOL, V291, pH2980; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Zhang QS, 2001, INT J ONCOL, V19, P1057; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje; Zheng CL, 2006, J BIOL CHEM, V281, P37215, DOI 10.1074/jbc.M603622200	60	113	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21598	21608		10.1074/jbc.M611316200	http://dx.doi.org/10.1074/jbc.M611316200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17510053	hybrid			2022-12-25	WOS:000248196800006
J	Beinrohr, L; Harmat, V; Dobo, J; Lorincz, Z; Gal, P; Zavodszky, P				Beinrohr, Laszlo; Harmat, Veronika; Dobo, Jozsef; Loerincz, Zsolt; Gal, Peter; Zavodszky, Peter			C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC DOMAIN; HUMAN-COMPLEMENT; DEXTRAN SULFATE; HUMAN C1-INHIBITOR; CRYSTAL-STRUCTURES; SYSTEM PROTEASES; C1BAR INHIBITOR; TERNARY COMPLEX; FACTOR XIA; IN-VIVO	C1 inhibitor, a member of the serpin family, is a major down-regulator of inflammatory processes in blood. Genetic deficiency of C1 inhibitor results in hereditary angioedema, a dominantly inheritable, potentially lethal disease. Here we report the first crystal structure of the serpin domain of human C1 inhibitor, representing a previously unreported latent form, which explains functional consequences of several naturally occurring mutations, two of which are discussed in detail. The presented structure displays a novel conformation with a seven-stranded beta-sheet A. The unique conformation of the C-terminal six residues suggests its potential role as a barrier in the active-latent transition. On the basis of surface charge pattern, heparin affinity measurements, and docking of a heparin disaccharide, a heparin binding site is proposed in the contact area of the serpin-proteinase encounter complex. We show how polyanions change the activity of the C1 inhibitor by a novel "sandwich" mechanism, explaining earlier reaction kinetic and mutagenesis studies. These results may help to improve therapeutic C1 inhibitor preparations used in the treatment of hereditary angioedema, organ transplant rejection, and heart attack.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary; Eotvos Lorand Univ, Hungarian Acad Sci, Inst Chem, Lab Struct Chem & Biol, H-1117 Budapest, Hungary; Eotvos Lorand Univ, Hungarian Acad Sci, Inst Chem, Protein Modeling Grp, H-1117 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Hungarian Academy of Sciences; Eotvos Lorand University; Hungarian Academy of Sciences	Beinrohr, L (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, Karolina Ut 29, H-1113 Budapest, Hungary.	lbeinrohr@enzim.hu; gal@enzim.hu; zxp@enzim.hu	Zavodszky, Peter/C-1214-2008; Dobo, Jozsef/C-7331-2014; Harmat, Veronika/B-8033-2016; Gal, Peter/B-5886-2011	Harmat, Veronika/0000-0002-1866-9904; Dobo, Jozsef/0000-0001-9187-8502				AULAK KS, 1993, J BIOL CHEM, V268, P18088; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; Bohne-Lang A, 2005, NUCLEIC ACIDS RES, V33, pW214, DOI 10.1093/nar/gki385; Bos I.G.A.C., 2003, C1 INHIBITOR POTENTI; Bos IGA, 2003, J BIOL CHEM, V278, P29463, DOI 10.1074/jbc.M302977200; Bos IGA, 2002, IMMUNOBIOLOGY, V205, P518, DOI 10.1078/0171-2985-00151; Bos IGAC, 2001, INT IMMUNOPHARMACOL, V1, P1583, DOI 10.1016/S1567-5769(01)00073-X; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; Budayova-Spano M, 2002, STRUCTURE, V10, P1509, DOI 10.1016/S0969-2126(02)00881-X; Cai SH, 2003, J IMMUNOL, V171, P4786, DOI 10.4049/jimmunol.171.9.4786; Caldwell EEO, 1999, ARCH BIOCHEM BIOPHYS, V361, P215, DOI 10.1006/abbi.1998.0996; Caliezi C, 2000, PHARMACOL REV, V52, P91; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CAUGHMAN GB, 1982, MOL IMMUNOL, V19, P287, DOI 10.1016/0161-5890(82)90342-X; COUTINHO M, 1994, J IMMUNOL, V153, P3648; Cumming SA, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.10.e114; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gaboriaud C, 2000, EMBO J, V19, P1755, DOI 10.1093/emboj/19.8.1755; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gozzo AJ, 2003, BRAZ J MED BIOL RES, V36, P1055, DOI 10.1590/S0100-879X2003000800011; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harmat V, 2004, J MOL BIOL, V342, P1533, DOI 10.1016/j.jmb.2004.07.014; Huntington JA, 2003, STRUCTURE, V11, P205, DOI 10.1016/S0969-2126(02)00944-9; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 2002, J BIOL CHEM, V277, P46347, DOI 10.1074/jbc.M207682200; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Jiang HX, 2001, J EXP MED, V194, P1609, DOI 10.1084/jem.194.11.1609; Jin L, 2005, J BIOL CHEM, V280, P4704, DOI 10.1074/jbc.M411309200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2006, EMBO J, V25, P2029, DOI 10.1038/sj.emboj.7601089; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kalmar L, 2005, HUM MUTAT, V25, P1, DOI 10.1002/humu.20112; Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; Liu DX, 2003, J IMMUNOL, V171, P2594, DOI 10.4049/jimmunol.171.5.2594; Mauron T, 1998, THROMB HAEMOSTASIS, V80, P82, DOI 10.1055/s-0037-1615143; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; ODERMATT E, 1981, FEBS LETT, V131, P283, DOI 10.1016/0014-5793(81)80385-7; PATSTON PA, 1995, FEBS LETT, V368, P401, DOI 10.1016/0014-5793(95)00694-5; PERKINS SJ, 1990, J MOL BIOL, V214, P751, DOI 10.1016/0022-2836(90)90290-3; Rezaie AR, 2006, BIOCHEMISTRY-US, V45, P9427, DOI 10.1021/bi060820+; SIM RB, 1980, BIOCHIM BIOPHYS ACTA, V612, P433, DOI 10.1016/0005-2744(80)90126-6; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Tang J, 2005, J BIOL CHEM, V280, P41077, DOI 10.1074/jbc.M506766200; van Doorn MBA, 2005, J ALLERGY CLIN IMMUN, V116, P876, DOI 10.1016/j.jaci.2005.05.019; Wuillemin WA, 1996, J BIOL CHEM, V271, P12913, DOI 10.1074/jbc.271.22.12913; Wuillemin WA, 1997, J IMMUNOL, V159, P1953; Zahedi R, 2001, J IMMUNOL, V167, P1500, DOI 10.4049/jimmunol.167.3.1500; Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396	60	79	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21100	21109		10.1074/jbc.M700841200	http://dx.doi.org/10.1074/jbc.M700841200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17488724	hybrid			2022-12-25	WOS:000248047500036
J	Donmez, I; Rajagopal, V; Jeong, YJ; Patel, SS				Donmez, Ilker; Rajagopal, Vaishnavi; Jeong, Yong-Joo; Patel, Smita S.			Nucleic acid unwinding by hepatitis C virus and bacteriophage T7 helicases is sensitive to base pair stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI UVRD; HEXAMERIC HELICASE; GENE-4 PROTEIN; IN-VITRO; THERMODYNAMIC PARAMETERS; HCVNS3 HELICASE; MECHANISM; REPLICATION; TRANSLOCATION	Helicases are motor enzymes that convert the chemical energy of NTP hydrolysis into mechanical force for motion and nucleic acid strand separation. Within the cell, helicases process a range of nucleic acid sequences. It is not known whether this composite rate of moving and opening the strands of nucleic acids depends on the base sequence. Our presteady state kinetic studies of helicases from two classes, the ring-shaped T7 helicase and two forms of non-ring-shaped hepatitis C virus (HCV) helicase, show that both the unwinding rate and processivity depend on the sequence and decrease as the nucleic acid stability increases. The DNA unwinding activity of T7 helicase and the RNA unwinding activity of HCV helicases decrease steeply with increasing base pair stability. On the other hand, the DNA unwinding activity of HCV helicases is less sensitive to base pair stability. These results predict that helicases will fall into a spectrum of modest to high sensitivity to base pair stability depending on their biological role in the cell. Modeling of the dependence provided the degree of the active involvement of helicase in base pair destabilization during the unwinding process and distinguished between passive and active mechanisms of unwinding.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Kookmin Univ, Dept Bio & Nanochem, Seoul 136702, South Korea	Rutgers State University New Brunswick; Rutgers State University Medical Center; Kookmin University	Patel, SS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	patelss@umdnj.edu	Rajagopal, Vaishnavi/E-5272-2012		NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Betterton MD, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.011904; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; Byrd AK, 2005, BIOCHEMISTRY-US, V44, P12990, DOI 10.1021/bi050703z; Byrd AK, 2004, NAT STRUCT MOL BIOL, V11, P531, DOI 10.1038/nsmb774; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; CHEN YZ, 1992, J BIOMOL STRUCT DYN, V10, P415, DOI 10.1080/07391102.1992.10508656; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Cunningham EL, 2005, CURR OPIN STRUC BIOL, V15, P68, DOI 10.1016/j.sbi.2005.01.003; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Donmez I, 2006, NUCLEIC ACIDS RES, V34, P4216, DOI 10.1093/nar/gkl508; Dumont S, 2006, NATURE, V439, P105, DOI 10.1038/nature04331; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Enemark EJ, 2006, NATURE, V442, P270, DOI 10.1038/nature04943; Eoff RL, 2006, NAT STRUCT MOL BIOL, V13, P242, DOI 10.1038/nsmb1055; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; FELSENFE.G, 1967, ANNU REV BIOCHEM, V36, P407, DOI 10.1146/annurev.bi.36.070167.002203; Fischer CJ, 2004, J MOL BIOL, V344, P1287, DOI 10.1016/j.jmb.2004.10.005; Galletto R, 2004, J MOL BIOL, V343, P101, DOI 10.1016/j.jmb.2004.07.056; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; He ZG, 2004, J BIOL CHEM, V279, P22190, DOI 10.1074/jbc.M401100200; Howe AYM, 1999, PROTEIN SCI, V8, P1332, DOI 10.1110/ps.8.6.1332; Jeong YJ, 2004, P NATL ACAD SCI USA, V101, P7264, DOI 10.1073/pnas.0400372101; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kim DE, 2002, J MOL BIOL, V321, P807, DOI 10.1016/S0022-2836(02)00733-7; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lam AMI, 2006, J VIROL, V80, P404, DOI 10.1128/JVI.80.1.404-411.2006; Lam AMI, 2003, J VIROL, V77, P3950, DOI 10.1128/JVI.77.7.3950-3961.2003; Levin M.K., 2003, MOL MOTORS, P179; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2004, J BIOL CHEM, V279, P26005, DOI 10.1074/jbc.M403257200; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lucius AL, 2003, BIOPHYS J, V85, P2224, DOI 10.1016/S0006-3495(03)74648-7; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Patel SS, 2006, J BIOL CHEM, V281, P18265, DOI 10.1074/jbc.R600008200; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Tackett AJ, 2005, J BIOL CHEM, V280, P10797, DOI 10.1074/jbc.M407971200; Tackett AJ, 2001, NUCLEIC ACIDS RES, V29, P565, DOI 10.1093/nar/29.2.565; Takahashi TS, 2005, TRENDS BIOCHEM SCI, V30, P437, DOI 10.1016/j.tibs.2005.06.007; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Xia TB, 1998, BIOCHEMISTRY-US, V37, P14719, DOI 10.1021/bi9809425; Yang SX, 2002, J MOL BIOL, V321, P839, DOI 10.1016/S0022-2836(02)00711-8	55	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21116	21123		10.1074/jbc.M702136200	http://dx.doi.org/10.1074/jbc.M702136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17504766	hybrid			2022-12-25	WOS:000248047500038
J	Grotenbreg, GM; Nicholson, MJ; Fowler, KD; Wilbuer, K; Octavio, L; Yang, MX; Chakraborty, AK; Ploegh, HL; Wucherpfennig, KW				Grotenbreg, Gijsbert M.; Nicholson, Melissa J.; Fowler, Kevin D.; Wilbuer, Kathrin; Octavio, Leah; Yang, Maxine; Chakraborty, Arup K.; Ploegh, Hidde L.; Wucherpfennig, Kai W.			Empty class II major histocompatibility complex created by peptide photolysis establishes the role of DM in peptide association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA-DR MOLECULES; RESTRICTED ANTIGEN PRESENTATION; MYELIN BASIC-PROTEIN; INVARIANT CHAIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MHC MOLECULES; BINDING; DISSOCIATION; EXPRESSION	DM catalyzes the exchange of peptides bound to Class II major histocompatibility complex (MHC) molecules. Because the dissociation and association components of the overall reaction are difficult to separate, a detailed mechanism of DM catalysis has long resisted elucidation. UV irradiation of DR molecules loaded with a photocleavable peptide (caged Class II MHC molecules) enabled synchronous and verifiable evacuation of the peptide-binding groove and tracking of early binding events in real time by fluorescence polarization. Empty DR molecules generated by photocleavage rapidly bound peptide but quickly resolved into species with substantially slower binding kinetics. DM formed a complex with empty DR molecules that bound peptide with even faster kinetics than empty DR molecules just having lost their peptide cargo. Mathematical models demonstrate that the peptide association rate of DR molecules is substantially higher in the presence of DM. We therefore unequivocally establish that DM contributes directly to peptide association through formation of a peptide-loading complex between DM and empty Class II MHC. This complex rapidly acquires a peptide analogous to the MHC class I peptide-loading complex.	Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Biol Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Wucherpfennig, KW (corresponding author), 44 Binney St, Boston, MA 02115 USA.	Kai_Wucherpfennig@dfci.harvard.edu			NIAID NIH HHS [R01 AI057493, P01 AI045757, P01 AI071195] Funding Source: Medline; NIH HHS [DP1 OD001022] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057493, P01AI071195, P01AI045757] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTMAN JD, 1993, P NATL ACAD SCI USA, V90, P10330, DOI 10.1073/pnas.90.21.10330; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Belmares MP, 2002, J IMMUNOL, V169, P5109, DOI 10.4049/jimmunol.169.9.5109; Busch R, 2000, CURR OPIN IMMUNOL, V12, P99, DOI 10.1016/S0952-7915(99)00057-6; Busch R, 1998, J BIOL CHEM, V273, P27557, DOI 10.1074/jbc.273.42.27557; Busch R, 2005, IMMUNOL REV, V207, P242, DOI 10.1111/j.0105-2896.2005.00306.x; Cresswell P, 2005, IMMUNOL REV, V207, P145, DOI 10.1111/j.0105-2896.2005.00316.x; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; Doebele RC, 2000, IMMUNITY, V13, P517, DOI 10.1016/S1074-7613(00)00051-0; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; Fremont DH, 1998, IMMUNITY, V9, P385, DOI 10.1016/S1074-7613(00)80621-4; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Joshi RV, 2000, BIOCHEMISTRY-US, V39, P3751, DOI 10.1021/bi9923656; Katz JF, 1996, J EXP MED, V184, P1747, DOI 10.1084/jem.184.5.1747; Kropshofer H, 1996, EMBO J, V15, P6144, DOI 10.1002/j.1460-2075.1996.tb01002.x; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; Lazarski CA, 2006, J EXP MED, V203, P1319, DOI 10.1084/jem.20060058; Lennon-Dumenil AM, 2002, CURR OPIN IMMUNOL, V14, P15, DOI 10.1016/S0952-7915(01)00293-X; Lovitch SB, 2003, J IMMUNOL, V171, P2183, DOI 10.4049/jimmunol.171.5.2183; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; Nanda NK, 2000, J EXP MED, V192, P781, DOI 10.1084/jem.192.6.781; Narayan K, 2007, NAT IMMUNOL, V8, P92, DOI 10.1038/ni1414; Nicholson MJ, 2006, J IMMUNOL, V176, P4208, DOI 10.4049/jimmunol.176.7.4208; Pashine A, 2003, IMMUNITY, V19, P183, DOI 10.1016/S1074-7613(03)00200-0; Rabinowitz JD, 1998, IMMUNITY, V9, P699, DOI 10.1016/S1074-7613(00)80667-6; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Rich JD, 2003, J IMMUNOL, V171, P853, DOI 10.4049/jimmunol.171.2.853; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Toebes M, 2006, NAT MED, V12, P246, DOI 10.1038/nm1360; Vogt AB, 1996, P NATL ACAD SCI USA, V93, P9724, DOI 10.1073/pnas.93.18.9724; Weber DA, 2001, J IMMUNOL, V167, P5167, DOI 10.4049/jimmunol.167.9.5167; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; Wu SH, 1996, MOL IMMUNOL, V33, P371, DOI 10.1016/0161-5890(95)00159-X; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279; Zarutskie JA, 2001, P NATL ACAD SCI USA, V98, P12450, DOI 10.1073/pnas.211439398	42	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21425	21436		10.1074/jbc.M702844200	http://dx.doi.org/10.1074/jbc.M702844200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17525157	hybrid, Green Accepted			2022-12-25	WOS:000248047500070
J	Tu, AW; Luo, K				Tu, Andrea W.; Luo, Kunxin			Acetylation of Smad2 by the co-activator p300 regulates activin and transforming growth factor ss response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; DNA-BINDING; TARGETED DISRUPTION; SNON ONCOPROTEIN; MH1 DOMAIN; PROTEINS; TRANSCRIPTION; ACTIVATION; CBP; PHOSPHORYLATION	Transforming growth factor beta (TGF beta) signals primarily through the Smad proteins to regulate cell growth, differentiation, and extracellular matrix production. Post-translational modifications, such as phosphorylation, play an important role in the regulation of the Smad proteins. TGF beta signaling results in the phosphorylation of Smad2 and Smad3 that then oligomerize with Smad4 and translocate into the nucleus to initiate transcription of TGF beta target genes. The initiation of transcription is significantly enhanced by the direct interaction of the Smad complex with p300/CBP (CREB-binding protein), a co-activator with intrinsic acetyltransferase activity. However, how p300/CBP enhances transcription through this interaction is not entirely understood. In this report, we show that Smad2, but not the highly homologous Smad3, can be acetylated by p300/CBP in a ligand-dependent manner. At least three lysine residues, Lys(19), Lys(20), and Lys(39), are required for efficient acetylation of Smad2, as mutations altering these lysines abolished Smad2 acetylation in vivo. This acetylation event is required for the ability of Smad2 to mediate activin and TGF beta signaling. Mutation of the three key lysine residues did not alter the stability of Smad2 or the ability of Smad2 to form a complex with Smad4 on promoter DNA, but it prevented nuclear accumulation of Smad2 and subsequent TGF beta and activin responses. Thus, our studies reveal a novel mechanism of modulating Smad2 activity and localization through protein acetylation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Luo, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall,Mail Code 3204, Berkeley, CA 94720 USA.	kluo@berkeley.edu			NIDDK NIH HHS [DK067074] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067074] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Chan HM, 2001, J CELL SCI, V114, P2363; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Dunn NR, 2005, GENE DEV, V19, P152, DOI 10.1101/gad.1243205; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heyer J, 1999, P NATL ACAD SCI USA, V96, P12595, DOI 10.1073/pnas.96.22.12595; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inoue Y, 2007, ONCOGENE, V26, P500, DOI 10.1038/sj.onc.1209826; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Krakowski AR, 2005, P NATL ACAD SCI USA, V102, P12437, DOI 10.1073/pnas.0504107102; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Ross S, 2006, EMBO J, V25, P4490, DOI 10.1038/sj.emboj.7601332; Schmierer B, 2005, MOL CELL BIOL, V25, P9845, DOI 10.1128/MCB.25.22.9845-9858.2005; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Simonsson M, 2005, J BIOL CHEM, V280, P21797, DOI 10.1074/jbc.M503134200; Simonsson M, 2006, J BIOL CHEM, V281, P39870, DOI 10.1074/jbc.M607868200; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu QW, 2005, MOL CELL BIOL, V25, P10731, DOI 10.1128/MCB.25.24.10731-10744.2005	49	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21187	21196		10.1074/jbc.M700085200	http://dx.doi.org/10.1074/jbc.M700085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17478422	hybrid			2022-12-25	WOS:000248047500045
J	van Straaten, KE; Barends, TRM; Dijkstra, BW; Thunnissen, AMWH				van Straaten, Karin E.; Barends, Thomas R. M.; Dijkstra, Bauke W.; Thunnissen, Andy-Mark W. H.			Structure of Escherichia coli lytic transglycosylase MltA with bound chitohexaose - Implications for peptidoglycan binding and cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-ASSISTED CATALYSIS; CRYSTAL-STRUCTURE; LYSOZYME; DOMAIN; PURIFICATION; REFINEMENT; MECHANISMS; DISTORTION; FAMILIES; REVEALS	Crystal structures of an inactive mutant (D308A) of the lytic transglycosylase MltA from Escherichia coli have been determined in two different apo-forms, as well as in complex with the substrate analogue chitohexaose. The chitohexaose binds with all six saccharide residues in the active site groove, with an intact glycosidic bond at the bond cleavage center. Its binding induces a large reorientation of the two structural domains in MltA, narrowing the active site groove and allowing tight interactions of the oligosaccharide with residues from both domains. The structures identify residues in MltA with key roles in the binding and recognition of peptidoglycan and confirm that Asp-308 is the single catalytic residue, acting as a general acid/base. Moreover, the structures suggest that catalysis involves a high energy conformation of the scissile glycosidic linkage and that the putative oxocarbenium ion intermediate is stabilized by the dipole moment of a nearby alpha-helix.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands	University of Groningen	Thunnissen, AMWH (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	a.m.w.h.thunnissen@rug.nl	Thunnissen, Andy-Mark/A-1777-2010; Dijkstra, Bauke W./H-4308-2019	Thunnissen, Andy-Mark/0000-0002-1915-9850; Dijkstra, Bauke W./0000-0001-9731-6586				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barends TRM, 2005, ACTA CRYSTALLOGR D, V61, P613, DOI 10.1107/S0907444905005743; Blackburn NT, 2001, J MOL EVOL, V52, P78, DOI 10.1007/s002390010136; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DAVIES GJ, 1993, NATURE, V365, P362, DOI 10.1038/365362a0; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOLTJE JV, 1995, ARCH MICROBIOL, V164, P243, DOI 10.1007/s002030050261; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Koraimann G, 2003, CELL MOL LIFE SCI, V60, P2371, DOI 10.1007/s00018-003-3056-1; Kraft AR, 1998, J BACTERIOL, V180, P3441, DOI 10.1128/JB.180.13.3441-3447.1998; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Powell AJ, 2006, J MOL BIOL, V359, P122, DOI 10.1016/j.jmb.2006.03.023; Reid CW, 2004, FEBS LETT, V574, P73, DOI 10.1016/j.febslet.2004.08.006; ROMEIS T, 1993, FEMS MICROBIOL LETT, V111, P141; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; THUNNISSEN AMWH, 1995, PROTEINS, V22, P245, DOI 10.1002/prot.340220305; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; THUNNISSEN AMWH, 1995, BIOCHEMISTRY-US, V34, P12729, DOI 10.1021/bi00039a032; URSINUS A, 1994, J BACTERIOL, V176, P338, DOI 10.1128/JB.176.2.338-343.1994; van Asselt EJ, 1999, J MOL BIOL, V291, P877, DOI 10.1006/jmbi.1999.3013; van Asselt EJ, 1999, STRUCT FOLD DES, V7, P1167, DOI 10.1016/S0969-2126(00)80051-9; van Asselt EJ, 2000, BIOCHEMISTRY-US, V39, P1924, DOI 10.1021/bi992161p; van Straaten KE, 2005, J MOL BIOL, V352, P1068, DOI 10.1016/j.jmb.2005.07.067; van Straaten KE, 2004, ACTA CRYSTALLOGR D, V60, P758, DOI 10.1107/S0907444904002574; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vollmer W, 1999, J BIOL CHEM, V274, P6726, DOI 10.1074/jbc.274.10.6726; Williams SJ, 2002, J BIOL CHEM, V277, P40055, DOI 10.1074/jbc.M206481200	38	30	30	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21197	21205		10.1074/jbc.M701818200	http://dx.doi.org/10.1074/jbc.M701818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17502382	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000248047500046
J	Heuts, DPHM; van Hellemond, EW; Janssen, DB; Fraaije, MW				Heuts, Dominic P. H. M.; van Hellemond, Erik W.; Janssen, Dick B.; Fraaije, Marco W.			Discovery, characterization, and kinetic analysis of an alditol oxidase from streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANILLYL-ALCOHOL OXIDASE; OXIDATION-REDUCTION; OXIDOREDUCTASE; FLAVINYLATION; FLAVOPROTEINS; REACTIVITY; MECHANISM; FAMILY	A gene encoding an alditol oxidase was found in the genome of Streptomyces coelicolor A3(2). This newly identified oxidase, AldO, was expressed at extremely high levels in Escherichia coli when fused to maltose-binding protein. AldO is a soluble monomeric flavoprotein with subunits of 45.1 kDa, each containing a covalently bound FAD cofactor. From sequence alignments with other flavoprotein oxidases, it was found that AldO contains a conserved histidine (His46) that is typically involved in covalent FAD attachment. Covalent FAD binding is not observed in the H46A AldO mutant, confirming its role in covalent attachment of the flavin cofactor. Steady-state kinetic analyses revealed that wild-type AldO is active with several polyols. The alditols xylitol (K-m = 0.32 mM, k(cat) = 13 s(-1)) and sorbitol (K-m = 1.4 mM, k(cat) = 17 s(-1)) are the preferred substrates. From pre-steady-state kinetic analyses, using xylitol as substrate, it can be concluded that AldO mainly follows a ternary complex kinetic mechanism. Reduction of the flavin cofactor by xylitol occurs at a relatively high rate ( 99 s(-1)), after which a second kinetic event is observed, which is proposed to represent ring closure of the formed aldehyde product, yielding the hemiacetal of D-xylose. Reduced AldO readily reacts with molecular oxygen (1.7 x 105 M-1 s(-1)), which confirms that the enzyme represents a true flavoprotein oxidase.	Univ Groningen, Biomol Sci & Biotechnol Inst, Biochem Lab, NL-9747 AG Groningen, Netherlands	University of Groningen	Fraaije, MW (corresponding author), Univ Groningen, Biomol Sci & Biotechnol Inst, Biochem Lab, NL-9747 AG Groningen, Netherlands.	m.w.fraaije@rug.nl	Fraaije, Marco/E-8421-2014	Fraaije, Marco/0000-0001-6346-5014				Bertram R, 2004, J BACTERIOL, V186, P1362, DOI 10.1128/JB.186.5.1362-1373.2004; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; Federico R, 1997, BIOCHEM BIOPH RES CO, V240, P150, DOI 10.1006/bbrc.1997.7630; Forneris F, 2006, ACTA CRYSTALLOGR F, V62, P1298, DOI 10.1107/S1744309106051128; Fraaije MW, 1999, J BIOL CHEM, V274, P35514, DOI 10.1074/jbc.274.50.35514; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; Fraaije MW, 1997, J BIOL CHEM, V272, P18111, DOI 10.1074/jbc.272.29.18111; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; FRAAIJE MW, 1999, FLAVINS FLAVOPROTEIN, P881; Hiraga K, 1997, BIOSCI BIOTECH BIOCH, V61, P1699, DOI 10.1271/bbb.61.1699; Huang CH, 2005, J BIOL CHEM, V280, P38831, DOI 10.1074/jbc.M506078200; HUANG CY, 1983, CONT ENZYME KINETICS, P54; Mao YQ, 1999, CHEM BIOL, V6, P251, DOI 10.1016/S1074-5521(99)80040-4; MASSEY V, 1977, J BIOL CHEM, V252, P5612; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1969, J BIOL CHEM, V244, P3999; Mattevi A, 2006, TRENDS BIOCHEM SCI, V31, P276, DOI 10.1016/j.tibs.2006.03.003; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; Rand T, 2006, FEBS J, V273, P2693, DOI 10.1111/j.1742-4658.2006.05285.x; SCHOPFER LM, 1988, BIOCHEMISTRY-US, V27, P6599, DOI 10.1021/bi00417a059; Stevens RC, 2000, STRUCTURE, V8, pR177, DOI 10.1016/S0969-2126(00)00193-3; van Hellemond EW, 2006, ADV APPL MICROBIOL, V60, P17, DOI 10.1016/S0065-2164(06)60002-6; Winkler A, 2006, J BIOL CHEM, V281, P21276, DOI 10.1074/jbc.M603267200; Wu XL, 2001, BIOCHEMISTRY-US, V40, P12886, DOI 10.1021/bi011244e; Xu F, 2001, EUR J BIOCHEM, V268, P1136, DOI 10.1046/j.1432-1327.2001.01982.x; Yamashita M, 2000, J BIOSCI BIOENG, V89, P350, DOI 10.1016/S1389-1723(00)88958-6	26	63	67	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20283	20291		10.1074/jbc.M610849200	http://dx.doi.org/10.1074/jbc.M610849200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17517896	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000247819300031
J	Morimoto, S; Tanaka, Y; Sasaki, K; Tanaka, H; Fukamizu, T; Shoyama, Y; Shoyama, Y; Taura, F				Morimoto, Satoshi; Tanaka, Yumi; Sasaki, Kaori; Tanaka, Hiroyuki; Fukamizu, Tomohide; Shoyama, Yoshinari; Shoyama, Yukihiro; Taura, Futoshi			Identification and characterization of cannabinoids that induce cell death through mitochondrial permeability transition in Cannabis leaf cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING MARIJUANA PSYCHOACTIVITY; ACID SYNTHASE; CYTOCHROME-C; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; ENDONUCLEASE-G; PORE; INVOLVEMENT; PROTEASES; CALCIUM	Cannabinoids are secondary metabolites stored in capitatesessile glands on leaves of Cannabis sativa. We discovered that cell death is induced in the leaf tissues exposed to cannabinoid resin secreted from the glands, and identified cannabichromenic acid ( CBCA) and Delta(1)-tetrahydrocannabinolic acid ( THCA) as unique cell death mediators from the resin. These cannabinoids effectively induced cell death in the leaf cells or suspension-cultured cells of C. sativa, whereas pretreatment with the mitochondrial permeability transition (MPT) inhibitor cyclosporin A suppressed this cell death response. Examinations using isolated mitochondria demonstrated that CBCA and THCA mediate opening of MPT pores without requiring Ca2+ and other cytosolic factors, resulting in high amplitude mitochondrial swelling, release of mitochondrial proteins ( cytochrome c and nuclease), and irreversible loss of mitochondrial membrane potential. Therefore, CBCA and THCA are considered to cause serious damage to mitochondria through MPT. The mitochondrial damage was also confirmed by a marked decrease of ATP level in cannabinoid-treated suspension cells. These features are in good accord with those of necrotic cell death, whereas DNA degradation was also observed in cannabinoid-mediated cell death. However, the DNA degradation was catalyzed by nuclease(s) released from mitochondria during MPT, indicating that this reaction was not induced via a caspase-dependent apoptotic pathway. Furthermore, the inhibition of the DNA degradation only slightly blocked the cell death induced by cannabinoids. Based on these results, we conclude that CBCA and THCA have the ability to induce necrotic cell death via mitochondrial dysfunction in the leaf cells of C. sativa.	Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 812, Japan	Kyushu University	Morimoto, S (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 812, Japan.	morimoto@phar.kyushu-u.ac.jp; taura@phar.kyushu-u.ac.jp						Arpagaus S, 2002, J BIOL CHEM, V277, P1780, DOI 10.1074/jbc.M109416200; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bais HP, 2003, SCIENCE, V301, P1377, DOI 10.1126/science.1083245; Balk J, 2003, PLANT J, V34, P573, DOI 10.1046/j.1365-313X.2003.01748.x; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Casolo V, 2005, J EXP BOT, V56, P997, DOI 10.1093/jxb/eri093; Curtis MJ, 2002, PLANT J, V29, P295, DOI 10.1046/j.0960-7412.2001.01213.x; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Feeney M, 2003, IN VITRO CELL DEV-PL, V39, P578, DOI 10.1079/IVP2003454; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; Gechev TS, 2005, J CELL BIOL, V168, P17, DOI 10.1083/jcb.200409170; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; HAMMOND CT, 1977, AM J BOT, V64, P1023, DOI 10.2307/2442258; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Ishihara Y, 2006, J BIOL CHEM, V281, P6726, DOI 10.1074/jbc.M510382200; JACOBS EE, 1960, J BIOL CHEM, V235, P531; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KUSHIMA H, 1980, CHEM PHARM BULL, V28, P594; Lam E, 2004, NAT REV MOL CELL BIO, V5, P305, DOI 10.1038/nrm1358; Lam E, 2001, NATURE, V411, P848, DOI 10.1038/35081184; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; McCaskill D, 1999, NAT BIOTECHNOL, V17, P31, DOI 10.1038/5202; MECHOULAM R, 1970, SCIENCE, V168, P1159, DOI 10.1126/science.168.3936.1159; Mlejnek P, 2003, PLANT CELL ENVIRON, V26, P1723, DOI 10.1046/j.1365-3040.2003.01090.x; Morimoto S, 1997, J NAT PROD, V60, P854, DOI 10.1021/np970210y; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Sirikantaramas S, 2005, PLANT CELL PHYSIOL, V46, P1578, DOI 10.1093/pcp/pci166; Sirikantaramas S, 2004, J BIOL CHEM, V279, P39767, DOI 10.1074/jbc.M403693200; Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105; Sun YL, 1999, CELL MOL LIFE SCI, V55, P310, DOI 10.1007/s000180050293; TAURA F, 1995, J AM CHEM SOC, V117, P9766, DOI 10.1021/ja00143a024; Taura F, 1996, J BIOL CHEM, V271, P17411, DOI 10.1074/jbc.271.29.17411; Tiwari BS, 2002, PLANT PHYSIOL, V128, P1271, DOI 10.1104/pp.010999; TURNER JC, 1977, AM J BOT, V64, P687, DOI 10.2307/2441721; Vacca RA, 2006, PLANT PHYSIOL, V141, P208, DOI 10.1104/pp.106.078683; Virolainen E, 2002, ANN BOT-LONDON, V90, P509, DOI 10.1093/aob/mcf221; Wang Y, 2006, J INTEGR PLANT BIOL, V48, P433, DOI 10.1111/j.1744-7909.2006.00219.x; Woltering EJ, 2002, PLANT PHYSIOL, V130, P1764, DOI 10.1104/pp.006338; Woltering EJ, 2004, TRENDS PLANT SCI, V9, P469, DOI 10.1016/j.tplants.2004.08.001	45	55	57	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20739	20751		10.1074/jbc.M700133200	http://dx.doi.org/10.1074/jbc.M700133200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17513301	hybrid			2022-12-25	WOS:000247819300076
J	Tesz, GJ; Guilherme, A; Guntur, KVP; Hubbard, AC; Tang, XQ; Chawla, A; Czech, MP				Tesz, Gregory J.; Guilherme, Adilson; Guntur, Kalyani V. P.; Hubbard, Andrea C.; Tang, Xiaoqing; Chawla, Anil; Czech, Michael P.			Tumor necrosis factor alpha (TNF alpha) stimulates Map4k4 expression through TNF alpha receptor 1 signaling to c-Jun and activating transcription factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; TYROSINE KINASE-ACTIVITY; NCK-INTERACTING KINASE; PROTEIN-KINASE; GENE-EXPRESSION; INSULIN-RESISTANCE; ADIPOSE-TISSUE; PPAR-GAMMA; ADIPOCYTE; OBESITY	Tumor necrosis factor alpha (TNF alpha) is a cytokine secreted by macrophages and adipocytes that contributes to the low grade inflammation and insulin resistance observed in obesity. TNF alpha signaling decreases peroxisome proliferator-activated receptor gamma and glucose transporter isoform 4 (GLUT4) expression in adipocytes, impairing insulin action, and this is mediated in part by the yeast Ste20 protein kinase ortholog Map4k4. Here we show that Map4k4 expression is selectively up-regulated by TNF alpha, whereas the expression of the protein kinases JNK1/2, ERK1/2, p38 stress-activated protein kinase, and mitogen-activated protein kinase kinases 4/7 shows little or no response. Furthermore, the cytokines interleukin 1 beta (IL-1 beta) and IL-6 as well as lipopolysaccharide fail to increase Map4k4 mRNA levels in cultured adipocytes under conditions where TNF alpha elicits a 3-fold effect. Using agonistic and antagonistic antibodies and small interfering RNA ( siRNA) against TNF alpha receptor 1 (TNFR1) and TNF alpha receptor 2 (TNFR2), we show that TNFR1, but not TNFR2, mediates the increase in Map4k4 expression. TNFR1, but not TNFR2, also mediates a potent effect of TNF alpha on the phosphorylation of JNK1/2 and p38 stress-activated protein kinase and their downstream transcription factor substrates c-Jun and activating transcription factor 2 (ATF2). siRNA-based depletion of c-Jun and ATF2 attenuated TNF alpha action on Map4k4 mRNA expression. Consistent with this concept, the phosphorylation of ATF2 along with the expression and phosphorylation of c-Jun by TNF alpha signaling was more robust and prolonged compared with that of IL-1 beta, which failed to modulate Map4k4. These data reveal that TNF alpha selectively stimulates the expression of a key component of its own signaling pathway, Map4k4, through a TNFR1-dependent mechanism that targets the transcription factors c-Jun and ATF2.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Suite 100, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Aouadi M, 2006, DIABETES, V55, P281, DOI 10.2337/diabetes.55.02.06.db05-0963; Aouadi M, 2006, STEM CELLS, V24, P1399, DOI 10.1634/stemcells.2005-0398; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bost F, 2005, BIOCHIMIE, V87, P51, DOI 10.1016/j.biochi.2004.10.018; Bouzakri K, 2007, J BIOL CHEM, V282, P7783, DOI 10.1074/jbc.M608602200; Chainy GBN, 1996, J IMMUNOL, V157, P2410; Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103; Demir AY, 2005, CELL TISSUE RES, V322, P299, DOI 10.1007/s00441-005-0002-6; Eder J, 1997, TRENDS PHARMACOL SCI, V18, P319, DOI 10.1016/S0165-6147(97)01097-3; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Haridas V, 1998, J IMMUNOL, V160, P3152; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hu YM, 2004, J BIOL CHEM, V279, P54387, DOI 10.1074/jbc.M404497200; Jager J, 2007, ENDOCRINOLOGY, V148, P241, DOI 10.1210/en.2006-0692; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kyosseva SV, 2004, INT REV NEUROBIOL, V59, P201; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Mracek T, 2004, CYTOKINE, V26, P9, DOI 10.1016/j.cyto.2003.12.001; Nishigaki K, 2003, J BIOL CHEM, V278, P13520, DOI 10.1074/jbc.M208601200; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Plomgaard P, 2005, DIABETES, V54, P2939, DOI 10.2337/diabetes.54.10.2939; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; SCOTT LM, 1992, BLOOD, V80, P1725; Sethi JK, 2000, FEBS LETT, V469, P77, DOI 10.1016/S0014-5793(00)01250-3; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Skolnik Edward Y., 1996, Cytokine and Growth Factor Reviews, V7, P161, DOI 10.1016/1359-6101(96)00021-4; Souza SC, 2003, J CELL BIOCHEM, V89, P1077, DOI 10.1002/jcb.10565; Taira K, 2004, J BIOL CHEM, V279, P49488, DOI 10.1074/jbc.M406370200; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Tang XQ, 2006, P NATL ACAD SCI USA, V103, P2087, DOI 10.1073/pnas.0507660103; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Willaime-Morawek S, 2003, NEUROSCIENCE, V119, P387, DOI 10.1016/S0306-4522(02)00996-X; Wright JH, 2003, MOL CELL BIOL, V23, P2068, DOI 10.1128/MCB.23.6.2068-2082.2003; Xu HY, 2001, FEBS LETT, V506, P97, DOI 10.1016/S0014-5793(01)02889-7; Xue YZ, 2001, DEVELOPMENT, V128, P1559; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Zerbini LF, 2003, CANCER RES, V63, P2206; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693; Zohn IE, 2006, CELL, V125, P957, DOI 10.1016/j.cell.2006.03.048	56	65	81	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19302	19312		10.1074/jbc.M700665200	http://dx.doi.org/10.1074/jbc.M700665200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17500068	hybrid			2022-12-25	WOS:000247650600005
J	Bernardinelli, L; Murgia, SB; Bitti, PP; Foco, L; Ferrai, R; Musu, L; Prokopenko, I; Pastorino, R; Saddi, V; Ticca, A; Piras, ML; Cox, DR; Berzuini, C				Bernardinelli, Luisa; Murgia, Salvatore Bruno; Bitti, Pier Paolo; Foco, Luisa; Ferrai, Raffaela; Musu, Luigina; Prokopenko, Inga; Pastorino, Roberta; Saddi, Valeria; Ticca, Anna; Piras, Maria Luisa; Cox, David Roxbee; Berzuini, Carlo			Association between the ACCN1 Gene and Multiple Sclerosis in Central East Sardinia	PLOS ONE			English	Article							SENSING ION CHANNELS; LINKAGE DISEQUILIBRIUM; CATION CHANNEL; DEGENERIN MDEG; POPULATION; RISK; SUSCEPTIBILITY; GENOTYPE; SUBUNIT; BRAIN	Multiple genome screens have been performed to identify regions in linkage or association with Multiple Sclerosis (MS, OMIM 126200), but little overlap has been found among them. This may be, in part, due to a low statistical power to detect small genetic effects and to genetic heterogeneity within and among the studied populations. Motivated by these considerations, we studied a very special population, namely that of Nuoro, Sardinia, Italy. This is an isolated, old, and genetically homogeneous population with high prevalence of MS. Our study sample includes both nuclear families and unrelated cases and controls. A multi-stage study design was adopted. In the first stage, microsatellites were typed in the 17q11.2 region, previously independently found to be in linkage with MS. One significant association was found at microsatellite D17S798. Next, a bioinformatic screening of the region surrounding this marker highlighted an interesting candidate MS susceptibility gene: the Amiloride-sensitive Cation Channel Neuronal 1 (ACCN1) gene. In the second stage of the study, we resequenced the exons and the 39 untranslated (UTR) region of ACCN1, and investigated the MS association of Single Nucleotide Polymorphisms (SNPs) identified in that region. For this purpose, we developed a method of analysis where complete, phase-solved, posterior-weighted haplotype assignments are imputed for each study individual from incomplete, multi-locus, genotyping data. The imputed assignments provide an input to a number of proposed procedures for testing association at a microsatellite level or of a sequence of SNPs. These include a Mantel-Haenszel type test based on expected frequencies of pseudocase/pseudocontrol haplotypes, as well as permutation based tests, including a combination of permutation and weighted logistic regression analysis. Application of these methods allowed us to find a significant association between MS and the SNP rs28936 located in the 39 UTR segment of ACCN1 with p = 0.0004 (p = 0.002, after adjusting for multiple testing). This result is in tune with several recent experimental findings which suggest that ACCN1 may play an important role in the pathogenesis of MS.	[Bernardinelli, Luisa; Foco, Luisa; Prokopenko, Inga; Pastorino, Roberta] Univ Pavia, Dipartimento Sci Sanit Applicate & Psicocomportam, I-27100 Pavia, Italy; [Bernardinelli, Luisa; Berzuini, Carlo] Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England; [Murgia, Salvatore Bruno; Ferrai, Raffaela; Musu, Luigina; Saddi, Valeria; Ticca, Anna; Piras, Maria Luisa] ASL N 3 Nuoro, Presidio Osped S Francesco, Div Neurol, Nuoro, Italy; [Bitti, Pier Paolo] ASL N 3 Nuoro, Presidio Osped S Francesco, SIT, Ctr Tipizzaz Tissutale, Nuoro, Italy; [Cox, David Roxbee] Univ Oxford Nuffield Coll, Oxford OX1 1NF, England; [Cox, David Roxbee] Univ Oxford, Dept Stat, Oxford OX1 3TG, England; [Berzuini, Carlo] Univ Pavia, Dipartimento Informat & Sistemist, I-27100 Pavia, Italy	University of Pavia; MRC Biostatistics Unit; University of Cambridge; University of Oxford; University of Oxford; University of Pavia	Bernardinelli, L (corresponding author), Univ Pavia, Dipartimento Sci Sanit Applicate & Psicocomportam, Via Palestro 3, I-27100 Pavia, Italy.	luisa.bernardinelli@mrc-bsu.cam.ac.uk	Bernardinelli, Luisa/AAL-5750-2021; Prokopenko, Inga/AAU-9895-2020; Prokopenko, Inga/H-3241-2014; Berzuini, Carlo/AAA-7023-2019; PASTORINO, Roberta/AAC-1866-2022	Prokopenko, Inga/0000-0003-1624-7457; Berzuini, Carlo/0000-0001-6056-0489; PASTORINO, Roberta/0000-0001-5013-0733	Fondazione Cariplo, Milano, Italy [1428/2004]; Azienda Sanitaria Locale Ndegrees3, Nuoro, Italy; MRC [MC_U105260799] Funding Source: UKRI; Medical Research Council [MC_U105260799] Funding Source: researchfish	Fondazione Cariplo, Milano, Italy(Fondazione Cariplo); Azienda Sanitaria Locale Ndegrees3, Nuoro, Italy; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by a grant from the Fondazione Cariplo, Project Number 1428/2004, Milano, Italy, and by the Azienda Sanitaria Locale N degrees 3, Nuoro, Italy.	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Antoniou AC, 2003, GENET EPIDEMIOL, V25, P190, DOI 10.1002/gepi.10261; Biernacka JM, 2006, GENET EPIDEMIOL, V30, P582, DOI 10.1002/gepi.20167; Coraddu F, 1998, NEUROGENETICS, V2, P24, DOI 10.1007/s100480050048; Cordell HJ, 2006, GENET EPIDEMIOL, V30, P259, DOI 10.1002/gepi.20142; Deval E, 2004, J BIOL CHEM, V279, P19531, DOI 10.1074/jbc.M313078200; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; HOLM S, 1979, SCAND J STAT, V6, P65; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Jagodic M, 2004, J IMMUNOL, V173, P1366, DOI 10.4049/jimmunol.173.2.1366; Lincoln MR, 2005, NAT GENET, V37, P1108, DOI 10.1038/ng1647; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Marchini J, 2006, AM J HUM GENET, V78, P437, DOI 10.1086/500808; Montomoli C, 2002, GENET EPIDEMIOL, V22, P265, DOI 10.1002/gepi.0173; Morahan G, 2001, NAT GENET, V27, P218, DOI 10.1038/84872; Pericak-Vance MA, 2001, MULT SCLER, V7, P3; Poser CM, 2001, CLIN NEUROL NEUROSUR, V103, P1, DOI 10.1016/S0303-8467(00)00125-6; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Prokopenko I, 2003, NEUROEPIDEMIOLOGY, V22, P290, DOI 10.1159/000071192; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; Saarela J, 2006, PLOS GENET, V2, P364, DOI 10.1371/journal.pgen.0020042; Sawcer S, 2005, AM J HUM GENET, V77, P454; SELF SG, 1991, BIOMETRICS, V47, P53, DOI 10.2307/2532495; Service S, 2006, NAT GENET, V38, P556, DOI 10.1038/ng1770; Spielman RS, 1996, AM J HUM GENET, V59, P983; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1996, GENOMICS, V37, P269, DOI 10.1006/geno.1996.0558; Waxman SG, 2001, NAT REV NEUROSCI, V2, P652, DOI 10.1038/35090026; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; WESTFALL PH, 1993, RESAMPLING BASED MUL, P320; Zavattari P, 2000, HUM MOL GENET, V9, P2947, DOI 10.1093/hmg/9.20.2947; Zipp F, 2006, TRENDS NEUROSCI, V29, P518, DOI 10.1016/j.tins.2006.07.006; Zody MC, 2006, NATURE, V440, P1045, DOI 10.1038/nature04689	36	28	29	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e480	10.1371/journal.pone.0000480	http://dx.doi.org/10.1371/journal.pone.0000480			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534430	gold, Green Published, Green Submitted			2022-12-25	WOS:000207448800010
J	Moll, K; Chene, A; Ribacke, U; Kaneko, O; Nilsson, S; Winter, G; Haeggstrom, M; Pan, WQ; Berzins, K; Wahlgren, M; Chen, Q				Moll, Kirsten; Chene, Arnaud; Ribacke, Ulf; Kaneko, Osamu; Nilsson, Sandra; Winter, Gerhard; Haeggstrom, Malin; Pan, Weiqing; Berzins, Klavs; Wahlgren, Mats; Chen, Qijun			A Novel DBL-Domain of the P. falciparum 332 Molecule Possibly Involved in Erythrocyte Adhesion	PLOS ONE			English	Article							HUMAN MONOCLONAL-ANTIBODY; RED-BLOOD-CELLS; PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; MALARIA PARASITES; PF332 GENE; HOST-CELL; IN-VITRO; INVASION; MEMBRANE	Plasmodium falciparum malaria is brought about by the asexual stages of the parasite residing in human red blood cells (RBC). Contact between the erythrocyte surface and the merozoite is the first step for successful invasion and proliferation of the parasite. A number of different pathways utilised by the parasite to adhere and invade the host RBC have been characterized, but the complete biology of this process remains elusive. We here report the identification of an open reading frame (ORF) representing a hitherto unknown second exon of the Pf332 gene that encodes a cysteine-rich polypeptide with a high degree of similarity to the Duffy-binding-like (DBL) domain of the erythrocyte-binding-ligand (EBL) family. The sequence of this DBL-domain is conserved and expressed in all parasite clones/strains investigated. In addition, the expression level of Pf332 correlates with proliferation efficiency of the parasites in vitro. Antibodies raised against the DBL-domain are able to reduce the invasion efficiency of different parasite clones/strains. Analysis of the DBL-domain revealed its ability to bind to uninfected human RBC, and moreover demonstrated association with the iRBC surface. Thus, Pf332 is a molecule with a potential role to support merozoite invasion. Due to the high level of conservation in sequence, the novel DBL-domain of Pf332 is of possible importance for development of novel anti-malaria drugs and vaccines.	[Moll, Kirsten; Chene, Arnaud; Ribacke, Ulf; Nilsson, Sandra; Winter, Gerhard; Haeggstrom, Malin; Wahlgren, Mats; Chen, Qijun] Karolinska Inst, Swedish Inst Infect Dis Control SMI, Dept Parasitol Mycol & Environm Microbiol PMV, Stockholm, Sweden; [Moll, Kirsten; Chene, Arnaud; Ribacke, Ulf; Nilsson, Sandra; Winter, Gerhard; Haeggstrom, Malin; Wahlgren, Mats; Chen, Qijun] Karolinska Inst, Dept Microbiol Tumour & Cell Biol MTC, Stockholm, Sweden; [Chene, Arnaud] Karolinska Inst, Ctr Infect Med, Stockholm, Sweden; [Kaneko, Osamu] Ehime Univ, Grad Sch Med, Dept Mol Parasitol, Matsuyama, Ehime 790, Japan; [Pan, Weiqing] Second Mil Med Univ, Dept Etiol Biol, Shanghai, Peoples R China; [Berzins, Klavs] Stockholm Univ, Wenner Gren Inst, Dept Immunol, S-10691 Stockholm, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Karolinska Institutet; Karolinska Institutet; Ehime University; Naval Medical University; Stockholm University	Chen, Q (corresponding author), Karolinska Inst, Swedish Inst Infect Dis Control SMI, Dept Parasitol Mycol & Environm Microbiol PMV, Stockholm, Sweden.	Qijun.Chen@smi.ki.se	Chene, Arnaud/O-4397-2017	Chene, Arnaud/0000-0002-6551-4382	European Malaria Consortium (BioMalPar); Swedish Research Council [348-2003-4845]; SIDA/SAREC [SWE2003-241]	European Malaria Consortium (BioMalPar); Swedish Research Council(Swedish Research CouncilEuropean Commission); SIDA/SAREC	This work was funded by grants from the European Malaria Consortium (BioMalPar), the Swedish Research Council (348-2003-4845), SIDA/SAREC (SWE2003-241).	AHLBORG N, 1991, MOL BIOCHEM PARASIT, V46, P89, DOI 10.1016/0166-6851(91)90202-H; ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; Baum J, 2005, PLOS PATHOG, V1, P299, DOI 10.1371/journal.ppat.0010037; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Chen QJ, 2004, VACCINE, V22, P2701, DOI 10.1016/j.vaccine.2004.02.015; Chitnis CE, 2000, PARASITOL TODAY, V16, P411, DOI 10.1016/S0169-4758(00)01756-7; Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006; Flick K, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-50; Gardner MJ, 2002, NATURE, V419, P531, DOI 10.1038/nature01094; Gaur D, 2004, INT J PARASITOL, V34, P1413, DOI 10.1016/j.ijpara.2004.10.010; Gilberger TW, 2003, J BIOL CHEM, V278, P14480, DOI 10.1074/jbc.M211446200; Glushakova S, 2005, CURR BIOL, V15, P1645, DOI 10.1016/j.cub.2005.07.067; Haeggstrom M, 2004, MOL BIOCHEM PARASIT, V133, P1, DOI 10.1016/j.molbiopara.2003.07.006; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; HINTERBERG K, 1994, EMBO J, V13, P4174, DOI 10.1002/j.1460-2075.1994.tb06735.x; HINTERBERG K, 1994, EXP PARASITOL, V79, P279, DOI 10.1006/expr.1994.1091; Howell DPG, 2006, MOL BIOCHEM PARASIT, V148, P1, DOI 10.1016/j.molbiopara.2006.03.004; Liang H, 1997, MOL BIOCHEM PARASIT, V84, P241, DOI 10.1016/S0166-6851(96)02791-0; Ljungstr?m I., 2004, METHODS MALARIA RES; Llinas M, 2006, NUCLEIC ACIDS RES, V34, P1166, DOI 10.1093/nar/gkj517; Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; MATTEI D, 1992, GENE, V110, P71, DOI 10.1016/0378-1119(92)90446-V; MATTEI D, 1992, MEM I OSWALDO CRUZ, V87, P163, DOI 10.1590/S0074-02761992000700026; MATTEI D, 1989, PARASITE IMMUNOL, V11, P15, DOI 10.1111/j.1365-3024.1989.tb00645.x; MERCEREAUPUIJAL.O, 1987, UCLA S MOL CELLULAR, V42, P343; MERCEREAUPUIJALON O, 1991, ACTA TROP, V49, P281, DOI 10.1016/0001-706X(91)90079-Y; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; Pan WQ, 2004, J IMMUNOL, V172, P6167, DOI 10.4049/jimmunol.172.10.6167; Pasvol G, 2003, TRENDS PARASITOL, V19, P430, DOI 10.1016/j.pt.2003.08.005; PERKINS M, 1981, J CELL BIOL, V90, P563, DOI 10.1083/jcb.90.3.563; Pettersson F, 2005, INFECT IMMUN, V73, P7736, DOI 10.1128/IAI.73.11.7736-7746.2005; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; UDOMSANGPETCH R, 1989, J IMMUNOL, V142, P3620; UDOMSANGPETCH R, 1989, NATURE, V338, P763, DOI 10.1038/338763a0; UHLEMANN AC, 2000, MACS MORE, V4, P7; WAHLGREN M, 1989, PARASITOL TODAY, V5, P183, DOI 10.1016/0169-4758(89)90141-5; WAHLIN B, 1992, INFECT IMMUN, V60, P443; Winter G, 2005, J EXP MED, V201, P1853, DOI 10.1084/jem.20041392	39	26	29	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2007	2	5							e477	10.1371/journal.pone.0000477	http://dx.doi.org/10.1371/journal.pone.0000477			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10FB	17534427	Green Published, Green Submitted, gold			2022-12-25	WOS:000207448800007
J	Lo, WS; Xu, ZW; Yu, ZL; Pun, FW; Ng, SK; Chen, JH; Tong, KL; Zhao, CY; Xu, XJ; Tsang, SY; Harano, M; Stober, G; Nimgaonkar, VL; Xue, H				Lo, Wing-Sze; Xu, Zhiwen; Yu, Zhiliang; Pun, Frank W.; Ng, Siu-Kin; Chen, Jianhuan; Tong, Ka-Lok; Zhao, Cunyou; Xu, Xiaojing; Tsang, Shui-Ying; Harano, Mutsuo; Stoeber, Gerald; Nimgaonkar, Vishwajit L.; Xue, Hong			Positive Selection within the Schizophrenia-Associated GABA(A) Receptor beta(2) Gene	PLOS ONE			English	Article							REGULATING BRAIN SIZE; NUCLEOTIDE SUBSTITUTIONS; GABRB2 ASSOCIATION; STATISTICAL-METHOD; MTDNA VARIATION; HOMO-SAPIENS; ALU REPEATS; EVOLUTION; POPULATION; SEQUENCE	The gamma-aminobutyric acid type-A (GABA(A)) receptor plays a major role in inhibitory neurotransmissions. Intronic SNPs and haplotypes in GABRB2, the gene for GABA(A) receptor beta(2) subunit, are associated with schizophrenia and correlated with the expression of two alternatively spliced beta(2) isoforms. In the present study, using chimpanzee as an ancestral reference, high frequencies were observed for the derived (D) alleles of the four SNPs rs6556547, rs187269, rs1816071 and rs1816072 in GABRB2, suggesting the occurrence of positive selection for these derived alleles. Coalescence-based simulation showed that the population frequency spectra and the frequencies of H56, the haplotype having all four D alleles, significantly deviated from neutral-evolution expectation in various demographic models. Haplotypes containing the derived allele of rs1816072 displayed significantly less diversity compared to haplotypes containing its ancestral allele, further supporting positive selection. The variations in DD-genotype frequencies in five human populations provided a snapshot of the evolutionary history, which suggested that the positive selections of the D alleles are recent and likely ongoing. The divergence between the DD-genotype profiles of schizophrenic and control samples pointed to the schizophrenia-relevance of positive selections, with the schizophrenic samples showing weakened selections compared to the controls. These DD-genotypes were previously found to increase the expression of beta(2), especially its long isoform. Electrophysiological analysis showed that this long beta(2) isoform favored by the positive selections is more sensitive than the short isoform to the inhibition of GABAA receptor function by energy depletion. These findings represent the first demonstration of positive selection in a schizophrenia-associated gene.	[Lo, Wing-Sze; Xu, Zhiwen; Pun, Frank W.; Chen, Jianhuan; Tong, Ka-Lok; Tsang, Shui-Ying; Xue, Hong] Hong Kong Univ Sci & Technol, Dept Biochem, Appl Genom Lab, Hong Kong, Hong Kong, Peoples R China; [Lo, Wing-Sze; Xu, Zhiwen; Pun, Frank W.; Chen, Jianhuan; Tong, Ka-Lok; Tsang, Shui-Ying; Xue, Hong] Hong Kong Univ Sci & Technol, HKH Bioinformat Ctr, Hong Kong, Hong Kong, Peoples R China; [Yu, Zhiliang] Hong Kong Univ Sci & Technol, Grad Program Atmospher Marine & Coastal Environm, Hong Kong, Hong Kong, Peoples R China; [Ng, Siu-Kin; Zhao, Cunyou; Xu, Xiaojing] Hong Kong Univ Sci & Technol, Grad Program Bioengn, Hong Kong, Hong Kong, Peoples R China; [Harano, Mutsuo] Kurume Univ, Sch Med, Dept Neuropsychiat, Fukuka, Japan; [Stoeber, Gerald] Univ Wurzburg, Dept Psychiat & Psychotherapy, Wurzburg, Germany; [Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Dept Human Genet, Sch Med, Pittsburgh, PA USA; [Nimgaonkar, Vishwajit L.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Kurume University; University of Wurzburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xue, H (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Appl Genom Lab, Hong Kong, Hong Kong, Peoples R China.	hxue@ust.hk	Chen, Jian-Huan/L-7188-2017; Lo, Cario Wing Sze/DGZ-8810-2022; Chen, Jian-Huan/ABB-9660-2021; ZHAO, Cunyou/Q-5076-2016	Chen, Jian-Huan/0000-0001-8714-2543; Chen, Jian-Huan/0000-0001-8714-2543; ZHAO, Cunyou/0000-0001-6116-4584; Xue, Hong/0000-0002-8133-9828	Research Grants Council; Innovation and Technology Fund of Hong Kong	Research Grants Council(Hong Kong Research Grants Council); Innovation and Technology Fund of Hong Kong	We thank the Research Grants Council and the Innovation and Technology Fund of Hong Kong for financial support.	Abou Jamra R, 2007, PSYCHIAT GENET, V17, P43, DOI 10.1097/YPG.0b013e32801118cd; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, V4th ed.; Austin Jehannine, 2005, J Genet Couns, V14, P329, DOI 10.1007/s10897-005-1622-4; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Bird CP, 2006, CURR OPIN GENET DEV, V16, P559, DOI 10.1016/j.gde.2006.10.003; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Chowdari KV, 2002, HUM MOL GENET, V11, P1373, DOI 10.1093/hmg/11.12.1373; Cohen MN, 1984, PALEOPATHOLOGY ORIGI, P585; Currat M, 2006, SCIENCE, V313, P172, DOI 10.1126/science.1122712; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402; Di Rienzo A, 2005, TRENDS GENET, V21, P596, DOI 10.1016/j.tig.2005.08.007; Drake JA, 2006, NAT GENET, V38, P223, DOI 10.1038/ng1710; Evans PD, 2005, SCIENCE, V309, P1717, DOI 10.1126/science.1113722; Fay JC, 2000, GENETICS, V155, P1405; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; Forster P, 2004, PHILOS T R SOC B, V359, P255, DOI 10.1098/rstb.2003.1394; Forster P, 1996, AM J HUM GENET, V59, P935; FU YX, 1993, GENETICS, V133, P693; Garrigan D, 2006, NAT REV GENET, V7, P669, DOI 10.1038/nrg1941; GLEIBERMANN L., 1973, Ecology of Food and Nutrition, V2, P143, DOI 10.1080/03670244.1973.9990329; GOTTESMAN II, 1989, SCHIZOPHRENIA BULL, V15, P5, DOI 10.1093/schbul/15.1.5; Greenfield LJ, 2002, NEUROPHARMACOLOGY, V42, P502, DOI 10.1016/S0028-3908(01)00196-4; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Huang RQ, 1998, J PHARMACOL EXP THER, V286, P243; HUDSON RR, 1987, GENETICS, V116, P153; Hudson RR, 2002, BIOINFORMATICS, V18, P337, DOI 10.1093/bioinformatics/18.2.337; Ikeda M, 2005, BIOL PSYCHIAT, V58, P440, DOI 10.1016/j.biopsych.2005.05.002; Kimura MA, 1985, NEUTRAL THEORY MOL E; Korpi ER, 2006, PHARMACOL THERAPEUT, V109, P12, DOI 10.1016/j.pharmthera.2005.05.009; Leonhard K., 1999, CLASSIFICATION ENDOG, V2nd; Liu JX, 2005, BIOCHEM BIOPH RES CO, V334, P817, DOI 10.1016/j.bbrc.2005.06.167; Lo WS, 2007, BIOL PSYCHIAT, V61, P653, DOI 10.1016/j.biopsych.2006.05.003; Lo WS, 2004, MOL PSYCHIATR, V9, P603, DOI 10.1038/sj.mp.4001461; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Mellars P, 2006, P NATL ACAD SCI USA, V103, P9381, DOI 10.1073/pnas.0510792103; Nakajima T, 2004, AM J HUM GENET, V74, P898, DOI 10.1086/420793; NEEL JV, 1962, AM J HUM GENET, V14, P353; NEI M, 1983, GENETICS, V105, P207; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; NURNBERGER JI, 1994, ARCH GEN PSYCHIAT, V51, P849, DOI 10.1001/archpsyc.1994.03950110009002; Otto SP, 1997, GENETICS, V147, P879; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PARNAS J, 1988, PSYCHIATRY, V51, P58, DOI 10.1080/00332747.1988.11024380; Petryshen TL, 2005, MOL PSYCHIATR, V10, P1074, DOI 10.1038/sj.mp.4001739; Pike RL, 2006, AM J HUM BIOL, V18, P729, DOI 10.1002/ajhb.20548; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359; Rozen S, 2000, Methods Mol Biol, V132, P365; Saillard J, 2000, AM J HUM GENET, V67, P718, DOI 10.1086/303038; Salem AH, 2003, MOL BIOL EVOL, V20, P1349, DOI 10.1093/molbev/msg150; Sapolsky RM, 2005, SCIENCE, V308, P648, DOI 10.1126/science.1106477; Sapolsky RM, 2004, PLOS BIOL, V2, P534, DOI 10.1371/journal.pbio.0020106; Smit A.F.A, 1996, REPEATMASKER OPEN 3; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; TAJIMA F, 1989, GENETICS, V123, P585; Thompson EE, 2004, AM J HUM GENET, V75, P1059, DOI 10.1086/426406; Thomson R, 2000, P NATL ACAD SCI USA, V97, P7360, DOI 10.1073/pnas.97.13.7360; Vander Molen J, 2005, AM J HUM GENET, V76, P548, DOI 10.1086/428784; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Voight BF, 2005, P NATL ACAD SCI USA, V102, P18508, DOI 10.1073/pnas.0507325102; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; White TD, 2003, NATURE, V423, P742, DOI 10.1038/nature01669; Yu ZL, 2006, CLIN BIOCHEM, V39, P210, DOI 10.1016/j.clinbiochem.2006.01.009; Zhao C, 2006, MOL PSYCHIATR, V11, P1092, DOI 10.1038/sj.mp.4001899	70	31	33	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e462	10.1371/journal.pone.0000462	http://dx.doi.org/10.1371/journal.pone.0000462			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520021	Green Published, gold, Green Accepted			2022-12-25	WOS:000207446000010
J	Brennan, IM; Peters, U; Kapoor, TM; Straight, AF				Brennan, Ian M.; Peters, Ulf; Kapoor, Tarun M.; Straight, Aaron F.			Polo-Like Kinase Controls Vertebrate Spindle Elongation and Cytokinesis	PLOS ONE			English	Article								During cell division, chromosome segregation must be coordinated with cell cleavage so that cytokinesis occurs after chromosomes have been safely distributed to each spindle pole. Polo-like kinase 1 (Plk1) is an essential kinase that regulates spindle assembly, mitotic entry and chromosome segregation, but because of its many mitotic roles it has been difficult to specifically study its post-anaphase functions. Here we use small molecule inhibitors to block Plk1 activity at anaphase onset, and demonstrate that Plk1 controls both spindle elongation and cytokinesis. Plk1 inhibition did not affect anaphase A chromosome to pole movement, but blocked anaphase B spindle elongation. Plk1-inhibited cells failed to assemble a contractile ring and contract the cleavage furrow due to a defect in Rho and Rho-GEF localization to the division site. Our results demonstrate that Plk1 coordinates chromosome segregation with cytokinesis through its dual control of anaphase B and contractile ring assembly.	[Brennan, Ian M.; Straight, Aaron F.] Stanford Med Sch, Dept Biochem, Stanford, CA USA; [Peters, Ulf; Kapoor, Tarun M.] Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA	Stanford University; Rockefeller University	Straight, AF (corresponding author), Stanford Med Sch, Dept Biochem, Stanford, CA USA.	astraigh@stanford.edu		Straight, Aaron/0000-0001-5885-7881; Peters, Ulf/0000-0003-4664-8198	National Science Foundation; NIH; Damon Runyon Cancer Research Foundation	National Science Foundation(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation	IMB is supported by the National Science Foundation. TMK receives support from the NIH. AFS is the Gordon Family Damon Runyon Scholar supported by the Damon Runyon Cancer Research Foundation and is supported by the NIH.	Balasubramanian MK, 2004, CURR BIOL, V14, pR806, DOI 10.1016/j.cub.2004.09.022; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Burkard ME, 2007, P NATL ACAD SCI USA, V104, P4383, DOI 10.1073/pnas.0701140104; Canman JC, 2000, CURR BIOL, V10, P611, DOI 10.1016/S0960-9822(00)00490-5; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Chalamalasetty RB, 2006, J CELL SCI, V119, P3008, DOI 10.1242/jcs.03032; DeLuca JG, 2002, J CELL BIOL, V159, P549, DOI 10.1083/jcb.200208159; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Eggert US, 2006, ANNU REV BIOCHEM, V75, P543, DOI 10.1146/annurev.biochem.74.082803.133425; Fink G, 2006, EMBO J, V25, P4897, DOI 10.1038/sj.emboj.7601354; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Kamijo K, 2006, MOL BIOL CELL, V17, P43, DOI 10.1091/mbc.e05-06-0569; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; Khodjakov A, 1997, J CELL BIOL, V136, P229, DOI 10.1083/jcb.136.2.229; KIEHART DP, 1982, J CELL BIOL, V94, P165, DOI 10.1083/jcb.94.1.165; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Maiato H, 2004, J CELL SCI, V117, P5461, DOI 10.1242/jcs.01536; MARTINEAU SN, 1995, J CELL BIOL, V131, P191, DOI 10.1083/jcb.131.1.191; McInnes C, 2006, NAT CHEM BIOL, V2, P608, DOI 10.1038/nchembio825; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; Neef R, 2003, J CELL BIOL, V162, P863, DOI 10.1083/jcb.200306009; Nishimura Y, 2006, J CELL SCI, V119, P104, DOI 10.1242/jcs.02737; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; PETERS U, 2006, NAT CHEM BIOL; Piekny A, 2005, TRENDS CELL BIOL, V15, P651, DOI 10.1016/j.tcb.2005.10.006; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHROEDER TE, 1972, J CELL BIOL, V53, P419, DOI 10.1083/jcb.53.2.419; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Steegmaier M, 2005, CLIN CANCER RES, V11, p9147S; Straight AF, 2005, MOL BIOL CELL, V16, P193, DOI 10.1091/mbc.E04-08-0758; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Yoshida S, 2006, SCIENCE, V313, P108, DOI 10.1126/science.1126747; Yuce O, 2005, J CELL BIOL, V170, P571, DOI 10.1083/jcb.200501097; Zhang DH, 1996, NATURE, V382, P466, DOI 10.1038/382466a0; Zhao WM, 2005, P NATL ACAD SCI USA, V102, P13158, DOI 10.1073/pnas.0504145102	51	98	102	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e409	10.1371/journal.pone.0000409	http://dx.doi.org/10.1371/journal.pone.0000409			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476331	Green Submitted, gold, Green Published			2022-12-25	WOS:000207445700011
J	Wasser, M; Chia, W				Wasser, Martin; Chia, William			The Extrachromosomal EAST Protein of Drosophila Can Associate with Polytene Chromosomes and Regulate Gene Expression	PLOS ONE			English	Article								The EAST protein of Drosophila is a component of an expandable extrachromosomal domain of the nucleus. To better understand its function, we studied the dynamics and localization of GFP-tagged EAST. In live larval salivary glands, EAST-GFP is highly mobile and localizes to the extrachromosomal nucleoplasm. When these cells are permeabilized, EAST-GFP rapidly associated with polytene chromosomes. The affinity to chromatin increases and mobility decreases with decreasing salt concentration. Deleting the C-terminal residues 1535 to 2301 of EAST strongly reduces the affinity to polytene chromosomes. The bulk of EAST-GFP co-localizes with heterochromatin and is absent from transcriptionally active chromosomal regions. The predominantly chromosomal localization of EAST-GFP can be detected in non-detergent treated salivary glands of pupae as they undergo apoptosis, however not in earlier stages of development. Consistent with this chromosomal pattern of localization, genetic evidence indicates a role for EAST in the repression of gene expression, since a lethal east mutation is allelic to the viable mutation suppressor of white-spotted. We propose that EAST acts as an ion sensor that modulates gene expression in response to changing intracellular ion concentrations.	[Wasser, Martin] Bioinformat Inst, Dept Imaging Informat, Singapore, Singapore; [Wasser, Martin; Chia, William] Natl Univ Singapore, Temasek LifeSci Lab, Singapore 117548, Singapore; [Chia, William] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); National University of Singapore; National University of Singapore	Wasser, M (corresponding author), Bioinformat Inst, Dept Imaging Informat, Singapore, Singapore.	martinw@bii.a-star.edu.sg		Wasser, Martin/0000-0002-8753-2346	Temasek LifeSciences Laboratories, Singapore	Temasek LifeSciences Laboratories, Singapore	The study was funded by the Temasek LifeSciences Laboratories, Singapore.	Alberts B, 2002, MOL BIOL CELL, P615; BRAND AH, 1993, DEVELOPMENT, V118, P401; DAVISON D, 1985, GENETICS, V110, P479; Gortchakov AA, 2005, CHROMOSOMA, V114, P54, DOI 10.1007/s00412-005-0339-3; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Lee CY, 2001, DEVELOPMENT, V128, P1443; LEVIS R, 1984, CELL, V38, P471, DOI 10.1016/0092-8674(84)90502-6; Long AR, 1998, GENE, V208, P191, DOI 10.1016/S0378-1119(97)00652-5; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Navarro M, 2001, NATURE, V414, P759, DOI 10.1038/414759a; Paro R., 2000, DROSOPHILA PROTOCOLS, P131; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Phair RD, 2001, NAT REV MOL CELL BIO, V2, P898, DOI 10.1038/35103000; PIRROTTA V, 1984, EMBO J, V3, P563, DOI 10.1002/j.1460-2075.1984.tb01847.x; Qi HY, 2005, J CELL BIOCHEM, V95, P1284, DOI 10.1002/jcb.20495; Rath U, 2004, J CELL BIOCHEM, V93, P1033, DOI 10.1002/jcb.20243; Rath U, 2006, J CELL SCI, V119, P2332, DOI 10.1242/jcs.02960; VIJAYRAGHAVAN K, 1992, DEV BIOL, V154, P23, DOI 10.1016/0012-1606(92)90044-H; Walker DL, 2000, J CELL BIOL, V151, P1401, DOI 10.1083/jcb.151.7.1401; Wasser M, 2000, NAT CELL BIOL, V2, P268, DOI 10.1038/35010535; Wasser M, 2003, J CELL SCI, V116, P1733, DOI 10.1242/jcs.00379; Wells WA, 2001, J CELL BIOL, V154, P1102, DOI 10.1083/jcb.200108139	26	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e412	10.1371/journal.pone.0000412	http://dx.doi.org/10.1371/journal.pone.0000412			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476334	Green Published, gold, Green Submitted			2022-12-25	WOS:000207445700014
J	Wong, KF; Luk, JM; Cheng, RH; Klickstein, LB; Fan, ST				Wong, Kwong-Fai; Luk, John M.; Cheng, R. Holland; Klickstein, Lloyd B.; Fan, Sheung-Tat			Characterization of two novel LPS-binding sites in leukocyte integrin beta A domain	FASEB JOURNAL			English	Article						lipopolysaccharide; endotoxin-neutralizing peptide; NF-kappa B; sepsis; prophylaxis; TNF-alpha	MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; LIPOPOLYSACCHARIDE; PROTEIN; ENDOTOXIN; RECEPTOR; CD14; EXPRESSION; BACTERIAL; MACROPHAGES	Lipopolysaccharide (LPS), a bacterial endotoxin, triggers deleterious systemic inflammatory responses when released into blood circulation, causing organ dysfunction and death. In response to LPS stimulation, CD14 and toll-like receptor (TLR)-4 elicit inflammatory signaling cascades. Although leukocyte integrins (CD11b/CD18 and CD11c/CD18) were reported to bind LPS and induce NF-kappa B translocation, the evidence on such epitope location remains elusive. The present study aims to delineate the LPS-binding sites on the integrin CD18 antigen and to design peptide(s) as potential prophylactic and/or therapeutic agents to modulate LPS effects in activated Jurkat cells. Epitope mapping analysis using a series of CD18 truncated variants revealed two putative LPS-binding sites within the beta A region (216 -248 and 266 -318 a. a.), which were further confirmed by point mutation studies. Inhibition assay demonstrated that the CD18- beta A(266)(318)(-) peptide could block LPS binding in a dose-dependent manner. Our data also indicated that treatment with the CD18-peptide modulated TNF-alpha mRNA transcription via the NF-kappa B signaling pathway in LPS-activated Jurkat cells. In conclusion, we have identified two novel LPS-binding sites located at the CD18 beta A domain of leukocyte integrin, and the integrin peptide beta A266 -318 is shown to inhibit LPS binding and subsequent inflammatory events, having therapeutic implications to cure Gram-negative endotoxemia.	Univ Hong Kong, Jockey Club Clin Res Ctr, Dept Surg, Pokfulam, Hong Kong, Peoples R China; Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	University of Hong Kong; University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Luk, JM (corresponding author), Univ Hong Kong, Jockey Club Clin Res Ctr, Dept Surg, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	jmluk@hkucc.hku.hk	Fan, Sheung Tat/C-4138-2009; Luk, John/A-4085-2008; Wong, Kwong Fai/C-4702-2009; Cheng, Holland/A-8973-2008	Luk, John/0000-0002-6323-7940; 				Andra J, 2006, J ENDOTOXIN RES, V12, P261, DOI 10.1179/096805106X118852; BATTAFARANO RJ, 1995, SURGERY, V118, P318, DOI 10.1016/S0039-6060(05)80340-X; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Flaherty SF, 1997, J SURG RES, V73, P85, DOI 10.1006/jsre.1997.5195; GESSANI S, 1993, J IMMUNOL, V151, P3758; Gopinath RS, 2005, INFECT IMMUN, V73, P6179, DOI 10.1128/IAI.73.9.6179-6182.2005; Hack CE, 1997, ADV IMMUNOL, V66, P101, DOI 10.1016/S0065-2776(08)60597-0; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Heumann D, 2002, CLIN CHIM ACTA, V323, P59, DOI 10.1016/S0009-8981(02)00180-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Lee NPY, 2006, PROTEIN PEPTIDE LETT, V13, P431, DOI 10.2174/092986606776819493; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; Lo CY, 2005, EUR J ENDOCRINOL, V152, P545, DOI 10.1530/eje.1.01883; Luk JM, 1995, ANAL BIOCHEM, V232, P217, DOI 10.1006/abio.1995.0010; LUK JMC, 1991, J BIOL CHEM, V266, P23215; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; OSBORN MJ, 1964, SCIENCE, V145, P783, DOI 10.1126/science.145.3634.783; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Reinhart K, 2004, CRIT CARE MED, V32, P1100, DOI 10.1097/01.CCM.0000124870.42312.C4; Rice TW, 2005, ANNU REV MED, V56, P225, DOI 10.1146/annurev.med.56.082103.104356; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WARREN HS, 1993, J EXP MED, V177, P89, DOI 10.1084/jem.177.1.89; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	39	34	36	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3231	3239		10.1096/fj.06-7579com	http://dx.doi.org/10.1096/fj.06-7579com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17522381				2022-12-25	WOS:000249781600023
J	Hurd, TR; Prime, TA; Harbour, ME; Lilley, KS; Murphy, MP				Hurd, Thomas R.; Prime, Tracy A.; Harbour, Michael E.; Lilley, Kathryn S.; Murphy, Michael P.			Detection of reactive oxygen species-sensitive thiol proteins by redox difference gel electrophoresis - Implications for mitochondrial redox signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT CHAIN; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; S-NITROSYLATION; NITRIC-OXIDE; COMPLEX-I; GLUTATHIONYLATION; DISULFIDE; CELLS; GENERATION	Reactive oxygen species (ROS) produced by the mitochondrial respiratory chain can be a redox signal, but whether they affect mitochondrial function is unclear. Here we show that low levels of ROS from the respiratory chain under physiological conditions reversibly modify the thiol redox state of mitochondrial proteins involved in fatty acid and carbohydrate metabolism. As these thiol modifications were specific and occurred without bulk thiol changes, we first had to develop a sensitive technique to identify the small number of proteins modified by endogenous ROS. In this technique, redox difference gel electrophoresis, control, and redox-challenged samples are labeled with different thiol-reactive fluorescent tags and then separated on the same two-dimensional gel, enabling the sensitive detection of thiol redox modifications by changes in the relative fluorescence of the two tags within a single protein spot, followed by protein identification by mass spectrometry. Thiol redox modification affected enzyme activity, suggesting that the reversible modification of enzyme activity by ROS from the respiratory chain may be an important and unexplored mode of mitochondrial redox signaling.	MRC, Dunn Human Nutr Unit, Cambridge CB2 0XY, England; Univ Cambridge, Dept Biochem, Cambridge Syst Biol Ctr, Cambridge CB2 1GA, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Cambridge	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 0XY, England.	mpm@mrc-dunn.cam.ac.uk	Murphy, Michael P/C-2120-2009; Lilley, Kathryn/ABF-5787-2020	Murphy, Michael P/0000-0003-1115-9618; Lilley, Kathryn/0000-0003-0594-6543	Medical Research Council [MC_U105663148, MC_U105663142] Funding Source: Medline; MRC [MC_U105663142, MC_U105663148] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akerboom T P, 1981, Methods Enzymol, V77, P373; Alban A, 2003, PROTEOMICS, V3, P36, DOI 10.1002/pmic.200390006; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Bartlett K, 2004, EUR J BIOCHEM, V271, P462, DOI 10.1046/j.1432-1033.2003.03947.x; Baty JW, 2005, BIOCHEM J, V389, P785, DOI 10.1042/BJ20050337; Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; Bersani NA, 2002, METHOD ENZYMOL, V347, P317; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; Chen K, 2004, J BIOL CHEM, V279, P35079, DOI 10.1074/jbc.M404859200; Dahm CC, 2006, J BIOL CHEM, V281, P10056, DOI 10.1074/jbc.M512203200; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Ghezzi P, 2005, ANTIOXID REDOX SIGN, V7, P964, DOI 10.1089/ars.2005.7.964; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; Hurd TR, 2005, ANTIOXID REDOX SIGN, V7, P999, DOI 10.1089/ars.2005.7.999; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KALOUSEK F, 1980, J BIOL CHEM, V255, P60; Karp NA, 2004, PROTEOMICS, V4, P1421, DOI 10.1002/pmic.200300681; KIL JS, 2005, J BIOL CHEM, V280, P10486; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Korge P, 2006, AM J PHYSIOL-HEART C, V291, pH1436, DOI 10.1152/ajpheart.01292.2005; Lilley KS, 2004, EXPERT REV PROTEOMIC, V1, P401, DOI 10.1586/14789450.1.4.401; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Low FM, 2007, BLOOD, V109, P2611, DOI 10.1182/blood-2006-09-048728; PETTIT FH, 1982, P NATL ACAD SCI-BIOL, V79, P3945, DOI 10.1073/pnas.79.13.3945; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schieke SM, 2006, BIOL CHEM, V387, P1357, DOI 10.1515/BC.2006.170; Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004; Shaw J, 2003, PROTEOMICS, V3, P1181, DOI 10.1002/pmic.200300439; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	53	119	122	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22040	22051		10.1074/jbc.M703591200	http://dx.doi.org/10.1074/jbc.M703591200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17525152	hybrid			2022-12-25	WOS:000248196800051
J	Ruiz-Ederra, J; Zhang, H; Verkman, AS				Ruiz-Ederra, Javier; Zhang, Hua; Verkman, A. S.			Evidence against functional interaction between aquaporin-4 water channels and Kir4.1 potassium channels in retinal muller cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNEL; ALPHA-SYNTROPHIN; GLIAL-CELLS; MICE; EXPRESSION; LACKING; MEMBRANE; BRAIN; K-AB-2/KIR4.1; LOCALIZATION	Indirect evidence suggests that the Muller/glial cell water channel aquaporin-4 (AQP4) modulates K+ channel function of the closely associated Kir4.1 protein. We used patch clamp to compare Kir4.1 K+ channel function in freshly isolated Muller cells from retinas of wild-type (+/+) and AQP4 knock-out (-/-) mice. Immunocytochemistry showed a comparable Kir4.1 protein expression pattern in Muller cells from +/+ and -/- retinas, with greatest expression at their end feet. Osmotic water permeability was >4-fold reduced in -/- than in +/+ Muller cells. Resting membrane potential did not differ significantly in +/+ versus -/- Muller cells (-64 +/- 1 versus -64 +/- 1 mV, S. E., n = 24). Whole-cell K+ currents recorded with a micropipette inserted into the cell soma were Ba2+-sensitive and showed no significant differences in magnitude in +/+ versus -/- Muller cells (1.3 +/- 0.1 versus 1.2 +/- 0.1 nA at -160 mV) or in inwardly rectifying current- voltage relationships. Spatially resolved K+ currents generated by pulsed K+ injections along Muller cell bodies were also comparable in +/+ versus -/- Muller cells. Single-channel cell-attached patch clamp showed comparable unitary conductance, current- voltage data, and open probability in +/+ versus -/- Muller cells. Thus, contrary to the generally accepted view, our results provide direct evidence against functionally significant AQP4 modulation of Muller cell Kir4.1 K+ channel function.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med & Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med & Physiol, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu	Ederra, Javier Ruiz/H-9687-2017	Ederra, Javier Ruiz/0000-0001-8486-8592	NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK72517, DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124, P30DK072517] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; CHAO TI, 1994, PFLUG ARCH EUR J PHY, V426, P51, DOI 10.1007/BF00374670; Connors NC, 2004, J BIOL CHEM, V279, P28387, DOI 10.1074/jbc.M402604200; Connors NC, 2002, J NEUROSCI, V22, P4321, DOI 10.1523/JNEUROSCI.22-11-04321.2002; Connors NC, 2006, GLIA, V53, P124, DOI 10.1002/glia.20271; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Ishii M, 1997, J NEUROSCI, V17, P7725; Kofuji P, 2000, J NEUROSCI, V20, P5733, DOI 10.1523/JNEUROSCI.20-15-05733.2000; Kusaka S, 1999, J PHYSIOL-LONDON, V520, P373, DOI 10.1111/j.1469-7793.1999.00373.x; Kusaka S, 1997, J PHYSIOL-LONDON, V500, P593, DOI 10.1113/jphysiol.1997.sp022045; Li J, 2002, INVEST OPHTH VIS SCI, V43, P573; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; Lourdel S, 2002, J PHYSIOL-LONDON, V538, P391, DOI 10.1113/jphysiol.2001.012961; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Newman EA, 1996, J NEUROSCI, V16, P159; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Solessio E, 2000, J NEUROPHYSIOL, V83, P418, DOI 10.1152/jn.2000.83.1.418; Tada Y, 1998, JPN J PHYSIOL, V48, P71, DOI 10.2170/jjphysiol.48.71; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; Takumi Y, 1998, EUR J NEUROSCI, V10, P3584, DOI 10.1046/j.1460-9568.1998.00360.x	31	87	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21866	21872		10.1074/jbc.M703236200	http://dx.doi.org/10.1074/jbc.M703236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17525153	hybrid			2022-12-25	WOS:000248196800034
J	Drake, EJ; Cao, J; Qu, J; Shah, MB; Straubinger, RM; Gulick, AM				Drake, Eric J.; Cao, Jin; Qu, Jun; Shah, Manish B.; Straubinger, Robert M.; Gulick, Andrew M.			The 1.8 A crystal structure of PA2412, an MbtH-like protein from the pyoverdine cluster of Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC GENE-CLUSTER; MYCOBACTERIUM-TUBERCULOSIS; SIDEROPHORE BIOSYNTHESIS; STREPTOMYCES-COELICOLOR; ESCHERICHIA-COLI; MASS-SPECTROMETRY; IDENTIFICATION; ENTEROBACTIN; ANTIBIOTICS; EXPRESSION	Many bacteria use nonribosomal peptide synthetase (NRPS) proteins to produce peptide antibiotics and siderophores. The catalytic domains of the NRPS proteins are usually linked in large multidomain proteins. Often, additional proteins are coexpressed with NRPS proteins that modify the NRPS peptide products, ensure the availability of substrate building blocks, or play a role in the import or export of the NRPS product. Many NRPS clusters include a small protein of similar to 80 amino acids with homology to the MbtH protein of mycobactin synthesis in Mycobacteria tuberculosis; no function has been assigned to these proteins. Pseudomonas aeruginosa utilizes an NRPS cluster to synthesize the siderophore pyoverdine. The pyoverdine peptide contains a dihydroxyquinoline-based chromophore, as well as two formyl-N-hydroxyornithine residues, which are involved in iron binding. The pyoverdine cluster contains four modular NRPS enzymes and 10 - 15 additional proteins that are essential for pyoverdine production. Coexpressed with the pyoverdine synthetic enzymes is a 72-amino acid MbtH-like family member designated PA2412. We have determined the three-dimensional structure of the PA2412 protein and describe here the structure and the location of conserved regions. Additionally, we have further analyzed a deletion mutant of the PA2412 protein for growth and pyoverdine production. Our results demonstrate that PA2412 is necessary for the production or secretion of pyoverdine at normal levels. The PA2412 deletion strain is able to use exogenously produced pyoverdine, showing that there is no defect in the uptake or utilization of the iron-pyoverdine complex.	Hauptman Woodward Med Res Inst, Buffalo, NY 14203 USA; SUNY Buffalo, Dept Biol Struct, Buffalo, NY 14260 USA; SUNY Buffalo, New York State Ctr Excellence Bioinformat & Life, Dept Pharmaceut Sci, Buffalo, NY 14203 USA	Hauptman Woodward Medical Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gulick, AM (corresponding author), Hauptman Woodward Med Res Inst, 700 Ellicott St, Buffalo, NY 14203 USA.	gulick@hwi.buffalo.edu	Shah, Manish/H-6158-2011	Gulick, Andrew/0000-0003-4238-7453; Shah, Manish/0000-0001-8593-6446	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR021221, S10RR014592, S10RR023650, S10RR024521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068440] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR 021221, S10 RR024521-01A1, S10 RR 023650, S10 RR023650, S10 RR014592-01, S10 RR024521, S10 RR021221-01, S10 RR 014592, S10 RR021221, S10 RR023650-01, S10 RR021221-010002] Funding Source: Medline; NIGMS NIH HHS [R01 GM068440, GM 068440] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blodgett JAV, 2005, ANTIMICROB AGENTS CH, V49, P230, DOI 10.1128/AAC.49.1.230-240.2005; Chen H, 2002, CHEM BIOL, V9, P103, DOI 10.1016/S1074-5521(02)00090-X; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Drake EJ, 2006, CHEM BIOL, V13, P409, DOI 10.1016/j.chembiol.2006.02.005; Edwards DJ, 2004, J AM CHEM SOC, V126, P11432, DOI 10.1021/ja047876g; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans SP, 1999, J MOL BIOL, V291, P661, DOI 10.1006/jmbi.1999.2971; Ferreras JA, 2005, NAT CHEM BIOL, V1, P29, DOI 10.1038/nchembio706; Fischbach MA, 2006, NAT CHEM BIOL, V2, P132, DOI 10.1038/nchembio771; Fuchs R, 2001, CURR ORG CHEM, V5, P265, DOI 10.2174/1385272013375562; Galm U, 2002, ARCH MICROBIOL, V178, P102, DOI 10.1007/s00203-002-0429-z; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P2648, DOI 10.1021/bi9726584; Gulick AM, 2002, ACTA CRYSTALLOGR D, V58, P306, DOI 10.1107/S0907444901018832; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Kilz S, 1999, J MASS SPECTROM, V34, P281, DOI 10.1002/(SICI)1096-9888(199904)34:4<281::AID-JMS750>3.0.CO;2-M; LaBaer J, 2004, GENOME RES, V14, P2190, DOI 10.1101/gr.2482804; Lauer B, 2000, EUR J BIOCHEM, V267, P1698, DOI 10.1046/j.1432-1327.2000.01162.x; Lautru S, 2007, MICROBIOL-SGM, V153, P1405, DOI 10.1099/mic.0.2006/003145-0; Lin H, 2005, J AM CHEM SOC, V127, P11075, DOI 10.1021/ja0522027; Magarvey NA, 2006, ANTIMICROB AGENTS CH, V50, P2167, DOI 10.1128/AAC.01545-05; Meyer JM, 1996, INFECT IMMUN, V64, P518, DOI 10.1128/IAI.64.2.518-523.1996; Meyer JM, 1997, MICROBIOL-UK, V143, P35, DOI 10.1099/00221287-143-1-35; Miao V, 2005, MICROBIOL-SGM, V151, P1507, DOI 10.1099/mic.0.27757-0; Miethke M, 2006, FEBS J, V273, P409, DOI 10.1111/j.1742-4658.2005.05077.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ochsner UA, 2002, MOL MICROBIOL, V45, P1277, DOI 10.1046/j.1365-2958.2002.03084.x; Quadri LEN, 1998, CHEM BIOL, V5, P631, DOI 10.1016/S1074-5521(98)90291-5; Rayment I, 2002, STRUCTURE, V10, P147, DOI 10.1016/S0969-2126(02)00711-6; Raymond KN, 2003, P NATL ACAD SCI USA, V100, P3584, DOI 10.1073/pnas.0630018100; Renders N, 2001, INFECT GENET EVOL, V1, P29, DOI 10.1016/S1567-1348(01)00004-1; RUSNAK F, 1991, BIOCHEMISTRY-US, V30, P2916, DOI 10.1021/bi00225a027; Somu RV, 2006, J MED CHEM, V49, P31, DOI 10.1021/jm051060o; Stegmann E, 2006, FEMS MICROBIOL LETT, V262, P85, DOI 10.1111/j.1574-6968.2006.00368.x; Stintzi A, 1999, J BACTERIOL, V181, P4118, DOI 10.1128/JB.181.13.4118-4124.1999; Sundlov JA, 2006, ACTA CRYSTALLOGR D, V62, P734, DOI 10.1107/S0907444906015824; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Van Roey P, 2002, NAT STRUCT BIOL, V9, P806, DOI 10.1038/nsb853; Visca P, 2007, TRENDS MICROBIOL, V15, P22, DOI 10.1016/j.tim.2006.11.004; Weeks CM, 2002, Z KRISTALLOGR, V217, P686, DOI 10.1524/zkri.217.12.686.20659; Wilderman PJ, 2001, INFECT IMMUN, V69, P5385, DOI 10.1128/IAI.69.9.5385-5394.2001; Wolpert M, 2007, MICROBIOL-SGM, V153, P1413, DOI 10.1099/mic.0.2006/002998-0; Yeats C, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-3	45	53	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20425	20434		10.1074/jbc.M611833200	http://dx.doi.org/10.1074/jbc.M611833200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17502378	hybrid			2022-12-25	WOS:000247819300045
J	Hong, E; Lee, HM; Ko, H; Kim, DU; Jeon, BY; Jung, J; Shin, J; Lee, SA; Kim, Y; Jeon, YH; Cheong, C; Cho, HS; Lee, W				Hong, Eunmi; Lee, Hyang Mi; Ko, Hyunsook; Kim, Dong-Uk; Jeon, Byoung-Young; Jung, Jinwon; Shin, Joon; Lee, Sung-Ah; Kim, Yangmee; Jeon, Young Ho; Cheong, Chaejoon; Cho, Hyun-Soo; Lee, Weontae			Structure of an atypical orphan response regulator protein supports a new phosphorylation-independent regulatory mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR STRUCTURE DETERMINATION; 2-COMPONENT SIGNAL-TRANSDUCTION; RNA-POLYMERASE INTERACTION; DNA-BINDING DOMAIN; HELICOBACTER-PYLORI; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL ACTIVATOR; STRUCTURE REFINEMENT; CHEMICAL-SHIFT; NMR	Two-component signal transduction systems, commonly found in prokaryotes, typically regulate cellular functions in response to environmental conditions through a phosphorylation-dependent process. A new type of response regulator, hp1043 (HP-RR) from Helicobacterpylori, hasbeenrecentlyidentified. HP-RR is essential for cell growth and does not require the well known phosphorelay scheme. Unphosphorylated HP-RR binds specifically to its own promoter (P-1043) and autoregulates the promoter of the tlpB gene (P-tlpB). We have determined the structure of HP-RR by NMR and x-ray crystallography, revealing a symmetrical dimer with two functional domains. The molecular topology resembles that of the OmpR/PhoB subfamily, however, the symmetrical dimer is stable even in the unphosphorylated state. The dimer interface, formed by three secondary structure elements (alpha 4-beta 5-alpha 5), resembles that of the active, phosphorylated forms of ArcA and PhoB. Several conserved residues of the HP-RR dimeric interface deviate from the OmpR/PhoB subfamily, although there are similar salt bridges and hydrophobic patches within the interface. Our findings reveal how a new type of response regulator protein could function as a cell growth-associated regulator in the absence of post-translational modification.	Yonsei Univ, Dept Biochem, HTSD NMR & Applicat NRL, Seoul 120749, South Korea; Yonsei Univ, Protien Network Res ctr, Dept Biol, Seoul, South Korea; Konkuk Univ, Dept Biosci & Biotechnol, Div Biosci & Biotechnol, Seoul 363883, South Korea; Korea Basic Sci Inst, Magnet Resonance Team, Chungbuk 363883, South Korea	Yonsei University; Yonsei University; Konkuk University; Korea Basic Science Institute (KBSI)	Cho, HS (corresponding author), Yonsei Univ, Coll Sci, Dept Biochem, 134 Shinchon-Dong, Seoul 120749, South Korea.	hscho8@yonsei.ac.kr; wlee@spin.yonsei.ac.kr	LEE, WEON TAE/AAQ-9088-2021; Jung, Jinwon/F-6038-2010; kim, yangmee/D-8297-2011; Jeon, Young Ho/F-4483-2011; Cheong, Chaejoon/GWC-3135-2022	Jung, Jinwon/0000-0002-7981-3316; Lee, Weontae/0000-0003-2347-1262				Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; Bachhawat P, 2005, STRUCTURE, V13, P1353, DOI 10.1016/j.str.2005.06.006; Baikalov I, 1998, BIOCHEMISTRY-US, V37, P3665, DOI 10.1021/bi972365a; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Beier D, 2000, J BACTERIOL, V182, P2068, DOI 10.1128/JB.182.8.2068-2076.2000; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; Boucher PE, 1997, J BACTERIOL, V179, P1755, DOI 10.1128/jb.179.5.1755-1763.1997; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clore GM, 1998, P NATL ACAD SCI USA, V95, P5891, DOI 10.1073/pnas.95.11.5891; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano WL, 2004, ABSTR PAP AM CHEM S, V228, pU313; Delany I, 2002, J BACTERIOL, V184, P4800, DOI 10.1128/JB.184.17.4800-4810.2002; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; Eisenbach M, 1996, MOL MICROBIOL, V20, P903, DOI 10.1111/j.1365-2958.1996.tb02531.x; Goddard T.D., 2004, SPARKY 3; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Halkides CJ, 2000, BIOCHEMISTRY-US, V39, P5280, DOI 10.1021/bi9925524; Hong EM, 2004, J BIOMOL NMR, V28, P85, DOI 10.1023/B:JNMR.0000012833.26132.f5; Jee JunGoo, 2003, Journal of Structural and Functional Genomics, V4, P179, DOI 10.1023/A:1026122726574; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; Kondo H, 1997, NAT STRUCT BIOL, V4, P28, DOI 10.1038/nsb0197-28; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KORDEL J, 1992, BIOCHEMISTRY-US, V31, P4856; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee HM, 2006, BBA-PROTEINS PROTEOM, V1764, P989, DOI 10.1016/j.bbapap.2005.10.024; Lee SY, 2001, J BIOL CHEM, V276, P16425, DOI 10.1074/jbc.M101002200; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; Liu W, 1997, J BACTERIOL, V179, P6302, DOI 10.1128/jb.179.20.6302-6310.1997; Maris AE, 2002, NAT STRUCT BIOL, V9, P771, DOI 10.1038/nsb845; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; Muller S, 2007, MICROBIOL RES, V162, P1, DOI 10.1016/j.micres.2006.01.003; Okamura H, 2000, J MOL BIOL, V295, P1225, DOI 10.1006/jmbi.1999.3379; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelton JG, 1999, J MOL BIOL, V292, P1095, DOI 10.1006/jmbi.1999.3140; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Schar J, 2005, J BACTERIOL, V187, P3100, DOI 10.1128/JB.187.9.3100-3109.2005; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Simonovic M, 2001, J BIOL CHEM, V276, P28637, DOI 10.1074/jbc.C100295200; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Toro-Roman A, 2005, J MOL BIOL, V349, P11, DOI 10.1016/j.jmb.2005.03.059; Zu T, 1996, MOL MICROBIOL, V21, P557, DOI 10.1111/j.1365-2958.1996.tb02564.x	49	48	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20667	20675		10.1074/jbc.M609104200	http://dx.doi.org/10.1074/jbc.M609104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17491010	hybrid			2022-12-25	WOS:000247819300069
J	Wood, A; Garg, P; Burgers, PMJ				Wood, Adam; Garg, Parie; Burgers, Peter M. J.			A ubiquitin-binding motif in the translesion DNA polymerase Rev1 mediates its essential functional interaction with ubiquitinated proliferating cell nuclear antigen in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; REPLICATION FACTOR-C; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; POL-ETA; IN-VIVO; PROTEIN INTERACTS; CLAMP LOADERS; ABASIC SITES; PCNA	During normalDNAreplication, the proliferating cell nuclear antigen (PCNA) enhances the processivity of DNA polymerases at the replication fork. When DNA damage is encountered, PCNA is monoubiquitinated on Lys-164 by the Rad6-Rad18 complex as the initiating step of translesion synthesis. DNA damage bypass by the translesion synthesis polymerase Rev1 is enhanced by the presence of ubiquitinated PCNA. Here we have carried out a mutational analysis of Rev1, and we have identified the functional domain in the C terminus of Rev1 that mediates interactions with PCNA. We show that a unique motif within this domain binds the ubiquitin moiety of ubiquitinated PCNA. Point mutations within this ubiquitin-binding motif of Rev1 (L821A, P822A, I825A) abolish its functional interaction with ubiquitinated PCNA in vitro and strongly attenuate damage-induced mutagenesis in vivo. Taken together, these studies suggest a specific mechanism by which the interaction between Rev1 and ubiquitinated PCNA is stabilized during the DNA damage response.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM032431, GM 032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Bylund GO, 2006, METHOD ENZYMOL, V409, P1, DOI 10.1016/S0076-6879(05)09001-4; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Friedberg EC, 2005, MOL CELL, V18, P499, DOI 10.1016/j.molcel.2005.03.032; Garg P, 2005, P NATL ACAD SCI USA, V102, P18361, DOI 10.1073/pnas.0505949102; Garg P, 2005, CELL CYCLE, V4, P221; Garg P, 2005, J BIOL CHEM, V280, P23446, DOI 10.1074/jbc.C500173200; Garg P, 2005, CRIT REV BIOCHEM MOL, V40, P115, DOI 10.1080/10409230590935433; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gibbs PEM, 2005, GENETICS, V169, P575, DOI 10.1534/genetics.104.034611; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Guo CX, 2006, MOL CELL BIOL, V26, P8892, DOI 10.1128/MCB.01118-06; Guo CX, 2006, MOL CELL, V23, P265, DOI 10.1016/j.molcel.2006.05.038; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Haracska L, 2006, P NATL ACAD SCI USA, V103, P6477, DOI 10.1073/pnas.0510924103; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; Haracska L, 2003, MOL CELL BIOL, V23, P1453, DOI 10.1128/MCB.23.4.1453-1459.2003; Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Hochegger H, 2004, BIOESSAYS, V26, P151, DOI 10.1002/bies.10403; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kao HI, 2003, CRIT REV BIOCHEM MOL, V38, P433, DOI 10.1080/10409230390259382; Lehmann AR, 2003, CELL CYCLE, V2, P300, DOI 10.4161/cc.2.4.407; LEMONTT JF, 1971, GENETICS, V68, P21; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Murakumo Y, 2001, J BIOL CHEM, V276, P35644, DOI 10.1074/jbc.M102051200; Nair DT, 2005, SCIENCE, V309, P2219, DOI 10.1126/science.1116336; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; Nelson JR, 2000, MOL MICROBIOL, V37, P549, DOI 10.1046/j.1365-2958.2000.01997.x; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Northam MR, 2006, EMBO J, V25, P4316, DOI 10.1038/sj.emboj.7601320; Otsuka C, 2005, MUTAT RES-FUND MOL M, V578, P79, DOI 10.1016/j.mrfmmm.2005.03.005; Pessoa-Brandao L, 2004, GENETICS, V167, P1597, DOI 10.1534/genetics.103.021675; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; QUAH SK, 1980, GENETICS, V96, P819; Ross AL, 2005, NUCLEIC ACIDS RES, V33, P1280, DOI 10.1093/nar/gki279; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zhao B, 2004, NUCLEIC ACIDS RES, V32, P3984, DOI 10.1093/nar/gkh710; Zhong XJ, 2006, NUCLEIC ACIDS RES, V34, P4731, DOI 10.1093/nar/gkl465	54	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20256	20263		10.1074/jbc.M702366200	http://dx.doi.org/10.1074/jbc.M702366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17517887	hybrid			2022-12-25	WOS:000247819300028
J	Wu, HY; Hsu, FC; Gleichman, AJ; Baconguis, I; Coulter, DA; Lynch, DR				Wu, Hai-Yan; Hsu, Fu-Chun; Gleichman, Amy J.; Baconguis, Isabelle; Coulter, Douglas A.; Lynch, David R.			Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTOR; NMDA-RECEPTOR; TYROSINE PHOSPHORYLATION; GLUTAMATE RECEPTORS; SURFACE EXPRESSION; EPSILON-2 SUBUNIT; MUTANT MICE; CELL-DEATH; PROTEIN; KINASE	Cleavage of the intracellular carboxyl terminus of the N-methyl-D-aspartate ( NMDA) receptor 2 subunit (NR2) by calpain regulates NMDA receptor function and localization. Here, we show that Fyn-mediated phosphorylation of NR2B controls calpain-mediated NR2B cleavage. In cultured neurons, calpain-mediated NR2B cleavage is significantly attenuated by blocking NR2B phosphorylation of Tyr-1336, but not Tyr-1472, via inhibition of Src family kinase activity or decreasing Fyn levels by small interfering RNA. In HEK cells, mutation of Tyr1336 eliminates the potentiating effect of Fyn on calpain-mediated NR2B cleavage. The potentiation of NR2B cleavage by Fyn is limited to cell surface receptors and is associated with calpain translocation to plasma membranes during NMDA receptor activation. Finally, reducing full-length NR2B by calpain does not decrease extrasynaptic NMDA receptor function, and truncated NR1/2B receptors similar to those generated by calpain have electrophysiological properties matching those of wild-type receptors. Thus, the Fyn-controlled regulation of NMDA receptor cleavage by calpain may play critical roles in controlling NMDA receptor properties during synaptic plasticity and excitotoxicity.	Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Lynch, DR (corresponding author), Childrens Hosp Philadelphia, Div Neurol, 502 Abramson Bldg, Philadelphia, PA 19104 USA.	lynch@pharm.med.upenn.edu	Baconguis, Isabelle/AAH-3790-2021	Baconguis, Isabelle/0000-0002-5440-2289; Coulter, Douglas/0000-0002-1486-119X; Gleichman, Amy/0000-0003-1029-4471	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS045986, R01NS032403, R01NS045986, R01NS038572, R37NS032403] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS038572-09, R01 NS038572, R01 NS032403-09, NS 45986, R37 NS032403-14, R56 NS045986, R37 NS032403, R01 NS032403, R01 NS045986] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANEGAWA NJ, 1995, J NEUROCHEM, V64, P2004; Araujo IM, 2005, NEUROREPORT, V16, P393; ARIYOSHI H, 1993, BIOCHEM MOL BIOL INT, V30, P63; Cheung HH, 2001, J NEUROCHEM, V78, P524, DOI 10.1046/j.1471-4159.2001.00433.x; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Dong YN, 2006, J NEUROCHEM, V99, P206, DOI 10.1111/j.1471-4159.2006.04096.x; Dong YN, 2004, J NEUROSCI, V24, P11035, DOI 10.1523/JNEUROSCI.3722-04.2004; Dunah AW, 2004, MOL PHARMACOL, V65, P121, DOI 10.1124/mol.65.1.121; Ebralidze AK, 1996, J NEUROSCI, V16, P5014; Grant ER, 1997, J BIOL CHEM, V272, P647; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Gurd JW, 1997, J NEUROCHEM, V69, P623; Guttmann RP, 2002, J PHARMACOL EXP THER, V302, P1023, DOI 10.1124/jpet.102.036962; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; HANKE JH, 1996, I BIOL CHEM, V271, P695; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kadotani H, 1996, J NEUROSCI, V16, P7859; Kalia LV, 2003, NEUROPHARMACOLOGY, V45, P720, DOI 10.1016/S0028-3908(03)00313-7; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Lavezzari G, 2003, NEUROPHARMACOLOGY, V45, P729, DOI 10.1016/S0028-3908(03)00308-3; Lynch DR, 2001, CURR DRUG TARGETS, V2, P215, DOI 10.2174/1389450013348434; Lynch DR, 2002, J PHARMACOL EXP THER, V300, P717, DOI 10.1124/jpet.300.3.717; Lynch DR, 2001, EUR J PHARMACOL, V416, P185, DOI 10.1016/S0014-2999(01)00868-8; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; PONTREMOLI S, 1989, BIOCHEM BIOPH RES CO, V160, P737, DOI 10.1016/0006-291X(89)92495-9; Prybylowski K, 2005, NEURON, V47, P845, DOI 10.1016/j.neuron.2005.08.016; Rong YQ, 2001, J NEUROCHEM, V79, P382, DOI 10.1046/j.1471-4159.2001.00565.x; Sala C, 1999, P NATL ACAD SCI USA, V96, P335, DOI 10.1073/pnas.96.2.335; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tovar KR, 2002, NEURON, V34, P253; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; Waxman EA, 2005, J BIOL CHEM, V280, P29322, DOI 10.1074/jbc.M502080200; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200; Yaka R, 2003, J NEUROSCI, V23, P3623; Yang M, 2001, J NEUROCHEM, V77, P580, DOI 10.1046/j.1471-4159.2001.00255.x; Zheng F, 1998, NAT NEUROSCI, V1, P185, DOI 10.1038/634	48	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20075	20087		10.1074/jbc.M700624200	http://dx.doi.org/10.1074/jbc.M700624200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17526495	hybrid, Green Accepted			2022-12-25	WOS:000247819300008
J	Fujimura, T; Esteban, R				Fujimura, Tsutomu; Esteban, Rosa			Interactions of the RNA polymerase with the viral genome at the 5 '- and 3 '-ends contribute to 20S RNA narnavirus persistence in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED RNA; BIPARTITE 3'-CIS-ACTING SIGNAL; INFLUENZA-VIRUS POLYMERASE; 23 S RNA; SACCHAROMYCES-CEREVISIAE; IN-VIVO; 20-S RNA; ENCAPSIDATION SIGNAL; POLIOVIRUS RNA; REPLICATION	20S RNA narnavirus is a positive strand RNA virus found in the yeast Saccharomyces cerevisiae. The viral genome (2514 nucleotides) only encodes a single protein (p91), the RNA-dependent RNA polymerase and does not have capsid proteins to form intracellular virions. The genomic RNA has no 3' poly(A) tail and perhaps no cap structure at the 5'-end; thus resembling an intermediate of mRNA degradation. The virus, however, escapes the host surveillance and replicates in the yeast cytoplasm persistently. The viral genome is not naked but exists in the form of a ribonucleoprotein complex with p91 in a 1:1 stoichiometry. Here we investigated interactions between p91 and the viral genome. Our results indicate that p91 directly or indirectly interacts with theRNAat the 5'- and 3'-end regions and to a lesser extent at a central part. The 3'-end site is identical to or overlaps with the 3'-cis signal for replication identified previously. The 5'-site is at the second stem loop structure from the 5'-end ( nucleotides 72-104), and this structure also contains a cis signal for replication. Analysis of mutants in the structure revealed a tight correlation between replication and formation of complexes. These results highlight the importance of ribonucleoprotein complexes for the viral life cycle. We will discuss implications of these findings especially on how the virus escapes from mRNA degradation pathways and resides in the cytoplasm persistently despite the lack of a protective capsid.	Univ Salamanca, Inst Microbiol Bioquim, CSIC, Dept Genet & Microbiol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Fujimura, T (corresponding author), Univ Salamanca, Inst Microbiol Bioquim, CSIC, Avda Campo Charro S-N, Salamanca 37007, Spain.	tfujimura@usal.es	Fujimura, Tsutomu/K-5807-2014; Esteban, Rosa/K-4356-2014	Fujimura, Tsutomu/0000-0002-9457-6769; Esteban, Rosa/0000-0001-6804-7209				AHMED R, 1999, PERSISTENT VIRAL INF; Area E, 2004, P NATL ACAD SCI USA, V101, P308, DOI 10.1073/pnas.0307127101; Barton DJ, 2001, EMBO J, V20, P1439, DOI 10.1093/emboj/20.6.1439; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; Esteban R, 2005, J BIOL CHEM, V280, P33725, DOI 10.1074/jbc.M506546200; Esteban R., 2006, RECENT ADV RNA VIRUS, P171; Fujimura T, 2005, J BIOL CHEM, V280, P7398, DOI 10.1074/jbc.M412048200; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; Fujimura T, 2004, J BIOL CHEM, V279, P44219, DOI 10.1074/jbc.M408530200; Fujimura T, 2004, J BIOL CHEM, V279, P13215, DOI 10.1074/jbc.M313797200; Fujimura T, 2000, J BIOL CHEM, V275, P37118, DOI 10.1074/jbc.M005245200; GARCIACUELLAR MP, 1995, J BIOL CHEM, V270, P20084, DOI 10.1074/jbc.270.34.20084; GARCIACUELLAR MP, 1996, IN VITRO REPLICATION; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; Klumpp K, 1997, EMBO J, V16, P1248, DOI 10.1093/emboj/16.6.1248; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P20363, DOI 10.1074/jbc.273.32.20363; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Solorzano A, 2000, J BIOL CHEM, V275, P26428, DOI 10.1074/jbc.M002281200; Stevens A, 2001, METHOD ENZYMOL, V342, P251, DOI 10.1016/S0076-6879(01)42549-3; TOHE A, 1978, J BACTERIOL, V136, P1002, DOI 10.1128/JB.136.3.1002-1007.1978; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 2000, VIRUS TAXONOMY, P651; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; ZUKER M, 1999, ALGORITHMS THERMODYN	34	15	15	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19011	19019		10.1074/jbc.M702432200	http://dx.doi.org/10.1074/jbc.M702432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17478418	hybrid			2022-12-25	WOS:000247475300043
J	Pillinger, MH; Marjanovic, N; Kim, SY; Lee, YC; Scher, JU; Roper, J; Abeles, AM; Izmirly, PI; Axelrod, M; Pillinger, MY; Tolani, S; Dinsell, V; Abramson, SB; Blaser, MJ				Pillinger, Michael H.; Marjanovic, Nada; Kim, Seok-Yong; Lee, Yong-Chan; Scher, Jose U.; Roper, Jatin; Abeles, Aryeh M.; Izmirly, Peter I.; Axelrod, Matthew; Pillinger, Mara Y.; Tolani, Sonia; Dinsell, Victoria; Abramson, Steven B.; Blaser, Martin J.			Helicobacter pylori stimulates gastric epithelial cell MMP-1 secretion via CagA-dependent and -independent ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; VIRULENCE FACTOR CAGA; P38 MAP KINASE; FACTOR-KAPPA-B; MATRIX METALLOPROTEINASES; PATHOGENICITY ISLAND; IN-VITRO; MATRIX-METALLOPROTEINASE-9 EXPRESSION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX	Because the mechanisms of Helicobacter pylori-induced gastric injury are incompletely understood, we examined the hypothesis that H. pylori induces matrix metalloproteinase-1 (MMP-1) secretion, with potential to disrupt gastric stroma. We further tested the role of CagA, an H. pylori virulence factor, in MMP-1 secretion. Co-incubation of AGS cells with Tx30a, an H. pylori strain lacking the cagA virulence gene, stimulated MMP-1 secretion, confirming cagA-independent secretion. Co-incubation with strain 147C (cagA(+)) resulted in CagA translocation into AGS cells and increased MMP-1 secretion relative to Tx30a. Transfection of cells with the recombinant 147C cagA gene also induced MMP-1 secretion, indicating that CagA can independently stimulate MMP-1 secretion. Co-incubation with strain 147A, containing a cagA gene that lacks an EPIYA tyrosine phosphorylation motif, as well as transfection with 147A cagA, yielded an MMP-1 secretion intermediate between no treatment and 147C, indicating that CagA tyrosine phosphorylation regulates cellular signaling in this model system. H. pylori induced activation of the MAP kinase ERK, with CagA-independent (early) and dependent (later) components. MEK inhibitors UO126 and PD98059 inhibited both CagA-independent and -dependent MMP-1 secretion, whereas p38 inhibition enhanced MMP-1 secretion and ERK activation, suggesting p38 negative regulation of MMP-1 and ERK. These data indicate H. pylori effects on host epithelial MMP-1 expression via ERK, with p38 playing a potential regulatory role.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; New York Harbor Helathcare Syst, Dept Vet Affairs, Med Serv, New York, NY 10010 USA; NYU, Hosp Joint Dis, Dept Rheumatol, New York, NY 10003 USA; Chungbuk Natl Univ, Coll Med, Dept Microbiol, Cheongju 361763, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea	New York University; New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; Chungbuk National University; Yonsei University; Yonsei University Health System	Pillinger, MH (corresponding author), New York Harbor Healthcare Syst, 423 E 23rd St, New York, NY 10010 USA.	michael.pillinger@med.nyu.edu	Abeles, Aryeh M./AAD-1874-2019	Pillinger, Michael/0000-0003-3168-1542; Pillinger, Mara/0000-0002-6692-5407; Abramson, Steven/0000-0002-0668-6344; Roper, Jatin/0000-0002-8851-1352; Dinsell, Victoria/0000-0002-5067-3698; Abeles, Aryeh/0000-0003-2940-7114	NIAMS NIH HHS [R01-AR47206-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM63270] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063270] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aras RA, 2003, J INFECT DIS, V188, P486, DOI 10.1086/377098; Aspholm-Hurtig M, 2004, SCIENCE, V305, P519, DOI 10.1126/science.1098801; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BARRANCO SC, 1983, CANCER RES, V43, P1703; Bebb JR, 2003, GUT, V52, P1408, DOI 10.1136/gut.52.10.1408; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; BLASER MJ, 1995, CANCER RES, V55, P2111; Bou-Gharios G, 2004, CELL PROLIFERAT, V37, P207, DOI 10.1111/j.1365-2184.2004.00306.x; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cunnane G, 2001, ARTHRITIS RHEUM-US, V44, P1744, DOI 10.1002/1529-0131(200108)44:8<1744::AID-ART309>3.0.CO;2-K; Danese S, 2004, GASTROENTEROLOGY, V126, P369, DOI 10.1053/j.gastro.2003.06.007; Ding XZ, 2001, BIOCHEM BIOPH RES CO, V282, P447, DOI 10.1006/bbrc.2001.4595; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Foster ML, 2000, DRUG NEWS PERSPECT, V13, P488; GILLESSEN A, 1993, SCAND J GASTROENTERO, V28, P688, DOI 10.3109/00365529309098273; Gooz M, 2001, AM J PHYSIOL-GASTR L, V281, pG823, DOI 10.1152/ajpgi.2001.281.3.G823; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Higuchi M, 2004, CANCER SCI, V95, P442, DOI 10.1111/j.1349-7006.2004.tb03229.x; Honda M, 1996, GUT, V39, P444, DOI 10.1136/gut.39.3.444; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Johansson N, 2000, J CELL SCI, V113, P227; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Keates S, 1999, J IMMUNOL, V163, P5552; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; Kersulyte D, 1999, MOL MICROBIOL, V31, P31, DOI 10.1046/j.1365-2958.1999.01140.x; Kim SY, 2006, CELL MICROBIOL, V8, P97, DOI 10.1111/j.1462-5822.2005.00603.x; Kitoh T, 2004, J GASTROENTEROL, V39, P434, DOI 10.1007/s00535-003-1316-3; Kobayashi N, 2001, J PHYSIOL PHARMACOL, V52, P195; Koyama S, 2004, SCAND J GASTROENTERO, V39, P1046, DOI 10.1080/00365520410003245; Krueger S, 2006, J BIOL CHEM, V281, P2868, DOI 10.1074/jbc.m511053200; Kundu P, 2006, J BIOL CHEM, V281, P34651, DOI 10.1074/jbc.M604574200; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; Lin B, 2001, J INFECT DIS, V184, P174, DOI 10.1086/322000; Lu H, 2005, MOL BIOL CELL, V16, P4954, DOI 10.1091/mbc.E05-05-0426; Menges M, 2000, Z GASTROENTEROL, V38, P887, DOI 10.1055/s-2000-10300; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Moss SF, 2005, NAT CLIN PRACT ONCOL, V2, P90, DOI 10.1038/ncponc0081; Moss SF, 2001, CANCER RES, V61, P1406; Murray GI, 1998, GUT, V43, P791, DOI 10.1136/gut.43.6.791; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; Nomura AMY, 2002, J INFECT DIS, V186, P1138, DOI 10.1086/343808; Nomura AMY, 2002, AM J EPIDEMIOL, V155, P1054, DOI 10.1093/aje/155.11.1054; Numazawa S, 2003, J BIOCHEM, V133, P599, DOI 10.1093/jb/mvg077; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; OKADA Y, 1995, LAB INVEST, V72, P311; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Peek RM, 1995, LAB INVEST, V73, P760; Pelletier JP, 2003, ARTHRITIS RHEUM-US, V48, P1582, DOI 10.1002/art.11014; Perides G, 1999, J NEUROSCI RES, V58, P779, DOI 10.1002/(SICI)1097-4547(19991215)58:6&lt;779::AID-JNR5&gt;3.0.CO;2-L; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; Pillinger MH, 2005, J BIOL CHEM, V280, P9973, DOI 10.1074/jbc.M413522200; Pillinger MH, 2004, BRIT J PHARMACOL, V142, P973, DOI 10.1038/sj.bjp.0705864; Pillinger MH, 2003, J IMMUNOL, V171, P6080, DOI 10.4049/jimmunol.171.11.6080; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Rutter JL, 1998, CANCER RES, V58, P5321; SaarialhoKere UK, 1996, AM J PATHOL, V148, P519; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Seo JH, 2004, LAB INVEST, V84, P49, DOI 10.1038/labinvest.3700010; Shahin M, 2001, MICROSC RES TECHNIQ, V53, P396, DOI 10.1002/jemt.1108; Sharma SA, 1998, J IMMUNOL, V160, P2401; SHARMA SA, 1995, INFECT IMMUN, V63, P1681, DOI 10.1128/IAI.63.5.1681-1687.1995; Slomiany BL, 2001, J PHYSIOL PHARMACOL, V52, P185; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Wroblewski LE, 2002, BIOCHEM J, V365, P873, DOI 10.1042/BJ20020068; Zhao ZH, 2003, J INFECT DIS, V188, P1098, DOI 10.1086/379039; Zhu YL, 2005, ONCOGENE, V24, P3886, DOI 10.1038/sj.onc.1208551	89	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18722	18731		10.1074/jbc.M703022200	http://dx.doi.org/10.1074/jbc.M703022200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17475625	hybrid			2022-12-25	WOS:000247475300010
J	Dadachova, E; Bryan, RA; Huang, XC; Moadel, T; Schweitzer, AD; Aisen, P; Nosanchuk, JD; Casadevall, A				Dadachova, Ekaterina; Bryan, Ruth A.; Huang, Xianchun; Moadel, Tiffany; Schweitzer, Andrew D.; Aisen, Philip; Nosanchuk, Joshua D.; Casadevall, Arturo			Ionizing Radiation Changes the Electronic Properties of Melanin and Enhances the Growth of Melanized Fungi	PLOS ONE			English	Article							VIRULENCE; RESISTANCE; ROLES	Background. Melanin pigments are ubiquitous in nature. Melanized microorganisms are often the dominating species in certain extreme environments, such as soils contaminated with radionuclides, suggesting that the presence of melanin is beneficial in their life cycle. We hypothesized that ionizing radiation could change the electronic properties of melanin and might enhance the growth of melanized microorganisms. Methodology/Principal Findings. Ionizing irradiation changed the electron spin resonance (ESR) signal of melanin, consistent with changes in electronic structure. Irradiated melanin manifested a 4-fold increase in its capacity to reduce NADH relative to non-irradiated melanin. HPLC analysis of melanin from fungi grown on different substrates revealed chemical complexity, dependence of melanin composition on the growth substrate and possible influence of melanin composition on its interaction with ionizing radiation. XTT/MTT assays showed increased metabolic activity of melanized C. neoformans cells relative to non-melanized cells, and exposure to ionizing radiation enhanced the electron-transfer properties of melanin in melanized cells. Melanized Wangiella dermatitidis and Cryptococcus neoformans cells exposed to ionizing radiation approximately 500 times higher than background grew significantly faster as indicated by higher CFUs, more dry weight biomass and 3-fold greater incorporation of 14 C-acetate than non-irradiated melanized cells or irradiated albino mutants. In addition, radiation enhanced the growth of melanized Cladosporium sphaerospermum cells under limited nutrients conditions. Conclusions/Significance. Exposure of melanin to ionizing radiation, and possibly other forms of electromagnetic radiation, changes its electronic properties. Melanized fungal cells manifested increased growth relative to non-melanized cells after exposure to ionizing radiation, raising intriguing questions about a potential role for melanin in energy capture and utilization.	[Dadachova, Ekaterina; Bryan, Ruth A.; Huang, Xianchun; Moadel, Tiffany; Schweitzer, Andrew D.] Albert Einstein Coll Med, Dept Nucl Med, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Dadachova, E (corresponding author), Albert Einstein Coll Med, Dept Nucl Med, Bronx, NY 10467 USA.	edadacho@aecom.yu.edu	Nosanchuk, Joshua/AAS-7801-2021; Dadachova, Ekaterina/I-7838-2013; Schweitzer, Andrew/M-3702-2013	Schweitzer, Andrew/0000-0001-9538-8076	NIH [AI52733]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052733] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The research was partially supported by NIH grant AI52733 (AC and JN). Funders played no role in this study.	Beatty JT, 2005, P NATL ACAD SCI USA, V102, P9306, DOI 10.1073/pnas.0503674102; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; Boomer SM, 2000, ARCH MICROBIOL, V174, P152, DOI 10.1007/s002030000189; Casadevall A, 2005, FUNGAL GENET BIOL, V42, P98, DOI 10.1016/j.fgb.2004.11.008; CONTER A, 1986, ARCH MICROBIOL, V144, P286, DOI 10.1007/BF00410964; CROUTE F, 1982, RADIAT RES, V92, P560, DOI 10.2307/3575928; DAVIS M, 1985, NATURE, V313, P503, DOI 10.1038/313503a0; Eisenman HC, 2005, BIOCHEMISTRY-US, V44, P3683, DOI 10.1021/bi047731m; ENOCHS WS, 1993, PIGM CELL RES, V6, P91, DOI 10.1111/j.1600-0749.1993.tb00587.x; Feng B, 2001, INFECT IMMUN, V69, P1781, DOI 10.1128/IAI.69.3.1781-1794.2001; Frases S, 2006, APPL ENVIRON MICROB, V72, P1542, DOI 10.1128/AEM.72.2.1542-1550.2006; GAN EV, 1976, ARCH BIOCHEM BIOPHYS, V173, P666, DOI 10.1016/0003-9861(76)90304-0; Garcia-Rivera J, 2005, FUNGAL GENET BIOL, V42, P989, DOI 10.1016/j.fgb.2005.09.003; Hicks JK, 2004, EUKARYOT CELL, V3, P14, DOI 10.1128/EC.3.1.14-26.2004; HILL HZ, 1992, BIOESSAYS, V14, P49, DOI 10.1002/bies.950140111; Hulot G, 2003, EARTH PLANET SC LETT, V210, P191, DOI 10.1016/S0012-821X(03)00130-4; ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2; Jacobson ES, 2000, CLIN MICROBIOL REV, V13, P708, DOI 10.1128/CMR.13.4.708-717.2000; Jansonius J., 2000, Palynology, V24, P37, DOI 10.2113/0240037; Kuhn DM, 2003, J CLIN MICROBIOL, V41, P506, DOI 10.1128/JCM.41.1.506-508.2003; Lin LH, 2006, SCIENCE, V314, P479, DOI 10.1126/science.1127376; MIRCHINK TG, 1972, MIKROBIOLOGIYA, V41, P83; Nicolaus R.A., 1968, MELANINS, Vfirst; Nosanchuk JD, 2003, CELL MICROBIOL, V5, P203, DOI 10.1046/j.1462-5814.2003.00268.x; Redman RS, 2002, SCIENCE, V298, P1581, DOI 10.1126/science.1072191; Robinson CH, 2001, NEW PHYTOL, V151, P341, DOI 10.1046/j.1469-8137.2001.00177.x; SALEH YG, 1988, APPL ENVIRON MICROB, V54, P2134, DOI 10.1128/AEM.54.8.2134-2135.1988; Sorenson JA, 1987, PHYS NUCL MED; Starratt AN, 2002, CAN J MICROBIOL, V48, P320, DOI 10.1139/w02-017; Steenbergen JN, 2001, P NATL ACAD SCI USA, V98, P15245, DOI 10.1073/pnas.261418798; Taylor TN, 2005, MYCOLOGIA, V97, P269, DOI 10.3852/mycologia.97.1.269; Vember V V, 2001, Mikrobiol Z, V63, P3; Wakamatsu K, 2002, PIGM CELL RES, V15, P174, DOI 10.1034/j.1600-0749.2002.02017.x; Wang YL, 1996, INFECT IMMUN, V64, P2420, DOI 10.1128/IAI.64.7.2420-2424.1996; WILCZOK T, 1984, ARCH BIOCHEM BIOPHYS, V231, P257, DOI 10.1016/0003-9861(84)90386-2; Zhdanova N N, 2002, Mikrobiol Z, V64, P47; ZHDANOVA N N, 1991, Mikrobiologicheskii Zhurnal (Kiev), V53, P9; Zhdanova NN, 2004, MYCOL RES, V108, P1089, DOI 10.1017/S0953756204000966	38	273	291	2	65	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e457	10.1371/journal.pone.0000457	http://dx.doi.org/10.1371/journal.pone.0000457			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520016	gold, Green Published, Green Submitted			2022-12-25	WOS:000207446000005
J	Buvoli, M; Buvoli, A; Leinwand, LA				Buvoli, Massimo; Buvoli, Ada; Leinwand, Leslie A.			Interplay between Exonic Splicing Enhancers, mRNA Processing, and mRNA Surveillance in the Dystrophic Mdx Mouse	PLOS ONE			English	Article								Background. Pre-mRNA splicing, the removal of introns from RNA, takes place within the spliceosome, a macromolecular complex composed of five small nuclear RNAs and a large number of associated proteins. Spliceosome assembly is modulated by the 5' and 3' splice site consensus sequences situated at the ends of each intron, as well as by exonic and intronic splicing enhancers/silencers recognized by SR and hnRNP proteins. Nonsense mutations introducing a premature termination codon (PTC) often result in the activation of cellular quality control systems that reduce mRNA levels or alter the mRNA splicing pattern. The mdx mouse, a commonly used genetic model for Duchenne muscular dystrophy (DMD), lacks dystrophin by virtue of a premature termination codon (PTC) in exon 23 that also severely reduces the level of dystrophin mRNA. However, the effect of the mutation on dystrophin RNA processing has not yet been described. Methodology/Principal Finding. Using combinations of different biochemical and cellular assays, we found that the mdx mutation partially disrupts a multisite exonic splicing enhancer (ESE) that is recognized by a 40 kDa SR protein. In spite of the presence of an inefficient intron 22 3' splice site containing the rare GAG triplet, the mdx mutation does not activate nonsense-associated altered splicing (NAS), but induces exclusively nonsense-mediated mRNA decay (NMD). Functional binding sites for SR proteins were also identified in exon 22 and 24, and in vitro experiments show that SR proteins can mediate direct association between exon 22, 23, and 24. Conclusions/Significance. Our findings highlight the complex crosstalk between trans-acting factors, cis-elements and the RNA surveillance machinery occurring during dystrophin mRNA processing. Moreover, they suggest that dystrophin exon-exon interactions could play an important role in preventing mdx exon 23 skipping, as well as in facilitating the pairing of committed splice sites.	[Buvoli, Massimo; Buvoli, Ada; Leinwand, Leslie A.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Leinwand, LA (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	Leslie.Leinwand@Colorado.edu		LEINWAND, LESLIE/0000-0003-1470-4810	NIH [GM29090]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029090] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work has been supported by a grant from the NIH (GM29090) to L. A. L.	Amrani N, 2006, NAT REV MOL CELL BIO, V7, P415, DOI 10.1038/nrm1942; Behm-Ansmant I, 2006, GENE DEV, V20, P391, DOI 10.1101/gad.1407606; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BIENVENU T, 1994, HUM GENET, V94, P65, DOI 10.1007/BF02272843; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Buvoli M, 2000, MOL CELL BIOL, V20, P3116, DOI 10.1128/MCB.20.9.3116-3124.2000; Buvoli M, 1997, EMBO J, V16, P7174, DOI 10.1093/emboj/16.23.7174; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Caudevilla C, 2001, NUCLEIC ACIDS RES, V29, P3108, DOI 10.1093/nar/29.14.3108; CHAMBERLAIN JS, 1988, SCIENCE, V239, P1416, DOI 10.1126/science.3347839; COFFEY AJ, 1992, GENOMICS, V12, P474, DOI 10.1016/0888-7543(92)90437-W; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; Davies KE, 2006, NAT REV MOL CELL BIO, V7, P762, DOI 10.1038/nrm2024; Disset A, 2006, HUM MOL GENET, V15, P999, DOI 10.1093/hmg/ddl015; Dye DT, 1998, RNA, V4, P1523, DOI 10.1017/S1355838298980360; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Gersappe A, 1999, J BIOL CHEM, V274, P22452, DOI 10.1074/jbc.274.32.22452; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hertel KJ, 2005, TRENDS BIOCHEM SCI, V30, P115, DOI 10.1016/j.tibs.2005.01.002; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Ito Toshiyuki, 2001, Kobe Journal of Medical Sciences, V47, P193; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; KESSLER O, 1993, MOL CELL BIOL, V13, P6211, DOI 10.1128/MCB.13.10.6211; Kessler O, 1996, MOL CELL BIOL, V16, P4426; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Konarska MM, 2005, GENE DEV, V19, P2255, DOI 10.1101/gad.1363105; Lam BJ, 2002, RNA, V8, P1233, DOI 10.1017/S1355838202028030; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Lejeune F, 2005, CURR OPIN CELL BIOL, V17, P309, DOI 10.1016/j.ceb.2005.03.002; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Maquat LE, 2002, GENE DEV, V16, P1743, DOI 10.1101/gad.1014502; Martinez-Contreras R, 2006, PLOS BIOL, V4, P172, DOI 10.1371/journal.pbio.0040021; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; MONACO AP, 1992, GENOMICS, V12, P465, DOI 10.1016/0888-7543(92)90436-V; Nasim FUH, 2002, RNA, V8, P1078, DOI 10.1017/S1355838202024056; Pollard AJ, 2002, J BIOL CHEM, V277, P15241, DOI 10.1074/jbc.M109046200; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Schaal TD, 1999, MOL CELL BIOL, V19, P261; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shen HH, 2006, GENE DEV, V20, P1755, DOI 10.1101/gad.1422106; Shiga N, 1997, J CLIN INVEST, V100, P2204, DOI 10.1172/JCI119757; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Singh R, 2005, NAT STRUCT MOL BIOL, V12, P645, DOI 10.1038/nsmb961; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; Smith PJ, 2006, HUM MOL GENET, V15, P2490, DOI 10.1093/hmg/ddl171; Stark JM, 1998, P NATL ACAD SCI USA, V95, P2163, DOI 10.1073/pnas.95.5.2163; Stark JM, 1999, J BIOL CHEM, V274, P29838, DOI 10.1074/jbc.274.42.29838; Sun HZ, 2000, MOL CELL BIOL, V20, P6414, DOI 10.1128/MCB.20.17.6414-6425.2000; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TAKESHIMA Y, 1995, J CLIN INVEST, V95, P515, DOI 10.1172/JCI117693; TENNYSON CN, 1995, NAT GENET, V9, P184, DOI 10.1038/ng0295-184; TIAN HC, 1995, MOL CELL BIOL, V15, P6291; Tian HH, 2001, J BIOL CHEM, V276, P33833, DOI 10.1074/jbc.M102957200; Tran Q, 2003, BBA-GENE STRUCT EXPR, V1625, P141, DOI 10.1016/S0167-4781(02)00600-0; Tran VK, 2006, J MED GENET, V43, P924, DOI 10.1136/jmg.2006.042317; TSUKAHARA T, 1994, NUCLEIC ACIDS RES, V22, P2318, DOI 10.1093/nar/22.12.2318; Wang J, 2002, MOL CELL, V10, P951, DOI 10.1016/S1097-2765(02)00635-4; Wang J, 2002, SCIENCE, V297, P108, DOI 10.1126/science.1069757; Wang JH, 2005, NUCLEIC ACIDS RES, V33, P5053, DOI 10.1093/nar/gki810; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Wilton SD, 2006, CURR OPIN MOL THER, V8, P130; WONG C, 1989, BLOOD, V73, P914; Wu YC, 2005, GENOMICS, V86, P329, DOI 10.1016/j.ygeno.2005.05.011; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; Yu J, 2001, MOL CELL BIOL, V21, P5879, DOI 10.1128/MCB.21.17.5879-5888.2001; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	84	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e427	10.1371/journal.pone.0000427	http://dx.doi.org/10.1371/journal.pone.0000427			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487273	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445800009
J	Peretti-Watel, P; Spire, B; Obadia, Y; Moatti, JP				Peretti-Watel, Patrick; Spire, Bruno; Obadia, Yolande; Moatti, Jean-Paul		VESPA Grp	Discrimination against HIV-Infected People and the Spread of HIV: Some Evidence from France	PLOS ONE			English	Article							SEXUAL RISK BEHAVIOR; UNPROTECTED SEX; AIDS; TRANSMISSION; PREVENTION; HIV/AIDS; EPIDEMIC; STIGMA; HAART; MEN	Background. Many people living with HIV/AIDS (PLWHA) suffer from stigma and discrimination. There is an ongoing debate, however, about whether stigma, fear and discrimination actually fuel the persisting spread of HIV, or slow it down by reducing contacts between the whole population and high-risk minorities. To contribute to this debate, we analysed the relationship between perceived discrimination and unsafe sex in a large sample of French PLWHAs. Methodology/Principal Findings. In 2003, we conducted a national cross-sectional survey among a random sample of HIV-infected patients. The analysis was restricted to sexually active respondents (N = 2,136). Unsafe sex was defined as sexual intercourse without a condom with a seronegative/unknown serostatus partner during the prior 12 months. Separate analyses were performed for each transmission group (injecting drug use (IDU), homosexual contact, heterosexual contact). Overall, 24% of respondents reported experiences of discrimination in their close social environment (relatives, friends and colleagues) and 18% reported unsafe sex during the previous 12 months. Both prevalences were higher in the IDU group (32% for perceived discrimination, 23% for unsafe sex). In multivariate analyses, experience of discrimination in the close social environment was associated with an increase in unsafe sex for both PLWHAs infected through IDU and heterosexual contact (OR = 1.65 and 1.80 respectively). Conclusions. Our study clearly confirms a relationship between discrimination and unsafe sex among PLWHAs infected through either IDU or heterosexual contact. This relationship was especially strong in the heterosexual group that has become the main vector of HIV transmission in France, and who is the more likely of sexual mixing with the general population. These results seriously question the hypothesis that HIV-stigma has no effect or could even reduce the infection spread of HIV.	[Peretti-Watel, Patrick; Spire, Bruno; Obadia, Yolande; Moatti, Jean-Paul] INSERM, U379, F-13258 Marseille, France; [Peretti-Watel, Patrick; Spire, Bruno; Obadia, Yolande; Moatti, Jean-Paul] Inst J Paoli I Calmettes, F-13009 Marseille, France; [Peretti-Watel, Patrick; Spire, Bruno; Obadia, Yolande] SE Hlth Reg Observ ORS PACA, Marseille, France; [Moatti, Jean-Paul] Univ Aix Marseille 2, Dept Econ, F-13284 Marseille 07, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Peretti-Watel, P (corresponding author), INSERM, U379, F-13258 Marseille, France.	peretti@marseille.inserm.fr	Peretti-Watel, Patrick/P-4535-2017; Spire, Bruno/F-5546-2013	Spire, Bruno/0000-0002-3546-8020	French National Agency of AIDS Research (ANRS, France) [ANRS-EN12-VESPA]	French National Agency of AIDS Research (ANRS, France)(ANRS)	This study was supported by the French National Agency of AIDS Research (ANRS, France, grant ANRS-EN12-VESPA).	ANDERSON VN, 1992, J APPL SOC PSYCHOL, V22, P248, DOI 10.1111/j.1559-1816.1992.tb01538.x; Bonnet F, 2005, SCAND J INFECT DIS, V37, P482, DOI 10.1080/00365540510035328; Botnick MR, 2000, J HOMOSEXUAL, V38, P77, DOI 10.1300/J082v38n04_04; Bouhnik AD, 2007, AIDS, V21, pS43, DOI 10.1097/01.aids.0000255084.69846.97; Bryant K J, 1999, Focus, V14, P1; Burkholder G. J., 1999, J APPL BIOBEHAVIORAL, V4, P27, DOI [DOI 10.1111/J.1751-9861.1999.TB00053.X, 10.1111/j.1751-9861.1999.tb00053.x]; Carrieri MP, 2006, CLIN INFECT DIS, V43, pS197, DOI 10.1086/508184; Chesney MA, 1999, AM BEHAV SCI, V42, P1162, DOI 10.1177/00027649921954822; Crepaz N, 2004, JAMA-J AM MED ASSOC, V292, P224, DOI 10.1001/jama.292.2.224; DAB W, 1989, AIDS, V3, P433, DOI 10.1097/00002030-198907000-00005; Delor F, 2000, SOC AS AIDS, P77; Delpierre C, 2006, AIDS PATIENT CARE ST, V20, P838, DOI 10.1089/apc.2006.20.838; Doherty T, 2006, B WORLD HEALTH ORGAN, V84, P90, DOI 10.2471/BLT.04.019448; Douglas M., 1992, RISK BLAME; Dray-Spira R, 2003, AIDS CARE, V15, P739, DOI 10.1080/09540120310001618595; Ehiri John E, 2005, AIDS Public Policy J, V20, P25; EHRHARDT AA, 1992, J PSYCHOL HUMAN SEXU, V5, P37; Gayet-Ageron A, 2004, HIV MED, V5, P163, DOI 10.1111/j.1468-1293.2004.00205.x; Gremy I, 2004, AIDS, V18, P805, DOI [10.1097/01.aids.0000111390.02002.f4, 10.1097/00002030-200403260-00013]; GREMY I, 2005, MED MOL INFECT, V5; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Herek GM, 2002, AM J PUBLIC HEALTH, V92, P371, DOI 10.2105/AJPH.92.3.371; Herek GM, 1999, AM BEHAV SCI, V42, P1130, DOI 10.1177/0002764299042007006; Herida M, 2005, MED MALADIES INFECT, V35, P281, DOI 10.1016/j.medmal.2005.03.011; *INVS, 2005, 3 INVS; KELLY JA, 1992, ARCH INTERN MED, V152, P2293, DOI 10.1001/archinte.152.11.2293; Kelly JA, 1998, HEALTH PSYCHOL, V17, P310, DOI 10.1037/0278-6133.17.4.310; Kippax SC, 2007, AIDS, V21, pS1, DOI 10.1097/01.aids.0000255078.01234.71; Kurzban R, 2001, PSYCHOL BULL, V127, P187, DOI 10.1037//0033-2909.127.2.187; Lievre L, 2006, AIDS, V20, P2392, DOI 10.1097/QAD.0b013e32801104b0; Liu H, 2005, SEX TRANSM INFECT, V81, P511, DOI 10.1136/sti.2005.014977; Luo RF, 2006, AIDS, V20, P935, DOI 10.1097/01.aids.0000218561.74779.77; Lupton D., 1994, QUALITATIVE HLTH RES, V4, P304, DOI DOI 10.1177/104973239400400304; Magee EM, 2006, J URBAN HEALTH, V83, P625, DOI 10.1007/s11524-006-9063-4; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; McLean J., 1994, AIDS Care, V6, P331, DOI 10.1080/09540129408258645; MILES L, 1993, WOMEN STUD INT FORUM, V16, P497, DOI 10.1016/0277-5395(93)90099-U; Peretti-Watel P, 2006, AIDS CARE, V18, P254, DOI 10.1080/09540120500456193; Peretti-Watel P, 2006, SOC SCI MED, V62, P2420, DOI 10.1016/j.socscimed.2005.10.020; Peretti-Watel P, 2005, POPULATION, V60, P525, DOI 10.2307/4150781; PERETTIWATEL P, 2005, PSYCHOL HEALTH MED, V10, P215, DOI DOI 10.1080/13548500412331334118; Reidpath DD, 2006, PLOS MED, V3, P1708, DOI 10.1371/journal.pmed.0030435; Reidpath DD, 2005, AIDS CARE, V17, pS117, DOI 10.1080/09540120500120195; Rhodes T, 1997, SOCIOL HEALTH ILL, V19, P208, DOI 10.1111/1467-9566.ep10934410; Rhodes T, 2002, SOC SCI MED, V55, P211, DOI 10.1016/S0277-9536(01)00162-9; ROSENBERG CE, 1988, SOC RES, V55, P327; Rosenbrock R, 2000, SOC SCI MED, V50, P1607, DOI 10.1016/S0277-9536(99)00469-4; Stall R, 1996, J ACQ IMMUN DEF SYND, V11, P151, DOI 10.1097/00042560-199602010-00006; Stein M, 2005, ALCOHOL CLIN EXP RES, V29, P837, DOI 10.1097/01.ALC.0000164363.40533.E0; *UNAIDS, 2004, REP GLOB AIDS EP; UNAIDS, 2000, PROT ID DISCR PEOPL; *UNAIDS, 2006, STIGM DISCR; *WHO, 2005, EMRO WORLD AIDS CAMP; WILTON T, 1991, SOC AS AIDS, P149	54	39	40	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e411	10.1371/journal.pone.0000411	http://dx.doi.org/10.1371/journal.pone.0000411			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476333	gold, Green Submitted, Green Published			2022-12-25	WOS:000207445700013
J	Berman-Golan, D; Elson, A				Berman-Golan, D.; Elson, A.			Neu-mediated phosphorylation of protein tyrosine phosphatase epsilon is critical for activation of Src in mammary tumor cells	ONCOGENE			English	Article						tyrosine phosphatase; breast cancer; mammary tumor; Src; Neu	HUMAN BREAST-CANCER; FAMILY KINASES; PTP-ALPHA; C-SRC; RPTP-ALPHA; CYTOPLASMIC FORMS; TRANSGENIC MICE; IN-VIVO; RECEPTOR; PP60(C-SRC)	The receptor-type protein tyrosine phosphatase epsilon (RPTPe) activates c-Src in mammary tumor cells induced in vivo by Neu. Tumor cells lacking RPTPe exhibit reduced c-Src activity, appear less transformed morphologically and proliferate slower in vitro and in vivo. Expression of Src rescues most of these phenotypes, indicating that c-Src activity is important for maintaining the transformed phenotype. However, the molecular mechanisms that control activation of c-Src by RPTPe are unknown. We show that Neu induces phosphorylation of RPTPe exclusively at its C-terminal Y695, and that this phosphorylation is required for activation of c-Src by RPTPe. Phosphorylation of RPTPe does not affect its activity toward another substrate, the voltage-gated potassium channel Kv2.1, suggesting that phosphorylation directs RPTPe activity toward c-Src. Phosphorylation of RPTPe reduces its dimerization at the cell membrane, although this does not affect its activity significantly. RPTPe is subject to strong auto-and trans-dephosphorylation, suggesting that dephosphorylation limits the activation of c-Src downstream of Neu. We conclude that an Neu-RPTP epsilon-Src signaling pathway exists in mammary tumor cells, in which phosphorylation of RPTPe by Neu directs RPTPe to activate c-Src. Reversible phosphorylation of RPTPe at Y695 may thus function as a 'molecular switch', which affects the substrate specificity of the phosphatase.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	ari.elson@weizmann.ac.il		Elson, Ari/0000-0001-9808-9135				Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Bodrikov V, 2005, J CELL BIOL, V168, P127, DOI 10.1083/jcb.200405073; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Cole PA, 2003, CURR OPIN CHEM BIOL, V7, P580, DOI 10.1016/j.cbpa.2003.08.009; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Granot-Attas S, 2004, EXP CELL RES, V294, P236, DOI 10.1016/j.yexcr.2003.11.003; Guo SL, 2004, P NATL ACAD SCI USA, V101, P14180, DOI 10.1073/pnas.0405878101; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lau KHW, 2006, J CELL BIOCHEM, V97, P940, DOI 10.1002/jcb.20667; Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Maksumova L, 2005, J IMMUNOL, V175, P7947, DOI 10.4049/jimmunol.175.12.7947; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUSTELIN T, 2002, SCI STKE, pPE3; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tiran Z, 2003, J BIOL CHEM, V278, P17509, DOI 10.1074/jbc.M212766200; Toledano-Katchalski H, 1999, ONCOGENE, V18, P5024, DOI 10.1038/sj.onc.1202883; Toledano-Katchalski H, 2003, MOL CELL BIOL, V23, P5460, DOI 10.1128/MCB.23.15.5460-5471.2003; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2002, J BIOL CHEM, V277, P21922, DOI 10.1074/jbc.M201394200; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	44	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					7028	7037		10.1038/sj.onc.1210505	http://dx.doi.org/10.1038/sj.onc.1210505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486066				2022-12-25	WOS:000250412200008
J	Crichlow, GV; Cheng, KF; Dabideen, D; Ochani, M; Aljabari, B; Pavlov, VA; Miller, EJ; Lolis, E; Al-Abed, Y				Crichlow, Gregg V.; Cheng, Kai Fan; Dabideen, Darrin; Ochani, Mahendar; Aljabari, Bayan; Pavlov, Valentin A.; Miller, Edmund J.; Lolis, Elias; Al-Abed, Yousef			Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MIF; SEPTIC SHOCK; TAUTOMERASE ACTIVITY; CRYSTAL-STRUCTURE; SEPSIS; PATHOGENESIS; ENDOTOXEMIA; DISCOVERY; CYTOKINE; SURVIVAL	Pharmacophores are chemical scaffolds upon which changes in chemical moieties (R-groups) at specific sites are made to identify a combination of R-groups that increases the therapeutic potency of a small molecule inhibitor while minimizing adverse effects. We developed a pharmacophore based on a carbonyloxime (OXIM) scaffold for macrophage migration inhibitory factor (MIF), a protein involved in the pathology of sepsis, to validate that inhibition of a catalytic site could produce therapeutic benefits. We studied the crystal structures of MIF.OXIM-based inhibitors and found two opposite orientations for binding to the active site that were dependent on the chemical structures of an R-group. One orientation was completely unexpected based on previous studies with hydroxyphenylpyruvate and (S, R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1). We further confirmed that the unexpected binding mode targets MIF in cellular studies by showing that one compound, OXIM-11, abolished the counter-regulatory activity of MIF on anti-inflammatory glucocorticoid action. OXIM-11 treatment of mice, initiated 24 h after the onset of cecal ligation and puncture-induced sepsis, significantly improved survival when compared with vehicle-treated controls, confirming that inhibition of the MIF catalytic site could produce therapeutic effects. The crystal structures of the MIF inhibitor complexes provide insight for further structure-based drug design efforts.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Feinstein Inst Med Res, Med Chem Lab, Manhasset, NY 11030 USA; Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY 11030 USA; Feinstein Inst Med Res, Lab Cardiopulm Res, Manhasset, NY 11030 USA	Yale University; Northwell Health; Northwell Health; Northwell Health	Lolis, E (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	elias.lolis@yale.edu; yalabed@nshs.edu		Pavlov, Valentin/0000-0002-1994-2853; Lolis, Elias/0000-0002-7902-7868	NATIONAL CANCER INSTITUTE [T32CA009085] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065029] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09085, T32 CA009085] Funding Source: Medline; NHLBI NIH HHS [R01 HL081655, HL081655] Funding Source: Medline; NIAID NIH HHS [R01 AI065029, AI065029, R01 AI065029-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Abed Y, 2005, J BIOL CHEM, V280, P36541, DOI 10.1074/jbc.C500243200; Bacher M, 1997, AM J PATHOL, V150, P235; Beishuizen A, 2001, J CLIN ENDOCR METAB, V86, P2811, DOI 10.1210/jc.86.6.2811; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calandra T, 1997, CRIT REV IMMUNOL, V17, P77, DOI 10.1615/CritRevImmunol.v17.i1.30; Calandra T, 2001, J CHEMOTHERAPY, V13, P173, DOI 10.1179/joc.2001.13.Supplement-2.173; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Cvetkovic I, 2005, ENDOCRINOLOGY, V146, P2942, DOI 10.1210/en.2004-1393; Dabideen DR, 2007, J MED CHEM, V50, P1993, DOI 10.1021/jm061477+; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nicoletti F, 2005, J NEUROIMMUNOL, V168, P168, DOI 10.1016/j.jneuroim.2005.07.019; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Sakuragi Tohru, 2007, Surg Infect (Larchmt), V8, P29, DOI 10.1089/sur.2006.031; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Xue CB, 1997, J MED CHEM, V40, P2064, DOI 10.1021/jm960799i	30	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23089	23095		10.1074/jbc.M701825200	http://dx.doi.org/10.1074/jbc.M701825200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17526494	Green Accepted, hybrid			2022-12-25	WOS:000248577500011
J	Izem, L; Morton, RE				Izem, Lahoucine; Morton, Richard E.			Possible role for intracellular cholesteryl ester transfer protein in adipocyte lipid metabolism and storage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; LIPOPROTEIN-DEFICIENT PLASMA; MEDIATES SELECTIVE UPTAKE; HUMAN ADIPOSE-TISSUE; GENE-EXPRESSION; MONOCLONAL-ANTIBODIES; DENSITY-LIPOPROTEINS; EXCHANGE PROTEIN; MESSENGER-RNA; AMINO-ACIDS	Cholesteryl ester transfer protein (CETP) transfers cholesteryl ester (CE) and triglyceride (TG) between lipoproteins in plasma. However, short term suppression of CETP biosynthesis in cells alters cellular cholesterol homeostasis, demonstrating an intracellular role for CETP as well. The consequences of chronic CETP deficiency in lipid-storing cells normally expressing have not been reported. Here, SW872 adipocytes stably expressing antisense CETP cDNA and synthesizing 20% of normal CETP were created. CETP-deficient cells had 4-fold more CE but an similar to 3-fold decrease in cholesterol biosynthesis. This phenotype of cholesterol overload is consistent with the observed 45% reduction in low density lipoprotein receptor and 2.5-fold increase in ABCA1 levels. However, cholesterol mass in CETP-deficient adipocytes was actually reduced. Strikingly, CETP- deficient adipocytes stored <50% of normal TG, principally reflecting reduced synthesis. The hydrolysis of cellular CE and TG in CETP- deficient cells was reduced by >50%, although hydrolase/lipase activity was increased 3-fold. Notably, the incorporation of recently synthesized CE and TG into lipid storage droplets in CETP- deficient cells was just 40% of control, suggesting that these lipids are inefficiently transported to droplets where the hydrolase/lipase resides. The capacity of cellular CETP to transport CE and TG into storage droplets was directly demonstrated in vitro. Overall, chronic CETP deficiency disrupts lipid homeostasis and compromises the TG storage function of adipocytes. Inefficient CETP-mediated translocation of CE and TG from the endoplasmic reticulum to their site of storage may partially explain these defects. These studies in adipocytic cells strongly support a novel role for CETP in intracellular lipid transport and storage.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Morton, RE (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NB20,9500 Euclid Ave, Cleveland, OH 44195 USA.	mortonr@ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060934] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60934] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1992, INT J CLIN LAB RES, V21, P264, DOI 10.1007/BF02591657; Benoist F, 1997, J BIOL CHEM, V272, P23572, DOI 10.1074/jbc.272.38.23572; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Bruce C, 1998, CURR OPIN STRUC BIOL, V8, P426, DOI 10.1016/S0959-440X(98)80118-8; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CLAY MA, 1989, BIOCHIM BIOPHYS ACTA, V1002, P173, DOI 10.1016/0005-2760(89)90284-1; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; Dugail I, 2003, HORM METAB RES, V35, P204, DOI 10.1055/s-2003-39475; Edwards PA, 2002, J LIPID RES, V43, P2; FAUST RA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P404, DOI 10.1016/0005-2760(90)90171-S; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; GAMBLE W, 1978, J LIPID RES, V19, P1068; Gauthier A, 2005, ARTERIOSCL THROM VAS, V25, P2177, DOI 10.1161/01.ATV.0000183613.13929.13; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; Hajjar D P, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P45; HASHIMOTO S, 1984, BIOCHEM BIOPH RES CO, V120, P586, DOI 10.1016/0006-291X(84)91295-6; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HESLER CB, 1988, J BIOL CHEM, V263, P5020; HESLER CB, 1987, J BIOL CHEM, V262, P2275; Huang ZP, 2003, AM J PHYSIOL-ENDOC M, V284, pE1210, DOI 10.1152/ajpendo.00453.2002; INAZU A, 1992, BIOCHEMISTRY-US, V31, P2352, DOI 10.1021/bi00123a021; Izem L, 2001, J BIOL CHEM, V276, P26534, DOI 10.1074/jbc.M103624200; JIANG XC, 1991, J BIOL CHEM, V266, P4631; JIANG XC, 1995, BIOCHEMISTRY-US, V34, P7258, DOI 10.1021/bi00021a042; Kellner-Weibel G, 2001, J LIPID RES, V42, P768; KRAEMER FB, 1993, J LIPID RES, V34, P663; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; KRAUSE BR, 1981, P SOC EXP BIOL MED, V167, P407, DOI 10.3181/00379727-167-41188; KRAUSE BR, 1984, J LIPID RES, V25, P97; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Large V, 1998, J LIPID RES, V39, P1688; Le Lay S, 2003, J LIPID RES, V44, P1499, DOI 10.1194/jlr.M200466-JLR200; Le Lay S, 2001, J BIOL CHEM, V276, P16904, DOI 10.1074/jbc.M010955200; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MENDEZ AJ, 1986, ANAL BIOCHEM, V156, P386, DOI 10.1016/0003-2697(86)90269-1; MILLER KW, 1983, J BIOL CHEM, V258, P3772; MILLER KW, 1983, BIOCHEMISTRY-US, V22, P443, DOI 10.1021/bi00271a030; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; MORTON RE, 1982, J LIPID RES, V23, P1058; MORTON RE, 1990, EXPERIENTIA, V46, P552, DOI 10.1007/BF01939693; MORTON RE, 1983, J BIOL CHEM, V258, P1751; MORTON RE, 1988, J LIPID RES, V29, P1367; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; PATTNAIK NM, 1978, BIOCHIM BIOPHYS ACTA, V530, P428, DOI 10.1016/0005-2760(78)90163-7; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; Roy P, 1996, J LIPID RES, V37, P22; Sawada S, 1999, ATHEROSCLEROSIS, V146, P291, DOI 10.1016/S0021-9150(99)00152-5; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Walczak R, 2002, J LIPID RES, V43, P177; WANG S, 1992, J BIOL CHEM, V267, P17487; WANG SK, 1995, J BIOL CHEM, V270, P612, DOI 10.1074/jbc.270.2.612; Yang TP, 1996, J BIOL CHEM, V271, P12603, DOI 10.1074/jbc.271.21.12603; ZECHNER R, 1991, J BIOL CHEM, V266, P10583; Zhang ZY, 2001, ATHEROSCLEROSIS, V159, P67, DOI 10.1016/S0021-9150(01)00490-7; Zhou HW, 2006, J LIPID RES, V47, P2011, DOI 10.1194/jlr.M600153-JLR200	60	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					21856	21865		10.1074/jbc.M701075200	http://dx.doi.org/10.1074/jbc.M701075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17522050	hybrid			2022-12-25	WOS:000248196800033
J	Tamehiro, N; Shigemoto-Mogami, Y; Kakeya, T; Okuhira, K; Suzuki, K; Sato, R; Nagao, T; Nishimaki-Mogami, T				Tamehiro, Norimasa; Shigemoto-Mogami, Yukari; Kakeya, Tomoshi; Okuhira, Kei-ichiro; Suzuki, Kazuhiro; Sato, Ryuichiro; Nagao, Taku; Nishimaki-Mogami, Tomoko			Sterol regulatory element-binding protein-2-and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression - Mechanism underlying the unique response to cellular cholesterol status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN-MEDIATED RELEASE; CASSETTE; EFFLUX; LXR; MICE; LIGANDS; STATINS; OVEREXPRESSION; IDENTIFICATION	ABC transporter A1 (ABCA1) mediates and rate-limits biogenesis of high density lipoprotein (HDL), and hepatic ABCA1 plays a major role in regulating plasma HDL levels. HDL generation is also responsible for release of cellular cholesterol. In peripheral cells ABCA1 is up-regulated by the liver X receptor (LXR) system when cell cholesterol increases. However, cholesterol feeding has failed to show a significant increase in hepatic ABCA1 gene expression, and its expression is up-regulated by statins (3-hydroy-3-methylglutaryl-CoA reductase inhibitors), suggesting distinct regulation. In this study we investigated the mechanism of regulation of the rat hepatic ABCA1 gene and identified two major ABCA1 transcripts and two corresponding promoter regions. Compactin activated the novel liver-type promoter in rat hepatoma McARH7777 cells by binding the sterol regulatory element-binding protein-2 (SREBP-2). In contrast, compactin repressed the previously identified peripheral-type promoter in an LXR-responsive element-dependent but not E-box-dependent manner. Thus, compactin increased the liver-type transcript and decreased the peripheral-type transcript. The same two transcripts were also dominant in human and mouse livers, whereas the intestine contains only the peripheral-type transcript. Treatment of rats with pravastatin and a bile acid binding resin (colestimide), which is known to activate SREBP-2 in the liver, caused a reduction in the hepatic cholesterol level and the same differential responses in vivo, leading to increases in hepatic ABCA1 mRNA and protein and plasma HDL levels. We conclude that the dual promoter system driven by SREBP-2 and LXR regulates hepatic ABCA1 expression and may mediate the unique response of hepatic ABCA1 gene expression to cellular cholesterol status.	Natl Inst Hlth Sci, Div Biosignaling, Setagaya Ku, Tokyo 1588501, Japan; Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan	National Institute of Health Sciences - Japan; University of Tokyo	Nishimaki-Mogami, T (corresponding author), Natl Inst Hlth Sci, Div Biosignaling, Setagaya Ku, Kamiyoga 1-18-1, Tokyo 1588501, Japan.	mogami@nihs.go.jp						Abe-Dohmae S, 2004, J BIOL CHEM, V279, P604, DOI 10.1074/jbc.M309888200; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; BRESLOW JL, 1985, ANNU REV BIOCHEM, V54, P699, DOI 10.1146/annurev.biochem.54.1.699; Brewer HB, 2004, ARTERIOSCL THROM VAS, V24, P387, DOI 10.1161/01.ATV.0000121505.88326.d2; Brewer HB, 2003, AM J CARDIOL, V92, p23K, DOI 10.1016/S0002-9149(03)00779-3; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Costet P, 2000, J BIOL CHEM, V275, P28240; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; Edwards PA, 2002, J LIPID RES, V43, P2; Engelking LJ, 2004, J CLIN INVEST, V113, P1168, DOI 10.1172/JCI200420978; FIELDING CJ, 1995, J LIPID RES, V36, P211; GLOMSET JA, 1968, J LIPID RES, V9, P155; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Hoekstra M, 2005, J HEPATOL, V42, P400, DOI 10.1016/j.jhep.2004.11.032; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Maejima T, 2004, BIOCHEM BIOPH RES CO, V324, P835, DOI 10.1016/j.bbrc.2004.09.122; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Naik SU, 2006, CIRCULATION, V113, P90, DOI 10.1161/CIRCULATIONAHA.105.560177; Nishimaki-Mogami T, 2004, J LIPID RES, V45, P1538, DOI 10.1194/jlr.M400102-JLR200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Ragozin S, 2005, ARTERIOSCL THROM VAS, V25, P1433, DOI 10.1161/01.ATV.0000166616.86723.d0; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Singaraja RR, 2006, CIRCULATION, V114, P1301, DOI 10.1161/CIRCULATIONAHA.106.621433; Singaraja RR, 2005, J LIPID RES, V46, P2061, DOI 10.1194/jlr.M500133-JLR200; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Sone H, 2004, BIOCHEM BIOPH RES CO, V316, P790, DOI 10.1016/j.bbrc.2004.02.121; Suzuki S, 2004, ARTERIOSCL THROM VAS, V24, P519, DOI 10.1161/01.ATV.0000117178.94087.ba; Tamehiro N, 2005, FEBS LETT, V579, P5299, DOI 10.1016/j.febslet.2005.08.054; Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915; Tsujita M, 2005, J LIPID RES, V46, P154, DOI 10.1194/jlr.M400402-JLR200; Vrecer M, 2003, INT J CLIN PHARM TH, V41, P567; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wellington CL, 2003, J LIPID RES, V44, P1470, DOI 10.1194/jlr.M300110-JLR200; Wong J, 2004, ARTERIOSCL THROM VAS, V24, P2365, DOI 10.1161/01.ATV.0000148707.93054.7d; Wong J, 2006, BIOCHEM J, V400, P485, DOI 10.1042/BJ20060914; Yang XP, 2002, J LIPID RES, V43, P297; Yokoyama S, 2006, ARTERIOSCL THROM VAS, V26, P20, DOI 10.1161/01.ATV.0000195789.39418.e8; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zeng LF, 2004, J BIOL CHEM, V279, P48801, DOI 10.1074/jbc.M407817200	52	82	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21090	21099		10.1074/jbc.M701228200	http://dx.doi.org/10.1074/jbc.M701228200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17526932	hybrid			2022-12-25	WOS:000248047500035
J	Blackwell, JS; Wilkinson, ST; Mosammaparast, N; Pemberton, LF				Blackwell, Jeffrey S., Jr.; Wilkinson, Sarah T.; Mosammaparast, Nima; Pemberton, Lucy F.			Mutational analysis of H3 and H4N termini reveals distinct roles in nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B HISTONE ACETYLTRANSFERASES; NUCLEOSOME CORE PARTICLE; DNA-REPLICATION; CELL-CYCLE; IN-VITRO; S-PHASE; YEAST; ACETYLATION; CHROMATIN; DEPOSITION	Core histones H3 and H4 are rapidly imported into the nucleus by members of the karyopherin (Kap)/importin family. We showed that H3 and H4 interact with Kap123p, histone acetyltransferase-B complex (HAT-B), and Asf1p in cytosol. In vivo analysis indicated that Kap123p is required for H3-mediated import, whereas H4 utilizes multiple Kaps including Kap123p. The evolutionary conservation of H3 and H4 cytoplasmic acetylation led us to analyze the role of acetylation in nuclear transport. We determined that lysine 14 is critical for H3 NLS function in vivo and demonstrated that mutation of H3 lysine 14 to the acetylation-mimic glutamine decreased association with Kap123p in vitro. Several lysines in the H4 NLS are important for its function. We showed that mutation of key lysines to glutamine resulted in a greater import defect than mutation to arginine, suggesting that positive charge promotes NLS function. Lastly we determined that six of ten N-terminal acetylation sites in H3 and H4 can be mutated to arginine, indicating that deposition acetylation is not absolutely necessary in vivo. However, the growth defect of these mutants suggests that acetylation does play an important role in import. These findings suggest a model where cytosolic histones bind import karyopherins prior to acetylation. Other factors are recruited to this complex such as HAT-B and Asf1p; these factors in turn promote acetylation. Acetylation may be important for modulating the interaction with transport factors and may play a role in the release of histones from karyopherins in the nucleus.	Univ Virginia, Hlth Sci Ctr, Ctr Cell Signalling, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia	Pemberton, LF (corresponding author), Univ Virginia, Hlth Sci Ctr, Ctr Cell Signalling, Dept Microbiol, Box 800577, Charlottesville, VA 22908 USA.	lfp2n@virginia.edu			NIGMS NIH HHS [R01 GM 65385] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065385] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adkins MW, 2007, J BIOL CHEM, V282, P1334, DOI 10.1074/jbc.M608025200; Ahn SH, 2005, CELL, V120, P25, DOI 10.1016/j.cell.2004.11.016; Ai X, 2004, MOL CELL, V14, P195, DOI 10.1016/S1097-2765(04)00184-4; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Daganzo SM, 2003, CURR BIOL, V13, P2148, DOI 10.1016/j.cub.2003.11.027; Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862; English CM, 2006, CELL, V127, P495, DOI 10.1016/j.cell.2006.08.047; Glowczewski L, 2004, MOL CELL BIOL, V24, P10180, DOI 10.1128/MCB.24.23.10180-10192.2004; Han JH, 2007, SCIENCE, V315, P653, DOI 10.1126/science.1133234; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Mosammaparast N, 2001, J CELL BIOL, V153, P251, DOI 10.1083/jcb.153.2.251; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Poveda A, 2004, J BIOL CHEM, V279, P16033, DOI 10.1074/jbc.M314228200; Recht J, 2006, P NATL ACAD SCI USA, V103, P6988, DOI 10.1073/pnas.0601676103; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Schneider J, 2006, J BIOL CHEM, V281, P37270, DOI 10.1074/jbc.C600265200; Sherman F., 1986, METHODS YEAST GENETI; Sklenar Amy R., 2004, BMC Biochemistry, V5, P11, DOI 10.1186/1471-2091-5-11; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TSUBOTA T, 2007, CELL; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; Verreault A, 2000, GENE DEV, V14, P1430; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207	39	61	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20142	20150		10.1074/jbc.M701989200	http://dx.doi.org/10.1074/jbc.M701989200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17507373	hybrid			2022-12-25	WOS:000247819300015
J	Balasubramanian, K; Mirnikjoo, B; Schroit, AJ				Balasubramanian, Krishnakumar; Mirnikjoo, Banafsheh; Schroit, Alan J.			Regulated externalization of phosphatidylserine at the cell surface - Implications for apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; CALCIUM; DEATH; ERYTHROCYTES; MITOCHONDRIA; CLEARANCE; TRANSPORT; PROTEIN	The regulated loss of plasma membrane phosphatidylserine ( PS) asymmetry is critical to many biological processes. In particular, the appearance of PS at the cell surface, a hallmark of apoptosis, prepares the dying cell for engulfment and elimination by phagocytes. While it is well established that PS externalization is regulated by activation of a calcium-dependent phospholipid scramblase activity in concert with inactivation of the aminophospholipid translocase, there is no evidence indicating that these processes are triggered and regulated by apoptotic regulatory mechanisms. Using a novel model system, we show that PS externalization is inducible, reversible, and independent of cytochrome c release, caspase activation, and DNA fragmentation. Additional evidence is presented indicating that the outward movement of plasma membrane PS requires sustained elevation in cytosolic Ca2+ in concert with inactivation of the aminophospholipid translocase and is inhibited by calcium channel blockers.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Schroit, AJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aschroit@mdanderson.org			NIGMS NIH HHS [GM70964] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam-Klages S, 2005, IMMUNOL RES, V33, P149, DOI 10.1385/IR:33:2:149; Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; Bevers EM, 1998, LUPUS, V7, pS126, DOI 10.1177/096120339800700228; CONNOR J, 1992, J BIOL CHEM, V267, P19412; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; de Jong K, 2002, BIOCHEMISTRY-US, V41, P12562, DOI 10.1021/bi025882o; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Gaipl US, 2005, AUTOIMMUN REV, V4, P189, DOI 10.1016/j.autrev.2004.10.007; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Jacobson J, 2004, MOL CELL BIOCHEM, V256, P209, DOI 10.1023/B:MCBI.0000009869.29827.df; JAIN SK, 1981, BIOCHIM BIOPHYS ACTA, V642, P46, DOI 10.1016/0005-2736(81)90136-X; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kuhtrelber WM, 2003, J MOL ENDOCRINOL, V31, P373, DOI 10.1677/jme.0.0310373; KURATA M, 1994, COMP BIOCHEM PHYS B, V109, P305, DOI 10.1016/0305-0491(94)90014-0; Lang KS, 2003, CELL DEATH DIFFER, V10, P249, DOI 10.1038/sj.cdd.4401144; MASON RP, 1989, MOL PHARMACOL, V36, P634; MASON RP, 1992, MOL PHARMACOL, V41, P315; Momoi T, 2004, J CHEM NEUROANAT, V28, P101, DOI 10.1016/j.jchemneu.2004.05.008; Moosmang S, 2005, PHARMACOL THERAPEUT, V106, P347, DOI 10.1016/j.pharmthera.2004.12.003; Moreau C, 1997, MOL MEMBR BIOL, V14, P5, DOI 10.3109/09687689709048163; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Sarkadi B, 2006, PHYSIOL REV, V86, P1179, DOI 10.1152/physrev.00037.2005; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Seelig A, 2000, EUR J PHARM SCI, V12, P31, DOI 10.1016/S0928-0987(00)00177-9; Sheu SS, 1999, J PHYSIOL-LONDON, V518, P577, DOI 10.1111/j.1469-7793.1999.0577p.x; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; Strehler EE, 2004, CURR MOL MED, V4, P323, DOI 10.2174/1566524043360735; Thomas JA, 2001, EXP GERONTOL, V36, P1519, DOI 10.1016/S0531-5565(01)00137-1; vanEngeland M, 1997, EXP CELL RES, V235, P421, DOI 10.1006/excr.1997.3738; WERTH JL, 1994, J NEUROSCI, V14, P348; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; Yan Y, 2006, ACTA PHARMACOL SIN, V27, P821, DOI 10.1111/j.1745-7254.2006.00390.x; Young HS, 2004, J MEMBRANE BIOL, V198, P55, DOI 10.1007/s00232-004-0666-y; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3	41	138	143	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18357	18364		10.1074/jbc.M700202200	http://dx.doi.org/10.1074/jbc.M700202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17470427	hybrid			2022-12-25	WOS:000247302000042
J	Campbell, EL; Louis, NA; Tomassetti, SE; Canny, GO; Arita, M; Serhan, CN; Colgan, SP				Campbell, Eric L.; Louis, Nancy A.; Tomassetti, Sarah E.; Canny, Geraldine O.; Arita, Makoto; Serhan, Charles N.; Colgan, Sean P.			Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution	FASEB JOURNAL			English	Article						transmigration; CD55; ICAM-1 transmigration; lipid mediator; epithelia	DECAY-ACCELERATING FACTOR; VASCULAR ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; COMPLEMENT; MIGRATION; EXPRESSION; PROTECTS; INDUCTION; LIGAND; CD47	Migration of neutrophils (PMN) across epithelia is a pathological hallmark of numerous mucosal diseases. Whereas lesions at mucosal surfaces are generally self-limiting, endogenous mechanisms of resolution are incompletely understood. Previous studies revealed that resolvins directly act on PMN to attenuate transendothelial migration, less is known about the influence of resolvins on PMN-epithelial interactions and whether they act on epithelia. We studied the dynamics of resolvin E1 (RvE1) actions on leukocyte transepithelial migration. PMN exposure to RvE1 or chemerin (peptide agonist of ChemR23) reduced transepithelial migration in a concentration-dependent manner. Conversely, activation of epithelial ChemR23 promoted apical clearance of PMN. A nonbiased screen of known PMN ligands expressed on epithelial cells in response to RvE1 revealed selective induction of CD55, an apically expressed antiadhesive molecule. CD55 promoter analysis demonstrated that both RvE1 and chemerin activate the CD55 promoter. Inhibition of CD55 by neutralizing antibody prevented RvE1-dependent augmentation of apical PMN clearance. Taken together these findings implicate a "two-hit" model of inflammatory resolution, whereby activation of the PMN RvE1 receptor attenuates transepithelial migration and subsequent actions on the epithelium promote CD55-dependent clearance of PMN across the epithelial cell surface promoting active inflammatory resolution.	Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Div Gastroenterol, Denver, CO 80262 USA; Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Colgan, SP (corresponding author), Univ Colorado, Hlth Sci Ctr, Mucosal Inflammat Program, Div Gastroenterol, Biomed Res Bldg Rm 702,4200 E 9th Ave, Denver, CO 80262 USA.	sean.colgan@uchsc.edu	Louis, Nancy/G-5163-2011; Campbell, Eric/N-5357-2015	Louis, Nancy/0000-0001-7092-8136; Campbell, Eric/0000-0003-0744-6577; Tomassetti, Sarah/0000-0001-6087-8788; Canny, Geraldine/0000-0003-0632-7365; Arita, Makoto/0000-0001-9902-0463	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499, P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050189, R29DK050189, R01DK050189] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60569] Funding Source: Medline; NIDCR NIH HHS [P50-DE016191, DE-13499] Funding Source: Medline; NIDDK NIH HHS [DK-50189] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad SR, 2003, IMMUNOLOGY, V110, P258, DOI 10.1046/j.1365-2567.2003.01733.x; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; BERGER M, 1987, J CLIN INVEST, V79, P214, DOI 10.1172/JCI112786; Borregaard N, 2005, J LEUKOCYTE BIOL, V77, P439, DOI 10.1189/jlb.0704381; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Huber D, 2000, J BIOL CHEM, V275, P5773, DOI 10.1074/jbc.275.8.5773; Hudert CA, 2006, P NATL ACAD SCI USA, V103, P11276, DOI 10.1073/pnas.0601280103; Jaye DL, 2000, ANN NY ACAD SCI, V915, P151; Khoury J, 2007, J CLIN INVEST, V117, P703, DOI 10.1172/JCI30049; Lawrence DW, 2003, J EXP MED, V198, P999, DOI 10.1084/jem.20030380; Lin F, 2004, J IMMUNOL, V172, P3836, DOI 10.4049/jimmunol.172.6.3836; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Louis NA, 2005, FASEB J, V19, P950, DOI 10.1096/fj.04-3251com; Louis NA, 2005, PROSTAG LEUKOTR ESS, V73, P197, DOI 10.1016/j.plefa.2005.05.006; Mason JC, 1999, BLOOD, V94, P1673, DOI 10.1182/blood.V94.5.1673.417a05_1673_1682; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356; Mitchell S, 2002, J AM SOC NEPHROL, V13, P2497, DOI 10.1097/01.ASN.0000032417.73640.72; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Shafren DR, 2000, J GEN VIROL, V81, P889, DOI 10.1099/0022-1317-81-4-889; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; Song WC, 2004, CURR DIRECT AUTOIMMU, V7, P181; SUN YP, 2007, J BIOL CHEM, V23, P23; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Zabel BA, 2006, EXP HEMATOL, V34, P1106, DOI 10.1016/j.exphem.2006.03.011; Zen K, 2003, CURR OPIN CELL BIOL, V15, P557, DOI 10.1016/S0955-0674(03)00103-0; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317; Zhuang LY, 2002, CANCER RES, V62, P2227	37	151	157	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3162	3170		10.1096/fj.07-8473com	http://dx.doi.org/10.1096/fj.07-8473com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17496159				2022-12-25	WOS:000249781600017
J	Lin, YC; Diccianni, MB; Kim, Y; Lin, HH; Lee, CH; Lin, RJ; Joo, SH; Li, J; Chuang, TJ; Yang, AS; Kuo, HH; Tsai, MD; Yu, AL				Lin, Y-C; Diccianni, M. B.; Kim, Y.; Lin, H-H; Lee, C-H; Lin, R-J; Joo, S. H.; Li, J.; Chuang, T-J; Yang, A-S; Kuo, H-H; Tsai, M-D; Yu, A. L.			Human p16 gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression	ONCOGENE			English	Article						INK4A; alternative splicing; cell-cycle inhibitor	TUMOR-SUPPRESSOR P16(INK4A); P16INK4A RNA TRANSCRIPTS; DEPENDENT KINASES; P16; GENE; MUTATIONS; PROTEINS; DELETION; FREQUENT; PATHWAY	The INK4A locus encodes two tumor suppressor genes, p16(INK4A) and p14(ARF), transcribed using alternative exons 1 alpha or 1 beta spliced onto the same exons 2 and 3. Both p16(INK4A) and p14(ARF) are capable of inhibiting the cell-cycle progression, albeit in different manner; p16(INK4A) is phosphorylation of retinoblastoma (pRB) dependent while p14(ARF) is p53-dependent. In this study, we report the discovery of a novel variant of p16(INK4A), termed p16 gamma, in a primary T-cell acute lymphoblastic leukemia (T-ALL) patient sample and a neuroblastoma cell line, which was expressed at both the transcriptional and translational levels. Cloning and sequencing of the p16 gamma cDNA revealed that p16 gamma was identical to p16(INK4A), except that it contained an in-frame insertion of 197 bp between exons 2 and 3. p16 gamma expression was detected in the majority of p16(INK4A)-expressing primary T-ALL and B-ALL patient samples and other p16(INK4A)-expressing tumor samples, but was only barely detectable in some normal mononuclear cells and other non-tumor samples. Structural analysis by nuclear magnetic resonance and circular dichroism con. firmed that p16 gamma, like p16(INK4A), is also an ankyrin-repeat protein. Functional analysis of p16 gamma revealed that p16 gamma protein interacted with cyclin D-dependent kinase4 and inhibited its kinase activity. Using a luciferase reporter assay, the transfection of p16 gamma repressed the E2F response, the downstream target of pRB, with an efficacy equivalent to that of p16(INK4A). Moreover p16 gamma, like p16(INK4A), induced cell-cycle arrest at G(0)/G(1), and inhibited cell growth in colony formation assay.	Acad Sinica, Ctr Gene Res, Taipei 115, Taiwan; Univ Calif San Diego, Dept Pediat Hematol Oncol, San Diego, CA USA; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	Academia Sinica - Taiwan; University of California System; University of California San Diego; University System of Ohio; Ohio State University	Yu, AL (corresponding author), Acad Sinica, Ctr Gene Res, 128 Acad Rd,Sec 2 Nankang Dist, Taipei 115, Taiwan.	aliceyu@ucsd.edu	Lin, Hsin-Hung/J-5254-2013; , MitchDiccianni/AAF-8486-2019; Tsai, Ming-Daw/G-4689-2019	Lin, Hsin-Hung/0000-0001-8327-6835; , MitchDiccianni/0000-0002-5017-9585; Tsai, Ming-Daw/0000-0003-1374-0414; Yang, An-Suei/0000-0002-4699-873X; yu, alice/0000-0003-2444-0505; Lin, Ruey-Jen/0000-0001-5586-1770	NATIONAL CANCER INSTITUTE [P30CA023100, R01CA069472] Funding Source: NIH RePORTER; NCI NIH HHS [2 P30CA23100-18, CA69472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Aretz S, 2004, HUM MUTAT, V24, P370, DOI 10.1002/humu.20087; Batova A, 1997, CANCER RES, V57, P832; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chen YJ, 1997, INT J CANCER, V71, P350, DOI 10.1002/(SICI)1097-0215(19970502)71:3<350::AID-IJC7>3.0.CO;2-X; CHENG JQ, 1994, CANCER RES, V54, P5547; Cho JW, 2003, LIVER INT, V23, P194, DOI 10.1034/j.1600-0676.2003.00821.x; Diccianni MB, 1996, CANCER LETT, V104, P183, DOI 10.1016/0304-3835(96)04250-4; Diccianni MB, 1999, INT J CANCER, V80, P145, DOI 10.1002/(SICI)1097-0215(19990105)80:1<145::AID-IJC26>3.3.CO;2-7; Diccianni Mitchell B, 2004, J Exp Ther Oncol, V4, P223; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ElSharawy A, 2006, HUM MUTAT, V27, P1129, DOI 10.1002/humu.20377; Fu GH, 2005, FEBS LETT, V579, P2105, DOI 10.1016/j.febslet.2005.02.063; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Hillman RT, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r8; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Li JN, 2003, BIOCHEMISTRY-US, V42, P13476, DOI 10.1021/bi035390r; Li JN, 2002, BIOCHEMISTRY-US, V41, P3977, DOI 10.1021/bi011550s; Li JN, 1999, BIOCHEMISTRY-US, V38, P2930, DOI 10.1021/bi982286e; Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q; Lin YC, 2000, ONCOGENE, V19, P2704, DOI 10.1038/sj.onc.1203582; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Omura-Minamisawa M, 2001, CLIN CANCER RES, V7, P3481; Omura-Minamisawa M, 2000, CLIN CANCER RES, V6, P1219; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pace C N, 1986, Methods Enzymol, V131, P266; QUELLE DE, 1995, CELL, V83, P993; Robertson KD, 1999, ONCOGENE, V18, P3810, DOI 10.1038/sj.onc.1202737; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Schutte M, 1997, CANCER RES, V57, P3126; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; STONE S, 1995, CANCER RES, V55, P2988; Suh SI, 2000, CANCER LETT, V160, P81, DOI 10.1016/S0304-3835(00)00566-8; Suh SI, 2000, CANCER LETT, V153, P175, DOI 10.1016/S0304-3835(00)00369-4; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yi Y, 2006, HUM MOL GENET, V15, P2192, DOI 10.1093/hmg/ddl144; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	26	29	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					7017	7027		10.1038/sj.onc.1210507	http://dx.doi.org/10.1038/sj.onc.1210507			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486064				2022-12-25	WOS:000250412200007
J	Wu, J; Tao, Y; Zhang, ML; Howard, MH; Gutteridge, S; Ding, JP				Wu, Jian; Tao, Yong; Zhang, Meilan; Howard, Michael H.; Gutteridge, Steven; Ding, Jianping			Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors reveal the functional roles of the N-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDA-ALBICANS; CRYPTOCOCCUS-NEOFORMANS; ESSENTIAL ENZYME; PROTEIN; TRANSFERASE; ACETYLTRANSFERASES; BENZOFURANS; ACYLATION; CATALYSIS; SYNTHASE	Protein N-myristoylation catalyzed by myristoyl-CoA:protein N-myristoyltransferase (NMT) plays an important role in a variety of critical cellular processes and thus is an attractive target for development of antifungal drugs. We report here three crystal structures of Saccharomyces cerevisiae NMT: in binary complex with myristoyl-CoA (MYA) alone and in two ternary complexes involving MYA and two different non-peptidic inhibitors. In all three structures, the majority of the N-terminal region, absent in all previously reported structures, forms a well defined motif that is located in the vicinity of the peptide substrate-binding site and is involved in the binding of MYA. The Ab loop, which might be involved in substrate recognition, adopts an open conformation, whereas a loop of the N-terminal region (residues 22-24) that covers the top of the substrate-binding site is in the position occupied by the Ab loop when in the closed conformation. Structural comparisons with other NMTs, together with mutagenesis data, suggest that the N-terminal region of NMT plays an important role in the binding of both MYA and peptide substrate, but not in subsequent steps of the catalytic mechanism. The two inhibitors occupy the peptide substrate-binding site and interact with the protein through primarily hydrophobic contacts. Analyses of the inhibitor-enzyme interactions provide valuable information for further improvement of antifungal inhibitors targeting NMT.	DuPont Co Inc, Stine Haskell Res Ctr, Newark, DE 19714 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China	DuPont; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Gutteridge, S (corresponding author), DuPont Co Inc, Stine Haskell Res Ctr, 1090 Elkton Rd, Newark, DE 19714 USA.	Gutteridge@usa.dupont.com; jpding@sibs.ac.cn		ding, jian ping/0000-0001-7029-7346				Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Devadas B, 1998, J MED CHEM, V41, P996, DOI 10.1021/jm980001q; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Farazi TA, 2001, BIOCHEMISTRY-US, V40, P6335, DOI 10.1021/bi0101401; Glover CJ, 1997, J BIOL CHEM, V272, P28680, DOI 10.1074/jbc.272.45.28680; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gunaratne RS, 2000, BIOCHEM J, V348, P459, DOI 10.1042/0264-6021:3480459; Howell DM, 1999, J BACTERIOL, V181, P331, DOI 10.1128/JB.181.1.331-333.1999; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawasaki K, 2003, BIOORG MED CHEM LETT, V13, P87, DOI 10.1016/S0960-894X(02)00844-2; KNOLL LJ, 1995, METHOD ENZYMOL, V250, P405; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; Lodge JK, 1997, MICROBIOL-UK, V143, P357, DOI 10.1099/00221287-143-2-357; Lodge JK, 1998, J BIOL CHEM, V273, P12482, DOI 10.1074/jbc.273.20.12482; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; Masubuchi M, 2001, BIOORG MED CHEM LETT, V11, P1833, DOI 10.1016/S0960-894X(01)00319-5; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OLSON EN, 1985, J BIOL CHEM, V260, P3784; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panethymitaki C, 2006, BIOCHEM J, V396, P277, DOI 10.1042/BJ20051886; PESECKIS SM, 1994, J BIOL CHEM, V269, P30888; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Price HP, 2003, J BIOL CHEM, V278, P7206, DOI 10.1074/jbc.M211391200; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; Selvakumar P, 2002, INT J MOL MED, V10, P493; Sikorski JA, 1997, BIOPOLYMERS, V43, P43, DOI 10.1002/(SICI)1097-0282(1997)43:1&lt;43::AID-BIP5&gt;3.0.CO;2-0; Smith S, 2003, PROG LIPID RES, V42, P289, DOI 10.1016/S0163-7827(02)00067-X; Sogabe S, 2002, CHEM BIOL, V9, P1119, DOI 10.1016/S1074-5521(02)00240-5; Takamune N, 2002, FEBS LETT, V527, P138, DOI 10.1016/S0014-5793(02)03199-X; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; WEINBURG RA, 1995, MOL MICROBIOL, V16, P241, DOI 10.1111/j.1365-2958.1995.tb02296.x; Weston SA, 1998, NAT STRUCT BIOL, V5, P213, DOI 10.1038/nsb0398-213; Zhang LT, 1996, J BIOL CHEM, V271, P33131, DOI 10.1074/jbc.271.51.33131	48	22	22	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22185	22194		10.1074/jbc.M702696200	http://dx.doi.org/10.1074/jbc.M702696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17513302	hybrid			2022-12-25	WOS:000248196800064
J	Kurup, S; Wijnhoven, TJM; Jenniskens, GJ; Kimata, K; Habuchi, H; Li, J; Lindahl, U; van Kuppevelt, TH; Spillmann, D				Kurup, Sindhulakshmi; Wijnhoven, Tessa J. M.; Jenniskens, Guido J.; Kimata, Koji; Habuchi, Hiroko; Li, Jin-ping; Lindahl, Ulf; van Kuppevelt, Toin H.; Spillmann, Dorothe			Characterization of anti-heparan sulfate phage display antibodies AO4B08 and HS4E4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; STRUCTURAL DIVERSITY; IDURONIC ACID; DOMAINS; IDENTIFICATION; BINDING; DEPOLYMERIZATION; HETEROGENEITY; BIOSYNTHESIS; PROTEIN	Heparan sulfates (HS) are linear carbohydrate chains, covalently attached to proteins, that occur on essentially all cell surfaces and in extracellular matrices. HS chains show extensive structural heterogeneity and are functionally important during embryogenesis and in homeostasis due to their interactions with various proteins. Phage display antibodies have been developed to probe HS structures, assess the availability of protein-binding sites, and monitor structural changes during development and disease. Here we have characterized two such antibodies, AO4B08 and HS4E4, previously noted for partly differential tissue staining. AO4B08 recognized both HS and heparin, and was found to interact with an ubiquitous, N-, 2-O-, and 6-O-sulfated saccharide motif, including an internal 2-O-sulfate group. HS4E4 turned out to preferentially recognize low-sulfated HS motifs containing iduronic acid, and N-sulfated as well as N-acetylated glucosamine residues. Contrary to AO4B08, HS4E4 did not bind highly O-sulfated structures such as found in heparin.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan	Uppsala University; Radboud University Nijmegen; Aichi Medical University	Spillmann, D (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Dorothe.Spillmann@imbim.uu.se	van Kuppevelt, A.H.M.S.M./L-4463-2015					BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; JACOBSSON I, 1979, BIOCHEM J, V179, P77, DOI 10.1042/bj1790077; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; Kreuger J, 2006, J CELL BIOL, V174, P323, DOI 10.1083/jcb.200604035; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Lensen JFM, 2005, J AM SOC NEPHROL, V16, P1279, DOI 10.1681/ASN.2004050413; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINKER A, 1973, CARBOHYD RES, V29, P41, DOI 10.1016/S0008-6215(00)82069-8; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Sedita J, 2004, DEV DYNAM, V231, P782, DOI 10.1002/dvdy.20173; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; ten Dam GB, 2006, J BIOL CHEM, V281, P4654, DOI 10.1074/jbc.M506357200; ten Dam GB, 2003, J HISTOCHEM CYTOCHEM, V51, P727; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960	33	67	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21032	21042		10.1074/jbc.M702073200	http://dx.doi.org/10.1074/jbc.M702073200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17517889	Green Published, hybrid			2022-12-25	WOS:000248047500030
J	Nguyen, TLA; de Walque, S; Veithen, E; Dekoninck, A; Martinelli, V; de Launoit, Y; Burny, A; Harrod, R; Van Lint, C				Nguyen, Thi Lien-Anh; de Walque, Stephane; Veithen, Emmanuelle; Dekoninck, Ann; Martinelli, Valerie; de Launoit, Yvan; Burny, Arsene; Harrod, Robert; Van Lint, Carine			Transcriptional regulation of the bovine leukemia virus promoter by the cyclic AMP-response element modulator tau isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; PROTEIN-KINASE-C; CAMP-INDUCED TRANSCRIPTION; MALE GERM-CELLS; BINDING PROTEIN; IN-VIVO; GENE-EXPRESSION; B-LYMPHOCYTES; TRANSACTIVATOR PROTEIN; GENOMIC INTEGRATION	Bovine leukemia virus (BLV) expression is controlled at the transcriptional level through three Tax(BLV)- responsive elements (TxREs) responsive to the viral transactivator Tax(BLV). The cAMP-responsive element (CRE)-binding protein (CREB) has been shown to interact with CRE-like sequences present in the middle of each of these TxREs and to play critical transcriptional roles in both basal and Tax(BLV)-transactivated BLV promoter activity. In this study, we have investigated the potential involvement of the cAMP-response element modulator (CREM) in BLV transcriptional regulation, and we have demonstrated that CREM proteins were expressed in BLV-infected cells and bound to the three BLV TxREs in vitro. Chromatin immuno-precipitation assays using BLV-infected cell lines demonstrated in the context of chromatin that CREM proteins were recruited to the BLV promoter TxRE region in vivo. Functional studies, in the absence of TaxBLV, indicated that ectopic CREM tau protein had a CRE-dependent stimulatory effect on BLV promoter transcriptional activity. Cross-link of the B-cell receptor potentiated CREM tau transactivation of the viral promoter. Further experiments supported the notion that this potentiation involved CREM tau Ser-117 phosphorylation and recruitment of CBP/p300 to the BLV promoter. Although CREB and TaxBLV synergistically transactivated the BLV promoter, CREM tau repressed this Tax(BLV)/CREB synergism, suggesting that a modulation of the level of TaxBLV transactivation through opposite actions of CREB and CREM tau could facilitate immune escape and allow tumor development.	Univ Libre Bruxelles, Mol Virol Lab, Inst Biol & Med Mol, B-6041 Gosselies, Belgium; Univ Lille 1, Inst Biol Lille, CNRS, UMR 8117, F-59021 Lille, France; Univ Lille 1, Inst Pasteur Lille, CNRS, UMR 8117, F-59021 Lille, France; So Methodist Univ, Mol Virol Lab, Dept Biol Sci, Dallas, TX 75275 USA; Fonds Natl Rech Sci, Bern, Switzerland	Universite Libre de Bruxelles; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Southern Methodist University	Van Lint, C (corresponding author), Univ Libre Bruxelles, Mol Virol Lab, Inst Biol & Med Mol, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.	cvlint@ulb.ac.be						Adam E, 1996, J VIROL, V70, P1990, DOI 10.1128/JVI.70.3.1990-1999.1996; ADAM E, 1994, J VIROL, V68, P5845, DOI 10.1128/JVI.68.9.5845-5853.1994; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bodor J, 1995, FEBS LETT, V377, P413, DOI 10.1016/0014-5793(95)01299-0; Bodor J, 1996, P NATL ACAD SCI USA, V93, P3536, DOI 10.1073/pnas.93.8.3536; Calomme C, 2004, J VIROL, V78, P13848, DOI 10.1128/JVI.78.24.13848-13864.2004; Calomme C, 2002, J BIOL CHEM, V277, P8775, DOI 10.1074/jbc.M107441200; Daniel PB, 2000, ENDOCRINOLOGY, V141, P3923, DOI 10.1210/en.141.11.3923; DE CD, 1999, TRENDS BIOCHEM SCI, V24, P281; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; De Cesare D, 2000, J ENDOCRINOL INVEST, V23, P592, DOI 10.1007/BF03343781; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1986, SCIENCE, V231, P1437, DOI 10.1126/science.3006241; Don J, 2002, MOL CELL ENDOCRINOL, V187, P115, DOI 10.1016/S0303-7207(01)00696-7; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Foulkes NS, 1996, P NATL ACAD SCI USA, V93, P14140, DOI 10.1073/pnas.93.24.14140; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; Gellersen B, 2002, MOL HUM REPROD, V8, P965, DOI 10.1093/molehr/8.11.965; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; GUPTA P, 1982, SCIENCE, V215, P405, DOI 10.1126/science.6276975; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; Harnett MA, 2005, IMMUNOL LETT, V98, P33, DOI 10.1016/j.imlet.2004.11.002; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; Kerkhofs P, 1996, J VIROL, V70, P2170, DOI 10.1128/JVI.70.4.2170-2177.1996; KETTMANN R, 1980, P NATL ACAD SCI-BIOL, V77, P2577, DOI 10.1073/pnas.77.5.2577; KETTMANN R, 1982, P NATL ACAD SCI-BIOL, V79, P2465, DOI 10.1073/pnas.79.8.2465; KETTMANN R, 1980, LEUKEMIA RES, V4, P509, DOI 10.1016/0145-2126(80)90062-4; KISSTOTH E, 1993, NUCLEIC ACIDS RES, V21, P3677, DOI 10.1093/nar/21.16.3677; KISTLER MK, 1994, BIOL REPROD, V51, P1322, DOI 10.1095/biolreprod51.6.1322; LAGARIAS DM, 1989, J VIROL, V63, P2099, DOI 10.1128/JVI.63.5.2099-2107.1989; Lamas M, 1996, PHILOS T R SOC B, V351, P561, DOI 10.1098/rstb.1996.0055; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; Laurance ME, 1997, J BIOL CHEM, V272, P2646, DOI 10.1074/jbc.272.5.2646; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Merezak C, 2002, J VIROL, V76, P5034, DOI 10.1128/JVI.76.10.5034-5042.2002; Monaco L, 2004, INT J ANDROL, V27, P322, DOI 10.1111/j.1365-2605.2004.00494.x; MURAKAMI K, 1994, VIROLOGY, V202, P458, DOI 10.1006/viro.1994.1362; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; Newbound GC, 2000, J MED VIROL, V62, P286, DOI 10.1002/1096-9071(200010)62:2<286::AID-JMV22>3.3.CO;2-P; Nguyen TLA, 2004, J BIOL CHEM, V279, P35025, DOI 10.1074/jbc.M404081200; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; SUN ZM, 1995, J BIOL CHEM, V270, P29507, DOI 10.1074/jbc.270.49.29507; Swart JM, 2000, J IMMUNOL, V164, P2311, DOI 10.4049/jimmunol.164.5.2311; TAYLOR JA, 1993, LAB INVEST, V69, P340; TSUKIYAMA K, 1987, ARCH VIROL, V96, P89, DOI 10.1007/BF01310992; Twizere JC, 2000, J VIROL, V74, P9895, DOI 10.1128/JVI.74.21.9895-9902.2000; Van den Broeke A, 1999, J VIROL, V73, P1054, DOI 10.1128/JVI.73.2.1054-1065.1999; Van den Broeke A, 2001, J VIROL, V75, P1095, DOI 10.1128/JVI.75.3.1095-1103.2001; van der Stoep N, 2002, J IMMUNOL, V169, P5061, DOI 10.4049/jimmunol.169.9.5061; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WILLEMS L, 1987, EMBO J, V6, P3385, DOI 10.1002/j.1460-2075.1987.tb02661.x; WILLEMS L, 1992, P NATL ACAD SCI USA, V89, P3957, DOI 10.1073/pnas.89.9.3957; WILLEMS L, 1992, J VIROL, V66, P766, DOI 10.1128/JVI.66.2.766-772.1992; WILLEMS L, 1990, EMBO J, V9, P1577, DOI 10.1002/j.1460-2075.1990.tb08277.x; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; Xie HJ, 1996, CELL IMMUNOL, V169, P264, DOI 10.1006/cimm.1996.0117; XIE HJ, 1995, J IMMUNOL, V154, P1717; ZANDOMENI RO, 1994, J INFECT DIS, V170, P787, DOI 10.1093/infdis/170.4.787; ZANDOMENI RO, 1992, J GEN VIROL, V73, P1915, DOI 10.1099/0022-1317-73-8-1915; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	76	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20854	20867		10.1074/jbc.M703060200	http://dx.doi.org/10.1074/jbc.M703060200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17526487	hybrid			2022-12-25	WOS:000248047500011
J	Land, SC; Tee, AR				Land, Stephen C.; Tee, Andrew R.			Hypoxia-inducible factor 1 alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; TUBEROUS SCLEROSIS; TRANSCRIPTIONAL ACTIVATION; BINDING PARTNER; GENE-PRODUCTS; PATHWAY; IDENTIFICATION; EXPRESSION; RHEB	Tumors that form as a result of heightened mammalian target of rapamycin ( mTOR) signaling are highly vascularized. This process of angiogenesis is regulated through hypoxia-inducible factor (HIF)-mediated transcription of angiogenic factors. It is recognized that inhibition of mTOR with rapamycin can diminish the process of angiogenesis. Our work shows that activation of mTOR by Ras homologue enriched in brain ( Rheb) overexpression potently enhances the activity of HIF1 alpha and vascular endothelial growth factor (VEGF)-A secretion during hypoxia, which is reversed with rapamycin. Mutants of Rheb, which do not bind guanine nucleotide (D60K, D60V, N119I, and D122N) and are unable to activate mTOR, inhibit the activity of HIF when overexpressed. We show that regulatory associated protein of mTOR ( Raptor) interacts with HIF1 alpha and requires an mTOR signaling (TOS) motif located in the N terminus of HIF1 alpha. Furthermore, a mutant of HIF1 alpha lacking this TOS motif dominantly impaired HIF activity during hypoxia and was unable to bind to the co-activator CBP/p300. Rapamycin treatments do not affect the stability of HIF1 alpha and modulate HIF activity via a Von Hippel-Lindau (VHL)-independent mechanism. We demonstrate that the high levels of HIF activity in cells devoid of TSC2 can be reversed by treatments with rapamycin or the readdition of TSC2. Our work explains why human cancers with aberrant mTOR signaling are prone to angiogenesis and suggests that inhibition of mTOR with rapamycin might be a suitable therapeutic strategy.	Univ Cardiff Wales, Coll Med, Inst Med Genet, Cardiff CF14 4XN, Wales; Univ Dundee, Ninewells Hosp, Sch Med, Div Maternal & Child Hlth Sci, Dundee DD1 9SY, Scotland	Cardiff University; University of Dundee	Tee, AR (corresponding author), Univ Cardiff Wales, Coll Med, Inst Med Genet, Heath Park, Cardiff CF14 4XN, Wales.	TeeA@cardiff.ac.uk		Land, Stephen/0000-0001-9216-5969; Tee, Andrew/0000-0002-5577-4631	Worldwide Cancer Research [06-0914] Funding Source: Medline	Worldwide Cancer Research		Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; El-Hashemite N, 2003, CANCER RES, V63, P5173; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kotsuji-Maruyama T, 2002, J DERMATOL, V29, P713, DOI 10.1111/j.1346-8138.2002.tb00208.x; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rapisarda A, 2002, CANCER RES, V62, P4316; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2005, FEBS LETT, V579, P4763, DOI 10.1016/j.febslet.2005.07.054; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Woo KJ, 2006, BIOCHEM BIOPH RES CO, V343, P8, DOI 10.1016/j.bbrc.2006.02.116; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074	41	370	391	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20534	20543		10.1074/jbc.M611782200	http://dx.doi.org/10.1074/jbc.M611782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17502379	hybrid			2022-12-25	WOS:000247819300056
J	North, BJ; Verdin, E				North, Brian J.; Verdin, Eric			Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC14A PHOSPHATASE; PROTEIN DEACETYLASES; CHROMOSOME SEGREGATION; HISTONE DEACETYLASE; TUBULIN DEACETYLASE; SIR2-LIKE PROTEINS; CELL-CYCLE; GENE; EXIT; HOMOLOGY	Sirtuins are evolutionarily conserved NAD(+)-dependent deacetylases and ADP-ribosyltransferases involved in the regulation of cell division, apoptosis, DNA damage repair, genomic silencing, and longevity. Recent studies have focused on identifying target substrates for human sirtuin enzymatic activity, but little is known about processes that directly regulate their function. Here, we demonstrate that SIRT2 is phosphorylated both in vitro and in vivo on serine 368 by the cell-cycle regulator, cyclin-dependent kinase 1, and dephosphorylated by the phosphatases CDC14A and CDC14B. Overexpression of SIRT2 mediates a delay in cellular proliferation that is dependent on serine 368 phosphorylation. Furthermore, mutation of serine 368 reduces hyperploidy in cells under mitotic stress due to microtubule poisons.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes	Verdin, E (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA.	everdin@gladstone.ucsf.edu	Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				Afshar G, 1999, GENE, V234, P161, DOI 10.1016/S0378-1119(99)00162-6; Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Bembenek J, 2003, FRONT BIOSCI, V8, pD1275, DOI 10.2741/1128; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Cho HP, 2005, MOL CELL BIOL, V25, P4541, DOI 10.1128/MCB.25.11.4541-4551.2005; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Inoue T, 2007, ONCOGENE, V26, P945, DOI 10.1038/sj.onc.1209857; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; North BJ, 2005, METHODS, V36, P338, DOI 10.1016/j.ymeth.2005.03.004; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Yang YH, 2000, GENOMICS, V69, P355, DOI 10.1006/geno.2000.6360; Zhao KH, 2003, NAT STRUCT BIOL, V10, P864, DOI 10.1038/nsb978	26	117	122	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19546	19555		10.1074/jbc.M702990200	http://dx.doi.org/10.1074/jbc.M702990200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17488717	hybrid			2022-12-25	WOS:000247650600029
J	Hwang, J; Kalinin, A; Hwang, M; Anderson, DE; Kim, MJ; Stojadinovic, O; Tomic-Canic, M; Lee, SH; Morasso, MI				Hwang, Joonsung; Kalinin, Alexandr; Hwang, Meeyul; Anderson, D. Eric; Kim, Min Jung; Stojadinovic, Olivera; Tomic-Canic, Marjana; Lee, Seung Hun; Morasso, Maria I.			Role of scarf and its binding target proteins in epidermal calcium homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-LIKE PROTEIN; BARRIER FUNCTION; GROWTH-INHIBITION; MURINE EPIDERMIS; DIFFERENTIATION; EXPRESSION; LOCALIZATION; ANNEXINS; IDENTIFICATION; ASSOCIATION	The novel Ca2+-binding protein, Scarf ( skin calmodulin-related factor) belongs to the calmodulin-like protein family and is expressed in the differentiated layers of the epidermis. To determine the roles of Scarf during stratification, we set out to identify the binding target proteins by affinity chromatography and subsequent analysis by mass spectrometry. Several binding factors, including 14-3-3s, annexins, calreticulin, ERp72 ( endoplasmic reticulum protein 72), and nucleolin, were identified, and their interactions with Scarf were corroborated by co-immunoprecipitation and co-localization analyses. To further understand the functions of Scarf in epidermis in vivo, we altered the epidermal Ca2+ gradient by acute barrier disruption. The change in the expression levels of Scarf and its binding target proteins were determined by immunohistochemistry and Western blot analysis. The expression of Scarf, annexins, calreticulin, and ERp72 were up-regulated by Ca2+ gradient disruption, whereas the expression of 14-3-3s and nucleolin was reduced. Because annexins, calreticulin, and ERp72 have been implicated in Ca2+-induced cellular trafficking, including the secretion of lamellar bodies and Ca2+ homeostasis, we propose that the interaction of Scarf with these proteins might be crucial in the process of barrier restoration. On the other hand, down-regulation of 14-3-3s and nucleolin is potentially involved in the process of keratinocyte differentiation and growth inhibition. The calcium-dependent localization and up-regulation of Scarf and its binding target proteins were studied in mouse keratinocytes treated with ionomycin and during the wound-healing process. We found increased expression and nuclear presence of Scarf in the epidermis of the wound edge 4 and 7 days post-wounding, entailing the role of Scarf in barrier restoration. Our results suggest that Scarf plays a critical role as a Ca2+ sensor, potentially regulating the function of its binding target proteins in a Ca2+-dependent manner in the process of restoration of epidermal Ca2+ gradient as well as during epidermal barrier formation.	NIAMS, NIH, Dev Skin Biol Unit, Bethesda, MD 20892 USA; NIDDK, NIH, Proteom & Mass Spectrometry Fac, Bethesda, MD 20892 USA; Yonsei Univ, Coll Med, Dept Dermatol, Seoul 135720, South Korea; Cornell Univ, Weill Med Coll, Dept Dermatol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Yonsei University; Yonsei University Health System; Cornell University	Morasso, MI (corresponding author), NIAMS, NIH, Dev Skin Biol Unit, Bldg 50,Rm1525, Bethesda, MD 20892 USA.	morassom@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041124, ZIAAR041124] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Broome AM, 2004, J INVEST DERMATOL, V122, P29, DOI 10.1046/j.0022-202X.2003.22105.x; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; Darling DL, 2005, CURR TOP DEV BIOL, V68, P281, DOI 10.1016/S0070-2153(05)68010-6; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; DYKES PJ, 1982, ARCH DERMATOL RES, V273, P225, DOI 10.1007/BF00409250; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Elias PM, 2002, J INVEST DERMATOL, V119, P1128, DOI 10.1046/j.1523-1747.2002.19512.x; FEINGOLD KR, 1990, J CLIN INVEST, V86, P1738, DOI 10.1172/JCI114899; Gelebart P, 2005, INT J BIOCHEM CELL B, V37, P260, DOI 10.1016/j.biocel.2004.02.030; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Ghahary A, 2005, J INVEST DERMATOL, V124, P170, DOI 10.1111/j.0022-202X.2004.23521.x; Ginisty H, 1999, J CELL SCI, V112, P761; GRUBAUER G, 1989, J LIPID RES, V30, P323; GRUBAUER G, 1987, J LIPID RES, V28, P746; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; HOLLERAN WM, 1991, J CLIN INVEST, V88, P1338, DOI 10.1172/JCI115439; Hwang M, 2005, GENE EXPR PATTERNS, V5, P801, DOI 10.1016/j.modgep.2005.03.010; Hwang M, 2003, J BIOL CHEM, V278, P47827, DOI 10.1074/jbc.M306561200; Jessop CE, 2004, BIOCHEM SOC T, V32, P655, DOI 10.1042/BST0320655; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; Lambert O, 1997, J MOL BIOL, V272, P42, DOI 10.1006/jmbi.1997.1183; Lee B, 2005, J MOL BIOL, V345, P1083, DOI 10.1016/j.jmb.2004.11.027; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Mauro T, 1998, J INVEST DERMATOL, V111, P1198, DOI 10.1046/j.1523-1747.1998.00421.x; Mehul B, 2000, J BIOL CHEM, V275, P12841, DOI 10.1074/jbc.275.17.12841; Menke M, 2005, BIOCHEMISTRY-US, V44, P15296, DOI 10.1021/bi051585i; MENON GK, 1992, J INVEST DERMATOL, V98, P279, DOI 10.1111/1523-1747.ep12497866; MENON GK, 1992, CELL TISSUE RES, V270, P503, DOI 10.1007/BF00645052; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Morasso MI, 2005, BIOL CELL, V97, P173; Nelson MR, 1998, PROTEIN SCI, V7, P270; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PROKSCH E, 1991, J CLIN INVEST, V87, P1668, DOI 10.1172/JCI115183; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rodriguez LG, 2005, J CELL PHYSIOL, V202, P285, DOI 10.1002/jcp.20122; Rogers MS, 2001, EXP CELL RES, V267, P216, DOI 10.1006/excr.2001.5254; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Sakaguchi M, 2004, J CELL BIOL, V164, P979, DOI 10.1083/jcb.200312041; Sakaguchi M, 2003, J CELL BIOL, V163, P825, DOI 10.1083/jcb.200304017; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Stojadinovic O, 2005, AM J PATHOL, V167, P59, DOI 10.1016/S0002-9440(10)62953-7; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Tomas A, 2003, J BIOL CHEM, V278, P20210, DOI 10.1074/jbc.M212669200; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Woodard GE, 2005, CURR TOP DEV BIOL, V65, P189; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	54	16	16	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18645	18653		10.1074/jbc.M702035200	http://dx.doi.org/10.1074/jbc.M702035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17470426	hybrid			2022-12-25	WOS:000247302000069
J	Mishra, S; Melino, G; Murphy, LJ				Mishra, Suresh; Melino, Gerry; Murphy, Liam J.			Transglutaminase 2 kinase activity facilitates protein kinase A-induced phosphorylation of retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; BINDING PROTEIN; GENE-PRODUCT; CELL-DEATH; IN-VIVO; APOPTOSIS; IDENTIFICATION; ACTIVATION; RHOA; GTP	Transglutaminase 2 (TG2, tissue transglutaminase) is a multifunctional protein involved in cross-linking a variety of proteins, including retinoblastoma protein (Rb). Here we show that Rb is also a substrate for the recently identified serine/threonine kinase activity of TG2 and that TG2 phosphorylates Rb at the critically important Ser(780) residue. Furthermore, phosphorylation of Rb by TG2 destabilizes the Rb center dot E2F1 complex. TG2 phosphorylation of Rb was abrogated by high Ca2+ concentrations, whereas TG2 transamidating activity was inhibited by ATP. TG2 was itself phosphorylated by protein kinase A (PKA). Phosphorylation of TG2 by PKA attenuated its transamidating activity and enhanced its kinase activity. Activation of PKA in mouse embryonic fibroblasts (MEF) with dibutyryl-cAMP enhanced phosphorylation of both TG2 and Rb by a process that was inhibited by the PKA inhibitor H89. Treatment with dibutyryl-cAMP enhanced Rb phosphorylation in MEFtg2+/+ cells but not in MEFtg2-/- cells. These data indicate that Rb is a substrate for TG2 kinase activity and suggest that phosphorylation of Rb, which results from activation of PKA in fibroblasts, is indirect and requires TG2 kinase activity.	Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0W3, Canada; Univ Roma Tor Vergata, Dept Expt Med & Biol Sci, Inst Dermapat Immaculata Inst Hosp Care & Sci Res, Biochem Lab, I-00133 Rome, Italy	University of Manitoba; University of Manitoba; University of Rome Tor Vergata	Mishra, S (corresponding author), Univ Manitoba, John Buhler Res Ctr, Rm 843,715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	mishra@cc.umanitoba.ca	Mishra, Suresh/W-1633-2019	Mishra, Suresh/0000-0002-0364-1538	Medical Research Council [MC_U132670600] Funding Source: Medline; MRC [MC_U132670600] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams PD, 1998, CURR OPIN CELL BIOL, V10, P791, DOI 10.1016/S0955-0674(98)80123-3; Bernassola F, 2002, FASEB J, V16, P1371, DOI 10.1096/fj.01-0689com; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Campisi A, 2003, BRAIN RES, V978, P24, DOI 10.1016/S0006-8993(03)02725-2; Caraglia M, 2002, J BIOCHEM, V132, P45, DOI 10.1093/oxfordjournals.jbchem.a003197; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Chung J, 2002, CELL PROLIFERAT, V35, P247, DOI 10.1046/j.1365-2184.2002.00245.x; Cummings M, 1996, J PATHOL, V179, P288, DOI 10.1002/(SICI)1096-9896(199607)179:3<288::AID-PATH574>3.0.CO;2-M; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1966, J BIOL CHEM, V241, P3238; Fry DW, 2004, MOL CANCER THER, V3, P1427; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Guo J, 2005, J BIOL CHEM, V280, P35992, DOI 10.1074/jbc.M504583200; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; Imhof A, 1999, BIOCHEMISTRY-US, V38, P13085, DOI 10.1021/bi9912490; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kang SK, 2002, BIOCHEM BIOPH RES CO, V293, P383, DOI 10.1016/S0006-291X(02)00197-3; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee SC, 2003, MOL CELLS, V16, P285; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Medina DL, 2000, J BIOL CHEM, V275, P15549, DOI 10.1074/jbc.275.20.15549; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Mishra S, 2006, BIOCHEM BIOPH RES CO, V339, P726, DOI 10.1016/j.bbrc.2005.11.071; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; Mishra S, 2006, BIOCHEM BIOPH RES CO, V347, P1166, DOI 10.1016/j.bbrc.2006.07.041; Nagy L, 1997, CELL DEATH DIFFER, V4, P534, DOI 10.1038/sj.cdd.4400290; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nurminskaya M, 2003, DEV BIOL, V263, P139, DOI 10.1016/S0012-1606(03)00445-7; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Porter GW, 2006, SEMIN CANCER BIOL, V16, P193, DOI 10.1016/j.semcancer.2006.03.003; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rice RH, 1996, BIOCHEM J, V320, P547, DOI 10.1042/bj3200547; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Sarang Z, 2005, HEPATOLOGY, V42, P578, DOI 10.1002/hep.20812; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; Soh Y, 2000, J BIOCHEM, V127, P95, DOI 10.1093/oxfordjournals.jbchem.a022589; Szondy Z, 1997, FEBS LETT, V404, P307, DOI 10.1016/S0014-5793(97)00140-3; Szondy Z, 2006, CELL DEATH DIFFER, V13, P1827, DOI 10.1038/sj.cdd.4401889; Tucholski J, 2003, J BIOL CHEM, V278, P26838, DOI 10.1074/jbc.M303683200; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	51	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18108	18115		10.1074/jbc.M607413200	http://dx.doi.org/10.1074/jbc.M607413200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17478427	hybrid			2022-12-25	WOS:000247302000017
J	Amrein, I; Dechmann, DKN; Winter, Y; Lipp, HP				Amrein, Irmgard; Dechmann, Dina K. N.; Winter, York; Lipp, Hans-Peter			Absent or Low Rate of Adult Neurogenesis in the Hippocampus of Bats (Chiroptera)	PLOS ONE			English	Article								Bats are the only flying mammals and have well developed navigation abilities for 3D-space. Even bats with comparatively small home ranges cover much larger territories than rodents, and long-distance migration by some species is unique among small mammals. Adult proliferation of neurons, i.e., adult neurogenesis, in the dentate gyrus of rodents is thought to play an important role in spatial memory and learning, as indicated by lesion studies and recordings of neurons active during spatial behavior. Assuming a role of adult neurogenesis in hippocampal function, one might expect high levels of adult neurogenesis in bats, particularly among fruit-and nectar-eating bats in need of excellent spatial working memory. The dentate gyrus of 12 tropical bat species was examined immunohistochemically, using multiple antibodies against proteins specific for proliferating cells (Ki-67, MCM2), and migrating and differentiating neurons (Doublecortin, NeuroD). Our data show a complete lack of hippocampal neurogenesis in nine of the species (Glossophaga soricina, Carollia perspicillata, Phyllostomus discolor, Nycteris macrotis, Nycteris thebaica, Hipposideros cyclops, Neoromicia rendalli, Pipistrellus guineensis, and Scotophilus leucogaster), while it was present at low levels in three species (Chaerephon pumila, Mops condylurus and Hipposideros caffer). Although not all antigens were recognized in all species, proliferation activity in the subventricular zone and rostral migratory stream was found in all species, confirming the appropriateness of our methods for detecting neurogenesis. The small variation of adult hippocampal neurogenesis within our sample of bats showed no indication of a correlation with phylogenetic relationship, foraging strategy, type of hunting habitat or diet. Our data indicate that the widely accepted notion of adult neurogenesis supporting spatial abilities needs to be considered carefully. Given their astonishing longevity, certain bat species may be useful subjects to compare adult neurogenesis with other long-living species, such as monkeys and humans, showing low rates of adult hippocampal neurogenesis.	[Amrein, Irmgard; Dechmann, Dina K. N.; Lipp, Hans-Peter] Univ Zurich, Inst Anat, Div Neuroanat & Behav, Zurich, Switzerland; [Winter, York] Univ Munich, Dept Biol, Munich, Germany	University of Zurich; University of Munich	Lipp, HP (corresponding author), Univ Zurich, Inst Anat, Div Neuroanat & Behav, Zurich, Switzerland.	hplipp@anatom.uzh.ch	Dechmann, Dina/A-1827-2010	Winter, York/0000-0002-7828-1872; Dechmann, Dina/0000-0003-0043-8267	Swiss National Science Foundation; NCCR "Neural Plasticity and Repair" (Switzerland); Volkswagen Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NCCR "Neural Plasticity and Repair" (Switzerland)(Swiss National Science Foundation (SNSF)); Volkswagen Foundation(Volkswagen)	Fundings through Swiss National Science Foundation, NCCR "Neural Plasticity and Repair" (Switzerland), and by a grant of the Volkswagen Foundation to WY. All fundings were given for the collection (African) and breeding (Neotropical) of the bat species.	AlvarezBuylla A, 1997, J NEUROBIOL, V33, P585, DOI 10.1002/(SICI)1097-4695(19971105)33:5<585::AID-NEU7>3.0.CO;2-0; Amrein I, 2004, EUR J NEUROSCI, V20, P3342, DOI 10.1111/j.1460-9568.2004.03795.x; Amrein I, 2004, HIPPOCAMPUS, V14, P1000, DOI 10.1002/hipo.20018; Anthony E.L.P., 1988, P47; Baron G, 1996, COMP NEUROBIOLOGY CH; Bedard A, 2004, DEV BRAIN RES, V151, P159, DOI 10.1016/j.devbrainres.2004.03.021; Belsky J.K, 1990, PSYCHOL AGING THEORY; Boekhoorn K, 2006, NEUROBIOL DIS, V24, P1, DOI 10.1016/j.nbd.2006.04.017; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Curtis MA, 2005, NEUROSCIENCE, V132, P777, DOI 10.1016/j.neuroscience.2004.12.051; Decher Jan, 2005, Mammalian Species, P1; Del Bigio MR, 1999, MICROSC RES TECHNIQ, V45, P353, DOI 10.1002/(SICI)1097-0029(19990615)45:6<353::AID-JEMT3>3.3.CO;2-D; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fahrner A, 2007, EXP NEUROL, V203, P320, DOI 10.1016/j.expneurol.2006.08.023; Fleming TH, 2003, BAT ECOLOGY, P156; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Hayes NL, 2002, DEV BRAIN RES, V134, P77, DOI 10.1016/S0165-3806(01)00324-8; Horn J. L., 1970, LIFE SPAN DEV PSYCH, V1, P423, DOI DOI 10.1016/B978-0-12-293850-4.50022-4; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lavenex P, 2000, EUR J NEUROSCI, V12, P643, DOI 10.1046/j.1460-9568.2000.00949.x; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Leuner B, 2006, HIPPOCAMPUS, V16, P216, DOI 10.1002/hipo.20153; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; LIPP HP, 1991, BEHAV BRAIN RES, V45, P135, DOI 10.1016/S0166-4328(05)80079-8; Matsuo N, 1998, BIOCHEM BIOPH RES CO, V252, P571, DOI 10.1006/bbrc.1998.9698; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Safi K, 2005, P ROY SOC B-BIOL SCI, V272, P179, DOI 10.1098/rspb.2004.2924; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Seress L, 2001, NEUROSCIENCE, V105, P831, DOI 10.1016/S0306-4522(01)00156-7; Starborg M, 1996, J CELL SCI, V109, P143; Stich KP, 2006, J EXP BIOL, V209, P4802, DOI 10.1242/jeb.02574; Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113; Thiele J, 2005, ANIM BEHAV, V69, P315, DOI 10.1016/j.anbehav.2004.05.012; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Ulanovsky N, 2007, NAT NEUROSCI, V10, P224, DOI 10.1038/nn1829; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wilkinson GS, 2002, AGING CELL, V1, P124, DOI 10.1046/j.1474-9728.2002.00020.x; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; Winter Y, 2005, J EXP BIOL, V208, P539, DOI 10.1242/jeb.01416	43	95	95	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e455	10.1371/journal.pone.0000455	http://dx.doi.org/10.1371/journal.pone.0000455			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520014	Green Published, Green Submitted, gold			2022-12-25	WOS:000207446000003
J	Kwezi, L; Meier, S; Mungur, L; Ruzvidzo, O; Irving, H; Gehring, C				Kwezi, Lusisizwe; Meier, Stuart; Mungur, Lyndon; Ruzvidzo, Oziniel; Irving, Helen; Gehring, Chris			The Arabidopsis thaliana Brassinosteroid Receptor (AtBRI1) Contains a Domain that Functions as a Guanylyl Cyclase In Vitro	PLOS ONE			English	Article								Background. Guanylyl cyclases (GCs) catalyze the formation of the second messenger guanosine 3',5'-cyclic monophosphate (cGMP) from guanosine 5'-triphosphate (GTP). Cyclic GMP has been implicated in an increasing number of plant processes, including responses to abiotic stresses such as dehydration and salt, as well as hormones. Principle Findings. Here we used a rational search strategy based on conserved and functionally assigned residues in the catalytic centre of annotated GCs to identify candidate GCs in Arabidopsis thaliana and show that one of the candidates is the brassinosteroid receptor AtBR1, a leucine rich repeat receptor like kinase. We have cloned and expressed a 114 amino acid recombinant protein (AtBR1-GC) that harbours the putative catalytic domain, and demonstrate that this molecule can convert GTP to cGMP in vitro. Conclusions. Our results suggest that AtBR1 may belong to a novel class of GCs that contains both a cytosolic kinase and GC domain, and thus have a domain organisation that is not dissimilar to that of atrial natriuretic peptide receptors, NPR1 and NPR2. The findings also suggest that cGMP may have a role as a second messenger in brassinosteroid signalling. In addition, it is conceivable that other proteins containing the extended GC search motif may also have catalytic activity, thus implying that a significant number of GCs, both in plants and animals, remain to be discovered, and this is in keeping with the fact that the single cellular green alga Chlamydomonas reinhardtii contains over 90 annotated putative CGs.	[Kwezi, Lusisizwe; Meier, Stuart; Mungur, Lyndon; Ruzvidzo, Oziniel; Gehring, Chris] Univ Western Cape, Dept Biotechnol, ZA-7535 Bellville, South Africa; [Irving, Helen] Monash Univ, Dept Pharmaceut Biol, Victorian Coll Pharm, Melbourne, Vic 3004, Australia	University of the Western Cape; Monash University	Gehring, C (corresponding author), Univ Western Cape, Dept Biotechnol, ZA-7535 Bellville, South Africa.	cgehring@uwc.ac.za	Irving, Helen/B-4425-2019	Irving, Helen/0000-0002-1514-0909; Gehring, Christoph/0000-0003-4355-4591	NRF (South Africa); ARC (Australia)	NRF (South Africa)(National Research Foundation - South Africa); ARC (Australia)(Australian Research Council)	This work was supported by the NRF (South Africa) and the ARC (Australia).	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bouquin T, 2001, PLANT PHYSIOL, V127, P450, DOI 10.1104/pp.010173; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; Clouse SD, 2002, PLANT CELL, V14, P1995, DOI 10.1105/tpc.140930; Donaldson L, 2004, FEBS LETT, V569, P317, DOI 10.1016/j.febslet.2004.06.016; Friedrichsen DM, 2000, PLANT PHYSIOL, V123, P1247, DOI 10.1104/pp.123.4.1247; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GEHRING CA, 1990, P NATL ACAD SCI USA, V87, P9645, DOI 10.1073/pnas.87.24.9645; Gehring CA, 2003, INT J BIOCHEM CELL B, V35, P1318, DOI 10.1016/S1357-2725(03)00032-3; GODA H, 2002, PLANT PHYSIOL, V130, P700; Haubrick LL, 2006, PLANT CELL ENVIRON, V29, P446, DOI 10.1111/j.1365-3040.2005.01481.x; Hu XY, 2005, PLANT PHYSIOL, V137, P663, DOI 10.1104/pp.104.054494; Jeffery CJ, 2003, TRENDS GENET, V19, P415, DOI 10.1016/S0168-9525(03)00167-7; Kende H, 1997, PLANT CELL, V9, P1197, DOI 10.1105/tpc.9.7.1197; Kinoshita T, 2005, NATURE, V433, P167, DOI 10.1038/nature03227; Leyser O, 2005, CURR OPIN GENET DEV, V15, P468, DOI 10.1016/j.gde.2005.06.010; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Lindsey K, 2002, TRENDS PLANT SCI, V7, P78, DOI 10.1016/S1360-1385(01)02194-X; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Ludidi N, 2003, J BIOL CHEM, V278, P6490, DOI 10.1074/jbc.M210983200; Maathuis FJM, 2006, PLANT J, V45, P700, DOI 10.1111/j.1365-313X.2005.02616.x; McCue LA, 2000, GENOME RES, V10, P204, DOI 10.1101/gr.10.2.204; Meier S, 2006, AFR J BIOTECHNOL, V5, P1687; Mussig C, 2006, PLANT BIOLOGY, V8, P291, DOI 10.1055/s-2005-873043; Nam KH, 2004, PLANT CELL, V16, P2406, DOI 10.1105/tpc.104.023903; Newton RP, 2004, PHYTOCHEMISTRY, V65, P2423, DOI 10.1016/j.phytochem.2004.07.026; Newton RP, 1999, NEW PHYTOL, V143, P427, DOI 10.1046/j.1469-8137.1999.00478.x; Pagnussat GC, 2004, PLANT PHYSIOL, V135, P279, DOI 10.1104/pp.103.038554; Penson SP, 1996, PLANT CELL, V8, P2325, DOI 10.1105/tpc.8.12.2325; Pharmawati M, 1998, PLANT SCI, V137, P107, DOI 10.1016/S0168-9452(98)00135-6; Pharmawati M, 2001, PLANT PHYSIOL BIOCH, V39, P385, DOI 10.1016/S0981-9428(01)01252-9; Prado AM, 2004, DEVELOPMENT, V131, P2707, DOI 10.1242/dev.01153; Schaap P, 2005, FRONT BIOSCI-LANDMRK, V10, P1485, DOI 10.2741/1633; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THORPE DS, 1990, J BIOL CHEM, V265, P14717; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597	39	100	105	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e449	10.1371/journal.pone.0000449	http://dx.doi.org/10.1371/journal.pone.0000449			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520012	gold, Green Published, Green Submitted			2022-12-25	WOS:000207446000001
J	Smith, MD; Rosenow, MA; Wang, MT; Allen, JP; Szostak, JW; Chaput, JC				Smith, Matthew D.; Rosenow, Matthew A.; Wang, Meitian; Allen, James P.; Szostak, Jack W.; Chaput, John C.			Structural Insights into the Evolution of a Non-Biological Protein: Importance of Surface Residues in Protein Fold Optimization	PLOS ONE			English	Article							IN-VITRO SELECTION; BINDING; SEQUENCES; STABILIZATION; DETERMINANTS; STABILITY	Phylogenetic profiling of amino acid substitution patterns in proteins has led many to conclude that most structural information is carried by interior core residues that are solvent inaccessible. This conclusion is based on the observation that buried residues generally tolerate only conserved sequence changes, while surface residues allow more diverse chemical substitutions. This notion is now changing as it has become apparent that both core and surface residues play important roles in protein folding and stability. Unfortunately, the ability to identify specific mutations that will lead to enhanced stability remains a challenging problem. Here we discuss two mutations that emerged from an in vitro selection experiment designed to improve the folding stability of a non-biological ATP binding protein. These mutations alter two solvent accessible residues, and dramatically enhance the expression, solubility, thermal stability, and ligand binding affinity of the protein. The significance of both mutations was investigated individually and together, and the X-ray crystal structures of the parent sequence and double mutant protein were solved to a resolution limit of 2.8 and 1.65 angstrom, respectively. Comparative structural analysis of the evolved protein to proteins found in nature reveals that our non-biological protein evolved certain structural features shared by many thermophilic proteins. This experimental result suggests that protein fold optimization by in vitro selection offers a viable approach to generating stable variants of many naturally occurring proteins whose structures and functions are otherwise difficult to study.	[Smith, Matthew D.; Rosenow, Matthew A.; Chaput, John C.] Arizona State Univ, Ctr BioOpt Nanotechnol, Biodesign Inst, Tempe, AZ 85287 USA; [Smith, Matthew D.; Rosenow, Matthew A.; Wang, Meitian; Allen, James P.; Chaput, John C.] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ USA; [Szostak, Jack W.] Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute	Chaput, JC (corresponding author), Arizona State Univ, Ctr BioOpt Nanotechnol, Biodesign Inst, Tempe, AZ 85287 USA.	john.chaput@asu.edu	Wang, Meitian/D-3208-2013		Biodesign Institute; NIH; NASA Astrobiology Institute	Biodesign Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NASA Astrobiology Institute	This work was supported by new laboratory start-up funds from the The Biodesign Institute to JCC and grants from the NIH and NASA Astrobiology Institute to JWS. JWS is an Investigator, and J.C.C. was a Research Associate of the Howard Hughes Medical Institute.	Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; Cappello V, 2002, PROTEINS, V47, P106, DOI 10.1002/prot.10070; Carothers JM, 2006, J AM CHEM SOC, V128, P7929, DOI 10.1021/ja060952q; Chaput JC, 2004, CHEM BIOL, V11, P865, DOI 10.1016/j.chembiol.2004.04.006; Chothia C, 2003, SCIENCE, V300, P1701, DOI 10.1126/science.1085371; Chothia C, 1998, J MOL BIOL, V278, P457, DOI 10.1006/jmbi.1998.1653; Dauter Z, 2002, ACTA CRYSTALLOGR D, V58, P494, DOI 10.1107/S090744490200118X; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DELANO WL, 2002, PYMOL MOL GRAPHICS P; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Hecht MH, 2004, PROTEIN SCI, V13, P1711, DOI 10.1110/ps.04690804; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Jung S, 1999, J MOL BIOL, V294, P163, DOI 10.1006/jmbi.1999.3196; Keefe AD, 2001, NATURE, V410, P715, DOI 10.1038/35070613; Kimura MA, 1985, NEUTRAL THEORY MOL E; Krishna SS, 2004, STRUCTURE, V12, P1125, DOI 10.1016/j.str.2004.06.004; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lo Surdo P, 2004, NAT STRUCT MOL BIOL, V11, P382, DOI 10.1038/nsmb745; LOVELL SC, 2003, PROTEINS STRUCTURE F, V50; Martin A, 2001, J MOL BIOL, V309, P717, DOI 10.1006/jmbi.2001.4698; Matsuura T, 2003, FEBS LETT, V539, P24, DOI 10.1016/S0014-5793(03)00178-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERUTZ MF, 1968, NATURE, V219, P902, DOI 10.1038/219902a0; PERUTZ MF, 1965, J MOL BIOL, V13, P669, DOI 10.1016/S0022-2836(65)80134-6; Petsko GA, 2001, METHOD ENZYMOL, V334, P469; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; Roodveldt C, 2005, CURR OPIN STRUC BIOL, V15, P50, DOI 10.1016/j.sbi.2005.01.001; Sauer RT, 1996, FOLD DES, V1, pR27, DOI 10.1016/S1359-0278(96)00015-6; Sterner R, 2001, CRIT REV BIOCHEM MOL, V36, P39, DOI 10.1080/20014091074174; Strickler SS, 2006, BIOCHEMISTRY-US, V45, P2761, DOI 10.1021/bi0600143; Takahashi TT, 2003, TRENDS BIOCHEM SCI, V28, P159, DOI 10.1016/S0968-0004(03)00036-7; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang QH, 2000, J MOL BIOL, V298, P917, DOI 10.1006/jmbi.2000.3716; WILSON D, 2000, CURRENT PROTOCOLS MO; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; Wunderlich M, 2005, J MOL BIOL, V347, P1063, DOI 10.1016/j.jmb.2005.02.014	47	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e467	10.1371/journal.pone.0000467	http://dx.doi.org/10.1371/journal.pone.0000467			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520026	gold, Green Submitted, Green Published			2022-12-25	WOS:000207446000015
J	Brennan, PLR; Prum, RO; McCracken, KG; Sorenson, MD; Wilson, RE; Birkhead, TR				Brennan, Patricia L. R.; Prum, Richard O.; McCracken, Kevin G.; Sorenson, Michael D.; Wilson, Robert E.; Birkhead, Tim R.			Coevolution of Male and Female Genital Morphology in Waterfowl	PLOS ONE			English	Article							FORCED COPULATION; SEXUAL SELECTION; INTROMITTENT ORGAN; EVOLUTION; SPERM; PATERNITY	Most birds have simple genitalia; males lack external genitalia and females have simple vaginas. However, male waterfowl have a phallus whose length (1.5->40 cm) and morphological elaborations vary among species and are positively correlated with the frequency of forced extra-pair copulations among waterfowl species. Here we report morphological complexity in female genital morphology in waterfowl and describe variation vaginal morphology that is unprecedented in birds. This variation comprises two anatomical novelties: (i) dead end sacs, and (ii) clockwise coils. These vaginal structures appear to function to exclude the intromission of the counter-clockwise spiralling male phallus without female cooperation. A phylogenetically controlled comparative analysis of 16 waterfowl species shows that the degree of vaginal elaboration is positively correlated with phallus length, demonstrating that female morphological complexity has co-evolved with male phallus length. Intersexual selection is most likely responsible for the observed coevolution, although identifying the specific mechanism is difficult. Our results suggest that females have evolved a cryptic anatomical mechanism of choice in response to forced extra-pair copulations.	[Brennan, Patricia L. R.; Prum, Richard O.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; [Brennan, Patricia L. R.; Prum, Richard O.] Yale Univ, Peabody Nat Hist Museum, New Haven, CT USA; [Brennan, Patricia L. R.; Birkhead, Tim R.] Univ Sheffield, Dept Anim & Plant Sci, Western Bank, Sheffield S10 2TN, S Yorkshire, England; [McCracken, Kevin G.; Wilson, Robert E.] Univ Alaska Fairbanks, Inst Arctic Biol, Dept Biol & Wildlife, Fairbanks, AK USA; [McCracken, Kevin G.; Wilson, Robert E.] Univ Alaska Fairbanks, Univ Alaska Museum, Fairbanks, AK USA; [Sorenson, Michael D.] Boston Univ, Dept Biol, Boston, MA 02215 USA	Yale University; Yale University; University of Sheffield; University of Alaska System; University of Alaska Fairbanks; University of Alaska System; University of Alaska Fairbanks; Boston University	Brennan, PLR (corresponding author), Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA.	patricia.brennan@yale.edu	Sorenson, Michael/D-8065-2011	Sorenson, Michael/0000-0001-5375-2917; Prum, Richard/0000-0002-4741-7132; Brennan, Patricia/0000-0002-1905-3327	NSF	NSF(National Science Foundation (NSF))	Funding was provided by an NSF post-doctoral research fellowship to P. Brennan.	Alexander Richard D., 1997, P4, DOI 10.1017/CBO9780511721946.002; Arnqvist G, 2002, NATURE, V415, P787, DOI 10.1038/415787a; Arnqvist G, 2002, EVOLUTION, V56, P936; Arnqvist G, 1998, NATURE, V393, P784, DOI 10.1038/31689; Arnqvist Goran, 2005, pUnpaginated; BOBR LW, 1964, J REPROD FERTIL, V8, P39, DOI 10.1530/jrf.0.0080039; Breazile J.E.H.E., 1993, HDB AVIAN ANATOMY NO, P329; Briskie JV, 1997, J AVIAN BIOL, V28, P73, DOI 10.2307/3677097; BURNS JT, 1980, AUK, V97, P875; Carayon J., 1966, MONOGRAPH CIMICIDAE, P81, DOI DOI 10.1002/(SICI)1097-0029(19971215)39:6<506::AID-JEMT5>3.0.CO;2-B; Chapman T, 2003, TRENDS ECOL EVOL, V18, P41, DOI 10.1016/S0169-5347(02)00004-6; Coker CR, 2002, AUK, V119, P403, DOI 10.1642/0004-8038(2002)119[0403:IOMATS]2.0.CO;2; Dixson AF, 2004, INT J PRIMATOL, V25, P1159, DOI 10.1023/B:IJOP.0000043356.60404.be; DIXSON AF, 1994, ARCH SEX BEHAV, V23, P267, DOI 10.1007/BF01541563; Dunn PO, 1999, ANIM BEHAV, V57, P1071, DOI 10.1006/anbe.1998.1066; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; Eberhard WG, 2003, TRENDS ECOL EVOL, V18, P438, DOI 10.1016/S0169-5347(03)00180-0; Eberhard WG, 1985, SEXUAL SELECTION ANI; EVARTS S, 1987, AUK, V104, P597, DOI 10.1093/auk/104.4.597; Fox H., 1977, BIOL REPTILIA, P1; Gavrilets S, 2001, P ROY SOC B-BIOL SCI, V268, P531, DOI 10.1098/rspb.2000.1382; Gilbert A.B., 1979, P237; GOMENDIO M, 1993, P ROY SOC B-BIOL SCI, V252, P7, DOI 10.1098/rspb.1993.0039; Gowaty PA, 1998, AM ZOOL, V38, P207; Holland B, 1998, EVOLUTION, V52, P1, DOI 10.1111/j.1558-5646.1998.tb05132.x; Hosken DJ, 2004, TRENDS ECOL EVOL, V19, P87, DOI 10.1016/j.tree.2003.11.012; Ilango K, 2000, J MED ENTOMOL, V37, P653, DOI 10.1603/0022-2585-37.5.653; Jacob M., 2007, REPROD BIOL PHYLOGEN, V6A, P149; Johnsgard PA, 1965, HDB WATERFOWL BEHAV; King A.S., 1981, P107; Koene JM, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-25; LOWRY R, 2007, CONCEPTS APPL INFERE; MADDISON WP, 2000, MACCLADE 4 0 ANAL PH; Mayr E., 1963, ANIMAL SPECIES EVOLU, P797; McCracken KG, 2000, AUK, V117, P820, DOI 10.1642/0004-8038(2000)117[0820:TCSPOT]2.0.CO;2; McCracken KG, 2001, NATURE, V413, P128, DOI 10.1038/35093160; MCKINNEY F, 1983, BEHAVIOUR, V86, P250, DOI 10.1163/156853983X00390; MCKINNEY F, 1998, AVIAN REPROD TACTICS, P163; Miller GT, 2002, SCIENCE, V298, P1230, DOI 10.1126/science.1076968; MILLER PL, 1991, ZOOL J LINN SOC-LOND, V102, P43, DOI 10.1111/j.1096-3642.1991.tb01536.x; Montgomerie R, 2007, REPROD BIOL PHYLOGEN, V1, P115; Pagel M, 1999, SYST BIOL, V48, P612, DOI 10.1080/106351599260184; Pagel M, 1997, ZOOL SCR, V26, P331, DOI 10.1111/j.1463-6409.1997.tb00423.x; Peters JL, 2003, AUK, V120, P883, DOI 10.1642/0004-8038(2003)120[0883:EPABSI]2.0.CO;2; PETERS JL, 2002, EXTRAPAIR PATERNITY; Pizzari T, 2000, NATURE, V405, P787, DOI 10.1038/35015558; Presgraves DC, 1999, P ROY SOC B-BIOL SCI, V266, P1041, DOI 10.1098/rspb.1999.0741; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Simmons L. W., 2001, MG BEH ECOL; SMITH JM, 1978, EVOLUTION SEX; THORBJARNARSON JB, 1993, J HERPETOL, V27, P371, DOI 10.2307/1564822	51	131	131	1	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e418	10.1371/journal.pone.0000418	http://dx.doi.org/10.1371/journal.pone.0000418			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476339	Green Published, gold, Green Accepted, Green Submitted			2022-12-25	WOS:000207445700020
J	Hung, SC; Pochampally, RR; Hsu, SC; Sanchez, C; Chen, SC; Spees, J; Prockop, DJ				Hung, Shih-Chieh; Pochampally, Radhika R.; Hsu, Shu-Ching; Sanchez, Cecelia; Chen, Sy-Chi; Spees, Jeffrey; Prockop, Darwin J.			Short-Term Exposure of Multipotent Stromal Cells to Low Oxygen Increases Their Expression of CX3CR1 and CXCR4 and Their Engraftment In Vivo	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; CHEMOKINE RECEPTOR CXCR4; BONE-MARROW; UTERO TRANSPLANTATION; PROMOTING MIGRATION; DIFFERENTIATION; RECRUITMENT; DELIVERY; TENSION; SITE	The ability of stem/progenitor cells to migrate and engraft into host tissues is key to their potential use in gene and cell therapy. Among the cells of interest are the adherent cells from bone marrow, referred to as mesenchymal stem cells or multipotent stromal cells (MSC). Since the bone marrow environment is hypoxic, with oxygen tensions ranging from 1% to 7%, we decided to test whether hypoxia can upregulate chemokine receptors and enhance the ability of human MSCs to engraft in vivo. Short-term exposure of MSCs to 1% oxygen increased expression of the chemokine receptors CX3CR1 and CXCR4, both as mRNA and as protein. After 1-day exposure to low oxygen, MSCs increased in vitro migration in response to the fractalkine and SDF-1 alpha in a dose dependent manner. Blocking antibodies for the chemokine receptors significantly decreased the migration. Xenotypic grafting into early chick embryos demonstrated cells from hypoxic cultures engrafted more efficiently than cells from normoxic cultures and generated a variety of cell types in host tissues. The results suggest that short-term culture of MSCs under hypoxic conditions may provide a general method of enhancing their engraftment in vivo into a variety of tissues.	[Hung, Shih-Chieh; Pochampally, Radhika R.; Hsu, Shu-Ching; Sanchez, Cecelia; Spees, Jeffrey; Prockop, Darwin J.] Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70118 USA; [Hung, Shih-Chieh; Chen, Sy-Chi] Vet Gen Hosp, Dept Med Res & Educ, Stem Cell Lab, Taipei, Taiwan; [Hung, Shih-Chieh] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan	Tulane University; National Yang Ming Chiao Tung University	Hung, SC (corresponding author), Tulane Univ, Hlth Sci Ctr, Ctr Gene Therapy, New Orleans, LA 70118 USA.	hungsc@vghtpe.gov.tw; dprocko@tulane.edu	Hsu, Shu-Ching/E-3869-2010	Pochampally, Radhika/0000-0002-4263-0364	NIH [HL73755, AR48323, HL73252]; NSC of Taiwan [NSC95-2314-B-075-047-MY3]; HCA the Healthcare Company; Louisiana Gene Therapy Research Consortium; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073252, R01HL073755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048323] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSC of Taiwan(Ministry of Science and Technology, Taiwan); HCA the Healthcare Company; Louisiana Gene Therapy Research Consortium; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	NIH grants HL73755, AR48323 and HL73252; the NSC of Taiwan (NSC95-2314-B-075-047-MY3), HCA the Healthcare Company; and the Louisiana Gene Therapy Research Consortium.	Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Becker M, 2002, BRIT J CANCER, V87, P1328, DOI 10.1038/sj.bjc.6600573; Brenner S, 2004, STEM CELLS, V22, P1128, DOI 10.1634/stemcells.2003-0196; Chou SH, 2006, J ORTHOP RES, V24, P301, DOI 10.1002/jor.20047; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Fink T, 2004, STEM CELLS, V22, P1346, DOI 10.1634/stemcells.2004-0038; Goldstein RS, 2002, DEV DYNAM, V225, P80, DOI 10.1002/dvdy.10108; Guo Y, 2005, STEM CELLS, V23, P1324, DOI 10.1634/stemcells.2005-0085; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jin KL, 2005, NEUROBIOL DIS, V18, P366, DOI 10.1016/j.nbd.2004.10.010; Kucia M, 2004, CIRC RES, V95, P1191, DOI 10.1161/01.RES.0000150856.47324.5b; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lennon DP, 2001, J CELL PHYSIOL, V187, P345, DOI 10.1002/jcp.1081; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matsuzaki Y, 2004, IMMUNITY, V20, P87, DOI 10.1016/S1074-7613(03)00354-6; OWEN M, 1988, CIBA F SYMP, V136, P42; Pochampally RR, 2004, P NATL ACAD SCI USA, V101, P9282, DOI 10.1073/pnas.0401558101; Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100; Salim A, 2004, J BIOL CHEM, V279, P40007, DOI 10.1074/jbc.M403715200; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Sigurjonsson OE, 2005, P NATL ACAD SCI USA, V102, P5227, DOI 10.1073/pnas.0501029102; Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood-2004-09-3507; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Zernecke A, 2005, CIRC RES, V96, P784, DOI 10.1161/01.RES.0000162100.52009.38; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	31	246	259	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e416	10.1371/journal.pone.0000416	http://dx.doi.org/10.1371/journal.pone.0000416			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476338	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445700018
J	Osan, R; Zhu, LP; Shoham, S; Tsien, JZ				Osan, Remus; Zhu, Liping; Shoham, Shy; Tsien, Joe Z.			Subspace Projection Approaches to Classification and Visualization of Neural Network-Level Encoding Patterns	PLOS ONE			English	Article							ENSEMBLE ACTIVITY; CORTICAL-NEURONS; TEMPORAL CORTEX; L-CURVE; INFORMATION; REPRESENTATIONS; REGULARIZATION; PERFORMANCE; ASSEMBLIES; PRINCIPLES	Recent advances in large-scale ensemble recordings allow monitoring of activity patterns of several hundreds of neurons in freely behaving animals. The emergence of such high-dimensional datasets poses challenges for the identification and analysis of dynamical network patterns. While several types of multivariate statistical methods have been used for integrating responses from multiple neurons, their effectiveness in pattern classification and predictive power has not been compared in a direct and systematic manner. Here we systematically employed a series of projection methods, such as Multiple Discriminant Analysis (MDA), Principal Components Analysis (PCA) and Artificial Neural Networks (ANN), and compared them with non-projection multivariate statistical methods such as Multivariate Gaussian Distributions (MGD). Our analyses of hippocampal data recorded during episodic memory events and cortical data simulated during face perception or arm movements illustrate how low-dimensional encoding subspaces can reveal the existence of network-level ensemble representations. We show how the use of regularization methods can prevent these statistical methods from over-fitting of training data sets when the trial numbers are much smaller than the number of recorded units. Moreover, we investigated the extent to which the computations implemented by the projection methods reflect the underlying hierarchical properties of the neural populations. Based on their ability to extract the essential features for pattern classification, we conclude that the typical performance ranking of these methods on under-sampled neural data of large dimension is MDA>PCA>ANN>MGD.	[Osan, Remus; Zhu, Liping; Tsien, Joe Z.] Boston Univ, Ctr Syst Neurobiol, Dept Pharmacol, Boston, MA 02215 USA; [Osan, Remus; Zhu, Liping; Tsien, Joe Z.] Boston Univ, Dept Biomed Engn, Ctr Syst Neurobiol, Boston, MA 02215 USA; [Zhu, Liping; Tsien, Joe Z.] E China Normal Univ, Shanghai Inst Brain Funct Genom, Key Labs, Minist Educ MOE, Shanghai 200062, Peoples R China; [Zhu, Liping; Tsien, Joe Z.] E China Normal Univ, SSTC, Shanghai 200062, Peoples R China; [Zhu, Liping; Tsien, Joe Z.] E China Normal Univ, Dept Math Stat, Shanghai 200062, Peoples R China; [Shoham, Shy] Technion Israel Inst Technol, Dept Biomed Engn, IL-32000 Haifa, Israel	Boston University; Boston University; East China Normal University; East China Normal University; East China Normal University; Technion Israel Institute of Technology	Osan, R (corresponding author), Boston Univ, Ctr Syst Neurobiol, Dept Pharmacol, Boston, MA 02215 USA.	osan@bu.edu; jtsien@bu.edu	Zhu, Li/GXH-9801-2022	Shoham, Shy/0000-0003-0376-3495	NIH [MH60236, MH61925, MH62632, AG02022]; Burroughs Welcome Fund; W. M. Keck Foundations; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060236, R01MH062632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034663] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Welcome Fund(Burroughs Wellcome Fund); W. M. Keck Foundations(W.M. Keck Foundation); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by funds from NIH (MH60236, MH61925, MH62632, AG02022), Burroughs Welcome Fund, and W. M. Keck Foundations (JZT).	BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Bishop C. M., 1995, NEURAL NETWORKS PATT; Broome BM, 2006, NEURON, V51, P467, DOI 10.1016/j.neuron.2006.07.018; Brown EN, 2004, NAT NEUROSCI, V7, P456, DOI 10.1038/nn1228; Brown GD, 2001, TRENDS NEUROSCI, V24, P54, DOI 10.1016/S0166-2236(00)01683-0; Buzsaki G, 2004, NAT NEUROSCI, V7, P446, DOI 10.1038/nn1233; Calvetti D, 2000, J COMPUT APPL MATH, V123, P423, DOI 10.1016/S0377-0427(00)00414-3; Carmena JM, 2005, J NEUROSCI, V25, P10712, DOI 10.1523/JNEUROSCI.2772-05.2005; Chapin JK, 2004, NAT NEUROSCI, V7, P452, DOI 10.1038/nn1234; Deadwyler SA, 1996, J NEUROSCI, V16, P354; Duda R.O., 2006, PATTERN CLASSIFICATI; Friedman J., 2001, ELEMENTS STAT LEARNI, DOI 10.1007/978-0-387-21606-5; FRIEDMAN JH, 1989, J AM STAT ASSOC, V84, P165, DOI 10.2307/2289860; Furukawa S, 2002, J NEUROPHYSIOL, V87, P1749, DOI 10.1152/jn.00491.2001; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Ghazanfar AA, 2000, J NEUROSCI, V20, P3761, DOI 10.1523/JNEUROSCI.20-10-03761.2000; GOCHIN PM, 1994, J NEUROPHYSIOL, V71, P2325, DOI 10.1152/jn.1994.71.6.2325; Gross CG, 2005, AM PSYCHOL, V60, P755, DOI 10.1037/0003-066X.60.8.755; GUO Y, 2007, BIOSTATISTI IN PRESS; Hansen P. C., 1997, RANK DEFICIENT DISCR; HANSEN PC, 1993, SIAM J SCI COMPUT, V14, P1487, DOI 10.1137/0914086; Harris KD, 2003, NATURE, V424, P552, DOI 10.1038/nature01834; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; Kim SJ, 2006, ANN BIOMED ENG, V34, P300, DOI 10.1007/s10439-005-9037-9; Laubach M, 2004, J NEUROSCI METH, V134, P159, DOI 10.1016/j.jneumeth.2003.11.007; Lin LN, 2006, TRENDS NEUROSCI, V29, P48, DOI 10.1016/j.tins.2005.11.004; Lin LN, 2005, P NATL ACAD SCI USA, V102, P6125, DOI 10.1073/pnas.0408233102; Lin LN, 2006, J NEUROSCI METH, V155, P28, DOI 10.1016/j.jneumeth.2005.12.032; Mazor O, 2005, NEURON, V48, P661, DOI 10.1016/j.neuron.2005.09.032; Nicolelis MAL, 1998, NAT NEUROSCI, V1, P621, DOI 10.1038/2855; Nicolelis MAL, 1997, J NEUROPHYSIOL, V78, P1691, DOI 10.1152/jn.1997.78.3.1691; NICOLELIS MAL, 1999, CRC METH NEUROSCI S, P121; Pinsk MA, 2005, P NATL ACAD SCI USA, V102, P6996, DOI 10.1073/pnas.0502605102; Rabinovich MI, 2006, REV MOD PHYS, V78, P1213, DOI 10.1103/RevModPhys.78.1213; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P147, DOI 10.1152/jn.1987.57.1.147; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P751, DOI 10.1152/jn.1995.74.2.751; Shoham S, 2005, IEEE T BIO-MED ENG, V52, P1312, DOI 10.1109/TBME.2005.847542; Stopfer M, 2003, NEURON, V39, P991, DOI 10.1016/j.neuron.2003.08.011; Tsao DY, 2006, SCIENCE, V311, P670, DOI 10.1126/science.1119983; Wang HM, 2006, PROG NEUROBIOL, V79, P123, DOI 10.1016/j.pneurobio.2006.06.004; Weber DJ, 2004, PROG BRAIN RES, V143, P477, DOI 10.1016/S0079-6123(03)43045-8; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582	42	12	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2007	2	5							e404	10.1371/journal.pone.0000404	http://dx.doi.org/10.1371/journal.pone.0000404			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DW	17476326	gold, Green Published, Green Submitted			2022-12-25	WOS:000207445700006
J	Mak, HHL; Peschard, P; Lin, T; Naujokas, MA; Zuo, D; Park, M				Mak, H. H. L.; Peschard, P.; Lin, T.; Naujokas, M. A.; Zuo, D.; Park, M.			Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway	ONCOGENE			English	Article						transforming gene; signal transduction; endocytosis; RTK; Cbl; ubiquitin	GROWTH-FACTOR RECEPTOR; DOMAIN BINDING-SITE; DOWN-REGULATION; C-CBL; JUXTAMEMBRANE DOMAIN; UBIQUITINATION; MULTIUBIQUITINATION; UBIQUITYLATION; CANCER	Multiple mechanisms of dysregulation of receptor tyrosine kinases (RTKs) are observed in human cancers. In addition to gain-of-function, loss of negative regulation also contributes to oncogenic activation of RTKs. Negative regulation of many RTKs involves their internalization and degradation in the lysosome, a process regulated through ubiquitination. RTK oncoproteins activated following chromosomal translocation, are no longer transmembrane proteins, and are predicted to escape lysosomal degradation. To test this, we used the Tpr-Met oncogene, generated following chromosomal translocation of the hepatocyte growth factor receptor (Met). Unlike Met, Tpr-Met is localized in the cytoplasm and also lacks the binding site for Cbl ubiquitin ligases. We determined whether subcellular localization of Tpr-Met, and/or loss of its Cbl-binding site, is important for oncogenic activity. Presence of a Cbl-binding site and ubiquitination of cytosolic Tpr-Met oncoproteins does not alter their transforming activity. In contrast, plasma membrane targeting allows Tpr-Met to enter the endocytic pathway, and Tpr-Met transforming activity as well as protein stability are decreased in a Cbl-dependent manner. We show that transformation by Tpr-Met is in part dependent on its ability to escape normal downregulatory mechanisms. This provides a paradigm for many RTK oncoproteins activated following chromosomal translocation.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, 687 Ave Pins Ouest, Rm H5-21, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca		Peschard, Pascal/0000-0001-6395-5566				Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303	28	35	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7213	7221		10.1038/sj.onc.1210522	http://dx.doi.org/10.1038/sj.onc.1210522			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17533376				2022-12-25	WOS:000250955600005
J	Zhong, Y; Jiang, L; Hiai, H; Toyokuni, S; Yamada, Y				Zhong, Y.; Jiang, L.; Hiai, H.; Toyokuni, S.; Yamada, Y.			Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice	ONCOGENE			English	Article						LYL1; lymphoma; basic helix-loop-helix transcription factor; E2A; transgenic mice; two-hybrid assay	LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSGENIC MICE; SCL GENE; TARGETED DISRUPTION; EXPRESSION; MALIGNANCIES; TAL1; BHLH; IMMUNOGLOBULIN	LYL1, a member of the class II basic helix-loop-helix transcription factors, is aberrantly expressed in a fraction of human T-cell acute lymphoblastic leukemia. Here, we generated transgenic mice ubiquitously overexpressing LYL1 using a construct expressing full-length cDNA driven by a human elongation factor lot promoter. Four independent lines exhibiting high LYL1 expression were established. Of these transgenic mice, 96% displayed loss of hair with a short kinked tail. Furthermore, 30% of them developed malignant lymphoma, with an average latent period of 352 days. In these mice, histological examination revealed tumor cell infiltration in multiple organs and immunohistochemical analysis showed that the infiltrated tumor cells were either CD3 or CD45R/B220-positive; fluorescence-activated cell sorter analysis indicated that each tumor consisted either of mainly CD4, CD8 double-positive T cells or mature B cells; the clonality of LYL1-induced lymphoma was confirmed by T-cell receptor rearrangement and immunoglobulin heavy-chain gene rearrangement analyses. Mammalian two-hybrid analysis and luciferase assay suggested that excess LYL1 blocked the dimerization of E2A and thus inhibited the regulatory activity of E2A on the CD4 promoter. Reverse transcription-polymerase chain reaction results showed that the expression of certain E2A/HEB target genes was downregulated. Taken together, our results provide direct evidence that aberrant expression of LYL1 plays a role in lymphomagenesis.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan; Shiga Med Ctr Adults, Shiga, Japan; Aino Univ, Fac Nursing & Rehabil, Osaka, Japan	Kyoto University	Toyokuni, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan.	toyokuni@path1.med.kyoto-u.ac.jp; yamada@aino.ac.jp	Toyokuni, Shinya/ABE-7714-2021; Zhong, Yi/K-7419-2012; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109				Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Begley CG, 1999, BLOOD, V93, P2760; Chervinsky DS, 1999, MOL CELL BIOL, V19, P5025; Condorelli GL, 1996, CANCER RES, V56, P5113; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Ferrando AA, 2003, SEMIN HEMATOL, V40, P274, DOI 10.1016/S0037-1963(03)00195-1; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Ferrier R, 1999, ONCOGENE, V18, P995, DOI 10.1038/sj.onc.1202374; Gilmore TD, 1996, ONCOGENE, V13, P1367; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hjalt T, 2004, INT REV CYTOL, V236, P251, DOI 10.1016/S0074-7696(04)36006-7; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; Jones S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-226; KUO SS, 1991, ONCOGENE, V6, P961; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lazorchak A, 2005, TRENDS IMMUNOL, V26, P334, DOI 10.1016/j.it.2005.03.011; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Meng YS, 2005, LEUKEMIA, V19, P1941, DOI 10.1038/sj.leu.2403836; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Toyokuni S, 2003, PATHOL INT, V53, P259, DOI 10.1046/j.1320-5463.2003.01465.x; Toyokuni S, 1997, LAB INVEST, V76, P365; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; VISVADER J, 1991, ONCOGENE, V6, P187; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wilm B, 1998, P NATL ACAD SCI USA, V95, P8692, DOI 10.1073/pnas.95.15.8692; Wilson V, 2002, GENOME BIOL, V3, P30081, DOI [10.1186/gb-2002-3-6-reviews3008, DOI 10.1186/GB-2002-3-6-REVIEWS3008]; XIA Y, 1994, ONCOGENE, V9, P1437; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317	42	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6937	6947		10.1038/sj.onc.1210494	http://dx.doi.org/10.1038/sj.onc.1210494			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486074	Green Submitted			2022-12-25	WOS:000250188400009
J	Donatello, S; Fiorino, A; Degl'Innocenti, D; Alberti, L; Miranda, C; Gorla, L; Bongarzone, I; Rizzetti, MG; Pierotti, MA; Borrello, MG				Donatello, S.; Fiorino, A.; Degl'Innocenti, D.; Alberti, L.; Miranda, C.; Gorla, L.; Bongarzone, I.; Rizzetti, M. G.; Pierotti, M. A.; Borrello, M. G.			SH2B1 beta adaptor is a key enhancer of RET tyrosine kinase signaling	ONCOGENE			English	Article						RET; SH2B1; signaling	INSULIN-RECEPTOR KINASE; SH2 DOMAIN; CELLULAR-TRANSFORMATION; REGULATED KINASE; ACTIVATION LOOP; DOCKING SITE; PROTEIN; SH2-B-BETA; IDENTIFICATION; JAK2	The RET gene encodes two main isoforms of a receptor tyrosine kinase (RTK) implicated in various human diseases. Activating germ-line point mutations are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinomas, inactivating germ-line mutations for Hirschsprung's disease, while somatic rearrangements (RET/PTCs) are specific to papillary thyroid carcinomas. SH2B1 beta, a member of the SH2B adaptors family, and binding partner for several RTKs, has been recently described to interact with proto-RET. Here, we show that both RET isoforms and its oncogenic derivatives bind to SH2B1 beta through the SRC homology 2 (SH2) domain and a kinase activity-dependent mechanism. As a result, RET phosphorylates SH2B1 beta, which in turn enhances its autophosphorylation, kinase activity, and downstream signaling. RET tyrosine residues 905 and 981 are important determinants for functional binding of the adaptor, as removal of both autophosphorylation sites displaces its recruitment. Binding of SH2B1 beta appears to protect RET from dephosphorylation by protein tyrosine phosphatases, and might represent a likely mechanism contributing to its upregulation. Thus, overexpression of SH2B1 beta, by enhancing phosphorylation/activation of RET transducers, potentiates the cellular differentiation and the neoplastic transformation thereby induced, and counteracts the action of RET inhibitors. Overall, our results identify SH2B1 beta as a key enhancer of RET physiologic and pathologic activities.	Ist Nazl Tumori, IRCCS, Dept Expt Oncol, UO3, I-20133 Milan, Italy; Dept Expt Oncol, Res Unit 3, Milan, Italy; Dept Expt Oncol, Res Unit 4, Milan, Italy; FIRC Inst Mol Oncol Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Borrello, MG (corresponding author), Ist Nazl Tumori, IRCCS, Dept Expt Oncol, UO3, Via Venezian 1, I-20133 Milan, Italy.	mariagrazia.borrello@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017; Bongarzone, Italia/B-9544-2017; Fiorino, Antonio/D-5828-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848; Bongarzone, Italia/0000-0003-2530-9170; Fiorino, Antonio/0000-0002-2621-9276				Ahmed Z, 2003, BIOCHEM J, V371, P405, DOI 10.1042/BJ20021589; Ahmed Z, 2001, BIOCHEM SOC T, V29, P529, DOI 10.1042/BST0290529; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Albert L, 2003, J CELL PHYSIOL, V195, P168, DOI 10.1002/jcp.10252; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Besser D, 1999, MOL CELL BIOL, V19, P1401; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Canu N, 1997, J NEUROCHEM, V68, P1390; Carlomagno F, 2002, CANCER RES, V62, P1077; Cuccuru G, 2004, JNCI-J NATL CANCER I, V96, P1006, DOI 10.1093/jnci/djh184; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Dhe-Sirano D, 2004, NAT STRUCT MOL BIOL, V11, P968, DOI 10.1038/nsmb829; DONATELLO S, 2004, TUMORI, V4, P122; Duan CJ, 2004, MOL CELL BIOL, V24, P7435, DOI 10.1128/MCB.24.17.7435-7443.2004; Gorla L, 2006, CELL SIGNAL, V18, P2272, DOI 10.1016/j.cellsig.2006.05.016; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; Hennige AM, 2001, ENDOCRINOLOGY, V142, P4441, DOI 10.1210/en.142.10.4441; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200; Kong M, 2002, J BIOL CHEM, V277, P15962, DOI 10.1074/jbc.M102777200; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; Kurzer JH, 2004, MOL CELL BIOL, V24, P4557, DOI 10.1128/MCB.24.10.4557-4570.2004; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; O'Brien KB, 2003, J BIOL CHEM, V278, P11970, DOI 10.1074/jbc.M210765200; Ohtsuka S, 2002, MOL CELL BIOL, V22, P3066, DOI 10.1128/MCB.22.9.3066-3077.2002; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ren DC, 2005, CELL METAB, V2, P95, DOI 10.1016/j.cmet.2005.07.004; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Roccato E, 2005, J BIOL CHEM, V280, P3382, DOI 10.1074/jbc.M407522200; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Wang CC, 1998, J ELECTROCERAM, V2, P273, DOI 10.1023/A:1009978607621; Yousaf N, 2001, J BIOL CHEM, V276, P40940, DOI 10.1074/jbc.M104191200; Zhang Y, 2006, J CELL SCI, V119, P1666, DOI 10.1242/jcs.02845	47	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6546	6559		10.1038/sj.onc.1210480	http://dx.doi.org/10.1038/sj.onc.1210480			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471236				2022-12-25	WOS:000249919800008
J	Silva, RLE; Shen, J; Hackett, SF; Kachi, S; Akiyama, H; Kiuchi, K; Yokoi, K; Hatara, MC; Lauer, T; Aslam, S; Gong, YY; Xiao, WH; Khu, NH; Thut, C; Campochiaro, PA				Silva, Raquel Lima e; Shen, Jikui; Hackett, Sean F.; Kachi, Shu; Akiyama, Hideo; Kiuchi, Katsuji; Yokoi, Katsutoshi; Hatara, Maria C.; Lauer, Thomas; Aslam, Sadia; Gong, Yuan Yuan; Xiao, Wei-Hong; Khu, Naw Htee; Thut, Catherine; Campochiaro, Peter A.			The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization	FASEB JOURNAL			English	Article						age-related macular degeneration; angiogenesis; chemokines; diabetic retinopathy; inflammation	ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; LYMPHOCYTE CHEMOATTRACTANT; CHEMOKINE RECEPTORS; MOLECULAR-CLONING; PROGENITOR CELLS; EXPRESSION; SDF-1; RETINOPATHY; MODEL	Hypoxia causes increased expression of several proteins that have the potential to promote neovascularization. Vascular endothelial growth factor (VEGF) is up-regulated by hypoxia in the retina and plays a central role in the development of several types of ocular neovascularization, but the effects of other hypoxia-regulated proteins are less clear. Stromal-derived factor-1 (SDF-1) and its receptor, CXCR4, have hypoxia response elements in the promoter regions of their genes and are increased in hypoxic liver and heart. In this study, we found that SDF-1 and CXCR4 are increased in hypoxic retina, with SDF-1 localized in glial cells primarily near the surface of the retina and CXCR4 localized in bone marrow-derived cells. Glial cells also expressed CXCR4, which suggested the possibility of autocrine stimulation, but influx of bone marrow-derived cells is the major source of increased levels of CXCR4. High levels of VEGF in the retina in the absence of hypoxia also increased levels of Cxcr4 and Sdf1 mRNA. CXCR4 antagonists reduced influx of bone marrow-derived cells into ischemic retina and strongly suppressed retinal neovascularization, VEGF-induced subretinal neovascularization, and choroidal neovascularization. These data suggest that SDF-1 and CXCR4 contribute to the involvement of bone marrow-derived cells and collaborate with VEGF in the development of several types of ocular neovascularization. They provide new targets for therapeutic intervention that may help to bolster and supplement effects obtained with VEGF antagonists.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Merck & Co Inc, Dept Ophthalm Res, West Point, PA USA	Johns Hopkins University; Johns Hopkins University; Merck & Company	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@jhmi.edu			NEI NIH HHS [P30EY1765, EY012609] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765, R01EY012609] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; AMOAKU WMK, 1990, EYE, V4, P195, DOI 10.1038/eye.1990.26; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brooks HL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1801, DOI 10.1001/archopht.122.12.1801; Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869; Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659; Klein R, 1992, Trans Am Ophthalmol Soc, V90, P561; KLEIN R, 1995, DIABETES AM, P293; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Murdoch C, 1999, CYTOKINE, V11, P704, DOI 10.1006/cyto.1998.0465; Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; OBERLIN E, 1996, NATURE, P382; Ohno S, 2004, J RHEUMATOL, V31, P1362; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; Verbeke G, 2000, LINEAR MIXED MODELS	50	119	130	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3219	3230		10.1096/fj.06-7359com	http://dx.doi.org/10.1096/fj.06-7359com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17522382				2022-12-25	WOS:000249781600022
J	Vincent, A; Perrais, M; Desseyn, JL; Aubert, JP; Pigny, P; Van Seuningen, I				Vincent, A.; Perrais, M.; Desseyn, J-L; Aubert, J-P; Pigny, P.; Van Seuningen, I.			Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells	ONCOGENE			English	Article						mucin; 11p15; methylation; acetylation; cancer; epithelial	TRANSCRIPTIONAL REGULATION; BILE-ACIDS; EXPRESSION; PROMOTER; CARCINOMA; HYPERMETHYLATION; IDENTIFICATION; CHROMOSOME-11; DEACETYLASES; SUPPRESSION	The human genes MUC2, MUC5AC, MUC5B and MUC6 are clustered on chromosome 11 and encode large secreted gel-forming mucins. The frequent occurrence of their silencing in cancers and the GC-rich structure of their promoters led us to study the influence of epigenetics on their expression. Pre- and post- confluent cells were treated with demethylating agent 5-aza-2 '-deoxycytidine and histone deacetylase ( HDAC) inhibitor, trichostatin A. Mapping of methylated cytosines was performed by bisulfate-treated genomic DNA sequencing. Histone modi. cation status at the promoters was assessed by chromatin immunoprecipitation assays. Our results indicate that MUC2 was regulated by site-specific DNA methylation associated with establishment of a repressive histone code, whereas hypermethylation of MUC5B promoter was the major mechanism responsible for its silencing. DNA methyltransferase 1 was identified by small interfering RNA approach as a regulator of MUC2 and MUC5B endogenous expression that was potentiated by HDAC2. MUC2 and MUC5B epigenetic regulation was cellspecific, depended on cell differentiation status and inhibited their activation by Sp1. The expression of MUC5AC was rarely influenced by epigenetic mechanisms and methylation of MUC6 promoter was not correlated to its silencing. In conclusion, this study demonstrates the important role for methylation and/or histone modi. cations in regulating the 11p15 mucin genes in epithelial cancer cells.	INSERM, U560, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Van Seuningen, I (corresponding author), INSERM, U560, Place de Verdun, F-59045 Lille, France.	isabelvs@lille.inserm.fr	Desseyn, Jean-Luc/M-5070-2018; Vincent, Audrey/I-2934-2016; VAN SEUNINGEN, Isabelle/N-6176-2016	Desseyn, Jean-Luc/0000-0001-6876-8049; Vincent, Audrey/0000-0003-0058-2058; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694				Bernier JN, 1999, ATHLET THER TODAY, V4, P5, DOI 10.1123/att.4.5.5; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Copin MC, 2001, FRONT BIOSCI, V6, pD1264, DOI 10.2741/Copin; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; Desseyn JL, 2000, MOL BIOL EVOL, V17, P1175, DOI 10.1093/oxfordjournals.molbev.a026400; Fahrner JA, 2002, CANCER RES, V62, P7213; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Gratchev A, 1998, ANN NY ACAD SCI, V859, P180, DOI 10.1111/j.1749-6632.1998.tb11122.x; Gratchev A, 2001, CANCER LETT, V168, P71, DOI 10.1016/S0304-3835(01)00498-0; Hamada T, 2005, CANCER LETT, V227, P175, DOI 10.1016/j.canlet.2004.11.058; Hanski C, 1997, LAB INVEST, V77, P685; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Ho JJL, 2003, INT J ONCOL, V22, P273; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Koo JS, 1999, AM J RESP CELL MOL, V20, P43, DOI 10.1165/ajrcmb.20.1.3310; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Leteurtre E, 2004, BIOL CELL, V96, P145, DOI 10.1016/j.biolcel.2003.12.005; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; Mesquita P, 2003, CANCER LETT, V189, P129, DOI 10.1016/S0304-3835(02)00549-9; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; Reis CA, 1998, GLYCOCONJUGATE J, V15, P51, DOI 10.1023/A:1006939432665; Rousseau K, 2003, HYBRIDOMA HYBRIDOM, V22, P293, DOI 10.1089/153685903322538818; Siedow A, 2002, TUMOR BIOL, V23, P54, DOI 10.1159/000048689; Sylvester PA, 2001, J PATHOL, V195, P327; Van Seuningen I, 2000, BIOCHEM J, V348, P675; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; Yamada N, 2006, INT J CANCER, V119, P1850, DOI 10.1002/ijc.22047; Zhu P, 2004, CELL CYCLE, V3, P1240, DOI 10.4161/cc.3.10.1195	35	86	88	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6566	6576		10.1038/sj.onc.1210479	http://dx.doi.org/10.1038/sj.onc.1210479			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471237	Green Published			2022-12-25	WOS:000249919800010
J	Martinez-Moreno, M; Martinez-Ruiz, A; Alvarez-Barrientos, A; Gavilanes, F; Lamas, S; Rodriguez-Crespo, I				Martinez-Moreno, Monica; Martinez-Ruiz, Antonio; Alvarez-Barrientos, Alberto; Gavilanes, Francisco; Lamas, Santiago; Rodriguez-Crespo, Ignacio			Nitric oxide down-regulates caveolin-3 levels through the interaction with myogenin, its transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; S-NITROSYLATED PROTEINS; LOOP-HELIX PROTEINS; DNA-BINDING; MUSCLE DEVELOPMENT; C2C12 MYOBLASTS; EXPRESSION; INHIBITION; INDUCTION; SYNTHASE	Certain patients suffering from chronic diseases such as AIDS or cancer experience a constant cellular secretion of tumor necrosis factor alpha and other pro-inflammatory cytokines that results in a continuous release of nitric oxide (center dot NO) to the bloodstream. One immediate consequence of the deleterious action of center dot NO is weight loss and the progressive destruction of muscular mass in a process known as cachexia. We have previously reported that caveolin-3, a specific marker of muscle cells, becomes down-regulated by the action of center dot NO on muscular myotubes. We describe herein that the changes observed in caveolin-3 levels are due to the alteration of the DNA binding activity of the muscular transcription factor myogenin. In the presence of center dot NO, the binding of transcription factors from cell nuclear extracts of muscular tissues to the E boxes present in the caveolin-3 promoter become substantially reduced. When we purified recombinant myogenin and treated it with center dot NO donors, we could detect its S-nitrosylation by three independent methods, suggesting that very likely one of the cysteine residues of the molecule is being modified. Given the role of myogenin as a regulatory protein that determines the level of multiple muscle genes expressed during late myogenesis, our results might represent a novel mode of regulation of muscle development under conditions of nitric oxide-mediated toxicity.	Univ Complutense Madrid, Fac Ciencias Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Ctr Invest Biol, Inst Reina Sofia Invest Nefrol, Madrid 28040, Spain; Inst Salud Carlos III, Fdn Ctr Nacl Invest Cardiovasc, Madrid 28040, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Instituto de Salud Carlos III	Rodriguez-Crespo, I (corresponding author), Univ Complutense Madrid, Fac Ciencias Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.	nacho@bbm1.ucm.es	Alvarez-Barrientos, Alberto/L-9299-2014; Martínez, Mónica/J-9689-2014; Gavilanes, Francisco/K-9903-2014; Lamas, Santiago/G-7308-2015; Martínez-Ruiz, Antonio/A-5672-2009; Rodriguez-Crespo, J. Ignacio/M-1966-2018	Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Martínez, Mónica/0000-0002-1640-6297; Gavilanes, Francisco/0000-0003-1047-2362; Lamas, Santiago/0000-0001-5166-4155; Martínez-Ruiz, Antonio/0000-0001-5394-9824; Rodriguez-Crespo, J. Ignacio/0000-0002-2582-129X				Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; Chanoine C, 2004, DEV DYNAM, V231, P662, DOI 10.1002/dvdy.20174; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Cuenca J, 2006, AM J PATHOL, V169, P1567, DOI 10.2353/ajpath.2006.060109; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Di Marco S, 2005, MOL CELL BIOL, V25, P6533, DOI 10.1128/MCB.25.15.6533-6545.2005; Fan X, 2003, J BIOL CHEM, V278, P10232, DOI 10.1074/jbc.M209911200; Fang KZ, 1998, BIOCHEM BIOPH RES CO, V252, P535, DOI 10.1006/bbrc.1998.9688; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Galbiati F, 1999, J BIOL CHEM, V274, P30315, DOI 10.1074/jbc.274.42.30315; Garban HJ, 2005, P NATL ACAD SCI USA, V102, P2632, DOI 10.1073/pnas.0409854102; Hongo F, 2005, BIOCHEM BIOPH RES CO, V336, P692, DOI 10.1016/j.bbrc.2005.08.150; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Maleki SJ, 2002, BIOCHEMISTRY-US, V41, P10888, DOI 10.1021/bi025528q; Maleki SJ, 1997, PROTEIN EXPRES PURIF, V9, P91, DOI 10.1006/prep.1996.0669; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Martinez-Ruiz A, 2005, METHOD ENZYMOL, V396, P131, DOI 10.1016/S0076-6879(05)96013-8; Martinez-Ruiz A, 2005, P NATL ACAD SCI USA, V102, P8525, DOI 10.1073/pnas.0407294102; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; Martinez-Ruiz A, 2004, ARCH BIOCHEM BIOPHYS, V423, P192, DOI 10.1016/j.abb.2003.12.006; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Navarro-Lerida I, 2004, J CELL SCI, V117, P1687, DOI 10.1242/jcs.01002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Shi Y, 2000, FREE RADICAL BIO MED, V29, P695, DOI 10.1016/S0891-5849(00)00364-6; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; Spinner DS, 2002, J MOL BIOL, V317, P431, DOI 10.1006/jmbi.2002.5440; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927; Tisdale MJ, 2001, FRONT BIOSCI, V6, pD164, DOI 10.2741/Tisdale; Vinals F, 2004, J BIOL CHEM, V279, P45766, DOI 10.1074/jbc.M408059200; WILLIAMS G, 1994, AM J PHYSIOL-REG I, V267, pR1020, DOI 10.1152/ajpregu.1994.267.4.R1020; Yun Z, 2005, MOL CELL BIOL, V25, P3040, DOI 10.1128/MCB.25.8.3040-3055.2005	39	7	8	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23044	23054		10.1074/jbc.M610751200	http://dx.doi.org/10.1074/jbc.M610751200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17519233	hybrid, Green Published			2022-12-25	WOS:000248577500007
J	Hansen, JE; Tse, CM; Chan, G; Heinze, ER; Nishimura, RN; Weisbart, RH				Hansen, James E.; Tse, Chung-Ming; Chan, Grace; Heinze, Emil R.; Nishimura, Robert N.; Weisbart, Richard H.			Intranuclear protein transduction through a nucleoside salvage pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENETRATES LIVING CELLS; CANCER-CELLS; ANTIBODY; TRANSPORTERS; DELIVERY; AUTOANTIBODY; THERAPY	Regulation of gene expression by intranuclear transduction of macromolecules such as transcription factors is an alternative to gene therapy for the treatment of numerous diseases. The identification of an effective intranuclear delivery vehicle and pathway for the transport of therapeutic macromolecules across plasma and nuclear membranes, however, has posed a significant challenge. The anti-DNA antibody fragment 3E10 Fv has received attention as a novel molecular delivery vehicle due to its penetration into living cells with specific nuclear localization, absence of toxicity, and successful delivery of therapeutic cargo proteins in vitro and in vivo. Elucidation of the pathway that allows 3E10 Fv to cross cell membranes is critical to the development of new molecular therapies. Here we show that 3E10 Fv penetrates cells through a nucleoside salvage transporter. 3E10 Fv is unable to penetrate into cells deficient in the equilibrative nucleoside transporter ENT2, and reconstitution of ENT2 into ENT2-deficient cells restores 3E10 Fv transport into cell nuclei. Our results represent the first demonstration of protein transport through a nucleoside salvage pathway. We expect that our finding will facilitate a variety of methods of gene regulation in the treatment of human diseases, open up new avenues of research in nucleoside salvage pathways, and enhance our understanding of the pathophysiology of autoimmune diseases.	VAGLAHS, Sepulveda, CA 91343 USA; Univ Calif Los Angeles, San Fernando Valley Program, Dept Med, Sylmar, CA 91342 USA; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21205 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Johns Hopkins University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Weisbart, RH (corresponding author), Vet Affairs Med Ctr 111S, 16111 Plummer St, Sepulveda, CA 91343 USA.	rweisbar@ucla.edu						Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Hansen JE, 2007, CANCER RES, V67, P1769, DOI 10.1158/0008-5472.CAN-06-3783; Hansen JE, 2006, BRAIN RES, V1088, P187, DOI 10.1016/j.brainres.2006.03.025; Huang M, 2004, NUCLEOS NUCLEOT NUCL, V23, P1445, DOI 10.1081/NCN-200027667; Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Kong W, 2004, CURR DRUG METAB, V5, P63, DOI 10.2174/1389200043489162; Mani RS, 1998, J BIOL CHEM, V273, P30818, DOI 10.1074/jbc.273.46.30818; Toan SV, 2003, PFLUG ARCH EUR J PHY, V447, P195, DOI 10.1007/s00424-003-1166-0; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Weisbart RH, 2004, INT J ONCOL, V25, P1867; Weisbart RH, 2003, CANCER LETT, V195, P211, DOI 10.1016/S0304-3835(03)00151-4; Weisbart RH, 1998, J AUTOIMMUN, V11, P539, DOI 10.1006/jaut.1998.0212; Weisbart RH, 2000, J IMMUNOL, V164, P6020, DOI 10.4049/jimmunol.164.11.6020; Zack DJ, 1996, J IMMUNOL, V157, P2082	15	40	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					20790	20793		10.1074/jbc.C700090200	http://dx.doi.org/10.1074/jbc.C700090200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17525162	hybrid			2022-12-25	WOS:000248047500002
J	Li, B; van der Donk, WA				Li, Bo; van der Donk, Wilfred A.			Identification of essential catalytic residues of the cyclase NisC involved in the biosynthesis of nisin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT METHIONINE SYNTHASE; PEPTIDE ANTIBIOTIC NISIN; ESCHERICHIA-COLI ADA; ZINC-THIOLATE COMPLEXES; PROTEIN FARNESYLTRANSFERASE; LACTICIN-481 SYNTHETASE; LANTIBIOTIC NISIN; POSTTRANSLATIONAL MODIFICATION; LANTHIONINE FORMATION; BIOLOGICAL-ACTIVITY	Nisin is a post-translationally modified antimicrobial peptide that has been widely used in the food industry for several decades. It contains five cyclic thioether cross-links of varying sizes that are installed by a single enzyme, NisC, that catalyzes the addition of cysteines to dehydroamino acids. The recent x-ray crystal structure of NisC has provided the first insights into the catalytic residues responsible for the cyclization step during nisin biosynthesis. In this study, the conserved residues His(212), Arg(280), Asp(141), and Tyr(285) as well as the ligands to the zinc in the active site (Cys(284), Cys(330), and His(331)) were substituted by site-directed mutagenesis. Binding studies showed that all mutants had similar affinities for NisA. Activity assays showed that whereas His(212) and Asp(141) were essential for correct cyclization as judged by the antimicrobial activity of the final product, Arg(280) and Tyr(285) were not. Mutation of zinc ligands to alanine also abolished the enzymatic activity, and these mutant proteins were shown to contain decreased levels of zinc. These results show that the zinc is essential for activity and support a model in which the zinc is used to activate the cysteines in the substrate for nucleophilic attack. These findings also argue against an essential role of Arg(280) and Tyr(285) as an active site general acid/base in the mechanism of cyclization.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	van der Donk, WA (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	vddonk@uiuc.edu	Li, Bo/H-8516-2013; van der Donk, Wilfred/K-2961-2015	van der Donk, Wilfred/0000-0002-5467-7071; Li, Bo/0000-0002-8019-8891				BEDNAR RA, 1990, BIOCHEMISTRY-US, V29, P3684, DOI 10.1021/bi00467a014; Bierbaum G, 1996, APPL ENVIRON MICROB, V62, P385, DOI 10.1128/AEM.62.2.385-392.1996; Brand U, 2001, INORG CHEM, V40, P6151, DOI 10.1021/ic0105112; Bregant S, 2005, J ORG CHEM, V70, P2430, DOI 10.1021/jo048222t; Breksa AP, 1999, BIOCHEMISTRY-US, V38, P13991, DOI 10.1021/bi991003v; Breukink E, 2006, NAT REV DRUG DISCOV, V5, P321, DOI 10.1038/nrd2004; Burrage S, 2000, CHEM-EUR J, V6, P1455, DOI 10.1002/(SICI)1521-3765(20000417)6:8<1455::AID-CHEM1455>3.3.CO;2-D; Chan WC, 1996, FEBS LETT, V390, P129, DOI 10.1016/0014-5793(96)00638-2; CHAN WC, 1989, FEBS LETT, V252, P29, DOI 10.1016/0014-5793(89)80884-1; Chatterjee C, 2005, CHEM REV, V105, P633, DOI 10.1021/cr030105v; Chatterjee C, 2005, J AM CHEM SOC, V127, P15332, DOI 10.1021/ja0543043; Chatterjee C, 2006, CHEM BIOL, V13, P1109, DOI 10.1016/j.chembiol.2006.08.015; Chen P, 1998, APPL ENVIRON MICROB, V64, P2335; Chiou SJ, 2003, P NATL ACAD SCI USA, V100, P3695, DOI 10.1073/pnas.0637221100; Chiou SJ, 2000, INORG CHEM, V39, P4347, DOI 10.1021/ic000505q; Cotter PD, 2005, CURR PROTEIN PEPT SC, V6, P61, DOI 10.2174/1389203053027584; ENGELKE G, 1992, APPL ENVIRON MICROB, V58, P3730, DOI 10.1128/AEM.58.11.3730-3743.1992; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Evans JC, 2002, STRUCTURE, V10, P1159, DOI 10.1016/S0969-2126(02)00796-7; FUKASE K, 1992, B CHEM SOC JPN, V65, P2227, DOI 10.1246/bcsj.65.2227; Gonzalez JC, 1996, BIOCHEMISTRY-US, V35, P12228, DOI 10.1021/bi9615452; Goulding CW, 1997, BIOCHEMISTRY-US, V36, P15749, DOI 10.1021/bi971988l; Harris CM, 2002, BIOCHEMISTRY-US, V41, P10554, DOI 10.1021/bi020349u; Helfrich M, 2007, BIOCHEMISTRY-US, V46, P3224, DOI 10.1021/bi062124f; Hightower KE, 1998, BIOCHEMISTRY-US, V37, P15555, DOI 10.1021/bi981525v; Hsu STD, 2004, NAT STRUCT MOL BIOL, V11, P963, DOI 10.1038/nsmb830; Huang CC, 1997, J BIOL CHEM, V272, P20; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Ibrahim MM, 2005, INORG CHEM, V44, P8531, DOI 10.1021/ic0508270; Jack RW, 2000, CURR OPIN CHEM BIOL, V4, P310, DOI 10.1016/S1367-5931(00)00094-6; Ji M, 2005, INORG CHEM, V44, P3518, DOI 10.1021/ic0484147; Kluskens LD, 2005, BIOCHEMISTRY-US, V44, P12827, DOI 10.1021/bi050805p; Koponen O, 2002, MICROBIOL-SGM, V148, P3561, DOI 10.1099/00221287-148-11-3561; Krum JG, 2002, BIOCHEMISTRY-US, V41, P5005, DOI 10.1021/bi0255221; Kuipers A, 2004, J BIOL CHEM, V279, P22176, DOI 10.1074/jbc.M312789200; KUIPERS OP, 1995, J BIOL CHEM, V270, P27299, DOI 10.1074/jbc.270.45.27299; Kuipers OP, 1996, ANTON LEEUW INT J G, V69, P161, DOI 10.1007/BF00399421; Li B, 2006, SCIENCE, V311, P1464, DOI 10.1126/science.1121422; Li YM, 1996, SCIENCE, V274, P1188, DOI 10.1126/science.274.5290.1188; Melnick JG, 2006, J INORG BIOCHEM, V100, P1147, DOI 10.1016/j.jinorgbio.2005.12.023; Miller LM, 2006, J AM CHEM SOC, V128, P1420, DOI 10.1021/ja057203d; Morlok MM, 2005, J AM CHEM SOC, V127, P14039, DOI 10.1021/ja0536670; Okeley NM, 2003, BIOCHEMISTRY-US, V42, P13613, DOI 10.1021/bi0354942; Okeley NM, 2000, ORG LETT, V2, P3603, DOI 10.1021/ol006485d; Osapay G, 1997, J MED CHEM, V40, P2241, DOI 10.1021/jm960850i; OSAPAY G, 1995, INT J PEPT PROT RES, V46, P290; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Parkin G, 2004, CHEM REV, V104, P699, DOI 10.1021/cr0206263; Paul M, 2005, MINI-REV ORG CHEM, V2, P23, DOI 10.2174/1570193052774108; Pejchal R, 2005, PLOS BIOL, V3, P254, DOI 10.1371/journal.pbio.0030031; Penner-Hahn J, 2007, CURR OPIN CHEM BIOL, V11, P166, DOI 10.1016/j.cbpa.2007.02.038; Rew Y, 2002, J MED CHEM, V45, P3746, DOI 10.1021/jm020108k; Rollema HS, 1996, EUR J BIOCHEM, V241, P716, DOI 10.1111/j.1432-1033.1996.00716.x; Rombach M, 2006, INORG CHEM, V45, P4571, DOI 10.1021/ic060301v; Rozema DB, 1999, BIOCHEMISTRY-US, V38, P13138, DOI 10.1021/bi990794y; Sun LJ, 2001, BIOCHEMISTRY-US, V40, P11596, DOI 10.1021/bi011001m; Walsh C., 2003, ANTIBIOTICS ACTIONS; Wilker JJ, 1997, INORG CHEM, V36, P969, DOI 10.1021/ic961082o; WILKER JJ, 1995, J AM CHEM SOC, V117, P8682, DOI 10.1021/ja00138a031; Xie LL, 2002, BIOCHEM BIOPH RES CO, V295, P952, DOI 10.1016/S0006-291X(02)00783-0; Zhang XG, 2007, J AM CHEM SOC, V129, P2212, DOI 10.1021/ja067672v; Zhou H, 2002, ORG LETT, V4, P1335, DOI 10.1021/ol025629g; Zhou ZHS, 1999, BIOCHEMISTRY-US, V38, P15915, DOI 10.1021/bi992062b; Zhu YT, 2003, ORG BIOMOL CHEM, V1, P3304, DOI 10.1039/b304945k	64	66	66	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21169	21175		10.1074/jbc.M701802200	http://dx.doi.org/10.1074/jbc.M701802200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17513866	hybrid			2022-12-25	WOS:000248047500043
J	Nobles, KN; Guan, ZQ; Xiao, KH; Oas, TG; Lefkowitz, RJ				Nobles, Kelly N.; Guan, Ziqiang; Xiao, Kunhong; Oas, Terrence G.; Lefkowitz, Robert J.			The active conformation of beta-arrestin1 - Direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins1 and -2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-REGULATED KINASES; BETA-ARRESTIN; VISUAL ARRESTIN; CRYSTAL-STRUCTURE; PHOSPHORYLATION-RECOGNITION; NONVISUAL ARRESTINS; CARBOXYL-TERMINUS; BINDING STATE; ACTIVATION	beta-Arrestins are multifunctional adaptor proteins that regulate seven transmembrane-spanning receptor (7TMR) desensitization and internalization and also initiate alternative signaling pathways. Studies have shown that beta-arrestins undergo a conformational change upon interaction with agonist-occupied, phosphorylated 7TMRs. Although conformational changes have been reported for visual arrestin and beta-arrestin2, these studies are not representative of conformational changes in beta-arrestin1. Accordingly, in this study, we determine conformational changes in beta-arrestin1 using limited tryptic proteolysis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis in the presence of a phosphopeptide derived from the C terminus of the V-2 vasopressin receptor (V(2)Rpp) or the corresponding unphosphorylated peptide (V(2)Rnp). V(2)Rpp binds specifically to beta-arrestin1 causing significant conformational changes, whereas V(2)Rnp does not alter the conformation of beta-arrestin1. Upon V(2)Rpp binding, we show that the previously shielded Arg(393) becomes accessible, which indicates release of the C terminus. Moreover, we show that Arg(285) becomes more accessible, and this residue is located in a region of beta-arrestin1 responsible for stabilization of its polar core. These two findings demonstrate "activation" of beta-arrestin1, and we also show a functional consequence of the release of the C terminus of beta-arrestin1 by enhanced clathrin binding. In addition, we show marked protection of the N-domain of beta-arrestin1 in the presence of V(2)Rpp, which is consistent with previous studies suggesting the N-domain is responsible for recognizing phosphates in 7TMRs. A striking difference in conformational changes is observed in beta-arrestin1 when compared with beta-arrestin2, namely the flexibility of the inter-domain hinge region. This study represents the first direct evidence that the "receptor-bound" conformations of beta-arrestins1 and 2 are different.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Oas, Terrence/F-8916-2011; Xiao, Kunhong/AAG-4275-2020; Guan, Ziqiang/AAE-5110-2019; Lefkowitz, Robert/AAW-2649-2021	Oas, Terrence/0000-0002-3067-2743; Xiao, Kunhong/0000-0002-1069-1226; 	NHLBI NIH HHS [HL70631, HL16037] Funding Source: Medline; NIGMS NIH HHS [GM069338] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R01HL070631, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM069338] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200; Bruchas MR, 2006, J BIOL CHEM, V281, P18081, DOI 10.1074/jbc.M513640200; Carter JM, 2005, J MOL BIOL, V351, P865, DOI 10.1016/j.jmb.2005.06.048; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; FREEDMAN NJ, 1996, RECENT PROG HORM RES, V51, P352; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; Gurevich VV, 2006, PHARMACOL THERAPEUT, V110, P465, DOI 10.1016/j.pharmthera.2005.09.008; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hanson SM, 2006, J BIOL CHEM, V281, P9765, DOI 10.1074/jbc.M510738200; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDowell JH, 2001, INVEST OPHTH VIS SCI, V42, P1439; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Miller WE, 2003, J BIOL CHEM, V278, P21663, DOI 10.1074/jbc.M303219200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Raman D, 2003, J NEUROCHEM, V84, P1040, DOI 10.1046/j.1471-4159.2003.01598.x; Shilton BH, 2002, EUR J BIOCHEM, V269, P3801, DOI 10.1046/j.1432-1033.2002.03071.x; Song XF, 2006, J BIOL CHEM, V281, P21491, DOI 10.1074/jbc.M603659200; Sutton RB, 2005, J MOL BIOL, V354, P1069, DOI 10.1016/j.jmb.2005.10.023; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Xiao KH, 2004, J BIOL CHEM, V279, P55744, DOI 10.1074/jbc.M409785200	46	95	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21370	21381		10.1074/jbc.M611483200	http://dx.doi.org/10.1074/jbc.M611483200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17513300	hybrid			2022-12-25	WOS:000248047500065
J	Zhong, XT; Desilva, T; Lin, L; Bodine, P; Bhat, RA; Presman, E; Pocas, J; Stahl, M; Kriz, R				Zhong, Xiaotian; Desilva, Thamara; Lin, Laura; Bodine, Peter; Bhat, Ramesh A.; Presman, Eleonora; Pocas, Jennifer; Stahl, Mark; Kriz, Ron			Regulation of secreted frizzled-related protein-1 by heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTORS; TYROSINE SULFATION; TYROSYLPROTEIN SULFOTRANSFERASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; AMINO-TERMINUS; SPEMANN ORGANIZER; LIGAND-BINDING; P-SELECTIN; WNT	Secreted Frizzled-related protein-1 (sFRP-1) belongs to a class of extracellular antagonists that modulate Wnt signaling pathways by preventing ligand-receptor interactions among Wnts and Frizzled membrane receptor complexes. sFRP-1 and Wnts are heparin-binding proteins, and their interaction can be stabilized by heparin in vitro. Here we report that heparin can specifically enhance recombinant sFRP-1 accumulation in a cell type-specific manner. The effect requires O-sulfation in heparin, and involves fibroblast growth factor-2 as well as fibroblast growth factor receptor-1. Interestingly, further investigation uncovers that heparin can also affect the post-translational modification of sFRP-1. We demonstrate that sFRP-1 is posttranslationally modified by tyrosine sulfation at tyrosines 34 and 36, which is inhibited by the treatment of heparin. The results suggest that accumulation of sFRP-1 induced by heparin is in part due to the relative stabilization of unsulfated sFRP-1 and the direct stabilization by heparin. The study has revealed a multifaceted regulation on sFRP-1 protein by heparin.	Wyeth Ayerst Res, Dept Chem Screening Sci, Cambridge, MA 02140 USA; Wyeth Ayerst Res, Dept Womens Hlth & Musculoskeletal Biol, Collegeville, PA 19426 USA	Pfizer; Pfizer	Zhong, XT (corresponding author), 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	xzhong@wyeth.com						BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat RA, 2004, PROTEIN EXPRES PURIF, V37, P327, DOI 10.1016/j.pep.2004.06.029; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; Chong JM, 2002, J BIOL CHEM, V277, P5134, DOI 10.1074/jbc.M108533200; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Dale TC, 1998, BIOCHEM J, V329, P209; Dong JF, 2001, J BIOL CHEM, V276, P16690, DOI 10.1074/jbc.M101035200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kispert A, 1996, DEVELOPMENT, V122, P3627; KLINT P, 1999, FRONT BIOSCI, V4, P165; LEE RWH, 1983, J BIOL CHEM, V258, P1326; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Salic AN, 1997, DEVELOPMENT, V124, P4739; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wolf V, 1997, FEBS LETT, V417, P385, DOI 10.1016/S0014-5793(97)01324-0; Zhong XT, 2004, FEBS LETT, V562, P111, DOI 10.1016/S0014-5793(04)00191-7	53	29	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20523	20533		10.1074/jbc.M609096200	http://dx.doi.org/10.1074/jbc.M609096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17500071	hybrid			2022-12-25	WOS:000247819300055
J	Kobayashi, T; Habuchi, H; Tamura, K; Ide, H; Kimata, K				Kobayashi, Takashi; Habuchi, Hiroko; Tamura, Koji; Ide, Hiroyuki; Kimata, Koji			Essential role of heparan sulfate 2-O-sulfotransferase in chick limb bud patterning and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; APICAL ECTODERMAL RIDGE; VERTEBRATE LIMB; EXPRESSION PATTERNS; MOUSE DEVELOPMENT; CRYSTAL-STRUCTURE; MICE DEFICIENT; BINDING-SITES; BASIC FGF; 6-O-SULFOTRANSFERASE	The interactions of heparan sulfate (HS) with heparin-binding growth factors, such as fibroblast growth factors (FGFs), depend greatly on the chain structures. O-Sulfations at various positions on the chain are major factors determining HS structure; therefore, O-sulfation patterns may play a crucial role in controlling the developmental and morphogenetic processes of various tissues and organs by spatiotemporally regulating the activities of heparin-binding growth factors. In a previous study, we found that HS-2-O-sulfotransferase is strongly expressed throughout the mesoderm of chick limb buds during the early stages of development. Here we show that inhibition of HS-2-O-sulfotransferase in the prospective limb region by small inhibitory RNA resulted in the truncation of limb buds and reduced Fgf-8 expression in the apical ectodermal ridge. The treatment also reduced Fgf-10 expression in the mesenchyme. Moreover 2-O-sulfated HS, normally abundant in the basement membranes and mesoderm under ectoderm in limb buds, was significantly reduced in the treated buds. Phosphorylation levels of ERK and Akt were up-regulated in such truncated buds. Thus, we have shown for the first time that 2-O-sulfation of HS is essential for the FGF signaling required for limb bud development and outgrowth.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 48011, Japan; Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Aoba Ku, Sendai, Miyagi 980, Japan	Aichi Medical University; Tohoku University	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 48011, Japan.	kimata@amugw.aichi-med-u.ac.jp	KOBAYASHI, TAKASHI/G-3798-2014	KOBAYASHI, TAKASHI/0000-0001-9358-6829				Agarwal P, 2003, DEVELOPMENT, V130, P623, DOI 10.1242/dev.00191; Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903; Bink RJ, 2003, J BIOL CHEM, V278, P31118, DOI 10.1074/jbc.M213124200; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cadwallader AB, 2006, DEV DYNAM, V235, P3432, DOI 10.1002/dvdy.20990; Chen E, 2005, DEV BIOL, V284, P364, DOI 10.1016/j.ydbio.2005.05.032; Church VL, 2002, INT J DEV BIOL, V46, P927; Corson LB, 2003, DEVELOPMENT, V130, P4527, DOI 10.1242/dev.00669; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Dealy CN, 1997, DEV BIOL, V184, P343, DOI 10.1006/dbio.1997.8525; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Eblaghie MC, 2003, CURR BIOL, V13, P1009, DOI 10.1016/S0960-9822(03)00381-6; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Habuchi H, 2007, J BIOL CHEM, V282, P15578, DOI 10.1074/jbc.M607434200; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; Kamimura K, 2006, J CELL BIOL, V174, P773, DOI 10.1083/jcb.200603129; Kawakami Y, 2001, CELL, V104, P891, DOI 10.1016/S0092-8674(01)00285-9; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Koziel L, 2004, DEV CELL, V6, P801, DOI 10.1016/j.devcel.2004.05.009; Lewandoski M, 2000, NAT GENET, V26, P460, DOI 10.1038/82609; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Loo BM, 2002, J BIOL CHEM, V277, P32616, DOI 10.1074/jbc.M204961200; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; MORITA H, 1994, LAB INVEST, V71, P528; Nakato H, 2002, BBA-GEN SUBJECTS, V1573, P312, DOI 10.1016/S0304-4165(02)00398-7; Niswander L, 2003, NAT REV GENET, V4, P133, DOI 10.1038/nrg1001; NISWANDER L, 1994, MOL REPROD DEV, V39, P83, DOI 10.1002/mrd.1080390113; Niu S, 1996, DEV DYNAM, V207, P25, DOI 10.1002/(SICI)1097-0177(199609)207:1<25::AID-AJA3>3.0.CO;2-Y; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; Norton WHJ, 2005, DEVELOPMENT, V132, P4963, DOI 10.1242/dev.02084; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Pan Y, 2006, DEVELOPMENT, V133, P4933, DOI 10.1242/dev.02679; PARR BA, 1993, DEVELOPMENT, V119, P247; Pekarik V, 2003, NAT BIOTECHNOL, V21, P93, DOI 10.1038/nbt770; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pratt T, 2006, J NEUROSCI, V26, P6911, DOI 10.1523/JNEUROSCI.0505-06.2006; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sedita J, 2004, DEV DYNAM, V231, P782, DOI 10.1002/dvdy.20173; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Smith TG, 2006, FEBS LETT, V580, P4242, DOI 10.1016/j.febslet.2006.06.081; Stickens D, 2005, DEVELOPMENT, V132, P5055, DOI 10.1242/dev.02088; Tamura K, 2003, MECH DEVELOP, V120, P199, DOI 10.1016/S0925-4773(02)00411-2; Tickle C, 2001, CURR OPIN GENET DEV, V11, P476, DOI 10.1016/S0959-437X(00)00220-3; Tickle C, 2003, DEV CELL, V4, P449, DOI 10.1016/S1534-5807(03)00095-9; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; Vogel A, 1996, DEVELOPMENT, V122, P1737; Wilson VA, 2002, GLYCOCONJUGATE J, V19, P347, DOI 10.1023/A:1025325222530; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264; Yang Yingzi, 2003, Birth Defects Research, V69, P305, DOI 10.1002/bdrc.10026; YONEI S, 1995, DEV BIOL, V170, P542, DOI 10.1006/dbio.1995.1235; Yonei-Tamura S, 1999, DEV BIOL, V211, P133, DOI 10.1006/dbio.1999.9290; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	74	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19589	19597		10.1074/jbc.M610707200	http://dx.doi.org/10.1074/jbc.M610707200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17493930	hybrid			2022-12-25	WOS:000247650600033
J	Tanaka, T; Mizukoshi, T; Sasaki, K; Kohda, D; Masai, H				Tanaka, Taku; Mizukoshi, Toshimi; Sasaki, Kaori; Kohda, Daisuke; Masai, Hisao			Escherichia coli PriA protein, two modes of DNA binding and activation of ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-Y; HOMOLOGOUS RECOMBINATION; FORK BINDING; IN-VITRO; HELICASE; PRIMOSOME; SEQUENCE; MUTANTS; PATHWAY; DOMAIN	Escherichia coli PriA protein plays crucial roles in processing of arrested replication forks. PriA serves as a sensor/stabilizer for an arrested replication fork and eventually promotes restart of DNA replication through assembly of a primosome. PriA carries a 3' terminus binding pocket required for its high affinity binding to a specific arrested fork as well as for its biological functions. We show here that PriA binds to DNA in a manner either dependent on or independent of 3' terminus recognition. The former mode of binding requires the 3' terminus binding pocket present at the N- terminal half of the 181-residue DNA binding domain and exhibits specific bipartite interaction on the template DNA. The latter mode is independent of the pocket function, but requires the C-terminal half of the same domain. ATP hydrolysis activity of PriA can be stimulated in vitro by either of the two binding modes. We propose architecture of PriA bound to various arrested replication fork structures and discuss its implication in helicase activation and ATP hydrolysis.	Ajinomoto Co Inc, Inst Life Sci, Basic Anal Chem Grp, Kawasaki, Kanagawa 2108681, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan; Biomed Engn Res Inst, Dept Biol Struct, Suita, Osaka 5650874, Japan; Kyushu Univ, Med Inst Bioregulat, Div Struct Biol, Fukuoka 812, Japan	Ajinomoto Co Inc; Tokyo Metropolitan Institute of Medical Science; Kyushu University	Masai, H (corresponding author), Ajinomoto Co Inc, Inst Life Sci, Basic Anal Chem Grp, Kawasaki, Kanagawa 2108681, Japan.	hmasai@rinshoken.or.jp	Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776				Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Chen HW, 2004, J BIOL CHEM, V279, P38503, DOI 10.1074/jbc.M404769200; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Heller RC, 2005, MOL CELL, V17, P733, DOI 10.1016/j.molcel.2005.01.019; Jones JM, 2001, J MOL BIOL, V312, P935, DOI 10.1006/jmbi.2001.4930; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; Masai H, 1999, BIOCHIMIE, V81, P847, DOI 10.1016/S0300-9084(99)00211-4; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Mizukoshi T, 2003, J BIOL CHEM, V278, P42234, DOI 10.1074/jbc.C300285200; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; OUZOUNIS CA, 1991, NUCLEIC ACIDS RES, V19, P6953, DOI 10.1093/nar/19.24.6953; Sasaki K, 2006, BBA-PROTEINS PROTEOM, V1764, P157, DOI 10.1016/j.bbapap.2005.09.007; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; Tanaka T, 2006, J BIOL CHEM, V281, P3484, DOI 10.1074/jbc.M510979200; Tanaka T, 2003, GENES CELLS, V8, P251, DOI 10.1046/j.1365-2443.2003.00630.x; Tanaka T, 2002, J BIOL CHEM, V277, P38062, DOI 10.1074/jbc.M204397200; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; Xu LW, 2003, MOL CELL, V11, P817, DOI 10.1016/S1097-2765(03)00061-3	33	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19917	19927		10.1074/jbc.M701848200	http://dx.doi.org/10.1074/jbc.M701848200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17483094	hybrid			2022-12-25	WOS:000247650600066
J	Auxilien, S; El Khadali, F; Rasmussen, A; Douthwaite, S; Grosjean, H				Auxilien, Sylvie; El Khadali, Fatima; Rasmussen, Anette; Douthwaite, Stephen; Grosjean, Henri			Archease from Pyrococcus abyssi improves substrate specificity and solubility of a tRNA m(5)C Methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEDIMENTATION-VELOCITY ANALYSIS; PROTEIN-PROTEIN INTERACTIONS; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; MODIFIED NUCLEOSIDES; THERMOTOGA-MARITIMA; STRUCTURAL GENOMICS; HSP33 CHAPERONE; GEL-FILTRATION; IDENTIFICATION	Members of the archease superfamily of proteins are represented in all three domains of life. Archease genes are generally located adjacent to genes encoding proteins involved in DNA or RNA processing. Archease have therefore been predicted to play a modulator or chaperone role in selected steps of DNA or RNA metabolism, although the roles of archeases remain to be established experimentally. Here we report the function of one of these archeases from the hyperthermophile Pyrococcus abyssi. The corresponding gene (PAB1946) is located in a bicistronic operon immediately upstream from a second open reading frame (PAB1947), which is shown here to encode a tRNA m(5)C methyltransferase. In vitro, the purified recombinant methyltransferase catalyzes m(5)C formation at several cytosines within tRNAs with preference for C49. The specificity of the methyltransferase is increased by the archease. In solution, the archease exists as a monomer, trimer, and hexamer. Only the oligomeric states bind the methyltransferase and prevent its aggregation, in addition to hindering dimerization of the methyltransferaset-RNA complex. This P. abyssi system possibly reflects the general function of archeases in preventing protein aggregation and modulating the function of their accompanying proteins.	CNRS, LEBS, F-91198 Gif Sur Yvette, France; Univ Paris 11, Inst Genet & Microbiol, CNRS, F-91405 Orsay, France; CNRS, Lab Enzymol & Biochem Struct, F-91198 Gif Sur Yvette, France; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Southern Denmark	Auxilien, S (corresponding author), Inst Curie, CNRS, 26 Rue Ulm, F-75248 Paris, France.	Sylvie.Auxilien@lebs.cnrs-gif.fr		Douthwaite, Stephen/0000-0001-5468-8486				Agris PF, 1996, PROG NUCLEIC ACID RE, V53, P79, DOI 10.1016/S0079-6603(08)60143-9; Akhtar MW, 2004, J BIOL CHEM, V279, P55760, DOI 10.1074/jbc.M406333200; Alm EJ, 2005, GENOME RES, V15, P1015, DOI 10.1101/gr.3844805; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anantharaman V, 2004, PROTEINS, V56, P795, DOI 10.1002/prot.20140; Andersen NM, 2006, J MOL BIOL, V359, P777, DOI 10.1016/j.jmb.2006.04.007; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; Becker HF, 1997, J MOL BIOL, V274, P505, DOI 10.1006/jmbi.1997.1417; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Brule H, 1998, BIOCHIMIE, V80, P977, DOI 10.1016/S0300-9084(99)80003-0; Brzezicha B, 2006, NUCLEIC ACIDS RES, V34, P6034, DOI 10.1093/nar/gkl765; Bujnicki JM, 2004, NUCLEIC ACIDS RES, V32, P2453, DOI 10.1093/nar/gkh564; Canaves JM, 2004, PROTEINS, V56, P19, DOI 10.1002/prot.20141; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Dam J, 2005, BIOPHYS J, V89, P619, DOI 10.1529/biophysj.105.059568; Dam J, 2005, BIOPHYS J, V89, P651, DOI 10.1529/biophysj.105.059584; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Graf PCF, 2002, CELL MOL LIFE SCI, V59, P1624, DOI 10.1007/PL00012489; Grosjean H, 2007, PHYSIOLOGY AND BIOCHEMISTRY OF EXTREMOPHILES, P39; Gu WF, 2005, MOL CELL BIOL, V25, P8191, DOI 10.1128/MCB.25.18.8191-8201.2005; Gu XR, 1999, BIOCHEMISTRY-US, V38, P4053, DOI 10.1021/bi982364y; Janda I, 2004, STRUCTURE, V12, P1901, DOI 10.1016/j.str.2004.08.003; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; Jaroszewski L, 2005, PROTEINS, V61, P669, DOI 10.1002/prot.20542; KEITH JM, 1980, J BIOL CHEM, V255, P4636; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; King MY, 2002, BIOCHEMISTRY-US, V41, P11218, DOI 10.1021/bi026055q; Kirpekar F, 2001, RAPID COMMUN MASS SP, V15, P8, DOI 10.1002/1097-0231(20010115)15:1<8::AID-RCM185>3.0.CO;2-S; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; Lesley SA, 2002, P NATL ACAD SCI USA, V99, P11664, DOI 10.1073/pnas.142413399; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Nobles KN, 2002, NUCLEIC ACIDS RES, V30, P4751, DOI 10.1093/nar/gkf595; Price MN, 2005, NUCLEIC ACIDS RES, V33, P880, DOI 10.1093/nar/gki232; Romanowski MJ, 2002, PROTEINS, V47, P403, DOI 10.1002/prot.10102; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Schuck P, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P26; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SOWERS LC, 1987, BIOCHEM BIOPH RES CO, V148, P790, DOI 10.1016/0006-291X(87)90945-4; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; Tscherne JS, 1999, BIOCHEMISTRY-US, V38, P1884, DOI 10.1021/bi981880l; Vijayalakshmi J, 2001, STRUCTURE, V9, P367, DOI 10.1016/S0969-2126(01)00597-4; Yee A, 2002, P NATL ACAD SCI USA, V99, P1825, DOI 10.1073/pnas.042684599; [No title captured]	44	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18711	18721		10.1074/jbc.M607459200	http://dx.doi.org/10.1074/jbc.M607459200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17470432	hybrid			2022-12-25	WOS:000247475300009
J	Bush, CF; Jones, SV; Lyle, AN; Minneman, KP; Ressler, KJ; Hall, RA				Bush, Cristina F.; Jones, Seth V.; Lyle, Alicia N.; Minneman, Kenneth P.; Ressler, Kerry J.; Hall, Randy A.			Specificity of olfactory receptor interactions with other G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; ODORANT RECEPTOR; NUCLEOTIDE RECEPTORS; SURFACE EXPRESSION; MAMMALIAN SWEET; GENE-EXPRESSION; PATCH-CLAMP; OLIGOMERIZATION; DOMAIN; RAT	Studies on olfactory receptor ( OR) pharmacology have been hindered by the poor plasma membrane localization of most ORs in heterologous cells. We previously reported that association with the beta(2)-adrenergic receptor (beta(2)-AR) facilitates functional expression of the OR M71 at the plasma membrane of HEK-293 cells. In the present study, we examined the specificity of M71 interactions with other G protein-coupled receptors (GPCRs). M71 was co-expressed in HEK-293 cells with 42 distinct GPCRs, and the vast majority of these receptors had no significant effect on M71 surface expression. However, co-expression with three subtypes of purinergic receptor (P2Y(1)R, P2Y(2)R, and A(2A)R) resulted in markedly enhanced plasma membrane localization of M71. Agonist stimulation of M71 co-expressed with P2Y1R and P2Y2R activated the mitogen-activated protein kinase pathway via coupling of M71 to G alpha(o). We also examined the ability of beta(2)-AR, P2Y(1)R, P2Y(2)R, and A(2A)R to interact with and regulate ORs beyond M71. We found that coexpression of beta(2)-AR or the purinergic receptors enhanced the surface expression for an M71 subfamily member but not for several other ORs from different subfamilies. In addition, through chimeric receptor studies, we determined that the second transmembrane domain of beta(2)-AR is necessary for beta(2)-AR facilitation of M71 plasma membrane localization. These studies shed light on the specificity of OR interactions with other GPCRs and the mechanisms governing olfactory receptor trafficking.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Yerkes Natl Primate Ctr, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rhall@pharm.emory.edu	Ressler, Kerry J/N-8741-2018	Ressler, Kerry J/0000-0002-5158-1103; Hall, Randy/0000-0002-8318-8728; Lyle, Alicia/0000-0001-7527-9200				Alvaro JD, 1996, MOL PHARMACOL, V50, P583; Balasubramanian S, 2004, J BIOL CHEM, V279, P18840, DOI 10.1074/jbc.M313470200; Benton R, 2006, PLOS BIOL, V4, P240, DOI 10.1371/journal.pbio.0040020; Bozza T, 2002, J NEUROSCI, V22, P3033, DOI 10.1523/JNEUROSCI.22-08-03033.2002; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buzas B, 1997, NEUROSCIENCE, V76, P479, DOI 10.1016/S0306-4522(96)00242-4; Chen WC, 1998, GLIA, V22, P360, DOI 10.1002/(SICI)1098-1136(199804)22:4<360::AID-GLIA5>3.0.CO;2-7; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Filippov AK, 1998, J NEUROSCI, V18, P5170, DOI 10.1523/JNEUROSCI.18-14-05170.1998; Gaillard I, 2004, CELL MOL LIFE SCI, V61, P456, DOI 10.1007/s00018-003-3273-7; Gayle S, 2005, CELL TISSUE RES, V319, P27, DOI 10.1007/s00441-004-0979-2; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Gimelbrant AA, 1999, J NEUROCHEM, V72, P2301, DOI 10.1046/j.1471-4159.1999.0722301.x; Godfrey PA, 2004, P NATL ACAD SCI USA, V101, P2156, DOI 10.1073/pnas.0308051100; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P1692, DOI 10.1073/pnas.96.4.1692; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hague C, 2006, MOL PHARMACOL, V69, P45, DOI 10.1124/mol.105.014985; Hague C, 2004, P NATL ACAD SCI USA, V101, P13672, DOI 10.1073/pnas.0403854101; Hardy A, 2005, NEUROSCIENCE, V131, P717, DOI 10.1016/j.neuroscience.2004.10.034; Harikumar KG, 2006, BIOCHEMISTRY-US, V45, P14706, DOI 10.1021/bi061107n; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hegg CC, 2004, J NEUROPHYSIOL, V91, P1492, DOI 10.1152/jn.00670.2003; Hegg CC, 2003, J NEUROSCI, V23, P8291; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; JAHN K, 1995, N-S ARCH PHARMACOL, V352, P386; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaelin-Lang A, 1999, NEUROSCI LETT, V261, P189, DOI 10.1016/S0304-3940(99)00022-1; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kawai F, 1999, NAT NEUROSCI, V2, P133, DOI 10.1038/5686; Kikkawa H, 1998, MOL PHARMACOL, V53, P128, DOI 10.1124/mol.53.1.128; Ko HJ, 2006, BIOL CHEM, V387, P59, DOI 10.1515/BC.2006.009; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Larsson MC, 2004, NEURON, V43, P703, DOI 10.1016/j.neuron.2004.08.019; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Liberles SD, 2006, NATURE, V442, P645, DOI 10.1038/nature05066; Luo AH, 2002, BRAIN RES, V941, P62, DOI 10.1016/S0006-8993(02)02566-0; Matsuki M, 2006, P NATL ACAD SCI USA, V103, P1112, DOI 10.1073/pnas.0506954103; McClintock TS, 1997, MOL BRAIN RES, V48, P270, DOI 10.1016/S0169-328X(97)00099-5; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Paysan J, 2001, PFLUG ARCH EUR J PHY, V441, P579, DOI 10.1007/s004240000492; Prinster SC, 2006, J PHARMACOL EXP THER, V318, P974, DOI 10.1124/jpet.106.106526; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Thevenin D, 2005, PROTEIN SCI, V14, P2177, DOI 10.1110/ps.051409205; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; Uberti MA, 2003, MOL PHARMACOL, V64, P1379, DOI 10.1124/mol.64.6.1379; Ulas J, 2000, GLIA, V30, P352, DOI 10.1002/(SICI)1098-1136(200006)30:4<352::AID-GLIA40>3.0.CO;2-6; Vasquez C, 2003, NEUROSCIENCE, V118, P603, DOI 10.1016/S0306-4522(03)00024-1; Vassalli A, 2002, NEURON, V35, P681, DOI 10.1016/S0896-6273(02)00793-6; Vicentic A, 2002, J PHARMACOL EXP THER, V302, P58, DOI 10.1124/jpet.302.1.58; Von Dannecker LEC, 2006, P NATL ACAD SCI USA, V103, P9310, DOI 10.1073/pnas.0600697103; Watt WC, 2001, J BIOL CHEM, V276, P2047, DOI 10.1074/jbc.M006703200; Wekesa KS, 1999, BRAIN RES, V837, P117, DOI 10.1016/S0006-8993(99)01630-3; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	62	37	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19042	19051		10.1074/jbc.M610781200	http://dx.doi.org/10.1074/jbc.M610781200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17472961	hybrid			2022-12-25	WOS:000247475300046
J	Yoshizawa, JM; Li, C; Gershon, PD				Yoshizawa, Janice M.; Li, Changzheng; Gershon, Paul D.			Saltatory forward movement of a Poly(A) polymerase during Poly(A) tail addition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURES; RNA; POLYADENYLATION; COMPLEX; BINDING; POLYADENYLYLATION; HETERODIMER; MECHANISM	Vaccinia poly(A) polymerase (VP55) interacts with >= 33-nucleotide (nt) primers via uridylates at two sites (-27/-26 and -10). It adds similar to 30-nt poly(A) tails with a rapid, processive burst in which the first few nt are added without substantial primer movement, and addition of the remaining adenylates is dependent upon a six-uridylate tract at the extreme 3' end of the primer and accompanied by polymerase translocation. Interaction of VP55 with 2-aminopurine (2-AP)-containing primers was associated with a 3-fold enhancement in 2-AP fluorescence. In stopped-flow experiments, fluorescence intensity changed with time during the polyadenylation burst in a manner dependent upon the position of 2-AP, indicating a non-uniform isomerization of the polymerase-primer complex with time consistent with a discontinuous (saltatory) translocation mechanism. Three distinct translocatory phases could be discerned: a -10(U)-binding site forward movement, a -27/-26(UU)-binding site jump to -10, then a -27/-26(UU)-binding site movement further downstream. Poly(A) tail elongation showed no apparent pauses during these isomerizations. Fluorescence changes during polyadenylation of 2-AP-containing primers with short preformed oligo(A) tails reinforced the above observations. Primers composed entirely of oligo(U) (apart from the 2-AP sensor), in which the polymerase modules might be most able to "slide" uniformly, also showed the characteristic saltatory pattern of translocation. These data indicate, for the first time, a discontinuous mode of translocation for a non-templated polymerase.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA	University of California System; University of California Irvine	Gershon, PD (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Rm 1222, Irvine, CA 92717 USA.	pgershon@uci.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051953] Funding Source: NIH RePORTER; NIAID NIH HHS [T32AI007319-19] Funding Source: Medline; NIGMS NIH HHS [R01GM51953] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aphasizhev R, 2005, CELL MOL LIFE SCI, V62, P2194, DOI 10.1007/s00018-005-5198-9; Bard J, 2000, SCIENCE, V289, P1346, DOI 10.1126/science.289.5483.1346; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Delarue M, 2002, EMBO J, V21, P427, DOI 10.1093/emboj/21.3.427; Deng L, 1997, J BIOL CHEM, V272, P31542, DOI 10.1074/jbc.272.50.31542; Deng L, 1999, J MOL BIOL, V285, P1417, DOI 10.1006/jmbi.1998.2417; Gershon PD, 2000, NAT STRUCT BIOL, V7, P819, DOI 10.1038/79555; GERSHON PD, 1993, EMBO J, V12, P4705, DOI 10.1002/j.1460-2075.1993.tb06159.x; Gershon PD, 1998, SEMIN VIROL, V8, P343, DOI 10.1006/smvy.1997.0137; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1992, GENE DEV, V6, P1575, DOI 10.1101/gad.6.8.1575; Hall TMT, 2002, CURR OPIN STRUC BIOL, V12, P82, DOI 10.1016/S0959-440X(02)00293-2; Johnson L, 2004, J MOL BIOL, V337, P843, DOI 10.1016/j.jmb.2004.01.058; Kadaba S, 2006, RNA, V12, P508, DOI 10.1261/rna.2305406; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; LaCava J, 2005, CELL, V121, P713, DOI 10.1016/j.cell.2005.04.029; Li DN, 1997, EMBO J, V16, P1103, DOI 10.1093/emboj/16.5.1103; MANLEY JL, 1995, P NATL ACAD SCI USA, V92, P1800, DOI 10.1073/pnas.92.6.1800; Martin G, 2000, EMBO J, V19, P4193, DOI 10.1093/emboj/19.16.4193; MOSS B, 1975, J BIOL CHEM, V250, P4722; Moss B, 2001, FIELDS VIROLOGY, P2849; Moure CM, 2006, MOL CELL, V22, P339, DOI 10.1016/j.molcel.2006.03.015; Oguro A, 2002, CHEM BIOL, V9, P679, DOI 10.1016/S1074-5521(02)00163-1; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	25	5	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19144	19151		10.1074/jbc.M700183200	http://dx.doi.org/10.1074/jbc.M700183200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17488726	hybrid			2022-12-25	WOS:000247475300056
J	Long, XM; Lin, YS; Ortiz-Vega, S; Busch, S; Avruch, J				Long, Xiaomeng; Lin, Yenshou; Ortiz-Vega, Sara; Busch, Susann; Avruch, Joseph			The rheb switch 2 segment is critical for signaling to target of rapamycin complex 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; CELL-GROWTH; MAMMALIAN TARGET; RAS; ACTIVATION; GTPASE; MTOR; BINDING; TSC2; IDENTIFICATION	The small GTPase Rheb is a positive upstream regulator of the target of rapamycin ( TOR) complex 1 in mammalian cells and can bind directly to TOR complex 1. To identify the regions of the Rheb surface most critical for signaling to TOR complex 1, we created a set of 26 mutants wherein clusters of 1 - 5 putative solvent-exposed residues were changed to alanine, ultimately changing 65 residues distributed over the entire Rheb surface. The signaling function of these mutants was assessed by their ability, in comparison to wild type Rheb, to restore the phosphorylation of S6K1(Thr(389)) when expressed transiently in amino acid-deprived 293T cells. The major finding is that two mutants situated in the Rheb switch 2 segment, Y67A/I69A and I76A/ D77A, exhibit a near total loss of function, whereas extensive replacement of the switch 1 segment and other surface residues with alanines causes relatively little disturbance of Rheb rescue of S6K1 from amino acid withdrawal. This is surprising in view of the minimal impact of guanyl nucleotide on Rheb switch 2 configuration. The loss of function Rheb switch 2 mutants are well expressed and exhibit partial agonist function in amino acid-replete cells. They are unimpaired in their ability to bind GTP or mammalian ( m) TOR in vivo or in vitro, and the mTOR polypeptides retrieved with these inactive Rheb mutants exhibit kinase activity in vitro comparable with mTOR bound to wild type Rheb. We conclude that Rheb signaling to mTOR in vivo requires a Rheb switch 2-dependent interaction with an element other than the three known polypeptide components of TOR complex 1.	Massachusetts Gen Hosp, Harvard Med Sch, Diabet & Unit Serv, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, 185 Cambridge St, Boston, MA 02114 USA.	avruch@molbio.mgh.harvard.edu	Long, Samuel/AAR-8118-2021	Long, Samuel/0000-0001-7559-3232	NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776, P30DK040561] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA073818, CA73818] Funding Source: Medline; NIDDK NIH HHS [R37 DK017776, P30 DK040561-12, P30 DK040561, DK17776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashery U, 2006, CELL MOL NEUROBIOL, V26, P471, DOI 10.1007/s10571-006-9059-3; Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Li WQ, 2000, GENE DEV, V14, P895; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2005, FEBS LETT, V579, P4763, DOI 10.1016/j.febslet.2005.07.054; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yu YD, 2005, J BIOL CHEM, V280, P17093, DOI 10.1074/jbc.M501253200; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	29	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18542	18551		10.1074/jbc.M610736200	http://dx.doi.org/10.1074/jbc.M610736200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17470430	hybrid, Green Accepted			2022-12-25	WOS:000247302000059
J	Mu, JJ; Wang, Y; Luo, H; Leng, M; Zhang, JL; Yang, T; Besusso, D; Jung, SY; Qin, J				Mu, Jung-Jung; Wang, Yi; Luo, Hao; Leng, Mei; Zhang, Jinglan; Yang, Tao; Besusso, Dario; Jung, Sung Yun; Qin, Jun			A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; HUMAN CDC25A; PHOSPHORYLATION; PROTEIN; PATHWAY; KINASE; LIGASE; SMC1; COACTIVATOR; ACTIVATION	ATM (ataxia telangiectasia-mutated) and ATR (ATM-Rad3-related) are proximal checkpoint kinases that regulate DNA damage response (DDR). Identification and characterization of ATM/ ATR substrates hold the keys for the understanding of DDR. Few techniques are available to identify protein kinase substrates. Here, we screened for potential ATM/ ATR substrates using phospho-specific antibodies against known ATM/ ATR substrates. We identified proteins cross-reacting to phospho-specific antibodies in response to DNA damage by mass spectrometry. We validated a subset of the candidate substrates to be phosphorylated in an ATM/ ATR-dependent manner in vivo. Combining with a functional checkpoint screen, we identified proteins that belong to the ubiquitin-proteasome system (UPS) to be required in mammalian DNA damage checkpoint control, particularly the G(1) cell cycle checkpoint, thus revealing protein ubiquitylation as an important regulatory mechanism downstream of ATM/ ATR activation for checkpoint control.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wang, Y (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	yiw@bcm.tmc.edu; jqin@bcm.tmc.edu	Zhang, Jinglan/AAI-1793-2020; Zhang, Jinglan/D-4752-2011	Zhang, Jinglan/0000-0002-4600-7123; Besusso, Dario/0000-0001-9793-9644	NCI NIH HHS [CA98500, CA84199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084199, R01CA098500] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Boeddrich A, 2006, EMBO J, V25, P1547, DOI 10.1038/sj.emboj.7601043; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chehab NH, 2000, GENE DEV, V14, P278; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; Jung SY, 2005, MOL ENDOCRINOL, V19, P2451, DOI 10.1210/me.2004-0476; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Livingstone M, 2005, CANCER RES, V65, P7533, DOI 10.1158/0008-5472.CAN-04-3729; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Shi YL, 2007, J BIOL CHEM, V282, P9236, DOI 10.1074/jbc.M609256200; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Wang Y, 2000, GENE DEV, V14, P927; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	32	134	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17330	17334		10.1074/jbc.C700079200	http://dx.doi.org/10.1074/jbc.C700079200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17478428	Green Published, hybrid			2022-12-25	WOS:000247084500002
J	Marks, JL; McLellan, MD; Zakowski, MF; Lash, AE; Kasai, Y; Broderick, S; Sarkaria, IS; Pham, D; Singh, B; Miner, TL; Fewell, GA; Fulton, LL; Mardis, ER; Wilson, RK; Kris, MG; Rusch, VW; Varmus, H; Pao, W				Marks, Jenifer L.; McLellan, Michael D.; Zakowski, Maureen F.; Lash, Alex E.; Kasai, Yumi; Broderick, Stephen; Sarkaria, Inderpal S.; Pham, DuyKhanh; Singh, Bhuvanesh; Miner, Tracie L.; Fewell, Ginger A.; Fulton, Lucinda L.; Mardis, Elaine R.; Wilson, Richard K.; Kris, Mark G.; Rusch, Valerie W.; Varmus, Harold; Pao, William			Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4	PLOS ONE			English	Article								Background. Fifty percent of lung adenocarcinomas harbor somatic mutations in six genes that encode proteins in the EGFR signaling pathway, i.e., EGFR, HER2/ERBB2, HER4/ERBB4, PIK3CA, BRAF, and KRAS. We performed mutational profiling of a large cohort of lung adenocarcinomas to uncover other potential somatic mutations in genes of this signaling pathway that could contribute to lung tumorigenesis. Methodology/Principal Findings. We analyzed genomic DNA from a total of 261 resected, clinically annotated non-small cell lung cancer (NSCLC) specimens. The coding sequences of 39 genes were screened for somatic mutations via high-throughput dideoxynucleotide sequencing of PCR-amplified gene products. Mutations were considered to be somatic only if they were found in an independent tumor-derived PCR product but not in matched normal tissue. Sequencing of 9MB of tumor sequence identified 239 putative genetic variants. We further examined 22 variants found in RAS family genes and 135 variants localized to exons encoding the kinase domain of respective proteins. We identified a total of 37 non-synonymous somatic mutations; 36 were found collectively in EGFR, KRAS, BRAF, and PIK3CA. One somatic mutation was a previously unreported mutation in the kinase domain (exon 16) of FGFR4 (Glu681Lys), identified in 1 of 158 tumors. The FGFR4 mutation is analogous to a reported tumor-specific somatic mutation in ERBB2 and is located in the same exon as a previously reported kinase domain mutation in FGFR4 (Pro712Thr) in a lung adenocarcinoma cell line. Conclusions/Significance. This study is one of the first comprehensive mutational analyses of major genes in a specific signaling pathway in a sizeable cohort of lung adenocarcinomas. Our results suggest the majority of gain-of-function mutations within kinase genes in the EGFR signaling pathway have already been identified. Our findings also implicate FGFR4 in the pathogenesis of a subset of lung adenocarcinomas.	[Marks, Jenifer L.; Pao, William] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA; [McLellan, Michael D.; Kasai, Yumi; Miner, Tracie L.; Fewell, Ginger A.; Fulton, Lucinda L.; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO USA; [Broderick, Stephen; Sarkaria, Inderpal S.; Pham, DuyKhanh; Singh, Bhuvanesh; Rusch, Valerie W.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; [Lash, Alex E.] Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10021 USA; [Zakowski, Maureen F.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Kris, Mark G.; Pao, William] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, New York, NY 10021 USA; [Varmus, Harold] Mem Sloan Kettering Canc Ctr, Program Canc Biol & Genet, New York, NY 10021 USA; [Kris, Mark G.; Pao, William] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Washington University (WUSTL); Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Pao, W (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.	paow@mskcc.org	Wilson, Richard K./AAF-4139-2019; Sarkaria, Inderpal/ABA-7401-2021; Mardis, Elaine/W-2202-2019	Wilson, Richard K./0000-0002-1992-1358; MCLELLAN, MICHAEL/0000-0002-2703-8784; Rusch, Valerie/0000-0003-2345-6900; Kris, Mark/0000-0002-7317-5341; Lash, Alex/0000-0003-3787-1590	Doris Duke Charitable Foundation [NIH K08-CA097980]; Bristol-Myers Squibb Foundation; Jodi Spiegel Fisher Cancer Foundation; Carmel Hill Fund; NATIONAL CANCER INSTITUTE [K08CA097980] Funding Source: NIH RePORTER	Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Bristol-Myers Squibb Foundation(Bristol-Myers Squibb); Jodi Spiegel Fisher Cancer Foundation; Carmel Hill Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Doris Duke Charitable Foundation (WP), Joan's Legacy: The Joan Scarangello Foundation to Conquer Lung Cancer (WP), NIH K08-CA097980 (WP), the Bristol-Myers Squibb Foundation (AL), the Jodi Spiegel Fisher Cancer Foundation (WP), and The Carmel Hill Fund. WP is the incumbent of the Miner Family Chair for Intrathoracic Cancers. The funders of this study had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, or preparation and review of the manuscript.	Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301; Bredel M, 2005, J MOL DIAGN, V7, P171, DOI 10.1016/S1525-1578(10)60543-0; Brose MS, 2002, CANCER RES, V62, P6997; CHEN K, GENOME RES IN PRESS; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ebright MI, 2002, ANN THORAC SURG, V74, P1640, DOI 10.1016/S0003-4975(02)03897-3; Endoh H, 2006, J THORAC ONCOL, V1, P629; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Gabrielson E, 2006, RESPIROLOGY, V11, P533, DOI 10.1111/j.1440-1843.2006.00909.x; Giaccone G, 2006, CLIN CANCER RES, V12, P6049, DOI 10.1158/1078-0432.CCR-06-0260; HAN SW, 2005, J CLIN ONCOL, V23; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kawano O, 2006, LUNG CANCER, V54, P209, DOI 10.1016/j.lungcan.2006.07.006; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maglott D, 2006, NUCL ACIDS RES; MARCHLERBAUER A, 2006, NUCL ACIDS RES; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Naoki K, 2002, CANCER RES, V62, P7001; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Paez JG, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh069; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; SHIGEMATSU H, 2005, P AACR LB, V39; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Wheeler DL, 2006, NUCLEIC ACIDS RES, V34, pD173, DOI 10.1093/nar/gkj158; Zhao BH, 2001, P NATL ACAD SCI USA, V98, P5898, DOI 10.1073/pnas.101116598	39	73	82	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e426	10.1371/journal.pone.0000426	http://dx.doi.org/10.1371/journal.pone.0000426			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487277	Green Submitted, Green Published, gold			2022-12-25	WOS:000207445800008
J	Sethi, G; Ahn, KS; Chaturvedi, MM; Aggarwal, BB				Sethi, G.; Ahn, K. S.; Chaturvedi, M. M.; Aggarwal, B. B.			Epidermal growth factor (EGF) activates nuclear factor-kappa B through I kappa B alpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of I kappa B alpha	ONCOGENE			English	Article						NF; kappa B; EGF; TNF; IKK; AKT	TUMOR-NECROSIS-FACTOR; CELL LUNG-CANCER; GENE-EXPRESSION; DEGRADATION; INHIBITION; APOPTOSIS; INDUCTION; GEFITINIB; PATHWAY; COMPLEX	Overexpression of epidermal growth factor (EGF) receptor and constitutive activation of nuclear factor-kappa B (NF-kappa B) are frequently encountered in tumor cells. Although EGF has been shown to induce NF-kappa B activation, the mechanism is poorly understood. EGF activated NF-kappa B DNA binding, induced NF-kappa B reporter activity and the expression of antiapoptotic and cell-proliferative gene products. Interestingly, non-small cell lung adenocarcinoma cell lines (HCC827 and H3255), which exhibit EGFR amplification, showed ligand-independent activation of NF-kappa B. Unlike tumor-necrosis factor (TNF), however, EGF failed to induce I kappa B alpha phosphorylation and ubiquitination and the activation of I kappa B alpha kinase (IKK). Although DN-IKK beta inhibited TNF-induced NF-kappa B activity, DN-IKK beta had no effect on EGF-induced NF-kappa B activation, suggesting that EGF-induced NF-kappa B activation is IKK independent. Using dominant-negative plasmids, we also demonstrated the role of TRADD, TRAF2, NIK and Ras in EGF-induced NF-kappa B activation. By using specific antibodies and I kappa B alpha plasmid, which is mutated at tyrosine 42 to phenylalanine, we show that EGF induced the tyrosine phosphorylation of I kappa B alpha at residue 42. Furthermore, EGF receptor kinase inhibitor blocked I kappa B alpha phosphorylation and consequent NF-kappa B activation. Overall, our results indicate that tyrosine phosphorylation of I kappa B alpha at residue 42 is critical for EGF-induced NF-kappa B activation pathway.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Delhi, Dept Zool, Delhi 110007, India.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013; Ahn, Kwang Seok/G-4249-2013; Sethi, Gautam/F-2372-2011	Sethi, Gautam/0000-0002-8677-8475	NCI NIH HHS [P01 CA91844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Amann J, 2005, CANCER RES, V65, P226; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Haussler U, 2005, AM J PHYSIOL-RENAL, V289, pF808, DOI 10.1152/ajprenal.00434.2003; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014	29	84	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7324	7332		10.1038/sj.onc.1210544	http://dx.doi.org/10.1038/sj.onc.1210544			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533369				2022-12-25	WOS:000250955700004
J	Minella, AC; Grim, JE; Welcker, M; Clurman, BE				Minella, A. C.; Grim, J. E.; Welcker, M.; Clurman, B. E.			P53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability	ONCOGENE			English	Article						cyclin E; p53; p21; Fbw7; hCdc4; genome instability	UBIQUITIN LIGASE; DEPENDENT DEGRADATION; C-MYC; PHOSPHORYLATION; FBW7; CANCER; NOTCH; HCDC4; TUMORIGENESIS; DEREGULATION	Cancers often exhibit high levels of cyclin E expression, and aberrant cyclin E activity causes genomic instability and increased tumorigenesis. Two tumor suppressor pathways protect cells against cyclin E deregulation. The p53 pathway is induced by excess cychn E in primary cells and opposes cyclin E activity through induction of p21Cip1. In contrast, the Fbw7 pathway targets cyclin E for degradation, and Fbw7 mutations occur commonly in cancers. We investigated the cooperativity of these two pathways in countering cyclin E-induced genomic instability in primary human cells. We find that loss of p53 and Fbw7 synergistically unmasks cyclin E-induced instability. In normal cells, impaired cychn E degradation produces genome instability, but this is rapidly mitigated by induction of p53 and p21. In contrast, p53 loss allows the high level of cyclin E kinase activity that results from Fbw7 loss to persist and continuously drive genome instability. Moreover, p21 plays a critical role in suppressing cyclin E when Fbw7 is disabled, and in the absence of p21, sustained cyclin E activity induces rapid cell death via apoptosis. These data directly demonstrate the cooperative roles of these Fbw7 and p53 pathways in restraining cyclin E activity and its associated genome instability.	Fred Hutchinson Canc Res Ctr, Div Clin Res & Human Biol, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Clurman, BE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res & Human Biol, 1100 Fairview Ave N,D2-100, Seattle, WA 98109 USA.	bclurman@fhcrc.org	Clurman, Bruce/AAV-3854-2021	Welcker, Markus/0000-0001-6723-4790; Minella, Alex/0000-0001-6693-3362	NATIONAL CANCER INSTITUTE [R01CA102742, K08CA101800, R01CA084069] Funding Source: NIH RePORTER; NCI NIH HHS [K08CA101800, R01CA84069, R01CA102742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Minella AC, 2005, P NATL ACAD SCI USA, V102, P9649, DOI 10.1073/pnas.0503677102; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Smith APL, 2006, ONCOGENE, V25, P7245, DOI 10.1038/sj.onc.1209713; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	27	43	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6948	6953		10.1038/sj.onc.1210518	http://dx.doi.org/10.1038/sj.onc.1210518			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486057				2022-12-25	WOS:000250188400010
J	Sainte-Marie, Y; Cat, AND; Perrier, R; Mangin, L; Soukaseum, C; Peuchmaur, M; Tronche, F; Farman, N; Escoubet, B; Benitah, JP; Jaisser, F				Sainte-Marie, Yannis; Cat, Aurelie Nguyen Dinh; Perrier, Romain; Mangin, Laurence; Soukaseum, Christelle; Peuchmaur, Michel; Tronche, Francois; Farman, Nicolette; Escoubet, Brigitte; Benitah, Jean-Pierre; Jaisser, Frederic			Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block	FASEB JOURNAL			English	Article						corticosteroids; electrical remodeling; ion channel; conditional model	SARCOPLASMIC-RETICULUM FUNCTION; MINERALOCORTICOID RECEPTOR; CA2+ CURRENT; RAT; ALDOSTERONE; DEXAMETHASONE; MICE; DENSITY; DISEASE; CONSEQUENCES	Corticosteroid hormones (aldosterone and glucocorticoids) and their receptors are now recognized as major modulators of cardiovascular pathophysiology, but their specific roles remain elusive. Glucocorticoid hormones (GCs), which are widely used to treat acute and chronic diseases, often have adverse cardiovascular effects such as heart failure, hypertension, atherosclerosis, or metabolic alterations. The direct effects of GC on the heart are difficult to evaluate, as changes in plasma GC concentrations have multiple consequences due to the ubiquitous expression of the glucocorticoid receptor (GR), resulting in secondary effects on cardiac function. We evaluated the effects of GR on the heart in a conditional mouse model in which the GR was overexpressed solely in cardiomyocytes. The transgenic mice displayed electrocardiogram (ECG) abnormalities: a long PQ interval, increased QRS and QTc duration as well as chronic atrio-ventricular block, without cardiac hypertrophy or fibrosis. The ECG alterations were reversible on GR expression shutoff. Isolated ventricular cardiomyocytes showed major ion channel remodeling, with decreases in I-Na, I-to, and I-Kslow activity and changes in cell calcium homeostasis (increase in C-a1, in Ca2+ transients and in sarcoplasmic reticulum Ca2+ load). This phenotype differs from that observed in mice overexpressing the mineralocorticoid receptor in the heart, which displayed ventricular arrhythmia. Our mouse model highlights novel effects of GR activation in the heart indicating that GR has direct and specific cardiac effects in the mouse.	INSERM, U772, F-75231 Paris, France; Coll France, F-75231 Paris, France; Univ Paris 05, Paris, France; INSERM, U673 IFR3, F-75231 Paris, France; Univ Montpellier 1, Montpellier, France; INSERM, U698, F-75231 Paris, France; Hop Bichat Claude Bernard, AP HP, F-75877 Paris, France; Univ Paris 07, Fac Med 10, Paris, France; Hop Robert Debre, AP HP, Serv Pathol, F-75019 Paris, France; Univ Paris 07, EA3102, Paris, France; CNRS, FRE2401, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Jaisser, F (corresponding author), INSERM, U772, 11 Pl Marcelin Berthelot, F-75231 Paris, France.	frederic.jaisser@college-de-france.fr	TRONCHE, François/F-3895-2011; CAT, Aurelie NGUYEN DINH/H-8182-2013; Benitah, Jean-Pierre/L-6060-2018; Jaisser, Frederic/P-4287-2017	Benitah, Jean-Pierre/0000-0002-9866-9081; Jaisser, Frederic/0000-0001-9051-1901; Perrier, Romain/0000-0003-2229-4700; Sainte-Marie, Yannis/0000-0002-0646-1591				BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Benitah JP, 2001, J PHYSIOL-LONDON, V537, P151, DOI 10.1111/j.1469-7793.2001.0151k.x; Brotman DJ, 2005, J CLIN ENDOCR METAB, V90, P3202, DOI 10.1210/jc.2004-2379; Brunner M, 2001, AM J PHYSIOL-HEART C, V281, pH1201, DOI 10.1152/ajpheart.2001.281.3.H1201; Bujard H, 1999, J GENE MED, V1, P372; Couette B, 1996, BIOCHEM J, V315, P421, DOI 10.1042/bj3150421; Delano FA, 2004, MICROCIRCULATION, V11, P69, DOI 10.1080/10739680490266207; Dobrzynski H, 2006, J MOL CELL CARDIOL, V41, P855, DOI 10.1016/j.yjmcc.2006.07.018; EVANS N, 1994, ARCH DIS CHILD-FETAL, V70, P25; Funder JW, 2004, TRENDS ENDOCRIN MET, V15, P139, DOI 10.1016/j.tem.2004.03.006; Girod JP, 2004, CARDIOVASC RES, V64, P217, DOI 10.1016/j.cardiores.2004.07.006; Guo J, 2006, AM J PHYSIOL-HEART C, V291, pH2669, DOI 10.1152/ajpheart.01247.2005; Guo WN, 2000, CIRC RES, V87, P73, DOI 10.1161/01.RES.87.1.73; Gutstein DE, 2001, CELL COMMUN ADHES, V8, P345, DOI 10.3109/15419060109080751; ISRAEL BA, 1993, AM J PERINAT, V10, P307, DOI 10.1055/s-2007-994747; LEFER AM, 1968, AM J PHYSIOL, V214, P518, DOI 10.1152/ajplegacy.1968.214.3.518; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; Narayanan N, 2004, MOL CELL BIOCHEM, V266, P31, DOI 10.1023/B:MCBI.0000049130.58074.73; Ouvrard-Pascaud A, 2005, CIRCULATION, V111, P3025, DOI 10.1161/CIRCULATIONAHA.104.503706; Ouvrard-Pascaud A, 2003, PFLUG ARCH EUR J PHY, V445, P477, DOI 10.1007/s00424-002-0953-3; Papadatos GA, 2002, P NATL ACAD SCI USA, V99, P6210, DOI 10.1073/pnas.082121299; PENEFSKY ZJ, 1971, EUR J PHARMACOL, V15, P259, DOI 10.1016/0014-2999(71)90091-4; Perrier R, 2005, J PHYSIOL-LONDON, V569, P153, DOI 10.1113/jphysiol.2005.092692; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rao MK, 2001, AM J PHYSIOL-HEART C, V281, pH325, DOI 10.1152/ajpheart.2001.281.1.H325; Sheppard KE, 2003, VITAM HORM, V66, P77, DOI 10.1016/S0083-6729(03)01003-3; Souverein PC, 2004, HEART, V90, P859, DOI 10.1136/hrt.2003.020180; Struthers AD, 2002, AM HEART J, V144, pS2, DOI 10.1067/mhj.2002.129969; Takimoto K, 1997, J MOL CELL CARDIOL, V29, P3035, DOI 10.1006/jmcc.1997.0532; TAKIMOTO K, 1994, CIRC RES, V75, P1006, DOI 10.1161/01.RES.75.6.1006; WANG Z, 1999, P 2 INT S AN DIG SOL, V2, P85; Wei L, 2004, ANN INTERN MED, V141, P764, DOI 10.7326/0003-4819-141-10-200411160-00007; Whitehurst RM, 1999, J MOL CELL CARDIOL, V31, P1551, DOI 10.1006/jmcc.1999.0990; Yoshida Masahiro, 2005, Congest Heart Fail, V11, P12, DOI 10.1111/j.1527-5299.2005.03722.x; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	36	44	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2007	21	12					3133	3141		10.1096/fj.07-8357com	http://dx.doi.org/10.1096/fj.07-8357com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17517920				2022-12-25	WOS:000249781600014
J	Zanone, MM; Favaro, E; Ferioli, E; Huang, GC; Klein, NJ; Perin, PC; Peakman, M; Conaldi, PG; Camussi, G				Zanone, Maria M.; Favaro, Enrica; Ferioli, Elena; Huang, Guo C.; Klein, Nigel J.; Perin, Paolo Cavallo; Peakman, Mark; Conaldi, Pier G.; Camussi, Giovanni			Human pancreatic islet endothelial cells express coxsackievirus and adenovirus receptor and are activated by coxsackie B virus infection	FASEB JOURNAL			English	Article						autoimmunity; adhesion molecules; cytokines; viral infection	DILATED CARDIOMYOPATHY; PERSISTENT INFECTION; ADHESION MOLECULE-1; ALPHA-INTERFERON; T-CELLS; BETA; INDUCTION; DAMAGE; IDENTIFICATION; LYMPHOTACTIN	Enteroviruses, such as the coxsackievirus ( CV) group, have been linked to the induction of inflammatory and autoimmune diseases. Virus tropism and tissue access are modulated by endothelial cells. To examine the susceptibility of microvascular endothelial cells ( MECs) derived from pancreatic islets to infection with CV group B ( CVB), purified cultured human islet MECs were infected with CVB-4 strain, and the immunological phenotype of the infected cells was analyzed. CVB-4 persistently infected the islet MECs, which expressed the CV receptors human coxsackievirus and adenovirus receptor ( HCAR) and decay accelerating factor ( DAF) and maintained EC characteristics, without overt cytopathic effects. CVB-4 infection transiently upregulated expression of the adhesion molecules ICAM-1 and VCAM-1 and increased production of the proinflammatory cytokines IL-1 beta and IL-6, and chemokines IL-8 and lymphotactin, as well as IFN-alpha. Mononuclear cell adhesion to CVB infected monolayers was increased, compared to uninfected monolayers. Moreover, infection up-regulated the viral receptors HCAR and DAF and coreceptor alpha(v)beta(3) integrin on islet MECs, while down-regulating expression of HCAR on human aortic endothelial cells, indicating potential tissue-specific influence on the pathological outcome of infection. These results provide evidence that islet MECs are natural targets and reservoirs for persistent CVB infection resulting in acute endothelial cell activation by virus, which may contribute to selective recruitment of subsets of leukocytes during inflammatory immune responses, such as insulitis in type 1 diabetes. - Zanone, M. M., Favaro, E., Ferioli, E., Huang, G. C., Klein, N. J., Perin, P. C., Peakman, M., Conaldi, P. G., Camussi, G. Human pancreatic islet endothelial cells express coxsackievirus and adenovirus receptor and are activated by coxsackie B virus infection.	Univ Turin, Dept Internal Med, Div Univ Med 1, I-10126 Turin, Italy; Univ Insubria, Dept Med & Publ Hlth, Varese, Italy; Guys Kings & St Thomas Hosp, Dept Immunobiol & Diabet, London, England; Inst Child Hlth, Dept Immunobiol, London, England	University of Turin; University of Insubria; University of London; King's College London; University of London; University College London	Zanone, MM (corresponding author), Univ Turin, Dept Internal Med, Div Univ Med 1, Corso Dogliotti 4, I-10126 Turin, Italy.	mmz@libero.it	Camussi, Giovanni/J-7624-2016; Conaldi, Pier Giulio/AAC-1573-2019	Camussi, Giovanni/0000-0003-2795-232X; Conaldi, Pier Giulio/0000-0003-1994-8005; Klein, Nigel/0000-0003-3925-9258				Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Blaschke S, 2003, ARTHRITIS RHEUM, V48, P1858, DOI 10.1002/art.11171; CAMUSSI G, 1983, J IMMUNOL, V131, P2397; CARLOS TM, 1994, BLOOD, V84, P2068; Carson SD, 1999, J VIROL, V73, P7077, DOI 10.1128/JVI.73.8.7077-7079.1999; Chakrabarti D, 1996, J IMMUNOL, V157, P522; Charakida M, 2005, CIRCULATION, V111, P1660, DOI 10.1161/01.CIR.0000160365.18879.1C; CHATTERJEE NK, 1988, J MED VIROL, V26, P57, DOI 10.1002/jmv.1890260109; Chehadeh T, 2000, J INFECT DIS, V181, P1929, DOI 10.1086/315516; Chehadeh W, 2000, J VIROL, V74, P10153, DOI 10.1128/JVI.74.21.10153-10164.2000; Conaldi PG, 1997, J VIROL, V71, P9180, DOI 10.1128/JVI.71.12.9180-9187.1997; Conaldi PG, 1997, J INFECT DIS, V175, P693, DOI 10.1093/infdis/175.3.693; Fechner H, 2003, CIRCULATION, V107, P876, DOI 10.1161/01.CIR.0000050150.27478.C5; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; Flodstrom M, 2003, DIABETES, V52, P2025, DOI 10.2337/diabetes.52.8.2025; Flodstrom M, 2002, NAT IMMUNOL, V3, P373, DOI 10.1038/ni771; FOULIS AK, 1987, LANCET, V2, P1423; FRIEDMAN HM, 1981, J INFECT DIS, V143, P266, DOI 10.1093/infdis/143.2.266; Greening JE, 2003, DIABETES, V52, P717, DOI 10.2337/diabetes.52.3.717; HANNINEN A, 1993, J CLIN INVEST, V92, P2509, DOI 10.1172/JCI116859; HANNINEN A, 1992, J CLIN INVEST, V90, P1901, DOI 10.1172/JCI116067; Hedrick JA, 1997, J IMMUNOL, V158, P1533; HEIM A, 1992, J INFECT DIS, V166, P958, DOI 10.1093/infdis/166.5.985; Hingorani AD, 2000, CIRCULATION, V102, P994, DOI 10.1161/01.CIR.102.9.994; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Huang GC, 2004, TRANSPLANTATION, V77, P143, DOI 10.1097/01.TP.0000100401.62912.B2; HUANG XJ, 1995, DIABETES, V44, P658, DOI 10.2337/diabetes.44.6.658; HUBER SA, 1990, J VIROL, V64, P4516, DOI 10.1128/JVI.64.9.4516-4522.1990; Hyoty H, 2002, DIABETOLOGIA, V45, P1353, DOI 10.1007/s00125-002-0852-3; Ito M, 2000, CIRC RES, V86, P275, DOI 10.1161/01.RES.86.3.275; KENNEDY J, 1995, J IMMUNOL, V155, P203; KLINGEL K, 1992, P NATL ACAD SCI USA, V89, P314, DOI 10.1073/pnas.89.1.314; Lidington EA, 1999, TRANSPL IMMUNOL, V7, P239, DOI 10.1016/S0966-3274(99)80008-2; Luppi P, 1998, CIRCULATION, V98, P777, DOI 10.1161/01.CIR.98.8.777; Middel P, 2001, AM J PATHOL, V159, P1751, DOI 10.1016/S0002-9440(10)63022-2; Noutsias M, 1999, CIRCULATION, V99, P2124, DOI 10.1161/01.CIR.99.16.2124; Noutsias M, 2001, CIRCULATION, V104, P275; Olsson R, 2006, INT J BIOCHEM CELL B, V38, P492, DOI 10.1016/j.biocel.2005.06.021; Peterson FC, 2004, J BIOL CHEM, V279, P12598, DOI 10.1074/jbc.M311633200; Roivainen M, 2000, J CLIN ENDOCR METAB, V85, P432, DOI 10.1210/jc.85.1.432; ROSE NR, 1993, CLIN IMMUNOL IMMUNOP, V68, P95, DOI 10.1006/clin.1993.1102; Saijets S, 2003, J MED VIROL, V70, P430, DOI 10.1002/jmv.10413; Savinov AY, 2003, J EXP MED, V197, P643, DOI 10.1084/jem.20021378; SEKO Y, 1993, J CLIN INVEST, V91, P1327, DOI 10.1172/JCI116333; Selinka HC, 2004, MED MICROBIOL IMMUN, V193, P127, DOI 10.1007/s00430-003-0193-y; Shafren DR, 1998, J VIROL, V72, P9407, DOI 10.1128/JVI.72.11.9407-9412.1998; SOMOZA N, 1994, J IMMUNOL, V153, P1360; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; SWERLICK RA, 1992, J IMMUNOL, V148, P78; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; Varela-Calvino R, 2003, DIABETES-METAB RES, V19, P431, DOI 10.1002/dmrr.407; Wucherpfennig KW, 2001, J CLIN INVEST, V108, P1097, DOI 10.1172/JCI200114235; Zanone MM, 2005, DIABETOLOGIA, V48, P1789, DOI 10.1007/s00125-005-1865-5; Zanone MM, 2003, J IMMUNOL, V171, P438, DOI 10.4049/jimmunol.171.1.438	54	25	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2007	21	12					3308	3317		10.1096/fj.06-7905com	http://dx.doi.org/10.1096/fj.06-7905com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	215BE	17494992				2022-12-25	WOS:000249781600031
J	Herrera, FE; Zucchelli, S; Jezierska, A; Lavina, ZS; Gustincich, S; Carloni, P				Herrera, Fernando E.; Zucchelli, Silvia; Jezierska, Aneta; Lavina, Zeno Scotto; Gustincich, Stefano; Carloni, Paolo			On the oligomeric state of DJ-1 protein and its mutants associated with Parkinson disease - A combined computational and in vitro study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICLE MESH EWALD; MOLECULAR-DYNAMICS; OXIDATIVE STRESS; ANTIOXIDATIVE STRESS; CRYSTAL-STRUCTURE; 2 PARTS; MUTATIONS; SURFACE; MODEL; SIMULATION	Mutations in the DJ-1 protein are present in patients suffering from familial Parkinson disease. Here we use computational methods and biological assays to investigate the relationship between DJ-1 missense mutations and the protein oligomeric state. Molecular dynamics calculations suggest that: (i) the structure of DJ-1 wild type (WT) in aqueous solution, in both oxidized and reduced forms, is similar to the crystal structure of the reduced form; (ii) the Parkinson disease-causing M26I variant is structurally similar to the WT, consistent with the experimental evidence showing the protein is a dimer as WT; (iii) R98Q is structurally similar to the WT, consistent with the fact that this is a physiological variant; and (iv) the L166P monomer rapidly evolves toward a conformation significantly different from WT, suggesting a change in its ability to oligomerize. Our combined computational and experimental approach is next used to identify a mutant (R28A) that, in contrast to L166P, destabilizes the dimer subunit-subunit interface without significantly changing secondary structure elements.	INFM, DEMOCRITOS, Int Sch Adv Studies, I-34014 Trieste, Italy; Italian Inst Technol, SISSA Unit, I-34014 Trieste, Italy; Giovanno Armenise Garvard Fdn Lab, I-34012 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); International School for Advanced Studies (SISSA); International School for Advanced Studies (SISSA); Istituto Italiano di Tecnologia - IIT	Carloni, P (corresponding author), INFM, DEMOCRITOS, Int Sch Adv Studies, Via Beirut 2-4, I-34014 Trieste, Italy.	carloni@sissa.it	Carloni, Paolo/H-8736-2013	Zucchelli, Silvia/0000-0003-4556-2990; Herrera, Fernando E./0000-0002-8595-3382; Gustincich, Stefano/0000-0002-2749-2514; Jezierska, Aneta/0000-0001-6601-9124	Telethon [GGP06268] Funding Source: Medline	Telethon(Fondazione Telethon)		Abou-Sleiman PM, 2003, ANN NEUROL, V54, P283, DOI 10.1002/ana.10675; ADELMAN SA, 1976, J CHEM PHYS, V64, P2375, DOI 10.1063/1.432526; Allard L, 2005, CLIN CHEM, V51, P2043, DOI 10.1373/clinchem.2005.053942; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Baulac S, 2004, MOL CELL NEUROSCI, V27, P236, DOI 10.1016/j.mcn.2004.06.014; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Blackinton J, 2005, MOL BRAIN RES, V134, P76, DOI 10.1016/j.molbrainres.2004.09.004; Bonifati V, 2004, J MOL MED, V82, P163, DOI 10.1007/s00109-003-0512-1; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290; CASE DA, 2002, AMBER 8; Chen LN, 2005, J BIOL CHEM, V280, P21418, DOI 10.1074/jbc.M413955200; Choi J, 2006, J BIOL CHEM, V281, P10816, DOI 10.1074/jbc.M509079200; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648; Gorner K, 2007, J BIOL CHEM, V282, P13680, DOI 10.1074/jbc.M609821200; Goldberg MS, 2005, NEURON, V45, P489, DOI 10.1016/j.neuron.2005.01.041; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; Hedrich K, 2004, ANN NEUROL, V55, P145, DOI 10.1002/ana.10816; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Inden M, 2006, NEUROBIOL DIS, V24, P144, DOI 10.1016/j.nbd.2006.06.004; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Kinumi T, 2004, BIOCHEM BIOPH RES CO, V317, P722, DOI 10.1016/j.bbrc.2004.03.110; Kortemme T, 2002, P NATL ACAD SCI USA, V99, P14116, DOI 10.1073/pnas.202485799; KORTEMME T, 2004, SCI STKE, V219, P1; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Lev N, 2006, J MOL NEUROSCI, V29, P215, DOI 10.1385/JMN:29:3:215; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; Martinat C, 2004, PLOS BIOL, V2, P1754, DOI 10.1371/journal.pbio.0020327; MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468; Meulener MC, 2006, P NATL ACAD SCI USA, V103, P12517, DOI 10.1073/pnas.0601891103; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Moore DJ, 2005, HUM MOL GENET, V14, P71, DOI 10.1093/hmg/ddi007; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Pankratz Nathan, 2004, NeuroRx, V1, P235, DOI 10.1007/BF03206607; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sagui C, 1999, ANNU REV BIOPH BIOM, V28, P155, DOI 10.1146/annurev.biophys.28.1.155; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Takahashi-Niki K, 2004, BIOCHEM BIOPH RES CO, V320, P389, DOI 10.1016/j.bbrc.2004.05.187; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Waragai M, 2006, BIOCHEM BIOPH RES CO, V345, P967, DOI 10.1016/j.bbrc.2006.05.011; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100; WOLFENDEN R, 1982, BIOCHEMISTRY-US, V157, P105; Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134; Zhou WB, 2006, J MOL BIOL, V356, P1036, DOI 10.1016/j.jmb.2005.12.030	62	26	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2007	282	34					24905	24914		10.1074/jbc.M701013200	http://dx.doi.org/10.1074/jbc.M701013200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	202VU	17504761	hybrid			2022-12-25	WOS:000248933000047
J	Nishida, M; Onohara, N; Sato, Y; Suda, R; Ogushi, M; Tanabe, S; Inoue, R; Mori, Y; Kurose, H				Nishida, Motohiro; Onohara, Naoya; Sato, Yoji; Suda, Reiko; Ogushi, Mariko; Tanabe, Shihori; Inoue, Ryuji; Mori, Yasuo; Kurose, Hitoshi			G alpha(12/13)-mediated up-regulation of TRPC6 negatively regulates endothelin-1-induced cardiac myofibroblast formation and collagen synthesis through nuclear factor of activated T cells activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR POTENTIAL CHANNELS; JUN NH2-TERMINAL KINASE; ANGIOTENSIN-II; PROTEIN-KINASE; CA2+ ENTRY; HYPERTROPHY; FIBROBLASTS; EXPRESSION; PATHWAY; G-ALPHA(12)	Sustained elevation of [Ca2+](i) has been implicated in many cellular events. We previously reported that alpha subunits of G(12) family G proteins (G alpha(12/13)) participate in sustained Ca2+ influx required for the activation of nuclear factor of activated T cells (NFAT), a Ca2+-responsive transcriptional factor, in rat neonatal cardiac fibroblasts. Here, we demonstrate that G alpha(12/13)-mediated up-regulation of canonical transient receptor potential 6 (TRPC6) channels participates in sustained Ca2+ influx and NFAT activation by endothelin (ET)-1 treatment. Expression of constitutively active G alpha(12) or G alpha(13) increased the expression of TRPC6 proteins and basal Ca2+ influx activity. The treatment with ET-1 increased TRPC6 protein levels through G alpha(12/13), reactive oxygen species, and c-Jun N-terminal kinase (JNK)-dependent pathways. NFAT is activated by sustained increase in [Ca2+](i) through up-regulated TRPC6. A G alpha(12/13)-inhibitory polypeptide derived from the regulator of the G-protein signaling domain of p115-Rho guanine nucleotide exchange factor and a JNK inhibitor, SP600125, suppressed the ET-1-induced increase in expression of marker proteins of myofibroblast formation through a G alpha(12/13)-reactive oxygen species-JNK pathway. The ET-1- induced myofibroblast formation was suppressed by overexpression of TRPC6 and CA NFAT, whereas it was enhanced by TRPC6 small interfering RNAs and cyclosporine A. These results suggest two opposite roles of G alpha(12/13) in cardiac fibroblasts. First, G alpha(12/13) mediate ET-1- induced myofibroblast formation. Second, G alpha(12/13) mediate TRPC6 up-regulation and NFAT activation that negatively regulates ET-1-induced myofibroblast formation. Furthermore, TRPC6 mediates hypertrophic responses in cardiac myocytes but suppresses fibrotic responses in cardiac fibroblasts. Thus, TRPC6 mediates opposite responses in cardiac myocytes and fibroblasts.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Toxicol, Higashi Ku, Fukuoka 8128582, Japan; Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan; Fukuoka Univ, Sch Med, Dept Physiol, Jonan Ku, Fukuoka 8140180, Japan; Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Mol Biol Lab, Kyoto 6158510, Japan	Kyushu University; National Institute of Health Sciences - Japan; Fukuoka University; Kyoto University	Kurose, H (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol & Toxicol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	kurose@phar.kyushu-u.ac.jp	Tanabe, Shihori/AAH-6584-2019	Tanabe, Shihori/0000-0003-3706-0616; Nishida, Motohiro/0000-0002-2587-5458				Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; BRAUDINO TA, 2006, AM J PHYSIOL, V291, pH1015; Brown RD, 2005, ANNU REV PHARMACOL, V45, P657, DOI 10.1146/annurev.pharmtox.45.120403.095802; Bush EW, 2006, J BIOL CHEM, V281, P33487, DOI 10.1074/jbc.M605536200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Fujii T, 2005, J BIOL CHEM, V280, P23041, DOI 10.1074/jbc.M409397200; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hisatsune C, 2004, J BIOL CHEM, V279, P18887, DOI 10.1074/jbc.M311274200; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Inoue R, 2006, CIRC RES, V99, P119, DOI 10.1161/01.RES.0000233356.10630.8a; Katwa LC, 2003, AM J PHYSIOL-HEART C, V285, pH1132, DOI 10.1152/ajpheart.01141.2002; Kawano H, 2000, CIRCULATION, V101, P1130, DOI 10.1161/01.CIR.101.10.1130; Kim M, 2006, BIOCHEM BIOPH RES CO, V339, P271, DOI 10.1016/j.bbrc.2005.11.014; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Kolar F, 1996, MOL CELL BIOCHEM, V164, P253, DOI 10.1007/BF00408666; Kunichika N, 2004, AM J RESP CRIT CARE, V170, P1101, DOI 10.1164/rccm.200312-1668OC; Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Manabe I, 2002, CIRC RES, V91, P1103, DOI 10.1161/01.RES.0000046452.67724.B8; Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Nagamatsu Y, 2006, J PHARMACOL SCI, V101, P144, DOI 10.1254/jphs.FP0051036; Nakayama H, 2006, FASEB J, V20, P1660, DOI 10.1096/fj.05-5560com; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishida M, 2005, J BIOL CHEM, V280, P18434, DOI 10.1074/jbc.M409710200; Nishida M, 2003, EMBO J, V22, P4677, DOI 10.1093/emboj/cdg457; Oie E, 2000, AM J PHYSIOL-HEART C, V278, pH2115; Onohara N, 2006, EMBO J, V25, P5305, DOI 10.1038/sj.emboj.7601417; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Seth M, 2004, P NATL ACAD SCI USA, V101, P16683, DOI 10.1073/pnas.0407537101; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P16586, DOI 10.1073/pnas.0606894103; Swaney JS, 2005, P NATL ACAD SCI USA, V102, P437, DOI 10.1073/pnas.0408704102; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Yang GP, 2001, J MOL CELL CARDIOL, V33, P1505, DOI 10.1006/jmcc.2001.1413; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002	48	107	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2007	282	32					23117	23128		10.1074/jbc.M611780200	http://dx.doi.org/10.1074/jbc.M611780200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	197ST	17533154	hybrid			2022-12-25	WOS:000248577500014
J	Olson, E; Nievera, CJ; Lee, AYL; Chen, LC; Wu, XH				Olson, Erin; Nievera, Christian J.; Lee, Alan Yueh-Luen; Chen, Longchuan; Wu, Xiaohua			The mre11-Rad50-Nbs1 complex acts both upstream and downstream of ataxia telangiectasia mutated and Rad3-related protein (ATR) to regulate the S-phase checkpoint following UV treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; TELOMERASE CATALYTIC SUBUNIT; DEPENDENT NUCLEAR-DYNAMICS; FORKHEAD-ASSOCIATED DOMAIN; MRE11 COMPLEX; REPLICATION CHECKPOINT; FUNCTIONAL-ANALYSIS; IONIZING-RADIATION	The Mre11-Rad50-Nbs1 (MRN) complex is required for mediating the S-phase checkpoint following UV treatment, but the underlying mechanism is not clear. Here we demonstrate that at least two mechanisms are involved in regulating the S-phase checkpoint in an MRN-dependent manner following UV treatment. First, when replication forks are stalled, MRN is required upstream of ataxia telangiectasia mutated and Rad3-related protein (ATR) to facilitate ATR activation in a substrate and dosage-dependent manner. In particular, MRN is required for ATR-directed phosphorylation of RPA2, a critical event in mediating the S-phase checkpoint following UV treatment. Second, MRN is a downstream substrate of ATR. Nbs1 is phosphorylated by ATR at Ser-343 when replication forks are stalled, and this phosphorylation event is also important for down-regulating DNA replication following UV treatment. Moreover, we demonstrate that MRN and ATR/ATR-interacting protein ( TRIP) interact with each other, and the forkhead-associated/ breast cancer C-terminal domains (FHA/ BRCT) of Nbs1 play a significant role in mediating this interaction. Mutations in the FHA/ BRCT domains do not prevent ATR activation but specifically impair ATR-mediated Nbs1 phosphorylation at Ser-343, which results in a defect in the S-phase checkpoint. These data suggest that MRN plays critical roles both upstream and downstream of ATR to regulate the S-phase checkpoint when replication forks are stalled.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Vet Affairs Med Ctr, Dept Pathol, Long Beach, CA 90822 USA	Scripps Research Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System	Wu, XH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	xiaohwu@scripps.edu	Lee, Alan Yueh-Luen/A-9141-2010; Lee, Alan Yueh-Luen/B-1097-2010	Lee, Alan Yueh-Luen/0000-0003-0252-0571	NCI NIH HHS [CA102361] Funding Source: Medline; NIDDK NIH HHS [5 T32 DK007022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Assenmacher N, 2004, CHROMOSOMA, V113, P157, DOI 10.1007/s00412-004-0306-4; Ball HL, 2005, MOL BIOL CELL, V16, P2372, DOI 10.1091/mbc.e04-11-1006; Becker E, 2006, BIOINFORMATICS, V22, P1289, DOI 10.1093/bioinformatics/btl075; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; Garcia V, 2005, DNA REPAIR, V4, P1227, DOI 10.1016/j.dnarep.2005.04.001; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Itakura E, 2004, BIOCHEM BIOPH RES CO, V323, P1197, DOI 10.1016/j.bbrc.2004.08.228; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Matsuura S, 2004, ADV BIOPHYS, V38, P65, DOI 10.1016/S0065-227X(04)80076-5; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Olson E, 2006, J BIOL CHEM, V281, P39517, DOI 10.1074/jbc.M605121200; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Smits VAJ, 2006, CURR BIOL, V16, P150, DOI 10.1016/j.cub.2005.11.066; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Taylor AMR, 2004, DNA REPAIR, V3, P1219, DOI 10.1016/j.dnarep.2004.04.009; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Williams RS, 2005, BIOCHEM CELL BIOL, V83, P721, DOI 10.1139/O05-153; Wu X, 2000, Science, V289, P11; Wu XH, 2004, GENE DEV, V18, P1305, DOI 10.1101/gad.1182804; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yang YG, 2006, EMBO J, V25, P5527, DOI 10.1038/sj.emboj.7601411; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612; Zhong H, 2005, HUM MOL GENET, V14, P2685, DOI 10.1093/hmg/ddi302; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	70	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2007	282	31					22939	22952		10.1074/jbc.M702162200	http://dx.doi.org/10.1074/jbc.M702162200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	194OR	17526493	hybrid			2022-12-25	WOS:000248354200071
J	Kaimori, A; Potter, J; Kaimori, JY; Wang, C; Mezey, E; Koteish, A				Kaimori, Aki; Potter, James; Kaimori, Jun-ya; Wang, Connie; Mezey, Esteban; Koteish, Ayman			Transforming growth factor-beta 1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HEPATIC STELLATE CELLS; FETAL-RAT HEPATOCYTES; TGF-BETA; COLLAGEN PRODUCTION; CONFERS RESISTANCE; LIVER FIBROSIS; SNAIL; FIBROGENESIS; EXPRESSION	Liver fibrosis is a progressive pathologic process that involves deposition of excess extracellular matrix leading to distorted architecture and culminating in cirrhosis. The role of transforming growth factor-beta (TGF-beta) as a key molecule in the development and progression of hepatic fibrosis via the activation of hepatic stellate cells, among other fibroblast populations, is without controversy. We hereby show that TGF-beta 1 induces an epithelial-to-mesenchymal transition (EMT) state in mature hepatocytes in vitro. EMT state was marked by significant up-regulation of alpha(1) (I) collagen mRNA expression and type I collagen deposition. Similar changes were found in a " normal" mouse hepatocyte cell line (AML12), thus confirming that hepatocytes are capable of EMT changes and type I collagen synthesis. We also show that in hepatocytes in the EMT state, TGF-beta 1 induces the snail-1 transcription factor and activates the Smad2/3 pathway. Evidence for a central role of the TGF-beta 1/Smad pathway is further supported by the inhibition of EMT by Smad4 silencing using small interference RNA technology. In conclusion, TGF-beta 1, a known pro-apoptotic cytokine in mature hepatocytes, is capable of mediating phenotypic changes and plasticity in the form of EMT, resulting in collagen deposition. Our findings support a potentially crucial role for EMT in the development and progression of hepatic fibrogenesis.	Johns Hopkins Univ, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Koteish, A (corresponding author), Johns Hopkins Univ, Sch Med, Div Gastroenterol & Hepatol, 720 Rutland Ave,Ross Res Bldg 933C, Baltimore, MD 21205 USA.	akoteish@jhmi.edu			NIAAA NIH HHS [AA000626] Funding Source: Medline; NIDDK NIH HHS [P50 DK57325] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK057325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA000626] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Chagraoui J, 2003, BLOOD, V101, P2973, DOI 10.1182/blood-2002-05-1341; CHOJKIER M, 1986, J CLIN INVEST, V78, P333, DOI 10.1172/JCI112581; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dooley S, 2001, BIOCHEM BIOPH RES CO, V283, P554, DOI 10.1006/bbrc.2001.4811; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Forbes SJ, 2004, GASTROENTEROLOGY, V126, P955, DOI 10.1053/j.gastro.2004.02.025; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Grille SJ, 2003, CANCER RES, V63, P2172; Inoue A, 2006, J DRUG TARGET, V14, P448, DOI 10.1080/10611860600845397; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Ju WJ, 2006, MOL CELL BIOL, V26, P654, DOI 10.1128/MCB.26.2.654-667.2006; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Lenferink AE, 2004, BREAST CANCER RES, V6, pR514, DOI 10.1186/bcr907; Li YJ, 2003, J CLIN INVEST, V112, P503, DOI 10.1172/JCI200317913; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MCGEE JO, 1972, J PATHOL, V106, pPR6; Medici D, 2006, MOL BIOL CELL, V17, P1871, DOI 10.1091/mbc.E05-08-0767; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OGATA I, 1991, HEPATOLOGY, V14, P361, DOI 10.1016/0270-9139(91)91427-3; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Ramadori G, 2004, LAB INVEST, V84, P153, DOI 10.1038/labinvest.3700030; Rees JRE, 2006, CANCER RES, V66, P9583, DOI 10.1158/0008-5472.CAN-06-1842; Reeves HL, 2002, FRONT BIOSCI-LANDMRK, V7, pD808, DOI 10.2741/reeves; Sato M, 2003, CELL STRUCT FUNCT, V28, P105; Seyhan H, 2006, J CELL MOL MED, V10, P922, DOI 10.1111/j.1582-4934.2006.tb00535.x; Sicklick JK, 2006, AM J PHYSIOL-GASTR L, V291, pG575, DOI 10.1152/ajpgi.00102.2006; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Valdes F, 2002, MOL CANCER RES, V1, P68; Valdes F, 2004, EXP CELL RES, V292, P209, DOI 10.1016/j.yexcr.2003.08.015; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Veveris-Lowe TL, 2005, ENDOCR-RELAT CANCER, V12, P631, DOI 10.1677/erc.1.00958; Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yao HW, 2004, LIFE SCI, V76, P29, DOI 10.1016/j.lfs.2004.06.019; Ye L, 2006, INT J ONCOL, V29, P1149; Yokoyama K, 2003, INT J ONCOL, V22, P891; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zeisberg M, 2004, J MOL MED, V82, P175, DOI 10.1007/s00109-003-0517-9; Zhang F, 2003, EXP CELL RES, V291, P275, DOI 10.1016/j.yexcr.2003.07.007	49	288	315	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22089	22101		10.1074/jbc.M700998200	http://dx.doi.org/10.1074/jbc.M700998200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17513865	hybrid			2022-12-25	WOS:000248196800056
J	Xing, WR; Singgih, A; Kapoor, A; Alarcon, CM; Baylink, DJ; Mohan, S				Xing, Weirong; Singgih, Anny; Kapoor, Anil; Alarcon, Catrina M.; Baylink, David J.; Mohan, Subburaman			Nuclear factor-E2-related factor-1 mediates ascorbic acid induction of osterix expression via interaction with antioxidant-responsive element in bone cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BZIP TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; GENE-EXPRESSION; OSTEOBLAST DIFFERENTIATION; PROGRESSIVE DEVELOPMENT; EXTRACELLULAR-MATRIX; COLLAGEN-SYNTHESIS; MC3T3-E1 CELLS; HIP FRACTURE	We recently found that deletion of the gulonolactone oxidase gene, which is involved in the synthesis of ascorbic acid (AA), was responsible for the fracture phenotype in spontaneous fracture mice. To explore the molecular mechanisms by which AA regulates osteoblast differentiation, we examined the effect of AA on osterix expression via Nrf1 (NF-E2-related factor-1) binding to antioxidant-responsive element (ARE) in bone marrow stromal (BMS) cells. AA treatment caused a 6-fold increase in osterix expression in mutant BMS cells at 24 h, which was unaffected by pretreatment with protein synthesis inhibitor. Sequence analyses of mouse osterix promoter revealed a putative ARE located at -1762 to -1733 upstream of the transcription start site to which Nrf potentially binds. A gel mobility shift assay revealed that nuclear proteins from AA-treated BMS cells bound to radiolabeled ARE much more strongly than nuclear extracts from AA-untreated cells. Achromatin immunoprecipitation assay with Nrf1 antibody confirmed the interaction of Nrf1 with the mouse osterix promoter. A reporter assay demonstrated that the promoter activity of mouse osterix containing an ARE was stimulated 4-fold by a 48-h treatment with AA in spontaneous fracture BMS cells. Treatment of mutant BMS cells with AA resulted in a 3.9-fold increase in the nuclear accumulation of Nrf1. Transfection of mutant BMS cells with Nrf1 small interfering RNA decreased Nrf1 protein by 4.5-fold, blocked AA induction of osterix expression, and impaired BMS cell differentiation. Our data provided the first experimental evidence that AA modulated osterix expression via a novel mechanism involving Nrf1 nuclear translocation and Nrf1 binding to ARE to activate genes critical for cell differentiation.	Loma Linda Univ, Dept Med, Loma Linda, CA 92357 USA; Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA	Loma Linda University	Mohan, S (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA.	Subburaman.Mohan@va.gov	Kapoor, Anil/AAQ-7184-2021	Kapoor, Anil/0000-0001-9180-8029	NATIONAL INSTITUTE ON AGING [R01AG019698] Funding Source: NIH RePORTER; NIA NIH HHS [AG19698] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amaar YG, 2005, J BONE MINER RES, V20, P1430, DOI 10.1359/JBMR.050311; ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; Beamer WG, 2000, BONE, V27, P619, DOI 10.1016/S8756-3282(00)00369-0; BENTLEY JP, 1965, BIOCHIM BIOPHYS ACTA, V107, P519; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chen LY, 2003, MOL CELL BIOL, V23, P4673, DOI 10.1128/MCB.23.13.4673-4686.2003; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Chung YS, 2004, J BONE MINER RES, V19, P1395, DOI 10.1359/JBMR.040412; Derjuga A, 2004, MOL CELL BIOL, V24, P3286, DOI 10.1128/MCB.24.8.3286-3294.2004; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; GREEN J, 1995, AM J PHYSIOL-CELL PH, V268, pC1090, DOI 10.1152/ajpcell.1995.268.5.C1090; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jiao Y, 2005, MAMM GENOME, V16, P20, DOI 10.1007/s00335-004-2414-0; KAWAI T, 1992, J BIOL CHEM, V267, P21973; Koh WS, 1998, ANTICANCER RES, V18, P2487; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200; Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002-021496; Melhus H, 1999, J BONE MINER RES, V14, P129, DOI 10.1359/jbmr.1999.14.1.129; Mohan S, 2005, J BONE MINER RES, V20, P1597, DOI 10.1359/JBMR.050406; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Parsons KK, 2006, AM J PHYSIOL-ENDOC M, V290, pE1131, DOI 10.1152/ajpendo.00339.2005; PETERKOFSKY B, 1991, AM J CLIN NUTR, V54, pS1135, DOI 10.1093/ajcn/54.6.1135s; Prieschl EE, 1998, NUCLEIC ACIDS RES, V26, P2291, DOI 10.1093/nar/26.10.2291; Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071; Sankaranarayanan K, 2004, J BIOL CHEM, V279, P50810, DOI 10.1074/jbc.M404984200; Shin DM, 2004, NEUROREPORT, V15, P1959, DOI 10.1097/00001756-200408260-00025; SULLIVAN TA, 1994, J BIOL CHEM, V269, P22500; Wang WP, 2006, J BIOL CHEM, V281, P19676, DOI 10.1074/jbc.M602802200; Wang YZ, 2006, BIOMATERIALS, V27, P3265, DOI 10.1016/j.biomaterials.2006.01.036; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Xing WR, 2006, MOL BIOTECHNOL, V34, P29, DOI 10.1385/MB:34:1:29; Xing WR, 2004, BIOCHEM BIOPH RES CO, V319, P781, DOI 10.1016/j.bbrc.2004.05.053; Xing WR, 1998, MOL ENDOCRINOL, V12, P1310, DOI 10.1210/me.12.9.1310; Xing WR, 2002, BIOL REPROD, V67, P204, DOI 10.1095/biolreprod67.1.204; Xu ZR, 2005, P NATL ACAD SCI USA, V102, P4120, DOI 10.1073/pnas.0500660102; Yang HP, 2005, MOL CELL BIOL, V25, P5933, DOI 10.1128/MCB.25.14.5933-5946.2005; Zhang JJ, 2006, AM J EPIDEMIOL, V163, P9, DOI 10.1093/aje/kwj005	47	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2007	282	30					22052	22061		10.1074/jbc.M702614200	http://dx.doi.org/10.1074/jbc.M702614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	192JG	17510056	hybrid			2022-12-25	WOS:000248196800052
J	Feige, JN; Gelman, L; Rossi, D; Zoete, V; Metivier, R; Tudor, C; Anghel, SI; Grosdidier, A; Lathion, C; Engelborghs, Y; Michielin, O; Wahli, W; Desvergne, B				Feige, Jerome N.; Gelman, Laurent; Rossi, Daniel; Zoete, Vincent; Metivier, Raphael; Tudor, Cicerone; Anghel, Silvia I.; Grosdidier, Aurelien; Lathion, Caroline; Engelborghs, Yves; Michielin, Olivier; Wahli, Walter; Desvergne, Beatrice			The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA MICROARRAY DATA; PPAR-GAMMA; TRANSCRIPTIONAL ACTIVITY; ORGANOTIN COMPOUNDS; LIGAND-BINDING; HUMAN RISK; IN-VITRO; ALPHA; CHEMICALS; PROTEIN	The ability of pollutants to affect human health is a major concern, justified by the wide demonstration that reproductive functions are altered by endocrine disrupting chemicals. The definition of endocrine disruption is today extended to broader endocrine regulations, and includes activation of metabolic sensors, such as the peroxisome proliferator-activated receptors (PPARs). Toxicology approaches have demonstrated that phthalate plasticizers can directly influence PPAR activity. What is now missing is a detailed molecular understanding of the fundamental basis of endocrine disrupting chemical interference with PPAR signaling. We thus performed structural and functional analyses that demonstrate how monoethyl-hexyl-phthalate ( MEHP) directly activates PPAR gamma and promotes adipogenesis, albeit to a lower extent than the full agonist rosiglitazone. Importantly, we demonstrate that MEHP induces a selective activation of different PPAR gamma target genes. Chromatin immunoprecipitation and fluorescence microscopy in living cells reveal that this selective activity correlates with the recruitment of a specific subset of PPAR gamma coregulators that includes Med1 and PGC-1 alpha, but not p300 and SRC-1. These results highlight some key mechanisms in metabolic disruption but are also instrumental in the context of selective PPAR modulation, a promising field for new therapeutic development based on PPAR modulation.	Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland; Friedrich Miescher Inst, Facil Adv Imaging & Microscopy, CH-4002 Basel, Switzerland; Univ Lausanne, Natl Res Ctr Mol Oncol, Ludwig Inst, CH-1015 Lausanne, Switzerland; Univ Rennes 1, CNRS, UMR 6026, Spatiotemporal Regulat Transcript Eukaryotes, F-35042 Rennes, France; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium	University of Lausanne; Friedrich Miescher Institute for Biomedical Research; Ludwig Institute for Cancer Research; University of Lausanne; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; KU Leuven	Desvergne, B (corresponding author), Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland.	beatrice.desvergne@unil.ch	Wahli, Walter/B-1398-2009; Michielin, Olivier/ABE-7924-2020; Wahli, Walter/I-3194-2019; Rose, Rebecca J/B-7812-2011; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X; Grosdidier, Aurelien/0000-0001-9873-3461; Rossi, Daniele/0000-0002-6191-8734; Gelman, Laurent/0000-0003-3277-3115				Balint B. L., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P33; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Bility MT, 2004, TOXICOL SCI, V82, P170, DOI 10.1093/toxsci/kfh253; Burgermeister E, 2006, MOL ENDOCRINOL, V20, P809, DOI 10.1210/me.2005-0171; Chui PC, 2005, J CLIN INVEST, V115, P2244, DOI 10.1172/JCI24130; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; Feige JN, 2005, MICROSC RES TECHNIQ, V68, P51, DOI 10.1002/jemt.20215; Feige JN, 2005, J BIOL CHEM, V280, P17880, DOI 10.1074/jbc.M500786200; Fujimura T, 2005, J PHARMACOL SCI, V99, P342, DOI 10.1254/jphs.FP0050578; Fujimura T, 2006, J PHARMACOL EXP THER, V318, P863, DOI 10.1124/jpet.106.102459; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; GELMAN L, 2007, IN PRESS BIOCH BIOPH; Grun F, 2006, MOL ENDOCRINOL, V20, P2141, DOI 10.1210/me.2005-0367; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Henley DV, 2006, ENDOCRINOLOGY, V147, pS25, DOI 10.1210/en.2005-1117; Huber WW, 1996, CRIT REV TOXICOL, V26, P365, DOI 10.3109/10408449609048302; Hurst CH, 2003, TOXICOL SCI, V74, P297, DOI 10.1093/toxsci/kfg145; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jeannin E, 1998, J BIOL CHEM, V273, P24239, DOI 10.1074/jbc.273.37.24239; Kanayama T, 2005, MOL PHARMACOL, V67, P766, DOI 10.1124/mol.104.008409; Lai DY, 2004, J ENVIRON SCI HEAL C, V22, P37, DOI 10.1081/GNC-120038005; Lapinskas PJ, 2005, TOXICOLOGY, V207, P149, DOI 10.1016/j.tox.2004.09.008; Lee MS, 2003, J COMPUT CHEM, V24, P1348, DOI 10.1002/jcc.10272; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maloney EK, 1999, TOXICOL APPL PHARM, V161, P209, DOI 10.1006/taap.1999.8809; Markey CM, 2002, J STEROID BIOCHEM, V83, P235, DOI 10.1016/S0960-0760(02)00272-8; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Michalik L, 2007, J BIOL CHEM, V282, P9666, DOI 10.1074/jbc.M610523200; Minoura H, 2004, EUR J PHARMACOL, V494, P273, DOI 10.1016/j.ejphar.2004.04.038; Nadra K, 2006, MOL CELL BIOL, V26, P3266, DOI 10.1128/MCB.26.8.3266-3281.2006; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; *NTP CERHR EXP PAN, 2000, DI 2 ETHYLHEXYL PHTH; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rusyn I, 2006, CRIT REV TOXICOL, V36, P459, DOI 10.1080/10408440600779065; Schupp M, 2005, DIABETES, V54, P3442, DOI 10.2337/diabetes.54.12.3442; Shi GQ, 2005, J MED CHEM, V48, P4457, DOI 10.1021/jm0502135; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Stein M S, 1973, Environ Health Perspect, V3, P149, DOI 10.2307/3428042; Tabb MM, 2006, MOL ENDOCRINOL, V20, P475, DOI 10.1210/me.2004-0513; Takeuchi S, 2006, TOXICOL APPL PHARM, V217, P235, DOI 10.1016/j.taap.2006.08.011; Tudor C, 2007, J BIOL CHEM, V282, P4417, DOI 10.1074/jbc.M608172200; Waring RH, 2005, MOL CELL ENDOCRINOL, V244, P2, DOI 10.1016/j.mce.2005.02.007; WILLIAMS DT, 1974, B ENVIRON CONTAM TOX, V11, P371, DOI 10.1007/BF01684945; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yu C, 2005, J BIOL CHEM, V280, P13600, DOI 10.1074/jbc.M409468200	56	254	263	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19152	19166		10.1074/jbc.M702724200	http://dx.doi.org/10.1074/jbc.M702724200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17468099	hybrid			2022-12-25	WOS:000247475300057
J	Dackor, R; Fritz-Six, K; Smithies, O; Caron, K				Dackor, Ryan; Fritz-Six, Kim; Smithies, Oliver; Caron, Kathleen			Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-MODIFYING PROTEINS; RECEPTOR-LIKE-RECEPTOR; CALCITONIN-RECEPTOR; ADRENOMEDULLIN RECEPTOR; ACCESSORY PROTEINS; GENE-EXPRESSION; MICE LACKING; TRAFFICKING; RAMPS; ISOFORM	RAMPs (receptor activity modifying proteins) impart remarkable effects on G protein-coupled receptor (GPCR) signaling. First identified through an interaction with the calcitonin receptor-like receptor (CLR), these single transmembrane proteins are now known to modulate the in vitro ligand binding affinity, trafficking, and second messenger pathways of numerous GPCRs. Consequently, the receptor-RAMP interface represents an attractive pharmacological target for the treatment of disease. Although the three known mammalian RAMPs differ in their sequences and tissue expression, results from in vitro biochemical and pharmacological studies suggest that they have overlapping effects on the GPCRs with which they interact. Therefore, to determine whether RAMP2 and RAMP3 have distinct functions in vivo, we generated mice with targeted deletions of either the RAMP2 or RAMP3 gene. Strikingly, we found that, although RAMP2 is required for survival, mice that lack RAMP3 appear normal until old age, at which point they have decreased weight. In addition, mice with reduced expression of RAMP2 (but not RAMP3) display remarkable subfertility. Thus, each gene has functions in vivo that cannot be accomplished by the other. Because RAMP2, RAMP3, and CLR transduce the signaling of the two potent vasodilators adrenomedullin and calcitonin gene-related peptide, we tested the effects of our genetic modifications on blood pressure, and no effects were detected. Nevertheless, our studies reveal that RAMP2 and RAMP3 have distinct physiological functions throughout embryogenesis, adulthood, and old age, and the mice we have generated provide novel genetic tools to further explore the utility of the receptor-RAMP interface as a pharmacological target.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Caron, K (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, CB 7545,6330 MBRB 103 Mason Farm Rd, Chapel Hill, NC 27599 USA.	Kathleen_caron@med.unc.edu		Caron, Kathleen/0000-0002-7033-9232	NHLBI NIH HHS [R01 HL049277-14, R01 HL049277, R01 HL049277-16, R01 HL049277-15, HL49277] Funding Source: Medline; NICHD NIH HHS [HD046970] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD046970] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049277] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bomberger JM, 2005, J BIOL CHEM, V280, P23926, DOI 10.1074/jbc.M501751200; Bomberger JM, 2005, J BIOL CHEM, V280, P9297, DOI 10.1074/jbc.M413786200; Bouschet T, 2005, J CELL SCI, V118, P4709, DOI 10.1242/jcs.02598; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Dackor RT, 2006, MOL CELL BIOL, V26, P2511, DOI 10.1128/MCB.26.7.2511-2518.2006; Doods H, 2000, BRIT J PHARMACOL, V129, P420, DOI 10.1038/sj.bjp.0703110; Doods H, 2001, Curr Opin Investig Drugs, V2, P1261; Foord SM, 2005, J MOL NEUROSCI, V26, P265, DOI 10.1385/JMN:26:2-3:265; GIBBONS C, 2006, MOL ENDOCRINOL; Hay DL, 2006, PHARMACOL THERAPEUT, V109, P173, DOI 10.1016/j.pharmthera.2005.06.015; Hay DL, 2005, MOL PHARMACOL, V67, P1655, DOI 10.1124/mol.104.008615; Hay DL, 2004, PEPTIDES, V25, P2019, DOI 10.1016/j.peptides.2004.06.007; Hewitt SC, 2005, MOL ENDOCRINOL, V19, P657, DOI 10.1210/me.2004-0142; Julian M, 2005, EUR J MED CHEM, V40, P737, DOI 10.1016/j.ejmech.2004.10.016; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8927, DOI 10.1073/pnas.86.22.8927; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Kuwasako K, 2004, PEPTIDES, V25, P2003, DOI 10.1016/j.peptides.2004.06.002; Kuwasako K, 2004, MOL PHARMACOL, V65, P207, DOI 10.1124/mol.65.1.207; Li MY, 2006, J CLIN INVEST, V116, P2653, DOI 10.1172/JC128462; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu JT, 1999, MOL CELL NEUROSCI, V14, P99, DOI 10.1006/mcne.1999.0767; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Ono Y, 2000, BIOCHEM BIOPH RES CO, V271, P197, DOI 10.1006/bbrc.2000.2606; Tam CW, 2006, CIRC RES, V98, P262, DOI 10.1161/01.RES.0000200737.63865.58; Tilakaratne N, 2000, J PHARMACOL EXP THER, V294, P61; Udawela M, 2004, SEMIN CELL DEV BIOL, V15, P299, DOI 10.1016/j.semcdb.2003.12.019	27	84	86	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18094	18099		10.1074/jbc.M703544200	http://dx.doi.org/10.1074/jbc.M703544200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17470425	Green Published, hybrid			2022-12-25	WOS:000247302000015
J	Melov, S; Tarnopolsky, MA; Beckman, K; Felkey, K; Hubbard, A				Melov, Simon; Tarnopolsky, Mark A.; Beckman, Kenneth; Felkey, Krysta; Hubbard, Alan			Resistance Exercise Reverses Aging in Human Skeletal Muscle	PLOS ONE			English	Article								Human aging is associated with skeletal muscle atrophy and functional impairment (sarcopenia). Multiple lines of evidence suggest that mitochondrial dysfunction is a major contributor to sarcopenia. We evaluated whether healthy aging was associated with a transcriptional profile reflecting mitochondrial impairment and whether resistance exercise could reverse this signature to that approximating a younger physiological age. Skeletal muscle biopsies from healthy older (N=25) and younger (N=26) adult men and women were compared using gene expression profiling, and a subset of these were related to measurements of muscle strength. 14 of the older adults had muscle samples taken before and after a six-month resistance exercise-training program. Before exercise training, older adults were 59% weaker than younger, but after six months of training in older adults, strength improved significantly (P<0.001) such that they were only 38% lower than young adults. As a consequence of age, we found 596 genes differentially expressed using a false discovery rate cut-off of 5%. Prior to the exercise training, the transcriptome profile showed a dramatic enrichment of genes associated with mitochondrial function with age. However, following exercise training the transcriptional signature of aging was markedly reversed back to that of younger levels for most genes that were affected by both age and exercise. We conclude that healthy older adults show evidence of mitochondrial impairment and muscle weakness, but that this can be partially reversed at the phenotypic level, and substantially reversed at the transcriptome level, following six months of resistance exercise training.	[Melov, Simon; Felkey, Krysta; Hubbard, Alan] Buck Inst Age Res, Novato, CA USA; [Tarnopolsky, Mark A.] McMaster Univ, Dept Pediat & Med, Hamilton, ON, Canada; [Beckman, Kenneth] Childrens Hosp Oakland, Res Inst, Ctr Genet, Oakland, CA 94609 USA	Buck Institute for Research on Aging; McMaster University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Melov, S (corresponding author), Buck Inst Age Res, Novato, CA USA.	smelov@buckinstitute.org; tarnopol@mcmaster.ca	Melov, Simon/AAC-9469-2020	Melov, Simon/0000-0001-8554-2834	National Institutes of Health [AG18679, AG024385]; Nathan Shock [P30AG025708]; Ellison Medical Foundation; Canadian Institute for Health Research (CIHR) [108073]; NATIONAL INSTITUTE ON AGING [R01AG024385, R01AG018679] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nathan Shock; Ellison Medical Foundation(Lawrence Ellison Foundation); Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institutes of Health Grants AG18679 (SM), AG024385 (SM), a Nathan Shock Award to the Buck Institute (P30AG025708), an Ellison Medical Foundation Senior Scholar award (SM), and a grant to MT from the Canadian Institute for Health Research (CIHR # 108073).	Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; Bronikowski AM, 2003, PHYSIOL GENOMICS, V12, P129, DOI 10.1152/physiolgenomics.00082.2002; Brose A, 2003, J GERONTOL A-BIOL, V58, P11; Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Canales RD, 2006, NAT BIOTECHNOL, V24, P1115, DOI 10.1038/nbt1236; Castillo EM, 2003, AM J PREV MED, V25, P226, DOI 10.1016/S0749-3797(03)00197-1; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Colman RJ, 2005, EXP GERONTOL, V40, P573, DOI 10.1016/j.exger.2005.05.001; DePinieux G, 1996, BRIT J CLIN PHARMACO, V42, P333, DOI 10.1046/j.1365-2125.1996.04178.x; Devries MC, 2006, AM J PHYSIOL-REG I, V291, pR1120, DOI 10.1152/ajpregu.00700.2005; Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003; Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843; Ferrucci L, 1999, AM J EPIDEMIOL, V149, P645, DOI 10.1093/oxfordjournals.aje.a009865; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; Fuss JO, 2006, PLOS BIOL, V4, P899, DOI 10.1371/journal.pbio.0040203; Giresi PG, 2005, PHYSIOL GENOMICS, V21, P253, DOI 10.1152/physiolgenomics.00249.2004; Guo L, 2006, NAT BIOTECHNOL, V24, P1162, DOI 10.1038/nbt1238; Hacker TA, 2006, AM J PHYSIOL-HEART C, V290, pH304, DOI 10.1152/ajpheart.00290.2005; Janssen I, 2004, J AM GERIATR SOC, V52, P80, DOI 10.1111/j.1532-5415.2004.52014.x; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kujoth GC, 2006, CANCER RES, V66, P7386, DOI 10.1158/0008-5472.CAN-05-4670; LAUKKANEN P, 1995, AGE AGEING, V24, P468, DOI 10.1093/ageing/24.6.468; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102; Luukinen H, 1997, J AM GERIATR SOC, V45, P1302, DOI 10.1111/j.1532-5415.1997.tb02928.x; Mahoney DJ, 2005, FASEB J, V19, P1498, DOI 10.1096/fj.04-3149fje; Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974; MELOV S, 1995, NUCLEIC ACIDS RES, V23, P1419, DOI 10.1093/nar/23.8.1419; MELOV S, 2004, SCI AGING KNOWLEDGE, pRE7; Melton LJ, 2000, J AM GERIATR SOC, V48, P625; OHTA S, 1987, FEBS LETT, V226, P171, DOI 10.1016/0014-5793(87)80573-2; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; Parise G, 2005, FREE RADICAL BIO MED, V39, P289, DOI 10.1016/j.freeradbiomed.2005.03.024; Parise G, 2005, EXP GERONTOL, V40, P173, DOI 10.1016/j.exger.2004.09.002; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; RANTANEN T, 1994, AGE AGEING, V23, P132, DOI 10.1093/ageing/23.2.132; Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364; Sanchis D, 1998, FEBS LETT, V436, P415, DOI 10.1016/S0014-5793(98)01178-8; Sanz A, 2006, ANTIOXID REDOX SIGN, V8, P582, DOI 10.1089/ars.2006.8.582; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Short KR, 2005, J APPL PHYSIOL, V99, P95, DOI 10.1152/japplphysiol.00129.2005; Tarnopolsky MA, 2001, MED SCI SPORT EXER, V33, P2044, DOI 10.1097/00005768-200112000-00011; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; van der Laan MJ, 2003, J STAT PLAN INFER, V117, P275, DOI 10.1016/S0378-3758(02)00388-9; Welle S, 2004, EXP GERONTOL, V39, P369, DOI 10.1016/j.exger.2003.11.011; Welle S, 2003, PHYSIOL GENOMICS, V14, P149, DOI 10.1152/physiolgenomics.00049.2003; Yasuda N, 2005, J APPL PHYSIOL, V99, P1085, DOI 10.1152/japplphysiol.00247.2005; Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	54	205	209	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e465	10.1371/journal.pone.0000465	http://dx.doi.org/10.1371/journal.pone.0000465			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520024	Green Published, Green Submitted, gold			2022-12-25	WOS:000207446000013
J	Moodley, Y; Bruford, MW				Moodley, Yoshan; Bruford, Michael W.			Molecular Biogeography: Towards an Integrated Framework for Conserving Pan-African Biodiversity	PLOS ONE			English	Article								Background. Biogeographic models partition ecologically similar species assemblages into discrete ecoregions. However, the history, relationship and interactions between these regions and their assemblages have rarely been explored. Methodology/Principal Findings. Here we develop a taxon-based approach that explicitly utilises molecular information to compare ecoregion history and status, which we exemplify using a continentally distributed mammalian species: the African bushbuck (Tragelaphus scriptus). We reveal unprecedented levels of genetic diversity and structure in this species and show that ecoregion biogeographic history better explains the distribution of molecular variation than phenotypic similarity or geography. We extend these data to explore ecoregion connectivity, identify core habitats and infer ecological affinities from them. Conclusions/Significance. This analysis defines 28 key biogeographic regions for sub-Saharan Africa, and provides a valuable framework for the incorporation of genetic and biogeographic information into a more widely applicable model for the conservation of continental biodiversity.	[Moodley, Yoshan; Bruford, Michael W.] Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales	Cardiff University	Moodley, Y (corresponding author), Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales.	moodley@mpiib-berlin.mpg.de	Bruford, Michael W/D-3750-2009; Bruford, Michael/Y-7463-2019	Bruford, Michael W/0000-0001-6357-6080; Bruford, Michael/0000-0001-6357-6080; Moodley, Yoshan/0000-0003-4216-2924	National Research Foundation of the Republic of South Africa; Cardiff University	National Research Foundation of the Republic of South Africa(National Research Foundation - South Africa); Cardiff University	This work was supported by a postdoctoral fellowship from the National Research Foundation of the Republic of South Africa and by Cardiff University. Neither had a role in the preparation of the manuscript nor in the design, conduct or analysis of the study.	ALLEN GLOVER M., 1939, BULL MUS COMP ZOOLOGY, V83, P1; Allen JA., 1871, B MUS COMP ZOOL HARV, V2, P161; Anderson M.J., 2003, DISTLM FORWARD FORTR; Anderson MJ, 2004, DISTLM V 5 FORTRAN C; ANSELL WFH, MAMMALS AFRICA IDENT, V15, P1; Arctander P, 1999, MOL BIOL EVOL, V16, P1724, DOI 10.1093/oxfordjournals.molbev.a026085; ARNASON U, 1993, MOL BIOL EVOL, V10, P960; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Behrensmeyer AK, 1997, SCIENCE, V278, P1589, DOI 10.1126/science.278.5343.1589; Best GA, 1962, ROWLAND WARDS RECORD, P198; Birungi J, 2000, MOL ECOL, V9, P1997, DOI 10.1046/j.1365-294X.2000.01107.x; Bobe R, 2001, PALEOBIOLOGY, V27, P1, DOI 10.1666/0094-8373(2001)027<0001:ROABTP>2.0.CO;2; Debruyne R, 2003, CR BIOL, V326, P687, DOI 10.1016/S1631-0691(03)00158-6; Doggart N, 2006, AFR J ECOL, V44, P134, DOI 10.1111/j.1365-2028.2006.00572.x; DORST J, 1970, FIELD GUIDE LARGER M, P252; EAST R, 1999, AFRICAN ANTELOPE DAT, P116; EXCOFFIER L, 1992, GENETICS, V131, P491; Flagstad O, 2001, P ROY SOC B-BIOL SCI, V268, P667, DOI 10.1098/rspb.2000.1416; GLEASON HA, 1964, NATURAL GEOGRAPHY PL, P420; GOOD R, 1964, GEOGRAPHY FLOWERING, P518; Grubb P., 1985, P11; Haltenorth T., 1963, Handbuch der Zoologie Berlin, V8, P1; HALTENORTH T, 1980, FIELD GUIDE MAMMALS, P57; HARRIS JM, 1988, LOS ANGELES COUNTY M, V399, P1; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Fernandez MH, 2006, J HUM EVOL, V50, P595, DOI 10.1016/j.jhevol.2005.11.004; Hewitt Godfrey M., 2004, Frontiers in Zoology, V1, P1, DOI 10.1186/1742-9994-1-4; Jobb G, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-18; Kalb JE, 1982, NATURE, V298, P98, DOI [10.1038/298098a0, DOI 10.1038/298098A0]; Kingdon J., 1997, KINGDON FIELD GUIDE, P476; Kishino H, 2001, MOL BIOL EVOL, V18, P352, DOI 10.1093/oxfordjournals.molbev.a003811; Leake MG, 2003, LOTHAGAM DAWN HUMANI, P678; Lorenzen ED, 2006, J HERED, V97, P119, DOI 10.1093/jhered/esj012; LYDEKKER R, 1914, CATALOGUE UNGULATE M, V3, P317; Muwanika VB, 2003, HEREDITY, V91, P361, DOI 10.1038/sj.hdy.6800341; Nersting LG, 2001, MOL ECOL, V10, P711, DOI 10.1046/j.1365-294x.2001.01205.x; Olson DM, 1998, CONSERV BIOL, V12, P502, DOI 10.1046/j.1523-1739.1998.012003502.x; Olson DM, 2001, BIOSCIENCE, V51, P933, DOI 10.1641/0006-3568(2001)051[0933:TEOTWA]2.0.CO;2; PAABO S, 1988, NATURE, V334, P387, DOI 10.1038/334387b0; PARTRIDGE TC, 1995, PALEOCLIMATE EVOLUTI, P330; Pennington RT, 2004, PHILOS T R SOC B, V359, P515, DOI 10.1098/rstb.2003.1435; Pickford M., 1990, Human Evolution, V5, P1, DOI 10.1007/BF02436472; Pilot M, 2006, MOL ECOL, V15, P4533, DOI 10.1111/j.1365-294X.2006.03110.x; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Ramachandran S, 2005, P NATL ACAD SCI USA, V102, P15942, DOI 10.1073/pnas.0507611102; Reed KE, 1997, J HUM EVOL, V32, P289, DOI 10.1006/jhev.1996.0106; Roelants K, 2004, MOL PHYLOGENET EVOL, V31, P730, DOI 10.1016/j.ympev.2003.09.011; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Simonsen BT, 1998, MOL ECOL, V7, P225, DOI 10.1046/j.1365-294x.1998.00343.x; Thorne JL, 1998, MOL BIOL EVOL, V15, P1647, DOI 10.1093/oxfordjournals.molbev.a025892; Udvardy M.D.F, 1975, 18 IUCN; VRBA ES, 1985, S AFR J SCI, V81, P229; Whittaker RJ, 2005, DIVERS DISTRIB, V11, P3, DOI 10.1111/j.1366-9516.2005.00143.x; Yang ZH, 1997, MOL BIOL EVOL, V14, P717, DOI 10.1093/oxfordjournals.molbev.a025811; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	55	79	83	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e454	10.1371/journal.pone.0000454	http://dx.doi.org/10.1371/journal.pone.0000454			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520013	Green Submitted, Green Published, gold			2022-12-25	WOS:000207446000002
J	Savir, Y; Tlusty, T				Savir, Yonatan; Tlusty, Tsvi			Conformational Proofreading: The Impact of Conformational Changes on the Specificity of Molecular Recognition	PLOS ONE			English	Article								To perform recognition, molecules must locate and specifically bind their targets within a noisy biochemical environment with many look-alikes. Molecular recognition processes, especially the induced-fit mechanism, are known to involve conformational changes. This raises a basic question: Does molecular recognition gain any advantage by such conformational changes? By introducing a simple statistical-mechanics approach, we study the effect of conformation and flexibility on the quality of recognition processes. Our model relates specificity to the conformation of the participant molecules and thus suggests a possible answer: Optimal specificity is achieved when the ligand is slightly off target; that is, a conformational mismatch between the ligand and its main target improves the selectivity of the process. This indicates that deformations upon binding serve as a conformational proofreading mechanism, which may be selected for via evolution.	[Savir, Yonatan; Tlusty, Tsvi] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Tlusty, T (corresponding author), Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel.	tsvi.tlusty@weizmann.ac.il	Tlusty, Tsvi/A-9880-2008	Tlusty, Tsvi/0000-0002-9662-3725	Minerva Foundation; Center for Complexity Science	Minerva Foundation; Center for Complexity Science	This work was supported by the Minerva Foundation and the Center for Complexity Science.	Atilgan AR, 2001, BIOPHYS J, V80, P505, DOI 10.1016/S0006-3495(01)76033-X; Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2; Bar-Ziv R, 2002, P NATL ACAD SCI USA, V99, P11589, DOI 10.1073/pnas.162369099; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; Frank DE, 1997, J MOL BIOL, V267, P1186, DOI 10.1006/jmbi.1997.0920; Gakamsky DM, 2004, P NATL ACAD SCI USA, V101, P9063, DOI 10.1073/pnas.0402840101; Goh CS, 2004, CURR OPIN STRUC BIOL, V14, P104, DOI 10.1016/j.sbi.2004.01.005; Hammes GG, 2002, BIOCHEMISTRY-US, V41, P8221, DOI 10.1021/bi0260839; HERSCHLAG D, 1988, BIOORG CHEM, V16, P62, DOI 10.1016/0045-2068(88)90038-7; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; James LC, 2005, P NATL ACAD SCI USA, V102, P12730, DOI 10.1073/pnas.0500909102; Jimenez R, 2003, P NATL ACAD SCI USA, V100, P92, DOI 10.1073/pnas.262411399; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KLEANTHOUS C, 2000, PROTEIN PRTOEIN RECO; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PAULING LINUS, 1940, SCIENCE, V92, P77, DOI 10.1126/science.92.2378.77; Post CB, 1995, BIOCHEMISTRY-US, V34, P15881, DOI 10.1021/bi00049a001; Reiss H, 1997, PHYS REV LETT, V78, P4506, DOI 10.1103/PhysRevLett.78.4506; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Rodnina MV, 2001, ANNU REV BIOCHEM, V70, P415, DOI 10.1146/annurev.biochem.70.1.415; Sagi D, 2006, NUCLEIC ACIDS RES, V34, P5021, DOI 10.1093/nar/gkl586; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Tama F, 2001, PROTEIN ENG, V14, P1, DOI 10.1093/protein/14.1.1; TANFORD C, 1979, P NATL ACAD SCI USA, V76, P4175, DOI 10.1073/pnas.76.9.4175; Tirion MM, 1996, PHYS REV LETT, V77, P1905, DOI 10.1103/PhysRevLett.77.1905; Tlusty T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.258103; Tobi D, 2005, P NATL ACAD SCI USA, V102, P18908, DOI 10.1073/pnas.0507603102; Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575; WOLFENDEN R, 1974, MOL CELL BIOCHEM, V3, P207, DOI 10.1007/BF01686645	38	91	92	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e468	10.1371/journal.pone.0000468	http://dx.doi.org/10.1371/journal.pone.0000468			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520027	Green Published, Green Submitted, gold			2022-12-25	WOS:000207446000016
J	von Brunn, A; Teepe, C; Simpson, JC; Pepperkok, R; Friedel, CC; Zimmer, R; Roberts, R; Baric, R; Haas, J				von Brunn, Albrecht; Teepe, Carola; Simpson, Jeremy C.; Pepperkok, Rainer; Friedel, Caroline C.; Zimmer, Ralf; Roberts, Rhonda; Baric, Ralph; Haas, Juergen			Analysis of Intraviral Protein-Protein Interactions of the SARS Coronavirus ORFeome	PLOS ONE			English	Article							RESPIRATORY SYNDROME CORONAVIRUS; HEPATITIS-VIRUS; SUBCELLULAR-LOCALIZATION; NUCLEOCAPSID PROTEIN; MEMBRANE-PROTEIN; INTERACTION MAP; 3A PROTEIN; GENOME; RNA; IDENTIFICATION	The severe acute respiratory syndrome coronavirus (SARS-CoV) genome is predicted to encode 14 functional open reading frames, leading to the expression of up to 30 structural and non-structural protein products. The functions of a large number of viral ORFs are poorly understood or unknown. In order to gain more insight into functions and modes of action and interaction of the different proteins, we cloned the viral ORFeome and performed a genome-wide analysis for intraviral protein interactions and for intracellular localization. 900 pairwise interactions were tested by yeast-two-hybrid matrix analysis, and more than 65 positive non-redundant interactions, including six self interactions, were identified. About 38% of interactions were subsequently confirmed by CoIP in mammalian cells. Nsp2, nsp8 and ORF9b showed a wide range of interactions with other viral proteins. Nsp8 interacts with replicase proteins nsp2, nsp5, nsp6, nsp7, nsp8, nsp9, nsp12, nsp13 and nsp14, indicating a crucial role as a major player within the replication complex machinery. It was shown by others that nsp8 is essential for viral replication in vitro, whereas nsp2 is not. We show that also accessory protein ORF9b does not play a pivotal role for viral replication, as it can be deleted from the virus displaying normal plaque sizes and growth characteristics in Vero cells. However, it can be expected to be important for the virus-host interplay and for pathogenicity, due to its large number of interactions, by enhancing the global stability of the SARS proteome network, or play some unrealized role in regulating protein-protein interactions. The interactions identified provide valuable material for future studies.	[von Brunn, Albrecht; Teepe, Carola; Haas, Juergen] Univ Munich, Genzentrum, Max Von Pettenkofer Inst, Lehrstuhl Virol, Munich, Germany; [Friedel, Caroline C.; Zimmer, Ralf] Univ Munich, Inst Informat, D-8000 Munich, Germany; [Simpson, Jeremy C.; Pepperkok, Rainer] European Mol Biol Lab, Heidelberg, Germany; [Roberts, Rhonda; Baric, Ralph] Univ N Carolina, Chapel Hill, NC USA	University of Munich; University of Munich; European Molecular Biology Laboratory (EMBL); University of North Carolina; University of North Carolina Chapel Hill	von Brunn, A (corresponding author), Univ Munich, Genzentrum, Max Von Pettenkofer Inst, Lehrstuhl Virol, Marchioninistr 15, Munich, Germany.	vonbrunn@lmb.uni-muenchen.de; haas@lmb.uni-muenchen.de	Zimmer, Ralf/L-9295-2019; Friedel, Caroline/AAG-5017-2019	Friedel, Caroline/0000-0003-3569-4877; Pepperkok, Rainer/0000-0002-9762-3583; Simpson, Jeremy/0000-0002-7956-7805	LMU Munchen; Bayerisches Staatsministerum fur Wissenschaft, Forschung und Kunst; National Institute of Health [AI059136, AI059443]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059136, P01AI059443] Funding Source: NIH RePORTER; Medical Research Council [G0501453] Funding Source: researchfish; MRC [G0501453] Funding Source: UKRI	LMU Munchen; Bayerisches Staatsministerum fur Wissenschaft, Forschung und Kunst; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the LMU Munchen (FoeFoLe Predoctoral Program to C.T.) and in part by a grant provided by the Bayerisches Staatsministerum fur Wissenschaft, Forschung und Kunst. The work was also supported in part by a grant from the National Institute of Health AI059136 and AI059443 to RSB.	Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Bartlam M, 2005, CURR OPIN STRUC BIOL, V15, P664, DOI 10.1016/j.sbi.2005.10.004; Bhardwaj K, 2006, J MOL BIOL, V361, P243, DOI 10.1016/j.jmb.2006.06.021; Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000; Brockway SM, 2003, J VIROL, V77, P10515, DOI 10.1128/JVI.77.19.10515-10527.2003; Chan WS, 2005, MODERN PATHOL, V18, P1432, DOI 10.1038/modpathol.3800439; Choi IR, 2000, VIROLOGY, V267, P185, DOI 10.1006/viro.1999.0117; Chow SCS, 2006, J CLIN PATHOL, V59, P468, DOI 10.1136/jcp.2005.029868; Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Erdos P, 1959, PUBL MATH-DEBRECEN, V6, P290, DOI DOI 10.2307/1999405; Fang XN, 2005, J BIOCHEM MOL BIOL, V38, P381; Flajolet M, 2000, GENE, V242, P369, DOI 10.1016/S0378-1119(99)00511-9; Gorbalenya AE, 2004, J VIROL, V78, P7863, DOI 10.1128/JVI.78.15.7863-7866.2004; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4847, DOI 10.1093/nar/17.12.4847; Graham RL, 2005, J VIROL, V79, P13399, DOI 10.1128/JVI.79.21.13399-13411.2005; Guo DY, 2001, J GEN VIROL, V82, P935, DOI 10.1099/0022-1317-82-4-935; Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004; He RT, 2004, VIRUS RES, V105, P121, DOI 10.1016/j.virusres.2004.05.002; Huang C, 2006, J VIROL, V80, P210, DOI 10.1128/JVI.80.1.210-217.2006; Huang C, 2006, J VIROL, V80, P7287, DOI 10.1128/JVI.00414-06; Imbert I, 2006, EMBO J, V25, P4933, DOI 10.1038/sj.emboj.7601368; Ito N, 2005, J VIROL, V79, P3182, DOI 10.1128/JVI.79.5.3182-3186.2005; Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Lehner B, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r63; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Meier C, 2006, STRUCTURE, V14, P1157, DOI 10.1016/j.str.2006.05.012; Peri S, 2003, GENOME RES, V13, P2363, DOI 10.1101/gr.1680803; Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728; Shen S, 2005, BIOCHEM BIOPH RES CO, V330, P286, DOI 10.1016/j.bbrc.2005.02.153; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Sutton G, 2004, STRUCTURE, V12, P341, DOI 10.1016/j.str.2004.01.016; Tan YJ, 2006, ANTIVIR RES, V72, P78, DOI 10.1016/j.antiviral.2006.05.010; Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0; Uetz P, 2006, SCIENCE, V311, P239, DOI 10.1126/science.1116804; Xenarios I, 2000, NUCLEIC ACIDS RES, V28, P289, DOI 10.1093/nar/28.1.289; Yount B, 2005, J VIROL, V79, P14909, DOI 10.1128/JVI.79.23.14909-14922.2005; Yuan XL, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-66; Yuan XL, 2005, VIRUS RES, V109, P191, DOI 10.1016/j.virusres.2005.01.001; Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	48	167	171	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2007	2	5							e459	10.1371/journal.pone.0000459	http://dx.doi.org/10.1371/journal.pone.0000459			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DZ	17520018	gold, Green Published, Green Submitted			2022-12-25	WOS:000207446000007
J	Cyrklaff, M; Linaroudis, A; Boicu, M; Chlanda, P; Baumeister, W; Griffiths, G; Krijnse-Locker, J				Cyrklaff, Marek; Linaroudis, Alexandros; Boicu, Marius; Chlanda, Petr; Baumeister, Wolfgang; Griffiths, Gareth; Krijnse-Locker, Jacomine			Whole Cell Cryo-Electron Tomography Reveals Distinct Disassembly Intermediates of Vaccinia Virus	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM; INTRACELLULAR CORES; MEMBRANE; ENTRY; DNA; ENVELOPE; RECEPTOR; MODE	At each round of infection, viruses fall apart to release their genome for replication, and then reassemble into stable particles within the same host cell. For most viruses, the structural details that underlie these disassembly and assembly reactions are poorly understood. Cryo-electron tomography (cryo-ET), a unique method to investigate large and asymmetric structures at the near molecular resolution, was previously used to study the complex structure of vaccinia virus (VV). Here we study the disassembly of VV by cryo-ET on intact, rapidly frozen, mammalian cells, infected for up to 60 minutes. Binding to the cell surface induced distinct structural rearrangements of the core, such as a shape change, the rearrangement of its surface spikes and de-condensation of the viral DNA. We propose that the cell surface induced changes, in particular the decondensation of the viral genome, are a prerequisite for the subsequent release of the vaccinia DNA into the cytoplasm, which is followed by its cytoplasmic replication. Generally, this is the first study that employs whole cell cryo-ET to address structural details of pathogen-host cell interaction.	[Cyrklaff, Marek; Linaroudis, Alexandros; Boicu, Marius; Chlanda, Petr; Baumeister, Wolfgang] Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany; [Griffiths, Gareth; Krijnse-Locker, Jacomine] European Mol Biol Lab, Heidelberg, Germany	Max Planck Society; European Molecular Biology Laboratory (EMBL)	Cyrklaff, M (corresponding author), Max Planck Inst Biochem, Dept Mol Struct Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	cyrklaff@biochem.mpg.de; Krijnse@embl.de	Chlanda, Petr/AAK-6368-2021; Locker, Jacomine Krijnse/E-1009-2016; Locker, Jacomine Krijnse/AAX-1185-2020	Chlanda, Petr/0000-0002-7782-2139; 	EU; DFG [SPP1175]	EU(European Commission); DFG(German Research Foundation (DFG))	JKL is supported by a fifth framework EU grant, MC and JKL by the DFG priority program SPP1175.	ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ARMSTRONG JA, 1973, J GEN VIROL, V21, P533, DOI 10.1099/0022-1317-21-3-533; Baker TS, 1999, MICROBIOL MOL BIOL R, V63, P862, DOI 10.1128/MMBR.63.4.862-922.1999; Baumeister W, 2005, PROTEIN SCI, V14, P257, DOI 10.1110/ps.041148605; Carter GC, 2005, J GEN VIROL, V86, P1279, DOI 10.1099/vir.0.80831-0; CHANG A, 1976, J GEN VIROL, V32, P275, DOI 10.1099/0022-1317-32-2-275; Cudmore S, 1996, J VIROL, V70, P6909, DOI 10.1128/JVI.70.10.6909-6921.1996; Cyrklaff M, 2005, P NATL ACAD SCI USA, V102, P2772, DOI 10.1073/pnas.0409825102; CYRKLAFF M, 1990, J ELECTRON MICR TECH, V16, P351, DOI 10.1002/jemt.1060160407; DALES S, 1968, VIROLOGY, V35, P564, DOI 10.1016/0042-6822(68)90286-9; Fernandez JJ, 2003, J STRUCT BIOL, V144, P152, DOI 10.1016/j.jsb.2003.09.010; Griffiths G, 2001, J VIROL, V75, P11056, DOI 10.1128/JVI.75.22.11056-11070.2001; Griffiths G, 2001, J VIROL, V75, P11034, DOI 10.1128/JVI.75.22.11034-11055.2001; Grimm R, 1998, BIOPHYS J, V74, P1031, DOI 10.1016/S0006-3495(98)74028-7; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; Heuser J, 2005, J CELL BIOL, V169, P269, DOI 10.1083/jcb.200412169; Hollinshead M, 1999, J VIROL, V73, P1503, DOI 10.1128/JVI.73.2.1503-1517.1999; HOLOWCZAK JA, 1972, VIROLOGY, V50, P216, DOI 10.1016/0042-6822(72)90362-5; Jensen ON, 1996, J VIROL, V70, P7485, DOI 10.1128/JVI.70.11.7485-7497.1996; JOKLIK WK, 1964, J MOL BIOL, V8, P263, DOI 10.1016/S0022-2836(64)80136-4; KRIJNSELOCKER J, 1999, J CELL BIOL, V144, P267; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Locker JK, 2000, MOL BIOL CELL, V11, P2497, DOI 10.1091/mbc.11.7.2497; Mallardo M, 2002, J VIROL, V76, P5167, DOI 10.1128/JVI.76.10.5167-5183.2002; Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007; McIntosh R, 2005, TRENDS CELL BIOL, V15, P43, DOI 10.1016/j.tcb.2004.11.009; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Moss B, 2006, VIROLOGY, V344, P48, DOI 10.1016/j.virol.2005.09.037; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; Moss B, 2001, FIELDS VIROLOGY, P2849; Pedersen K, 2000, J VIROL, V74, P3525, DOI 10.1128/JVI.74.8.3525-3536.2000; Roos N, 1996, EMBO J, V15, P2343, DOI 10.1002/j.1460-2075.1996.tb00590.x; Rossmann MG, 2002, TRENDS MICROBIOL, V10, P324, DOI 10.1016/S0966-842X(02)02383-1; SAROV I, 1972, VIROLOGY, V50, P593, DOI 10.1016/0042-6822(72)90410-2; Schramm B, 2006, TRAFFIC, V7, P1352, DOI 10.1111/j.1600-0854.2006.00470.x; Senkevich TG, 2005, P NATL ACAD SCI USA, V102, P18572, DOI 10.1073/pnas.0509239102; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Sodeik B, 2002, TRENDS MICROBIOL, V10, P15, DOI 10.1016/S0966-842X(01)02256-9; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; Stewart PL, 2003, ADV PROTEIN CHEM, V64, P455; Tolonen N, 2001, MOL BIOL CELL, V12, P2031, DOI 10.1091/mbc.12.7.2031	42	51	52	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2007	2	5							e420	10.1371/journal.pone.0000420	http://dx.doi.org/10.1371/journal.pone.0000420			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DX	17487274	Green Published, Green Submitted, gold			2022-12-25	WOS:000207445800002
